(en)Nutritive polypeptides are provided herein. Also provided are various other embodiments including nucleic acids encoding the polypeptides, recombinant microorganisms that make the polypeptides, vectors for expressing the polypeptides, methods of making the polypeptides using recombinant microorganisms, compositions and formulations that comprise the polypeptides, and methods of using the polypeptides, compositions and formulations.

1.ApplicationNumber: US-201415024641-A
1.PublishNumber: US-2016228506-A1
2.Date Publish: 20160811
3.Inventor: AFEYAN NOUBAR B.
LEE CHUNG-WEI
SILVER NATHANIEL W.
BERRY DAVID ARTHUR
HAMILL MICHAEL J.
ERBE DAVID V.

4.Inventor Harmonized: AFEYAN NOUBAR B(US)
LEE CHUNG-WEI(US)
SILVER NATHANIEL W(US)
BERRY DAVID ARTHUR(US)
HAMILL MICHAEL J(US)
ERBE DAVID V(US)

5.Country: US
6.Claims:
(en)Nutritive polypeptides are provided herein. Also provided are various other embodiments including nucleic acids encoding the polypeptides, recombinant microorganisms that make the polypeptides, vectors for expressing the polypeptides, methods of making the polypeptides using recombinant microorganisms, compositions and formulations that comprise the polypeptides, and methods of using the polypeptides, compositions and formulations.

7.Description:
(en)CROSS REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of U.S. Provisional Application Nos. 61/882,211, filed Sep. 25, 2013, 61/882,214, filed Sep. 25, 2013, 61/882,219, filed Sep. 25, 2013, 61/882,220, filed Sep. 25, 2013, 61/882,225, filed Sep. 25, 2013, 61/882,229, filed Sep. 25, 2013, 61/882,232, filed Sep. 25, 2013, 61/882,234, filed Sep. 25, 2013, 61/882,235, filed Sep. 25, 2013, 61/882,240, filed Sep. 25, 2013, 61/882,129, filed Sep. 25, 2013, 61/882,243, filed Sep. 25, 2013, 61/882,246, filed Sep. 25, 2013, 61/882,250, filed Sep. 25, 2013, 61/882,254, filed Sep. 25, 2013, 61/882,260, filed Sep. 25, 2013, 61/882,264, filed Sep. 25, 2013, 61/882,267, filed Sep. 25, 2013, 61/882,271, filed Sep. 25, 2013, 61/882,274, filed Sep. 25, 2013, 61/882,180, filed Sep. 25, 2013, 61/882,189, filed Sep. 25, 2013, 61/882,198, filed Sep. 25, 2013, 61/882,212, filed Sep. 25, 2013, 61/882,222, filed Sep. 25, 2013, 61/882,300, filed Sep. 25, 2013, 61/882,295, filed Sep. 25, 2013, and 61/882,305, filed Sep. 25, 2013; the entire disclosures of which are hereby incorporated by reference in their entirety for all purposes.


BACKGROUND
Dietary protein is an essential nutrient for human health and growth. The World Health Organization recommends that dietary protein should contribute approximately 10 to 15% of energy intake when in energy balance and weight stable. Average daily protein intakes in various countries indicate that these recommendations are consistent with the amount of protein being consumed worldwide. Meals with an average of 20 to 30% of energy from protein are representative of high-protein diets when consumed in energy balance. The body cannot synthesize certain amino acids that are necessary for health and growth, and instead must obtain them from food. These amino acids, called “essential amino acids”, are Histidine (H), Isoleucine (I), Leucine (L), Lysine (K), Methionine (M), Phenylalanine (F), Threonine (T), Tryptophan (W), and Valine (V). Dietary protein sources that provide all the essential amino acids are referred to as “high quality” proteins. Animal foods such as meat, fish, poultry, eggs, and dairy products are generally regarded as high quality protein sources that provide a good balance of essential amino acids. Casein (a protein commonly found in mammalian milk, making up 80% of the proteins in cow milk) and whey (the protein in the liquid that remains after milk has been curdled and strained) are major sources of high quality dietary protein. Foods that do not provide a good balance of essential amino acids are referred to as “low quality” protein sources. Most fruits and vegetables are poor sources of protein. Some plant foods including beans, peas, lentils, nuts and grains (such as wheat) are better sources of protein but may have allergenicity issues. Soy, a vegetable protein manufactured from soybeans, is considered by some to be a high quality protein. Studies of high protein diets for weight loss have shown that protein positively affects energy expenditure and lean body mass. Further studies have shown that overeating produces significantly less weight gain in diets containing at least 5% of energy from protein, and that a high-protein diet decreases energy intake. Proteins commonly found in foods do not necessarily provide an amino acid composition that meets the amino acid requirements of a mammal, such as a human, in an efficient manner. The result is that, in order to attain the minimal requirements of each essential amino acid, a larger amount of total protein must be consumed in the diet than would be required if the quality of the dietary protein were higher. By increasing the quality of the protein in the diet it is possible to reduce the total amount of protein that must be consumed compared to diets that include lower quality proteins. Traditionally, desirable mixtures of amino acids, such as mixtures comprising essential amino acids, have been provided by hydrolyzing a protein with relatively high levels of essential amino acids, such as whey protein, and/or by combining free amino acids in a mixture that optionally also includes a hydrolyzed protein such as whey. Mixtures of this type may have a bitter taste, undesirable mouthfeel and are poorly soluble, and may be deemed unsuitable or undesirable for certain uses. As a result, such mixtures sometimes include flavoring agents to mask the taste of the free amino acids and/or hydrolyzed protein. In some cases compositions in which a proportion of the amino acid content is provided by polypeptides or proteins are found to have a better taste than compositions with a high proportion of total amino acids provided as free amino acids and/or certain hydrolyzed proteins. The availability of such compositions has been limited, however, because nutritional formulations have traditionally been made from protein isolated from natural food products, such as whey isolated from milk, or soy protein isolated from soy. The amino acid profiles of those proteins do not necessarily meet the amino acid requirements for a mammal. In addition, commodity proteins typically consist of mixtures of proteins and/or protein hydrolysates which can vary in their protein composition, thus leading to unpredictability regarding their nutritional value. Moreover, the limited number of sources of such high quality proteins has meant that only certain combinations of amino acids are available on a large scale for ingestion in protein form. The agricultural methods required for the supply of high quality animal protein sources such as casein and whey, eggs, and meat, as well as plant proteins such as soy, also require significant energy inputs and have potentially deleterious environmental impacts.
Accordingly, it would be useful in certain situations to have alternative sources and methods of supplying proteins for mammalian consumption. One feature that can enhance the utility of a nutritive protein is its solubility. Nutritive proteins with higher solubility can exhibit desirable characteristics such as increased stability, resistance to aggregation, and desirable taste profiles. For example, a nutritive protein that exhibits enhanced solubility can be formulated into a beverage or liquid formulation that includes a high concentration of nutritive protein in a relatively low volume of solution, thus delivering a large dose of protein nutrition per unit volume. A soluble nutritive protein can be useful in sports drinks or recovery drinks wherein a user (e.g., an athlete) wants to ingest nutritive protein before, during or after physical activity. A nutritive protein that exhibits enhanced solubility can also be particularly useful in a clinical setting wherein a subject (e.g., a patient or an elderly person) is in need of protein nutrition but is unable to consume solid foods or large volumes of liquids.
SUMMARY OF THE INVENTION
In one aspect, the invention provides methods of preventing or reducing loss of muscle mass and/or muscle function in a human subject, including the steps of: i) identifying a human subject suffering from or at risk of cancer, and ii) administering to the human subject a nutritional formulation in an amount sufficient to prevent or reduce a loss of muscle mass and/or muscle function, wherein the nutritional formulation includes an isolated nutritive polypeptide including an amino acid sequence at least about 90% identical over at least about 50 amino acids to a polypeptide sequence selected from the group consisting of SEQID 00001-03909; wherein the formulation includes at least 1.0 g of the nutritive polypeptide; wherein the formulation is present as a liquid, semi-liquid or gel in a volume not greater than about 500 ml or as a solid or semi-solid in a total mass not greater than about 200 g; and wherein the formulation is substantially free of non-comestible products. In one embodiment, the human subject is suffering from cancer and has received one or more doses of a pharmaceutical composition, wherein administration of the pharmaceutical composition increases a risk of loss of muscle mass and/or muscle function. In one embodiment, the human subject is suffering from cancer and has received one or more doses of a pharmaceutical composition, wherein i) the disease, disorder or condition or ii) the administration of the pharmaceutical composition, or both i) and ii) increases a risk of loss of muscle mass and/or muscle function.
In another aspect, the invention provides methods of treating a muscle wasting disease, disorder or condition in a human subject suffering from cancer, including the step of administering to the human subject a nutritional formulation in an amount sufficient to treat such muscle wasting disease, disorder or condition, wherein the nutritional formulation includes an isolated nutritive polypeptide including an amino acid sequence at least about 90% identical over at least about 50 amino acids to a polypeptide sequence provided herein; wherein the formulation includes at least 1.0 g of the nutritive polypeptide. In one embodiment, the formulation is administered on a dosage schedule sufficient to provide substantial protein nutrition to the human subject in the absence of consumption by the subject of an agriculturally-derived food product.
In another aspect, the invention provides methods of reducing the risk of a human subject developing a disease, disorder or condition characterized or exacerbated by protein malnourishment, including the steps of (i) identifying the human subject as suffering from cancer and being at risk of developing the disease, disorder or condition; and (ii) administering in one or more doses a nutritional formulation including an isolated nutritive polypeptide including an amino acid sequence at least about 90% identical over at least about 50 amino acids to a polypeptide sequence provided herein; wherein the formulation includes at least 1.0 g of the nutritive polypeptide. In one embodiment, the human subject is at risk of developing malnutrition or protein malnutrition. In one embodiment, the human subject exhibits sarcopenia and/or cachexia. In one embodiment, the human subject has an inflammatory reaction or an autoimmune disorder. In one embodiment, the human subject has carcinoma, lymphoma, blastoma, sarcoma, leukemia, mesothelioma, squamous cell cancer, lung cancer including small-cell lung cancer and non-small cell lung cancer (which includes large-cell carcinoma, adenocarcinoma of the lung, and squamous carcinoma of the lung), cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer (including gastrointestinal cancer and gastrointestinal stromal cancer), pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, cervical cancer, vulval cancer, thyroid cancer, head and neck cancer, melanoma, superficial spreading melanoma, lentigo maligna melanoma, acral lentiginous melanomas, nodular melanomas, T-cell lymphomas, B-cell lymphomas (including low grade/follicular non-Hodgkin's lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade/follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic NHL; high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom's Macroglobulinemia); chronic lymphocytic leukemia (CLL); acute myeloid leukemia (AML); chronic myeloid leukemia (CML); acute lymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblastic leukemia; or post-transplant lymphoproliferative disorder (PTLD). In one embodiment, the human subject has an infectious disease. In one embodiment, the human subject has undergone a surgical procedure. In one embodiment, includes identifying the human subject as suffering from a metastatic cancer. In one embodiment, the nutritional formulation is administered in conjunction with at least a therapy selected from a surgical, radiation, hormonal, cancer cell-targeted or chemotherapeutic anticancer therapy. In one embodiment, the nutritional formulation is administered in conjunction with an exercise regimen. In one embodiment, the nutritional formulation is administered as an adjunct to administration of a radiotherapeutic composition or a chemotherapeutic pharmaceutical composition. In one embodiment, the human subject has HIV/AIDS. HCV?TB?
In another aspect, the invention provides methods of increasing muscle anabolism in a human subject suffering from cancer, including administering to a human subject in one or more doses a nutritional formulation including an isolated nutritive polypeptide including an amino acid sequence at least about 90% identical over at least about 50 amino acids to a polypeptide sequence provided herein; wherein the formulation includes at least 1.0 g of the nutritive polypeptide, wherein the nutritive formulation is administered to the human subject at a frequency sufficient to increase muscle anabolism in the subject after the administration thereof.
In another aspect, the invention provides methods of formulating a nutritional product for use in treating a human subject, including the steps of providing to a human subject suffering from cancer, a nutritive composition including an isolated nutritive polypeptide including an amino acid sequence at least about 90% identical over at least about 50 amino acids to a polypeptide sequence provided herein; and formulating the nutritive polypeptide with an acceptable excipient, wherein the isolated nutritive polypeptide has an aqueous solubility at pH 7 of at least 12.5 g/L, and wherein the isolated nutritive polypeptide has a simulated gastric digestion half-life of less than 30 minutes. In one embodiment, the methods further include combining the nutritive composition with at least one of a tastant, a nutritional carbohydrate and a nutritional lipid, wherein the product is present as a liquid, semi-liquid or gel in a volume not greater than about 500 ml or as a solid or semi-solid in a total mass not greater than about 200 g. In one embodiment, the product is substantially free of non-comestible products.
In another aspect, the invention provides methods for selecting an amino acid sequence of a nutritive polypeptide wherein the nutritive polypeptide is suitable for use in treating a human subject suffering from cancer, including i) providing a library of amino acid sequences including a plurality of amino acid sequences, ii) identifying in the library one or more amino acid sequences including at least one amino acid of interest, and iii) selecting the one or more identified amino acid sequences, thereby selecting an amino acid sequence of a nutritive polypeptide.
In another aspect, the invention provides methods for selecting an amino acid sequence of a nutritive polypeptide wherein the nutritive polypeptide is suitable for use in treating a human subject suffering from cancer, including i) providing a library of amino acid sequences including a plurality of amino acid sequences, ii) identifying in the library one or more amino acid sequences including a ratio of at least one amino acid residues of interest to total amino acid residues greater than or equal to a selected ratio, and iii) selecting the one or more identified amino acid sequences, thereby selecting an amino acid sequence of a nutritive polypeptide.
In another aspect, the invention provides methods for selecting an amino acid sequence of a nutritive polypeptide wherein the nutritive polypeptide is suitable for use in treating a human subject suffering from cancer, including i) providing a library of amino acid sequences including a plurality of amino acid sequences, ii) identifying in the library one or more amino acid sequences including a ratio of at least one amino acid residues of interest to total amino acid residues less than or equal to a selected ratio, and iii) selecting the one or more identified amino acid sequences, thereby selecting an amino acid sequence of a nutritive polypeptide.
In another aspect, the invention provides nutritive formulations for the treatment or prevention of a muscle wasting disease, disorder or condition in a human subject suffering from cancer, including an isolated nutritive polypeptide including an amino acid sequence at least about 0.90% identical over at least about 50 amino acids to a polypeptide sequence provided herein; wherein the nutritive polypeptide is present in an amount sufficient to provide a nutritional benefit to a human subject having or at risk of having reduced protein absorption capacity. In one embodiment, the polypeptide sequence includes a ratio of essential amino acid residues to total amino acid residues of at least 34% and wherein the polypeptide sequence is nutritionally complete, except that the polypeptide sequence is optionally free or reduced in methionine. In one embodiment, the essential amino acids present in the nutritive polypeptide are substantially bioavailable. In one embodiment, the isolated nutritive polypeptide has an aqueous solubility at pH 7 of at least 12.5 g/L. In one embodiment, the isolated nutritive polypeptide has a simulated gastric digestion half-life of less than 30 minutes. In one embodiment, the nutritive polypeptide is formulated in a pharmaceutically acceptable carrier. In one embodiment, the nutritive polypeptide is formulated in or as a food or a food ingredient. In one embodiment, the nutritive polypeptide is formulated in or as a beverage or a beverage ingredient. In one embodiment, the amino acid sequence encodes an enzyme having a primary activity, and wherein the nutritive polypeptide substantially lacks the primary activity. In one embodiment, the formulation is present as a liquid, semi-liquid or gel in a volume not greater than about 500 ml or as a solid or semi-solid in a total mass not greater than about 200 g. In one embodiment, the nutritive polypeptide includes an amino acid sequence at least about 90% identical to an edible species polypeptide or fragment thereof at least 50 amino acids in length, wherein the amino acid sequence has less than about 50% identity over at least 25 amino acids to a known allergen. In one embodiment, including a component selected from a tastant, a protein mixture, a polypeptide, a peptide, a free amino acid, a carbohydrate, a lipid, a mineral or mineral source, a vitamin, a supplement, an organism, a pharmaceutical, and an excipient. In one embodiment, the human subject is suffering from cancer. In one embodiment, the amino acid sequence contains a density of essential amino acids about equal to or greater than the density of essential chain amino acids present in a full-length reference nutritional polypeptide or a reference polypeptide-containing mixture. In one embodiment, the amino acid sequence contains a density of at least one amino acid selected from the group consisting of leucine, arginine and glutamine about equal to or greater than the density of the selected amino acid present in a full-length reference nutritional polypeptide or a reference polypeptide-containing mixture.
In another aspect, the invention provides formulations including at least one nutritive polypeptide including an amino acid sequence at least about 99% identical to an edible species polypeptide capable of being secreted from a microorganism, wherein the nutritive polypeptide is present in the formulation in an amount sufficient to provide a nutritional benefit equivalent to or greater than at least about 2% of a reference daily intake value of protein.
In another aspect, the invention provides nutritive formulations for the treatment or prevention of a muscle wasting disease, disorder or condition in a human subject suffering from cancer, including a nutritive amino acid composition including a plurality of free amino acids including an amino acid ratio at least about 90% identical to an amino acid ratio of a polypeptide sequence provided herein, wherein the nutritive amino acid composition is nutritionally complete; wherein the nutritive amino acid composition is present in an amount sufficient to provide a nutritional benefit to a human subject having reduced protein absorption capacity. In one embodiment, the formulation is present as a liquid, semi-liquid or gel in a volume not greater than about 500 ml or as a solid or semi-solid in a total mass not greater than about 200 g.



BRIEF DESCRIPTION OF THE FIGURES
These and other features, aspects, and advantages of the present invention will become better understood with regard to the following description, and accompanying drawings, where:
FIG. 1 is an image demonstrating SDS-PAGE analysis of the purification of SEQID-00105 by IMAC.
FIG. 2 is a chart demonstrating net charge per amino acid as a function of pH for nutritive polypeptides predicted to bind to either anion or cation exchange resin. (1) SEQID-00105, (2) SEQID-00008, (3) SEQID-00009, (4) SEQID-00475, (5) SEQID-00472, (6) SEQID-00640, (7) SEQID-00019.
FIG. 3 is a chart demonstrating total charge per amino acid over a range of pHs for exemplary nutritive polypeptides. (1) SEQID-00475, (2) SEQID-00009, (3) SEQID-00478, (4) SEQID-00433, (5) SEQID-00472.
FIG. 4 is a chart demonstrating purity of SEQID-00009 is as a function of ammonium sulfate concentration.
FIG. 5 is an image demonstrating SDS-PAGE analysis demonstrating secretion of SEQID-00409 (left) and SEQID-00420 (right) with new signal peptide compared to native signal peptide.
FIG. 6 is a chart demonstrating supernatant concentration of GLP-1 (7-36) detected in the supernatant following stimulation, error bars are the standard deviation of the technical replicates.
FIG. 7 is a chart demonstrating average blood glucose values over time during OGTT of vehicle, SEQID-00105, Arginine, and SEQID-00338. The error bars shown are the standard errors of the mean.
FIG. 8 is a chart demonstrating the area under curve for blood glucose integrated from 0-120 minutes (Left) and from 0-60 minutes (Right) after acute dosing of SEQID-00105, Arginine, and SEQID-00338.
FIG. 9 is a chart demonstrating average plasma insulin concentration for n=6 rats per treatment group over time. The error bars show the standard error of the mean.
FIG. 10 is a chart demonstrating plasma insulin area under curve integrated between 0-240 and 0-60 minutes for all treatment groups. The error bars show the standard error of the mean.
FIG. 11 is a chart demonstrating average plasma GLP-1 concentration for n=6 rats per treatment group over time. The error bars shown here correspond to the standard error of the mean.
FIG. 12 is a chart demonstrating average blood glucose values over time. The error bars shown are the standard errors of the mean.
FIG. 13 is a chart demonstrating integrated AUC for each treatment group between the time of glucose challenge (0 min.) and 60 minutes, and between time 0 and 120 minutes. The error bars shown are the standard errors of the mean.
FIG. 14 is a chart demonstrating average plasma insulin concentration for n=6 rats per treatment group in vehicle & SEQID-00105 and n=5 rats per treatment group in the case of SEQID-00338 over the course of the experiment. The error bars shown are the standard errors of the mean.
FIG. 15 is a chart demonstrating integrated area under the curve for vehicle, SEQID-00105 and SEQID-00338 between 0 and 90 minutes and between 0 and 60 minutes. Error bars shown here correspond to the standard error of the mean.
FIG. 16 is a chart demonstrating average plasma GLP-1 concentration for n=6 rats per treatment group for vehicle and SEQID-00105 and n=5 rats for SEQID-00338 over the course of the experiment. Error bars shown here correspond to the standard error of the mean.
FIG. 17 is a chart demonstrating area under curve for GLP-1 (7-36) for each treatment group integrated to 0-90 and 0-60 minutes. Error bars shown here correspond to the standard error of the mean.
FIG. 18 is a chart demonstrating average blood glucose values during OGTT of vehicle, SEQID-00105, Alogliptin, and the combination for n=6 rats per treatment group. Error bars shown here correspond to the standard error of the mean.
FIG. 19 is a chart demonstrating AlphaLISA plasma insulin over time for vehicle and SEQID-00105 administered at three different doses. Error bars shown here are the standard error of the mean.
FIG. 20 is a chart demonstrating AlphaLISA plasma insulin over time for vehicle and SEQID-00426, SEQID-00338, SEQID-00341. Error bars shown here are the standard error of the mean.
FIG. 21 is a chart demonstrating integrated area under curves for plasma insulin concentrations for SEQID-00105 at three doses between 0 and 240 minutes and between 0 and 60 minutes. Error bars shown here are the standard error of the mean.
FIG. 22 is a chart demonstrating integrated area under curves for plasma insulin concentrations for vehicle, SEQID-00426, SEQID-00338, and SEQID-00341 between 0 and 240 minutes and between 0 and 60 minutes. Error bars shown here are the standard error of the mean.
FIG. 23 is a chart demonstrating AlphaLISA plasma insulin over time for SEQID-00423, SEQID-00587, SEQID-00105. Error bars shown here are the standard error of the mean.
FIG. 24 is a chart demonstrating AlphaLISA plasma insulin over time for vehicle SEQID-00424, SEQID-00425, and SEQID-00429. Error bars shown here are the standard error of the mean.
FIG. 25 is a chart demonstrating integrated area under curves for plasma insulin concentrations for vehicle, SEQID-00423, SEQID-00587, and SEQID-00105 between 0 and 240 minutes and between 0 and 60 minutes. Error bars shown here are the standard error of the mean.
FIG. 26 is a chart demonstrating integrated area under curves for plasma insulin concentrations for vehicle, SEQID-00424, SEQID-00425, and SEQID-00429 between 0 and 240 minutes and between 0 and 60 minutes. Error bars shown here are the standard error of the mean.
FIG. 27 is a chart demonstrating ELISA plasma insulin over time for vehicle and SEQID-00105, SEQID-00240, and SEQID-00559. Error bars shown here are the standard error of the mean.
FIG. 28 is a chart demonstrating integrated area under curves for plasma insulin concentrations for vehicle, SEQID-00105, SEQID-00240, and SEQID-00559 between 0 and 240 minutes and 0 and 60 minutes. Error bars shown here are the standard error of the mean.
FIG. 29 is a chart demonstrating GLP-2 concentration over a 4 hour time course for vehicle and SEQID-00240, n=4 and n=5 rats, respectively. Error bars shown are the standard error of the mean.
FIG. 30 is a chart demonstrating integrated GLP-2 area under the curve over the first hour and the full 4 hours. Error bars shown are the 95% confidence interval.
FIG. 31 is a chart demonstrating average plasma insulin response to SEQID-00105 of all subjects over time.
FIG. 32 is a chart demonstrating average plasma insulin fold response to SEQID-00105 over baseline.
FIG. 33 is a chart demonstrating average plasma insulin response to SEQID-00426 of all subjects over time.
FIG. 34 is a chart demonstrating average plasma insulin fold response to SEQID-00426 over baseline.
FIG. 35 is a chart demonstrating average total Gastric Inhibitory Polypeptide (GIP) response of all patients to SEQID-00426.
FIG. 36 is a chart demonstrating a Gastric Inhibitory Polypeptide (GIP) fold response of all patients to SEQID-00426.
FIG. 37 is a chart demonstrating alphascreen signal (y-axis) measured at different Leucine concentrations. Error bars shown are the standard deviation of replicates.
FIG. 38 is a chart demonstrating Leucine Dose Response in Minimal Amino Acid Media in Primary RSKMC. Error bars shown are the standard deviation.
FIG. 39 is a chart demonstrating In vitro Leucine Dose Response of rps6 Phosphorylation in Isolate Soleus Muscle. Error bars shown are the standard deviation.
FIG. 40 is a chart demonstrating In vitro Leucine Dose Response of rps6 Phosphorylation in Isolated Gastrocnemius Muscle. Error bars shown are the standard deviation.
FIG. 41 is a chart demonstrating In vitro Leucine Dose Response of rps6 Phosphorylation in Isolate Extensor Digitorum Longus Muscle. Error bars shown are the standard deviation.
FIG. 42 is a chart demonstrating Combined Activity of Leu/Tyr/Arg on RPS6 Phosphorylation. Error bars shown are the standard deviation.
FIG. 43 is a chart demonstrating Arginine Stimulation of RPS6 in Leu/Tyr Background. Error bars shown are the standard deviation.
FIG. 44 is a chart demonstrating Leucine Stimulation of RPS6 in Arg/Tyr Background. Error bars shown are the standard deviation.
FIG. 45 is a chart demonstrating Tyrosine Stimulation of RPS6 in Arg/Leu Background. Error bars shown are the standard deviation.
FIG. 46 is a chart demonstrating a time-course of free Leu release during Pancreatin digest of SEQID-00105.
FIG. 47 is a chart demonstrating viscosity measured in centipoise for SEQID-00105 at 4 C (closed circles) and 25 C (open circles) and whey at 4 C (closed squares) and 25 C (open squares) over a range of protein concentrations.
FIG. 48 is a chart demonstrating (Left) Initial and final (after heating to 90° C. and then cooling to 20° C.) protein circular dichroism spectrum for SEQID-00105 and (Right) change in ellipticity at a given wavelength over the temperature range for that SEQID-00105.
FIG. 49 is an image demonstrating Western blot analysis for mannose-containing glycans. A) Coomassie-stained gel. B) GNA blotted membrane. In both panels, lanes are as follows: 1) Pre-stained protein ladder, 2) SEQID-00363 (5 μg) from A. niger, 3) whole cell extract (5 μg) from E. coli transformed with an expression vector encoding SEQID-00363, 4), GNA positive control carboxypeptidase (5 μg), 5) soluble lysate (5 μg) from E. coli transformed with an expression vector encoding SEQID-00363.
FIG. 50 is an image demonstrating Western blot analysis for Neu5Gc. A) Coomassie-stained gel. B) anti-Neu5Gc probed membrane. In both panels, lanes are as follows: 1&10) Pre-stained protein ladder (New England Biolab), 2& 11) beef extract (30 μg), 3) pork extract (30 μg), 4) deer extract (30 μg), 5) lamb extract (30 g), 6) turkey extract (30 μg), 7) chicken extract (30 μg), 8) cod extract (30 μg), 9) Protein Mixture 1 (10 μg), 12-15) 168 nutritive polypeptide library (30 μg) expressed in 12) E. coli (IMAC-purified lysate), 13) B. subtilis (supernatant), 14) B. subtilis (lysate), 15) B. subtilis (IMAC-purified lysate), 16-20) cDNA Library (30 μg) expressed in 16) B. subtilis (PH951 Grac lysate), 17) E. coli (Rosetta soluble lysate), 18) E. coli (Rosetta whole cell), 19) E. coli (GamiB lysate), and 20) E. coli (Gami2 lysate).
FIG. 51 is an image demonstrating Western blot analysis for Xylose and Fucose. A) Coomassie-stained gel. B) anti-Neu5Gc probed membrane. In western blot analysis of samples of protein extracted from plants and fungi or recombinantly expressed by E. coli and A. niger . xylose- and fucose-containing glycans in A) Coomassie-stained gel. B) anti-Neu5Gc-blotted membrane. In both panels, lanes are as follows: 1&11) Pre-stained protein ladder (New England Biolab), 2) yeast extract (30 μg), 3) flaxseed extract (30 μg), 4) chicken extract (30 μg), 5) corn extract (30 μg), 6) potato extract (30 μg), 7) mushroom extract (30 μg), 8) Protein Mixture 2 (30 μg), 9) HRP (2 μg), 10) fetuin (2 μg), 12) soy extract (30 μg), 13) rice extract (30 μg), 14) broccoli extract (30 μg), 15) tomato extract (30 μg), 16) blueberry extract (30 μg), 17) grape extract (30 μg), 18) Protein Mixture 2 (30 μg), 19) HRP (2 μg), 20) fetuin (2 μg).
FIG. 52 is a series of charts demonstrating change in average area under the curve (AUC) (±SD) of plasma amino acid concentrations (μM·h) measured in blood samples collected from rats (n=2-4) over 4 h following oral administration of the indicated nutritive polypeptides at the doses listed in Table E33A. BCAA: branched chain amino acids, EAA: essential amino acids.
FIG. 53 is a series of charts demonstrating average plasma amino acid concentration (±SD)-time curve for rats (n=4) orally administered of SEQID-00105 at 2.85 g/kg. BCAA: branched chain amino acids, EAA: essential amino acids.
FIG. 54 is a series of charts demonstrating dose-response effect of SEQID-00105 (Left) Average plasma Leu concentration (±SD)-time curve (Right) Average area under the curve (AUC) (±SD) of plasma amino acid concentrations (μM·h) measured in blood samples collected from rats (n=4) over 4 h following oral administration of SEQID-00105 at the doses listed in Table E33A.
FIG. 55 is a series of charts demonstrating plasma amino acid concentrations during rat pharmacokinetic studies of native and modified forms of SEQID-00363. Plasma amino acid profile of essential amino acids (EAAs) (A), Leucine (B), Serine (C), and Threonine (D) following oral administration of saline (circle (), solid line) (n=4), native SEQID-00363 (square (▪), solid line) (n=4), deglycosylated SEQID-00363′ (open circe (∘), dashed line) (n=2), and hydrolyzed SEQID-00363 (open square (□), dashed line) (n=4). Data represent the mean±the standard deviation of the mean for n=2-4 rats, as indicated above.
FIG. 56 is a series of charts demonstrating change in average FSR for WPI, SEQID-00105, and SEQID-363
FIG. 57 is a series of charts demonstrating human plasma time course of measured amino acid s for WPI and SEQID-00105.
FIG. 58 is a series of charts demonstrating human plasma time course of measured amino acid s for WPI and SEQID-00105.
FIG. 59 is a series of charts demonstrating human plasma time course of measured amino acid s for WPI and SEQID-00105.
FIG. 60 is a series of charts demonstrating human plasma time course of measured amino acid and the aggregate groups, essential amino acids (EAA), branched chain amino acids (BCAA), and total amino acids (TAA) for WPI and SEQID-00105.
FIG. 61 is a chart demonstrating integrated area under the curve (AUC) of measured amino acids, for WPI and SEQID-00105.
FIG. 62 is a chart demonstrating integrated area under the curve (AUC) of measured amino acids, for WPI and SEQID-00105.
FIG. 63 is a chart demonstrating integrated area under the curve (AUC) of aggregate groups, essential amino acids (EAA), branched chain amino acids (BCAA), and total amino acids (TAA), for WPI and SEQID-00105.
FIG. 64 is a series of charts demonstrating human plasma time course of measured amino acid s for WPI and SEQID-00105.
FIG. 65 is a series of charts demonstrating human plasma time course of measured amino acid s for WPI and SEQID-00105.
FIG. 66 is a series of charts demonstrating human plasma time course of measured amino acid s for WPI and SEQID-00105.
FIG. 67 is a series of charts demonstrating human plasma time course of measured amino acid and the aggregate groups, essential amino acids (EAA), branched chain amino acids (BCAA), and total amino acids (TAA) for WPI and SEQID-00105.
FIG. 68 is a chart demonstrating integrated area under the curve (AUC) of measured amino acids, for WPI and SEQID-00105.
FIG. 69 is a chart demonstrating integrated area under the curve (AUC) of measured amino acids, for WPI and SEQID-00105.
FIG. 70 is a chart demonstrating integrated area under the curve (AUC) of aggregate groups, essential amino acids (EAA), branched chain amino acids (BCAA), and total amino acids (TAA), for WPI and SEQID-00105
FIG. 71 is a series of charts demonstrating human plasma time course of measured amino acid s for WPI and SEQID-00363.
FIG. 72 is a series of charts demonstrating human plasma time course of measured amino acid s for WPI and SEQID-00363.
FIG. 73 is a series of charts demonstrating human plasma time course of measured amino acid s for WPI and SEQID-00363.
FIG. 74 is a series of charts demonstrating human plasma time course of measured amino acid and the aggregate groups, essential amino acids (EAA), branched chain amino acids (BCAA), and total amino acids (TAA) for WPI and SEQID-363.
FIG. 75 is a series of charts demonstrating human plasma time course of measured amino acid s for WPI and SEQID-00426.
FIG. 76 is a series of charts demonstrating human plasma time course of measured amino acid s for WPI and SEQID-00426.
FIG. 77 is a series of charts demonstrating human plasma time course of measured amino acid s for WPI and SEQID-00426.
FIG. 78 is a series of charts demonstrating human plasma time course of measured amino acid and the aggregate groups, essential amino acids (EAA), branched chain amino acids (BCAA), and total amino acids (TAA) for WPI and SEQID-00426.



DETAILED DESCRIPTION
Terms used in the claims and specification are defined as set forth below unless otherwise specified.
It must be noted that, as used in the specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise.
DEFINITIONS
An “agriculturally-derived food product” is a food product resulting from the cultivation of soil or rearing of animals.
The term “ameliorating” refers to any therapeutically beneficial result in the treatment of a disease state, e.g., including prophylaxis, lessening in the severity or progression, remission, or cure thereof.
As used herein, the term “autotrophic” refers to an organism that produces complex organic compounds (such as carbohydrates, fats, and proteins) from simple inorganic molecules using energy from light (by photosynthesis) or inorganic chemical reactions (chemosynthesis).
As used herein, a “body mass index” or “BMI” or “Quetelet index” is a subject's weight in kilograms divided by the square of the subject's height in meters (kg/m 2 ). For adults, a frequent use of the BMI is to assess how much an individual's body weight departs from what is normal or desirable for a person of his or her height. The weight excess or deficiency may, in part, be accounted for by body fat, although other factors such as muscularity also affect BMI significantly. The World Health Organization regards a BMI of less than 18.5 as underweight and may indicate malnutrition, an eating disorder, or other health problems, while a BMI greater than 25 is considered overweight and above 30 is considered obese. (World Health Organization. BMI classification).
As used herein, a “branched chain amino acid” is an amino acid selected from Leucine, Isoleucine, and Valine.
As used herein, “cachexia” refers to a multifaceted clinical syndrome that results in muscle wasting and weight loss. It is a complex condition where protein catabolism exceeds protein anabolism, which makes muscle wasting a primary feature of the condition. In addition to the metabolic derangements in protein metabolism, it is also characterized by anorexia and inflammation. These derangements plus impaired protein metabolism are responsive to nutrition therapy to varying degrees.
As used herein, “calorie control” and “calorie restriction” refer to the process of reducing a subject's calorie intake from food products, either relative to the subject's prior calorie intake or relative to an appropriate calorie intake standard.
Generally, the terms “cancer” and “cancerous” refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. More specifically, cancers that are treated using any one or more tyrosine kinase inhibitors, other drugs blocking the receptors or their ligands, or variants thereof, and in connection with the methods provided herein include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, leukemia, mesothelioma, squamous cell cancer, lung cancer including small-cell lung cancer and non-small cell lung cancer (which includes large-cell carcinoma, adenocarcinoma of the lung, and squamous carcinoma of the lung), cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer (including gastrointestinal cancer and gastrointestinal stromal cancer), pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, cervical cancer, vulval cancer, thyroid cancer, head and neck cancer, melanoma, superficial spreading melanoma, lentigo maligna melanoma, acral lentiginous melanomas, nodular melanomas, T-cell lymphomas, B-cell lymphomas (including low grade/follicular non-Hodgkin's lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade/follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic NHL; high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom's Macroglobulinemia); chronic lymphocytic leukemia (CLL); acute myeloid leukemia (AML); chronic myeloid leukemia (CML); acute lymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblastic leukemia; or post-transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with phakomatoses, edema (such as that associated with brain tumors), and Meigs' syndrome.
A “comestible product” includes an edible product, while a “non-comestible product” is generally an inedible product or contains an inedible product. To be “substantially free of non-comestible products” means a composition does not have an amount or level of non-comestible product sufficient to render the composition inedible, dangerous or otherwise unfit for consumption by its intended consumer. Alternatively, a polypeptide can be substantially free of non-comestible products, meaning the polypeptide does not contain or have associated therewith an amount or level of non-comestible product sufficient to render a composition containing the polypeptide inedible by, or unsafe or deleterious to, its intended consumer. In preferred embodiments a composition substantially free of non-comestible products can be consumed in a nutritional amount by an intended consumer who does not suffer or is not at increased risk of suffering a deleterious event from such consumption. For example, levels of lead and other metals are well-documented as having significant risk including toxicity to humans when present in food, particularly foods containing an agriculturally-derived product grown in soil contaminated with lead and/or other metals. Thus, products such as foods, beverages, and compounds containing industrially-produced polypeptides having metal content above a certain parts per million (ppm), are considered non-comestible products, such metal content depending upon the metal as recognized in the art. For example, inclusion of lead or cadmium in an industrially-produced polypeptide at levels such that the lead will have a deleterious biological effect when consumed by a mammal will generally render a composition containing the industrially-produced polypeptide non-comestible. Notwithstanding the above, some polypeptides have certain amounts of metals complexed to or incorporated therein (such as iron, zinc, calcium and magnesium) and such metals shall not necessarily render the polypeptides non-comestible.
The term “control sequences” is intended to encompass, at a minimum, any component whose presence is essential for expression, and can also encompass an additional component whose presence is advantageous, for example, leader sequences and fusion partner sequences.
As used herein, a patient is “critically-medically ill” if the patient, because of medical illness, experiences changes in at least one of body mass index and muscle mass (e.g., sarcopenia). In some embodiments the patient is confined to bed for at least 25%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or 100% of their waking time. In some embodiments the patient is unconscious. In some embodiments the patient has been confined to bed as described in this paragraph for at least 1 day, 2 days, 3 days, 4 days, 5 days, 10 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 10 weeks or longer.
As used herein, the phrase “degenerate variant” of a reference nucleic acid sequence encompasses nucleic acid sequences that can be translated, according to the standard genetic code, to provide an amino acid sequence identical to that translated from the reference nucleic acid sequence. The term “degenerate oligonucleotide” or “degenerate primer” is used to signify an oligonucleotide capable of hybridizing with target nucleic acid sequences that are not necessarily identical in sequence but that are homologous to one another within one or more particular segments.
As used herein a “desirable body mass index” is a body mass index of from about 18.5 to about 25. Thus, if a subject has a BMI below about 18.5, then an increase in the subject's BMI is an increase in the desirability of the subject's BMI. If instead a subject has a BMI above about 25, then a decrease in the subject's BMI is an increase in the desirability of the subject's BMI.
As used herein, the term “diabetes” includes any metabolic disease in which a subject is unable to produce any or a sufficient amount of insulin or is otherwise unable to regulate blood glucose level. The term “pre-diabetes” is also termed “impaired fasting glucose” includes a condition in which fasting glucose is above an accepted normal limit
As used herein, an “elderly” mammal is one who experiences age related changes in at least one of body mass index and muscle mass (e.g., age related sarcopenia). In some embodiments an “elderly” human is at least 50 years old, at least 60 years old, at least 65 years old, at least 70 years old, at least 75 years old, at least 80 years old, at least 85 years old, at least 90 years old, at least 95 years old, or at least 100 years old. In some embodiments and an elderly animal, mammal, or human is a human who has experienced a loss of muscle mass from peak lifetime muscle mass of at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, or at least 60%. Because age related changes to at least one of body mass index and muscle mass are known to correlate with increasing age, in some embodiments an elderly mammal is identified or defined simply on the basis of age. Thus, in some embodiments an “elderly” human is identified or defined simply by the fact that their age is at least 60 years old, at least 65 years old, at least 70 years old, at least 75 years old, at least 80 years old, at least 85 years old, at least 90 years old, at least 95 years old, or at least 100 years old, and without recourse to a measurement of at least one of body mass index and muscle mass.
As used herein, an “essential amino acid” is an amino acid selected from Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, and Valine. However, it should be understood that “essential amino acids” can vary through a typical lifespan, e.g., cysteine, tyrosine, and arginine are considered essential amino acids in infant humans. Imura K, Okada A (1998). “Amino acid metabolism in pediatric patients”. Nutrition 14 (1): 143-8. In addition, the amino acids arginine, cysteine, glycine, glutamine, histidine, proline, serine and tyrosine are considered “conditionally essential” in adults, meaning they are not normally required in the diet, but must be supplied exogenously to specific populations that do not synthesize them in adequate amounts. First P, Stehle P (1 Jun. 2004). “What are the essential elements needed for the determination of amino acid requirements in humans?”. Journal of Nutrition 134 (6 Suppl): 1558S-1565S; and Reeds P J (1 Jul. 2000). “Dispensable and indispensable amino acids for humans”. J. Nutr. 130 (7): 1835S-40S.
As used herein, “exercise” is, most broadly, any bodily activity that enhances or maintains physical fitness and overall health and wellness. Exercise is performed for various reasons including strengthening muscles and the cardiovascular system, honing athletic skills, weight loss or maintenance, as well as for the purpose of enjoyment.
As used herein, an “exercise regimen” includes any course of exercise for the promotion of health, or for the treatment or prevention of disease.
As used herein, an “expression control sequence” refers to polynucleotide sequences which are necessary to affect the expression of coding sequences to which they are operatively linked. Expression control sequences are sequences which control the transcription, post-transcriptional events and translation of nucleic acid sequences. Expression control sequences include appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (e.g., ribosome binding sites); sequences that enhance protein stability; and when desired, sequences that enhance protein secretion. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and transcription termination sequence.
As used herein, “function” and “functional performance” refers to a functional test that simulates daily activities. “Muscle function” or “functional performance” is measured by any suitable accepted test, including timed-step test (step up and down from a 4 inch bench as fast as possible 5 times), timed floor transfer test (go from a standing position to a supine position on the floor and thereafter up to a standing position again as fast as possible for one repetition), and physical performance battery test (static balance test, chair test, and a walking test) (Borsheim et al., “Effect of amino acid supplementation on muscle mass, strength and physical function in elderly,” Clin Nutr 2008; 27:189-195). As used herein, a “performance-associated” injury or damage, such as a tissue injury or tissue damage, results from a functional activity, such as a physical or athletic performance.
The term “fusion protein” refers to a polypeptide comprising a polypeptide or fragment coupled to heterologous amino acid sequences. Fusion proteins are useful because they can be constructed to contain two or more desired functional elements that can be from two or more different proteins. A fusion protein comprises at least 10 contiguous amino acids from a polypeptide of interest, or at least 20 or 30 amino acids, or at least 40, 50 or 60 amino acids, or at least 75, 100 or 125 amino acids. The heterologous polypeptide included within the fusion protein is usually at least 6 amino acids in length, or at least 8 amino acids in length, or at least 15, 20, or 25 amino acids in length. Fusions that include larger polypeptides, such as an IgG Fc region, and even entire proteins, such as the green fluorescent protein (“GFP”) chromophore-containing proteins, have particular utility. Fusion proteins can be produced recombinantly by constructing a nucleic acid sequence which encodes the polypeptide or a fragment thereof in frame with a nucleic acid sequence encoding a different protein or peptide and then expressing the fusion protein. Alternatively, a fusion protein can be produced chemically by crosslinking the polypeptide or a fragment thereof to another protein.
Sequence homology for polypeptides, which is also referred to as percent sequence identity, is typically measured using sequence analysis software. See, e.g., the Sequence Analysis Software Package of the Genetics Computer Group (GCG), University of Wisconsin Biotechnology Center, 910 University Avenue, Madison, Wis. 53705. Protein analysis software matches similar sequences using a measure of homology assigned to various substitutions, deletions and other modifications, including conservative amino acid substitutions. For instance, GCG contains programs such as “Gap” and “Bestfit” which can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from different species of organisms or between a wild-type polypeptide and a mutein thereof. See, e.g., GCG Version 6. An exemplary algorithm when comparing a particular polypeptide sequence to a database containing a large number of sequences from different organisms is the computer program BLAST (Altschul et al., J. Mol. Biol. 215:403-410 (1990); Gish and States, Nature Genet. 3:266-272 (1993); Madden et al., Meth. Enzymol. 266:131-141 (1996); Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997); Zhang and Madden, Genome Res. 7:649-656 (1997)), especially blastp or tblastn (Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997)).
As used herein, a “gastrointestinal disorder” or a “gastrointestinal disease” includes any disorder or disease involving the gastrointestinal tract or region thereof, namely the esophagus, stomach, small intestine, large intestine or rectum, as well as organs and tissues associated with digestion, e.g., the pancreas, the gallbladder, and the liver.
As used herein, the term “heterotrophic” refers to an organism that cannot fix carbon and uses organic carbon for growth.
As used herein, a polypeptide has “homology” or is “homologous” to a second polypeptide if the nucleic acid sequence that encodes the polypeptide has a similar sequence to the nucleic acid sequence that encodes the second polypeptide. Alternatively, a polypeptide has homology to a second polypeptide if the two polypeptides have similar amino acid sequences. (Thus, the term “homologous polypeptides” is defined to mean that the two polypeptides have similar amino acid sequences.) When “homologous” is used in reference to polypeptides or peptides, it is recognized that residue positions that are not identical often differ by conservative amino acid substitutions. A “conservative amino acid substitution” is one in which an amino acid residue is substituted by another amino acid residue having a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). In general, a conservative amino acid substitution will not substantially change the functional properties of a polypeptide. In cases where two or more amino acid sequences differ from each other by conservative substitutions, the percent sequence identity or degree of homology can be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well known to those of skill in the art. See, e.g., Pearson, 1994, Methods Mol. Biol. 24:307-31 and 25:365-89. The following six groups each contain amino acids that are conservative substitutions for one another: 1) Serine, Threonine; 2) Aspartic Acid, Glutamic Acid; 3) Asparagine, Glutamine; 4) Arginine, Lysine; 5) Isoleucine, Leucine, Methionine, Alanine, Valine, and 6) Phenylalanine, Tyrosine, Tryptophan. In some embodiments, polymeric molecules (e.g., a polypeptide sequence or nucleic acid sequence) are considered to be homologous to one another if their sequences are at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, %, at least 97%, %, at least 98%, or at least 99% identical. In some embodiments, polymeric molecules are considered to be “homologous” to one another if their sequences are at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, %, at least 97%, %, at least 98%, or at least 99% similar. The term “homologous” necessarily refers to a comparison between at least two sequences (nucleotides sequences or amino acid sequences). In some embodiments, two nucleotide sequences are considered to be homologous if the polypeptides they encode are at least about 50% identical, at least about 60% identical, at least about 70% identical, at least about 80% identical, or at least about 90% identical for at least one stretch of at least about 10, 15, 20, 25, 30, 35, 40, 45, 50 or over 50 amino acids. In some embodiments, homologous nucleotide sequences are characterized by the ability to encode a stretch of at least 4-5 uniquely specified amino acids. Both the identity and the approximate spacing of these amino acids relative to one another must be considered for nucleotide sequences to be considered homologous. In some embodiments of nucleotide sequences less than 60 nucleotides in length, homology is determined by the ability to encode a stretch of at least 4-5 uniquely specified amino acids. In some embodiments, two polypeptide sequences are considered to be homologous if the polypeptides are at least about 50% identical, at least about 60% identical, at least about 70% identical, at least about 80% identical, or at least about 90% identical for at least one stretch of at least about 20 amino acids. In other embodiments, two polypeptide sequences are considered to be homologous if the polypeptides are similar, such as at least about 50% similar, at least about 60% similar, at least about 70% similar, at least about 80% similar, or at least about 90% similar, or at least about 95% similar for at least one stretch of at least about 20 amino acids. In some embodiments similarity is demonstrated by fewer nucleotide changes that result in an amino acid change (e.g., a nucleic acid sequence having a single nucleotide change is more similar to a reference nucleic acid sequence than a nucleic acid sequence having two nucleotide changes, even if both changes result in an identical amino acid substitution.
The term “in situ” refers to processes that occur in a living cell growing separate from a living organism, e.g., growing in tissue culture.
As used herein, the term “in vitro” refers to events that occur in an artificial environment, e.g., in a test tube or reaction vessel, in cell culture, in a Petri dish, etc., rather than within an organism (e.g., animal, plant, or microbe). As used herein, the term “ex vivo” refers to experimentation done in or on tissue in an environment outside the organism.
The term “in vivo” refers to processes that occur in a living organism.
As used herein, a “modified derivative” refers to polypeptides or fragments thereof that are substantially homologous in primary structural sequence to a reference polypeptide sequence but which include, e.g., in vivo or in vitro chemical and biochemical modifications or which incorporate amino acids that are not found in the reference polypeptide. Such modifications include, for example, acetylation, carboxylation, phosphorylation, glycosylation, ubiquitination, labeling, e.g., with radionuclides, and various enzymatic modifications, as will be readily appreciated by those skilled in the art. A variety of methods for labeling polypeptides and of substituents or labels useful for such purposes are well known in the art, and include radioactive isotopes such as 125I, 32P, 35S, and 3H, ligands that bind to labeled antiligands (e.g., antibodies), fluorophores, chemiluminescent agents, enzymes, and antiligands that can serve as specific binding pair members for a labeled ligand. The choice of label depends on the sensitivity required, ease of conjugation with the primer, stability-requirements, and available instrumentation. Methods for labeling polypeptides are well known in the art. See, e.g., Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates (1992, and Supplements to 2002).
As used herein, “muscle strength” refers to the amount of force a muscle can produce with a single maximal effort. There are two types of muscle strength, static strength and dynamic strength. Static strength refers to isometric contraction of a muscle, where a muscle generates force while the muscle length remains constant and/or when there is no movement in a joint. Examples include holding or carrying an object, or pushing against a wall. Dynamic strength refers to a muscle generating force that results in movement. Dynamic strength can be isotonic contraction, where the muscle shortens under a constant load or isokinetic contraction, where the muscle contracts and shortens at a constant speed. Dynamic strength can also include isoinertial strength. In addition, the term “muscle strength” refers to maximum dynamic muscle strength, as described by the term “one repetition maximum” (1RM). This is a measurement of the greatest load (in kilograms) that can be fully moved (lifted, pushed or pulled) once without failure or injury. This value can be measured directly, but doing so requires that the weight is increased until the subject fails to carry out the activity to completion. Alternatively, 1RM is estimated by counting the maximum number of exercise repetitions a subject can make using a load that is less than the maximum amount the subject can move. Leg extension and leg flexion are often measured in clinical trials (Borsheim et al., “Effect of amino acid supplementation on muscle mass, strength and physical function in elderly,” Clin Nutr 2008; 27:189-195; Paddon-Jones, et al., “Essential amino acid and carbohydrate supplementation ameliorates muscle protein loss in humans during 28 days bed rest,” J Clin Endocrinol Metab 2004; 89:4351-4358).
As used herein, “muscle mass” refers to the weight of muscle in a subject's body. Similarly, “muscle anabolism” includes the synthesis of muscle proteins, and is a component of the process by which muscle mass is gained. Muscle mass includes the skeletal muscles, smooth muscles (such as cardiac and digestive muscles) and the water contained in these muscles. Muscle mass of specific muscles can be determined using dual energy x-ray absorptiometry (DEXA) (Padden-Jones et al., 2004). Total lean body mass (minus the fat), total body mass, and bone mineral content can be measured by DEXA as well. In some embodiments a change in the muscle mass of a specific muscle of a subject is determined, for example by DEXA, and the change is used as a proxy for the total change in muscle mass of the subject. Thus, for example, if a subject consumes a nutritive protein as disclosed herein and experiences an increase over a period of time in muscle mass in a particular muscle or muscle group, it can be concluded that the subject has experienced an increase in muscle mass. Changes in muscle mass can be measured in a variety of ways including protein synthesis, fractional synthetic rate, and certain key activities such mTor/mTorc. In general, “lean muscle mass” refers to the mass of muscle tissue in the absence of other tissues such as fat.
The term “nucleic acid fragment” as used herein refers to a nucleic acid sequence that has a deletion, e.g., a 5′-terminal or 3′-terminal deletion compared to a full-length reference nucleotide sequence. In an embodiment, the nucleic acid fragment is a contiguous sequence in which the nucleotide sequence of the fragment is identical to the corresponding positions in the naturally-occurring sequence. In some embodiments, fragments are at least 10, 15, 20, or 25 nucleotides long, or at least 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 nucleotides long. In some embodiments a fragment of a nucleic acid sequence is a fragment of an open reading frame sequence. In some embodiments such a fragment encodes a polypeptide fragment (as defined herein) of the protein encoded by the open reading frame nucleotide sequence.
A composition, formulation or product is “nutritional” or “nutritive” if it provides an appreciable amount of nourishment to its intended consumer, meaning the consumer assimilates all or a portion of the composition or formulation into a cell, organ, and/or tissue. Generally such assimilation into a cell, organ and/or tissue provides a benefit or utility to the consumer, e.g., by maintaining or improving the health and/or natural function(s) of said cell, organ, and/or tissue. A nutritional composition or formulation that is assimilated as described herein is termed “nutrition.” By way of non-limiting example, a polypeptide is nutritional if it provides an appreciable amount of polypeptide nourishment to its intended consumer, meaning the consumer assimilates all or a portion of the protein, typically in the form of single amino acids or small peptides, into a cell, organ, and/or tissue. “Nutrition” also means the process of providing to a subject, such as a human or other mammal, a nutritional composition, formulation, product or other material. A nutritional product need not be “nutritionally complete,” meaning if consumed in sufficient quantity, the product provides all carbohydrates, lipids, essential fatty acids, essential amino acids, conditionally essential amino acids, vitamins, and minerals required for health of the consumer. Additionally, a “nutritionally complete protein” contains all protein nutrition required (meaning the amount required for physiological normalcy by the organism) but does not necessarily contain micronutrients such as vitamins and minerals, carbohydrates or lipids.
In preferred embodiments, a composition or formulation is nutritional in its provision of polypeptide capable of decomposition (i.e., the breaking of a peptide bond, often termed protein digestion) to single amino acids and/or small peptides (e.g., two amino acids, three amino acids, or four amino acids, possibly up to ten amino acids) in an amount sufficient to provide a “nutritional benefit.” In addition, in certain embodiments provided are nutritional polypeptides that transit across the gastrointestinal wall and are absorbed into the bloodstream as small peptides (e.g., larger than single amino acids but smaller than about ten amino acids) or larger peptides, oligopeptides or polypeptides (e.g., >11 amino acids). A nutritional benefit in a polypeptide-containing composition can be demonstrated and, optionally, quantified, by a number of metrics. For example, a nutritional benefit is the benefit to a consuming organism equivalent to or greater than at least about 0.5% of a reference daily intake value of protein, such as about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% or greater than about 100% of a reference daily intake value. Alternatively, a nutritional benefit is demonstrated by the feeling and/or recognition of satiety by the consumer. In other embodiments, a nutritional benefit is demonstrated by incorporation of a substantial amount of the polypeptide component of the composition or formulation into the cells, organs and/or tissues of the consumer, such incorporation generally meaning that single amino acids or short peptides are used to produce polypeptides de novo intracellularly. A “consumer” or a “consuming organism” means any animal capable of ingesting the product having the nutritional benefit. Typically, the consumer will be a mammal such as a healthy human, e.g., a healthy infant, child, adult, or older adult. Alternatively, the consumer will be a mammal such as a human (e.g., an infant, child, adult or older adult) at risk of developing or suffering from a disease, disorder or condition characterized by (i) the lack of adequate nutrition and/or (ii) the alleviation thereof by the nutritional products of the present invention. An “infant” is generally a human under about age 1 or 2, a “child” is generally a human under about age 18, and an “older adult” or “elderly” human is a human aged about 65 or older.
In other preferred embodiments, a composition or formulation is nutritional in its provision of carbohydrate capable of hydrolysis by the intended consumer (termed a “nutritional carbohydrate”). A nutritional benefit in a carbohydrate-containing composition can be demonstrated and, optionally, quantified, by a number of metrics. For example, a nutritional benefit is the benefit to a consuming organism equivalent to or greater than at least about 2% of a reference daily intake value of carbohydrate.
A polypeptide “nutritional domain” as used herein means any domain of a polypeptide that is capable of providing nutrition. Preferably, a polypeptide nutritional domain provides one or more advantages over the full-length polypeptide containing the nutritional domain, such as the nutritional domain provides more nutrition than the full-length polypeptide. For example, a polypeptide nutritional domain has a higher concentration of desirable amino acids, has a lower concentration of undesirable amino acids, contains a site for cleavage by a digestive protease, is easier to digest and/or is easier to produce from the digestion of a larger polypeptide, has improved storage characteristics, or a combination of these and/or other factors, in comparison to (i) a reference polypeptide or a reference polypeptide-containing mixture or composition, (ii) the protein(s) or polypeptide(s) present in an agriculturally-derived food product, and/or (iii) the protein or polypeptide products present in the diet of a mammalian subject. Other advantages of a polypeptide nutritional domain includes easier and/or more efficient production, different or more advantageous physiochemical properties, and/or has different s or more advantageous safety properties (e.g., elimination of one or more allergy domains) relative to full-length polypeptide. A reference polypeptide can be a naturally occurring polypeptide or a recombinantly produced polypeptide, which in turn may have an amino acid sequence identical to or different from a naturally occurring polypeptide. A reference polypeptide may also be a consensus amino acid sequence not present in a naturally-occurring polypeptide. Additionally, a reference polypeptide-containing mixture or composition can be a naturally-occurring mixture, such as a mixture of polypeptides present in a dairy product such as milk or whey, or can be a synthetic mixture of polypeptides (which, in turn, can be naturally-occurring or synthetic). In certain embodiments the nutritional domain contains an amino acid sequence having an N-terminal amino acid and/or a C-terminal amino acid different from the N-terminal amino acid and/or a C-terminal amino acid of a reference secreted polypeptide, such as a full-length secreted polypeptide. For example, a nutritional domain has an N-terminal amino acid sequence that corresponds to an amino acid sequence internal to a larger secreted polypeptide that contains the nutritional domain. A nutritional domain may include or exclude a signal sequence of a larger secreted polypeptide. As used herein, a polypeptide that “contains” a polypeptide nutritional domain contains the entirety of the polypeptide nutritional domain as well as at least one additional amino acid, either N-terminal or C-terminal to the polypeptide nutritional domain. Generally polypeptide nutritional domains are secreted from the cell or organism containing a nucleic acid encoding the nutritional domain, and are termed “secreted polypeptide nutritional domains,” and, in circumstances wherein the nutritional domain is secreted from a unicellular (or single celled) organism, it is termed a “unicellular secreted polypeptide nutritional domain.”
In other preferred embodiments, a composition or formulation is nutritional in its provision of lipid capable of digestion, incorporation, conversion, or other cellular uses by the intended consumer (termed a “nutritional lipid”). A nutritional benefit in a lipid-containing composition can be demonstrated and, optionally, quantified, by a number of metrics. For example, a nutritional benefit is the benefit to a consuming organism equivalent to or greater than at least about 2% of a reference daily intake value of lipid (i.e., fat).
As used herein, an “obese” subject has a level of excess body fat that, increasing the likelihood of the subject suffering from diseases including heart disease, type II diabetes, osteoporosis and osteoarthritis, and cancer, while an “overweight” subject is above a weight recognized as normal, acceptable, or desirable, but not obese. In Western countries, a subject having a BMI value exceeding 30 is considered obese, while a subject having a BMI value between 25-30 is considered overweight.
As used herein, “operatively linked” or “operably linked” expression control sequences refers to a linkage in which the expression control sequence is contiguous with the gene of interest to control the gene of interest, as well as expression control sequences that act in trans or at a distance to control the gene of interest.
The term “percent sequence identity” or “identical” in the context of nucleic acid sequences refers to the residues in the two sequences that are the same when aligned for maximum correspondence. There are a number of different algorithms known in the art that can be used to measure nucleotide sequence identity. For instance, polynucleotide sequences can be compared using FASTA, Gap or Bestfit, which are programs in Wisconsin Package Version 10.0, Genetics Computer Group (GCG), Madison, Wis. FASTA provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences. Pearson, Methods Enzymol. 183:63-98 (1990).
The term “polynucleotide,” “nucleic acid molecule,” “nucleic acid,” or “nucleic acid sequence” refers to a polymeric form of nucleotides of at least 10 bases in length. The term includes DNA molecules (e.g., cDNA or genomic or synthetic DNA) and RNA molecules (e.g., mRNA or synthetic RNA), as well as analogs of DNA or RNA containing non-natural nucleotide analogs, non-native internucleoside bonds, or both. The nucleic acid can be in any topological conformation. For instance, the nucleic acid can be single-stranded, double-stranded, triple-stranded, quadruplexed, partially double-stranded, branched, hairpinned, circular, or in a padlocked conformation. A “synthetic” RNA, DNA or a mixed polymer is one created outside of a cell, for example one synthesized chemically. The term “nucleic acid fragment” as used herein refers to a nucleic acid sequence that has a deletion, e.g., a 5′-terminal or 3′-terminal deletion of one or more nucleotides compared to a full-length reference nucleotide sequence. In an embodiment, the nucleic acid fragment is a contiguous sequence in which the nucleotide sequence of the fragment is identical to the corresponding positions in the naturally-occurring sequence. In some embodiments, fragments are at least 10, 15, 20, or 25 nucleotides long, or at least 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800 or greater than 1800 nucleotides long. In some embodiments a fragment of a nucleic acid sequence is a fragment of an open reading frame sequence. In some embodiments such a fragment encodes a polypeptide fragment (as defined herein) of the polypeptide encoded by the open reading frame nucleotide sequence.
The terms “polypeptide” and “protein” can be interchanged, and these terms encompass both naturally-occurring and non-naturally occurring polypeptides, and, as provided herein or as generally known in the art, fragments, mutants, derivatives and analogs thereof. A polypeptide can be monomeric, meaning it has a single chain, or polymeric, meaning it is composed of two or more chains, which can be covalently or non-covalently associated. Further, a polypeptide may comprise a number of different domains each of which has one or more distinct activities. For the avoidance of doubt, a polypeptide can be any length greater than or equal to two amino acids. The term “isolated polypeptide” is a polypeptide that by virtue of its origin or source of derivation (1) is not associated with naturally associated components that accompany it in any of its native states, (2) exists in a purity not found in nature, where purity can be adjudged with respect to the presence of other cellular material (e.g., is free of other polypeptides from the same species or from the host species in which the polypeptide was produced) (3) is expressed by a cell from a different species, (4) is recombinantly expressed by a cell (e.g., a polypeptide is an “isolated polypeptide” if it is produced from a recombinant nucleic acid present in a host cell and separated from the producing host cell, (5) does not occur in nature (e.g., it is a domain or other fragment of a polypeptide found in nature or it includes amino acid analogs or derivatives not found in nature or linkages other than standard peptide bonds), or (6) is otherwise produced, prepared, and/or manufactured by the hand of man. Thus, an “isolated polypeptide” includes a polypeptide that is produced in a host cell from a recombinant nucleic acid (such as a vector), regardless of whether the host cell naturally produces a polypeptide having an identical amino acid sequence. A “polypeptide” includes a polypeptide that is produced by a host cell via overexpression, e.g., homologous overexpression of the polypeptide from the host cell such as by altering the promoter of the polypeptide to increase its expression to a level above its normal expression level in the host cell in the absence of the altered promoter. A polypeptide that is chemically synthesized or synthesized in a cellular system different from a cell from which it naturally originates will be “isolated” from its naturally associated components. A polypeptide may also be rendered substantially free of naturally associated components by isolation, using protein purification techniques well known in the art. As thus defined, “isolated” does not necessarily require that the protein, polypeptide, peptide or oligopeptide so described has been physically removed from a cell in which it was synthesized.
The term “polypeptide fragment” or “protein fragment” as used herein refers to a polypeptide or domain thereof that has less amino acids compared to a reference polypeptide, e.g., a full-length polypeptide or a polypeptide domain of a naturally occurring protein. A “naturally occurring protein” or “naturally occurring polypeptide” includes a polypeptide having an amino acid sequence produced by a non-recombinant cell or organism. In an embodiment, the polypeptide fragment is a contiguous sequence in which the amino acid sequence of the fragment is identical to the corresponding positions in the naturally-occurring sequence. Fragments typically are at least 5, 6, 7, 8, 9 or 10 amino acids long, or at least 12, 14, 16 or 18 amino acids long, or at least 20 amino acids long, or at least 25, 30, 35, 40 or 45, amino acids, or at least 50, 60, 70, 80, 90 or 100 amino acids long, or at least 110, 120, 130, 140, 150, 160, 170, 180, 190 or 200 amino acids long, or 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600 or greater than 600 amino acids long. A fragment can be a portion of a larger polypeptide sequence that is digested inside or outside the cell. Thus, a polypeptide that is 50 amino acids in length can be produced intracellularly, but proteolyzed inside or outside the cell to produce a polypeptide less than 50 amino acids in length. This is of particular significance for polypeptides shorter than about 25 amino acids, which can be more difficult than larger polypeptides to produce recombinantly or to purify once produced recombinantly. The term “peptide” as used herein refers to a short polypeptide or oligopeptide, e.g., one that typically contains less than about 50 amino acids and more typically less than about 30 amino acids, or more typically less than about 15 amino acids, such as less than about 10, 9, 8, 7, 6, 5, 4, or 3 amino acids. The term as used herein encompasses analogs and mimetics that mimic structural and thus biological function.
As used herein, “polypeptide mutant” or “mutein” refers to a polypeptide whose sequence contains an insertion, duplication, deletion, rearrangement or substitution of one or more amino acids compared to the amino acid sequence of a reference protein or polypeptide, such as a native or wild-type protein. A mutein may have one or more amino acid point substitutions, in which a single amino acid at a position has been changed to another amino acid, one or more insertions and/or deletions, in which one or more amino acids are inserted or deleted, respectively, in the sequence of the reference protein, and/or truncations of the amino acid sequence at either or both the amino or carboxy termini. A mutein may have the same or a different biological activity compared to the reference protein. In some embodiments, a mutein has, for example, at least 85% overall sequence homology to its counterpart reference protein. In some embodiments, a mutein has at least 90% overall sequence homology to the wild-type protein. In other embodiments, a mutein exhibits at least 95% sequence identity, or 98%, or 99%, or 99.5% or 99.9% overall sequence identity.
As used herein, a “polypeptide tag for affinity purification” is any polypeptide that has a binding partner that can be used to isolate or purify a second protein or polypeptide sequence of interest fused to the first “tag” polypeptide. Several examples are well known in the art and include a His-6 tag, a FLAG epitope, a c-myc epitope, a Strep-TAGII, a biotin tag, a glutathione 5-transferase (GST), a chitin binding protein (CBP), a maltose binding protein (MBP), or a metal affinity tag.
As used herein, “protein-energy malnutrition” refers to a form of malnutrition where there is inadequate protein intake. Types include Kwashiorkor (protein malnutrition predominant), Marasmus (deficiency in both calorie and protein nutrition), and Marasmic Kwashiorkor (marked protein deficiency and marked calorie insufficiency signs present, sometimes referred to as the most severe form of malnutrition). “Malnourishment” and “malnutrition” are used equivalently herein.
The terms “purify,” “purifying” and “purified” refer to a substance (or entity, composition, product or material) that has been separated from at least some of the components with which it was associated either when initially produced (whether in nature or in an experimental setting), or during any time after its initial production. A substance such as a nutritional polypeptide will be considered purified if it is isolated at production, or at any level or stage up to and including a final product, but a final product may contain other materials up to about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or above about 90% and still be considered “isolated.” Purified substances or entities can be separated from at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or more of the other components with which they were initially associated. In some embodiments, purified substances are more than about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more than about 99% pure. In the instance of polypeptides and other polypeptides provided herein, such a polypeptide can be purified from one or more other polypeptides capable of being secreted from the unicellular organism that secretes the polypeptide. As used herein, a polypeptide substance is “pure” if it is substantially free of other components or other polypeptide components.
As used herein, “recombinant” refers to a biomolecule, e.g., a gene or polypeptide, that (1) has been removed from its naturally occurring environment, (2) is not associated with all or a portion of a polynucleotide in which the gene is found in nature, (3) is operatively linked to a polynucleotide which it is not linked to in nature, or (4) does not occur in nature. Also, “recombinant” refers to a cell or an organism, such as a unicellular organism, herein termed a “recombinant unicellular organism,” a “recombinant host” or a “recombinant cell” that contains, produces and/or secretes a biomolecule, which can be a recombinant biomolecule or a non-recombinant biomolecule. For example, a recombinant unicellular organism may contain a recombinant nucleic acid providing for enhanced production and/or secretion of a recombinant polypeptide or a non-recombinant polypeptide. A recombinant cell or organism, is also intended to refer to a cell into which a recombinant nucleic acid such as a recombinant vector has been introduced. A “recombinant unicellular organism” includes a recombinant microorganism host cell and refers not only to the particular subject cell but to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the terms herein. The term “recombinant” can be used in reference to cloned DNA isolates, chemically-synthesized polynucleotide analogs, or polynucleotide analogs that are biologically synthesized by heterologous systems, as well as polypeptides and/or mRNAs encoded by such nucleic acids. Thus, for example, a polypeptide synthesized by a microorganism is recombinant, for example, if it is produced from an mRNA transcribed from a recombinant gene or other nucleic acid sequence present in the cell.
As used herein, an endogenous nucleic acid sequence in the genome of an organism (or the encoded polypeptide product of that sequence) is deemed “recombinant” herein if a heterologous sequence is placed adjacent to the endogenous nucleic acid sequence, such that the expression of this endogenous nucleic acid sequence is altered. In this context, a heterologous sequence is a sequence that is not naturally adjacent to the endogenous nucleic acid sequence, whether or not the heterologous sequence is itself endogenous (originating from the same host cell or progeny thereof) or exogenous (originating from a different host cell or progeny thereof). By way of example, a promoter sequence can be substituted (e.g., by homologous recombination) for the native promoter of a gene in the genome of a host cell, such that this gene has an altered expression pattern. This gene would now become “recombinant” because it is separated from at least some of the sequences that naturally flank it. A nucleic acid is also considered “recombinant” if it contains any modifications that do not naturally occur to the corresponding nucleic acid in a genome. For instance, an endogenous coding sequence is considered “recombinant” if it contains an insertion, deletion or a point mutation introduced artificially, e.g., by human intervention. A “recombinant nucleic acid” also includes a nucleic acid integrated into a host cell chromosome at a heterologous site and a nucleic acid construct present as an episome.
The term “recombinant host cell” (or simply “recombinant cell” or “host cell”), as used herein, is intended to refer to a cell into which a recombinant nucleic acid such as a recombinant vector has been introduced. In some instances the word “cell” is replaced by a name specifying a type of cell. For example, a “recombinant microorganism” is a recombinant host cell that is a microorganism host cell and a “recombinant cyanobacteria” is a recombinant host cell that is a cyanobacteria host cell. It should be understood that such terms are intended to refer not only to the particular subject cell but to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term “recombinant host cell,” “recombinant cell,” and “host cell”, as used herein. A recombinant host cell can be an isolated cell or cell line grown in culture or can be a cell which resides in a living tissue or organism.
As used herein, “sarcopenia” refers to the degenerative loss of skeletal muscle mass (typically 0.5-1% loss per year after the age of 25), quality, and strength associated with aging. Sarcopenia is a component of the frailty syndrome. The European Working Group on Sarcopenia in Older People (EWGSOP) has developed a practical clinical definition and consensus diagnostic criteria for age-related sarcopenia. For the diagnosis of sarcopenia, the working group has proposed using the presence of both low muscle mass and low muscle function (strength or performance). Sarcopenia is characterized first by a muscle atrophy (a decrease in the size of the muscle), along with a reduction in muscle tissue “quality,” caused by such factors as replacement of muscle fibres with fat, an increase in fibrosis, changes in muscle metabolism, oxidative stress, and degeneration of the neuromuscular junction. Combined, these changes lead to progressive loss of muscle function and eventually to frailty. Frailty is a common geriatric syndrome that embodies an elevated risk of catastrophic declines in health and function among older adults. Contributors to frailty can include sarcopenia, osteoporosis, and muscle weakness. Muscle weakness, also known as muscle fatigue, (or “lack of strength”) refers to the inability to exert force with one's skeletal muscles. Weakness often follows muscle atrophy and a decrease in activity, such as after a long bout of bedrest as a result of an illness. There is also a gradual onset of muscle weakness as a result of sarcopenia. Thus, sarcopenia is an exemplary condition associated with muscle wasting.
As used herein, “satiation” is the act of becoming full while eating or a reduced desire to eat. This halts or diminishes eating.
As used herein, “satiety” is the act of remaining full after a meal which manifests as the period of no eating follow the meal.
As used herein, “secrete,” “secretion” and “secreted” all refer to the act or process by which a polypeptide is relocated from the cytoplasm of a cell of a multicellular organism or unicellular organism into the extracellular milieu thereof. As provided herein, such secretion may occur actively or passively. Further, the terms “excrete,” “excretion” and “excreted” generally connote passive clearing of a material from a cell or unicellular organism; however, as appropriate such terms can be associated with the production and transfer of materials outwards from the cell or unicellular organism.
In general, “stringent hybridization” is performed at about 25° C. below the thermal melting point (Tm) for the specific DNA hybrid under a particular set of conditions. “Stringent washing” is performed at temperatures about 5° C. lower than the Tm for the specific DNA hybrid under a particular set of conditions. The Tm is the temperature at which 50% of the target sequence hybridizes to a perfectly matched probe. See Sambrook et al., Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989), page 9.51, hereby incorporated by reference. For purposes herein, “stringent conditions” are defined for solution phase hybridization as aqueous hybridization (i.e., free of formamide) in 6×SSC (where 20×SSC contains 3.0 M NaCl and 0.3 M sodium citrate), 1% SDS at 65° C. for 8-12 hours, followed by two washes in 0.2×SSC, 0.1% SDS at 65° C. for 20 minutes. It will be appreciated by the skilled worker that hybridization at 65° C. will occur at different rates depending on a number of factors including the length and percent identity of the sequences which are hybridizing.
The term “substantial homology” or “substantial similarity,” when referring to a nucleic acid or fragment thereof, indicates that, when optimally aligned with appropriate nucleotide insertions or deletions with another nucleic acid (or its complementary strand), there is nucleotide sequence identity in at least about 76%, 80%, 85%, or at least about 90%, or at least about 95%, 96%, 97%, 98% or 99% of the nucleotide bases, as measured by any well-known algorithm of sequence identity, such as FASTA, BLAST or Gap, as discussed above.
The term “sufficient amount” means an amount sufficient to produce a desired effect, e.g., an amount sufficient to modulate protein aggregation in a cell.
A “synthetic” RNA, DNA or a mixed polymer is one created outside of a cell, for example one synthesized chemically.
The term “therapeutically effective amount” is an amount that is effective to ameliorate a symptom of a disease. A therapeutically effective amount can be a “prophylactically effective amount” as prophylaxis can be considered therapy.
As used herein, “thermogenesis” is the process of heat production in a mammal. Thermogenesis is accompanied by an increase in energy expenditure. Thermogenesis is specifically the energy burned following the metabolism of a food component (such as protein). This may also be referred to as the thermic effect of food. Total energy expenditure by an individual equals the sum of resting energy expenditure (energy consumed at rest in a fasting state to support basal metabolism), the thermic effect of food, and energy expenditure related to physical activity. Resting energy expenditure accounts for about 65-75% of total energy expenditure in humans. The amount and activity of muscle mass is one influencer of resting energy expenditure. Adequate protein consumption to support muscle also influences resting energy expenditure. The ingestion of protein tends to increase energy expenditure following a meal; this is the thermic effect of food. The thermic effect of food accounts for about 10% of total energy expenditure in humans. While this is a small proportion of total energy expenditure, small increases in this value can impact body weight. Protein has a higher thermic effect than fat or carbohydrate; this effect along with other metabolic influences of protein makes it a useful substrate for weight control, diabetes management and other conditions.
As used herein, a “vector” is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a “plasmid,” which generally refers to a circular double stranded DNA loop into which additional DNA segments can be ligated, but also includes linear double-stranded molecules such as those resulting from amplification by the polymerase chain reaction (PCR) or from treatment of a circular plasmid with a restriction enzyme. Other vectors include cosmids, bacterial artificial chromosomes (BAC) and yeast artificial chromosomes (YAC). Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome (discussed in more detail below). Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., vectors having an origin of replication which functions in the host cell). Other vectors can be integrated into the genome of a host cell upon introduction into the host cell, and are thereby replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as “recombinant expression vectors” (or simply “expression vectors”).
Nutritive Polypeptides and Amino Acid Sequences
Proteins present in dietary food sources can vary greatly in their nutritive value. Provided are nutritive polypeptides that have enhanced nutritive value and physiological and pharmacological effects due to their amino acid content and digestibility. Provided are nutritive polypeptides that have enhanced levels of essential amino acids, the inadequate availability of such essential amino acids in a person negatively impacts general health and physiology through the perturbation of a network of cellular functions, and is associated with a wide array of health issues and diseases. Also provided are nutritive polypeptides that have reduced levels of certain amino acids, the presence or overabundance of such amino acids in the diet of an affected subject results in increased morbidity and mortality.
Traditionally, nutritionists and health researchers have utilized specific source ingredients (e.g., whey protein, egg whites, soya) or fractionates and isolates (e.g., soy protein isolates) to modulate the relative concentration of total protein in the diet, without the ability to modulate the specific amino acid constituents.
Herein provided are nutritive polypeptides capable of transforming health and treating, preventing and reducing the severity of a multitude of diseases, disorders and conditions associated with amino acid pathophysiology, as they are selected for specific physiologic benefits to improve health and address many nutrition-related conditions, including gastrointestinal malabsorption, muscle wasting, diabetes or pre-diabetes, obesity, oncology, metabolic diseases, and other cellular and systemic diseases. Also provided are the compositions and formulations that contain the nutritive polypeptides, as food, beverages, medical foods, supplements, and pharmaceuticals.
Herein are provided important elucidations in the genomics, proteomics, protein characterization and production of nutritive polypeptides. The present invention utilizes the synergistic advancements, described herein, of (a) the genomics of edible species—those human food source organisms, and human genomics, (b) substantial advances in protein identification and quantification in food protein and food nucleic acid libraries, (c) new correlations between protein physical chemistry, solubility, structure-digestibility relationships and amino acid absorption and metabolism in animals and humans, (d) physiology and pathophysiology information of how amino acids, the components of nutritive polypeptides, affect protein malnutrition, chronic disease, responses to acute injury, and aging, (e) recombinant nutritive polypeptide production utilizing a phylogenetically broad spectrum of host organisms, (f) qualification of allergenicity and toxicogenicity and in vitro and in vivo tests to assess human safety of orally consumed nutritive polypeptides.
Identification and Selection of Amino Acid Sequences Encoding Nutritive. Polypeptides.
In its broadest sense, a nutritive polypeptide encompasses a polypeptide capable of delivering amino acid and peptide nutrition to its intended consumer, who derives a benefit from such consumption. Each nutritive polypeptide contains one or more amino acid sequences, and the present invention provides methods by which an amino acid sequence is identified and utilized in production, formulation and administration of the nutritive polypeptide having such an amino acid sequence.
In some embodiments, the source of a nutritive polypeptide amino acid sequence encompasses any protein-containing material, e.g., a food, beverage, composition or other product, known to be eaten, or otherwise considered suitable for consumption, without deleterious effect by, e.g., a human or other organism, in particular a mammal.
Nutritive Polypeptide Amino Acid Sequences Derived from Edible Species.
In some embodiments a nutritive polypeptide comprises or consists of a protein or fragment of a protein that naturally occurs in an edible product, such as a food, or in the organism that generates biological material used in or as the food. In some embodiments an “edible species” is a species known to produce a protein that can be eaten by humans without deleterious effect. A protein or polypeptide present in an edible species, or encoded by a nucleic acid present in the edible species, is termed an “edible species protein” or “edible species polypeptide” or, if the edible species is a species consumed by a human, the term “naturally occurring human food protein” is used interchangeably herein. Some edible products are an infrequent but known component of the diet of only a small group of a type of mammal in a limited geographic location while others are a dietary staple throughout much of the world. In other embodiments an edible product is one not known to be previously eaten by any mammal, but that is demonstrated to be edible upon testing or analysis of the product or one or more proteins contained in the product.
Food organisms include but are not limited to those organisms of edible species disclosed in PCT/US2013/032232, filed Mar. 15, 2013, PCT/US2013/032180, filed Mar. 15, 2013, PCT/US2013/032225, filed Mar. 15, 2013, PCT/US2013/032218, filed Mar. 15, 2013, PCT/US2013/032212, filed Mar. 15, 2013, PCT/US2013/032206, filed Mar. 15, 2013, and PCT/US2013/038682, filed Apr. 29, 2013 and any phylogenetically related organisms.
In some embodiments a nutritive polypeptide amino acid sequence is identified in a protein that is present in a food source, such as an abundant protein in food, or is a derivative or mutein thereof, or is a fragment of an amino acid sequence of a protein in food or a derivative or mutein thereof. An abundant protein is a protein that is present in a higher concentration in a food relative to other proteins present in the food. Alternatively, a nutritive polypeptide amino acid sequence is identified from an edible species that produces a protein containing the amino acid sequence in relatively lower abundance, but the protein is detectable in a food product derived from the edible species, or from biological material produced by the edible species. In some embodiments a nucleic acid that encodes the protein is detectable in a food product derived from the edible species, or the nucleic acid is detectable from a biological material produced by the edible species. An edible species can produce a food that is a known component of the diet of only a small group of a type of mammal in a limited geographic location, or a dietary staple throughout much of the world.
Exemplary edible species include animals such as goats, cows, chickens, pigs and fish. In some embodiments the abundant protein in food is selected from chicken egg proteins such as ovalbumin, ovotransferrin, and ovomucuoid; meat proteins such as myosin, actin, tropomyosin, collagen, and troponin; cereal proteins such as casein, alpha1 casein, alpha2 casein, beta casein, kappa casein, beta-lactoglobulin, alpha-lactalbumin, glycinin, beta-conglycinin, glutelin, prolamine, gliadin, glutenin, albumin, globulin; chicken muscle proteins such as albumin, enolase, creatine kinase, phosphoglycerate mutase, triosephosphate isomerase, apolipoprotein, ovotransferrin, phosphoglucomutase, phosphoglycerate kinase, glycerol-3-phosphate dehydrogenase, glyceraldehyde 3-phosphate dehydrogenase, hemoglobin, cofilin, glycogen phosphorylase, fructose-1,6-bisphosphatase, actin, myosin, tropomyosin a-chain, casein kinase, glycogen phosphorylase, fructose-1,6-bisphosphatase, aldolase, tubulin, vimentin, endoplasmin, lactate dehydrogenase, destrin, transthyretin, fructose bisphosphate aldolase, carbonic anhydrase, aldehyde dehydrogenase, annexin, adenosyl homocysteinase; pork muscle proteins such as actin, myosin, enolase, titin, cofilin, phosphoglycerate kinase, enolase, pyruvate dehydrogenase, glycogen phosphorylase, triosephosphate isomerase, myokinase; and fish proteins such as parvalbumin, pyruvate dehydrogenase, desmin, and triosephosphate isomerase.
Nutritive polypeptides may contain amino acid sequences present in edible species polypeptides. In one embodiment, a biological material from an edible species is analyzed to determine the protein content in the biological material. An exemplary method of analysis is to use mass spectrometry analysis of the biological material, as provided in the Examples below. Another exemplary method of analysis is to generate a cDNA library of the biological material to create a library of edible species cDNAs, and then express the cDNA library in an appropriate recombinant expression host, as provided in the Examples below. Another exemplary method of analysis is query a nucleic acid and/or protein sequence database as provided in the Examples below.
Determination of Amino Acid Ratios and Amino Acid Density in a Nutritive Polypeptide.
In some instances herein the portion of amino acid(s) of a particular type within a polypeptide, protein or a composition is quantified based on the weight ratio of the type of amino acid(s) to the total weight of amino acids present in the polypeptide, protein or composition in question. This value is calculated by dividing the weight of the particular amino acid(s) in the polypeptide, protein or a composition by the weight of all amino acids present in the polypeptide, protein or a composition.
In other instances the ratio of a particular type of amino acid(s) residues present in a polypeptide or protein to the total number of amino acids present in the polypeptide or protein in question is used. This value is calculated by dividing the number of the amino acid(s) in question that is present in each molecule of the polypeptide or protein by the total number of amino acid residues present in each molecule of the polypeptide or protein. A skilled artisan appreciates that these two methods are interchangeable and that the weight proportion of a type of amino acid(s) present in a polypeptide or protein can be converted to a ratio of the particular type of amino acid residue(s), and vice versa.
In some aspects the nutritive polypeptide is selected to have a desired density of one or more essential amino acids (EAA). Essential amino acid deficiency can be treated or prevented with the effective administration of the one or more essential amino acids otherwise absent or present in insufficient amounts in a subject's diet. For example, EAA density is about equal to or greater than the density of essential amino acids present in a full-length reference nutritional polypeptide, such as bovine lactoglobulin, bovine beta-casein or bovine type I collagen, e.g., EAA density in a nutritive polypeptide is at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 200%, 300%, 400%, 500% or above 500% greater than a reference nutritional polypeptide or the polypeptide present in an agriculturally-derived food product.
In some aspects the nutritive polypeptide is selected to have a desired density of aromatic amino acids (“AAA”, including phenylalanine, tryptophan, tyrosine, histidine, and thyroxine). AAAs are useful, e.g., in neurological development and prevention of exercise-induced fatigue. For example, AAA density is about equal to or greater than the density of essential amino acids present in a full-length reference nutritional polypeptide, such as bovine lactoglobulin, bovine beta-casein or bovine type I collagen, e.g., AAA density in a nutritive polypeptide is at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 200%, 300%, 400%, 500% or above 500% greater than a reference nutritional polypeptide or the polypeptide present in an agriculturally-derived food product.
In some aspects the nutritive polypeptide is selected to have a desired density of branched chain amino acids (BCAA). For example, BCAA density, either individual BCAAs or total BCAA content is about equal to or greater than the density of branched chain amino acids present in a full-length reference nutritional polypeptide, such as bovine lactoglobulin, bovine beta-casein or bovine type I collagen, e.g., BCAA density in a nutritive polypeptide is at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 200%, 300%, 400%, 500% or above 500% greater than a reference nutritional polypeptide or the polypeptide present in an agriculturally-derived food product. BCAA density in a nutritive polypeptide can also be selected for in combination with one or more attributes such as EAA density.
In some aspects the nutritive polypeptide is selected to have a desired density of amino acids arginine, glutamine and/or leucine (RQL amino acids). For example, RQL amino acid density is about equal to or greater than the density of essential amino acids present in a full-length reference nutritional polypeptide, such as bovine lactoglobulin, bovine beta-casein or bovine type I collagen, e.g., RQL amino acid density in a nutritive polypeptide is at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 200%, 300%, 400%, 500% or above 500% greater than a reference nutritional polypeptide or the polypeptide present in an agriculturally-derived food product.
In some aspects the nutritive polypeptide is selected to have a desired density or distribution of post-translational modifications (PTMs). For example, PTMs include addition, removal or redistribution of biotinylation, pegylation, acylation, alkylation, butyrylation, glycosylation, hydroxylation, iodination, oxidation, propionylation, malonylation, myristoylation, palmitoylation, isoprenylation, succinylation, selenoylation, SUMOylation, ubiquitination, and glypiation removal or redistribution of disulfide bridges.
In certain embodiments herein the weight proportion of branched chain amino acids, leucine, and/or essential amino acids in whey, egg, or soy is used as a benchmark to measure the amino acid composition of a polypeptide, a protein, or a composition comprising at least one of a polypeptide and a protein. In those embodiments it is understood that the two measures are not completely equivalent, but it is also understood that the measures result in measurements that are similar enough to use for this purpose. For example, when a protein of interest is characterized as comprising a ratio of branched chain amino acid residues to total amino acid residues that is equal to or greater than 24% (the weight proportion of branched chain amino acid residues present in whey), that is a precise description of the branched chain amino acid content of the protein. At the same time, the weight proportion of branched chain amino acid residues present in that protein is not necessarily exactly equal to 24%. Even so, the skilled artisan understands that this is a useful comparison. If provided with the total number of amino acid residues present in the protein of interest the skilled artisan can also determine the weight proportion of branched chain amino acid residues in the protein of interest.
In some embodiments a protein according to this disclosure comprises a first polypeptide sequence comprising a fragment of an edible species polypeptide. In some embodiments of the nutritrive protein, the protein consists of the first polypeptide sequence. In some embodiments of the nutritrive protein, the protein consists of the fragment of an edible species polypeptide.
In some embodiments a protein according to this disclosure comprises a first polypeptide sequence that comprises ratio of branched chain amino acid residues to total amino acid residues that is equal to or greater than the ratio of branched chain amino acid residues to total amino acid residues present in at least one of whey protein, egg protein, and soy protein. Thus, in such embodiments the protein comprises a first polypeptide sequence that comprises a ratio of branched chain amino acid residues to total amino acid residues that is equal to or greater than a ratio selected from 24%, 20%, and 18%. In other embodiments, the protein comprises a first polypeptide sequence that comprises a ratio of branched chain amino acid residues to total amino acid residues that is equal to or greater than a percentage ratio selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 75, 80, 85, 90, 95, or 100%.
In some embodiments a protein according to this disclosure comprises a first polypeptide sequence that comprises a ratio of L (leucine) residues to total amino acid residues that is equal to or greater than the ratio of L residues to total amino acid residues present in at least one of whey protein, egg protein, and soy protein. In other embodiments, the protein comprises a first polypeptide sequence that comprises a ratio of leucine residues to total amino acid residues that is equal to or greater than a percentage ratio selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or greater than 30%.
In some embodiments a protein according to this disclosure comprises a first polypeptide sequence that comprises a ratio of essential amino acid residues to total amino acid residues that is equal to or greater than the ratio of essential amino acid residues to total amino acid residues present in at least one of whey protein, egg protein, and soy protein. In other embodiments, the protein comprises a first polypeptide sequence that comprises a ratio of essential chain amino acid residues to total amino acid residues that is equal to or greater than a percentage ratio selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 75, 80, 85, 90, 95, or 100%.
In some embodiments the protein comprises a first polypeptide sequence that comprises a ratio of branched chain amino acid residues to total amino acid residues that is equal to or greater than the ratio of branched chain amino acid residues to total amino acid residues present in at least one of whey protein, egg protein, and soy protein; and/or comprises a first polypeptide sequence that comprises a ratio ofL (leucine) residues to total amino acid residues that is equal to or greater than the ratio of L residues to total amino acid residues present in at least one of whey protein, egg protein, and soy protein, and/or comprises a first polypeptide sequence that comprises a ratio of essential amino acid residues to total amino acid residues that is equal to or greater than the ratio of essential amino acid residues to total amino acid residues present in at least one of whey protein, egg protein, and soy protein.
In some embodiments the protein comprises a first polypeptide sequence that comprises a ratio of branched chain amino acid residues to total amino acid residues that is equal to or greater than the ratio of branched chain amino acid residues to total amino acid residues present in at least one of whey protein, egg protein, and soy protein; and comprises a first polypeptide sequence that comprises a ratio of essential amino acid residues to total amino acid residues that is equal to or greater than the ratio of essential amino acid residues to total amino acid residues present in at least one of whey protein, egg protein, and soy protein. In some embodiments the protein comprises a first polypeptide sequence that comprises a ratio of branched chain amino acid residues to total amino acid residues equal to or greater than 24% and a ratio of essential amino acid residues to total amino acid residues that is equal to or greater than 49%. In some embodiments the protein comprises a first polypeptide sequence that comprises a ratio of branched chain amino acid residues to total amino acid residues equal to or greater than 20% and a ratio of essential amino acid residues to total amino acid residues that is equal to or greater than 51%. In some embodiments the protein comprises a first polypeptide sequence that comprises a ratio of branched chain amino acid residues to total amino acid residues equal to or greater than 18% and a ratio of essential amino acid residues to total amino acid residues that is equal to or greater than 40%.
In some embodiments the protein comprises a first polypeptide sequence that comprises a ratio of L (leucine) residues to total amino acid residues that is equal to or greater than the ratio of L residues to total amino acid residues present in at least one of whey protein, egg protein, and soy protein; and comprises a first polypeptide sequence that comprises a ratio of essential amino acid residues to total amino acid residues that is equal to or greater than the ratio of essential amino acid residues to total amino acid residues present in at least one of whey protein, egg protein, and soy protein. In some embodiments the protein comprises a first polypeptide sequence that comprises a ratio of L (leucine) residues to total amino acid residues equal to or greater than 11% and a ratio of essential amino acid residues to total amino acid residues that is equal to or greater than 49%. In some embodiments the protein comprises a first polypeptide sequence that comprises a ratio of L (leucine) amino acid residues to total amino acid residues equal to or greater than 9% and a ratio of essential amino acid residues to total amino acid residues that is equal to or greater than 51%. In some embodiments the protein comprises a first polypeptide sequence that comprises a ratio of L (leucine) amino acid residues to total amino acid residues equal to or greater than 8% and a ratio of essential amino acid residues to total amino acid residues that is equal to or greater than 40%. In some embodiments of the protein, the first polypeptide sequence comprises a first polypeptide sequence comprising a ratio of branched chain amino acid residues to total amino acid residues equal to or greater than 24%, a ratio of L (leucine) residues to total amino acid residues that is equal to or greater than 11%, and comprises at least one of every essential amino acid. In some embodiments of the protein, the first polypeptide sequence comprises a first polypeptide sequence comprising a ratio of branched chain amino acid residues to total amino acid residues equal to or greater than 24% and a ratio of essential amino acid residues to total amino acid residues equal to or greater than 49%.
Provided are nutritive polypeptides that are nutritionally complete. In some embodiments of the protein, the first polypeptide sequence comprises a first polypeptide sequence that contains at least one of every essential amino acid.
Nutritive Glycoproteins and Nutritive Polypeptides with Modulated Glycosylation.
The term “glycan” or “glycoyl” refers to a polysaccharide or oligosaccharide which may be linked to a polypeptide, lipid, or proteoglycan. In some embodiments, a glycan is linked covalently or non-covalently to the polypeptide. In some embodiments the linkage occurs via a glycosidic bond. In some embodiments, the linkage is directly between the glycan (or glycoyl) and polypeptide or via an intermediary molecule. In some embodiments, the glycosidic bond is N-linked or O-linked. The term “polysaccharide” or “oligosaccharide” refers to one or more monosaccharide units joined together by glycosidic bonds. In some embodiments, the polysaccharide or oligosaccharide has a linear or branched structure. In some embodiments, the monosaccharide units comprise N-acetyl galactosamine, N-acetylglucosamine, galactose, neuraminic acid, fructose, mannose, fucose, glucose, xylose, N-acetylneuraminic acid, N-glycolylneuraminic acid, O-lactyl-N-acetylneuraminic acid, O-acetyl-N-acetylneuraminic acid, or O-methyl-N-acetylneuraminic acid. In some embodiments, the monosaccharide is modified by a phosphate, sulfate, or acetate group. The term “glycosylation acceptor site” refers to an amino acid along a polypeptide which carries a glycan or glycoyl in the native composition. In some embodiments the acceptor site consists of a nucleophilic acceptor of a glycosidic bond. In some embodiments, the nucleophilic acceptor site consists of an amino group. In some embodiments the amino acid consists of an asparagine, arginine, serine, threonine, hydroxyproline, hydroxylysine, tryptophan, phosphothreonine, serine, or phosphoserine. The term “exogenous glycosylation acceptor site” refers to a glycosylation acceptor site not present in the native composition of the polypeptide. In some embodiments the amino acid for the exogenous glycosylation acceptor site did not carry a glycan or glycoyl in the native composition. In some embodiments, the amino acid does not occur in the primary sequence of the polypeptide in the native composition. The term “exogenous glycan” or “exogenous glycoyl” refers to a glycan or glycoyl that occupies a glycosylation acceptor site, which was not present in the native composition on the same glycosylation acceptor site. In some embodiments, the glycosylation acceptor site is an exogenous glycosylation site or a native glycosylation site. The term “glycoprotein” refers to a polypeptide that is bound to at least one glycan or glycoyl.
Disclosed herein are formulations containing isolated nutritive polypeptides at least one exogenous glycosylation acceptor site present on an amino acid of the nutritive polypeptide. In some aspects, the at least one exogenous glycosylation acceptor site is occupied by an exogenous glycoyl or glycan, or alternatively, is unoccupied or is occupied by a non-natively occupying glycol or glycan. In some embodiments, the nutritive polypeptide is a polypeptide having an amino acid sequence at least 90% identical to SEQID 00001-03909 and SEQID 04129-44483, or is an edible species polypeptide sequence or fragment thereof at least 50 amino acids in length, or is a polypeptide having substantial immunogenicity when the glycosylation acceptor site is not present or is unoccupied. The nutritive polypeptide is more thermostable, is more digestible, and/or has a lower aggregation score than a reference polypeptide that has an amino acid sequence identical to the nutritive polypeptide but the glycosylation acceptor site is not present or is unoccupied in the reference polypeptide. The amino acids, e.g., asparagine, arginine, serine, threonine, hydroxyproline, and hydroxylysine, containing an exogenous glycosylation acceptor site are resistant to proteolysis. Exemplary glycans are N-acetyl galactosamine, N-acetylglucosamine, galactose, neuraminic acid, fructose, mannose, fucose, glucose, xylose, N-acetylneuraminic acid, N-glycolylneuraminic acid, O-lactyl-N-acetylneuraminic acid, O-acetyl-N-acetylneuraminic acid, and O-methyl-N-acetylneuraminic acid.
In some embodiments provided are formulations containing a nutritive polypeptide that is identical to the amino acid sequence of a polypeptide in a reference edible species glycoprotein, but the carbohydrate component of the nutritive polypeptide differs from a carbohydrate component of the reference edible species glycoprotein. The nutritive polypeptide is produced, for example, by expressing the polypeptide of the reference glycoprotein in a non-native host such as Aspergillus, Bacillus, Saccharomyces or a mammalian cell. Also provided are variant nutritive polypeptides, where the amino acid sequence differs from the amino acid sequence of a polypeptide in a reference glycoprotein by <1%, <5%, <10%, or more than 10%, and the mass of the carbohydrate component of the nutritive polypeptide is different from the mass of the carbohydrate component of the reference glycoprotein. The nutritive polypeptide variant is created by the insertion, deletion, substitution, or replacement of amino acid residues in the amino acid sequence of the polypeptide of the reference glycoprotein. Preferably, the nutritive polypeptide has distinguishable chemical, biochemical, biophysical, biological, or immunological properties from the reference glycoprotein. For example, the nutritive polypeptide is more hygroscopic, hydrophilic, or soluble in aqueous solutions than the reference glycoprotein. Alternatively, the nutritive polypeptide is less hygroscopic, hydrophilic, or soluble in aqueous solutions than the reference glycoprotein.
In another example, the nutritive polypeptide is more antigenic, immunogenic, or allergenic than the reference glycoprotein, or alternatively, the nutritive polypeptide is less antigenic, immunogenic, or allergenic than the reference glycoprotein. The nutritive polypeptide is more stable or resistant to enzymatic degradation than the reference glycoprotein or the nutritive polypeptide is more unstable or susceptible to enzymatic degradation than the reference glycoprotein. The carbohydrate component of the nutritive polypeptide is substantially free of N-glycolylneuraminic acid or has reduced N-glycolylneuraminic acid in comparison to the reference glycoprotein. Alternatively, the carbohydrate component of the nutritive polypeptide has elevated N-glycolylneuraminic acid in comparison to the reference glycoprotein.
Also provided is a nutritive polypeptide that has at least one exogenous glycosylation acceptor site present on an amino acid of the nutritive polypeptide, and the at least one exogenous glycosylation acceptor site is occupied by an exogenous glycoyl or glycan, and the nutritive polypeptide includes a polypeptide having an amino acid sequence at least 90% identical to SEQID 00001-03909 and SEQID 04129-44483, where the nutritive polypeptide is present in at least 0.5 g at a concentration of at least 10% on a mass basis, and where the formulation is substantially free of non-comestible products
Reference Nutritional Polypeptides and Reference Nutritional Polypeptide Mixtures.
Three natural sources of protein generally regarded as good sources of high quality amino acids are whey protein, egg protein, and soy protein. Each source comprises multiple proteins. Table RNP1 presents the weight proportional representation of each amino acid in the protein source (g AA/g protein) expressed as a percentage.










TABLE RNP1





Amino Acid
Whey
Egg
Soy





Isoleucine
6.5%
5.5%
5.0%


Leucine
11.0%
8.6%
8.0%


Lysine
9.1%
7.2%
6.3%


Methionine
2.1%
3.1%
1.3%


Phenylalanine
3.4%
5.3%
1.2%


Threonine
7.0%
4.8%
3.7%


Tryptophan
1.7%
1.2%
1.3%


Valine
6.2%
6.1%
4.9%


Histidine
2.0%
2.4%
2.7%


Other
51.7%
49.5%
60.4%



























Table RNP2 presents the weight proportion of each protein source that is essential amino acids, branched chain amino acids (L, I, and V), and leucine (L) (alone).








TABLE RNP2



Protein
Essential Amino
Branched Chain


Source
Acids
Amino Acids
Leucine



Whey
49.0%
23.7%
11.0%

Egg
50.5%
20.1%
8.6%

Soy
39.6%
17.9%
8.0%




















The sources relied on to determine the amino acid content of Whey are: Belitz H D., Grosch W., and Schieberle P. Food Chemistry (4th Ed). Springer-Verlag, Berlin Heidelberg 2009; gnc.com/product/index.jsp?productId=2986027; nutrabio.com/Products/whey_protein_concentrate.htm; and nutrabio.com/Products/whey_protein_isolate.htm. The amino acid content values from those sources were averaged to give the numbers presented in Tables RNP1 and RNP2. The source for soy protein is Egg, National Nutrient Database for Standard Reference, Release 24 (ndb.nal.usda.gov/ndb/foods/list). The source for soy protein is Self Nutrition Data (nutritiondata.self.com/facts/legumes-and-legume-products/4389/2).
According to the USDA nutritional database whey can include various non-protein components: water, lipids (such as fatty acids and cholesterol), carbohydrates and sugars, minerals (such as Ca, Fe, Mg, P, K, Na, and Zn), and vitamins (such as vitamin C, thiamin, riboflavin, niacin, vitamin B-6, folate, vitamin B-12, and vitamin A). According to the USDA nutritional database egg white can include various non-protein components: water, lipids, carbohydrates, minerals (such as Ca, Fe, Mg, P, K, Na, and Zn), and vitamins (such as thiamin, riboflavin, niacin, vitamin B-6, folate, and vitamin B-12). According to the USDA nutritional database soy can include various non-protein components: water, lipids (such as fatty acids), carbohydrates, minerals (such as Ca, Fe, Mg, P, K, Na, and Zn), and vitamins (such as thiamin, riboflavin, niacin, vitamin B-6, folate).
Engineered Nutritive Polypeptides.
In some embodiments a protein comprises or consists of a derivative or mutein of a protein or fragment of an edible species protein or a protein that naturally occurs in a food product. Such a protein can be referred to as an “engineered protein.” In such embodiments the natural protein or fragment thereof is a “reference” protein or polypeptide and the engineered protein or a first polypeptide sequence thereof comprises at least one sequence modification relative to the amino acid sequence of the reference protein or polypeptide. For example, in some embodiments the engineered protein or first polypeptide sequence thereof is at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.5% identical to at least one reference protein amino acid sequence. Typically the ratio of at least one of branched chain amino acid residues to total amino acid residues, essential amino acid residues to total amino acid residues, and leucine residues to total amino acid residues, present in the engineered protein or a first polypeptide sequence thereof is greater than the corresponding ratio of at least one of branched chain amino acid residues to total amino acid residues, essential amino acid residues to total amino acid residues, and leucine residues to total amino acid residues present in the reference protein or polypeptide sequence.
Nutritive Polypeptides-Orthologs and Homologs.
In another aspect, provided are nutritive polypeptides that contain amino acid sequences homologous to edible species polypeptides, which are optionally secreted from unicellular organisms and purified therefrom. Such homologous polypeptides can be 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater than 99% similar, or can be 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater than 99% identical to an edible species polypeptide. Such nutritive polypeptides can be endogenous to the host cell or exogenous, can be naturally secreted in the host cell, or both, and can be engineered for secretion.
Also provided are orthologs of nutritive polypeptides. The disclosure of a nutritive polypeptide sequence encompasses the disclosure of all orthologs of such a nutritive polypeptide sequence, from phylogenetically related organisms or, alternatively, from a phylogenetically diverse organism that is homologous to the nutritive polypeptide, such as 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater than 99% similar, or can be 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater than 99% identical.
Nutritive Polypeptide Fragments, Nutritive Polypeptide Length.
In some embodiments herein a nutritive polypeptide contains a fragment of an edible species polypeptide. In some embodiments the fragment comprises at least 25 amino acids. In some embodiments the fragment comprises at least 50 amino acids. In some embodiments the fragment consists of at least 25 amino acids. In some embodiments the fragment consists of at least 50 amino acids. In some embodiments an isolated recombinant protein is provided. In some embodiments the protein comprises a first polypeptide sequence, and the first polypeptide sequence comprises a fragment of at least 25 or at least 50 amino acids of an edible species protein. In some embodiments the proteins is isolated. In some embodiments the proteins are recombinant. In some embodiments the proteins comprise a first polypeptide sequence comprising a fragment of at least 50 amino acids of an edible species protein. In some embodiments the proteins are isolated recombinant proteins. In some embodiments the isolated recombinant proteins disclosed herein are provided in a non-isolated and/or non-recombinant form.
In some embodiments the protein comprises from 10 to 5,000 amino acids, from 20-2,000 amino acids, from 20-1,000 amino acids, from 20-500 amino acids, from 20-250 amino acids, from 20-200 amino acids, from 20-150 amino acids, from 20-100 amino acids, from 20-40 amino acids, from 30-50 amino acids, from 40-60 amino acids, from 50-70 amino acids, from 60-80 amino acids, from 70-90 amino acids, from 80-100 amino acids, at least 10 amino acids, at least 11 amino acids, at least 12 amino acids, at least 13 amino acids, at least 14 amino acids, at least 15 amino acids, at least 16 amino acids, at least 17 amino acids, at least 18 amino acids, at least 19 amino acids, at least 20 amino acids, at least 21 amino acids, at least 22 amino acids, at least 23 amino acids, at least 24 amino acids, at least 25 amino acids, at least 30 amino acids, at least 35 amino acids, at least 40 amino acids, at least 45 amino acids, at least 50 amino acids, at least 55 amino acids, at least 60 amino acids, at least 65 amino acids, at least 70 amino acids, at least 75 amino acids, at least 80 amino acids, at least 85 amino acids, at least 90 amino acids, at least 95 amino acids, at least 100 amino acids, at least 105 amino acids, at least 110 amino acids, at least 115 amino acids, at least 120 amino acids, at least 125 amino acids, at least 130 amino acids, at least 135 amino acids, at least 140 amino acids, at least 145 amino acids, at least 150 amino acids, at least 155 amino acids, at least 160 amino acids, at least 165 amino acids, at least 170 amino acids, at least 175 amino acids, at least 180 amino acids, at least 185 amino acids, at least 190 amino acids, at least 195 amino acids, at least 200 amino acids, at least 205 amino acids, at least 210 amino acids, at least 215 amino acids, at least 220 amino acids, at least 225 amino acids, at least 230 amino acids, at least 235 amino acids, at least 240 amino acids, at least 245 amino acids, or at least 250 amino acids. In some embodiments the protein consists of from 20 to 5,000 amino acids, from 20-2,000 amino acids, from 20-1,000 amino acids, from 20-500 amino acids, from 20-250 amino acids, from 20-200 amino acids, from 20-150 amino acids, from 20-100 amino acids, from 20-40 amino acids, from 30-50 amino acids, from 40-60 amino acids, from 50-70 amino acids, from 60-80 amino acids, from 70-90 amino acids, from 80-100 amino acids, at least 25 amino acids, at least 30 amino acids, at least 35 amino acids, at least 40 amino acids, at least 2455 amino acids, at least 50 amino acids, at least 55 amino acids, at least 60 amino acids, at least 65 amino acids, at least 70 amino acids, at least 75 amino acids, at least 80 amino acids, at least 85 amino acids, at least 90 amino acids, at least 95 amino acids, at least 100 amino acids, at least 105 amino acids, at least 110 amino acids, at least 115 amino acids, at least 120 amino acids, at least 125 amino acids, at least 130 amino acids, at least 135 amino acids, at least 140 amino acids, at least 145 amino acids, at least 150 amino acids, at least 155 amino acids, at least 160 amino acids, at least 165 amino acids, at least 170 amino acids, at least 175 amino acids, at least 180 amino acids, at least 185 amino acids, at least 190 amino acids, at least 195 amino acids, at least 200 amino acids, at least 205 amino acids, at least 210 amino acids, at least 215 amino acids, at least 220 amino acids, at least 225 amino acids, at least 230 amino acids, at least 235 amino acids, at least 240 amino acids, at least 245 amino acids, or at least 250 amino acids. In some aspects, a protein or fragment thereof includes at least two domains: a first domain and a second domain. One of the two domains can include a tag domain, which can be removed if desired. Each domain can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or greater than 25 amino acids in length. For example, the first domain can be a polypeptide of interest that is 18 amino acids in length and the second domain can be a tag domain that is 7 amino acids in length. As another example, the first domain can be a polypeptide of interest that is 17 amino acids in length and the second domain can be a tag domain that is 8 amino acids in length.
In some embodiments herein a fragment of an edible species polypeptide is selected and optionally isolated. In some embodiments the fragment comprises at least 25 amino acids. In some embodiments the fragment comprises at least 50 amino acids. In some embodiments the fragment consists of at least 25 amino acids. In some embodiments the fragment consists of at least 50 amino acids. In some embodiments an isolated recombinant protein is provided. In some embodiments the protein comprises a first polypeptide sequence, and the first polypeptide sequence comprises a fragment of at least 25 or at least 50 amino acids of an edible species protein. In some embodiments the proteins is isolated. In some embodiments the proteins are recombinant. In some embodiments the proteins comprise a first polypeptide sequence comprising a fragment of at least 50 amino acids of an edible species protein. In some embodiments the proteins are isolated recombinant proteins. In some embodiments the isolated nutritive polypeptides disclosed herein are provided in a non-isolated and/or non-recombinant form.
Nutritive Polypeptide Physicochemical Properties.
Digestibility.
In some aspects the nutritive polypeptide is substantially digestible upon consumption by a mammalian subject. Preferably, the nutritive polypeptide is easier to digest than at least a reference polypeptide or a reference mixture of polypeptides, or a portion of other polypeptides in the consuming subject's diet. As used herein, “substantially digestible” can be demonstrated by measuring half-life of the nutritive polypeptide upon consumption. For example, a nutritive polypeptide is easier to digest if it has a half-life in the gastrointestinal tract of a human subject of less than 60 minutes, or less than 50, 40, 30, 20, 15, 10, 5, 4, 3, 2 minutes or 1 minute. In certain embodiments the nutritive polypeptide is provided in a formulation that provides enhanced digestion; for example, the nutritive polypeptide is provided free from other polypeptides or other materials. In some embodiments, the nutritive polypeptide contains one or more recognition sites for one or more endopeptidases. In a specific embodiment, the nutritive polypeptide contains a secretion leader (or secretory leader) sequence, which is then cleaved from the nutritive polypeptide. As provided herein, a nutritive polypeptide encompasses polypeptides with or without signal peptides and/or secretory leader sequences. In some embodiments, the nutritive polypeptide is susceptible to cleavage by one or more exopeptidases.
Digestion Assays
Digestibility is a parameter relevant to the benefits and utility of proteins. Information relating to the relative completeness of digestion can serve as a predictor of peptide bioavailability (Daniel, H., 2003. Molecular and Integrative Physiology of Intestinal Peptide Transport. Annual Review of Physiology, Volume 66, pp. 361-384). In some embodiments proteins disclosed herein are screened to assess their digestibility. Digestibility of proteins can be assessed by any suitable method known in the art. In some embodiments digestibility is assessed by a physiologically relevant in vitro digestion reaction that includes one or both phases of protein digestion, simulated gastric digestion and simulated intestinal digestion (see, e.g., Moreno, et al., 2005. Stability of the major allergen Brazil nut 2S albumin (Ber e 1) to physiologically relevant in vitro gastrointestinal digestion. FEBS Journal, pp. 341-352; Martos, G., Contreras, P., Molina, E. & Lopez-Fandino, R., 2010. Egg White Ovalbumin Digestion Mimicking Physiological Conditions. Journal of Agricultural and food chemistry, pp. 5640-5648; Moreno, F. J., Mackie, A. R. & Clare Mills, E. N., 2005). Phospholipid interactions protect the milk allergen a-Lactalbumin from proteolysis during in vitro digestion. Journal of agricultural and food chemistry, pp. 9810-9816). Briefly, test proteins are sequentially exposed to a simulated gastric fluid (SGF) for 120 minutes (the length of time it takes 90% of a liquid meal to pass from the stomach to the small intestine; see Kong, F. & Singh, R. P., 2008. Disintegration of Solid Foods in Human Stomach. Journal of Food Science, pp. 67-80) and then transferred to a simulated duodenal fluid (SDF) to digest for an additional 120 minutes. Samples at different stages of the digestion (e.g., 2, 5, 15, 30, 60 and 120 min) are analyzed by electrophoresis (e.g., chip electrophoresis or SDS-PAGE) to monitor the size and amount of intact protein as well as any large digestion fragments (e.g., larger than 4 kDa). The disappearance of protein over time indicates the rate at which the protein is digested in the assay. By monitoring the amount of intact protein observed over time, the half-life (τ1/2) of digestion is calculated for SGF and, if intact protein is detected after treatment with SGF, the τ1/2 of digestion, is calculated for SIF. This assay can be used to assess comparative digestibility (i.e., against a benchmark protein such as whey) or to assess absolute digestibility. In some embodiments the digestibility of the protein is higher (i.e., the SGF τ1/2 and/or SIF τ1/2 is shorter) than whey protein. In some embodiments the protein has a SGF τ1/2 of 30 minutes or less, 20 minutes or less, 15 minutes or less, 10 minutes or less, 5 minutes or less, 4 minutes or less, 3 minutes or less, 2 minutes or less or 1 minute or less. In some embodiments the protein has a SIF τ1/2 of 30 minutes or less, 20 minutes or less, 15 minutes or less, 10 minutes or less, 5 minutes or less, 4 minutes or less, 3 minutes or less, 2 minutes or less or 1 minute or less. In some embodiments the protein is not detectable in one or both of the SGF and SIF assays by 2 minutes, 5 minutes, 15 minutes, 30 minutes, 60 minutes, or 120 minutes. In some embodiments the protein is digested at a constant rate and/or at a controlled rate in one or both of SGF and SIF. In such embodiments the rate of digestion of the protein may not be optimized for the highest possible rate of digestion. In such embodiments the rate of absorption of the protein following ingestion by a mammal can be slower and the total time period over which absorption occurs following ingestion can be longer than for proteins of similar amino acid composition that are digested at a faster initial rate in one or both of SGF and SIF. In some embodiments the protein is completely or substantially completely digested in SGF. In some embodiments the protein is substantially not digested or not digested by SGF; in most such embodiments the protein is digested in SIF.
Assessing protein digestibility can also provide insight into a protein's potential allergenicity, as proteins or large fragments of proteins that are resistant to digestive proteases can have a higher risk of causing an allergenic reaction (Goodman, R. E. et al., 2008. Allergenicity assessment of genetically modified crops—what makes sense? Nature Biotechnology, pp. 73-81). To detect and identify peptides too small for chip electrophoresis analysis, liquid chromatography and mass spectrometry can be used. In SGF samples, peptides can be directly detected and identified by LC/MS. SIF protein digestions may require purification to remove bile acids before detection and identification by LC/MS.
In some embodiments digestibility of a protein is assessed by identification and quantification of digestive protease recognition sites in the protein amino acid sequence. In some embodiments the protein comprises at least one protease recognition site selected from a pepsin recognition site, a trypsin recognition site, and a chymotrypsin recognition site.
As used herein, a “pepsin recognition site” is any site in a polypeptide sequence that is experimentally shown to be cleaved by pepsin. In some embodiments it is a peptide bond after (i.e., downstream of) an amino acid residue selected from Phe, Trp, Tyr, Leu, Ala, Glu, and Gln, provided that the following residue is not an amino acid residue selected from Ala, Gly, and Val.
As used herein, a “trypsin recognition site” is any site in a polypeptide sequence that is experimentally shown to be cleaved by trypsin. In some embodiments it is a peptide bond after an amino acid residue selected from Lys or Arg, provided that the following residue is not a proline.
As used herein, a “chymotrypsin recognition site” is any site in a polypeptide sequence that is experimentally shown to be cleaved by chymotrypsin. In some embodiments it is a peptide bond after an amino acid residue selected from Phe, Trp, Tyr, and Leu.
Disulfide bonded cysteine residues in a protein tend to reduce the rate of digestion of the protein compared to what it would be in the absence of the disulfide bond. For example, it has been shown that the rate of digestion of the protein b-lactoglobulin is increased when its disulfide bridges are cleaved (I. M. Reddy, N. K. D. Kella, and J. E. Kinsella. “Structural and Conformational Basis of the Resistance of B-Lactoglobulin to Peptic and Chymotryptic Digestion”. J. Agric. Food Chem. 1988, 36, 737-741). Accordingly, digestibility of a protein with fewer disulfide bonds tends to be higher than for a comparable protein with a greater number of disulfide bonds. In some embodiments the proteins disclosed herein are screened to identify the number of cysteine residues present in each and in particular to allow selection of a protein comprising a relatively low number of cysteine residues. For example, edible species proteins or fragments can be identified that comprise a no Cys residues or that comprise a relatively low number of Cys residues, such as 10 or fewer Cys residues, 9 or fewer Cys residues, 8 or fewer Cys residues, 7 or fewer Cys residues, 6 or fewer Cys residues, 5 or fewer Cys residues, 4 or fewer Cys residues, 3 or fewer Cys residues, 2 or fewer Cys residues, 1 Cys residue, or no Cys residues. In some embodiments one or more Cys residues in an edible species protein or fragment thereof is removed by deletion and/or by substitution with another amino acid. In some embodiments 1 Cys residue is deleted or replaced, 1 or more Cys residues are deleted or replaced, 2 or more Cys residues are deleted or replaced, 3 or more Cys residues are deleted or replaced, 4 or more Cys residues are deleted or replaced, 5 or more Cys residues are deleted or replaced, 6 or more Cys residues are deleted or replaced, 7 or more Cys residues are deleted or replaced, 8 or more Cys residues are deleted or replaced, 9 or more Cys residues are deleted or replaced, or 10 or more Cys residues are deleted or replaced. In some embodiments the protein of this disclosure comprises a ratio of Cys residues to total amino acid residues equal to or lower than 5%, 4%, 3%, 2%, or 1%. In some embodiments the protein comprises 10 or fewer Cys residues, 9 or fewer Cys residues, 8 or fewer Cys residues, 7 or fewer Cys residues, 6 or fewer Cys residues, 5 or fewer Cys residues, 4 or fewer Cys residues, 3 or fewer Cys residues, 2 or fewer Cys residues, 1 Cys residue, or no Cys residues. In some embodiments, the protein comprises 1 or fewer Cys residues. In some embodiments, the protein comprises no Cys residues.
Alternatively or in addition, disulfide bonds that are or can be present in a protein can be removed. Disulfides can be removed using chemical methods by reducing the disulfide to two thiol groups with reducing agents such as beta-mercaptoethanol, dithiothreitol (DTT), or tris(2-carboxyethyl)phosphine (TCEP). The thiols can then be covalently modified or “capped” with reagents such as iodoacetamide, N-ethylmaleimide, or sodium sulfite (see, e.g., Crankshaw, M. W. and Grant, G. A. 2001. Modification of Cysteine. Current Protocols in Protein Science. 15.1.1-15.1.18).
Nutritive Polypeptides and Nutritive Polypeptide Formulations with Modulated Viscosity.
Disclosed herein are compositions, formulations, and food products that contain viscosity-modulating nutritive polypeptides. In one aspect, provided are formulations substantially free of non-comestible products that contain nutritive polypeptides present in a nutritional amount, and the nutritive polypeptide decreases the viscosity of a food product. In some embodiments, the nutritive polypeptide is present at about 10 g/l and the viscosity of the formulation is from about 1,000 mPas to about 10,000 mPas at 25 degrees C., such as from about 2,500 mPas to about 5,000 mPas at 25 degrees C.
The formulations are incorporated into food products having advantages over similar food products lacking the nutritive polypeptides, or the formulations are incorporated into other products such as beverage products or animal feed products. For example, the food products have a reduced fat content, a reduced sugar content, and/or a reduced calorie content compared to a food product not having the nutritive polypeptide. Preferably, the nutritive polypeptide is present in the food product such that consumption of a nutritional amount of the food product is satiating. In an embodiment of the invention, gelatin, an animal-derived material, is replaced by a non-animal derived product, containing one or more nutritive polypeptides. Typically the nutritive polypeptide is present in an amount effective to replace gelatin in the product. The gelatin replacement is incorporated into a food product, a beverage product, or an animal feed product, and the formulation is substantially free of non-comestible products.
Also provided are formulations containing a nutritive polypeptide present in a functional and/or nutritional amount, which increases the viscosity of a food or beverage product, such as formulations containing viscosity-increasing nutritive polypeptides incorporated into food products having advantages over similar food products lacking the nutritive polypeptides. For example, the food products have a reduced fat content, a reduced sugar content, and/or a reduced calorie content compared to a food product not having the nutritive polypeptide. Viscous nutritive polypeptides can be used as a nutritionally favorable low calorie substitute for fat. Additionally, it may be desired to add to the compositions and products one or more polysaccharides or emulsifiers, resulting in a further improvement in the creamy mouthfeel.
In some embodiments, the viscosity of nutritive polypeptide-containing materials is enhanced by crosslinking the nutritive polypeptides or crosslinking nutritive polypeptides to other proteins present in the material. An example of an effective crosslinker is transglutaminase, which crosslinks proteins between an ∈-aminogroup of a lysine residue and a γ-carboxamide group of glutamine residue, forming a stable covalent bond. The resulting gel strength and emulsion strength of nutritive polypeptides identified and produced as described herein are examined by preparing a transglutaminase-coupled nutritive protein composition, followed by gel strength and emulsion strength assays. A suitable transglutaminase derived from microorganisms in accordance with the teachings of U.S. Pat. No. 5,156,956 is commercially available. These commercially available transglutaminases typically have an enzyme activity of about 100 units. The amount of transglutaminase (having an activity of about 100 units) added to isolated nutritive polypeptide is expressed as a transglutaminase concentration which is the units of transglutaminase per 100 grams of isolated nutritive polypeptide. The isolated nutritive polypeptide contains from 5 to 95%, preferably 20 to 80%, preferably 58% to 72% protein and also preferably from 62% to 68% protein. The transglutaminase concentration is at least 0.15, preferably 0.25 and most preferably 0.30 units transglutaminase per gram protein up to 0.80 and preferably 0.65 units transglutaminase per gram protein. Higher and lower amounts may be used. This enzyme treatment can also be followed by thermal processing to make a viscous solution containing a nutritive polypeptide. To generate nutritive polypeptide samples containing crosslinks, a sample is mixed with a transglutaminase solution at pH 7.0 to give an enzyme to protein weight ratio of 1:25. The enzyme-catalyzed cross-linking reaction is conducted at 40° C. in most of the experiments.
Oscillatory shear measurements can be used to investigate the rheological properties of nutritive polypeptides. Also, to determine the viscosity of nutritive polypeptide solutions and gels viscoelasticity is investigated by dynamic oscillatory rheometry. A 2 mL sample of nutritive polypeptide solution or nutritive polypeptide solution containing transglutaminase is poured into the Couette-type cylindrical cell (2.5 cm i.d., 2.75 cm o.d.) of the rheometer and covered with a thin layer of low-viscosity silicone oil to prevent evaporation. For samples with enzyme present, gelation is induced in situ by incubation at 40° C. For nutritive polypeptide samples without enzyme, gelation is induced by subjecting the sample to the following thermal treatment process: temperature increased at constant rate of 2 K min-1 from 40 to 90° C., kept at 90° C. for 30 min, cooled at 1 K min-1 from 90 to 30° C., and kept at 30° C. for 15 min. Some samples can be subjected to this thermal treatment after the enzyme treatment. Small deformation shear rheological properties are mostly determined in the linear viscoelastic regime (maximum strain amplitude 0.5%) with storage and loss moduli (G′ and G″) measured at a constant frequency of 1 Hz. In addition, some small deformation measurements are made as a function of frequency e.g., 2×10-3 to 2 Hz, and some large deformation measurements are carried out at strains up to nearly 100%.
Nutritive Polypeptides for Prevention and Reduction of Tumorigenesis, Cancer Cell Proliferation and Invasion, and Methods of Production and Use Thereof in Cancer Treatment, and for Maintaining and Increasing Muscle Mass, Strength and Performance During Cancer Treatment
Cancer includes uncontrolled growth of abnormal cells that have undergone a metabolic change due to genetic defect or imbalance of progrowth and antigrowth factors. Cancer is a global issue: over 13 million cancer cases were reported in 2012 and it is a leading cause of mortality worldwide, causing the death of 8.2 million individuals in 2012 (See, e.g., de Martel C, Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. The Lancet Oncology (2012) 13: 607-615). Highly lethal forms of malignancy include cancers of the lung, liver, stomach, colon, breast, and esophagus.
While cancer is caused and exacerbated by a variety of factors, both inherited (genetic) and external, some major risk factors include tobacco use, obesity, poor diet, alcohol consumption, certain infections (hepatitis, human papillomavirus), pollutant and ionizing radiation exposure (Cancer Fact sheet No. 297 . World Health Organization . February 2014). During oncogenesis, these pro-cancer factors ultimately result in genetic changes to individual cells in the exposed tissue that results in uncontrolled growth and tumor development.
Cellular metabolism is substantially altered during oncogenesis and malignant tumor growth. In order to support constant growth and division, cancer cells uniquely rely on a number of metabolic pathways to shunt nutrients into the development of additional cellular material and meet their augmented energetic needs (See, e.g., Galluzzi, (2013), Nature reviews. Drug discovery: 12: 829-46). In many cases, these pathways are important to cancerous versus noncancerous cells, and the ability to differentially modulate such pathways offers a means to selectively affect cancer vs healthy tissue. Specifically, the metabolic auxotrophies of certain cancer cells can be exploited through metabolite starvation or overexposure, which can slow or prevent tumor growth.
Provided are nutritive polypeptides, and compositions and formulations containing nutritive polypeptides, which are useful for prevention and reduction of tumorigenesis, cancer cell proliferation and invasion, and methods of production and use thereof in cancer treatment. The nutritive polypeptides are also useful for treating and preventing loss of muscle mass and muscle function in a subject, particularly a subject undergoing cancer treatment. Moreover, the nutritive polypeptides are further useful for reducing or preventing a side effect (meaning a secondary effect, usually undesirable, of a pharmaceutical agent or medical treatment) of therapeutic or prophylactic regimens for cancer treatment such as chemotherapy and radiation therapy, as such therapeutic regimens result in decreased amino acid availability to the subject, in addition to causing loss of muscle mass and muscle function.
Cancer and tumor cells have a disproportionate requirement for certain amino acids as compared to non-cancer cells (Galluzzi, (2013) Nature reviews. Drug discovery: 12: 829-46). For example, serine and glycine play essential roles in mammalian metabolism including protein synthesis, de novo synthesis of nucleotides, methylation of DNA and polyamine synthesis (J. W. Locasale (2013) Nature reviews. Cancer: 13: 572-83). Certain tumor cells exhibit dependence on serine and glycine for survival and proliferation, due to amplification, deletions, polymorphisms or alterations in expression of genes in the serine and glycine metabolic pathways, while normal cells are less sensitive to starvation of serine and glycine (J. Locasale & Cantley, 2011, Cell Cycle: 10: 3812-3813) (Labuschagne, van den Broek, Mackay, Vousden, & Maddocks, 2014, Cell reports: 7: 1248-58)(Zhang et al., 2012, Cell: 148: 259-72). Certain tumor cells exhibit dependence on methionine for survival and proliferation, due to deletions, polymorphisms or alterations in expression of genes in the methionine de novo and salvage pathways (Cavuoto & Fenech, 2012, Cancer treatment reviews: 38: 726-36), while normal cells are not sensitive to methionine starvation (Kreis & Goodenow, 1978, Cancer Res: 38: 2259-2262). Certain tumor cells exhibit dependence on arginine due to deficient utilization of citrulline or arginosuccinate (Currie and Basham 1978) (Wheatley & Campbell, 2003, British journal of cancer: 89: 573-6). Certain tumor cells exhibit dependence on glutamine for survival and proliferation, due to upregulation of glutaminases (Hensley, 2013a, Journal of Clinical Investigation: 123: 3678-3684) (Hensley, 2013b, Journal of Clinical Investigation: 123: 3678-3684) (Yang et al., 2014, Molecular systems biology: 10: 728). Therefore, restriction of serine, glycine, methionine, arginine, and glutamine within a protein diet can limit tumor cell growth.
Selective inhibition of the proliferation of serine and glycine dependent cancer cells has been demonstrated using media deficient in serine and glycine (Maddocks et al., 2013, Nature: 493: 542-6), and animal studies utilizing a serine and glycine restricted diet show inhibition of cancer growth and extension of life-span (Labuschagne et al., 2014, Cell reports: 7: 1248-58). Selective killing of methionine dependent cancer cells in co-culture with normal cells has been demonstrated using media deficient in methionine, and animal studies utilizing a methionine restricted diet show inhibition of cancer growth and extension of life-span (Cavuoto & Fenech, 2012, Cancer treatment reviews: 38: 726-36). Moreover, homocysteine supplementation selectively rescues normal cells from the toxicity of methionine starvation while tumor cells fail to utilize homocysteine and strictly rely on methionine (Kreis & Goodenow, 1978, Cancer Res: 38: 2259-2262). Glutamine is a key mitochondrial substrate required for TCA cycle, and several approaches have been taken to target glutamine dependence of cancers in clinical trials (Wise & Thompson, 2010, Trends in Biochemical Sciences: 35: 427-433). One of the approaches is glutamine depletion by the use of L-asparaginase which degrades both asparagine and glutamine (Avramis & Panosyan, 2005, Clinical Pharmacokinetics: 44: 367-393). Arginine deprivation by arginase or arginine deaminase shows promising anti-cancer effects in clinical trials (Phillips, Sheaff, & Szlosarek, 2013, Cancer Res Treat: 45: 251-262).
Amino Acid Pharmacology.
Amino acids are organic molecules containing both amino and acid groups. All amino acids have asymmetric carbon except for glycine and all protein amino acids, except proline, have an alpha-carbon bound to a carboxyl group and a primary amino group.
Amino acids exhibit a diverse range of biochemical properties and biological function due to their varying side chains. They are stable in solution at physiological pH, save for glutamine and cysteine. In the context of some proteins, conditional upon the host and translational machinery, amino acids can undergo post-translational modification. This can have significant effects on their bioavailability, metabolic function, and bioactivity in vivo. Sugar moieties appended to proteins post-translationally may reduce the usefulness of the nutritive proteins by affecting the gastrointestinal release of amino acids and embedded peptides. A comparison of digestion of glycosylated and non-glycosylated forms of the same proteins shows that the non-glycosylated forms are digested more quickly than the glycosylated forms (our data).
Although over 300 amino acids exist in nature, 20 serve as building blocks in protein. Non-protein alpha-AAs and non-alpha AAs are direct products of these 20 protein amino acids and play significant roles in cell metabolism. Due to the metabolic reactions of amino acid catabolism that drive the interconversion between amino acids, a subset of 11 of the 20 standard protein amino acids are considered non-essential for humans because they can be synthesized from other metabolites (amino acids, ketones, etc.) in the body: Alanine; Arginine; Asparagine; Aspartic acid; Cysteine; Glutamic acid; Glutamine; Glycine; Proline; Serine; and Tyrosine.
Arginine, cysteine, glycine, glutamine, histidine, proline, serine and tyrosine are considered conditionally essential, as they are not normally used in the diet, and are not synthesized in adequate amounts in specific populations to meet optimal needs where rates of utilization are higher than rates of synthesis. Functional needs such as reproduction, disease prevention, or metabolic abnormalities, however, can be taken into account when considering whether an amino acid is truly non-essential or can be conditionally essential in a population. The other 9 protein amino acids, termed essential amino acids, are taken as food because their carbon skeletons are not synthesized de novo by the body to meet optimal metabolic requirements: Histidine; Isoleucine; Leucine; Lysine; Methionine; Phenylalanine; Threonine; Tryptophan; and Valine.
All 20 protein amino acids (and non-protein metabolites) are used for normal cell functionality, and shifts in metabolism driven by changing availability of a single amino acid can affect whole body homeostasis and growth. Additionally, amino acids function as signaling molecules and regulators of key metabolic pathways used for maintenance, growth, reproduction, immunity.
In the body skeletal muscle represents the largest store of both free and protein-bound amino acids due to its large composition of body mass (around 40-45%). The small intestine is another important site for amino acid catabolism, governing the first pass metabolism and entry of dietary amino acids into the portal vein and into the peripheral plasma. 30-50% of EAA in the diet may be catabolized by the small intestine in first-pass metabolism. The high activity of BCAA transaminases in the intestinal mucosa leads to BCAA conversion to branched-chain alpha-ketoacids to provide energy for enterocytes similar as is done in skeletal muscle. Differences in physiological state of muscle and small intestine metabolism have large implications on amino acid biology systemically across tissues in humans.
Amino acids can exist in both L- and D-isoforms, except for glycine (non-chiral). Almost all amino acids in proteins exist in the L-isoform, except for cysteine (D-cys) due to its sulfur atom at the second position of the side-chain, unless otherwise enzymatically postranslationally modified or chemically treated for storing or cooking purposes. Most D-amino acids, except for D-arg, D-cys, D-his, D-lys, and D-thr, can be converted into the L chirality by D-AA oxidases and transaminases. In order to be catabolized, these D enantiomers are transported across the plasma and other biological membranes and undergo D-oxidation or deaminate the amino acid to convert to its alpha-ketoacid or racemization to convert the D-AA to its L-isoform. The transport of D-isomers is limited by a lower affinity of L-AA transporters to D-AAs. For this reason the efficiency of D-AA utilization, on a molar basis of the L-isomer, can range from 20-100% depending on the amino acid and the species.
Alanine:
Alanine is a glucogenic non-essential amino acid due to its ability to be synthesized in muscle cells from BCAAs and pyruvate as part of the glucose-alanine cycle. This involves a tightly regulated process by which skeletal muscle frees energy from protein stores for the generation of glucose distally in the liver for use by extrahepatic cells (including immunocytes) and tissues. The resulting stimulation of gluconeogenesis provides a source of energy in the form of glucose during periods of food deprivation. Alanine becomes a very sensitive intermediary to balance the utilization of BCAAs in the muscle for protein production and generation of available energy through gluconeogenesis in the liver. Furthermore, the alanine induction of gluconeogenesis is integral to support the function of many tissues, not limited to muscle, liver, and immunocytes. Beyond acting as simply an intermediate, however, it also directly regulates activity of a key enzyme in this energy balance, pyruvate kinase. Alanine has the ability to inhibit pyruvate kinase by facilitating its phosphorylation, slowing glycolysis and driving the reverse reaction of pyruvate to phosphoenolpyruvate (PEP) for initiation of gluconeogenesis.
High Alanine
A lack of ATP-producing substrates, as occurs in a fasted state, can lead to autophagy and the turnover of intracellular protein in the lysosome to provide an energy source. Low levels of the glucogenic amino acids, including alanine can stimulate hepatic autophagy, leading to degradation of liver function.
Beta-cells show increased autophagy when under high fat diet feeding as a response to increased demand for insulin production and protein turnover as the body reacts to rising plasma glucose concentrations. This progression towards increased insulin production in obesity is an early marker for pre-diabetes, an indicator of insulin resistance, and a risk factor for the deterioration of islet beta cell functionality which eventually leads to the onset of diabetes in overweight individuals. The ability to regulate alanine levels via nutrition may provide a powerful lever for shifting hepatic and beta cell autophagy to perturb impaired insulin metabolism in overweight individuals.
Alanine directly produces beta-alanine, important to the biosynthesis of panthothenic acid (vitamin b5), coenzyme A, and carnosine (or which it is the rate-limiting precursor). Carnosine, as well as other beta-alanine derived di-peptides (which don't incorporate into proteins) carcinine, anserine, and balenine act as antioxidant buffers in the muscle tissue, constituting up to 20% of the buffer capacity in type I and II muscle fibres. This buffering is important for maintaining tissue pH in muscle during the breakdown of glycogen to lactic acid. In weight loss/gain trials in college athletes, supplementation with beta-alanine was shown to prevent loss of lean mass in weight loss and larger increases in lean mass during weight gain compared to placebo. Beta-alanine is also implicated in decreasing fatigue and increasing muscular work done.
Carnosine is an antioxidant and transition metal ion-sequestering agent. It acts as an anti-glycating agent by inhibiting the formation of advanced glycation end products (AGEs). AGEs are prevalent in diabetic vasculature and contribute to the development of atherosclerosis. The presence of AGEs in various cells types affect both the extracellular and intracellular structure and function. (Golden, A. et. al. Advanced Glycosylation End Products, Circulation 2006). Also, the accumulation of AGEs in the brain is a characteristic of aging and degeneration, particularly in Alzheimer's disease. AGE accumulation explains many neuropathological and biochemical features of Alzheimer's disease such as protein crosslinking, oxidative stress, and neuronal cell death. Because of its combination of antioxidant and antiglycating properties, carnosine is able to diminish cellular oxidative stress and inhibit the intracellular formation of reactive oxygen species and reactive nitrogen species.
Low Alanine
In states of obesity and diabetes, animals have been shown to exhibit reduced hepatic autophagy, leading to increased insulin resistance. Autophagy is important for maintenance of the ER and cellular homeostasis, which when stressed can lead to impaired insulin sensitivity. High fat diet feeding in animal models stresses the ER, while leading to depressed hepatic autophagy through over-stimulation of mTORC1, which reinforces the progression towards insulin sensitivity impaired beta cell function in diabetes. Reducing the level of systemic Alanine provides an opportunity to lower mTORC1 activity and restore healthy levels of autophagy.
Arginine:
Arginine is a glucogenic non-essential amino acid, which can be synthesized via glutamate, aspartate, glutamine, and proline. It is produced by the mammalian small intestine via oxidation of glutamate, glutamine, and aspartate, which generates ornithine, citrulline, arginine, and alanine. It can also be produced (along with ornithine and citrulline) via the proline oxidase pathway from active degradation of proline in enterocytes. Arginine is converted from citrulline released into circulation by the enterocytes in the kidneys and some endothelial cells (leukocytes and smooth muscle). Newborns utilize most of the free citrulline locally in the small intestine for arginine synthesis rather than systemic release. Arginine and proline oxidation is constrained to the mucosa due to reduced activity of pyrroline-5-carboxylate dehydrogenase across the other tissues.
High Arginine
Citrulline is produced from arginine as a by-product of a reaction catalyzed by the NOS family. Dietary supplement of either arginine or citrulline is known to reduce plasma levels of glucose, homocysteine, and asymmetric dimethylarginine, which are risk factors for metabolic syndrome. L-citrulline accelerates the removal of lactic acid from muscles, likely due to the affects on vascular tone and endothelial function. Recent studies have also shown that L-citrulline from watermelon juice provides greater recovery from exercise, and less soreness the next day. It also appears that delivery of L-citrulline as a free form results in less uptake into cells in vitro than in the context of watermelon juice (which contains high levels of L-citrulline). This suggests an opportunity to deliver peptide doses, which can traffic arginine into muscle tissue for conversion into citrulline by eNOS at the endothelial membrane for improved efficacy.
Arginine is a highly functional amino acid implicated in many signaling pathways and as a direct precursor of nitric oxide (NO), which facilitates systemic signaling between tissues and regulation of nutrient metabolism and immune function. NO is important for normal endothelial function and cardiovascular health (including vascular tone, hemodynamics, and angiogenesis). Arginine stimulates insulin secretion by directly depolarizing the plasma membrane of the β cell, leading to the influx of Ca 2+ and subsequent insulin exocytosis.
Arginine supplementation was shown to improve endothelium-dependent relaxation, an indicator of cardiovascular function in type I and type II models of diabetes mellitus. Notably, arginine supplementation reduced white adipose tissue but increased brown fat mass in Zucker diabetic rats and diet-induced obese rats. Arginine and/or its metabolites may enhance the proliferation, differentiation, and function of brown adipocytes. In addition, both skeletal muscle mass and whole body insulin sensitivity were enhanced in response to arginine supplementation via mechanisms involving increases in muscle mTOR and NO signaling. Surprisingly, long-term oral administration of arginine decreased fat mass in adult obese humans with type II diabetes (Lucotti et al 2006). Moreover, supplementation with arginine to a conventional corn- and soybean-based diet reduced fat accretion and promoted protein deposition in the whole body of growing-finishing pigs. In a small pilot trial in humans data indicated that defective insulin-mediated vasodilatation in obesity and non-insulin dependent diabetics (NIDDM) can be normalized by intravenous L-arginine; L-arginine also improved insulin sensitivity in healthy subjects, obese patients and NIDDM patients, indicating a possible mechanism that is different from the restoration of insulin-mediated vasodilatation. In addition, a chronic administration of L-arginine improved glucose levels, insulin induced-hepatic glucose production, and insulin sensitivity in type II diabetic patients (Piatti et al 2001). Arginine rich peptides have not been isolated and tested.
Amino acid administration at high doses (10-20× that available in diet, or 0.1-0.3 g/kg body weight dosed over 20 minutes, via intravenous or oral routes, can stimulate hormone secretion from the gut via endocrine cells. Arginine is a well-studied secretagogue that can stimulate the systemic release of insulin, growth hormone, prolactin, glucagon, progesterone, and placental lactogen. This biology has direct implications on both digestive biology and the absorption of nutrients present in the intestine, as well as affecting energy balance by triggering satiety signals mediated by endocrine hormones. The ability to modulate these hormones provides a therapeutic opportunity for decreasing caloric intake in metabolic disorders such as obesity or alternatively triggering appetite in muscle wasting, sarcopenia, and cachexia, as well as by shifting insulin sensitivity in the onset of diabetes.
Arginine is an important signaling molecule for stimulating mTOR1 phosphorylation in a cell-specific manner. This regulates cellular protein turnover (autophagy) and integrates insulin-like growth signals to protein synthesis initiation across tissues. This biology has been directly linked to biogenesis of lean tissue mass in skeletal muscle, metabolic shifts in disease states of obesity and insulin resistance, and aging. It is also a central signaling pathway which can be hijacked for the proliferation of fast-growing cancer cells.
There is evidence for Arginine increasing levels of protein synthesis in the small intestine under catabolic states such as viral infection and malnutrition, where amino acid levels are dramatically shifted from their normal post-absorptive states. Additionally, demonstrated mTOR activation in the intestinal epithelial cells by Arginine provides a mechanism to repair intestinal epithelium by stimulating protein synthesis and cell proliferation. Similar anabolic signaling has been observed in myocytes in response to rising plasma levels of Arginine, leading to increased whole body and skeletal muscle protein synthesis. Arginine is an amino acid maintained at sufficient levels to support the anabolic effects of EAAs. Lysine, Methionine, Threonine, Tryptophan, Leucine, Isoleucine, and Valine have been shown unable to support increased protein synthesis and whole-body growth when added to a 12.7% crude protein diet, indicating a deficiency in the anabolic mediating non-essential amino acids, including Arginine.
Arginine also up-regulates proteins and enzymes related to mitochondrial biogenesis and substrate oxidation, stimulating metabolism of fatty acid stores and reducing fat tissue mass. Supplementation of dietary Arginine provides a therapeutic benefit in obese and pre-diabetic populations who suffer from insulin resistance due to their increased caloric intake. Likewise, the ability to stimulate mitochondrial biogenesis has direct implications in aging and the ability to regenerate functional proteins and healthy cells subject to oxidative stress.
It is established that dietary deficiency of protein reduces the availability of most amino acids, including Arginine despite it not being considered essential. Arginine deficiency is known to cause decreases in sperm counts by 90% after 9 days, increasing the proportion of non-motile sperm by a factor of 10. Arginine supplementation has been demonstrated in animals to increase levels of Arginine, Proline, Ornithine, and other Arginine metabolites such as Polyamines in seminal fluid, corresponding with increased sperm counts and sperm motility. Changes in NO synthesis and polyamines (via), likewise are seen during gestation when placental growth rate peaks, indicating a role for Arginine in fetal development during pregnancy. In uterine fluids during early gestation, Arginine levels also decrease in response to expression of specific amino acid transporters at the embryo. Arginine supplementation to the diet of animals during early gestation has shown embryonic survival and increase in litter size, indicating a significant potential for delivering high levels of arginine during pregnancy.
Arginine has an extensively studied effect on enhancing immune function, based on direct effects on NO production (which can potentiate a phagocyte's killing ability), hormonal secretagogue activity, and stimulation of mTOR. Proline catabolism by proline oxidase is known to have high levels of activity in the placentae and small intestine of mammals. This activity points to a crucial role for Arginine in gut and placentae immunity, both through generation of H 2 O 2 , which is cytotoxic to pathogenic bacteria, and synthesis of arginine. In critically injured patients leukocyte count normalizes more quickly after 6 days of Arginine enriched diet, with recovery to normal TNF response after 10 days (100% improvement). A clinical study in 296 surgery, trauma, or sepsis patients examining Arginine enriched (12.5 g/L Arginine) formulation vs enteral formula indicates highly reduced hospital stay (8-10 days) and major reduction in frequency of acquired infections. A separate clinical study of 181 septic patients fed Arginine enriched (12.5 g/L Arginine) vs. enteral formula show significantly reduced bacteremia (8% vs 22%), nosocomial infection (6% vs 20%).
Arginine is also a key substrate for the synthesis of collagen. Oral supplementation of arginine enhances wound healing and lymphocyte immune response in healthy subjects. A 2.4× increase in collagen deposition was observe at wound sites (24 nmol/cm vs. 10.1 nmol/cm), along with increased lymphocyte proliferation vs. control.
Arginine is an allosteric activator of N-acetylglutamate synthase, an enzyme which converts glutamate and acetyl-CoA into N-acetylglutamate in the mitochondria. This pushes the hepatic urea cycle towards the active state, useful for ammonia detoxification. This means that dietary delivery of nutrients with low doses of arginine may be useful in the context of kidney disease, where patients struggle to clear urea from their circulation. Elimination of arginine to limit uremia from the available nitrogen sources, while being able to maintain a limited protein intake to prevent tissue catabolism, is a novel strategy against a disruptive nutritional consequence of kidney disease.
Arginine up-regulates the activity of GTP cyclohydrolase-I, freeing tetrahydrobiopterin (THB) for NO synthesis and the hydroxylation of aromatic amino acids (ArAAs) by aromatic amino acid hydroxylase (AAAH). For this reason, delivery of high levels of Arginine to raise cellular levels of THB directly stimulates the biosynthesis of many neurotransmitters in the CNS capillary endothelial cells. ArAAs serve as precursors for biosynthesis of monoamine neurotransmitters, including melatonin, dopamine, norepinephrine (noradrenaline), and epinephrine (adrenaline).
Low Arginine
Excessive arginine intake, stimulating production of high levels of NO in the blood can lead to oxidative injury and apoptosis of cells.
Arginine excess or depletion affects global gene expression in mammalian hepatocytes. Depletion leads to 1419 genes with significantly (p<0.05) altered expression using in-vitro models, of which 56 showed at least 2-fold variation using a 9-way bioinformatics analysis. The majority rise in expression, including multiple growth, survival, and stress-related genes such as GADD45, TA1/LAT1, and caspases 11 and 12. Many are relevant in luminal ER stress response. LDLr, a regulator of cholesterol and steroid biosynthesis, was also modulated in response to arginine depletion. Consistent with Arginine affecting gene expression, dietary arginine supplementation up-regulates anti-oxidative genes and lowers expression of proinflammatory genes in the adipose and small intestinal tissues.
Lower arginine levels inhibit neurotransmitter biosynthesis, which has shown clinical efficacy in indications such as mania, parkinsons, and dyskenisia.
Asparagine:
Asparagine is a glucogenic nonessential amino acid, whose precursor is oxaloacetate (OAA) and which is synthesized via glutamine and aspartate by a transaminase enzyme. It is used for the function of some neoplastic cells such as lymphoblasts.
Asparagine is typically located at the ends of alpha helices of proteins and provides important sites for N-linked glycosylation to add carbohydrate chains, which affects immune response to amino acid ingestion.
Acrylamide is formed by heat-induced reactions between Asparagine and carbonyl groups of glucose and fructose in many plant-derived foods. Acrylamide is an oxidant that can be cytotoxic, cause gene mutations, and generally affect food quality. Compositions with low levels of asparagine are useful in making safer food products that may be subject to cooking or non-refrigerated storage conditions.
Aspartate:
Aspartate is a glucogenic nonessential amino acid synthesized via the oxaloacetate (OAA) precursor by a transaminase enzyme. As part of the urea cycle, it can also be produced from ornithine and citrulline (or arginine) as the released fumarate is converted to malate and subsequently recycled to OAA. Aspartate provides a nitrogen atom in the synthesis of inosine, which is the precursor in purine biosynthesis. It is also involved in the synthesis of beta-alanine. Aspartate oxidizes in enterocytes of the small intestine, leading to nitrogeneous products ornithine, citrulline, arginine, and alanine.
Aspartate is an agonist of NMDA receptors (Glutamate receptors), releasing Ca2+ as a second messenger in many cellular signaling pathways. There are dopaminergic and glutaminergic abnormalities implicated in schitzophrenia, with NMDA antagonists mimicking some positive and negative symptoms of schitzophrenia, while carrying less risk of brain harm than do dopamine agonists. Ketamine and PCP, for example, produce similar phenotypes observed in schitzophrenia, with PCP showing less representative symptomology yet similar brain structure changes. Glutamate receptors have increased function, contributing to the onset of schizophrenia. An increased proportion of post-synaptic glutamate receptors to pre-synaptic glutamate receptors result in increased glutamate signaling. Both agonizing and antagonizing NMDA receptors has shown some benefit in treating Alzheimer's dementia, depending on the MOA and receptor specificity. Thus delivering proteins with either high or low levels of Aspartate, which also as NMDA agonist activity, could be therapeutic for this patient population. Proteins with low levels of Aspartate would likely provide a synergistic benefit along side NMDA antagonists, such as Memantine. Likewise, clinical trials on LY2140023 have demonstrated glutamate-based treatments as having potential for treating schizophrenia without the side effects seen with xenochemical anti-psychotics. Similar studies combining co-agonist glycine with anti-psychotics, showed improved symptomology, suggesting that delivering high doses of Aspartate, also a NMDA agonist, will yield similar therapeutic benefits in this patient population.
Aspartate is an acidic amino acid, with a low Pka of 3.9. Aspartate in the dipeptide form with phenylalanine via a methyl ester yields aspartame, which is used as a commercial artificial sweetener.
Cysteine:
Cysteine is a nonessential amino acid, and is synthesized from homocysteine, which is itself synthesized from the metabolism of methionine. Serine is involved in cysteine's synthesis by condensing with homocysteine to form cystathionine. Cystathionine is then deaminated and hydrolyzed to form cysteine and alpha ketobutyrate. Cysteine's sulfur comes from homocysteine, but the rest of the molecule comes from the initial serine residue. The biosynthesis of cysteine occurs via a different mechanism in plants and prokaryotes. Cysteine is a vital amino acid because it plays an important role in protein folding. The disulfide linkages formed between cysteine residues helps to stabilize the tertiary and quaternary structure of proteins, and these disulfide linkages are most common among the secreted proteins, where proteins are exposed to more oxidizing conditions that are found in the cellular interior. Despite the benefits of homocysteine, having high systemic levels is a risk factor for developing cardiovascular disease. Elevated homocysteine may be caused by a genetic deficiency of cystathionine beta-synthase and excess methionine intake may be another explanation. Control of methionine intake and supplementation with folic acid and vitamin B12 in the diet has been used to lower homocysteine levels. Furthermore, because the availability of cysteine is a key component that limits the synthesis of glutathionine, dietary supplementation with N-acetyl-cysteine, a precursor for cysteine, is highly effective in enhancing immunity under a wide range of disease states.
Cysteine undergoes rapid oxidation to Cystine. It facilitates the biosynthesis of glutathionine, a powerful antioxidant which can donate a reducing equivalent to unstable molecules such as reactive oxygen species (ROS) free radicals. After reducing an oxidative species, it can form a glutathionine sulfide with another reactive glutathionine, providing a mechanism of depleting oxidative stress inducing molecules from cells (The liver can maintain concentrations of up to 5 mM). Glutathionine is a powerful neutralizer of toxins in the liver, and helps to protect the liver from the damaging effects of toxins. Additionally, this detoxifying ability helps to diminish muscle weakness, prevents brittle hair, and protects against radiation associated with these toxins. As a result, it is beneficial for those suffering from chemical allergies or exposed to high levels of air pollution. Glutathionine also is a cofactor for iNOS, allow maximal synthesis of NO in the arg-NO pathway. NO is important for normal endothelial function and cardiovascular health (including vascular tone, hemodynamics, angiogenesis).
In addition to being a precursor to glutatithionine, cysteine is a precursor for the H2S, which can induce endothelial-dependent relaxation, and can be further converted to cysteine sulfinate. Cysteine sulfunate can be converted to taurine, which has the ability to decrease methionine uptake. An excess of methionine increases the risks of the development of atherosclerosis by inducing hyperhomocysteinemia because homocysteine is an intermediate between methionine and cysteine. However, it is not known whether cysteine decreases homocysteine directly or through the reduction of methionine (Sebastiaan Wesseling, et al., Hypertension. 2009; 53: 909-911).
Furthermore, Cysteine is a precursor for Taurine, which modulates the arginine-NO pathway. Taurine has several potentially protective effects. First, taurine has the ability to reduce oxidative stress by binding to hypochlorite. It has been hypothesized that taurine conjugates to mitochondrial transfer RNA, and in so doing, prevents the formation of mitochondrial superoxide. Additionally, taurine inhibits homocysteine-induced stress of the endoplasmic reticulum of vascular smooth muscle cells and thus restores the expression and secretion of extracellular superoxide dismutase.
Glutamate:
Glutamate oxidizes in enterocytes of the small intestine, leading to nitrogeneous products ornithine, citrulline, arginine, and alanine. Glutamate also modulates the arginine-NO pathway. NO is important for normal endothelial function and cardiovascular health (including vascular tone, hemodynamics, angiogenesis).
High Glutamate
A lack of ATP-producing substrates, as occurs in a fasted state, can lead to autophagy and the turnover of intracellular protein in the lysosome to provide an energy source. Low levels of the glucogenic amino acids, including glutamate can stimulate hepatic autophagy, leading to degradation of liver function.
Citrulline is produced from Glutamate as a by-product of a reaction catalyzed by the NOS family. Dietary supplement of citrulline is known to reduce plasma levels of glucose, homocysteine, and asymmetric dimethylarginine, which are risk factors for metabolic syndrome. L-citrulline accelerates the removal of lactic acid from muscles, likely due to the effects on vascular tone and endothelial function. Recent studies have also shown that L-citrulline from watermelon juice provides greater recovery from exercise, and less soreness the next day. It also appears that delivery of L-citrulline as a free form results in less uptake into cells in vitro than in the context of watermelon juice (which contains high levels of L-citrulline). This suggests an opportunity to deliver peptide doses, which can traffic arginine into muscle tissue for conversion into citrulline by eNOS at the endothelial membrane for improved efficacy.
Glutamate facilitates the biosynthesis of glutathione, which can donate a reducing equivalent to unstable molecules such as reactive oxygen species (ROS) and free radicals. After reducing an oxidative species, it can form a glutathione disulfide with another reactive glutathione, providing a mechanism of depleting oxidative stress inducing molecules from cells (maintains high concentrations of up to 5 mM in the liver). Glutathione also is a cofactor for iNOS, allow maximal synthesis of NO in the arg-NO pathway.
Gluatamate with co-agonists glycine or serine is an agonist of NMDA receptors, releasing Ca2+ as a second messenger in many cellular signaling pathways. There are dopaminergic and glutaminergic abnormalities implicated in schitzophrenia, with NMDA antagonists mimicking some positive and negative symptoms of schitzophrenia, while carrying less risk of brain harm than do dopamine agonists. Ketamine and PCP, for example, produce similar phenotypes observed in schitzophrenia, with PCP showing less representative symptomology yet similar brain structure changes. Glutamate receptors have increased function, contributing to the onset of schizophrenia. An increased proportion of post-synaptic glutamate receptors to pre-synaptic glutamate receptors result in increased glutamate signaling. Both agonizing and antagonizing NMDA receptors has shown some benefit in treating Alzheimer's dementia, depending on the MOA and receptor specificity. Thus delivering proteins with either high or low levels of Glutamate, which also as NMDA agonist activity, could be therapeutic for this patient population. Proteins with low levels of Glutamate would likely provide a synergistic benefit alongside NMDA antagonists, such as Memantine. Likewise, clinical trials on LY2140023 have demonstrated Glutamate-based treatments as having potential for treating schizophrenia without the side effects seen with xenochemical anti-psychotics. Similar studies combining co-agonist Glycine with anti-psychotics, showed improved symptomology, suggesting that delivering high doses of Aspartate, also a NMDA agonist, will yield similar therapeutic benefits in this patient population.
Low Glutamate
Glutamate and acetyl-CoA are converted into N-acetylglutamate in the mitochondria. This pushes the hepatic urea cycle towards the active state, useful for ammonia detoxification. This means that dietary delivery of nutrients with low doses of Glutamate may be useful in the context of kidney disease, where patients struggle to clear urea from their circulation. Elimination of Glutamate to limit uremia from the available nitrogen sources, while being able to maintain a limited protein intake to prevent tissue catabolism, is a novel strategy against a disruptive nutritional consequence of kidney disease.
Glutamine:
Glutamate oxidizes in enterocytes of the small intestine, leading to nitrogeneous products ornithine, citrulline, arginine, and alanine.
Citrulline is produced from Glutamine as a by-product of a reaction catalyzed by the NOS family. Dietary supplement of citrulline is known to reduce plasma levels of glucose, homocysteine, and asymmetric dimethylarginine, which are risk factors for metabolic syndrome. L-citrulline accelerates the removal of lactic acid from muscles, likely due to the affects on vascular tone and endothelial function. Recent studies have also shown that L-citrulline from watermelon juice provides greater recovery from exercise, and less soreness the next day. It also appears that delivery of L-citrulline as a free form results in less uptake into cells in vitro than in the context of watermelon juice (which contains high levels of L-citrulline). This suggests an opportunity to deliver peptide doses, which can traffic arginine into muscle tissue for conversion into citrulline by eNOS at the endothelial membrane for improved efficacy.
High Glutamine
Glutamine is a well studied secretagogue that can stimulate the systemic release of insulin from beta-cells, growth hormone, prolactin, glucagon, progesterone, and placental lactogen. It has also been shown to reduce circulating glucocorticoids and stress hormones. This biology has direct implications on both digestive biology and the absorption of nutrients present in the intestine, as well as affecting energy balance by triggering satiety signals mediated by endocrine hormones. The ability to modulate these hormones provides a therapeutic opportunity for decreasing caloric intake in metabolic disorders such as obesity or alternatively triggering appetite in muscle wasting, sarcopenia, and cachexia, as well as by shifting insulin sensitivity in the onset of diabetes.
Dietary Glutamine supplementation up-regulates anti-oxidative genes and lowers expression of proinflammatory genes in the adipose and small intestinal tissues.
Glutamine is an important signaling molecule for stimulating mTOR1 phosphorylation in a cell-specific manner. This regulates cellular protein turnover (autophagy) and integrates insulin-like growth signals to protein synthesis initiation across tissues. This biology has been directly linked to biogenesis of lean tissue mass in skeletal muscle, metabolic shifts in disease states of obesity and insulin resistance, and aging.
Glutamine is an amino acid that is maintained at sufficient levels to support the anabolic effects of EAAs. Lysine, Methionine, Threonine, Tryptophan, Leucine, Isoleucine, and Valine have been shown unable to support increased protein synthesis and whole-body growth when added to a 12.7% crude protein diet, indicating a deficiency in the anabolic mediating non-essential amino acids, including Glutamine.
Glutamine is slowly cyclized to pyroglutamate. Glutamine is the preferred source of fuel for rapidly dividing cells, including enterocytes, lymphocytes, macrophages, and tumors. Supplementation with glutamine in the diet has significant demonstrated benefits in gut integrity and immune function in surgery, critical illness, burn and infection. A 12-day burn injury study of Glutamine supplementation (0.35 g/kg) showed decreased intestinal permeability, lower endotoxin levels, and shorter length of hospital stay. It provided 8.8× decrease vs 5.5× decrease in Lactulose/mannitol ratio after 3 days and a 6-day reduction in hospital stay. 2 week Glutamine total parenteral nutrition (TPN) (0.23 g/kg) vs Glutamine-Free TPN study of malnourished patients waiting for surgery showed increased gut permeability in Glutamine-Free group. It provided a 3.6× vs 0.81× increase in Lactulose/Mannitol ratio after 2 weeks. These improvements point to an opportunity to deliver high levels of Glutamine in the clinic to improve intestinal immunity and reduced bacteraemia.
This also improves lymphocyte counts systemically and reduces infectious complications during a hospital stay. A study of glutamine supplementation (26 g/day until discharge) in patients with serious burn injury shows 3× more frequent positive blood culture in standard total enteral nutrition (TEN) vs Glutamine-enriched, significantly reducing mortality rate. Additionally, Glutamine supplementation shows increased lymphocyte count and function, increased HGH, reduced infectious complications, reduced hospital stay, reduced morbidity, reduced mortality, and reduced gut permeability.
Intramuscular levels of Glutamine decrease under catabolic states such as stress, burn, injury, and sepsis. This decrease causes an net negative protein in lean tissue. Administration of Glutamine to the skeletal muscle has been shown to increase protein synthesis while inhibiting breakdown in-vitro. Furthermore, dose dependence from physiological concentrations (1 mM Glutamine) up to 15-fold higher concentrations has been observed in skeletal muscle. The effect was further demonstrated in mucosal cells taken from the small intestine.
Branched chain amino acids are all metabolic substrates for glutamine synthesis, providing a source of Glutamine in the fetus, enhancing placental and fetal growth, suggesting a role for Glutamine in mediating their effects on anabolism in mammals. Moreover, it has been shown that Glutamine levels and timing of availability from the plasma affect the cellular uptake of Leucine, and the subsequent profile of mTOR activation. A buildup of intracellular Glutamine is used for uptake of Leucine via the Glutamine/Leucine antiporter, SLC7A5. Administration of glutamine at equal proportions to Leucine in-vitro causes a more sustained stimulation of protein synthesis via mTOR, whereas priming the cells with Glutamine prior to Leucine administration leads to a more rapid, yet transient mTOR activation (Nicklin, P. et. al. Cell 2009).
A lack of ATP-producing substrates, as occurs in a fasted state, can lead to autophagy and the turnover of intracellular protein in the lysosome to provide an energy source. Low levels of the glucogenic amino acids, including glutamine can stimulate hepatic autophagy, leading to degradation of liver function.
Low Glutamine
mTOR is a central signaling pathway which can be hijacked for the proliferation of fast-growing cancer cells, as is evidence by oncogenic cells' preferential uptake of Glutamine.
Glycine:
A lack of ATP-producing substrates, as occurs in a fasted state, can lead to autophagy and the turnover of intracellular protein in the lysosome to provide an energy source. Low levels of the glucogenic amino acids, including glycine can stimulate hepatic autophagy, leading to degradation of liver function.
Glycine facilitates the biosynthesis of glutathione, which can donate a reducing equivalent to unstable molecules such as reactive oxygen species (ROS) and free radicals. After reducing an oxidative species, it can form a glutathione disulfide with another reactive glutathione, providing a mechanism of depleting oxidative stress inducing molecules from cells (maintains high concentrations of up to 5 mM in the liver). Glutathione also is a cofactor for iNOS, allow maximal synthesis of NO in the arg-NO pathway.
Histidine:
Histidine is an essential amino acid, and is a precursor for carnosine. Carnosine is an antioxidant and transition metal ion-sequestering agent. It acts as an anti-glycating agent by inhibiting the formation of advanced glycation end products (AGEs). AGEs are prevalent in diabetic vasculature and contribute to the development of atherosclerosis. The presence of AGEs in various cells types affect both the extracellular and intracellular structure and function. (Golden, A. et. al. Advanced Glycosylation End Products, Circulation 2006). Also, the accumulation of AGEs in the brain is a characteristic of aging and degeneration, particularly in Alzheimer's disease. AGE accumulation explains many neuropathological and biochemical features of Alzheimer's disease such as protein crosslinking, oxidative stress, and neuronal cell death. Because of its combination of antioxidant and antiglycating properties, carnosine is able to diminish cellular oxidative stress and inhibit the intracellular formation of reactive oxygen species and reactive nitrogen species.
Histidine has antioxidant, anti-inflammatory, and anti-secretory properties. Histidine's imidazole rings have the ability to scavenge reactive oxygen species (ROS), which are made by cells during acute inflammatory response. Histidine administration inhibits cytokine and growth factors involved in cell and tissue damage. Histidine administration is instrumental in rheumatoid arthritis treatment, and administering 4.5 g daily has been used to effectively treat patients with severe rheumatoid arthritis. Rheumatoid arthritis patients have been found to have low serum histidine levels due to its very rapid removal from the blood. Low plasma Histidine levels have also been found in patients with chronic renal failure, obese women (where it also had negative impact on oxidative stress and inflammation), pediatric patients with pneumonia, and asthma patients. Histidine supplementation has been shown to diminish insulin resistance, reduce BMI and fat mass. Histidine suppresses inflammation and oxidative stress in obese subjects with a metabolic syndrome. Lastly, as a precursor to histamine, histidine increases levels of histamine in the blood and in the brain. Low blood histamine is found in some manic, schizophrenic, high copper and hyperactive groups of psychiatric patients.
Posttranslational modification of proteins involved in transcriptional regulation is a mechanisms used to regulate genes. This modification can alter protein functions in specific ways. One form of modification is protein methylation, which is one of the most abundant protein modifications. Protein methylation carries important biological functions, including gene regulation and signal transduction. Histidine plays a role in protein modification, and ultimately gene regulation, in that it accepts methyl group transferred from S-adenosylmethionine by protein methyltransferases (Young-Ho Lee and Michael R. Stallcup, Mol Endocrinol. 2009 April; 23(4): 425-433).
Histidine supplementation can be instrumental in the treatment of multiple diseases including: Alzheimer's disease, diabetes, atherosclerosis, metabolic syndrome in women, rheumatoid arthritis, and various psychiatric conditions (manic, schizophrenic, high copper, and hyperactive groups). Additionally, due to its role in protein modifications, Histidine provides an avenue to combat diseases resulting from gene deregulation, including cancer.
Low Histidine
There exists a mechanistic understanding of how uncharged tRNA allosterically activates GCN2, leading to downstream phosphorylation of transcription factors related to lipogenesis and protein synthesis, along with many biosynthetic pathways in eukaryotes (SREBP-1c, eIF2a, and GCN4p discussed below). Diets devoid of an essential amino acid remarkably trigger this signaling within minutes after diet introduction (Hao et. Al., science 2005). Signaling through SREBP-1c has been shown in vivo to have dramatic effects on mobilizing lipid stores by repressing genes related to lipogenesis. SREBP-1c has been shown to specifically act on hepatic lipid synthesis, and an ability to cause a hepatic steatosis phenotype as well as increase in visceral fat mass (Knebel, B. et. Al. Liver-Specific Expression of Transcriptionally Active SREBP-1c Is Associated with Fatty Liver and Increased Visceral Fat Mass. PLoS, 2012). An unbalanced diet lacking Histidine has been shown to signal GCN2 for rats on a basal casein diet with 1-5.4% of an amino acid mixture supplemented lacking Histidine. Histidine deprivation, through its action on GCN2, has an effect on SREBP-1c and decreased physiologic measures of liver weight (and fatty liver phenotype), adipose tissue weight, cholesterol/triglyceride content, and food intake. Driving decreased fat mass, while maintaining lean mass, provides a therapeutic opportunity in areas such as obesity, diabetes, and cardiovascular health.
Isoleucine:
Isoleucine is an EAA, and is also a BCAA. Isoleucine is used in combination with other BCAAs to improve the nutritional status of patients suffering from hepatic disease: BCAAs, including isoleucine, serve as fuel sources for skeletal muscle during periods of metabolic stress; promote protein synthesis, suppress protein catabolism, and serve as substrates for gluconeogenesis. BCAAs, and specifically isoleucine, are catabolized in the skeletal muscle, and stimulate the production of L-alanine and L-glutamine.
BCAAs have been shown to have anabolic effects on protein metabolism by increasing the rate of protein synthesis and decreasing the rate of protein degradation in resting human muscle. Additionally, BCAAs are shown to have anabolic effects in human muscle during post endurance exercise recovery. These effects are mediated through the phosphorylation of mTOR and sequential activation of 70-kD S6 protein kinase (p70-kD S6), and eukaryotic initiation factor 4E-binding protein 1. P70-kD S6 is known for its role in modulating cell-cycle progression, cell size, and cell survival. P70-kD S6 activation in response to mitogen stimulation up-regulates ribosomal biosynthesis and enhances the translational capacity of the cell (W-L An, et al., Am J Pathol. 2003 August; 163 (2): 591-607; E. Blomstrand, et al., J. Nutr. January 2006 136: 269S-273S). Eukaryotic initiation factor 4E-binding protein 1 is a limiting component of the multi-subunit complex that recruits 40S ribosomal subunits to the 5′ end of mRNAs. Activation of p70 S6 kinase, and subsequent phosphorylation of the ribosomal protein S6, is associated with enhanced translation of specific mRNAs.
BCAAs given to subjects during and after one session of quadriceps muscle resistance exercise show an increase in mTOR, p70 S6 kinase, and S6 phosphorylation was found in the recovery period after the exercise. However, there was no such effect of BCAAs on Akt or glycogen synthase kinase 3 (GSK-3). Exercise without BCAA intake leads to a partial phosphorylation of p70 S6 kinase without activating the enzyme, a decrease in Akt phosphorylation, and no change in GSK-3. BCAA infusion also increases p70 S6 kinase phosphorylation in an Akt-independent manner in resting subjects. This mTOR activity regulates cellular protein turnover (autophagy) and integrates insulin-like growth signals to protein synthesis initiation across tissues. This biology has been directly linked to biogenesis of lean tissue mass in skeletal muscle, metabolic shifts in disease states of obesity and insulin resistance, and aging.
Isoleucine supplementation can be used to improve athletic performance and muscle formation, prevent muscle loss that accompanies aging, aid those suffering from hepatic disease, support the growing bodies of children, and improve the nutritive quality of foods given to the starving populations. Additionally, as a precursor for L-alanine and L-glutamine, isoleucine mediates their significant metabolic signaling activities.
Low Isoleucine
In states of obesity and diabetes, animals have been shown to exhibit reduced hepatic autophagy, leading to increased insulin resistance. Autophagy is important for maintenance of the ER and cellular homeostasis, which when stressed can lead to impaired insulin sensitivity. High fat diet feeding in animal models stresses the ER, while leading to depressed hepatic autophagy through over-stimulation of mTORC1, which reinforces the progression towards insulin sensitivity impaired beta-cell function in diabetes. Reducing the level of systemic Isoleucine provides an opportunity to lower mTORC1 activity and restore healthy levels of autophagy.
There exists a mechanistic understanding of how uncharged tRNA allosterically activates GCN2, leading to downstream phosphorylation of transcription factors related to lipogenesis and protein synthesis, along with many biosynthetic pathways in eukaryotes (SREBP-1c, elF2a, and GCN4p discussed below). Diets devoid of any EAAs remarkably trigger this signaling within minutes after diet introduction (Hao et. Al., science 2005). Signaling through SREBP-1c has been shown in vivo to have dramatic effects on mobilizing lipid stores by repressing genes related to lipogenesis. SREBP-1c has been shown to specifically act on hepatic lipid synthesis, and an ability to cause a hepatic steatosis phenotype as well as increase in visceral fat mass (Knebel, B. et. Al. Liver-Specific Expression of Transcriptionally Active SREBP-1c Is Associated with Fatty Liver and Increased Visceral Fat Mass. PLoS, 2012). Isoleucine deprivation, through its action on GCN2, has an effect on SREBP-1c and decreased physiologic measures of liver weight (and fatty liver phenotype), adipose tissue weight, cholesterol/triglyceride content, and food intake. Driving decreased fat mass, while maintaining lean mass, provides a therapeutic opportunity in areas such as obesity, diabetes, and cardiovascular health.
Leucine:
Leucine is an essential amino acid and a branched chain amino acid. The branched chain amino acids, including Leucine, serve as fuel sources for skeletal muscle during periods of metabolic stress; promote protein synthesis, suppress protein catabolism, and serve as substrates for gluconeogenesis. BCAAs, and including Leucine, are catabolized in the skeletal muscle, and stimulate the production of L-alanine and L-glutamine. Leucine plays a direct role in the regulation of protein turnover through cellular mTOR signaling and gene expression as well as serving to activate glumatate dehydrogenase.
BCAAs have been shown to have anabolic effects on protein metabolism by increasing the rate of protein synthesis and decreasing the rate of protein degradation in resting human muscle. Additionally, BCAAs are shown to have anabolic affects in human muscle during post endurance exercise recovery. These affects are mediated through the phosphorylation of mTOR and sequential activation of 70-kD S6 protein kinase (p70-kD S6), and eukaryotic initiation factor 4E-binding protein 1. P70-kD S6 is known for its role in modulating cell-cycle progression, cell size, and cell survival. P70-kD S6 activation in response to mitogen stimulation up-regulates ribosomal biosynthesis and enhances the translational capacity of the cell (W-L An, et al., Am J Pathol. 2003 August; 163(2): 591-607; E. Blomstrand, et al., J. Nutr. January 2006 136: 269S-273S). Eukaryotic initiation factor 4E-binding protein 1 is a limiting component of the multi-subunit complex that recruits 40S ribosomal subunits to the 5′ end of mRNAs. Activation of p70 S6 kinase, and subsequent phosphorylation of the ribosomal protein S6, is associated with enhanced translation of specific mRNAs.
BCAAs given to subjects during and after one session of quadriceps muscle resistance exercise show an increase in mTOR, p70 S6 kinase, and S6 phosphorylation was found in the recovery period after the exercise. However, there was no such effect of BCAAs on Akt or glycogen synthase kinase 3 (GSK-3). Exercise without BCAA intake leads to a partial phosphorylation of p70 S6 kinase without activating the enzyme, a decrease in Akt phosphorylation, and no change in GSK-3. BCAA infusion also increases p70 S6 kinase phosphorylation in an Akt-independent manner in resting subjects. Leucine is furthermore known to be the primary signaling molecule for stimulating mTOR1 phosphorylation in a cell-specific manner. This regulates cellular protein turnover (autophagy) and integrates insulin-like growth signals to protein synthesis initiation across tissues. This biology has been directly linked to biogenesis of lean tissue mass in skeletal muscle, metabolic shifts in disease states of obesity and insulin resistance, and aging.
Leucine is a well-studied secretagogue that can stimulate the systemic release of insulin from beta-cells, growth hormone, prolactin, glucagon, progesterone, and placental lactogen. This biology has direct implications on both digestive biology and the absorption of nutrients present in the intestine, as well as affecting energy balance by triggering satiety signals mediated by endocrine hormones. The ability to modulate these hormones provides a therapeutic opportunity for decreasing caloric intake in metabolic disorders such as obesity or alternatively triggering appetite in muscle wasting, sarcopenia, and cachexia, as well as by shifting insulin sensitivity in the onset of diabetes.
Leucine activates glutamate dehydrogenase, which is an enzyme that catalyzes the reversible interconversion between glutamate, α-ketoglutarate, and ammonia. In mammals, glutamate dehydrogenase has high levels of activity in the liver, kidney, brain, and pancreas. In the liver, glutamate dehydrogenase provides the appropriate ratio of ammonia and amino acids for urea synthesis in periportal hepatocytes, and the glutamate dehydrogenase reactions seem to be in a close-to-equilibrium state. Additionally, glutamate dehydrogenase has been shown to produce glutamate for glutamine synthesis in a small rim of pericentral hepatocytes, enabling it to serve as either a source for ammonia or an ammonia scavenger. In the kidney, glutamate dehydrogenase functions to produce ammonia from glutamate to control acidosis (C. Spanaki and A. Plaitakis, Neurotox Res. 2012 January; 21(1):117-27).
Leucine supplementation can be used to improve athletic performance and muscle formation, prevent muscle loss that accompanies aging, aid those suffering from hepatic disease, support the growing bodies of children, and improve the nutritive quality of foods given to the starving populations. Additionally, leucine plays an important role in urea synthesis in hepatocytes, and may be given to treat those who suffer from conditions that cause them to be hyperammonemic. Lastly, leucine may be used to treat acidosis.
Low Leucine
In states of obesity and diabetes, animals have been shown to exhibit reduced hepatic autophagy, leading to increased insulin resistance. Autophagy is important for maintenance of the ER and cellular homeostasis, which when stressed can lead to impaired insulin sensitivity. High fat diet feeding in animal models stresses the ER, while leading to depressed hepatic autophagy through over-stimulation of mTORC1, which reinforces the progression towards insulin sensitivity impaired beta cell function in diabetes. Reducing the level of systemic Leucine provides an opportunity to lower mTORC1 activity and restore healthy levels of autophagy.
mTOR is a central signaling pathway which can be hijacked for the proliferation of fast-growing cancer cells. Depletion of Leucine may reduce a fast-growing cell's ability to sustain constitutive mTOR activation.
There exists a mechanistic understanding of how uncharged tRNA allosterically activates GCN2, leading to downstream phosphorylation of transcription factors related to lipogenesis and protein synthesis, along with many biosynthetic pathways in eukaryotes (SREBP-1c, eIF2a, and GCN4p discussed below). Diets devoid of an EAA remarkably trigger this signaling within minutes after diet introduction (Hao et. Al., science 2005). Signaling through SREBP-1c has been shown in vivo to have dramatic effects on mobilizing lipid stores by repressing genes related to lipogenesis. SREBP-1c has been shown to specifically act on hepatic lipid synthesis, and an ability to cause a hepatic steatosis phenotype as well as increase in visceral fat mass (Knebel, B. et. Al. Liver-Specific Expression of Transcriptionally Active SREBP-1c Is Associated with Fatty Liver and Increased Visceral Fat Mass. PLoS, 2012). Leucine deprivation, through its action on GCN2, has an affect on SREBP-1c and decreased physiologic measures of liver weight (and fatty liver phenotype), adipose tissue weight, cholesterol/triglyceride content, and food intake. Driving decreased fat mass, while maintaining lean mass, provides a therapeutic opportunity in areas such as obesity, diabetes, and cardiovascular health.
Leucine deprivation, furthermore, has directly shown up-regulation of UCP1 in brown adipose tissue (BAT), a direct measure of thermogenesis, an increase in energy expenditure (presumably due to an increase in thermogenesis in BAT), and a corresponding decrease in fat mass by stimulation of lipolysis in the white adipose tissue (WAT). UCP1 up-regulation results in decreased food intake, body weight, abdominal fat mass, fat mass, and maintenance of lean mass (Guo, F. The GCN2 elF2alpha kinase regulates fatty-acid homeostasis in the liver during deprivation of an essential amino acid. Cell Metab., 2007).
Lysine:
Lysine is an EAA that is important for proper growth, and plays a vital role in the production of carnitine. Carnitine is a quaternary amine that plays an important role in the production of energy in the myocardium. Carnitine transports free fatty acids into the mitochondria, and in so doing, increases the preferred substrate for oxidative metabolism in the heart. Additionally, carnitine prevents the fatty acid accumulation that occurs during ischemic events, which may lead to ventricular arrhythmias. As the myocardial carnitine levels are quickly diminished during an ischemic event, exogenous supplementation with carnitine replenishes the depleted myocardial carnitine levels and improve cardiac metabolic and left ventricular function. Additionally, an analysis of 4 studies demonstrated that supplementation with L-carnitine after an acute myocardial infarction (AMI), in comparison to a placebo, significantly reduces left ventricular dilation in the first year after the AMI. This is significant because the prevention of left ventricular dilation and the preservation of cardiac function after an AMI is a powerful predictor of the progression to heart failure and death. Additionally, carnitine aids in lowering cholesterol, which further supports heart health, and aids in the prevention of acute myocardial infarctions (James J. DiNicolantonio, et al., Mayo Clinic Proceedings, 2013; 88, 544-551).
Lysine supplementation is useful to support heart health and during ischemic events to prevent ventricular arrhythmia. In addition, Lysine supplementation may help heart attack patients recover effectively, and aid in the prevention of heart attacks in those with the left ventricular dilation. Also, Lysine can be used for to decrease cholesterol levels in patients with high cholesterol.
Lysine is instrumental in helping the body to absorb calcium and decreases the amount of calcium that is lost in urine. Due to calcium's role in bone health, Lysine supplementation is helpful in preventing the bone loss that is associated with osteoporosis. Furthermore, a combination of L-arginine and Lysine makes the bone building cells more active and enhances production of collagen, which is substance that is important for bones and connective tissues including: skin, tendon, and cartilage.
Lysine supplementation is useful for patients suffering from osteoporosis, and those at risk for developing osteoporosis; the elderly, menopausal women, growing children, in cosmetics due to its role in collagen production, and athletes for improved ligament integrity.
A lysine deficiency causes fatigue, nausea, dizziness, loss of appetite, agitation, bloodshot eyes, slow growth, anemia, and reproductive disorders.
Lysine helps to prevent and suppress outbreaks of cold sores and genital herpes when taken on a regular basis. When 45 patients with frequently recurring herpes infection were given 312-1200 mg of lysine daily in single or multiple doses, recovery from the infection and suppression of recurrence was evidenced (Griffith R. S., et al., Dermatologica 1978; 156:257-267). This is because lysine has antiviral effects, which act by blocking the activity of arginine, which promotes herpes simplex virus (HSV) replication. In tissue culture studies, herpes viral replication is enhanced when the arginine/lysine ratio favors arginine. However, when the arginine/lysine ratio favors lysine, viral replication is suppressed, ad cyto-pathogenicity of HSV is inhibited. (Griffith R. S., et al., Dermatologica 1978; 156:257-267). It has been shown that oral lysine is more effective for preventing an outbreak than it is at reducing the severity and duration of the outbreak.
Supplementing the diet with Lysine for those infected with the HSV suppresses outbreak of cold sores and genital warts, and when actively taken on a regular basis is very beneficial in the prevention of outbreaks.
Lysine modulates the arginine-NO pathway. NO is important for normal endothelial function and cardiovascular health (including vascular tone, hemodynamics, angiogenesis). Lysine is a natural inhibitor of L-arginine transport, and competes with L-arginine for uptake through the system y+, which is the major transport system of cationic amino acids in mammalian cells. Excess nitric oxide contributes to refractory hypotension associated with sepsis, and can be combatted with administration of L-lysine because it inhibits Arginine, which is an important component of NO synthesis (K. G. Allman, et al., British Journal of Anaesthesia (1998) 81: 188-192). Moreover, an excess of NO may lead to diseases, due to its release from cerebral vasculature, brain tissue, and nerve endings, which are prime regions for neurodegeneration. Excess NO may lead to migraines, brain cell damage that can lead to neurodegenerative diseases like Parkinson disease, Alzheimer's disease, Huntington disease, and amyotrophic lateral sclerosis. Furthermore, NO that is produced by the pancreas may damage the beta-cells as occurs in type 1 diabetes.
Lysine supplementation is useful for the prevention of hypotension associated with sepsis by preventing vasodilation. Additionally, lysine may be used to prevent/treat migraines, and prevent/slow down the progression of neurodegenerative diseases like AD, Parkinson's disease, Huntington, and amyotrophic lateral sceloris.
Low Lysine
There exists a mechanistic understanding of how uncharged tRNA allosterically activates GCN2, leading to downstream phosphorylation of transcription factors related to lipogenesis and protein synthesis, along with many biosynthetic pathways in eukaryotes (SREBP-1c, eIF2a, and GCN4p discussed below). Diets devoid of an EAA remarkably trigger this signaling within minutes after diet introduction (Hao et. Al., science 2005). Signaling through SREBP-1c has been shown in vivo to have dramatic effects on mobilizing lipid stores by repressing genes related to lipogenesis. SREBP-1c has been shown to specifically act on hepatic lipid synthesis, with an ability to cause a hepatic steatosis phenotype as well as increase in visceral fat mass (Knebel, B. et. Al. Liver-Specific Expression of Transcriptionally Active SREBP-1c Is Associated with Fatty Liver and Increased Visceral Fat Mass. PLoS, 2012). Lysine deprivation, through its action on GCN2, has an affect on SREBP-1c and decreased physiologic measures of liver weight (and fatty liver phenotype), adipose tissue weight, cholesterol/triglyceride content, and food intake. Driving decreased fat mass, while maintaining lean mass, provides a therapeutic opportunity in areas such as obesity, diabetes, and cardiovascular health.
Methionine:
Methionine is an essential amino acid, and is the initiating amino acid in the synthesis of virtually all eukaryotic proteins. Methionine is one of the most hydrophobic AAs. Most of the methionine residues in globular proteins can be found in the interior of the hydrophobic core. Methionine is often found to interact with the lipid bilayer in membrane-spanning protein domains. Due to its location and powerful antioxidative properties, methionine has been regarded as endogenous antioxidants in proteins (John T. Brosnan and Margaret E. Brosnan, J. Nutr. June 2006 vol. 136 no. 6 1636S-1640S). Methionine residues have a high susceptibility to oxidation by oxidases, ozone, hydrogen peroxide, superoxide, γ-irradiation, metal-catalyzed oxidation, “leakage” from the electron transport chain, and auto-oxidation of flavins or xenobiotics. Once oxidized, the Methionine residue is converted to methionine sulfoxide, which can be converted back to Methionine though methionine sulfoxide reductases (Rodney L. Levine, et al., Proc Natl Acad Sci USA, 1996 Dec. 24; 93(26): 15036-15040). As an antioxidant, methionine supplementation can aid in the prevention of cancer, degenerative diseases, heart disease, liver and kidney pathologies. It can also be used in cosmetics to fight the damage of UV rays to the skin.
Methionine is a lipotropic AA, and helps the liver process lipids, and thereby helps prevent the build-up of fat in the liver and arteries that may ultimately lead to an obstruction of blood flow to the brain, heart, and kidneys. Additionally, the build-up of fat in the liver drives a pathology known as hepatic steatosis, which may ultimately lead to cirrhosis of the liver. Methionine supplementation for individuals undergoing drug detoxification may improve the process, as well as for those taking medications which have toxic side effects.
In addition, to being a lipotropic AA, Methionine promotes heart health by increasing of the liver's production of lectithin, which is known to help reduce cholesterol levels. Methionine supplementation can prevent cirrhosis of the liver from fat deposition therein. Additionally, it can promote cardiovascular health by preventing the deposition of fat into the arteries, thereby preventing possible myocardial infarctions and strokes. Further, Methionine may help those with high cholesterol levels lower their cholesterol, improving the risk of cardiovascular disease
Methionine aids in the proper functioning of the immune system in that elevated levels of methionine increases the levels of taurine, and homocysteine and glutathione which help improve immune function. The underlying mechanism for the immune functions may involve mTOR activation, NO and glutathionine synthesis, H2S signaling, and cellular redox state. Methionine is a precursor for Taurine, which modulates the arginine-NO pathway. NO is important for normal endothelial function and cardiovascular health (including vascular tone, hemodynamics, angiogenesis).
Methionine is also converted into cysteine, which is a precursor for Glutathionine. Glutathionine is a powerful neutralizer of toxins in the liver, and helps to protect the liver from the damaging effects of toxins. Additionally, this detoxifying ability helps to diminish muscle weakness, prevents brittle hair, and protects against radiation associated with these toxins. As a result, it is beneficial for those suffering from chemical allergies or exposure to high levels of air pollution. Methionine can be helpful to patients with compromised immune systems, such as AIDS patients and cancer patients. Likewise, it can be a useful supplement during flu seasons, particularly to groups who are most susceptible, including: the elderly, children, and pregnant women. Furthermore, it can be used for those travelling to countries where they will likely be susceptible to regional infections. Methionine levels are observed to be lower in patients with AIDS. This decreased level of methionine has been linked to deterioration in the nervous system that leads to symptoms like dementia, and diminished memory recall. Supplementing with 6 grams of methionine per day can lead to improvements in the memory recall in these patients. Likewise, Methionine can be beneficial to those who have diseases that involve nervous system degeneration including Alzheimer's Disease, ALS, MS, and Huntington's.
Methionine participates in one-carbon metabolism, and thereby also participates in the methylation of proteins and DNA, which in turn helps regulate gene expression and the biological activity of proteins. Methionine supplementation for those at risk for related genetic disorders can be used to promote proper gene regulation in all individuals.
Low Methionine
Methionine is a precursor for the toxic homocysteine, which mediates ADMA by down-regulating DDAH in body to metabolize ADMA, interfering with the arginine-NO pathway. NO is important for normal endothelial function and cardiovascular health (including vascular tone, hemodynamics; angiogenesis).
There exists a mechanistic understanding of how uncharged tRNA allosterically activates GCN2, leading to downstream phosphorylation of transcription factors related to lipogenesis, protein synthesis, along with many biosynthetic pathways in eukaryotes (SREBP-1c, eIF2a, and GCN4p discussed below). Diets devoid of any EEAs remarkably trigger this signaling within minutes after diet introduction (Hao et. Al., science 2005). Signaling through SREBP-1c has been shown in vivo to have dramatic effects on mobilizing lipid stores by repressing genes related to lipogenesis. SREBP-1c has been shown to specifically act on hepatic lipid synthesis, and an ability to cause a hepatic steatosis phenotype as well as increase in visceral fat mass (Knebel, B. et. Al; Liver-Specific Expression of Transcriptionally Active SREBP-1c Is Associated with Fatty Liver and Increased Visceral Fat Mass. PLoS, 2012). Methionine deprivation, through its action on GCN2, has an affect on SREBP-1c and decreased physiologic measures of liver weight (and fatty liver phenotype), adipose tissue weight, cholesterol/triglyceride content, and food intake. Driving decreased fat mass, while maintaining lean mass, provides a therapeutic. opportunity in areas such as obesity, diabetes, and cardiovascular health.
Phenylalanine:
Phenylalanine is an EEA, AuAA, and precursor for synthesis of norepinephrine in the brain, as well as a metabolic precursor for tyrosine, which is another aromatic amino acid and precursor for the synthesis of dopamine.
Norepinephrine (NE) is synthesized in the adrenal medulla and postganglionic neurons in the sympathetic nervous system by the β-oxidation of dopamine by β-hydroxylase along with the cofactor ascorbate. It works by being secreted into the synaptic cleft where it stimulates adrenergic receptors and is then either degraded or up-taken by surrounding cells. As a cathecolamine, it does not cross the blood-brain barrier.
NE can be used to combat attention-deficit/hyperactivity disorders (ADHD), depression, and hypotension. In terms of attention disorders, like ADHD, medications prescribed tend to help increase levels of NE and dopamine. Furthermore, depression is typically treated with medications that inhibit the reuptake of serotonin and NE thereby increasing the amount of serotonin and NE that is available in the postsynaptic cells in the brain. Recent evidence has suggested that serotonin-norepinephrine reuptake inhibitors (SNRIs) may also increase dopamine transmission because if the norepinephrine transporter ordinarily recycled dopamine as well, then SNRIs will also enhance the dopaminergic transmission. As a result, the effects antidepressants may also be associated with the increased NE levels may partly be due to the simultaneous increase in dopamine (in particular in the prefrontal cortex of the brain).
NE is used to treat patients with critical hypotension. NE is a vasopressor and acts on both α1 and α2 adrenergic receptors to cause vasoconstriction, thereby increasing the blood pressure.
As a precursor for NE, Phenylalanine can be used to treat attention disorders like ADHD and ADD. Additionally, it can be used to treat those suffering from depression or post-traumatic stress syndrome. Phenylalaline can also be used to treat depression or alter the function of neurotransmitter modulating drugs such as SSRIs. Additionally, due to its ability to increase blood pressure through the increase of vascular tone, it may be used to treat those with a hypotensive tendency. Furthermore, phenylalanine may be used as an upstream regulator of tyrosine levels, and thereby Tyrosine function.
Tyrosine supplementation can help in the treatment of Parkinson's disease due to its role as a precursor to L-DOPA and dopamine. Additionally, it can be used in the treatment of those with emotional/psychiatric disorder like depression and in the treatment of addiction. Furthermore, it can promote learning by increasing the reward/pleasure response during learning difficult or complex concepts or movements.
Dopamine, which is a monoamine catecholamine neurotransmitter, plays a regulatory role in the immune system. Neurotransmitters and neuropeptides that interact with specific receptors present in particular immune effector cells are released by the immune system to influence the functions of these cells in the host against disease and other environmental stress. The immunoregulatory actions of dopamine have been shown to be regulated via five different G protein-coupled receptors that are present in target cells. There are two broad classes of these receptors: G1 and G2, which encompass the varying subtypes. The D1 class of receptors includes D2 and D5 subtypes, and increase intracellular cAMP upon activation. The D2 class of receptors consists of the D2, D3, and D4 subtypes, and has been reported to inhibit intracellular cAMP upon stimulation. Dopamine receptors have been found on normal human leukocytes. Likewise, the lymphoid tissues have dopaminergic innervations through sympathetic nerves, which suggests that dopamine may be able to regulate the immune system effector cells (Basu, Sujit & Sarkar, Chandrani, Dopamine and immune system. SciTopics 2010).
Dopamine affects T cells by activating the resting T cells and inhibiting the activation of stimulated T cells. In normal resting peripheral human T lymphocytes, dopamine activates the D2 and D3 subclass of receptors, which in turn activates integrins (α4β1 and α5β1). These integrins are hetrodimeric transmembrane glycoproteins that attach cells to the extracellular matrix component, fibronectin. Fibronectin is used for the trafficking and extravasation of T cells across the tissue barriers and blood vessels. Furthermore, dopamine acts through the D3 receptors to selectively induce the migration and homing of CD8+ T cells. Moreover, dopamine affects T cells by influencing the secretions of cytokines by the T cells. When dopamine stimulates the D3 and D1/D5 receptors, the secretion of TNF-α (a pleiotropic inflammatory cytokine) is increased. When the D2 receptors are stimulated, IL-10 (an anti-inflammatory cytokine) is induced to secrete. Dopamine, however, can inhibit the activated T cell receptor induced cell proliferation and secretion of a number of cytokines like Il-2, IFN-γ and IL-4 through the down-regulation of the expression of non-receptor tyrosine kinases Ick and fyn, which are important tyrosine kinases in the initiation of TCR activation (Basu, Sujit & Sarkar, Chandrani Dopamine and immune system. SciTopics 2010).
The B cells have a very high expression of dopamine D2, D3, and D5 receptors. Dopamine has the ability to inhibit the proliferation of the resting and the malignant B lymphocytes. Dopamine acts by promoting apoptosis in cycling B cells through oxidative stress. However, this dopaminergic action has not been observed in resting lymphocytes, therefore suggesting a role in the prevention of cancer (Basu, Sujit & Sarkar, Chandrani, Dopamine and immune system. SciTopics 2010).
Tyrosine, as a precursor for Dopamine, can be used to improve immune responses and improve the overall immune system functionality. It can provide a benefit to the elderly, women who are pregnant, children, and those with compromised immune functions like AIDS patients, and cancer patients. It also can be given to teachers, those travelling, and anyone frequently exposed to germs.
Epinephrine, which is popularly known as adrenaline, is a hormone that is secreted by the medulla of the adrenal glands. Epinephrine is released in response to strong emotions such as fear or anger, which causes an increase in heart rate, muscle strength, blood pressure, and sugar metabolism. It is responsible for the flight or fight response that prepares the body for difficult or strenuous activity. Epinephrine is used as a stimulant during cardiac arrest, as a vasoconstrictor during shock to increase blood pressure, and as a bronchodilator and antispasmodic in bronchial asthma. Epinephrine is not found in large quantities in the body, but is nevertheless very important in the maintenance of cardiovascular homeostasis because it has the ability to divert blood to tissues under stress. Epinephrine has this effect by influencing muscle contraction. Contraction of the muscles occurs through the binding calmodulin to calcium ions when the concentration is 10× larger than normal in the cell. The calcium-calmodulin complex then goes on to activate the myosin light chain kinase, which then phosphorylates the LC2 causing the contraction. Epinephrine binds to the epinephrine receptors, which activates adenylyl cyclase, and produces cyclic AMP from ATP. cAMP activates a protein kinase which thus phosphorylates the myosin light chain kinase. This phosphorylated myosin light chain kinase has a lower affinity for the calcium-calmodulin complex, and is thus inactive. As such, the smooth muscle tissue is relaxed. It is this action of epinephrine that makes it very useful in treating asthma, cardiac arrest, and anaphylactic shock. Tyrosine, as a precursor for Epinephrine, can be used for patients who are at risk for cardiac arrest, those suffering from asthma, and those who are at risk for anaphylactic shock.
Epinephrine is one of two main hormones that breakdown glycogen by binding to a receptor on exterior of a liver cell. This binding causes a conformational change to take place thereby allowing G protein to bind and become active. The activation of the G-protein coupled receptor causes a conformational change on the molecule to occur which causes adenylate cyclase to bind. Onceadenylate cyclase binds the complex, adenylate cyclase breaks down ATP into cAMP, which then becomes the second messenger protein in this process and activates protein kinase. The activated protein kinase activates phosphorylase, which is an enzyme that catalyzes breaks down the glycogen to glucose. Tyrosine, as a precursor for Epinephrine, can be used to improve athletic performance by making glucose readily available to fuel exercise.
Melanin is a metabolite of Tyrosine, and is a powerful antioxidant. Additionally, it is influential in the inhibition of the production of inflammatory cytokines and superoxide. When pro-inflammatory cytokines are overproduced, it mediates the damaging effects of inflammation in pathologic conditions like rheumatoid arthritis, graft vs. host reactions, cachexia, and sepsis syndrome. It has been found that melanin inhibits ongoing cytokine synthesis, which strongly suggests that melanin may be useful as a superimposed therapy for conditions that involve proinflammatory cytokines (Mohagheghpour N., et al., Cell Immunol. 2000 Jan. 10; 199(1):25-36).
Tyrosine can be used in the treatment of rheumatoid arthritis, cachexia, sepsis syndrome, those with inflammation related to autoimmune disorder, and other inflammatory sequela of pathologic conditions.
Phenylalanine up-regulates the activity of GTP cyclohydrolase-I, freeing tetrahydrobiopterin (THB) for NO synthesis and the hydroxylation of ArAAs by aromatic amino acid hydroxylase (AAAH). For this reason, delivery of high levels of Phenylalanine to raise cellular levels of THB directly stimulates the biosynthesis of many neurotransmitters in the CNS capillary endothelial cells. ArAAs serve as precursors for biosynthesis of monoamine neurotransmitters, including melatonin, dopamine, norepinephrine (noradrenaline), and epinephrine (adrenaline). In promoting NO synthesis, phenylalanine can be used to treat hypertension, to decrease blood pressure, and may be used in the context of diving, or those travelling to high altitudes to increase vasodilation.
Low Phenylalanine
There exists a mechanistic understanding of how uncharged tRNA allosterically activates GCN2, leading to downstream phosphorylation of transcription factors related to lipogenesis and protein synthesis, along with many biosynthetic pathways in eukaryotes (SREBP-1c, eIF2a, and GCN4p discussed below). Diets devoid of any EAAs remarkably trigger this signaling within minutes after diet introduction (Hao et. Al., science 2005). Signaling through SREBP-1c has been shown in vivo to have dramatic effects on mobilizing lipid stores by repressing genes related to lipogenesis. SREBP-1c has been shown to specifically act on hepatic lipid synthesis, and an ability to cause a hepatic steatosis phenotype as well as increase in visceral fat mass (Knebel, B. et. Al. Liver-Specific Expression of Transcriptionally Active SREBP-1c Is Associated with Fatty Liver and Increased Visceral Fat Mass. PLoS, 2012). Phenylalanine deprivation, through its action on GCN2, has an effect on SREBP-1c and decreased physiologic measures of liver weight (and fatty liver phenotype), adipose tissue weight, cholesterol/triglyceride content, and food intake. Driving decreased fat mass, while maintaining lean mass, provides a therapeutic opportunity in areas such as obesity, diabetes, and cardiovascular health.
Proline:
Citrulline is produced from Glutamine as a by-product of a reaction catalyzed by the NOS family. Dietary supplement of citrulline is known to reduce plasma levels of glucose, homocysteine, and asymmetric dimethylarginine, which are risk factors for metabolic syndrome. L-citrulline accelerates the removal of lactic acid from muscles, likely due to the effects on vascular tone and endothelial function. Recent studies have also shown that L-citrulline from watermelon juice provides greater recovery from exercise and less soreness the next day. It also appears that delivery of L-citrulline as a free form results in less uptake into cells in vitro than in the context of watermelon juice (which contains high levels of L-citrulline). This suggests an opportunity to deliver peptide doses, which can traffic arginine into muscle tissue for conversion into citrulline by eNOS at the endothelial membrane for improved efficacy.
Changes in NO synthesis and polyamines (via Proline), are seen during gestation when placental growth rate peaks, indicating a role for arginine in fetal development during pregnancy.
Serine:
Serine is a nonessential amino acid, and is biosynthesized from glycolysis via 3-phosphoglycerate. Serine plays a vital role in intermediary metabolism in that it contributes to phospholipid, sphingolipid, and cysteine biosynthesisas well as tryptophan synthesis in bacteria and is a primary source of glycine. The body has a need for glycine, which probably exceeds dietary intake by 10-50 fold. This demand is not only for the synthesis of protein, particularly collagen, but also for glycine being a precursor for 5 major metabolic biosynthetic pathways: creatine, porphyrins, purines, bile acids, and glutathione. Additionally, due to its role in glycine production, serine is also a major donor of folate-linked one-carbon units that are used in the biosynthesis of purines and 2′ deoxythymidine 5′-monophosphate and the remethylation of homocystein to methionine. It is important to note that for every glycine molecule that is derived from serine, there is one-carbon unit formed. (Cook, R. Defining the steps of the folate one-carbon shuffle and homocysteine metabolism 1 ′ 2 ; Am. J Clin Nutr; 2000)
In one-carbon metabolism, one-carbon units for biosynthesis are carried and chemically activated by a family of cofactors called tetrahydrofolate (THF) polyglutamates. THF-mediated one-carbon metabolism is a metabolic system of interdependent biosynthetic pathways compartmentalized in the cytoplasm, the mitochondria, and the nucleus. In the cytoplasm, one-carbon metabolism is used for the synthesis of purines and thymidylates and the remethylation of homocysteine to methionine (an overabundance of homocysteine may be harmful to the body). In the mitochondria, one-carbon metabolism is used for the synthesis of formylated methionyl-tRNA; the catabolism of choline, purines, and histidine; and the interconversion of serine and glycine. Additionally, the mitochondria is the primary source for one-carbon units for cytoplasmic metabolism. Disruption of the folate-mediated one-carbon metabolism has been linked with many pathologies and developmental anomalies. (J. T. Fox and P. J. Stover, Chapter 1, Folate-Mediated One-Carbon Metabolism, In: Gerald Litwack, Editor(s), Vitamins & Hormones, Academic Press, 2008, Volume 79, Pages 1-44).
Serine hydroxymethyltransferase (SHMT) catalyzes the freely reversible interconversion of serine and glycine in a reaction that is both folate- and pyridoxal 5-phosphate dependent. The conversion of serine to glycine involves the removal of the C-3 serine and the formation of 5,10-methylenetetrahydrofolate, which can be utilized in the folate-dependent one-carbon metabolism or oxidized to carbon dioxide via 10-foryltetrahydrofolate (Robert J Cook, Am J Clin Nutr December 2000 vol. 72 no. 6 1419-1420).
Serine is a precursor for cysteine. Cysteine is synthesized from homocysteine, which is itself synthesized from the metabolism of methionine. Serine is involved in cysteine's synthesis by condensing with homocysteine to form cystathionine. Cystathionine is then deaminated and hydrolyzed to form cysteine and alpha ketobutyrate. Cysteine's sulfur comes from homocysteine, but the rest of the molecule comes from the initial serine residue. The biosynthesis of cysteine occurs via a different mechanism in plants and prokaryotes. Cysteine is a vital amino acid because it plays an important role in protein folding. The disulfide linkages formed between cysteine residues helps to stabilize the tertiary and quaternary structure of proteins, and these disulfide linkages are most common among the secreted proteins, where proteins are exposed to more oxidizing conditions that are found in the cellular interior. Despite the benefits of homocysteine, high levels can be a risk factor for developing cardiovascular disease. Elevated homocysteine may be caused by a genetic deficiency of cystathionine beta-synthase and excess methionine intake may be another explanation. Control of methionine intake and supplementing with folic acid and vitamin B12 in the diet have been used to lower homocysteine levels. Likewise, increased Serine levels to support homocysteine to cysteine conversion can be beneficial.
N-methyl-D-aspartate (NMDA) is one of the most fundamental neurotransmitters in the brain. It is a glutamate receptor and is a vital molecular device for the control of synaptic plasticity and memory function. This receptor is an ionotropic receptor for glutamate and is characterized by high affinity for glutamate, a high unitary conductance, high calcium permeability, and a voltage-dependent block by magnesium ions. In order for the NMDA receptor to open, it is bound by glutamate and glycine or D-serine. D-serine is a neurotransmitter and a gliotransmitter that is biosynthesized in the brain by serine racemase from L-serine. It is a powerful or potent agonist to glycine for the NMDA receptor binding site. (Jean-Pierre Mothet, et al., Proc Natl Acad Sci USA, 2000, 97 (9) 4926-4931; Zito K and Scheuss V. (2009) NMDA Receptor Function and Physiological Modulation. In: Encyclopedia of Neuroscience (Squire L R, ed), volume 6, pp. 1157-1164. Oxford: Academic Press).
Serine plays an important role in learning and synaptic plasticity, as a result, serine supplementation can be useful to the elderly, growing children, school age children, and those experiencing learning difficulties. Additionally, it can be given to anyone trying to learn a new task, be it an instrument, or athletes/dancers trying to improve or learn new exercises and movements. Furthermore, due to its role as a precursor for cysteine, may be given as an upstream regulator for the effects of cysteine. As a precursor for the synthesis of glycine, serine may be used in cosmetic products, to combat aging, and promote proper growth because of its role in collagen synthesis. Furthermore, it can be used to improve athletic abilities because of its role in the creatine biosynthetic pathway. Moreover, it may be very useful in the detoxification and immune health because of its role in the glutathionine metabolic pathway.
Threonine:
Threonine is an EAA, and is one of the few AAs that is not converted into its L-isomer via transaminases and d-AA oxidases. Threonine is used for the synthesis of mucin protein, which is used for maintaining the integrity and function of the intestines. Mucus, which is composed of mucin and inorganic salts suspended in water, serve as a diffusion barrier against contact with noxious substances such as gastric acid and smoke. Mucus also acts as a lubricant to minimize shear stresses (G. K. Law, et al., Am J Physiol Gastrointest Liver Physiol 292:G1293-G1301, 2007).
90% of dietary threonine is used in the gut for mucus synthesis. Mucin is continuously synthesized and is very resistant to intestinal proteolysis, and is therefore not very easily recycled. As such, a substantial and consistent supply of threonine is used in order to effectively maintain gut function and structure. As a result, it is very important that the diet is rich with threonine in order to prevent mucus production from decreasing, which can lead to cancers in the gut, ulcers, etc. (G. K. Law, et al., Am J Physiol Gastrointest Liver Physiol 292:G1293-G1301, 2007; A. Hamard, et al., Journal of Nutritional Biochemistry, October 2010, Volume 21, Issue 10, Pages 914-921). Due to the importance of mucus to the integrity and structure of the gut, threonine supplementation can be useful in the prevention of gut disorder including cancers, ulcers, infections, and erosions.
Threonine plays a key role in humoral immunity because threonine is a major component of immunoglobulins, which are secreted by B lymphocytes in the blood. Once released, they reach the site of infection, recognize, bind, and inactivate their antigens. Because of the high threonine content of immunoglobulins, a threonine deficiency may have negatively affect immunoglobulin production, and thereby decrease immune response. Threonine supplementation is essential for its role in the immune response and can support leukemia patients, AIDS patients, and individuals who have immunodeficiency. Additionally, it can support those susceptible to infection during the flu season, such as the elderly and small children, as well as throughout the year to strengthen immune response.
Low Threonine
There exists a mechanistic understanding of how uncharged tRNA allosterically activates GCN2, leading to downstream phosphorylation of transcription factors related to lipogenesis, protein synthesis, along with many biosynthetic pathways in eukaryotes (SREBP-1c, elF2a, and GCN4p discussed below). Diets devoid of any EAAs remarkably trigger this signaling within minutes after diet introduction (Hao et. Al., science 2005). Signaling through SREBP-1c has been shown in vivo to have dramatic effects on mobilizing lipid stores by repressing genes related to lipogenesis. SREBP-1c has been shown to specifically act on hepatic lipid synthesis, and an ability to cause a hepatic steatosis phenotype as well as increase in visceral fat mass (Knebel, B. et. Al. Liver-Specific Expression of Transcriptionally Active SREBP-1c Is Associated with Fatty Liver and Increased Visceral Fat Mass. PLoS, 2012). An unbalanced diet lacking Threonine has been shown to signal GCN2 for rats on a basal casein diet with 1-5.4% of an amino acid mixture supplemented lacking Threonine. Threonine deprivation, through its action on GCN2, has an effect on SREBP-1c and decreased physiologic measures of liver weight (and fatty liver phenotype), adipose tissue weight, cholesterol/triglyceride content, and food intake. Driving decreased fat mass, while maintaining lean mass, provides a therapeutic opportunity in areas such as obesity, diabetes, and cardiovascular health.
Tryptophan:
Tryptophan is both an EAA that plays an important role in immune functions. For example, concentrations of tryptophan progressively decline due to chronic lung inflammation. This suggests that catabolism of tryptophan via the indoleamine 2,3-dioxygenase (IDO) appears to be very important for function of macrophages and lymphocytes. Thus, antranilic acid (ANS) inhibits the production of proinflammatory T-helper 1 cytokines and prevents autoimmune neuroinflammation. Tryptophan can be used to treat the inflammatory effects of certain diseases include arthritis and asthma or other autoimmune diseases.
It is also a precursor for serotonin (5-HT) synthesis, a neurotransmitter that affects appetite, sleep and is widely implicated in onset of depression. Abnormality in 5-HT activity in recovered depression patients (on SSRIs or other neurotransmitter re-uptake inhibitors) leads to an acute sensitivity to low levels of Tryptophan in the bloodstream. 5-HT production can be increased 2-fold by oral intake of free Tryptophan, indicating a role for Tryptophan administration in depression. Furthermore, Tryptophan can potentiate the effects of SSRIs due to the apparent dependence on 5-HT availability for improvement in patient outcome.
Tryptophan can furthermore be used to help in weight loss/maintenance, benefit those suffering from sleep disorders, recovery from travel and jet lag; in addition to those suffering from mood disorders like depression or the effects of PMS.
Low Tryptophan
There exists a mechanistic understanding of how uncharged tRNA allosterically activates GCN2, leading to downstream phosphorylation of transcription factors related to lipogenesis, protein synthesis, along with many biosynthetic pathways in eukaryotes (SREBP-1c, eIF2a, and GCN4p discussed below). Diets devoid of any EAAs remarkably trigger this signaling within minutes after diet introduction (Hao et. Al., science 2005). Signaling through SREBP-1c has been shown in vivo to have dramatic effects on mobilizing lipid stores by repressing genes related to lipogenesis. SREBP-1c has been shown to specifically act on hepatic lipid synthesis, and an ability to cause a hepatic steatosis phenotype as well as increase in visceral fat mass (Knebel, B. et. Al. Liver-Specific Expression of Transcriptionally Active SREBP-1c Is Associated with Fatty Liver and Increased Visceral Fat Mass. PLoS, 2012). Tryptophan deprivation, through its action on GCN2, has an effect on SREBP-1c and decreased physiologic measures of liver weight (and fatty liver phenotype), adipose tissue weight, cholesterol/triglyceride content, and food intake. Driving decreased fat mass, while maintaining lean mass, provides a therapeutic opportunity in areas such as obesity, diabetes, and cardiovascular health.
Tyrosine:
Tyrosine is a nonessential amino acid that is synthesized from phenylalanine. It is used as a precursor for many important neurotransmitters including, epinephrine, norepinephrine, and dopamine. Tyrosine helps produce melanin, and helps the organs that make and regulate hormones, like the adrenal gland, thyroid gland, and pituitary gland: Additionally, tyrosine is involved in the structure of almost every protein in the body.
Tyrosine hydroxylase converts L-tyrosine into Levodopa using tetrahydropteridine as a cofactor or by tyrosinase. The conversion that is mediated by tyrosinase specifically oxidizes Levodopa to Dopaquinone, and levodopa is further decarboxylated to Dopamine by Dopa decarboxylase. Dopamine is a very important hormone and neurotransmitter, and plays a vital role in both mental and physical health. Dopamine helps to control the brain's reward and pleasure centers, helps to regulate movement and emotional responses, and enables one to see rewards and take action to move towards those rewards. The neurons that contain dopamine are clustered in the midbrain, in an area called the susbtantia nigra. In those afflicted with Parkinson's disease, the neurons that transmit dopamine in this area die resulting in an inability to control bodily movement. In order to relieve the symptoms of Parkinson's disease, L-Dopa, which can be converted to dopamine is given to the patients.
Tyrosine supplementation can help in the treatment of Parkinson's disease due to its role as a precursor to L-DOPA and dopamine. Additionally, it can be used in the treatment of those with emotional/psychiatric disorder like depression and in the treatment of addiction. Furthermore, it can promote learning by increasing the reward/pleasure response during learning difficult or complex concepts or movements.
Dopamine, which is a monoamine catecholamine neurotransmitter, plays a regulatory role in the immune system. Neurotransmitters and neuropeptides that interact with specific receptors present in particular immune effector cells are released by the immune system to influence the functions of these cells in the host against disease and other environmental stress. The immunoregulatory actions of dopamine have been shown to be regulated via five different G protein-coupled receptors that are present in target cells. There are two broad classes of these receptors: G1 and G2, which encompass the varying subtypes. The D1 class of receptors includes D2 and D5 subtypes, and increase intracellular cAMP upon activation. The D2 class of receptors consists of the D2, D3, and D4 subtypes, and has been reported to inhibit intracellular cAMP upon stimulation. Dopamine receptors have been found on normal human leukocytes. Likewise, the lymphoid tissues have dopaminergic innervations through sympathetic nerves, which suggests that dopamine may be able to regulate the immune system effector cells (Basu, Sujit & Sarkar, Chandrani, Dopamine and immune system. SciTopics 2010).
Dopamine affects T cells by activating the resting T cells and inhibiting the activation of stimulated T cells. In normal resting peripheral human T lymphocytes, dopamine activates the D2 and D3 subclass of receptors, which in turn activates integrins (α4β1 and α5⊖1). These integrins are hetrodimeric transmembrane glycoproteins that attach cells to the extracellular matrix component, fibronectin. Fibronectin is used for the trafficking and extravasation of T cells across the tissue barriers and blood vessels. Furthermore, dopamine acts through the D3 receptors to selectively induce the migration and homing of CD8+ T cells. Moreover, dopamine affects T cells by influencing the secretions of cytokines by the T cells. When dopamine stimulates the D3 and D1/D5 receptors, the secretion of TNF-α (a pleiotropic inflammatory cytokine) is increased. When the D2 receptors are stimulated, IL-10 (an anti-inflammatory cytokine) is induced to secrete. Dopamine, however, can inhibit the activated T cell receptor induced cell proliferation and secretion of a number of cytokines like Il-2, IFN-γ and IL-4 through the down-regulation of the expression of non-receptor tyrosine kinases Ick and fyn, which are important tyrosine kinases in the initiation of TCR activation (Basu, Sujit & Sarkar, Chandrani Dopamine and immune system. SciTopics 2010).
The B cells have a very high expression of dopamine D2, D3, and D5 receptors. Dopamine has the ability to inhibit the proliferation of the resting and the malignant B lymphocytes. Dopamine acts by promoting apoptosis in cycling B cells through oxidative stress. However, this dopaminergic action has not been observed in resting lymphocytes, therefore suggesting a role in the prevention of cancer (Basu, Sujit & Sarkar, Chandrani, Dopamine and immune system. SciTopics 2010).
Tyrosine, as a precursor for Dopamine, can be used to improve immune responses and improve the overall immune system functionality. It can provide a benefit to the elderly, women who are pregnant, children, and those with compromised immune functions like AIDS patients and cancer patients. It also can be given to teachers, those travelling, and anyone frequently exposed to germs.
NE is synthesized in the adrenal medulla and postganglionic neurons in the sympathetic nervous system by the β-oxidation of dopamine by β-hydroxylase along with the cofactor ascorbate. It works by being secreted into the synaptic cleft where it stimulates adrenergic receptors, and is then either degraded or up-taken by surrounding cells. As a cathecolamine, it does not cross the blood-brain barrier.
NE can be used to combat ADHD, depression, and hypotension. In terms of attention disorders, like ADHD, medications prescribed tend to help increase levels of NE and dopamine. Furthermore, depression is typically treated with medications that inhibit the reuptake of serotonin and NE thereby increasing the amount of serotonin and NE that is available in the postsynaptic cells in the brain. Recent evidence has suggested that SNRIs may also increase dopamine transmission because if the norepinephrine transporter ordinarily recycled dopamine as well, then SNRIs will also enhance the dopaminergic transmission. As a result, the effects antidepressants may also be associated with the increased NE levels may partly be due to the simultaneous increase in dopamine (in particular in the prefrontal cortex of the brain).
NE is used to treat patients with critical hypotension. NE is a vasopressor and acts on both α1 and α2 adrenergic receptors to cause vasoconstriction, thereby increasing the blood pressure.
As a precursor for NE, Tyrosine can be used to treat attention disorders like ADHD and ADD. Additionally, it can be used to treat those suffering from depression, post-traumatic stress syndrome, and those with acute hypotension.
Epinephrine, which is popularly known as adrenaline, is a hormone that is secreted by the medulla of the adrenal glands. Epinephrine is released in response to strong emotions such as fear or anger, which causes an increase in heart rate, muscle strength, blood pressure, and sugar metabolism. It is responsible for the flight or fight response that prepares the body for difficult or strenuous activity. Epinephrine is used as a stimulant during cardiac arrest, as a vasoconstrictor during shock to increase blood pressure, and as a bronchodilator and antispasmodic in bronchial asthma. Epinephrine is not found in large quantities in the body, but is nevertheless very important in the maintenance of cardiovascular homeostasis because it has the ability to divert blood to tissues under stress. Epinephrine has this effect by influencing muscle contraction. Contraction of the muscles occurs through the binding calmodulin to calcium ions when the concentration is 10× larger than normal in the cell. The calcium-calmodulin complex then goes on to activate the myosin light chain kinase, which then phosphorylates the LC2 causing the contraction. Epinephrine binds to the epinephrine receptors, which activates adenylyl cyclase, and produces cyclic AMP from ATP. cAMP activates a protein kinase which thus phosphorylates the myosin light chain kinase. This phosphorylated myosin light chain kinase has a lower affinity for the calcium-calmodulin complex, and is thus inactive. As such, the smooth muscle tissue is relaxed. It is this action of epinephrine that makes it very useful in treating asthma, cardiac arrest, and anaphylactic shock. Tyrosine, as a precursor for Epinephrine, can be used for patients who are at risk for cardiac arrest, those suffering from asthma, and those who are at risk for anaphylactic shock.
Epinephrine is one of two main hormones that breakdown glycogen by binding to a receptor on exterior of a liver cell. This binding causes a conformational change to take place thereby allowing G protein to bind and become active. The activation of the G-protein coupled receptor causes a conformational change on the molecule to occur which causes adenylate cyclase to bind. Once adenylate cyclase binds the complex, adenylate cyclase breaks down ATP into cAMP, which then becomes the second messenger protein in this process and activates protein kinase. The activated protein kinase activates phosphorylase, which is an enzyme that catalyzes breaks down the glycogen to glucose. Tyrosine, as a precursor for Epinephrine, can be used to improve athletic performance by making glucose readily available to fuel exercise.
Melanin is a metabolite of Tyrosine, and is a powerful antioxidant. Additionally, it is influential in the inhibition of the production of inflammatory cytokines and superoxide. When pro-inflammatory cytokines are overproduced, it mediates the damaging effects of inflammation in pathologic conditions like rheumatoid arthritis, graft vs. host reactions, cachexia, and sepsis syndrome. It has been found that melanin inhibits ongoing cytokine synthesis, which strongly suggests that melanin may be useful as a superimposed therapy for conditions that involve proinflammatory cytokines (Mohagheghpour N., et al., Cell Immunol. 2000 Jan. 10; 199(1):25-36).
Tyrosine can be used in the treatment of rheumatoid arthritis, cachexia, sepsis syndrome, those with inflammation related to autoimmune disorder, and other inflammatory sequela of pathologic conditions.
Valine:
Valine is an EAA, and is also a BCAA. The BCAAs, including valine, serve as fuel sources for skeletal muscle during periods of metabolic stress by promoting protein synthesis, suppressing protein catabolism, and serving as substrates for gluconeogenesis. The BCAAs, including valine, are substrates for glutamine synthesis in animal tissues, and it has been shown that glutamine may play a role in mediating the anabolic effect of BCAAs in animals. Such an effect is likely to be important for the lactating mammary gland because it produces more glutamine than it takes up from arterial blood. Catabolism of BCAAs in the placenta results in glutamine synthesis and its release into the fetal circulation, which is a major source of the glutamine that circulates in the fetus. This suggests that supplementing a diet with Valine as well as the other BCAAs, or a combination thereof, may increase fetal growth in mammals. Additionally, Valine plays a direct role in the synthesis of alanine, and therefore has a regulatory function with regards to alanine.
BCAAs have been shown to have anabolic effects on protein metabolism by increasing the rate of protein synthesis and decreasing the rate of protein degradation in resting human muscle. Additionally, BCAAs are shown to have anabolic effects in human muscle during post endurance exercise recovery. These effects are mediated through the phosphorylation of mTOR and sequential activation of 70-kD S6 protein kinase (p70-kD S6), and eukaryotic initiation factor 4E-binding protein 1. P70-kD S6 is known for its role in modulating cell-cycle progression, cell size, and cell survival. P70-kD S6 activation in response to mitogen stimulation up-regulates ribosomal biosynthesis and enhances the translational capacity of the cell (W-L An, et al., Am J Pathol. 2003 August; 163(2): 591-607; E. Blomstrand, et al., J. Nutr. January 2006 136: 269S-273S). Eukaryotic initiation factor 4E-binding protein 1 is a limiting component of the multi-subunit complex that recruits 40S ribosomal subunits to the 5′ end of mRNAs. Activation of p70 S6 kinase, and subsequent phosphorylation of the ribosomal protein S6, is associated with enhanced translation of specific mRNAs.
BCAAs given to subjects during and after one session of quadriceps muscle resistance exercise show an increase in mTOR, p70 S6 kinase, and S6 phosphorylation was found in the recovery period after the exercise. However, there was no such effect of BCAAs on Akt or glycogen synthase kinase 3 (GSK-3). Exercise without BCAA intake leads to a partial phosphorylation of p70 S6 kinase without activating the enzyme, a decrease in Akt phosphorylation, and no change in GSK-3. BCAA infusion also increases p70 S6 kinase phosphorylation in an Akt-independent manner in resting subjects. This mTOR activity regulates cellular protein turnover (autophagy) and integrates insulin-like growth signals to protein synthesis initiation across tissues. This biology has been directly linked to biogenesis of lean tissue mass in skeletal muscle, metabolic shifts in disease states of obesity and insulin resistance, and aging.
Valine plays a key role in muscle metabolism, tissue repair, and the maintenance of proper nitrogen balance in the body. As one of the three BCAAs, it can be utilized as an energy source by muscle tissue. Valine is a glucogenic AA, and therefore provides glucose. Valine may be useful in the treatment of liver and gallbladder disease. Additionally, valine may be useful in correcting the type of severe AA deficiencies caused by drug addiction. Furthermore, Valine has been found to promote mental vigor, muscle coordination, and calm emotions. It may also be used to prevent muscle loss at high altitudes.
Valine supplementation can be used to improve athletic performance and muscle formation, aid in drug addiction rehabilitation, to enhance mental vigor in elderly and growing children, prevent muscle loss that accompanies aging, aid those suffering from hepatic disease, support the growing bodies of children, serve as a therapy for gallbladder and liver disease, to increase lactation in mammals, to increase fetal growth in mammals, and improve the nutritive quality of foods given to the starving populations.
Low Valine
In states of obesity and diabetes, animals have been shown to exhibit reduced hepatic autophagy, leading to increased insulin resistance. Autophagy is important for maintenance of the ER and cellular homeostasis, which when stressed can lead to impaired insulin sensitivity. High fat diet feeding in animal models stresses the ER, while leading to depressed hepatic autophagy through over-stimulation of mTORC1, which reinforces the progression towards insulin sensitivity impaired beta cell function in diabetes. Reducing the level of systemic Valine provides an opportunity to lower mTORC1 activity and restore healthy levels of autophagy.
There exists a mechanistic understanding of how uncharged tRNA allosterically activates GCN2, leading to downstream phosphorylation of transcription factors related to lipogenesis and protein synthesis, along with many biosynthetic pathways in eukaryotes (SREBP-1c, eIF2a, and GCN4p discussed below). Diets devoid of any EAAs remarkably trigger this signaling within minutes after diet introduction (Hao et. Al., science 2005). Signaling through SREBP-1c has been shown in vivo to have dramatic effects on mobilizing lipid stores by repressing genes related to lipogenesis. SREBP-1c has been shown to specifically act on hepatic lipid synthesis, and an ability to cause a hepatic steatosis phenotype as well as increase in visceral fat mass (Knebel, B. et. Al. Liver-Specific Expression of Transcriptionally Active SREBP-1c Is Associated with Fatty Liver and Increased Visceral Fat Mass. PLoS, 2012). Valine deprivation, through its action on GCN2, has an effect on SREBP-1c and decreased physiologic measures of liver weight (and fatty liver phenotype), adipose tissue weight, cholesterol/triglyceride content, and food intake. Driving decreased fat mass, while maintaining lean mass, provides a therapeutic opportunity in areas such as obesity, diabetes, and cardiovascular health.
In Vitro Analyses of Amino Acid Pharmacology.
As provided herein, amino acids behave both as necessary substrates for the synthesis of new proteins and also serve as signaling molecules. Analysis of the pharmacological properties of a given amino acid is dependent on the cell line and model system utilized. For example, the amino acid leucine has been shown to increase phosphorylation of the mammalian target of rapamycin complex I and downstream targets involved in anabolism in skeletal muscle cells (Gran P & D Cameron-Smith. 2011. The actions of exogenous leucine on mTOR signaling and amino acid transporters in human myotubes. BMC Physiol. 11:10). In vitro assays of amino acid pharmacology can also reveal auxotrophies in certain types of cancer. Auxotrophies to methionine have been reported in multiple immortalized cancer cell lines (Cavuoto P & M F Fenech. 2012. A review of methionine dependency and the role of methionine restriction in cancer growth control and life-span extension. Cancer Treat Rev. 38: 726-736).
An in vitro assay may be designed utilizing amino acids, protein digests, or di- and tri-peptides as the independent or manipulated variable after identifying a relevant cell line. An appropriate cell line is selected based on its relevance as a model of cellular processes. For example, C2C12 (ATCC, CRL-1772) is a murine myoblast cell line that differentiates into myofibers and is used as a model of skeletal muscle fiber differentiation and development. Cells are maintained in a complete medium supplemented with fetal bovine serum up to 10% which supplies necessary growth factors, and penicillin and streptomycin. Adherent cell lines are grown in T75 flasks with phenolic caps for filtered gas exchange and incubated at 37° C. at 5% CO2 in a humidified environment. Table AA lists cell lines that are used to assay amino acid pharmacology. For an in vitro assay, cells are seeded in T75 flasks, 6-, 12-, 24-, 48- or 96-well plates at an appropriate cell density, determined empirically. Following an incubation period the complete growth medium is replaced with medium deficient in the test article. Following a period of medium depletion the test article is added in the appropriate medium. Following the treatment period, the relevant dependent variable is measured.





TABLE AA



List of exemplary cell lines utilized in vitro assays of amino acid

pharmacology.








Tissue or


Cell Line
Species
Cell Type
Systems Modeled



C2C12

Mus musculus

Skeletal
Skeletal muscle growth and



muscle
differentiation

RSkMC

Rattus

Skeletal
Skeletal muscle growth and



norvegicus

muscle
differentiation

3T3-L1

Mus musculus

Embryo
White adipose tissue




development

CHO-K1

Cricetulus

Ovary
Heterologous protein



griseus


expression

FHs 74 Int

Homo sapiens

Small
Gastrointestinal and



intestine
enteroendocrine systems

293T

Homo sapiens

Embryonic
Heterologous protein



kidney
expression

IEC-6

Rattus

Small
Gastrointestinal and



norvegicus

intestine/
enteroendocrine systems



epithelium


NCI-H716

Homo sapiens

Cecum
Gastrointestinal and




enteroendocrine systems

STC-1

Mus musculus

Intestine
Gastrointestinal and




enteroendocrine systems

MCF-7

Homo sapiens

Lung
Breast cancer




adenocarcinoma

LNCaP clone

Homo sapiens

Prostate
Prostate cancer carcinoma

FGC




PC-3

Homo sapiens

Prostate
Prostate cancer




adenocarcinoma















































See, e.g., Wu, G. Amino acids: Metabolism, functions, and nutrition. Amino Acids 37(1):1-17 (2009); Wu, G. Functional amino acids in nutrition and health. Amino Acids 45(3):407-11 (2013); Schworer, C. Glucagon-induced autophagy and proteolysis in rat liver: Mediation by selective deprivation of intracellular amino acids. PNAS 76(7):3169-73 (1979); Codongo, P. Autophagy: A Potential Link between Obesity and Insulin Resistance. Cell Metabolism 11(6):449-51 (2010); Leong, H et. al. Short-term arginine deprivation results in large-scale modulation of hepatic gene expression in both normal and tumor cells: microarray bioinformatic analysis. Nutrition and metabolism 3:37 (2006); Harbrecht, B. G. Glutathione regulates nitric oxide synthase in cultured hepatocytes. Annals of Surgery 225 (1): 76-87 (1997); Watermelon juice: a potential functional drunk for sore muscle relief in athletes. J. Agric. Food Chem. 61(31):7522-8 (2013).
Secreted Nutritive Polypeptides.
In another aspect, provided are nutritive polypeptides that contain the amino acid sequences of edible species polypeptides, which are engineered to be secreted from unicellular organisms and purified therefrom. Such nutritive polypeptides can be endogenous to the host cell or exogenous, and can be naturally secreted in either the polypeptide or the host cell, or both, and are engineered for secretion of the nutritive polypeptide.
Advantageous properties of a nutritive polypeptide include the ability to be expressed and secreted in a host cell, solubility in a wide variety of solvents, and when consumed by an intended subject, nutritional benefit, reduced allergenicity or nonallergenicity, lack of toxicity, and digestibility. Such properties can be weighted based, at least in part, on the intended consumer and the reason(s) for consumption of the nutritive polypeptide (e.g., for general health, muscle anabolism, immune health, or treatment or prevention of a disease, disorder or condition). One or multiple nutritional criteria are satisfied for example, by computing the mass fractions of all relevant amino acid(s) based on primary sequence.
By way of non-limiting examples, polypeptides of the present invention are provided in Table 1. The Predicted leader column shows the sequence indices of predicted leaders (if a leader exists). The Fragment Indices column shows the sequence indices of fragment sequences. The DBID column lists either the UniProt or GenBank Accession numbers for each sequence as available as of Sep. 24, 2014, each of which is herein incorporated by reference. DBIDs with only numerical characters are from a GenBank database, and those with mixed alphabetical/numerical characters are from a UniProt database.
Nucleic Acids
Also provided herein are nucleic acids encoding polypeptides or proteins. In some embodiments the nucleic acid is isolated. In some embodiments the nucleic acid is purified.
In some embodiments of the nucleic acid, the nucleic acid comprises a nucleic acid sequence that encodes a first polypeptide sequence disclosed herein. In some embodiments of the nucleic acid, the nucleic acid consists of a nucleic acid sequence that encodes a first polypeptide sequence disclosed herein. In some embodiments of the nucleic acid, the nucleic acid comprises a nucleic acid sequence that encodes a protein disclosed herein. In some embodiments of the nucleic acid, the nucleic acid consists of a nucleic acid sequence that encodes a protein disclosed herein. In some embodiments of the nucleic acid the nucleic acid sequence that encodes the first polypeptide sequence is operatively linked to at least one expression control sequence. For example, in some embodiments of the nucleic acid the nucleic acid sequence that encodes the first polypeptide sequence is operatively linked to a promoter such as a promoter described herein.
Accordingly, in some embodiments the nucleic acid molecule of this disclosure encodes a polypeptide or protein that itself is a polypeptide or protein. Such a nucleic acid molecule can be referred to as a “nucleic acid.” In some embodiments the nucleic acid encodes a polypeptide or protein that itself comprises at least one of: a) a ratio of branched chain amino acid residues to total amino acid residues of at least 24%; b) a ratio of Leu residues to total amino acid residues of at least 11%; and c) a ratio of essential amino acid residues to total amino acid residues of at least 49%. In some embodiments the nucleic acid comprises at least 10 nucleotides, at least 20 nucleotides, at least 30 nucleotides, at least 40 nucleotides, at least 50 nucleotides, at least 60 nucleotides, at least 70 nucleotides, at least 80 nucleotides, at least 90 nucleotides, at least 100 nucleotides, at least 200 nucleotides, at least 300 nucleotides, at least 400 nucleotides, at least 500 nucleotides, at least 600 nucleotides, at least 700 nucleotides, at least 800 nucleotides, at least 900 nucleotides, at least 1,000 nucleotides. In some embodiments the nutritrive nucleic acid comprises from 10 to 100 nucleotides, from 20 to 100 nucleotides, from 10 to 50 nucleotides, or from 20 to 40 nucleotides. In some embodiments the nucleic acid comprises all or part of an open reading frame that encodes an edible species polypeptide or protein. In some embodiments the nucleic acid consists of an open reading frame that encodes a fragment of an edible species protein, wherein the open reading frame does not encode the complete edible species protein.
In some embodiments the nucleic acid is a cDNA.
In some embodiments nucleic acid molecules are provided that comprise a sequence that is at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.9% identical to an edible species nucleic acid. In some embodiments nucleic acids are provided that hybridize under stringent hybridization conditions with at least one reference nucleic acid.
The nucleic acids and fragments thereof provided in this disclosure display utility in a variety of systems and methods. For example, the fragments can be used as probes in various hybridization techniques. Depending on the method, the target nucleic acid sequences can be either DNA or RNA. The target nucleic acid sequences can be fractionated (e.g., by gel electrophoresis) prior to the hybridization, or the hybridization can be performed on samples in situ. One of skill in the art will appreciate that nucleic acid probes of known sequence find utility in determining chromosomal structure (e.g., by Southern blotting) and in measuring gene expression (e.g., by Northern blotting). In such experiments, the sequence fragments are preferably detectably labeled, so that their specific hydridization to target sequences can be detected and optionally quantified. One of skill in the art will appreciate that the nucleic acid fragments of this disclosure can be used in a wide variety of blotting techniques not specifically described herein.
It should also be appreciated that the nucleic acid sequence fragments disclosed herein also find utility as probes when immobilized on microarrays. Methods for creating microarrays by deposition and fixation of nucleic acids onto support substrates are well known in the art. Reviewed in DNA Microarrays: A Practical Approach (Practical Approach Series), Schena (ed.), Oxford University Press (1999) (ISBN: 0199637768); Nature Genet. 21 (1)(suppl):1-60 (1999); Microarray Biochip: Tools and Technology, Schena (ed.), Eaton Publishing Company/BioTechniques Books Division (2000) (ISBN: 1881299376), the disclosures of which are incorporated herein by reference in their entireties. Analysis of, for example, gene expression using microarrays comprising nucleic acid sequence fragments, such as the nucleic acid sequence fragments disclosed herein, is a well-established utility for sequence fragments in the field of cell and molecular biology. Other uses for sequence fragments immobilized on microarrays are described in Gerhold et al., Trends Biochem. Sci. 24:168-173 (1999) and Zweiger, Trends Biotechnol. 17:429-436 (1999); DNA Microarrays: A Practical Approach (Practical Approach Series), Schena (ed.), Oxford University Press (1999) (ISBN: 0199637768); Nature Genet. 21 (1)(suppl):1-60 (1999); Microarray Biochip: Tools and Technology, Schena (ed.), Eaton Publishing Company/BioTechniques Books Division (2000) (ISBN: 1881299376).
Expression
Vectors
Also provided are one or more vectors, including expression vectors, which comprise at least one of the nucleic acid molecules disclosed herein, as described further herein. In some embodiments, the vectors comprise at least one isolated nucleic acid molecule encoding a protein as disclosed herein. In alternative embodiments, the vectors comprise such a nucleic acid molecule operably linked to one or more expression control sequence. The vectors can thus be used to express at least one recombinant protein in a recombinant microbial host cell. In some aspects, a vector or set of vectors can include a nucleic acid sequence coding for a signal peptide, e.g., to cause secretion of a protein disclosed herein. See below for further discussion of signal peptides and secretion.
Suitable vectors for expression of nucleic acids in microorganisms are well known to those of skill in the art. Suitable vectors for use in cyanobacteria are described, for example, in Heidorn et al., “Synthetic Biology in Cyanobacteria: Engineering and Analyzing Novel Functions,” Methods in Enzymology, Vol. 497, Ch. 24 (2011). Exemplary replicative vectors that can be used for engineering cyanobacteria as disclosed herein include pPMQAK1, pSL1211, pFC1, pSB2A, pSCR119/202, pSUN119/202, pRL2697, pRL25C, pRL1050, pSG111M, and pPBH201.
Other vectors such as pJB161 which are capable of receiving nucleic acid sequences disclosed herein may also be used. Vectors such as pJB161 comprise sequences which are homologous with sequences present in plasmids endogenous to certain photosynthetic microorganisms (e.g., plasmids pAQ1, pAQ3, and pAQ4 of certain Synechococcus species). Examples of such vectors and how to use them is known in the art and provided, for example, in Xu et al., “Expression of Genes in Cyanobacteria: Adaptation of Endogenous Plasmids as Platforms for High-Level Gene Expression in Synechococcus sp. PCC 7002,” Chapter 21 in Robert Carpentier (ed.), “Photosynthesis Research Protocols,” Methods in Molecular Biology, Vol. 684, 2011, which is hereby incorporated herein by reference. Recombination between pJB161 and the endogenous plasmids in vivo yield engineered microbes expressing the genes of interest from their endogenous plasmids. Alternatively, vectors can be engineered to recombine with the host cell chromosome, or the vector can be engineered to replicate and express genes of interest independent of the host cell chromosome or any of the host cell's endogenous plasmids.
A further example of a vector suitable for recombinant protein production is the pET system (Novagen®). This system has been extensively characterized for use in E. coli and other microorganisms. In this system, target genes are cloned in pET plasmids under control of strong bacteriophage T7 transcription and (optionally) translation signals; expression is induced by providing a source of T7 RNA polymerase in the host cell. T7 RNA polymerase is so selective and active that, when fully induced, almost all of the microorganism's resources are converted to target gene expression; the desired product can comprise more than 50% of the total cell protein a few hours after induction. It is also possible to attenuate the expression level simply by lowering the concentration of inducer. Decreasing the expression level may enhance the soluble yield of some target proteins. In some embodiments this system also allows for maintenance of target genes in a transcriptionally silent un-induced state.
In some embodiments of using this system, target genes are cloned using hosts that do not contain the T7 RNA polymerase gene, thus alleviating potential problems related to plasmid instability due to the production of proteins potentially toxic to the host cell. Once established in a non-expression host, target protein expression can be initiated either by infecting the host with λCE6, a phage that carries the T7 RNA polymerase gene under the control of the λ pL and pI promoters, or by transferring the plasmid into an expression host containing a chromosomal copy of the T7 RNA polymerase gene under lacUV5 control. In the second case, expression is induced by the addition of IPTG or lactose to the bacterial culture or using an autoinduction medium. Other plasmids systems that are controlled by the lac operator, but do not require the T7 RNA polymerase gene and rely upon E. coli 's native RNA polymerase include the pTrc plasmid suite (Invitrogen) or pQE plasmid suite (QIAGEN).
In other embodiments it is possible to clone directly into expression hosts. Two types of T7 promoters and several hosts that differ in their stringency of suppressing basal expression levels are available, providing great flexibility and the ability to optimize the expression of a wide variety of target genes.
Suitable vectors for expression of nucleic acids in mammalian cells typically comprise control functions provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma virus, Adenovirus 2, cytomegalovirus, or Simian Virus 40.
Promoters
Promoters useful for expressing the recombinant genes described herein include both constitutive and inducible/repressible promoters. Examples of inducible/repressible promoters include nickel-inducible promoters (e.g., PnrsA, PnrsB; see, e.g., Lopez-Mauy et al., Cell (2002) v. 43: 247-256) and urea repressible promoters such as PnirA (described in, e.g., Qi et al., Applied and Environmental Microbiology (2005) v. 71: 5678-5684). Additional examples of inducible/repressible promoters include PnirA (promoter that drives expression of the nirA gene, induced by nitrate and repressed by urea) and Psuf (promoter that drives expression of the sufB gene, induced by iron stress). Examples of constitutive promoters include Pcpc (promoter that drives expression of the cpc operon), Prbc (promoter that drives expression of rubisco), PpsbAII (promoter that drives expression of PpsbAII), Pcro (lambda phage promoter that drives expression of cro). In other embodiments, a PaphII and/or a lacIq-Ptrc promoter can used to control expression. Where multiple recombinant genes are expressed in an engineered microorganism, the different genes can be controlled by different promoters or by identical promoters in separate operons, or the expression of two or more genes can be controlled by a single promoter as part of an operon.
Further non-limiting examples of inducible promoters may include, but are not limited to, those induced by expression of an exogenous protein (e.g., T7 RNA polymerase, SP6 RNA polymerase), by the presence of a small molecule (e.g., IPTG, galactose, tetracycline, steroid hormone, abscisic acid), by absence of small molecules (e.g., CO 2 , iron, nitrogen), by metals or metal ions (e.g., copper, zinc, cadmium, nickel), and by environmental factors (e.g., heat, cold, stress, light, darkness), and by growth phase. In some embodiments, the inducible promoter is tightly regulated such that in the absence of induction, substantially no transcription is initiated through the promoter. In some embodiments, induction of the promoter does not substantially alter transcription through other promoters. Also, generally speaking, the compound or condition that induces an inducible promoter is not naturally present in the organism or environment where expression is sought.
In some embodiments, the inducible promoter is induced by limitation of CO 2 supply to a cyanobacteria culture. By way of non-limiting example, the inducible promoter can be the promoter sequence of Synechocystis PCC 6803 that are up-regulated under the CO 2 -limitation conditions, such as the cmp genes, ntp genes, ndh genes, sbt genes, chp genes, and rbc genes, or a variant or fragment thereof.
In some embodiments, the inducible promoter is induced by iron starvation or by entering the stationary growth phase. In some embodiments, the inducible promoter can be variant sequences of the promoter sequence of cyanobacterial genes that are up-regulated under Fe-starvation conditions such as isiA, or when the culture enters the stationary growth phase, such as isiA, phrA, sigC, sigB, and sigH genes, or a variant or fragment thereof.
In some embodiments, the inducible promoter is induced by a metal or metal ion. By way of non-limiting example, the inducible promoter can be induced by copper, zinc, cadmium, mercury, nickel, gold, silver, cobalt, and bismuth or ions thereof. In some embodiments, the inducible promoter is induced by nickel or a nickel ion. In some embodiments, the inducible promoter is induced by a nickel ion, such as Ni 2+ . In another exemplary embodiment, the inducible promoter is the nickel inducible promoter from Synechocystis PCC 6803. In another embodiment, the inducible promoter can be induced by copper or a copper ion. In yet another embodiment, the inducible promoter can be induced by zinc or a zinc ion. In still another embodiment, the inducible promoter can be induced by cadmium or a cadmium ion. In yet still another embodiment, the inducible promoter can be induced by mercury or a mercury ion. In an alternative embodiment, the inducible promoter can be induced by gold or a gold ion. In another alternative embodiment, the inducible promoter can be induced by silver or a silver ion. In yet another alternative embodiment, the inducible promoter can be induced by cobalt or a cobalt ion. In still another alternative embodiment, the inducible promoter can be induced by bismuth or a bismuth ion.
In some embodiments, the promoter is induced by exposing a cell comprising the inducible promoter to a metal or metal ion. The cell can be exposed to the metal or metal ion by adding the metal to the microbial growth media. In certain embodiments, the metal or metal ion added to the microbial growth media can be efficiently recovered from the media. In other embodiments, the metal or metal ion remaining in the media after recovery does not substantially impede downstream processing of the media or of the bacterial gene products.
Further non-limiting examples of constitutive promoters include constitutive promoters from Gram-negative bacteria or a bacteriophage propagating in a Gram-negative bacterium. For instance, promoters for genes encoding highly expressed Gram-negative gene products can be used, such as the promoter for Lpp, OmpA, rRNA, and ribosomal proteins. Alternatively, regulatable promoters can be used in a strain that lacks the regulatory protein for that promoter. For instance P lac , P tac , and P trc , can be used as constitutive promoters in strains that lack Lacl. Similarly, P22 P R and P L can be used in strains that lack the lambda C2 repressor protein, and lambda P R and P L can be used in strains that lack the lambda C1 repressor protein. In one embodiment, the constitutive promoter is from a bacteriophage. In another embodiment, the constitutive promoter is from a Salmonella bacteriophage. In yet another embodiment, the constitutive promoter is from a cyanophage. In some embodiments, the constitutive promoter is a Synechocystis promoter. For instance, the constitutive promoter can be the PpsbAll promoter or its variant sequences, the Prbc promoter or its variant sequences, the P cpc promoter or its variant sequences, and the PrnpB promoter or its variant sequences.
Hosts
Also provided are host cells transformed with the nucleic acid molecules or vectors disclosed herein, and descendants thereof. In some embodiments the host cells are microbial cells. In some embodiments, the host cells carry the nucleic acid sequences on vectors, which may but need not be freely replicating vectors. In other embodiments, the nucleic acids have been integrated into the genome of the host cells and/or into an endogenous plasmid of the host cells. The transformed host cells find use, e.g., in the production of recombinant proteins disclosed herein.
A variety of host microorganisms can be transformed with a nucleic acid sequence disclosed herein and can in some embodiments be used to produce a recombinant protein disclosed herein. Suitable host microorganisms include both autotrophic and heterotrophic. microbes. In some applications the autotrophic microorganisms allows for a reduction in the fossil fuel and/or electricity inputs required to make a protein encoded by a recombinant nucleic acid sequence introduced into the host microorganism. This, in turn, in some applications reduces the cost and/or the environmental impact of producing the protein and/or reduces the cost and/or the environmental impact in comparison to the cost and/or environmental impact of manufacturing alternative proteins, such as whey, egg, and soy. For example, the cost and/or environmental impact of making a protein disclosed herein using a host microorganism as disclosed herein is in some embodiments lower that the cost and/or environmental impact of making whey protein in a form suitable for human consumption by processing of cow's milk.
Non-limiting examples of heterotrophs include Escherichia coli, Salmonella typhimurium, Bacillus subtilis, Bacillus megaterium, Corynebacterium glutamicum, Streptomyces coelicolor, Streptomyces lividans, Streptomyces vanezuelae, Streptomyces roseosporus, Streptomycesfradiae, Streptomyces griseus, Streptomyces calvuligerus, Streptomyces hygroscopicus, Streptomyces platensis, Saccharopolyspora erythraea, Corynebacterium glutamicum, Aspergillus niger, Aspergillus nidulans, Aspergillus oryzae, Aspergillus terreus, Aspergillus sojae, Penicillium chrysogenum, Trichoderma reesei, Clostridium acetobutylicum, Clostridium beijerinckii, Clostridium thermocellum, Fusibacter paucivorans, Saccharomyces cerevisiae, Saccharomyces boulardii, Pichia pastoris , and Pichia stipitis.
Photoautotrophic microrganisms include eukaryotic algae, as well as prokaryotic cyanobacteria, green-sulfur bacteria, green non-sulfur bacteria, purple sulfur bacteria, and purple non-sulfur bacteria. Extremophiles are also contemplated as suitable organisms. Such organisms are provided, e.g., in Mixotrophic organisms are also suitable organisms. Algae and cyanobacteria are contemplated as suitable organisms. See the organisms disclosed in, e.g., PCT/US2013/032232, filed Mar. 15, 2013, PCT/US2013/032180, filed Mar. 15, 2013, PCT/US2013/032225, filed Mar. 15, 2013, PCT/US2013/032218, filed Mar. 15, 2013, PCT/US2013/032212, filed Mar. 15, 2013, PCT/US2013/032206, filed Mar. 15, 2013, and PCT/US2013/038682, filed Apr. 29, 2013
Yet other suitable organisms include synthetic cells or cells produced by synthetic genomes as described in Venter et al. US Pat. Pub. No. 2007/0264688, and cell-like systems or synthetic cells as described in Glass et al. US Pat. Pub. No. 2007/0269862.
Still other suitable organisms include Escherichia coli, Acetobacter aceti, Bacillus subtilis , yeast and fungi such as Clostridium ljungdahlii, Clostridium thermocellum, Penicillium chrysogenum, Pichia pastoris, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Pseudomonas fluorescens , or Zymomonas mobilis . In some embodiments those organisms are engineered to fix carbon dioxide while in other embodiments they are not.
In some embodiments eukaryotic cells, such as insect cells or mammalian cells, such as human cells are used as host cells. Vectors and expression control sequences including promoters and enhancers are well known for such cells. Examples of useful mammalian host cell lines for this purpose are monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/-DHFR (CHO, Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); mouse sertoli cells (TM4, Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather et al., Annals N.Y. Acad. Sci. 383:44-68 (1982)); MRC 5 cells; FS4 cells; and a human hepatoma line (Hep G2).
Transfection
Proteins can be produced in a host cell using, for example, a combination of recombinant DNA techniques and gene transfection methods as is well known in the art (e.g., Morrison, S. (1985) Science 229:1202). For expression of the protein, the expression vector(s) encoding the protein is transfected into a host cell by standard techniques. The various forms of the term transfection are intended to encompass a wide variety of techniques commonly used for the introduction of exogenous DNA into a prokaryotic or eukaryotic host cell, e.g., electroporation, calcium-phosphate precipitation, DEAE-dextran transfection and the like.
Production
Skilled artisans are aware of many suitable methods available for culturing recombinant cells to produce (and optionally secrete) a protein as disclosed herein, as well as for purification and/or isolation of expressed proteins. The methods chosen for protein purification depend on many variables, including the properties of the protein of interest, its location and form within the cell, the vector, host strain background, and the intended application for the expressed protein. Culture conditions can also have an effect on solubility and localization of a given target protein. Many approaches can be used to purify target proteins expressed in recombinant microbial cells as disclosed herein, including without limitation ion exchange and gel filtration.
In some embodiments a peptide fusion tag is added to the recombinant protein making possible a variety of affinity purification methods that take advantage of the peptide fusion tag. In some embodiments, the use of an affinity method enables the purification of the target protein to near homogeneity in one step. Purification may include cleavage of part or all of the fusion tag with enterokinase, factor Xa, thrombin, or HRV 3C proteases, for example. In some embodiments, before purification or activity measurements of an expressed target protein, preliminary analysis of expression levels, cellular localization, and solubility of the target protein is performed. The target protein can be found in any or all of the following fractions: soluble or insoluble cytoplasmic fractions, periplasm, or medium. Depending on the intended application, preferential localization to inclusion bodies, medium, or the periplasmic space can be advantageous, in some embodiments, for rapid purification by relatively simple procedures.
While Escherichia coli is widely regarded as a robust host for heterologous protein expression, it is also widely known that over-expression of many proteins in this host is prone to aggregation in the form of insoluble inclusion bodies. One of the most commonly used methods for either rescuing inclusion body formation, or to improve the titer of the protein itself, is to include an amino-terminal maltose-binding protein (MBP) (Austin B P, Nallamsetty S, Waugh D S. Hexahistidine-tagged maltose-binding protein as a fusion partner for the production of soluble recombinant proteins in Escherichia coli . Methods Mol Biol. 2009; 498:157-72), or small ubiquitin-related modifier (SUMO) (Saitoh H, Uwada J, Azusa K. Strategies for the expression of SUMO-modified target proteins in Escherichia coli . Methods Mol Biol. 2009; 497:211-21; Malakhov M P, Mattern M R, Malakhova O A, Drinker M, Weeks S D, Butt T R. SUMO fusions and SUMO-specific protease for efficient expression and purification of proteins. J Struct Funct Genomics. 2004; 5 (1-2):75-86; Panavas T, Sanders C, Butt TR. SUMO fusion technology for enhanced protein production in prokaryotic and eukaryotic expression systems. Methods Mol Biol. 2009; 497:303-17) fusion to the protein of interest. These two proteins are expressed extremely well, and in the soluble form, in Escherichia coli such that the protein of interest is also effectively produced in the soluble form. The protein of interest can be cleaved by designing a site specific protease recognition sequence (such as the tobacco etch virus (TEV) protease) in-between the protein of interest and the fusion protein. In some embodiments, a protein of interest can be present in an inclusion body; in some aspects the inclusion body can be formulated for delivery to a subject. Formulation is discussed in further detail below.
In some embodiments the protein is initially not folded correctly or is insoluble. A variety of methods are well known for refolding of insoluble proteins. Most protocols comprise the isolation of insoluble inclusion bodies by centrifugation followed by solubilization under denaturing conditions. The protein is then dialyzed or diluted into a non-denaturing buffer where refolding occurs. Because every protein possesses unique folding properties, the optimal refolding protocol for any given protein can be empirically determined by a skilled artisan. Optimal refolding conditions can, for example, be rapidly determined on a small scale by a matrix approach, in which variables such as protein concentration, reducing agent, redox treatment, divalent cations, etc., are tested. Once the optimal concentrations are found, they can be applied to a larger scale solubilization and refolding of the target protein.
In some embodiments the protein does not comprise a tertiary structure. In some embodiments less than half of the amino acids in the protein partipate in a tertiary structure. In some embodiments the protein does not comprise a secondary structure. In some embodiments less than half of the amino acids in the protein partipate in a secondary structure. Recombinant proteins can be isolated from a culture of cells expressing them in a state that comprises one or more of these structural features. In some embodiments the tertiary structure of a recombinant protein is reduced or eliminated after the protein is isolated from a culture producing it. In some embodiments the secondary structure of a recombinant protein is reduced or eliminated after the protein is isolated from a culture producing it.
In some embodiments a CAPS buffer at alkaline pH in combination with N-lauroylsarcosine is used to achieve solubility of the inclusion bodies, followed by dialysis in the presence of DTT to promote refolding. Depending on the target protein, expression conditions, and intended application, proteins solubilized from washed inclusion bodies can be >90% homogeneous and may not require further purification. Purification under fully denaturing conditions (before refolding) is possible using His•Tag® fusion proteins and His•Bind® immobilized metal affinity chromatography (Novogen®). In addition, S•Tag™, T7•Tag®, and Strep•Tag® II fusion proteins solubilized from inclusion bodies using 6 M urea can be purified under partially denaturing conditions by dilution to 2 M urea (S•Tag and T7•Tag) or 1 M urea (Strep•Tag II) prior to chromatography on the appropriate resin. Refolded fusion proteins can be affinity purified under native conditions using His•Tag, S•Tag, Strep•Tag II, and other appropriate affinity tags (e.g., GST•Tag™, and T7•Tag) (Novogen®).
In some embodiments the protein is an endogenous protein of the host cell used to express it. That is, the cellular genome of the host cell comprises an open reading frame that encodes the recombinant protein. In some embodiments regulatory sequences sufficient to increase expression of the protein are inserted into the host cell genome and operatively linked to the endogenous open reading frame such that the regulatory sequences drive overexpression of the recombinant protein from a recombinant nucleic acid. In some embodiments heterologous nucleic acid sequences are fused to the endogenous open reading frame of the protein and cause the protein to be synthesized comprising a hetgerologous amino acid sequence that changes the cellular trafficking of the recombinant protein, such as directing it to an organelle or to a secretion pathway. In some embodiments an open reading frame that encodes the endogeneous host cell protein is introduced into the host cell on a plasmid that further comprises regulatory sequences operatively linked to the open reading frame. In some embodiments the recombinant host cell expresses at least 2 times, at least 3 times, at least 4 times, at least 5 times, at least 10 times, or at least 20 times, at least 30 times, at least 40 times, at least 50 times, or at least 100 times more of the recombinant protein than the amount of the protein produced by a similar host cell grown under similar conditions.
Production of Recombinant Proteins in Plants
Nutritive polypeptides can be produced recombinantly from plants, including but not limited to those organisms and methods of production disclosed in PCT/US2013/032232, filed Mar. 15, 2013, PCT/US2013/032180, filed Mar. 15, 2013, PCT/US2013/032225, filed Mar. 15, 2013, PCT/US2013/032218, filed Mar. 15, 2013, PCT/US2013/032212, filed Mar. 15, 2013, PCT/US2013/032206, filed Mar. 15, 2013, and PCT/US2013/038682, filed Apr. 29, 2013- and any phylogenetically related organisms, and other methods of production known in the art.
Purification
Secreted
It is generally recognized that nearly all secreted bacterial proteins, and those proteins from other unicellular hosts, are synthesized as pre-proteins that contain N-terminal sequences known as signal peptides. These signal peptides influence the final destination of the protein and the mechanisms by which they are transported. Most signal peptides can be placed into one of four groups based on their translocation mechanism (e.g., Sec- or Tat-mediated) and the type of signal peptidase used to cleave the signal peptide from the preprotein. Also provided are N-terminal signal peptides containing a lipoprotein signal peptide. Although proteins carrying this type of signal are transported via the Sec translocase, their peptide signals tend to be shorter than normal Sec-signals and they contain a distinct sequence motif in the C-domain known as the lipo box (L(AS)(GA)C) at the −3 to +1 position. The cysteine at the +1 position is lipid modified following translocation whereupon the signal sequence is cleaved by a type II signal peptidase. Also provided are type IV or prepilin signal peptides, wherein type IV peptidase cleavage domains are localized between the N- and H-domain rather than in the C-domain common in other signal peptides.
As provided herein, the signal peptides can be attached to a heterologous polypeptide sequence (i.e., different than the protein the signal peptide is derived or obtained from) containing a nutritive polypeptide, in order to generate a recombinant nutritive polypeptide sequence. Alternatively, if a nutritive polypeptide is naturally secreted in the host organism, it can be sufficient to use the native signal sequence or a variety of signal sequences that directs secretion. In some embodiments of the nutritive polypeptides, the heterologous nutritive polypeptide sequence attached to the carboxyl terminus of the signal peptide is an edible species eukaryotic protein, a mutein or derivative thereof, or a polypeptide nutritional domain. In other embodiments of the polypeptide, the heterologous nutritive polypeptide sequence attached to the carboxyl terminus of the signal peptide is an edible species intracellular protein, a mutein or derivative thereof, or a polypeptide nutritional domain.
Purification of Nutritive Polypeptides.
Also provided are methods for recovering the secreted nutritive polypeptide from the culture medium. In some embodiments the secreted nutritive polypeptide is recovered from the culture medium during the exponential growth phase or after the exponential growth phase (e.g., in pre-stationary phase or stationary phase). In some embodiments the secreted nutritive polypeptide is recovered from the culture medium during the stationary phase. In some embodiments the secreted nutritive polypeptide is recovered from the culture medium at a first time point, the culture is continued under conditions sufficient for production and secretion of the recombinant nutritive polypeptide by the microorganism, and the recombinant nutritive polypeptide is recovered from the culture medium at a second time point. In some embodiments the secreted nutritive polypeptide is recovered from the culture medium by a continuous process. In some embodiments the secreted nutritive polypeptide is recovered from the culture medium by a batch process. In some embodiments the secreted nutritive polypeptide is recovered from the culture medium by a semi-continuous process. In some embodiments the secreted nutritive polypeptide is recovered from the culture medium by a fed-batch process. Those skilled in the art are aware of many suitable methods available for culturing recombinant cells to produce (and optionally secrete) a recombinant nutritive polypeptide as disclosed herein, as well as for purification and/or isolation of expressed recombinant polypeptides. The methods chosen for polypeptide purification depend on many variables, including the properties of the polypeptide of interest. Various methods of purification are known in the art including diafilitration, precipitation, and chromatography.
Non-Secreted
In some aspects, proteins can be isolated in the absence of secretion. For example, a cell having the protein (e.g., on the cell surface or intracellularly) can be lysed and the protein can be purified using standard methods such as chromatography or antibody-based isolation of the protein from the lysate. In some aspects, a cell surface expressed protein can be enzymatically cleaved from the surface.
Isolation of Nutritive Polypeptides from Biological Materials from Edible Species
In some embodiments a nutritive polypeptide having a desired amino acid or plurality of amino acids, which are optionally present in a desired amino acid sequence, is isolated or purified from a food source, or from a biological material from an edible species. For example, a biological material of a plant includes nuts, seeds, leaves, and roots; a biological material of a mammal includes milk, muscle, sera, and liver. Isolation methods include solubilization, chromatography, and precipitation.
Nutritive polypeptides are isolated from biological materials by specific solubilization of the targeted nutritive polypeptide. The biological material is suspended and homogenized in a solubilization solution. The solubilization solution is selected based on the nutritive polypeptides physiochemical properties. Composition of the solubilization solution is a mixture of water, detergent, salt, pH, chaotrope, cosmotrope, and/or organic solvent. As an example, proteins high in proline are known to be soluble in ethanol solutions (Dickey, L. C., et al. Industrial Crops and Products 10.2 (1999): 137-143). A nutritive polypeptide with high proline content is selected and isolated by suspending the biological material in ethanol at a ratio (w/w) of liquid to biological material of 1:1, 2:1, 3:1, 4:1 or other ratio recognized in the art. The suspension is blended and insoluble material is removed by centrifugation. The ethanol soluble nutritive polypeptide is purified solubly in the ethanol fraction.
Nutritive polypeptides are isolated from biological materials by precipitation of the targeted nutritive polypeptide or precipitation of other proteins. Precipitating agents include salt, pH, heat, flocculants, chaotropes, cosmotropes, and organic solvents. The mode of precipitation is selected for a given nutritive polypeptide based on the proteins physiochemical properties. As an example, a nutritive polypeptide is selected to be thermal stable at pH 7 by low solvation score and low aggregation score as described herein. To purify this protein the biological material is suspended in a neutral pH aqueous solution and homogenized. Insoluble material is removed from solution by centrifugation. To purify the nutritive polypeptide from other proteins, the supernatant is heated to 90 degrees C. for 10 minutes. Insoluble material is removed by centrifugation. Small molecules are removed from the supernatant by dialyzing using a 3 kDa membrane, resulting in pure nutritive polypeptide.
Nutritive polypeptides are isolated from biological materials by various chromatographic methods. The mode of chromatography selected for use depends on the physicochemical properties of the target nutritive polypeptide. Charged nutritive polypeptides bind to ion exchange chromatography resin through electrostatic interactions. Hydrophobic nutritive polypeptides bind to hydrophobic interaction chromatography resin through hydrophobic association. Mixed-mode chromatography can be used for a variety of nutritive polypeptides, and can act through a variety of interactions. Metal affinity chromatography can be used for nutritive polypeptides that bind to metal ions. As an example, a nutritive polypeptide is selected to have a high charge per amino acid at pH 4 so that it binds tightly to a cation-exchange resin. The biological material is added to a low ionic strength pH 4 aqueous solution and homogenized. Insoluble material is removed by centrifugation. The soluble material is added to a cation exchange resin, such as POROS® XS Strong Cation Exchange Resin from Life Technologies, and washed with a low ionic strength pH 4 solution. The nutritive polypeptide is eluted from the resin by adding high ionic strength (eg. 500 mM NaCl) pH 4 solution, resulting in purified nutritive polypeptide.
Synthetic Nutritive Polypeptide Amino Acid Compositions
In some embodiments compositions of this disclosure contain a plurality of free amino acids that represents the molar ratio of the plurality of amino acids present in a selected nutritive polypeptide, herein termed a “nutritive polypeptide blend”. The compositions in certain embodiments include both free amino acids and nutritive polypeptides. As used herein in these embodiments, disclosure of a nutritive polypeptide and compositions and formulations containing the nutritive polypeptide includes disclosure of a nutritive polypeptide blend and compositions and formulations containing the nutritive polypeptide blend, as well as a composition in which a first amount of amino acids are present in the form of a nutritive polypeptide and a second amount of amino acids are present in free amino acid form.
Synthetic Methods of Production
In some embodiments proteins of this disclosure are synthesized chemically without the use of a recombinant production system. Protein synthesis can be carried out in a liquid-phase system or in a solid-phase system using techniques known in the art (see, e.g., Atherton, E., Sheppard, R. C. (1989). Solid Phase peptide synthesis: a practical approach. Oxford, England: IRL Press; Stewart, J. M., Young, J. D. (1984). Solid phase peptide synthesis (2nd ed.). Rockford: Pierce Chemical Company.
Peptide chemistry and synthetic methods are well known in the art and a protein of this disclosure can be made using any method known in the art. A non-limiting example of such a method is the synthesis of a resin-bound peptide (including methods for deprotection of amino acids, methods for cleaving the peptide from the resin, and for its purification).
For example, Fmoc-protected amino acid derivatives that can be used to synthesize the peptides are the standard recommended: Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Gly-OH, Fmoc-His(Trt)-OH, Fmoc-Ile-OH, Fmoc-Leu-OH, Fmoc-Lys(BOC)—OH, Fmoc-Met-OH, Fmoc-Phe-OH, Fmoc-Pro-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Trp(BOC)—OH, Fmoc-Tyr(tBu)-OH and Fmoc-Val-OH (supplied from, e.g., Anaspec, Bachem, Iris Biotech, or NovabioChem). Resin bound peptide synthesis is performed, for example, using Fmoc based chemistry on a Prelude Solid Phase Peptide Synthesizer from Protein Technologies (Tucson, Ariz. 85714 U.S.A.). A suitable resin for the preparation of C-terminal carboxylic acids is a pre-loaded, low-load Wang resin available from NovabioChem (e.g. low load fmoc-Thr(tBu)-Wang resin, LL, 0.27 mmol/g). A suitable resin for the synthesis of peptides with a C-terminal amide is PAL-ChemMatrix resin available from Matrix-Innovation. The N-terminal alpha amino group is protected with Boc.
Fmoc-deprotection can be achieved with 20% piperidine in NMP for 2×3 min. The coupling chemistry is DIC/HOAt/collidine in NMP. Amino acid/HOAt solutions (0.3 M/0.3 M in NMP at a molar excess of 3-10 fold) are added to the resin followed by the same molar equivalent of DIC (3 M in NMP) followed by collidine (3 M in NMP). For example, the following amounts of 0.3 M amino acid/HOAt solution are used per coupling for the following scale reactions: Scale/ml, 0.05 mmol/1.5 mL, 0.10 mmol/3.0 mL, 0.25 mmol/7.5 mL. Coupling time is either 2×30 min or 1×240 min. After synthesis the resin is washed with DCM, and the peptide is cleaved from the resin by a 2-3 hour treatment with TFA/TIS/water (95/2.5/2.5) followed by precipitation with diethylether. The precipitate is washed with diethylether. The crude peptide is dissolved in a suitable mixture of water and MeCN such as water/MeCN (4:1) and purified by reversed-phase preparative HPLC (Waters Deltaprep 4000 or Gilson) on a column containing C18-silica gel. Elution is performed with an increasing gradient of MeCN in water containing 0.1% TFA. Relevant fractions are checked by analytical HPLC or UPLC. Fractions containing the pure target peptide are mixed and concentrated under reduced pressure. The resulting solution is analyzed (HPLC, LCMS) and the product is quantified using a chemiluminescent nitrogen specific HPLC detector (Antek 8060 HPLC-CLND) or by measuring UV-absorption at 280 nm. The product is dispensed into glass vials. The vials are capped with Millipore glassfibre prefilters. Freeze-drying affords the peptide trifluoroacetate as a white solid. The resulting peptides can be detected and characterized using LCMS and/or UPLC, for example, using standard methods known in the art. LCMS can be performed on a setup consisting of Waters Acquity UPLC system and LCT Premier XE mass spectrometer from Micromass. The UPLC pump is connected to two eluent reservoirs containing: A) 0.1% Formic acid in water; and B) 0.1% Formic acid in acetonitrile. The analysis is performed at RT by injecting an appropriate volume of the sample (preferably 2-10 μl) onto the column which is eluted with a gradient of A and B. The UPLC conditions, detector settings and mass spectrometer settings are: Column: Waters Acquity UPLC BEH, C-18, 1.7 μm, 2.1 mm×50 mm. Gradient: Linear 5%-95% acetonitrile during 4.0 min (alternatively 8.0 min) at 0.4 ml/min. Detection: 214 nm (analogue output from TUV (Tunable UV detector)). MS ionisation mode: API-ES Scan: 100-2000 amu (alternatively 500-2000 amu), step 0.1 amu. UPLC methods are well known. Non-limiting examples of methods that can be used are described at pages 16-17 of US 2013/0053310 A1, published Feb. 28, 2013, for example.
Inactivating Enzyme Activity
In some aspects, a protein is an enzyme or has enzymatic activity. In some aspects, it can be desirable to inactivate or reduce the enzymatic activity of the enzyme. Various methods are known in the art for enzyme inactivation including application of heat, application of one or more detergents, application of one or more metal chelators, reduction, oxidation, application of one or more chaotropes, covalent modification, alternating post translational modifications, e.g., via enzymatic or chemical alteration, altering pH (acidic and basic), or altering the salt concentration. For example, heat inactiviation is typically performed at a certain temperature for a certain amount of time, e.g., most endonucleases are inactivated by incubation at 65° C. for 20 minutes. In some aspects, enzymes can be mutated to eliminate or reduce enzymatic activity, e.g., by causing the enzyme to misfold. In addition, high pressure carbon dioxide (HPCD) has been demonstrated to to an effective non-thermal processing technique for inactivating enzymes. See Hu et al., Enzyme Inactivation in Food Processing using High Pressure Carbon Dioxide Technology; Critical Review in Food Science and Nutrition; Volume 52, Issue 2, 2013. Various other forms of enzyme inactivation are known in the art, the parameters of which can be adjusted as needed to alter enzyme activity accordingly. Various methods for enzyme inactivation and excipients such as oxidation, e.g., bleach, H 2 O 2 , and ethylene oxide; to reduce disulphides, e.g., DTT, BME, and TCEP; high pH using Na 2 CO 3 , Tris Base, or Na 2 HPO 4 ; low pH using Citric Acid, Boric Acid, Acetic Acid, or Tris HCl; Heat using temperatures 30° C.-100° C. over a period of time; protein unfolding with chaotropes such as Thiocyanate, Urea, Guanidine HCl, or CaCl 2 ; protein unfold with surfactants (e.g., detergents) such as MPD, Triton (non-ionic), CHAPS (zwitterionic), or Tween (non-ionic), or to chelate metals with EDTA or Citrate.
Cell Proliferation Assays
Cell proliferation assays can be used to measure the relative importance of a protein or portion thereof to the proliferative process. In some aspects, cell proliferation can be measured under starvation conditions in the presence or absence of a protein or interest. For example, cells can be starved over a period of time (e.g., 48 hours) with a medium having or lacking each, respective protein of interest in a tissue culture incubator. After the incubation, a detection agent such as AlamarBlue can be added and fluorescence measured as an output for proliferation. In some aspects, cell proliferation can be measured as part of a dose response to a protein of interest. For example, cells can be starved in medium having or lacking each, respective protein of interest in a tissue culture incubator. After starvation, the cells can then be treated with varying concentrations of the protein (e.g., 0, 20, 100, or 1000 μM) that was lacking in the initial culture in the same, source medium lacking the respective protein. The cells can then be incubated again in a for tissue culture incubator. After the incubation a detection agent such as AlamarBlue can be added and fluorescence read.
Allergenicity Assays
For some embodiments it is preferred that the protein not exhibit inappropriately high allergenicity. Accordingly, in some embodiments the potential allergenicy of the protein is assessed. This can be done by any suitable method known in the art. In some embodiments an allergenicity score is calculated. The allergenicity score is a primary sequence based metric based on WHO recommendations (fao.org/ag/agn/food/pdf/allergygm.pdf) for assessing how similar a protein is to any known allergen, the primary prediction being that high percent identity between a target and a known allergen is likely indicative of cross reactivity. For a given protein, the likelihood of eliciting an allergic response can be assessed via one or both of a complimentary pair of sequence homology based tests. The first test determines the protein's percent identity across the entire sequence via a global-global sequence alignment to a database of known allergens using the FASTA algorithm with the BLOSUM50 substitution matrix, a gap open penalty of 10, and a gap extension penalty of 2. It has been suggested that proteins with less than 50% global homology are unlikely to be allergenic (Goodman R. E. et al. Allergenicity assessment of genetically modified crops—what makes sense? Nat. Biotech. 26, 73-81 (2008); Aalberse R. C. Structural biology of allergens. J. Allergy Clin. Immunol. 106, 228-238 (2000)).
In some embodiments of a protein, the protein has less than 50% global homology to any known allergen in the database used for the analysis. In some embodiments a cutoff of less than 40% homology is used. In some embodiments a cutoff of less than 30% homology is used. In some embodiments a cutoff of less than 20% homology is used. In some embodiments a cutoff of less than 10% homology is used. In some embodiments a cutoff of from 40% to 50% is used. In some embodiments a cutoff of from 30% to 50% is used. In some embodiments a cutoff of from 20% to 50% is used. In some embodiments a cutoff of from 10% to 50% is used. In some embodiments a cutoff of from 5% to 50% is used. In some embodiments a cutoff of from 0% to 50% is used. In some embodiments a cutoff of greater than 50% global homology to any known allergen in the database used for the analysis is used. In some embodiments a cutoff of from 50% to 60% is used. In some embodiments a cutoff of from 50% to 70% is used. In some embodiments a cutoff of from 50% to 80% is used. In some embodiments a cutoff of from 50% to 90% is used. In some embodiments a cutoff of from 55% to 60% is used. In some embodiments a cutoff of from 65% to 70% is used. In some embodiments a cutoff of from 70% to 75% is used. In some embodiments a cutoff of from 75% to 80% is used.
The second test assesses the local allergenicity along the protein sequence by determining the local allergenicity of all possible contiguous 80 amino acid fragments via a global-local sequence alignment of each fragment to a database of known allergens using the FASTA algorithm with the BLOSUM50 substitution matrix, a gap open penalty of 10, and a gap extension penalty of 2. The highest percent identity of any 80 amino acid window with any allergen is taken as the final score for the protein of interest. The WHO guidelines suggest using a 35% identity cutoff with this fragment test. In some embodiments of a protein, all possible fragments of the protein have less than 35% local homology to any known allergen in the database used for the analysis using this test. In some embodiments a cutoff of less than 30% homology is used. In some embodiments a cutoff of from 30% to 35% homology is used. In some embodiments a cutoff of from 25% to 30% homology is used. In some embodiments a cutoff of from 20% to 25% homology is used. In some embodiments a cutoff of from 15% to 20% homology is used. In some embodiments a cutoff of from 10% to 15% homology is used. In some embodiments a cutoff of from 5% to 10% homology is used. In some embodiments a cutoff of from 0% to 5% homology is used. In some embodiments a cutoff of greater than 35% homology is used. In some embodiments a cutoff of from 35% to 40% homology is used. In some embodiments a cutoff of from 40% to 45% homology is used. In some embodiments a cutoff of from 45% to 50% homology is used. In some embodiments a cutoff of from 50% to 55% homology is used. In some embodiments a cutoff of from 55% to 60% homology is used. In some embodiments a cutoff of from 65% to 70% homology is used. In some embodiments a cutoff of from 70% to 75% homology is used. In some embodiments a cutoff of from 75% to 80% homology is used.
Skilled artisans are able to identify and use a suitable database of known allergens for this purpose. In some embodiments the database is custom made by selecting proteins from more than one database source. In some embodiments the custom database comprises pooled allergen lists collected by the Food Allergy Research and Resource Program (allergenonline.org/), UNIPROT annotations (uniprot.org/docs/allergen), and the Structural Database of Allergenic Proteins (SDAP, fermi.utmb.edu/SDAP/sdap_lnk.html). This database includes all currently recognized allergens by the International Union of Immunological Societies (IUIS, allergen.org/) as well as a large number of additional allergens not yet officially named. In some embodiments the database comprises a subset of known allergen proteins available in known databases; that is, the database is a custom selected subset of known allergen proteins. In some embodiments the database of known allergens comprises at least 10 proteins, at least 20 proteins, at least 30 proteins, at least 40 proteins, at least 50 proteins, at least 100, proteins, at least 200 proteins, at least 300 proteins, at least 400 proteins, at least 500 proteins, at least 600 proteins, at least 700 proteins, at least 800 proteins, at least 900 proteins, at least 1,000 proteins, at least 1,100 proteins, at least 1,200 proteins, at least 1,300 proteins, at least 1,400 proteins, at least 1,500 proteins, at least 1,600 proteins, at least 1,700 proteins, at least 1,800 proteins, at least 1,900 proteins, or at least 2,000 proteins. In some embodiments the database of known allergens comprises from 100 to 500 proteins, from 200 to 1,000 proteins, from 500 to 1,000 proteins, from 500 to 1,000 proteins, or from 1,000 to 2,000 proteins.
In some embodiments all (or a selected subset) of contiguous amino acid windows of different lengths (e.g., 70, 60, 50, 40, 30, 20, 10, 8 or 6 amino acid windows) of a protein are tested against the allergen database and peptide sequences that have 100% identity, 95% or higher identity, 90% or higher identity, 85% or higher identity, 80% or higher identity, 75% or higher identity, 70% or higher identity, 65% or higher identity, 60% or higher identity, 55% or higher identity, or 50% or higher identity matches are identified for further examination of potential allergenicity.
Another method of predicting the allergenicity of a protein is to assess the homology of the protein to a protein of human origin. The human immune system is exposed to a multitude of possible allergenic proteins on a regular basis and has the intrinsic ability to differentiate between the host body's proteins and exogenous proteins. The exact nature of this ability is not always clear, and there are many diseases that arise as a result of the failure of the body to differentiate self from non-self (e.g., arthritis). Nonetheless, the fundamental analysis is that proteins that share a degree of sequence homology to human proteins are less likely to elicit an immune response. In particular, it has been shown that for some protein families with known allergenic members (tropomyosins, parvalbumins, caseins), those proteins that bear more sequence homology to their human counterparts relative to known allergenic proteins, are not thought to be allergenic (Jenkins J. A. et al. Evolutionary distance from human homologs reflects allergenicity of animal food proteins. J. Allergy Clin Immunol. 120 (2007): 1399-1405). For a given protein, a human homology score is measured by determining the maximum percent identity of the protein to a database of human proteins (e.g., the UNIPROT database) from a global-local alignment using the FASTA algorithm with the BLOSUM50 substitution matrix, a gap open penalty of 10, and a gap extension penalty of 2. According to Jenkins et al. (Jenkins J. A. et al. Evolutionary distance from human homologs reflects allergenicity of animal food proteins. J. Allergy Clin Immunol. 120 (2007): 1399-1405) proteins with a sequence identity to a human protein above about 62% are less likely to be allergenic. Skilled artisans are able to identify and use a suitable database of known human proteins for this purpose, for example, by searching the UNIPROT database (uniprot.org). In some embodiments the database is custom made by selecting proteins from more than one database source. Of course the database may but need not be comprehensive. In some embodiments the database comprises a subset of human proteins; that is, the database is a custom selected subset of human proteins. In some embodiments the database of human proteins comprises at least 10 proteins, at least 20 proteins, at least 30 proteins, at least 40 proteins, at least 50 proteins, at least 100, proteins, at least 200 proteins, at least 300 proteins, at least 400 proteins, at least 500 proteins, at least 600 proteins, at least 700 proteins, at least 800 proteins, at least 900 proteins, at least 1,000 proteins, at least 2,000 proteins, at least 3,000 proteins, at least 4,000 proteins, at least 5,000 proteins, at least 6,000 proteins, at least 7,000 proteins, at least 8,000 proteins, at least 9,000 proteins, or at least 10,000 proteins. In some embodiments the database comprises from 100 to 500 proteins, from 200 to 1,000 proteins, from 500 to 1,000 proteins, from 500 to 1,000 proteins, from 1,000 to 2,000 proteins, from 1,000 to 5,000 proteins, or from 5,000 to 10,000 proteins. In some embodiments the database comprises at least 90%, at least 95%, or at least 99% of all known human proteins.
In some embodiments of a protein, the protein is at least 20% homologous to a human protein. In some embodiments a cutoff of at least 30% homology is used. In some embodiments a cutoff of at least 40% homology is used. In some embodiments a cutoff of at least 50% homology is used. In some embodiments a cutoff of at least 60% homology is used. In some embodiments a cutoff of at least 70% homology is used. In some embodiments a cutoff of at least 80% homology is used. In some embodiments a cutoff of at least 62% homology is used. In some embodiments a cutoff of from at least 20% homology to at least 30% homology is used. In some embodiments a cutoff of from at least 30% homology to at least 40% homology is used. In some embodiments a cutoff of from at least 50% homology to at least 60% homology is used. In some embodiments a cutoff of from at least 60% homology to at least 70% homology is used. In some embodiments a cutoff of from at least 70% homology to at least 80% homology is used.
Thermostability Assays
As used herein, a “stable” protein is one that resists changes (e.g., unfolding, oxidation, aggregation, hydrolysis, etc.) that alter the biophysical (e.g., solubility), biological (e.g., digestibility), or compositional (e.g. proportion of Leucine amino acids) traits of the protein of interest.
Protein stability can be measured using various assays known in the art and proteins disclosed herein and having stability above a threshold can be selected. In some embodiments a protein is selected that displays thermal stability that is comparable to or better than that of whey protein. Thermal stability is a property that can help predict the shelf life of a protein. In some embodiments of the assay stability of protein samples is determined by monitoring aggregation formation using size exclusion chromatography (SEC) after exposure to extreme temperatures. Aqueous samples of the protein to be tested are placed in a heating block at 90° C. and samples are taken after 0, 1, 5, 10, 30 and 60 min for SEC analysis. Protein is detected by monitoring absorbance at 214 nm, and aggregates are characterized as peaks eluting faster than the protein of interest. No overall change in peak area indicates no precipitation of protein during the heat treatment. Whey protein has been shown to rapidly form ˜80% aggregates when exposed to 90° C. in such an assay.
In some embodiments the thermal stability of a protein is determined by heating a sample slowly from 25° C. to 95° C. in presence of a hydrophobic dye (e.g., ProteoStat® Thermal shift stability assay kit, Enzo Life Sciences) that binds to aggregated proteins that are formed as the protein denatures with increasing temperature (Niesen, F. H., Berglund, H. & Vadadi, M., 2007. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nature Protocols, Volume 2, pp. 2212-2221). Upon binding, the dye's fluorescence increases significantly, which is recorded by an rtPCR instrument and represented as the protein's melting curve (Lavinder, J. J., Hari, S. B., Suillivan, B. J. & Magilery, T. J., 2009. High-Throughput Thermal Scanning: A General, Rapid Dye-Binding Thermal Shift Screen for Protein Engineering. Journal of the American Chemical Society, pp. 3794-3795). After the thermal shift is complete, samples are examined for insoluble precipitates and further analyzed by analytical size exclusion chromatography (SEC).
Solubility Assays
In some embodiments of the proteins disclosed herein the protein is soluble. Solubility can be measured by any method known in the art. In some embodiments solubility is examined by centrifuge concentration followed by protein concentration assays. Samples of proteins in 20 mM HEPES pH 7.5 are tested for protein concentration according to protocols using two methods, Coomassie Plus (Bradford) Protein Assay (Thermo Scientific) and Bicinchoninic Acid (BCA) Protein Assay (SigmadAldrich). Based on these measurements 10 mg of protein is added to an Amicon Ultra 3 kDa centrifugal filter (Millipore). Samples are concentrated by centrifugation at 10,000×g for 30 minutes. The final, now concentrated, samples are examined for precipitated protein and then tested for protein concentration as above using two methods, Bradford and BCA.
In some embodiments the proteins have a final solubility limit of at least 5 g/L, 10 g/L, 20 g/L, 30 g/L, 40 g/L, 50 g/L, or 100 g/L at physiological pH. In some embodiments the proteins are greater than 50%, greater than 60%, greater than 70%, greater than 80%, greater than 90%, greater than 95%, greater than 96%, greater than 97%, greater than 98%, greater than 99%, or greater than 99.5% soluble with no precipitated protein observed at a concentration of greater than 5 g/L, or 10 g/L, or 20 g/L, or 30 g/L, or 40 g/L, or 50 g/L, or 100 g/L at physiological pH. In some embodiments, the solubility of the protein is higher than those typically reported in studies examining the solubility limits of whey (12.5 g/L; Pelegrine et al., Lebensm.-Wiss. U.-Technol. 38 (2005) 77-80) and soy (10 g/L; Lee et al., JAOCS 80 (1) (2003) 85-90).
Eukaryotic proteins are often glycosylated, and the carbohydrate chains that are attached to proteins serve various functions. N-linked and O-linked glycosylation are the two most common forms of glycosylation occurring in proteins. N-linked glycosylation is the attachment of a sugar molecule to a nitrogen atom in an amino acid residue in a protein. N-linked glycosylation occurs at Asparagine and Arginine residues. O-linked glycosylation is the attachment of a sugar molecule to an oxygen atom in an amino acid residue in a protein. O-linked glycosylation occurs at Threonine and Serine residues.
Glycosylated proteins are often more soluble than their un-glycosylated forms. In terms of protein drugs, proper glycosylation usually confers high activity, proper antigen binding, better stability in the blood, etc. However, glycosylation necessarily means that a protein “carries with it” sugar moieties. Such sugar moieties may reduce the usefulness of the proteins of this disclosure including recombinant proteins. For example, as demonstrated in the examples, a comparison of digestion of glycosylated and non-glycosylated forms of the same proteins shows that the non-glycosylated forms are digested more quickly than the glycosylated forms. For these reasons, in some embodiments the nutrive proteins according to the disclosure comprise low or no glycosylation. For example, in some embodiments the proteins comprise a ratio of non-glycosilated to total amino acid residues of at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%. In some embodiments the proteins to not comprise any glycosylation.
In some embodiments, the protein according to the disclosure is de-glycosylated after it is produced or after it is isolated. Proteins of low or no glycosylation can be made by any method known in the art. For example, enzymatic and/or chemical methods can be used (Biochem. J. (2003) 376, p339-350). Enzymes are produced commercially at research scales for the removal of N-linked and O-linked oligosaccharides. Chemical methods include use of trifluoromethanesulfonic acid to selectively break N-linked and O-linked peptide-saccharide bonds. This method often results in a more complete deglycosylation than does the use of enzymatic methods.
In other embodiments, the protein according to the disclosure is produced with low or no glycosylation by a host organism. Most bacteria and other prokaryotes have very limited capabilities to glycosylate proteins, especially heterologous proteins. Accordingly, in some embodiments of this disclosure a protein is made recombinantly in a microorganism such that the level of glycosylation of the recombinant protein is low or no glycosylation. In some embodiments the level of glycosylation of the recombinant protein is lower than the level of glycosylation of the protein as it occurs in the organism from which it is derived. Glycosylation of a protein can vary based on the host organism, in other words some hosts will produce more glycosylation relative to one or more other hosts; while other hosts will produce less g glycosylation relative to one or more other hosts. Differences in the amount of glycosylation can be measured based upon, e.g., the mass of glycosylation present and/or the total number of glycosylation sites present.
Toxicity and Anti-Nutricity Assays
For most embodiments it is preferred that the protein not exhibit inappropriately high toxicity. Accordingly, in some embodiments the potential toxicity of the protein is assessed. This can be done by any suitable method known in the art. In some embodiments a toxicity score is calculated by determining the protein's percent identity to databases of known toxic proteins (e.g., toxic proteins identified from the UNIPROT database). A global-global alignment of the protein of interest against the database of known toxins is performed using the FASTA algorithm with the BLOSUM50 substitution matrix, a gap open penalty of 10, and a gap extension penalty of 2. In some embodiments of a protein, the protein is less than 35% homologous to a known toxin. In some embodiments a cutoff of less than 35% homology is used. In some embodiments a cutoff of from 30% to 35% homology is used. In some embodiments a cutoff of from 25% to 35% homology is used. In some embodiments a cutoff of from 20% to 35% homology is used. In some embodiments a cutoff of from 15% to 35% homology is used. In some embodiments a cutoff of from 10% to 35% homology is used. In some embodiments a cutoff of from 5% to 35% homology is used. In some embodiments a cutoff of from 0% to 35% homology is used. In some embodiments a cutoff of greater than 35% homology is used. In some embodiments a cutoff of from 35% to 40% homology is used. In some embodiments a cutoff of from 35% to 45% homology is used. In some embodiments a cutoff of from 35% to 50% homology is used. In some embodiments a cutoff of from 35% to 55% homology is used. In some embodiments a cutoff of from 35% to 60% homology is used. In some embodiments a cutoff of from 35% to 70% homology is used. In some embodiments a cutoff of from 35% to 75% homology is used. In some embodiments a cutoff of from 35% to 80% homology is used. Skilled artisans are able to identify and use a suitable database of known toxins for this purpose, for example, by searching the UNIPROT database (uniprot.org). In some embodiments the database is custom made by selecting proteins identified as toxins from more than one database source. In some embodiments the database comprises a subset of known toxic proteins; that is, the database is a custom selected subset of known toxic proteins. In some embodiments the database of toxic proteins comprises at least 10 proteins, at least 20 proteins, at least 30 proteins, at least 40 proteins, at least 50 proteins, at least 100, proteins, at least 200 proteins, at least 300 proteins, at least 400 proteins, at least 500 proteins, at least 600 proteins, at least 700 proteins, at least 800 proteins, at least 900 proteins, at least 1,000 proteins, at least 2,000 proteins, at least 3,000 proteins, at least 4,000 proteins, at least 5,000 proteins, at least 6,000 proteins, at least 7,000 proteins, at least 8,000 proteins, at least 9,000 proteins, or at least 10,000 proteins. In some embodiments the database comprises from 100 to 500 proteins, from 200 to 1,000 proteins, from 500 to 1,000 proteins, from 500 to 1,000 proteins, from 1,000 to 2,000 proteins, from 1,000 to 5,000 proteins, or from 5,000 to 10,000 proteins.
Anti-Nutricity and Anti-Nutrients
For some embodiments it is preferred that the protein not exhibit anti-nutritional activity (“anti-nutricity”), i.e., proteins that have the potential to prevent the absorption of nutrients from food. Examples of anti-nutritive sequences causing such anti-nutricity include protease inhibitors, which inhibit the actions of trypsin, pepsin and other proteases in the gut, preventing the digestion and subsequent absorption of protein.
Disclosed herein are formulations containing isolated nutritive polypeptides that are substantially free of anti-nutritive sequences. In some embodiments the nutritive polypeptide has an anti-nutritive similarity score below about 1, below about 0.5, or below about 0.1. The nutritive polypeptide is present in the formulation in an amount greater than about 10 g, and the formulation is substantially free of anti-nutritive factors. The formulation is present as a liquid, semi-liquid or gel in a volume not greater than about 500 ml or as a solid or semi-solid in a mass not greater than about 200 g. The nutritive polypeptide may have low homology with a protease inhibitor, such as a member of the serpin family of polypeptides, e.g., it is less than 90% identical, or is less than 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, or less than 5% identical.
Accordingly, in some embodiments the potential anti-nutricity of the protein is assessed. This can be done by any suitable method known in the art. In some embodiments an anti-nutricity score is calculated by determining the protein's percent identity to databases of known protease inhibitors (e.g., protease inhibitors identified from the UNIPROT database). A global-global alignment of the protein of interest against the database of known protease inhibitors is performed using the FASTA algorithm with the BLOSUM50 substitution matrix, a gap open penalty of 10, and a gap extension penalty of 2, to identify whether the protein is homologous to a known anti-protein. In some embodiments of a protein, the protein has less than 35% global homology to any known anti-protein (e.g., any known protease inhibitor) in the database used for the analysis. In some embodiments a cutoff of less than 35% identify is used. In some embodiments a cutoff of from 30% to 35% is used. In some embodiments a cutoff of from 25% to 35% is used. In some embodiments a cutoff of from 20% to 35% is used. In some embodiments a cutoff of from 15% to 35% is used. In some embodiments a cutoff of from 10% to 35% is used. In some embodiments a cutoff of from 5% to 35% is used. In some embodiments a cutoff of from 0% to 35% is used. In some embodiments a cutoff of greater than 35% identify is used. In some embodiments a cutoff of from 35% to 40% is used. In some embodiments a cutoff of from 35% to 45% is used. In some embodiments a cutoff of from 35% to 50% is used. In some embodiments a cutoff of from 35% to 55% is used. In some embodiments a cutoff of from 35% to 60% is used. In some embodiments a cutoff of from 35% to 70% is used. In some embodiments a cutoff of from 35% to 75% is used. In some embodiments a cutoff of from 35% to 80% is used. Skilled artisans are able to identify and use a suitable database of known protease inhibitors for this purpose, for example, by searching the UNIPROT database (uniprot.org). In some embodiments the database is custom made by selecting proteins identified protease-inhibitors as from more than one database source. In some embodiments the database comprises a subset of known protease inhibitors available in databases; that is, the database is a custom selected subset of known protease inhibitor proteins. In some embodiments the database of known protease inhibitor proteins comprises at least 10 proteins, at least 20 proteins, at least 30 proteins, at least 40 proteins, at least 50 proteins, at least 100, proteins, at least 200 proteins, at least 300 proteins, at least 400 proteins, at least 500 proteins, at least 600 proteins, at least 700 proteins, at least 800 proteins, at least 900 proteins, at least 1,000 proteins, at least 1,100 proteins, at least 1,200 proteins, at least 1,300 proteins, at least 1,400 proteins, at least 1,500 proteins, at least 1,600 proteins, at least 1,700 proteins, at least 1,800 proteins, at least 1,900 proteins, or at least 2,000 proteins. In some embodiments the database of known protease inhibitor proteins comprises from 100 to 500 proteins, from 200 to 1,000 proteins, from 500 to 1,000 proteins, from 500 to 1,000 proteins, or from 1,000 to 2,000 proteins, or from 2,000 to 3,000 proteins.
In other embodiments a protein that does exhibit some degree of protease inhibitor activity is used. For example, in some embodiments such a protein can be useful because it delays protease digestion when the nuttirive protein is consumed such that the protein traverses a greater distance within the GI tract before it is digested, thus delaying absorption. For example, in some embodiments the protein inhibits gastric digestion but not intestinal digestion. Delaney B. et al. (Evaluation of protein safety in the context of agricultural biotechnology. Food. Chem. Toxicol. 46 (2008: S71-S97)) suggests that one should avoid both known toxic and anti-proteins when assessing the safety of a possible food protein. In some embodiments of a protein, the protein has a favorably low level of global homology to a database of known toxic proteins and/or a favorably low level of global homology to a database of known anti-nutricity proteins (e.g., protease inhibitors), as defined herein.
Antinutrients.
Provided are nutritional compositions that lack anti-nutrients (or antinutrients). Antinutrients are compounds, usually other than proteins, which are typically found in plant foods and have been found to have both adverse effects and, in some situations, certain health benefits. For instance, phytic acid, lectins, phenolic compounds, saponins, and enzyme inhibitors have been shown to reduce the availability of nutrients and to cause the inhibition of growth, and phytoestrogens and lignans have been linked with infertility problems. On the other hand, phytic acid, lectins, phenolic compounds, amylase inhibitors, and saponins have been shown to reduce the blood glucose and insulin response to starch foods and/or the plasma cholesterol and triglycerides. Furthermore, phytic acid, phenolics, saponins, protease inhibitors, phytoestrogens, and lignans have been linked to reduced cancer risks.
Provided are methods for reducing the amount of anti-nutritional factors in a food product, by treating the food product with a thermal treatment comprising steam or hot air having a temperature greater than about 90 degrees C. for at least 1 minute, combining with the treated food product with a composition containing an isolated nutritive polypeptide. Optionally, the step of thermal treatment degrades at least one anti-nutritional factor such as a saponin, a lectin, and a prolamin, a protease inhibitor, or phytic acid.
Anti-nutritional factors are detected in a protein composition as follows. Phytic acid: The procedure of Wheeler and Ferrel (Wheeler, E. L., Ferrel, R. E., Cereal Chem. 1971, 48, 312) is used for the determination of phytic acid extracted in 3% trichloroacetic acid. Raffinose family oligosaccharides: Protein samples are extracted with 70% ethanol using Soxhlet apparatus for 6-8 h and thin-layer chromatography is used for the quantitative determination of raffinose and stachyose in the extract according to the procedure of Tanaka et al. (Tanaka, M., Thananunkul, D., Lee, T. C., Chichester, C. O., J. Food Sci. 1975, 40, 1087-1088). Trypsin inhibitor: The method of Kakade et al. (Kakade, M. L., Rackis, J. J., McGhee, J. E., Puski, G., Cereal Chem. 1974, 51, 376-82) is used for determining the trypsin inhibitor activity in raw and treated samples. One trypsin inhibitor unit (TIU) is defined as a decrease in absorbance at 410 nm by 0.01 in 10 min and data were expressed as TIU*mg−1. Amylase inhibitor: The inhibitor is extracted in 0.15 m NaCl according to the procedure of Baker et al. (Baker, J. E., Woo, S. M., Throne, J. E., Finny, P. L., Environm. Entomol. 1991, 20, 53±60) and assayed by the method of Huesing et al. (Huesing, J. E., Shade, R. E., Chrispeels, M. J., Murdok, L. L., Plant Physiol. 1991, 96, 993±996). One amylase inhibitor unit (AIU) is defined as the amount that gives 50% inhibition of a portion of the amylase that produced one mg maltose monohydrate per min. Lectins: The procedure of Paredes-Lopez et al. (Paredes-Lopez, O., Schevenin, M. L., Guevara-Lara, F., Food Chem. 1989, 31, 129-137) is applied to the extraction of lectins using phosphate-buffered saline (PBS). The hemagglutinin activity (HA) of lectins in the sample extract is determined according to Kortt (Kortt, A. A. (Ed.), Eur. J. Biochem. 1984, 138, 519). Trypsinized human red blood cell (A, B and O) suspensions are prepared according to Lis and Sharon (Lis, H., Sharon, N., Methods Enzymol. 1972, 28, 360±368). HA is expressed as the reciprocal of the highest dilution giving positive agglutination. Tannins: The tannin contents are determined as tannic acid by Folin-Denis reagent according to the procedure of the AOAC (Helrich, K. (Ed.), AOAC, Official Methods of Analysis, Association of Official Analytical Chemists, Arlington, Va. 1990)
Charge Assays and Solvation Scoring
One feature that can enhance the utility of a protein is its charge (or per amino acid charge). Proteins with higher charge can in some embodiments exhibit desirable characteristics such as increased solubility, increased stability, resistance to aggregation, and desirable taste profiles. For example, a charged protein that exhibits enhanced solubility can be formulated into a beverage or liquid formulation that includes a high concentration of protein in a relatively low volume of solution, thus delivering a large dose of protein nutrition per unit volume. A charged protein that exhibits enhanced solubility can be useful, for example, in sports drinks or recovery drinks wherein a user (e.g., an athlete) wants to ingest protein before, during or after physical activity. A charged protein that exhibits enhanced solubility can also be particularly useful in a clinical setting wherein a subject (e.g., a patient or an elderly person) is in need of protein nutrition but is unable to ingest solid foods or large volumes of liquids.
For example, the net charge (ChargeP) of a polypeptide at pH 7 can be calculated using the following formula:
Charge P=− 0.002−( C )(0.045)−( D )(0.999)−( E )(0.998)+( H )(0.091)+( K )(1.0)+( R )(1.0)−( Y )(−0.001)

where C is the number of cysteine residues, D is the number of aspartic acid residues, E is the number of glutamic acid residues, H is the number of histidine residues, K is the number of lysine residues, R is the number of arginine residues and Y is the number of tyrosine residues in the polypeptide. The per amino acid charge (ChargeA) of the polypeptide can be calculated by dividing the net charge (ChargeP) by the number of amino acid residues (N), i.e., ChargeA=ChargeP/N. (See Bassi S (2007), “A Primer on Python for Life Science Researchers.” PLoS Comput Biol 3 (11): e199. doi: 10.1371/journal.pcbi.0030199).
One metric for assessing the hydrophilicity and potential solubility of a given protein is the solvation score. Solvation score is defined as the total free energy of solvation (i.e. the free energy change associated with transfer from gas phase to a dilute solution) for all amino acid side chains if each residue were solvated independently, normalized by the total number of residues in the sequence. The side chain solvation free energies are found computationally by calculating the electrostatic energy difference between a vacuum dielectric of I and a water dielectric of 80 (by solving the Poisson-Boltzmann equation) as well as the non-polar, Van der Waals energy using a linear solvent accessible surface area model (D. Sitkoff, K. A. Sharp, B. Honig. “Accurate Calculation of Hydration Free Energies Using Macroscopic Solvent Models”. J. Phys. Chem. 98, 1994). For amino acids with ionizable sidechains (Arg, Asp, Cys, Glu, His, Lys and Tyr), an average solvation free energy is used based on the relative probabilities for each ionization state at the specified pH. Solvation scores start at 0 and continue into negative values, and the more negative the solvation score, the more hydrophilic and potentially soluble the protein is predicted to be. In some embodiments of a protein, the protein has a solvation score of −10 or less at pH 7. In some embodiments of a protein, the protein has a solvation score of −15 or less at pH 7. In some embodiments of a protein, the protein has a solvation score of −20 or less at pH 7. In some embodiments of a protein, the protein has a solvation score of −25 or less at pH 7. In some embodiments of a protein, the protein has a solvation score of −30 or less at pH 7. In some embodiments of a protein, the protein has a solvation score of −35 or less at pH 7. In some embodiments of a protein, the protein has a solvation score of −40 or less at pH 7.
The solvation score is a function of pH by virtue of the pH dependence of the molar ratio of undissociated weak acid ([HA]) to conjugate base ([A-]) as defined by the Henderson-Hasselbalch equation:




pH
=

pKa
+

log


(


[

A
-

]


[
HA
]


)







All weak acids have different solvation free energies compared to their conjugate bases, and the solvation free energy used for a given residue when calculating the solvation score at a given pH is the weighted average of those two values.
Accordingly, in some embodiments of a protein, the protein has a solvation score of −10 or less at an acidic pH. In some embodiments of a protein, the protein has a solvation score of −15 or less at an acidic pH. In some embodiments of a protein, the protein has a solvation score of −20 or less at an acidic pH. In some embodiments of a protein, the protein has a solvation score of −25 or less at an acidic pH. In some embodiments of a protein, the protein has a solvation score of −30 or less at an acidic pH. In some embodiments of a protein, the protein has a solvation score of −35 or less at an acidic pH. In some embodiments of a protein, the protein has a solvation score of −40 or less at acidic pH.
Accordingly, in some embodiments of a protein, the protein has a solvation score of −10 or less at a basic pH. In some embodiments of a protein, the protein has a solvation score of −15 or less at a basic pH. In some embodiments of a protein, the protein has a solvation score of −20 or less at a basic pH. In some embodiments of a protein, the protein has a solvation score of −25 or less at a basic pH. In some embodiments of a protein, the protein has a solvation score of −30 or less at a basic pH. In some embodiments of a protein, the protein has a solvation score of −35 or less at a basic pH. In some embodiments of a protein, the protein has a solvation score of −40 or less at basic pH.
Accordingly, in some embodiments of a protein, the protein has a solvation score of −10 or less at a pH range selected from 2-3, 3-4, 4-5, 5-6, 6-7, 7-8, 8-9, 9-10, 10-11, and 11-12. In some embodiments of a protein, the protein has a solvation score of −15 or less at at a pH range selected from 2-3, 3-4, 4-5, 5-6, 6-7, 7-8, 8-9, 9-10, 10-11, and 11-12. In some embodiments of a protein, the protein has a solvation score of −20 or less at a pH range selected from 2-3, 3-4, 4-5, 5-6, 6-7, 7-8, 8-9, 9-10, 10-11, and 11-12. In some embodiments of a protein, the protein has a solvation score of −25 or less at a pH range selected from 2-3, 3-4, 4-5, 5-6, 6-7, 7-8, 8-9, 9-10, 10-11, and 11-12. In some embodiments of a protein, the protein has a solvation score of −30 or less at a pH range selected from 2-3, 3-4, 4-5, 5-6, 6-7, 7-8, 8-9, 9-10, 10-11, and 11-12. In some embodiments of a protein, the protein has a solvation score of −35 or less at a pH range selected from 2-3, 3-4, 4-5, 5-6, 6-7, 7-8, 8-9, 9-10, 10-11, and 11-12. In some embodiments of a protein, the protein has a solvation score of −40 or less at a pH range selected from 2-3, 3-4, 4-5, 5-6, 6-7, 7-8, 8-9, 9-10, 10-11, and 11-12.
Aggregation Assays and Aggregation Scoring
In some embodiments a protein of this disclosure shows resistance to aggregation, exhibiting, for example, less than 80% aggregation, 10% aggregation, or no detectable aggregation at elevated temperatures (e.g., 50° C., 60° C., 70° C., 80° C., 85° C., 90° C., or 95° C.).
One benefit of stable proteins as disclosed herein is that they can be able to be stored for an extended period of time before use, in some instances without the need for refrigeration or cooling. In some embodiments, proteins are processed into a dry form (e.g., by lyophilization). In some embodiments, proteins are stable upon lyophilization. In some embodiments, such lyophilized proteins maintain their stability upon reconstitution (e.g., liquid formulation).
The aggregation score is a primary sequence based metric for assessing the hydrophobicity and likelihood of aggregation of a given protein. Using the Kyte and Doolittle hydrophobity scale (Kyte J, Doolittle R F (May 1982) “A simple method for displaying the hydropathic character of a protein”. J. Mol. Biol. 157 (1): 105-32), which gives hydrophobic residues positive values and hydrophilic residues negative values, the average hydrophobicity of a protein sequence is calculated using a moving average of five residues. The aggregation score is drawn from the resulting plot by determining the area under the curve for values greater than zero and normalizing by the total length of the protein. The underlying view is that aggregation is the result of two or more hydrophobic patches coming together to exclude water and reduce surface exposure, and the likelihood that a protein will aggregate is a function of how densely packed its hydrophobic (i.e., aggregation prone) residues are. Aggregation scores start at 0 and continue into positive values, and the smaller the aggregation score, the less hydrophobic and potentially less prone to aggregation the protein is predicted to be. In some embodiments of a protein, the protein has an aggregation score of 2 or less. In some embodiments of a protein, the protein has an aggregation score of 1.5 or less. In some embodiments of a protein, the protein has an aggregation score of 1 or less. In some embodiments of a protein, the protein has an aggregation score of 0.9 or less. In some embodiments of a protein, the protein has an aggregation score of 0.8 or less. In some embodiments of a protein, the protein has an aggregation score of 0.7 or less. In some embodiments of a protein, the protein has an aggregation score of 0.6 or less. In some embodiments of a protein, the protein has an aggregation score of 0.5 or less. In some embodiments of a protein, the protein has an aggregation score of 0.4 or less. In some embodiments of a protein, the protein has an aggregation score of 0.3 or less. In some embodiments of a protein, the protein has an aggregation score of 0.2 or less. In some embodiments of a protein, the protein has an aggregation score of 0.1 or less.
In some cases, soluble expression is desirable because it can increase the amount and/or yield of the protein and facilitate one or more of the isolation and purification of the protein. In some embodiments, the proteins of this disclosure are solubly expressed in the host organism. Solvation score and aggregation score can be used to predict soluble expression of recombinant proteins in a host organism. As shown in Example 8, this disclosure provides evidence suggesting that proteins with solvation scores of ≦−20 and aggregation scores of ≦0.75 are more likely to be recombinantly expressed in a particular E. coli expression system. Moreover, the data also suggests that proteins with solvation scores of ≦−20 and aggregation scores of ≦0.5 are more likely to be solubly expressed in this system. Therefore, in some embodiments the protein of this disclosure has a solvation score of −20 or less. In some embodiments the nutitive protein has an aggregation score of 0.75 or less. In some embodiments the nutitive protein has an aggregation score of 0.5 or less. In some embodiments the protein has a solvation score of −20 or less and an aggregation score of 0.75 or less. In some embodiments the protein has a solvation score of −20 or less and an aggregation score of 0.5 or less.
Taste and Mouth Characteristics
Certain free amino acids and mixtures of free amino acids are known to have a bitter or otherwise unpleasant taste. In addition, hydrolysates of common proteins (e.g., whey and soy) often have a bitter or unpleasant taste. In some embodiments, proteins disclosed and described herein do not have a bitter or otherwise unpleasant taste. In some embodiments, proteins disclosed and described herein have a more acceptable taste as compared to at least one of free amino acids, mixtures of free amino acids, and/or protein hydrolysates. In some embodiments, proteins disclosed and described herein have a taste that is equal to or exceeds at least one of whey protein.
Proteins are known to have tastes covering the five established taste modalities: sweet, sour, bitter, salty, and umami. Fat can be considered a sixth taste. The taste of a particular protein (or its lack thereof) can be attributed to several factors, including the primary structure, the presence of charged side chains, and the electronic and conformational features of the protein. In some embodiments, proteins disclosed and described herein are designed to have a desired taste (e.g., sweet, salty, umami) and/or not to have an undesired taste (e.g., bitter, sour). In this context “design” includes, for example, selecting edible species proteins embodying features that achieve the desired taste property, as well as creating muteins of edible species polypeptides that have desired taste properties. For example, proteins can be designed to interact with specific taste receptors, such as sweet receptors (T1R2-T1R3 heterodimer) or umami receptors (T1R1-T1R3 heterodimer, mGluR4, and/or mGluR1). Further, proteins can be designed not to interact, or to have diminished interaction, with other taste receptors, such as bitter receptors (T2R receptors).
Proteins disclosed and described herein can also elicit different physical sensations in the mouth when ingested, sometimes referred to as “mouth feel.” The mouth feel of the proteins can be due to one or more factors including primary structure, the presence of charged side chains, and the electronic and conformational features of the protein. In some embodiments, proteins elicit a buttery or fat-like mouth feel when ingested.
Nutritive Compositions and Formulations
At least one protein disclosed herein can be combined with at least one second component to form a composition. In some embodiments the only source of amino acid in the composition is the at least one protein disclosed herein. In such embodiments the amino acid composition of the composition will be the same as the amino acid composition of the at least one protein disclosed herein. In some embodiments the composition comprises at least one protein disclosed herein and at least one second protein. In some embodiments the at least one second protein is a second protein disclosed herein, while in other embodiments the at least one second protein is not a protein disclosed herein. In some embodiments the composition comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more proteins disclosed herein. In some embodiments the composition comprises 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more proteins that are not proteins disclosed herein. In some embodiments the composition comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more proteins and the composition comprises 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more proteins that are not proteins disclosed herein.
Also provided are formulations containing the nutritive polypeptides described herein. In one aspect, provided is a formulation containing a unicellular organism secreted polypeptide nutritional domain. For example, the polypeptide nutritional domain contains an amino acid sequence having an N-terminal amino acid that does not correspond to the N-terminal amino acid of an amino acid sequence comprising a unicellular organism secreted polypeptide that contains the polypeptide nutritional domain. In some embodiments the amino acid sequence comprising the unicellular organism secreted polypeptide is an edible species polypeptide sequence, and the N-terminal amino acid is a common edible species amino acid. In addition or in the alternative, the polypeptide nutritional domain contains an amino acid sequence having a C-terminal amino acid that does not correspond to the C-terminal amino acid of an amino acid sequence comprising a unicellular organism secreted polypeptide that contains the polypeptide nutritional domain. In some embodiments the amino acid sequence comprising the unicellular organism secreted polypeptide is an edible species polypeptide sequence, and the C-terminal amino acid is a common edible species amino acid. Thus, in some embodiments the secreted polypeptide nutritional domain is at least one amino acid shorter than a homologous edible species polypeptide. The nutritional domain can be about 99%, 98%, 97%, 96%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5% or less than 5% the length of a homologous edible species peptide. In other embodiments, the polypeptide nutritional domain consists of from about 1% to about 99% of the unicellular organism secreted polypeptide that contains the polypeptide nutritional domain. As described herein, the polypeptide nutritional domain is generally preferred to the larger polypeptide containing the polypeptide nutritional domain. A polypeptide nutritional domain may contain, on a mass basis, more nutrition than the larger including polypeptide. In some embodiments, a polypeptide nutritional domain may provide desirable features when compared to the larger including polypeptide, such as increased solubility and better shelf-life stability.
In some embodiments the composition as described in the preceding paragraph, further comprises at least one of at least one polypeptide, at least one peptide, and at least one free amino acid. In some embodiments the composition comprises at least one polypeptide and at least one peptide. In some embodiments the composition comprises at least one polypeptide and at least one free amino acid. In some embodiments the composition comprises at least one peptide and at least one free amino acid. In some embodiments the at least one polypeptide, at least one peptide, and/or at least one free amino acid comprises amino acids selected from 1) branched chain amino acids, 2) leucine, and 3) essential amino acids. In some embodiments the at least one polypeptide, at least one peptide, and/or at least one free amino acid consists of amino acids selected from 1) branched chain amino acids, 2) leucine, and 3) essential amino acids. In some embodiments, the composition comprises at least one modified amino acid or a non-standard amino acid. Modified amino acids include amino acids that have modifications to one or more of the carboxy terminus, amino terminus, and/or side chain. Non-standard amino acids can be selected from those that are formed by post-translational modification of proteins, for example, carboxylated glutamate, hydroxyproline, or hypusine. Other non-standard amino acids are not found in proteins. Examples include lanthionine, 2-aminoisobutyric acid, dehydroalanine, gamma-aminobutyric acid, ornithine and citrulline. In some embodiments, the composition comprises one or more D-amino acids. In some embodiments, the composition comprises one or more L-amino acids. In some embodiments, the composition comprises a mixture of one or more D-amino acids and one or more L-amino acids.
By adding at least one of a polypeptide, a peptide, and a free amino acid to a composition the proportion of at least one of branched chain amino acids, leucine, and essential amino acids, to total amino acid, present in the composition can be increased.
In some embodiments the composition comprises at least one carbohydrate. A “carbohydrate” refers to a sugar or polymer of sugars. The terms “saccharide,” “polysaccharide,” “carbohydrate,” and “oligosaccharide” can be used interchangeably. Most carbohydrates are aldehydes or ketones with many hydroxyl groups, usually one on each carbon atom of the molecule. Carbohydrates generally have the molecular formula CnH2nOn. A carbohydrate can be a monosaccharide, a disaccharide, trisaccharide, oligosaccharide, or polysaccharide. The most basic carbohydrate is a monosaccharide, such as glucose, sucrose, galactose, mannose, ribose, arabinose, xylose, and fructose. Disaccharides are two joined monosaccharides. Exemplary disaccharides include sucrose, maltose, cellobiose, and lactose. Typically, an oligosaccharide includes between three and six monosaccharide units (e.g., raffinose, stachyose), and polysaccharides include six or more monosaccharide units. Exemplary polysaccharides include starch, glycogen, and cellulose. Carbohydrates may contain modified saccharide units such as 2′-deoxyribose wherein a hydroxyl group is removed, 2′-fluororibose wherein a hydroxyl group is replace with a fluorine, or N-acetylglucosamine, a nitrogen-containing form of glucose (e.g., 2′-fluororibose, deoxyribose, and hexose). Carbohydrates may exist in many different forms, for example, conformers, cyclic forms, acyclic forms, stereoisomers, tautomers, anomers, and isomers.
In some embodiments the composition comprises at least one lipid. As used herein a “lipid” includes fats, oils, triglycerides, cholesterol, phospholipids, fatty acids in any form including free fatty acids. Fats, oils and fatty acids can be saturated, unsaturated (cis or trans) or partially unsaturated (cis or trans). In some embodiments the lipid comprises at least one fatty acid selected from lauric acid (12:0), myristic acid (14:0), palmitic acid (16:0), palmitoleic acid (16:1), margaric acid (17:0), heptadecenoic acid (17:1), stearic acid (18:0), oleic acid (18:1), linoleic acid (18:2), linolenic acid (18:3), octadecatetraenoic acid (18:4), arachidic acid (20:0), eicosenoic acid (20:1), eicosadienoic acid (20:2), eicosatetraenoic acid (20:4), eicosapentaenoic acid (20:5) (EPA), docosanoic acid (22:0), docosenoic acid (22:1), docosapentaenoic acid (22:5), docosahexaenoic acid (22:6) (DHA), and tetracosanoic acid (24:0). In some embodiments the composition comprises at least one modified lipid, for example a lipid that has been modified by cooking.
In some embodiments the composition comprises at least one supplemental mineral or mineral source. Examples of minerals include, without limitation: chloride, sodium, calcium, iron, chromium, copper, iodine, zinc, magnesium, manganese, molybdenum, phosphorus, potassium, and selenium. Suitable forms of any of the foregoing minerals include soluble mineral salts, slightly soluble mineral salts, insoluble mineral salts, chelated minerals, mineral complexes, non-reactive minerals such as carbonyl minerals, and reduced minerals, and combinations thereof.
In some embodiments the composition comprises at least one supplemental vitamin. The at least one vitamin can be fat-soluble or water soluble vitamins. Suitable vitamins include but are not limited to vitamin C, vitamin A, vitamin E, vitamin B12, vitamin K, riboflavin, niacin, vitamin D, vitamin B6, folic acid, pyridoxine, thiamine, pantothenic acid, and biotin. Suitable forms of any of the foregoing are salts of the vitamin, derivatives of the vitamin, compounds having the same or similar activity of the vitamin, and metabolites of the vitamin.
In some embodiments the composition comprises at least one organism. Suitable examples are well known in the art and include probiotics (e.g., species of Lactobacillus or Bifidobacterium ), spirulina, chlorella , and porphyra.
In some embodiments the composition comprises at least one dietary supplement. Suitable examples are well known in the art and include herbs, botanicals, and certain hormones. Non limiting examples include ginko, gensing, and melatonin.
In some embodiments the composition comprises an excipient. Non-limiting examples of suitable excipients include a tastant, a flavorant, a buffering agent, a preservative, a stabilizer, a binder, a compaction agent, a lubricant, a dispersion enhancer, a disintegration agent, a flavoring agent, a sweetener, a coloring agent.
In some embodiments the excipient is a buffering agent. Non-limiting examples of suitable buffering agents include sodium citrate, magnesium carbonate, magnesium bicarbonate, calcium carbonate, and calcium bicarbonate.
In some embodiments the excipient comprises a preservative. Non-limiting examples of suitable preservatives include antioxidants, such as alpha-tocopherol and ascorbate, and antimicrobials, such as parabens, chlorobutanol, and phenol.
In some embodiments the composition comprises a binder as an excipient. Non-limiting examples of suitable binders include starches, pregelatinized starches, gelatin, polyvinylpyrolidone, cellulose, methylcellulose, sodium carboxymethylcellulose, ethylcellulose, polyacrylamides, polyvinyloxoazolidone, polyvinylalcohols, C12-C18 fatty acid alcohol, polyethylene glycol, polyols, saccharides, oligosaccharides, and combinations thereof.
In some embodiments the composition comprises a lubricant as an excipient. Non-limiting examples of suitable lubricants include magnesium stearate, calcium stearate, zinc stearate, hydrogenated vegetable oils, sterotex, polyoxyethylene monostearate, talc, polyethyleneglycol, sodium benzoate, sodium lauryl sulfate, magnesium lauryl sulfate, and light mineral oil.
In some embodiments the composition comprises a dispersion enhancer as an excipient. Non-limiting examples of suitable dispersants include starch, alginic acid, polyvinylpyrrolidones, guar gum, kaolin, bentonite, purified wood cellulose, sodium starch glycolate, isoamorphous silicate, and microcrystalline cellulose as high HLB emulsifier surfactants.
In some embodiments the composition comprises a disintegrant as an excipient. In some embodiments the disintegrant is a non-effervescent disintegrant. Non-limiting examples of suitable non-effervescent disintegrants include starches such as corn starch, potato starch, pregelatinized and modified starches thereof, sweeteners, clays, such as bentonite, micro-crystalline cellulose, alginates, sodium starch glycolate, gums such as agar, guar, locust bean, karaya, pecitin, and tragacanth. In some embodiments the disintegrant is an effervescent disintegrant. Non-limiting examples of suitable effervescent disintegrants include sodium bicarbonate in combination with citric acid, and sodium bicarbonate in combination with tartaric acid.
In some embodiments the excipient comprises a flavoring agent. Flavoring agents incorporated into the outer layer can be chosen from synthetic flavor oils and flavoring aromatics; natural oils; extracts from plants, leaves, flowers, and fruits; and combinations thereof. In some embodiments the flavoring agent is selected from cinnamon oils; oil of wintergreen; peppermint oils; clover oil; hay oil; anise oil; eucalyptus ; vanilla; citrus oil such as lemon oil, orange oil, grape and grapefruit oil; and fruit essences including apple, peach, pear, strawberry, raspberry, cherry, plum, pineapple, and apricot.
In some embodiments the excipient comprises a sweetener. Non-limiting examples of suitable sweeteners include glucose (corn syrup), dextrose, invert sugar, fructose, and mixtures thereof (when not used as a carrier); saccharin and its various salts such as the sodium salt; dipeptide sweeteners such as aspartame; dihydrochalcone compounds, glycyrrhizin; Stevia Rebaudiana (Stevioside); chloro derivatives of sucrose such as sucralose; and sugar alcohols such as sorbitol, mannitol, sylitol, and the like. Also contemplated are hydrogenated starch hydrolysates and the synthetic sweetener 3,6-dihydro-6-methyl-1,2,3-oxathiazin-4-one-2,2-dioxide, particularly the potassium salt (acesulfame-K), and sodium and calcium salts thereof.
In some embodiments the composition comprises a coloring agent. Non-limiting examples of suitable color agents include food, drug and cosmetic colors (FD&C), drug and cosmetic colors (D&C), and external drug and cosmetic colors (Ext. D&C). The coloring agents can be used as dyes or their corresponding lakes.
The weight fraction of the excipient or combination of excipients in the formulation is usually about 50% or less, about 45% or less, about 40% or less, about 35% or less, about 30% or less, about 25% or less, about 20% or less, about 15% or less, about 10% or less, about 5% or less, about 2% or less, or about 1% or less of the total weight of the amino acids in the composition.
The proteins and compositions disclosed herein can be formulated into a variety of forms and administered by a number of different means. The compositions can be administered orally, rectally, or parenterally, in formulations containing conventionally acceptable carriers, adjuvants, and vehicles as desired. The term “parenteral” as used herein includes subcutaneous, intravenous, intramuscular, or intrasternal injection and infusion techniques. In an exemplary embodiment, the protein or composition is administered orally.
Solid dosage forms for oral administration include capsules, tablets, caplets, pills, troches, lozenges, powders, and granules. A capsule typically comprises a core material comprising a protein or composition and a shell wall that encapsulates the core material. In some embodiments the core material comprises at least one of a solid, a liquid, and an emulsion. In some embodiments the shell wall material comprises at least one of a soft gelatin, a hard gelatin, and a polymer. Suitable polymers include, but are not limited to: cellulosic polymers such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose (HPMC), methyl cellulose, ethyl cellulose, cellulose acetate, cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose succinate and carboxymethylcellulose sodium; acrylic acid polymers and copolymers, such as those formed from acrylic acid, methacrylic acid, methyl acrylate, ammonio methylacrylate, ethyl acrylate, methyl methacrylate and/or ethyl methacrylate (e.g., those copolymers sold under the trade name “Eudragit”); vinyl polymers and copolymers such as polyvinyl pyrrolidone, polyvinyl acetate, polyvinylacetate phthalate, vinylacetate crotonic acid copolymer, and ethylene-vinyl acetate copolymers; and shellac (purified lac). In some embodiments at least one polymer functions as taste-masking agents.
Tablets, pills, and the like can be compressed, multiply compressed, multiply layered, and/or coated. The coating can be single or multiple. In one embodiment, the coating material comprises at least one of a saccharide, a polysaccharide, and glycoproteins extracted from at least one of a plant, a fungus, and a microbe. Non-limiting examples include corn starch, wheat starch, potato starch, tapioca starch, cellulose, hemicellulose, dextrans, maltodextrin, cyclodextrins, inulins, pectin, mannans, gum arabic, locust bean gum, mesquite gum, guar gum, gum karaya, gum ghatti, tragacanth gum, funori, carrageenans, agar, alginates, chitosans, or gellan gum. In some embodiments the coating material comprises a protein. In some embodiments the coating material comprises at least one of a fat and oil. In some embodiments the at least one of a fat and an oil is high temperature melting. In some embodiments the at least one of a fat and an oil is hydrogenated or partially hydrogenated. In some embodiments the at least one of a fat and an oil is derived from a plant. In some embodiments the at least one of a fat and an oil comprises at least one of glycerides, free fatty acids, and fatty acid esters. In some embodiments the coating material comprises at least one edible wax. The edible wax can be derived from animals, insects, or plants. Non-limiting examples include beeswax, lanolin, bayberry wax, carnauba wax, and rice bran wax. Tablets and pills can additionally be prepared with enteric coatings.
Alternatively, powders or granules embodying the proteins and compositions disclosed herein can be incorporated into a food product. In some embodiments the food product is be a drink for oral administration. Non-limiting examples of a suitable drink include fruit juice, a fruit drink, an artificially flavored drink, an artificially sweetened drink, a carbonated beverage, a sports drink, a liquid diary product, a shake, an alcoholic beverage, a caffeinated beverage, infant formula and so forth. Other suitable means for oral administration include aqueous and nonaqueous solutions, creams, pastes, emulsions, suspensions and slurries, each of which may optionally also containin at least one of suitable solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, coloring agents, a tastant, a flavorant, and flavoring agents.
In some embodiments the food product is a solid foodstuff. Suitable examples of a solid foodstuff include without limitation a food bar, a snack bar, a cookie, a brownie, a muffin, a cracker, a biscuit, a cream or paste, an ice cream bar, a frozen yogurt bar, and the like.
In some embodiments, the proteins and compositions disclosed herein are incorporated into a therapeutic food. In some embodiments, the therapeutic food is a ready-to-use food that optionally contains some or all essential macronutrients and micronutrients. In some embodiments, the proteins and compositions disclosed herein are incorporated into a supplementary food that is designed to be blended into an existing meal. In some embodiments, the supplemental food contains some or all essential macronutrients and micronutrients. In some embodiments, the proteins and compositions disclosed herein are blended with or added to an existing food to fortify the food's protein nutrition. Examples include food staples (grain, salt, sugar, cooking oil, margarine), beverages (coffee, tea, soda, beer, liquor, sports drinks), snacks, sweets and other foods.
The compositions disclosed herein can be utilized in methods to increase at least one of muscle mass, strength and physical function, thermogenesis, metabolic expenditure, satiety, mitochondrial biogenesis, weight or fat loss, and lean body composition for example.
A formulation can contain a nutritive polypeptide up to about 25 g per 100 kilocalories (25 g/100 kcal) in the formulation, meaning that all or essentially all of the energy present in the formulation is in the form of the nutritive polypeptide. More typically, about 99%, 98%, 97%, 96%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5% or less than 5% of the energy present in the formulation is in the form of the nutritive polypeptide. In other formulations, the nutritive polypeptide is present in an amount sufficient to provide a nutritional benefit equivalent to or greater than at least about 0.1% of a reference daily intake value of polypeptide. Suitable reference daily intake values for protein are well known in the art. See, e.g., Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein and Amino Acids, Institute of Medicine of the National Academies, 2005, National Academies Press, Washington D.C. A reference daily intake value for protein is a range wherein 10-35% of daily calories are provided by protein and isolated amino acids. Another reference daily intake value based on age is provided as grams of protein per day: children ages 1-3: 13 g, children ages 4-8: 19 g, children ages 9-13: 34 g, girls ages 14-18: 46, boys ages 14-18: 52, women ages 19-70+: 46, and men ages 19-70+: 56. In other formulations, the nutritive polypeptide is present in an amount sufficient to provide a nutritional benefit to a human subject suffering from protein malnutrition or a disease, disorder or condition characterized by protein malnutrition. Protein malnutrition is commonly a prenatal or childhood condition. Protein malnutrition with adequate energy intake is termed kwashiorkor or hypoalbuminemic malnutrition, while inadequate energy intake in all forms, including inadequate protein intake, is termed marasmus. Adequately nourished individuals can develop sarcopenia from consumption of too little protein or consumption of proteins deficient in nutritive amino acids. Prenatal protein malnutrition can be prevented, treated or reduced by administration of the nutritive polypeptides described herein to pregnant mothers, and neonatal protein malnutrition can be prevented, treated or reduced by administration of the nutritive polypeptides described herein to the lactation mother. In adults, protein malnutrition is commonly a secondary occurrence to cancer, chronic renal disease, and in the elderly. Additionally, protein malnutrition can be chronic or acute. Examples of acute protein malnutrition occur during an acute illness or disease such as sepsis, or during recovery from a traumatic injury, such as surgery, thermal injury such as a burn, or similar events resulting in substantial tissue remodeling. Other acute illnesses treatable by the methods and compositions described herein include sarcopenia, cachexia, diabetes, insulin resistance, and obesity.
A formulation can contain a nutritive polypeptide in an amount sufficient to provide a feeling of satiety when consumed by a human subject, meaning the subject feels a reduced sense or absence of hunger, or desire to eat. Such a formulation generally has a higher satiety index than carbohydrate-rich foods on an equivalent calorie basis.
A formulation can contain a nutritive polypeptide in an amount based on the concentration of the nutritive polypeptide (e.g., on a weight-to-weight basis), such that the nutritive polypeptide accounts for up to 100% of the weight of the formulation, meaning that all or essentially all of the matter present in the formulation is in the form of the nutritive polypeptide. More typically, about 99%, 98%, 97%, 96%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5% or less than 5% of the weight present in the formulation is in the form of the nutritive polypeptide. In some embodiments, the formulation contains 10 mg, 100 mg, 500 mg, 750 mg, 1 g, 2 g, 3 g, 4 g, 5 g, 6 g, 7 g, 8 g, 9, 10 g, 15 g, 20 g, 25 g, 30 g, 35 g, 40 g, 45 g, 50 g, 60 g, 70 g, 80 g, 90 g, 100 g or over 100 g of nutritive polypeptide.
Preferably, the formulations provided herein are substantially free of non-comestible products. Non-comestible products are often found in preparations of recombinant proteins of the prior art, produced from yeast, bacteria, algae, insect, mammalian or other expression systems. Exemplary non-comestible products include surfactant, a polyvinyl alcohol, a propylene glycol, a polyvinyl acetate, a polyvinylpyrrolidone, a non-comestible polyacid or polyol, a fatty alcohol, an alkylbenzyl sulfonate, an alkyl glucoside, or a methyl paraben.
In aspects, the provided formulations contain other materials, such as a tastant, a nutritional carbohydrate and/or a nutritional lipid. In addition, formulations may include bulking agents, texturizers, and fillers.
In preferred embodiments, the nutritive polypeptides provided herein are isolated and/or substantially purified. The nutritive polypeptides and the compositions and formulations provided herein, are substantially free of non-protein components. Such non-protein components are generally present in protein preparations such as whey, casein, egg and soy preparations, which contain substantial amounts of carbohydrates and lipids that complex with the polypeptides and result in delayed and incomplete protein digestion in the gastrointestinal tract. Such non-protein components can also include DNA. Thus, the nutritive polypeptides, compositions and formulations are characterized by improved digestability and decreased allergenicity as compared to food-derived polypeptides and polypeptide mixtures. Furthermore, these formulations and compositions are characterized by more reproducible digestability from a time and/or a digestion product at a given unit time basis. In certain embodiments, a nutritive polypeptide is at least 10% reduced in lipids and/or carbohydrates, and optionally one or more other materials that decreases digestibility and/or increases allergenicity, relative to a reference polypeptide or reference polypeptide mixture, e.g., is reduced by 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99% or greater than 99%. In certain embodiments, the nutritive formulations contain a nutritional carbohydrate and/or nutritional lipid, which may be selected for digestibility and/or reduced allegenicity.
Methods of Use
In some embodiments the proteins and compositions disclosed herein are administered to a patient or a user (sometimes collectively refered to as a “subject”). As used herein “administer” and “administration” encompasses embodiments in which one person directs another to consume a protein or composition in a certain manner and/or for a certain purpose, and also situations in which a user uses a protein or composition in a certain manner and/or for a certain purpose independently of or in variance to any instructions received from a second person. Non-limiting examples of embodiments in which one person directs another to consume a protein or composition in a certain manner and/or for a certain purpose include when a physician prescribes a course of conduct and/or treatment to a patient, when a trainer advises a user (such as an athlete) to follow a particular course of conduct and/or treatment, and when a manufacturer, distributer, or marketer recommends conditions of use to an end user, for example through advertisements or labeling on packaging or on other materials provided in association with the sale or marketing of a product.
In some embodiments the proteins or compositions are provided in a dosage form. In some embodiments the dosage form is designed for administration of at least one protein disclosed herein, wherein the total amount of protein administered is selected from 0.1 g to 1 g, 1 g to 5 g, from 2 g to 10 g, from 5 g to 15 g, from 10 g to 20 g, from 15 g to 25 g, from 20 g to 40 g, from 25-50 g, and from 30-60 g. In some embodiments the dosage form is designed for administration of at least one protein disclosed herein, wherein the total amount of protein administered is selected from about 0.1 g, 0.1 g-1 g, 1 g, 2 g, 3 g, 4 g, 5 g, 6 g, 7 g, 8 g, 9 g, 10 g, 15 g, 20 g, 25 g, 30 g, 35 g, 40 g, 45 g, 50 g, 55 g, 60 g, 65 g, 70 g, 75 g, 80 g, 85 g, 90 g, 95 g, and 100 g.
In some embodiments the dosage form is designed for administration of at least one protein disclosed herein, wherein the total amount of essential amino acids administered is selected from 0.1 g to 1 g, from 1 g to 5 g, from 2 g to 10 g, from 5 g to 15 g, from 10 g to 20 g, and from 1-30 g. In some embodiments the dosage form is designed for administration of at least one protein disclosed herein, wherein the total amount of protein administered is selected from about 0.1 g, 0.1-1 g, 1 g, 2 g, 3 g, 4 g, 5 g, 6 g, 7 g, 8 g, 9 g, 10 g, 15 g, 20 g, 25 g, 30 g, 35 g, 40 g, 45 g, 50 g, 55 g, 60 g, 65 g, 70 g, 75 g, 80 g, 85 g, 90 g, 95 g, and 100 g.
In some embodiments the protein or composition is consumed at a rate of from 0.1 g to 1 g a day, 1 g to 5 g a day, from 2 g to 10 g a day, from 5 g to 15 g a day, from 10 g to 20 g a day, from 15 g to 30 g a day, from 20 g to 40 g a day, from 25 g to 50 g a day, from 40 g to 80 g a day, from 50 g to 100 g a day, or more.
In some embodiments, of the total protein intake by the subject, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or about 100% of the total protein intake by the subject over a dietary period is made up of at least one protein according to this disclosure. In some embodiments, of the total protein intake by the subject, from 5% to 100% of the total protein intake by the subject, from 5% to 90% of the total protein intake by the subject, from 5% to 80% of the total protein intake by the subject, from 5% to 70% of the total protein intake by the subject, from 5% to 60% of the total protein intake by the subject, from 5% to 50% of the total protein intake by the subject, from 5% to 40% of the total protein intake by the subject, from 5% to 30% of the total protein intake by the subject, from 5% to 20% of the total protein intake by the subject, from 5% to 10% of the total protein intake by the subject, from 10% to 100% of the total protein intake by the subject, from 10% to 100% of the total protein intake by the subject, from 20% to 100% of the total protein intake by the subject, from 30% to 100% of the total protein intake by the subject, from 40% to 100% of the total protein intake by the subject, from 50% to 100% of the total protein intake by the subject, from 60% to 100% of the total protein intake by the subject, from 70% to 100% of the total protein intake by the subject, from 80% to 100% of the total protein intake by the subject, or from 90% to 100% of the total protein intake by the subject, over a dietary period, is made up of at least one protein according to this disclosure. In some embodiments the at least one protein of this disclosure accounts for at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, or at least 50% of the subject's calorie intake over a dietary period.
In some embodiments the at least one protein according to this disclosure comprises at least 2 proteins of this disclosure, at least 3 proteins of this disclosure, at least 4 proteins of this disclosure, at least 5 proteins of this disclosure, at least 6 proteins of this disclosure, at least 7 proteins of this disclosure, at least 8 proteins of this disclosure, at least 9 proteins of this disclosure, at least 10 proteins of this disclosure, or more.
In some embodiments the dietary period is 1 meal, 2 meals, 3 meals, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, or at least 1 year. In some embodiments the dietary period is from 1 day to 1 week, from 1 week to 4 weeks, from 1 month, to 3 months, from 3 months to 6 months, or from 6 months to 1 year.
Clinical studies provide evidence that protein prevents muscle loss due to aging or disuse, such as from immobility or prolonged bed rest. In particular, studies have shown that protein supplementation increases muscle fractional synthetic rate (FSR) during prolonged bed rest, maintains leg mass and strength during prolonged bed rest, increases lean body mass, improves functional measures of gait and balance, and may serve as a viable intervention for individuals at risk of sarcopenia due to immobility or prolonged bed rest. See, e.g., Paddon-Jones D, et al. J Clin Endocrinol Metab 2004, 89:4351-4358; Ferrando, A et al. Clinical Nutrition 2009 1-6; Katsanos C et al. Am J Physiol Endocrinol Metab. 2006, 291: 381-387.
Studies on increasing muscle protein anabolism in athletes have shown that protein provided following exercise promotes muscle hypertrophy to a greater extent than that achieved by exercise alone. It has also been shown that protein provided following exercise supports protein synthesis without any increase in protein breakdown, resulting in a net positive protein balance and muscle mass accretion. While muscle protein synthesis appears to respond in a dose-response fashion to essential amino acid supplementation, not all proteins are equal in building muscle. For example, the amino acid leucine is an important factor in stimulating muscle protein synthesis. See, e.g., Borscheim E et al. Am J Physiol Endocrinol Metab 2002, 283: E648-E657; Borsheim E et al. Clin Nutr. 2008, 27: 189-95; Esmarck B et al J Physiol 2001, 535: 301-311; Moore D et al. Am J Clin Nutr 2009, 89: 161-8).
In another aspect this disclosure provides methods of maintaining or increasing at least one of muscle mass, muscle strength, and functional performance in a subject. In some embodiments the methods comprise providing to the subject a sufficient amount of a protein of this disclosure, a composition of this disclosure, or a composition made by a method of this disclosure. In some embodiments the subject is at least one of elderly, critically-medically ill, and suffering from protein-energy malnutrition. In some embodiments the sufficient amount of a protein of this disclosure, a composition of this disclosure, or a composition made by a method of this disclosure is consumed by the subject in coordination with performance of exercise. In some embodiments the protein of this disclosure, composition of this disclosure, or composition made by a method of this disclosure is consumed by the subject by an oral, enteral, or parenteral route. In some embodiments the protein of this disclosure, composition of this disclosure, or composition made by a method of this disclosure is consumed by the subject by an oral route. In some embodiments the protein of this disclosure, composition of this disclosure, or composition made by a method of this disclosure is consumed by the subject by an enteral route.
In another aspect this disclosure provides methods of maintaining or achieving a desirable body mass index in a subject. In some embodiments the methods comprise providing to the subject a sufficient amount of a protein of this disclosure, a composition of this disclosure, or a composition made by a method of this disclosure. In some embodiments the subject is at least one of elderly, critically-medically ill, and suffering from protein-energy malnutrition. In some embodiments the sufficient amount of a protein of this disclosure, a composition of this disclosure, or a composition made by a method of this disclosure is consumed by the subject in coordination with performance of exercise. In some embodiments the protein of this disclosure, composition of this disclosure, or composition made by a method of this disclosure is consumed by the subject by an oral, enteral, or parenteral route.
In another aspect this disclosure provides methods of providing protein to a subject with protein-energy malnutrition. In some embodiments the methods comprise providing to the subject a sufficient amount of a protein of this disclosure, a composition of this disclosure, or a composition made by a method of this disclosure. In some embodiments the protein of this disclosure, composition of this disclosure, or composition made by a method of this disclosure is consumed by the subject by an oral, enteral, or parenteral route.
The need for essential amino acid supplementation has been suggested in cancer patients and other patients suffering from muscle wasting and cachexia. Dietary studies in mice have shown survival and functional benefits to cachectic cancer-bearing mice through dietary intervention with essential amino acids. Beyond cancer, essential amino acid supplementation has also shown benefits, such as improved muscle function and muscle gain, in patients suffering from other diseases that have difficulty exercising and therefore suffer from muscular deterioration, such as chronic obstructive pulmonary disease, chronic heart failure, HIV, and other disease states.
Studies have shown that specific amino acids have advantages in managing cachexia. A relatively high content of BCAAs and Leu in diets are thought to have a positive effect in cachexia by promoting total protein synthesis by signaling an increase in translation, enhancing insulin release, and inhibiting protein degradation. Thus, consuming increased dietary BCAAs in general and/or Leu in particular will contribute positively to reduce or reverse the effects of cachexia. Because nitrogen balance is important in countering the underlying cause of cachexia it is thought that consuming increased dietary glutamine and/or arginine will contribute positively to reduce or reverse the effects of cachexia. See, e.g., Op den Kamp C, Langen R, Haegens A, Schols A. “Muscle atrophy in cachexia: can dietary protein tip the balance?” Current Opinion in Clinical Nutrition and Metabolic Care 2009, 12:611-616; Poon R T-P, Yu W-C, Fan S-T, et al. “Long-term oral branched chain amino acids in patients undergoing chemoembolization for hepatocellular carcinoma: a randomized trial.” Aliment Pharmacol Ther 2004; 19:779-788; Tayek J A, Bistrian B R, Hehir D J, Martin R, Moldawer L L, Blackburn G L. “Improved protein kinetics and albumin synthesis by branched chain amino acid-enriched total parenteral nutrition in cancer cachexia.” Cancer. 1986; 58:147-57; Xi P, Jiang Z, Zheng C, Lin Y, Wu G “Regulation of protein metabolism by glutamine: implications for nutrition and health.” Front Biosci. 2011 Jan. 1; 16:578-97.
Accordingly, also provided herein are methods of treating cachexia in a subject. In some embodiments a sufficient amound of a protein of this disclosure, a composition of this disclosure, or a composition made by a method of this disclosure for a subject with cachexia is an amount such that the amount of protein of this disclosure ingested by the person meets or exceeds the metabolic needs (which are often elevated). A protein intake of 1.5 g/kg of body weight per day or 15-20% of total caloric intake appears to be an appropriate target for persons with cachexia. In some embodiments all of the protein consumed by the subject is a protein according to this disclosure. In some embodiments protein according to this disclosure is combined with other sources of protein and/or free amino acids to provide the total protein intake of the subject. In some embodiments the subject is at least one of elderly, critically-medically ill, and suffering from protein-energy malnutrition. In some embodiments the subject suffers from a disease that makes exercise difficult and therefore causes muscular deterioration, such as chronic obstructive pulmonary disease, chronic heart failure, HIV, cancer, and other disease states. In some embodiments, the protein according to disclosure, the composition according to disclosure, or the composition made by a method according to disclosure is consumed by the subject in coordination with performance of exercise. In some embodiments, the protein according to this disclosure, the composition according to disclosure, or the composition made by a method according to disclosure is consumed by the subject by an oral, enteral, or parenteral route.
Sarcopenia is the degenerative loss of skeletal muscle mass (typically 0.5-1% loss per year after the age of 25), quality, and strength associated with aging. Sarcopenia is a component of the frailty syndrome. The European Working Group on Sarcopenia in Older People (EWGSOP) has developed a practical clinical definition and consensus diagnostic criteria for age-related sarcopenia. For the diagnosis of sarcopenia, the working group has proposed using the presence of both low muscle mass and low muscle function (strength or performance). Sarcopenia is characterized first by a muscle atrophy (a decrease in the size of the muscle), along with a reduction in muscle tissue “quality,” caused by such factors as replacement of muscle fibres with fat, an increase in fibrosis, changes in muscle metabolism, oxidative stress, and degeneration of the neuromuscular junction. Combined, these changes lead to progressive loss of muscle function and eventually to frailty. Frailty is a common geriatric syndrome that embodies an elevated risk of catastrophic declines in health and function among older adults. Contributors to frailty can include sarcopenia, osteoporosis, and muscle weakness. Muscle weakness, also known as muscle fatigue, (or “lack of strength”) refers to the inability to exert force with one's skeletal muscles. Weakness often follows muscle atrophy and a decrease in activity, such as after a long bout of bedrest as a result of an illness. There is also a gradual onset of muscle weakness as a result of sarcopenia.
The proteins of this disclosure are useful for treating sarcopenia or frailty once it develops in a subject or for preventing the onset of sarcopenia or frailty in a subject who is a member of an at risk groups. In some embodiments all of the protein consumed by the subject is a protein according to this disclosure. In some embodiments protein according to this disclosure is combined with, other sources of protein and/or free amino acids to provide the total protein intake of the subject. In some embodiments the subject is at least one of elderly, critically-medically ill, and suffering from protein-energy malnutrition. In some embodiments, the protein according to disclosure, the composition according to disclosure, or the composition made by a method according to disclosure is consumed by the subject in coordination with performance of exercise. In some embodiments, the protein according to this disclosure, the composition according to disclosure, or the composition made by a method according to disclosure is consumed by the subject by an oral, enteral, or parenteral route.
Obesity is a multifactorial disorder associated with a host of comorbidities including hypertension, type 2 diabetes, dyslipidemia, coronary heart disease, stroke, cancer (eg, endometrial, breast, and colon), osteoarthritis, sleep apnea, and respiratory problems. The incidence of obesity, defined as a body mass index >30 kg/m2, has increased dramatically in the United States, from 15% (1976-1980) to 33% (2003-2004), and it continues to grow. Although the mechanisms contributing to obesity are complex and involve the interplay of behavioral components with hormonal, genetic, and metabolic processes, obesity is largely viewed as a lifestyle-dependent condition with 2 primary causes: excessive energy intake and insufficient physical activity. With respect to energy intake, there is evidence that modestly increasing the proportion of protein in the diet, while controlling total energy intake, may improve body composition, facilitate fat loss, and improve body weight maintenance after weight loss. Positive outcomes associated with increased dietary protein are thought to be due primarily to lower energy intake associated with increased satiety, reduced energy efficiency and/or increased thermogenesis, positive effects on body composition (specifically lean muscle mass), and enhanced glycemic control.
Dietary proteins are more effective in increasing post-prandial energy expenditure than isocaloric intakes of carbohydrates or fat (see, e.g., Dauncey M, Bingham S. “Dependence of 24 h energy expenditure in man on composition of the nutrient intake.” Br J Nutr 1983, 50: 1-13; Karst H et al. “Diet-induced thermogenesis in man: thermic effects of single proteins, carbohydrates and fats depending on their energy amount.” Ann Nutr Metab. 1984, 28: 245-52; Tappy L et al “Thermic effect of infused amino acids in healthy humans and in subjects with insulin resistance.” Am J Clin Nutr 1993, 57 (6): 912-6). This property along with other properties (satiety induction; preservation of lean body mass) make protein an attractive component of diets directed at weight management. The increase in energy expenditure caused by such diets may in part be due to the fact that the energy cost of digesting and metabolizing protein is higher than for other calorie sources. Protein turnover, including protein synthesis, is an energy consuming process. In addition, high protein diets may also up-regulate uncoupling protein in liver and brown adipose, which is positively correlated with increases in energy expenditure. It has been theorized that different proteins may have unique effects on energy expenditure.
Studies suggest that ingestion of protein, particularly proteins with high EAA and/or BCAA content, leads to distinct effects on thermogenesis and energy expenditure (see, e.g., Mikkelsen P. et al. “Effect of fat-reduced diets on 24 h energy expenditure: comparisons between animal protein, vegetable protein and carbohydrate.” Am J Clin Nutr 2000, 72:1135-41; Acheson K. et al. “Protein choices targeting thermogenesis and metabolism.” Am J Clin Nutr 2011, 93:525-34; Alfenas R. et al. “Effects of protein quality on appetite and energy metabolism in normal weight subjects” Arg Bras Endocrinol Metabol 2010, 54 (1): 45-51; Lorenzen J. et al. “The effect of milk proteins on appetite regulation and diet-induced thermogenesis.” J Clin Nutr 2012 66 (5): 622-7). Additionally, L-tyrosine has been identified as an amino acid that plays a role in thermogenesis (see, e.g., Belza A. et al. “The beta-adrenergic antagonist propranolol partly abolishes thermogenic response to bioactive food ingredients.” Metabolism 2009, 58 (8):1137-44). Further studies suggest that Leucine and Arginine supplementation appear to alter energy metabolism by directing substrate to lean body mass rather than adipose tissue (Dulloo A. “The search for compounds that stimulate thermogenesis in obesity management: from pharmaceuticals to functional food ingredients.” Obes Rev 2011 12: 866-83).
Collectively the literature suggests that different protein types leads to distinct effects on thermogenesis. Because proteins or peptides rich in EAAs, BCAA, and/or at least one of Tyr, Arg, and Leu are believed to have a stimulatory effect on thermogenesis, and because stimulation of thermogenesis is believed to lead to positive effects on weight management, this disclosure also provides products and methods useful to stimulation thermogenesis and/or to bring about positive effects on weight management in general.
More particularly, this disclosure provides methods of increasing thermogenesis in a subject. In some embodiments the methods comprise providing to the subject a sufficient amount of a protein of this disclosure, a composition of this disclosure, or a composition made by a method of this disclosure. In some embodiments the subject is obese. In some embodiments, the protein according to disclosure, the composition according to disclosure, or the composition made by a method according to disclosure is consumed by the subject in coordination with performance of exercise. In some embodiments, the protein according to disclosure, the composition according to disclosure, or the composition made by a method according to disclosure is consumed by the subject by an oral, enteral, or parenteral route.
At the basic level, the reason for the development of an overweight condition is due to an imbalance between energy intake and energy expenditure. Attempts to reduce food at any particular occasion (satiation) and across eating occasions (satiety) have been a major focus of recent research. Reduced caloric intake as a consequence of feeling satisfied during a meal and feeling full after a meal results from a complex interaction of internal and external signals. Various nutritional studies have demonstrated that variation in food properties such as energy density, content, texture and taste influence both satiation and satiety.
There are three macronutrients that deliver energy: fat, carbohydrates and proteins. A gram of protein or carbohydrate provides 4 calories while a gram of fat 9 calories. Protein generally increases satiety to a greater extent than carbohydrates or fat and therefore may facilitate a reduction in calorie intake. However, there is considerable evidence that indicates the type of protein matters in inducing satiety (see, e.g., W. L. Hall, et al. “Casein and whey exert different effects on plasma amino acid profiles, gastrointestinal hormone secretion and appetite.” Br J Nutr. 2003 February, 89(2):239-48; R. Abou-Samra, et al. “Effect of different protein sources on satiation and short-term satiety when consumed as a starter.” Nutr J. 2011 Dec. 23, 10:139; T. Akhavan, et al. “Effect of premeal consumption of whey protein and its hydrolysate on food intake and postmeal glycemia and insulin responses in young adults.” Am J Clin Nutr. 2010 April, 91(4):966-75, Epub 2010 Feb. 17; MA Veldhorst “Dose-dependent satiating effect of whey relative to casein or soy” Physiol Behav. 2009 Mar. 23, 96 (4-5):675-82). Evidence indicates that protein rich in Leucine is particularly effective at inducing satiety (see, e.g., Fromentin G et al “Peripheral and central mechanisms involved in the control of food intake by dietary amino acids and proteins.” Nutr Res Rev 2012 25: 29-39).
In some embodiments a protein of this disclosure is consumed by a subject concurrently with at least one pharmaceutical or biologic drug product. In some embodiments the beneficial effects of the protein and the at least one pharmaceutical or biologic drug product have an additive effect while in some embodiments the beneficial effects of the protein and the at least one pharmaceutical or biologic drug product have a synergistic effect. Examples of pharmaceutical or biologic drug products that can be administered with the proteins of this disclosure are well known in the art. For example, when a protein of this disclosure is used to maintain or increase at least one of muscle mass, muscle strength, and functional performance in a subject, the protein can be consumed by a subject concurrently with a therapeutic dosage regime of at least one pharmaceutical or biologic drug product indicated to maintain or increase at least one of muscle mass, muscle strength, and functional performance in a subject, such as an anabolic steroid. When a protein of this disclosure is used to maintain or achieve a desirable body mass index in a subject, the protein can be consumed by a subject concurrently with a therapeutic dosage regime of at least one pharmaceutical or biologic drug product indicated to maintain or achieve a desirable body mass index in a subject, such as orlistat, lorcaserin, sibutramine, rimonabant, metformin, exenatide, or pramlintide. When a protein of this disclosure is used to induce at least one of a satiation response and a satiety response in a subject, the protein can be consumed by a subject concurrently with a therapeutic dosage regime of at least one pharmaceutical or biologic drug product indicated to induce at least one of a satiation response and a satiety response in a subject, such as rimonabant, exenatide, or pramlintide. When a protein of this disclosure is used to treat at least one of cachexia, sarcopenia and frailty in a subject, the protein can be consumed by a subject concurrently with a therapeutic dosage regime of at least one pharmaceutical or biologic drug product indicated to treat at least one of cachexia, sarcopenia and frailty, such as omega-3 fatty acids or anabolic steroids. Because of the role of dietary protein in inducing satiation and satiety, the proteins and compositions disclosed herein can be used to induce at least one of a satiation response and a satiety response in a subject. In some embodiments the methods comprise providing to the subject a sufficient amount of a protein of this disclosure, a composition of this disclosure, or a composition made by a method of this disclosure. In some embodiments the subject is obese. In some embodiments; the protein according to disclosure, the composition according to disclosure, or the composition made by a method according to disclosure is consumed by the subject in coordination with performance of exercise. In some embodiments, the protein according to disclosure, the composition according to disclosure, or the composition made by a method according to disclosure is consumed by the subject by an oral, enteral, or parenteral route.
In some embodiments incorporating a least one protein or composition of this disclosure into the diet of a subject has at least one effect selected from inducing postprandial satiety (including by suppressing hunger), inducing thermogenesis, reducing glycemic response, positively affecting energy expenditure positively affecting lean body mass, reducing the weight gain caused by overeating, and decreasing energy intake. In some embodiments incorporating a least one protein or omposition of this disclosure into the diet of a subject has at least one effect selected from increasing loss of body fat, reducing lean tissue loss, improving lipid profile, and improving glucose tolerance and insulin sensitivity in the subject.
Examples of the techniques and protocols described herein can be found in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed), 1980.
EXAMPLES
Below are examples of specific embodiments for carrying out the present invention. The examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should, of course, be allowed for.
The practice of the present invention will employ, unless otherwise indicated, conventional methods of protein chemistry, biochemistry, recombinant DNA techniques and pharmacology, within the skill of the art. Such techniques are explained fully in the literature. See, e.g., T. E. Creighton, Proteins: Structures and Molecular Properties (W.H. Freeman and Company, 1993); A. L. Lehninger, Biochemistry (Worth Publishers, Inc., current addition); Sambrook, et al., Molecular Cloning: A Laboratory Manual (2nd Edition, 1989); Methods In Enzymology (S. Colowick and N. Kaplan eds., Academic Press, Inc.); Remington's Pharmaceutical Sciences, 18th Edition (Easton, Pa.: Mack Publishing Company, 1990); Carey and Sundberg Advanced Organic Chemistry 3 rd Ed. (Plenum Press) Vols A and B (1992).
Example 1
Identification and Selection of Amino Acid Sequences of Nutritive Polypeptides of Edible Species Using Mass Spectrometric Analyses
Provided is a process for identifying one or a plurality of nutritive polypeptide amino acid sequences, such as from a polypeptide or nucleic acid library, or from a relevant database of protein sequences. Here, nutritive polypeptide amino acid sequences were identified by mass spectroscopy analysis of proteins extracted and purified from edible species.
Protein Isolation for Mass Spectroscopy.
Proteins were extracted from solid edible sources. Samples from the following species were included in the analysis: Actinidia deliciosa, Agaricus bisporus var. bisporus, Arthrospira platensis, Bos taurus, Brassica oleracea, Cannabis, Chenopodium quinoa, Chlorella regularis, Chlorella variabilis, Cicer arietinum, Cucurbita maxima, Fusarium graminearum, Gadus morhua, Gallus gallus, Glycine Max, Lactobacillus acidophilus , Laminariales, Linum usitatissimum, Meleagris gallopavo, Odocoileus virginianus, Oreochromis niloticus, Oryza sativa, Ovis aries, Palmaria palmata, Persea americana, Prunus mume, Saccharomyces cerevisiae, Salmo salar, Solanum lycopesicum, Solanum tuberosum, Sus scrofa, Thunnus thynnus, Vaccinium corymbosum, Vitis vinifera , and Zea mays . Each sample was first frozen at −80 C and then ground using a mortar and pestle before weighing 50 mg of material into a microcentrifuge tube. The 50 mg sample was then resuspended in 1 mL of extraction buffer (8.3 M urea, 2 M thiourea, 2% w/v CHAPS, 1% w/v DTT) and agitated for 30 minutes. Addition of 500 μL of 100-μm zirconium beads (Ops Diagnostics) was followed by continued agitation for an additional 30 minutes. Samples were run on a TissueLyser II (Qiagen) at 30 Hz for 3 minutes and then centrifuged for 10 minutes at 21,130 g, in a benchtop microcentrifuge (Eppendorf). Supernatants were transferred to clean microcentrifuge tubes, aliquoted into 50 μL aliquots, and stored at −80° C. The amount of soluble protein extracted was measured by Coomassie Plus (Bradford) Protein Assay (Thermo Scientific). 20 ug of protein was run on 10% 10-lane BisTris SDS-PAGE gel (Invitrogen) and then excised for analysis by LC/MS/MS.
Proteins were also isolated from liquid cultures of the following edible organisms: Aspergillus niger, Bacillus subtilis, Bacillus licheniformis , and Bacillus amyloliquefaciens. Aspergillus and bacillus organisms were cultured as described herein. Clarified supernatants were isolated by centrifuging (10,000×g) cultures for 10 minutes, followed by filtering the supernatant using a 0.2 μM filter. The amount of soluble protein in the clarified supernatant was measured by Coomassie Plus (Bradford) Protein Assay (Thermo Scientific). Protein samples (20 μg) were run on a 10% Precast BisTris SDS-PAGE gel (Invitrogen) according to the manufacturer's protocol.
Mass Spectroscopy.
For LC/MS/MS analysis each gel was excised into five equally sized pieces. Trypsin digestion was performed using a robot (ProGest, DigiLab) with the following protocol: washed with 25 mM ammonium bicarbonate followed by acetonitrile, reduced with 10 mM dithiothreitol at 60° C. followed by alkylation with 50 mM iodoacetamide at RT, digested with trypsin (Promega) at 37° C. for 4 h, quenched with formic acid and the supernatant was analyzed directly without further processing. The gel digests for each sample were pooled and analyzed by nano LC/MS/MS with a Waters NanoAcquity HPLC system interfaced to a ThermoFisher Q Exactive. Peptides were loaded on a trapping column and eluted over a 75 μm analytical column at 350 nL/min; both columns were packed with Jupiter Proteo resin (Phenomenex). The mass spectrometer was operated in data-dependent mode, with MS and MS/MS performed in the Orbitrap at 70,000 FWHM and 17,500 FWHM resolution, respectively. The fifteen most abundant ions were selected for MS/MS. Resulting data were searched against a Uniprot and/or NCBI protein database from the corresponding organism using Mascot with the following parameters: Enzyme—Trypsin/P, Fixed modification—Carbamidomethyl (C) Variable modifications—Oxidation (M), Acetyl (Protein N-term), Pyro-Glu (N-term Q), Deamidation (NQ), Mass values—Monoisotopic, Peptide Mass Tolerance—10 ppm, Fragment Mass Tolerance—0.015 Da, Max Missed Cleavages—2. Mascot DAT files were parsed into the Scaffold software for validation, filtering and to create a non-redundant list per sample. Data were filtered using a minimum protein value of 90%, a minimum peptide value of 50% (Prophet scores) and requiring at least two unique peptides per protein. Relative abundance of detected proteins was determined by spectral counts, which is the number of spectra acquired for each protein. Spectral counting is a label-free quantification method commonly used by the protein mass spec field (Liu, Hongbin et al. Analytical chemistry 76.14 (2004): 4193-4201). To calculate the relative abundance of each protein in the protein isolate the number of protein spectral counts is divided by the total protein spectral counts. SEQID 894-3415 were identified using this method.
Homolog Discovery.
For the nutritive polypeptide sequences identified, as described, similar sequences are identified from other species, SEQID-00093, which was identified by this method, was used to search for homologs using the computer program BLAST as described herein. Example nutritive polypeptide homologs from the edible database identified in this way are shown in table E1A. Example nutritive polypeptide homologous from the expressed sequence database identified in this way are shown in table E1B.





TABLE E1A



Edible Sequences identified as

homologs to SEQID-00093.







Percent ID to

SEQID
EAA
SEQID-00093



SEQID-00094
0.45
98.8

SEQID-00092
0.42
89.9

SEQID-00075
0.46
67.9

SEQID-00072
0.46
67.3

SEQID-03712
0.46
66.0

SEQID-03763
0.44
50.3

SEQID-03708
0.45
51.6

SEQID-03798
0.46
51.6

SEQID-03860
0.45
50.9

SEQID-03651
0.46
50.9





































TABLE E1B



Expressed Sequences identified as

homologs to SEQID-00093







Percent ID to

SEQID
EAA
SEQID-00093







SEQID-00074
0.42
91.2

SEQID-00092
0.42
89.9

SEQID-00075
0.46
66.9

SEQID-00078
0.46
65

SEQID-00106
0.46
50.3

SEQID-00104
0.45
50.3

SEQID-00864
0.45
50.3

SEQID-00870
0.45
43.8

SEQID-00867
0.47
44.5

SEQID-00105
0.44
41.1

SEQID-00103
0.45
40.5

SEQID-00866
0.40
39.8





































Example 2
Identification and Selection of Amino Acid Sequences of Nutritive Polypeptides of Edible Species Using cDNA Libraries
Here, nutritive polypeptide amino acid sequences were identified by analysis of proteins produced from nucleic acid sequences extracted and purified from edible species.
Construction of cDNA Library.
A library of cDNA from twelve edible species was constructed. The twelve edible species were divided into five categories for RNA extraction. Animal tissues including ground beef, pork, lamb, chicken, turkey, and a portion of tilapia was combined with 50 mg from each edible species. Fruit tissues from grape and tomato including both the skin and the fruit were grounded and combined with 2.5 g from each species. Seeds of rice and soybean were combined with 1 g from each species and grounded into powder. 12 ml of Saccharomyces cerevisiae were grown overnight and spun down to obtain 110 mg of wet cell weight of yeast. 1 g of mushroom mycelium was grounded and processed using fungi RNA extraction protocols. All five categories of samples were snap frozen with liquid nitrogen, thawed and lysed using category-specific RNA extract protocols. The RNA from different food categories was extracted and combined as one pooled sample. The combined pool of RNA was reverse transcribed into cDNA using oligo-dT as primers resulting in cDNA of length between 500 bp to 4 kb. Adaptors were ligated to each end of the cDNA and used as PCR primers for amplification of the cDNA library and also included Sfi I restriction digestion sites for cloning the library into an expression vector. The cDNA library was denatured and re-annealed and the single-stranded DNA was selected using gel electrophoresis. This process removed extra cDNA from highly abundant RNA species to obtain a normalized cDNA library. The normalized cDNA library was precipitated using ethanol precipitation before PCR amplification and cloning into the expression vectors.





TABLE E2A



Primer and adapter

sequences flanking the cDNA.









Sequence


Adapter
SEQID
(underlined: Sfi I site)




5′ adapter
3910
CAGTGGTATCAACGCAGAGTGGCCAT




TACGGCCAAGTTACGGG




3′ adapter
3911
CAGTGGTATCAACGCAGAGTGGCCGA




GGCGGCCTTTTTTTTTTTTTTT



























Cloning of cDNA Library into E. coli for Protein Expression.
The cDNA library was cloned into the pET15b backbone vector, which was amplified with primers with overhangs that contain the corresponding SfiI restriction sites (forward primer overhang: TACGTGTATGGCCGCCTCGGCC; reverse primer overhang: TACGTGTATGGCCGTAATGGCC). pETI 5b contains a pBR322 origin of replication, lac-controlled T7 promoter, and a bla gene conferring resistance to carbenicillin. Both the cDNA library and PCR amplified backbone were cut with SfiI, PCR purified, and ligated. The ligation reaction was transformed into 10-Beta High Efficiency Competent Cells (New England Biolabs), and transformed cells were plated onto four LB agar plates containing 100 mg/L carbenicillin. Plates were incubated at 37° C. overnight. After colonies had grown, 2 mL of liquid LB medium was added to each plate. Cells were scraped into the liquid and mixed together, and the suspension was prepared for plasmid extraction to form the multiplex cDNA plasmid library.
E. coli cDNA Multiplex Expression Methods.
Four strains were used to express the cDNA libraries: T7 Express from New England Biolabs; and Rosetta 2(DE3), Rosetta-gami B(DE3), and Rosetta-gami 2(DE3) from EMD Millipore. T7 Express is an enhanced BL21 derivative which contains the T7 RNA polymerase in the lac operon, while lacking the Lon and OmpT proteases. The genotype of T7 Express is: fhuA2 lacZ::T7 gene1[lon]ompT gal sulA11 R(mcr-73::miniTn10—Tet S )2 [dcm]R(zgb-210::Tn10—Tet S ) endA1 d(mcrC-mrr)114::IS10. Rosetta 2(DE3) is a BL21 derivative that supplies tRNAs for 7 rare codons (AGA, AGG, AUA, CUA, GGA, CCC, CGG). The strain is a lysogen of ADE3, and carries the T7 RNA polymerase gene under the lacUV5 promoter. The genotype of Rosetta 2(DE3) is: F − ompT hsdS B (r B − m B − ) gal dcm (DE3) pRARE2 (Cam R ). Rosetta-gami B(DE3) has the same properties as Rosetta 2(DE3) but includes characteristics that enhance the formation of protein disulfide bonds in the cytoplasm. The genotype of Rosetta-gami B(DE3) is F − ompT hsdS B (r B − m B − ) gal dcm lacY1 ahpC (DE3) gor522::Tn10 trxBpRARE (Cam R , Kan R , Tet R ). Rosetta-gami 2(DE3), similarly to Rosetta-gami B(DE3), alleviates codon bias, enhances disulfide bond formation, and have the T7 RNA polymerase gene under the lacUV5 promoter in the chromosome. The genotype of Rosetta-gami 2(DE3) is Δ(ara-leu)7697 ΔlacX74 ΔphoA PvuII phoR araD139 ahpC galE galK rpsL(DE3) F′[lac + lacI q pro]gor522::Tn10 trxB pRARE2 (Cam R , Str R , Tet R )
Roughly 200 ng of prepared cDNA libraries were transformed into the four background strains: T7 Express, Rosetta 2(DE3), Rosetta-gami B(DE3), and Rosetta-gami 2(DE3) competent cells. After transforming, 100 μL of each strain was plated onto four LB (10 g/l NaCl, 10 g/l tryptone, and 5 g/l yeast extract) 1.5% agar plates containing 100 mg/L carbenicillin and incubated at 37° C. for 16 hrs. After incubation, 2 mL of LB media with 100 mg/L carbenicillin was added to the surface of each plate containing several thousand transformants, and the cells were suspended in the surface medium by scraping with a cell spreader and mixing. Suspended cells from the four replicate plates from each background were combined to form the pre-inoculum cultures for the expression experiments.
The OD 600 of the pre-inoculum cultures made from re-suspended cells were measured using a plate reader to be between 35 and 40 (T7, Rosetta 2(DE3) or 15 and 20 (Rosetta-gami B(DE3) and 2(DE3)). For the four background strains, 125 mL baffled shake flasks containing 10 mL of LB medium with 100 mg/L carbenicillin were inoculated to OD 600 0.2 to form the inoculum cultures, and incubated at 37° C. shaking at 250 rpm for roughly 6 hours. OD 600 was measured and the inoculum cultures were used to inoculate expression cultures in 2 L baffled shake flasks containing 250 mL of BioSilta Enbase medium with 100 mg/L carbenicillin, 600 mU/L of glucoamylase and 0.01% Antifoam 204 to an OD 600 of 0.1. Cultures were shaken at 30° C. and 250 rpm for 18 hours, and were induced with 1 mM IPTG and supplemented with additional EnBase media components and another 600 mU/L of glucoamylase. Heterologous expression was carried out for 24 hours at 30° C. and 250 rpm, at which point the cultures were terminated. The terminal cell density was measured and the cells were harvested by centrifugation (5000×g, 10 min, RT). Cells were stored at −80° C. before being lysed with B-PER (Pierce) according to the manufacturer's protocol. After cell lysis, the whole cell lysate is sampled for analysis. In the Rosetta (DE3) strain, the whole cell lysate is centrifuged (3000×g, 10 min RT) and the supernatant is collect as the soluble fraction of the lysate. Cell lysates were run on SDS-PAGE gels, separated into ten fractions, and then analyzed using MS-MS.
Cloning of cDNA Library into Bacillus for Protein Secretion.
The cDNA library was cloned into the pHT43 vector for protein secretion assay in Bacillus subtilis . The unmodified pHT43 vector from MoBiTec contains the Pgrac promoter, the SamyQ signal peptide, Amp and Cm resistance genes, a lacI region, a repA region, and the ColE1 origin of replication. The SamyQ signal peptide was removed. The pHT43 backbone vector with no signal peptide as well as a modified version with the aprE promoter substituted for the grac promoter and with the lacI region removed were amplified with primers with overhangs that contain the corresponding SfiI restriction sites (forward primer overhang: TACGTGTATGGCCGCCTCGGCC; reverse primer overhang: TACGTGTATGGCCGTAATGGCC). Both the cDNA library and the two PCR amplified backbones were cut with SfiI and PCR purified. The cDNA library inserts were ligated into each background. The ligation reactions were transformed into 10-Beta High Efficiency Competent Cells (New England Biolabs), and cells from each ligation were plated onto four LB agar plates containing 100 mg/L carbenicillin. Plates were incubated at 37° C. overnight. After colonies had grown, 2 mL of liquid LB medium was added to each plate. For each ligation, cells were scraped into the liquid and mixed together, and the suspensions were prepped for plasmid extraction to form the multiplex cDNA plasmid libraries (henceforth referred to as the multiplex Grac-cDNA and AprE-cDNA libraries).
The expression strains used in this expression experiment are based off of the WB800N strain (MoBiTec). The WB800N strain has the following genotype: nprE aprE epr bpr mpr::ble nprB::bsr vpr wprA::hyg cm::neo; NeoR. Strain cDNA-1 contains a mutation that synergizes with the paprE promoter and has these alterations in addition to the WB800N genotype: pXylA-comK::Erm, degU32(Hy), sigF::Str. Strain cDNA-2 has these alterations to WB800N: pXylA-comK::Erm.
Roughly 1 μg of the multiplex Grac-cDNA library was transformed into both Strain cDNA-1 and Strain cDNA-2, and 1 μg of the multiplex AprE-cDNA library was transformed into Strain cDNA-1. After transforming, 100 μL of each strain was plated onto four LB (10 g/l NaCl, 10 g/l tryptone, and 5 g/l yeast extract) 1.5% agar plates containing 5 mg/L chloramphenicol and incubated at 37° C. for 16 hrs. After incubation, 2 mL of LB media with 5 mg/L chloramphenicol was added to the surface of each plate containing several thousand transformants, and the cells were suspended in the surface medium by scraping with a cell spreader and mixing. Suspended cells from the four replicate plates from each transformation were combined to form the preinoculum cultures for the expression experiments.
The OD 600 of the preinoculum cultures made from resuspended cells were measured using a plate reader to be roughly 20-25. For the three strains (strain cDNA-1+multiplex Grac-cDNA, strain cDNA-1+multiplex AprE-cDNA, strain cDNA-2+Grac-cDNA), 500 mL baffled shake flasks containing 50 mL of 2×Mal medium (20 g/L NaCl, 20 g/L Tryptone, 10 g/L yeast extract, 75 g/L D-Maltose) with 5 mg/L chloramphehicol were inoculated to OD 600 ≈0.2 to form the inoculum cultures, and incubated at 30° C. shaking at 250 rpm for roughly 6 hours. OD 600 was measured and the inoculum cultures were used to inoculate expression cultures in 2 L baffled shake flasks containing 2×Mal medium with 5 mg/L chloramphenicol, 1× Teknova Trace Metals, and 0.01% Antifoam 204 to an OD 600 of 0.1. The strain cDNA-1+multiplex AprE cDNA culture was shaken for 30° C. and 250 rpm for 18 hours, at which point the culture was harvested. The terminal cell density was measured and the cells were harvested by centrifugation (5000×g, 30 min, RT). The strain cDNA-1+multiplex Grac-cDNA and strain cDNA-2+multiplex Grac-cDNA cultures were shaken at 37° C. and 250 rpm for 4 hours, and were induced with 1 mM IPTG. Heterologous expression was carried out for 4 hours at 37° C. and 250 rpm, at which point the cultures were harvested. Again, the terminal cell density was measured and the cells were harvested by centrifugation (5000×g, 30 min, RT). The supernatant was collected and run on SDS-PAGE gels, separated into ten fractions, and then analyzed using LC-MS/MS to identify secreted proteins.
Mass Spectrometry Analysis.
Whole cell lysate and soluble lysate samples were analyzed for protein expression using LC-MS/MS. To analyze samples, 10 μg of sample was loaded onto a 10% SDS-PAGE gel (Invitrogen) and separated approximately 5 cm. The gel was excised into ten segments and the gel slices were processed by washing with 25 mM ammonium bicarbonate, followed by acetonitrile. Gel slices were then reduced with 10 mM dithiothreitol at 60° C., followed by alkylation with 50 mM iodoacetamide at room temperature. Finally, the samples were digested with trypsin (Promega) at 37° C. for 4 h and the digestions were quenched with the addition of formic acid. The supernatant samples were then analyzed by nano LC/MS/MS with a Waters NanoAcquity HPLC system interfaced to a ThermoFisher Q Exactive. Peptides were loaded on a trapping column and eluted over a 75 sm analytical column at 350 nL/min; both columns were packed with Jupiter Proteo resin (Phenomenex). A 1 h gradient was employed. The mass spectrometer was operated in data-dependent mode, with MS and MS/MS performed in the Orbitrap at 70,000 FWHM resolution and 17,500 FWHM resolution, respectively. The fifteen most abundant ions were selected for MS/MS. Data were searched against a database using Mascot to identify peptides. The database was constructed by combining the complete proteome sequences from all twelve species including Bos taurus, Gallus gallus, Vitis vinifera, Ovis aries, Sus scrofa, Oryza sativa, Glycine max, Oreochromis niloticus, Solanum lycopesicum, Agaricus bisporus var. bisporus, Saccharomyces cerevisiae , and Meleagris gallopavo . Mascot DAT files were parsed into the Scaffold software for validation, filtering and to create a nonredundant list per sample. Data were filtered at 1% protein and peptide false discovery rate (FDR) and requiring at least two unique peptides per protein.
Expressed Proteins Identified.
Mass spectrometry analysis identified a total of 125 proteins across expression strains. Spectrum counts, which are related to the protein abundance, are reported to confirm protein expression or secretion. Fifty three proteins were identified in whole cell lysate of the Rosetta (DE3) strain, 46 in the soluble fraction of the Rosetta (DE3) strain, 36 in Rosetta-Gami B (DE3), 10 in Rosetta-Gami 2 (DE3), and 15 in the secreted supernatant of Bacillus subtilis.
The nutritive polypeptides detected in the secreted supernatant of Bacillus subtilis are SEQID-00718, SEQID-00762, SEQID-00763, SEQID-00764, SEQID-00765, SEQID-00766, SEQID-00767, SEQID-00768, SEQID-00769, SEQID-00770, SEQID-00771, SEQID-00772, SEQID-00773, SEQID-00774, SEQID-00775.
The nutritive polypeptides detected in the whole cell lysate of the E. coli Rosetta (DE3) strain are SEQID-00716, SEQID-00718, SEQID-00720, SEQID-00723, SEQID-00724, SEQID-00725, SEQID-00729, SEQID-00732, SEQID-00737, SEQID-00751, SEQID-00776, SEQID-00790, SEQID-00797, SEQID-00798, SEQID-00799, SEQID-00800, SEQID-00801, SEQID-00802, SEQID-00803, SEQID-00804, SEQID-00805, SEQID-00806, SEQID-00807, SEQID-00808, SEQID-00809, SEQID-00810, SEQID-00811, SEQID-00812, SEQID-00813, SEQID-00814, SEQID-00815, SEQID-00816, SEQID-00817, SEQID-00818, SEQID-00819, SEQID-00820, SEQID-00821, SEQID-00822, SEQID-00823, SEQID-00824, SEQID-00825, SEQID-00826, SEQID-00827, SEQID-00828, SEQID-00829, SEQID-00830, SEQID-00831, SEQID-00832, SEQID-00833, SEQID-00834, SEQID-00835, SEQID-00836, SEQID-00837.
The nutritive polypeptides detected in the soluble lysate of the E. coli Rosetta (DE3) strain are SEQID-00716, SEQID-00717, SEQID-00718, SEQID-00719, SEQID-00720, SEQID-00721, SEQID-00722, SEQID-00724, SEQID-00725, SEQID-00726, SEQID-00727, SEQID-00728, SEQID-00729, SEQID-00730, SEQID-00731, SEQID-00732, SEQID-00733, SEQID-00734, SEQID-00735, SEQID-00736, SEQID-00737, SEQID-00738, SEQID-00739, SEQID-00740, SEQID-00741, SEQID-00742, SEQID-00743, SEQID-00744, SEQID-00745, SEQID-00746, SEQID-00747, SEQID-00748, SEQID-00749, SEQID-00750, SEQID-00751, SEQID-00752, SEQID-00753, SEQID-00754, SEQID-00755, SEQID-00756, SEQID-00757, SEQID-00758, SEQID-00759, SEQID-00760, SEQID-00761.
The nutritive polypeptides detected in the E. coli Rosetta-Gami B (DE3) strain are SEQID-00003, SEQID-00004, SEQID-00005, SEQID-00716, SEQID-00718, SEQID-00719, SEQID-00720, SEQID-00729, SEQID-00730, SEQID-00731, SEQID-00732, SEQID-00734, SEQID-00736, SEQID-00740, SEQID-00743, SEQID-00752, SEQID-00760, SEQID-00763, SEQID-00764, SEQID-00776, SEQID-00777, SEQID-00778, SEQID-00779, SEQID-00780, SEQID-00781, SEQID-00782, SEQID-00783, SEQID-00784, SEQID-00785, SEQID-00786, SEQID-00787, SEQID-00788, SEQID-00789, SEQID-00790, SEQID-00791, SEQID-00792.
The nutritive polypeptides detected in the E. coli Rosetta-Gami 2 (DE3) strain are SEQID-00716, SEQID-00737, SEQID-00747, SEQID-00763, SEQID-00789, SEQID-00790, SEQID-00793, SEQID-00794, SEQID-00795, SEQID-00796.
Example 3
Identification and Selection of Amino Acid Sequences of Nutritive Polypeptides of Edible Species Using Annotated Protein Sequence Databases
Construction of Protein Databases. The UniProtKB/Swiss-Prot (a collaboration between the European Bioinformatics Institute and the Swiss Institute of Bioinformatics) is a manually curated and reviewed protein database, and was used as the starting point for constructing a protein database. To construct a protein database of edible species, a search was performed on the UniProt database for proteins from edible species as disclosed in, e.g., PCT/US2013/032232, filed Mar. 15, 2013, PCT/US2013/032180, filed Mar. 15, 2013, PCT/US2013/032225, filed Mar. 15, 2013, PCT/US2013/032218, filed Mar. 15, 2013, PCT/US2013/032212, filed Mar. 15, 2013, and PCT/US2013/032206, filed Mar. 15, 2013. To identify proteins that are secreted from microorganisms, the UniProt database was searched for species from microorganisms as disclosed herein and proteins that are annotated with keywords or annotations that includes secreted, extracellular, cell wall, and outer membrane. To identify proteins that are abundant in the human diet, the reference proteomes of edible species were assembled from genome databases. As provided herein, mass spectrometry was performed on proteins extracted from each edible species. The peptides identified by mass spectrometry were mapped to the reference proteomes and the spectrum counts of the peptides associated with the reference protein sequences were converted to a measure for the abundance of the corresponding protein in food. All proteins that were detected above a cutoff spectrum count with high confidence were assembled into a database. These databases are used for identifying proteins that are derived from edible species, which are secreted, and/or are abundant in the human diet.
Processes for Selection of Amino Acid Sequences.
A process for picking a protein or group of proteins can include identifying a set of constraints that define the class of protein one is interested in finding, the database of proteins from which to search, and performing the actual search.
The protein class criteria can be defined by nutritional literature (i.e., what has been previously identified as efficacious), desired physiochemical traits (e.g., expressible, soluble, nonallergenic, nontoxic, digestible, etc), and other characteristics. A relevant database of proteins that can be used for searching purposes can be derived from the sequences disclosed herein.
One example of proteins that can be searched is a highly soluble class of proteins for muscle anabolism/immune health/diabetes treatment. These proteins are generally solubly expressible, highly soluble upon purification/isolation, non-allergenic, non-toxic, fast digesting, and meet some basic nutritional criteria (e.g., [EAA]>0.3, [BCAA]>0.15, [Leucine or Glutamine or Arginine]>0.08, eaa complete).
A search is conducted for expressible, soluble proteins using a binary classification model based on two parameters related to the hydrophilicity and hydrophobicity of the protein sequence: solvation score and aggregation score (see examples below for various descriptions of these two metrics and measures of efficacy of the model). Alternatively, a search can be conducted for highly charged proteins with high (or low) net charge per amino acid, which is indicative of a net excess of negative or positive charges per amino acid (see example below for additional description).
The nutritional criteria are satisfied by computing the mass fractions of all relevant amino acids based on primary sequence. For cases in which it is desired to match a known, clinically efficacious amino acid blend a weighted Euclidean distance method can be used (see example below).
As provided herein, allergenicity/toxicity/nonallergenicity/antinutrticity criteria are searched for using sequence based homology assessments in which each candidate sequence is compared to libraries of known allergens, toxins, nonallergens, or antinutritive (e.g., protease inhibitory) proteins (see examples herein). In general, cutoffs of <50% global or <35% local (over any given 80aa window) homology (percent ID) can be used for the allergenicity screens, and <35% global for the toxicity and antinutricity screens. In all cases, smaller implies less allergenic/toxic/antinutritive. The nonallergenicity screen is less typically used as a cutoff, but >62% as a cutoff can be used (greater implies is more nonallergenic). These screens reduce the list to a smaller subset of proteins enriched in the criteria of interest. This list is then ranked using a variety of aggregate objective functions and selections are made from this rank ordered list.
Example 4
Selection of Amino Acid Sequences to Demonstrate Amino Acid Pharmacology of Nutritive Polypeptides
Identification of Proteins Enriched in Leucine and Essential Amino Acids for the Treatment of Sarcopenia.
As described herein, sarcopenia is the degenerative loss of skeletal muscle mass (typically 0.5-1% loss per year after the age of 25), quality, and strength associated with aging. Sarcopenia is characterized first by a muscle atrophy (a decrease in the size of the muscle), along with a reduction in muscle tissue “quality,” caused by such factors as replacement of muscle fibres with fat, an increase in fibrosis, changes in muscle metabolism, oxidative stress, and degeneration of the neuromuscular junction. Combined, these changes lead to progressive loss of muscle function and eventually to frailty. It has been shown that essential amino acid supplementation in elderly, sarcopenia individuals can have an anabolic and/or sparing effect on muscle mass. Furthermore, this supplementation can also translate to improvements in patient strength and muscle quality. See, e.g., Paddon-Jones D, et al. J Clin Endocrinol Metab 2004, 89:4351-4358; Ferrando, A et al. Clinical Nutrition 2009 1-6; Katsanos C et al. Am J Physiol Endocrinol Metab. 2006, 291: 381-387. It has also been shown that the essential amino acid leucine is a particularly important factor in stimulating muscle protein synthesis. See, e.g., Borscheim E et al. Am J Physiol Endocrinol Metab 2002, 283: E648-E657; Borsheim E et al. Clin Nutr. 2008, 27: 189-95; Esmarck B et al J Physiol 2001, 535: 301-311; Moore D et al. Am J Clin Nutr 2009, 89: 161-8). One can identify beneficial nutritive polypeptides for individuals that suffer from sarcopenia by selecting proteins that are enriched by mass in leucine and the other essential amino acids.
Using a database of all protein sequences derived from edible species as described herein, candidate sequences that are enriched in leucine (≧15% by mass) and essential amino acids (≧40% by mass) were identified and rank ordered by their total leucine plus essential amino acid mass relative to total amino acid mass. In order to increase the probability that these proteins are solubly expressed, as well as highly soluble at pH 7 with reduced aggregation propensity, solvation score and aggregation score upper bounds of −20 kcal/mol/AA and 0.5 were applied. In order to reduce the likelihood that these proteins would elicit an allergenic response, upper bounds of 50% and 35% were set for the global allergen homology and allergenicity scores, respectively. In order to reduce the likelihood that these proteins would have toxic effects upon ingestion, an upper bound of 35% was set for the toxicity score. In order to reduce the likelihood that these proteins would act as inhibitors of digestive proteases, an upper bound of 35% was set for the anti-nutricity score.
An exemplary list of the top 10 nutritive polypeptide sequences that are enriched in leucine (≧15% by mass) and essential amino acids (≧40% by mass), and meet the afore mentioned cutoffs in solvation score, aggregation score, global allergen homology, allergenicity score, toxicity score, and anti-nutricity score is shown in Table E4A.









TABLE E4A





SEQID
EAA
L





SEQID-03552
0.56
0.21


SEQID-03581
0.60
0.15


SEQID-03532
0.58
0.16


SEQID-03475
0.56
0.17


SEQID-03499
0.58
0.15


SEQID-03494
0.54
0.18


SEQID-03460
0.54
0.17


SEQID-03485
0.54
0.16


SEQID-03513
0.54
0.15


SEQID-03491
0.52
0.17



























An exemplary list of the top 10 nutritive polypeptide sequences from the expressed protein database that are enriched in leucine (≧15% by mass) and essential amino acids (≧40% by mass) is shown in Table E4B.









TABLE E4B





SEQID
EAA
L





SEQID-00162
0.64
0.34


SEQID-00132
0.60
0.32


SEQID-00166
0.65
0.26


SEQID-00169
0.60
0.25


SEQID-00137
0.64
0.20


SEQID-00134
0.58
0.24


SEQID-00175
0.63
0.19


SEQID-00194
0.54
0.26


SEQID-00193
0.53
0.26


SEQID-00195
0.52
0.26



























Example 5
Selection of Amino Acid Sequences of Nutritive Polypeptides Enriched in Essential Amino Acids and Enriched or Reduced in Various Individual Amino Acids of Interest
Using a database of all protein sequences derived from edible species as described herein, candidate sequences enriched in essential amino acids with elevated or reduced amounts of each amino acid were identified. In order to increase the probability that these proteins would be solubly expressed, as well as highly soluble at pH 7 with reduced aggregation propensity, solvation score and aggregation score upper bounds of −20 kcal/mol/AA and 0.5 were applied. In order to reduce the likelihood that these proteins would elicit an allergenic response, upper bounds of 50% and 35% were set for the global allergen homology and allergenicity scores, respectively. In order to reduce the likelihood that these proteins would have toxic effects upon ingestion, an upper bound of 35% was set for the toxicity score. In order to reduce the likelihood that these proteins would act as inhibitors of digestive proteases, an upper bound of 35% was set for the anti-nutricity score. When searching for proteins enriched or reduced in a given amino acid, the cutoffs described above were applied, and proteins were rank ordered by their calculated amino acid mass fraction of the desired amino acid and then by their essential amino acid content.
An exemplary list of the top 10 nutritive polypeptide sequences enriched in alanine that met the above cutoffs in solvation score, aggregation score, global allergen homology, allergenicity score, toxicity score, and anti-nutricity score is shown in Table E5A. The top 10 nutritive polypeptide sequences reduced in alanine are shown in Table E5B.









TABLE E5A





SEQID
EAA
A





SEQID-03678
0.46
0.18


SEQID-03682
0.44
0.18


SEQID-03646
0.46
0.18


SEQID-03653
0.39
0.16


SEQID-03717
0.38
0.16


SEQID-03686
0.41
0.15


SEQID-03807
0.46
0.15


SEQID-03864
0.44
0.15


SEQID-03663
0.35
0.15


SEQID-03777
0.46
0.14




































TABLE E5B





SEQID
EAA
A





SEQID-03874
0.62
0.00


SEQID-03552
0.56
0.00


SEQID-03880
0.52
0.00


SEQID-03673
0.52
0.00


SEQID-03667
0.50
0.00


SEQID-03657
0.50
0.00


SEQID-03842
0.49
0.00


SEQID-03623
0.49
0.00


SEQID-03817
0.48
0.00


SEQID-03875
0.48
0.00



























An exemplary list of the top 10 nutritive polypeptide sequences enriched in arginine that met the above cutoffs in solvation score, aggregation score, global allergen homology, allergenicity score, toxicity score, and anti-nutricity score is shown in table E5C. The top 10 nutritive polypeptide sequences reduced in arginine are shown in Table E5D.









TABLE E5C





SEQID
EAA
R





SEQID-03473
0.06
0.72


SEQID-03855
0.09
0.65


SEQID-03727
0.10
0.63


SEQID-03767
0.17
0.62


SEQID-03704
0.17
0.60


SEQID-03459
0.10
0.60


SEQID-03731
0.16
0.48


SEQID-03698
0.47
0.40


SEQID-03687
0.37
0.38


SEQID-03732
0.19
0.38




































TABLE E5D





SEQID
EAA
R





SEQID-03744
0.60
0.00


SEQID-03770
0.56
0.00


SEQID-03880
0.52
0.00


SEQID-03736
0.49
0.00


SEQID-03706
0.49
0.00


SEQID-03881
0.49
0.00


SEQID-03668
0.49
0.00


SEQID-03733
0.46
0.00


SEQID-03764
0.46
0.00


SEQID-03832
0.44
0.00



























An exemplary list of the top 10 nutritive polypeptide sequences enriched in asparagine that met the above cutoffs in solvation score, aggregation score, global allergen homology, allergenicity score, toxicity score, and anti-nutricity score is shown in table E5E. The top 10 nutritive polypeptide sequences reduced in asparagine are shown in table E5F.









TABLE E5E





SEQID
EAA
N





SEQID-03723
0.39
0.15


SEQID-03721
0.39
0.15


SEQID-03803
0.42
0.15


SEQID-03801
0.38
0.15


SEQID-03714
0.40
0.14


SEQID-03742
0.41
0.14


SEQID-03724
0.38
0.14


SEQID-03884
0.42
0.14


SEQID-03778
0.39
0.13


SEQID-03746
0.41
0.13




































TABLE E5F





SEQID
EAA
N





SEQID-03874
0.62
0.00


SEQID-03793
0.59
0.00


SEQID-03789
0.57
0.00


SEQID-03869
0.57
0.00


SEQID-03809
0.57
0.00


SEQID-03662
0.56
0.00


SEQID-03850
0.55
0.00


SEQID-03783
0.55
0.00


SEQID-03753
0.54
0.00


SEQID-03677
0.53
0.00



























An exemplary list of the top 10 nutritive polypeptide sequences enriched in aspartic acid that met the above cutoffs in solvation score, aggregation score, global allergen homology, allergenicity score, toxicity score, and anti-nutricity score is shown in table E5G. The top 10 nutritive polypeptide sequences reduced in aspartic acid are shown in table E5H.








TABLE E5G




SEQID
EAA
D




SEQID-03630
0.33
0.28


SEQID-03425
0.34
0.26


SEQID-03564
0.33
0.25


SEQID-03543
0.34
0.25


SEQID-03607
0.32
0.24


SEQID-03621
0.35
0.23


SEQID-03604
0.37
0.21


SEQID-03827
0.42
0.20


SEQID-03540
0.37
0.20


SEQID-03624
0.39
0.19


































TABLE E5H




SEQID
EAA
D




SEQID-03795
0.62
0.00


SEQID-03468
0.62
0.00


SEQID-03672
0.62
0.00


SEQID-03656
0.61
0.00


SEQID-03517
0.60
0.00


SEQID-03493
0.60
0.00


SEQID-03816
0.60
0.00


SEQID-03796
0.59
0.00


SEQID-03868
0.59
0.00


SEQID-03740
0.59
0.00


























An exemplary list of the top 10 nutritive polypeptide sequences enriched in cysteine that met the above cutoffs in solvation score, aggregation score, global allergen homology, allergenicity score, toxicity score, and anti-nutricity score is shown in table E5I. The top 10 nutritive polypeptide sequences reduced in cysteine are shown in table E5J.








TABLE E5I




SEQID
EAA
C




SEQID-03495
0.24
0.30


SEQID-03514
0.24
0.30


SEQID-03571
0.24
0.28


SEQID-03430
0.36
0.27


SEQID-03419
0.37
0.16


SEQID-03478
0.29
0.16


SEQID-03523
0.33
0.16


SEQID-03504
0.35
0.16


SEQID-03477
0.28
0.16


SEQID-03459
0.10
0.16


































TABLE E5J




SEQID
EAA
C




SEQID-03636
0.65
0.00


SEQID-03492
0.63
0.00


SEQID-03484
0.62
0.00


SEQID-03442
0.61
0.00


SEQID-03417
0.61
0.00


SEQID-03563
0.61
0.00


SEQID-03512
0.61
0.00


SEQID-03517
0.60
0.00


SEQID-03606
0.60
0.00


SEQID-03493
0.60
0.00


























An exemplary list of the top 10 nutritive polypeptide sequences enriched in glutamine that met the above cutoffs in solvation score, aggregation score, global allergen homology, allergenicity score, toxicity score, and anti-nutricity score is shown in table E5K. The top 10 nutritive polypeptide sequences reduced in glutamine are shown in table E5L.








TABLE E5K




SEQID
EAA
Q




SEQID-03676
0.29
0.19


SEQID-03720
0.29
0.19


SEQID-03683
0.33
0.19


SEQID-03782
0.46
0.18


SEQID-03681
0.46
0.18


SEQID-03852
0.46
0.18


SEQID-03671
0.43
0.17


SEQID-00515
0.25
0.17


SEQID-03866
0.40
0.17


SEQID-03824
0.36
0.16


































TABLE E5L




SEQID
EAA
Q




SEQID-03636
0.65
0.00


SEQID-03795
0.62
0.00


SEQID-03468
0.62
0.00


SEQID-03484
0.62
0.00


SEQID-03570
0.59
0.00


SEQID-03422
0.58
0.00


SEQID-03432
0.58
0.00


SEQID-03590
0.58
0.00


SEQID-03515
0.58
0.00


SEQID-03499
0.58
0.00


























An exemplary list of the top 10 nutritive polypeptide sequences enriched in histidine that met the above cutoffs in solvation score, aggregation score, global allergen homology, allergenicity score, toxicity score, and anti-nutricity score is shown in table E5M. The top 10 nutritive polypeptide sequences reduced in histidine are shown in table E5N.








TABLE E5M




SEQID
EAA
H




SEQID-03744
0.60
0.25


SEQID-03551
0.48
0.24


SEQID-03745
0.56
0.19


SEQID-03793
0.59
0.19


SEQID-03468
0.62
0.15


SEQID-03743
0.38
0.13


SEQID-03711
0.56
0.12


SEQID-03847
0.58
0.12


SEQID-03637
0.43
0.12


SEQID-03739
0.52
0.12


































TABLE E5N




SEQID
EAA
H




SEQID-03795
0.62
0.00


SEQID-03874
0.62
0.00


SEQID-03656
0.61
0.00


SEQID-03517
0.60
0.00


SEQID-03493
0.60
0.00


SEQID-03816
0.60
0.00


SEQID-03796
0.59
0.00


SEQID-03740
0.59
0.00


SEQID-03814
0.58
0.00


SEQID-03837
0.57
0.00


























An exemplary list of the top 10 nutritive polypeptide sequences enriched in isoleucine that met the above cutoffs in solvation score, aggregation score, global allergen homology, allergenicity score, toxicity score, and anti-nutricity score is shown in table E5O. The top 10 nutritive polypeptide sequences reduced in isoleucine are shown in table E5P.








TABLE E5O




SEQID
EAA
I




SEQID-03722
0.40
0.15


SEQID-03805
0.38
0.15


SEQID-03435
0.40
0.15


SEQID-03838
0.42
0.15


SEQID-03655
0.54
0.15


SEQID-03828
0.49
0.15


SEQID-03593
0.39
0.15


SEQID-03818
0.51
0.15


SEQID-03841
0.49
0.15


SEQID-03843
0.48
0.14


































TABLE E5P




SEQID
EAA
I




SEQID-03581
0.60
0.00


SEQID-03685
0.57
0.00


SEQID-03705
0.56
0.00


SEQID-03660
0.55
0.00


SEQID-03779
0.53
0.00


SEQID-03781
0.52
0.00


SEQID-03647
0.51
0.00


SEQID-03785
0.50
0.00


SEQID-03865
0.50
0.00


SEQID-03802
0.49
0.00


























An exemplary list of the top 10 nutritive polypeptide sequences enriched in leucine that met the above cutoffs in solvation score, aggregation score, global allergen homology, allergenicity score, toxicity score, and anti-nutricity score is shown in table E5Q. The top 10 nutritive polypeptide sequences reduced in leucine are shown in table E5R.








TABLE E5Q




SEQID
EAA
L




SEQID-03552
0.56
0.21


SEQID-03428
0.49
0.18


SEQID-03623
0.49
0.18


SEQID-03702
0.47
0.18


SEQID-03701
0.49
0.18


SEQID-03703
0.49
0.18


SEQID-03599
0.51
0.18


SEQID-03494
0.54
0.18


SEQID-03632
0.45
0.18


5EQID-03423
0.44
0.18


































TABLE E5R




SEQID
EAA
L




SEQID-03661
0.53
0.00


SEQID-03849
0.52
0.00


SEQID-03644
0.42
0.00


SEQID-03878
0.39
0.00


SEQID-03652
0.38
0.00


SEQID-03419
0.37
0.00


SEQID-03654
0.36
0.00


SEQID-03804
0.36
0.00


SEQID-03504
0.35
0.00


SEQID-03477
0.28
0.00


























An exemplary list of the top 10 nutritive polypeptide sequences enriched in lysine that met the above cutoffs in solvation score, aggregation score, global allergen homology, allergenicity score, toxicity score, and anti-nutricity score is shown in table E5S. The top 10 nutritive polypeptide sequences reduced in lysine are shown in table E5T.








TABLE E5S




SEQID
EAA
K




SEQID-03648
0.52
0.36


SEQID-03797
0.56
0.34


SEQID-03830
0.52
0.31


SEQID-03829
0.54
0.30


SEQID-03581
0.60
0.30


SEQID-03520
0.36
0.30


SEQID-03457
0.37
0.30


SEQID-03471
0.36
0.29


SEQID-03859
0.53
0.29


SEQID-03456
0.34
0.29


































TABLE E5T




SEQID
EAA
K




SEQID-03583
0.42
0.00


SEQID-03684
0.40
0.00


SEQID-03813
0.36
0.00


SEQID-03771
0.28
0.00


SEQID-03873
0.26
0.00


SEQID-03585
0.25
0.00


SEQID-03704
0.17
0.00


SEQID-03767
0.17
0.00


SEQID-03731
0.16
0.00


SEQID-03459
0.10
0.00


























An exemplary list of the top 10 nutritive polypeptide sequences enriched in methionine that met the above cutoffs in solvation score, aggregation score, global allergen homology, allergenicity score, toxicity score, and anti-nutricity score is shown in table E5U. The top 10 nutritive polypeptide sequences reduced in arginine are shown in table E5V.








TABLE E5U




SEQID
EAA
M




SEQID-00552
0.45
0.16


SEQID-03870
0.52
0.15


SEQID-03680
0.49
0.15


SEQID-03888
0.39
0.13


SEQID-03738
0.37
0.13


SEQID-03698
0.47
0.13


SEQID-03584
0.53
0.12


SEQID-03487
0.53
0.11


SEQID-03858
0.49
0.11


SEQID-03787
0.46
0.11



































TABLE E5V





SEQID
EAA
M





SEQID-03701
0.49
0.00


SEQID-03861
0.49
0.00


SEQID-03703
0.49
0.00


SEQID-03702
0.47
0.00


SEQID-03773
0.46
0.00


SEQID-03707
0.45
0.00


SEQID-03726
0.41
0.00


SEQID-03725
0.39
0.00


SEQID-03734
0.39
0.00


SEQID-03700
0.37
0.00



























An exemplary list of the top 10 nutritive polypeptide sequences enriched in phenylalanine that met the above cutoffs in solvation score, aggregation score, global allergen homology, allergenicity score, toxicity score, and anti-nutricity score is shown in table E5W. The top 10 nutritive polypeptide sequences reduced in phenylalanine are shown in table E5X.









TABLE E5W





SEQID
EAA
F





SEQID-03761
0.48
0.14


SEQID-03831
0.56
0.14


SEQID-03836
0.55
0.13


SEQID-03437
0.41
0.13


SEQID-03749
0.41
0.13


SEQID-03558
0.44
0.13


SEQID-03791
0.49
0.13


SEQID-03729
0.50
0.12


SEQID-03846
0.40
0.12


SEQID-03862
0.50
0.12




































TABLE E5X





SEQID
EAA
F





SEQID-03581
0.60
0.00


SEQID-03441
0.57
0.00


SEQID-03685
0.57
0.00


SEQID-03573
0.55
0.00


SEQID-03661
0.53
0.00


SEQID-03859
0.53
0.00


SEQID-03688
0.53
0.00


SEQID-03675
0.53
0.00


SEQID-03609
0.53
0.00


SEQID-03584
0.53
0.00



























An exemplary list of the top 10 nutritive polypeptide sequences enriched in proline that met the above cutoffs in solvation score, aggregation score, global allergen homology, allergenicity score, toxicity score, and anti-nutricity score is shown in table E5Y. The top 10 nutritive polypeptide sequences reduced in proline are shown in table E5Z.









TABLE E5Y





SEQID
EAA
P





SEQID-03800
0.33
0.16


SEQID-03756
0.32
0.14


SEQID-03839
0.35
0.14


SEQID-03810
0.33
0.13


SEQID-03888
0.39
0.13


SEQID-03845
0.41
0.13


SEQID-03834
0.39
0.13


SEQID-03658
0.35
0.13


SEQID-03856
0.44
0.12


SEQID-03799
0.37
0.12




































TABLE E5Z





SEQID
EAA
P





SEQID-03636
0.65
0.00


SEQID-03468
0.62
0.00


SEQID-03790
0.57
0.00


SEQID-03486
0.57
0.00


SEQID-03665
0.56
0.00


SEQID-03833
0.56
0.00


SEQID-03588
0.56
0.00


SEQID-03808
0.56
0.00


SEQID-03719
0.56
0.00


SEQID-03815
0.55
0.00



























An exemplary list of the top 10 nutritive polypeptide sequences enriched in serine that met the above cutoffs in solvation score, aggregation score, global allergen homology, allergenicity score, toxicity score, and anti-nutricity score is shown in table E5AA. The top 10 nutritive polypeptide sequences reduced in serine are shown in table E5AB.









TABLE E5AA





SEQID
EAA
S





SEQID-03747
0.45
0.16


SEQID-03863
0.27
0.15


SEQID-03737
0.32
0.15


SEQID-03759
0.40
0.15


SEQID-03882
0.39
0.15


SEQID-03748
0.41
0.14


SEQID-03792
0.41
0.14


SEQID-03844
0.37
0.14


SEQID-03751
0.47
0.14


SEQID-03822
0.45
0.14




































TABLE E5AB





SEQID
EAA
S





SEQID-03441
0.57
0.00


SEQID-03867
0.55
0.00


SEQID-03645
0.43
0.00


SEQID-03455
0.35
0.00


SEQID-03775
0.30
0.00


SEQID-03771
0.28
0.00


SEQID-03772
0.28
0.00


SEQID-03716
0.26
0.00


SEQID-03873
0.26
0.00


SEQID-03508
0.41
0.01



























An exemplary list of the top 10 nutritive polypeptide sequences enriched in threonine that met the above cutoffs in solvation score, aggregation score, global allergen homology, allergenicity score, toxicity score, and anti-nutricity score is shown in table E5AC. The top 10 nutritive polypeptide sequences reduced in threonine are shown in table E5AD.









TABLE E5AC





SEQID
EAA
T





SEQID-03718
0.42
0.16


SEQID-03777
0.46
0.14


SEQID-03713
0.42
0.12


SEQID-03871
0.44
0.12


SEQID-03867
0.55
0.12


SEQID-03819
0.48
0.12


SEQID-03820
0.41
0.11


SEQID-03653
0.39
0.11


SEQID-03717
0.38
0.11


SEQID-03877
0.45
0.11




































TABLE E5AD





SEQID
EAA
T





SEQID-03744
0.60
0.00


SEQID-03745
0.56
0.00


SEQID-03661
0.53
0.00


SEQID-03830
0.52
0.00


SEQID-03849
0.52
0.00


SEQID-03887
0.51
0.00


SEQID-03886
0.50
0.00


SEQID-03670
0.48
0.00


SEQID-03551
0.48
0.00


SEQID-03780
0.47
0.00



























An exemplary list of the top 10 nutritive polypeptide sequences enriched in tryptophan that met the above cutoffs-in solvation score, aggregation score, global allergen homology, allergenicity score, toxicity score, and anti-nutricity score is shown in table ESAE. The top 10 nutritive polypeptide sequences reduced in tryptophan are shown in table E5AF.









TABLE E5AE





SEQID
EAA
W





SEQID-03583
0.42
0.15


SEQID-03635
0.40
0.13


SEQID-03555
0.50
0.11


SEQID-03679
0.48
0.09


SEQID-03440
0.44
0.09


SEQID-03439
0.45
0.09


SEQID-03468
0.62
0.08


SEQID-01546
0.51
0.08


SEQID-03576
0.42
0.08


SEQID-03821
0.44
0.08




































TABLE E5AF





SEQID
EAA
W





SEQID-03672
0.62
0.00


SEQID-03512
0.61
0.00


SEQID-03606
0.60
0.00


SEQID-03744
0.60
0.00


SEQID-03581
0.60
0.00


SEQID-03868
0.59
0.00


SEQID-03762
0.59
0.00


SEQID-03857
0.59
0.00


SEQID-03793
0.59
0.00


SEQID-03769
0.59
0.00



























An exemplary list of the top 10 nutritive polypeptide sequences enriched in tyrosine that met the above cutoffs in solvation score, aggregation score, global allergen homology, allergenicity score, toxicity score, and anti-nutricity score is shown in table E5AG. The top 10 nutritive polypeptide sequences reduced in tyrosine are shown in table E5AH.









TABLE E5AG





SEQID
EAA
Y





SEQID-03848
0.32
0.16


SEQID-03831
0.56
0.15


SEQID-03876
0.26
0.15


SEQID-00325
0.42
0.14


SEQID-03794
0.43
0.14


SEQID-03826
0.38
0.14


SEQID-03659
0.46
0.14


SEQID-03786
0.35
0.14


SEQID-03784
0.38
0.14


SEQID-03823
0.39
0.14




































TABLE E5AH





SEQID
EAA
Y





SEQID-03468
0.62
0.00


SEQID-03442
0.61
0.00


SEQID-03417
0.61
0.00


SEQID-03563
0.61
0.00


SEQID-03606
0.60
0.00


SEQID-03469
0.60
0.00


SEQID-03443
0.60
0.00


SEQID-03581
0.60
0.00


SEQID-03796
0.59
0.00


SEQID-03762
0.59
0.00



























An exemplary list of the top 10 nutritive polypeptide sequences enriched in valine that met the above cutoffs in solvation score, aggregation score, global allergen homology, allergenicity score, toxicity score, and anti-nutricity score is shown in table E5AI. The top 10 nutritive polypeptide sequences reduced in valine are shown in table E5AJ.









TABLE E5AI





SEQID
EAA
V





SEQID-03881
0.49
0.17


SEQID-03790
0.57
0.17


SEQID-03808
0.56
0.17


SEQID-03606
0.60
0.17


SEQID-03688
0.53
0.16


SEQID-03806
0.55
0.16


SEQID-03643
0.51
0.15


SEQID-03788
0.58
0.14


SEQID-03762
0.59
0.14


SEQID-03674
0.51
0.14




































TABLE E5AJ





SEQID
EAA
V





SEQID-03879
0.56
0.00


SEQID-03552
0.56
0.00


SEQID-03835
0.54
0.00


SEQID-03851
0.53
0.00


SEQID-03757
0.53
0.00


SEQID-03648
0.52
0.00


SEQID-03766
0.50
0.00


SEQID-03710
0.46
0.00


SEQID-03764
0.46
0.00


SEQID-00552
0.45
0.00



























Selection of Expressed Proteins Enriched in Essential Amino Acids and Enriched or Reduced in Various Individual Amino Acids.
Using the database of all expressed protein sequences described herein, candidate sequences enriched in essential amino acids with elevated or reduced amounts of each amino acid were identified. When searching for proteins enriched or reduced in a given amino acid, proteins were rank ordered by their calculated amino acid mass fraction of the desired amino acid and then by their essential amino acid content.
An exemplary list of the top 10 nutritive polypeptide sequences enriched in alanine is shown in table E5AK. The top 10 nutritive polypeptide sequences reduced in alanine are shown in table E5AL.









TABLE E5AK





SEQID
EAA
A





SEQID-00499
0.34
0.18


SEQID-00512
0.44
0.17


SEQID-00651
0.39
0.17


SEQID-00519
0.38
0.16


SEQID-02704
0.42
0.16


SEQID-02703
0.42
0.13


SEQID-00530
0.37
0.13


SEQID-00544
0.45
0.12


SEQID-00549
0.40
0.12


SEQID-02675
0.50
0.11




































TABLE E5AL





SEQID
EAA
A





SEQID-00140
0.70
0.00


SEQID-00057
0.41
0.00


SEQID-00652
0.28
0.00


SEQID-00199
0.52
0.00


SEQID-00198
0.53
0.00


SEQID-00197
0.52
0.00


SEQID-00196
0.53
0.00


SEQID-00722
0.53
0.01


SEQID-00204
0.51
0.01


SEQID-00203
0.51
0.01



























An exemplary list of the top 10 nutritive polypeptide sequences enriched in arginine is shown in table E5AM. The top 10 nutritive polypeptide sequences reduced in arginine are shown in table E5AN.









TABLE E5AM





SEQID
EAA
R





SEQID-00540
0.41
0.23


SEQID-00567
0.42
0.22


SEQID-00636
0.47
0.22


SEQID-00556
0.33
0.22


SEQID-00637
0.42
0.22


SEQID-00575
0.33
0.22


SEQID-00492
0.42
0.21


SEQID-00631
0.38
0.21


SEQID-00551
0.41
0.21


SEQID-00328
0.45
0.20




































TABLE E5AN





SEQID
EAA
R





SEQID-00140
0.70
0.00


SEQID-00146
0.67
0.00


SEQID-00150
0.67
0.00


SEQID-00143
0.65
0.00


SEQID-00525
0.64
0.00


SEQID-00162
0.64
0.00


SEQID-00175
0.63
0.00


SEQID-00169
0.60
0.00


SEQID-00548
0.59
0.00


SEQID-00536
0.58
0.00



























An exemplary list of the top 10 nutritive polypeptide sequences enriched in asparagine is shown in table E5AO. The top 10 nutritive polypeptide sequences reduced in asparagine are shown in table E5AP.









TABLE ESAO





SEQID
EAA
N





SEQID-00195
0.52
0.14


SEQID-00194
0.54
0.14


SEQID-00193
0.53
0.12


SEQID-03872
0.47
0.12


SEQID-01388
0.36
0.12


SEQID-00552
0.45
0.12


SEQID-00169
0.60
0.11


SEQID-00196
0.53
0.10


SEQID-00197
0.52
0.10


SEQID-03693
0.34
0.10




































TABLE E5AP





SEQID
EAA
N





SEQID-00536
0.58
0.00


SEQID-00284
0.54
0.00


SEQID-00212
0.51
0.00


SEQID-00101
0.51
0.00


SEQID-00219
0.50
0.00


SEQID-00634
0.50
0.00


SEQID-00624
0.49
0.00


SEQID-00639
0.46
0.00


SEQID-00597
0.45
0.00


SEQID-00527
0.40
0.00



























An exemplary list of the top 10 nutritive polypeptide sequences enriched in aspartic acid is shown in table E5AQ. The top 10 nutritive polypeptide sequences reduced in aspartic acid are shown in table E5AR.









TABLE E5AQ





SEQID
EAA
D





SEQID-00562
0.40
0.19


SEQID-03853
0.34
0.17


SEQID-00116
0.32
0.16


SEQID-00102
0.45
0.16


SEQID-00115
0.32
0.16


SEQID-00484
0.38
0.16


SEQID-00100
0.46
0.15


SEQID-00220
0.52
0.15


SEQID-00098
0.50
0.15


SEQID-00078
0.46
0.14




































TABLE E5AR





SEQID
EAA
D





SEQID-00166
0.65
0.00


SEQID-00051
0.59
0.00


SEQID-00052
0.59
0.00


SEQID-00053
0.57
0.00


SEQID-00054
0.55
0.00


SEQID-00055
0.55
0.00


SEQID-00523
0.51
0.00


SEQID-00635
0.46
0.00


SEQID-00230
0.45
0.00


SEQID-00637
0.42
0.00



























An exemplary list of the top 10 nutritive polypeptide sequences enriched in cysteine is shown in table E5AS. The top 10 nutritive polypeptide sequences reduced in cysteine are shown in table E5AT.









TABLE E5AS





SEQID
EAA
C





SEQID-00737
0.28
0.18


SEQID-00652
0.28
0.16


SEQID-00007
0.28
0.13


SEQID-00007
0.28
0.13


SEQID-00558
0.36
0.13


SEQID-00013
0.28
0.12


SEQID-00014
0.30
0.12


SEQID-00989
0.34
0.12


SEQID-00566
0.38
0.11


SEQID-00596
0.44
0.11




































TABLE E5AT





SEQID
EAA
C





SEQID-00166
0.65
0.00


SEQID-00137
0.64
0.00


SEQID-00525
0.64
0.00


SEQID-00162
0.64
0.00


SEQID-03297
0.62
0.00


SEQID-00169
0.60
0.00


SEQID-00132
0.60
0.00


SEQID-00298
0.59
0.00


SEQID-00536
0.58
0.00


SEQID-00297
0.58
0.00



























An exemplary list of the top 10 nutritive polypeptide sequences enriched in glutamine is shown in table E5AU. The top 10 nutritive polypeptide sequences reduced in glutamine are shown in table E5AV.









TABLE ESAU





SEQID
EAA
Q





SEQID-00743
0.29
0.22


SEQID-00513
0.33
0.17


SEQID-03695
0.38
0.17


SEQID-00522
0.40
0.17


SEQID-00515
0.25
0.17


SEQID-03692
0.44
0.14


SEQID-03666
0.35
0.13


SEQID-00613
0.36
0.13


SEQID-00585
0.44
0.13


SEQID-00223
0.50
0.13




































TABLE E5AV





SEQID
EAA
Q





SEQID-00143
0.65
0.00


SEQID-00137
0.64
0.00


SEQID-00525
0.64
0.00


SEQID-00134
0.58
0.00


SEQID-00194
0.54
0.00


SEQID-00193
0.53
0.00


SEQID-00195
0.52
0.00


SEQID-00650
0.50
0.00


SEQID-00563
0.50
0.00


SEQID-00598
0.49
0.00



























An exemplary list of the top 10 nutritive polypeptide sequences enriched in histidine is shown in table E5AW. The top 10 nutritive polypeptide sequences reduced in histidine are shown in table E5AX.









TABLE E5AW





SEQID
EAA
H





SEQID-00536
0.58
0.23


SEQID-00560
0.55
0.18


SEQID-01162
0.48
0.12


SEQID-00585
0.44
0.10


SEQID-00298
0.59
0.10


SEQID-00615
0.40
0.10


SEQID-00525
0.64
0.10


SEQID-00297
0.58
0.10


SEQID-00764
0.56
0.09


SEQID-00128
0.53
0.08




































TABLE E5AX





SEQID
EAA
H





SEQID-00043
0.57
0.00


SEQID-00531
0.55
0.00


SEQID-00592
0.53
0.00


SEQID-00224
0.53
0.00


SEQID-00024
0.52
0.00


SEQID-00625
0.52
0.00


SEQID-00233
0.52
0.00


SEQID-00587
0.51
0.00


SEQID-00213
0.51
0.00


SEQID-00214
0.51
0.00



























An exemplary list of the top 10 nutritive polypeptide sequences enriched in isoleucine is shown in table E5AY. The top 10 nutritive polypeptide sequences reduced in isoleucine are shown in table E5AZ.









TABLE E5AY





SEQID
EAA
I





SEQID-00561
0.68
0.18


SEQID-00134
0.58
0.14


SEQID-00175
0.63
0.14


SEQID-00162
0.64
0.14


SEQID-00234
0.51
0.13


SEQID-00233
0.52
0.13


SEQID-00169
0.60
0.13


SEQID-00025
0.48
0.13


SEQID-00043
0.57
0.12


SEQID-00584
0.50
0.12




































TABLE E5AZ





SEQID
EAA
I





SEQID-00762
0.56
0.00


SEQID-00764
0.56
0.00


SEQID-00571
0.54
0.00


SEQID-00212
0.51
0.00


SEQID-00237
0.48
0.00


SEQID-00236
0.45
0.00


SEQID-00551
0.41
0.00


SEQID-00515
0.25
0.01


SEQID-00128
0.53
0.01


SEQID-00651
0.39
0.01



























An exemplary list of the top 10 nutritive polypeptide sequences enriched in leucine is shown in table E5BA. The top 10 nutritive polypeptide sequences reduced in leucine are shown in table E5BB.









TABLE E5BA





SEQID
EAA
L





SEQID-00162
0.64
0.34


SEQID-00132
0.60
0.32


SEQID-00195
0.52
0.26


SEQID-00194
0.54
0.26


SEQID-00193
0.53
0.26


SEQID-00166
0.65
0.26


SEQID-00169
0.60
0.25


SEQID-00134
0.58
0.24


SEQID-00212
0.51
0.23


SEQID-00139
0.49
0.23




































TABLE E5BB





SEQID
EAA
L





SEQID-00553
0.39
0.00


SEQID-00743
0.29
0.00


SEQID-00522
0.40
0.01


SEQID-00554
0.38
0.01


SEQID-00585
0.44
0.01


SEQID-00560
0.55
0.01


SEQID-00529
0.38
0.01


SEQID-00552
0.45
0.01


SEQID-00547
0.49
0.01


SEQID-00575
0.33
0.01



























An exemplary list of the top 10 nutritive polypeptide sequences enriched in lysine is shown in table E5BC. The top 10 nutritive polypeptide sequences reduced in lysine are shown in table E5BD.









TABLE E5BC





SEQID
EAA
K





SEQID-00560
0.55
0.26


SEQID-00573
0.54
0.23


SEQID-00619
0.51
0.23


SEQID-00553
0.39
0.23


SEQID-00572
0.54
0.23


SEQID-00623
0.54
0.23


SEQID-03691
0.52
0.23


SEQID-00503
0.49
0.22


SEQID-00564
0.51
0.22


SEQID-00517
0.49
0.22




































TABLE ESBD





SEQID
EAA
K





SEQID-00166
0.65
0.00


SEQID-00175
0.63
0.00


SEQID-00169
0.60
0.00


SEQID-00134
0.58
0.00


SEQID-00535
0.30
0.00


SEQID-00513
0.33
0.01


SEQID-02675
0.50
0.01


SEQID-00490
0.58
0.01


SEQID-00512
0.44
0.01


SEQID-00500
0.40
0.01



























An exemplary list of the top 10 nutritive polypeptide sequences enriched in methionine is shown in table E5BE. The top 10 nutritive polypeptide sequences reduced in arginine are shown in table E5BF.









TABLE E5BE





SEQID
EAA
M





SEQID-00552
0.45
0.16


SEQID-00513
0.33
0.13


SEQID-00529
0.38
0.09


SEQID-00526
0.41
0.09


SEQID-00868
0.48
0.09


SEQID-00595
0.44
0.09


SEQID-00584
0.50
0.09


SEQID-00486
0.56
0.09


SEQID-00092
0.42
0.08


SEQID-00074
0.42
0.08




































TABLE E5BF





SEQID
EAA
M





SEQID-00132
0.60
0.00


SEQID-00051
0.59
0.00


SEQID-00052
0.59
0.00


SEQID-00043
0.57
0.00


SEQID-00053
0.57
0.00


SEQID-00055
0.55
0.00


SEQID-00054
0.55
0.00


SEQID-00224
0.53
0.00


SEQID-00024
0.52
0.00


SEQID-00220
0.52
0.00



























An exemplary list of the top 10 nutritive polypeptide sequences enriched in phenylalanine is shown in table E5BG. The top 10 nutritive polypeptide sequences reduced in phenylalanine are shown in table E5BH.









TABLE E5BG





SEQID
EAA
F





SEQID-00150
0.67
0.13


SEQID-00595
0.44
0.13


SEQID-00561
0.68
0.13


SEQID-00118
0.51
0.12


SEQID-00597
0.45
0.12


SEQID-00507
0.51
0.12


SEQID-00594
0.44
0.12


SEQID-00501
0.50
0.12


SEQID-00175
0.63
0.11


SEQID-00485
0.46
0.11




































TABLE E5BH





SEQID
EAA
F





SEQID-00162
0.64
0.00


SEQID-00560
0.55
0.00


SEQID-00224
0.53
0.00


SEQID-00220
0.52
0.00


SEQID-00195
0.52
0.00


SEQID-00241
0.52
0.00


SEQID-00215
0.51
0.00


SEQID-00213
0.51
0.00


SEQID-00214
0.51
0.00


SEQID-00212
0.51
0.00



























An exemplary list of the top 10 nutritive polypeptide sequences enriched in proline is shown in table E5BI. The top 10 nutritive polypeptide sequences reduced in proline are shown in table E5BJ.









TABLE E5BI





SEQID
EAA
P





SEQID-00743
0.29
0.28


SEQID-00553
0.39
0.24


SEQID-03641
0.24
0.20


SEQID-03444
0.23
0.16


SEQID-00169
0.60
0.14


SEQID-00005
0.48
0.14


SEQID-00805
0.50
0.13


SEQID-00737
0.28
0.13


SEQID-03451
0.40
0.11


SEQID-03447
0.30
0.10




































TABLE E5BJ





SEQID
EAA
P





SEQID-00150
0.67
0.00


SEQID-00137
0.64
0.00


SEQID-00287
0.59
0.00


SEQID-00548
0.59
0.00


SEQID-00142
0.56
0.00


SEQID-00560
0.55
0.00


SEQID-00224
0.53
0.00


SEQID-00220
0.52
0.00


SEQID-00241
0.52
0.00


SEQID-00216
0.52
0.00



























An exemplary list of the top 10 nutritive polypeptide sequences enriched in serine is shown in table E5BK. The top 10 nutritive polypeptide sequences reduced in serine are shown in table E5BL.









TABLE E5BK





SEQID
EAA
S





SEQID-03447
0.30
0.27


SEQID-00483
0.42
0.16


SEQID-00535
0.30
0.16


SEQID-00630
0.35
0.14


SEQID-00134
0.58
0.14


SEQID-00557
0.47
0.13


SEQID-03760
0.39
0.12


SEQID-03642
0.37
0.12


SEQID-00652
0.28
0.12


SEQID-00577
0.47
0.12




































TABLE E5BL





SEQID
EAA
S





SEQID-00175
0.63
0.00


SEQID-00051
0.59
0.00


SEQID-00052
0.59
0.00


SEQID-00536
0.58
0.00


SEQID-00043
0.57
0.00


SEQID-00053
0.57
0.00


SEQID-00643
0.57
0.00


SEQID-00055
0.55
0.00


SEQID-00054
0.55
0.00


SEQID-00112
0.50
0.00



























An exemplary list of the top 10 nutritive polypeptide sequences enriched in threonine is shown in table E5BM. The top 10 nutritive polypeptide sequences reduced in threonine are shown in table E5BN.









TABLE E5BM





SEQID
EAA
T





SEQID-00404
0.49
0.14


SEQID-00547
0.49
0.13


SEQID-00522
0.40
0.13


SEQID-00569
0.56
0.13


SEQID-00528
0.53
0.11


SEQID-00504
0.47
0.11


SEQID-03768
0.42
0.11


SEQID-00523
0.51
0.11


SEQID-03649
0.49
0.11


SEQID-00116
0.32
0.11




































TABLE E5BN





SEQID
EAA
T





SEQID-00560
0.55
0.00


SEQID-00057
0.41
0.00


SEQID-00542
0.41
0.00


SEQID-00059
0.41
0.00


SEQID-00015
0.30
0.00


SEQID-00014
0.30
0.00


SEQID-00013
0.28
0.00


SEQID-00007
0.28
0.00


SEQID-00007
0.28
0.00


SEQID-00621
0.39
0.01



























An exemplary list of the top 10 nutritive polypeptide sequences enriched in tryptophan is shown in table E5BM. The top 10 nutritive polypeptide sequences reduced in tryptophan are shown in table E5BN.









TABLE E5BM





SEQID
EAA
W





SEQID-01546
0.51
0.08


SEQID-00642
0.45
0.08


SEQID-03690
0.43
0.08


SEQID-03776
0.43
0.08


SEQID-03297
0.62
0.07


SEQID-03244
0.46
0.07


SEQID-00512
0.44
0.07


SEQID-00814
0.42
0.07


SEQID-00110
0.49
0.06


SEQID-03137
0.50
0.06




































TABLE E5BN





SEQID
EAA
W





SEQID-00166
0.65
0.00


SEQID-00137
0.64
0.00


SEQID-00525
0.64
0.00


SEQID-00162
0.64
0.00


SEQID-00169
0.60
0.00


SEQID-00051
0.59
0.00


SEQID-00052
0.59
0.00


SEQID-00134
0.58
0.00


SEQID-00536
0.58
0.00


SEQID-00043
0.57
0.00



























An exemplary list of the top 10 nutritive polypeptide sequences enriched in tyrosine is shown in table E5BO. The top 10 nutritive polypeptide sequences reduced in tyrosine are shown in table E5BP.









TABLE E5BO





SEQID
EAA
Y





SEQID-00013
0.28
0.16


SEQID-00007
0.28
0.15


SEQID-00007
0.28
0.15


SEQID-00015
0.30
0.14


SEQID-00325
0.42
0.14


SEQID-00014
0.30
0.13


SEQID-00513
0.33
0.12


SEQID-03689
0.41
0.11


SEQID-00521
0.41
0.11


SEQID-00640
0.47
0.11




































TABLE E5BP





SEQID
EAA
Y





SEQID-00140
0.70
0.00


SEQID-00146
0.67
0.00


SEQID-00051
0.59
0.00


SEQID-00052
0.59
0.00


SEQID-00548
0.59
0.00


SEQID-00134
0.58
0.00


SEQID-00043
0.57
0.00


SEQID-00053
0.57
0.00


SEQID-00054
0.55
0.00


SEQID-00055
0.55
0.00



























An exemplary list of the top 10 nutritive polypeptide sequences enriched in valine is shown in table E5BQ. The top 10 nutritive polypeptide sequences reduced in valine are shown in table E5BR.









TABLE E5BQ





SEQID
EAA
V





SEQID-00550
0.49
0.18


SEQID-00592
0.53
0.16


SEQID-00532
0.44
0.15


SEQID-00620
0.50
0.15


SEQID-00644
0.42
0.14


SEQID-00514
0.46
0.13


SEQID-00518
0.52
0.13


SEQID-00598
0.49
0.13


SEQID-00581
0.51
0.13


SEQID-00145
0.51
0.13




































TABLE E5BR





SEQID
EAA
V





SEQID-00239
0.48
0.00


SEQID-00552
0.45
0.00


SEQID-00240
0.45
0.00


SEQID-00615
0.40
0.00


SEQID-00652
0.28
0.00


SEQID-00515
0.25
0.01


SEQID-00522
0.40
0.01


SEQID-00560
0.55
0.01


SEQID-00645
0.56
0.01


SEQID-00647
0.42
0.01



























Example 6
Selection of Amino Acid Sequences of Nutritive Polypeptides Enriched in Essential Amino Acids to Provide Protein Nutrition and for the Treatment of Protein Malnutrition
It has been shown that humans cannot endogenously synthesize nine of the twenty naturally occurring amino acids: histidine, leucine, isoleucine, valine, phenylalanine, methionine, threonine, lysine, and tryptophan (Young, V. R. and Tharakan, J. F. Nutritional essentiality of amino acids and amino acid requirements in healthy adults. In Metabolic and Therapeutic Aspects of Amino Acids in Clinical Nutrition. Second Edition . Cynober, L. A. Ed.; CRC Press: New York, 2004; pp 439-470). As such, there is a need to ingest sufficient quantities of these nine essential amino acids to avoid protein malnutrition and the deleterious health effects that result from this state. Nutritive polypeptides are identified that are useful for the fulfillment of these essential amino acid requirements either in healthy or malnourished individuals by selecting those that are enriched in essential amino acids by mass and contain a non-zero amount of each essential amino acid (i.e., the nutritive polypeptide sequence is essential amino acid complete).
Using a database of all protein sequences derived from edible species as described herein, candidate sequences that are essential amino acid complete and enriched in essential amino acids were identified. In order to increase the probability of these proteins being solubly expressed and highly soluble at pH 7 with reduced aggregation propensity, solvation score and aggregation score upper bounds of −20 kcal/mol/AA and 0.5 were applied. In order to reduce the likelihood that these proteins would elicit an allergenic response, upper bounds of 50% and 35% were set for the global allergen homology and allergenicity scores, respectively. In order to reduce the likelihood that these proteins would have toxic effects upon ingestion, an upper bound of 35% was set for the toxicity score. In order to reduce the likelihood that these proteins would act as inhibitors of digestive proteases, an upper bound of 35% was set for the anti-nutricity score.
An exemplary list of the top 10 nutritive polypeptide sequences that are essential amino acid complete, enriched in essential amino acids, and meet the aforementioned cutoffs in solvation score, aggregation score, global allergen homology, allergenicity score, toxicity score, and anti-nutricity score is shown in table E6A.









TABLE E6A





SEQID
EAAc
EAA





SEQID-03636
1
0.65


SEQID-03492
1
0.63


SEQID-03468
1
0.62


SEQID-03544
1
0.62


SEQID-03484
1
0.62


SEQID-03442
1
0.61


SEQID-03417
1
0.61


SEQID-03563
1
0.61


SEQID-03469
1
0.60


SEQID-03443
1
0.60



























An exemplary list of the top 10 nutritive polypeptide sequences from the expressed protein database that are essential amino acid complete and enriched in essential amino acids is shown in table E6B.









TABLE E6B





SEQID
EAAc
EAA





SEQID-00140
1
0.70


SEQID-00561
1
0.68


SEQID-00146
1
0.67


SEQID-00150
1
0.67


SEQID-00143
1
0.65


SEQID-03297
1
0.62


SEQID-00487
1
0.61


SEQID-00287
1
0.59


SEQID-00298
1
0.59


SEQID-00548
1
0.59



























Example 7
Selection of Amino Acid Sequences of Nutritive Polypeptides Enriched in Branched Chain Amino Acids for Muscle Health, and Selection of Amino Acid Sequences of Nutritive Polypeptides Reduced in Branched Chain Amino Acids for Treatment of Diabetes, Cardiovascular Disease, Chronic Kidney Disease and Stroke
Identification of Proteins Enriched in Branched Chain Amino Acids for the Treatment of Hepatic and/or Renal Disease.
Using a database of all protein sequences derived from edible species as described herein, candidate sequences that are enriched or reduced in branched chain amino acids were identified. In order to increase the probability that these proteins are solubly expressed, as well as highly soluble at pH 7 with reduced aggregation propensity, solvation score and aggregation score upper bounds of −20 kcal/mol/AA and 0.5 were applied. In order to reduce the likelihood that these proteins would elicit an allergenic response, upper bounds of 50% and 35% were set for the global allergen homology and allergenicity scores, respectively. In order to reduce the likelihood that these proteins would have toxic effects upon ingestion, an upper bound of 35% was set for the toxicity score. In order to reduce the likelihood that these proteins would act as inhibitors of digestive proteases, an upper bound of 35% was set for the anti-nutricity score.
An exemplary list of the top 10 nutritive polypeptide sequences that are enriched in branched chain amino acids, and meet the afore mentioned cutoffs in solvation score, aggregation score, global allergen homology, allergenicity score, toxicity score, and anti-nutricity score is shown in table E7A.









TABLE E7A





SEQID
EAA
BCAA





SEQID-03532
0.58
0.31


SEQID-03616
0.53
0.31


SEQID-03629
0.56
0.31


SEQID-03619
0.52
0.29


SEQID-03542
0.49
0.29


SEQID-03519
0.49
0.29


SEQID-03603
0.53
0.29


SEQID-03536
0.52
0.29


SEQID-03597
0.48
0.29


SEQID-03623
0.49
0.29



























An exemplary list of the top 10 nutritive polypeptide sequences from the expressed protein database that are enriched in branched chain amino acids is shown in table E7B.









TABLE E7B





SEQID
EAA
BCAA





SEQID-00162
0.64
0.53


SEQID-00166
0.65
0.46


SEQID-00134
0.58
0.46


SEQID-00169
0.60
0.43


SEQID-00043
0.57
0.41


SEQID-00132
0.60
0.41


SEQID-00137
0.64
0.39


SEQID-00175
0.63
0.38


SEQID-00550
0.49
0.38


SEQID-00234
0.51
0.37



























An exemplary list of the top 10 nutritive polypeptide sequences that are reduced in branched chain amino acids, and meet the afore mentioned cutoffs in solvation score, aggregation score, global allergen homology, allergenicity score, toxicity score, and anti-nutricity score is shown in table E7C.









TABLE E7C





SEQID
EAA
BCAA





SEQID-03471
0.36
0.01


SEQID-03473
0.06
0.01


SEQID-03571
0.24
0.01


SEQID-03495
0.24
0.01


SEQID-03514
0.24
0.01


SEQID-00552
0.45
0.03


SEQID-03611
0.37
0.03


SEQID-03457
0.37
0.03


SEQID-03456
0.34
0.03


SEQID-03520
0.36
0.03



























An exemplary list of the top 10 nutritive polypeptide sequences from the expressed protein database that are reduced in branched chain amino acids is shown in table E7D.









TABLE E7D





SEQID
EAA
BCAA





SEQID-00552
0.45
0.03


SEQID-00522
0.40
0.03


SEQID-00515
0.25
0.05


SEQID-00553
0.39
0.05


SEQID-00585
0.44
0.06


SEQID-00637
0.42
0.07


SEQID-00652
0.28
0.08


SEQID-00615
0.40
0.08


SEQID-00743
0.29
0.08


SEQID-00547
0.49
0.09



























Example 8
Selection of Amino Acid Sequences of Nutritive Polypeptides Having Low or No Phenylalanine and Enriched in Tyrosine and all Other Essential Amino Acids for Treatment or Prevention of Phenylketonuria
Individuals who suffer from phenylketonuria (PKU) are unable to process the amino acid phenylalanine and catalyze its conversion to tyrosine often due to a malfunctioning hepatic enzyme phenylalnine hydroxylase (MacLeod E. L. and Ney D. M. Nutritional Management of Phenylketonuria. Annales Nestle . (2010) 68:58-69). In these individuals, when protein containing the amino acid phenylalanine is ingested, phenylalanine accumulates in the blood. Untreated PKU has serious untoward health effects, including impaired school performance, impaired executive functioning, and long term intellectual disability (Matalon, R., Michals-Matalon, K., Bhatia, G., Grechanina, E., Novikov, P., McDonald, J. D., Grady, J., Tyring, S. K., Guttler, F. Large neutral amino acids in the treatment of phenylketonuria. J. Inherit. Metab. Dis . (2006) 29: 732-738). One way phenylalanine blood levels can be kept low to avoid neurological effects is to avoid the ingestion of phenylalanine containing proteins and/or only consume protein sources that are low in phenylalanine. As basic protein nutritional requirements of all other amino acids must also be met, sufficient intake of the other essential amino acids (histidine, leucine, isoleucine, valine, methionine, threonine, lysine, and tryptophan) and tyrosine, which becomes conditionally essential in these individuals, is required. One can identify beneficial nutritive polypeptides for individuals that suffer from phenylketonuria by selecting proteins that contain low or no phenylalanine and are enriched by mass in tyrosine and the other essential amino acids.
Using a database of all protein sequences derived from edible species as described herein, candidate sequences that contain low or no phenylalanine by mass, are essential amino acid and tyrosine complete (aside from phenylalanine), and enriched in tyrosine and essential amino acids were identified and rank ordered first by their phenylalanine mass fraction and then by their total tyrosine plus essential amino acid mass fraction. In order to increase the probability that these proteins are solubly expressed, as well as highly soluble at pH 7 with reduced aggregation propensity, solvation score and aggregation score upper bounds of −20 kcal/mol/AA and 0.5 were applied. In order to reduce the likelihood that these proteins would elicit an allergenic response, upper bounds of 50% and 35% were set for the global allergen homology and allergenicity scores, respectively. In order to reduce the likelihood that these proteins would have toxic effects upon ingestion, an upper bound of 35% was set for the toxicity score. In order to reduce the likelihood that these proteins would act as inhibitors of digestive proteases, an upper bound of 35% was set for the anti-nutricity score.
An exemplary list of the top 10 nutritive polypeptide sequences that contain low or no phenylalanine by mass, are essential amino acid and tyrosine complete (aside from phenylalanine), enriched in tyrosine and essential amino acids, and meet the afore mentioned cutoffs in solvation score, aggregation score, global allergen homology, allergenicity score, toxicity score, and anti-nutricity score is shown in table E8A.
TABLE E8A SEQID EAA F Y SEQID-03584 0.53 0.00 0.09 SEQID-03479 0.52 0.00 0.04 SEQID-03573 0.55 0.00 0.01 SEQID-00634 0.50 0.00 0.05 SEQID-03466 0.49 0.00 0.05 SEQID-03609 0.53 0.00 0.01 SEQID-03498 0.45 0.00 0.06 SEQID-03465 0.40 0.00 0.08 SEQID-03587 0.46 0.00 0.01 SEQID-03463 0.41 0.00 0.05
An exemplary list of the top 10 nutritive polypeptide sequences from the expressed protein database that contain low or no phenylalanine by mass, are essential amino acid and tyrosine complete (aside from phenylalanine), and enriched in tyrosine and essential amino acids is shown in table E8B.











TABLE E8B





SEQID
EAA
F
Y





SEQID-00634
0.50
0.00
0.05


SEQID-00514
0.46
0.01
0.01


SEQID-00329
0.47
0.01
0.03


SEQID-00628
0.51
0.01
0.02


SEQID-00636
0.47
0.01
0.04


SEQID-03634
0.45
0.01
0.04


SEQID-00335
0.38
0.01
0.07


SEQID-00639
0.46
0.01
0.06


SEQID-03448
0.40
0.01
0.03


SEQID-03889
0.42
0.02
0.01



























Example 9
Selection of Amino Acid Sequences of Nutritive Polypeptides Containing Fragments or Regions of Naturally-Occurring Protein Sequences: Nutritive Polypeptide Fragments Enriched in Leucine and all Essential Amino Acids
In some cases, full length proteins identified from the databases described herein are not particularly advantageous in view of one or more selection requirements defined by one or more important parameters, or otherwise do not provide enough of one or more specific amino acid(s) by mass relative to the total mass of the nutritive polypeptide. In these cases, one or more fragments (also termed “regions” herein) of nutritive polypeptides identified in the database are able meet the desired search criteria. Databases containing possible fragments of nutritive polypeptides are generated and searched by taking each full length sequences in the database and examining all possible subsequences at least 25 amino acids in length contained therein. For example, it was desired to find a nutritive polypeptide sequence that had leucine mass fractions greater than about 0.2 and highly charged to increase the likelihood of soluble expression. The protein edible species database described herein was searched using a solvation score cutoff of less than −30, and in order to reduce the likelihood that these proteins would elicit an allergenic response, upper bounds of 50% were set for the global allergen homology and allergenicity scores. In order to reduce the likelihood that these proteins would have toxic effects upon ingestion, an upper bound of 35% was set for the toxicity score. In order to reduce the likelihood that these proteins would act as inhibitors of digestive proteases, an upper bound of 35% was set for the anti-nutricity score.
An exemplary list of the top 10 nutritive polypeptide fragments that are enriched in leucine (≧20% by mass) and meet the afore mentioned cutoffs in solvation score, global allergen homology, allergenicity score, toxicity score, and anti-nutricity score is shown in table E9A.









TABLE E9A





DBID
EAA
L





P58797
0.47
0.26


A7A1V1
0.49
0.24


P04467
0.56
0.23


Q9AWA5
0.45
0.22


Q2NL14
0.52
0.22


Q60CZ8
0.42
0.22


Q10MN8
0.32
0.22


P50275
0.47
0.22


Q2YDE5
0.45
0.22


QOP5B4
0.51
0.22



























An exemplary list of the top 10 nutritive polypeptide fragments from the expressed protein database that are enriched in leucine (≧20% by mass) is shown in Table E9B.









TABLE E9B





SEQID
EAA
L





SEQID-00132
0.60
0.32


SEQID-00195
0.52
0.26


SEQID-00194
0.54
0.26


SEQID-00193
0.53
0.26


SEQID-00166
0.65
0.26


SEQID-00134
0.58
0.24


SEQID-00212
0.51
0.23


SEQID-00139
0.49
0.23


SEQID-00213
0.51
0.21


SEQID-00148
0.47
0.21



























Example 10
Purification of Nutritive Polypeptides
Various methods of purification have been used to isolate nutritive polypeptides from or away other materials such as raw foods, cells, salts, small molecules, host cell proteins, and lipids. These methods include diafiltration, precipitation, flocculation, aqueous two phase extraction, and chromatography.
Purification by Anti-FLAG Affinity Chromatography.
Anti-FLAG purification provides a method to purify nutritive polypeptides from low-titer expression systems or from similarly charged host cell proteins. Nutritive polypeptides were engineered to contain either a single FLAG tag (DYKDDDDK) or a triple tandem FLAG tag (DYKDDDDKDYKDDDDKDYKDDDDK) appended to the C-terminus of the protein. Anti-FLAG affinity purification offers a single-step purification process that offers non-denaturing process conditions and elution purities of >95% (Einhauer et al., 2001 Journal of Biochemical and Biophysical Methods).
Nutritive polypeptides were purified using Anti-FLAG M2 Affinity Agarose Gel (Sigma Aldrich, St. Louis, Mo.). The M2 affinity resin is designed specifically for use with C-terminal FLAG epitopes. For purification of N-terminally appended FLAG epitopes, the M1 Affinity Agarose Gel was used. The M2 Affinity Agarose Gel (resin) has an advertised static binding capacity (SBC) of approximately 0.5 mg nutritive polypeptide per mL of resin.
Purification of nutritive polypeptides from Aspergillus niger secretion media and Bacillus subtilis secretion media were performed using 20-40 mL of anti-FLAG resin. Prior to purification, secretion media was adjusted to 150 mM NaCl and pH 7.4. Resin was equilibrated by rinsing the media with an excess of 1× tris-buffered saline (TBS) pH 7.4±0.1 and collecting it through a 0.2 um polyethersulfone (PES) vacuum filter. Equilibrated resin was then mixed with secretion media in batch mode and allowed to mix at room temperature for one hour. Unbound material was removed from the resin by passing the entire mixture through a 0.2 um PES vacuum filter. The resin was physically collected on the surface of the filter and was subsequently washed with 20 resin volumes of TBS pH 7.4±0.1 to further remove unbound material through the 0.2 um PES vacuum filter. Washed resin was transferred to drip columns (10 mL each) and the bound polypeptides were eluted with two column volumes (CV) of 0.1M glycine pH 3.0. The eluted polypeptides were flowed directly from the drip columns into conical tubes that contained 1M Tris pH 8.0; this strategy was used to neutralize the pH of the eluted polypeptide solution as quickly as possible. Resin was regenerated using an additional 3 CV of 0.1M glycine pH 3.0. For short term storage, resin was stored in 1×TBS pH 7.4 at 4° C.; for long term storage, resin was stored in 0.5×TBS pH 7.4, 50% glycerol at −20° C.
Exemplary anti-FLAG purification of SEQID-00105 from B. subtilis yielded 4.0 mg of protein in a 4.3 ml elution. The sample was loaded onto a polyacrylamide gel at three different dilutions for increased sensitivity and SEQID-00105 was found to be 95% pure. Exemplary anti-FLAG purification of SEQID-00298 from A. niger was performed according to the same procedure. The elution fraction was neutralized, as described, and analyzed by SDS-PAGE and Bradford assay as described herein. The main band in the elution was found to be 95% pure. The main band in the elution is compared to the MW ladder on the same gel, and matched the expected molecular weight of SEQID-00298. Forty mL of anti-FLAG resin captured 4.0 mg of material, resulting in an estimated resin capacity of 0.10 mg/mL.
Purification by 5 ml Immobilized Metal Affinity Chromatography (IMAC).
E. coli was grown in shake flask fermentation with targeted expression of individual nutritive polypeptides with HIS8 tags, as described herein. Cells were harvested from each shake-flask by bucket centrifugation. The supernatant was discarded, and the cells were suspended in 30 mM imidazole, 50 mM sodium phosphate, 0.5 M NaCl, pH 7.5 at a wet cell weight (WCW) concentration of 20% w/v. The suspended cells were then lysed with two passes through a M110-P microfluidizer (Microfluidics, Westwood, Mass.) at 20,000 psi through an 87 um interaction chamber. The lysed cells were centrifuged at 15,000 relative centrifugal force (RCF) for 120 minutes, and then decanted. Cellular debris was discarded, and the supernatants were 0.2 um filtered. These filtered protein solutions were then purified by immobilized metal affinity chromatography (IMAC) on an ÄKTA Explorer 100 FPLC (GE Healthcare, Piscataway, N.J.). Nutritive polypeptides were purified over 5 mL (1.6 cm diameter×2.5 cm height) IMAC Sepharose 6 Fast Flow columns (GE Healthcare, Piscataway, N.J.).
IMAC resin (GE Healthcare, IMAC Sepharose 6 Fast Flow) was charged with nickel using 0.2 NiSO4 and washed with 500 mM NaCl, 200 mM imidazole, pH 7.5 followed by equilibration in 30 mM imidazole, 50 mM sodium phosphate, 0.5 M NaCl, pH 7.5. 50 mL of each protein load solution was applied onto a 5 mL IMAC column, and washed with additional equilibration solution to remove unbound impurities. The protein of interest was then eluted with 15 mL of IMAC Elution Solution, 0.25 M imidazole, 0.5 M NaCl, pH 7.5. All column blocks were performed at a linear flow rate of 150 cm/hr. Each IMAC elution fraction was buffer exchanged by dialysis into a neutral pH formulation solution. The purified proteins were analyzed for concentration and purity by capillary electrophoresis and/or SDS-PAGE. Concentration was also tested by Bradford and A280 measurement, as described herein. Table E9A demonstrates a list of nutritive polypeptides that were purified by IMAC at 5 mL scale.





TABLE E9A



Nutritive polypeptides thatwere purified by IMAC at 5 mL








SEQID
Mass (mg)
Purity
SEQID
Mass (mg)
Purity










00533
3
22%
00598
60.3
91%

00522
25.5
36%
00647
73.7
93%

00085
34
51%
00105
3.8
93%

00103
4.5
56%
00343
35.3
95%

00359
40.5
56%
00103
112
95%

00346
30.7
56%
00511
179
95%

00510
112
61%
00354
85.8
96%

00622
70
70%
00587
93
96%

00522
47
72%
00610
90.5
97%

00546
235.6
75%
00485
269
98%

00353
5.6
76%
00356
76.9
98%

00601
83.8
77%
00352
134.9
99%

00418
14
80%
00345
196.2
100%

00502
93.2
84%
00338
123.2
100%

00100
68
87%
00298
0.6
100%

00606
77.8
87%
00357
104.8
100%

00104
93
89%
00605
202
100%

00076
92
91%
00559
241.8
100%

00341
176.6
91%
00338
268
100%










































Purification by 1 L Immobilized Metal Affinity Chromatography (IMAC).
E. coli was grown in 20 L fermentation with targeted expression of individual nutritive polypeptides with HIS8 tags, as described herein. Cells were harvested from the fermenter and centrifuged using a Sharples AS-16P centrifuge to collect wet cell mass. Cells were subsequently resuspended in 30 mM imidazole, 50 mM sodium phosphate, 0.5 M NaCl, pH 7.5 at a wet cell weight (WCW) concentration of 20% w/v. The cell suspension was then lysed using four passes through a Niro Soavi Homogenizer (Niro Soavi, Parma, Italy) at an operational pressure of 12,500-15,000 psi and a flow rate of 1 L/min. The lysate was clarified using a Beckman J2-HC bucket centrifuge (Beckman-Coulter, Brea, Calif.) at 13,700×g for 1 hour. Cellular debris was discarded, and the supernatant was filtered through a Sartopore II XLG 0.8/0.2 um filter (Sartorius Stedim, Bohemia, N.Y.) at 30 L/m2/hr. Filtered lysate was purified by IMAC using IMAC Sepharose 6 Fast Flow resin packed in a 0.9 L column (9 cm diameter×13.8 cm height).
IMAC resin was equilibrated, as described herein, at a linear flow rate of 300 cm/hr. Once equilibrated, the entirety of the filtered lysate was passed over the column at a linear flow rate of 150 cm/hr. Load volumes ranged from six to ten column volumes. After the load, unbound material was washed off of the column, and the target protein was eluted. Elution pools were shipped at room temperature, 4′C or frozen. This decision was dependent on the stability of the nutritive polypeptide in Elution Solution. Table E9B summarizes a number of nutritive polypeptides that have been purified by IMAC at the 1 L column scale.





TABLE E9B



Nutritive polypeptides that have been

purified by IMAC at 1 L scale





SEQID
IMAC Elution Mass
IMAC Elution Purity



00240
9.00 grams
98%

00338
43.5 grams
100%

00341
54.3 grams
100%

00352
19.8 grams
100%

00559
19.5 grams
89%

00587
8.6 grams
69%



























Nutritive polypeptides were filtered through a Sartopore II XLG 0.8/0.20□□m filter and loaded directly into an ultrafiltration/diafiltration (UF/DF) unit operation. Membrane area and nominal molecular weight cutoff were chosen as appropriate for each nutritive polypeptide. Nutritive polypeptides were ultrafiltered at a cross flow of 12 L/m2/min and a TMP target of 25 psi. Nutritive polypeptides were concentrated approximately ten-fold on Hydrosart ultrafiltration cassettes (Sartorius Stedim, Bohemia, N.Y.), and diafiltered seven diavolumes into a formulation buffer that is specific to the nutritive polypeptide. Ultrafiltration permeate was discarded. The diafiltered, concentrated retentate was collected, filtered through a 0.22 um membrane filter and frozen at −80° C.
In some cases, frozen protein concentrates were lyophilized using a Labconco lyophilizer (Labconco, Kansas City, Mo.). Residual water content of the cake is analyzed using the Karl Fisher method.
Purification by 10 L Immobilized Metal Affinity Chromatography (IMAC).
E. coli was grown in 250 L fermentation with targeted expression of individual nutritive polypeptides with HIS8 tags, as described herein. Cells were harvested from the 250 L fermenter and centrifuged using a Sharples AS-16P centrifuge to collect wet cell mass. Cells were subsequently resuspended in 30 mM imidazole, 50 mM sodium phosphate, 0.5 M NaCl, pH 7.5 at a WCW concentration of 20% w/v. The cells suspension was then lysed using four passes through a Niro Soavi Homogenizer (Niro Soavi, Parma, Italy) at an operational pressure of 12,500-15,000 psi and a flow rate of 1 L/min. Clarified lysate was generated using four passes through a Sharples AS-16P centrifuge at 15,000 rpm operated at 0.5 L/min. Cellular debris was discarded, and the supernatant was filtered through a series of filters. Clarified lysate was passed sequentially through a SartoPure GF+0.65 um, a SartoGuard PES 1.2/0.2 um and a Sartopore II XLG 0.8/0.2 um filter (Sartorius Stedim, Bohemia, N.Y.). Filtered lysate was purified by IMAC using IMAC Sepharose 6 Fast Flow resin packed in an 8.5 column (20 cm diameter×27.1 cm height).
IMAC resin was equilibrated as described at a linear flow rate of 150 cm/hr. Once equilibrated, the filtered lysate was passed over the column at a linear flow rate of 150 cm/hr. Load volumes ranged from 3.8 to 5.0 CV. After the load, unbound material was washed off of the column with additional equilibration. Nutritive polypeptides manufactured at the 10 L IMAC scale were subject to an additional set of washes with 2 CV of 10 mM sodium phosphate dibasic, 300 mM NaCl; 3 CV of 0.5% w/v sodium deoxycholate, 50 mM sodium phosphate dibasic, 300 mM NaCl; and 5CV of 10 mM sodium phosphate dibasic, 300 mM NaCl. Following the washes, the target polypeptide was eluted as described. Elution pools were stored at room temperature.
Multiple nutritive polypeptides were purified by IMAC chromatography at the 10 L column scale. Table E9C summarizes the purification of SEQID-00105 and SEQID-00338. FIG. 1 provides an exemplary SDS-PAGE analysis of the purification of SEQID-00105.





TABLE E9C



Nutritive polypeptides were purified by IMAC

chromatography at the 10 L column scale





SEQID
Mass
Purity



00105
179 g
98%

00105
265 g
98%

00105
131 g
91%

00105
147 g
92%

00105
164 g
94%

00105
148 g
95%

00105
229 g
100%

00105
228 g
100%

00338
137 g
92%

00338
196 g
100%

00338
169 g
100%
































After IMAC purification at the 10 L column scale, nutritive polypeptides were filtered through a Sartopore II XLG 0.8/0.2 um filter and loaded directly into an ultrafiltration/diafiltration (UF/DF) unit operation. Membrane area and nominal molecular weight cutoff were chosen as appropriate for each nutritive polypeptide. Nutritive polypeptides were ultrafiltered at a cross flow of 12 L/m2/min and a TMP target of 25 psi. Nutritive polypeptides were concentrated approximately ten-fold on Hydrosart ultrafiltration cassettes (Sartorius Stedim, Bohemia, N.Y.), and diafiltered sequentially into four diavolumes of 10% phosphate buffered saline (PBS), pH 8.7; followed by two diavolumes of 25 mM tetrasodium ethylenediaminetetraacetic acid (Na4EDTA); followed by seven diavolumes of 10% PBS, pH 8.7. Intermediate diafiltration into Na4EDTA was performed in order to chelate any leached nickel (II) from the IMAC resin. Ultrafiltration permeate was discarded; the diafiltered, concentrated retentate was filtered through a 0.2 um membrane filter, and frozen at −80° C.
The ultrafiltration pool was filtered with a sterilizing-grade filter with the goal of bioburden reduction. The nutritive polypeptide was filtered into glass trays that were rinsed with ethanol. Filled glass trays were subsequently frozen at −80° C. The frozen material was then lyophilized to a dry cake using a Labconco lyophilization unit (Labconco, Kansas City, Mo.). The mass of the protein in the tray was monitored with time, until it plateaued, which was considered to be complete drying. The dried protein cake was sealed by the lid of the tray, and over-packaged by vacuum sealing in a plastic bag. The entire package was stored at −80° C.
Ion Exchange Chromatography.
Selecting an appropriate method of purifying a nutritive polypeptide has implications for the speed of process development, cost of manufacture, final purity, and robustness of the purification. Nutritive polypeptides have been isolated by various chromatographic methods. The mode of chromatography selected for use depends on the physicochemical properties of the target nutritive polypeptide. Charged nutritive polypeptides bind to ion exchange chromatography resin through electrostatic interactions.
In the present application, we have defined two methods of screening a library of polypeptides to rank-order them for their ability to bind to ion exchange resins. One method is an in silico prediction based on calculation of protein net charge across a range of pH using the primary sequence of the polypeptides, as described herein. The second method is a multiplexed purification screen in vitro, as described herein. The two methods have successfully been used independently of each other, and they have been used together on the same set of 168 nutritive polypeptides with supportive data, as described herein.
The in silico method of predictive ranking for ion exchange purification is based on calculating net charge of a nutritive polypeptide at a range of pH based on the primary sequence. The primary sequence of a nutritive polypeptide is used to predict the mode of chromatography that is most likely to successfully isolate that nutritive polypeptide from host cell proteins and other impurities. Highly charged nutritive polypeptides are likely to bind tightly to ion exchange chromatography resin. The tightest binding is achieved for nutritive polypeptides which have one predominant charge, either positive or negative. It is possible for a nutritive polypeptide with a mixture of positive and negative charges to have tight binding to ion exchange resin, but it is also possible that those charges may work against each other. Similarly, a nutritive polypeptide with alternating positive and negative patches on its surface may not bind as tightly as one with a dominant portion of its surface that is one single charge. Similarly, a nutritive polypeptide that has a strongly positive or negative terminus, tail, tag, or linker sequence may effectively display that highly charged group allowing for extremely tight binding.
A prevalence of one or more certain amino acids, e.g., histidine, arginine, and lysine in a polypeptide imparts in that polypeptide, or a portion thereof, a positive charge when the pH of the protein solvent is below the pKa of the one or more amino acids. Polypeptide charge includes total protein charge, net charge, or the charge of a portion of the polypeptide. In embodiments wherein a polypeptide or portion thereof is positively charged, a cation exchange resin is used.
A prevalence of one or more certain amino acids, e.g., glutamic acid and aspartic acid in a polypeptide imparts in that polypeptide, or a portion thereof, a negative charge when the pH of the protein solvent is above the pKa of the one or more amino acids. Polypeptide charge includes total protein charge, net charge, or the charge of a portion of the polypeptide. In embodiments wherein a polypeptide or portion thereof is negatively charged, an anion exchange resin is used.
The net charge of a polypeptide changes as a function of the pH of the protein solvent. The number of positive charges and negative charges can be calculated at any pH based on the primary sequence of the polypeptide. The sum of the positive charges and negative charges at any one pH results in the calculated net charge. The isoelectric point (pI) of the polypeptide is the pH at which its calculated net charge is 0. To make comparisons, the net charge of a sequence is normalized by the number of amino acids in the sequence and the parameter “net charge per amino acid” results as the novel comparator between sequences, which is used to predict chromatographic performance.
Nutritive polypeptide sequences have been evaluated by calculating the net charge per amino acid of each polypeptide at every pH (1-14). Additionally, the pI of each polypeptide was calculated. Nutritive polypeptides were ranked by pI and by net charge per amino acid. Polypeptides with a low pI and very negative net charge per amino acid across a wide range of pH are predicted to bind to anion exchange chromatography resin with high affinity. Polypeptides with a high pI and very positive net charge per amino acid across a wide range of pH are predicted to bind to cation exchange chromatography resin with high affinity. In some embodiments herein, only a portion of the polypeptide is charged (as in a terminus, tail, tag, or linker), it is recognized that the pI and net polypeptide charge may be variable, and other factors or empirical measurements may be useful to predict the binding affinity of such a polypeptide to chromatography resins.
FIG. 2 demonstrates example nutritive polypeptides, which, based on primary sequence, are predicted to bind to either anion or cation exchange resin. Nutritive polypeptides with a pI of <4.0, and a net charge per amino acid that is negative across a broad range of pH are predicted to bind anion exchange resin with high affinity ((1) SEQID-00105, (2) SEQID-00008, (3) SEQID-00009, (4) SEQID-00475). Nutritive polypeptides with a pI of >10.0, and a net charge per amino acid that is positive across a broad range of pH are predicted to bind cation exchange resin with high affinity ((5) SEQID-00472, (6) SEQID-00640, (7) SEQID-00019).
The primary sequence analyses presented herein indicate that SEQID-00105 and SEQID-00009 are likely to bind to anion exchange chromatography resin with high affinity, and that SEQID-00640 is likely to bind to cation exchange chromatography resin with high affinity. These predictions were tested and demonstrated to be true, as demonstrated in the following four examples of polypeptide purification after microbial cell culture. In the first example, SEQID-00009 was purified directly from lysed E. coli cells to 99% purity using anion exchange chromatography. In the second example, SEQID-00105 was isolated from bacillus subtilis supernatant by anion exchange chromatography. In the third example, SEQID-00105 expressed intracellularly in E. coli was refined to 100% purity using anion exchange chromatography after it had been initially purified by IMAC chromatography. In the fourth example, SEQID-00640 was isolated from bacillus subtilis supernatant by cation exchange chromatography.
SEQID-00009 was expressed intracellularly in E. coli , as described herein. The cells were suspended in solution and ruptured. Three solutions were tested (0.1 M Na2CO3 pH 11.4, 0.1 M tris HCl pH 4.1, and 0.1 M potassium phosphate pH 7.0). These lysed solutions were clarified by centrifugation and mixed with anion exchange resin for binding. Two resins were tested (Fractogel® EMD TMAE Hicap (M) from EMD and POROS® D 50 μm from Life Technologies). These six binding conditions were performed in batch mode and the resins were washed with the appropriate lysis buffer to remove any unbound protein. The maximally-bound damp resin was then transferred to smaller drip columns. Each drip column was then eluted with up to six sequential washes of increasing NaCl concentration (each NaCl wash solution was buffered with the appropriate lysis buffer). SEQID-00009 was eluted in these fractions, collected, and analyzed by chip electrophoresis, as described herein. SEQID-00009 was identified as an eluting band at the expected molecular weight. In every case, SEQID-00009 eluted from the drip column at a purity higher than the load purity. This observation indicates that SEQID-00009 did bind to the anion exchange resins, as predicted, and that purification was achieved. The maximum purity achieved was 99%. In every case, SEQID-00009 was among the last proteins to elute from the resin indicating that the binding affinity of SEQID-00009 to two resins at a range of pH is generally higher than the binding affinity of any host cell protein from E. coli.
Microbial cell culture of Bacillus subtilis was performed as described herein expressing and secreting SEQID-00105 into the fermentation media. The cells were removed by centrifugation, and the supernatant was further clarified by membrane filtration. The clarified supernatant was concentrated by ultrafiltration to decrease load time on the anion exchange column and the solution was exchanged into a low salt solution buffered at pH 6.0. This solution was passed over a chromatography column (1 cm diameter, 20 cm height) containing POROS® XQ Strong Anion Exchange Resin from Life Technologies. The unbound proteins were rinsed from the resin with 20 mM Bistris, pH 6.3. The bound proteins were then eluted using a 30 column volume gradient to 400 mM NaCl, 20 mM Bistris, pH 6.3. The column effluent was collected in sequential fractions and analyzed by chip electrophoresis, as described herein. SEQID-00105 was identified as an eluting band at the expected molecular weight. The maximum purity achieved in one fraction was 100%.
SEQID-00105 was expressed intracellularly in E. coli , as described herein. The cells were ruptured, and the SEQID-00105 was purified by IMAC chromatography, according to the procedure described herein. The IMAC elution pool was further refined to 100% purity using anion exchange chromatography. The IMAC elution pool was concentrated and then diluted into 50 mM tris pH 8.0. This solution was then passed through a column (1.6 cm diameter, 20 cm height) packed with anion exchange resin: Fractogel® EMD TMAE Hicap (M) from EMD. The bound protein was rinsed with equilibration solution, and then eluted with 350 mM NaCl 50 mM tris pH 8.0. This procedure was repeated multiple times, and all samples were analyzed by chip electrophoresis, as described herein. The elution samples ranged from 79% to 99% pure.
Microbial cell culture of Bacillus subtilis was performed as described herein expressing and secreting SEQID-00640 into the fermentation media. The cells were removed by centrifugation, and the supernatant was further clarified by membrane filtration. The clarified supernatant was diluted 1:2 with deionized water and titrated to pH 5 with 1 M acetic acid. The resulting solution was membrane filtered prior to loading onto a cation exchange column (1.2 cm diameter 10 cm height) packed with POROS® XS Strong Cation Exchange Resin from Life Technologies. The bound resin was flushed with a 50 mM Acetate, 50 mM NaCl, pH 5.0 solution. The protein was then eluted with a 20 CV gradient to 1.05 M NaCl pH 5.0. Elution fractions were collected and analyzed by SDS-PAGE, Coomassie Blue Stain. The peak sample demonstrated 100% purity and no impurities eluted later in the gradient, indicating that the SEQID-00640 polypeptide bound to the cation exchange resin with more affinity than, any host cell proteins.
Purification by Precipitation.
Protein precipitation is a well-known method for purification of polypeptides (Scopes R. 1987. Protein Purification: Principles and Practice. N.Y.: Springer). Many polypeptides precipitate as salt concentrations increase, a phenomenon known as salting out. Salt types have been ranked and organized on the Hofmeister series for their different abilities to salt out proteins (F. Hofmeister Arch. Exp. Pathol. Pharmacol. 24, (1888) 247-260). Proteins also have different propensity to precipitate due to high salt concentration based on their physicochemical properties, however, a universal metric to rank proteins for this characteristic has not been established. The use of such a ranking metric to select nutritive polypeptides for their ability to be purified has implications for the speed of process development, cost of manufacture, final purity, and robustness of the purification.
In most industrial applications of purification by polypeptides precipitation, the polypeptide of interest is selectively precipitated, and the impurities are then rinsed away from the solid precipitate. In certain embodiments, polypeptides do not precipitate with high levels of salt, and purification is achieved by precipitating the impurities. In the present application, we have defined two methods of screening a library of polypeptides to rank-order them for their ability to remain soluble through harsh precipitation conditions. One method is an in silico prediction based on calculation of protein total charge across a range of pH using the primary sequence of the polypeptides, as described herein. The second method is a multiplexed purification screen in vitro, as described herein. The two methods have successfully been used independently of each other, and they have been used together on the same set of 168 nutritive polypeptides with supportive data, as described herein.
The solubility of a polypeptide correlates directly with the abundance of surface charges (Jim Kling, Highly Concentrated Protein Formulations: Finding Solutions for the Next Generation of Parenteral Biologics, BioProcess International, 2014). It has been established that surface charges can impart physical characteristics to a polypeptide (Lawrence, M. S., Phillips, K. J., & Liu, D. R. (2007). Supercharging proteins can impart unusual resilience. Journal of the American Chemical Society, 129(33), 10110-2. doi: 10.1021/ja071641y).
The in silico method of predictive solubility ranking is based on calculating total number of charges of a nutritive polypeptide at a range of pH based on the primary sequence.
A prevalence of one or more certain amino acids, e.g., histidine, arginine, and lysine in a polypeptide imparts in that polypeptide, or a portion thereof, a positive charge when the pH of the protein solvent is below the pKa of the one or more amino acids. A prevalence of one or more certain amino acids, e.g., glutamic acid and aspartic acid in a polypeptide imparts in that polypeptide, or a portion thereof, a negative charge when the pH of the protein solvent is above the pKa of the one or more amino acids.
The total number of charges of a polypeptide changes as a function of the pH of the protein solvent. The number of positive charges and negative charges can be calculated at any pH based on the primary sequence of the polypeptide, as described herein. The sum of the positive charges and negative charges at any one pH results in the calculated net charge. The isoelectric point (pI) of the polypeptide is the pH at which its calculated net charge is 0. To make comparisons across nutritive polypeptides, the total number of positive charges is added to the total number of negative charges (the absolute value), and that total charge is normalized by the number of amino acids in the sequence, and the parameter “total charge per amino acid” results as the novel comparator between sequences, which is used to predict the polypeptide's resistance to precipitation. The more resistant a polypeptide is, the higher the likelihood that it can be purified to a high degree by precipitating out the impurities. Unlike predicting chromatographic performance, solubility is not affected by the polarity of the charges. While it is often true that a polypeptide experiences its lowest solubility at the pI of the sequence, some polypeptides have a high total charge and are still extremely soluble at their pI, as shown herein.
Nutritive polypeptide sequences have been evaluated by calculating the total charge per amino acid of each polypeptide at a range of pH (1-14). Nutritive polypeptides were ranked by total charge per amino acid. Polypeptides with a low pI and very negative net charge per amino acid across a wide range of pH and polypeptides with a high pI and very positive net charge per amino acid across a wide range of pH are all expected to score equally well by this ranking. Polypeptides with a large number of both charges score the best.
FIG. 3 demonstrates example nutritive polypeptides, which, based on primary sequence, are predicted to have extremely high solubility. This set includes polypeptides with a low pI (<4) and very negative net charge per amino acid across a wide range ((1) SEQID-00475, (2) SEQID-00009). This set includes polypeptides with a high pI (>10) and very positive net charge per amino acid across a wide range of pH ((4) SEQID-00433, (5) SEQID-00472). This set includes polypeptides with more neutral pI ((3) SEQID-00478). Many of the polypeptides displayed here show high charge even at extreme pH values, such as <4 and >12. The entire set is expected to be extremely soluble and resist precipitation across a wide range of pH.
In this demonstration, the E. coli cells were harvested from shake flask fermentation by centrifugation, and the whole cells were distributed into tubes (1 gram of cells per tube). To each tube, 4 mL of lysis solution was added, and cells were lysed by sonication at 75 Amps for 30 seconds. Lysis solutions included: Water, 8 M Urea 0.1 M Tris 0.1M NaCl, 0.1 M Acetate 10% gly 0.1% Tween-80 0.3 M Arg 0.3M NaCl 10 mM EDTA, 10 mM Imidazole pH 5.0, 0.1 M Acetate 10% gly 0.1% Tween-80 0.3 M Arg 0.3M NaCl 10 mM EDTA, 10 mM Imidazole pH 7.0, 100 NaCl 100 Hepes 10 Imidazole pH 7.5, 500 NaCl 100 Hepes 10 Imidazole pH 7.5, 100 mM Phos, 150 mM NaCl, 10 mM Imidazole pH 7.5, 0.1 M NaCl 0.1 M Hepes 10 mM Imidazole 50 mM CaCl2 PH 7.5, 0.1 M Hepes 3.5 M Am Sulfate pH 7.5, 0.1 M Hepes 2 M Am. Sulfate pH 7.5, 0.1 M Tris, 0.1 M Tris 0.5 M NaCl, 150 mM NaCl 10 mM Acetate 15 mM Imidazole pH 6.04, and 500 mM NaCl 100 mM Acetate 15 mM Imidazole pH 6.04. The lysate was clarified by centrifugation and 0.2 um filtration. The clarified supernatant was analyzed by SDS-PAGE (blue stain), as described herein. SEQID-00009 demonstrated solubility in each of these conditions. E. coli host cell proteins generally demonstrated solubility in these conditions as well, with one exception. In the presence of 3.5 M ammonium sulfate effectively precipitated the majority of the host cell proteins resulting in 85% purified SEQID-00009 after the cell harvest stage of the process. This result indicates that SEQID-00009 is more soluble than most E. coli host cell proteins and that precipitation can be used as part of a low cost method for isolation. This correlates with the high total charge of SEQID-00009 and supports that the prediction is accurate. Furthermore, it is predicted that polypeptides with more charge than SEQID-00009 would be even more soluble which could have the benefit over SEQID-00009 of higher polypeptide yield.
In subsequent experiments, SEQID-00009 was purified to 99% purity with a single stage of ammonium sulfate precipitation. In this demonstration, the E. coli cells were harvested from shake flask fermentation by centrifugation, and the whole cells were suspended in 0.1 M sodium carbonate, pH 10 (1 gram of cells in 4 mL of solution). The cells were lysed by sonication (80 Amp for 2 minutes). The lysate was clarified by centrifugation and 0.2 □m membrane filtration. The clarified supernatant was divided into a series of 3 mL fractions, to which a stock solution of 4 M ammonium sulfate, pH 9.8 was added. Variable amounts of stock solution were added to achieve a range of ammonium sulfate concentrations. The samples were mixed for 10 minutes at room temperature, and clarified by centrifugation and 0.2 um membrane filtration. The clarified supernatants were analyzed by SDS-PAGE (blue stain), as described herein. FIG. 4 shows the purity of SEQID-00009 is as a function of ammonium sulfate concentration.
Multiplexed Purification: Ion Exchange Chromatography.
In some cases, an entire library of proteins is tested in a multiplexed screening experimental platform. 168 nutritive polypeptides were transfected and expressed in a multiplexed expression system in which a single growth condition was used to produce each polypeptide in a single container. This multiplexed expression system allows any set of polypeptide sequences to be tested in parallel for a wide range of manufacturability parameters, each of which can be used to rank order the set of polypeptides being examined. A set of manufacturability parameters includes expression level, polypeptide solubility, ability of polypeptide to be purified by chromatography, ability to resist thermal denaturation, ability of polypeptide to digest, ability of polypeptide to be purified by resisting harsh treatments.
The set of 168 nutritive polypeptides was tested for intracellular expression in E. coli . The solubly expressed polypeptides were pre-treated as a group and then subjected to a series of purification conditions so that the set could be rank ordered in terms of their ease of purification by multiple methodologies. As described herein, it is expected that the same subset of proteins will be identified from each expression system to bind a particular mode of chromatography based on the primary sequence analysis, specifically net charge per amino acid.
For E. coli multiplexed purification, the set of nutritive polypeptide sequences was HIS8 tagged. The cells were cultured, as described herein, ruptured, and the solution was clarified, as described herein. This production resulted in a solution containing all of the polypeptides from the set which were both expressed and soluble. That set of soluble polypeptides was passed over an 5 ml IMAC column, and eluted, as described herein. This IMAC purification effectively isolated the solubly expressed nutritive polypeptides as a set by removing the majority of E. coli host cell proteins. The elution fraction was concentrated and buffer exchanged into a low salt solution buffered near neutral pH before testing various purification methods. The methods tested include anion exchange chromatography, cation exchange chromatography, and negative precipitation, in which the impurities precipitate and the polypeptides that remain soluble rank the highest. In this case, impurities have been removed, so the polypeptides are rank ordered amongst themselves. Additionally, the set of proteins was tested for thermal stability, by heating, wherein the polypeptides which remain soluble after heating are more thermal stable than those which precipitate.
This mixture of polypeptides was rank ordered for their ability to bind anion exchange and cation exchange chromatography resins. Four chromatography resins were tested. Two anion exchange resins: Capto DEAE, from GE Lifesciences and Eshmuno® Q Resin from EMD. Two cation exchange resins: POROS® XS Strong Cation Exchange Resin from Life Technologies and Eshmuno® S Resin from EMD. Each resin was tested with eight different buffering conditions, as follows. Buffers used for anion wxchange: Water (no buffer), pH 7; 15 mM Na2HPO4, pH 8.7; 30 mM Na2HPO4, pH 9.0; 15 mM Tris Base, pH 9.6; 30 mM Tris Base, pH 10.0; 30 mM Na2CO3, pH 11.2; 25 mM Arginine, pH 10.1. Buffers used for cation exchange:Water (no buffer), pH 7; 15 mM KH2PO4, pH 4.2; 30 mM KH2PO4, pH 4.5; 15 mM Tris Acid, pH 4.9; 30 mM Tris Acid, pH 4.7; 15 mM MES Acid, pH 3.9; 25 mM MES Acid, pH 4.1.
The resins were distributed to a 96 well filterplate (20 uL of resin per well) and each was equilibrated three times. The protein set was mixed with the equilibration buffers and allowed to bind to the resins. The unbound proteins in solution were separated from the resin by centrifuging the liquid through the filterplate for collection in a 96 well plate below. The remaining unbound proteins were further rinsed off the resin with a wash of equilibration buffer. The bound proteins were then sequentially eluted with three stages of increasing salt concentration (50, 250, 1500 mM NaCl buffered in the appropriate set of buffers above). The loosely bound proteins were removed first, and the proteins that were removed in the final elution condition were very tightly bound to the resin. Thus, a library of 168 proteins was expressed in E. coli and rank ordered for their binding affinity to anion exchange and cation exchange chromatography resin.
The experiment described herein produced 160 samples (four resins, eight buffers, five collections). The five collection stages include: the flow through fraction, the wash fraction, the 50 mM NaCl elution, the 250 mM NaCl elution, and the 1500 mM NaCl elution. All 160 samples were analyzed by UV-vis absorbance at 280 nm, by Bradford total protein assay, by Chip electrophoresis, and select samples were analyzed by LC/MS/MS. All analytical assays are described herein.
The assays demonstrated that some protein flowed through the resin and was not bound. In most cases, the wash fraction did not elute a significant amount of protein, indicating that any further protein to elute was in fact bound to the resin. As the NaCl concentration increased, the total protein being removed also increased demonstrating successful binding and elution in nearly every condition. The proteins detected by electrophoresis in 1500 mM NaCl elution conditions remained bound through the 250 mM NaCl wash condition, indicating strong binding. Select conditions were selected for LC/MS/MS analysis. The LC/MS/MS analysis was performed with the 1500 mM NaCl elution sample from anion exchange chromatography resin (Capto DEAE) in the 30 mM Tris Base buffering condition. The LC/MS/MS results were searched against the sequences of all 168 nutritive polypeptides originally expressed in the library. Eight unique polypeptides were identified as having high binding affinity to this anion exchange resin in this condition are SEQID-00341, SEQID-00346, SEQID-00497, SEQID-00525, SEQID-00555, SEQID-00605, SEQID-00606, SEQID-00610. For each polypeptide sequence in this set, the net charge per amino acid was calculated based on primary sequence across the range of pH tested. As described herein, it is expected that polypeptides which bind tightly to anion exchange resins have a net charge per amino acid below 0 across the pH range, and this is demonstrated to be true, with a single exception. Any exception is expected to be due to the fact that there is charge heterogeneity across the length of the sequence, and as described, net charge per amino acid does not always capture that. This multiplexed screen identified a set of polypeptides from a larger library based on their affinity to bind anion exchange resin, and this result can be predicted based on the primary sequence analysis, as described herein.
The LC/MS/MS analysis was performed with the 1500 mM NaCl elution sample from cation exchange chromatography resin (Poros XS) in the 15 mM Tris Acid buffering condition. The LC/MS/MS results were searched against the sequences of all 168 nutritive polypeptides originally expressed in the library. Eight unique polypeptides were identified as having high binding affinity to this cation exchange resin in this condition are SEQID-00302, SEQID-495, SEQID-00522, SEQID-00537, SEQID-00546, SEQID-00547, SEQID-00560, SEQID-00598. For each polypeptide sequence in this set, the net charge per amino acid was calculated based on primary sequence across the range of pH tested. As described herein, it is expected that polypeptides which bind tightly to cation exchange resins have a net charge per amino acid above 0 across the pH range, and this is demonstrated to be true, with minor exception. Any exception is expected to be due to the fact that there is charge heterogeneity across the length of the sequence, and as described, net charge per amino acid does not always capture that. This multiplexed screen identified a set of polypeptides from a larger library based on their affinity to bind cation exchange resin, and this result can be predicted based on the primary sequence analysis, as described herein.
In the Bacillus subtilis example of multiplexed purification, the set of polypeptide sequences was expressed without any type of purification tag. The cells were cultured in flasks, as described herein and expressed and secreted the polypeptides into the growth media. The cells were removed by centrifugation and the solution was further clarified by membrane filtration, as described herein. This production process resulted in a solution containing all of the polypeptides from the set which were both expressed and solubly secreted. That set of soluble polypeptides was concentrated and buffer exchanged into a solution of phosphate, pH 7.0 before testing various purification methods. The methods tested include anion exchange chromatography, cation exchange chromatography, and negative precipitation, in which the impurities precipitate and the polypeptides that remain soluble rank the highest. In these multiplexed purification studies, the polypeptides are purified away from each other and from the host cell proteins in order to be rank ordered amongst themselves.
This mixture of polypeptides was rank ordered for their ability to bind to anion exchange and cation exchange chromatography resins. Four chromatography resins were tested. Two anion exchange resins: Capto DEAE, from GE Lifesciences and Eshmuno® Q Resin from EMD. Two cation exchange resins: POROS® XS Strong Cation Exchange Resin from Life Technologies and Eshmuno® S Resin from EMD. Each resin was tested with eight different buffering conditions. Buffers used for Anion Exchange: 18 mM BIS-TRIS, pH 6.5; 13 mM HEPES, pH 7.0; 18 mM HEPES, pH 7.5; 16 mM TRIS, pH 8.0; 32 mM TRIS, pH 8.5; 88 mM TRIS, pH 9.0; 13 mM Na2CO3, pH 9.5; 20 mM Na2CO3, pH 10.0. Buffers used for Cation Exchange: 19 mM Citrate, pH 3.0; 13 mM Citrate, pH 3.5; 49 mM Acetate, pH 4.0; 22 mM Acetate, pH 4.5; 14 mM Acetate, pH 5.0; 10 mM Acetate, pH 5.5; 24 mM MES, pH 6.0; 15 mM MES, pH 6.5.
The resins were distributed to a 96 well filterplate (50 μL of resin per well) and each was equilibrated three times. The protein set was mixed with the equilibration buffers and allowed to bind to the resins. The unbound proteins in solution were separated from the resin by centrifuging the liquid through the filterplate for collection in a 96 well plate below. The remaining unbound proteins were further rinsed off the resin with two wash cycles of equilibration buffer. The bound proteins were then sequentially eluted with increasing salt concentration (250, 500, 1000 mM, 2000 mM NaCl). Each salt solution was buffered in the appropriate equilibration buffer except for the 2000 mM NaCl solution which was buffered with MES at pH 6.0 for anion exchange resins and with TRIS at pH 8.0 for cation exchange resins. The loosely bound proteins were removed first, and the proteins that were removed in the final elution condition were very tightly bound to the resin. Thus, the library of proteins was expressed in Bacillus subtilis and rank ordered for their binding affinity to anion exchange and cation exchange chromatography resin.
The experiment described herein produced 192 samples (four resins, eight buffers, six collections). The six collection stages include: the flow through fraction, the wash fraction, the 250 mM NaCl elution, the 500 mM NaCl elution, the 1000 mM NaCl elution, and the 2000 mM NaCl elution. All 192 samples were analyzed by Chip electrophoresis. Select samples were analyzed by SDS-PAGE. Select samples were analyzed by LC/MS/MS. All analytical assays are described herein. Identification of strongly bound proteins is performed by a combination of Chip electrophoresis, SDS-PAGE, and LC/MS/MS.
SDS-PAGE results demonstrate that the majority of polypeptides do not bind to these resins, in fact they are found in the flow through fraction. Therefore, the polypeptides that bind to the resins are unique in their ability to be purified from the majority of other polypeptides. The set of polypeptides in the various elution fractions have been isolated from a larger set based on their properties in a purification process, which has implications for the manufacture, cost, development time, and eventual purity of these polypeptides. Furthermore, of the polypeptides that bind to resins, these can be rank ordered by their ability to remain bound to the resin through stringent wash conditions with increasing concentrations of NaCl. Those polypeptides found in the 2000 mM NaCl samples have been able to remain bound through 1000 mM NaCl wash conditions. It is widely accepted that any polypeptide which can remain bound to an ion exchange resin above 500 mM NaCl is considered to have very high affinity for that resin. The banding pattern is similar between the two cation exchange resins supporting that the proposed mechanism. Likewise, the banding pattern is similar between the two anion exchange resins, and represents a different sample set than those identified by cation exchange. To rank order the individual polypeptides identified in any subset, LC/MS/MS is utilized.
As an exemplary dataset, the LC/MS/MS results identified the following polypeptides as binding to the Capto DEAE anion exchange resin at pH 7.5: P39645, P37869, P80698, P80868, P21880, P80239, P50849, P12425, O34669, P39138, P37871, P19669, P29727, P80643, O34981, P80879, P54716, P37477. As an exemplary dataset, the LC/MS/MS results identified the following polypeptides as binding to the Poros XS cation exchange resin at pH 4.0: O34669, P19405, O31803, O05411, O31973, O31643, P80239, P26901, P08821, P80240, P49814, O34310, POC178, 031925, P71014, P42111.
These polypeptides identified as having high binding affinity were analyzed for physicochemical properties based on their primary sequence. The net charge per amino acid was calculated based on primary sequence across the range of pH tested. As described herein, it is expected that polypeptides which bind tightly to anion exchange resins have a net charge per amino acid below 0 across the pH range, and this was generally demonstrated to be true. As described herein, it is expected that polypeptides which bind tightly to cation exchange resins have a net charge per amino acid above 0 across the pH range, and this was generally demonstrated to be true. Any exception is expected to be due to the fact that there is charge heterogeneity across the length of the sequence, and as described, net charge per amino acid does not always capture that. This multiplexed screen identified a set of polypeptides from a larger library based on their affinity to bind anion exchange resin, and this result can be predicted based on the primary sequence analysis, as described herein.
In the Bacillus subtilis example of multiplexed purification, the set of 168 nutritive polypeptide sequences was expressed without any type of purification tag. The cells were cultured in flasks, as described herein and expressed and secreted the polypeptides into the growth media. The methods tested included negative flocculation/precipitation, in which the impurities precipitate and the polypeptides that remain soluble rank the highest. In these multiplexed purification studies, impurities are present in the form of soluble impurities (e.g. host cell proteins, DNA, phospholipids, and product-related impurities, such as isoforms or aggregated species), insoluble impurities, cells, or cellular debris (e.g. membrane fragments). Negative precipitation was performed prior to and following removal of insoluble impurities, cells, and cellular debris centrifugation and further clarification by membrane filtration.
The set of solubly expressed and secreted polypeptides in the cell suspension (prior to centrifugation and membrane filtration) and clarified supernatant (following centrifugation and membrane filtration) were rank ordered for their ability to associate with the flocculating agents. Furthermore, the flocculating agents were rank ordered for their ability to associate with the impurities. 48 flocculating agents were tested at two different concentrations, as follows: Ammonium Bicarbonate (100 mM, 200 mM); Manganese Chloride (100 mM, 200 mM); Nickel Sulfate (100 mM, 200 mM); Sodium Citrate (100 mM, 200 mM); Lithium Acetate (100 mM, 200 mM); Propylene Glycol (10% v/v, 20% v/v); Ammonium Nitrate (100 mM, 200 mM); Potassium Chloride (100 mM, 200 mM); Sodium Sulfate (100 mM, 200 mM); Sodium Molybdate (100 mM, 200 mM); Acetic Acid (100 mM, 200 mM); Chitosan MMW (0.1% w/v, 0.2% w/v); Ammonium Sulfate (100 mM, 200 mM); Sodium Chloride (0.5M, 1.0M); Zinc Sulfate (100 mM, 200 mM); Sodium Nitrate (100 mM, 200 mM); Citric Acid (100 mM, 200 mM); Guanidine HCl (0.6M, 1.2M); Ammonium Chloride (100 mM, 200 mM); Zinc Chloride (100 mM, 200 mM); Potassium Carbonate (100 mM, 200 mM); Sodium Phosphate (100 mM, 200 mM); Hydrochloric Acid (100 mM, 200 mM); PEG 1000 (5% w/v, 10% w/v); Calcium Chloride (100 mM, 200 mM); Iron Citrate (100 mM, 200 mM); Potassium Nitrate (100 mM, 200 mM); Sodium Propionate (100 mM, 200 mM); Potassium Hydroxide (100 mM, 200 mM); PEG 4000 (5% w/v, 10% w/v); Choline Chloride (100 mM, 200 mM); Copper Sulfate (100 mM, 200 mM); Potassium Phosphate (100 mM, 200 mM); Sodium Succinate (100 mM, 200 mM); Sodium Hydroxide (100 mM, 200 mM); Triton X-100 (0.5% w/v, 1.0% w/v); Iron Chloride (100 mM, 200 mM); Iron Sulfate (100 mM, 200 mM); Deoxycholic Acid (0.5% w/v, 1.0% w/v); Sodium Thiocyanate (100 mM, 200 mM); Ethanol (10% v/v, 20% v/v); Tween 80 (0.5% w/v, 1.0% w/v); Magnesium Chloride (100 mM, 200 mM); Magnesium Sulfate (100 mM, 200 mM); Sodium Carbonate (100 mM, 200 mM); Sodium Thiosulfate (100 mM, 200 mM); Isopropanol (10% v/v, 20% v/v); Urea (0.8M, 1.6M).
The cell suspension (prior to centrifugation and membrane filtration) and clarified supernatant (following centrifugation and membrane filtration) were distributed into a 96-well filter plate (300 μL per well for the low flocculating agent concentration and 267 μL for the high flocculating agent concentration). These loads were diluted 0.1× or 0.2× by adding 33 μL or 67 μL, respectively, of concentrated flocculating agent solutions. The resulting solution was mixed for 1 hour at room temperature. Following mixing, the remaining soluble material was separated from the insoluble material by centrifuging the liquid through the filterplate for collection in a 96 well plate below. All 192 samples were analyzed by Chip electrophoresis. Select samples were analyzed by SDS-PAGE. Select samples were analyzed by LC/MS/MS. All analytical assays are described herein.
SDS-PAGE results demonstrated that some conditions effectively precipitated many polypeptides, indicating that the soluble polypeptides in those conditions were rather soluble, and can be isolated in these conditions. The polypeptides that were soluble in the various precipitation conditions were isolated from a larger set based on their properties in a purification process, which has implications for the manufacture, cost, development time, and eventual purity of these polypeptides. Some polypeptides are widely soluble across a range of conditions due to their high charge, according the mechanism described herein. To rank order the individual polypeptides identified in any subset, LC/MS/MS is utilized.
As an exemplary dataset, the LC/MS/MS results demonstrated that the following polypeptides were isolated due to their sustained solubility in 100 mM Acetic Acid, pH 5.18: O34669, P54423, P21879, P10475, P28598, O31803, P40767, P17889, O34918, Q08352, P24327, P37871, O31973, P81101, P50849, P26901, P80700, O34385, P70960, P42111, P21880, P27876, P80868, P54716, O34313, O07603, O05411, P54531, O05497, P12425, O07921, P19405, Q06797, P02394, P24141, P09339, P37965, P07343, P37809, P0CI78, P39824, P49814, P39632, P39773, P51777, P21883, O06989, P25152, P70961, O07593, O34310, P80860, P37437, P80698, P13243, P38494, P39645, P39148, O31398, P08821, P08877, O05268, P04957, P28366, P31103, P94421, P14949, P80864, P37869, P80240, P80859, O06993, O34666, O34714, P37546, Q9KWU4, O31605, P16616, P80239, O34788, P71014, P37571, P09124, P42971, 031925, P39793, P17865, P16263, P18429, P05653, P26908, P33166, O34499, P08750, P54602, Q45071, P12047, P42919, O34334, O34358, P39120, P39126, P00691, P14192, P22250, P37870, P39116, P54484, P54488, P54547, P56849, O31579, O34629, P30949, P54422, P54530, P54542, P96739.
As an exemplary dataset, the LC/MS/MS results demonstrated that the following polypeptides were isolated due to their sustained solubility in 100 mM Potassium Carbonate, pH 9.66: O34669, P54423, P21879, P24327, P40767, P17889, O31973, P10475, P28598, P80700, P37871, P80868, O31803, P81101, P70960, P27876, P19405, P28366, P71014, P26901, O34385, P21880, Q06797, P24141, P07343, P80698, P13243, P42971, P39793, O31643, P39071, O32210, P21468, P42199, P54531, P37965, P37809, P21883, P38494, P39148, P08877, P09124, P17865, P16263, P54602, P46906, O34918, Q08352, P42111, O05411, O05497, O07921, P02394, P09339, P49814, P39632, P37437, P39645, P08821, P04957, P31103, Q9KWU4, P80239, O34788, P18429, P05653, P26908, O34499, P08750, P12047, P37870, P54547, Q06796, Q45477, P25144, P46898, P40871, 031501, P21464, P21465, P40409.
As an exemplary dataset, the LC/MS/MS results demonstrated that the following polypeptides were isolated due to their sustained solubility in 100 mM Calcium Chloride, pH 7.50: O34669, P54423, P21879, O34918, O31803, P10475, P28598, P24327, P40767, P80700, P27876, P37871, O34385, P13243, Q08352, O07921, P17889, O31973, P80868, P26901, P24141, P80698, P02394, Q06797, P39148, P19405, P54531, P37965, P09339, P39645, O34788, P37571, 007909, P70960, P21880, P42971, P37809, P80239, Q45477, P94421, P81101, P07343, P39793, P39071, P38494, P17865, P42111, P12425, P39773, O06989, P80864, O05411, O05497, P25144, P0CI78, P39824, P25152, P70961, O31398, O05268, P37869, P80859, O32150, P39138, O31643, P21468, P42199, P21883, P09124, P49814, P05653, Q06796, O34313, P51777, O34310, O06993, O34666, 031925, P33166, P39634, P37808, P39779, P28366, P08877, P16263, P39632, P08821, P04957, O34499, P08750, P46898, P50849, P54716, P80860, P14949, P80240, Q45071, O34334, O34358, P39120, P39126, P20278, P53001, P54375, O06006, O06988, O34667, O34981, P08164, P19669, P30950, P37487, P45694, P81102, P71014, P54602, P46906, P31103, P18429, P26908, P12047, P40871, O07603, O34714, P37546, P42919, P00691, P22250, P39116, P54488, P40924, C0SP93, O31760, O32023, O32106, O32167, O34962, P12048, P25995, P28015, P28599, P34957, P35137, P37253, P37477, P37812, P37940, P46354, P49778, P54169, P54418, P54550, P54941, P80885, P94576, Q04796, Q06004, Q07868, Q9R911.
As an exemplary dataset, the LC/MS/MS results demonstrated that the following polypeptides were isolated due to their sustained solubility in 100 mM Iron Chloride, pH 4.54: P26901, O34669, O34918, P54423, O31803, P96657, O31973, P37871, O07921, O31643, Q06796, P17889, P80698, P80239, O05411, 007909, 031925, P20278, P71014, P21879, P10475, P80700, P27876, Q08352, P81101, P42111, P0CI78, P39824, O32210, P28598, P24327, O34385, Q06797, P19405, P37571, P38494, O31398, P09124, P51777, P08821, P18429, O07593, P80868, P09339, P39645, O34788, O05268, P49814, P08877, P39632, P04957, P14949, P31103, O06746, O07555, P40767, P02394, P54531, P37965, P70960, P37809, P07343, P39773, P33166, P39634, P16263, P46898, P50849, P54716, P80240, Q45071, P53001, P54375, P26908, P42919, P40924, P14192, P54484, P56849, 006748, P12878, P21477, P32081, P46899, P50620, P54464.
These polypeptides identified as having high solubility were analyzed for physicochemical properties based on their primary sequence. The total charge per amino acid was calculated based on primary sequence across the range of pH tested. As described herein, it is expected that the most soluble polypeptides have a high total charge per amino acid, and this was generally demonstrated to be true. This multiplexed screen identified a set of polypeptides from a larger library based on their affinity to bind anion exchange resin, and this result can be predicted based on the primary sequence analysis, as described herein.
Multiplexed Purification: Precipitation & Flocculation.
Conventional biopharmaceutical protein purification methods used to remove cells and cellular debris include centrifugation, microfiltration, and depth filters. Filter aids, such as diatomaceous earth, can be used to enhance performance of these steps, but they are not always effective and sometimes significantly bind the product of interest. Their use may also require the addition of a solid or a homogeneous suspension that can be challenging as part of large-scale biopharmaceutical operations.
Polymeric flocculants can be used to aid in the clarification of mammalian cell culture process streams, but they can have limitations. For example, protamine sulfate preparations typically used as processing aids are limited in application due to concerns about inactivation of the protein of interest or product loss due to precipitation (Scopes, Protein Purification Principles and Practice 3rd edition, Cantor eds. 22-43; 171 (1994)).
High quality reagents, such as that sold for medical use, can be expensive. In certain instances, removal to very low levels be required to ensure there are no adverse effects in patients. For example, chitosan is not a well-defined reagent and there are concerns about its consistent performance in routine use in clarification applications. Multiple charged polymers, such as DEAE dextran, acrylamide-based polymers often used in waste-water treatment (NALCO Water Handbook, Section 2.1: Applications—Impurity Removal, 3rd ed., McGraw-Hill, 2009) and polyethylene amine (PEI) have been considered for use in clarification applications. With respect to the latter two types of polymers, the acrylamide reagents have the potential for contamination with toxic reagents and polyethylene amine, while a highly effective clarification reagent, is often contaminated with varying amounts of ethylenimine monomer, a suspected cancer agent (Scawen et al., Handbook of Enzyme Biotechnology 2nd edition, Wiseman eds.:15-53 (1985)). Moreover, many of these polymers, including PEI, tend to bind almost irreversibly to many chromatography resins, thereby limiting downstream processing options. The regulatory and raw material reuse concerns associated with these polymers have limited their application primarily to academic studies.
Non-polymer based flocculants, such as alum and iron salts, have been utilized in the wastewater treatment industry (NALCO Water Handbook, Section 2.1: Applications-Impurity Removal, 3rd ed., McGraw-Hill, 2009). These substances may appear to be non-useful in processing protein products, because they may bind to the protein product or may catalyze chemical reactions resulting in modifications of the protein that could affect safety or efficacy.
In some cases, an entire library of proteins is tested in a multiplexed screening experimental platform. The 168 nutritive polypeptide library was transfected and expressed in a multiplexed expression system in which a single growth condition was used to produce each polypeptide in a single container. This multiplexed expression system allows any set of polypeptide sequences to be tested in parallel for a wide range of manufacturability parameters, each of which can be used to rank order the set of polypeptides being examined. A set of manufacturability parameters includes expression level, polypeptide solubility, ability of polypeptide to be purified by chromatography, ability to resist thermal denaturation, ability of polypeptide to digest, ability of polypeptide to be purified by resisting harsh treatments.
For E. coli multiplexed purification by precipitation, the set of 168 nutritive polypeptide sequences was HIS8 tagged. The cells were cultured, as described herein, ruptured, and the solution was clarified, as described herein. This production resulted in a solution containing all of the polypeptides from the set which were both expressed and soluble. That set of soluble polypeptides was passed over an IMAC column, and eluted, as described herein. This IMAC purification effectively isolated the solubly expressed nutritive polypeptides as a set by removing the majority of E. coli host cell proteins. The elution fraction was concentrated and buffer exchanged into a low salt solution buffered near neutral pH before testing various purification methods. The methods tested include anion exchange chromatography, cation exchange chromatography, and negative precipitation, in which the impurities precipitate and the polypeptides that remain soluble rank the highest. In this case, impurities have been removed, so the polypeptides are rank ordered amongst themselves. Additionally, the set of proteins was tested for thermal stability, by heating, wherein the polypeptides which remain soluble after heating are more thermal stable than those which precipitate.
The pre-treated group of polypeptides expressed by E. coli was distributed to 32 wells of a 96 well plate (4.7 uL of protein stock per well at a total protein concentration of 43 g/L). Stock solutions were added to each well to create the following conditions: Control (No Additives); 42 mM Citrate/Phosphate, pH 7.1; 42 mM Citrate/Phosphate, pH 6.5; 42 mM Citrate/Phosphate, pH 6.0; 42 mM Citrate/Phosphate, pH 5.6; 42 mM Citrate/Phosphate, pH 5.0; 42 mM Citrate/Phosphate, pH 4.6; 42 mM Citrate/Phosphate, pH 4.3; 42 mM Citrate/Phosphate, pH 3.9; 42 mM Citrate/Phosphate, pH 3.7; 42 mM Citrate/Phosphate, pH 2.8; 75 mM Tris Base; 50 mM Na2CO3; 50 mM Piperazine Base; 100 mM sodium phosphate dibasic; 50 mM ethanolamine; 100 mM sodium phosphate monobasic; 100 mM MES Acid; 100 mM Sodium Acetate, pH 4.1; 100 mM MOPS Acid; 100 mM Tris HCl; 25 mM Acetic Acid; 25 mM Boric Acid; 25 mM Citric Acid; 50 mM PIPES Acid; 50 mM Succinic Acid; 1.2 M sodium sulfite; 1.5 M sodium sulfite; 2.5 M Ammonium Sulfate; 3.5 M Ammonium Sulfate; 200 mM CaCl2; 60% methanol. Water was added such that each well contained a total of 40 uL of solution at 5 g/L. The plates were mixed for 30 minutes at room temperature, then centrifuged at 3,000 RCF for 10 minutes to pellet any precipitated protein. A sample was taken from each well for analysis. The 96 well plate sas then heated at 95° C. for 2 minutes. The plate was again centrifuged at 3,000 RCF for 10 minutes to pellet any precipitated protein, and a sample was taken from each well for analysis. All 64 samples were analyzed by Bradford assay, and select samples were analyzed by chip electrophoresis, followed by LC/MS/MS. All analytical assays are described herein. The measurements of total protein remaining in solution demonstrate that many conditions caused polypeptide precipitation, indicating that a portion of the conditions tested were rigorous harsh conditions.
LC/MS/MS analysis was performed with four select samples, described in the Table E9D. The detection of nutritive polypeptide in the soluble fraction is noted with an X.





TABLE E9D



Nutritive polypeptides detected in the soluble fraction

of select conditions. Detection is noted with an X.








42 mM





citrate/
100 mM
50 mM



phosphate,
sodium
PIPES
2.5M


pH 5.6,
phosphate
acid,
Ammonium

SEQID
heated
monobasic
heated
sulfate



SEQID-00105
X




SEQID-00115
X




SEQID-00302
X
X
X
X

SEQID-00304
X




SEQID-00305
X
X
X
X

SEQID-00316
X
X



SEQID-00323
X
X



SEQID-00338
X
X
X
X

SEQID-00341
X
X
X
X

SEQID-00343
X
X
X
X

SEQID-00345
X
X
X
X

SEQID-00346
X
X
X


SEQID-00352
X
X
X
X

SEQID-00354
X
X
X
X

SEQID-00356
X




SEQID-00357
X

X
X

SEQID-00485

X
X


SEQID-00495
X
X
X


SEQID-00497

X
X


SEQID-00502
X
X
X
X

SEQID-00507


X


SEQID-00509
X




SEQID-00510
X
X
X
X

SEQID-00511
X
X
X


SEQID-00515
X




SEQID-00518
X




SEQID-00521

X
X


SEQID-00522
X
X
X
X

SEQID-00525
X
X
X
X

SEQID-00528

X
X


SEQID-00529
X
X



SEQID-00533

X
X


SEQID-00537
X

X


SEQID-00540
X
X
X


SEQID-00546
X
X



SEQID-00547
X
X
X


SEQID-00553
X
X
X
X

SEQID-00555

X
X


SEQID-00559
X




SEQID-00560
X
X

X

SEQID-00564
X
X
X
X

SEQID-00570
X
X
X


SEQID-00585
X
X
X
X

SEQID-00587
X
X
X


SEQID-00592
X
X
X


SEQID-00598
X
X
X


SEQID-00601
X
X
X


SEQID-00603


X


SEQID-00605

X
X
X

SEQID-00606

X
X


SEQID-00610


X


SEQID-00613
X
X
X


SEQID-00619
X




SEQID-00622

X
X


SEQID-00623
X
X
X
X

SEQID-00631
X
X
X


SEQID-00632
X
X
X
X

SEQID-00633
X
X
X


SEQID-00641
X




SEQID-00647
X
X
X


SEQID-00648


X






















































































LC/MS/MS data identified a number of soluble polypeptides in each condition. The different conditions tested across the screen represent a number of different mechanisms of precipitation, and these different conditions were able to identify different sets of polypeptides based on their different physicochemical properties. Based on the number of polypeptides which remained soluble, of the conditions examined by LC/MS/MS, the harshest condition is the 2.5 M ammonium sulfate condition at room temperature. The polypeptides that were soluble in that condition were generally soluble in all three other conditions tested, with few exceptions. A large number of polypeptides were identified as being soluble after being heated to 95° C. for two minutes. In this experiment, a library of nutritive polypeptides was physically screened for solubility across a wide variety of conditions, and subsets of soluble peptides were identified within each condition.
Example 11
Selection of Amino Acid Sequences of Nutritive Polypeptides from Amino Acid Sequence Libraries Based on Solvation Scores and Aggregation Scores, and Other Sequence-Based Analyses
Solvation Score.
The solvation score is a primary sequence-based metric for assessing the hydrophilicity and potential solubility of a given protein. It is defined as the total free energy of solvation (i.e. the free energy change associated with transfer from gas phase to a dilute solution) for all amino acid side chains, assuming each residue were solvated independently, normalized by the total number of residues in the sequence. The side chain solvation free energies were found computationally by calculating the electrostatic energy difference between a vacuum dielectric of 1 and a water dielectric of 80 (by solving the Poisson-Boltzmann equation) as well as the non-polar, Van der Waals energy using a linear solvent accessible surface area model (D. Sitkoff, K. A. Sharp, B. Honig. “Accurate Calculation of Hydration Free Energies Using Macroscopic Solvent Models”. J. Phys. Chem. 98, 1994). These solvation free energies correlate well with experimental measurements. For amino acids with ionizable sidechains (Arg, Asp, Cys, Glu, His, Lys and Tyr), an average solvation free energy is based on the relative probabilities for each ionization state at the specified pH. The solvation score is effectively a measure of the solvation free energy assuming all polar residues are solvent exposed and non-polar residues are solvent excluded upon folding.
Aggregation Score.
The aggregation score is a primary sequence based metric for assessing the hydrophobicity and likelihood of aggregation of a given protein. Using the Kyte and Doolittle hydrophobity scale (Kyte J, Doolittle R F (May 1982). “A simple method for displaying the hydropathic character of a protein”. J. Mol. Biol. 157 (1): 105-32), which gives hydrophobic residues positive values and hydrophilic residues negative values, the effective hydrophobicity as a function of sequence position is calculated using a moving average of 5 residues centered around each residue. The aggregation score is found by summing all those average hydrophobicity values greater than 0 and normalizing by the total length of the protein. The underlying understanding is that aggregation is the result of two or more hydrophobic patches coming together to exclude water and reduce surface exposure, and the likelihood that a protein will aggregate is a function of how densely packed its hydrophobic (i.e., aggregation prone) residues are.
Charge Content.
The absolute or net charge per amino acid is calculated as a function of pH and independently of the location of the residue within the protein. Given a pH value and the pKa of a titratable residue, the Henderson-Hasselbalch equation is solved to determine the relative concentrations of each titration state (e.g. −1 or 0 for the acidic residue glutamate).




pH
=


pK
a

+


log
10



(


[

A
-

]


[
HA
]


)







The Henderson-Hasselbalch Equation
The average charge for that titratable residue is found by converting these relative concentrations into effective probabilities of being charged and multiplying by the charge and number of instances of that amino acid. The net or absolute charge found from this procedure is then divided by the number of amino acids to get the per amino acid value.
The residue types shown below in Table E11A are used with the corresponding pKa values and relevant titration states: These pKa values come from the pKa table provided in the European Molecular Biology Open Software Suite (Rice, P. Longden, I. and Bleasby, A. EMBOSS: The European Molecular Biology Open Software Suite. Trends in Genetics, 16, 2000).







TABLE E11A



Residue
pKa
Titration States









Glutamate
−4.1
−1, 0

Aspartate
−3.9
−1, 0

Arginine
−12.5
0, +1

Lysine
−10.8
0, +1

Histidine
−6.5
0, +1

Cysteine
−8.5
−1, 0

Tyrosine
−10.1
−1, 0

C-terminus
−3.6
−1, 0

N-terminus
−8.6
0, +1





























Weighted Euclidean Distance.
To identify candidate proteins with a similar amino acid breakdown to a known, clinically efficacious blend, a weighted Euclidean distance based search strategy is used. In principle, this means computing the weighted percent differences for each amino acid relative to the target amino acid distribution, as defined by the following equation:









Distance
=


∑


?





α
i



(


x
i

-

x
i
T


)


2












?



indicates text missing or illegible when filed





where AA is the set of all amino acids in the target distribution, x i is the fraction by weight of amino acid i in the candidate protein sequence, x i T is the fraction by weight of amino acid i in the target amino, acid distribution, and α i is the relative weight associated with amino acid i. The relative weights were applied to ensure that large deviations from the most important amino acid targets were appropriately penalized.
As an example, for treatment of sarcopenia, support of exercise, and stimulation of thermogenesis amino acid blends (given the relative importance of Leucine and the other two branched chain amino acids, Isoleucine and Valine) relative weights of 3:2:2 for Leucine, Valine, and Isoleucine were used. All other amino acids were given a relative weight of 1.
Allergenicity.
The allergenicity score is a primary sequence based metric based on WHO recommendations (fao.org/ag/agn/food/pdf/allergygm.pdf) for assessing how similar a protein is to any known allergen, the primary understanding being that high percent identity between a target and a known allergen is likely indicative of cross reactivity. For a given protein, the likelihood of eliciting an allergic response is assessed via a complimentary pair of sequence homology based tests. The first test determines the protein's percent identity across the entire sequence via a global-local sequence alignment to a database of known allergens using the FASTA algorithm with the BLOSUM50 substitution matrix, a gap open penalty of 10, and a gap extension penalty of 2. It is suggested that proteins with less than 50% global homology across both sequences are unlikely to be allergenic (Goodman R. E. et al. Allergenicity assessment of genetically modified crops—what makes sense? Nat. Biotech. 26, 73-81 (2008).; Aalberse R. C. Structural biology of allergens. J. Allergy Clin. Immunol. 106, 228-238 (2000).). The second test assesses the local allergenicity along the protein sequence by determining the local allergenicity of all possible contiguous 80 amino acid fragments via a global-local sequence alignment of each fragment to a database of known allergens using the FASTA algorithm with the BLOSUM50 substitution matrix, a gap open penalty of 10, and a gap extension penalty of 2. The highest percent identity of any 80 amino acid window with any allergen is taken as the final score for the protein of interest. The WHO guidelines suggest using a 35% identity cutoff. The custom database comprises pooled allergen lists collected by the Food Allergy Research and Resource Program (allergenonline.org/), UNIPROT annotations (uniprot.org/docs/allergen), and the Structural Database of Allergenic Proteins (SDAP, fermi.utmb.edu/SDAP/sdap_lnk.html). This database includes all currently recognized allergens by the International Union of Immunological Socieities (IUIS, allergen.org/) as well as a large number of additional allergens not yet officially named.
Toxicity/Nonallergenicity/Antinutricity.
The toxicity, nonallergenicity, and anti-nutricity of a protein are all assessed similarly, by determining the protein's percent identity to databases of known toxic, nonallergenic, and protease inhibitory proteins, respectively. The toxicity and anti-nutritive qualities are assumed to be a function of the whole protein (i.e., a fragment of a known toxic protein will not be toxic), as their toxic and inhibitory mechanisms of action are often structural in nature (Huntington J, Read R, Carrell R. “Structure of a serpin-protease complex shows inhibition by deformation”. Nature 407 (2000): 923-6; Van den Born H. K. et al. Theoretical analysis of the structure of the peptide fasciculin and its docking to acetylcholinesterase. Protein Sci. 4 (1995): 703-715; and Harel M. Crystal structure of an acetylcholinesterase-fasciculin complex: interaction of a three-fingered toxin from snake venom with its target. Structure. 3 (1995): 1355-1366). Given that protein structure is a function of the entire protein sequence, a global-global alignment is performed of the protein of interest against the two respective databases using the FASTA algorithm with the BLOSUM50 substitution matrix, a gap open penalty of 10, and a gap extension penalty of 2. A cut off of 35% can be used. While it does not provide specific instructions of how to avoid toxic/antinutritive polypeptides, reference Delaney B. et al. Evaluation of protein safety in the context of agricultural biotechnology. Food. Chem. Toxicol. 46 (2008: S71-S97 suggests that one should avoid both known toxic and antinutritive polypeptides when assessing the safety of a possible food protein.
The nonallergenicity of a protein is related to its likelihood of eliciting an allergenic response upon exposure (similar to but opposite ofallergenicity). Specifically, the human immune system is exposed to a multitude of possible allergenic proteins on a regular basis, and has the intrinsic ability to determine self from non-self. The exact nature of this ability is not always clear, and there are many diseases that arise as a result of the failure of the body to differentiate self from non-self (e.g. arthritis). Nonetheless, the understanding is that proteins that look (i.e. share a large degree of sequence homology to) a lot like nonallergenic (i.e., human) proteins are less likely to elicit an immune response. In particular, it has been shown that for some protein families with known allergenic members (tropomyosins, parvalbumins, caseins), those proteins that bear more sequence homology to their human counterparts relative to known allergenic proteins, are not thought to be allergenic (Jenkins J. A. et al. Evolutionary distance from human homologs reflects allergenicity of animcal food proteins. J. Allergy Clin Immunol. 120 (2007): 1399-1405.) For a given protein, the nonallergenicity score is measured by determining the maximum percent identity of the protein to a database of human proteins from a global-local alignment using the FASTA algorithm with the BLOSUM50 substitution matrix, a gap open penalty of 10, and a gap extension penalty of 2. Cutoffs can vary. For example, Jenkins J. A. et al. (Evolutionary distance from human homologs reflects allergenicity of animal food proteins. J. Allergy Clin Immunol. 120 (2007): 1399-1405) claim that proteins with a sequence identity to a human protein above ˜62% are less likely to be allergenic.
Example 12
Expression of Nutritive Polypeptides
The lists below include all the nutritive protein sequences that were expressed in Escherichia coli, Bacillus, Aspergillus niger , and mammalian cells. In E. coli , the proteins were detected in either whole cell lysates or in the soluble fraction of the cell lysate. In Bacillus , expression was detected in either cell lysates or secreted supernatants of Bacillus subtilis or Bacillus megaterium . In Aspergillus niger , proteins were secreted from the fungus and detected in the supernatant. For proteins expressed in mammalian cells, they were expressed in either in Chinese Hamster Ovarian-S strain (CHO-S) or Human Embryonic Kidney 293F strain (HEK293F). Expression was measured by the following metrics: mass spectrometry spectrum counts for protein expression data acquired from LC-MS/MS in pooled library, SDS-PAGE, Chip Electrophoresis, dot blot, Western blot and ELISA for individual protein expression as described above.
The following nutritive polypeptides were detected in either whole cell lysates or in the soluble fraction of the cell lysates of Escherichia coli : SEQID-00001, SEQID-00002, SEQID-00003, SEQID-00004, SEQID-00005, SEQID-00007, SEQID-00008, SEQID-00009, SEQID-00011, SEQID-00012, SEQID-00013, SEQID-00014, SEQID-00015, SEQID-00016, SEQID-00020, SEQID-00021, SEQID-00024, SEQID-00025, SEQID-00027, SEQID-00028, SEQID-00029, SEQID-00030, SEQID-00031, SEQID-00033, SEQID-00043, SEQID-00049, SEQID-00051, SEQID-00052, SEQID-00053, SEQID-00054, SEQID-00055, SEQID-00057, SEQID-00059, SEQID-00060, SEQID-00061, SEQID-00068, SEQID-00070, SEQID-00071, SEQID-00073, SEQID-00074, SEQID-00075, SEQID-00076, SEQID-00077, SEQID-00078, SEQID-00083, SEQID-00084, SEQID-00085, SEQID-00086, SEQID-00087, SEQID-00088, SEQID-00090, SEQID-00091, SEQID-00092, SEQID-00093, SEQID-00098, SEQID-00099, SEQID-00100, SEQID-00101, SEQID-00102, SEQID-00103, SEQID-00104, SEQID-00105, SEQID-00106, SEQID-00107, SEQID-00108, SEQID-00110, SEQID-00112, SEQID-00113, SEQID-00115, SEQID-00116, SEQID-00117, SEQID-00118, SEQID-00123, SEQID-00124, SEQID-00128, SEQID-00130, SEQID-00131, SEQID-00132, SEQID-00134, SEQID-00137, SEQID-00139, SEQID-00140, SEQID-00141, SEQID-00142, SEQID-00143, SEQID-00145, SEQID-00146, SEQID-00148, SEQID-00150, SEQID-00151, SEQID-00152, SEQID-00153, SEQID-00154, SEQID-00155, SEQID-00157, SEQID-00158, SEQID-00159, SEQID-00162, SEQID-00166, SEQID-00169, SEQID-00175, SEQID-00193, SEQID-00194, SEQID-00195, SEQID-00196, SEQID-00197, SEQID-00198, SEQID-00199, SEQID-00200, SEQID-00201, SEQID-00202, SEQID-00203, SEQID-00204, SEQID-00205, SEQID-00211, SEQID-00212, SEQID-00213, SEQID-00214, SEQID-00215, SEQID-00216, SEQID-00218, SEQID-00219, SEQID-00220, SEQID-00221, SEQID-00223, SEQID-00224, SEQID-00225, SEQID-00226, SEQID-00227, SEQID-00228, SEQID-00230, SEQID-00232, SEQID-00233, SEQID-00234, SEQID-00235, SEQID-00236, SEQID-00237, SEQID-00239, SEQID-00240, SEQID-00241, SEQID-00264, SEQID-00265, SEQID-00266, SEQID-00267, SEQID-00268, SEQID-00269, SEQID-00270, SEQID-00271, SEQID-00273, SEQID-00274, SEQID-00275, SEQID-00276, SEQID-00284, SEQID-00287, SEQID-00297, SEQID-00298, SEQID-00299, SEQID-00302, SEQID-00303, SEQID-00304, SEQID-00305, SEQID-00306, SEQID-00307, SEQID-00309, SEQID-00318, SEQID-00322, SEQID-00325, SEQID-00326, SEQID-00327, SEQID-00328, SEQID-00329, SEQID-00332, SEQID-00335, SEQID-00336, SEQID-00337, SEQID-00338, SEQID-00341, SEQID-00343, SEQID-00344, SEQID-00345, SEQID-00346, SEQID-00349, SEQID-00350, SEQID-00352, SEQID-00353, SEQID-00354, SEQID-00355, SEQID-00356, SEQID-00357, SEQID-00358, SEQID-00359, SEQID-00360, SEQID-00362, SEQID-00363, SEQID-00408, SEQID-00409, SEQID-00415, SEQID-00416, SEQID-00418, SEQID-00424, SEQID-00481, SEQID-00482, SEQID-00483, SEQID-00484, SEQID-00485, SEQID-00486, SEQID-00487, SEQID-00488, SEQID-00489, SEQID-00490, SEQID-00491, SEQID-00492, SEQID-00493, SEQID-00494, SEQID-00495, SEQID-00496, SEQID-00497, SEQID-00498, SEQID-00499, SEQID-00500, SEQID-00501, SEQID-00502, SEQID-00503, SEQID-00504, SEQID-00505, SEQID-00506, SEQID-00507, SEQID-00508, SEQID-00509, SEQID-00510, SEQID-00511, SEQID-00512, SEQID-00513, SEQID-00514, SEQID-00515, SEQID-00516, SEQID-00517, SEQID-00518, SEQID-00519, SEQID-00520, SEQID-00521, SEQID-00522, SEQID-00523, SEQID-00524, SEQID-00525, SEQID-00526, SEQID-00527, SEQID-00528, SEQID-00529, SEQID-00530, SEQID-00531, SEQID-00532, SEQID-00533, SEQID-00534, SEQID-00535, SEQID-00536, SEQID-00537, SEQID-00538, SEQID-00539, SEQID-00540, SEQID-00541, SEQID-00542, SEQID-00543, SEQID-00544, SEQID-00545, SEQID-00546, SEQID-00547, SEQID-00548, SEQID-00549, SEQID-00550, SEQID-00551, SEQID-00552, SEQID-00553, SEQID-00554, SEQID-00555, SEQID-00556, SEQID-00557, SEQID-00558, SEQID-00559, SEQID-00560, SEQID-00561, SEQID-00562, SEQID-00563, SEQID-00564, SEQID-00565, SEQID-00566, SEQID-00567, SEQID-00568, SEQID-00569, SEQID-00570, SEQID-00571, SEQID-00572, SEQID-00573, SEQID-00574, SEQID-00575, SEQID-00576, SEQID-00577, SEQID-00578, SEQID-00579, SEQID-00580, SEQID-00581, SEQID-00582, SEQID-00583, SEQID-00584, SEQID-00585, SEQID-00586, SEQID-00587, SEQID-00588, SEQID-00589, SEQID-00590, SEQID-00591, SEQID-00592, SEQID-00593, SEQID-00594, SEQID-00595, SEQID-00596, SEQID-00597, SEQID-00598, SEQID-00599, SEQID-00600, SEQID-00601, SEQID-00602, SEQID-00603, SEQID-00604, SEQID-00605, SEQID-00606, SEQID-00607, SEQID-00608, SEQID-00609, SEQID-00610, SEQID-00611, SEQID-00612, SEQID-00613, SEQID-00614, SEQID-00615, SEQID-00616, SEQID-00617, SEQID-00618, SEQID-00619, SEQID-00620, SEQID-00621, SEQID-00622, SEQID-00623, SEQID-00624, SEQID-00625, SEQID-00626, SEQID-00627, SEQID-00628, SEQID-00629, SEQID-00630, SEQID-00631, SEQID-00632, SEQID-00633, SEQID-00634, SEQID-00635, SEQID-00636, SEQID-00637, SEQID-00638, SEQID-00639, SEQID-00640, SEQID-00641, SEQID-00642, SEQID-00643, SEQID-00644, SEQID-00645, SEQID-00646, SEQID-00647, SEQID-00648, SEQID-00669, SEQID-00670, SEQID-00671, SEQID-00672, SEQID-00673, SEQID-00674, SEQID-00675, SEQID-00676, SEQID-00677, SEQID-00678, SEQID-00679, SEQID-00680, SEQID-00681, SEQID-00682, SEQID-00716, SEQID-00717, SEQID-00718, SEQID-00719, SEQID-00720, SEQID-00723, SEQID-00724, SEQID-00725, SEQID-00726, SEQID-00727, SEQID-00728, SEQID-00729, SEQID-00730, SEQID-00731, SEQID-00732, SEQID-00734, SEQID-00735, SEQID-00736, SEQID-00737, SEQID-00738, SEQID-00739, SEQID-00740, SEQID-00741, SEQID-00742, SEQID-00743, SEQID-00744, SEQID-00745, SEQID-00746, SEQID-00747, SEQID-00748, SEQID-00749, SEQID-00750, SEQID-00751, SEQID-00752, SEQID-00753, SEQID-00754, SEQID-00755, SEQID-00756, SEQID-00757, SEQID-00758, SEQID-00759, SEQID-00760, SEQID-00761, SEQID-00763, SEQID-00765, SEQID-00766, SEQID-00767, SEQID-00768, SEQID-00769, SEQID-00770, SEQID-00771, SEQID-00772, SEQID-00773, SEQID-00774, SEQID-00775, SEQID-00777, SEQID-00778, SEQID-00780, SEQID-00781, SEQID-00782, SEQID-00783, SEQID-00784, SEQID-00785, SEQID-00786, SEQID-00787, SEQID-00788, SEQID-00789, SEQID-00790, SEQID-00791, SEQID-00792, SEQID-00793, SEQID-00794, SEQID-00795, SEQID-00796, SEQID-00797, SEQID-00798, SEQID-00799, SEQID-00801, SEQID-00802, SEQID-00803, SEQID-00804, SEQID-00805, SEQID-00806, SEQID-00807, SEQID-00808, SEQID-00809, SEQID-00810, SEQID-00811, SEQID-00812, SEQID-00813, SEQID-00814, SEQID-00815, SEQID-00816, SEQID-00817, SEQID-00818, SEQID-00819, SEQID-00820, SEQID-00821, SEQID-00822, SEQID-00823, SEQID-00824, SEQID-00825, SEQID-00826, SEQID-00827, SEQID-00828, SEQID-00829, SEQID-00830, SEQID-00831, SEQID-00832, SEQID-00833, SEQID-00834, SEQID-00835, SEQID-00836, SEQID-00837.
The following nutritive polypeptides were detected in either cell lysates or secreted supernatants of Bacillus subtilis or Bacillus megaterium : SEQID-00003, SEQID-00004, SEQID-00005, SEQID-00087, SEQID-00099, SEQID-00102, SEQID-00103, SEQID-00105, SEQID-00115, SEQID-00218, SEQID-00220, SEQID-00223, SEQID-00226, SEQID-00236, SEQID-00240, SEQID-00267, SEQID-0027 I, SEQID-00276, SEQID-00297, SEQID-00298, SEQID-00299, SEQID-00302, SEQID-00303, SEQID-00304, SEQID-00305, SEQID-00306, SEQID-00307, SEQID-00309, SEQID-00318, SEQID-00322, SEQID-00325, SEQID-00326, SEQID-00327, SEQID-00328, SEQID-00329, SEQID-00330, SEQID-00332, SEQID-00335, SEQID-00336, SEQID-00337, SEQID-00338, SEQID-00340, SEQID-00341, SEQID-00343, SEQID-00344, SEQID-00345, SEQID-00346, SEQID-00349, SEQID-00350, SEQID-00352, SEQID-00353, SEQID-00354, SEQID-00355, SEQID-00356, SEQID-00357, SEQID-00358, SEQID-00359, SEQID-00360, SEQID-00361, SEQID-00362, SEQID-00363, SEQID-00374, SEQID-00389, SEQID-00398, SEQID-00403, SEQID-00404, SEQID-00405, SEQID-00407, SEQID-00409, SEQID-00415, SEQID-00416, SEQID-00417, SEQID-00418, SEQID-00419, SEQID-00420, SEQID-00421, SEQID-00424, SEQID-00481, SEQID-00482, SEQID-00483, SEQID-00484, SEQID-00485, SEQID-00486, SEQID-00487, SEQID-00488, SEQID-00489, SEQID-00490, SEQID-00491, SEQID-00492, SEQID-00493, SEQID-00494, SEQID-00495, SEQID-00496, SEQID-00497, SEQID-00498, SEQID-00499, SEQID-00500, SEQID-00501, SEQID-00502, SEQID-00503, SEQID-00504, SEQID-00505, SEQID-00506, SEQID-00507, SEQID-00508, SEQID-00509, SEQID-00510, SEQID-00511, SEQID-00512, SEQID-00513, SEQID-00514, SEQID-00515, SEQID-00516, SEQID-00517, SEQID-00518, SEQID-00519, SEQID-00520, SEQID-00521, SEQID-00522, SEQID-00523, SEQID-00524, SEQID-00525, SEQID-00526, SEQID-00527, SEQID-00528, SEQID-00529, SEQID-00530, SEQID-00531, SEQID-00532, SEQID-00533, SEQID-00534, SEQID-00535, SEQID-00536, SEQID-00537, SEQID-00538, SEQID-00539, SEQID-00540, SEQID-00541, SEQID-00542, SEQID-00543, SEQID-00544, SEQID-00545, SEQID-00546, SEQID-00547, SEQID-00548, SEQID-00549, SEQID-00550, SEQID-00551, SEQID-00552, SEQID-00553, SEQID-00554, SEQID-00555, SEQID-00556, SEQID-00557, SEQID-00558, SEQID-00559, SEQID-00560, SEQID-00561, SEQID-00562, SEQID-00563, SEQID-00564, SEQID-00565, SEQID-00566, SEQID-00567, SEQID-00568, SEQID-00569, SEQID-00570, SEQID-00571, SEQID-00572, SEQID-00573, SEQID-00574, SEQID-00575, SEQID-00576, SEQID-00577, SEQID-00578, SEQID-00579, SEQID-00580, SEQID-00581, SEQID-00582, SEQID-00583, SEQID-00584, SEQID-00585, SEQID-00586, SEQID-005 87, SEQID-00588, SEQID-00589, SEQID-00590, SEQID-00591, SEQID-00592, SEQID-00593, SEQID-00594, SEQID-00595, SEQID-00596, SEQID-00597, SEQID-00598, SEQID-00599, SEQID-00600, SEQID-00601, SEQID-00602, SEQID-00603, SEQID-00604, SEQID-00605, SEQID-00606, SEQID-00607, SEQID-00608, SEQID-00609, SEQID-00610, SEQID-00611, SEQID-00612, SEQID-00613, SEQID-00614, SEQID-00615, SEQID-00616, SEQID-00617, SEQID-00618, SEQID-00619, SEQID-00620, SEQID-00621, SEQID-00622, SEQID-00623, SEQID-00624, SEQID-00625, SEQID-00626, SEQID-00627, SEQID-00628, SEQID-00629, SEQID-00630, SEQID-00631, SEQID-00632, SEQID-00633, SEQID-00634, SEQID-00635, SEQID-00636, SEQID-00637, SEQID-00638, SEQID-00639, SEQID-00640, SEQID-00641, SEQID-00642, SEQID-00643, SEQID-00644, SEQID-00645, SEQID-00646, SEQID-00647, SEQID-00648, SEQID-00653, SEQID-00654, SEQID-00655, SEQID-00656, SEQID-00657, SEQID-00659, SEQID-00660, SEQID-00664, SEQID-00668, SEQID-00670, SEQID-00671, SEQID-00672, SEQID-00673, SEQID-00674, SEQID-00675, SEQID-00676, SEQID-00678, SEQID-00679, SEQID-00680, SEQID-00681, SEQID-00682, SEQID-00690, SEQID-00710, SEQID-00711, SEQID-00712, SEQID-00713, SEQID-00714, SEQID-00715, SEQID-00716, SEQID-00717, SEQID-00718, SEQID-00719, SEQID-00720, SEQID-00723, SEQID-00724, SEQID-00725, SEQID-00726, SEQID-00727, SEQID-00728, SEQID-00729, SEQID-00730, SEQID-00731, SEQID-00734, SEQID-00735, SEQID-00736, SEQID-00737, SEQID-00738, SEQID-00739, SEQID-00740, SEQID-00741, SEQID-00742, SEQID-00743, SEQID-00744, SEQID-00745, SEQID-00746, SEQID-00747, SEQID-00748, SEQID-00749, SEQID-00750, SEQID-00751, SEQID-00752, SEQID-00753, SEQID-00754, SEQID-00755, SEQID-00756, SEQID-00757, SEQID-00758, SEQID-00759, SEQID-00760, SEQID-00761, SEQID-00763, SEQID-00765, SEQID-00766, SEQID-00767, SEQID-00768, SEQID-00769, SEQID-00770, SEQID-00771, SEQID-00772, SEQID-00773, SEQID-00774, SEQID-00775, SEQID-00777, SEQID-00778, SEQID-00780, SEQID-00781, SEQID-00782, SEQID-00783, SEQID-00784, SEQID-00785, SEQID-00786, SEQID-00787, SEQID-00788, SEQID-00789, SEQID-00790, SEQID-00791, SEQID-00792, SEQID-00793, SEQID-00794, SEQID-00795, SEQID-00796, SEQID-00797, SEQID-00798, SEQID-00799, SEQID-00800, SEQID-00801, SEQID-00802, SEQID-00803, SEQID-00804, SEQID-00805, SEQID-00806, SEQID-00807, SEQID-00808, SEQID-00809, SEQID-00810, SEQID-00811, SEQID-00812, SEQID-00813, SEQID-00814, SEQID-00815, SEQID-00816, SEQID-00817, SEQID-00818, SEQID-00819, SEQID-00820, SEQID-00821, SEQID-00822, SEQID-00823, SEQID-00824, SEQID-00825, SEQID-00826, SEQID-00827, SEQID-00828, SEQID-00829, SEQID-00830, SEQID-00831, SEQID-00832, SEQID-00833, SEQID-00834, SEQID-00835, SEQID-00836, SEQID-00837.
The following nutritive polypeptides were detected from the secreted supernatant of Aspergillus niger : SEQID-00087, SEQID-00103, SEQID-00105, SEQID-00112, SEQID-00115, SEQID-00218, SEQID-00298, SEQID-00341, SEQID-00352, SEQID-00354, SEQID-00363, SEQID-00406, SEQID-00409, SEQID-00415, SEQID-00416, SEQID-00417, SEQID-00418, SEQID-00419, SEQID-00420, SEQID-00421, SEQID-00424, SEQID-00552, SEQID-00554.
The following nutritive polypeptides were expressed in the mammalian cell lines Chinese Hamster Ovarian-S strain (CHO-S) or Human Embryonic Kidney 293F strain (HEK293F): SEQID-00001, SEQID-00103, SEQID-00105, SEQID-00298.
Example 13
Expression of Nutritive Polypeptides in E. coli Bacteria
A nutritive polypeptide sequence library was generated from edible species and screened to demonstrate nutritive polypeptide expression in E. coli.
Gene Synthesis & Plasmid Construction.
All genes were made synthetically by either Life Technologies/GeneArt or DNA2.0, and optimized for expression in Escherichia coli . The genes were cloned into pETI 5b (EMD Millipore/Novagen) using the NdeI-BamHI restriction sites within the multiple cloning site (therefore containing an amino-terminal MGSSHHHHHHSSGLVPRGSH tag), or cloned into the NcoI-BamHI sites (therefore removing the amino terminal tag on the plasmid) using primers to include an amino terminal tag containing MGSHHHHHHHH or MGSHHHHHHHHSENLYFQG. pET15b contains a pBR322 origin of replication, a lac-controlled T7 promoter, and a bla gene conferring resistance to carbenicillin. For manually cloned fragments, inserts were verified by Sanger sequencing using both the T7 promoter primer and the T7 terminator primer. For the secreted constructs, the genes were cloned into pJ444 vector (DNA 2.0, USA) upstream of T5 terminator with C-terminal HHHHHHHH tag and DsbA signal peptide (ATGAAAAAGATTTGGCTGGCGCTGGCTGGTTTAGTTTTAGCGTTTAGCGCATCGG CG) in N-terminal.
Strain Construction.
T7 Express Competent E. coli was purchased from New England Biolabs and was used as the parent strain. T7 Express is an enhanced BL21 derivative which contains the T7 RNA polymerase in the lac operon, while still lacking the Lon and OmpT proteases. The genoptype of T7 Express is: fhuA2 lacZ::T7 gene1 [lon]ompT gal sulA11 R(mcr-73::miniTn10—TetS)2 [dcm]R(zgb-210::Tn10—TetS) endA1 Δ(mcrC-mrr)114::IS10. For secreted constructs, CGSC 5610 (Yale E. coli genetic stock center, USA) was used for the study. The genotype of CGSC 5610 is F-, lacY1 or Δ(cod-lacI)6, glnV44(AS), galK2(Oc), galT22, λ-, e14-, mcrA0, rfbC1, metB1, mcrB1, hsdR2. Roughly 1 ng of purified plasmid DNA described above was used to transform chemically competent T7 Express and single colonies were selected on LB agar plates containing 100 mg/l carbenicillin after roughly 16 hr of incubation at 37° C. Single colonies were inoculated into liquid LB containing 100 mg/l carbenicillin and grown to a cell-density of OD600 nm≈0.6, at which point, glycerol was supplemented to the medium at 10% (v/v) and an aliquot was taken for storage in a cryovial at −80° C.
Expression Testing.
Expression cultures were grown in LB medium (10 g/l NaCl, 10 g/l tryptone, and 5 g/l yeast extract) or in BioSilta EnBase medium and induced with isopropyl β-D-1-thiogalactopyranoside (IPTG). For expression testing in LB media, a colony or stab from a glycerol stock was inoculated into 3 ml LB supplemented with 100 mg/l carbenicillin and grown overnight (roughly 16 hr) at 37° C. and 250 rpm. The next morning, the cell-density (spectrophotometrically at OD600 nm) was measured and diluted back to OD600 nm=0.05 into 3 ml LB medium supplemented with carbenicillin and grown at 37° C. and 250 rpm. At OD600 nm≈0.8±0.2 the cultures were induced with 1 mM IPTG. Heterologous expression was allowed to proceed for 2 hr at 37° C. and 250 rpm, at which point the cultures were terminated. The terminal cell-density was measured. For expression with Enbase media, a colony or stab from a glycerol stock was inoculated into 3 ml LB with 100 mg/l carbenicillin and transferred to Enbase media with 100 mg/l carbenicillin and 600 mU/I of glucoamylase at OD600=0.1 and grown overnight at 37° C. and 250 rpm and induced with 1 mM IPTG next day. Heterologous expression was allowed for 24 hours at 37° C. and 250 rpm, at which point the cultures were terminated. The terminal cell-density was measured and the cells were harvested by centrifugation (3000 rpm, 10 min, RT). To determine intracellular production the cells were lyzed with B-PER (Pierce) according to manufacturer's protocol and then assayed to measure protein of interest (POI). To determine the levels of secreted protein, 0.5-ml aliquots of the culture supernatants were filtered by a 0.22 μm filter. The filtrates were then assayed to determine the levels of secreted protein of interest (POI).
Fermentation.
The intracellular soluble proteins SEQID-00105, SEQID-00240, SEQID-00338, SEQID-00341, SEQID-00352, SEQID-00363, SEQID-00423, SEQID-00424, SEQID-00425, SEQID-00426, SEQID-00429, SEQID-00559, and SEQID-00587 were expressed in E. coli host cells NEB T7 Express (New England BioLabs) in 20 and/or 250 L fermentations. The fermentation occurred in a carbon and nitrogen rich media containing: Yeast Extract, Soy Hydrolysate, Glycerol, Glucose, and Lactose. The fermentation occurred at 30° C. and induction occurred when the Glucose present in the media was exhausted and Lactose became the primary carbon source sugar. The fermentation process time generally lasted 24-26 hrs. Fermentation run parameters were controlled at a pH of 6.9, temperature of 30° C., and a percent dissolved oxygen of 35%. The culture was supplemented with a Glycerol based feed in the later stages of the culture duration. Harvest occurred when the cells entered stationary phase and no longer required oxygen supplementation to maintain the 35% set point.
Nutritive Polypeptide Library Gene Synthesis & Plasmid Construction.
Genes encoding for 168 different edible species polypeptide sequences were generated as linear fragments and codon-selected for expression in Escherichia coli . In some cases, a single linear fragment contained two or more nucleic acid sequences encoding two or more distinct polypeptide sequences that had a flanking 5′ NdeI restriction site and 3′ BamHI restriction site. All linear fragments were combined at equal molar concentrations. The linear fragments were digested with NdeI and BamHI and the digested mixture was cloned into pETI 5b (EMD Millipore/Novagen) using primers to include an amino terminal tag containing MGSHHHHHHHH and NdeI-BamHI restriction sites. pET15b contains a pBR322 origin of replication, a lac-controlled T7 promoter, and a bla gene conferring resistance to carbenicillin. For cloned fragments, inserts were verified by Sanger sequencing using both the T7 promoter primer and the T7 terminator primer.
168 nutritive polypeptide library strain construction. T7 Express Competent E. coli (New England Biolabs) was used as the parent strain. T7 Express is an enhanced BL21 derivative which contains the T7 RNA polymerase in the lac operon, while lacking the Lon and OmpT proteases. The genotype of T7 Express is: fhuA2 lacZ::T7 gene1 [lon]ompT gal sulA11 R(mcr-73::miniTn10—TetS)2 [dcm]R(zgb-210::Tn10—TetS) endA1 Δ(mcrC-mrr)114::IS10. For secreted constructs, CGSC 5610 (Yale E. coli genetic stock center, USA) was used. The genotype of CGSC 5610 is F-, lacY1 or Δ(cod-lacI) 6, glnV44(AS), galK2(Oc), galT22, λ-, e14-, mcrA0, rfbC1, metB, mcrB1, hsdR2. Approximately 10 ng of ligated DNA mixture were transformed into chemically competent T7 Express and single colonies were selected on LB agar plates containing 100 mg/l carbenicillin after roughly 16 hr of incubation at 37° C. Multiple transformations were done and approximately 1000 colonies were pooled together and suspended into LB medium. The DNA from 50-100 colonies was sequenced to determine the diversity of the generated library.
168 Nutritive Polypeptide Library Expression Testing.
The colony mixtures resuspended in LB medium were initially grown in 3 ml of LB medium (10 g/l NaCl, 10 g/l tryptone, and 5 g/l yeast extract) with 100 mg/l carbenicillin, then transferred to BioSilta Enbase media with 100 mg/l carbenicillin and 600 mU/l of glucoamylase at OD600=0.1, grown overnight at 37° C. and 250 rpm and induced with 1 mM IPTG next day. Heterologous expression was allowed for 24 hours at 37° C. and 250 rpm, at which point the cultures were terminated. The terminal cell-density was measured and the cells were harvested by centrifugation (3000 rpm, 10 min, RT). To determine intracellular production the cells were lysed using a microfluidizer and the soluble fraction was purified in 5 ml Nickel Affinity column according to manufacturer's protocol and then assayed using LC-MS/MS to identify the proteins that were expressed as described below. 114/168 different proteins were successfully solubly expressed in E. coli based on MS spectral count. Based on this result, certain genes were individually cloned and tested for intracellular soluble expression in E. coli.
Fungal Nutritive Polypeptides Expressed in E. coli Strain Backgrounds.
Four strains were used to express fungal nutritive polypeptides: T7 Express, Shuffle T7, and Shuffle T7 Express from New England Biolabs; and Origami B(DE3) from EMD Millipore.
T7 Express is an enhanced BL21 derivative which contains the T7 RNA polymerase in the lac operon, while lacking the Lon and OmpT proteases. The genotype of T7 Express is: fhuA2 lacZ::T7 gene1 [lon]ompT gal sulA11 R(mcr-73::miniTn10—TetS)2 [dcm]R(zgb-210::Tn10—TetS) endA1 Δ(mcrC-mrr) 14::IS10.
Shuffle T7 is a K12 derivative strain that promotes cytoplasmic disulfide bond formation and expresses a chromosomal copy of T7 RNAP. The genotype of Shuffle T7 is F′ lac, pro, lacIQ/Δ(ara-leu)7697 araD139 fhuA2 lacZ::T7 gene1 Δ(phoA)PvuII phoR ahpC*galE (or U) galK λatt::pNEB3-r1-cDsbC (SpecR, lacIq) ΔtrxB rpsL150(StrR) Δgor Δ(malF)3.
Shuffle T7 Express is a BL21 derivative strain that promotes cytoplasmic disulfide bond formation and expresses a chromosomal copy of T7 RNAP. The genotype of Shuffle T7 Express is fhuA2 lacZ::T7 gene1 [Ion]ompT ahpC gal att::pNEB3-r1-cDsbC (SpecR, lacIq) ΔtrxB sulA11 R(mcr-73::miniTn10—TetS)2 [dcm]R(zgb-210::Tn10—TetS) endA1 Δgor. Δ(mcrC-mrr) 114::IS 10.
Origami B(DE3) is a BL21 derivative that contains mutations in trxB and gor that promote disulfide bond formation in the cytoplasm. The genotype of Origami B(DE3) is F-ompT hsdSB(rB- mB-) gal dcm lacY1 ahpC (DE3) gor522::Tn10 trxB (KanR, TetR)
Expression screening of these strains was completed as described for E. coli.
Example 14
Expression of Nutritive Polypeptides in B. subtilis Bacteria
Gene Synthesis & Plasmid Construction.
All of the genes encoding proteins of interest (POI) were cloned by PCR. The templates for PCR amplification of these genes were either synthetic genes, generated for expression in E. coli (see above), or genomic DNA from a source organism (e.g. B. subtilis ). Synthetic genes were codon optimized for expression in E. coli . All of the genes were cloned with a sequence encoding a 1× FLAG tag (a.a.=DYKDDDK) fused, in frame, to their 3′-terminus immediately preceding the stop codon. For expression in B. subtilis , genes were cloned in the MoBiTec (Göttingen, Germany) expression vector, pHT43, using the Gibson Assembly Master Mix (New England Biolabs, Beverly, Mass.) and the cloning host E. coli Turbo (New England Biolabs) according to manufacturer's instructions. The genes were cloned into pHT43 either as secretion expression constructs (gene fused in-frame with DNA encoding the α-amylase signal peptide (SamyQ) from Bacillus amyloliquefaciens ) or as an intracellular expression constructs (gene inserted immediately downstream of the ribosomal binding site (RBS), removing the SamyQ sequence). Following transformation into E. coli , cells containing recombinant plasmids were selected on LB agar plates containing 100 μg/ml carbenicillin (Cb100). Recombinant plasmids were isolated from E. coli and their DNA sequences were verified by Sanger sequencing prior to transformation into the B. subtilis expression host.
Strain Construction.
B. subtilis strain WB800N was purchased from MoBiTec (Göttingen, Germany) and used as the expression host. WB800N is a derivative of a well-studied strain ( B. subtilis 168) and it has been engineered to reduce proteolytic degradation of secreted proteins by deletion of genes encoding 8 extracellular proteases (nprE, aprE, epr, bpr, mpr, nprB, vpr and wprA). B. subtilis transformations were performed according to the manufacturer's instructions. Approximately 1 μg of each expression construct was transformed into WB800N and single colonies were selected at 37° C. by plating on LB agar containing 5.0 μg/ml chloramphenicol (Cm5). Individual transformants were grown in LB broth containing Cm5 until they reached log phase. Aliquots of these cultures were mixed with glycerol (20% final concentration) and frozen at −80° C.
Expression Testing.
Frozen glycerol stocks of B. subtilis expression strains were used to inoculate 1-ml of 2×-MAL medium (20 g/l NaCl, 20 g/l tryptone, and 10 g/l yeast extract, 75 g/l maltose) with Cm5, in deep well blocks (96-square wells). Culture blocks were covered with porous adhesive plate seals and incubated overnight in a micro-expression chamber (Glas-Col, Terre Haute, Ind.) at 37° C. and 880 rpm. Overnight cultures were used to inoculate fresh, 2×-MAL, Cm5 cultures, in deep well blocks, to a starting OD600=0.1. These expression cultures were incubated at 37° C., 880 rpm until the OD600=1.0 (approx. 4 hrs) at which time they were induced by adding isopropyl β-D-1-thiogalactopyranoside (IPTG) at a final concentration of 0.1 M and continuing incubation for 4 hrs. After 4 hrs, the cell densities of each culture was measured (OD600) and cells were harvested by centrifugation (3000 rpm, 10 min, RT). After centrifugation, culture supernatant was carefully removed and transferred to a new block and cell pellets were frozen at −80° C. To determine the levels of secreted protein, 0.5-ml aliquots of the culture supernatants were filtered first through a 0.45-μm filter followed by a 0.22 μm filter. The filtrates were then assayed to determine the levels of secreted protein of interest (POI).
To determine levels of intracellularly produced POI, frozen cell pellets were thawed and 0.5 g of 0.1 mm zirconium beads were added to each sample followed by 0.5 ml of PBS. The cells were lysed in the cold room (4° C.) by bead-beating for 5 min in a Qiagen TissuelyserII (Qiagen, Hilden, Germany) equipped with a 96-well plate adapter. Cell lysates were centrifuged at 3000 rpm for 10 min and the supernatant was removed and analyzed for POI concentration as described below. To determine the levels of secreted protein, 0.5-ml aliquots of the culture supernatants were filtered by a 0.22 μm filter. The filtrates were then assayed to determine the levels of secreted protein of interest (POI).
Shake Flask Expression.
A single colony was picked from an agar plate for each SEQID and inoculated into 5 mL of 2×Mal media. These shake flasks inocula were grown in a 30° C. shaker incubator overnight. 5 mLs of this overnight culture was used to inoculate 250 mL 2×Mal. Cultures were grown for 4 hours at 30° C. then induced for 4 hours at 30° C. Cultures were harvested by centrifugation. Centrifuged supernatants for each SEQID were sterile filtered and frozen at −80° C.
Fermentation Expression.
Soluble protein for SEQID-00105 has been secreted from engineered Bacillus subtilis strains containing episomal or integrated plasmids. The fermentation occurred at a volume of 4 L in a carbon and nitrogen rich media containing Phytone Peptone, Yeast Extract, and Glucose. Fermentation cultures were grown at 30° C., at a pH of 7.0 and a percent dissolved oxygen of 40%. Induction, via the addition of IPTG, occurred at an OD600 nm of 5.0 (+/−1.0). The cultures were supplemented with a Glucose based feed post induction. The cultures were harvested 5-8 hours post induction. The biomass was then removed via centrifugation and the supernatant was clarified via filtration and stored at 4° C. until processing.
168 Nutritive Polypeptide Library Gene Synthesis & Plasmid Construction.
For expression in B. subtilis , the vector that was used was derived from pHT43 backbone vector (MoBiTec Göttingen, Germany) with no signal peptide and grac promoter substituted with aprE promoter and lacI expression cassette removed. 168 genes encoding for 168 different protein sequences that were identified above were made synthetically by Life Technologies/GeneArt as linear fragments (GeneStrings) and selected for expression in Escherichia coli . In most cases two genes were synthesized together in a single linear fragment that had a flanking 5′ NdeI restriction site and 3′ BamHI restriction site. All the linear fragments were mixed together at equal molar concentrations. Then the linear fragments mixture was digested with NdeI and BamHI. The digested mixtures were cloned into the vector either as secretion expression constructs (gene fused in-frame with DNA encoding the lipase signal peptide (LipAsp) from Bacillus subtilis ) or as an intracellular expression constructs (gene inserted immediately downstream of the ribosomal binding site (RBS), with and without N-terminal tag containing MGSHHHHHHH). The library of genes was ligated to the vector PCR product using T4 DNA ligase (New England Biolabs, Beverly, Mass.). The ligation products were transformed into the cloning host, E. coli Turbo (New England Biolabs) according to manufacturer's instructions. 50-100 colonies were sequenced to determine the diversity of the leader peptide library. The colonies on the agar plate were then suspended in LB media and harvested for plasmid purification.
168 Nutritive Polypeptide Library Strain Construction.
WB800N is a derivative of a well-studied strain ( B. subtilis 168) and it has been engineered to reduce proteolytic degradation of secreted proteins by deletion of genes encoding 8 extracellular proteases (nprE, aprE, epr, bpr, mpr, nprB, vpr and wprA). B. subtilis strain WB800N was purchased from MoBiTec (Göttingen, Germany) and was modified to have the following mutations WB800N: pXylA-comK::Erm, degU32(Hy), ΔsigF. This new strain was used as the expression host. Roughly 1 μg of the plasmid mixture purified from E. coli cells was transformed into the expression strain. After transformation, 100 μL of the culture were plated onto four LB. 1.5% agar plates containing 5 mg/L chloramphenicol and incubated at 37° C. for 16 hrs. After incubation, 2 mL of LB media with 5 mg/L chloramphenicol were added to the surface of each plate containing several thousand transformants, and the cells were suspended in the surface medium by scraping with a cell spreader and mixing. Suspended cells from the four replicates were pooled together to form the preinoculum culture for the expression experiment.
168 Nutritive Polypeptide Expression Testing.
The OD600 of the preinoculum culture made from resuspended cells was measured using a plate reader to be roughly 20-25. A 500 mL baffled shake flask containing 50 mL of 2×Mal medium (20 g/L NaCl, 20 g/L. Tryptone, 10 g/L yeast extract, 75 g/L D-Maltose) with 5 mg/L chloramphenicol was inoculated to OD600≈0.2 to form the inoculum culture, and incubated at 30° C. shaking at 250 rpm for roughly 6 hours. OD600 was measured and the inoculum culture was used to inoculate the expression culture in a 2 L baffled shake flask containing 250 ml 2×Mal medium with 5 mg/L chloramphenicol, 1× Teknova Trace Metals, and 0.01% Antifoam 204 to an OD600 of 0.1. The culture was shaken for 30° C. and 250 rpm for 18 hours, at which point the culture was harvested. For the secreted protein library constructs, the terminal cell density was measured and the supernatant was harvested by centrifugation (5000×g, 30 min, RT) and filtered using 0.22 um filter. For the intracellular protein library constructs, the terminal cell density was measured and the cells were harvested by centrifugation (5000×g, 30 min, RT). Cells were then lysed using microfluidizer and the soluble fraction was purified using nickel affinity column if the construct library had N-terminal His tag. Otherwise the soluble fraction was used for further analysis. All the samples were run on SDS-PAGE gels, separated into ten fractions, and then analyzed using LC-MS/MS as described below. 40/168 proteins were successfully secreted, 10/168 proteins were successfully produced intracellularly without His tag and 28/168 proteins were successfully produced intracellularly with 5′ 8×His tag in Bacillus subtilis . Based on the results, certain genes were individually cloned and tested for individual secretion in Bacillus subtilis.
Secreted Nutritive Polypeptide Plasmid Construction.
For this study, the pHT43 backbone vector with no signal peptide was modified by removing the SamyQ signal peptide to allow for the native signal peptide to guide secretion, substituting the grac promoter with the aprE promoter, removing the lacI region, and adding a IxFLAG tag (DYKDDDDK) before the terminator region. The unmodified pHT43 vector from MoBiTec contains the Pgrac promoter, the SamyQ signal peptide, Amp and Cm resistance genes, a lacI region, a repA region, and the ColE1 origin of replication. To amplify the genes of interest, genomic DNA preps were made from wild-type Bacillus strains. Secreted nutritive polypeptide genes including their native signal peptide coding regions were PCR amplified using PCR primers with tails containing 25 bp homology regions to the pHT43 backbone and were run on a 1% Agarose TAE gel to check for correct insert size. 10 μL from each PCR were pooled together into a single library of inserts, and the mix was Gibson ligated to a pHT43 backbone vector. The ligation was transformed into 10-Beta electrocompetent cells (New England Biolabs), and transformed cells were plated at a 10-1 dilution onto four LB agar plates with 100 mg/L carbenicillin. One plate was sequenced using a forward primer that binds in the promoter region and a reverse primer that binds in the terminator region. 2 mL of LB medium with 100 mg/L carbenicillin was added to the remaining three plates. Cells were scraped and suspended into the LB medium, and the plasmids were extracted from the cell suspensions to form the multiplex plasmid mix to be transformed into the expression strain. The secreted polypeptide library strain construction and expression were done similar to 168 nutritive polypeptide library strain construction and expression testing.
Secretion Leader Peptide Library Construction.
Secretion signal peptide libraries facilitate the secretion of any given protein of interest. One approach to enhancing secretion is to fuse a library of signal peptide sequences to the protein of interest and screen for those that result in the highest level of secretion. The signal peptide library described here consists of 173 signal peptides that were identified as being associated to naturally Sec mediated secreted proteins in Bacillus subtilis (Brockmeier et al Molecular Biology, 2006). A signal peptide library was generated for SEQID-43136, starting with plasmid pES1207 which has SEQID-43136 fused to the signal peptide from the B. amyloliquefaciens α-amylase (SamyQ). pES1207 was used as template for a PCR reaction with primers, Pfwd and Prev, which amplified the entire plasmid except for the SamyQ sequence. Pfwd and Prev possessed tails that had AarI restriction sites and the PCR products were purified and cut with Aar I. The fragment was then dephosphorylated using Antarctic phosphatase (New England Biolabs, Beverly, Mass.). DNA encoding the individual signal peptides was constructed by duplexing single stranded oligonucleotides comprising the forward- and reverse-strands of each signal peptide sequence. The oligonucleotides were designed such that single strand tails were formed at the 5′-ends of the duplexed molecule. These were complementary of the overhangs generated by the AarI digestion of the vector PCR fragment. To duplex the oligonucleotides, the direct strand and the reverse strand oligonucleotides were mixed together, phosphorylated using T4 polynucleotide kinase (New England Biolabs, Beverly, Mass.) and annealed. Post annealing, signal peptide DNA sequences were mixed in equal proportion in a single tube. The library of signal peptides was ligated to the vector PCR product using T4 DNA ligase (New England Biolabs, Beverly, Mass.). The ligation products were transformed into the cloning host, E. coli Turbo (New England Biolabs) according to manufacturer's instructions. 50-100 colonies were sequenced to determine the diversity of the leader peptide library for SEQID-00298 and SEQID-00338. The colonies on the agar plate were then suspended in LB media and harvested for plasmid purification.
Secretion Leader Peptide Library Strain Construction.
B. subtilis strain WB800N (MoBiTec, Göttingen, Germany) was used as the expression host. Approximately 10 μg of signal peptide library of a particular protein construct was transformed into WB800N and single colonies were selected at 37° C. by plating on LB agar containing 5.0 μg/ml chloramphenicol (Cm5). The leader peptide library screening for SEQID-00105, SEQID-00352, SEQID-00341, SEQID-00103 were carried out in B. subtilis WB800N that has been modified to have mutations in the sigF sporulation factor and also the intracellular serine protease (ispA) was disrupted with an antibiotic marker. The strain also had an inducible comK (the competence initiation transcription factor) integrated into chromosome for higher transformation efficiency.
Secretion Leader Peptide Library Expression Screening.
400-500 individual transformants of the B. subtilis signal peptide library were used to inoculate individual, 1-ml cultures of 2×-MAL medium (20 g/l NaCl, 20 g/l tryptone, and 10 g/l yeast extract, 75 g/l maltose) with Cm5, in deep well blocks (96-square wells). In addition to the signal peptide library strains, a strain containing plasmid with the protein of interest and the SamyQ leader peptide was inoculated as a control. Culture blocks were covered with porous adhesive plate seals and incubated overnight in a micro-expression chamber (Glas-Col, Terre Haute, Ind.) at 37° C. and 800 rpm. Overnight cultures were used to inoculate fresh, 2×-MAL, Cm5 cultures, in deep well blocks, to a starting OD600=0.15.
Expression cultures were incubated at 37° C., 880 rpm until the OD600=1.0 (approx. 4 hrs) at which time they were induced by adding isopropyl 13-D-1-thiogalactopyranoside (IPTG) at a final concentration of 1 mM and continuing incubation for 4 hrs. After 4 hrs, the cell densities of each culture was measured (OD600) and cells were harvested by centrifugation (3000 rpm, 10 min, RT). After centrifugation, the culture supernatant was carefully removed and transferred to a new block and cell pellets were frozen at −80° C. To determine the levels of secreted protein, 0.5-ml aliquots of the culture supernatants were filtered first through a 0.45-μm filter followed by a 0.22 μm filter. The filtrates were then assayed by Chip electrophoresis, as described herein, to determine the levels of secreted protein of interest (POI) and compared with the level of secretion of base construct.
Diluted overnight cultures were used as inoculum for LB broth cultures containing Cm5. These cultures were grown at 37 C until they reached log phase. Aliquots of these cultures were mixed with glycerol (20% final concentration) and frozen at −80° C. The top 10-15 hits were then purified using Instagene matrix (Biorad, USA) and amplified around the signal peptide and sent for sequencing to identify the signal peptide sequence.





TABLE E14A



Exemplary results of B. subtilis

leader peptide library screening.















SEQID-
SEQID-
SEQID-
SEQID-
SEQID-
SEQID-
Other


Gene

298
00338
00105
00352
00341
00103
SEQ IDs

SEQID
Name
Protein Sequence
mg/l/OD
mg/l/OD
mg/l/OD
mg/l/OD
mg/l/OD
mg/l/OD
mg/l/OD



3921
abnA
MKKKKTWKRFLHFSSA
4.4
9.5
135.7
~
148.14
12.1
3.1



ALAAGLIFTSAAPAEA






SEQID-










00405



3922
bglC
MKRSISIFITCLLITL
7.8
~
73.6
2.7
33.9
12.1
~



LTMGGMIASPASA










3923
bpr
MRKKTKNRLISSVLST
~
~
~
~
40.4
~
~



VVISSLLFPGAAGA










3924
glpQ
MRKNRILALFVLSLGL
~
5.7
~
~
41.9
~
5.5



LSFMVTPVSA






SEQID-










00398



3925
lipA
MKFVKRRIIALVTILM
14.1
~
~
10.9
~
16.1
~



LSVTSLFALQPSAKAA










3926
lytB
MKSCKQLIVCSLAAIL
~
3.4
~
~
~
~
~



LLIPSVSFA










3927
lytF
MKKKLAAGLTASAIVG
~
~
~
~
~
14.8
~



TTLVVTPAEA










3928
mpr
MKLVPRFRKQWFAYLT
10.8
~
~
~
~
~
~



VLCLALAAAVSFGVPA










KA










3929
nprB
MRNLTKTSLLLAGLCT
~
~
~
~
37.5
~
~



AAQMVFVTHASA










3930
pelB
MKRLCLWFTVFSLFLV
~
~
~
~
64.4
~
~



LLPGKALG










3931
penP
MKLKTICASIKFGICV
~
~
~
2.8
~
~
~



GLLCLSITGFTPFFNS










THAEA










3932
phoB
MKKFPKKLLPIAVLSS
7.9
~
~
~
~
~
~



IAFSSLASGSVPEASA










3933
wapA
MKKRKRRNFKRFIAAF
~
7
~
2.14
~
~
~



LVLALMISLVPADVLA










3934
xynA
MFKFKKNFLVGLSAAL
4.3
9.8
114.4
~
83.3
13.4
~



MSISLFSATASA










3935
ybfO
MKRMIVRMTLPLLIVC
~
~
~
0.69
~
~
~



LAFSSFSASARA










3936
yckD
MKRITINIITMFIAAA
~
~
~
~
61.7
~
~



VISLTGTAEA










3937
yddT
MRKKRVITCVMAASLT
~
~
135.6
~
~
~
~



LGSLLPAGYASA










3938
yfhK
MKKKQVMLALTAAAGL
~
~
~
~
~
20.8
~



GLTALHSAPAAKA










3939
yfjS
MKWMCSICCAAVLLAG
~
~
~
~
~
9.4
~



GAAQA










3940
yjcM
MKKELLASLVLCLSLS
~
~
83.4
~
80.2
~
~



PLVSTNEVFA










3941
yjdB
MNFKKTVVSALSISAL
~
~
152.7
~
~
14.3
~



ALSVSGVASA










3942
yjfA
MKRLFMKASLVLFAVV
~
~
~
~
~
20
~



FVFAVKGAPAKA










3943
ykoJ
MLKKKWMVGLLAGCLA
~
~
~
2.23
132.5
~
~



AGGFSYNAFA










3944
ylqB
MKKIGLLFMLCLAALF
~
~
~
~
~
13.3
~



TIGFPAQQADA










3945
yndA
MRFTKVVGFLSVLGLA
~
~
124.3
~
~
~
~



AVFPLTAQA










3946
yqgA
MKQGKFSVFLILLLML
3.9
~
~
~
~
~
~



TLVVAPKGKAEA










3947
yraJ
MTLTKLKMLSMLTVMI
~
6.3
~
~
~
~
~



ASLFIFSSQALA










3948
yuaB
MKRKLLSSLAISALSL
~
~
~
~
~
~
2.5



GLLVSAPTASFAAE






SEQID-










00404



3949
yurI
MTKKAWFLPLVCVLLI
~
~
~
2.26
~
~
~



SGWLAPAASASA










3950
yvcE
MRKSLITLGLASVIGT
~
~
124.4
~
~
14.6
~



SSFLIPFTSKTASA










3951
yvgO
MKRIRIPMTLALGAAL
~
~
~
~
~
17.7
~



TIAPLSFASA










3952
yvnB
MRKYTVIASILLSFLS
~
~
~
~
~
26.2
~



VLSGG










3953
ywaD
MKKLLTVMTMAVLTAG
~
~
~
~
~
~
3.4



TLLLPAQSVTPAAHA






SEQID-










403



3954
ywsB
MNKPTKLFSTLALAAG
~
~
131
~
~
~
~



MTAAAAGGAGTIHA










3955
yxaK
MVKSFRMKALIAGAAV
~
~
~
3.7
~
~
~



AAAVSAGAVSDVPAAK










VLQPTAAYA










3956
yxiT
MKWNNMLKAAGIAVLL
~
7.9
~
0.95
41.5
~
~



FSVFAYAAPSLKAVQA









































































































































Example 15
Expression of Nutritive Polypeptides in Aspergillus niger Fungi
Gene Synthesis & Plasmid Construction.
Genes encoding natively secreted proteins were PCR amplified from the Aspergillus niger ATCC 64974 using primers designed from the genome sequence of Aspergillus niger CBS 513.88. In one example, genes included native 5′ secretion sequences and were cloned into the expression vector pAN56-1 (Genbank: Z32700.1) directly under the control of the gpdA promoter from Aspergillus nidulans with the addition of a C-terminal 3× FLAG tag (DYKDHDGDYKDHDIDYKDDDDK). In another example genes included only the mature peptide with the addition of a heterologous 5′ secretion signal. Plasmids were constructed using the Gibson Assembly Kit (New England Biolabs, Beverly, Mass.). Recombinant plasmids were sequence verified before transformation into Aspergillus hosts.
pFGLAHIL6T was obtained from the BCCM/LMBP (Ghent, Netherlands). Plasmids were constructed using the Gibson Assembly Kit (New England Biolabs, Beverly, Mass.). Recombinant plasmids were sequence verified before transformation into Aspergillus hosts.
The pyrA nutritional marker was PCR amplified from Aspergillus niger ATCC 64974 using primers designed from genome sequence of Aspergillus niger ATCC 1015. The pyrA PCR fragment was digested with XbaI and ligated into an XbaI fragment of pCSN44 (Staben et al., 1989) to construct pES1947. pCSN44 was obtained from the BCCM/LMBP (Ghent, Netherlands). The recombinant plasmid was sequence verified before transformation into Aspergillus hosts.
Strain Construction.
A protease deficient derivate of Aspergillus niger ATCC 62590 was used as the expression host. Expression vectors were co-transformed with pES1947 using the protoplast method as described in Punt et al., 1992, Methods in Enzymology, 216, 447-457. Approximately 5 ug of each plasmid was transformed into Aspergillus niger protoplasts. Transformants were selected on minimal media supplemented with 1.2 M sorbitol and 1.5% bacto agar (10 g/l glucose, 4 g/l sodium nitrate, 20 ml/I salts solution (containing 26.2 g/l potassium chloride and 74.8 g/l Potassium phosphate monobasic at pH 5.5); 1 ml/1 vitamin solution (containing 100 mg/l Pyridoxine hydrochloride, 150 mg/l Thiamine hydrochloride, 750 mg/l 4-Aminobenzoic acid, 2.5 g/l Nicotinic acid, 2.5 g/l riboflavin, 20 g/l choline chloride, and 30 mg/l biotin), and 1 ml/l of metals solution (containing 20 g/l Zinc sulfate heptahydrate (ZnSO4-7H2O), 11 g/l Boric acid (H3BO3), 5 g/l Manganese (II) chloride tetrahydrate (MnCl2-4H2O), 5 g/l Iron (11) sulfate heptahydrate (FeSO4-7H2O), 1.7 g/l Cobalt (II) chloride hexahydrate (CoCl2-6H2O), 1.6 g/l Copper(II) sulfate pentahydrate (CuSO4-5H2O), 1.5 g/l Sodium molybdate dihydrate (NaMoO4-2H2O), and 5.0 g/l EDTA disodium salt dihydrate (Na2EDTA-2H2O) at pH 6.5). Individual transformants were isolated on minimal media plates and allowed to grow at 30 C until they sporulated. Spores were harvested in water and stored at 4 C.
Expression Testing.
Spore stocks of Aspergillus niger strains were inoculated at 10 6 spores/mL into 2 mL of CM (MM plus 5.0 g/l yeast extract, 2.0 g/l casamino acids) adjusted to pH 7 with 40 mM MES and SigmaFast Protease Inhibitor Cocktail (1 tab/100 mL, Sigma Aldrich) in 24 well square bottom deep well blocks. Culture blocks were covered with porous adhesive plate seals and incubated for 48 hrs in a micro-expression chamber (Glas-Col, Terre Haute, Ind.) at 30° C. at 600 rpm. After the growth period, 0.5-ml aliquots of the culture supernatants were filtered first through a 25 μm/0.45-μm dual stage filter followed by a 0.22 μm filter. The filtrates were then assayed to determine the levels of secreted protein of interest (POI).





TABLE E15A



Exemplary results of Aspergillus

leader peptide library screening.







signal peptide




name (gene




name_species



SEQID
name)
signal sequence
Genotype



3957
native signal
MRWLLTSSALLVPAAA
PgpdA-native signal peptide-SEQID-


peptide

00409-3XFlag



3958
AXHA_ASPNG
MKFLKAKGSLLSSGIYLIALAPFVNA
PgpdA-AXHA_ASPNG-SEQID-00409-3XFlag



3959
PPIB_ASPNG
MNFKNIFLSFFFVLAVGLALVHA
PgpdA-PPIB_ASPNG-SEQID-00409-3XFlag



3960
FAEA_ASPNG
MKQFSAKYALILLATAGQALA
PgpdA-FAEA_ASPNG-SEQID-00409-3XFlag



3961
BGAL_ASPNG
MKLSSACAIALLAAQAAGA
PgpdA-BGAL_ASPNG-SEQID-00409-3XFlag



3962
PLYA_ASPNG
MKYSTIFSAAAAVFAGSAAA
PgpdA-PLYA_ASPNG-SEQID-00409-3XFlag



3963
PRTA_ASPNG
MKFSTILTGSLFATAALA
PgpdA-PRTA_ASPNG-SEQID-00409-3XFlag



3964
AGALC_ASPNG
MIGSSHAVVALGLFTLYGHSAA
PgpdA-AGALC_ASPNG-SEQID-00409-3XFlag



3965
PHYB_ASPNG
MPRTSLLTLACALATGASA
PgpdA-PHYB_ASPNG-SEQID-00409-3XFlag



3966
AORSN_ASPOR
MRPLSHLSFFNGLLLGLSALSA
PgpdA-AORSN_ASPOR-SEQID-00409-3XFlag



3967
DPPS_ASPOR
MGALRWLSIAATASTALA
PgpdA-DPPS_ASPOR-SEQID-00409-3XFlag



3968
PHYA_ASPNG
MGVSAVLLPLYLLSGVTSGLAVP
PgpdA-PHYA_ASPNG-SEQID-00409-3XFlag



3969
EXG_ASPOR
MLPLLLCIVPYCWS
PgpdA-EXG_ASPOR-SEQID-00409-3XFlag



3970
native signal
MHFLQNAVVAATMGAALA
PgpdA-native signal peptide-SEQID-


peptide

00420-3XFlag



3971
PPA1_ASPNG
MKGTAASALLIALSATAAQA
PgpdA-PPA1_ASPNG-SEQID-00420-3XFlag



3972
PEPC_ASPNG
MKGILGLSLLPLLTAA
PgpdA-PEPC_ASPNG-SEQID-00420-3XFlag



3973
PRTA_ASPNG
MKFSTILTGSLFATAALA
PgpdA-PRTA_ASPNG-SEQID-00420-3XFlag



3974
AGALC_ASPNG
MIGSSHAVVALGLFTLYGHSAA
PgpdA-AGALC_ASPNG-SEQID-00420-3XFlag



3975
RNT1_ASPOR
MMYSKLLTLTTLLLPTALALPSLVER
PgpdA-RNT1_ASPOR-SEQID-00420-3XFlag



3976
PGLR1_ASPNG
MHSYQLLGLAAVGSLVSA
PgpdA-PGLR1_ASPNG-SEQID-00420-3XFlag



3977
ORYZ_ASPOR
MQSIKRTLLLLGAILPAVLGA
PgpdA-ORYZ_ASPOR-SEQID-00420-3XFlag



3978
PLYB_ASPNG
MHYKLLFAAAAASLASAVSA
PgpdA-PLYB_ASPNG-SEQID-00420-3XFlag



3979
NUS1_ASPOR
MPRLLPISAATLALAQLTYG
PgpdA-NUS1_ASPOR-SEQID-00420-3XFlag



3980
PHYB_ASPNG
MPRTSLLTLACALATGASA
PgpdA-PHYB_ASPNG-SEQID-00420-3XFlag



3981
TAN_ASPOR
MRQHSRMAVAALAAGANA
PgpdA-TAN_ASPOR-SEQID-00420-3XFlag



3982
PDI_ASPNG
MRSFAPWLVSLLGASAWAA
PgpdA-PDI_ASPNG-SEQID-00420-3XFlag





3983
XYN2_ASPNG
MLTKNLLLCFAAAKAALA
PgpdA-XYN2_ASPNG-SEQID-00420-3XFlag



3984
PHYA_ASPOR
MAVLSVLLPITFLLSSVTG
PgpdA-PHYA_ASPOR-SEQID-00420-3XFlag



3985
DPP5_ASPOR
MGALRWLSIAATASTALA
PgpdA-DPPS_ASPOR-SEQID-00420-3XFlag



3986
PHYA_ASPNG
MGVSAVLLPLYLLSGVTSGLAVP
PgpdA-PHYA_ASPNG-SEQID-00420-3XFlag



3987
PEPA_ASPNG
MVVFSKTAALVLGLSTAVSA
PgpdA-PEPA_ASPNG-SEQID-00420-3XFlag



3988
AGLU_ASPNG
MVKLTHLLARAWLVPLAYGASQSLL
PgpdA-AGLU_ASPNG-SEQID-00420-3XFlag



3989
ABFA_ASPNG
MVAFSALSGVSAVSLLLSLVQNAHG
PgpdA-ABFA_ASPNG-SEQID-00420-3XFlag



3990
AMYG_ASPNG
MSFRSLLALSGLVCTGLA
PgpdA-AMYG_ASPNG-SEQID-00420-3XFlag



3991
PHOA_ASPNG
MFTKQSLVTLLGGLSLAVA
PgpdA-PHOA_ASPNG-SEQID-00420-3XFlag



3992
ABFB_ASPNG
MFSRRNLVALGLAATVSA
PgpdA-ABFB_ASPNG-SEQID-00420-3XFlag


































































































Aspergillus niger Signal Peptide Library Construction.
It is difficult to predict which secretion signal peptide will facilitate the secretion of any given protein of interest best. Therefore, one approach to optimizing secretion is to fuse a library of signal peptide sequences to the protein and screen for those that result in the highest level of secretion. We constructed a signal peptide library for SEQID-00409 and SEQID-00420. Table E15A shows the signal peptides that were fused with SEQID-00409 and SEQID-00420. DNA encoding the individual signal peptides was constructed by duplexing single stranded oligonucleotides comprising the forward- and reverse-strands of each signal peptide sequence. The oligonucleotides were designed such that single strand tails were formed at the 5′-ends of the duplexed molecule. Genes encoding natively secreted proteins SEQID-00409 and SEQID-00420 were PCR amplified from the Aspergillus niger ATCC 64974 using primers designed from the genome sequence of Aspergillus niger CBS 513.88. Genes included native 5′ secretion sequences and were cloned into the expression vector pAN56-1 (Genbank: Z32700.1) directly under the control of the gpdA promoter from Aspergillus nidulans with the additionof a C-terminal 3× FLAG tag (DYKDHDGDYKDHDIDYKDDDDK). Then the vectors were amplified without the native signal peptide and plasmids with different signal peptides were reconstructed with the duplex signal peptide sequences using the Gibson Assembly Kit (New England Biolabs, Beverly, Mass.). Recombinant plasmids were sequence verified before transformation into Aspergillus hosts.
The pyrA nutritional marker was PCR amplified from Aspergillus niger ATCC 64974 using primers designed from genome sequence of Aspergillus niger ATCC 1015. The pyrA PCR fragment was digested with XbaI and ligated into an XbaI fragment of pCSN44 (Staben et al., 1989) to construct pES1947. pCSN44 was obtained from the BCCM/LMBP (Ghent, Netherlands). The recombinant plasmid was sequence verified before transformation into Aspergillus hosts.
Aspergillus niger Signal Peptide Library Strain Construction.
A protease deficient derivate of Aspergillus niger ATCC 62590 was used as the expression host. Each signal peptide-gene combination vector was individually co-transformed with plasmid containing the nutritional marker pyrG using the protoplast method as described in Punt et al., 1992. Approximately 5 ug of each plasmid were transformed into Aspergillus niger protoplasts. Transformants were selected on minimal media supplemented with 1.2 M sorbitol and 1.5% bacto agar (10 g/l glucose, 4 g/l sodium nitrate, 20 ml/1 salts solution (containing 26.2 g/l potassium chloride and 74.8 g/l Potassium phosphate monobasic at pH 5.5), 1 ml/l vitamin solution (containing 100 mg/l Pyridoxine hydrochloride, 150 mg/l Thiamine hydrochloride, 750 mg/l 4-Aminobenzoic acid, 2.5 g/l Nicotinic acid, 2.5 g/l riboflavin, 20 g/l. choline chloride, and 30 mg/l biotin), and 1 ml/l of metals solution (containing 20 g/l Zinc sulfate heptahydrate (ZnSO4-7H2O), 11 g/l Boric acid (H3BO3), 5 g/l Manganese (II) chloride tetrahydrate (MnCl2-4H2O), 5 g/l Iron (II) sulfate heptahydrate (FeSO4-7H2O), 1.7 g/l Cobalt(II) chloride hexahydrate (CoCl2-6H2O), 1.6 g/l Copper(II) sulfate pentahydrate (CuSO4-5H2O), 1.5 g/l Sodium molybdate dihydrate (NaMoO4-2H2O), and 5.0 g/l EDTA disodium salt dihydrate (Na2EDTA-2H2O) at pH 6.5). Individual transformants were isolated on minimal media plates and allowed to grow at 30 C until they sporulated.
Aspergillus niger Signal Peptide Library Expression Testing.
Six different primary transformants from each construct were inoculated into 1 ml of minimal media as defined above supplemented with 5.0 g/l yeast extract, 2.0 g/l casamino acids) adjusted to pH 7 with 160 mM MES in 96 deep well culture blocks. Culture blocks were covered with porous adhesive plate seals and incubated for 48 hrs in a micro-expression chamber (Glas-Col, Terre Haute, Ind.) at 33° C. at 800 rpm. After the growth period, 0.5-ml aliquots of the culture supernatants were filtered first through a 25 μm/0.45-μm dual stage filter followed by a 0.22 μm filter. The filtered supernatants were then analyzed using Chip Electrophoresis as described below or anti-FLAG DOT-BLOT and SDS-PAGE as described below. Based on these results the primary transformants, which demonstrated higher secretion than the native signal peptide, were isolated on minimal media plate and allowed to grow at 30° C. until they sporulated.
Spore stocks of the above Aspergillus niger strains along with the control Aspergillus niger strain that contain expression construct of pgpdA promoter and native signal peptide of SEQID-00409 and SEQID-00424 were inoculated at 10 6 spores/mL into 10 mL of minimal media as defined above supplemented with 5.0 g/l yeast extract, 2.0 g/l casamino acids) adjusted to pH 7 with 160 mM MES in 125 ml plastic flask. Aspergillus spores were then grown at 30° C. with 150 RPM for two days. After the growth period, aliquots of the culture supernatants were filtered first through a 25 μm/0.45-μm dual stage filter followed by a 0.22 m filter. The filtrates were then analyzed using SDS-PAGE as described herein.
FIG. 5 . demonstrates the secretion of SEQID-00409 (left) and SEQID-00420 (right) with new signal peptide compared to native signal peptide.
Aspergillus niger Heterologous Nutritive Polypeptide Gene Synthesis & Plasmid Construction.
Genes encoding nutritive polypeptides were synthesized (Geneart, Life Technologies). Genes were codon optimized for expression in Aspergillus niger . Synthesized genes were PCR amplified and cloned into the expression vector pAN56-1 (Genbank: Z32700.1) fused to glucoamylase with its native leader sequence under the control of the gpdA promoter from Aspergillus nidulans with the addition of a C-terminal 3× FLAG tag (DYKDHDGDYKDHDIDYKDDDDK) and Kexin protease site (NVISKR) between glucoamylase gene and gene of interest. Plasmids were constructed using the Gibson Assembly Kit (New England Biolabs, Beverly, Mass.). Recombinant plasmids were sequence verified before transformation into Aspergillus hosts.
SEQID-00087, SEQID-00103, SEQID-00105, SEQID-00115, SEQID-00218, SEQID-00298, SEQID-00302, SEQID-00341, SEQID-00352, SEQID-00354 genes were utilized.
Aspergillus niger Heterologous Nutritive Polypeptide Strain Construction.
A protease deficient derivate of Aspergillus niger D15#26 (E. Karnaukhova et al, Microbial Cell Factories, 6:34) was used as the expression host. 10 ug of Expression vectors were co-transformed with lug plasmid containing pyrG selection marker using the protoplast method described in Punt et al., 1992, Methods in Enzymology, 216, 447-457. Transformants were selected on minimal media containing 10 g/l glucose, 6 g/l sodium nitrate, 20 ml/l salts solution (containing 26 g/l potassium chloride and 76 g/l Potassium phosphate monobasic at pH 5.5), 2 mM magnesium sulphate, I ml/I vitamin solution (containing 100 mg/l Pyridoxine hydrochloride, 150 mg/l Thiamine hydrochloride, 750 mg/l 4-Aminobenzoic acid, 2.5 g/l Nicotinic acid, 2.5 g/l riboflavin, 20 g/l choline chloride, and 30 mg/l biotin), and 1 ml/l of metals solution (containing 20 g/l Zinc sulfate heptahydrate (ZnSO4-7H2O), 11 g/l Boric acid (H3BO3), 5 g/l Manganese (II) chloride tetrahydrate (MnCl2-4H2O), 5 g/l Iron (II) sulfate heptahydrate (FeSO4-7H2O), 1.7 g/l Cobalt(II) chloride hexahydrate (CoCl2-6H2O), 1.6 g/l Copper(II) sulfate pentahydrate (CuSO4-5H2O), 1.5 g/l Sodium molybdate dihydrate (NaMoO4-2H2O), and 5.0 g/l EDTA disodium salt dihydrate (Na2EDTA-2H2O) at pH 6.5) and supplemented with 1.2 M sorbitol and 1.5% bacto agar. Individual transformants were isolated on minimal media plates and allowed to grow at 30 C until they sporulated. Spores were harvested in water at stored at 4 C.
Aspergillus niger Heterologous Nutritive Polypeptide Expression Testing.
90 different primary transformants from each construct were inoculated into 1 ml of minimal media as defined above supplemented with 1 g/L casamino acids in 96 deep well culture blocks (1 st MTP). Culture blocks were covered with porous adhesive plate seals and incubated for 72 hrs in a micro-expression chamber (Glas-Col, Terre Haute, Ind.) at 33° C. at 800 rpm. After the growth period, 0.5-ml aliquots of the culture supernatants were filtered first through a 25 μm/0.45-μm dual stage filter followed by a 0.22 μm filter. The filtrates were then assayed using an anti-FLAG ELISA method, as described herein, to determine the levels of secreted protein of interest (POI). At least five colonies from nine expression constructs excluding SEQID-00302 yielded positive signals in an anti-flag ELISA as reported in Table E15B. At least 5 primary transformants that showed positive signals in anti-FLAG ELISA assay from each of the nine expression strains were also streaked onto a fresh minimal media agar plate for single spore purification and retested for confirmation (2 nd MTP).
Spores were harvested from the plate and inoculation was done with fresh spore crops with a density of approximately 1E9 spores/ml. 10 ul of these spore crops were added to 10 ml of minimal medium giving a start density of 1E6 spores/ml. Aspergillus spores were then grown at 33 C with 150 RPM for three days. After the growth period, aliquots of the culture supernatants were filtered first through a 25 μm/0.45-μm dual stage filter followed by a 0.22 μm filter. The filtrates were then analyzed using anti-FLAG ELISA, anti-flag western blot and SDS-PAGE described below.
Certain clones from different expression construct were grown using fresh spore crops with a final density of approximately. 1E6 spores/ml in one litre minimal media. Aspergillus spores were then grown at 33 C with 150 RPM for three days. After the growth period, aliquots of the culture supernatants were filtered first through a 25 μm/0.45-μm dual stage filter followed by a 0.22 μm filter. The filtrates were then analyzed using anti-FLAG ELISA, anti-flag western blot and SDS-PAGE described below. Any secreted protein above 39 mg/l in an anti-flag ELISA from a one liter shake flask were detected by an anti-FLAG western blot and SDS-PAGE.





TABLE E15B



demonstrates the anti-flag ELISA results and anti-FLAG western blot

results of different protein secretion in Aspergillus niger









ELISA
ELISA
ELISA 10 ml
Western
ELISA 1


1st MTP
2nd MTP
shake flask
10 ml shake
litre shake

Seq ID #
(mg/l)
(mg/l)
(mg/l)
flask
flask (mg/l)



SEQID-00103
14.7-42.2
3.0-29.1
1.6-4.0
++
1.2-5.6

SEQID-00105
1.4-20.2
0-2.1
0-2.4
+
0.2-1.6

SEQID-00298
66.0-215.4
5.2-119.5
1.3-79.4
+++
93.9-224.3

SEQID-00897
11.9-21.4
3.6-17.5
0.6-2.2
+
−

SEQ1D-00115
16.3-96.2
0-4.9
0.7-3.7
−
−

SEQID-00218
28.2-69.3
0.4-191.7
2.1-13.3
+
−

SEQID-00341
10.4-25.3
1.9-20.5
3.0-8.3
+++
1.0-3.6

SEQID-00352
27.1-207.6
0-16.2
0.7-245.70
+++
39.0-124.3

SEQID-00354
9.1-120.4
0-47.2
0.9-7.8
+++
0-1.2
































Example 16
Expression of Nutritive Polypeptides in Cultured Mammalian Cells
Gene Synthesis and Plasmid Construction.
All genes were made synthetically (GeneArt, Life Technologies) and optimized for expression in Homo Sapiens . Genes encoding SEQID-00001, SEQID-00103, SEQID-00105, SEQID-00298 and SEQID-00363 were chosen for secretion in mammalian cells. All the genes were fused with 5′ signal peptide sequence from Ig-kappa protein (METDTLLLWVLLLWVPGSTGD) and HHHHHHHH tag in the 3′ end. All the gene constructs were cloned to pcDNA 3.1 (+) vector (Life Technologies) downstream of pCMV promoter in the multiple cloning site of NheI and BamHI. All gene sequences contained the GCC sequence upstream of start codon to generate GCCATGG Kozak sequence. All plasmids were transformed in E. coli , sequence verified and 10 mg of each plasmid were purified for transfection into mammalian cells.
Strain Construction.
The cell lines selected for experimentation are 2 transient lines from Invitrogen, FreeStyle™ CHO-S Cells (PN 51-4448) and FreeStyle™ 293F Cells (PN 51-0029). Cell lines were received from Invitrogen and stored in liquid nitrogen until sub-culturing was initiated. For sub-culturing prior to transfection, cells were thawed into specific media: CHO-S cells were thawed into 30 mL of FreeStyle™ CHO Expression Media (Invitrogen PN 12651-014) supplemented with 8 mM Glutamax (Invitrogen PN 35050-061) and 1×HT (Invitrogen PN 11067-030). 293F cells were thawed into 30 mL FreeStyle™ 293 Expression Medium (Invitrogen PN 12338-018). Cells were allowed to recover in suspension for 72 hrs under 80% humidity, 8% Carbon Dioxide, 36.5° C., shaking at 110 rotations per minute. Cells were passed from viable cell densities (VCD) not exceeding 2.0×10 6 cells/mL to 0.2×10 6 cells/mL. Sub-culturing continued for 5 passages prior to transfection.
At 26 hrs prior to transfection the cultures were passed back to 0.6×10 6 viable cells/mL in a volume of 60 mL. Each nutritive polypeptide was transfected in duplicate with 2 mock transfections performed as control for each cell line. On the day of transfection cells were counted and determined to be at 1.1×10 6 cells/mL with greater than 98% viability.
Transfection Procedure.
Preparation of DNA-lipid complexes for 120 mL total volume (60 mL/250 mL shake flask) transfections.
The following procedure was performed in a Laminar Flow Hood. 150 μg of plasmid DNA were diluted into OptiPRO™ SFM Reduced Serum Medium (Invitrogen PN: 12307-050 to a total volume of 2.4 mL. This solution was mixed gently and 0.2 μm filter sterilized. Diluted 150 uL of FreeStyle™ MAX Reagent (Invitrogen PN 16447-100) in OptiPRO™ SFM Reduced Serum Medium to a total volume of 2.4 mL, mixed gently and incubated for 5 minutes at room temperature. After 5-minute incubation, the 2.4 mL of diluted DNA was added to the 2.4 mL of the diluted reagent, gently mixed and incubated for 20 min at room temperature to form the DNA-lipid complex. After 20-minute incubation, 2.4 mL of complex was added to each duplicate flask. Control Flask received 2.4 mL of OptiPRO™ SFM reduced serum medium. Transfected flasks were placed back in incubated shaker under 80% humidity, 8% Carbon Dioxide 36.5° C., shaking at 110 rotations per minute. Cultures were monitored for % Viability and VCD. All flasks were supplemented on Day 3 with a 20% Phytone Peptone Feed made in the media specific to each cell line. The final concentration of Phytone Peptone in the flask equaled 2%. Cultures were harvested on Day 4 via centrifugation and 0.2 um filtration of the supernatant. Supernatants were run on a non-reducing SDS-PAGE 12% Bis-Tris Gel to confirm expression of nutritive polypeptides at molecular weights. SEQID-00001, SEQID-00103, SEQID-00105, and SEQID-00298 were confirmed as being expressed from 293F cells but no visible bands could be detected in any of the CHO-S cultures. SEQID-00363 could not be visualized on the gel from either 293F or CHO-S cultures. Supernatants from 293F cultures for SEQID-00001, SEQID-00103, SEQID-00105, SEQID-00298, and SEQID-00363 as well as CHO-S supernatants for SEQID-00103 and SEQID-00105 were purified via IMAC. SEQID-00103, SEQID-00105, and SEQID-00298 were scaled up to 190 mL transfection volume in a 1 L shake flask using 293F cells. Transfection procedure was also scaled accordingly. 4×190 mL cultures for both SEQID-00103 and SEQID-00105 and 2×190 mL cultures for SEQID-00298 were run. On Day 2 these cultures were fed with the 20% Phytone Peptone feed to a final concentration of 2% in culture and were harvested on Day 5.
Example 17
Nutritive Polypeptide Expression Analysis
Nutritive polypeptides intracellularly expressed and/or secreted were detected using a variety of methods. These methods include electrophoresis, western blot, dot-blot, ELISA, and quantitative LC/MS/MS.
Electrophoresis Analysis.
Extracellular and/or intracellular expressed proteins were analyzed by chip electrophoresis (Labchip GXII) or SDS-PAGE analysis to evaluate expression level.
For SDS-PAGE, 10 μl sample in Invitrogen LDS Sample Buffer mixed with 5% β-mercaptoethanol was boiled and loaded onto either: 1) a Novex® NuPAGE® 12% Bis-Tris gel (Life Technologies), or 2) a Novex® 16% Tricine gel (Life Technologies), and run using standard manufacturer's protocols. Gels were stained using SimplyBlue™ SafeStain (Life Technologies) using the standard manufacturer's protocol and imaged using the Molecular Imager® Gel Doc™ XR+ System (Bio-Rad). Over-expressed heterologous proteins were identified by comparison against a molecular weight marker and control cultures.
For chip electrophoresis (Labchip GX II) samples were analyzed using a HT Low MW Protein Express LabChip® Kit (following the manufacturer's protocol) by adding 2 l of sample to 7 μl sample buffer. A protein ladder was loaded every 12 samples for molecular weight determination and quantification (molecular weight in kDa).
LC-MS/MS Analysis.
Whole cell, cell lysate and secreted samples can be analyzed for protein expression using LC-MS/MS. To analyze samples, 10 μg of sample were loaded onto a 10% SDS-PAGE gel (Invitrogen) and separated approximately 2 cm. The gel was excised into ten segments and the gel slices were processed by washing with 25 mM ammonium bicarbonate, followed by acetonitrile. Gel slices were then reduced with 10 mM dithiothreitol at 60° C., followed by alkylation with 50 mM iodoacetamide at room temperature. Finally, the samples were digested with trypsin (Promega) at 37° C. for 4 h and the digestions were quenched with the addition of formic acid. The supernatant samples were then analyzed by nano LC/MS/MS with a Waters NanoAcquity HPLC system interfaced to a ThermoFisher Q Exactive. Peptides were loaded on a trapping column and eluted over a 75 jim analytical column at 350 nL/min; both columns were packed with Jupiter Proteo resin (Phenomenex). A 1 h gradient was employed. The mass spectrometer was operated in data-dependent mode, with MS and MS/MS performed in the Orbitrap at 70,000 FWHM resolution and 17,500 FWHM resolution, respectively. The fifteen most abundant ions were selected for MS/MS. Data were searched against an appropriate database using Mascot to identify peptides. Mascot DAT files were parsed into the Scaffold software for validation, filtering and to create a nonredundant list per sample. Data were filtered at 1% protein and peptide false discovery rate (FDR) and requiring at least two unique peptides per protein.
Anti-FLAG Western Blot.
Extracellular and/or intracellular protein was analyzed using western blot to evaluate expression level.
For SDS-PAGE, 10 μl sample in Invitrogen LDS Sample Buffer mixed with 5% (3-mercaptoethanol was boiled and loaded onto a Novex® NuPAGE® 12% Bis-Tris gel (Life Technologies). For standards, 0.5 μg to 2 μg Amino-terminal FLAG-BAP™ Fusion Protein (Sigma) were loaded as a positive control. Gel electrophoresis was performed according to manufacturer's protocol. Once run, the gel was transferred onto an iBlot® Mini Transfer Stack nitrocellulose 0.2 μm pore size membrane (Life Technologies) according to manufacturer protocol. Next, the nitrocellulose membrane was removed from the stack and assembled into a Millipore SNAP I.d.® 2.0 Protein Detection Apparatus. 30 ml of Millipore Blok CH Noise Cancelling reagent was placed into an assembled reservoir tray and vacuumed through. 3 ml of antibody solution was prepared by diluting 2 μl of Sigma Monoclonal ANTI-FLAG® M2-Peroxidase (HRP) antibody into 3 ml of Millipore Blok CH Noise Cancelling Reagent. Antibody solution was added to reservoir tray and allowed to incubate for 10 minutes without vacuum. After incubation, the reservoir tray was filled with 90 ml of 1×PBS+0.1% Tween 20 and vacuumed through as the final wash step. After wash, the nitrocellulose membrane was removed and placed into a reagent tray. 20 ml of Millipore Luminata Classico Western HRP substrate was added and allowed to incubate for 1 minute. After incubation, the membrane was placed into imaging tray of Gel Doc™ XR+System (Bio-rad) and imaged using a chemiluminescent protocol.
Anti-FLAG Dot Blot.
Extracellular and/or intracellular proteins were analyzed using dot blot to evaluate expression level.
110 μl of 0.2 μm filtered sample was mixed with 110 μl 8.0M Guanidine Hydrochloride, 0.1M Sodium Phosphate (Denaturing Buffer) to allow for even protein binding. A standard curve of Amino-terminal FLAG-BAP™ Fusion Protein (Sigma) was prepared in the same matrix as the samples, starting at 2 μg, diluting 2× serially to 0.0313 μg. Invitrogen 0.45 μm nitrocellulose membrane was pre-wet in 1×PBS buffer for 5 minutes and then loaded onto Bio-Rad Dot Blot Apparatus. 300 μl of PBS was vacuumed through to further wet the membrane. Next, 200 μl the 1:1 Sample:Denaturing Buffer mixture was loaded into each well and allowed to drain through the dot blot apparatus by gravity for 30 minutes. Next, a 300 μl PBS is wash was performed on all wells by vacuum followed by loading 300 μl of Millipore Blok CH Noise Cancelling reagent and incubating for 60 minutes. After blocking, membrane was washed with 300 μl of 1×PBS+0.1% Tween 20. Next, antibody solution was prepared by adding 2.4 μl of Sigma Monoclonal ANTI-FLAG® M2-Peroxidase (HRP) antibody to 12 ml of Millipore Blok CH Noise Cancelling reagent (1:5000 dilution). 100 μl of the resulting antibody solution was added to each well and allowed to incubate for 30 minutes by gravity. After antibody incubation, three final washes were performed with 300 μl 1×PBS+0.1% Tween 20 by vacuum. After washes, nitrocellulose membrane was removed and placed into a reagent tray. 20 ml of Millipore Luminata Classico Western HRP substrate was added and allowed to incubate for 1 minute. After incubation, membrane was placed into imaging tray of Gel Doc™ XR+ System (Bio-rad) and imaged using a chemiluminescent protocol.
Anti-FLAG ELISA. Protein expression was detected by direct ELISA using an anti-FLAG antibody. Briefly, a dilution series (0.005-10 μg/mL) of FLAG fusion protein (Sigma) was prepared in 0.1 M NaHCO3 (pH 9.5). A dilution series (0.01-20 μg/mL) of FLAG fusion protein was also prepared in spent medium from an empty fungus culture diluted 10-fold in 0.1 M NaHCO3 (pH 9.5). Experimental cultured medium samples were diluted 10-fold in 0.1 M NaHCO3 (pH 9.5). The FLAG fusion protein dilution series and the experimental samples were then transferred (0.2 mL) to the wells of a Nunc-immuno™ Maxisorp™ (Thermo) 96-well plate and incubated overnight at 2-8° C. to facilitate protein adsorption. The following morning, plates were rinsed three times with Tris-buffered saline (TBS) containing 0.05% TWEEN 80 (TBST). The wells were blocked from non-specific protein binding by incubation with 0.2 mL of 1% non-fat dried milk dissolved in TBST for 1 h at room temperature. The plates were rinsed three more times with TBST and then incubated at room temperature for 1 h with 0.2 mL of the monoclonal antibody anti-FLAG M2-HRP (Sigma) diluted 1:2000 in blocking buffer. The plates were again rinsed three more times with TBST before incubation with 0.2 mL/well of SIGMAFAST™ o-phenylenediamine dihydrocholride (OPD) (Sigma) for 30 min at room temperature. The reaction was terminated with the addition of 0.05 mL/well of 1 M HCl and the absorbance of samples was measured at 492 nm on a spectrophotometer equipped with a plate reader.
Example 18
Therapeutic Liquid Formulations of Nutritive Polypeptides
Nutritive polypeptide sequences were administered for therapeutic purposes in a variety of liquid formulations. For example, the formulations utilized differ by protein concentration, solution pH, presence or absence of particulates, minerals, tastants, and/or excipient additives. In therapeutic liquid formulations, the concentration of protein ranges from 0.1% to 60% w/w in solution. In certain instances, a lower concentration is preferable. For example, SEQID-00105 has been dosed as low as 10%. In some cases a higher concentration is preferable. For example, SEQID-00105 and SEQID-00363 were dosed as 35% solutions. In some cases a nutritive polypeptide sequence is dosed at its maximum solubility, which varies by protein and is generally in the range of 0.1% to 60% w/w. Both SEQID-00105 and SEQID-00363 were shown to be a soluble liquid at 50% w/w in solution. In therapeutic liquid formulations, the solution pH generally ranges from 2 to 11. Protein solubility is known to be a strong function of solution pH (C. Tanford, Physical Chemistry of Macromolecules, p. 242, Wiley, New York, 1961.) In most cases, nutritive polypeptide sequences are least soluble at their isoelectric point (pI), and thus solution pH is often adjusted to be above or below the pI of the nutritive polypeptide sequence. This modulation of pH allows control over protein solubility. For example, SEQID-00105 and SEQID-00363 have isoelectric points near 4. These nutritive polypeptide sequences were purposely formulated at pH 8-9, so they would be above their pI. For example, SEQID-00587 has a pI of 9.7 and was purposely formulated at pH 7, so that it would be below its pI. Nutritive polypeptides that are soluble at their pI, can be formulated at their pI so that the liquid formulation does not require an additional buffering species to maintain the solution pH. In this case, the protein itself acts to buffer the solution pH, as its own amino acids are protonated and deprotonated. A protein solution formulated at the pI of the protein shows resistance to changes in pH when acid or base are added, indicating that the solution is, in fact, buffered by the protein itself. In some therapeutic liquid formulations, a nutritive polypeptide includes particulate matter. Particulate matter is visible to the eye, and/or it contains subvisible particulates (example soluble aggregates). Particulate matter is product-related, and/or it is foreign. Particulate matter occurs in suspension, as a slurry, and/or settles at the bottom of the solution. In some embodiments, particulate matter is desirable because wherein it is indigestible or slowly digestible in the stomach, it acts as a carrier delivering the nutritive polypeptide to the intestine. In some embodiments, particulate matter is desirable in a liquid formulation because it allows dosing the nutritive polypeptide above its limit of solubility. In the case of SEQID-00105, there is no visible particulate matter. SEQID-00424 was dosed with suspended particulate matter.
In therapeutic liquid formulations, a nutritive polypeptide sequence is typically formulated with one or more excipients dissolved in the formulation. Each excipient is included for a specific purpose. Buffers (examples: Tris, phosphate, ammonium bicarbonate, sodium carbonate, acetate, citrate, arginine) are added to control the solution pH. Sugars are added to control aggregation and solubility (examples: trehalose, glucose, sucrose, and mannitol). Detergents are added to control solubility and aggregation (examples tween, triton, CHAPS, and deoxycholate). Polyalcohols are added to control solubility and aggregation (glycerol, PEG). Chaotropes are added to increase protein solubility (example thiocyanate and urea). Antioxidants are added to prevent protein oxidation (examples ascorbic acid and methionine). Salts are added to increase protein solubility and/or are added to achieve a desired osmolality (example sodium chloride). SEQID-00105, SEQID-00363, SEQID-00426 were formulated in sodium phosphate and sodium chloride and dosed orally. SEQID-00587 and SEQID-00559 were formulated in ammonium bicarbonate and dosed orally. SEQID-00240 was formulated in sodium carbonate and dosed orally. Tastants were added to nutritive polypeptides to enhance the gustatory experience of the user, with successful result. Vanilla extract was added in combination with sucralose according to Tang et al. (Tang J E, Moore D R, Kujbida G W, Tamopolsky M A, Phillips S M. J Appl Physiol (1985). 2009 September; 107(3):987-92). The qualitative benefit of enhanced flavor was documented by users as being “quite pleasant.”
The two tables Table E18A and Table E18B summarize a number of administrations of nutritive polypeptides to humans and to rats.





TABLE E18A



Therapeutic liquid formulations of nutritive

polypeptides used for human administration.

Human Administration











Protein






Conc
dosed

SEQID
(g/L)
(g)
pH
Buffer
NaCl
Tastants












SEQID-00105
350
35
8.7
2 mM
6
mM
Each formulation





phosphate


contained 8 mL of

SEQID-00363
350
35
7
3 mM
14
mM
vanilla extract per





phosphate


liter and 4 grams

SEQID-00105
117
20
8.7
2 mM
6
mM
of sucralose per





phosphate


liter, according to

SEQID-00105
117
20
8.7
2 mM
6
mM
Tang, et al.





phosphate

SEQID-00363
117
20
7
3 mM
14
mM





phosphate









SEQID-00426
117
20
7
none
none














































TABLE E18B



Therapeutic liquid formulations of nutritive polypeptides used for

human administration.

Rat Administration










dosage






(mg protein





Conc
per kg body




SEQID
(g/L)
weight)
pH
Buffer
NaCl










SEQID-00105
250
2,850
8.7
2 mM phosphate
6 mM

SEQID-00105
250
2,850
8.7
2 mM phosphate
6 mM

SEQID-00338
250
2,850
8.7
2 mM phosphate
6 mM

SEQID-00338
250
2,850
8.7
2 mM phosphate
6 mM

SEQID-00105
98
1,113
8.7
2 mM phosphate
6 mM

SEQID-00240
135
1,539
10.8
25 mM Na2CO3
0 mM

SEQID-00105
156
1,781
8.7
2 mM phosphate
6 mM

SEQID-00363
229
2,850
7
3 mM phosphate
14 mM

(a-mannosidase






treated)






SEQID-00363
250
2,850
7
3 mM phosphate
14 mM

(hydrolyzed)






SEQID-00105
250
2,850
8.7
2 mM phosphate
6 mM

SEQID-00105
250
2,850
8.7
2 mM phosphate
6 mM

SEQID-00105
250
2,850
8.7
2 mM phosphate
6 mM

SEQID-00105
250
2,850
8.7
2 mM phosphate
6 mM

SEQID-00105
250
2,850
8.7
2 mM phosphate
6 mM

SEQID-00338
250
2,850
8.7
2 mM phosphate
6 mM

SEQID-00352
250
2,850
7
3 mM phosphate
14 mM

SEQID-00363
250
2,850
7
3 mM phosphate
14 mM

SEQID-00363
250
2,850
7
3 mM phosphate
14 mM

SEQID-00423
250
2,850
7
3 mM phosphate
14 mM

SEQID-00424
250
2,850
7
3 mM phosphate
14 mM

SEQID-00425
250
2,850
7
3 mM phosphate
14 mM

SEQID-00426
250
2,850
7
none
0 mM

SEQID-00426
250
2,850
7
none
0 mM

SEQID-00429
250
2,850
7
3 mM phosphate
14 mM

SEQID-00559
250
2,850
7.7
25 mM NH4HCO3
0 mM

SEQID-00587
250
2,850
7.7
25 mM NH4HCO3
0 mM

























































Example 19
Therapeutic Formulations of Nutritive Polypeptides
Alternative to soluble, homogenous, liquid formulations, nutritive polypeptides can be prepared alternatively. This example describes alternative nutritive polypeptide formulations such as slurries, gels, tablets and food ingredients.
Slurry Formulations.
Slurries are semiliquid mixtures that contain both soluble and insoluble material which generally appear as fine granules in solution. Nutritive polypeptide slurries are prepared when a nutritive polypeptide is either concentrated above its maximum solubility, or, when a lyophilized or freeze dried preparation of a nutritive polypeptide is resuspended above its maximum solubility. Optionally, addition of an emulsifier such as soy lecithin is added at a concentration between 0.1-1% to stabilize the homogeneity of a slurry (van Nieuwenhuyzen et al., 1999 Eur. Journal of Lipid Sci. and Tech.).
Gel Formulations.
Alternatively, nutritive polypeptides are formulated as gels. Gels are solid, jelly-like formulations that are generally formed through molecular cross linking. Nutritive polypeptides are formulated as gels through treatment with transglutaminase (EC Number 2.3.2.13). Transglutaminase can catalyze the cross linking of nutritive polypeptides between g-carboxamide groups of peptide bound glutamine residues and the e-amino groups of nutritive polypeptide bound lysine residues. This formation of a g-glutamyl-e-lysine cross links proteins in solution; thus, promoting gel formation.
Human transglutaminase is a calcium (Ca2+) dependent enzyme with a Kd for calcium in the range of 0.3-3 uM (Ahvazi et al., 2003 Journal of Biological Chemistry). Due to the precipitave effects of calcium in preparations of nutritive polypeptides, a microbial ( Streptomyces mobaraensis ) orthologue of transglutaminase has been identified that acts in a calcium-independent manner (Ando et al, 1989 Agric Biol Chem). To prepare a gelatinous preparation of nutritive polypeptides, nutritive polypeptides are solubly formulated at 250 g/L at neutral pH. Transglutaminase is spiked into the preparation at 10 EU per g nutritive polypeptide and allowed to react at 35° C. until adequate gel formation has occurred (Chen et al., 2003 Biomaterials).
Tablet Formulations.
Preparation of solid tablets of nutritive polypeptides is accomplished according to Sakarkar et al. 2009 (International Journal of Applied Pharmaceutics). Tablets are formulated as a mixture of nutritive polypeptides, excipients and binding agents. Tablets are composed of 50% w/w nutritive polypeptide, 26% w/w microcrystalline cellulose, 7.5 w/w sodium bicarbonate-citric acid mixture (70:30), 6.5% w/w lactose, 5.5% w/w magnesium stearate and bound by 4.5% w/w polyvinyl pyrrolidone solution in isopropanol. Tablets are dehumidified and granulated prior to compression into 100 mg tablets. Tablets are coated with 12.5% w/w ethyl cellulose solution in dichloromethane and diethyl phthalate as a plasticizer.
Inhalable Dry Powder.
Nutritive polypeptides are formulated to be administered as an inhalable dry powder as described in Lucas et al., 1998 Pharm Res. Nutritive proteins are co-processed with malto-dextrin by spray-drying to produce model protein particles. Aerosol formulations are then prepared by tumble mixing protein powders with α-lactose monohydrate (63-90 μm) or modified lactoses containing between 2.5 and 10% w/w fine particle lactose (FPL) or micronised polyethylene glycol 6000. Powder blends are then characterized in terms of particle size distribution, morphology and powder flow.
Conventional Food Formulations.
Nutritive polypeptides are formulated as a food ingredients as dry, solid formulations. For example, nutritive polypeptides are incorporated into pasta dough by mixing dry nutritive polypeptide formulations into water, durum semolina, Arabica gum, mono- and diglycerides, fiber, yeast and citric acid. Dough is cut to shape, dried and packaged.
Example 20
In Vitro Screening of Amino Acids and Nutritive Polypeptides for GLP-1 Production
Glucagon-like peptide-1 (GLP-1) is a peptide hormone produced by L-cells of the intestine in response to multiple nutrient stimuli. GLP-1 is an incretin that decreases blood glucose levels by increasing insulin release from the pancreas. GLP-1 acts on other peripheral tissues increasing glucose uptake and storage in skeletal muscle and adipose tissue, decreasing the rate of gastric emptying, and decreasing hepatic glucose production (Baggio L L & D J Drucker. 2007. Biology of incretins: GLP-1 and GIP. Gastroenterology. 132:2131-2157). GLP-1 is a product of the post-translational cleavage of proglucagon to generate active GLP-1 (7-36) this is rapidly degraded after secretion by dipeptidyl peptidase IV (DPPIV) to GLP-1 (9-36).
Several mammalian gastrointestinal cell lines are used as models for L-cell secretion of GLP-1 (IEC-6 from rats, NCI-H716 and FHs74Int from Humans, and STC-1 and GLUTag from mice). The purpose of these experiments is to determine which amino acid combinations, nutritive protein digests, and/or full length nutritive proteins induce GLP-1 secretion in vitro.
The NCI-H716 cell line is obtained from the American Type Culture Collection (Catalog number ATCC® CCL-251™, Manassas, Va.). RPMI-1640, Dulbecco's Modified Eagle Medium (DMEM) and Dulbecco's Phosphate Buffered Saline (DPBS) are obtained from Life Technologies (Catalog numbers 11875, 11965 and 14190, respectively; Carlsbad, Calif.). Penicillin-Streptomycin Solution is obtained from ATCC (Catalog number 30-2300, Manassas, Va.). Antibiotic-Antimycotic Solution (100×) is obtained from Sigma-Aldrich (Catalog number A5955, St. Louis, Mo.). Fetal bovine serum is obtained from GE Healthcare (Catalog number SH3007103HI, Wilmington, Mass.). Bovine serum albumin is obtained from Fisher Scientific (Catalog number BP1600-100, Pittsburgh, Pa.). Fatty-acid free bovine serum albumin is obtained from Sigma-Aldrich (Catalog number A7030, St. Louis, Mo.). Phenylmethyl sulfonyl fluoride (PMSF), a protease inhibitor, is obtained from Thermo Scientific (Catalog number 36978, Waltham, Mass.). Diprotin A, a DPPIV inhibitor, is obtained from Sigma-Aldrich (Catalog number 19759, St. Louis, Mo.). Tissue Protein Extraction Reagent (T-PER) is obtained from Thermo Scientific (Catalog number 78510, Waltham, Mass.). Active GLP-1 concentration is determined using the AlphaLisa GLP-1 (7-36 amide) Immunoassay Research Kit (Catalog number AL215, PerkinElmer, Waltham, Mass.) and read on an EnSpire Alpha plate reader (PerkinElmer, Waltham, Mass.). Data are analyzed using Microsoft Excel version 14.0.7128.5000 (Microsoft Corporation, Redmond, Wash.) and GraphPad Prism version 6.03 for Windows (GraphPad Software, La Jolla, Calif.). Krebs Ringer Buffer (KRB) is prepared and the AlphaLISA GLP-1 (7-36 amide) Immunoassay Research Kit is obtained from PerkinElmer (Catalog number AL215, Waltham, Mass.).
Ninety-six well plates are pre-coated with MatriGel. 80 μL of MatriGel is added to 5 mL Dulbecco's Modified Eagle Medium (DMEM) without glucose. 50 μL are added per well and the plate incubated at 37° C., 5% CO2 for 30 minutes. MatriGel solution is aspirated prior to addition of cells.
NCI-H716 cells are maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% Antibiotic-Antimycotic Solution and incubated in T-75 tissue culture flasks at 37° C., 5% CO2. Cells are passaged 1:3 or 1:6 every 2 to 3 days.
Cells are detached with 0.25% trypsin-EDTA incubated at 37° C., 5% CO2 and centrifuged at 750 rpm for 10 minutes to pellet cells. Cell pellet is washed twice with 1×Dulbecco's Phosphate Buffered Saline (DPBS) supplemented with 1% FBS and centrifuged at 750 rpm for 10 minutes to pellet cells. The cells are resuspended in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% FBS and 1% penicillin/streptomycin and counted on a hemocytometer. Cells are diluted to 1.8×106 cells/mL and 200 μL added to each well of a 96 well plate pre-coated with Matri-Gel. Cells are incubated for 2 days at 37° C., 5% C02.
Screening of GLP-1 Secretion to Amino Acid Treatments in NCI-H716 Cells
Following two day incubation, medium is aspirated and replaced with 200 μL Starvation Buffer [i.e. Krebs-Ringer Buffer (KRB) containing 50 μg/mL PMSF, 34 g/mL Diprotin A, and 0.2% fatty-acid free bovine serum albumin (BSA)] and incubated for 30 minutes at 37° C., 5% CO 2 . Starvation buffer is then aspirated and replaced with 100 μL/well of treatment article in Starvation Buffer. Cells are stimulated with treatment article for 2 hours then medium is removed and frozen at −80° C. Treatment articles include individual amino acids, amino acid blends, nutritive protein digests, and/or full length nutritive proteins.
Determination of Active GLP-1 Concentration from Supernatant.
Supernatant is assayed for the active form of GLP-1 (7-36)NH2 using the AlphaLISA GLP-1 (7-36 amide) Immunoassay Research Kit (PerkinElmer, AL215) in accordance with the manufacturer's instructions. The standard is assayed in Assay Buffer supplemented to an equivalent concentration of Starvation Buffer. Alternatively, the active form of GLP-1 is measured using an enzyme-linked immunosorbent assay (ELISA) as described herein. Luminescence data from the AlphaLISA GLP-1 (7-36 amide) Immunoassay or GLP-1 ELISA is analyzed on Microsoft Excel and GraphPad Prism.
Duplicate sample concentrations are determined by non-linear regression using a 4 parameter logistic model of the standard following an x=log(x) transformation of the active GLP-1 concentration in GraphPad Prism 6. ANOVA and multiple comparison tests are conducted on GraphPad Prism 6.
Comparisons of the GLP-1 content from samples collected after test article treatment to those collected after vehicle control treatment describe the degree of GLP-1 secretion due to a test article over time. Comparison of this difference across treatments describes the differential effects of each amino acid, amino acid blend, nutritive protein digest, and nutritive protein treatment relative to the other, and provides a means of ranking their efficacy.
GLP-1 Secretion by Amino Acids
Cells were starved of amino acids as described herein and stimulated with stimulation buffer alone, 19 amino acids, 17 amino acids (without leucine, isoleucine or valine), 20 amino acids or leucine alone at their concentration in DME/F12 medium (see Table E20C) for two hours. Supernatant was harvested and frozen at −80° C. GLP-1 (7-36) amide concentration was assayed subsequently. FIG. 6 shows supernatant concentration of GLP-1 (7-36) detected in the supernatant following stimulation, error bars are the standard deviation of the technical replicates. Fourteen compositions increased the concentration of GLP-1 above 10% greater than that observed in the larger buffer only stimulation (those lacking either Asn, Met, Gin, Tyr, His, Gly, Cys, Phe, Trp, Ala, Glu, Leu, Ile and Val). Two compositions, amino acids lacking Arg & Leu only treatment, showed decreased concentration of GLP-1 (7-36) below 10% below the lower buffer only stimulation.










TABLE E20A





Amino Acids
μM
Amino Acids
μM













Glycine
250
L-Leucine
451


L-Alanine
50
L-Lysine
500


L-Arginine
700
L-Methionine
116


L-Asparagine
57
L-Phenylalanine
215


L-Aspartic Acid
50
L-Proline
150


L-Cysteine
100
L-Serine
250


L-Glutamic Acid
100
L-Threonine
449


L-Glutamine
2500
L-Tryptophan
44


L-Histidine
150
L-Tyrosine
214


L-Isoleucine
416
L-Valine
452































Example 21
Use of Nutritive Polypeptides to Improve Glycemic Control in Healthy, Fasted Rats
Glucose tolerance tests are a common method of measuring glycemic control in both clinical and preclinical settings. During the test, a large dose of glucose is given and blood samples are taken at subsequent time points to determine how quickly blood glucose levels renormalize. In an oral glucose tolerance test (OGTT), a dose of glucose is ingested by mouth. Such tests are clinically used to identify individuals with poor glucose control (Cobelli et al., 2014), and pre-clinically to assess the therapeutic efficacy of anti-diabetes medications (Wagman & Nuss, 2001)(Moller, 2001). Glucose levels are modulated by a number of different gastrointestinal hormones, including insulin, glucagon, somatostatin, glucose-dependent insulinotropic peptide (GIP), and glucagon-like peptide 1 (GLP-1), which both directly and indirectly modulate glucose levels. Combined measurements of glucose and gastrointestinal hormones are used to assess glucose intolerance, insulin resistance, and the severity of metabolic disease (Ferrannini & Mari, 2014).
An OGTT was performed on twenty five healthy, fasted, male Sprague-Dawley rats with indwelling jugular vein catheters (JVC) to assess the acute effects of nutritive polypeptide dosing on glycemic control as well as insulin and GLP-1 levels.
Oral Glucose Tolerance Test.
All rodents were approximately 10-12 weeks old, weighed average of approximately 350 g and acclimated for 4 days prior to testing. Animals were housed singly with bedding and fed a regular rodent chow diet (Lab Diet 5001) prior to the study. Housing temperature was at kept at 22±2° C., humidity at 50±20%, and a 12 hour light/12 hour dark cycle was implemented. Air circulation was ten or more air changes per hour with 100% fresh air. Prior to treatment, all rats were fasted overnight for fourteen hours. Fasted animals were treated with formulations of nutritive polypeptides dissolved in water by oral gavage (see Table E21A), and fifteen minutes after treatment gavage were then challenged with an oral gavage of glucose (2 g/kg). Blood glucose was measured and blood was collected at seven time points (−15, 0, 15, 30, 60, 90, 120 minutes relative to the glucose challenge). Blood was collected in an EDTA collection tube containing plasma stablizers (a DPP4 inhibitor and a protease cocktail inhibitor). One additional rat was sacrificed at and bled out to provide naïve blood for analytical standards. Glucose was measured using small drops of blood collected via the JVC using a glucometer (AlphaTrak 2, Abbott).













TABLE E21A






Dose
Average
Total
Glucose
Glucose
Glucose


Dose
Conc.
Volume
BW
Protein
Volume
Dose
Conc.

Group
(mg/kg)
(mg/mL)
(mL/kg)
(kg)
(mg)
(mL/kg)
(g/kg)
(mg/mL)



Vehicle
NA
NA
11.4
0.35
NA
4
2
500

SEQID-
2850
250
11.4
0.35
5,985
4
2
500

00105

Arginine
1000
87.7
11.4
0.35
2,100
4
2
500

HCl

SEQID-
2850
250
11.4
0.35
5,985*
4
2
500

00338

























Approximately 300 μL of blood was collected from the JVC of all rats in Group 1-4 at six time points (−15, 0, 15, 30, 60, and 120 minutes). Glucose gavages and blood collections were timed to take the same amount of time per animal so that sample times were accurate for each animal. All time points were collected within 5% of the target time. Blood was collected into pre-chilled (0-4° C.) K2EDTA blood collection tubes containing Protease Inhibitor Cocktail (Catalog number D8340, Sigma-Aldrich, St. Louis, Mo.) and DPPIV inhibitor (Millipore, Billerica, Mass.) added to the tubes at 1:100 prior to collection. After blood collection, blood samples were maintained chilled (2-6° C.) and centrifuged within 30 minutes. The collected plasma was placed in sample tubes and immediately stored at −80° C.
Prior to immunoassay analysis samples were thawed on ice for 1 hour, mixed thoroughly by pipette, rearrayed to 96 well microplates. Separate aliquots were prepared for insulin immunoassay and GLP-1 immunoassay. Master plate and aliquots were stored frozen at −80° C.
FIG. 7 shows the average blood glucose values during the OGTT described herein. The error bars shown are the standard errors of the mean. All groups showed significant differences in blood glucose from fasting at times t=15, and t=30 min after the glucose challenge (p<0.05, Dunnett multiple comparison test). The groups that received SEQID-00105 and SEQID-00338 showed a significant difference in blood glucose relative to vehicle at times t=15, and t=30 after the glucose challenge (p<0.05, Tukey-Kramer multiple comparison test, comparing treatment group to each other at each time point). These data indicated that acute ingestion of SEQID-00105 and SEQID-00338 can significantly improve glycemic control after a glucose challenge in outbred male Sprague-Dawley rats.
The area under curve for blood glucose was calculated using the Linear-Log Trapezoidal Method in Microsoft Excel, and statistical analysis was conducted on GraphPad Prism 6.
The area under curve for blood glucose integreated from 0-120 minutes and from 0-60 minutes ( FIG. 8 ) show that acute dosing of SEQID-00105 and SEQID-00338 improves blood glucose control by reducing blood glucose excursion in the context of an oral glucose tolerance test. Between 0 and 60 minutes both SEQID-00105 and SEQID-00338 have significantly smaller change in blood glucose in comparison to vehicle (P<0.05, Dunnett's multiple comparisons test).
Rat Insulin Enzyme Linked Immunosorbent Assay (ELISA).
An Ultra-Sensitive Rat Insulin ELISA Kit was obtained from Crystal Chem, Inc. (Catalog number 90060, Downers Grove, Ill.). Plates were washed using a BioTek ELx50 microplate strip washer (BioTek, Winooski, Vt.). Absorbance was read on a Synergy Mx monochromator-based microplate reader (BioTek, Winooski, Vt.). Data was analyzed using Microsoft Excel version 14.0.7128.5000 (Microsoft Corporation, Redmond, Wash.) and GraphPad Prism version 6.03 for Windows (GraphPad Software, La Jolla, Calif.).
The ELISA kit was prewarmed to room temperature for 30 minutes prior to beginning the assay set up. The standard curve dilutions were prepared in accordance with the manufacturer's instructions for running the assay in Wide Range format.
Plasma matrix from the naïve group and sample plasma were thawed on ice and then centrifuged at approximately 1000×rcf for 10 minutes at 4° C. to pellet any insoluble material.
Matrix Assay Buffer for running the insulin standard was prepared using plasma matrix from the naïve group to a concentration of 5.26% in 95 μL. 95 μL of Assay Buffer was added to all sample wells, and 95 μL of Matrix Assay Buffer was added to all standard wells. 5 L of each sample and standard were added in duplicate. The plates were incubated at 4° C. for 2 hours. The plates were then washed five times with 300 μL/well 1× Wash Buffer. The plates were tapped sharply several times on paper towels to remove any residual wash buffer.
Anti-Insulin Enzyme Conjugate Working Solution was prepared by combining 2 volumes Anti-Insulin Enzyme Conjugate Stock with 1 volume Enyme Conjugate Diluent, and mixing by pipetting up and down and gently vortexing. 100 μL/well of Anti-Insulin Enzyme Conjugate Working Solution was added to all wells. The plates were sealed and incubated at room temperature for 30 minutes and then washed seven times with 300 μL/well 1× Wash Buffer. The plates were tapped sharply several times on paper towels to remove any residual wash buffer. 100 μL/well Enzyme Substrate Solution was then added to each well and incubated in the dark at room temperature for 40 minutes. 100 μL/well Stop Solution was added to all wells.
The absorbance was read on the Synergy Mx plate reader at 450 nm and 630 nm. Final values obtained were the A450 nm-A630 nm values.
The insulin standard curve was corrected for matrix concentration of insulin by subtracting the mean of the 0 ng/mL insulin standard from each of the standard well A450 nm-A630 nm values in Excel. Duplicate sample concentrations were determined by non-linear regression using a 4 parameter logistic model of the background corrected standard following an x=log(x) transformation of insulin concentration in GraphPad Prism 6. ANOVA and multiple comparison tests were conducted on GraphPad Prism 6. The area under curve was integrated using the Linear-Log Trapezoidal Method on Microsoft Excel, with post hoc testing conducted in GraphPad.
FIG. 9 shows the average plasma insulin concentration for n=6 rats per treatment group over the course of the experiment. The error bars show the standard error of the mean. All treatment groups had statistically significant increases in plasma insulin relative to their treatment or vehicle gavage at 15, 30 and 60 minutes following the glucose challenge (Dunnett's multiple comparisons test). Only SEQID-00105 had a statistically significant increase in plasma insulin concentration at the time of the glucose challenge (0) relative to the plasma insulin at the time of the treatment gavage (P<0.0001, Dunnett's multiple. comparisons test). Both SEQID-00105 and SEQID-00338 had statistically significant greater insulin concentrations at 120 minutes following the glucose challenge (P<0.05 and P<0.01, respectively; Dunnett's multiple comparisons test).
In comparison to the vehicle, only SEQID-00105 showed a statistically significantly greater increase in plasma insulin concentration at the time of the glucose challenge (P<0.001, Dunnett's multiple comparisons test).
These data indicated that an acute ingestion of SEQID-00105 can stimulate insulin release within 15 minutes of ingestion in outbred male Sprague-Dawley rats.
FIG. 10 shows the area under curve integrated between 0-240 and 0-60 minutes for all treatment groups. No treatment group was statistically significantly greater than vehicle.
Total GLP-1 Enzyme Linked Immunosorbent Assay (ELISA).
A rat GLP-1 ELISA Kit was obtained from Crystal Chem, Inc. (Catalog number 81507, Downers Grove, Ill.). Plates were washed using a BioTek ELx50 microplate strip washer (BioTek, Winooski, Vt.). Absorbance was read on a Synergy Mx monochromator-based microplate reader (BioTek, Winooski, Vt.). Data was analyzed using Microsoft Excel version 14.0.7128.5000 (Microsoft Corporation, Redmond, Wash.) and GraphPad Prism version 6.03 for Windows (GraphPad Software, La Jolla, Calif.).
The ELISA kit was prewarmed to room temperature for 30 minutes prior to beginning the assay set up. The standard curve dilutions were prepared in accordance with the manufacturer's instructions.
Plasma matrix from Group 5 and sample plasma were thawed on ice and then centrifuged at approximately 1000×rcf for 10 minutes at 4° C. to pellet any insoluble material.
Matrix Assay Buffer for running the GLP-1 standard was prepared using plasma matrix from the naïve group to a concentration of 25% in 100 μL. The ELISA microplates were washed three times with 350 μL/well 1× Wash Buffer and tapped sharply on paper towels to remove residual wash buffer. 100 μL of Assay Buffer was added to all sample wells, and 100 μL of Matrix Assay Buffer was added to all standard wells. 25 μL of each sample and standard were added in duplicate. Wells were mixed by pipetting. The plates were covered with adhesive foil and incubated for 18 hours at room temperature on a horizontal plate shaker at 100 rpm. The plates were then washed three times with 350 μL/well 1× Wash Buffer then tapped sharply several times on paper towels to remove any residual wash buffer. 100 μL/well of Biotin Labeled Antibody Solution was added to all wells. The plates were then sealed and incubated at room temperature for 1 hour on a horizontal plate shaker at 100 rpm. The plates were then washed three times with 350 μL/well 1× Wash Buffer then tapped sharply several times on paper towels to remove any residual wash buffer. 100 μL/well SA-HRP Solution was added to all wells. The plates were then sealed and incubated at room temperature for 30 minutes on a horizontal plate shaker at 100 rpm. The plates were then washed three times with 350 μL/well 1× Wash Buffer then tapped sharply several times on paper towels to remove any residual wash buffer. 100 L/well Enzyme Substrate Solution was added to all wells. The plates were then sealed and incubated in the dark, without shaking, for 30 minutes at room temperature. Following substrate incubation, 100 μL Stop Solution was added to all wells.
The absorbance values were read on the Synergy Mx plate reader at 450 nm and 630 nm. Final values obtained were the A450 nm-A630 nm values.
The standard curve was corrected for matrix concentration of total GLP-1 by subtracting the mean of the 0 μM GLP-1 standard from each of the standard well A450 nm-A630 nm values in Excel. Duplicate sample concentrations were determined by non-linear regression using a 4 parameter logistic model of the background corrected standard following an x=log(x) transformation of GLP-1 concentration. ANOVA and multiple comparison tests were conducted using GraphPad Prism 6. The area under curve was integrated using the Linear-Log Trapezoidal Method on Microsoft Excel, with post hoc testing conducted in GraphPad.
FIG. 11 shows average plasma GLP-1 concentration for n=6 rats per treatment group over the course of the experiment. The error bars shown here correspond to the standard error of the mean. The SEQID-00338 treatment group shows a statistically significant greater concentration of GLP-1 at the time of the glucose challenge than vehicle (p<0.0005, Dunnett's multiple comparisons test).
Example 22
Use of Nutritive Polypeptides to Improve Glycemic Control in Zucker Fatty (Fa/Fa) Rats
An OGTT was performed in 18, fasted, male Zucker fatty rats with indwelling jugular vein catheters (JVC) to assess the acute effects of nutritive polypeptide dosing on glycemic control as well as insulin and GLP-1 levels.
Oral Glucose Tolerance Test.
All rodents were approximately 10-11 weeks old, weighed average of approximately 450 g and acclimated for 4 days prior to testing. Animals were housed singly with bedding and fed a regular rodent chow diet (Lab Diet 5001) prior to the study. Housing temperature was at kept at 22±2° C., humidity at 50±20%, and a 12 hour light/12 hour dark cycle was implemented. Air circulation was ten or more air changes per hour with 100% fresh air. Prior to treatment, all rats were fasted overnight for fourteen hours. Fasted animals were treated with formulations of nutritive polypeptides dissolved in water by oral gavage (see Table E22A), and fifteen minutes after treatment gavage were then challenged with an oral gavage of glucose (5 g/kg). Blood glucose was measured and blood was collected at seven time points (−15, 0, 15, 30, 60, 90, 120 minutes relative to the glucose challenge). Blood was collected in an EDTA collection tube containing plasma stablizers (a. DPP4 inhibitor and a protease cocktail inhibitor). One additional rat was sacrificed at and bled out to provide naïve blood for analytical standards. Glucose was measured using small drops of blood collected via the JVC using a glucometer (AlphaTrak 2, Abbott).












TABLE E22A






Body













weight
Polypeptides
Glucose











(average,

Dose
Volume
Dose


Group
g)
SEQID
(mg/kg)
(ml/kg)
(g/kg)













1
450
Vehicle
0
11.4
5


2
450
00105
2850
11.4
5


3
450
00338
2850
11.4
5
































Approximately 300 μL of blood was collected from the JVC of all rats in Group 1-3 at six time points (−15, 0, 15, 30, 60, 90, and 120 minutes). Glucose gavages and blood collections were timed to take the same amount of time per animal so that sample times were accurate for each animal. All time points were collected within 5% of the target time. Blood was collected into pre-chilled (0-4° C.) K2EDTA blood collection tubes containing Protease Inhibitor Cocktail (Catalog number D8340, Sigma-Aldrich, St. Louis, Mo.) and DPPIV inhibitor (Millipore, Billerica, Mass.) added to the tubes at 1:100 prior to collection. After blood collection, blood samples were maintained chilled (2-6° C.) and centrifuged within 30 minutes. The collected plasma was placed in sample tubes and immediately stored at −80° C.
Prior to immunoassay analysis samples were thawed on ice for 1 hour, mixed thoroughly by pipette, rearrayed to 96 well microplates. Separate aliquots were prepared for insulin immunoassay and GLP-1 immunoassay. Master plate and aliquots were stored frozen at −80° C.
FIG. 12 shows the average blood glucose values during the OGTT described herein. The error bars shown are the standard errors of the mean.
The integrated area under curve (AUC) was calculated on Microsoft Excel using the Linear-Log Trapezoidal Method and statistical testing was conducted on GraphPad Prism 6.03.
FIG. 13 shows the integrated AUC for each treatment group between the time of glucose challenge (0 min.) and 60 minutes, and between time 0 and 120 minutes. No treatment showed statistically significant difference from vehicle between time 0 and 60 minutes. Between time 0 and 120 minutes SEQID-00105 but not SEQID-00338 shows a statistically significant decrease in integrated area under curve compared to vehicle (P<0.005, Dunnett's multiple comparisons test). These data show that acute dosing of SEQID-00105 can reduce glucose excursion due to an oral glucose challenge in a Zucker Fatty (fa/fa) model rodent model.
Rat Insulin Enzyme Linked Immunosorbent Assay (ELISA).
An Ultra-Sensitive Rat Insulin ELISA Kit was obtained from Crystal Chem, Inc. (Catalog number 90060, Downers Grove, Ill.). Plates were washed using a BioTek ELx50 microplate strip washer (BioTek, Winooski, Vt.). Absorbance was read on a Synergy Mx monochromator-based microplate reader (BioTek, Winooski, Vt.). Data was analyzed using Microsoft Excel version 14.0.7128.5000 (Microsoft Corporation, Redmond, Wash.) and GraphPad Prism version 6.03 for Windows (GraphPad Software, La Jolla, Calif.).
The ELISA kit was prewarmed to room temperature for 30 minutes prior to beginning the assay set up. The standard curve dilutions were prepared in accordance with the manufacturer's instructions for running the assay in Wide Range format.
Plasma matrix from the naïve group and sample plasma were thawed on ice and then centrifuged at approximately 1000×rcf for 10 minutes at 4° C. to pellet any insoluble material.
Matrix Assay Buffer for running the insulin standard was prepared using plasma matrix from the naïve group to a concentration of 5.26% in 95 μL. 95 L of Assay Buffer was added to all sample wells, and 95 L of Matrix Assay Buffer was added to all standard wells. 5 μL of each sample and standard were added in duplicate. The plates were incubated at 4° C. for 2 hours. The plates were then washed five times with 300 μL/well 1× Wash Buffer. The plates were tapped sharply several times on paper towels to remove any residual wash buffer.
Anti-Insulin Enzyme Conjugate Working Solution was prepared by combining 2 volumes Anti-Insulin Enzyme Conjugate Stock with 1 volume Enyme Conjugate Diluent, and mixing by pipetting up and down and gently vortexing. 100 μL/well of Anti-Insulin Enzyme Conjugate Working Solution was added to all wells. The plates were sealed and incubated at room temperature for 30 minutes and then washed seven times with 300 piL/well 1× Wash Buffer. The plates were tapped sharply several times on paper towels to remove any residual wash buffer. 100 μL/well Enzyme Substrate Solution was then added to each well and incubated in the dark at room temperature for 40 minutes. 100 μL/well Stop Solution was added to all wells.
The absorbance was read on the Synergy Mx plate reader at 450 nm and 630 nm. Final values obtained were the A450 nm-A630 nm values. Samples in which the value exceeded the standard curve were rerun at 1:1 dilution against a 2.5% matrix standard
The insulin standard curve was corrected for matrix concentration of insulin by subtracting the mean of the 0 ng/mL insulin standard from each of the standard well A450 nm-A630 nm values in Excel. Duplicate sample concentrations were determined by non-linear regression using a 4 parameter logistic model of the background corrected standard following an x=log(x) transformation of insulin concentration in GraphPad Prism 6. ANOVA and multiple comparison tests were conducted on GraphPad Prism 6. The area under curve was integrated using the Linear-Log Trapezoidal Method on Microsoft Excel, with post hoc testing conducted in GraphPad.
FIG. 14 shows the average plasma insulin concentration for n=6 rats per treatment group in Vehicle & SEQID-00105 and n=5 rats per treatment group in the case of SEQID-00338 over the course of the experiment. One-way ANOVA with Dunnett's multiple comparisons tests were used to compare within each treatment to time 0 and between treatments at the same time point to vehicle. Vehicle had no statistically significant change in plasma insulin compared to the time of vehicle gavage. SEQID-00105 had statistically significantly greater plasma insulin compared to the time of treatment gavage (time −15) at the time of the glucose challenge (time 0) and at 15 minutes and 90 minutes following glucose challenge (P=0.0002, P<0.05 and P<0.05, respectively). SEQID-00338 had statistically significantly greater plasma insulin concentration compared to the time of treatment gavage at all subsequent sampled time points (P<0.0001, P<0.05, P<0.005, P<0.005, and P=0.0005, respectively).
In comparisons between treatments, neither SEQID-00105 nor SEQID-00338 was significantly different from Vehicle at the time of treatment or vehicle gavage. At the time of the glucose challenges and all subsequent time points sampled (0, 15, 30, 60 and 90 minutes) both SEQID-00105 and SEQID-00338 had a significantly greater plasma insulin concentration than vehicle. This shows that both treatments stimulate insulin secretion in the Zucker Fatty (fa/fa) model.
FIG. 15 shows the integrated area under the curve for each group. Only SEQID-00338 treatment integrated between 0 and 90 minutes was statistically significantly greater than vehicle (P<0.005).
Active GLP-1 Enzyme Linked Immunosorbent Assay (ELISA).
A rat active GLP-1 ELISA Kit was obtained from Eagle Biosciences (Catalog number GPI21-K01, Nashua, N.H.). Plates were washed using a BioTek ELx50 microplate strip washer (BioTek, Winooski, Vt.). Absorbance was read on a Synergy Mx monochromator-based microplate reader (BioTek, Winooski, Vt.). Data was analyzed using Microsoft Excel version 14.0.7128.5000 (Microsoft Corporation, Redmond, Wash.) and GraphPad Prism version 6.03 for Windows (GraphPad Software, La Jolla, Calif.).
The ELISA kit was prewarmed to room temperature for at least 30 minutes prior to beginning the assay set up. The standard curve dilutions were prepared in accordance with the manufacturer's instructions.
Plasma matrix from Group 5 and sample plasma were thawed on ice and then centrifuged at approximately 1000×rcf for 10 minutes at 4° C. to pellet any insoluble material.
Matrix Assay Buffer for running the active GLP-1 standard was prepared using plasma matrix from the naïve group to a concentration of 10% in 100 μL for samples tested at 1:1 dilution or 20% in 100 μL for samples tested undiluted. 20 μL of standards and samples were added to the pre-coated microplate and 100 μL appropriate assay buffer added to the standard and sample wells. The plates were covered with adhesive foil and incubated for 24 hours at 4° C. protected from light. The plates were then washed five times with 350 μL/well 1× Wash Buffer then tapped sharply several times on paper towels to remove any residual wash buffer. 100 μL/well of ELISA HRP Substrate was added to all wells. The plates were then sealed and incubated at room temperature for 20 minutes protected from light. 100 μL/well ELISA Stop Solution was added to all wells and gently mixed.
The absorbance values were read on the Synergy Mx plate reader at 450 nm and 620 nm. Final values obtained were the A450 nm-A620 nm values.
The standard curve was corrected for matrix concentration of active GLP-1 by subtracting the mean of the 0 μM GLP-1 standard from each of the standard well A450 nm-A620 nm values in Excel. Duplicate sample concentrations were determined by non-linear regression using a 4 parameter logistic model of the background corrected standard following an x=log(x) transformation of GLP-1 concentration. ANOVA and multiple comparison tests were conducted using GraphPad Prism 6. The area under curve was integrated using the Linear-Log Trapezoidal Method on Microsoft Excel, with post hoc testing conducted in GraphPad.
FIG. 16 shows average plasma GLP-1 concentration for n=6 rats per vehicle and SEQID-00105, and n=5 rats per SEQID-00338 treatment group, over the course of the experiment. One-way ANOVA with Dunnett's multiple comparisons tests were used to compare within each treatment to time 0 and between treatments at the same time point to vehicle. Vehicle showed no significant difference in GLP-1 (7-36) concentration at any time point after vehicle gavage. SEQID-00105 showed significantly greater GLP-1 (7-36) concentration at 15 minutes and 30 minutes after glucose challenge (P<0.0001 and P<0.05, respectively). SEQID-00338 had a significantly greater GLP-1 concentration at 15 minutes following glucose challenge (P<0.005).
When compared to vehicle at each time point only SEQID-00105 had a significantly greater GLP-1 (7-36) concentration than vehicle at 15 minutes following glucose challenge (P<0.005).
FIG. 17 shows the area under curve for GLP-1 (7-36) for each treatment group integrated to 0-90 and 0-60 minutes. No treatment had a significantly different GLP-1 (7-36) integrated AUC compared to vehicle at either 0-90 or 0-60 minutes.
In another experiment, an OGTT was performed in 24, fasted, male Zucker fatty rats with indwelling jugular vein catheters (JVC) to assess the acute effects of nutritive protein dosing on glycemic control as well as insulin and GLP-1 levels. The capacity of SEQID-00105 to improve glucose control was tested by comparing the blood glucose excursion of SEQID-00105 to alogliptin to SEQID-00105+alogliptin to vehicle in the context of an oral glucose tolerance test. All rodents were approximately 10-11 weeks old, weighed average of approximately 430 g and acclimated for 4-5 days prior to testing. Prior to treatment, all rats were fasted overnight for fourteen hours. Fasted animals were treated with formulations of nutritive proteins dissolved in water by oral gavage (see table E22B), and fifteen minutes after treatment gavage were then challenged with an oral gavage of glucose (2 g/kg). Blood glucose was measured and blood was collected at nine time points (−15, 0, 15, 30, 60, 90, 120, 180 and 240 minutes relative to the glucose challenge).










TABLE E22B





Body

DPP IV










weight

Polypeptides
Inhibitor
Glucose










(average,
Treatment
Dose
Volume
Dose
Dose

Group
g)
ID
(mg/kg)
(ml/kg)
(mg/kg)
(g/kg)











1
430.5
Vehicle
0
11.4
0
2

2
432.3
SEQID-00105
2850
11.4
0
2

3
431.7
Alogliptin
0
11.4
0.3
2

4
435.5
SEQID-00105 +
2850
11.4
0.3
2



Alogliptin

































FIG. 18 shows the average blood glucose values during the OGTT described herein. N=6 rats per treatment group. The error bars shown are the standard errors of the mean. Each group was compared post hoc on GraphPad Prism 6, two-way ANOVA, Dunnett's multiple comparisons test first comparing within each group to the fasting glucose concentration, followed by a comparison of each time point to vehicle. No treatment group blood glucose was significantly different from fasting at the time of the glucose challenge.
Fasting glucose and blood glucose at the time of the glucose challenge was not significantly different between each group and vehicle. At 15 minutes following glucose challenge, SEQID-00105 only and SEQID-00105+Alogliptin had significantly lower blood glucose compare to vehicle (P=0.0003 & P<0.0001, respectively). At 30 minutes following the glucose challenge Alogliptin alone and SEQID-00105+Alogliptin had significantly lower blood glucose than vehicle (P=0.0424 & P=0.0021, respectively). At 60 minutes following the glucose challenge, only Alogliptin alone was significantly lower than vehicle (P<0.0001). No group after 60 minutes had significantly different blood glucose than vehicle.
The integrated area under curve (AUC) was calculated on Microsoft Excel using the Linear-Log Trapezoidal Method and two-way ANOVA and Dunnett's multiple comparisons tests was conducted on GraphPad Prism 6.03. No treatment showed statistically significant difference in glucose AUC from vehicle between time 0 and 60 minutes. Between time 0 and 120 minutes and between time 0 and 240 minutes only the alogliptin alone treatment was significantly less than vehicle (P=0.0051 & P=0.0054, respectively).
Example 23
Use of Nutritive Polypeptides to Improve Glycemic Control and Fasting Glucose in Diet Induced Obese Mice
The effects of chronic dosing of therapeutic nutritive polypeptides described herein are evaluated by oral glucose tolerance tests in diet induced obese (DIO) mice. In particular, chronic dosing in this animal model of metabolic disease can affect glycemic control, insulin resistance, fasting glucose and insulin levels, and comparison of fasting levels as well as glucose area under the curve (AUC) during an OGTT before and after a period of daily dosing provides a measure of compound efficacy.
Four groups of 10 male C57BL/6 mice are fed a high fat diet ad libitum for 14 weeks to ensure that they develop elevated fasting glucose levels (hyperglycemia), elevated fasting insulin levels (hyperinsulinemia), and impaired glucose control (Xu. H. et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. (2003) 112: 1821-1830). A single group of 10 male C57BL/6 mice (group 1) is fed a normal diet for comparison of treatment arms on HFD to normal diet at the same age, handling, and housing conditions. All mice are housed and acclimated for three days prior to the start of the study.
All Mice are fasted overnight for fourteen hours before OGTT treatment, and a blood sample is collected the morning of the study prior to dosing for analysis of fasting glucose and hormone levels. Fasted animals are treated with formulation of provided nutritive polypeptides by oral gavage fifteen minutes before glucose challenge. Glucose (2 g/kg) is orally administered at time zero. Blood glucose is measured at seven time points (−15, 0, 15, 30, 60, 90, 120 minutes). Age-matched normal mice under regular diet are used as an internal standard for the analytics. In groups 2-5, mice receive daily dose of provided therapeutic nutritive polypeptides (2.85 g/kg) (groups 4 and 5) or vehicle control (groups 2 and 3) for 15-30 days via daily gavage or formulation into chow. All blood is collected in an EDTA collection tube containing plasma stabilizers (a DPP4 inhibitor and a protease cocktail inhibitor), processed for plasma, and stored frozen at −80 C.
An OGTT as described above is performed again on the final day of the study with either vehicle (groups 2 and 4) or test article (groups 1, 3, and 5). Prior to the final test article or vehicle dose, a blood sample is collected for analysis of fasting glucose and hormone levels. At the completion of the final OGTT, all mice are sacrificed and entire blood volume is collected via cardiac puncture. Analysis of insulin levels are performed using an ELISA method described herein.
Comparisons of end of study OGTT glucose AUC across groups 2 and 4 describe the effect of chronic test article administration without the acute effects of test article administration on the OGTT. Comparisons of end of study OGTT glucose AUC across groups 3 and 5 describe the effect of chronic test article administration and include the acute effects of test article administration on the OGTT. Comparisons of fasting glucose and insulin levels at the beginning and end of the study within group 4 or within group 5 describe the effect of chronic dosing on fasting glucose and insulin levels.
Example 24
Use of Nutritive Polypeptides to Induce Insulin Secretion in Rodents
Ingested amino acids have been shown to have the capacity to induce insulin secretion (Gannon M. C. and F. Q. 2010. Nuttall. Amino Acid Ingestion and Glucose Metabolism—A Review. IUBMB Life, 62(9): 660-668). Protein ingestion increases plasma insulin significantly in comparison to ingestion of glucose alone (Nuttall, et al. 1984. Effect of protein ingestion on the glucose and insulin response to a standardized oral glucose load. Diabetes Care. 7(5):465-470). Ingested protein increases insulin secretion in part via the action of incretin hormones, i.e., glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), which are secreted by endocrine cells upon luminal exposure to nutrients (Baggio L L & D J Drucker. 2007. Biology of incretins: GLP-1 and GIP. Gastroenterology. 132:2131-2157). Amino acids such as leucine and arginine have also been shown to directly stimulate insulin release (Newsholme P. et al. New insights into amino acid metabolism, B-cell function and diabetes. Clin. Sci . (2005) 108: 185-194). In these studies, the insulin response after acute dosing of various nutritive proteins was measured in rodents.
Animals were treated and acutely dosed with various test articles as part of pharmacokinetic rodent experiments according to methods described herein. Unless otherwise stated all dosing was at 2.85 g/kg body weight. All treatment groups except for SEQID-00240 which had n=5 rats, and SEQID-00587 which had n=3, contained n=4 rats.
Quantification of Plasma Insulin Using AlphaLISA® Insulin Immunoassay
Plasma samples were thawed on ice and centrifuged for 10 minutes at 1109×g to pellet insoluble material. AlphaLISA® Insulin Immunoassay Kit (PerkinElmer, AL204C) was removed from 4° C. cold room and kept on ice during assay set up. 1× Assay Buffer was prepared by diluting 10× Assay Buffer with milliQ water.
Standard buffer for dilution of insulin was prepared at 25.9% fasted rat plasma in. 1× Assay Buffer and used to prepare a 16 point standard curve. Plasma samples were prepared by diluting 7:20 in 1× Assay Buffer in a 96-well PCR microplate.
Acceptor bead mix was prepared by diluting Acceptor Beads and Biotinylated Anti-Insulin Antibody 1/400 in 1× Assay Buffer. Acceptor bead mix was pipetted, 20 μL/well, into a white opaque 384 well microplate (PerkinElmer, OptiPlate-384), to this mixture was added 10 μL/well of insulin standard in fasted rat plasma or sample rat plasma in duplicate. The plate was sealed with a foil plate seal and incubated on a horizontal shaker at ˜600 rpm for 60 minutes at room temperature.
It was necessary to protect the Streptavidin Coated Donor Beads from light; as such, in a darkened room, donor bead mix was prepared by diluting the streptavidin coated donor beads 1/125 in 1× Assay Buffer. After the first incubation step, 20 μL/well donor bead mix was added to the standard and samples. The assay plate was sealed and returned to the horizontal shaker at ˜600 rpm, for 30 minutes at room temperature. Following the donor bead incubation, luminescence was read on the EnSpire Alpha plate reader.
Data were analyzed with Microsoft Excel version 14.0.7128.5000 (32-bit) and GraphPad Prism version 6.03. A standard curve was generated to log(Insulin (μIU)). Rat plasma insulin concentrations were interpolated using a sigmoidal, four parameter logistic equation. The mean of duplicate concentration of insulin in the technical replicates for each rat were plotted against time. Area under curve was integrated for 0-240 minutes and 0-60 minutes using the Linear-Log Linear Method in Microsoft Excel.
Quantification of Plasma Insulin Using a Rat Insulin Enzyme Linked Immunosorbent Assay (ELISA).
An Ultra-Sensitive Rat Insulin ELISA Kit was obtained from Crystal Chem, Inc. (Catalog number 90060, Downers Grove, Ill.). Plates were washed using a BioTek ELx50 microplate strip washer (BioTek, Winooski, Vt.). Absorbance was read on a Synergy Mx monochromator-based microplate reader (BioTek, Winooski, Vt.). Data was analyzed using Microsoft Excel version 14.0.7128.5000 (Microsoft Corporation, Redmond, Wash.) and GraphPad Prism version 6.03 for Windows (GraphPad Software, La Jolla, Calif.).
The ELISA kit was pre-warmed to room temperature for 30 minutes prior to beginning the assay set up. The standard curve dilutions were prepared in accordance with the manufacturer's instructions for running the assay in Wide Range format.
Plasma matrix from the naïve group and sample plasma were thawed on ice and then centrifuged at approximately 1000×rcf for 10 minutes at 4° C. to pellet any insoluble material.
Matrix Assay Buffer for running the insulin standard was prepared using plasma matrix from the naïve group to a concentration of 5.26% in 95 μL. 95 μL of Assay Buffer was added to all sample wells, and 95 μL of Matrix Assay Buffer was added to all standard wells. 5 μL of each sample and standard were added in duplicate. The plates were incubated at 4° C. for 2 hours. The plates were then washed five times with 300 μL/well 1× Wash Buffer. The plates were tapped sharply several times on paper towels to remove any residual wash buffer:
Anti-Insulin Enzyme Conjugate Working Solution was prepared by combining 2 volumes Anti-Insulin Enzyme Conjugate Stock with 1 volume Enzyme Conjugate Diluent, and mixing by pipetting up and down and gently vortexing. 100 μL/well of Anti-Insulin Enzyme Conjugate Working Solution was added to all wells. The plates were sealed and incubated at room temperature for 30 minutes and then washed seven times with 300 μL/well 1× Wash Buffer. The plates were tapped sharply several times on paper towels to remove any residual wash buffer. 100 μL/well Enzyme Substrate Solution was then added to each well and incubated in the dark at room temperature for 40 minutes. 100 μL/well Stop Solution was added to all wells. The absorbance was read on the Synergy Mx plate reader at 450 nm and 630 nm. Final values obtained were the A450 nm-A630 nm values.
The insulin standard curve was corrected for matrix concentration of insulin by subtracting the mean of the 0 ng/mL insulin standard from each of the standard well A 450 nm -A 630 nm values in Excel. Duplicate sample concentrations were determined by non-linear regression using a 4 parameter logistic model of the background corrected standard following an x=log(x) transformation of insulin concentration in GraphPad Prism 6. ANOVA and multiple comparison tests were conducted on GraphPad Prism 6. Area under curve was integrated for 0-240 minutes and 0-60 minutes using the Linear-Log Linear Method in Microsoft Excel.
In Vivo Plasma Insulin Concentrations
FIGS. 19 and 20 show the combined biological replicate data for a study of vehicle and SEQID-00105 administered at three different doses and SEQID-00426, SEQID-00338, SEQID-00341 administered at one dose, where plasma insulin was measured using the AlphaLISA Insulin kit. All error bars represent the standard error of the mean. A one-way ANOVA with Dunnett's multiple comparisons tests were used to compare within each treatment to time 0 and between treatments at the same time point to vehicle.
In FIG. 19 , SEQID-00105 at 2.85 g/kg had a statistically significant increase in plasma insulin concentration at 15, 30 and 60 minutes following gavage (P<0.0001, P<0.0001, and P<0.05, respectively); SEQID-00105 at 1.78 g/kg had a statistically significant increase in plasma insulin concentration at 15 and 30 minutes following gavage (P=0.0005 and P<0.05, respectively); at the lowest SEQID-00105 dose plasma insulin concentration over the time course was not significantly different from time 0. When compared to the plasma insulin concentration of the vehicle control at each time point, SEQID-00105 at 2.85 g/kg showed statistically significant greater plasma insulin than vehicle at 15 minutes and 30 minutes following oral gavage (P<0.0001 and P<0.001, respectively), SEQID-00105 at 1.78 g/kg showed a statistically significant increase in plasma insulin concentration at 15 minutes following oral gavage (P=0.0005). In FIG. 20 , only SEQID-00338 had a statistically significant increase in plasma insulin concentration from 0 at 15 and 30 minutes following oral gavage (P=0.005 and P<0.05, respectively). When compared to vehicle plasma insulin concentration at each concentration SEQID-00338 was significantly greater than vehicle at 15 minutes following oral gavage (P<0.01).
FIGS. 21 and 22 show the integrated area under curves for plasma insulin concentrations measured for vehicle of SEQID-00105, SEQID-00426, SEQID-00338, SEQID-00341, error bars are the standard error of the mean. One-way ANOVA with Dunnett's multiple comparisons tests were used to compare the AUCs to vehicle. SEQID-00105 at 2.85 g/kg had a statistically significantly greater plasma insulin AUC than vehicle when integrated from 0-240 minutes and 0-60 minutes (P=0.0005 and P<0.05, respectively).
FIGS. 23 and 24 show the combined biological replicate data for a study of vehicle and SEQID-00423, SEQID-00587, SEQID-00105, SEQID-00424, SEQID-00425, and SEQID-00429, where plasma insulin was measured using the AlphaLISA Insulin kit. All error bars represent the standard error of the mean. One-way ANOVA with Dunnett's multiple comparisons tests were used to compare within each treatment to time 0 and between treatments at the same time point to vehicle.
FIGS. 25 and 26 shows the integrated area under curves for plasma insulin concentrations shown in FIGS. 23 and 24 . One-way ANOVA with Dunnett's multiple comparisons tests were used to compare the AUCs to vehicle. SEQID-00587 had a significantly greater plasma insulin AUC when integrated at 0-240 minutes (P<0.005).
FIG. 27 shows the combined biological replicate data for a study of vehicle and SEQID-00105, SEQID-00240, and SEQID-00559, where plasma insulin was measured using the Rat Insulin ELISA kit. All error bars represent the standard error of the mean. One-way ANOVA with Dunnett's multiple comparisons tests were used to compare within each treatment to time 0. SEQID-00105, and SEQID-00559 both had a statistically significant increase in plasma insulin concentration at 15 minutes post gavage compared to time 0 (P<0.05, both). SEQID-00240 had statistically significant increase in plasma insulin at 15 and 30 minutes post gavage compared to time 0 (P<0.05 & P<0.01, respectively). The vehicle had no statistically significant change in plasma insulin concentration compared to time 0.
FIG. 28 shows the integrated area under curve from 0-240 and 0-60 minutes post gavage for each treatment, error bars are the standard error of the mean. No treatment showed a significantly greater AUC compared to vehicle at 0-60 or 0-240 minutes by a Dunnett's multiple comparisons test.
Example 25
Nutritive Polypeptide Stimulation of Glucagon Like Peptide 2 Secretion in Healthy, Fasted Rats
Glucagon-like peptide-2 (GLP-2) is a thirty three amino acid peptide produced by the post-translational cleavage of proglucagon. GLP-2 is secreted by the intestinal enteroendocrine L-cells of humans and rodents along with GLP-1 in response to exposure to nutrients in the gut lumen. GLP-2 has been shown previously to improve outcomes in the treatment of short bowel syndrome (Brinkman A S, Murali S G, Hitt S, Solverson P M, Hoist J J, Ney D M. 2012. Enteral nutrients potentiate glucagon-like peptide-2 action and reduce dependence on parenteral nutrition in a rat model of human intestinal failure. Am. J. Physiol. Gastrointest. Liver Physiol. 303 (5):G610-G622) by supporting intestinal growth (Liu X, Murali S G, Hoist J J, Ney D M. 2008. Enteral nutrients potentiate the intestinotrophic action of glucagon-like peptide-2 in association with increased insulin-like growth factor-I responses in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 295 (6):R1794-R1802).
Animals were treated and acutely dosed with test articles as part of pharmacokinetic rodent experiments according to methods described herein. In this experiment, two test articles were analyzed, vehicle and a nutritive formulation of SEQiD-240, dosed at 1.54 g/kg.
Total GLP-2 Enzyme-Linked Immunosorbent Assay (ELISA)
Total GLP-2 was measured with Millipore Total GLP-2 ELISA Kit (Millipore, EZGLP2-37K). The ELISA kit was equilibrated to room temperature for a minimum of 30 minutes prior to running the assay. The kit GLP-2 Standard, Quality Control 1 and Quality Control 2 were reconstituted with 500 μL MilliQ water, inverted 5 times and incubated at room temperature for 5 minutes, then gently vortexed to mix. The standard curve was prepared by diluting the GLP-2 Standard serially 1:1 in kit Assay Buffer to generate an eight point standard curve including 0 ng/mL GLP-2. Plasma samples were thawed on ice and centrifuged for 10 minutes at approximately 1109×rcf to pellet insoluble material. Fasted plasma matrix from untreated, fasted rat was prepared for running the standard and quality controls in duplicate at 20% (2×).
1× Wash Buffer was prepared in a clean 500 mL glass bottle by combining 50 mL 10× Wash Buffer with 450 mL MilliQ water. Strips were prepared by washing 3 times with 300 L 1× Wash Buffer applied with a 30-300 L 8-channel pipette. Between washes the wash buffer was decanted into a waste receptacle and the plate tapped sharply on a stack of paper towels to remove remaining wash buffer.
Following the first wash, 90 L of Assay Buffer was added to sample wells, and 50 μL of 20% matrix in Assay Buffer was added to all standard and quality control wells. 10 L of sample was added to each sample well and 50 μL of standard and quality control were added to matrix containing wells. Samples, standards and quality control wells were run in duplicate, except for 0 ng/mL GLP-2 standard which was run in quadruplicate.
The plate was sealed with a plastic plate seal and incubated at room temperature on a horizontal plate shaker at 450 rpm for 2 hours. Following the first incubation, the plate was washed three times with 1× Wash Buffer, decanting into a waste receptacle and tapping the inverted plate sharply on a stack of paper towels to remove excess wash buffer after each wash.
100 μL of Detection Antibody was added to each well and the plate was sealed with a plastic plate seal and incubated at room temperature on a horizontal plate shaker at 450 rpm for 1 hour. Following the second incubation, the plate was washed three times with 1× Wash Buffer, decanting into a waste receptacle and tapping the inverted plate sharply on a stack of paper towels to remove excess wash buffer after each wash.
100 μL Enzyme Solution was added to each well and the plate was sealed with a plastic plate seal and incubated at room temperature on a horizontal plate shaker at 450 rpm for 30 minutes. Following the third incubation, the plate was washed three times with 1× Wash Buffer, decanting into a waste receptacle and tapping the inverted plate sharply on a stack of paper towels to remove excess wash buffer after each wash.
100 μL Substrate was added to each well and the plate was sealed with a plastic plate seal and an opaque foil seal and incubated at room temperature on a horizontal plate shaker at 450 rpm for 20 minutes. Following substrate reaction, 100 μL of Stop Solution was added to each well and the plate gently shaken to mix.
Absorbance was measured on a SynergyMX Plate Reader at 450 nm and 590 nm. Measured values were the difference between 450 nm and 590 nm absorbance values.
Data were analyzed with GraphPad Prism 6.03. A standard curve was generated to log(Total GLP-2 (ng/mL)) after subtracting the 0 ng/mL background value. Rat plasma GLP-2 concentrations were interpolated using a sigmoidal, four parameter logistic equation. The mean of duplicate concentration of GLP-2 in the technical replicates for each rat were plotted against time. The integrated area under curve was calculated on Microsoft Excel where the area between each time point was calculated for each biological replicate as the sum of the areas using the Linear-Log Trapezoidal Method.
FIG. 29 shows the calculated total GLP-2 concentration over a 4 hour time course for SEQID-00240 and vehicle control. Vehicle GLP-2 concentration did not change significantly at any of the time points sampled compared to time 0, whereas SEQID-00240 showed a statistically significant increase in GLP-2 concentration relative to time 0 at 15 (P<0.00), 30 (P<0.0001) and 60 minutes (P<0.01) following SEQID-00240 gavage (Dunnett's multiple comparison test). SEQID-00240 was compared to vehicle at each time point by ordinary One-Way ANOVA with a Dunnett's multiple comparisons test post hoc analysis. GLP-2 concentration was not significantly different between treatments at time 0. GLP-2 concentrations were statistically significantly greater than vehicle at 15 (P<0.001), 30 (P<0.0001), 60 (P<0.0001) and 120 minutes (P<0.05) following treatment. These data show that an acute dose of SEQID-00240 but not vehicle induces secretion of GLP-2 in healthy fasted rodents.
FIG. 30 shows the integrated GLP-2 area under the curve over the first hour and the full 4 hours. The area under curve for GLP-2 was significantly greater in the SEQID-00240 treatment compared to vehicle when integrated over 0-60 minutes and over 0-240 minutes (P<0.005 & P<0.01, respectively, unpaired 2-tailed Student's t-test). This data indicated that acute dosing of SEQID-00240 significantly stimulated GLP-2 secretion in comparison to vehicle within the first hour of acute dosing in healthy fasted rodents.
Example 26
Effect of Orally Delivered Nutritive Polypeptides on Plasma Insulin and Incretin Levels in Humans
The insulin and incretin response to protein ingestion is predicated on the delivery of amino acids. The purpose of this study was to examine the changes in plasma insulin concentrations in response to SEQID-00426 and SEQID-00105 over a period of 240 minutes. Two groups of four apparently healthy subjects between the ages of 18 and 50 received 20 grams of the nutritive polypeptide formulations orally. All subjects were fasted overnight (>8 hrs) before starting the study. Venous blood samples were collected at specified time points (i.e. 0, 15, 30, 60, 90, 120, 150, 180, 210 and 240 minutes) following the oral ingestion of nutritive polypeptide to assess changes in plasma insulin and incretin concentrations. FIG. 31 shows the average insulin response of all subjects to SEQID-00105, and FIG. 32 shows the average fold response over baseline (time 0 min), measured as described herein. The error bars on all figures correspond to the standard error of the mean. The first phase insulin response occurs between time 0 min and 90 min. The second phase insulin response occurs between 90 min and 210 min. A 1-way ANOVA comparison across time indicates that there is a significant change in plasma insulin over time (p=0.003). A Dunnett multicomparison test indicates that the insulin values at 15 and 30 min time points are significantly different from that at time 0 min (p<0.05).
FIG. 33 shows the average insulin response of all patients to SEQID-00426, and FIG. 34 shows the average fold response over baseline (time 0 min), measured as described herein. The error bars on all figures correspond to the standard error of the mean.
FIG. 35 shows the average total Gastric Inhibitory Polypeptide (GIP) response of all patients to SEQID-00426, and FIG. 36 shows the average fold response over baseline (time 0 min), measured as described herein. The error bars on all figures correspond to the standard error of the mean.
Example 27
In Vitro Demonstration of Skeletal Muscle Cell Growth and Signaling Using Nutritive Polypeptide Amino Acid Compositions Containing Tyrosine, Arginine, and/or Leucine
The mammalian target of rapamycin (mTOR) is a protein kinase an a key regulator of cell growth, notably via protein synthesis. mTOR acts as a master regulator of cellular metabolism that nucleates two complexes, mTORC1 and mTORC2 that have different kinase specificity and distinct protein partners (citations from ESS-020).
mTOR drives protein synthesis across tissues. mTORC1 mediated response to growth signaling is gated by amino acids. The localization of the response to lysosomes couples mTOR activation to muscle protein catabolism. mTORC1 can be gated by essential amino acids (EAAs), leucine, and glutamine. Amino acids must be present for any upstream signal, including growth factors, to activate mTORC1 (citations from ESS-020).
These experiments demonstrated the capacity of arginine, tyrosine as well as leucine to modulate mTORC1 activation by measuring downstream phosphorylation of the ribosomal protein S6 (rps6) in response to stimulation by single amino acids in vitro.
Primary Rat Skeletal Muscle Cell (RSKMC) culture medium was purchased from Cell Applications (Catalog number: R150-500, San Diego, Calif.). Starvation medium DMEM/F12 was bought from Sigma (Catalog number: D9785, St. Louis, Mo.). Customized starvation medium Mod.4 was purchased from Life Technologies (Catalog number: 12500062, Grand Island, N.Y.), which does not contain any amino acids, phenol red, or glucose. Fetal bovine serum (FBS) and other growth factors were obtained from Cell Applications (Catalog number: R151-GS, San Diego, Calif.). Tissue culture flasks and clear bottom 96-well tissue culture plates were purchased from Corning Incorporated (Catalog number: 430641 and 353072, respectively, Corning, N.Y.). Trypsin/EDTA was obtained from Life Technology (Catalog number: 25200, Grand Island, N.Y.). DPBS and HBSS were also purchased from Life Technologies (Catalog number: 14190, 14175, respectively). AlphaScreen® SureFire® Ribosomal Protein S6 Assay Kits was obtained from Perkin Elmer (Catalog number: TGRS6P2S10K).
Primary Rat Skeletal Muscle Cell (RSKMC) culture. RSKMC were isolated using protocol described herein and cryopreserved in liquid nitrogen. The cells were also maintained in RSKMC medium (Cell Applications) in T75 tissue flask in a 37° C., 5% CO2 tissue culture incubator (Model 3110, Thermo Fisher Scientific). The cells were split every three day when they reached ˜90% confluency. RSKMC cells were cultured in RSKMC medium in T75 tissue flask to 100% confluency. The culture medium was aspirated from the culture flask and rinsed once with 10 ml of DPBS, and then 1.5 ml of 0.25% trypsin/EDTA was added to the cells. After the cells were detached from the flask, 10 ml of culture medium were added. The medium was pipetted up and down with a 10 ml pipet to detach the cells from the flask. The cells were then seeded into clear bottom 96-well tissue culture plates at a density of 50,000 cells per well. Following overnight culture in a 37° C., 5% CO2 incubator, the cells were starved over a period of 4 hours with starvation DME/F12 medium without FBS and leucine in a 37° C., 5% CO2 tissue culture incubator, then starved for another hour incubation with Hank's Buffered Salt Solution (HBSS). The cells were stimulated with different concentrations of leucine in starvation medium for 15 and 30 minutes. The cells were also treated with 5 nM of Rapamycin (R0395, Sigma) or 100 nM of Insulin (19278, Sigma) for 15 and 30 minutes. The cells were lysed in 20 μL of Lysis Buffer (Perkin Elmer) for 10 minutes at room temperature with shaking at 725 rpm. The cell lysates were stored at −80° C. and AlphaScreen® assay was performed the next day. AlphaScreen® SureFire® Ribosomal Protein S6 Assay was performed according to manufacturer's manual.
FIG. 37 shows the relative alphascreen signal (y-axis) measured at different Leucine concentrations, demonstrating that leucine stimulates phorphorylation of rps6 in primary RSkMC in a dose-dependent manner. This stimulation was inhibited in a dose dependent manner by the mTOR inhibitor, rapamycin.
FIG. 38 shows that leucine stimulates phosphorylation of rps6 in primary RSkMC in a dose-dependent manner in both a complete amino acid medium (Arg, His, Lys, Asp, Glu, Ser, Thr, Asn, Gln, Cys, Gly, Pro, Ala Val, Ile, Met, Phe, Tyr, Trp), as well as a minimal 12 amino acid mixture containing only (Arg, His, Lys, Thr, Gln, Cys, Val, Ile, Met, Phe, Tyr, and Trp) at their DME/F12 concentrations (see table E27B).
Primary skeletal muscle cells obtained from the Soleus (Sol), gastrocnemius (GS) and extensor digitorum longus (EDL) of two Sprague-Dawley rats. FIGS. 39, 40, and 41 shows that leucine stimulates mTOR RPS6 pathway using isolated primary cells in a dose dependent manner.
Arginine, tyrosine and leucine are required to fully stimulate the mTOR pathway. Cells were starved as described above in Mod.4 medium without fetal bovine serum and then stimulated in Mod.4 medium lacking each of the respective single amino acids (see table E27A and E27B for composition of Mod.4 medium and DME/F12 amino acid levels, respectively).










TABLE E27A



Vitamins
μM
Other
mM
Inorganic Salts
mM












Choline chloride
64.1
D-Glucose
17.5
Calcium chloride,
1.05



(Dextrose)

anhydrous


D-Calcium
47
Sodium Pyruvate
0.5
Copper (II) Sulfate
5.21E−

pantothenate



Pentahydrate
06

Folic Acid
6.01
HEPES
15
Magnesium Sulfate
0.407





(anhyd.)


Niacinamide
16.56
Hypoxanthine
0.018
Magnesium Chloride
0.301

Pyrodoxine
9.88
Linoleic Acid
1.50E−04
Potassium Chloride
4.157

hydrochloride






Riboflavin
0.58
Putrescine
5.03E−04
Sodium Bicarbonate
0.014



Hydrochloride




Thiamine
6.44
Thioctic Acid
5.10E−04
Sodium Chloride
120.6

hydrochloride






i-inositol
70
Thymidine
1.51E−03
Sodium Phosphate
0.521





Monobasic


D-biotin
1.43E−
Phenol Red
5.00 × 10{circumflex over ( )} −4
Sodium Phosphate
0.5


02

(%)
Dibasic


Vitamin B-12
0.5


Iron (III) Nitrate
1.24E−





Nonahydrate
04





Iron (II) Sulfate
1.50E−





Heptahydrate
03





Zinc Sulfate
1.50E−





heptahydrate
03



















































TABLE E27B





Amino Acids μM
Amino Acids μM













Glycine
250
L-Leucine
451


L-Alanine
50
L-Lysine
500


L-Arginine
700
L-Methionine
116


L-Asparagine
57
L-
215


L-Aspartic
50
Phenylalanine



Acid

L-Proline
150


L-Cysteine
100
L-Serine
250


L-Glutamic
100
L-Threonine
449


Acid

L-Tryptophan
44


L-Glutamine
2500
L-Tyrosine
214


L-Histidine
150
L-Valine
452


L-Isoleucine
416

































Primary muscle cells were starved for 2 hours, and then stimulated with 0 μM or 500 μM single amino acid in 37 C, 5% CO2 tissue culture incubator for 30 minutes. The treatment was performed in triplicate. FIG. 42 demonstrates that the combination of leucine, arginine, and tyrosine are necessary and sufficient to activate the mTOR pathway in RMSKC to the same degree as a full-complement of all 20 amino acids at their DME/F12 concentrations, and that none of the individual or paired treatments of Leu, Arg, or Tyr were capable of a similar response.
FIGS. 43, 44, and 45 show the effect of a dose response of each amino acid (Leu, Arg, Tyr) in the background of all other 19 amino acids vs the other 2 amino acids (e.g. dose response of Arg in a background of Tyr and Leu) on rps6 phosphorylation. These data indicate the synergy between Leu, Arg, and Tyr is dose dependent. Comparing the 20 amino acids response at low doses of Arg to that in a comparable high Leu and Tyr background, there is a reduction in the degree of stimulation caused by the other 17 amino acids. At high doses of Arg, the response in both backgrounds equalizes. Comparing the 20 amino acids response at low doses of Leu to that in a comparable high Arg and Tyr background, there is no difference in rps6 phosphorylation response. Comparing the 20 amino acid response at low doses of Tyr to that in a comparable high Leu and Arg background, the other 17 amino acids can further potentiate the mTOR response.
Example 28
Determination of Safety and Lack of Toxicity of Leucine-Enriched Nutritive Polypeptides Following Oral Consumption by Rodents
An acute toxicology study was completed to confirm the expected safety of nutritive polypeptides SEQID-00105, SEQID-00363, and SEQID-00426 in rodents.
Each study group contained 5 male rats and 5 female rats (10 Wistar, 6-7 weeks old, Males 220-250 g, Females 180-200 g). Test formulations were 350 g/L nutritive polypeptide and aqueous buffer as a control. Animals were acclimated for 1 week upon arrival and given a diet of regular chow always available. Before dosing, animals were weighed and pre-bleeds were taken. Single dosage of 10 ml/kg was completed via oral gavage. On days 2, 6 and 7, body and food weights were taken. On day 6 animals were bled in EDTA and Sodium Heparin tubes. On day 7 weights were taken and animals were euthanized followed by immediate necropsies. Eight organs (heart, liver, lung, spleen, kidney, brain, bladder, and small intestine) were removed, weighed and stored in 10% formaldehyde. During the study clinical observations for signs of stress, pain, and abnormal activity were performed daily.
For all three tested nutritive polypeptides the protein and buffer were well tolerated as no abnormalities were seen in the animals. All activity from the animals was normal and no other signs of pain or distress were observed.
Example 29
Analytical Demonstration of Nutritive Polypeptide Digestibility
The digestion of nutritive polypeptides was analyzed via in vitro simulated digestion assays. In vitro digestion systems are used to simulate the breakdown of polypeptides into bioaccessible peptides and amino acids, as occurs in vivo while passing through the stomach and intestine (Kopf-Bolanz, K. A. et al., The Journal of nutrition 2012; 142: 245-250, Hur, S. J. et al., Food Chemistry 2011; 125: 1-12). Simulated gastrointestinal digestion is also predictive of potential protein allergenicity, since digestion-resistant polypeptides may be absorbed and cause sensitization (Astwood et al., Nature Biotechnology 1996; 14: 1269-1273).
Nutritive Polypeptide Half-Life During Simulated Digestion.
One metric for quantifying the breakdown of polypeptides from an intact form to smaller peptides is the intact half-life. In this experiment the nutritive polypeptide was exposed to a series of proteases that are active in the stomach (pepsin) and intestine (trypsin and chymotrypsin), and the presence of intact protein was measured over time. Specifically, the nutritive polypeptide was first treated at a concentration of 2 g/L with simulated gastric fluid (SGF) (0.03 M NaCl, titrated with HCl to pH 1.5 with a final pepsin:polypeptide ratio of 1:20 w/w) at 37° C. Time points were sampled from the reaction and quenched by addition of 0.2 M Na2CO3. After 120 min in SGF, the remaining reaction was mixed 50:50 with simulated intestinal fluid (SIF) (18.4 mM CaCl2, 50 mM MES pH 6.5 with a final trypsin:chymotrypsin:substrate ratio of 1:4:400 w/w) and neutralized with NaOH to pH 6.5. Time points were sampled from the reaction and quenched by addition of Trypsin/Chymotrypsin Inhibitor (Sigma) solution until 240 min.
Time point samples were analyzed for intact protein by chip electrophoresis, polyacrylamide gel electrophoresis, or western blot. For chip electrophoresis (Labchip GX II), samples were analyzed using a HT Low MW Protein Express LabChip® Kit (following the manufacturer's protocol). A protein ladder was loaded every 12 samples for molecular weight determination (kDa) and quantification. For polyacrylamide gel electrophoresis, samples (1 μg) were separated on a NuPAGE® Novex® Bis-Tris Precast gel (Life Technologies) according to the manufacturer's protocol. The gel was stained using SimplyBlue™ SafeStain (Invitrogen) and imaged using a Chemidoc XRS+ (BioRad) or transferred onto nitrocellulose membranes using the iBlot® Dry Blotting System (Life Technologies) and iBlot® Western Detection Kit (Life Technologies) according to the manufacturer's protocol. Proteins were detected by blotting with Anti-His [C-term]-HRP antibody diluted 3:5000 in Blok™-PO Blocking Buffer using the SNAP I.d.® Protein Detection System (Millipore) according to the manufacturer's protocol. Blots were treated with Luminata Classico Western HRP Substrate (Millipore) according to the manufacturer's protocol and imaged using chemiluminescent detection on the Molecular Imager® Gel Doc™ XR+ System (Bio-Rad). Quantification of intact protein was determined by densitometry using ImageLab (BioRad). For all analysis methods the relative concentration of the polypeptide at each time point (if detected) was plotted overtime and fit to an exponential curve to calculate the intact half-life.
Alternatively, samples were analyzed by determining the percentage of intact protein remaining at a single time point (eg. half-life less than 2 min). Specifically, the t=0 (enzyme-free control) and t=2 min samples from the SGF digest were analyzed for intact protein as described by chip electrophoresis, SDS-PAGE, western blot, and/or LC-MS/MS. Relative quantities of polypeptides at each time point were determined and the percentage of intact protein remaining at t=2 was determined. Intact half-life values determined using this method are reported as greater or less than 2 min to indicate more or less than 50% of the protein remained intact at t=2 min, respectively. Results for intact SGF half-life determined by either method are reported in Table E29A.
Table E29A. Intact half-lives calculated from in vitro intact protein detection during SGF treatment. All proteins were produced in E. coli , unless otherwise noted. AN= Aspergillus niger , AO= Aspergillus oryzae , BS= Bacillus subtilis , BA= Bacillus amyloliquefaciens , KL= Kluyveromyces lactis , TL= Thermomyces lanuginosus , BL= Bacillus licheniformis . Alpha-mannosidase-treated SEQID-00363 and protein proteins originating from AO, BA, KL, TL, and BL were produced as described herein.







SGF Half-life (t½) in

min










SEQID-00001
5


SEQID-00001 (HEK293)
8.6


SEQID-00008
0.9


SEQID-00009
3


SEQID-00076
0.3


SEQID-00085
0.9


SEQID-00087
0.3


SEQID-00098
0.4


SEQID-00099
1


SEQID-00100
2


SEQID-00102
0.6


SEQID-00103
0.3


SEQID-00103 (HEK293)
<2


SEQID-00104
0.3


SEQID-00105
0.2


SEQID-00105 (BS)
0.5


SEQID-00105 (HEK293)
<2


SEQID-00143
0.3


SEQID-00212
0.3


SEQID-00215
2


SEQID-00218
6


SEQID-00220
0.5


SEQID-00226
0.7


SEQID-00236
10


SEQID-00237
0.6


SEQID-00240
0.7


SEQID-00241
0.3


SEQID-00265
29


SEQID-00269
41


SEQID-00284
1


SEQID-00287
3


SEQID-00298 (AN)
0.3


SEQID-00298 (BS)
0.1


SEQID-00302
0.2


SEQID-00305
0.2


SEQID-00338
0.2


SEQID-00338 (BS)
0.2


SEQID-00341
0.2


SEQID-00343
0.3


SEQID-00345
0.8


SEQID-00346
0.2


SEQID-00352
0.2


SEQID-00354
0.2


SEQID-00356
0.2


SEQID-00357
0.2


SEQID-00359
0.2


SEQID-00363
20


SEQID-00363 ( E. coli )
<10


SEQID-00407 (BS)
0.2


SEQID-00417
0.2


SEQID-00418
0.2


SEQID-00418 ( E. coli )
0.5


SEQID-00420
1.2


SEQID-00423 (BA)
0.3


SEQID-00423 (BA)
3


SEQID-00424 (AO)
0.2


SEQID-00424 (AO)
0.6


SEQID-00425 (KL)
0.3


SEQID-00426 (TL)
0.3


SEQID-00429 (BL)
5


SEQID-00485
0.5


SEQID-00502
0.6


SEQID-00510
0.3


SEQID-00511
0.3


SEQID-00546
<10


SEQID-00559
0.5


SEQID-00587
2.4


SEQID-00598
0.5


SEQID-00601
0.2


SEQID-00605
0.2


SEQID-00606
0.3


SEQID-00610
0.4


SEQID-00622
6.6


SEQID-00647
0.2


SEQID-00672 (BS)
0.3


SEQID-00678 (BS)
0.2


SEQID-00690 (BS)
4.4


































































































Nutritive Polypeptide Release of Amino Acids During Simulated Digestion.
An additional method of quantifying polypeptide digestion is to measure the amount of free amino acids present after exposure to a simulated digestive system. In this method, pancreatin, a mixture of enzymes, is used to simulate intestinal proteases. Specifically, the digestion of polypeptides into amino acids was analyzed by an in vitro Pancreatin-based digestion assay followed by free amino acid analysis using reversed phase HPLC (RP-HPLC). The nutritive polypeptide was added to SGF (0.92 g/L Pepsin (Sigma), 0.03 M NaCl titrated with HCl to pH 1.5) at a final concentration of 4 g/L and incubated at 37° C. for 120 min. After 120 min, Na2CO3 was added to a final concentration of 16 mM to quench the pepsin reaction. The resulting reaction was mixed 50:50 with 2× concentrated SIF (0.78 mg/ml Porcine Pancreatin (Sigma), 18.4 mM CaCl2, 50 mM MES pH 6.5) and incubated for 240 min. Time points were sampled from the reaction and quenched by heating to 95° C. for 5 min. Control samples were protease-free.
Time points were analyzed for free amino acids using RP-HPLC amino acid analysis as described in Henderson, J. W., et al. Agilent Technologies (2010). Analyses were performed using an Agilent 1100 series system. Primary amino acids were derivitized pre-column at room temperature, online, using o-phthalaldehyde (OPA). The OPA-derivatives were separated using the Zorbax Eclipse-AAA 4.6×150 mm, 3.5 μm column at 40° C. The separation gradient transitioned from 100% 40 mM Na2HPO4 pH 7.8 to 65%, acetonitrile/methanol/water mixture (45/45/10) over 23 minutes. Analytes were detected by fluorescence at 340 nm Ex/450 nm Em. FIG. 46 demonstrates a representative time-course of free Leu concentration during a Pancreatin digest of SEQID-00105. Free Leu concentrations for samples at the 120 min time point of the Pancreatin digest are summarized in Table E29B.





TABLE E29B



Free Leu detected at 120 min time point of

Pancreatin digest of nutritive polypeptides.







Free Leu (μM) at 120 min



time point of Pancreatin digest









SEQID-00076
824.3


SEQID-00103
793.8


SEQID-00105
1357.6


SEQID-00298 (BS)
1030.8


SEQID-00338
1181.7


SEQID-00341
1143.5


SEQID-00352
906.1


SEQID-00363
511


SEQID-00363
561.5


SEQID-00423
587.1


SEQID-00424
758.7


SEQID-00425
713.1


SEQID-00426
952.3


SEQID-00426
955.2


SEQID-00429
580.7


SEQID-00485
764.9


SEQID-00605
937.1











































Nutritive polypeptide release of peptides during simulated digestion. Samples from the simulated Pancreatin-based in vitro digestion described herein were analyzed for peptides by LC-MS/MS. To prepare the samples for LC-MS/MS analysis, the sample pH was adjusted to pH 3 with trifluoroacetic acid (TFA) and peptides were extracted using Hydrophilic-lipophilic Balance (HLB) solid phase extraction cartridges (Waters). Cartridges were activated with 2 mL of acetonitrile and equilibrated with 2 mL of 0.1% TFA. Samples were loaded and cartridges washed with 2 mL 0.1% TFA and eluted with 1 mL of 70% acetonitrile/0.1% TFA. The eluted peptides were dried to completion and reconstituted in 50 L 0.1% TFA. The eluted peptides (4 μL) were loaded on-column and analyzed by nano LC-MS/MS with a Waters NanoAcquity HPLC system interfaced to a ThermoFisher Orbitrap Velos Pro. Peptides were loaded on a trapping column and eluted over a 75 m analytical column at 350 nL/min; both columns were packed with Jupiter Proteo resin (Phenomenex). A 1 h gradient was employed. The mass spectrometer was operated in data-dependent mode, with MS performed in the Orbitrap mass analyzer at 60,000 FWHM resolution and MS/MS performed in the LTQ linear ion trap mass spectrometer. The fifteen most abundant ions were selected for MS/MS. Data were searched against an appropriate database using Mascot to identify peptides. Mascot DAT files were parsed into the Scaffold software for validation, filtering and to create a nonredundant list per sample. Data were filtered using a minimum protein value of 95% and a minimum peptide value of 50%.
Unique peptides were detected at the 240 min time point of the Pancreatin digest by LC-MS/MS after in vitro digestion of a given SEQID. Unique peptides detected for the SEQID-00105 sample were: LFDKDNNGSIS, FDKDNNGS, FDKDNNGSIS/FDKDNnGSIS, FDKDNNGSISS, FDKDNNGSISSSEL, DKDNNGSI, DKDNNGSIS, SLGLSPSE, NEIDVDGN, IDVDGNH, IDVDGNHQ, IDVDGNHQIE/IDVDGNHQIE, KVFDKNGDG, VFDKNGDGLIS, DKNGDGL, KLTDAEV, LREVSDGSGEINIQQF, REVSDGSG, REVSDGSGE, REVSDGSGEI, REVSDGSGEIN/REVSDGSGEIN, REVSDGSGEINIQ, REVSDGSGEINIQQF, EVSDGSGEI, EVSDGSGEIN. Unique peptides detected for the SEQID-00426 sample were: YSFEDSGVGDVT, YSFEDSGVGDVTG, SFEDSGVGDVTG, FEDSGVGDV, EDSGVGDVT, EDSGVGDVTG, EDSGVGDVTGF, DSGVGDVT, LRGnGYD, LRGnGYDIDV, ITHTNDIVPR, HTNDIVPR, TNDIVPR, NDIVPR, YSHSSPE, DIVKIEGIDATGGNNQPNIPDIPAHL, KIEGID, KIEGIDATGGNNQPNIPDIPA, IEGIDATGGNNQPNIPDIPA, EGIDATGGNNQPNIPDIPA, GIDATGGNNQPNIPDIPA, IDATGGNNQPNIPD, IDATGGNNQPNIPDIP, IDATGGNNQPNIPDIPA/IDATGGNNQPnIPDIPA, IDATGGNNQPNIPDIPAH, DATGGNNQPNIPDIPA/DATGGNNqPNIPDIPA, ATGGNNQPNIPD, ATGGNNQPNIPDIP, ATGGNNQPNIPDIPA/ATGGNNqPNIPDIPA, ATGGNNQPNIPDIPAH, TGGNNQPNIPDIPA, GGNNQPNIPDIP/GGNnQPNIPDIP, GGNNQPNIPDIPA/GGnNQPNIPDIPA/GGnnQPNIPDIPA, GNNQPNIPDIPA/GNNqPNIPDIPA, NNQPNIPDIPA, NQPNIPDIPA, PNIPDIPA.
Nutritive Polypeptide Intact Half-Life Determination in a Complex Mixture.
The in vitro intact half-life of multiple polypeptides in a complex mixture was determined using the simulated gastric in vitro digestion described above. Briefly, the 168 nutritive polypeptide library was generated as described herein by cloning, transforming, and expressing a gene library encoding 168 proteins as a single mixture. The recombinantly expressed proteins were purified from host cell proteins by IMAC purification as described herein.
The 168 Protein Library was treated with SGF as described above and the t=0 and t=10 min samples were analyzed for intact protein by LC-MS/MS. To begin, 10 μg of sample was loaded onto a 10% SDS-PAGE gel (Invitrogen) and run approximately 5 cm into the gel. The gel was excised into ten fractions from 100 kD to the dye front and the gel slices were processed by washing with 25 mM ammonium bicarbonate, followed by acetonitrile. Gel fractions were then reduced with 10 mM dithiothreitol at 60° C., followed by alkylation with 50 mM iodoacetamide at room temperature. Finally, the samples were digested with trypsin (Promega) at 37° C. for 4 h and the digestions were quenched with the addition of formic acid. The samples were then analyzed by nano LC/MS/MS using an EasynLC 1000 HPLC system interfaced to a ThermoFisher Q Exactive. Peptides were loaded on a trapping column and eluted over a 75 μm analytical column at 350 nL/min; both columns were packed with PepMap C18 3 μm resin (ThemoFisher). A 1 hour gradient was employed. The mass spectrometer was operated in data-dependent mode, with MS and MS/MS performed in the Orbitrap at 70,000 FWHM resolution and 17,500 FWHM resolution, respectively. The fifteen most abundant ions were selected for MS/MS. Data were searched against an appropriate database using Mascot to identify peptides. Mascot DAT files were parsed into the Scaffold software for validation, filtering and to create a nonredundant list per sample. Data were filtered at 1% protein and peptide false discovery rate (FDR) and requiring at least two unique peptides per protein. A full list of detected proteins and their spectral counts (SpC) was generated and reported as a function of each collected gel fraction. SpC are a count of the number of spectra identified for a given protein and are used as a measure of relative protein abundance (Liu, H. et al., Analytical Chemistry 2004, 76: 4193-4201). To calculate the percentage of intact protein remaining at the 10 min time point of the SGF digest the number of SpC representative of intact peptide in the t=10 min sample were divided by the number of SpC representative of intact peptide in the t=0 min sample. The number of SpC representative of intact peptide was defined as the sum of the SpC in the fraction with the highest number of SpC assigned to that protein in the t=0 min sample and the two flanking fractions. Results for % Intact Protein at 10 min are shown in Table E20C. Intact half-life values for purified proteins, determined by chip electrophoresis, and percentage of intact peptide remaining at 10 min for proteins detected in the 168 SEQID Library, determined by LC-MS/MS analysis, are compared for fourteen polypeptides in Table E20D. The linear relationship between percentage protein remaining intact at t=10 min and half-life value was analyzed and the R2 value determined to be 0.72.





TABLE E20C



Percent intact protein remaining at 10 min time point

of 168 nutritive polypeptide library SGF digest.







% Intact



Protein



at 10


Protein
min









SEQID-00338
3.9


SEQID-00484
0


SEQID-00485
0


SEQID-00489
0


SEQID-00495
0


SEQID-00496
0


SEQID-00497
20.3


SEQID-00502
9.7


SEQID-00507
0


SEQID-00509
36.4


SEQID-00510
13.4


SEQID-00511
4.3


SEQID-00515
17


SEQID-00518
0


SEQID-00520
0


SEQID-00521
11.5


SEQID-00524
0


SEQID-00525
13.7


SEQID-00528
11.8


SEQID-00529
0


SEQID-00532
0


SEQID-00533
19


SEQID-00534
0


SEQID-00536
11.8


SEQID-00540
0


SEQID-00541
0


SEQID-00544
0


SEQID-00545
0


SEQID-00546
0


SEQID-00552
79


SEQID-00555
6.8


SEQID-00559
3.1


SEQID-00562
0


SEQID-00564
89.6


SEQID-00570
91.4


SEQID-00573
66.7


SEQID-00574
0


SEQID-00577
30.8


SEQID-00581
33.3


SEQID-00582
15.2


SEQID-00583
0


SEQID-00587
21.7


SEQID-00590
0


SEQID-00591
20


SEQID-00592
24.3


SEQID-00598
24.3


SEQID-00599
0


SEQID-00601
1.1


SEQID-00602
0


SEQID-00603
0


SEQID-00605
0


SEQID-00606
0


SEQID-00607
0


SEQID-00609
0


SEQID-00610
3.3


SEQID-00612
0


SEQID-00613
0


SEQID-00615
85.7


SEQID-00617
43.9


SEQID-00618
0


SEQID-00619
68.5


SEQID-00620
0


SEQID-00622
43.6


SEQID-00623
63.6


SEQID-00624
0


SEQID-00625
0


SEQID-00626
0


SEQID-00628
0


SEQID-00629
40


SEQID-00631
17.1


SEQID-00632
1.2


SEQID-00633
92.1


SEQID-00634
36.8


SEQID-00636
60


SEQID-00638
0


SEQID-00639
0


SEQID-00640
50


SEQID-00641
21.2


SEQID-00642
75


SEQID-00643
13.6


SEQID-00644
0


SEQID-00645
0


SEQID-00647
12


SEQID-00648
39.5





















































































































TABLE E20D



Comparison of intact half-life values for purified proteins, determined

by chip electrophoresis, and percentage of intact peptide remaining at

10 min for proteins detected in the 168 nutritive polypeptide library,

determined by LC-MS/MS analysis.






Half-life


Protein
(min)
% Remaining at 10 min







SEQID-00338
0.2
3.9

SEQID-00601
0.2
1.1

SEQID-00605
0.2
0

SEQID-00647
0.2
12

SEQID-00510
0.3
13.4

SEQID-00511
0.3
4.3

SEQID-00606
0.3
0

SEQID-00610
0.4
3.3

SEQID-00559
0.5
3.1

SEQID-00485
0.5
0

SEQID-00598
0.5
24.3

SEQID-00502
0.6
9.7

SEQID-00587
2.4
21.7

SEQID-00622
6.6
43.6









































Example 30
Viscosity of Nutritive Polypeptides
It has been demonstrated that the presence of strong attractive self-associating interactions results in higher viscosity solutions (Yadav, Sandeep, et al. Journal of pharmaceutical sciences 99.12 (2010): 4812-4829). Specifically, electrostatic interactions of oppositely charged residues results in high viscosity solutions (Liu, Jun, et al. Journal of pharmaceutical sciences 94.9 (2005): 1928-1940). A nutritive polypeptide with low viscosity can be selected using net charge, or charge per amino acid calculations described herein, and selecting proteins with highly positive or highly negative charges. Proteins selected in this way would lack complementary electrostatic interactions and would instead have an overall repulsive force that limits the ability to self-associate thus reducing viscosity of the solutions.
Solutions of a nutritive polypeptide (SEQID-00105) and whey were measured for relative viscosity. Both proteins were resuspended with water to the desired concentration for analysis. Viscosity was measured using a Brookfield LVDV-II+ PRO Cone/Plate with a CPE-40 spindle. All tests were performed at 4 C and 25 C. Sample volume was 0.5 ml. Temperature was maintained with a Brookfield TC-550AP-115 Programmable Temperature Bath. All samples were equilibrated for a minimum of two minutes at 4 C and one minute at 25 C. All readings were taken between 10% and 100% torque. FIG. 47 shows viscosity measured in centipoise for SEQID-00105 at 4 C (closed circles) and 25 C (open circles) and whey at 4 C (closed squares) and 25 C (open squares).
SEQID-00105 has been shown herein to have a negative net charge across a range of pH, and SEQID-00105 is presently shown at multiple temperatures and polypeptide concentrations to be less viscous than whey, which is a disperse mixture of proteins without a dominant single charge.
To generate a solution with increased viscosity transglutaminase can be used to create a network consisting of enzyme-induced permanent covalent cross-links between nutritive polypeptides thereby generating additionally viscous solutions. This enzyme treatment can also be followed by thermal processing to make a viscous solution containing a nutritive polypeptide. To generate nutritive polypeptide samples containing crosslinks that increase viscosity, a sample is mixed with a transglutaminase solution at pH 7.0 to give an enzyme to protein weight ratio of 1:25. The enzyme-catalyzed cross-linking reaction is conducted at 40° C. in most of the experiments.
Example 31
Analytical Demonstration of Nutritive Polypeptide Solubility and Thermostability
Solubility.
The solubility of proteins was evaluated by determining the protein concentration of reconstituted lyophilized powder, centrifugal filtered, and/or ultrafiltered solutions (Carpenter et al. (2002) Rational Design of Stable Lyopholized Protein Formulations: Theorty and Practice, Kluwer Academic/Plenum publishers, New York, pp. 109-133; Millipore publication, Amicon Ultra: Centrifugal Filter Devices for the Concentration and Purification of Biological Samples (2001); Oss et al. (1969) A membrane for the rapid concentration of dilute protein samples in an ultrafilter, Clinical Chemistry, 15(8): 699-707). Protein samples were dried by lyophilization on a FreeZone Freeze Dry System (Labconco) using the manufacturer's standard protocol and then resuspended in buffer to the desired concentration. Centrifugal and tangential ultrafiltration were used to selectively remove buffer from the protein sample until the desired concentration was reached. Centrifugal ultrafiltration of protein solutions was performed by centrifugation (10,000×g) of 10 mg of protein in an Amicon centrifugal filter (Millipore) with a molecular weight cutoff of 3 kDa, 10 kDa, or 30 kDa, depending on the protein size, until the desired contrentration was reached. Ultrafiltration of protein solutions was performed on Hydrosart ultrafiltration cassettes (Sartorius Stedim, Bohemia, N.Y.) with a molecular weight cutoff of 3 kDa, 10 kDa, or 30 kDa, depending on the protein size, at a cross flow rate of 12 L/m2/min. For most processes, transmembrane pressure was maintained at 20 psi and performed until the desired contrentration was reached.
The protein concentration of the above samples was measured by one or a combination of the following methods: Coomassie Plus Protein Assay, absorbance at 280 nm (A280), and total amino acid analysis. Coomassie Plus Protein Assays (Pierce) were performed according to the manufacturer's protocol. Absorbance at 280 nm was measured on a Nanodrop 2000 UV-Vis spectrophotometer. Protein concentration was determined using the A280 value and molar extinction coefficient, which was calculated by primary amino acid sequence using ProtParam (Gasteiger, Elisabeth, et al. The proteomics protocols handbook. Humana Press, 2005, 571-607). Total amino acids were analyzed by HPLC after acid hydrolysis as described in Henderson, J. W., et al. Agilent Technologies (2010).





TABLE E31A



Solubility of proteins. All proteins were produced in E. coli ,

unless otherwise noted. Alpha-mannosidase-treated

SEQID-00363 and protein originating from AO, BA, KL,

TL, and BL were produced as described herein.






Protein
Solubility (g/L)









SEQID-00008
265


SEQID-00009
53


SEQID-00076
150


SEQID-00085
50


SEQID-00087
176


SEQID-00099
91


SEQID-00100
107


SEQID-00102
120


SEQID-00103
133


SEQID-00104
192


SEQID-00105
500


SEQID-00115
70


SEQID-00220
166


SEQID-00226
107


SEQID-00236
60


SEQID-00240
163


SEQID-00241
207


SEQID-00265
95


SEQID-00269
159


SEQID-00287
192


SEQID-00298 (BS)
209


SEQID-00302
158


SEQID-00305
231


SEQID-00338
254


SEQID-00341
166


SEQID-00345
196


SEQID-00346
161


SEQID-00352
223


SEQID-00354
235


SEQID-00357
211


SEQID-00363 (AN)
336


SEQID-00363
229


a-mannosidase treated



SEQID-00423 (BA)
193


SEQID-00424 (AO)
205


SEQID-00425 (KL)
190


SEQID-00426 (TL)
138


SEQID-00429 (BL)
214


SEQID-00485
99


SEQID-00510
135


SEQID-00511
135


SEQID-00546
149


SEQID-00559
156


SEQID-00587
223


SEQID-00598
150


SEQID-00605
128





AN = Aspergillus niger ,


AO = Aspergillus oryzae ,


BS = Bacillus subtilis ,


BA = Bacillus amyloliquefaciens ,


KL = Kluyveromyces lactis ,


TL = Thermomyces lanuginosus ,


BL = Bacillus licheniformis .













































































pH Solubility. The pH solubility of proteins was determined in a buffer cocktail of Citric Acid and Dibasic Sodium Phosphate over a pH range of 2.8 to 7.1. pH solutions were prepared as outlined in Table E31B. Protein was either lyophilized and then resuspended in buffer cocktail mixtures, or concentrated and then spiked into buffer cocktail mixtures at a final protein concentration of 5 to 30 mg/ml. As a control, protein was also dissolved in a solution of 8 M urea. Protein solutions were shaken for 10 min at room temperature. Turbidity of proteins was determined by measuring the absorbance of protein solutions at 650 nm. The protein solution was then centrifuged for 10 min at 1100×g to pellet undissolved or precipitated protein. The soluble protein fraction (supernatant) was sampled and protein concentration was measured by one or more of the following methods: Coomassie Plus Protein Assay (Pierce), Chip electrophoresis, gel electrophoresis, and/or absorbance at 280 nm. The pH range over which select proteins remained greater than 80% soluble as determined by Bradford and the A650 value are listed in Table E31C.





TABLE E31B



Buffer composition for pH solubility screen.












mL of 42 mM




Sodium
Citric
Sodium
mL of 42 mM

Buffer

Phosphate
Acid
Phosphate
Citric Acid (10

#
pH
Dibasic (mM)
(mM)
(10 mL total)
mL total)










1
7.1
38
4
9
1

2
6.5
34
8
8.1
1.9

3
6
32
10
7.6
2.4

4
5.6
30
12
7.1
2.9

5
5
28
14
6.7
3.3

6
4.6
26
16
6.2
3.8

7
4.3
24
18
5.7
4.3

8
3.9
22
20
5.2
4.8

9
3.7
20
22
4.8
5.2

10
2.8
10
32
2.4
7.6









































TABLE E31C



Solubility of proteins over a range of pHs.







pH Range where Protein is >80% detected



as Soluble and A650 <1 OD








Protein
High
Low
Other











SEQID-00009
9.1
3.7



SEQID-00076
7.1
4.6



SEQID-00085
7.1
7.1



SEQID-00100
7.1
4.3



SEQID-00103
7.1
5.6



SEQID-00104
7.1
5



SEQID-00105
9.1
4.3



SEQID-00226
9.1
2.6



SEQID-00240
9.1
6.6
3.0-2.6


SEQID-00241
9.1
4.3



SEQID-00265
9.1
5.1
3


SEQID-00269
9.1
7.2
3.0-2.6


SEQID-00287
9.1
6.2
2.6


SEQID-00338
7.1
2.8



SEQID-00485
7.1
4.6
2.8


SEQID-00502

7.1
2.8


SEQID-00510
7.1
6.5
2.8


SEQID-00511
7.1
5.6



SEQID-00587
7.1
2.8



SEQID-00605
7.1
5.6



SEQID-00622
7.1
2.8





N/A: not applicable.
















































Thermostability.
The thermostability of proteins in a buffer cocktail of Citric Acid and Dibasic Sodium Phosphate over a pH range of 2.8 to 7.1 (preparation described above in Table E31B) was determined using the ProteoStat® Thermal Shift Stability Kit (Enzo Life Sciences) according to the manufacturer's standard protocol. Briefly, protein solutions (˜10 mg/ml) containing 1× ProteoStat TS Detection Reagent were heated from 25° C. to 95° C. at a rate of 0.5° C. per 30 sec using a real-time PCR (rtPCR) thermocycler (BioRad) equipped with a plate reader (SynergyMx, Biotek) while monitoring the fluorescence with a Texas Red filter. The temperature of aggregation (Tagg) was identified as the temperature at which the steepest slope was observed in the trace of fluorescence intensity as a function of temperature. The temperature of aggregation at pH 7.1 for a subset of proteins is listed in Table E31D. The temperature of aggregation over a range of pHs for a subset of proteins is listed in Table E31E.





TABLE E31D



Temperature of aggregation (Tagg) at pH 7.1






Protein
Tagg (pH 7.1)









SEQID-00008
>95


SEQID-00009
56


SEQID-00087
>95


SEQID-00099
64


SEQID-00102
>95


SEQID-00220
>95


SEQID-00226
>95


SEQID-00237
45


SEQID-00240
>95


SEQID-00241
>95


SEQID-00265
>95


SEQID-00269
>95


SEQID-00302
46


SEQID-00305
48


SEQID-00510
57.5


SEQID-00606
95


SEQID-00610
54.5














































TABLE E31E



Temperature of aggregation (Tagg) as a function of pH.





T agg














pH
pH
pH
pH
pH
pH
pH
pH
pH
pH

Protein
7.1
6.5
6.0
5.6
5.0
4.6
4.3
3.9
3.7
2.8















SEQID-00076
>95
95
95
73.5
75
34.5
NS
NS
NS
NS

SEQID-00098
>95
NS
NS
NS
NS
NS
NS
NS
NS
NS

SEQID-00100
>95
95
95
95
95
84
83
95
95
95

SEQID-00103
>95
95
67.5
62
61
59.5
37.5
41.5
45.5
NS

SEQID-00104
>95
95
95
80
66
59.5
60
74.5
NS
NS

SEQID-00105
>95
95
95
70.5
75.5
61.5
36.5
NS
NS
NS

SEQID-00338
51.5
51
51.5
51
50.5
84.5
40.5
38
37
95

SEQID-00485
36
36.5
36
34.5
31.5
NS
NS
NS
NS
NS

SEQID-00502
95
78.5
76.5
77
77
95
95
NT
95
95

SEQID-00511
42
45.5
39.5
NS
NS
NS
NS
NS
NS
NS

SEQID-00559
64.5
64
62
59
57
57.5
NS
NS
NS
NS

SEQID-00587
95
95
95
69.5
67
63
58.5
54
50.5
50

SEQID-00601
48.5
45.5
NS
NS
NS
NS
95
NT
95
95

SEQID-00605
39
38.5
44.5
37
33.5
40.5
NS
NS
NS
NS

SEQID-00622
95
47
46
45.5
42.5
43.5
43.5
42
42
58.5



NS = condition where protein was not soluble for thermal stability assay.










































Thermal Unfolding.
Thermal unfolding of proteins was monitored by circular dichroism on an Applied Photophysics CS/2 Chirascan spectrophotometer. Far-UV measurements (200-260 nm) of protein solutions (0.5 to 1.0 mg/mL) in buffer (20 mM potassium phosphate, pH 7.5) were recorded every 5° C. from 20 to 90° C. using a 0.1 cm optical path length cell. After collection of the spectrum at 90° C. the protein sample was immediately cooled to 20° C. and a final spectrum was recorded. The melting temperature (Tmelt) was calculated as the temperature with the strongest slope, and the final spectrum was compared to the initial 20 OC spectrum to determine if protein unfolding was reversible or if a permanent change in structure had occurred. FIG. 48 displays a representative CD spectra of SEQID-00105, demonstrating the nutritive polypeptide does not completely unfold at even 90 C and returns to it's original fold when cooled to 20 C.
Example 32
Nutritive Polypeptide Glycosylation
The glycans present on proteins often affect properties such as solubility, activity, and stability. Changing the pattern on glycosylation of nutritive peptides can also affect their bioavailability, nutritional quality, and product formulation attributes. Furthermore, specific sugar patterns on nutritive food peptides augment metabolic response to the ingestion of isolated nutritive food peptides based both the kinetics of amino acid absorption and the incorporation of exogenous glycans during human protein production.
Host Selection for Glycosylation State.
As described herein nutritive polypeptides were produced in a variety of hosts. Choice of host has an impact on the glycosylation state of the nutritive polypeptide which has biophysical, digestion, and immunogenic implications. For example, hosts for expression include, E. coli, B. subtilis, B. licheniformis, Aspergillus niger, Aspergillus nidulans , human embryonic kidney (HEK), and chinese hamster ovary cells (CHO). E. coli, B. subtilis and Bacillus licheniformis are used as an expression host due to their ability to produce polypeptides with unglycated (or minimally glycated) backbones compared to eukaryotic hosts such as aspergillus, s. cerevisiae , and pichia. Aspergillus niger is selected as a protein secretion host due to its unique glycosylation machinery that drives the addition of mannose-rich glycans to the polypeptide backbone. Aspergillus nidulans is selected as a protein secretion host, due to the previously demonstrated ability (Kainz et. al. N-Glycan modification in aspergillus species, Appl. Environ. Microbiol., 2008) to engineer the host glycosylation machinery towards reduced glycan structure complexity in to place of extensive oligomannose polysaccharides. Chinese hamster ovarian (CHO) cells are selected as an expression host for their ability to glycosylate proteins in patterns similar to human cells. Differences include the Gal α1-3 Gal epitope and the N-glycolylneuraminic acid (NeuSgc) have both been found on glycoproteins produced by CHO cells but are not found in normal human glycans (Galili, Uri, et al. Journal of Biological Chemistry 263.33 (1988): 17755-17762). Also, certain proteins produced in CHO cells have more acidic isoforms suggesting higher content of sialic acid. Human Embryonic Kidney 293 (HEK293) cells are selected as an expression host for their ability to have human glycosylation of proteins.
Gel Electrophoresis and Protein Transfer.
To analyze glycosylation, western blot analysis was performed with antibodies or lectins that recognize specific glycan antigens to evaluate and compare the glycosylation profile of proteins produced in eukaryotes and prokaryotes. First, protein separation was performed by gel electrophoresis using Novex® NuPAGE® Bis-Tris Pre-cast gels (Life Technologies) according to the manufacturer's protocol. Proteins were transferred from the gel to a nitrocellulose membrane using the iBlot® Dry Blotting System (Life Technologies) and iBlot® Western Detection Kit (Life Technologies) according to the manufacturer's protocol. Protein brands were visualized by staining polyacrylamide gels with Coomassie® G-250 stain SimplyBlue™ SafeStain (Life Technologies) according to the manufacturer's protocol and imaged using the Molecular Imager® Gel Doc™ XR+ System (Bio-Rad).
Glycosylation Profile of SEQID-00363 Expressed in E. coli and A. niger.
The mannose content of proteins was examined using a glycoprotein detection kit (DIG Glycan Differentiation Kit, Roche) according to the manufacturer's standard protocol. To begin, whole cell extract (5 μg) and soluble cell lysate (5 μg) from E. coli transformed with an expression vector encoding the gene for SEQID-00363 (as described herein), SEQID-00363 expressed in A. niger (5 μg), and the DIG Glycan Differentiation Kit positive control carboxypeptidase Y (5 μg) were loaded onto a Novex® NuPAGE® 10% Bis-Tris gel (Life Technologies). Protein separation and transfer were performed as described herein. Briefly, nitrocellulose membranes were incubated with digoxifenin (DIG)-labeled Galanthus nivalis agglutinin (GNA), a lectin that binds terminal mannose. Membranes were then incubated with anti-Digoxidenin-alkaline phosphatase (AP), followed by incubation with an AP substrate solution (NBT/BCIP). The intensity of AP staining was qualitatively visualized by the naked eye and membranes were photographed. FIG. 49 displays a representative Coomassie-stained gel (panel A) and a GNA probed western blot membrane (panel B) of SEQID-00363 isolated from A. niger and SEQID-00363 expressed recombinantly in E. coli. In lane 2, a prominent band around 120 kD is representative of glycosylated SEQID-00363. In lane 3, a band around 80 kD is representative of non-glycosylated SEQID-00363. These results demonstrate that SEQID-00363 expressed in A. niger ( FIG. 49B , Lane 2) is a terminally mannosylated protein ( FIG. 49B , Lane 3), while SEQID-00363 expressed in E. coli contains no terminal mannose residues on its glycans.
Protein Extraction from Food for Glycan Analysis.
Flaxseed (Organic Brown Flaxseed, Farmers Direct Coop), chickpea (Garbanzo Beans, 365 Everyday Value Organic), corn (frozen, Super Sweet Bicolor Corn, 365 Everyday Value Organic), potato (conventional yellow potato), mushroom (organic white mushroom), broccoli (frozen, Broccoli Flortes, 365 Everyday Value), tomato (conventional Roma tomato), blueberry (Organic Blueberries, Little Buck Organics), grape (Organic Red Seedless Grapes, Anthony's Organic), beef (85% Lean Ground Beef), chicken (Ground Chicken Thighs, Boneless, Skinless, Airchilled), lamb (Ground New Zealand Lamb), turkey (Ground Turkey Thighs), cod (Wild Cod Fillet), and pork (Ground Pork) were purchased from Whole Foods. Venison was provided. Aliquots of each food source (50-2,500 mg) were frozen at −80° C. Proteins were extracted from the food source by grinding the sample with a mortar and pestle before adding 1.0 mL of extraction buffer (8.3 M urea, 2 M thiourea, 2% w/v CHAPS, 1% w/v DTT) and additional grinding with the pestle. The samples were transferred to microcentrifuge tubes and agitated for 30 min at room temperature, followed by addition of 500 μL of 100-μm zirconium beads (Ops Diagnostics) and further agitation for an additional 30 min. Samples were then lysed on a TissueLyser II (Qiagen) at 30 Hz for 3 min, centrifuged for 10 min at 21,130×g, and supernatants were collected. Yeast (Nutritional Yeast, Whole Foods), soy protein isolate (Soy Protein Powder, Whole Foods), and rice protein isolate (Organic Rice Protein, Growing Naturals) were prepared by solubilization in extraction buffer. The total protein concentration of samples was determined by Coomassie Plus Protein Assays (Pierce) according to the manufacturer's standard protocol.
N-Glycolylneuraminic Acid (Neu5Gc) Detection by Western Blot Analysis.
N-glycolylneuraminic acid (Neu5Gc) is a sialic acid found on most mammalian glycans, but is not present on human protein glycoproteins. Human biochemical pathways don't recognize the Neu5Gc sialic acid as foreign, leading to trace amounts found in human glycoproteins following uptake into golgi and incorporation onto newly synthesized proteins. Despite integrating biochemically, however, the immune system recognizes as foreign the adjusted surface conformation containing an externally-derived sialic acid, increasing the risk of many diseases. Anti-Neu5Gc antibodies, which have been detected in human plasma, cause chronic inflammation in response to the ingestion of Neu5Gc containing protein sources (Varki et. al. “Uniquely human evolution of sialic acid genetics and biology”, PNAS 2011). The main sources of Neu5Gc include lamb, beef, pork, and even dairy products, with trace amounts also found in fish (Tangvoranuntakul et al., 2003, PNAS, 100(21): 12045-12050).
Western blot analysis was performed with an anti-Neu5Gc antibody to characterize the Neu5Gc content of proteins extracted from food as well as proteins expressed recombinantly by bacterial hosts. Proteins were extracted from meat sources as described herein. Also, proteins were recombinantly expressed in E. coli and/or B. subtilis by transformation with individual expression vectors, as described herein, or by transformation with a library of expression vectors, as described in herein. Proteins originating from individual expression vectors, and in some cases protein originating from a library of expression vectors, were purified by IMAC purification, as described herein. A mixture (Protein Mixture 1) of purified proteins recombinantly expressed in E. coli was prepared to contain each protein at a final concentration of approximately 1 mg/mL. The proteins included in this mixture, as well as the species in which they are naturally produced, SEQID-00076 Cow, SEQID-00240 Cow, SEQID-00298 Cow, SEQID-00359 Sheep, and SEQID-00510 Turkey.
A sample of each meat extract (beef, pork, deer, lamb, turkey, chicken, and cod), Protein Mixture 1, the 168 nutritive polypeptide library expressed in E. coli (IMAC-purified lysate) and B. subtilis (IMAC-purified lysate and unpurified supernatant and lysate), and the cDNA Library expressed in E. coli (Rosetta, GamiB, and Gami2 soluble lysate and Rosetta whole cell) and B. subtilis (PH951 Grac lysate) were loaded onto a Novex® NuPAGE® 10% Bis-Tris gel (Life Technologies). Protein separation and transfer were performed as described herein. Neu5Gc was detected using the SNAP I.d.® Protein Detection System (Millipore) according to the standard manufacturer's protocol with chicken anti-Neu5Gc (IgY) primary antibody (BioLegend) and goat anti-chicken IgY-horseradish peroxidase (HRP) secondary antibody, both diluted 3:5,000 in Blok™-PO Blocking Buffer. Blots were treated with Luminata Classico Western HRP Substrate (Millipore) according to the manufacturer's protocol and imaged using chemiluminescent detection on the Molecular Imager® Gel Doc™ XR+ System (Bio-Rad). FIG. 50 displays representative Coomassie-stained gels (panel A) and anti-Neu5Gc probed western blot membranes (panel B). These results demonstrate that while Neu5Gc is present in proteins extracted from cow, pig, sheep, turkey, and chicken meat, it is not present in proteins from these animals that have been recombinantly expressed in E. coli or B. subtilis.
Xylose and Fucose Detection by Western Blot Analysis.
Xylose and fucose are sugars that are often present on plant glycoproteins and can be immunogenic to humans (Bardor et al., 2003, Glycobiology, 13(6): 427-434). The xylose and fucose content of proteins extracted from food sources and proteins recombinantly expressed by bacterial hosts was examined by western blot analysis using anti-Xylose and anti-Fucose antibodies. As described herein, protein samples were prepared either by extraction from food sources or by reconstitution of purchased protein isolates. Proteins were recombinantly expressed in E. coli and purified by IMAC purification, as described in herein. A mixture (Protein Mixture 2) of purified proteins recombinantly expressed in E. coli was prepared to contain each protein at a final concentration of approximately 1 mg/mL. The proteins included in this mixture, as well as the species in which they are naturally produced, are SEQID-00103 Rice, SEQID-00104 Corn, SEQID-00352 Corn, SEQID-00485 Chickpea, SEQID-00559 Rice, SEQID-00598 Flaxseed, and SEQID-00605 Mushroom.
A sample of each plant and fungi extract (yeast, flaxseed, chickpea, corn, potato, mushroom, soy, rice, broccoli, tomato, blueberry, and grape), Protein Mixture 2, horseradish peroxidase (positive control), and fetuin (negative control) were loaded onto a Novex® NuPAGE® 10% Bis-Tris gel (Life Technologies). Protein separation and transfer were performed as described herein. Western blot analysis was performed using the SNAP I.d.® Protein Detection System (Millipore) according to the standard manufacturer's protocol. Xylose was detected by blotting with rabbit anti-xylose primary antibody (Agrisera) and donkey anti-rabbit IgG-HRP secondary antibody (abcam) diluted 3:5,000 and 3:2,500 in Blok™-PO Blocking Buffer, respectively. Fucose was detected by blotting with rabbit anti-fucose primary antibody (Agrisera) and donkey anti-rabbit IgG-HRP secondary antibody (abcam) diluted 3:10,000 and 3:3,000 in Blok™-PO Blocking Buffer, respectively. Blots were treated with Luminata Classico Western HRP Substrate (Millipore) according to the manufacturer's protocol and imaged using chemiluminescent detection on the Molecular Imager® Gel Doc™ XR+ System (Bio-Rad). FIG. 51 demonstrates a representative Coomassie-stained gel, anti-xylose probed western blot membrane, and anti-fucose probed western blot membrane. These results demonstrate that while xylose and fucose are both present in plant proteins extracted from flaxseed, chickpea, corn, potato, soy, rice, broccoli, tomato, blueberry, and grape, they are not present in proteins from plant and fungi sources that have been recombinantly expressed in E. coli.
Selection of Proteins with High Asparagine, Serine, and/or Threonine Mass Compositions to Decrease Nutritive Polypeptide Glycosylation.
The glycosylation state of a nutritive polypeptide can be decreased by selecting sequences low in glycosylation sites. These sites include Asparagine, for N-linked glycosylation, and serine and threonine, for 0-linked glycosylation. These isolated polypeptides contain a higher amino acid percentage by mass due to the reduced level of bound polysaccharide composition along the polypeptide, allowing a higher digestible amino acid dose per gram of nutritive polypeptide, and have reduced immune activity upon consumption. The N-linked glycosylation of available glycan acceptor sites along a nutritive polypeptide backbone occurs predominantly at Asparagine amino acid residues. Expression of heterologous polypeptides selected for their low levels of Asparagine allows for polypeptides to be isolated with decreased glycan structures. The O-linked glycosylation of available glycan acceptor sites along a nutritive polypeptide backbone occurs predominantly at Serine and Threonine amino acid residues. Expression of heterologous polypeptides selected for their low levels of either Serine or Threonine allows for polypeptides to be isolated with decreased glycan structures
Selection of proteins with high Asparagine, Serine, and/or Threonine mass compositions to increase nutritive polypeptide glycosylation. The glycosylation state of a nutritive polypeptide can be increased by selecting sequences rich in glycosylation sites. These sites include Asparagine, for N-linked glycosylation, and serine and threonine, for O-linked glycosylation. Increase in glycosylation can enable increased solubility and thermostability of the nutritive polypeptide. The N-linked glycosylation of available glycan acceptor sites along a nutritive polypeptide backbone occurs predominantly at Asparagine amino acid residues. Expression of heterologous polypeptides selected for their high levels of Asparagine allows for polypeptides to be isolated with increased glycan structures. The O-linked glycosylation of available glycan acceptor sites along a nutritive polypeptide backbone occurs predominantly at Serine and Threonine amino acid residues. Expression of heterologous polypeptides selected for their high levels of either Serine or Threonine allows for polypeptides to be isolated with increased glycan structures
Removal of Glycans from Isolated Nutritive Polypeptides.
The glycosylation state of nutritive polypeptides can have an effect on structure and physical properties. As described herein, nutritive polypeptides expressed in recombinant hosts can have a different glycosylation than occurs naturally. If a nutritive polypeptide is produced with glycosylation, the glycans can be released to alter structural and physical properties using chemical or enzymatic methods. Common chemical methods of glycan release are hydrazinolysis and alkali/reducing conditions (β-elimination) (Takasaki, Seiichi, et al. Methods in enzymology 83 (1981): 263-268). Glycans can be released from proteins using an Endoglycosidases such as PNGaseF, Endo-H, Endo F2, PNGaseA, or O-Glycanase or using an Exoglycosidases such as Sialidase, Alpha Galactosidase, Beta Galactosidase, Hexosaminidase, Galactosaminidase, Alpha Mannosidase, Beta Mannosidase, Alpha Fucosidase, exact enzymes are selected based on oligosaccharide composition and linkage (Merry, Tony, et al. Capillary Electrophoresis of Carbohydrates. Humana Press, 2003, 27-40).
PNGase F is a very effective enzymatic method for removing almost all N-linked oligosaccharides from glycoproteins. PNGase F digestion deaminates the aspargine residue to aspartic acid, and leaves the oligosaccharide intact. To deglycosylate a protein using an Endoglycosidase, 500 ug of glycoprotein is resuspended in 50 ul of 50 mM sodium phosphate pH 7.5. PNGase F is added at 0.1 U/ml and the solution is incubated at 37 C for 24 hours. The reaction is monitored for completion by SDS-PAGE.
Screening for IgE-Mediated Allergic Response Due to Glycan.
A change in glycan modifications to a nutritive polypeptide affects the IgE binding interactions. About 20% or more of allergic patients generate specific anti-glycan IgE, which is often accompanied by IgG (Altmann, F. The role of protein glycosylation in allergy, Int Arch Allergy Immunol. 2007). For polypeptides which induce an IgE-mediated immune response, as is the case with allergens, a glycan modification as described herein may reduce the isolated polypeptide's allergenicity compared to in its native composition. In this example, polypeptides are screened for IgE binding in an in-vitro serum assay as well as for reactivity by skin prick test (as described in Mari, A et. al. IgE to Cross-Reactive Carbohydrate Determinants: Analysis of the Distribution and Appraisal of the in vivo and in vitro Reactivity, 2002).
Allergenic response due to the glycan (termed cross-reactive carbohydrate determinants), can be determined by comparing results of a skin prick test with an IgE serum binding assay. Unselected consecutive subjects presenting respiratory symptoms that suggest an allergic disease, and referred to an allergy unit, are enrolled. Demographical and clinical data are recorded for each patient. Patients with a clinical history of anaphylaxis are excluded from the study. Those patients who haven't previously received a specific immunotherapy (SIT) course are not excluded. All the treated patients receive alum-adsorbed extract of the nutritive polypeptide in both the isolated form and in the native composition. For statistical purposes, only pollen treated patients are evaluated. Patients undergo skin prick testing (SPT), with a standardized procedure and recording (Mari, A. et. al Specific IgE to cross-reactive carbohydrate determinants strongly affect the in vitro diagnosis of allergic diseases. J Allergy Clin Immunol 1999), using the allergenic extracts described above. Following the SPT, sera are obtained from patients who consent to blood sampling for an in vitro diagnostic procedure. Sera are stored at −20° C. until required. Informed consent for skin testing and blood sampling is obtained by patients or caregivers during the allergy consultation.
Total IgE is determined in all the sera (Radim, Pomezia, Italy). Allergen-specific IgE is detected by the CAP system following the manufacturer's instructions (Pharmacia, Uppsala, Sweden). Values 60.4 kUA/l is considered positive. As there is not a single test to detect CCD-IgE, discrepancy of the results between a positive in vitro test to the nutritive polypeptide bearing carbohydrate moieties recognized by IgE and a negative SPT to the same glycoprotein is assumed to be indicative of the presence of CCD-IgE. IgE detection is performed on the largest random samples of sera recorded negative in the SPT to the same allergenic extract. Modification in the glycan structure that mediates binding to IgE is observed by a shift in the distribution in patients for which a CCD-IgE is detected upon isolation of the nutritive polypeptide and confirmation of altered glycan structure.
Example 33
In Animal Demonstration of Nutritive Polypeptide Amino Acid Pharmacokinetics
Pharmacokinetic (PK) studies may be performed to evaluate the plasma concentration of amino acids following oral administration of a nutritive polypeptide formulation. Such analyses provide information on the rate and extent of digestion of the protein in the gastrointestinal intact and the bioavailability of the free amino acids and/or peptides released during digestion. Growing rats, which have a similar small intestinal transit rat to adult humans (3-4 h), are accepted as a suitable model for pharmacokinetic studies with oral administration (DeSesso and Jacobson (2001) Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats, Food and Chemical Toxicology 39: 209-228).
Rat Pharmacokinetic Studies.
Male Sprague Dawley rats with indwelling jugular vein cannula (JVC) were purchased from Harlan Laboratories and acclimated to the Test Facility (Agilux Laboratories) for at least two days prior to study initiation. Prior to dose administration animals were fasted overnight (11-13 h) and remained fasted until completion of the study. Test articles were orally administered via a bulb-tipped 18 gauge stainless steel gavage needle attached to a syringe. The weight of all dose syringes were recorded prior to and following dosing to more accurately determine the amount of solution dosed. Serial blood samples (˜300 μL) were collected from the JVC at time 0 (pre-dose) and 0.25, 0.5, 1, 2, and 4 h post-dose. Blood samples were collected into tubes containing the anti-coagulant K2EDTA, a general protease inhibitor cocktail (Sigma P8340, diluted 1:100 in whole blood), and a DPP IV inhibitor (Millipore DPP4, diluted 1:100 in whole blood). Immediately following blood collection tubes were vortexed and stored on wet ice until processing to plasma by centrifugation (3,500 rpm at 5° C.) within 1 h of collection. Plasma samples were then transferred into new tubes and stored at −80° C. In some cases, following the terminal blood collection animals were euthanized and the terminal ileum and its contents were collected and analyzed as described herein.
The concentration of Glu, Ser, His, Gly, Thr, Arg, Ala, Tyr, Val, Met, Phe, Ile, Leu, and Lys in the plasma samples was determined by HPLC amino acid analysis, as described herein. Prior to HPLC amino acid analysis, insoluble particles were removed from plasma samples by centrifugation (1100×g at 4° C.) for 10 min. A 25 μL sample of the soluble fraction was then transferred to a 96-well plate, for some samples an internal standard (Norvaline, Agilent) was added to each plasma sample at final concentration of 0.5 mM. Amino acids not measured in the current HPLC amino acid analysis, including Gin, Asn, Trp, Hydroxyproline (Hyp), and Sarcosine (Sar), are analyzed by using a standard mixture that includes the individual standard stocks provided in the supplemental amino acid kit (Agilent) and comparing the chromatographic profiles of the samples against that of the combined standards. Because solutions containing the supplemental standards are unstable at room temperature the supplemental amino acid standards are prepared immediately prior to use and used for no longer than 24 h.
FIG. 52 displays the change in average area under the curve (AUC) (±SD) of plasma amino acid concentrations (μM·h) measured in blood samples collected from rats over 4 h following oral administration of the indicated nutritive polypeptides at the doses listed in Table E33A. FIG. 53 shows SEQID-00105 as an example of oral administration of nutritive polypeptides altering the concentration of amino acids in rat plasma. The profile of amino acids detected in the rat plasma after oral administration was dependent on the amino acid sequence of the nutritive polypeptide. For example, oral administration of the polypeptides SEQID-00240, SEQID-00338, and SEQID-00352 increased the change in AUC0-4 h for plasma Lys, whereas administration of the polypeptides SEQID-00363, SEQID-00424, and SEQID-00426 did not alter the change in AUC0-4 h for plasma Lys ( FIG. 52 ). Additionally, the nutritive polypeptide SEQID-00240 serves as an example of a polypeptide that is capable of delivering essential amino acids (EAAs) while causing no flux in plasma Phe concentration. FIG. 54 demonstrates representative plasma amino acid concentration time curves for oral administration of SEQID-00105 (2.85 g/kg) to rats. FIG. 54 demonstrates a dose-response effect on plasma Leu concentrations following oral administration of SEQID-00105 at the doses indicated in Table E33A. Taken together, these results demonstrate that oral administration of nutritive polypeptides can be used to deliver specific amino acid profiles to the systemic circulation in rats.





TABLE E33A



List of the nutritive polypeptides and doses used in rat

pharmacokinetic studies.





FIG. 52 and 53



Symbol
SEQID
Dose (g/kg)







1
Vehicle
NA

2
105
2.85

3
240
1.54

4
338
2.85

5
352
2.85

6
363
2.85

7
423
2.85

8
424
2.85

9
425
2.85

10
426
2.85

11
429
2.85

12
559
2.85

13
587
2.85

14
105
2.85

15
105
1.78

16
105
1.11



NA: not applicable.








































Example 34
Modulation of Nutritive Polypeptide Digestibility
Multiple methods of protein modification were used to alter the structure of a model nutritive polypeptide, SEQID-00363. These methods were performed to assess the relevance of specific structural features in regards to protein digestibility and bioavailability. These modifications include reduction of glycans, hydrolysis of the protein, reduction/alkylation of disulfide bonds, and thermal denaturing of protein structure. Resulting materials from these modifications were evaluated for improved digestion using in vitro digestion assays and, in some cases, in vivo assays. These methods or other means of producing similar structural changes end can be applied to other nutritive polypeptides.
Enzymatic Deglycosylation.
It is predicted that SEQID-00363 contains high-mannose O-linked glycosylation (Goto et al., 2007 Biosci. Biotechnol. Biochem.). To assess the effect of glycosylation on the digestion of SEQID-00363 the mannose glycans were significantly reduced enzymatically. A non-specific alpha mannosidase (M7257, Lot SLBC4303V, Sigma Aldrich, St. Louis, Mo.) was used to cleave all 1-3, 1-4 and 1-6 glycosidic linkages within the O-glycans. This alpha mannosidase does not cleave any non-mannose glycosidic linkages; it is predicted that this enzyme is ineffective against N-linked glycan release.
The deglycosylation reaction was adapted from Jafari-Aghdam et al., 2005 Biochimica et Biophysica Acta. The protein stock of SEQID-00363 was resuspended from lyophilized powder to an enzyme concentration of 100 g/L into deglycosylation reaction buffer: 20 mM sodium acetate, 2 mM zinc chloride, 0.01% 2-mercaptoethanol, pH 4.3. Reagent stocks were diluted into the deglycosylation reaction to a final volume of 0.5 L. The reaction was performed at a SEQID-00363 concentration of 10 g/L and an alpha mannosidase concentration of 0.5 EU per mg of SEQID-00363. The reaction was sterile filtered through a 0.2 um filter directly into 7×70 mL 3.5 kD dialysis cassettes in 20 L of deglycosylation reaction buffer. The reaction was performed in di lysis in order to decrease proposed feedback inhibition of the alpha mannosidase by released (mono/poly)saccharides. The reaction was then stored at 37° C. for six days. Throughout the course of the reaction, approximately 10% of SEQID-00363 was lost due to insoluble aggregate formation. At the terminal (6 day) time point, the reaction was collected from dialysis, sterile filtered, concentrated, and diafiltered into 10% phosphate buffered saline, pH 7.4. Successfully reduction of mannose glycans was monitored by a decrease in size by SDS-PAGE and anti-GNA western blot as described herein. In order to create a high protein concentration formulation of deglycosylated SEQID-00363, the remaining pool was concentrated in an Amicon spin concentrator (EMD Millipore, Billerica, Mass.) until the final concentration approached 250 g/L. The high-concentration formulation remained soluble at 4° C., and was held at that temperature for long-term storage.
Protein Hydrolysis.
Another approach to increasing bioavailability relative to a preparation of native protein was hydrolysis into short peptides. Protein hydrolysates of commodity proteins, such as whey (Perea et al., 1993 Enzyme Microb. Technol.) and soy (Kong et al., 2008 Bioresource Technology) are generated enzymatically through subtilisin-mediated proteolysis.
Subtilisin is most active at pH 8.5 and 55° C. (Alder-Nissen, 1986). For the intent of this experiment, a lyophilized preparation of a model protein enzyme was resuspended to 275 g/L in 100 mM sodium carbonate in order to bring the pH of the resulting protein solution to approximately pH 8. Subtilisin (Alcalase 2.4 L, Sigma Aldrich, St. Louis, Mo.) was added to the protein solution at a concentration of 5.93×10-4 U per mg of model protein enzyme. The reaction was then diluted to 250 g/L model protein enzyme and transferred to 55′C for 24 hours. Once completed, the hydrolyzed material was stored at 4° C.
Reaction progress was monitored by size exclusion chromatography (SEC) using a Superdex 75 (5×150 mm) column (GE Healthcare, Uppsala, Sweden) and also by SDS-PAGE analysis.
Protein Reduction and Alkylation.
Disulfide containing proteins can be reduced and alkylated in order to break disulfide bonds and stabilize free thiols. This modification disrupts all disulfide bridge structure and furthermore prevents disulfide bridges from reforming both intramolecularly or extramolecularly. SEQID-00363 contains 10 cysteines, and four disulfide bonds as predicted by SCRATCH Protein Predictor (Cheng et al., 2005 Nucleic Acids Res.).
SEQID-00363 was reduced and alkylated at a final concentration of 6 g/L using Bio-Rad ready Prep Reduction/Alkylation Kit (Bio-Rad, Hercules, Calif.). The reduction/alkylation reaction was performed as recommended by the manufacturer's instructions. SEQID-00363 was reduced and alkylated in 50 mM phosphate, pH 8.0. Samples were analyzed by non-reducing SDS-PAGE analysis.
Heat-Induced Protein Destabilization.
Denaturation of protein involves the disruption of ordered structure of the molecule; i.e., reduction of all quaternary, tertiary and secondary structure to primary structure. Denaturation disrupts all non-covalent intramolecular interactions; i.e., hydrogen bonding, ionic interaction, Vander Waals interaction and hydrophobic interaction. Heat can be used to disrupt these interactions, and reduce a native protein to its primary structure (with the exception of disulfide linkages).
SEQID-00363 was diluted to 30 g/L in 10% PBS, pH 7.4 and rapidly heated to 95° C. Upon boiling, the protein was removed from heat treatment and immediately transferred to in vitro digestion analysis as described in herein.
In Vitro Digestibility of Modified Forms of SEQID-00363.
The digestibility of native SEQID-003.63 and modified forms (ie. deglycosylated, reduced and alkylated, and heat-denatured) of SEQID-00363 was evaluated using the methods described herein. Briefly, native and modified forms of SEQID-00363 were treated with simulated gastric fluid (SGF) and the presence of intact protein remaining at various time points was analyzed by gel electrophoresis as described herein. Additionally, the amount of free amino acids present after exposure to a Pancreatin-based simulated digestive system was analyzed by reverse phase HPLC amino acid analysis as described herein. Results from the SGF digest of native and modified forms of SEQID-00363 demonstrate that modification of SEQID-00363 via deglycosylation, reduction and alkylation, and heat-denaturation enhances the digestibility of the protein to varying degrees. Results from the Pancreatin digest of native and modified forms of SEQID-00363 demonstrate that modification of SEQID-00363 via deglycosylation and heat-denaturation, but not reduction and alkylation, enhanced the release of free Leu during digestion. Table E34A lists half-life values calculated from the exponential decay curves and free Leu (pM) at 120 min time point.





TABLE E34A



SGF Half-life (t½) in min and Free Leu (μM) at 120 min time point

of Pancreatin digest of modified nutritive polypeptide






SGF Half-life
Free Leu (μM) at 120


(t½) in
min time point of


min
Pancreatin digest







SEQID-00363
36
574.2

Heat-denatured SEQID-
20.4
763.5

00363



Reduced and alkylated
20.4
598.1

SEQID-00363



Deglycosylated SEQID-
4.3
799.2

00363



































Bioavailability of Modified Forms of SEQID-00363.
The boavailability o native and modified forms (ie. deglycosylated and hydrolyzed) of SEQID-00363 was evaluated using the methods described in herein. Briefly, native and modified forms of SEQID-00363 were orally administered to intrajugular-cannulated rats and concentration of free amino acids in plasma samples collected over a 4 h period was determined by HPLC amino acid analysis. Amino acid analysis of plasma samples collected in the rat pharmacokinetic study of native and modified forms of SEQID-00363 are displayed in FIG. 55 . These results demonstrate that hydrolysis of SEQID-00363 increased the bioavailability of Leucine, Serine, Threonine, and in general essential amino acids (EAAs). While deglycosylation of SEQID-00363 did not increase the bioavailability of Leucine or EAAs, it did increase the bioavailability of Serine and Threonine.
Ileal Digestibility of Modified Forms of SEQID-00363.
Protein quality is a function of amino acid composition, digestibility, and bioavailability. Ileal digestibility assays may be used to measure the difference between the contents (ie. amino acid, nitrogen, dry matter weight) of a protein and the contents of the digesta in the terminal ileum following ingestion of the protein. Results from ileal digestibility assays can be used to calculate amino acid, nitrogen, and dry matter ileal digestibility coefficients and provide knowledge about the protein's digestibility and amino acid bioavailability (Darragh and Hodgkinson, 2000, Journal of Nutrition, 130(7): 1850S-1856S). Fecal digestibility coefficients, determined over the entire digestive tract, tend to overestimate amino acid digestibility and bioavailability due to microbial metabolism in the large intestine. Since protein digestion and amino acid absorption occurs mainly in the upper small intestine and is effectively complete by the end of the ileum, ileal digestibility assays are now accepted as the method of choice for determining protein and amino acid digestibility in monogastric mammals. Growing rats, which have a similar small intestinal transit rate to adult humans (3-4 h), are accepted as a suitable model for ileal digestibility assays (Amidon et al., 1986, The Journal of Pharmacy and Pharmacology, 38(5): 363-368).
A rat pharmacokinetic study with oral administration of native and modified forms of SEQID-00363 was performed as described herein. The indigestible marker Cobalt-EDTA was formulated at 50 mg/L in the dosed protein solutions to monitor differences in intestinal transit rate between treatment groups and individual rats. Following the final blood collection (at t=4 h) rats were euthanized and the terminal ileum (20 cm of small intestine prior to the cecum) and its contents (the digesta) were collected into a pre-weighed tube. The ileum was flushed with saline and pooled with the digesta. The pH of the digesta was adjusted to ˜3.0 with HCl in order to inactivate all enzymes. The ileum samples were placed into separate pre-weighed 15 mL conical tubes. All samples were flash frozen in liquid nitrogen, and stored at −80° C. until further analysis. Individual ileum and ileum content weights were calculated and recorded for each sample.
A sample of the digesta, which exists as a heterogenous solution containing insoluble particles, was used in the Coomassie Plus Protein Assay, as described herein, to determine protein concentration. The average total protein concentration in digesta samples harvested from rats administered vehicle, native SEQID-00363, deglycosylated SEQID-00363, and hydrolyzed SEQID-00363 was 0.1, 0.9, 0.9, and 0.3 mg/mL, respectively. Based on the volumes of collected digesta the total protein mass in digesta samples harvested from rats administered vehicle, native SEQID-00363, deglycosylated SEQID-00363, and hydrolyzed SEQID-00363 was 1.2, 6.9, 7.7, and 2.2 mg, respectively. These results demonstrate that the concentration and total mass of protein is higher in the digesta of rats administered native and deglycosylated SEQID-00363 than in rats administered either vehicle or hydrolyzed SEQID-00363. Together these results suggest that hydrolyzed SEQID-00363 is more completely digested in the rat gastrointestinal system than either native or deglycosylated SEQID-00363.
To determine ileal digestibility coefficients an aliquot of the dosing sample and the ileal digesta sample are analyzed for total amino acid content by reverse phase HPLC amino acid analysis (Lookhart and Jones, 1985, Cereal Chemistry, 62(2):97-102), total nitrogen content by Kjeldhal analysis (Lynch and Barbano, 1999, JOURNAL OF AOAC INTERNATIONAL, 82(6): 1389-1398), and Cobalt content by Inductively Coupled Plasma Mass Spectrometry (ICP-MS) (Taylor, H. E., Inductively Coupled Plasma-mass Spectrometry: Practices and Techniques, Academic Press, 2001) to determine ileal amino acid and nitrogen digestibility coefficients.
Example 35
Treatment of Nutritive Polypeptides for Reduced Activity
Modification of enzymatically active nutritive polypeptides can alter both the enzymatic activity, and the structural stability of the protein. It can be advantageous for an orally administered nutritive polypeptides to lack activity that is not required for delivery of amino acid nutrients. Furthermore, deactivation is indicative of destabilization that can be more digestible and bioavailable than its native counterpart. Enzyme modification was achieved through either chemical or heat treatment(s). Enzymatic activity was measured through an in vitro assay.
Activity Assay.
Inactivation of SEQID-00363 was tested by a glucoamylase activity assay. Glucoamylase acts to hydrolyze p-nitrophenyl-α-D-glucopyranoside to p-nitrophenol (PNP) and glucose. The activity of the enzyme in units (U) per mL was determined by measuring the absorbance of release PNP at 400 nm (method adapted from Glucoamylase Activity Assay (U.S. Pharmacopeia. Food Chemicals Codex, 8th edition; 2012:1314-1315)) PNP standards at 0.12, 0.06, 0.03, 0.015 and 0.0075 μmol/mL in 0.3 M sodium carbonate were used to determine the millimolar extinction coefficient (∈) using the follow equation: ∈=A400 nm/C where the average value considered where A400 nm is the absorbance at 400 nm measured using a spectrophotometer with a 10 mm light path and C is the standard concentration in mol/mL. The samples were made at dilutions in 0.1 M sodium acetate pH 4.5 that fall in the absorbance range of the standards. 100 μL of sample wass incubated at 50° C. for 5 minutes prior to addition of 100 μL of PNPG solution (100 mg PNPG, dilute to 100 mL in 0.1 M sodium acetate pH 4.5) that had been equilibrated at 50° C. for at least 15 minutes. The sample was then incubated at 50° C. and 100 μL of 0.3 M sodium carbonate added 10 minutes after PNPG addition to stop the reaction. The absorbance at 400 nm was then measured and the activity in U/mL calculated as follows: Activity=[(Asample−Ablank)×0.3 mL×Dilution Factor]/ex 10 min×0.10 mol/min/unit×0.1 mL where Asample is the sample absorbance and Ablank is the blank absorbance at 400 nm, 0.3 mL is the volume of the reaction, 10 min is the reaction time, 0.10 μmol/min is the amount of PNP cleaved per unit of enzyme and 0.1 mL is the sample aliquot. 1:1:1:0.1 M sodium acetate pH 4.5:0.3 M sodium carbonate: PNPG solution is used as a blank. Activity is reported as specific activity (U/mL or U/mg) or as a relative activity (i.e. compared to a control protein).
Protein Modification for Deactivation.
Protein enzymes can be deactivated through chemical-induced destabilization of the enzymatic active site of the molecule. An experiment was performed that screened a subset of reagents that represented different chemical classes and mechanisms of action including: Oxidation (Bleach, H202, ethylene oxide); Reduction (DTT, bME, TCEP); Chaotrope (CaCl2, Urea, Gnd HCl, NaSCN); High pH (Na2CO3, Tris Base, Na2HPO4); Low pH (Na3Citrate, Tris HCl, Acetic acid, Boric acid); Neutral pH (Na-Citrate, MOPS Acid, MES Acid, Na-Acetate); Detergents (Tween 80, Triton-X-100, CHAPS, SDS, MPD); Chelation (EDTA, citrate).
SEQID-00363 was formulated in water to 300 g/L and diluted 10× into an array of chemical deactivation conditions (final concentration=30 g/L). SEQID-00363 was subsequently assayed for enzymatic activity after 10 minutes of deactivation and 4 days of deactivation Table E35A.





TABLE E35A



Chemical deactivation of SEQID-00363. Results of enzyme activity

assay at 4 day time point. All enzyme activities are normalized to the

negative control (water).







Activity After

Activity After


4 Days

4 Days

Condition
(% of Water)
Condition
(% of Water)



Water Control
100%
1M Gnd HCl
58%

1% Triton-X-100
93%
250 mM Tris Base
56%

200 mM CaCl2
92%
100 mM Tris Base
54%

1% CHAPS
85%
2M Gnd HCl
46%

50 mM CaCl2
84%
500 mM Tris Base
41%

400 mM CaCl2
79%
5M Urea
41%

100 mM CaCl2
78%
0.1% Bleach
21%

5% BME
77%
50 mM Na2CO3
19%

250 mM EDTA
76%
10M Urea
15%

0.1% H2O2
76%
4M Gnd HCl
10%

0.01% Bleach
73%
0.615% Bleach
9%

50 mM DTT
73%
100 mM Na2CO3
6%

0.3% H2O2
72%
200 mM Na2CO3
4%

1% Tween 80
66%
500 mM Na2CO3
0%

1% SDS
65%
6M Gnd HCl
0%

0.5M Gnd HCl
60%








































Relative to a water deactivation negative control, SEQID-00363 displayed greatest deactivation in strong chaotropes such as 6M Gnd.HCl and 4M urea; high pH formulations of sodium carbonate; and the strong oxidizer, sodium hypochlorite (household bleach). At t=4 days, these conditions all displayed less than 20% of relative enzymatic activity after four days of treatment. Due to the health risks associated with consumption of vigorous oxidizers and strong chaotropes, treatment of SEQID-00363 with high pH was identified as the best condition for deactivation of the enzyme. Relative to the 10 minute time point, samples taken at the four day time point suggest that chemical deactivation at room temperature is not a fast-acting process. The kinetics of deactivation are likely not very fast in many of the assayed conditions.
An experiment measured deactivation of SEQID-00363 by heat at multiple buffer conditions was tested. SEQID-00363 was diluted to 3 g/L in 20 mM sodium phosphate pH 7, 20 mM sodium phosphate pH 9, 20 mM sodium carbonate pH 11 and water. 100 μL of sample was then treated at ambient temperature, 60° C., 70° C., 80° C. and 90° C. for each buffer for 5 minutes in a PCR thermocycler. The activity of each enzyme was tested by the glucoamylase activity assay and each activity normalized to the activity in water at ambient temperature (control). The results are shown below in Table E35B.





TABLE E35B



Chemical deactivation of SEQID-00363. Results of enzyme activity

assay at 4 day time point. All enzyme activities are normalized to the

negative control (water).





Activity (% of Water,

Condition
Ambient)



Water, Ambient
100%

Water, 60° C.
84%

Water, 70° C.
14%

Water, 80° C.
3%

Water, 90° C.
3%

20 mM Sodium Phosphate pH 7, Ambient
101%

20 mM Sodium Phosphate pH 7, 60° C.
53%

20 mM Sodium Phosphate pH 7, 70° C.
2%

20 mM Sodium Phosphate pH 7, 80° C.
1%

20 mM Sodium Phosphate pH 7, 90° C.
1%

20 mM Sodium Phosphate pH 9, Ambient
99%

20 mM Sodium Phosphate pH 9, 60° C.
27%

20 mM Sodium Phosphate pH 9, 70° C.
2%

20 mM Sodium Phosphate pH 9, 80° C.
1%

20 mM Sodium Phosphate pH 9, 90° C.
1%

20 mM Sodium Carbonate pH 11, Ambient
93%

20 mM Sodium Carbonate pH 11, 60° C.
0%

20 mM Sodium Carbonate pH 11, 70° C.
0%

20 mM Sodium Carbonate pH 11, 80° C.
0%

20 mM Sodium Carbonate pH 11, 90° C.
1%











































An additional multifactorial experiment was performed that assayed the effect of temperature and pH for varying exposure time on the enzymatic activity of SEQID-00363. SEQID-00363 was formulated to 100 g/L, and the effect of either a high pH spike, or a diafiltration into high pH buffers was tested against a gradient of temperatures across 25′C to 70′C over a time course of 0 hours to 24 hours. Upon analysis, samples were neutralized to ˜pH 7 using a spike of 1M sodium acetate buffer.
SEQID-00363 experimental overview and design was as follows. SEQID-00363 was resuspended to 100 g/L and either spiked with 0.25M sodium carbonate pH 10, diafiltered into 50 mM sodium carbonate pH 10, or diafiltered into 10% phosphate buffered saline pH 9.0. Samples were incubated at either 40, 50, 60 or 70′C across a time course that included sampling points at t=0, 1, 2, 4 and 24 h.
Inactivation of SEQID-00363 was assayed using an activity assay as described herein. Samples were analyzed by specific activity (U/mg) and visual solubility, as either a gel, viscous or fluid. This study found SEQID-00363 is enzymatically deactivated by both temperature and pH. Some treatments caused irreversible aggregation, and gel formation of the nutritive polypeptide; these samples were not analyzed for enzymatic activity. The results of this experiment suggest that SEQID-00363 can be solubly deactivated at pH 10 at 25° C. As the temperature of the reaction increases, the protein remains deactivated, but becomes insoluble.
pH was therefore defined as a critical process variable in regard to SEQID-00363 deactivation. A subsequent study was performed to explored SEQID-00363 deactivation as a function of pH at room temperature. A process which can be performed at room temperature is less costly and easier to scale up than a heated process. SEQID-00363 was formulated to 100 g/L at pH 3.6 and using an ultrafiltration membrane, the buffer was exchanged into a series of sodium carbonate buffers. The SEQID-00363 solution pH increased from 3.6 to 11.0 during the course of buffer exchange. Samples of the protein were taken from the ultrafiltration system systematically during the course of buffer exchange, resulting in a set of samples across the pH range. These samples were held at room temperature and each sample was split in half. Half of each sample was neutralized into sodium acetate buffer after 2-5 hours. Neutralized samples were then assayed for enzyme activity as described and results are in the Table E35C.





TABLE E35C



Effect of 2-5 hour incubation over pH range on activity.







Relative activity


pH
(%)









3.6
100


4
91


5
83


6
82


7
89


8
86


9
56


9.7
54


10
37


10.9
13



































Deactivation by hydrolysis of SEQID-00363 was also tested by g ucoamy ase activity assay. The procedure of protein hydrolysis is described herein. Hydrolysis was found to reduce activity to 7% relative to control.
Other amylase nutritive polypeptide deactivation was also tested. Deactivation of SEQID-00424 was tested by the glucoamylase activity assay as described herein, but instead utilizing a pH 5.0 acetate buffer (recommended for Aspergillus oryzae derived enzymes). Samples were deactivated by hydrolysis or by boiling, as described herein. Boiling reduced activity to 0% and hydrolysis reduced activity to 51% relative to control.
Example 36
Disruption of Nutritive Polypeptide Enzymatic Activity
Construction of Mutant Proteins.
Multiple mutations were tested to determine the degree of enzymatic inactivation that could be achieved for a model protein known to have enzymatic activity (SEQID-00338, UniProt ID: P07170). In this protein, the substrate binding sites includes positions 42, 134, 167, and 178. In addition, there is a magnesium ion binding site at position 91. Single amino acid mutations were made at several substrate-binding positions. The mutants were expressed and tested for enzymatic activity.
The single amino acid mutant proteins were constructed by PCR amplification of two pieces. The first piece is amplified using a forward primer that binds to the 5′-end of the gene (ATCACCACCATCACCATCATAGCAGCAGCGAAAGCATTCGTATG) with an overhang that is compatible with a His-tag and a reverse primer (Table E36A) containing the most common codon for the target amino acid in Escherichia coli and the 20-bp flanking region upstream and downstream of the mutation. The second piece amplifies the 3′-end of the protein immediately following the mutation site using a forward primer specific to the position of the mutation (Table E36A) and a reverse primer that binds to the 3′-end of the gene (TGTTAGCAGCCGGATCCTTAATCTTTGCCCAGTTTATTCAGAATATC).
Standard PCR reaction conditions were used for all pieces, which contains 0.5 uM forward primer, 0.5 uM reverse primer, 1× Phusion Polymerase Master Mix (New England Biolabs), and 1-100 ng template DNA in 50 ul final volume. The thermocycle conditions are initial denaturing at 98° C. for 30 sec, cycle 30 times with denaturing temperature at 98° C. for 10 sec, annealing temperature at 55-60° C. 15 sec, extension temperature at 72° C. for 15 sec/kb product. The template DNA are removed from the final products by adding 1 ul Dpn I (New England Biolabs) and 5 ul 10× CutSmart buffer and incubating at 37° C. for 1 hour. Each PCR product is cleaned and concentrated following a Gel Recovery kit (Zymo Research) and eluted in 20 ul sterile water before proceeding to the next assembly step.





TABLE E36A



List of reverse primers used to amplify

PCR piece 1 for the mutants.










Mutation
Reverse Primer 1




D91F
GGAATGGTACGCGGAAAACCAAACAGAATAAA



GCCATTTTTGCATGCC




D91I
GGAATGGTACGCGGAAAACCAATCAGAATAAA



GCCATTTTTGCATGCC




R134M
CCGCTTGCCGGATGAATCAGCATACCGGTAAT



ACGTGCAACCAG




R134Y
CCGCTTGCCGGATGAATCAGATAACCGGTAAT



ACGTGCAACCAG




R42A
GTACCTTTTGCAATCTGGCTTGCCAGCATATC



ACCGGTTGCCAG




R42C
GTACCTTTTGCAATCTGGCTACACAGCATATC



ACCGGTTGCCAG




R42G
GTACCTTTTGCAATCTGGCTACCCAGCATATC



ACCGGTTGCCAG




R42I
GTACCTTTTGCAATCTGGCTAATCAGCATATC



ACCGGTTGCCAG




R42K
GTACCTTTTGCAATCTGGCTTTTCAGCATATC



ACCGGTTGCCAG




R42L
GTACCTTTTGCAATCTGGCTCAGCAGCATATC



ACCGGTTGCCAG




R42Q
GTACCTTTTGCAATCTGGCTCTGCAGCATATC



ACCGGTTGCCAG




R42T
GTACCTTTTGCAATCTGGCTGGTCAGCATATC



ACCGGTTGCCAG




R42V
GTACCTTTTGCAATCTGGCTAACCAGCATATC



ACCGGTTGCCAG




Position
Forward Primer 2




91
GGTTTTCCGCGTACCATTCC




134
CTGATTCATCCGGCAAGCG




42
AGCCAGATTGCAAAAGGTACAC





































































Mutations are specified by original amino acid in its single letter abbreviation followed by the position and the final amino acid in its single letter abbreviation.
The PCR amplified pieces were inserted into the expression plasmid by Gibson assembly and transformed into T7 Express (New England Biolabs) cells for expression. The expression plasmid pET15b containing a T7 promoter, an 8×His-tag, and a stop codon was amplified by PCR using primers GGATCCGGCTGCTAACAAAGCC and ATGATGGTGATGGTGGTGATGATGAC so that there will be 20 bp overlap between each PCR piece, so that they will be properly assembled by Gibson assembly. In Gibson assembly, 1 ul of each PCR piece is combined into 10 ul final volume with 1× Gibson Assembly Master Mix (New England Biolabs) and incubated at 50° C. for 1 hour. The assembly reaction mixture was diluted 3× by adding 20 ul water. 3 ul of the diluted mixture was transformed into 30 ul T7 Express (New England Biolabs) cells. Single colonies were picked and plasmids extracted and sequence confirmed before moving on to expression studies.
Expression and Purification of Mutant Proteins.
Single colonies were used to inoculate a 2 mL deep well block with 1 mL of LB medium with 100 mg/L carbenicillin in each well. Cultures were shaken at 37° C. and 900 rpm overnight in a deep well block shaker. The deep well block was used to inoculate another deep well block with 1 mL of BioSilta Enbase medium with 600 mU/L glucoamylase to an OD600 of 0.1. Cultures were shaken for 16 hours at 37° C. and 900 rpm, at which point 1 mM IPTG was added to induce the cultures, and additional Enbase supplemental media and another 600 mU/L of glucoamylase was added to supplement the cultures. Expression was carried out for another 6 hours at 37° C. and 900 rpm. Cultures were harvested by spinning the deep well block at 3,000×g for 10 minutes at RT. After centrifugation, the supernatant was carefully removed the cell pellets were frozen at −20° C. Frozen cell pellets were thawed and 0.3 g of 0.1 mm zirconium beads were added to each sample followed by 0.5 ml of PBS. The cells were lysed in the cold room (4° C.) by bead-beating for 5 min in a Qiagen TissuelyserII (Qiagen, Hilden, Germany) equipped with a 96-well plate adapter. Cell lysates were centrifuged at 3000 rpm for 10 min and the supernatant was removed, sampled, and analyzed for protein concentration by chip electrophoresis. Samples were prepared by adding 2 μl of sample to 7 μl sample buffer, heating at 95 C for 5 minutes, and then adding 35 μl of water. Analysis was completed using HT Low MW Protein Express LabChip® Kit or HT Protein Express LabChip® Kit (following the manufacturer's protocol). A protein ladder ran every 12 samples for molecular weight determination (kDa) and quantification (ng/μl).
The mutant proteins were purified using the His Multitrap HP (GE Healthcare) system according to manufacturer's protocol. The concentrations of the proteins were measured by SDS-PAGE stained by Coomasie Blue and absorbance at 280 nm. The proteins were diluted in 40 mM Tris buffer for kinase activity assay.
Determination of the Kinase Activity of SEQID-00338.
The ADP-Glo™ Max Assay was obtained from Promega (Catalog number V7001, Madison, Wis.). Adenosine Monophosphate was obtained from Sigma-Aldrich (Catalog number A1752, St. Louis, Mo.). 5× Kinase Buffer was prepared w/ 1.211 g Tris Base (Catalog number BP152-2, Fisher Bioreagents, Pittsburgh, Pa.), 692 μL 12% hydrochloric acid solution (Catalog number BDH3026-500MLP, VWR, Radnor, Pa.), 10.0 mL 500 mM magnesium chloride (Catalog number BP214-500, Fisher Bioreagents, Pittsburgh, Pa.) and the volume brought to 50 mL with MilliQ water and filtered through 0.22 μm PES filter (Catalog number SCGP00525, Millipore, Billerica, Mass.) into a sterile 50 mL tube.
Twelve his-tag purified mutant proteins and the wild-type protein at 35 μg/mL in Tris buffer were serially diluted to 7.0 and 1.4 μg/mL. Prepared kinase reaction mix at 0.5 mM AMP/0.5 mM ATP to test for activity and at 0 mM AMP/0 mM ATP to assay background activity by diluting 5× Kinase Buffer with appropriate volumes of 10 mM AMP and 10 mM ATP in MilliQ water. Duplicate reactions were prepared by mixing 9 μL of the reaction mixture with 6 μL of diluted SEQID-00338, mixing by pipetting up and down and dispensing 5 μL into a 384-well white OptiPlate (PerkinElmer, Waltham, Mass.). An ADP standard curve was prepared by serially diluting 4 mM ADP in MilliQ water and adding kinase buffer to 1× for a standard at 0.0005, 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1, 2, 3, and 4 mM ADP. The plate was covered with a foil plate seal and incubated at 30° C. for 30 min. Following the kinase reaction, 5 μL of ADP-Glo™ Reagent was added to each well. The plate was sealed with a foil plate seal and placed on a horizontal plate shaker at 450 rpm for 2 minutes at room temperature. The plate was removed from the plate shaker and incubated at room temperature for 40 minutes. The plate was then centrifuged for 15 seconds at 1109×rcf and 10 μL of ADP-Glo™ Max Detection Reagent was added. The plate was sealed with a foil plate seal and shaken on a horizontal plate shaker at 450 rpm at room temperature for 2 minutes. The plate was then removed from the plate shaker and incubated at room temperature for 60 minutes. The plate was centrifuged for 15 seconds at 1109×rcf and the luminescence read on an EnspireAlpha plate reader (PerkinElmer, Waltham, Mass.).
The ADP standard curve was used to determine the concentration of ADP in sample wells in the presence or absence of substrate. Concentrations were determined by performing a non-linear 4 parameter logistic on the X=log(X) transformed ADP standard luminescence values. Background ADP was found to be below the limit of detection in most samples. Where the background concentration of ADP in the absence of substrate was calculable the average of those values were subtracted from the calculated ADP concentration in the substrate incubated wells. Activity knock out was calculated by percentage activity relative to purified wild-type protein at the same concentration.
Table E36B lists the average percent activity of variants relative to purified wild-type protein. All of the variants have decreased activity compared to the wild-type protein. Kinase variants exhibit differences in activity at 7 μg/mL.





TABLE E36B



The proportion activity was calculated as the percentage

AMP + ATP→ADP converted by SEQID-00338 at 7

μg/mL during a 30 minute reaction at 30° C.








KINASE
AVG
SD
N











Wild-type
100.0%
11.2%
2


D91F
0.9%
0.60%
2


D91I
0.4%
0.20%
2


R134M
0.3%
0.09%
2


R134Y
0.2%
0.08%
2


R42A
0.9%
0.08%
2


R42C
1.8%
0.14%
2


R42G
1.2%
0.06%
2


R42I
1.5%
0.07%
2


R42K
2.2%
0.14%
2


R42L
1.7%
0.08%
2


R42Q
1.2%
0.05%
2


R42T
1.9%
0.06%
2







































Example 37
Engineering of Secreted Polypeptide for Reduced Enzymatic Activity
A mutant protein was constructed to reduce the enzymatic activity of a nutritive polypeptide. The active sites of SEQID-00407 are predicted to be residues D217 and E249, which are acidic residues lying in the center of the catalytic domain. To produce a polypeptide free of enzymatic activity and enriched in amino acids important to nutrition and health, we mutated those two sites to disrupt the catalytic activity of SEQID-00407. D217 and E249 in SEQID-00407 may act as nucleophiles and proton donors or acceptors to form hydrogen bonds with their ligands.
To remove enzymatic activity from SEQID-00407, we engineered a protein with a single amino acid mutation at E249, changing it from glutamic acid to phenylalanine. The mutant was constructed by assembling two PCR fragments. The first contains the 5′-end of the enzyme up to 20 bp downstream of the mutation site. The second contains the 3′-end of the enzyme starting immediately after the mutation site. In the first PCR fragment, specific PCR primers were designed to bind the targeted mutation site and incorporate the desired mutant amino acid codon. The TTT codon was selected because it is the most highly used codon for phenylalanine in Bacillus subtilis . The two PCR fragments were assembled and inserted into the plasmid vector using Gibson Assembly method (NEB Gibson Assembly Master Mix) at 50° C. for 1 hour. The constructs were built in E. coli and confirmed by DNA sequencing before transforming into Bacillus subtilis for secretion and enzymatic activity assays.
Secretion of Nutritive Polypeptides from Bacillus subtilis.
Three separate colonies of B. subtilis expression strains were used to inoculate 1-ml of 2×L-Mal medium (20 g/l NaCl, 20 g/l tryptone, and 10 g/l yeast extract, 75 g/l maltose) with Cm5, in deep well blocks (96-square wells). Culture blocks were covered with porous adhesive plate seals and incubated overnight in a micro-expression chamber (Glas-Col, Terre Haute, Ind.) at 37° C. and 880 rpm. Overnight cultures were used to inoculate fresh, 2×L-Mal, Cm5 cultures, in deep well blocks, to a starting OD600=0.1. These expression cultures were incubated at 37° C., 880 rpm until the OD600=1.0 (approx. 4 hrs) at which time they were induced by adding isopropyl 3-D-1-thiogalactopyranoside (IPTG) at a final concentration of 0.1 M and continuing incubation for 4 hrs. After 4 hrs, the cell densities of each culture was measured (OD600) and cells were harvested by centrifugation (3000 rpm, 10 min, RT). After centrifugation, culture supernatant was carefully removed and transferred to a new block and cell pellets were frozen at −80° C. To determine the levels of secreted protein, the supernatants were assayed to determine the levels of secreted protein of interest (POI) by chip electrophoresis. Briefly, samples were prepared by adding 2 μl of sample to 7 μl sample buffer, heating at 95 C for 5 minutes, and then adding 35 μl of water. Analysis was completed using HT Low MW Protein Express LabChip® Kit or HT Protein Express LabChip® Kit (following the manufacturer's protocol). A protein ladder ran every 12 samples for molecular weight determination (kDa) and quantification (ng/μl).
Amylase Activity Assay.
SEQID-00407 is an α-amylase in Bacillus subtilis that has the activity of breaking down polysaccharides, such as starch, into monosaccharides or disaccharides. To demonstrate that the specific mutants have removed enzymatic activity, Bacillus subtilis secreting the enzyme were plated onto agar plates containing starch. If there is enzymatic activity, the secreted enzyme will breakdown the starch and upon staining by iodine, there will be a halo surrounding the Bacillus subtilis colonies. 1% starch plates were made by combining 25 g Luria Broth-Miller, 10 g starch, 15 g bacteriological agar, and 1 L water. 10 mM IPTG was added to the starch plates after the agar has solidified. Single colonies of Bacillus subtilis strains expressing the mutant polypeptides were inoculated in 5 ml LB at 37° C. for 4 hours and 50 μl of the liquid culture were spotted at the center for the starch plates. After 20 hours of growth and induced secretion, 10% iodine was added to the starch plates to stain for starch. When the wild-type enzyme is secreted, it creates a large halo around the cells. However, when the engineered enzymes are secreted, the halo reduces in area, similar to the negative control strain, which expresses the empty vector without the enzyme. Table E37A quantifies the area of the halos relative to the area of the cells. It is shown that the difference in area between the halo and the cells is larger for the wild-type than engineered mutants. From the data shown, we demonstrated the engineering of secreted nutritive polypeptide with reduced enzymatic activity.





TABLE E37A



Quantified area of cells, halos, and their differences measured in in2.






Protein
Cell Area (in 2 )
Halo Area (in 2 )
Halo/Cell








No protein control
0.413
0.6
1.45

Wild-type
1.27
2.246
1.77

E249F sample 1
0.331
0.496
1.50

E249F sample 2
1.335
1.936
1.45



























Example 38
Engineering of Nutritive Polypeptide Amino Acid Content to Modulate Polypeptide Activity and to Enrich Essential Amino Acid Content
To demonstrate the engineering of secreted polypeptides for enriched amino acid content, we chose a microorganism known to secrete protein at high levels Bacillus subtilis . SEQID-00407 was identified a major secreted protein in Bacillus subtilis . Using sequence conservation and crystal structure data for SEQID-00407, we identified contiguous regions within each protein that were predicted to be tolerant to mutations without negatively affecting the structural stability of the protein and/or the ability of the host organism to secrete the protein.
We analyzed the secondary structure of SEQID-00407 reported in the structural protein databank entry 1UA7. We identified 19 loop regions within the sequence of the protein that are not part of an α-helix or a β-sheet. These loop regions are defined by the following amino acid residues: 73-76, 130-133, 147-152, 157-161, 189-192, 222-227, 239-244, 283-286, 291-298, 305-308, 318-323, 336-340, 356-360, 365-368, 387-392, 417-421, 428-432, 437-442, and 464-466. Loop regions less than 4 amino acids in length were not considered for mutation.
Conservation of sequence over evolutionary space was also considered for identifying positions amenable for engineering while maintaining structural stability and secretion competency. Positions that are less conserved within a family of homologous sequences are inherently variable and likely more amenable to mutation without affecting activity, which is intrinsically tied to structure. To find positions that are less conserved, we downloaded the alignment of the pfam00128 from the NCBI Conserved Domain Database, which contains 31 protein sequences including the SEQID-00407 catalytic domain (Marchler-Bauer A., Zheng C., Chitsaz F., Derbyshire M. K., Geer L. Y., Geer R. C., Gonzales N. R., Gwadz M., Hurwitz D. I., Lanczycki C. J., Lu F., Lu S., Marchler G. H., Song J. S., Thanki N., Yamashita R. A., Zhang D., and S. H. Bryant. Nucleic Acids Res. (2013) 41:D348-52). We also performed a PSI-BLAST search of the NCBI protein reference sequence database (Pruitt K. D., Tatusova T., and D. R. Maglott. Nucleic Acids Res. (2005) 33:D501-504) using SEQID-00407 and obtained 500 sequences homologous to SEQID-00407. In both cases, a single iteration was performed using the BLOSUM62 position specific scoring matrix, a gap penalty of −11, a gap extension penalty of −1, and an alignment inclusion e-value cutoff of 0.005 (Altschul S. F., Nucleic Acids Res. (1997) 25:3389-3402). All protein sequence alignments were used to generate position-specific scoring matrices (PSSM) specific to each query sequence as part of the PSI-BLAST search. From the PSSMs, we identified regions predicted to be tolerant to mutation by counting the number of different amino acids associated with a positive PSSM score at each position within each loop as well as the sum and average of the PSSM scores for essential amino acid substitutions at each position Furthermore, from the multiple sequence alignments obtained from each PSI-BLAST search, we calculated the amino acid entropy at each position, as defined by










E
j

=

-

∑


?



?












?



indicates text missing or illegible when filed





where Sj is the entropy at position j and pi is the probability of observing amino acid i at position j.
Using these measures of mutation tolerance, we identified four loop regions expected to be tolerant to mutations into essential amino acids. To enrich the identified regions in essential amino acids we used a combinatorial codon library where any selected position could be either a F, I, L, V, or M (denoted Z) or a R, K, T, I, or M (denoted X). In each of the loop regions selected for mutation into an essential amino acid, each variable position was assigned as a Z or X depending upon its relative tolerance of hydrophobic residues (based upon their respective PSSM values). Positions that were tolerant of hydrophobic residues were assigned as Z and genetically encoded using the codon NTN. Positions more tolerant of hydrophilic residues were assigned as an X and genetically encoded using the codon ANR. We note that in one of the identified variable regions of SEQID-00407 (147-153), a glycine residue was inserted into the center of the loop in an attempt to enhance the conformational flexibility of this region. For SEQID-00407 the sequences of the identified regions are summarized in Table E38A.







TABLE E38A



Start residue #
original
degenerate



148
YAAI
XXGXX



240
NTSA
ZXXZ



291
SHYASD
XZYXXZ



389
QPEE
XPZZ



X = NTN, codes for F, L, I, M, V

Z = ANR, codes for I, M, T, K, R























Library Design and Construction.
Based on identification of variable regions, we designed primers that can amplify each variable region as explained herein. For example if there are four variable regions, we need four pair of primers to generate four variable fragments. In step 1 we used pES1205 as the template which contains SEQID-00407 fused with N-terminal AmyQ signal peptide and downstream of pGrac promoter. pES1205 is a derivative of the vector, pHT43 (MoBiTec), containing a 1905-bp DNA fragment encoding the amyE gene from B. subtilis (minus the initial 93-bp encoding the AmyE signal peptide) plus a C-terminal 1× FLAG tag. The amyE::1XFL:AG sequence is cloned, in-frame with the SamyQ sequence encoded on pHT43. For fragment 1, 2, 3, 4, the forward PRIMERID-45053, PRIMERID-45054, PRIMERID-45055, and PRIMERID-45056 contain 25 bases of constant sequence before the variable region followed by degenerate sequences to represent the variable region and 25 bases of constant sequence downstream of the variable region. For fragment 1, 2, 3, the reverse primers PRIMERID-45061, PRIMERID-45062, and PRIMERID-45063 contain 25 bases of reverse complementary sequence upstream of next variable region respectively. For fragment 4, the reverse primer PRIMERID-45064 contains 25 bases of reverse complementary sequence at an arbitrary distance from variable region 4. Four separate PCR amplifications were run using Phusion DNA polymerase (New England Biolabs, Beverly, Mass.) and reaction parameters recommended by the manufacturer. As separate reactions, four wild type fragments, WT-frag-1, WT-frag-2, WT-frag-3 and WT-frag-4 were generated using PES1205 as template and primer pairs PRIMERID-45057 & PRIMERID-45061, PRIMERID-45058 & PRIMERID-45062, PRIMERID-45059 & PRIMERID-45063, and PRIMERID-45060 & PRIMERID-45064, respectively. All PCR fragments were gel purified. In step 2, two separate PCR reactions were set. The first PCR reaction contain fragment 1 and 2 in equimolar ratio as template and PRIMERID-45057 and PRIMERID-45062 as primers. The second PCR reaction contain fragment 3 and 4 in equimolar ratio and PRIMERID-45059 and PRIMERID-45064 as primers. In both the reactions, respective wild type fragments were added in a molar ratio of library members present in each variable fragments. Fragment 5 and 6 are gel purified and used as templates in equimolar ratio in step 3. The primers used in the PCR reaction include PRIMERID-45057 and PRIMERID-45064. The vector PCR product was generated using pES1205 and primer pairs, PRIMERID-45065 and PRIMERID-45066. Both fragment 7 and vector PCR product were gel purified and cloned together using the Gibson Assembly Master Mix (New England Biolabs, Beverly, Mass.) and transformed into the cloning host E. coli Turbo (New England Biolabs) according to manufacturer's instructions. 50 colonies were sequenced to determine the diversity of the library. The colonies on the agar plate were then suspended in LB media and harvested for plasmid purification. In a similar fashion, we generated 9 specific variants of SEQID-00407 which were altered with 9 specific amino acids, F, L, I, M, V, T, K, R, W at every variable position identified in the mutant design. Specific variant primers are denoted by the single letter amino acid abbreviation in the name. All primers are listed in Table E38B.





TABLE E38B



Primer sequence







GGTCATCAATCATACCACCAGTGATNTNNTNGGCNTNNTNTCCAATGA

GGTTAAGAGTATTCCAAACTGG



CAGTCAATTTTGGCCGAATATCACAANRNTNNTNANRGAGTTCCAATA

CGGAGAAATCCTGC



TCGTAATCTGGGCGTGTCGAATATCNTNANRTATNTNNTNANRGTGTC

TGCGGACAAGCTAGTGAC



GATTTCACAATGTGATGGCTGGANTNCCTANRANRCTCTCGAACCCGA

ATGGAAAC



GGTCATCAATCATACCACCAGTG



CAGTCAATTTTGGCCGAATATCAC



TCGTAATCTGGGCGTGTCG



GATTTCACAATGTGATGGCTGG



TGTGATATTCGGCCAAAATTGACTG



GATATTCGACACGCCCAGATTACG



TCCAGCCATCACATTGTGAAATC



ATCTGCACGCAAGGTAATCGTCAG



CTGACGATTACCTTGCGTGCAG



CACTGGTGGTATGATTGATGACC



GGTCATCAATCATACCACCAGTGATCTTCTGGGCCTTCTGTCCAATGA

GGTTAAGAGTATTCCAAACTGG



GGTCATCAATCATACCACCAGTGATATTATCGGCATTATCTCCAATGA

GGTTAAGAGTATTCCAAACTGG



GGTCATCAATCATACCACCAGTGATGTTGTGGGCGTTGTGTCCAATGA

GGTTAAGAGTATTCCAAACTGG



GGTCATCAATCATACCACCAGTGATTTTTTCGGCTTTTTCTCCAATGA

GGTTAAGAGTATTCCAAACTGG



GGTCATCAATCATACCACCAGTGATTGGTGGGGATGGTGGTCCAATGA

GGTTAAGAGTATTCCAAACTGG



GGTCATCAATCATACCACCAGTGATATGATGGGCATGATGTCCAATGA

GGTTAAGAGTATTCCAAACTGG



GGTCATCAATCATACCACCAGTGATACAACGGGCACAACGTCCAATGA

GGTTAAGAGTATTCCAAACTGG



GGTCATCAATCATACCACCAGTGATTATAAGAAAGGCAAGAAAAATGA

GGTTAAGAGTATTCCAAACTGG



GGTCATCAATCATACCACCAGTGATTATCATCATGGCCATCACAATGA

GGTTAAGAGTATTCCAAACTGG



CAGTCAATTTTGGCCGAATATCACAAAGCTTCTGGGCGAGTTCCAATA

CGGAGAAATCCTGC



CAGTCAATTTTGGCCGAATATCACAAAGATTATCGGCGAGTTCCAATA

CGGAGAAATCCTGC



CAGTCAATTTTGGCCGAATATCACAAAGGTTGTGGGCGAGTTCCAATA

CGGAGAAATCCTGC



CAGTCAATTTTGGCCGAATATCACAAAGTTCTTTGGCGAGTTCCAATA

CGGAGAAATCCTGC



CAGTCAATTTTGGCCGAATATCACAAAGTGGTGGGGCGAGTTCCAATA

CGGAGAAATCCTGC



CAGTCAATTTTGGCCGAATATCACAAAGATGATGGGCGAGTTCCAATA

CGGAGAAATCCTGC



CAGTCAATTTTGGCCGAATATCACAAAGACGACAGGCGAGTTCCAATA

CGGAGAAATCCTGC



CAGTCAATTTTGGCCGAATATCACAAAGAAAGGAGCAGAGTTCCAATA

CGGAGAAATCCTGC



CAGTCAATTTTGGCCGAATATCACACATCATGGAGCAGAGTTCCAATA

CGGAGAAATCCTGC



TCGTAATCTGGGCGTGTCGAATATCCTTCACTATCTTCTGGATGTGTC

TGCGGACAAGCTAGTGAC



TCGTAATCTGGGCGTGTCGAATATCATTCACTATATCATTGATGTGTC

TGCGGACAAGCTAGTGAC



TCGTAATCTGGGCGTGTCGAATATCGTTCACTATGTTGTGGATGTGTC

TGCGGACAAGCTAGTGAC



TCGTAATCTGGGCGTGTCGAATATCTTCCACTATTTCTTTGATGTGTC

TGCGGACAAGCTAGTGAC



TCGTAATCTGGGCGTGTCGAATATCYGGCACTATTGGTGGGATGTGTC

TGCGGACAAGCTAGTGAC



TCGTAATCTGGGCGTGTCGAATATCATGCACTATATGATGGATGTGTC

TGCGGACAAGCTAGTGAC



TCGTAATCTGGGCGTGTCGAATATCACACACTATACAACGGATGTGTC

TGCGGACAAGCTAGTGAC



TCGTAATCTGGGCGTGTCGAATATCTCCAAGTATAAAGCAAAGGTGTC

TGCGGACAAGCTAGTGAC



TCGTAATCTGGGCGTGTCGAATATCTCCCATTATCACGCACATGTGTC

TGCGGACAAGCTAGTGAC



GATTTCACAATGTGATGGCTGGACTTCCTGAGGAACTCTCGAACCCGA

ATGGAAAC



GATTTCACAATGTGATGGCTGGAATTCCTGAGGAACTCTCGAACCCGA

ATGGAAAC



GATTTCACAATGTGATGGCTGGAGTTCCTGAGGAACTCTCGAACCCGA

ATGGAAAC



GATTTCACAATGTGATGGCTGGATTCCCTGAGGAACTCTCGAACCCGA

ATGGAAAC



GATTTCACAATGTGATGGCTGGATGGCCTGAGGAACTCTCGAACCCGA

ATGGAAAC



GATTTCACAATGTGATGGCTGGAATGCCTGAGGAACTCTCGAACCCGA

ATGGAAAC



GATTTCACAATGTGATGGCTGGAACACCTGAGGAACTCTCGAACCCGA

ATGGAAAC



GATTTCACAATGTGATGGCTGGAAAGCCTGAGGAACTCTCGAACCCGA

ATGGAAAC



GATTTCACAATGTGATGGCTGGACATCCTGAGGAACTCTCGAACCCGA

ATGGAAAC































































































































































Bacillus subtilis Strain Construction.
B. subtilis strain WB800N (MoBiTec, Göttingen, Germany) and used as the expression host. WB800N is a derivative of a well-studied strain ( B. subtilis 168) and it has been engineered to reduce protease degradation of secreted proteins by deletion of genes encoding 8 extracellular proteases (nprE, aprE, epr, bpr, mpr, nprB, vpr and wprA). B. subtilis transformations were performed according to the manufacturer's instructions. Approximately 5 μg of library for SEQID-00407 variant constructs was transformed into WB800N and single colonies were selected at 37° C. by plating on LB agar containing 5.0 μg/ml chloramphenicol (Cm5). For 9 specific variants, 1 μg of specific SEQID-00407 variant was transformed into WB800N and single colonies were selected at 37° C. by plating on LB agar containing 5.0 μg/ml chloramphenicol (Cm5).
Bacillus subtilis Library Screening.
˜800 individual transformants of the B. subtilis SEQID-00407 library were used to inoculate individual, 1-ml cultures of 2×-MAL medium (20 g/l NaCl, 20 g/l tryptone, and 10 g/l yeast extract, 75 g/l maltose) with Cm5, in deep well blocks (96-square wells). In addition to the library strains, a strain containing plasmid with AmyE and the SamyQ leader peptide was inoculated as a positive control and a strain containing plasmid with no gene of interest was inoculated as negative control. Culture blocks were covered with porous adhesive plate seals and incubated overnight in a micro-expression chamber (Glas-Col, Terre Haute, Ind.) at 37° C. and 880 rpm. Overnight cultures were used to inoculate fresh, 2×-MAL, Cm5 cultures, in deep well blocks, to a starting OD600=0.1.
Expression cultures were incubated at 37° C., 880 rpm until the OD600=1.0 (approx. 4 hrs) at which time they were induced by adding isopropyl β-D-1-thiogalactopyranoside (IPTG) at a final concentration of 1 mM and continuing incubation for 4 hrs. After 4 hrs, the cell densities of each culture was measured (OD600) and cells were harvested by centrifugation (3000 rpm, 10 min, RT). After centrifugation, culture supernatant was carefully removed and transferred to a new block and cell pellets were frozen at −80° C. To determine the levels of secreted protein, 0.5-ml aliquots of the culture supernatants were filtered first through a 0.45-μm filter followed by a 0.22 μm filter. The filtrates were then assayed to determine the levels of secreted protein of interest (POI) by chip electrophoresis system and compared with the level of secretion of base construct. Briefly, samples were prepared by adding 2 μl of sample to 7 μl sample buffer, heating at 95 C for 5 minutes, and then adding 35 μl of water. Analysis was completed using HT Low MW Protein Express LabChip® Kit or HT Protein Express LabChip® Kit (following the manufacturer's protocol). A protein ladder ran every 12 samples for molecular weight determination (kDa) and quantification (ng/μl).
SEQID-00690 and SEQID-00702 were confirmed by LC/MS/MS of the gel band of interest. Selected hits were mixed with Invitrogen LDS Sample Buffer containing 5% (3-mercaptoethanol, boiled and loaded on a Novex® NuPAGE® 10% Bis-Tris gel (Life Technologies). After running, the gels were stained using SimplyBlue™ SafeStain (Life Technologies) and desired bands were excised and submitted for analysis. Gel bands were washed, reduced and alkylated, and then digested with Trypsin for 4 hours followed by quenching with formic acid. Digests were then analyzed by nano LC/MS/MS with a Waters NanoAcquity HPLC system interfaced to a ThermoFisher Q Exactive. Peptides were loaded on a trapping column and eluted over a 75 μm analytical column at 350 nL/min; both columns were packed with Jupiter Proteo resin (Phenomenex). The mass spectrometer was operated in data-dependent mode, with MS and MS/MS performed in the Orbitrap at 70,000 FWHM resolution and 17,500 FWHM resolution, respectively. The fifteen most abundant ions were selected for MS/MS. The resulting peptide data were searched using Mascot against the relevant host database with relevant variant protein sequence appended.
Diluted overnight cultures were used as inoculum for LB broth cultures containing Cm5. These cultures were grown at 37 C until they reached log phase. Aliquots of these cultures were mixed with glycerol (20% final concentration) and frozen at −80° C. The top 30 hits are then purified using Instagene matrix (Biorad, USA) and amplified using CTTGAAATTGGAAGGGAGATTC and GTATAAACTTTTCAGTTGCAGAC, and sequenced using the same primers to identify the SEQID-00407 variant sequence.
Bacillus subtilis Secretion Library Analysis.
All the secreted variants of SEQID-00407 (SEQIDs 45002-45028) were analyzed to determine if there were any position specific biases in the amino acids present in the secreted variants, relative to the expected position specific biases present in the initial genetic library. To this end, an exact binomial test was performed for each amino acid at each position to determine the likelihood that the observed number of each amino acid was significantly (p<0.05) more or less than expected by chance. Table E38C shows the p-values of this single tailed test, where those highlighted elements have p values <0.05. Note that aside from wild type values, which were all significantly higher than expected, all other significant different amino acid frequencies were less than expected. The expected position specific amino acid biases are shown in Table E38D, and were found by sequencing 47 randomly selected variants after the library had been constructed and transformed into e. coli . It was assumed that all positions designed to be an X effectively sampled from the same distribution of L, I, V, F, and M codons (i.e., for all X positions, there were no position specific amino acid biases). As such, the observed counts of each amino acid were aggregated across positions to determine the expected amino acid likelihoods for all X positions. A similar assumption was made for all positions designed to be a Z. As can be seen in Table E38C, in addition to the strong bias toward the wild type sequence at each position, there are a number of different amino acids that were observed significantly less than expected, indicating a bias away from those amino acids at that position in the secreted library. This data provides additional information for the design of specific, rationally designed variants with specific mutations at each position. As an example, to enrich a secreted variant in leucine, positions 241 and 291 may be less desired choices. Alternatively, to enrich a secreted variant in valine, positions 149, 241, 242, 291, 294, 295, and 389 may be less desired choices.





TABLE E38C



Single tailed binomial test p-values assessing position specific amino acid biases in secreted variants of SEQID-450001































TABLE E38D



Position specific, expected amino acid likelihoods in the

constructed SEQID-450001 library






X
Z



L
30.2%
—

I
12.3%
9.7%

V
36.4%
—

F
6.7%
—

M
10.7%
12.2%

T
—
18.3%

K
—
17.9%

R
—
36.2%

Wt
3.7%
5.7%






























Bacillus subtilis Expression Testing of Specific Variants.
Three separate colonies of B. subtilis expression strains were used to inoculate 1-ml of 2×-MAL medium (20 g/l NaCl, 20 g/l tryptone, and 10 g/l yeast extract, 75 g/l maltose) with Cm5, in deep well blocks (96-square wells). Culture blocks were covered with porous adhesive plate seals and incubated overnight in a micro-expression chamber (Glas-Col, Terre Haute, Ind.) at 37° C. and 880 rpm. Overnight cultures were used to inoculate fresh, 2×-MAL, Cm5 cultures, in deep well blocks, to a starting OD600=0.1. These expression cultures were incubated at 37° C., 880 rpm until the OD600=1.0 (approx. 4 hrs) at which time they were induced by adding isopropyl β-D-1-thiogalactopyranoside (IPTG) at a final concentration of 0.1 M and continuing incubation for 4 hrs. After 4 hrs, the cell densities of each culture was measured (OD600) and cells were harvested by centrifugation (3000 rpm, 10 min, RT). After centrifugation, culture supernatant was carefully removed and transferred to a new block and cell pellets were frozen at −80° C. To determine the levels, of secreted protein, 0.5-ml aliquots of the culture supernatants were filtered first through a 0.45-μm filter followed by a 0.22 μm filter. The filtrates were then assayed to determine the levels of secreted protein of interest (POI) by chip electrophoresis. Briefly, samples were prepared by adding 2 μl of sample to 7 μl sample buffer, heating at 95 C for 5 minutes, and then adding 35 μl of water. Analysis was completed using HT Low MW Protein Express LabChip® Kit or HT Protein Express LabChip® Kit (following the manufacturer's protocol). A protein ladder ran every 12 samples for molecular weight determination (kDa) and quantification (ng/μl).
SEQID-45025, SEQID-45026, SEQID-45027, and SEQID-45028 were confirmed by LC/MS/MS of the gel band of interest. Selected hits were mixed with Invitrogen LDS Sample Buffer containing 5% β-mercaptoethanol, boiled and loaded on a Novex® NuPAGE® 10% Bis-Tris gel (Life Technologies). After running, the gels were stained using SimplyBlue™ SafeStain (Life Technologies) and desired bands were excised and submitted for analysis. Gel bands Were washed, reduced and alkylated, and then digested with Trypsin for 4 hours followed by quenching with formic acid. Digests were then analyzed by nano LC/MS/MS with a Waters NanoAcquity HPLC system interfaced to a ThermoFisher Q Exactive. Peptides were loaded on a trapping column and eluted over a 75 μm analytical column at 350 nL/min; both columns were packed with Jupiter Proteo resin (Phenomenex). The mass spectrometer was operated in data-dependent mode, with MS and MS/MS performed in the Orbitrap at 70,000 FWHM resolution and 17,500 FWHM resolution, respectively. The fifteen most abundant ions were selected for MS/MS. The resulting peptide data were searched using Mascot against the relevant host database with relevant variant protein sequence appended.
Amylase Activity Assay for Engineered Polypeptides.
One of the engineered polypeptides were tested to demonstrate enzymatic activity. SEQID-00407 is an α-amylase in Bacillus subtilis that has the activity of breaking down polysaccharides, such as starch, into monosaccharides or disaccharides. To demonstrate that the SEQID-00690 has retained enzymatic activity, Bacillus subtilis secreting the enzyme were plated onto agar plates containing starch. If there is enzymatic activity, the secreted enzyme will breakdown the starch and upon staining by iodine, there will be a halo surrounding the Bacillus subtilis colonies. 1% starch plates were made by combining 25 g Luria Broth-Miller, 10 g starch, 15 g bacteriological agar, and 1 L water. 10 mM IPTG was added to the starch plates after the agar has solidified. Single colonies of Bacillus subtilis strains expressing the mutant polypeptides were inoculated in 5 ml LB at 37° C. for 4 hours and 50 μl of the liquid culture were spotted at the center for the starch plates. After 20 hours of growth and induced secretion, 10% iodine was added to the starch plates to stain for starch. When SEQID-00690 was plated on the starch plates, the enzyme is secreted and creates a large halo around the cells, similar to wild-type strain, and much larger than the negative control strain, which expresses the empty vector without the enzyme. Table E38E quantifies the area of the halos relative to the area of the cells. From the data shown, we demonstrated the engineering of secreted nutritive polypeptide enriched in essential amino acids which retains enzymatic activity.





TABLE E38E



Quantified area of cells, halos, and their differences measured in in2.






Protein
Cell Area (in 2 )
Halo Area (in 2 )
Halo/Cell



No protein control
0.413
0.600
1.45

Wild-type
1.270
2.246
1.77

SEQID-00690
0.469
1.234
2.63























Example 39
Determination of Muscle Protein Fractional Synthesis Rate in Human Subjects Following Oral Consumption of Leucine-Enriched Nutritive Polypeptides
Oral ingestion of leucine or leucine-containing proteins stimulates muscle protein synthesis (Layman & Walker, 2006, The Journal of nutrition: 136: 319-323). Many of the leucine-enriched nutritive polypeptides described herein are highly water soluble and readily digested and absorbed in human subjects. The pharmacokinetics of amino acids as delivered via nutritive polypeptides and their effect on muscle protein synthesis are described here.
Effects of the leucine-enriched nutritive polypeptides on muscle protein synthesis were measured in apparently healthy subjects. Twelve (12) apparently healthy subjects (average height: 1.7 m, weight: 78.5 kg, age: 56.2, and BMI: 26.8) between the ages of 50 and 70 were randomly assigned in a single-blinded manner to a sequence of treatments. One group of six received formulations of SEQID-105 and 90% whey protein isolate (WPI) control, and the other group received SEQID-363 and 90% whey protein isolate control. The treatments were staggered such that each individual received 35 grams of each nutritive polypeptide formulation on separate days (2-3 days apart) to allow for washout of the initial formulation. Each subject served as their own control in the within-subject cross-over comparison.
Subjects were excluded from the study if they met any of the following exclusion criteria: History of diabetes. History of malignancy in the previous 6 months. Prior gastrointestinal bypass surgery (Lapband, etc.). Chronic inflammatory condition or disease (Lupus, HIV/AIDS, etc.). Known sensitivity or allergy to whey protein, mold spores or fungi. Do not refrain from eating animal proteins during their participation in this study. Cannot refrain from consuming protein or amino acid supplements during their participation in this study. Cannot refrain from resistance training during the study period. Currently participating in another research study with an investigational product. Hemoglobin less than 9.5 mg/dl at the screening visit. Concomitant use of corticosteroids or testosterone replacement therapy (ingestion, injection, or transdermal). Any other diseases or conditions that would place the subject at increased risk of harm if they were to participate, at the discretion of the medical staff.
All subjects were asked to maintain their current dietary habits, maintain their activities of daily living, and to not participate in any resistance exercise during the study.
The anabolic effect of each nutritive formulation was measured using the fractional rate of muscle protein synthesis (FSR) (Smith, Villareal, & Mittendorfer, 2007, American journal of physiology—Endocrinology and metabolism: 293: E666-E671). Research procedures included venous blood draws and vastus lateralis muscle biopsies during a primed, constant infusion of L-[ring-d5]-phenylalanine (Cambridge Isotope Laboratories, Tewksbury, Mass.). The fractional rate of muscle protein synthesis (FSR) was measured by muscle biopsies during a primed, constant infusion of L-[ring-d5]-phenylalanine. Specifically, the fractional rate of muscle protein synthesis (FSR) was measured in fasted human subjects after an overnight fast (>8 hrs) using the stable isotope tracer incorporation technique from vastus lateralis muscle biopsies performed 2, 4, and 7 hrs after initiating stable isotope tracer infusion. Blood samples were also collected at specified time points after the beginning of stable isotope tracer infusion (i.e. 2, 3, 4, 4+30, 5, 5+30, 6, 6+30, and 7 hrs) to assess changes in amino acid concentrations.
For each subject, on the morning of the study and after an overnight fast (8 hrs), an 18-22 gauge polyethylene catheter was inserted into each arm. One catheter was inserted into a distal vein for heated blood sampling to obtain a background blood sample (5 ml), and another into the forearm for infusion of the stable isotope tracers. After insertion of peripheral catheters, a primed (5.04 μmol/kg), constant (0.084 μmol/kg/min) infusion of the stable isotope (GRAS substance) ring-d5-phenylalanine was started. Stable isotopes were obtained from Cambridge Isotope Laboratories (Tewksbury, Mass.) and were tested for sterility and pyrogenicity (by CIL and the preparing pharmacy—PharmaCare). Prior to infusion, the tracer was reconstituted with sterile saline. The stable isotope was filtered during infusion through a sterile 0.22 micron (Millipore) filter placed in the infusion line.
Blood samples (5 ml) were collected in serum separator tubes at specified time points after the beginning of isotope infusion (2, 3, 4, 4+30, 5, 5+30, 6, 6+30, and 7 hrs). About 60 ml of blood was drawn during the entire study, and this volume was replaced with saline infused with a stable isotope tracer.
Muscle biopsies from the vastus lateralis were performed at 2, 4, and 7 hrs of tracer infusion. After the biopsy at 4 hr, the nutritive protein formulation was administered orally. All muscle biopsies were performed under local anesthesia (using sterile 1% lidocaine, without epinephrine) for normal pain management and strict sterile procedures. Prior to each muscle biopsy, skin was cleaned using a sterile skin preparation kit Betadine), and the skin and tissue below was injected with local anesthetic (Lidocaine) to minimize pain.
Through a small incision (about 1 cm), a 5 mm Bergstrim needle “O” was advanced into the muscle and suction applied. A piece of the muscle was then removed with the needle (approximately 50-100 mg). The skin was then cleansed, edges approximated with inch×1.5 inch adhesive Steri-strips, and a transparent, breathable film dressing (Tegaderm) was applied to the site. Firm pressure was maintained until bleeding at the site ceased. To minimize the risk of infection and bruising, an antibiotic ointment and pressure dressing (with self-adhesive elastic bandage) was applied, respectively, by the medical staff before the subject was released.
FSR, measured in (%/hr), was calculated as follows:





FSR
=


[



E

P





1


-

E

P





2




E
m


]

*

1
t

*
60
*
100


,




where enrichments (EP1, EP2, and Em) are expressed as mole percent excess (MPE) and calculated as the ratio of labeled phenylalanine tracer to unlabeled phenylalanine tracee (TTR), once the tracer concentration has plateaued. EP1 and EP2 are the enrichments of bound ring-2H5-phenylalanine in the first and second biopsies (or second and third), respectively, and Em is the mean value of the enrichments of ring-2H5-phenylalanine in the intracellular pool. “t” is the time in minutes elapsed between 1st and 2nd muscle biopsy in min (or between the second and third). Constant conversion factors of 60 min/hr and 100 were used to express FSR in percent per hour. Outcome variables (muscle protein synthesis and blood amino acid concentrations) were analyzed via paired t-tests. Statistical significance was established a priori at P<0.05 and trends were accepted as 0.051<P<0.10.
Tables E39A-C show the calculated FSR data for each subject before and after an acute, oral dose of each nutritive protein formulation, and FIG. 56 shows the change in average FSR. The data shown is the mean+/−standard error of the mean. Note that the fasted FSR value from subject 3 in the WPI group had a very elevated FSR, inconsistent with normal fasted values, with a z-value of 2.85. A two-tailed grubbs' outlier test indicated that it was a significant (p<0.05) outlier and it was removed when calculating the mean and standard error as shown in FIG. 56 .






TABLE E39A



Subject
WPI FSR (hr −1 )





ID
Fasted
Fed







1
0.00023651
0.00072108

2
0.00041336
0.00037967

3
0.00168551
0.00022099

4
0.00032137
0.00112458

5
0.00064807
0.0005574

6
0.00078224
0.00133908

7
0.00029799
0.00058582

8
0.00063563
0.0007537

9
0.00043453
0.000653

10
0.0006604
0.00088189

11
0.00056282
0.00067366

12
0.00040945
0.00070602









































TABLE E39B



Subject
SEQID-363 FSR (hr −1 )





ID
Fasted
Fed



1
0.00040882
0.00106664

2
0.00090652
0.00040036

3
0.00040061
0.00094592

4
0.00078852
0.00082819

5
0.00057147
0.00038021

6
0.00054359
0.00047435
































TABLE E39C



Subject
SEQID-105 FSR (hr −1 )





ID
Fasted
Fed







7
0.00037724
0.00090154

8
0.00041119
0.00047965

9
0.00043875
0.00075389

10
0.00039112
0.00032007

11
0.00049953
0.00088001

12
0.00022427
0.00085157





























Paired t-tests comparing the fasted and fed response of each group indicate that the fed response in the WPI treated subjects is significantly different from the fasted response when subject 3 is removed. (p=0.007), consistent with previous studies examining the FSR response to WPI (Paddon-Jones, D., Sheffield-Moore, M., Katsanos C. S., Xiao-Jun Z., Wolfe, R. R. Differential stimulation of muscle protein synthesis in elderly humans following isocaloric ingestion in amino acids or whey protein. Exp. Gerontol. (2006) 41: 215-219). If subject three is included, the difference loses significance (p=0.45). The fasted and fed FSR response in the SEQID-105 fed group are significantly different (p=0.04), but the fasted and fed FSR response in the SEQID-363 fed group are not significantly different (p=0.68).
Example 40
Oral Pharmacokinetics of Formulations Containing Nutritive Polypeptides
The anabolic response to protein ingestion is predicated on the delivery of essential amino acids. The purpose of this study was to examine the changes in plasma amino acid concentrations in response to various proteins over a period of 240 minutes. Four apparently healthy subjects between the ages of 18 and 50 were randomly assigned in a double-blinded manner to a sequence of treatments, receiving 20 grams of either whey protein isolate or SEQID-105 orally, in a volume of 170 ml. Subjects were fasted overnight (>8 hrs) before oral pharmacokinetic study. Venous blood samples were collected at specified time points (i.e. 0, 15, 30, 60, 90, 120, 150, 180, 210 and 240 minutes) following the oral ingestion of nutritive polypeptide to assess changes in plasma amino acid concentrations. Plasma amino acid concentrations were quantified by Quest Diagnostics or Laboratory Corporation of America.
FIGS. 57-60 show the plasma time course of each measured amino acid and the aggregate groups, essential amino acids (EAA), branched chain amino acids (BCAA), and total amino acids (TAA), for WPI and SEQID-105.
Using a 1-way ANOVA test to assess significant differences in plasma amino acid levels across the time points measured, for WPI, these data indicate that there are significant differences across time for Asn, Ile, Leu, Lys, Met, Phe, Pro, Trp, Tyr, EAA, BCAA, and TAA (p<0.05).
Using a 1-way ANOVA test to assess significant differences in plasma amino acid levels across the time points measured, for a nutritive formulation of SEQID-105, these data indicate that there are significant differences across time for Arg, Asn, Asp, Glu, Gly, His, lie, Leu, Lys, Met, Phe, Ser, Tyr, Val, EAA, BCAA, and TAA (p<0.05).
FIGS. 61-63 show the integrated area under the curve (AUC) of each measured amino acid as well as the aggregate groups, essential amino acids (EAA), branched chain amino acids (BCAA), and total amino acids (TAA), for WPI and SEQID-105.
Using a t-test to compare the AUCs of each amino acid or amino acid group between WPI and SEQID-105, there are significant differences in the Asp (p=0.01), His (p=0.04), Leu (0.023), Met (0.002), Phe (0.04), Pro (p<0.01), Ser (p=0.03), and Trp (p=0.002) responses.
In another study, a 35 gram dose of SEQID-105 and WPI was given orally in 100 ml and 1151 ml, respectively, to six, apparently healthy subjects between the ages of 18 and 50. FIGS. 64-67 show the plasma time course of each measured amino acid and the aggregate groups, essential amino acids (EAA), branched chain amino acids (BCAA), and total amino acids (TAA), for WPI and SEQID-105.
Using a 1-way ANOVA test to assess significant differences in plasma amino acid levels across the time points measured, for WPI, these data indicate that there are significant differences across time for Arg, Asn, Asp, Gln, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val, EAA, BCAA, and TAA (p<0.05).
Using a 1-way ANOVA test to assess significant differences in plasma amino acid levels across the time points measured, for a nutritive formulation of SEQID-105, these data indicate that there are significant differences across time for
Arg, Asn, Asp, Glu, His, Ile, Ley, Lys, Met, Phe, Ser, Thr, Trp, Val, EAA, BCAA, and TAA (p<0.05).
FIGS. 68-70 show the integrated area under the curve (AUC) of each measured amino acid as well as the aggregate groups, essential amino acids (EAA), branched chain amino acids (BCAA), and total amino acids (TAA), for WPI and SEQID-105 dosed at 35 g.
Using a two-tailed, unequal variance t-test to compare the AUCs of each amino acid or amino acid group between WPI and SEQID-105, there are significant differences in the Asn (p=0.006), His (p=0.01), Ile (p=0.03), Lys (p=0.02), Met (p<0.001), Phe (p<0.001), Pro (p=0.002), Ser (p=0.005), Thr (p=0.004), Trp (p<0.001), Tyr (p=0.003), and Val (p=0.012) responses.
In another study examining the pharmacokinetics of amino acid delivery via nutritive polypeptides, three apparently healthy subjects between the ages of 18 and 50 were randomly assigned in a double-blinded manner to a sequence of treatments, receiving 20 grams of either whey protein isolate or SEQID-363 orally. Subjects were fasted overnight (>8 hrs) before oral pharmacokinetic study. Venous blood samples were collected at specified time points (i.e. 0, 15, 30, 60, 90, 120, 150, 180, 210 and 240 minutes) following the oral ingestion of nutritive polypeptide to assess changes in plasma amino acid concentrations. Plasma amino acid concentrations were quantified by Quest Diagnostics or Laboratory Corporation of America.
FIGS. 71-74 show the plasma time course of each measured amino acid and the aggregate groups, essential amino acids (EAA), branched chain amino acids (BCAA), and total amino acids (TAA), for WPI and SEQID-363.
Using a 1-way ANOVA test to assess significant differences in plasma amino acid levels across the time points measured, for WPI, these data indicate that there are significant differences across time for Gln, Ile, Leu, Lys, Phe, Ser, Tyr, Val, EAA, BCAA, and TAA (p<0.05).
Using a 1-way ANOVA test to assess significant differences in plasma amino acid levels across the time points measured, for SEQID-363, these data indicate that there are no significant differences across time (p<0.05).
Example 41
Chronic Treatment of Sarcopenia and Loss of Physical Function in Elderly Frail Subjects Using Nutritive Polypeptides
Supplementation of leucine or leucine-containing proteins improve muscle mass build-up after exercise and maintain skeletal muscle mass during long-term disuse (Layman & Walker, 2006, The Journal of nutrition: 136: 319-323). Nutritive polypeptides enriched in leucine and essential amino acids are described herein. Elderly, frail subjects are randomly assigned in a double blind manner to a specific treatment group: a control group receiving an isocaloric control or one of 3 dose ranging treatment arm receiving 3 times daily a dose of 15, 30, or 40 grams of a nutritive polypeptide formulation for 30 days. Enrolled subjects are provided with a control diet based upon individual's body mass index (BMI) and physical activities throughout the trial period. Food and calorie intakes are recorded. Enrolled subjects maintain their regular daily activities. Daily physical activities and calorie consumption are measured by a physical activity tracker (FitBit Flex wrist band). Lean body mass is measured by MRI (Müller, M. J., et al. “Assessment and definition of lean body mass deficiency in the elderly.” European journal of clinical nutrition (2014)) or dual-energy X-ray absorptiometry (DEXA; Nielsen, Palle Kjrerulff, Jorgen Ladefoged, and Klaus Olgaard. “Lean body mass by Dual Energy X-ray Absorptiometry (DEXA) and by urine and dialysate creatinine recovery in CAPD and pre-dialysis patients compared to normal subjects.” Adv Perit Dial 10 (1994): 99-103) on day 1 (prior to nutritive polypeptide dosing) and day 31 after treatment has concluded to assess the change of skeletal muscle mass. Physical function is also assessed at the start and end of the treatment period using the short physical performance battery score (Volpato, Stefano, et al. “Predictive value of the Short Physical Performance Battery following hospitalization in older patients.” The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 66.1 (2011): 89-96), measures of gait speed, 6 minute walk test (6MWT), and the timed up and go test (TUGS; Podsiadlo, D; Richardson, S. “The timed ‘Up & Go’: A test of basic functional mobility for frail elderly persons”. Journal of the American Geriatrics Society (1991) 39: 142-8). The absolute and percent change in lean body mass as well as SPPB score, gait speed, 6MWT, and TUGS, from baseline is compared across treatment arms and relative to control to assess treatment efficacy.
Example 42
Oral Pharmacokinetics of Formulations Containing Nutritive Polypeptides Deficient in Methionine
The purpose of this study was to examine the changes in plasma amino acid concentrations in response to a methionine deficient nutritive protein over a period of 240 minutes. Four apparently healthy subjects between the ages of 18 and 50 were randomly assigned in a double-blinded manner to a sequence of treatments, receiving 20 grams of SEQID-426 orally, in a volume of 170 ml. Subjects were fasted overnight (>8 hrs), and the following morning venous blood samples were collected at specified time points (i.e. 0, 15, 30, 60, 90, 120, 150, 180, 210 and 240 minutes) after the oral ingestion of nutritive polypeptide to assess changes in plasma amino acid concentrations. Plasma amino acid concentrations were quantified by Quest Diagnostics or Laboratory Corporation of America.
FIGS. 75-78 show the plasma time course of each measured amino acid and the aggregate groups, essential amino acids (EAA), branched chain amino acids (BCAA), and total amino acids (TAA), for SEQID-426.
Using a 1-way ANOVA test to assess significant differences in plasma amino acid levels across the time points measured, for SEQID-426, these data indicate that there are significant differences across time for Glu and EAA (p<0.05). A Dunnett multiple comparison test examining the plasma EAA time course further indicates that the plasma EAA levels at the 30 and 60 min. time points are significantly different from the basal levels at time 0 min. Methionine shows no significant change over time.
Example 43
Selection and Formulation of Nutritive Polypeptides for Cancer Therapy
Cancer and tumor cells have a disproportionate requirement for certain amino acids than non-cancer cells (Galluzzi, Kepp, Vander Heiden, & Kroemer, 2013, Nature reviews. Drug discovery: 12: 829-46). For example, serine and glycine play essential roles in mammalian metabolism including protein synthesis, de novo synthesis of nucleotides, methylation of DNA and polyamine synthesis (J. W. Locasale, 2013, Nature reviews. Cancer: 13: 572-83). Certain tumor cells exhibit dependence on serine and glycine for survival and proliferation, due to amplification, deletions, polymorphisms or alterations in expression of genes in the serine and glycine metabolic pathways, while normal cells are less sensitive to starvation of serine and glycine (J. Locasale & Cantley, 2011, Cell Cycle: 10: 3812-3813)(Labuschagne, van den Broek, Mackay, Vousden, & Maddocks, 2014, Cell reports: 7: 1248-58)(Zhang et al., 2012, Cell: 148: 259-72). Certain tumor cells exhibit dependence on methionine for survival and proliferation, due to deletions, polyrinorphisms or alterations in expression of genes in the methionine de novo and salvage pathways (Cavuoto & Fenech, 2012, Cancer treatment reviews: 38: 726-36), while normal cells are not sensitive to methionine starvation (Kreis & Goodenow, 1978, Cancer Res: 38: 2259-2262). Certain tumor cells exhibit dependence on arginine due to deficient utilization of citrulline or arginosuccinate (Currie and Basham 1978)(Wheatley & Campbell, 2003, British journal of cancer: 89: 573-6). Certain tumor cells exhibit dependence on glutamine for survival and proliferation, due to upregulation of glutaminases (Hensley, 2013a, Journal of Clinical Investigation: 123: 3678-3684) (Hensley, 2013b, Journal of Clinical Investigation: 123: 3678-3684) (Yang et al., 2014, Molecular systems biology: 10: 728). Therefore, restriction of serine, glycine, methionine, arginine, and glutamine within a protein diet can limit tumor cell growth.
Selective inhibition of the proliferation of serine and glycine dependent cancer cells has been demonstrated using media deficient in serine and glycine (Maddocks et al., 2013, Nature: 493: 542-6), and animal studies utilizing a serine and glycine restricted diet show inhibition of cancer growth and extension of life-span (Labuschagne et al., 2014, Cell reports: 7: 1248-58). Selective killing of methionine dependent cancer cells in co-culture with normal cells has been demonstrated using media deficient in methionine, and animal studies utilizing a methionine restricted diet show inhibition of cancer growth and extension of life-span (Cavuoto & Fenech, 2012, Cancer treatment reviews: 38: 726-36). Moreover, homocysteine supplementation selectively rescues normal cells from the toxicity of methionine starvation while tumor cells fail to utilize homocysteine and strictly rely on methionine (Kreis & Goodenow, 1978, Cancer Res: 38: 2259-2262). Glutamine is a key mitochondrial substrate required for TCA cycle, and several approaches have been taken to target glutamine dependence of cancers in clinical trials (Wise & Thompson, 2010, Trends in Biochemical Sciences: 35: 427-433). One of the approaches is glutamine depletion by the use of L-asparaginase which degrades both asparagine and glutamine (Avramis & Panosyan, 2005, Clinical Pharmacokinetics: 44: 367-393). Arginine deprivation by arginase or arginine deaminase shows promising anti-cancer effects in clinical trials (Phillips, Sheaff, & Szlosarek, 2013, Cancer Res Treat: 45: 251-262).
Example 44
In Vitro Screening of Cancer Cells for Amino Acid Dependence and Auxotrophy
To evaluate the dependence of cancer cells on amino acids, a chemically defined cell culture media deficient in one or more amino acids is used and cell growth and death is monitored (Hensley, 2013b, Journal of Clinical Investigation: 123: 3678-3684) (Zhang et al., 2012, Cell: 148: 259-72) (Maddocks et al., 2013, Nature: 493: 542-6). In one experiment, an individual NCI60 human tumor cell line selected from Table E40A is plated (2,000/96-well) for 24-72 hours in culture media deficient in one or more amino acid. A comparable, noncancerous cell line is used as a control. Effects of the defined media on cancer and control cell health are analyzed by cell proliferation (numbers), nucleotide incorporation, and cell death (TUNEL and annexin V assays) (Hensley, 2013b, Journal of Clinical Investigation: 123: 3678-3684) (Zhang et al., 2012, Cell: 148: 259-72)(Maddocks et al., 2013, Nature: 493: 542-6).





TABLE E44A



NCI-60 Human Cancer Cell Lines








LUNG
NCI-H23, NCI-H522, A549-ATCC, EKVX, NCI-H226,


NCI-H332M, H460, HOP62, HOP92

COLON
HT29, HCC-2998, HCT116, SW620, COLO205, HCT15,


KM12

BREAST
MCF7, MCF7ADRr, MDAMB231, HS578T, MDAMB435,


MDN, BT549, T47D

OVARIAN
OVCAR3, OVCAR4, OVCAR5, OVCAR8, IGROV1,


SKOV3

LEUKEMIA
CCRFCEM, K562, MOLT4, HL60, RPMI8266, SR

RENAL
UO31, SN12C, A498, CAKI1, RXF393, 7860, ACHN, TK10

MELANOMA
LOXIMVI, MALME3M, SKMEL2, SKMEL5, SKMEL28,


M14, UACC62, UACC257

PROSTATE
PC3, DU145

CNS
SNB19, SNB75, U251, SF268, SF295, SM539


































In another experiment, a media comprising an amino acid blend with molar amino acid ratios equivalent to that found in a nutritive polypeptide (with or without basal plasma amino acid supplementation to account for background amino acid levels), is used in combination with one of the cell lines in Table E40A to assess the efficacy of a nutritive polypeptide derived amino acid blend. In another experiment, a media comprising a nutritive polypeptide that has undergone in vitro digestion as described herein (with or without basal plasma amino acid supplementation to account for background amino acid levels), is used. In another experiment, a media comprising the nutritive polypeptide with or without basal plasma amino acid supplementation to account for background amino acid levels is used.
Effects of polypeptides on cancer stem cells (or tumor initiating cells) are also determined in vitro. Cancer stem cells are a subset of cancer cells which are resistant to anticancer therapies and responsible for drug resistance, recurrence, invasion, tumorigenesis, and metastasis (Chaffer & Weinberg, 2011, Science (New York, N.Y.): 331: 1559-1564). Cancer stem cells are capable of in vitro anchorage-independent growth. To characterize the amino acid dependence of cancer stem cells, cancer cells are grown in monolayer adherent culture in chemically defined cell culture media as described above for 3 days. Cancer stem cell frequency in the bulk of cancer cells derived from the culture media is determined by plating the treated cells into anchorage-independent culture in vitro. The culture plate for anchorage-independent culture is sealed with complete culture media containing 1% agar, overlaid by single cells suspended in complete culture media containing 0.4% agar for 21-35 days, depending on cell types. Cells are fed weekly with complete culture media containing 0.3% agar. Cell colonies in anchorage-independent culture are stained with p-iodonitrotetrazolium violet (0.2%), and numbers of cell colonies are counted.
Formula to calculate cancer stem cell frequency is:





Cancer





stem





cell






frequency


(
%
)



=


Number





of





colonies





in





anchorage





independent





culture


Total





cell





numbers





plated





in





anchorage





independent





culture






Low cancer stem cell frequency relative to a control grown in complete amino acid medium indicate a sensitivity towards the amino acid depleted in the supplied medium. These data are also compared to primary non-cancerous cell lines of the same cell or tissue type to determine the sensitivity of non-cancerous cell to an amino acid milieu lacking a particular amino acid.
Representative nutritive polypeptides from the protein database of edible species selected for solubility, aggregation resistance, and ease of expression as described herein that are also deficient in serine, glycine, methionine, arginine, glutamine, and other amino acids required to support cancer cell survival and proliferation, and prevent cell apoptosis, autophagy, death, and necrosis are provided in tables Table E44B, Table E44C, Table E44D, Table E44E, Table E44F, and Table E44G.










TABLE E44B





SEQID
EAAc
EAA
S





SEQID-03455
1
0.35
0.00


SEQID-03508
1
0.41
0.01


SEQID-03612
1
0.45
0.01


SEQID-03569
1
0.38
0.01


SEQID-03521
1
0.46
0.01


SEQID-03524
1
0.39
0.01


SEQID-03533
1
0.46
0.01


SEQID-03588
1
0.56
0.01


SEQID-03527
1
0.37
0.01


SEQID-03625
1
0.47
0.01





































TABLE E44C





SEQID
EAAc
EAA
G





SEQID-03437
1
0.41
0.00


SEQID-03505
1
0.50
0.00


SEQID-03510
1
0.51
0.00


SEQID-03549
1
0.44
0.00


SEQID-03492
1
0.63
0.00


SEQID-03482
1
0.45
0.00


SEQID-03546
1
0.49
0.00


SEQID-03488
1
0.52
0.00


SEQID-03507
1
0.50
0.00


SEQID-03506
1
0.51
0.00






































TABLE E44D





SEQID
EAAc
EAA
G
S





SEQID-03899
1
0.67
0.12
0.06


SEQID-03897
1
0.60
0.11
0.06


SEQID-03898
1
0.59
0.10
0.05


SEQID-03896
1
0.58
0.11
0.06


SEQID-03892
1
0.57
0.07
0.03


SEQID-03891
1
0.57
0.13
0.03


SEQID-03895
1
0.57
0.11
0.05


SEQID-03900
1
0.57
0.05
0.03


SEQID-03894
1
0.56
0.10
0.02


SEQID-03893
1
0.56
0.08
0.03





































TABLE E44E





SEQID
EAAc
EAA
Q





SEQID-03636
1
0.65
0.00


SEQID-03468
1
0.62
0.00


SEQID-03484
1
0.62
0.00


SEQID-03570
1
0.59
0.00


SEQID-03422
1
0.58
0.00


SEQID-03432
1
0.58
0.00


SEQID-03590
1
0.58
0.00


SEQID-03515
1
0.58
0.00


SEQID-03416
1
0.58
0.00


SEQID-03577
1
0.57
0.00





































TABLE E44F





SEQID
EAAc
EAA
M





SEQID-03497
1
0.54
0.01


SEQID-03461
1
0.53
0.01


SEQID-03592
1
0.52
0.01


SEQID-00489
1
0.52
0.01


SEQID-03481
1
0.52
0.01


SEQID-03426
1
0.51
0.01


SEQID-03608
1
0.51
0.01


SEQID-01546
1
0.51
0.00


SEQID-03602
1
0.51
0.01


SEQID-03539
1
0.51
0.00





































TABLE E44G





SEQID
EAAc
EAA
R





SEQID-03534
1
0.37
0.00


SEQID-03438
1
0.37
0.00


SEQID-03640
1
0.42
0.00


SEQID-03600
1
0.52
0.01


SEQID-03490
1
0.54
0.01


SEQID-03500
1
0.48
0.01


SEQID-03516
1
0.53
0.01


SEQID-03628
1
0.54
0.01


SEQID-03633
1
0.42
0.01


SEQID-03436
1
0.57
0.01



























Representative nutritive polypeptides that have been expressed that are similarly deficient in the amino acids outlined above are shown in tables Table E44H, Table E441, Table E44J, Table E44K, Table E44L, and Table E44M.










TABLE E44H





SEQID
EAAc
EAA
S





SEQID-00112
1
0.50
0.00


SEQID-00211
1
0.48
0.01


SEQID-00648
1
0.39
0.01


SEQID-00488
1
0.52
0.01


SEQID-00084
1
0.32
0.01


SEQID-00142
1
0.56
0.01


SEQID-00155
1
0.49
0.01


SEQID-00141
1
0.58
0.01


SEQID-00337
1
0.46
0.02


SEQID-00330
1
0.49
0.02





































TABLE E44I





SEQID
EAAc
EAA
G





SEQID-00113
1
0.52
0.00


SEQID-00800
1
0.46
0.00


SEQID-00780
1
0.47
0.00


SEQID-00211
1
0.48
0.00


SEQID-00150
1
0.67
0.00


SEQID-00809
1
0.41
0.01


SEQID-00505
1
0.42
0.01


SEQID-03696
1
0.48
0.01


SEQID-00112
1
0.50
0.01


SEQID-03445
1
0.42
0.01






































TABLE E44J





SEQID
EAAc
EAA
G
S





SEQID-00112
1
0.50
0.01
0.00


SEQID-00211
1
0.48
0.00
0.01


SEQID-00113
1
0.52
0.00
0.02


SEQID-00141
1
0.58
0.02
0.01


SEQID-00150
1
0.67
0.00
0.03


SEQID-00117
1
0.52
0.01
0.02


SEQID-00151
1
0.48
0.01
0.02


SEQID-00142
1
0.56
0.03
0.01


SEQID-03696
1
0.48
0.01
0.04


SEQID-00131
1
0.50
0.02
0.03





































TABLE E44K





SEQID
EAAc
EAA
Q





SEQID-00648
1
0.39
0.00


SEQID-00143
1
0.65
0.00


SEQID-00598
1
0.49
0.00


SEQID-00554
1
0.38
0.00


SEQID-00563
1
0.50
0.00


SEQID-00485
1
0.46
0.00


SEQID-00627
1
0.48
0.01


SEQID-02703
1
0.42
0.01


SEQID-00150
1
0.67
0.01


SEQID-03872
1
0.47
0.01





































TABLE E44L





SEQID
EAAc
EAA
M





SEQID-03649
1
0.49
0.00


SEQID-01546
1
0.51
0.00


SEQID-03768
1
0.42
0.00


SEQID-03051
1
0.48
0.00


SEQID-03297
1
0.62
0.00


SEQID-01388
1
0.36
0.00


SEQID-03730
1
0.45
0.00


SEQID-00340
1
0.41
0.00


SEQID-00484
1
0.38
0.00


SEQID-03447
1
0.30
0.00





































TABLE E44M





SEQID
EAAc
EAA
R





SEQID-00406
1
0.48
0.00


SEQID-00143
1
0.65
0.00


SEQID-00140
1
0.70
0.00


SEQID-00146
1
0.67
0.00


SEQID-00548
1
0.59
0.00


SEQID-00117
1
0.52
0.00


SEQID-00150
1
0.67
0.00


SEQID-00112
1
0.50
0.00


SEQID-01625
1
0.51
0.01


SEQID-03691
1
0.52
0.01



























Example 45
Improved Therapy for Cancer Through Nutritive Polypeptide Co-Administration with a Chemotherapeutic Regiment
Provided are chemotherapeutic treatments for cancer and other oncological diseases in combination with administration of nutritive polypeptides. In particular, a nutritive polypeptide having no or low levels of serine, glycine, methionine, arginine, glutamine, and/or other amino acids are provided to human subjects undergoing chemotherapeutic treatments. These formulations containing nutritive polypeptides provide essential amino acids necessary for normal metabolic support while selectively limiting serine, glycine, methionine, glutamine, arginine, and/or any other amino acids selectively required by the tumor.
In vitro efficacy of co-administration of nutritive polypeptides and chemotherapeutic regimens are determined in NCI-60 human tumor cell lines as described herein. A comparable, noncancerous cell line is used as a control. Examples of agents used in such chemotherapeutic regimens include 5-fluorouracil, cyclophosphamide, doxorubicin, cisplatin, and methotrexate. Cancer cells are plated in plates (2,000/96-well) for 24 hours in chemically defined cell culture media comprising elemental amino acids, nutritive polypeptide derived amino acid blends, in vitro digested nutritive polypeptides, or untreated nutritive polypeptides. Chemotherapeutic regiments are then added into cells. Efficacies of co-administration of the polypeptide and chemotherapeutic regiments on suppression of cell proliferation and induction of cell death relative to controls are determined by number of cells, nucleotide incorporation, and cell death (TUNEL and annexin V assays). Such co-administration of a nutritive polypeptide with chemotherapy provides improved therapy of cancer including reduced cell growth and increased cell death when compared to chemotherapy alone by depleting the amino acids required for survival of cancer cells.
Example 46
Suppression of Cancer in Pre-Clinical Animal Models with Nutritive Polypeptides
Tumors that exhibit dependence on serine, glycine, methionine, glutamine, arginine, and/or any other amino acids for survival demonstrate in vivo dependence on these specific amino acids (Zhang et al., 2012, Cell: 148: 259-72) (Maddocks et al., 2013, Nature: 493: 542-6)(Gross et al., 2014, Molecular cancer therapeutics: 13: 890-901). To evaluate this effect in vivo, a specific amino acid-deficient nutritive polypeptide is mixed into animal test diet or water. Human cancer cells are injected into immunocompromised mice (Table E46A), by re-suspending in 100 □l PBS buffer and injecting into the designated location. Immediately following cancer cell injection, mice are randomly placed either on control or test diet or water supplemented with the nutritive polypeptide. Survival and longevity of tumor-bearing mice are recorded. Tumor growth (volume) is measured over time. Cell proliferation (Ki67 and BrdU labeling) and apoptosis (TUNEL assay) are quantified in the tumors.





TABLE E46A



Human cancer xenograft











Cells
HCT116
MDA-MB-231


Origin
colon
breast


p53
WT
Mut


Host
CD1-Nude
NOD-SCID


Gender
Female
Female


Route
s.c.
mammary fat pad


Injected cell #
3 × 10{circumflex over ( )}6
2.5 × 10{circumflex over ( )}6




























Example 47
Improved Therapy for Cancer Through Co-Administration with a Chemotherapeutic Regiment in Pre-Clinical Animal Models
Efficacy of co-administration of nutritive polypeptides and chemotherapeutic regimens are determined in human cancer xenograft in immunocompromised mice. Human cancer cells are injected into immunocompromised mice as described herein. Immediately following cancer cell injection, mice are randomly placed either on control or test diet or water supplemented with a nutritive polypeptide deficient in serine, glycine, glutamine, arginine, methionine and/or any other amino acids. Chemotherapeutic regimens are injected daily into tumor-bearing animals. Survival and longevity of tumor-bearing mice are recorded. Tumor growth (volume) is measured over time. Cell proliferation (Ki67 and BrdU labeling) and apoptosis (TUNEL assay) are quantified in the tumors. Examples of agents used in such chemotherapeutic regimens include 5-fluorouracil, cyclophosphamide, doxorubicin, cisplatin, and methotrexate. Such co-administration of a nutritive polypeptide with chemotherapy provides benefits including reduced tumor growth and increased cell death when compared to chemotherapy or nutritive polypeptide administration alone.
Example 48
Improved Therapy for Cancer in Humans with Nutritive Polypeptides
Provided are chemotherapeutic treatments for cancer and other oncological diseases in combination with administration of nutritive polypeptides described herein. In humans with cancers of the breast, prostate, lung, melanoma, CNS, leukemia, ovarian, or gastrointestinal tract, for example, a formulation of a nutritive polypeptide at a daily dose of 10-30 grams is administered orally to patients, concomitantly with a chemotherapeutic regimen. Provided nutritive polypeptides are the major/only dietary sources of amino acids of treated human subjects. Examples of agents used in such chemotherapeutic regimens include 5-fluorouracil, cyclophosphamide, doxorubicin, cisplatin, and methotrexate. Such co-administration of a nutritive polypeptide deficient in serine, glycine, glutamine, methionine, arginine, and other amino acids with chemotherapy provides benefits including improved tumor-free patient survival when compared to chemotherapy alone, by supporting life functions necessary for survival and tumor clearance.
In particular, provided are nutritive polypeptides deficient in serine and glycine. Provided nutritive polypeptides with serine and glycine deficiency are co-administered at a daily dose of 10-30 grams as the major dietary source of amino acids with chemotherapeutic regimens to human subjects as the described herein. Co-administration of provided nutritive polypeptides with serine and glycine deficiency and chemotherapeutic regimens has additive/synergistic therapeutic efficacies.
In an additional particular embodiment, provided are nutritive polypeptides deficient in methionine. Provided nutritive polypeptides with methionine deficiency are co-administered at a daily dose of 10-30 grams as the major dietary source of amino acids with chemotherapeutic regimens to human subjects as the described herein. In conjunction, dietary homocysteinse is supplemented at a daily dose of 1 gram to rescue normal cells from the toxicity of methionine deficiency in selected patients whose tumors have stringent dependence on methionine (Kreis & Goodenow, 1978, Cancer Res: 38: 2259-2262). Co-administration of provided nutritive polypeptides with methionine deficiency and chemotherapeutic regimens has additive/synergistic therapeutic efficacies.
In particular, provided are nutritive polypeptides deficient in glutamine. Provided nutritive polypeptides with glutamine deficiency are co-administered at a daily dose of 10-30 grams as the major dietary source of amino acids with chemotherapeutic regimens to human subjects as the described herein. Co-administration of provided nutritive polypeptides with glutamine deficiency and chemotherapeutic regimens has additive/synergistic therapeutic efficacies.
In particular, provided are nutritive polypeptides deficient in arginine. Provided nutritive polypeptides with arginine deficiency are co-administered at a daily dose of 10-30 grams as the major dietary source of amino acids with chemotherapeutic regimens to human subjects as the described herein. In conjunction, dietary citrulline or arginosuccinate is supplemented at a daily dose of I gram to rescue normal cells from the toxicity of arginine deficiency in selected patients whose tumors have stringent dependence on arginine (Phillips et al., 2013, Cancer Res Treat: 45: 251-262). Co-administration of provided nutritive polypeptides with arginine deficiency and chemotherapeutic regimens has additive/synergistic therapeutic efficacies.
Example 49
Improved Adverse Effects for Cancer Chemotherapy in Humans
Chemotherapy for cancer and other oncological diseases induces morbidity and side effects that can be directly life-threatening to the patient as well as limiting the ability to provide optimal dosing for tumor removal and cancer free survival (Evans et al., 2008, Clinical nutrition (Edinburgh, Scotland): 27: 793-9). These include anemia, appetite loss, fatigue, increased bruising, bleeding, and infection, nausea, vomiting, nerve damage, skeletal muscle mass loss, and muscle damage. In general, the cause of such morbidity and side effects is undesired damage to healthy cells due to the mechanism of each chemotherapeutic regimen. Such normal cells most commonly include blood-forming cells in the bone marrow; hair follicles, cells in the mouth, digestive tract, and reproductive system. Some chemotherapeutic regimens damage cells in the heart, kidneys, bladder, lungs, and nervous system as well. Providing nutritional support to normal cells has been shown to ameliorate some of these side effects in animals and people (Muscaritoli M, Costelli P, Aversa Z, Bonetto A, Baccino FM, 2008, Asia Pac J Clin Nutr: 17: 387-90), through supplementation of specific amino acids required to mitigate each mechanism while not interfering with anti-tumor effects of chemotherapy (Durham, Dillon, & Sheffield-Moore, 2009, Current opinion in clinical nutrition and metabolic care: 12: 72-7).
Provided are additional chemotherapeutic treatments for cancer and other oncological diseases in combination with administration of nutritive polypeptides selected to provide nutritional support to specifically ameliorate the morbidity and side effects of such chemotherapy.
In particular, provided are nutritive polypeptides having increased levels of leucine and other amino acids relative to other polypeptides, in particular polypeptides that are present in the food generally provided to human subjects undergoing chemotherapeutic treatments (Op den Kamp, Langen, Haegens, & Schols, 2009, Current opinion in clinical nutrition and metabolic care: 12: 611-6). Exemplary nutritive polypeptides that are essential amino acid complete with higher levels of leucine are provided in Table E49A and Table E49B, and were identified in the edible and expressed nutritive protein databases, respectively.










TABLE E49A





SEQID
EAAc
EAA
L





SEQID-03428
1
0.49
0.18


SEQID-03623
1
0.49
0.18


SEQID-03599
1
0.51
0.18


SEQID-03494
1
0.54
0.18


SEQID-03632
1
0.45
0.18


SEQID-03423
1
0.44
0.18


SEQID-03547
1
0.43
0.18


SEQID-03598
1
0.44
0.18


SEQID-03503
1
0.47
0.18


SEQID-03572
1
0.44
0.17





































TABLE E49B





SEQID
EAAc
EAA
L





SEQID-00142
1
0.56
0.18


SEQID-00083
1
0.51
0.18


SEQID-00645
1
0.56
0.17


SEQID-00153
1
0.51
0.17


SEQID-00490
1
0.58
0.17


SEQID-00128
1
0.53
0.17


SEQID-00145
1
0.51
0.17


SEQID-03446
1
0.49
0.16


SEQID-00512
1
0.44
0.16


SEQID-00003
1
0.50
0.15



























Formulations containing nutritive polypeptides provide essential metabolic support for life while selectively increasing leucine levels to ameliorate such side effects as cachexia, skeletal muscle mass loss, and peripheral neuropathy induced by chemotherapy. In humans with cancers of the breast, prostate, lung, melanoma, CNS, leukemia, ovarian, or gastrointestinal tract, for example, such a nutritive polypeptide at an initial dose of 10-30 grams is administered orally to patients, concomitantly with a chemotherapeutic regimen. Examples of agents used in such chemotherapeutic regimens include 5-fluorouracil, cyclophosphamide, doxorubicin, cisplatin, and methotrexate. Such co-administration of a nutritive polypeptide enriched in leucine with chemotherapy provides benefits including decreased incidence and severity of cachexia, skeletal muscle mass loss, and peripheral neuropathy compared to chemotherapy alone, by supporting life functions necessary for normal cell survival and function.
In an additional particular embodiment, provided are nutritive polypeptides having increased levels of branched-chain amino acids relative to other polypeptides, in particular polypeptides that are present in the food generally provided to human subjects undergoing chemotherapeutic treatments. Exemplary nutritive polypeptides that are essential amino acid complete with higher levels of branched-chain amino acids are provided in tables E49C and E49D, and were identified in the edible and expressed nutritive protein databases, respectively.










TABLE E49C





SEQID
EAAc
EAA
BCAA





SEQID-03542
1
0.49
0.29


SEQID-03623
1
0.49
0.29


SEQID-03618
1
0.52
0.28


SEQID-03491
1
0.52
0.28


SEQID-03559
1
0.51
0.28


SEQID-03503
1
0.47
0.28


SEQID-03528
1
0.53
0.28


SEQID-03620
1
0.54
0.28


SEQID-03535
1
0.54
0.28


SEQID-03529
1
0.49
0.28





































TABLE E49D





SEQID
EAAc
EAA
BCAA





SEQID-00561
1
0.68
0.36


SEQID-00490
1
0.58
0.34


SEQID-00145
1
0.51
0.33


SEQID-00140
1
0.70
0.32


SEQID-00494
1
0.57
0.32


SEQID-00141
1
0.58
0.31


SEQID-00620
1
0.50
0.30


SEQID-00143
1
0.65
0.30


SEQID-00287
1
0.59
0.30


SEQID-00541
1
0.48
0.29



























Formulations containing nutritive polypeptides provide essential metabolic support for life while selectively increasing branched-chain amino acids levels to ameliorate such side effects as cachexia and skeletal muscle mass loss induced by chemotherapy (Laviano et al., 2005, Current opinion in clinical nutrition and metabolic care: 8: 408-414). In humans with cancers of the breast, prostate, lung, melanoma, CNS, leukemia, ovarian, or gastrointestinal tract, for example, such a nutritive polypeptide at an initial dose of 10-30 grams is administered orally to patients, concomitantly with a chemotherapeutic regimen. Examples of agents used in such chemotherapeutic regimens include 5-fluorouracil, cyclophosphamide, doxorubicin, cisplatin, and methotrexate. Such co-administration of a nutritive polypeptide enriched in branched-chain amino acids with chemotherapy provides benefits including decreased incidence and severity of cachexia and skeletal muscle mass loss compared to chemotherapy alone, by supporting life functions necessary for normal cell survival and function.
In an additional particular embodiment, provided are nutritive polypeptides having increased levels of aspartate relative to other polypeptides, in particular polypeptides that are present in the food generally provided to human subjects undergoing chemotherapeutic treatments. Exemplary nutritive polypeptides that are essential amino acid complete with higher levels of aspartate are provided in table E49E and in table E49F, and were identified in the edible and expressed nutritive protein databases, respectively.










TABLE E49E





SEQID
EAAc
EAA
D





SEQID-03630
1
0.33
0.28


SEQID-03425
1
0.34
0.26


SEQID-03564
1
0.33
0.25


SEQID-03543
1
0.34
0.25


SEQID-03607
1
0.32
0.24


SEQID-03621
1
0.35
0.23


SEQID-03604
1
0.37
0.21


SEQID-03540
1
0.37
0.20


SEQID-03624
1
0.39
0.19


SEQID-03537
1
0.37
0.19





































TABLE E49F





SEQID
EAAc
EAA
D





SEQID-00484
1
0.38
0.16


SEQID-03883
1
0.44
0.14


SEQID-00496
1
0.38
0.13


SEQID-00515
1
0.25
0.13


SEQID-03758
1
0.42
0.13


SEQID-00084
1
0.32
0.12


SEQID-00870
1
0.45
0.12


SEQID-00877
1
0.40
0.12


SEQID-00667
1
0.40
0.11


SEQID-00642
1
0.45
0.11



























Formulations containing nutritive polypeptides provide essential metabolic support for life while selectively increasing aspartate levels to stimulate ureagenesis and remove excess ammonia caused by chemotherapy (Kleef & Scheller, 1999, Forschende Komplementirmedizin: 6: 216). In humans with cancers of the breast, prostate, lung, melanoma, CNS, leukemia, ovarian, or gastrointestinal tract, for example, such a nutritive polypeptide at an initial dose of 10-30 grams is administered orally to patients, concomitantly with a chemotherapeutic regimen. Examples of agents used in such chemotherapeutic regimens include 5-fluorouracil, cyclophosphamide, doxorubicin, cisplatin, and methotrexate. Such co-administration of a nutritive polypeptide enriched in aspartate with chemotherapy provides benefits including decreased incidence and severity of confusion, fatigue, and nausea compared to chemotherapy alone.
In an additional particular embodiment, provided are nutritive polypeptides having increased levels of glycine relative to other polypeptides, in particular polypeptides that are present in the food generally provided to human subjects undergoing chemotherapeutic treatments. Exemplary nutritive polypeptides that are essential amino acid complete with higher levels ofglycine are provided in Table E49G and in Table E49H, and were identified in the edible and expressed nutritive protein databases, respectively.










TABLE E49G





SEQID
EAAc
EAA
G





SEQID-03591
1
0.42
0.09


SEQID-03474
1
0.41
0.08


SEQID-03558
1
0.44
0.08


SEQID-03429
1
0.50
0.08


SEQID-03522
1
0.38
0.08


SEQID-03622
1
0.35
0.08


SEQID-03525
1
0.39
0.08


SEQID-03458
1
0.39
0.08


SEQID-03420
1
0.36
0.08


SEQID-03610
1
0.35
0.08





































TABLE E49H





SEQID
EAAc
EAA
G





SEQID-03641
1
0.24
0.15


SEQID-03447
1
0.30
0.12


SEQID-03450
1
0.37
0.12


SEQID-00084
1
0.32
0.10


SEQID-03614
1
0.38
0.10


SEQID-03449
1
0.38
0.10


SEQID-00500
1
0.40
0.09


SEQID-02675
1
0.50
0.07


SEQID-00563
1
0.50
0.07


SEQID-03649
1
0.49
0.07



























Formulations containing nutritive polypeptides provide essential metabolic support for life while selectively increasing glycine levels to protect from hepatotoxicity following treatment with a chemotherapy regimen such as the one commonly referred to by the abbreviation FOLFOX (FOL—Folinic acid, F—Fluorouracil, OX—Oxaliplatin) (Wang et al., 2013, Amino acids: 45: 463-77). In humans with cancers of the colon, for example, such a nutritive polypeptide at an initial dose of 10-30 grams is administered orally to patients, concomitantly with a FOLFOX chemotherapeutic regimen. Such co-administration of a nutritive polypeptide enriched in glycine with chemotherapy provides benefits including decreased incidence and severity of hepatotoxicity compared to chemotherapy alone.
In an additional particular, provided are nutritive polypeptides having increased levels of lysine relative to other polypeptides, in particular polypeptides that are present in the food generally provided to human subjects undergoing chemotherapeutic treatments. Exemplary nutritive polypeptides that are essential amino acid complete with higher levels of lysine are provided in Table E491 and in Table E49J, and were identified in the edible and expressed nutritive protein databases, respectively.










TABLE E49I





SEQID
EAAc
EAA
K





SEQID-03530
1
0.50
0.27


SEQID-03615
1
0.51
0.25


SEQID-03489
1
0:50
0.24


SEQID-03511
1
0.53
0.23


SEQID-03431
1
0.53
0.23


SEQID-03501
1
0.41
0.23


SEQID-03544
1
0.62
0.23


SEQID-03502
1
0.40
0.23


SEQID-03480
1
0.49
0.23


SEQID-03496
1
0.51
0.23





































TABLE E49J





SEQID
EAAc
EAA
K





SEQID-03691
1
0.52
0.23


SEQID-00503
1
0.49
0.22


SEQID-00517
1
0.49
0.22


SEQID-00509
1
0.43
0.19


SEQID-00495
1
0.46
0.19


SEQID-03696
1
0.48
0.19


SEQID-01625
1
0.51
0.19


SEQID-00491
1
0.46
0.18


SEQID-00336
1
0.46
0.18


























Formulations containing nutritive polypeptides provide essential metabolic support for life while selectively increasing lysine levels to prevent oral mucositis following chemotherapy for cancers of the head and neck. In humans with cancers of the head and neck, for example, such a nutritive polypeptide at an initial dose of 10-30 grams is administered orally to patients, concomitantly with a chemotherapeutic regimen (Colella G, Cannavale R, Vicidomini A, Rinaldi G, Compilato D, 2010, Int J Immunopathol Pharmacol: 23: 143-51)(Blount, Wang, Lim, Sudarsan, & Breaker, 2007, Nature chemical biology: 3: 44-9). Such co-administration of a nutritive polypeptide enriched in lysine with chemotherapy provides benefits including decreased incidence and severity of oral mucositis compared to chemotherapy alone.
In an additional particular embodiment, provided are nutritive polypeptides having increased levels of histidine relative to other polypeptides, in particular polypeptides that are present in the food generally provided to human subjects undergoing chemotherapeutic treatments. Exemplary nutritive polypeptides that are essential amino acid complete with higher levels of histidine are provided in in Table E49K and in Table E349L, and were identified in the edible and expressed nutritive protein databases, respectively.










TABLE E49K





SEQID
EAAc
EAA
H





SEQID-03468
1
0.62
0.15


SEQID-03637
1
0.43
0.12


SEQID-03638
1
0.42
0.12


SEQID-03464
1
0.52
0.11


SEQID-00298
1
0.59
0.10


SEQID-03526
1
0.59
0.10


SEQID-03518
1
0.58
0.10


SEQID-03474
1
0.41
0.10


SEQID-03483
1
0.60
0.10


SEQID-01489
1
0.56
0.10





































TABLE E49L





SEQID
EAAc
EAA
H





SEQID-01162
1
0.48
0.12


SEQID-00298
1
0.59
0.10


SEQID-00297
1
0.58
0.10


SEQID-00128
1
0.53
0.08


SEQID-00299
1
0.56
0.07


SEQID-00141
1
0.58
0.07


SEQID-03162
1
0.40
0.06


SEQID-03854
1
0.46
0.06


SEQID-00113
1
0.52
0.06


SEQID-00130
1
0.56
0.06



























Formulations containing nutritive polypeptides provide essential metabolic support for life while selectively increasing histidine levels to reduce hemorrhagic cystitis caused by chemotherapy (Farshid, Tamaddonfard, & Ranjbar, 2013, Indian journal of pharmacology: 45: 126-9). In humans with cancers of the breast, prostate, lung, melanoma, CNS, leukemia, ovarian, or gastrointestinal tract, for example, such a nutritive polypeptide at an initial dose of 10-30 grams is administered orally to patients, concomitantly with a chemotherapeutic regimen. Examples of agents used in such chemotherapeutic regimens include 5-fluorouracil, cyclophosphamide, doxorubicin, cisplatin, and methotrexate. Such co-administration of a nutritive polypeptide enriched in histidine with chemotherapy provides benefits including decreased incidence and severity of hemorrhagic cystitis compared to chemotherapy alone.
In an additional particular embodiment, provided are nutritive polypeptides having increased levels of arginine relative to other polypeptides, in particular polypeptides that are present in the food generally provided to human subjects undergoing chemotherapeutic treatments. Exemplary nutritive polypeptides that are essential amino acid complete with higher levels of arginine are provided in table E49M and in table E49N, and were identified in the edible and expressed nutritive protein databases, respectively.










TABLE E49M





SEQIDs
EAAc
EAA
R





SEQID-03468
1
0.62
0.21


SEQID-03841
1
0.49
0.17


SEQID-03487
1
0.53
0.17


SEQID-03623
1
0.49
0.16


SEQID-03761
1
0.48
0.16


SEQID-03800
1
0.33
0.16

































TABLE E49N





SEQID
EAAc
EAA
R





SEQID-00567
1
0.42
0.22


SEQID-00636
1
0.47
0.22


SEQID-00637
1
0.42
0.22


SEQID-00492
1
0.42
0.21


SEQID-00328
1
0.45
0.20






















Formulations containing nutritive polypeptides provide essential metabolic support for life while selectively increasing arginine levels to postoperative infections in patients with burn and cancer caused by chemotherapy (Heyland D K, Cook D J, 1994, Crit Care Med: 22: 1192-202). In humans with cancers of the breast, prostate, lung, melanoma, CNS, leukemia, ovarian, or gastrointestinal tract, for example, such a nutritive polypeptide at an initial dose of 10-30 grams is administered orally to patients following surgery, concomitantly with a chemotherapeutic regimen. Examples of agents used in such chemotherapeutic regimens include 5-fluorouracil, cyclophosphamide, doxorubicin, cisplatin, and methotrexate. Such co-administration of a nutritive polypeptide enriched in histidine with chemotherapy provides benefits including decreased incidence of postoperational infection compared to chemotherapy alone.
Example 50
Selection of Nutritive Polypeptides for Hepatic Diseases and Hepatocellular Carcinoma
Etiology of hepatocellular carcinoma (HCC), a disease with poor outcomes and limited therapeutic options, is multifactorial involving host genetic, viral (hepatitis B and C viruses (HBV and HVC, respectively)), nutritional (lipids, branched-chain amino acids, alcohol), an metabolic factors (diabetes mellitus (DM), metabolic syndrome) (Michelotti, Machado, & Diehl, 2013, Nature reviews. Gastroenterology & hepatology: 10: 656-65). Natural course of HCC progresses from liver inflammation, liver cirrhosis, and cancer. Among these causes of HCC, nutritional and metabolic factors play important roles in initiating and promoting progression of HCC. Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) cause cirrhosis which can progress to HCC. As with other liver diseases that cause cirrhosis, such as HBV-, HCV-, alcohol-mediated cirrhosis, NAFLD further increases the risk of HCC (Michelotti et al., 2013, Nature reviews. Gastroenterology & hepatology: 10: 656-65). Furthermore, incidences of HCC and intrahepatic cholangiocarcinoma are also rising, and HCC is now the leading cause of obesity-related cancer deaths in middle-aged men in the USA (Michelotti et al., 2013, Nature reviews. Gastroenterology & hepatology: 10: 656-65). Dietary supplementation with branched-chain amino acids ameliorates cirrhosis and reduces HCC risk in animals (Cha et al., 2013, PLoS ONE: 8)(Terakura et al., 2012, Carcinogenesis: 33: 2499-2506) and humans (Yoshiji et al., 2013, Oncology Reports: 30: 545-552)(H. et al., 2013, Journal of Clinical Gastroenterology: 47: 359-366). Dietary supplementation with branched-chain amino acids decreases incidence of primary HCC and post-treatment recurrence of HCC (Yoshiji et al., 2013, Oncology Reports: 30: 545-552)(H. et al., 2013, Journal of Clinical Gastroenterology: 47: 359-366)(Ichikawa et al., 2012). Dietary supplementation with branched-chain amino acids decreases recurrent HCC in DM and insulin resistance (Yoshiji et al., 2013, Oncology Reports: 30: 545-552). Moreover, many patients with end-stage liver disease and cirrhosis are protein malnourished (Moriwaki et al., 2000, Journal of gastroenterology: 35 Suppl 1: 13-17). Supplementation with branched-chain amino acids alleviates chronic liver failure and hepatic encephalopathy (HE), improves the protein nutritional state, and subsequently prolongs survival (Moriwaki et al., 2000, Journal of gastroenterology: 35 Suppl 1: 13-17).
Provided are treatments for NAFLD, HASH, HBV- and HCV-mediated liver cirrhosis, end-stage liver disease, chronic liver failure, HE, and HCC with administration of nutritive polypeptides selected to provide nutritional support to specifically ameliorate the morbidity and mortality of these liver diseases.
In particular, nutritive polypeptides having increased levels of branched-chain amino acids and other amino acids relativeto other polypeptides are provided to the STAM mouse model of HAFLD, HASH, and HCC (Fujii et al., 2013, Medical Molecular Morphology: 46: 141-152) ( FIG. 1 ). STAM mice develop high fat diet-induced HAFLD, HASH, and HCC (Fujii et al., 2013, Medical Molecular Morphology: 46: 141-152). Exemplary nutritive polypeptides that are essential amino acid complete with higher levels of branched-chain amino acids are described herein.
Example 51
Improvement of NAFLD, NASH and HCC in a Pre-Clinical Animal Model
Formulations of nutritive polypeptides mixed in mouse chow are provided to STAM mice starting at 6 weeks of age. Animals are euthanized at 9, 12, 15, and 18 weeks of age. Identical control groups are run using normal chow. Disease severities of NAFLD, NASH, and HCC numbers are quantified by histological analysis within each treatment group and compared to control animals treated for the same amount of time.
Example 52
Improvement of NAFLD, NASH and HCC in Humans
In an additional particular embodiment, nutritive polypeptides having increased levels of branched-chain amino acids are provided to human subjects with liver diseases such as NAFLD, HASH, HBV- and HCV-mediated liver cirrhosis, end-stage liver disease, chronic liver failure, HE, and HCC at an initial, oral dose of 10-30 grams (Yoshiji et al., 2013, Oncology Reports: 30: 545-552)(H. et al., 2013, Journal of Clinical Gastroenterology: 47: 359-366)(Ichikawa et al., 2012)(Moriwaki et al., 2000, Journal of gastroenterology: 35 Suppl 1: 13-17). Exemplary nutritive polypeptides with higher levels of branched-chain amino acids are described herein. Formulations containing nutritive polypeptides provide essential metabolic support for life while selectively increasing branched-chain amino acids levels.
While the invention has been particularly shown and described with reference to a preferred embodiment and various alternate embodiments, it will be understood by persons skilled in the relevant art that various changes in form and details can be made therein without departing from the spirit and scope of the invention.
All references, issued patents and patent applications cited within the body of the instant specification are hereby incorporated by reference in their entirety, for all purposes.























TABLE 1





Predicted
Fragment
EAAcom-















SEQID
DBID
Leader
Indices
plete
EAA
BCAA
A
R
N
D
C
Q
E
G
H
I
L
K



SEQID-00001
P01012
—
—
1
0.47
0.22
0.06
0.05
0.05
0.04
0.01
0.04
0.10
0.03
0.02
0.07
0.08
0.06

SEQID-00002
P04405
—
—
1
0.36
0.18
0.04
0.08
0.08
0.04
0.02
0.12
0.09
0.04
0.01
0.05
0.08
0.04

SEQID-00003
P02754
—
—
1
0.50
0.16
0.07
0.02
0.03
0.06
0.04
0.06
0.10
0.01
0.01
0.06
0.15
0.10

SEQID-00004
P02662
—
—
1
0.44
0.21
0.03
0.04
0.04
0.03
0.00
0.07
0.13
0.02
0.03
0.06
0.10
0.08

SEQID-00005
P02666
—
—
1
0.48
0.25
0.03
0.02
0.02
0.02
0.00
0.10
0.10
0.01
0.03
0.05
0.12
0.06

SEQID-00006
P00711
—
—
1
0.53
0.23
0.02
0.01
0.06
0.09
0.05
0.06
0.06
0.02
0.03
0.06
0.12
0.09

SEQID-00007
P56552
—
—
0
0.28
0.10
0.02
0.05
0.07
0.09
0.13
0.03
0.08
0.01
0.02
0.02
0.05
0.14

SEQID-00008
P29290
—
—
0
0.45
0.21
0.03
0.05
0.03
0.11
0.00
0.02
0.21
0.04
0.00
0.07
0.10
0.06

SEQID-00009
Q5ZMN0
—
—
0
0.34
0.20
0.01
0.05
0.06
0.17
0.01
0.01
0.23
0.03
0.01
0.03
0.14
0.06

SEQID-00010
P04699
—
—
0
0.41
0.29
0.10
0.02
0.05
0.00
0.00
0.22
0.01
0.00
0.01
0.05
0.19
0.00

SEQID-00011
P42212
—
—
1
0.50
0.20
0.02
0.03
0.05
0.08
0.01
0.04
0.08
0.05
0.05
0.05
0.09
0.09

SEQID-00012
P56552
—
—
0
0.28
0.10
0.02
0.05
0.07
0.09
0.13
0.08
0.08
0.01
0.02
0.02
0.05
0.14

SEQID-00013
P565S2
—
5:54
0
0.28
0.11
0.02
0.05
0.08
0.08
0.12
0.06
0.09
0.01
0.02
0.02
0.06
0.13

SEQID-00014
P56552
—
1:51
0
0.30
0.11
0.02
0.05
0.07
0.09
0.12
0.08
0.06
0.01
0.02
0.02
0.06
0.15

SEQID-00015
P56552
—
5:51
0
0.30
0.12
0.03
0.06
0.08
0.08
0.11
0.07
0.07
0.01
0.02
0.02
0.06
0.14

SEQID-00016
—
—
—
0
0.45
0.25
0.08
0.00
0.03
0.07
0.04
0.06
0.14
0.02
0.00
0.05
0.18
0.07

SEQID-00017
—
—
—
1
0.45
0.20
0.06
0.01
0.05
0.07
0.02
0.03
0.12
0.03
0.02
0.08
0.08
0.04

SEQID-00018
P10568
—
693:792
1
0.52
0.19
0.04
0.17
0.03
0.00
0.01
0.08
0.00
0.02
0.02
0.06
0.11
0.13

SEQID-00019
—
—
—
0
0.46
0.21
0.07
0.31
0.00
0.00
0.00
0.13
0.00
0.02
0.04
0.04
0.11
0.13

SEQID-00020
—
—
—
0
0.52
0.20
0.07
0.09
0.03
0.03
0.03
0.06
0.03
0.02
0.02
0.07
0.09
0.13

SEQID-00021
—
—
—
0
0.39
0.23
0.05
0.12
0.08
0.03
0.02
0.05
0.02
0.02
0.01
0.06
0.10
0.10

SEQID-00022
P04700
—
—
0
0.42
0.29
0.10
0.01
0.05
0.00
0.00
0.22
0.00
0.01
0.01
0.04
0.20
0.00

SEQID-00023
P04705
—
40:139
0
0.41
0.36
0.08
0.04
0.05
0.00
0.01
0.23
0.01
0.01
0.02
0.06
0.26
0.00

SEQID-00024
P15989
—
388:487
0
0.52
0.36
0.07
0.07
0.04
0.06
0.00
0.07
0.06
0.03
0.00
0.12
0.15
0.04

SEQID-00025
P15989
—
341:442
0
0.48
0.36
0.08
0.06
0.04
0.05
0.00
0.06
0.11
0.03
0.00
0.13
0.16
0.02

SEQID-00026
—
—
—
0
0.74
0.59
0.06
0.05
0.00
0.00
0.00
0.00
0.09
0.06
0.00
0.04
0.52
0.00

SEQID-00027
—
—
—
0
0.51
0.36
0.01
0.03
0.04
0.02
0.01
0.05
0.11
0.02
0.01
0.07
0.20
0.05

SEQID-00028
—
—
—
0
0.50
0.41
0.03
0.00
0.01
0.09
0.01
0.02
0.20
0.02
0.02
0.09
0.16
0.00

SEQID-00029
—
—
—
0
0.37
0.27
0.02
0.08
0.03
0.07
0.00
0.07
0.15
0.02
0.00
0.05
0.16
0.03

SEQID-00030
P10587
—
1287:1386
0
0.49
0.26
0.02
0.04
0.06
0.06
0.00
0.12
0.15
0.00
0.02
0.04
0.17
0.13

SEQID-00031
Q27991
—
1353:1452
0
0.46
0.23
0.04
0.07
0.02
0.10
0.00
0.11
0.16
0.00
0.01
0.02
0.17
0.17

SEQID-00032
P29616
—
51:151
0
0.48
0.23
0.04
0.04
0.04
0.09
0.02
0.04
0.22
0.00
0.01
0.04
0.15
0.15

SEQID-00033
—
—
—
0
0.64
0.33
0.04
0.03
0.01
0.05
0.00
0.03
0.13
0.01
0.02
0.06
0.21
0.18

SEQID-00034
—
—
—
0
0.53
0.27
0.08
0.01
0.01
0.05
0.03
0.07
0.09
0.03
0.00
0.07
0.16
0.14

SEQID-00035
P47807
—
887:986
0
0.57
0.33
0.07
0.06
0.02
0.05
0.01
0.05
0.05
0.03
0.04
0.02
0.21
0.11

SEQID-00036
—
—
—
1
0.64
0.28
0.02
0.01
0.03
0.05
0.03
0.04
0.04
0.03
0.04
0.06
0.17
0.11

SEQID-00037
—
—
—
1
1.00
0.49
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.04
0.12
0.28
0.19

SEQID-00038
Q90584
—
424:529
1
0.55
0.28
0.02
0.05
0.06
0.03
0.03
0.01
0.10
0.03
0.02
0.03
0.19
0.03

SEQID-00039
Q02440
—
1443:1545
1
0.54
0.25
0.02
0.05
0.05
0.07
0.03
0.04
0.06
0.02
0.02
0.05
0.14
0.14

SEQID-00040
P15989
—
399:498
0
0.51
0.34
0.06
0.03
0.04
0.06
0.00
0.05
0.07
0.03
0.00
0.10
0.13
0.03

SEQID-00041
P10568
—
680:779
1
0.48
0.18
0.04
0.13
0.03
0.00
0.01
0.08
0.02
0.02
0.02
0.06
0.10
0.10

SEQID-00042
P79114
—
982:1083
0
0.25
0.09
0.05
0.03
0.03
0.13
0.01
0.04
0.15
0.03
0.04
0.01
0.04
0.01

SEQID-00043
P15989
—
398:447
0
0.57
0.41
0.03
0.03
0.06
0.04
0.00
0.02
0.09
0.01
0.00
0.12
0.18
0.05

SEQID-00044
P15989
—
399:448
0
0.59
0.43
0.06
0.03
0.06
0.04
0.00
0.02
0.09
0.01
0.00
0.12
0.20
0.05

SEQID-00045
P15989
—
402:454
0
0.56
0.43
0.06
0.03
0.06
0.06
0.00
0.02
0.09
0.02
0.00
0.14
0.20
0.04

SEQID-00046
P15989
—
403:454
0
0.55
0.42
0.06
0.08
0.06
0.06
0.00
0.02
0.09
0.02
0.00
0.14
0.18
0.05

SEQID-00047
P15989
—
406:455
0
0.58
0.44
0.07
0.06
0.06
0.04
0.00
0.02
0.10
0.02
0.00
0.13
0.21
0.05

SEQID-00048
P69012
—
—
0
0.08
0.03
0.03
0.76
0.00
0.00
0.00
0.00
0.00
0.01
0.00
0.03
0.00
0.00

SEQID-00049
—
—
—
1
0.52
0.19
0.03
0.04
0.05
0.07
0.01
0.04
0.07
0.05
0.08
0.04
0.08
0.09

SEQID-00050
P02662
—
1:50
0
0.59
0.31
0.05
0.06
0.04
0.00
0.02
0.05
0.09
0.02
0.05
0.04
0.18
0.09

SEQID-00051
P02662
—
2:51
0
0.59
0.31
0.05
0.06
0.04
0.00
0.02
0.05
0.09
0.02
0.05
0.04
0.18
0.11

SEQID-00052
P02662
—
3:52
0
0.59
0.33
0.05
0.06
0.04
0.00
0.02
0.05
0.09
0.02
0.05
0.04
0.18
0.09

SEQID-00053
P02662
—
4:53
0
0.57
0.31
0.05
0.06
0.06
0.00
0.02
0.05
0.09
0.02
0.05
0.04
0.16
0.09

SEQID-00054
P02662
—
5:54
0
0.55
0.29
0.05
0.06
0.06
0.00
0.02
0.05
0.11
0.02
0.05
0.04
0.14
0.09

SEQID-00055
P02662
—
6:55
0
0.55
0.29
0.05
0.06
0.06
0.00
0.02
0.05
0.11
0.02
0.05
0.02
0.16
0.09

SEQID-00056
P02662
—
78:127
0
0.41
0.28
0.00
0.05
0.02
0.02
0.00
0.09
0.18
0.01
0.02
0.08
0.12
0.11

SEQID-00057
P02662
—
79:128
0
0.41
0.28
0.00
0.05
0.02
0.02
0.00
0.09
0.15
0.01
0.02
0.08
0.12
0.11

SEQID-00058
P02662
—
80:129
0
0.41
0.28
0.00
0.05
0.04
0.02
0.00
0.09
0.15
0.01
0.02
0.08
0.12
0.11

SEQID-00059
P02662
—
86:135
0
0.41
0.27
0.01
0.08
0.04
0.02
0.00
0.09
0.15
0.01
0.02
0.06
0.13
0.11

SEQID-00060
—
—
—
1
0.48
0.19
0.03
0.03
0.04
0.10
0.01
0.03
0.11
0.05
0.08
0.04
0.08
0.06

SEQID-00061
—
—
—
1
0.55
0.17
0.02
0.11
0.04
0.04
0.01
0.02
0.04
0.05
0.08
0.04
0.08
0.16

SEQID-00062
P33465
—
—
0
0.67
0.49
0.03
0.07
0.04
0.03
0.03
0.02
0.02
0.02
0.04
0.05
0.32
0.02

SEQID-00063
Q9B8D7
—
—
0
0.63
0.48
0.05
0.01
0.02
0.01
0.00
0.01
0.04
0.04
0.01
0.20
0.19
0.01

SEQID-00064
P48923
—
—
1
0.62
0.46
0.04
0.00
0.04
0.02
0.01
0.01
0.04
0.03
0.01
0.19
0.20
0.02

SEQID-00065
P44110
—
—
1
0.66
0.49
0.05
0.00
0.02
0.01
0.00
0.04
0.02
0.07
0.01
0.16
0.24
0.05

SEQID-00066
O57248
—
—
0
0.70
0.43
0.02
0.01
0.06
0.02
0.00
0.01
0.03
0.02
0.00
0.10
0.23
0.08

SEQID-00067
P81327
—
—
0
0.68
0.48
0.04
0.00
0.03
0.02
0.01
0.03
0.02
0.03
0.00
0.21
0.18
0.07

SEQID-00068
—
—
—
0
0.57
0.43
0.00
0.04
0.04
0.03
0.00
0.07
0.13
0.00
0.03
0.12
0.21
0.03

SEQID-00069
—
—
—
0
0.56
0.47
0.06
0.04
0.04
0.05
0.00
0.04
0.09
0.03
0.00
0.12
0.23
0.02

SEQID-00070
—
—
—
0
0.50
0.40
0.06
0.06
0.04
0.05
0.00
0.06
0.11
0.03
0.00
0.12
0.19
0.02

SEQID-00071
—
—
—
0
0.62
0.46
0.05
0.08
0.06
0.04
0.00
0.02
0.09
0.01
0.00
0.12
0.20
0.05

SEQID-00072
P09860
—
—
0
0.46
0.18
0.03
0.03
0.03
0.14
0.01
0.03
0.17
0.04
0.00
0.06
0.08
0.09

SEQID-00073
P35622
—
—
0
0.49
0.20
0.04
0.05
0.02
0.12
0.02
0.02
0.16
0.03
0.00
0.05
0.10
0.23

SEQID-00074
P02586
—
—
0
0.42
0.16
0.05
0.06
0.02
0.12
0.01
0.04
0.19
0.04
0.01
0.06
0.06
0.06

SEQID-00075
P63317
—
—
0
0.46
0.18
0.03
0.03
0.03
0.14
0.01
0.03
0.17
0.04
0.00
0.06
0.08
0.09

SEQID-00076
P63315
—
—
0
0.46
0.18
0.03
0.03
0.03
0.14
0.01
0.03
0.17
0.04
0.00
0.06
0.08
0.09

SEQID-00077
D7F1Q2
—
—
0
0.47
0.21
0.04
0.03
0.02
0.14
0.00
0.03
0.18
0.03
0.00
0.08
0.09
0.07

SEQID-00078
Q7ZZ89
—
—
0
0.46
0.17
0.03
0.02
0.04
0.14
0.02
0.04
0.16
0.03
0.00
0.06
0.07
0.10

SEQID-00079
Q9FF58
—
—
0
0.58
0.38
0.01
0.13
0.00
0.02
0.05
0.02
0.02
0.03
0.00
0.07
0.24
0.04

SEQID-00080
P93280
—
—
1
0.62
0.33
0.01
0.03
0.02
0.02
0.03
0.04
0.04
0.03
0.02
0.08
0.21
0.02

SEQID-00081
Q67E55
—
—
1
0.55
0.30
0.04
0.03
0.02
0.03
0.03
0.05
0.02
0.01
0.04
0.06
0.19
0.02

SEQID-00082
Q35Z72
—
—
1
0.48
0.30
0.07
0.11
0.03
0.04
0.03
0.03
0.04
0.04
0.03
0.03
0.20
0.02

SEQID-00083
P14622
—
—
1
0.51
0.26
0.03
0.12
0.01
0.01
0.03
0.03
0.05
0.04
0.04
0.04
0.18
0.05

SEQID-00084
P33626
—
1:61
1
0.32
0.15
0.04
0.02
0.02
0.12
0.05
0.03
0.16
0.10
0.04
0.10
0.03
0.02

SEQID-00085
P60660
—
—
0
0.47
0.20
0.03
0.05
0.05
0.07
0.02
0.05
0.13
0.05
0.03
0.03
0.09
0.07

SEQID-00086
P02607
—
—
0
0.46
0.18
0.03
0.05
0.05
0.06
0.02
0.06
0.14
0.05
0.02
0.03
0.09
0.08

SEQID-00087
P02605
—
—
0
0.48
0.19
0.05
0.04
0.08
0.06
0.01
0.04
0.15
0.04
0.02
0.05
0.08
0.08

SEQID-00088
Q9FRT9
—
1:90
1
0.32
0.11
0.05
0.02
0.06
0.09
0.11
0.03
0.04
0.05
0.01
0.02
0.07
0.04

SEQID-00089
Q95M18
—
—
1
0.46
0.19
0.04
0.06
0.03
0.08
0.01
0.03
0.15
0.02
0.01
0.05
0.08
0.11

SEQID-00090
Q41784
—
—
1
0.43
0.17
0.04
0.07
0.05
0.06
0.02
0.05
0.10
0.04
0.03
0.04
0.08
0.04

SEQID-00091
P09643
—
1:322
1
0.44
0.20
0.06
0.06
0.04
0.06
0.03
0.04
0.09
0.03
0.03
0.06
0.08
0.04

SEQID-00092
P02587
—
—
0
0.42
0.16
0.05
0.06
0.02
0.12
0.01
0.04
0.19
0.04
0.01
0.07
0.05
0.06

SEQID-00093
P10246
—
—
0
0.45
0.16
0.05
0.05
0.03
0.12
0.01
0.04
0.18
0.04
0.01
0.07
0.06
0.07

SEQID-00094
P02588
—
—
0
0.45
0.16
0.05
0.05
0.03
0.13
0.01
0.03
0.18
0.04
0.01
0.07
0.06
0.07

SEQID-00095
P04119
—
—
1
0.50
0.28
0.05
0.05
0.02
0.08
0.03
0.06
0.10
0.01
0.02
0.03
0.18
0.07

SEQID-00096
Q9TSR4
—
—
1
0.53
0.23
0.02
0.01
0.05
0.10
0.05
0.06
0.06
0.02
0.03
0.06
0.12
0.09

SEQID-00097
Q5KR47
—
—
0
0.39
0.18
0.08
0.07
0.02
0.07
0.00
0.06
0.24
0.01
0.01
0.04
0.12
0.15

SEQID-00098
QO30J7
—
—
0
0.50
0.25
0.03
0.00
0.04
0.15
0.00
0.03
0.20
0.01
0.00
0.07
0.08
0.09

SEQID-00099
Q8DH53
—
—
0
0.45
0.28
0.07
0.00
0.05
0.10
0.00
0.04
0.19
0.01
0.00
0.06
0.10
0.09

SEQID-00100
Q5FJ18
—
—
0
0.46
0.12
0.03
0.00
0.06
0.15
0.00
0.03
0.16
0.02
0.02
0.11
0.06
0.08

SEQID-00101
Q9WZD0
—
—
0
0.51
0.29
0.03
0.02
0.00
0.14
0.00
0.01
0.15
0.03
0.00
0.09
0.10
0.12

SEQID-00102
Q74IP1
—
—
0
0.45
0.20
0.04
0.03
0.05
0.16
0.00
0.04
0.14
0.01
0.01
0.10
0.06
0.07

SEQID-00103
Q84MN0
—
—
0
0.45
0.19
0.03
0.05
0.05
0.11
0.01
0.05
0.16
0.04
0.00
0.05
0.09
0.06

SEQID-00104
P41040
—
—
0
0.45
0.18
0.05
0.05
0.05
0.12
0.01
0.05
0.15
0.03
0.01
0.05
0.08
0.08

SEQID-00105
P06787
—
—
0
0.44
0.23
0.05
0.03
0.06
0.09
0.00
0.05
0.14
0.03
0.02
0.06
0.13
0.06

SEQID-00106
P93087
—
—
0
0.46
0.17
0.04
0.05
0.05
0.14
0.01
0.05
0.14
0.03
0.01
0.05
0.07
0.08

SEQID-00107
P52193
—
—
1
0.42
0.14
0.03
0.03
0.04
0.13
0.01
0.04
0.15
0.03
0.02
0.05
0.06
0.11

SEQID-00108
Q95P22
—
—
1
0.44
0.14
0.05
0.02
0.03
0.14
0.00
0.03
0.12
0.03
0.03
0.06
0.05
0.14

SEQID-00109
P32018
—
656:709
0
0.42
0.33
0.05
0.00
0.02
0.10
0.00
0.00
0.20
0.04
0.00
0.04
0.16
0.00

SEQID-00110
Q9HD67
—
472:521
0
0.49
0.29
0.02
0.03
0.04
0.10
0.02
0.02
0.16
0.03
0.02
0.08
0.20
0.04

SEQID-00111
Q03472
—
140:189
0
0.48
0.26
0.01
0.00
0.02
0.02
0.05
0.06
0.22
0.01
0.02
0.02
0.21
0.13

SEQID-00112
Q02440
—
461:511
1
0.50
0.23
0.01
0.00
0.06
0.07
0.02
0.12
0.12
0.01
0.02
0.07
0.13
0.06

SEQID-00113
Q13402
—
452:509
1
0.52
0.24
0.03
0.02
0.08
0.08
0.01
0.07
0.11
0.00
0.06
0.10
0.11
0.04

SEQID-00114
Q90688
—
446:495
1
0.51
0.24
0.01
0.05
0.00
0.04
0.02
0.02
0.25
0.03
0.02
0.04
0.08
0.07

SEQID-00115
Q29092
—
703:803
0
0.32
0.13
0.04
0.05
0.01
0.16
0.00
0.02
0.27
0.01
0.00
0.02
0.08
0.04

SEQID-00116
Q29092
—
704:803
0
0.32
0.14
0.04
0.06
0.01
0.16
0.00
0.02
0.26
0.02
0.00
0.02
0.03
0.05

SEQID-00117
Q02440
—
413:512
1
0.52
0.22
0.02
0.00
0.08
0.06
0.02
0.09
0.12
0.01
0.05
0.09
0.09
0.06

SEQID-00118
Q28970
—
427:527
1
0.51
0.21
0.02
0.04
0.08
0.03
0.01
0.05
0.12
0.01
0.03
0.09
0.10
0.05

SEQID-00119
Q90688
—
332:481
1
0.46
0.24
0.05
0.03
0.04
0.05
0.03
0.03
0.17
0.03
0.02
0.07
0.07
0.07

SEQID-00120
Q90688
—
398:498
1
0.46
0.22
0.04
0.04
0.03
0.04
0.03
0.03
0.20
0.03
0.02
0.07
0.06
0.07

SEQID-00121
Q28083
—
23:225
0
0.29
0.12
0.03
0.02
0.04
0.08
0.00
0.03
0.21
0.05
0.01
0.04
0.04
0.04

SEQID-00122
Q28083
—
2:202
0
0.26
0.10
0.04
0.02
0.04
0.09
0.01
0.05
0.21
0.04
0.01
0.03
0.03
0.04

SEQID-00123
Q95M18
—
118:318
1
0.46
0.20
0.04
0.02
0.06
0.07
0.00
0.03
0.18
0.03
0.02
0.06
0.08
0.09

SEQID-00124
P03110
—
120:321
1
0.43
0.19
0.03
0.02
0.06
0.07
0.00
0.03
0.13
0.03
0.02
0.05
0.07
0.11

SEQID-00125
P22418
—
75:275
1
0.40
0.27
0.05
0.03
0.04
0.08
0.03
0.05
0.10
0.05
0.01
0.09
0.08
0.03

SEQID-00126
P79114
—
913:1115
1
0.26
0.11
0.04
0.06
0.03
0.11
0.02
0.06
0.15
0.03
0.02
0.02
0.06
0.02

SEQID-00127
P04119
—
—
1
0.50
0.28
0.05
0.05
0.02
0.08
0.03
0.06
0.10
0.01
0.02
0.03
0.18
0.07

SEQID-00128
P06714
—
—
1
0.53
0.24
0.09
0.10
0.01
0.05
0.01
0.02
0.04
0.03
0.08
0.01
0.17
0.04

SEQID-00129
A1AAQ3
—
—
1
0.51
0.26
0.06
0.08
0.01
0.05
0.01
0.09
0.06
0.03
0.06
0.02
0.13
0.02

SEQID-00130
P02114
—
—
1
0.56
0.24
0.07
0.06
0.05
0.05
0.02
0.04
0.05
0.03
0.06
0.05
0.12
0.08

SEQID-00131
P67975
—
—
1
0.50
0.25
0.06
0.03
0.04
0.05
0.03
0.06
0.11
0.02
0.02
0.06
0.13
0.11

SEQID-00132
Q90584
—
436:486
0
0.60
0.41
0.04
0.05
0.03
0.02
0.00
0.02
0.07
0.04
0.02
0.04
0.32
0.07

SEQID-00133
A6QPB3
—
473:523
0
0.61
0.35
0.04
0.10
0.02
0.00
0.00
0.00
0.15
0.04
0.00
0.02
0.30
0.11

SEQID-00134
P22281
—
82:134
0
0.58
0.46
0.04
0.06
0.02
0.06
0.02
0.00
0.02
0.02
0.02
0.14
0.24
0.00

SEQID-00135
P01958
—
63:114
0
0.61
0.38
0.06
0.03
0.04
0.10
0.02
0.00
0.00
0.03
0.12
0.00
0.29
0.05

SEQID-00136
Q9TSN7
—
63:114
0
0.62
0.36
0.09
0.03
0.02
0.06
0.00
0.00
0.02
0.02
0.12
0.00
0.27
0.07

SEQID-00137
Q17R14
—
270:321
0
0.64
0.39
0.06
0.03
0.02
0.03
0.00
0.00
0.07
0.03
0.02
0.10
0.20
0.09

SEQID-00138
P47807
—
952:1003
0
0.59
0.35
0.08
0.03
0.00
0.06
0.00
0.05
0.05
0.04
0.08
0.04
0.27
0.05

SEQID-00139
Q27991
—
1396:1446
0
0.49
0.31
0.02
0.08
0.02
0.11
0.00
0.11
0.11
0.00
0.02
0.02
0.23
0.13

SEQID-00140
P12106
—
170:120
1
0.70
0.32
0.00
0.00
0.02
0.06
0.02
0.02
0.04
0.02
0.05
0.10
0.14
0.11

SEQID-00141
P32191
—
112:163
1
0.58
0.31
0.05
0.05
0.04
0.02
0.02
0.02
0.09
0.02
0.07
0.11
0.15
0.06

SEQID-00142
P19524
—
1398:1449
1
0.56
0.25
0.01
0.10
0.06
0.02
0.03
0.08
0.06
0.03
0.04
0.04
0.18
0.08

SEQID-00143
Q03262
—
225:277
1
0.65
0.30
0.01
0.00
0.04
0.02
0.02
0.00
0.11
0.03
0.02
0.06
0.13
0.15

SEQID-00144
P32492
—
1275:1325
1
0.67
0.25
0.02
0.00
0.09
0.08
0.03
0.02
0.02
0.00
0.02
0.04
0.15
0.11

SEQID-00145
P12863
—
82:132
1
0.51
0.33
0.05
0.06
0.04
0.02
0.02
0.02
0.12
0.06
0.03
0.04
0.17
0.05

SEQID-00146
P12106
—
159:209
1
0.67
0.29
0.01
0.00
0.02
0.06
0.02
0.04
0.04
0.02
0.05
0.08
0.14
0.09

SEQID-00147
P32492
—
1092:1193
1
0.57
0.36
0.00
0.04
0.08
0.04
0.01
0.01
0.08
0.04
0.01
0.07
0.17
0.06

SEQID-00148
A6QR56
—
583:691
0
0.47
0.34
0.10
0.14
0.02
0.01
0.02
0.05
0.09
0.03
0.02
0.01
0.21
0.03

SEQID-00149
P47807
—
888:988
0
0.56
0.32
0.07
0.06
0.02
0.05
0.01
0.06
0.05
0.03
0.05
0.02
0.21
0.09

SEQID-00150
P32492
—
1218:1319
1
0.67
0.25
0.02
0.00
0.08
0.08
0.01
0.01
0.06
0.00
0.03
0.06
0.14
0.13

SEQID-00151
P79114
—
688:788
1
0.48
0.26
0.05
0.14
0.03
0.03
0.02
0.06
0.09
0.01
0.02
0.04
0.15
0.10

SEQID-00152
Q5MIB5
—
492:592
1
0.53
0.27
0.01
0.05
0.07
0.05
0.02
0.05
0.09
0.01
0.02
0.07
0.14
0.13

SEQID-00153
P04119
—
28:129
1
0.51
0.26
0.06
0.01
0.04
0.10
0.02
0.05
0.08
0.02
0.02
0.03
0.17
0.10

SEQID-00154
P06642
—
14:115
1
0.55
0.27
0.03
0.05
0.07
0.06
0.02
0.01
0.06
0.04
0.04
0.05
0.14
0.08

SEQID-00155
Q2XQV4
—
108:213
1
0.49
0.26
0.05
0.06
0.04
0.08
0.02
0.02
0.03
0.04
0.02
0.05
0.15
0.06

SEQID-00156
Q02440
—
1448:1548
1
0.52
0.25
0.02
0.07
0.05
0.06
0.03
0.04
0.07
0.03
0.02
0.05
0.15
0.12

SEQID-00157
Q49068
—
—
1
0.45
0.23
0.04
0.03
0.06
0.06
0.01
0.06
0.07
0.03
0.03
0.06
0.10
0.05

SEQID-00158
P32492
—
1086:1287
1
0.58
0.29
0.02
0.03
0.07
0.06
0.00
0.02
0.08
0.02
0.02
0.05
0.15
0.10

SEQID-00159
Q76FS2
—
59:260
1
0.46
0.23
0.03
0.06
0.06
0.07
0.03
0.03
0.06
0.05
0.03
0.04
0.12
0.03

SEQID-00160
P32492
—
1115:1316
1
0.61
0.28
0.02
0.01
0.07
0.06
0.00
0.02
0.07
0.02
0.02
0.05
0.14
0.11

SEQID-00161
Q41874
—
113:313
1
0.49
0.27
0.04
0.09
0.07
0.04
0.01
0.06
0.04
0.01
0.02
0.05
0.12
0.05

SEQID-00162
P52768
—
—
0
0.64
0.53
0.01
0.00
0.08
0.02
0.00
0.02
0.02
0.01
0.02
0.14
0.34
0.02

SEQID-00163
P80479
—
—
1
0.72
0.43
0.02
0.01
0.02
0.02
0.00
0.02
0.03
0.01
0.05
0.13
0.26
0.07

SEQID-00164
Q31K24
—
—
0
0.67
0.51
0.04
0.05
0.05
0.02
0.00
0.04
0.00
0.04
0.00
0.05
0.24
0.00

SEQID-00165
P51316
—
—
0
0.69
0.52
0.03
0.00
0.02
0.00
0.00
0.06
0.02
0.05
0.00
0.12
0.23
0.02

SEQID-00166
Q36967
—
1:105
0
0.65
0.46
0.08
0.04
0.02
0.00
0.00
0.03
0.03
0.02
0.02
0.12
0.26
0.00

SEQID-00167
O21402
—
—
1
0.65
0.39
0.05
0.03
0.05
0.00
0.00
0.05
0.02
0.02
0.02
0.08
0.29
0.02

SEQID-00168
Q47872
—
—
1
0.68
0.41
0.04
0.02
0.05
0.00
0.00
0.05
0.02
0.02
0.03
0.10
0.27
0.02

SEQID-00169
Q85X26
—
—
0
0.60
0.43
0.01
0.00
0.11
0.02
0.00
0.02
0.02
0.01
0.02
0.13
0.25
0.00

SEQID-00170
P14092
—
—
1
0.63
0.39
0.05
0.03
0.05
0.00
0.00
0.04
0.02
0.02
0.02
0.09
0.28
0.02

SEQID-00171
Q36964
—
1:219
1
0.65
0.40
0.06
0.04
0.04
0.00
0.00
0.04
0.02
0.03
0.02
0.09
0.25
0.01

SEQID-00172
Q70RQ2
—
—
0
0.64
0.39
0.07
0.01
0.06
0.01
0.03
0.02
0.02
0.02
0.04
0.07
0.24
0.00

SEQID-00173
P48178
—
—
1
0.64
0.37
0.05
0.04
0.04
0.00
0.00
0.05
0.02
0.03
0.02
0.09
0.23
0.01

SEQID-00174
Q36090
—
1:133
1
0.65
0.34
0.02
0.05
0.05
0.00
0.00
0.03
0.03
0.03
0.03
0.07
0.23
0.01

SEQID-00175
Q31721
—
1:58
0
0.63
0.38
0.07
0.00
0.05
0.02
0.03
0.02
0.04
0.04
0.02
0.14
0.19
0.00

SEQID-00176
Q3LTZ5
—
—
1
0.67
0.35
0.05
0.03
0.05
0.00
0.00
0.05
0.02
0.03
0.03
0.10
0.20
0.02

SEQID-00177
A4GYW9
—
13:120
1
0.66
0.41
0.01
0.00
0.07
0.01
0.02
0.01
0.01
0.05
0.01
0.11
0.21
0.01

SEQID-00178
Q31720
—
150:252
1
0.64
0.37
0.06
0.03
0.02
0.00
0.03
0.01
0.03
0.04
0.02
0.10
0.22
0.01

SEQID-00179
P27572
—
6:106
1
0.61
0.40
0.01
0.04
0.02
0.03
0.04
0.02
0.03
0.02
0.01
0.15
0.21
0.01

SEQID-00180
P11631
—
360:460
1
0.67
0.35
0.03
0.03
0.03
0.00
0.01
0.01
0.04
0.02
0.05
0.11
0.23
0.01

SEQID-00181
Q00506
—
30:130
1
0.68
0.36
0.03
0.01
0.02
0.02
0.01
0.03
0.03
0.00
0.01
0.07
0.28
0.03

SEQID-00182
P92487
—
272:373
1
0.63
0.38
0.04
0.04
0.01
0.01
0.01
0.04
0.02
0.02
0.02
0.13
0.21
0.02

SEQID-00183
B2XWJ4
—
62:163
1
0.63
0.38
0.01
0.01
0.07
0.04
0.01
0.06
0.03
0.04
0.01
0.18
0.17
0.02

SEQID-00184
P27572
—
50:150
1
0.65
0.33
0.02
0.03
0.01
0.03
0.03
0.02
0.05
0.02
0.01
0.10
0.17
0.02

SEQID-00185
P27572
—
22:122
1
0.62
0.37
0.01
0.05
0.02
0.02
0.02
0.02
0.03
0.03
0.01
0.16
0.17
0.02

SEQID-00186
P27572
—
130:236
1
0.68
0.35
0.04
0.05
0.00
0.02
0.01
0.05
0.03
0.02
0.01
0.11
0.17
0.03

SEQID-00187
Q31720
—
43:144
1
0.69
0.35
0.01
0.00
0.05
0.01
0.02
0.04
0.02
0.04
0.02
0.10
0.18
0.04

SEQID-00188
O47872
—
105:206
0
0.70
0.48
0.04
0.04
0.02
0.00
0.00
0.02
0.03
0.02
0.02
0.12
0.32
0.00

SEQID-00189
P50681
—
14:114
1
0.69
0.37
0.02
0.04
0.05
0.00
0.00
0.03
0.00
0.02
0.01
0.06
0.30
0.03

SEQID-00190
P14092
—
69:170
0
0.63
0.39
0.06
0.04
0.04
0.00
0.00
0.02
0.02
0.03
0.03
0.06
0.32
0.00

SEQID-00191
O47872
—
54:154
1
0.68
0.43
0.03
0.03
0.03
0.00
0.00
0.03
0.02
0.02
0.04
0.14
0.27
0.02

SEQID-00192
P50681
—
111:212
0
0.64
0.45
0.03
0.04
0.02
0.00
0.00
0.04
0.04
0.02
0.03
0.14
0.29
0.00

SEQID-00193
Q5ZMN0
—
44:93
0
0.53
0.36
0.01
0.08
0.12
0.02
0.00
0.00
0.09
0.02
0.02
0.06
0.26
0.07

SEQID-00194
Q5ZMN0
—
46:95
0
0.54
0.36
0.01
0.03
0.14
0.02
0.00
0.00
0.07
0.02
0.02
0.06
0.26
0.07

SEQID-00195
Q5ZMN0
—
47:96
0
0.52
0.36
0.01
0.08
0.14
0.02
0.00
0.00
0.07
0.02
0.02
0.06
0.26
0.07

SEQID-00196
Q5ZMN0
—
1:146
0
0.53
0.30
0.00
0.07
0.14
0.02
0.01
0.01
0.09
0.02
0.02
0.05
0.21
0.10

SEQID-00197
Q5ZMN0
—
1:147
0
0.52
0.30
0.00
0.07
0.10
0.06
0.01
0.01
0.09
0.02
0.02
0.05
0.21
0.10

SEQID-00198
Q5ZMN0
—
1:142
0
0.53
0.30
0.00
0.06
0.10
0.05
0.01
0.01
0.09
0.02
0.02
0.05
0.21
0.10

SEQID-00199
Q5ZMN0
—
1:149
0
0.52
0.29
0.00
0.06
0.10
0.06
0.01
0.01
0.09
0.02
0.02
0.05
0.21
0.10

SEQID-00200
Q5ZMN0
—
1:150
0
0.52
0.29
0.01
0.06
0.10
0.06
0.01
0.01
0.09
0.02
0.02
0.05
0.21
0.10

SEQID-00201
Q5ZMN0
—
1:151
0
0.52
0.29
0.01
0.06
0.10
0.07
0.01
0.01
0.09
0.02
0.02
0.05
0.20
0.10

SEQID-00202
Q5ZMN0
—
1:152
0
0.51
0.29
0.01
0.06
0.10
0.07
0.01
0.01
0.10
0.02
0.02
0.05
0.20
0.10

SEQID-00203
Q5ZMN0
—
1:153
0
0.51
0.29
0.01
0.06
0.10
0.07
0.01
0.01
0.10
0.02
0.02
0.05
0.20
0.10

SEQID-00204
Q5ZMN0
—
1:154
0
0.51
0.28
0.01
0.06
0.10
0.07
0.01
0.01
0.10
0.02
0.02
0.05
0.20
0.09

SEQID-00205
Q5ZMN0
—
1:161
0
0.49
0.27
0.01
0.06
0.09
0.08
0.01
0.01
0.11
0.02
0.02
0.04
0.19
0.09

SEQID-00206
P35580
—
117:166
0
0.56
0.24
0.03
0.10
0.02
0.02
0.02
0.10
0.10
0.00
0.02
0.00
0.16
0.14

SEQID-00207
Q9JLT0
—
127:193
1
0.54
0.22
0.01
0.07
0.01
0.01
0.00
0.11
0.20
0.01
0.03
0.01
0.15
0.15

SEQID-00208
Q61879
—
152:206
0
0.43
0.20
0.04
0.02
0.02
0.02
0.00
0.12
0.33
0.01
0.02
0.02
0.16
0.14

SEQID-00209
Q27991
—
102:206
1
0.49
0.21
0.06
0.07
0.02
0.01
0.01
0.13
0.17
0.00
0.02
0.01
0.15
0.14

SEQID-00210
Q9JLT0
—
127:226
1
0.49
0.21
0.05
0.03
0.01
0.01
0.00
0.11
0.23
0.00
0.03
0.02
0.15
0.13

SEQID-00211
Q9JLT0
—
137:231
1
0.48
0.21
0.04
0.09
0.01
0.02
0.00
0.10
0.23
0.00
0.03
0.02
0.15
0.12

SEQID-00212
Q27991
—
141:190
0
0.51
0.28
0.04
0.05
0.00
0.12
0.00
0.09
0.15
0.00
0.02
0.00
0.23
0.17

SEQID-00213
Q27991
—
136:185
0
0.51
0.28
0.04
0.05
0.02
0.08
0.00
0.07
0.18
0.01
0.00
0.02
0.21
0.18

SEQID-00214
Q27991
—
116:185
0
0.51
0.27
0.04
0.04
0.01
0.11
0.00
0.11
0.13
0.01
0.00
0.01
0.21
0.17

SEQID-00215
Q27991
—
146:200
0
0.51
0.29
0.02
0.07
0.02
0.11
0.00
0.10
0.12
0.00
0.02
0.02
0.21
0.18

SEQID-00216
Q27991
—
146:210
0
0.52
0.27
0.03
0.06
0.01
0.10
0.00
0.12
0.12
0.00
0.02
0.01
0.20
0.18

SEQID-00217
Q27991
—
131:185
0
0.50
0.29
0.03
0.05
0.02
0.13
0.00
0.06
0.16
0.01
0.00
0.02
0.21
0.16

SEQID-00218
Q27991
—
136:190
0
0.50
0.27
0.03
0.05
0.02
0.11
0.00
0.08
0.16
0.01
0.02
0.02
0.21
0.16

SEQID-00219
Q27991
—
146:195
0
0.50
0.30
0.02
0.08
0.00
0.12
0.00
0.11
0.11
0.00
0.02
0.02
0.21
0.15

SEQID-00220
Q27991
—
126:190
0
0.52
0.26
0.03
0.04
0.02
0.15
0.00
0.07
0.14
0.01
0.02
0.01
0.19
0.19

SEQID-00221
Q27991
—
141:200
0
0.51
0.28
0.03
0.07
0.02
0.10
0.00
0.09
0.15
0.00
0.02
0.02
0.21
0.18

SEQID-00222
Q27991
—
31:80
0
0.41
0.20
0.06
0.03
0.06
0.06
0.00
0.11
0.21
0.02
0.00
0.02
0.16
0.14

SEQID-00223
Q27991
—
161:210
0
0.50
0.24
0.04
0.05
0.02
0.12
0.00
0.13
0.11
0.00
0.02
0.02
0.19
0.17

SEQID-00224
Q27991
—
126:185
0
0.53
0.27
0.03
0.04
0.02
0.13
0.00
0.06
0.15
0.01
0.00
0.02
0.19
0.20

SEQID-00225
Q27991
—
111:210
0
0.50
0.26
0.04
0.05
0.02
0.11
0.00
0.12
0.12
0.00
0.01
0.02
0.19
0.18

SEQID-00226
Q27991
—
116:215
0
0.50
0.26
0.04
0.04
0.03
0.11
0.00
0.12
0.12
0.00
0.01
0.03
0.18
0.18

SEQID-00227
Q27991
—
126:225
0
0.46
0.22
0.04
0.03
0.03
0.12
0.00
0.08
0.14
0.00
0.01
0.03
0.15
0.17

SEQID-00228
Q27991
—
126:237
0
0.45
0.21
0.05
0.03
0.03
0.11
0.00
0.07
0.17
0.00
0.01
0.03
0.15
0.18

SEQID-00229
Q9JLT0
—
124:174
0
0.40
0.22
0.04
0.13
0.06
0.06
0.00
0.06
0.21
0.01
0.00
0.02
0.19
0.06

SEQID-00230
Q9JLT0
—
194:244
0
0.45
0.20
0.11
0.03
0.04
0.00
0.00
0.11
0.21
0.02
0.00
0.04
0.14
0.20

SEQID-00231
Q27991
—
139:227
0
0.41
0.20
0.03
0.08
0.06
0.03
0.00
0.11
0.18
0.01
0.00
0.03
0.15
0.11

SEQID-00232
Q61879
—
154:252
0
0.41
0.19
0.09
0.11
0.05
0.03
0.00
0.10
0.16
0.01
0.00
0.02
0.14
0.15

SEQID-00233
P15989
—
99:308
0
0.52
0.37
0.07
0.05
0.04
0.07
0.00
0.04
0.08
0.04
0.00
0.13
0.17
0.03

SEQID-00234
P15989
—
99:203
0
0.51
0.37
0.07
0.06
0.04
0.07
0.00
0.05
0.08
0.04
0.00
0.13
0.16
0.03

SEQID-00235
P15989
—
49:166
0
0.44
0.28
0.10
0.06
0.04
0.06
0.00
0.05
0.09
0.05
0.00
0.07
0.15
0.04

SEQID-00236
Q90339
—
201:265
0
0.45
0.21
0.06
0.06
0.02
0.11
0.00
0.12
0.16
0.02
0.02
0.00
0.18
0.15

SEQID-00237
Q9BE41
—
216:265
0
0.48
0.21
0.04
0.08
0.02
0.10
0.00
0.07
0.18
0.02
0.00
0.00
0.18
0.20

SEQID-00238
Q8MJV0
—
146:200
0
0.56
0.21
0.05
0.00
0.04
0.09
0.02
0.00
0.23
0.01
0.02
0.04
0.14
0.22

SEQID-00239
Q9TV62
—
241:290
0
0.48
0.17
0.02
0.08
0.02
0.09
0.00
0.08
0.19
0.01
0.00
0.02
0.15
0.21

SEQID-00240
Q5SX39
—
236:285
0
0.45
0.19
0.02
0.08
0.02
0.12
0.00
0.09
0.17
0.02
0.00
0.02
0.17
0.20

SEQID-00241
Q9TV61
—
151:265
0
0.52
0.21
0.05
0.04
0.03
0.10
0.00
0.07
0.18
0.01
0.02
0.02
0.16
0.19

SEQID-00242
Q79102
—
55:104
0
0.75
0.53
0.04
0.03
0.00
0.02
0.00
0.04
0.02
0.01
0.00
0.08
0.42
0.00

SEQID-00243
Q3ZBI9
—
192:241
0
0.66
0.47
0.04
0.03
0.00
0.00
0.02
0.05
0.02
0.04
0.00
0.02
0.43
0.00

SEQID-00244
P18937
—
119:170
0
0.71
0.46
0.03
0.00
0.02
0.00
0.00
0.05
0.00
0.04
0.00
0.08
0.37
0.02

SEQID-00245
P18937
—
106:157
1
0.73
0.43
0.01
0.00
0.02
0.00
0.00
0.04
0.02
0.02
0.02
0.04
0.36
0.02

SEQID-00246
Q90592
—
200:250
0
0.69
0.51
0.04
0.00
0.02
0.04
0.00
0.07
0.02
0.06
0.03
0.06
0.39
0.00

SEQID-00247
Q90592
—
152:250
1
0.61
0.43
0.06
0.03
0.01
0.02
0.01
0.04
0.03
0.07
0.03
0.08
0.30
0.01

SEQID-00248
O47868
—
56:109
0
0.69
0.43
0.09
0.00
0.02
0.02
0.00
0.00
0.02
0.01
0.00
0.04
0.39
0.04

SEQID-00249
O47868
—
11:109
1
0.65
0.40
0.07
0.03
0.02
0.02
0.00
0.02
0.02
0.03
0.01
0.07
0.31
0.05

SEQID-00250
A1L504
—
57:107
0
0.65
0.44
0.05
0.03
0.00
0.02
0.00
0.05
0.07
0.04
0.05
0.00
0.40
0.00

SEQID-00251
A1L504
—
260:327
1
0.63
0.37
0.06
0.06
0.05
0.03
0.00
0.02
0.02
0.02
0.02
0.03
0.30
0.05

SEQID-00252
Q32LM8
—
203:253
0
0.63
0.44
0.04
0.11
0.00
0.06
0.00
0.07
0.00
0.03
0.07
0.00
0.39
0.02

SEQID-00253
Q767L9
—
139:230
1
0.66
0.44
0.03
0.06
0.00
0.02
0.02
0.01
0.04
0.03
0.05
0.03
0.31
0.02

SEQID-00254
Q32LM8
—
150:230
1
0.63
0.43
0.03
0.07
0.00
0.03
0.01
0.01
0.04
0.03
0.04
0.02
0.32
0.03

SEQID-00255
Q6F4F5
—
6:55
0
0.70
0.45
0.05
0.03
0.02
0.00
0.00
0.00
0.02
0.03
0.05
0.02
0.38
0.05

SEQID-00256
Q6F4F5
—
1:52
1
0.70
0.46
0.05
0.03
0.02
0.00
0.00
0.00
0.05
0.05
0.02
0.02
0.37
0.05

SEQID-00257
Q35920
—
58:111
1
0.73
0.41
0.02
0.00
0.06
0.00
0.00
0.02
0.00
0.04
0.02
0.02
0.36
0.02

SEQID-00258
P49208
—
1:50
1
0.69
0.39
0.00
0.18
0.02
0.00
0.00
0.02
0.00
0.01
0.05
0.02
0.34
0.08

SEQID-00259
P00729
—
2:52
0
0.60
0.35
0.07
0.03
0.00
0.11
0.02
0.05
0.02
0.04
0.03
0.02
0.31
0.12

SEQID-00260
Q58CT4
—
337:386
0
0.69
0.43
0.03
0.03
0.02
0.04
0.04
0.00
0.02
0.05
0.03
0.02
0.34
0.05

SEQID-00261
Q06639
—
422:473
0
0.64
0.43
0.00
0.03
0.10
0.04
0.02
0.02
0.04
0.01
0.02
0.06
0.34
0.02

SEQID-00262
Q9UKT8
—
15:69
0
0.61
0.37
0.01
0.05
0.05
0.05
0.00
0.04
0.06
0.01
0.04
0.02
0.32
0.06

SEQID-00263
A1A4P6
—
17:68
0
0.64
0.41
0.02
0.00
0.00
0.02
0.03
0.04
0.00
0.02
0.02
0.02
0.34
0.02

SEQID-00264
Q9TV61
—
102:344
0
0.44
0.19
0.06
0.06
0.02
0.08
0.01
0.08
0.21
0.01
0.01
0.04
0.12
0.17

SEQID-00265
Q27991
—
20:289
0
0.38
0.20
0.06
0.10
0.03
0.07
0.00
0.09
0.20
0.01
0.01
0.02
0.15
0.13

SEQID-00266
—
—
—
0
0.52
0.26
0.03
0.04
0.01
0.15
0.00
0.07
0.14
0.01
0.02
0.01
0.22
0.18

SEQID-00267
—
—
—
0
0.52
0.26
0.03
0.04
0.01
0.15
0.00
0.07
0.14
0.01
0.02
0.00
0.25
0.18

SEQID-00268
—
—
—
0
0.52
0.28
0.03
0.04
0.01
0.15
0.00
0.07
0.14
0.01
0.02
0.00
0.28
0.17

SEQID-00269
—
—
—
0
0.53
0.31
0.02
0.04
0.01
0.15
0.00
0.07
0.13
0.01
0.02
0.00
0.31
0.17

SEQID-00270
—
—
—
0
0.56
0.33
0.00
0.04
0.01
0.15
0.00
0.07
0.13
0.01
0.02
0.00
0.33
0.16

SEQID-00271
—
—
—
0
0.57
0.36
0.00
0.04
0.00
0.15
0.00
0.07
0.13
0.01
0.02
0.00
0.36
0.16

SEQID-00272
—
—
—
0
0.53
0.28
0.02
0.04
0.01
0.15
0.00
0.07
0.13
0.01
0.02
0.00
0.28
0.18

SEQID-00273
—
—
—
0
0.56
0.31
0.01
0.04
0.00
0.15
0.00
0.07
0.13
0.01
0.02
0.00
0.31
0.18

SEQID-00274
—
—
—
0
0.57
0.33
0.01
0.04
0.00
0.15
0.00
0.07
0.13
0.00
0.02
0.00
0.33
0.18

SEQID-00275
—
—
—
0
0.58
0.36
0.00
0.04
0.00
0.15
0.00
0.07
0.13
0.00
0.02
0.00
0.36
0.16

SEQID-00276
—
—
—
0
0.60
0.36
0.01
0.04
0.00
0.15
0.00
0.07
0.13
0.00
0.02
0.00
0.36
0.18

SEQID-00277
Q1WLP9
—
170:263
1
0.67
0.33
0.06
0.02
0.01
0.00
0.04
0.01
0.05
0.01
0.04
0.08
0.14
0.11

SEQID-00278
A3DBX3
—
—
1
0.43
0.15
0.02
0.06
0.07
0.07
0.00
0.02
0.05
0.05
0.01
0.04
0.05
0.07

SEQID-00279
—
—
—
0
0.57
0.35
0.00
0.04
0.00
0.15
0.00
0.07
0.13
0.01
0.02
0.00
0.35
0.16

SEQID-00280
—
—
—
0
0.57
0.35
0.01
0.04
0.00
0.15
0.00
0.07
0.13
0.00
0.02
0.00
0.35
0.18

SEQID-00281
P05804
—
—
1
0.46
0.19
0.05
0.07
0.05
0.07
0.01
0.06
0.08
0.04
0.04
0.05
0.07
0.05

SEQID-00282
O60167
—
51:75
1
0.75
0.32
0.00
0.05
0.00
0.00
0.03
0.04
0.08
0.00
0.04
0.07
0.15
0.13

SEQID-00283
Q0WVK7
—
53:105
1
0.57
0.27
0.01
0.14
0.02
0.05
0.03
0.02
0.06
0.00
0.04
0.07
0.12
0.12

SEQID-00284
Q94A52
—
149:261
1
0.54
0.26
0.02
0.10
0.00
0.06
0.02
0.03
0.11
0.02
0.03
0.06
0.12
0.10

SEQID-00285
Q5F479
—
556:615
1
0.64
0.28
0.03
0.13
0.00
0.02
0.01
0.02
0.11
0.00
0.06
0.06
0.14
0.11

SEQID-00286
Q08213
—
177:230
1
0.65
0.31
0.00
0.05
0.04
0.04
0.03
0.04
0.06
0.02
0.04
0.07
0.14
0.12

SEQID-00287
P38111
—
1093:1165
1
0.59
0.30
0.02
0.04
0.05
0.10
0.04
0.02
0.06
0.01
0.03
0.08
0.13
0.11

SEQID-00288
O93262
—
—
1
0.55
0.27
0.02
0.06
0.02
0.06
0.03
0.06
0.07
0.01
0.03
0.06
0.13
0.09

SEQID-00289
O64837
—
—
1
0.61
0.26
0.02
0.06
0.02
0.03
0.01
0.01
0.10
0.03
0.03
0.06
0.12
0.09

SEQID-00290
Q54K39
—
—
1
0.53
0.28
0.03
0.05
0.03
0.04
0.01
0.02
0.09
0.05
0.03
0.09
0.11
0.09

SEQID-00291
P38111
—
1093:1182
1
0.57
0.27
0.03
0.03
0.06
0.08
0.03
0.04
0.06
0.01
0.03
0.07
0.13
0.10

SEQID-00292
P38111
—
1093:1162
1
0.57
0.27
0.02
0.04
0.06
0.10
0.04
0.02
0.06
0.01
0.03
0.07
0.13
0.11

SEQID-00293
P38111
—
1092:1166
1
0.59
0.29
0.02
0.04
0.05
0.09
0.04
0.01
0.06
0.01
0.03
0.08
0.13
0.10

SEQID-00294
P33111
—
1093:1168
1
0.58
0.29
0.02
0.04
0.05
0.09
0.04
0.01
0.06
0.01
0.03
0.08
0.13
0.10

SEQID-00295
P38111
—
1091:1164
1
0.59
0.30
0.02
0.04
0.05
0.09
0.04
0.02
0.06
0.01
0.03
0.09
0.13
0.11

SEQID-00296
P38111
—
1089:1164
1
0.58
0.29
0.02
0.04
0.05
0.11
0.04
0.01
0.06
0.01
0.03
0.09
0.13
0.10

SEQID-00297
P02190
—
—
1
0.58
0.20
0.07
0.02
0.03
0.05
0.00
0.04
0.10
0.05
0.10
0.04
0.11
0.14

SEQID-00298
P02192
—
—
1
0.59
0.20
0.07
0.02
0.03
0.05
0.00
0.03
0.10
0.04
0.10
0.04
0.11
0.14

SEQID-00299
P02189
—
—
1
0.56
0.21
0.06
0.02
0.02
0.05
0.00
0.05
0.11
0.05
0.07
0.04
0.12
0.14

SEQID-00300
F1RJW7
—
—
1
0.45
0.21
0.04
0.03
0.03
0.14
0.00
0.02
0.15
0.02
0.02
0.05
0.10
0.07

SEQID-00301
Q05JF3
—
—
1
0.44
0.21
0.05
0.03
0.04
0.12
0.00
0.02
0.16
0.02
0.02
0.04
0.10
0.07

SEQID-00302
406710553
—
—
1
0.49
0.26
0.08
0.04
0.02
0.07
0.01
0.04
0.09
0.05
0.02
0.05
0.12
0.09

SEQID-00303
406715845
—
—
1
0.46
0.23
0.05
0.07
0.03
0.07
0.01
0.05
0.08
0.04
0.02
0.09
0.08
0.06

SEQID-00304
406711970
—
—
1
0.44
0.23
0.02
0.09
0.03
0.09
0.01
0.04
0.08
0.04
0.04
0.07
0.09
0.06

SEQID-00305
A6QLL8
—
—
1
0.44
0.21
0.03
0.06
0.04
0.04
0.02
0.05
0.03
0.04
0.03
0.06
0.10
0.09

SEQID-00306
B7TJ13
—
—
1
0.52
0.23
0.06
0.04
0.05
0.06
0.02
0.02
0.07
0.05
0.02
0.05
0.10
0.12

SEQID-00307
P39824
—
—
1
0.51
0.22
0.07
0.06
0.06
0.07
0.01
0.02
0.05
0.03
0.02
0.08
0.09
0.11

SEQID-00308
P25152
—
—
1
0.43
0.21
0.07
0.04
0.04
0.05
0.00
0.04
0.09
0.04
0.03
0.06
0.09
0.11

SEQID-00309
O32150
—
—
1
0.40
0.16
0.05
0.07
0.07
0.09
0.00
0.02
0.07
0.04
0.04
0.03
0.06
0.06

SEQID-00310
Q9K6A3
—
—
1
0.39
0.14
0.05
0.14
0.04
0.05
0.03
0.05
0.09
0.05
0.02
0.03
0.06
0.02

SEQID-00311
P42249
—
—
1
0.38
0.14
0.07
0.15
0.05
0.03
0.03
0.06
0.06
0.03
0.02
0.03
0.06
0.03

SEQID-00312
D3FTP5
—
—
1
0.47
0.23
0.03
0.05
0.04
0.04
0.00
0.06
0.13
0.04
0.04
0.06
0.10
0.05

SEQID-00313
P39844
—
—
1
0.49
0.23
0.05
0.04
0.04
0.07
0.00
0.03
0.07
0.05
0.02
0.05
0.11
0.10

SEQID-00314
P38422
—
—
1
0.55
0.18
0.06
0.04
0.04
0.04
0.00
0.02
0.10
0.04
0.01
0.05
0.09
0.16

SEQID-00315
P96600
—
—
1
0.49
0.20
0.04
0.03
0.06
0.06
0.00
0.06
0.10
0.03
0.02
0.07
0.10
0.10

SEQID-00316
P39597
—
—
1
0.47
0.16
0.05
0.05
0.04
0.07
0.01
0.07
0.06
0.05
0.02
0.04
0.09
0.11

SEQID-00317
Q9K6W0
—
—
1
0.41
0.20
0.05
0.09
0.07
0.06
0.00
0.07
0.08
0.03
0.01
0.07
0.08
0.04

SEQID-00318
O05512
—
—
1
0.47
0.19
0.05
0.04
0.07
0.06
0.01
0.04
0.05
0.03
0.03
0.06
0.09
0.07

SEQID-00319
E6TXL6
—
—
1
0.48
0.21
0.04
0.05
0.06
0.06
0.01
0.05
0.07
0.03
0.04
0.06
0.08
0.06

SEQID-00320
Q9K742
—
—
1
0.42
0.18
0.03
0.14
0.04
0.06
0.00
0.02
0.13
0.03
0.03
0.06
0.08
0.07

SEQID-00321
P37548
—
—
1
0.49
0.22
0.04
0.08
0.03
0.06
0.01
0.05
0.07
0.03
0.05
0.07
0.08
0.10

SEQID-00322
O31526
—
—
1
0.43
0.18
0.06
0.07
0.06
0.09
0.00
0.04
0.04
0.06
0.02
0.04
0.08
0.07

SEQID-00323
O07544
—
—
1
0.46
0.20
0.03
0.07
0.02
0.05
0.02
0.06
0.06
0.03
0.03
0.07
0.09
0.10

SEQID-00324
O32123
—
—
1
0.44
0.16
0.03
0.07
0.02
0.04
0.01
0.08
0.10
0.02
0.04
0.04
0.09
0.06

SEQID-00325
P46784
—
—
1
0.42
0.18
0.02
0.07
0.04
0.02
0.00
0.10
0.10
0.02
0.03
0.04
0.08
0.09

SEQID-00326
406713168
—
—
1
0.44
0.19
0.03
0.08
0.02
0.03
0.02
0.09
0.10
0.02
0.02
0.04
0.10
0.05

SEQID-00327
C3AUB3
—
—
1
0.53
0.25
0.04
0.04
0.05
0.07
0.00
0.02
0.08
0.03
0.02
0.09
0.10
0.12

SEQID-00328
291571454
—
—
1
0.45
0.17
0.08
0.20
0.06
0.04
0.00
0.06
0.03
0.02
0.01
0.06
0.07
0.14

SEQID-00329
O82579
—
—
1
0.47
0.22
0.02
0.20
0.03
0.04
0.01
0.03
0.05
0.02
0.04
0.05
0.06
0.12

SEQID-00330
P0CX55
—
—
1
0.49
0.22
0.03
0.15
0.06
0.05
0.01
0.06
0.05
0.03
0.06
0.07
0.10
0.08

SEQID-00331
P00648
—
—
1
0.51
0.19
0.06
0.06
0.04
0.06
0.01
0.03
0.04
0.04
0.03
0.06
0.08
0.10

SEQID-00332
291572097
—
—
1
0.45
0.22
0.06
0.09
0.03
0.09
0.00
0.05
0.07
0.03
0.03
0.05
0.13
0.04

SEQID-00333
C3B4Y1
—
—
1
0.52
0.23
0.02
0.05
0.06
0.04
0.01
0.04
0.05
0.02
0.03
0.07
0.11
0.10

SEQID-00334
C6TFG0
—
—
1
0.42
0.21
0.04
0.18
0.04
0.05
0.00
0.04
0.03
0.03
0.05
0.03
0.11
0.03

SEQID-00335
291571495
—
—
1
0.38
0.22
0.05
0.19
0.05
0.02
0.00
0.05
0.07
0.04
0.02
0.03
0.11
0.05

SEQID-00336
B4FL64
—
—
1
0.46
0.15
0.06
0.19
0.02
0.02
0.00
0.03
0.07
0.02
0.03
0.04
0.07
0.18

SEQID-00337
I1K8X7
—
—
1
0.46
0.19
0.05
0.06
0.05
0.07
0.02
0.07
0.07
0.03
0.04
0.04
0.08
0.09

SEQID-00338
P07170
—
—
1
0.47
0.21
0.06
0.06
0.04
0.09
0.00
0.06
0.06
0.04
0.03
0.07
0.10
0.10

SEQID-00339
F0TI61
—
—
1
0.47
0.21
0.04
0.06
0.06
0.09
0.00
0.03
0.09
0.03
0.05
0.06
0.11
0.09

SEQID-00340
406715507
—
—
1
0.41
0.23
0.06
0.15
0.03
0.06
0.00
0.03
0.07
0.04
0.02
0.10
0.07
0.06

SEQID-00341
P29311
—
—
1
0.39
0.18
0.06
0.06
0.03
0.05
0.01
0.08
0.13
0.02
0.03
0.05
0.09
0.07

SEQID-00342
P33673
—
—
1
0.47
0.15
0.06
0.06
0.07
0.07
0.01
0.04
0.05
0.04
0.01
0.04
0.08
0.10

SEQID-00343
I1LLC0
—
—
1
0.46
0.22
0.05
0.10
0.04
0.07
0.01
0.03
0.10
0.02
0.05
0.06
0.09
0.10

SEQID-00344
291571381
—
—
1
0.39
0.22
0.07
0.11
0.05
0.04
0.00
0.08
0.06
0.04
0.03
0.06
0.09
0.04

SEQID-00345
291567248
—
—
1
0.42
0.21
0.05
0.07
0.06
0.06
0.02
0.08
0.07
0.04
0.02
0.05
0.10
0.06

SEQID-00346
291569666
—
—
1
0.45
0.21
0.07
0.07
0.03
0.05
0.01
0.05
0.10
0.05
0.03
0.06
0.09
0.07

SEQID-00347
H8XE54
—
—
1
0.48
0.18
0.09
0.03
0.03
0.08
0.00
0.04
0.07
0.03
0.02
0.03
0.09
0.13

SEQID-00348
B5DG39
—
—
1
0.59
0.29
0.03
0.03
0.03
0.05
0.01
0.02
0.07
0.05
0.06
0.05
0.11
0.10

SEQID-00349
291567247
—
—
1
0.45
0.21
0.03
0.09
0.04
0.07
0.01
0.04
0.08
0.03
0.05
0.05
0.10
0.05

SEQID-00350
P28675
—
—
1
0.49
0.27
0.03
0.06
0.09
0.04
0.02
0.04
0.07
0.03
0.03
0.07
0.14
0.08

SEQID-00351
I1MJC7
—
—
1
0.52
0.27
0.06
0.04
0.03
0.07
0.00
0.02
0.08
0.06
0.01
0.05
0.13
0.11

SEQID-00352
B4G0K4
—
—
1
0.54
0.26
0.03
0.03
0.02
0.07
0.00
0.01
0.09
0.05
0.01
0.05
0.12
0.12

SEQID-00353
P45741
—
—
1
0.43
0.23
0.06
0.05
0.03
0.08
0.00
0.07
0.05
0.03
0.02
0.05
0.12
0.06

SEQID-00354
B7TJ13
—
—
1
0.52
0.23
0.06
0.04
0.05
0.06
0.02
0.02
0.07
0.05
0.02
0.05
0.10
0.12

SEQID-00355
P50448
—
—
1
0.51
0.24
0.04
0.06
0.03
0.06
0.01
0.06
0.06
0.03
0.03
0.05
0.14
0.06

SEQID-00356
I1MBR7
—
—
1
0.50
0.27
0.04
0.03
0.07
0.06
0.00
0.03
0.09
0.04
0.02
0.07
0.12
0.09

SEQID-00357
291570796
—
—
1
0.48
0.28
0.05
0.05
0.05
0.05
0.01
0.06
0.09
0.04
0.02
0.10
0.11
0.07

SEQID-00358
291569660
—
—
1
0.47
0.18
0.05
0.09
0.03
0.06
0.02
0.03
0.08
0.05
0.04
0.05
0.08
0.06

SEQID-00359
291566695
—
—
1
0.42
0.23
0.06
0.14
0.03
0.07
0.00
0.07
0.07
0.03
0.03
0.07
0.11
0.04

SEQID-00360
Q42795
—
—
1
0.45
0.21
0.04
0.05
0.06
0.07
0.01
0.05
0.07
0.04
0.03
0.05
0.09
0.07

SEQID-00361
C5IWV2
—
—
1
0.44
0.20
0.04
0.10
0.04
0.05
0.01
0.07
0.09
0.03
0.03
0.05
0.06
0.07

SEQID-00362
P11412
—
—
1
0.47
0.21
0.04
0.07
0.04
0.07
0.00
0.03
0.09
0.03
0.02
0.05
0.09
0.10

SEQID-00363
P69328
—
25:640
1
0.42
0.17
0.07
0.04
0.04
0.08
0.01
0.03
0.05
0.04
0.01
0.04
0.07
0.02

SEQID-00364
F1NXK1
—
1220:1292
0
0.33
0.07
0.02
0.05
0.00
0.06
0.00
0.00
0.35
0.02
0.03
0.04
0.00
0.12

SEQID-00365
P02702
—
81:162
1
0.44
0.10
0.01
0.11
0.06
0.05
0.03
0.04
0.08
0.02
0.04
0.02
0.05
0.08

SEQID-00366
P38158
—
118:186
0
0.48
0.07
0.03
0.09
0.07
0.06
0.00
0.02
0.06
0.03
0.00
0.01
0.04
0.09

SEQID-00367
Q12329
—
69:133
0
0.11
0.01
0.02
0.09
0.07
0.12
0.01
0.09
0.12
0.05
0.02
0.00
0.00
0.00

SEQID-00368
I3LP30
—
84:159
1
0.51
0.29
0.01
0.12
0.06
0.04
0.01
0.01
0.17
0.00
0.01
0.10
0.17
0.07

SEQID-00369
F1MZX6
—
1169:1337
0
0.48
0.23
0.06
0.04
0.03
0.03
0.00
0.20
0.12
0.01
0.05
0.03
0.17
0.11

SEQID-00370
I3KZL6
—
1621:1693
0
0.37
0.23
0.03
0.07
0.08
0.07
0.00
0.17
0.14
0.01
0.02
0.04
0.16
0.06

SEQID-00371
K7TNK3
—
1070:1154
1
0.36
0.18
0.05
0.08
0.01
0.04
0.00
0.16
0.24
0.01
0.05
0.03
0.12
0.05

SEQID-00372
291570621
—
821:890
1
0.40
0.21
0.03
0.13
0.03
0.05
0.00
0.12
0.11
0.03
0.02
0.07
0.11
0.05

SEQID-00373
291572019
—
775:851
1
0.37
0.21
0.02
0.12
0.01
0.06
0.01
0.11
0.10
0.01
0.02
0.09
0.09
0.04

SEQID-00374
P38427
—
534:617
1
0.44
0.21
0.02
0.17
0.02
0.06
0.01
0.10
0.05
0.02
0.03
0.04
0.09
0.05

SEQID-00375
A6QP89
—
288:356
0
0.45
0.21
0.04
0.19
0.01
0.06
0.00
0.03
0.06
0.03
0.00
0.06
0.08
0.13

SEQID-00376
I1JDH6
—
29:142
1
0.48
0.25
0.03
0.17
0.02
0.03
0.01
0.05
0.09
0.05
0.03
0.08
0.08
0.10

SEQID-00377
406710335
—
6:235
0
0.37
0.17
0.04
0.03
0.02
0.03
0.01
0.25
0.19
0.01
0.02
0.02
0.11
0.06

SEQID-00378
I3JTN2
—
3518:3693
1
0.38
0.17
0.05
0.02
0.07
0.06
0.01
0.16
0.14
0.02
0.02
0.04
0.09
0.10

SEQID-00379
F1NPH8
—
520:646
1
0.39
0.20
0.05
0.03
0.02
0.02
0.02
0.25
0.15
0.00
0.04
0.01
0.14
0.08

SEQID-00380
F1NPH8
—
673:746
1
0.43
0.25
0.04
0.11
0.04
0.03
0.02
0.06
0.20
0.01
0.02
0.03
0.20
0.07

SEQID-00381
G3MYN5
—
12:124
1
0.46
0.25
0.06
0.15
0.01
0.06
0.02
0.03
0.13
0.01
0.03
0.03
0.18
0.12

SEQID-00382
G3MYN5
—
88:158
1
0.50
0.23
0.03
0.19
0.01
0.08
0.00
0.00
0.03
0.02
0.02
0.01
0.14
0.17

SEQID-00383
C6TFG0
—
19:88
0
0.36
0.22
0.03
0.24
0.05
0.03
0.01
0.01
0.12
0.03
0.00
0.03
0.17
0.06

SEQID-00384
C6TFG0
—
42:140
1
0.46
0.25
0.04
0.21
0.06
0.03
0.00
0.04
0.03
0.02
0.03
0.05
0.15
0.05

SEQID-00385
P0C0X0
—
—
0
0.47
0.27
0.02
0.21
0.03
0.05
0.00
0.02
0.10
0.04
0.00
0.04
0.09
0.07

SEQID-00386
291568762
—
—
0
0.39
0.26
0.03
0.08
0.03
0.06
0.00
0.10
0.08
0.02
0.00
0.07
0.12
0.05

SEQID-00387
B4FKR5
—
—
1
0.49
0.25
0.05
0.07
0.02
0.08
0.02
0.04
0.08
0.05
0.01
0.06
0.08
0.13

SEQID-00388
B4FKR5
—
1:169
1
0.49
0.25
0.05
0.07
0.02
0.08
0.02
0.04
0.08
0.05
0.01
0.06
0.08
0.13

SEQID-00389
291567798
—
—
0
0.44
0.26
0.04
0.13
0.05
0.02
0.01
0.05
0.08
0.06
0.01
0.06
0.08
0.11

SEQID-00390
P39824
—
37:306
1
0.43
0.22
0.07
0.06
0.07
0.08
0.00
0.05
0.06
0.03
0.01
0.08
0.09
0.11

SEQID-00391
P39844
—
30:491
1
0.46
0.22
0.05
0.04
0.04
0.08
0.00
0.03
0.08
0.05
0.02
0.05
0.11
0.10

SEQID-00392
P96600
—
19:350
1
0.48
0.20
0.03
0.03
0.06
0.07
0.00
0.07
0.10
0.03
0.03
0.06
0.09
0.10

SEQID-00393
P39597
—
29:416
1
0.47
0.17
0.05
0.05
0.05
0.07
0.01
0.07
0.06
0.05
0.02
0.04
0.09
0.11

SEQID-00394
O05512
—
27:362
1
0.45
0.17
0.05
0.04
0.07
0.07
0.01
0.05
0.05
0.04
0.03
0.06
0.08
0.06

SEQID-00395
P45741
—
31:409
1
0.41
0.22
0.06
0.06
0.03
0.08
0.00
0.07
0.06
0.03
0.02
0.05
0.11
0.05

SEQID-00396
P25959
—
29:124
1
0.45
0.21
0.01
0.10
0.03
0.03
0.01
0.10
0.12
0.03
0.02
0.07
0.10
0.09

SEQID-00397
P54450
—
45:250
1
0.50
0.18
0.03
0.04
0.08
0.06
0.01
0.03
0.05
0.04
0.04
0.06
0.08
0.13

SEQID-00398
P37965
—
27:293
1
0.52
0.21
0.04
0.04
0.04
0.06
0.00
0.05
0.07
0.03
0.05
0.04
0.11
0.11

SEQID-00399
O34966
—
31:319
1
0.49
0.19
0.05
0.00
0.03
0.08
0.00
0.05
0.12
0.02
0.05
0.05
0.08
0.13

SEQID-00400
P54427
—
24:267
1
0.52
0.19
0.03
0.07
0.04
0.08
0.00
0.05
0.08
0.03
0.03
0.05
0.08
0.10

SEQID-00401
P39632
—
31:154
1
0.51
0.25
0.04
0.07
0.04
0.07
0.00
0.04
0.07
0.04
0.01
0.06
0.11
0.07

SEQID-00402
O34348
—
29:315
1
0.50
0.22
0.04
0.05
0.06
0.09
0.00
0.02
0.09
0.03
0.03
0.07
0.08
0.14

SEQID-00403
P25152
—
25:455
1
0.46
0.20
0.07
0.04
0.04
0.05
0.00
0.04
0.10
0.04
0.03
0.07
0.08
0.11

SEQID-00404
P71014
—
29:181
1
0.49
0.18
0.06
0.06
0.08
0.03
0.01
0.02
0.06
0.03
0.01
0.03
0.12
0.08

SEQID-00405
P94522
—
33:323
1
0.43
0.17
0.04
0.03
0.08
0.06
0.01
0.03
0.03
0.06
0.01
0.06
0.09
0.07

SEQID-00406
P54507
—
28:261
1
0.48
0.17
0.05
0.00
0.09
0.10
0.00
0.05
0.07
0.04
0.01
0.04
0.08
0.15

SEQID-00407
P00691
—
34:659
1
0.42
0.16
0.05
0.05
0.09
0.08
0.00
0.05
0.04
0.04
0.03
0.06
0.06
0.06

SEQID-00408
A2QLC7
—
19:265
1
0.41
0.19
0.06
0.08
0.07
0.07
0.00
0.04
0.08
0.03
0.04
0.06
0.09
0.02

SEQID-00409
A2QEJ9
—
17:443
1
0.44
0.16
0.05
0.05
0.07
0.08
0.02
0.02
0.05
0.04
0.02
0.05
0.08
0.06

SEQID-00410
A2QXG2
—
21:338
1
0.49
0.25
0.05
0.04
0.06
0.06
0.00
0.05
0.06
0.03
0.02
0.08
0.12
0.04

SEQID-00411
A2QUK3
—
20:392
1
0.42
0.19
0.04
0.11
0.05
0.09
0.01
0.03
0.06
0.05
0.03
0.05
0.06
0.04

SEQID-00412
A2QAC1
—
15:865
1
0.43
0.19
0.04
0.06
0.05
0.08
0.01
0.04
0.05
0.04
0.03
0.04
0.08
0.04

SEQID-00413
A2QJI1
—
18:375
1
0.44
0.18
0.05
0.04
0.08
0.08
0.02
0.04
0.04
0.03
0.02
0.03
0.10
0.04

SEQID-00414
A2QAN3
—
19:1007
1
0.44
0.20
0.04
0.04
0.06
0.06
0.00
0.03
0.06
0.05
0.02
0.05
0.10
0.05

SEQID-00415
A2QWU9
—
21:931
1
0.45
0.20
0.04
0.06
0.05
0.07
0.00
0.05
0.05
0.04
0.03
0.05
0.09
0.04

SEQID-00416
A2QE24
—
24:403
1
0.45
0.22
0.04
0.04
0.07
0.08
0.01
0.07
0.05
0.05
0.02
0.08
0.07
0.04

SEQID-00417
A2QFV7
—
20:327
1
0.47
0.20
0.07
0.03
0.06
0.07
0.01
0.03
0.05
0.04
0.03
0.08
0.07
0.08

SEQID-00418
A2RAR6
—
23:416
1
0.43
0.16
0.06
0.05
0.04
0.03
0.01
0.07
0.04
0.05
0.03
0.03
0.07
0.04

SEQID-00419
B0YIR9
—
20:860
1
0.39
0.18
0.06
0.06
0.07
0.07
0.01
0.04
0.07
0.06
0.01
0.04
0.08
0.04

SEQID-00420
A2QCV8
—
19:362
1
0.49
0.19
0.04
0.02
0.06
0.08
0.03
0.03
0.04
0.07
0.02
0.08
0.05
0.10

SEQID-00421
P56526
—
20.985
1
0.43
0.19
0.06
0.05
0.06
0.06
0.01
0.05
0.05
0.04
0.03
0.04
0.08
0.03

SEQID-00422
A2QUZ1
—
20:458
1
0.38
0.15
0.06
0.05
0.06
0.09
0.01
0.02
0.05
0.05
0.00
0.03
0.06
0.07

SEQID-00423
P00692
—
32:514
1
0.43
0.15
0.04
0.06
0.05
0.03
0.00
0.05
0.07
0.05
0.04
0.04
0.06
0.07

SEQID-00424
P0C1B3
—
22:499
1
0.43
0.19
0.05
0.03
0.06
0.09
0.02
0.05
0.03
0.05
0.02
0.06
0.07
0.05

SEQID-00425
P00723
—
—
1
0.47
0.19
0.03
0.05
0.06
0.07
0.01
0.03
0.09
0.03
0.04
0.05
0.07
0.09

SEQID-00426
O59952
—
23:291
0
0.42
0.20
0.05
0.07
0.07
0.07
0.02
0.03
0.05
0.05
0.03
0.06
0.08
0.03

SEQID-00427
D4PHA8
—
—
1
0.44
0.21
0.09
0.03
0.05
0.05
0.01
0.05
0.05
0.04
0.02
0.07
0.09
0.05

SEQID-00428
P19515
—
95:363
0
0.55
0.00
0.02
0.04
0.01
0.14
0.00
0.06
0.13
0.01
0.02
0.00
0.00
0.16

SEQID-00429
P06278
—
—
0
0.56
0.00
0.02
0.04
0.01
0.14
0.00
0.06
0.13
0.01
0.37
0.00
0.00
0.16

SEQID-00430
NA

—
0
0.55
0.00
0.02
0.04
0.01
0.14
0.00
0.06
0.13
0.01
0.02
0.00
0.00
0.16

SEQID-00431
NA

—
0
0.56
0.00
0.02
0.04
0.01
0.14
0.00
0.06
0.13
0.01
0.37
0.00
0.00
0.16

SEQID-00432
NA

—
0
0.55
0.00
0.02
0.04
0.01
0.14
0.00
0.06
0.13
0.01
0.02
0.00
0.00
0.50

SEQID-00433
NA

—
0
0.20
0.00
0.02
0.42
0.01
0.13
0.00
0.06
0.12
0.01
0.02
0.00
0.00
0.15

SEQID-00434
NA

—
0
0.22
0.00
0.02
0.04
0.01
0.14
0.00
0.40
0.13
0.01
0.02
0.00
0.00
0.16

SEQID-00435
NA

—
0
0.30
0.28
0.02
0.34
0.01
0.13
0.00
0.03
0.13
0.01
0.00
0.00
0.28
0.00

SEQID-00436
NA

—
1
0.72
0.22
0.00
0.00
0.00
0.14
0.00
0.00
0.13
0.00
0.07
0.04
0.13
0.21

SEQID-00437
NA

—
1
1.00
0.26
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.12
0.04
0.17
0.35

SEQID-00438
NA

—
0
0.53
0.31
0.02
0.04
0.01
0.15
0.00
0.07
0.13
0.01
0.02
0.12
0.19
0.17

SEQID-00439
NA

—
0
0.53
0.30
0.02
0.04
0.02
0.15
0.00
0.07
0.14
0.01
0.02
0.00
0.19
0.17

SEQID-00440
NA

—
0
0.55
0.18
0.02
0.04
0.01
0.14
0.00
0.06
0.13
0.01
0.02
0.00
0.18
0.16

SEQID-00441
NA

—
0
0.57
0.18
0.02
0.04
0.01
0.14
0.00
0.06
0.12
0.01
0.02
0.00
0.18
0.15

SEQID-00442
NA

—
0
0.53
0.19
0.02
0.04
0.02
0.15
0.00
0.07
0.14
0.01
0.02
0.00
0.19
0.17

SEQID-00443
NA

—
0
0.54
0.19
0.02
0.04
0.01
0.15
0.00
0.07
0.13
0.01
0.02
0.00
0.19
0.16

SEQID-00444
NA

—
0
0.54
0.20
0.02
0.04
0.01
0.15
0.00
0.07
0.13
0.01
0.14
0.00
0.19
0.16

SEQID-00445
NA

—
0
0.41
0.19
0.02
0.04
0.01
0.15
0.00
0.20
0.13
0.01
0.02
0.00
0.19
0.16

SEQID-00446
NA

—
0
0.32
0.28
0.02
0.27
0.01
0.14
0.00
0.06
0.13
0.01
0.00
0.00
0.28
0.00

SEQID-00447
NA

—
0
0.58
0.19
0.02
0.00
0.01
0.15
0.00
0.07
0.13
0.01
0.00
0.00
0.19
0.35

SEQID-00448
NA

—
0
0.21
0.18
0.02
0.39
0.01
0.14
0.00
0.06
0.12
0.01
0.00
0.00
0.18
0.00

SEQID-00449
NA

—
0
0.53
0.31
0.02
0.04
0.01
0.15
0.00
0.07
0.13
0.01
0.02
0.31
0.00
0.17

SEQID-00450
NA

—
0
0.51
0.28
0.02
0.04
0.02
0.16
0.00
0.07
0.14
0.01
0.02
0.00
0.00
0.17

SEQID-00451
NA

—
0
0.57
0.00
0.02
0.04
0.01
0.14
0.00
0.06
0.12
0.01
0.02
0.00
0.00
0.15

SEQID-00452
NA

—
0
0.61
0.00
0.02
0.03
0.01
0.12
0.00
0.06
0.11
0.01
0.01
0.00
0.00
0.14

SEQID-00453
NA

—
0
0.52
0.00
0.02
0.04
0.02
0.15
0.00
0.07
0.14
0.01
0.02
0.00
0.00
0.17

SEQID-00454
NA

—
0
0.59
0.78
0.00
0.41
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.28
0.30

SEQID-00455
NA

—
0
0.69
0.40
0.00
0.30
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.40
0.30

SEQID-00456
NA

—
0
0.71
0.51
0.00
0.29
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.51
0.20

SEQID-00457
NA

—
0
0.32
0.32
0.00
0.00
0.00
0.30
0.00
0.00
0.38
0.00
0.00
0.00
0.32
0.00

SEQID-00458
NA

—
0
0.43
0.43
0.00
0.00
0.00
0.29
0.00
0.00
0.27
0.00
0.00
0.00
0.43
0.00

SEQID-00459
NA

—
0
0.55
0.55
0.00
0.00
0.00
0.20
0.00
0.00
0.26
0.00
0.00
0.00
0.55
0.00

SEQID-00460
NA

—
0
0.41
0.30
0.00
0.25
0.00
0.15
0.00
0.00
0.19
0.00
0.00
0.00
0.30
0.12

SEQID-00461
NA

—
0
0.49
0.40
0.00
0.27
0.00
0.12
0.00
0.00
0.12
0.00
0.00
0.00
0.40
0.08

SEQID-00462
NA

—
0
0.62
0.53
0.00
0.15
0.00
0.13
0.00
0.00
0.11
0.00
0.00
0.00
0.53
0.09

SEQID-00463
NA

—
0
0.59
0.28
0.00
0.41
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.28
0.30

SEQID-00464
NA

—
0
0.62
0.36
0.00
0.33
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.36
0.26

SEQID-00465
NA

—
0
0.71
0.46
0.00
0.29
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.46
0.25

SEQID-00466
NA

—
0
0.32
0.32
0.00
0.00
0.00
0.30
0.00
0.00
0.38
0.00
0.00
0.00
0.32
0.00

SEQID-00467
NA

—
0
0.40
0.40
0.00
0.00
0.00
0.26
0.00
0.00
0.34
0.00
0.00
0.00
0.40
0.00

SEQID-00468
NA

—
0
0.50
0.50
0.00
0.00
0.00
0.24
0.00
0.00
0.26
0.00
0.00
0.00
0.50
0.00

SEQID-00469
NA

—
0
0.42
0.30
0.00
0.25
0.00
0.20
0.00
0.00
0.14
0.00
0.00
0.00
0.30
0.12

SEQID-00470
NA

—
0
0.50
0.38
0.00
0.19
0.00
0.19
0.00
0.00
0.12
0.00
0.00
0.00
0.38
0.12

SEQID-00471
NA

—
0
0.58
0.48
0.00
0.19
0.00
0.17
0.00
0.00
0.05
0.00
0.00
0.00
0.48
0.10

SEQID-00472
NA

—
0
0.57
0.25
0.00
0.43
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.25
0.32

SEQID-00473
NA

—
0
0.75
0.37
0.00
0.24
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.37
0.38

SEQID-00474
NA

—
0
0.67
0.46
0.00
0.32
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.46
0.22

SEQID-00475
NA

—
0
0.28
0.28
0.00
0.00
0.00
0.32
0.00
0.00
0.39
0.00
0.00
0.00
0.28
0.00

SEQID-00476
NA

—
0
0.00
0.40
0.00
0.00
0.00
0.38
0.00
0.00
0.22
0.00
0.00
0.00
0.40
0.00

SEQID-00477
NA

—
0
0.49
0.49
0.00
0.00
0.00
0.21
0.00
0.00
0.29
0.00
0.00
0.00
0.49
0.00

SEQID-00478
NA

—
0
0.40
0.17
0.00
0.24
0.00
0.15
0.00
0.00
0.20
0.00
0.00
0.00
0.27
0.13

SEQID-00479
NA

—
0
0.52
0.37
0.00
0.29
0.00
0.08
0.00
0.00
0.12
0.00
0.00
0.00
0.37
0.15

SEQID-00480
NA

—
0
0.62
0.48
0.00
0.11
0.00
0.16
0.00
0.00
0.11
0.00
0.00
0.00
0.48
0.14

SEQID-00481
K9HYS1

—
1
0.54
0.22
0.07
0.07
0.03
0.02
0.00
0.05
0.01
0.02
0.02
0.06
0.11
0.05

SEQID-00482
P39929

—
1
0.44
0.20
0.04
0.05
0.08
0.06
0.00
0.06
0.17
0.02
0.02
0.06
0.09
0.10

SEQID-00483
F1MLW7

—
1
0.42
0.19
0.04
0.04
0.03
0.03
0.03
0.04
0.04
0.05
0.01
0.03
0.08
0.05

SEQID-00484
P17891

—
1
0.38
0.14
0.05
0.06
0.05
0.16
0.00
0.06
0.14
0.02
0.01
0.05
0.06
0.11

SEQID-00485
G1K3R9

—
1
0.46
0.16
0.05
0.06
0.06
0.08
0.01
0.00
0.05
0.04
0.01
0.08
0.06
0.09

SEQID-00486
O78750

—
1
0.56
0.27
0.02
0.04
0.02
0.04
0.01
0.03
0.07
0.02
0.03
0.08
0.14
0.03

SEQID-00487
D5A2W2

—
1
0.61
0.27
0.03
0.05
0.00
0.02
0.01
0.03
0.04
0.04
0.03
0.09
0.09
0.05

SEQID-00488
K9HRR8

—
1
0.52
0.21
0.04
0.05
0.05
0.05
0.02
0.04
0.09
0.04
0.03
0.06
0.08
0.10

SEQID-00489
P07260

—
1
0.52
0.20
0.03
0.05
0.04
0.08
0.00
0.03
0.10
0.03
0.04
0.05
0.09
0.10

SEQID-00490
K1WPG5

—
1
0.53
0.34
0.06
0.04
0.04
0.03
0.00
0.03
0.05
0.04
0.01
0.06
0.17
0.01

SEQID-00491
D7SYA1

—
1
0.46
0.15
0.05
0.19
0.03
0.02
0.00
0.03
0.07
0.02
0.03
0.03
0.07
0.18

SEQID-00492
D7SLS3

—
1
0.42
0.16
0.03
0.21
0.04
0.02
0.01
0.04
0.04
0.03
0.04
0.04
0.06
0.10

SEQID-00493
A5PJM2

—
1
0.42
0.14
0.04
0.15
0.02
0.06
0.02
0.05
0.14
0.02
0.04
0.02
0.09
0.12

SEQID-00494
B9VGZ5

—
1
0.57
0.32
0.05
0.05
0.03
0.05
0.00
0.04
0.05
0.03
0.02
0.08
0.15
0.10

SEQID-00495
D7UC61

—
1
0.46
0.15
0.09
0.04
0.04
0.04
0.01
0.02
0.17
0.02
0.01
0.02
0.06
0.19

SEQID-00496
P52286

—
1
0.38
0.18
0.03
0.09
0.09
0.13
0.00
0.02
0.13
0.01
0.02
0.05
0.07
0.06

SEQID-00497
P49435

—
0
0.50
0.26
0.07
0.03
0.04
0.04
0.01
0.04
0.11
0.04
0.01
0.07
0.14
0.09

SEQID-00498
K1VXA7

—
0
0.49
0.30
0.05
0.09
0.05
0.05
0.00
0.06
0.08
0.04
0.01
0.07
0.15
0.06

SEQID-00499
B6UI23

—
1
0.34
0.17
0.18
0.12
0.01
0.09
0.03
0.03
0.05
0.03
0.02
0.03
0.08
0.04

SEQID-00500
Q67VZ0

—
1
0.40
0.16
0.03
0.10
0.03
0.06
0.03
0.03
0.05
0.09
0.04
0.02
0.06
0.01

SEQID-00501
K9HZV3

—
1
0.50
0.16
0.03
0.04
0.04
0.05
0.00
0.03
0.07
0.05
0.02
0.04
0.07
0.05

SEQID-00502
C6SZX7

—
1
0.43
0.20
0.05
0.03
0.09
0.07
0.02
0.03
0.06
0.04
0.01
0.04
0.09
0.12

SEQID-00503
B4FFR7

—
1
0.49
0.14
0.07
0.14
0.01
0.03
0.01
0.05
0.07
0.04
0.02
0.05
0.05
0.22

SEQID-00504
K9HEB9

—
1
0.47
0.21
0.06
0.07
0.08
0.02
0.01
0.09
0.03
0.05
0.02
0.07
0.06
0.02

SEQID-00505
Q3SYR8

—
1
0.42
0.21
0.03
0.09
0.06
0.08
0.05
0.04
0.07
0.01
0.01
0.06
0.06
0.06

SEQID-00506
K9I599

—
1
0.62
0.29
0.07
0.03
0.02
0.02
0.00
0.02
0.04
0.03
0.05
0.11
0.12
0.05

SEQID-00507
K9HG54

—
1
0.51
0.14
0.05
0.03
0.04
0.06
0.00
0.02
0.07
0.02
0.00
0.03
0.06
0.10

SEQID-00508
D7U394

—
1
0.54
0.25
0.05
0.04
0.03
0.05
0.03
0.03
0.07
0.06
0.03
0.05
0.07
0.08

SEQID-00509
Q3IJ07

—
1
0.43
0.13
0.03
0.13
0.03
0.08
0.00
0.05
0.17
0.02
0.03
0.04
0.07
0.19

SEQID-00510
G1NCP5

—
1
0.44
0.15
0.04
0.06
0.05
0.03
0.02
0.05
0.16
0.02
0.01
0.05
0.06
0.10

SEQID-00511
K1WAW9

—
1
0.40
0.15
0.05
0.06
0.03
0.03
0.02
0.07
0.08
0.06
0.02
0.02
0.07
0.05

SEQID-00512
Q8H920

—
1
3.44
0.21
0.17
0.09
0.02
0.02
0.02
0.03
0.03
0.07
0.04
0.01
0.16
0.01

SEQID-00513
P06673

—
0
0.33
0.16
0.10
0.04
0.02
0.01
0.04
0.17
0.02
0.04
0.00
0.01
0.11
0.01

SEQID-00514
D4ZPH7

—
1
0.46
0.26
0.07
0.11
0.06
0.02
0.00
0.06
0.07
0.07
0.01
0.06
0.07
0.12

SEQID-00515
Q08969

—
1
0.25
0.05
0.01
0.10
0.09
0.13
0.00
0.17
0.06
0.07
0.03
0.01
0.04
0.03

SEQID-00516
P04037

—
1
0.46
0.22
0.03
0.07
0.03
0.07
0.02
0.04
0.07
0.04
0.03
0.05
0.11
0.07

SEQID-00517
P04449

—
1
0.49
0.13
0.07
0.14
0.03
0.02
0.00
0.05
0.07
0.03
0.02
0.04
0.04
0.22

SEQID-00518
FOTIG9

—
1
0.52
0.73
0.03
0.08
0.04
0.04
0.00
0.03
0.07
0.06
0.03
0.06
0.04
0.14

SEQID-00519
B6UD91

—
1
0.38
0.70
0.16
0.08
0.02
0.09
0.03
0.02
0.07
0.05
0.01
0.04
0.11
0.05

SEQID-00520
P63246

—
1
0.45
0.17
0.05
0.11
0.03
0.07
0.01
0.05
0.14
0.02
0.03
0.01
0.11
0.16

SEQID-00521
P72505

—
0
0.41
0.23
0.09
0.07
0.04
0.07
0.01
0.04
0.04
0.04
0.00
0.08
0.09
0.06

SEQID-00522
O49817

—
0
0.40
0.03
0.10
0.04
0.03
0.08
0.00
0.17
0.08
0.04
0.02
0.01
0.01
0.16

SEQID-00523
K1X7Q4

—
0
0.51
0.19
0.04
0.05
0.05
0.00
0.00
0.06
0.08
0.04
0.00
0.05
0.12
0.04

SEQID-00524
P79395

—
1
0.48
0.19
0.03
0.06
0.07
0.01
0.00
0.02
0.08
0.02
0.04
0.04
0.06
0.10

SEQID-00525
P01095

—
0
0.64
0.25
0.02
0.00
0.07
0.08
0.00
0.00
0.11
0.02
0.10
0.08
0.07
0.17

SEQID-00526
B1N67B

—
0
0.41
0.13
0.05
0.17
0.03
0.01
0.10
0.02
0.08
0.04
0.02
0.01
0.07
0.03

SEQID-00527
D4ZQAB

—
1
0.40
0.18
0.05
0.09
0.00
0.07
0.11
0.03
0.06
0.04
0.02
0.05
0.06
0.04

SEQID-00528
P38711

—
0
0.53
0.21
0.05
0.07
0.01
0.03
0.06
0.04
0.04
0.03
0.05
0.01
0.11
0.10

SEQID-00529
B2BN60

—
0
0.38
0.14
0.02
0.11
0.06
0.04
0.00
0.05
0.11
0.05
0.00
0.07
0.01
0.05

SEQID-00530
Q10ST8

—
0
0.37
0.20
0.13
0.10
0.04
0.01
0.10
0.05
0.00
0.08
0.01
0.02
0.07
0.04

SEQID-00531
P14903

—
0
0.55
0.25
0.03
0.03
0.05
0.04
0.06
0.05
0.05
0.02
0.00
0.06
0.15
0.08

SEQID-00532
D4ZX53

—
0
0.44
0.28
0.06
0.10
0.02
0.03
0.00
0.02
0.11
0.05
0.02
0.09
0.03
0.03

SEQID-00533
D4ZPG3

—
0
0.47
0.23
0.04
0.16
0.03
0.06
0.00
0.05
0.08
0.01
0.00
0.05
0.08
0.08

SEQID-00534
D4ZUU2

—
0
0.33
0.13
0.04
0.15
0.03
0.07
0.01
0.01
0.12
0.09
0.00
0.02
0.05
0.05

SEQID-00535
G5E604

—
0
0.30
0.16
0.06
0.10
0.06
0.04
0.02
0.08
0.02
0.06
0.00
0.04
0.06
0.00

SEQID-00536
O82575

—
0
0.55
0.10
0.09
0.00
0.00
0.04
0.00
0.01
0.20
0.04
0.23
0.04
0.05
0.18

SEQID-00537
Q08245

—
0
0.42
0.14
0.08
0.01
0.07
0.03
0.00
0.11
0.21
0.02
0.00
0.04
0.04
0.20

SEQID-00538
F1P2P7

—
0
0.49
0.18
0.06
0.04
0.04
0.05
0.02
0.04
0.14
0.03
0.08
0.04
0.09
0.08

SEQID-00539
Q9N109

—
0
0.53
0.30
0.05
0.06
0.06
0.06
0.01
0.07
0.07
0.03
0.02
0.09
0.12
0.09

SEQID-00540
K1W1H1

—
0
0.41
0.21
0.05
0.23
0.02
0.06
0.00
0.03
0.05
0.05
0.01
0.06
0.08
0.08

SEQID-00541
K9I1Y2

—
1
0.48
0.29
0.01
0.14
0.06
0.03
0.01
0.04
0.04
0.05
0.04
0.12
0.08
0.07

SEQID-00542
K9HG97

—
0
0.41
0.23
0.08
0.09
0.04
0.03
0.00
0.05
0.08
0.08
0.03
0.04
0.12
0.13

SEQID-00543
K9HDT0

—
1
0.42
0.16
0.03
0.11
0.06
0.06
0.02
0.04
0.06
0.04
0.01
0.05
0.05
0.04

SEQID-00544
Q5XQ56

—
0
0.45
0.20
0.12
0.06
0.01
0.07
0.00
0.07
0.06
0.03
0.05
0.04
0.11
0.06

SEQID-00545
P00427

—
0
0.39
0.19
0.06
0.13
0.05
0.06
0.01
0.03
0.12
0.01
0.02
0.03
0.10
0.07

SEQID-00546
Q12513

—
0
0.39
0.20
0.04
0.07
0.09
0.11
0.01
0.03
0.12
0.03
0.02
0.08
0.07
0.08

SEQID-00547
E78SD7

—
0
0.49
0.09
0.08
0.04
0.04
0.03
0.00
0.04
0.10
0.08
0.08
0.01
0.01
0.12

SEQID-00548
Q7VS10

—
1
0.59
0.27
0.03
0.00
0.03
0.05
0.02
0.09
0.12
0.04
0.03
0.08
0.13
0.11

SEQID-00549
P21306

—
0
0.40
0.15
0.12
0.07
0.05
0.02
0.00
0.09
0.04
0.02
0.00
0.05
0.07
0.08

SEQID-00550
D4ZT86

—
0
0.49
0.38
0.09
0.06
0.01
0.05
0.00
0.02
0.10
0.02
0.00
0.09
0.10
0.05

SEQID-00551
B6S149

—
0
0.41
0.18
0.05
0.21
0.03
0.00
0.09
0.03
0.06
0.04
0.05
0.00
0.11
0.01

SEQID-00552
P50263

—
0
0.45
0.03
0.03
0.04
0.12
0.10
0.00
0.06
0.06
0.06
0.05
0.01
0.01
0.16

SEQID-00553
K6EQ38

—
0
0.39
0.05
0.08
0.00
0.00
0.07
0.00
0.01
0.15
0.00
0.01
0.01
0.00
0.23

SEQID-00554
K9H8HS

—
1
0.38
0.16
0.09
0.17
0.06
0.03
0.04
0.00
0.05
0.04
0.03
0.06
0.01
0.12

SEQID-00555
D4ZXX9

—
0
0.45
0.26
0.03
0.17
0.02
0.02
0.00
0.07
0.09
0.04
0.01
0.12
0.04
0.08

SEQID-00556
B4FEE7

—
0
0.33
0.13
0.08
0.22
0.05
0.04
0.05
0.03
0.03
0.04
0.06
0.04
0.02
0.03

SEQID-00557
G3MXD9

—
0
0.47
0.27
0.03
0.06
0.03
0.03
0.02
0.06
0.03
0.04
0.00
0.02
0.14
0.04

SEQID-00558
P53849

—
0
0.36
0.09
0.02
0.07
0.06
0.05
0.13
0.05
0.07
0.04
0.06
0.03
0.03
0.10

SEQID-00559
P0C030

—
0
0.50
0.26
0.03
0.07
0.02
0.08
0.00
0.07
0.10
0.04
0.02
0.11
0.11
0.11

SEQID-00560
Q6PY61

—
0
0.55
0.10
0.02
0.00
0.02
0.13
0.00
0.01
0.12
0.07
0.18
0.08
0.01
0.26

SEQID-00561
D5A2Z0

—
1
0.68
0.36
0.03
0.02
0.03
0.02
0.01
0.02
0.03
0.06
0.03
0.18
0.14
0.04

SEQID-00562
F0TIX0

—
0
0.40
0.18
0.07
0.00
0.08
0.19
0.01
0.04
0.11
0.03
0.01
0.03
0.08
0.13

SEQID-00563
Q65XV6

—
1
0.50
0.21
0.07
0.07
0.04
0.07
0.02
0.00
0.05
0.07
0.04
0.08
0.06
0.09

SEQID-00564
B6T878

—
0
0.51
0.17
0.09
0.05
0.02
0.03
0.00
0.02
0.09
0.03
0.02
0.07
0.06
0.22

SEQID-00565
O7UCH9

—
1
0.56
0.28
0.06
0.04
0.02
0.05
0.01
0.01
0.06
0.03
0.04
0.09
0.13
0.10

SEQID-00566
M1B8F8

—
0
0.38
0.15
0.04
0.02
0.04
0.03
0.11
0.02
0.07
0.06
0.03
0.05
0.07
0.03

SEQID-00567
B4FUW2

—
1
0.42
0.17
0.03
0.22
0.04
0.02
0.01
0.05
0.04
0.04
0.04
0.03
0.07
0.10

SEQID-00568
B4FUS2

—
1
0.51
0.20
0.02
0.16
0.05
0.07
0.01
0.04
0.04
0.04
0.03
0.04
0.09
0.12

SEQID-00569
P02701

—
1
0.56
0.22
0.03
0.07
0.07
0.03
0.01
0.03
0.05
0.04
0.02
0.05
0.11
0.07

SEQID-00570
P40185

—
0
0.48
0.23
0.07
0.05
0.09
0.03
0.01
0.04
0.06
0.01
0.03
0.04
0.08
0.08

SEQID-00571
P02074

—
0
0.54
0.25
0.08
0.06
0.05
0.05
0.01
0.02
0.07
0.05
0.06
0.00
0.13
0.07

SEQID-00572
M0ZHK8

—
0
0.54
0.17
0.06
0.05
0.02
0.02
0.00
0.02
0.10
0.03
0.02
0.07
0.05
0.23

SEQID-00573
Q9M3H6

—
0
0.54
0.17
0.08
0.05
0.02
0.02
0.00
0.02
0.10
0.02
0.02
0.07
0.04
0.23

SEQID-00574
F0TIG5

—
0
0.44
0.19
0.04
0.14
0.05
0.03
0.00
0.03
0.03
0.05
0.04
0.04
0.07
0.12

SEQID-00575
B6SIA2

—
0
0.33
0.13
0.03
0.22
0.03
0.04
0.05
0.03
0.04
0.04
0.05
0.04
0.01
0.09

SEQID-00576
K9HNE7

—
1
0.42
0.21
0.09
0.04
0.06
0.07
0.06
0.05
0.00
0.04
0.03
0.03
0.05
0.04

SEQID-00577
P02294

—
0
0.47
0.16
0.08
0.07
0.02
0.02
0.00
0.04
0.07
0.02
0.02
0.06
0.05
0.17

SEQID-00578
B6T2K5

—
0
0.54
0.22
0.05
0.15
0.01
0.02
0.00
0.04
0.06
0.01
0.02
0.05
0.13
0.21

SEQID-00579
B4FGQ6

—
0
0.47
0.19
0.03
0.17
0.02
0.01
0.01
0.06
0.04
0.03
0.02
0.04
0.07
0.18

SEQID-00580
F0TGC0

—
1
0.49
0.15
0.02
0.16
0.04
0.04
0.00
0.04
0.02
0.03
0.02
0.04
0.07
0.16

SEQID-00581
D4ZPH2

—
0
0.51
0.21
0.02
0.12
0.03
0.04
0.00
0.04
0.07
0.04
0.03
0.04
0.04
0.15

SEQID-00582
K9I7W3

—
1
0.54
0.18
0.05
0.07
0.04
0.08
0.00
0.03
0.02
0.03
0.03
0.06
0.06
0.17

SEQID-00583
B6SGX0

—
0
0.56
0.18
0.05
0.16
0.01
0.02
0.00
0.01
0.06
0.05
0.04
0.03
0.09
0.21

SEQID-00584
G3UV10

—
1
0.50
0.18
0.05
0.05
0.03
0.05
0.02
0.04
0.06
0.04
0.02
0.12
0.04
0.08

SEQID-00585
Q5BYT2

—
0
0.44
0.06
0.02
0.00
0.04
0.10
0.00
0.13
0.09
0.10
0.10
0.03
0.01
0.21

SEQID-00586
K1VX49

—
0
0.44
0.09
0.05
0.10
0.01
0.07
0.00
0.02
0.08
0.03
0.00
0.02
0.06
0.15

SEQID-00587
P38910

—
0
0.51
0.29
0.06
0.04
0.05
0.07
0.00
0.07
0.06
0.04
0.00
0.07
0.11
0.12

SEQID-00588
K9HK97

—
1
0.44
0.20
0.04
0.17
0.04
0.01
0.00
0.03
0.03
0.05
0.02
0.07
0.06
0.11

SEQID-00589
Q12497

—
0
0.42
0.12
0.03
0.13
0.05
0.10
0.00
0.06
0.07
0.03
0.03
0.02
0.08
0.13

SEQID-00590
F0TEQ9

—
0
0.49
0.20
0.10
0.06
0.04
0.04
0.00
0.04
0.12
0.04
0.01
0.06
0.06
0.16

SEQID-00591
P01098

—
0
0.37
0.18
0.04
0.14
0.09
0.03
0.01
0.06
0.10
0.03
0.03
0.06
0.10
0.11

SEQID-00592
B6SPL7

—
0
0.53
0.21
0.07
0.02
0.01
0.04
0.02
0.04
0.10
0.05
0.00
0.01
0.04
0.12

SEQID-00593
D5A0N7

—
1
0.49
0.20
0.05
0.08
0.01
0.04
0.00
0.08
0.07
0.04
0.01
0.11
0.06
0.03

SEQID-00594
K4CBP6

—
0
0.44
0.14
0.05
0.16
0.03
0.01
0.09
0.01
0.07
0.03
0.03
0.03
0.06
0.04

SEQID-00595
K7WJX3

—
0
0.44
0.10
0.06
0.16
0.04
0.01
0.09
0.00
0.07
0.03
0.03
0.01
0.06
0.03

SEQID-00596
Q2I2W0

—
1
0.44
0.16
0.05
0.09
0.04
0.08
0.11
0.02
0.06
0.03
0.03
0.01
0.09
0.08

SEQID-00597
I1K5S4

—
0
0.45
0.18
0.03
0.19
0.00
0.05
0.10
0.05
0.03
0.05
0.03
0.01
0.12
0.06

SEQID-00598
P82381

—
1
0.49
0.20
0.06
0.12
0.07
0.04
0.03
0.00
0.07
0.04
0.05
0.04
0.03
0.07

SEQID-00599
K9HN29

—
1
0.50
0.22
0.04
0.06
0.04
0.08
0.01
0.02
0.05
0.04
0.04
0.05
0.08
0.06

SEQID-00600
G1NGA7

—
1
0.50
0.21
0.06
0.06
0.02
0.02
0.02
0.04
0.06
0.04
0.01
0.05
0.09
0.08

SEQID-00601
K9HJD1

—
1
0.40
0.14
0.06
0.05
0.03
0.05
0.02
0.09
0.09
0.05
0.06
0.04
0.07
0.09

SEQID-00602
F0TGH0

—
1
0.51
0.17
0.07
0.01
0.04
0.06
0.00
0.09
0.03
0.02
0.01
0.05
0.06
0.19

SEQID-00603
Q04491

—
1
0.51
0.22
0.05
0.04
0.04
0.06
0.01
0.03
0.09
0.04
0.05
0.05
0.08
0.08

SEQID-00604
K9HHN3

—
1
0.48
0.20
0.08
0.05
0.05
0.07
0.00
0.04
0.04
0.04
0.04
0.03
0.09
0.09

SEQID-00605
K9I605

—
1
0.51
0.26
0.04
0.05
0.04
0.04
0.00
0.04
0.10
0.04
0.03
0.10
0.11
0.09

SEQID-00606
C6T9B1

—
1
0.48
0.20
0.06
0.07
0.05
0.03
0.01
0.02
0.08
0.05
0.12
0.06
0.09
0.05

SEQID-00607
K1WSX8

—
1
0.38
0.11
0.07
0.10
0.02
0.04
0.00
0.17
0.10
0.01
0.02
0.02
0.07
0.07

SEQID-00608
Q3ZBI6

—
1
0.34
0.10
0.03
0.03
0.01
0.06
0.12
0.07
0.07
0.05
0.04
0.01
0.06
0.04

SEQID-00609
P39015

—
1
0.36
0.12
0.08
0.10
0.12
0.03
0.00
0.04
0.08
0.02
0.00
0.02
0.05
0.14

SEQID-00610
P38886

—
0
0.41
0.20
0.05
0.07
0.06
0.06
0.00
0.10
0.11
0.03
0.03
0.06
0.09
0.04

SEQID-00611
Q9FWV6

—
1
0.50
0.26
0.11
0.07
0.02
0.03
0.00
0.01
0.03
0.07
0.04
0.04
0.14
0.01

SEQID-00612
Q6YTX5

—
1
0.42
0.25
0.16
0.06
0.02
0.04
0.00
0.02
0.06
0.03
0.04
0.03
0.12
0.05

SEQID-00613
K1WS36

—
0
0.36
0.19
0.08
0.08
0.07
0.04
0.00
0.13
0.13
0.02
0.00
0.04
0.11
0.08

SEQID-00614
K9H9H7

—
1
0.57
0.16
0.08
0.06
0.03
0.04
0.02
0.05
0.02
0.03
0.05
0.09
0.12
0.06

SEQID-00615
F6HMP1

—
0
0.40
0.03
0.01
0.06
0.00
0.00
0.00
0.07
0.22
0.18
0.10
0.06
0.02
0.14

SEQID-00616
P05745

—
0
0.49
0.20
0.07
0.17
0.05
0.01
0.00
0.00
0.06
0.04
0.01
0.08
0.06
0.16

SEQID-00617
D4ZMN8

—
0
0.44
0.16
0.10
0.07
0.05
0.03
0.02
0.05
0.11
0.04
0.01
0.06
0.02
0.10

SEQID-00618
C6SWA6

—
0
0.46
0.73
0.08
0.11
0.04
0.02
0.00
0.02
0.06
0.07
0.02
0.04
0.11
0.17

SEQID-00619
FB334983.1

—
0
0.51
0.16
0.09
0.06
0.04
0.02
0.00
0.02
0.11
0.02
0.02
0.06
0.05
0.23

SEQID-00620
P48589

—
1
0.50
0.30
0.06
0.06
0.04
0.05
0.00
0.04
0.15
0.04
0.02
0.04
0.11
0.07

SEQID-00621
M1B1K7

—
0
0.39
0.22
0.08
0.11
0.06
0.02
0.00
0.04
0.06
0.03
0.02
0.05
0.11
0.10

SEQID-00622
Q0DT04

—
1
0.40
0.18
0.09
0.09
0.00
0.08
0.01
0.04
0.06
0.04
0.03
0.04
0.04
0.04

SEQID-00623
O65819

—
0
0.54
0.17
0.08
0.05
0.02
0.03
0.00
0.03
0.09
0.02
0.02
0.07
0.05
0.23

SEQID-00624
D4ZXX3

—
0
0.49
0.21
0.11
0.01
0.00
0.05
0.00
0.04
0.18
0.04
0.00
0.06
0.10
0.14

SEQID-00625
C6SY27

—
0
0.52
0.24
0.05
0.14
0.03
0.08
0.00
0.03
0.04
0.01
0.00
0.07
0.07
0.17

SEQID-00626
F0TII3

—
1
0.46
0.26
0.05
0.09
0.06
0.06
0.00
0.02
0.07
0.04
0.01
0.12
0.06
0.11

SEQID-00627
Q62GV5

—
1
0.48
0.20
0.05
0.14
0.04
0.05
0.01
0.01
0.12
0.03
0.02
0.07
0.06
0.15

SEQID-00628
P38701

—
1
0.51
0.25
0.01
0.07
0.05
0.02
0.00
0.10
0.11
0.02
0.02
0.10
0.05
0.13

SEQID-00629
P39939

—
0
0.37
0.16
0.08
0.19
0.07
0.03
0.03
0.01
0.04
0.01
0.03
0.05
0.03
0.14

SEQID-00630
G3N028

—
1
0.35
0.16
0.03
0.06
0.04
0.03
0.03
0.07
0.04
0.06
0.01
0.05
0.06
0.03

SEQID-00631
F07IJ3

—
0
0.38
0.20
0.04
0.21
0.04
0.09
0.01
0.02
0.06
0.04
0.01
0.07
0.06
0.10

SEQID-00632
P38804

—
0
0.47
0.20
0.05
0.03
0.07
0.04
0.00
0.02
0.14
0.06
0.00
0.05
0.08
0.13

SEQID-00633
P22943

—
0
0.35
0.10
0.08
0.04
0.03
0.11
0.00
0.07
0.12
0.06
0.02
0.01
0.03
0.16

SEQID-00634
Q3E792

—
0
0.50
0.21
0.08
0.09
0.00
0.04
0.00
0.05
0.05
0.02
0.03
0.08
0.08
0.19

SEQID-00635
P41056

—
1
0.46
0.20
0.05
0.14
0.07
0.00
0.00
0.03
0.04
0.04
0.03
0.06
0.06
0.09

SEQID-00636
HC499955.1

—
1
0.47
0.23
0.04
0.22
0.02
0.03
0.00
0.02
0.04
0.07
0.02
0.07
0.08
0.11

SEQID-00637
B6SGI4

—
1
0.42
0.07
0.06
0.22
0.04
0.00
0.04
0.01
0.02
0.05
0.04
0.03
0.02
0.12

SEQID-00638
D4ZUU9

—
0
0.48
0.21
0.06
0.11
0.03
0.03
0.00
0.04
0.14
0.02
0.00
0.04
0.07
0.14

SEQID-00639
P0CX26

—
1
0.46
0.16
0.08
0.15
0.00
0.01
0.05
0.04
0.04
0.05
0.01
0.04
0.03
0.14

SEQID-00640
F0T1H8

—
0
0.47
0.19
0.01
0.13
0.06
0.05
0.00
0.02
0.06
0.01
0.03
0.04
0.02
0.16

SEQID-00641
P01097

—
0
0.39
0.14
0.04
0.17
0.01
0.05
0.00
0.03
0.12
0.03
0.01
0.02
0.09
0.10

SEQID-00642
Q01519

—
1
0.45
0.11
0.04
0.03
0.06
0.11
0.04
0.08
0.05
0.02
0.04
0.03
0.03
0.09

SEQID-00643
D4P880

—
0
0.57
0.24
0.02
0.07
0.02
0.07
0.03
0.03
0.03
0.04
0.01
0.05
0.13
0.15

SEQID-00644
D5A1R0

—
0
0.42
0.22
0.06
0.09
0.07
0.04
0.01
0.04
0.09
0.04
0.00
0.05
0.03
0.09

SEQID-00645
P37299

—
1
0.56
0.20
0.03
0.04
0.03
0.04
0.00
0.01
0.05
0.05
0.05
0.01
0.17
0.07

SEQID-00646
B6UDM4

—
1
0.54
0.23
0.06
0.09
0.01
0.04
0.01
0.03
0.03
0.05
0.03
0.03
0.15
0.09

SEQID-00647
K1XDJ4

—
0
0.42
0.24
0.04
0.15
0.04
0.04
0.00
0.09
0.12
0.01
0.05
0.05
0.18
0.08

SEQID-00648
K1WP04

—
1
0.39
0.12
0.03
0.19
0.03
0.06
0.00
0.00
0.17
0.04
0.03
0.04
0.04
0.08

SEQID-00649
Q6H6I1

—
1
0.42
0.19
0.13
0.08
0.02
0.04
0.03
0.01
0.06
0.05
0.03
0.05
0.06
0.05

SEQID-00650
F1NXK2

—
0
0.50
0.23
0.04
0.11
0.02
0.08
0.00
0.00
0.09
0.04
0.00
0.08
0.03
0.07

SEQID-00651
B6UHQ3

—
1
0.39
0.19
0.17
0.03
0.01
0.06
0.02
0.07
0.04
0.04
0.05
0.01
0.13
0.02

SEQID-00652
P01064

—
0
0.23
0.08
0.00
0.03
0.02
0.13
0.16
0.05
0.03
0.01
0.01
0.02
0.06
0.07

SEQID-00653
E1UJV6

—
0
0.47
0.22
0.10
0.07
0.05
0.05
0.01
0.03
0.09
0.04
0.00
0.08
0.05
0.11

SEQID-00654
E1USS1

—
1
0.54
0.28
0.07
0.05
0.04
0.06
0.00
0.03
0.09
0.03
0.05
0.11
0.11
0.07

SEQID-00655
E1UU33

—
0
0.47
0.21
0.07
0.06
0.05
0.06
0.01
0.05
0.13
0.04
0.02
0.06
0.08
0.12

SEQID-00656
E1UV85

—
0
0.44
0.20
0.07
0.01
0.06
0.05
0.00
0.14
0.07
0.04
0.00
0.05
0.06
0.13

SEQID-00657
E1UR32

—
1
0.49
0.17
0.05
0.02
0.09
0.07
0.00
0.04
0.07
0.04
0.01
0.05
0.07
0.13

SEQID-00658
E1URC8

—
1
0.42
0.17
0.06
0.04
0.06
0.09
0.00
0.07
0.09
0.04
0.01
0.05
0.07
0.16

SEQID-00659
E1UV03

—
1
0.44
0.17
0.05
0.06
0.10
0.05
0.00
0.05
0.05
0.03
0.04
0.05
0.05
0.05

SEQID-00660
E1UKZ8

—
1
0.43
0.17
0.06
0.02
0.03
0.09
0.00
0.04
0.08
0.04
0.02
0.04
0.08
0.14

SEQID-00661
P00780

—
1
0.44
0.22
0.10
0.02
0.07
0.05
0.00
0.03
0.04
0.06
0.03
0.05
0.06
0.08

SEQID-00662
E1UMM6

—
1
0.43
0.17
0.04
0.04
0.08
0.06
0.01
0.02
0.04
0.06
0.01
0.06
0.08
0.07

SEQID-00663
QBGCB2

—
1
0.47
0.20
0.03
0.05
0.12
0.06
0.00
0.01
0.04
0.05
0.03
0.09
0.05
0.08

SEQID-00664
Q65EF5

—
1
0.50
0.19
0.05
0.05
0.07
0.06
0.00
0.04
0.07
0.05
0.03
0.07
0.04
0.10

SEQID-00665
D5DEH5

—
1
0.41
0.17
0.06
0.03
0.07
0.07
0.00
0.04
0.04
0.05
0.02
0.04
0.06
0.09

SEQID-00666
G2RXU3

—
1
0.46
0.24
0.07
0.05
0.05
0.07
0.00
0.03
0.10
0.06
0.01
0.07
0.09
0.07

SEQID-00667
E1UPU6

—
1
0.40
0.15
0.05
0.09
0.05
0.11
0.00
0.04
0.07
0.04
0.01
0.03
0.07
0.10

SEQID-00668
E1UQB7

—
1
0.52
0.16
0.05
0.01
0.03
0.10
0.00
0.05
0.09
0.03
0.01
0.03
0.08
0.23

SEQID-00669
P07170

—
1
0.48
0.21
0.06
0.06
0.04
0.09
0.00
0.06
0.06
0.04
0.03
0.07
0.10
0.10

SEQID-00670
P07170

—
1
0.48
0.21
0.06
0.06
0.04
0.09
0.00
0.06
0.06
0.04
0.03
0.07
0.10
0.10

SEQID-00671
P07170

—
1
0.46
0.21
0.06
0.05
0.04
0.09
0.00
0.06
0.06
0.04
0.03
0.07
0.10
0.10

SEQID-00672
P07170

—
1
0.47
0.21
0.06
0.06
0.04
0.09
0.00
0.06
0.06
0.04
0.03
0.07
0.10
0.10

SEQID-00673
P07170

—
1
0.47
0.21
0.06
0.05
0.04
0.09
0.00
0.06
0.06
0.04
0.03
0.07
0.10
0.10

SEQID-00674
P07170

—
1
0.47
0.21
0.07
0.05
0.04
0.09
0.00
0.06
0.06
0.04
0.03
0.07
0.10
0.10

SEQID-00675
P07170

—
1
0.47
0.21
0.06
0.05
0.04
0.09
0.01
0.06
0.06
0.04
0.03
0.07
0.10
0.10

SEQID-00676
P07170

—
1
0.47
0.21
0.06
0.05
0.04
0.09
0.00
0.06
0.06
0.04
0.03
0.07
0.10
0.10

SEQID-00677
P07170

—
1
0.48
0.21
0.06
0.05
0.04
0.09
0.00
0.06
0.06
0.04
0.03
0.07
0.10
0.10

SEQID-00678
P07170

—
1
0.48
0.21
0.06
0.05
0.04
0.09
0.00
0.06
0.06
0.04
0.03
0.07
0.10
0.11

SEQID-00679
P07170

—
1
0.48
0.21
0.06
0.05
0.04
0.09
0.00
0.06
0.06
0.04
0.03
0.07
0.10
0.10

SEQID-00680
P07170

—
1
0.47
0.21
0.06
0.05
0.04
0.09
0.00
0.06
0.06
0.04
0.03
0.07
0.10
0.10

SEQID-00681
P07170

—
1
0.43
0.21
0.06
0.05
0.04
0.09
0.00
0.06
0.06
0.04
0.03
0.07
0.10
0.10

SEQID-00682
P07170

—
1
0.43
0.21
0.06
0.05
0.04
0.09
0.00
0.06
0.06
0.04
0.03
0.07
0.10
0.10

SEQID-00683
P00691

34:659
1
0.43
0.16
0.05
0.05
0.09
0.03
0.00
0.05
0.04
0.04
0.03
0.06
0.06
0.06

SEQID-00684
P00691

34:659
1
0.44
0.17
0.05
0.05
0.09
0.07
0.00
0.05
0.04
0.05
0.03
0.06
0.06
0.06

SEQID-00685
P00691

34:659
1
0.43
0.16
0.05
0.05
0.09
0.08
0.00
0.05
0.04
0.05
0.03
0.05
0.06
0.06

SEQID-00686
P00691

34:659
1
0.43
0.16
0.05
0.05
0.09
0.08
0.00
0.05
0.04
0.05
0.03
0.05
0.06
0.06

SEQID-00687
P00691

34:659
1
0.42
0.16
0.05
0.05
0.09
0.07
0.00
0.05
0.04
0.04
0.03
0.06
0.06
0.06

SEQID-00688
P00691

34:659
1
0.43
0.16
0.05
0.05
0.09
0.07
0.00
0.05
0.04
0.05
0.03
0.05
0.06
0.06

SEQID-00689
P00691

34:659
1
0.43
0.16
0.05
0.05
0.09
0.08
0.00
0.05
0.04
0.05
0.03
0.05
0.06
0.06

SEQID-00690
P00691

34:659
1
0.44
0.17
0.05
0.05
0.09
0.07
0.00
0.05
0.04
0.05
0.03
0.06
0.06
0.06

SEQID-00691
P00691

34:659
1
0.44
0.17
0.05
0.05
0.09
0.07
0.00
0.05
0.04
0.05
0.03
0.06
0.06
0.06

SEQID-00692
P00691

34:659
1
0.44
0.17
0.05
0.05
0.09
0.07
0.00
0.05
0.04
0.05
0.03
0.06
0.07
0.06

SEQID-00693
P00691

34:659
1
0.44
0.16
0.05
0.05
0.09
0.07
0.00
0.05
0.04
0.05
0.03
0.05
0.06
0.06

SEQID-00694
P00691

34:659
1
0.43
0.16
0.05
0.05
0.09
0.08
0.00
0.05
0.04
0.05
0.03
0.06
0.06
0.06

SEQID-00695
P00691

34:659
1
0.43
0.16
0.05
0.05
0.09
0.08
0.00
0.05
0.04
0.05
0.03
0.05
0.06
0.06

SEQID-00696
P00691

34:659
1
0.44
0.17
0.05
0.05
0.09
0.07
0.00
0.05
0.04
0.05
0.03
0.06
0.06
0.06

SEQID-00697
P00691

34:659
1
0.43
0.17
0.05
0.05
0.09
0.07
0.00
0.05
0.04
0.05
0.03
0.06
0.06
0.06

SEQID-00698
P00691

34:659
1
0.44
0.17
0.05
0.05
0.09
0.07
0.00
0.05
0.04
0.05
0.03
0.06
0.06
0.06

SEQID-00699
P00691

34:659
1
0.43
0.16
0.05
0.05
0.09
0.07
0.00
0.05
0.04
0.05
0.03
0.05
0.06
0.06

SEQID-00700
P00691

34:659
1
0.44
0.17
0.05
0.05
0.09
0.07
0.00
0.05
0.04
0.05
0.03
0.06
0.06
0.06

SEQID-00701
P00691

34:659
1
0.44
0.17
0.05
0.05
0.09
0.07
0.00
0.05
0.04
0.05
0.03
0.06
0.06
0.06

SEQID-00702
P00691

34:659
1
0.44
0.17
0.05
0.05
0.09
0.07
0.00
0.05
0.04
0.05
0.03
0.06
0.06
0.06

SEQID-00703
P00691

34:659
1
0.43
0.16
0.05
0.05
0.09
0.07
0.00
0.05
0.04
0.05
0.03
0.06
0.06
0.06

SEQID-00704
P00691

34:659
1
0.43
0.17
0.05
0.06
0.09
0.07
0.00
0.05
0.04
0.05
0.03
0.06
0.06
0.06

SEQID-00705
P00691

34:659
1
0.44
0.17
0.05
0.05
0.09
0.07
0.00
0.05
0.04
0.05
0.03
0.05
0.06
0.06

SEQID-00706
P00691

34:659
1
0.42
0.16
0.05
0.05
0.09
0.08
0.00
0.06
0.04
0.05
0.03
0.05
0.05
0.06

SEQID-00707
P00691

34:659
1
0.42
0.16
0.05
0.05
0.09
0.08
0.00
0.06
0.04
0.05
0.03
0.05
0.05
0.06

SEQID-00708
P00691

34:659
1
0.42
0.16
0.05
0.05
0.09
0.08
0.00
0.06
0.04
0.05
0.03
0.05
0.05
0.06

SEQID-00709
P00691

34:659
1
0.42
0.16
0.05
0.05
0.09
0.08
0.00
0.06
0.04
0.05
0.03
0.05
0.05
0.06

SEQID-00710
P00691

34:659
1
0.42
0.16
0.05
0.05
0.09
0.07
0.00
0.05
0.04
0.04
0.03
0.06
0.06
0.06

SEQID-00711
P00691

34:659
1
0.43
0.16
0.05
0.05
0.09
0.06
0.00
0.05
0.04
0.04
0.03
0.06
0.06
0.06

SEQID-00712
P00691

34:659
1
0.42
0.16
0.05
0.05
0.09
0.08
0.00
0.05
0.04
0.04
0.03
0.06
0.06
0.06

SEQID-00713
P00691

34:659
1
0.42
0.16
0.05
0.05
0.09
0.08
0.00
0.05
0.04
0.04
0.03
0.06
0.06
0.06

SEQID-00714
P00691

34:659
1
0.43
0.16
0.05
0.05
0.09
0.08
0.00
0.05
0.04
0.04
0.03
0.06
0.06
0.06

SEQID-00715
P00691

34:659
1
0.43
0.16
0.05
0.05
0.05
0.08
0.00
0.05
0.04
0.04
0.03
0.06
0.06
0.06

SEQID-00716
E7Q2B6

—
1
0.46
0.20
0.06
0.07
0.04
0.09
0.01
0.06
0.07
0.04
0.03
0.07
0.10
0.10

SEQID-00717
E1BKT9

—
1
0.41
0.20
0.03
0.10
0.04
0.06
0.01
0.09
0.12
0.03
0.02
0.06
0.10
0.09

SEQID-00718
W5Q7Z7

—
1
0.42
0.20
0.03
0.10
0.04
0.06
0.01
0.09
0.12
0.02
0.02
0.06
0.11
0.10

SEQID-00719
F1RW75

—
1
0.41
0.20
0.04
0.10
0.04
0.06
0.01
0.09
0.12
0.02
0.02
0.06
0.10
0.10

SEQID-00720
Q8SPI1

—
1
0.45
0.20
0.06
0.07
0.05
0.05
0.02
0.06
0.07
0.03
0.03
0.05
0.13
0.05

SEQID-00721
Q6PVZ5

—
1
0.38
0.19
0.05
0.10
0.04
0.04
0.00
0.05
0.09
0.10
0.01
0.04
0.10
0.06

SEQID-00722
E7Q6N3

—
0
0.53
0.26
0.01
0.07
0.02
0.07
0.00
0.08
0.08
0.04
0.01
0.09
0.12
0.11

SEQID-00723
E7Q6P3

—
0
0.43
0.23
0.05
0.03
0.04
0.08
0.01
0.07
0.10
0.03
0.02
0.08
0.11
0.09

SEQID-00724
E7Q142

—
1
0.53
0.20
0.06
0.03
0.07
0.05
0.00
0.04
0.07
0.04
0.04
0.06
0.09
0.03

SEQID-00725
Q28161

—
1
0.38
0.16
0.05
0.10
0.06
0.05
0.03
0.06
0.05
0.04
0.02
0.03
0.10
0.06

SEQID-00726
P53478

—
1
0.47
0.20
0.05
0.07
0.02
0.06
0.01
0.04
0.09
0.04
0.03
0.08
0.07
0.06

SEQID-00727
A25W69

—
1
0.45
0.21
0.04
0.03
0.03
0.09
0.01
0.04
0.08
0.03
0.01
0.06
0.10
0.11

SEQID-00728
F1S3U9

—
1
0.51
0.21
0.04
0.05
0.03
0.08
0.01
0.05
0.05
0.04
0.02
0.09
0.06
0.11

SEQID-00729
E7Q765

—
1
0.40
0.18
0.04
0.03
0.07
0.06
0.01
0.04
0.17
0.02
0.03
0.05
0.06
0.09

SEQID-00730
E7Q9J9

—
1
0.51
0.23
0.04
0.04
0.05
0.06
0.02
0.04
0.07
0.04
0.03
0.07
0.09
0.10

SEQID-00731
F1SGG1

—
1
0.40
0.23
0.05
0.11
0.04
0.06
0.00
0.07
0.12
0.03
0.02
0.05
0.13
0.06

SEQID-00732
Q03763

—
1
0.43
0.22
0.03
0.07
0.07
0.05
0.02
0.03
0.07
0.06
0.02
0.07
0.07
0.04

SEQID-00733
F1STM4

—
1
0.52
0.21
0.06
0.06
0.04
0.05
0.01
0.03
0.07
0.04
0.03
0.07
0.06
0.11

SEQID-00734
E7Q5T7

—
1
0.42
0.19
0.03
0.05
0.07
0.06
0.00
0.06
0.16
0.01
0.02
0.05
0.11
0.11

SEQID-00735
E7Q880

—
1
0.44
0.21
0.06
0.06
0.04
0.06
0.01
0.10
0.09
0.01
0.03
0.06
0.11
0.07

SEQID-00736
K4BLT8

—
1
0.48
0.25
0.05
0.05
0.04
0.07
0.02
0.04
0.07
0.03
0.02
0.08
0.09
0.08

SEQID-00737
F1SFT0

—
0
0.28
0.09
0.02
0.04
0.02
0.03
0.18
0.11
0.00
0.04
0.00
0.01
0.02
0.06

SEQID-00738
I3LK01

—
1
0.38
0.20
0.06
0.11
0.04
0.03
0.03
0.06
0.13
0.03
0.02
0.05
0.09
0.07

SEQID-00739
ASD984

—
1
0.48
0.23
0.07
0.08
0.04
0.06
0.02
0.03
0.08
0.04
0.03
0.08
0.08
0.08

SEQID-00740
E7Q1Q3

—
0
0.48
0.23
0.03
0.06
0.03
0.07
0.01
0.04
0.11
0.04
0.02
0.07
0.11
0.12

SEQID-00741
E7Q1V1

—
1
0.39
0.21
0.02
0.10
0.07
0.06
0.01
0.08
0.09
0.02
0.03
0.06
0.12
0.05

SEQID-00742
I1N6A2

—
1
0.43
0.22
0.05
0.11
0.04
0.06
0.00
0.06
0.10
0.03
0.02
0.07
0.10
0.07

SEQID-00743
P35323

—
0
0.29
0.08
0.01
0.00
0.00
0.00
0.09
0.22
0.08
0.00
0.03
0.01
0.00
0.14

SEQID-00744
F1SAM0

—
1
0.46
0.20
0.03
0.05
0.04
0.07
0.03
0.05
0.08
0.04
0.03
0.05
0.09
0.08

SEQID-00745
F1SGS9

—
1
0.43
0.16
0.05
0.08
0.06
0.07
0.01
0.05
0.06
0.03
0.05
0.04
0.06
0.06

SEQID-00746
I3LR13

—
1
0.40
0.19
0.04
0.11
0.02
0.04
0.01
0.07
0.09
0.03
0.04
0.02
0.12
0.02

SEQID-00747
P0C522

—
0
0.42
0.25
0.07
0.09
0.04
0.05
0.01
0.06
0.08
0.04
0.01
0.07
0.10
0.06

SEQID-00748
Q6KB38

—
1
0.46
0.23
0.05
0.09
0.03
0.04
0.01
0.07
0.06
0.03
0.02
0.05
0.12
0.07

SEQID-00749
Q2KJ64

—
1
0.51
0.24
0.03
0.05
0.02
0.07
0.01
0.02
0.08
0.05
0.03
0.06
0.10
0.10

SEQID-00750
F1MUE4

—
1
0.49
0.24
0.04
0.07
0.03
0.05
0.01
0.05
0.12
0.01
0.02
0.02
0.16
0.08

SEQID-00751
E1BLN6

—
1
0.23
0.12
0.02
0.11
0.01
0.02
0.10
0.10
0.06
0.03
0.01
0.02
0.04
0.03

SEQID-00752
E7Q207

—
1
0.48
0.20
0.06
0.07
0.04
0.04
0.00
0.03
0.11
0.03
0.01
0.05
0.08
0.11

SEQID-00753
E7QAF4

—
1
0.51
0.28
0.03
0.04
0.07
0.08
0.01
0.04
0.07
0.02
0.02
0.09
0.15
0.09

SEQID-00754
D7TRY0

—
1
0.37
0.13
0.04
0.06
0.05
0.05
0.00
0.03
0.19
0.03
0.01
0.03
0.05
0.14

SEQID-00755
Q9SWB6

—
1
0.50
0.20
0.05
0.04
0.04
0.04
0.02
0.04
0.12
0.03
0.02
0.06
0.09
0.09

SEQID-00756
W5P481

—
1
0.24
0.10
0.07
0.08
0.02
0.05
0.01
0.05
0.06
0.15
0.01
0.02
0.04
0.05

SEQID-00757
W5PVF9

—
1
0.37
0.15
0.04
0.09
0.05
0.06
0.02
0.05
0.08
0.03
0.04
0.03
0.07
0.06

SEQID-00758
F15GP9

—
1
0.41
0.19
0.03
0.10
0.05
0.06
0.02
0.04
0.07
0.05
0.03
0.04
0.07
0.04

SEQID-00759
F15II1

—
1
0.45
0.17
0.03
0.02
0.06
0.04
0.01
0.05
0.13
0.05
0.02
0.06
0.05
0.13

SEQID-00760
Q3SYU2

—
1
0.46
0.22
0.05
0.07
0.03
0.06
0.02
0.04
0.08
0.04
0.02
0.06
0.09
0.09

SEQID-00761
F1MWJ0

—
1
0.30
0.18
0.02
0.03
0.02
0.02
0.03
0.05
0.01
0.12
0.02
0.05
0.07
0.04

SEQID-00762
P02075

—
0
0.56
0.23
0.07
0.04
0.06
0.06
0.01
0.03
0.06
0.04
0.08
0.00
0.12
0.10

SEQID-00763
P60706

—
1
0.47
0.20
0.05
0.07
0.02
0.06
0.01
0.04
0.03
0.04
0.03
0.08
0.07
0.06

SEQID-00764
P01966

—
0
0.56
0.23
0.09
0.03
0.02
0.06
0.00
0.01
0.04
0.03
0.09
0.00
0.15
0.09

SEQID-00765
F1MKE9

—
1
0.43
0.19
0.05
0.09
0.03
0.07
0.01
0.08
0.12
0.02
0.03
0.04
0.11
0.07

SEQID-00766
Q3H7U1

—
1
0.43
0.17
0.04
0.07
0.05
0.07
0.02
0.05
0.09
0.04
0.03
0.03
0.08
0.04

SEQID-00767
O64937

—
1
0.52
0.21
0.04
0.06
0.04
0.06
0.01
0.02
0.08
0.04
0.03
0.07
0.06
0.13

SEQID-00768
K7LZH1

—
1
0.45
0.21
0.06
0.07
0.05
0.08
0.01
0.04
0.10
0.04
0.01
0.08
0.07
0.09

SEQID-00769
O77642

—
1
0.38
0.18
0.07
0.07
0.03
0.06
0.01
0.04
0.16
0.03
0.01
0.04
0.10
0.08

SEQID-00770
P28752

—
1
0.44
0.21
0.05
0.07
0.04
0.07
0.02
0.03
0.09
0.04
0.04
0.06
0.08
0.05

SEQID-00771
F6H7U7

—
1
0.43
0.21
0.06
0.08
0.05
0.06
0.01
0.05
0.11
0.02
0.02
0.05
0.11
0.09

SEQID-00772
F6HN28

—
1
0.44
0.21
0.05
0.09
0.03
0.06
0.01
0.04
0.12
0.02
0.03
0.06
0.11
0.06

SEQID-00773
W5PC91

—
1
0.42
0.19
0.05
0.09
0.04
0.08
0.01
0.08
0.14
0.02
0.03
0.04
0.12
0.08

SEQID-00774
C7IZV3

—
1
0.44
0.20
0.04
0.15
0.02
0.05
0.03
0.03
0.05
0.04
0.05
0.06
0.08
0.06

SEQID-00775
E1C4S8

—
1
0.42
0.19
0.06
0.08
0.04
0.05
0.02
0.10
0.08
0.03
0.05
0.02
0.11
0.10

SEQID-00776
G3MXL3

—
1
0.37
0.18
0.05
0.08
0.04
0.04
0.01
0.06
0.08
0.12
0.01
0.04
0.09
0.06

SEQID-00777
F1SKJ1

—
1
0.42
0.19
0.06
0.09
0.04
0.05
0.01
0.08
0.15
0.02
0.02
0.04
0.11
0.11

SEQID-00778
F1SSA6

—
1
0.42
0.19
0.06
0.09
0.04
0.05
0.01
0.09
0.16
0.02
0.02
0.04
0.11
0.11

SEQID-00779
F1SSS0

—
1
0.48
0.23
0.05
0.05
0.05
0.05
0.01
0.04
0.08
0.04
0.02
0.07
0.09
0.08

SEQID-00780
P02663

—
1
0.47
0.18
0.03
0.04
0.06
0.02
0.01
0.08
0.12
0.00
0.02
0.05
0.07
0.12

SEQID-00781
G1NEY4

—
1
0.38
0.19
0.05
0.10
0.04
0.04
0.00
0.05
0.09
0.10
0.01
0.04
0.10
0.06

SEQID-00782
P02543

—
1
0.37
0.19
0.04
0.13
0.05
0.06
0.00
0.08
0.13
0.01
0.02
0.03
0.12
0.05

SEQID-00783
K4CAJ3

—
1
0.45
0.20
0.04
0.10
0.04
0.06
0.02
0.03
0.10
0.03
0.03
0.06
0.08
0.06

SEQID-00784
E7Q2C6

—
1
0.47
0.25
0.05
0.10
0.04
0.08
0.01
0.04
0.09
0.03
0.02
0.07
0.11
0.10

SEQID-00785
P68103

—
1
0.51
0.21
0.06
0.05
0.04
0.06
0.01
0.03
0.07
0.05
0.03
0.07
0.06
0.12

SEQID-00786
Q04619

—
1
0.47
0.20
0.03
0.06
0.04
0.07
0.01
0.03
0.15
0.02
0.02
0.06
0.08
0.12

SEQID-00787
P31691

—
1
0.45
0.18
0.07
0.08
0.05
0.05
0.01
0.04
0.03
0.07
0.00
0.05
0.08
0.08

SEQID-00788
P00929

—
0
0.45
0.26
0.08
0.07
0.02
0.06
0.00
0.06
0.08
0.05
0.02
0.07
0.10
0.05

SEQID-00789
Q0IWN2

—
1
0.47
0.21
0.09
0.09
0.04
0.04
0.01
0.03
0.11
0.02
0.03
0.04
0.12
0.11

SEQID-00790
P0C276

—
0
0.48
0.22
0.02
0.11
0.05
0.05
0.04
0.07
0.06
0.03
0.03
0.03
0.10
0.15

SEQID-00791
E1B9D0

—
1
0.38
0.21
0.07
0.14
0.02
0.05
0.01
0.05
0.08
0.04
0.03
0.02
0.14
0.02

SEQID-00792
E1BXJ2

—
1
0.47
0.21
0.03
0.03
0.05
0.05
0.01
0.07
0.10
0.02
0.03
0.06
0.11
0.03

SEQID-00793
I1JFH4

—
1
0.50
0.20
0.05
0.03
0.03
0.05
0.01
0.03
0.11
0.02
0.03
0.04
0.09
0.09

SEQID-00794
I1NGL1

—
1
0.42
0.20
0.04
0.08
0.05
0.06
0.03
0.03
0.09
0.02
0.03
0.05
0.11
0.08

SEQID-00795
I3JQE4

—
1
0.48
0.24
0.06
0.05
0.03
0.05
0.02
0.06
0.08
0.03
0.03
0.05
0.13
0.08

SEQID-00796
W5NX33

—
1
0.47
0.23
0.04
0.07
0.05
0.05
0.02
0.04
0.08
0.02
0.05
0.06
0.10
0.05

SEQID-00797
E7Q6A3

—
1
0.46
0.22
0.02
0.05
0.10
0.05
0.02
0.05
0.11
0.02
0.01
0.05
0.13
0.12

SEQID-00798
E7Q9U4

—
1
0.45
0.21
0.04
0.04
0.05
0.06
0.01
0.05
0.10
0.03
0.01
0.05
0.08
0.07

SEQID-00799
E7Q306

—
1
0.43
0.22
0.04
0.05
0.07
0.07
0.01
0.03
0.06
0.04
0.03
0.06
0.10
0.09

SEQID-00800
E7BQS1

—
1
0.46
0.16
0.03
0.04
0.06
0.02
0.01
0.03
0.12
0.00
0.03
0.05
0.06
0.12

SEQID-00801
I1LP26

—
1
0.48
0.17
0.03
0.05
0.05
0.08
0.01
0.04
0.07
0.02
0.03
0.05
0.07
0.17

SEQID-00802
Q14BH5

—
1
0.38
0.20
0.05
0.09
0.05
0.05
0.02
0.05
0.10
0.04
0.01
0.05
0.10
0.08

SEQID-00803
P04653

—
1
0.42
0.21
0.04
0.04
0.05
0.03
0.00
0.08
0.11
0.02
0.02
0.06
0.11
0.08

SEQID-00804
E7QAF7

—
1
0.48
0.21
0.06
0.05
0.03
0.07
0.01
0.04
0.09
0.04
0.01
0.07
0.08
0.12

SEQID-00805
P11839

—
1
0.50
0.26
0.02
0.02
0.02
0.02
0.00
0.11
0.10
0.01
0.03
0.05
0.12
0.07

SEQID-00806
E7Q3D2

—
1
0.47
0.21
0.04
0.07
0.02
0.05
0.01
0.04
0.08
0.04
0.03
0.08
0.07
0.06

SEQID-00807
E7Q6T4

—
1
0.50
0.24
0.03
0.06
0.06
0.07
0.01
0.03
0.07
0.02
0.02
0.08
0.10
0.11

SEQID-00808
E7QA23

—
1
0.42
0.19
0.03
0.06
0.03
0.06
0.00
0.05
0.14
0.02
0.02
0.06
0.09
0.07

SEQID-00809
P02669

—
1
0.41
0.19
0.07
0.04
0.05
0.04
0.01
0.09
0.07
0.01
0.03
0.06
0.06
0.05

SEQID-00810
E7Q742

—
1
0.48
0.24
0.03
0.06
0.06
0.07
0.01
0.04
0.09
0.03
0.04
0.07
0.10
0.06

SEQID-00811
E7Q4K4

—
1
0.48
0.22
0.04
0.03
0.03
0.08
0.01
0.04
0.08
0.04
0.03
0.05
0.12
0.07

SEQID-00812
E7Q3Y5

—
1
0.47
0.22
0.02
0.05
0.06
0.09
0.00
0.04
0.09
0.01
0.02
0.06
0.13
0.07

SEQID-00813
O22493

—
1
0.48
0.20
0.04
0.08
0.03
0.06
0.01
0.03
0.09
0.05
0.02
0.05
0.09
0.07

SEQID-00814
P00698

—
1
0.42
0.20
0.06
0.12
0.10
0.05
0.06
0.02
0.02
0.05
0.01
0.05
0.10
0.05

SEQID-00815
E7Q1A8

—
1
0.48
0.20
0.03
0.03
0.07
0.08
0.00
0.04
0.07
0.02
0.03
0.06
0.10
0.10

SEQID-00816
E7Q2C3

—
1
0.50
0.17
0.05
0.06
0.06
0.07
0.01
0.04
0.09
0.02
0.03
0.08
0.12
0.08

SEQID-00817
E7Q315

—
1
0.51
0.25
0.02
0.01
0.08
0.08
0.03
0.05
0.04
0.03
0.03
0.09
0.11
0.09

SEQID-00818
E7Q0X9

—
1
0.44
0.21
0.03
0.08
0.09
0.07
0.01
0.06
0.07
0.01
0.02
0.06
0.11
0.09

SEQID-00819
P62796

—
0
0.48
0.22
0.04
0.19
0.02
0.03
0.00
0.02
0.05
0.09
0.02
0.06
0.08
0.12

SEQID-00820
E7Q903

—
1
0.34
0.09
0.03
0.07
0.10
0.08
0.00
0.10
0.06
0.05
0.01
0.03
0.04
0.08

SEQID-00821
E7QA30

—
1
0.48
0.21
0.04
0.05
0.04
0.07
0.00
0.03
0.15
0.02
0.01
0.07
0.09
0.12

SEQID-00822
Q69IM0

—
1
0.48
0.24
0.07
0.09
0.02
0.07
0.01
0.04
0.09
0.05
0.03
0.07
0.08
0.08

SEQID-00823
F6HQQ4

—
1
0.50
0.24
0.04
0.08
0.04
0.05
0.02
0.05
0.06
0.02
0.04
0.08
0.09
0.07

SEQID-00824
F6HHW7

—
1
0.47
0.19
0.04
0.05
0.05
0.05
0.01
0.04
0.07
0.04
0.04
0.05
0.08
0.08

SEQID-00825
E7Q876

—
1
0.48
0.22
0.02
0.06
0.07
0.07
0.01
0.07
0.11
0.01
0.02
0.07
0.11
0.13

SEQID-00826
E7Q4C4

—
1
0.42
0.16
0.03
0.04
0.08
0.08
0.00
0.07
0.10
0.03
0.03
0.04
0.06
0.08

SEQID-00827
E7Q7F8

—
1
0.45
0.21
0.04
0.06
0.06
0.06
0.01
0.06
0.06
0.02
0.03
0.07
0.09
0.07

SEQID-00828
K9HAR9

—
1
0.45
0.22
0.05
0.09
0.03
0.07
0.01
0.03
0.08
0.05
0.02
0.06
0.10
0.07

SEQID-00829
F1MPS8

—
1
0.44
0.19
0.03
0.08
0.04
0.05
0.01
0.10
0.14
0.02
0.03
0.04
0.11
0.12

SEQID-00830
K7K247

—
1
0.43
0.12
0.04
0.04
0.05
0.04
0.01
0.07
0.15
0.01
0.03
0.03
0.07
0.19

SEQID-00831
K9HJK7

—
1
0.47
0.22
0.05
0.09
0.03
0.06
0.01
0.04
0.08
0.03
0.03
0.06
0.10
0.05

SEQID-00832
K9HV52

—
1
0.42
0.19
0.05
0.11
0.04
0.04
0.03
0.03
0.10
0.05
0.03
0.05
0.10
0.04

SEQID-00833
E1C4H7

—
1
0.44
0.22
0.05
0.07
0.03
0.05
0.02
0.06
0.08
0.04
0.04
0.04
0.12
0.05

SEQID-00834
E1BTL7

—
1
0.42
0.19
0.03
0.09
0.05
0.05
0.02
0.08
0.06
0.02
0.02
0.05
0.06
0.07

SEQID-00835
I1N1P3

—
1
0.43
0.21
0.05
0.08
0.04
0.05
0.02
0.05
0.08
0.03
0.04
0.05
0.09
0.11

SEQID-00836
W5PEW5

—
1
0.42
0.20
0.03
0.06
0.04
0.04
0.01
0.10
0.18
0.01
0.02
0.03
0.13
0.11

SEQID-00837
B0JEU3

—
1
0.35
0.16
0.03
0.12
0.06
0.04
0.02
0.13
0.11
0.04
0.02
0.04
0.07
0.06

SEQID-00838
P00724

—
1
0.45
0.16
0.04
0.03
0.08
0.06
0.00
0.04
0.06
0.03
0.01
0.04
0.07
0.05

SEQID-00839
P00724

—
1
0.45
0.16
0.04
0.03
0.08
0.06
0.00
0.04
0.06
0.03
0.01
0.04
0.07
0.05

SEQID-00840
K9HWU9

—
1
0.43
0.20
0.07
0.07
0.05
0.07
0.01
0.03
0.06
0.05
0.02
0.06
0.07
0.04

SEQID-00841
Q653V7

—
1
0.45
0.21
0.06
0.10
0.04
0.06
0.00
0.02
0.03
0.06
0.03
0.03
0.10
0.03

SEQID-00842
K5HXA6

—
1
0.46
0.17
0.05
0.06
0.05
0.05
0.01
0.07
0.05
0.05
0.03
0.05
0.07
0.04

SEQID-00843
P23776

—
1
0.43
0.19
0.04
0.05
0.06
0.09
0.02
0.05
0.07
0.03
0.03
0.06
0.09
0.04

SEQID-00844
F1MM32

—
1
0.46
0.20
0.06
0.10
0.03
0.03
0.02
0.04
0.06
0.04
0.03
0.03
0.10
0.05

SEQID-00845
P80025

—
1
0.46
0.20
0.04
0.09
0.06
0.05
0.02
0.05
0.06
0.03
0.03
0.04
0.11
0.06

SEQID-00846
Q67UF5

—
1
0.46
0.21
0.08
0.03
0.04
0.05
0.02
0.04
0.10
0.04
0.01
0.03
0.10
0.11

SEQID-00847
Q95114

—
1
0.45
0.18
0.04
0.07
0.06
0.05
0.04
0.06
0.05
0.05
0.03
0.05
0.09
0.04

SEQID-00848
F1MGU7

—
1
0.44
0.17
0.03
0.04
0.06
0.07
0.02
0.06
0.06
0.04
0.03
0.06
0.07
0.08

SEQID-00849
P15703

—
1
0.46
0.17
0.06
0.02
0.05
0.08
0.01
0.05
0.06
0.04
0.01
0.04
0.06
0.06

SEQID-00850
P53334

—
1
0.39
0.18
0.10
0.02
0.06
0.06
0.01
0.05
0.05
0.03
0.01
0.05
0.05
0.06

SEQID-00851
B4FBO6

—
1
0.38
0.17
0.07
0.07
0.04
0.06
0.04
0.05
0.04
0.05
0.02
0.02
0.10
0.04

SEQID-00852
E0CQY0

—
1
0.45
0.16
0.06
0.05
0.07
0.04
0.03
0.06
0.01
0.06
0.02
0.04
0.05
0.05

SEQID-00853
P01888

—
1
0.45
0.22
0.02
0.07
0.03
0.07
0.02
0.06
0.06
0.02
0.04
0.05
0.12
0.08

SEQID-00854
F1SU23

—
1
0.39
0.16
0.05
0.11
0.03
0.09
0.01
0.06
0.05
0.03
0.03
0.01
0.11
0.06

SEQID-00855
Q3SZR3

—
1
0.47
0.19
0.06
0.05
0.04
0.05
0.02
0.04
0.11
0.02
0.03
0.06
0.09
0.09

SEQID-00856
Q9MZ06

—
1
0.47
0.18
0.03
0.08
0.05
0.04
0.04
0.05
0.09
0.03
0.02
0.03
0.10
0.11

SEQID-00857
Q3ZCH5

—
1
0.38
0.15
0.06
0.09
0.02
0.05
0.01
0.06
0.10
0.04
0.03
0.02
0.09
0.04

SEQID-00858
G1MZ49

—
0
0.48
0.25
0.04
0.07
0.07
0.06
0.02
0.03
0.07
0.02
0.02
0.07
0.14
0.07

SEQID-00859
P80195

—
0
0.50
0.23
0.04
0.05
0.05
0.03
0.01
0.05
0.12
0.01
0.04
0.07
0.14
0.10

SEQID-00860
P04272

—
1
0.45
0.21
0.04
0.08
0.03
0.09
0.01
0.04
0.08
0.03
0.01
0.06
0.10
0.11

SEQID-00861
P60712

—
1
0.47
0.20
0.05
0.07
0.02
0.06
0.01
0.04
0.08
0.04
0.03
0.08
0.07
0.06

SEQID-00862
P63258

—
1
0.47
0.20
0.05
0.07
0.02
0.06
0.01
0.04
0.09
0.04
0.03
0.08
0.07
0.06

SEQID-00863
I1M076

—
0
0.52
0.26
0.02
0.07
0.03
0.08
0.00
0.09
0.08
0.04
0.02
0.09
0.12
0.11

SEQID-00864
P27161

—
0
0.45
0.17
0.05
0.05
0.04
0.11
0.01
0.05
0.17
0.03
0.01
0.05
0.08
0.08

SEQID-00865
Q84MN0

—
0
0.45
0.19
0.03
0.05
0.05
0.11
0.01
0.05
0.16
0.04
0.00
0.05
0.09
0.06

SEQID-00866
Q948R0

—
0
0.40
0.19
0.05
0.10
0.02
0.12
0.01
0.05
0.16
0.05
0.01
0.04
0.08
0.03

SEQID-00867
O23320

—
0
0.47
0.21
0.04
0.01
0.05
0.11
0.01
0.05
0.17
0.02
0.02
0.08
0.09
0.08

SEQID-00868
Q95744

—
0
0.48
0.16
0.05
0.03
0.02
0.11
0.01
0.06
0.11
0.04
0.02
0.07
0.07
0.08

SEQID-00869
Q41420

—
0
0.46
0.19
0.04
0.06
0.06
0.11
0.01
0.03
0.15
0.03
0.01
0.06
0.07
0.07

SEQID-00870
Q2R1Z5

—
1
0.45
0.16
0.03
0.06
0.06
0.12
0.01
0.03
0.13
0.02
0.01
0.06
0.06
0.07

SEQID-00871
Q046AS

—
0
0.48
0.22
0.03
0.06
0.05
0.08
0.02
0.02
0.11
0.04
0.02
0.07
0.09
0.11

SEQID-00872
P00571

—
0
0.49
0.22
0.03
0.08
0.01
0.06
0.01
0.04
0.11
0.05
0.01
0.05
0.09
0.12

SEQID-00873
P05081

—
0
0.50
0.22
0.03
0.07
0.01
0.06
0.01
0.04
0.11
0.05
0.03
0.05
0.10
0.13

SEQID-00874
A5PJA1

—
1
0.46
0.24
0.01
0.05
0.06
0.08
0.02
0.04
0.12
0.03
0.04
0.07
0.11
0.08

SEQID-00875
Q9TTU2

—
1
0.45
0.22
0.01
0.07
0.05
0.07
0.02
0.04
0.14
0.03
0.03
0.07
0.10
0.06

SEQID-00876
Q9UU88

—
1
0.49
0.23
0.01
0.05
0.05
0.06
0.03
0.03
0.17
0.03
0.03
0.08
0.10
0.08

SEQID-00877
Q12055

—
1
0.40
0.20
0.02
0.07
0.06
0.12
0.02
0.03
0.11
0.03
0.04
0.05
0.07
0.07

SEQID-00878
Q2KIW9

—
1
0.44
0.20
0.03
0.03
0.05
0.08
0.02
0.05
0.10
0.04
0.01
0.07
0.07
0.11

SEQID-00879
Q5ZKE7

—
1
0.43
0.20
0.03
0.11
0.04
0.08
0.02
0.04
0.09
0.05
0.01
0.07
0.07
0.09

SEQID-00880
P54877

—
0
0.28
0.09
0.10
0.10
0.02
0.12
0.04
0.02
0.03
0.14
0.02
0.06
0.03
0.10

SEQID-00881
Q10980

—
0
0.21
0.01
0.07
0.13
0.03
0.07
0.21
0.02
0.03
0.10
0.03
0.00
0.00
0.02

SEQID-00882
Q08000

—
0
0.28
0.09
0.04
0.16
0.02
0.05
0.00
0.06
0.18
0.10
0.01
0.02
0.05
0.08

SEQID-00883
Q6H595

—
1
0.31
0.09
0.11
0.16
0.02
0.09
0.08
0.05
0.05
0.07
0.03
0.01
0.04
0.08

SEQID-00884
Q6Z461

—
0
0.26
0.10
0.12
0.17
0.03
0.05
0.03
0.05
0.05
0.07
0.04
0.01
0.05
0.05

SEQID-00885
Q3T0I4

—
1
0.31
0.13
0.07
0.19
0.04
0.08
0.00
0.07
0.03
0.11
0.02
0.03
0.07
0.05

SEQID-00886
P46202

96:211
1
0.60
0.23
0.03
0.07
0.06
0.10
0.01
0.06
0.06
0.00
0.05
0.07
0.11
0.17

SEQID-00887
Q03338

261:356
1
0.48
0.16
0.02
0.12
0.09
0.06
0.01
0.06
0.11
0.00
0.04
0.04
0.05
0.15

SEQID-00888
P40568

331:406
1
0.37
0.17
0.02
0.03
0.04
0.26
0.00
0.03
0.18
0.00
0.01
0.06
0.06
0.08

SEQID-00889
Q32LH1

21:116
1
0.38
0.17
0.04
0.12
0.01
0.01
0.00
0.14
0.26
0.00
0.01
0.03
0.12
0.06

SEQID-00890
Q29RL0

676:821
1
0.33
0.17
0.04
0.21
0.01
0.07
0.00
0.13
0.17
0.00
0.02
0.04
0.09
0.05

SEQID-00891
Q2TBK0

56:181
1
0.40
0.14
0.07
0.11
0.02
0.03
0.01
0.13
0.21
0.00
0.04
0.04
0.07
0.10

SEQID-00892
Q06698

146:226
1
0.47
0.16
0.04
0.11
0.03
0.08
0.00
0.08
0.07
0.00
0.03
0.03
0.09
0.13

SEQID-00893
P53061

251:321
1
0.56
0.18
0.01
0.05
0.06
0.08
0.02
0.04
0.10
0.00
0.02
0.05
0.10
0.22

SEQID-00894
Q9BE40
—
—
1
0.45
0.19
0.05
0.07
0.04
0.05
0.01
0.07
0.15
0.02
0.02
0.05
0.10
0.12

SEQID-00895
F1MRC2
—
—
1
0.45
0.19
0.05
0.07
0.04
0.05
0.01
0.07
0.15
0.02
0.02
0.05
0.10
0.12

SEQID-00896
F1N757
—
—
1
0.47
0.21
0.04
0.06
0.03
0.05
0.02
0.05
0.11
0.03
0.02
0.06
0.07
0.09

SEQID-00897
Q9BE39
—
—
1
0.45
0.19
0.05
0.08
0.05
0.05
0.01
0.07
0.15
0.02
0.02
0.05
0.11
0.12

SEQID-00898
P68138
—
—
1
0.47
0.20
0.05
0.07
0.03
0.06
0.01
0.03
0.09
0.04
0.03
0.08
0.07
0.06

SEQID-00899
P63258
—
—
1
0.47
0.20
0.05
0.07
0.02
0.06
0.01
0.04
0.09
0.04
0.03
0.08
0.07
0.06

SEQID-00900
F1MZX6
—
—
1
0.44
0.19
0.05
0.07
0.05
0.05
0.01
0.08
0.14
0.02
0.02
0.04
0.11
0.11

SEQID-00901
Q9XSC6
—
—
1
0.50
0.20
0.03
0.07
0.05
0.07
0.01
0.04
0.03
0.04
0.05
0.04
0.10
0.10

SEQID-00902
F1MJ28
—
—
1
0.46
0.21
0.05
0.10
0.05
0.06
0.01
0.04
0.09
0.03
0.03
0.06
0.09
0.07

SEQID-00903
Q3ZCS5
—
—
1
0.44
0.20
0.05
0.09
0.05
0.06
0.01
0.07
0.11
0.02
0.03
0.07
0.09
0.07

SEQID-00904
Q0III9
—
—
1
0.43
0.20
0.06
0.10
0.04
0.06
0.01
0.07
0.11
0.03
0.03
0.05
0.10
0.06

SEQID-00905
Q5KR49
—
—
0
0.40
0.18
0.03
0.07
0.02
0.08
0.00
0.05
0.22
0.00
0.01
0.04
0.11
0.15

SEQID-00906
Q3ZC09
—
—
1
0.47
0.22
0.07
0.06
0.05
0.06
0.01
0.03
0.08
0.05
0.02
0.06
0.09
0.10

SEQID-00907
A6QP89
—
—
1
0.46
0.19
0.05
0.06
0.04
0.07
0.01
0.03
0.11
0.03
0.02
0.07
0.06
0.11

SEQID-00908
Q5KR48
—
—
0
0.39
0.17
0.07
0.07
0.02
0.08
0.01
0.06
0.23
0.01
0.00
0.04
0.10
0.15

SEQID-00909
P10096
—
—
1
0.52
0.22
0.06
0.04
0.06
0.06
0.01
0.02
0.05
0.05
0.04
0.07
0.06
0.09

SEQID-00910
P19858
—
—
1
0.53
0.28
0.04
0.05
0.05
0.05
0.02
0.04
0.06
0.04
0.03
0.08
0.11
0.09

SEQID-00911
E1BF23
—
—
1
0.45
0.20
0.04
0.08
0.03
0.06
0.02
0.04
0.09
0.03
0.04
0.04
0.08
0.08

SEQID-00912
A0JNJ5
—
—
0
0.44
0.17
0.08
0.03
0.06
0.05
0.01
0.05
0.14
0.03
0.01
0.04
0.08
0.12

SEQID-00913
P02769
—
—
1
0.46
0.19
0.05
0.06
0.02
0.07
0.05
0.04
0.11
0.01
0.03
0.03
0.11
0.11

SEQID-00914
Q0VCY0
—
—
1
0.49
0.25
0.06
0.07
0.04
0.05
0.02
0.03
0.09
0.04
0.02
0.07
0.10
0.06

SEQID-00915
A5D984
—
—
1
0.48
0.23
0.07
0.08
0.04
0.06
0.02
0.03
0.03
0.04
0.03
0.08
0.08
0.08

SEQID-00916
Q0BDP0
—
—
1
0.48
0.23
0.05
0.06
0.04
0.06
0.01
0.04
0.06
0.05
0.02
0.09
0.08
0.08

SEQID-00917
F1MR86
—
—
1
0.46
0.12
0.04
0.04
0.04
0.05
0.10
0.05
0.04
0.03
0.06
0.02
0.03
0.14

SEQID-00918
Q3SZX4
—
—
1
0.47
0.17
0.05
0.06
0.05
0.05
0.02
0.02
0.07
0.03
0.06
0.04
0.09
0.09

SEQID-00919
Q0IIG5
—
—
1
0.48
0.22
0.05
0.10
0.04
0.05
0.02
0.03
0.07
0.05
0.03
0.06
0.08
0.06

SEQID-00920
F1MQI3
—
—
1
0.47
0.17
0.04
0.06
0.04
0.08
0.01
0.05
0.07
0.02
0.04
0.05
0.07
0.13

SEQID-00921
Q3ZBD7
—
—
1
0.51
0.20
0.04
0.06
0.05
0.04
0.01
0.05
0.07
0.04
0.04
0.06
0.09
0.07

SEQID-00922
G3MYN5
—
—
1
0.47
0.20
0.05
0.14
0.02
0.06
0.01
0.03
0.12
0.02
0.03
0.02
0.12
0.15

SEQID-00923
E1BNV1
—
—
1
0.47
0.20
0.04
0.07
0.03
0.06
0.01
0.04
0.10
0.03
0.02
0.05
0.07
0.11

SEQID-00924
E1BE25
—
—
1
0.44
0.20
0.05
0.06
0.03
0.06
0.02
0.03
0.08
0.06
0.03
0.05
0.05
0.07

SEQID-00925
F1MV90
—
—
1
0.40
0.19
0.07
0.10
0.02
0.05
0.02
0.08
0.21
0.01
0.01
0.05
0.11
0.12

SEQID-00926
Q3TDP6
—
—
1
0.52
0.23
0.06
0.04
0.05
0.06
0.02
0.02
0.07
0.05
0.02
0.05
0.10
0.12

SEQID-00927
Q0P571
—
—
1
0.48
0.16
0.06
0.05
0.05
0.09
0.01
0.05
0.10
0.04
0.01
0.06
0.05
0.11

SEQID-00928
A5PJM2
—
—
1
0.41
0.15
0.04
0.15
0.02
0.06
0.02
0.05
0.14
0.02
0.04
0.02
0.09
0.12

SEQID-00929
Q5E956
—
—
1
0.48
0.22
0.08
0.05
0.05
0.05
0.02
0.05
0.08
0.05
0.02
0.06
0.07
0.10

SEQID-00930
P02510
—
—
1
0.48
0.19
0.03
0.11
0.01
0.06
0.00
0.02
0.09
0.02
0.06
0.06
0.08
0.06

SEQID-00931
Q8MKI3
—
—
1
0.37
0.13
0.05
0.13
0.02
0.06
0.00
0.06
0.21
0.01
0.03
0.03
0.07
0.15

SEQID-00932
Q3ZBP1
—
—
1
0.45
0.21
0.04
0.11
0.04
0.07
0.02
0.04
0.07
0.04
0.03
0.05
0.10
0.07

SEQID-00933
O62654
—
—
1
0.37
0.19
0.06
0.13
0.04
0.05
0.00
0.08
0.14
0.02
0.02
0.04
0.10
0.05

SEQID-00934
F1MPR3
—
—
1
0.50
0.24
0.05
0.06
0.04
0.05
0.03
0.03
0.09
0.03
0.01
0.07
0.09
0.07

SEQID-00935
P00929
—
—
0
0.45
0.26
0.08
0.07
0.02
0.06
0.00
0.06
0.08
0.05
0.02
0.07
0.10
0.05

SEQID-00936
Q32KV0
—
—
1
0.48
0.18
0.06
0.09
0.03
0.05
0.01
0.04
0.10
0.03
0.03
0.06
0.08
0.10

SEQID-00937
F1MHT1
—
—
1
0.45
0.21
0.04
0.08
0.05
0.05
0.02
0.04
0.07
0.03
0.04
0.05
0.10
0.06

SEQID-00938
Q04467
—
—
1
0.50
0.19
0.05
0.07
0.04
0.07
0.02
0.05
0.06
0.04
0.04
0.06
0.07
0.09

SEQID-00939
P19483
—
—
0
0.44
0.25
0.07
0.10
0.03
0.06
0.00
0.05
0.07
0.05
0.01
0.08
0.10
0.07

SEQID-00940
E18B91
—
—
1
0.42
0.23
0.05
0.09
0.04
0.06
0.01
0.06
0.07
0.05
0.01
0.05
0.10
0.06

SEQID-00941
P85100
—
—
0
0.46
0.15
0.06
0.04
0.03
0.06
0.01
0.04
0.14
0.04
0.02
0.04
0.07
0.12

SEQID-00942
Q14BH2
—
—
0
0.44
0.22
0.04
0.07
0.02
0.06
0.01
0.04
0.12
0.03
0.02
0.04
0.10
0.10

SEQID-00943
F1MME6
—
—
1
0.44
0.19
0.05
0.07
0.03
0.05
0.01
0.04
0.10
0.03
0.03
0.05
0.06
0.09

SEQID-00944
Q3SZE5
—
—
0
0.50
0.16
0.05
0.04
0.06
0.08
0.00
0.05
0.12
0.03
0.01
0.06
0.06
0.11

SEQID-00945
P00570
—
—
0
0.48
0.22
0.03
0.09
0.02
0.05
0.01
0.04
0.11
0.05
0.01
0.05
0.09
0.11

SEQID-00946
Q3T149
—
—
1
0.40
0.17
0.05
0.10
0.02
0.04
0.00
0.06
0.10
0.04
0.03
0.03
0.09
0.04

SEQID-00947
Q5EA88
—
—
1
0.52
0.25
0.05
0.04
0.05
0.04
0.03
0.05
0.08
0.05
0.04
0.08
0.09
0.09

SEQID-00948
Q32LG3
—
—
0
0.50
0.25
0.08
0.05
0.04
0.04
0.02
0.03
0.07
0.04
0.02
0.07
0.10
0.09

SEQID-00949
Q27965
—
—
1
0.45
0.21
0.06
0.08
0.05
0.07
0.01
0.05
0.09
0.04
0.02
0.07
0.08
0.09

SEQID-00950
P02070
—
—
0
0.57
0.23
0.07
0.04
0.05
0.06
0.01
0.02
0.06
0.04
0.05
0.00
0.12
0.10

SEQID-00951
P12344
—
—
1
0.47
0.19
0.07
0.07
0.04
0.05
0.02
0.05
0.06
0.04
0.03
0.06
0.08
0.08

SEQID-00952
A4FV78
—
—
1
0.47
0.24
0.04
0.05
0.04
0.08
0.02
0.04
0.09
0.03
0.01
0.06
0.11
0.10

SEQID-00953
F1MJW7
—
—
1
0.35
0.17
0.06
0.07
0.03
0.06
0.01
0.04
0.16
0.05
0.03
0.04
0.09
0.05

SEQID-00954
E1BF59
—
—
1
0.37
0.20
0.07
0.13
0.01
0.04
0.01
0.09
0.14
0.03
0.02
0.03
0.12
0.06

SEQID-00955
P01966
—
—
0
0.56
0.23
0.09
0.03
0.02
0.06
0.00
0.01
0.04
0.03
0.09
0.00
0.15
0.09

SEQID-00956
Q8SQ24
—
—
1
0.41
0.16
0.03
0.06
0.04
0.04
0.00
0.06
0.07
0.08
0.03
0.04
0.09
0.08

SEQID-00957
Q5E9B1
—
—
1
0.53
0.29
0.04
0.04
0.05
0.05
0.01
0.04
0.08
0.04
0.03
0.08
0.11
0.09

SEQID-00958
P33097
—
—
1
0.46
0.20
0.05
0.03
0.05
0.05
0.01
0.04
0.07
0.03
0.02
0.05
0.09
0.06

SEQID-00959
P19120
—
—
1
0.46
0.20
0.05
0.06
0.05
0.07
0.01
0.05
0.09
0.04
0.01
0.07
0.07
0.10

SEQID-00960
Q148F8
—
—
1
0.37
0.22
0.11
0.10
0.00
0.04
0.01
0.04
0.09
0.03
0.05
0.03
0.11
0.02

SEQID-00961
QSMKH62
—
—
1
0.38
0.14
0.04
0.14
0.02
0.04
0.00
0.06
0.22
0.02
0.03
0.04
0.07
0.14

SEQID-00962
F1MPU4
—
—
1
0.33
0.16
0.05
0.08
0.06
0.04
0.01
0.09
0.06
0.02
0.02
0.04
0.07
0.07

SEQID-00963
F1MLX6
—
—
1
0.48
0.18
0.03
0.06
0.06
0.05
0.01
0.04
0.07
0.02
0.04
0.04
0.09
0.09

SEQID-00964
G3N3C9
—
—
1
0.37
0.14
0.07
0.06
0.03
0.04
0.03
0.06
0.05
0.03
0.03
0.04
0.06
0.06

SEQID-00965
Q9N0V4
—
—
1
0.50
0.22
0.03
0.08
0.04
0.07
0.01
0.02
0.08
0.03
0.02
0.06
0.12
0.09

SEQID-00966
P02722
—
—
1
0.51
0.21
0.07
0.08
0.03
0.05
0.01
0.05
0.02
0.05
0.01
0.07
0.08
0.09

SEQID-00967
Q3T145
—
—
1
0.51
0.25
0.06
0.04
0.04
0.08
0.01
0.03
0.06
0.04
0.02
0.07
0.10
0.11

SEQID-00968
P68252
—
—
1
0.39
0.19
0.06
0.07
0.06
0.07
0.01
0.05
0.13
0.02
0.02
0.04
0.10
0.08

SEQID-00969
P45879
—
—
1
0.50
0.19
0.05
0.04
0.07
0.05
0.01
0.03
0.06
0.06
0.01
0.04
0.10
0.10

SEQID-00970
P81948
—
—
1
0.44
0.20
0.05
0.07
0.04
0.07
0.03
0.04
0.09
0.04
0.04
0.06
0.07
0.05

SEQID-00971
E1BI98
—
—
1
0.37
0.18
0.05
0.09
0.03
0.08
0.02
0.05
0.08
0.08
0.02
0.04
0.07
0.07

SEQID-00972
P68432
—
—
0
0.43
0.18
0.08
0.18
0.01
0.03
0.01
0.07
0.06
0.03
0.02
0.05
0.09
0.11

SEQID-00973
Q5E946
—
—
0
0.49
0.26
0.07
0.05
0.02
0.06
0.02
0.03
0.10
0.05
0.02
0.06
0.10
0.12

SEQID-00974
Q77834
—
—
1
0.50
0.22
0.05
0.07
0.04
0.07
0.00
0.02
0.08
0.03
0.02
0.07
0.10
0.10

SEQID-00975
P62261
—
—
1
0.41
0.20
0.06
0.07
0.04
0.09
0.01
0.04
0.13
0.02
0.01
0.05
0.10
0.08

SEQID-00976
Q2KHU5
—
—
1
0.44
0.20
0.08
0.11
0.02
0.04
0.03
0.03
0.07
0.04
0.03
0.04
0.11
0.08

SEQID-00977
P31800
—
—
1
0.41
0.20
0.07
0.09
0.04
0.05
0.03
0.05
0.07
0.04
0.04
0.04
0.11
0.03

SEQID-00978
E1BE77
—
—
1
0.41
0.20
0.06
0.11
0.02
0.04
0.03
0.05
0.10
0.04
0.04
0.02
0.13
0.05

SEQID-00979
P62803
—
—
0
0.48
0.22
0.04
0.19
0.02
0.03
0.00
0.02
0.05
0.09
0.02
0.06
0.08
0.12

SEQID-00980
G3MZF7
—
—
0
0.45
0.15
0.05
0.07
0.00
0.11
0.01
0.04
0.18
0.04
0.00
0.06
0.06
0.06

SEQID-00981
A1A4R1
—
—
0
0.44
0.23
0.09
0.13
0.05
0.02
0.00
0.05
0.06
0.05
0.03
0.05
0.12
0.13

SEQID-00982
P62803
—
—
0
0.48
0.16
0.07
0.09
0.02
0.02
0.00
0.03
0.06
0.03
0.03
0.05
0.05
0.18

SEQID-00983
Q5E947
—
—
1
0.51
0.20
0.04
0.05
0.03
0.08
0.02
0.06
0.04
0.04
0.02
0.08
0.06
0.11

SEQID-00984
P13621
—
—
0
0.52
0.26
0.06
0.07
0.03
0.02
0.01
0.04
0.07
0.02
0.01
0.05
0.12
0.11

SEQID-00985
P28801
—
—
1
0.43
0.23
0.05
0.06
0.04
0.06
0.02
0.09
0.05
0.04
0.02
0.03
0.14
0.07

SEQID-00986
Q3SYR3
—
—
1
0.42
0.17
0.06
0.07
0.04
0.03
0.02
0.05
0.16
0.02
0.02
0.04
0.09
0.07

SEQID-00987
Q3ZBU0
—
—
1
0.46
0.17
0.04
0.09
0.04
0.05
0.01
0.06
0.06
0.04
0.05
0.05
0.07
0.10

SEQID-00988
P13272
—
—
1
0.43
0.22
0.07
0.10
0.02
0.05
0.02
0.03
0.06
0.03
0.03
0.04
0.08
0.07

SEQID-00989
Q3Z8I6
—
—
1
0.34
0.10
0.03
0.08
0.01
0.06
0.12
0.07
0.07
0.05
0.04
0.01
0.06
0.04

SEQID-00990
Q3SYZ8
—
—
1
0.38
0.17
0.07
0.10
0.05
0.06
0.02
0.06
0.06
0.04
0.04
0.05
0.07
0.06

SEQID-00991
P04272
—
—
1
0.45
0.21
0.04
0.08
0.03
0.09
0.01
0.04
0.08
0.03
0.01
0.06
0.10
0.11

SEQID-00992
P23004
—
—
1
0.43
0.22
0.09
0.06
0.05
0.04
0.00
0.05
0.06
0.04
0.04
0.04
0.11
0.06

SEQID-00993
P11179
—
—
1
0.44
0.22
0.08
0.10
0.03
0.05
0.01
0.03
0.07
0.03
0.01
0.06
0.07
0.07

SEQID-00994
Q32PH8
—
—
1
0.50
0.22
0.05
0.06
0.04
0.05
0.01
0.03
0.08
0.05
0.03
0.08
0.06
0.12

SEQID-00995
Q29RK1
—
—
1
0.46
0.22
0.06
0.06
0.04
0.05
0.01
0.05
0.06
0.04
0.03
0.04
0.13
0.06

SEQID-00996
F1N690
—
—
1
0.44
0.21
0.08
0.07
0.03
0.04
0.01
0.04
0.07
0.04
0.01
0.07
0.07
0.07

SEQID-00997
P79134
—
—
1
0.45
0.20
0.06
0.09
0.02
0.08
0.01
0.04
0.10
0.03
0.02
0.07
0.10
0.09

SEQID-00998
P20004
—
—
1
0.47
0.22
0.05
0.07
0.05
0.06
0.02
0.04
0.06
0.05
0.04
0.08
0.09
0.08

SEQID-00999
Q76LV2
—
—
1
0.47
0.19
0.03
0.06
0.04
0.07
0.01
0.04
0.15
0.02
0.02
0.07
0.08
0.12

SEQID-01000
E1BCU2
—
—
1
0.42
0.19
0.04
0.10
0.03
0.06
0.01
0.05
0.10
0.03
0.02
0.04
0.08
0.07

SEQID-01001
P02789
—
—
1
0.45
0.18
0.05
0.06
0.04
0.07
0.04
0.04
0.07
0.04
0.02
0.04
0.08
0.10

SEQID-01002
E1BQC2
—
—
1
0.46
0.19
0.05
0.06
0.04
0.07
0.04
0.03
0.07
0.04
0.02
0.04
0.08
0.09

SEQID-01003
F1NZY2
—
—
1
0.42
0.17
0.03
0.04
0.05
0.06
0.09
0.04
0.07
0.03
0.03
0.05
0.05
0.07

SEQID-01004
P01014
—
—
1
0.52
0.21
0.04
0.04
0.06
0.04
0.01
0.01
0.10
0.03
0.02
0.06
0.09
0.07

SEQID-01005
P00698
—
—
1
0.42
0.20
0.06
0.12
0.10
0.05
0.06
0.02
0.02
0.05
0.01
0.05
0.10
0.05

SEQID-01006
P01005
—
—
0
0.41
0.16
0.05
0.04
0.07
0.09
0.09
0.01
0.07
0.05
0.02
0.02
0.07
0.07

SEQID-01007
F1NFY4
—
—
1
0.39
0.17
0.04
0.08
0.05
0.06
0.09
0.03
0.07
0.04
0.04
0.05
0.06
0.06

SEQID-01008
E1C546
—
—
1
0.49
0.23
0.04
0.05
0.05
0.05
0.02
0.06
0.07
0.02
0.02
0.07
0.09
0.07

SEQID-01009
F1NIV0
—
—
1
0.49
0.22
0.05
0.05
0.03
0.03
0.02
0.06
0.06
0.03
0.03
0.04
0.10
0.06

SEQID-01010
P01013
—
—
1
0.54
0.22
0.04
0.04
0.05
0.05
0.00
0.03
0.10
0.02
0.03
0.06
0.10
0.03

SEQID-01011
E1BTF4
—
—
1
0.53
0.24
0.05
0.05
0.05
0.05
0.01
0.03
0.08
0.02
0.02
0.05
0.13
0.10

SEQID-01012
F1N8Q8
—
—
1
0.43
0.18
0.03
0.12
0.03
0.06
0.02
0.07
0.11
0.03
0.03
0.03
0.11
0.04

SEQID-01013
E1C1X2
—
—
1
0.49
0.28
0.06
0.06
0.02
0.04
0.03
0.05
0.05
0.03
0.04
0.02
0.16
0.04

SEQID-01014
F1P2P7
—
—
0
0.49
0.18
0.06
0.04
0.04
0.05
0.02
0.04
0.14
0.03
0.08
0.04
0.09
0.08

SEQID-01015
O42273
—
—
1
0.50
0.29
0.07
0.06
0.01
0.05
0.02
0.05
0.06
0.02
0.03
0.04
0.16
0.04

SEQID-01016
F1NTK2
—
—
1
0.52
0.22
0.03
0.05
0.03
0.04
0.02
0.06
0.06
0.03
0.03
0.06
0.09
0.07

SEQID-01017
F1NBL0
—
—
1
0.42
0.17
0.03
0.05
0.06
0.05
0.08
0.04
0.07
0.03
0.02
0.06
0.06
0.07

SEQID-01018
P02701
—
—
1
0.56
0.22
0.03
0.07
0.07
0.03
0.01
0.03
0.05
0.04
0.02
0.05
0.11
0.07

SEQID-01019
P02752
—
—
1
0.39
0.12
0.04
0.05
0.04
0.05
0.07
0.05
0.11
0.01
0.04
0.04
0.06
0.07

SEQID-01020
P21760
—
—
1
0.46
0.19
0.07
0.10
0.01
0.06
0.02
0.01
0.12
0.02
0.01
0.02
0.10
0.08

SEQID-01021
F1NVN3
—
—
1
0.42
0.18
0.06
0.06
0.06
0.05
0.04
0.06
0.06
0.04
0.02
0.04
0.08
0.06

SEQID-01022
F1N9M9
—
—
1
0.57
0.21
0.03
0.02
0.02
0.00
0.09
0.02
0.00
0.03
0.02
0.05
0.13
0.11

SEQID-01023
F1NPI8
—
—
1
0.43
0.21
0.04
0.06
0.06
0.04
0.02
0.06
0.06
0.05
0.01
0.04
0.10
0.07

SEQID-01024
P01038
—
—
1
0.42
0.24
0.06
0.09
0.03
0.05
0.03
0.06
0.08
0.03
0.01
0.04
0.11
0.06

SEQID-01025
P41366
—
—
1
0.43
0.20
0.04
0.09
0.04
0.06
0.04
0.04
0.04
0.06
0.01
0.04
0.10
0.06

SEQID-01026
P02668
—
—
1
0.44
0.20
0.05
0.04
0.04
0.02
0.01
0.09
0.07
0.01
0.02
0.07
0.07
0.06

SEQID-01027
P02663
—
—
1
0.47
0.18
0.03
0.04
0.06
0.02
0.01
0.08
0.12
0.00
0.02
0.05
0.07
0.12

SEQID-01028
G5E5H7
—
—
1
0.50
0.26
0.06
0.02
0.03
0.06
0.04
0.06
0.10
0.01
0.01
0.06
0.15
0.10

SEQID-01029
P24627
—
—
1
0.44
0.19
0.06
0.07
0.04
0.05
0.05
0.05
0.07
0.04
0.02
0.02
0.11
0.09

SEQID-01030
F1MUT3
—
—
1
0.43
0.20
0.05
0.06
0.04
0.04
0.03
0.04
0.08
0.04
0.03
0.05
0.09
0.08

SEQID-01031
Q2UVX4
—
—
1
0.47
0.23
0.04
0.07
0.04
0.06
0.01
0.06
0.03
0.03
0.02
0.06
0.09
0.08

SEQID-01032
Q95114
—
—
1
0.45
0.18
0.04
0.07
0.06
0.05
0.04
0.06
0.05
0.05
0.03
0.05
0.09
0.04

SEQID-01033
P18892
—
—
1
0.45
0.21
0.04
0.09
0.02
0.05
0.02
0.03
0.11
0.03
0.02
0.05
0.09
0.05

SEQID-01034
P81265
—
—
1
0.42
0.19
0.05
0.07
0.04
0.06
0.03
0.05
0.07
0.04
0.02
0.04
0.07
0.07

SEQID-01035
P80025
—
—
1
0.46
0.20
0.04
0.09
0.06
0.05
0.02
0.05
0.06
0.03
0.03
0.04
0.11
0.06

SEQID-01036
P80195
—
—
0
0.50
0.23
0.04
0.05
0.05
0.03
0.01
0.05
0.12
0.01
0.04
0.07
0.14
0.10

SEQID-01037
Q9TUM6-2
—
—
1
0.45
0.23
0.06
0.05
0.05
0.06
0.01
0.07
0.08
0.03
0.02
0.05
0.11
0.08

SEQID-01038
P11151
—
—
1
0.48
0.20
0.04
0.06
0.05
0.05
0.02
0.03
0.07
0.04
0.04
0.05
0.09
0.08

SEQID-01039
F1N726
—
—
1
0.41
0.21
0.03
0.07
0.05
0.06
0.05
0.05
0.07
0.04
0.02
0.04
0.11
0.03

SEQID-01040
Q29443
—
—
1
0.44
0.17
0.05
0.05
0.06
0.07
0.05
0.03
0.07
0.04
0.03
0.03
0.08
0.11

SEQID-01041
F1MLW7
—
—
1
0.42
0.19
0.04
0.04
0.03
0.03
0.03
0.04
0.04
0.05
0.01
0.03
0.08
0.05

SEQID-01042
G5EST5
—
—
1
0.48
0.22
0.03
0.04
0.03
0.05
0.02
0.04
0.07
0.03
0.02
0.04
0.08
0.05

SEQID-01043
G5E513
—
—
1
0.46
0.19
0.04
0.05
0.03
0.05
0.02
0.04
0.07
0.03
0.02
0.03
0.07
0.06

SEQID-01044
Q3ZCH5
—
—
1
0.38
0.15
0.06
0.09
0.02
0.05
0.01
0.06
0.10
0.04
0.03
0.02
0.09
0.04

SEQID-01045
P26201
—
—
1
0.52
0.24
0.03
0.04
0.06
0.04
0.02
0.03
0.06
0.03
0.02
0.08
0.09
0.08

SEQID-01046
Q0P569
—
—
1
0.39
0.18
0.05
0.10
0.03
0.06
0.00
0.09
0.15
0.02
0.04
0.01
0.12
0.07

SEQID-01047
E1BGX8
—
—
1
0.41
0.17
0.05
0.12
0.04
0.06
0.03
0.04
0.05
0.05
0.03
0.04
0.09
0.07

SEQID-01048
F1MLW8
—
—
1
0.44
0.20
0.06
0.03
0.02
0.07
0.03
0.06
0.04
0.03
0.02
0.03
0.11
0.07

SEQID-01049
G3N0V0
—
—
1
0.46
0.18
0.03
0.06
0.03
0.05
0.03
0.05
0.06
0.03
0.03
0.02
0.05
0.07

SEQID-01050
F1MGU7
—
—
1
0.44
0.17
0.03
0.04
0.06
0.07
0.02
0.06
0.06
0.04
0.03
0.06
0.07
0.08

SEQID-01051
G5E604
—
—
0
0.30
0.17
0.06
0.10
0.06
0.04
0.02
0.08
0.02
0.06
0.00
0.04
0.06
0.00

SEQID-01052
F6R3I5
—
—
1
0.44
0.15
0.05
0.04
0.08
0.04
0.06
0.05
0.04
0.03
0.03
0.03
0.06
0.07

SEQID-01053
Q4GZT4
—
—
1
0.55
0.26
0.04
0.05
0.05
0.04
0.02
0.03
0.06
0.04
0.02
0.07
0.13
0.07

SEQID-01054
F1N647
—
—
1
0.45
0.23
0.05
0.07
0.04
0.04
0.02
0.07
0.07
0.04
0.03
0.04
0.13
0.04

SEQID-01055
G3MXB5
—
—
1
0.42
0.22
0.04
0.02
0.05
0.03
0.05
0.07
0.04
0.04
0.02
0.02
0.12
0.04

SEQID-01056
Q27960
—
—
1
0.56
0.28
0.04
0.04
0.04
0.03
0.04
0.03
0.06
0.03
0.01
0.09
0.12
0.07

SEQID-01057
G3N028
—
—
1
0.34
0.16
0.03
0.06
0.04
0.03
0.03
0.07
0.04
0.07
0.01
0.05
0.06
0.03

SEQID-01058
P10790
—
—
1
0.60
0.22
0.02
0.04
0.04
0.08
0.01
0.04
0.06
0.04
0.02
0.05
0.07
0.11

SEQID-01059
Q3SZR3
—
—
1
0.47
0.19
0.06
0.05
0.04
0.05
0.02
0.04
0.11
0.02
0.03
0.06
0.09
0.09

SEQID-01060
Q9MZ06
—
—
1
0.47
0.18
0.03
0.08
0.05
0.04
0.04
0.05
0.09
0.03
0.02
0.03
0.10
0.11

SEQID-01061
P02702
—
—
1
0.41
0.12
0.05
0.08
0.06
0.04
0.06
0.05
0.06
0.02
0.04
0.03
0.06
0.06

SEQID-01062
A2I7M9
—
—
1
0.50
0.36
0.04
0.07
0.05
0.05
0.00
0.05
0.09
0.02
0.03
0.06
0.14
0.06

SEQID-01063
Q9XSG3
—
—
1
0.48
0.19
0.05
0.05
0.04
0.06
0.01
0.05
0.08
0.04
0.02
0.07
0.07
0.10

SEQID-01064
A6OL27
—
—
1
0.42
0.17
0.04
0.08
0.04
0.05
0.05
0.04
0.06
0.04
0.03
0.03
0.06
0.08

SEQID-01065
F1MM32
—
—
1
0.46
0.20
0.06
0.10
0.03
0.03
0.02
0.04
0.06
0.04
0.03
0.03
0.10
0.05

SEQID-01066
A0JNP2
—
—
0
0.51
0.28
0.08
0.06
0.06
0.04
0.04
0.01
0.05
0.01
0.00
0.05
0.15
0.07

SEQID-01067
P01888
—
—
1
0.45
0.22
0.02
0.07
0.03
0.07
0.02
0.06
0.06
0.02
0.04
0.05
0.12
0.08

SEQID-01068
G3MXD9
—
—
0
0.47
0.27
0.03
0.06
0.03
0.03
0.02
0.06
0.03
0.04
0.00
0.02
0.14
0.04

SEQID-01069
P10152
—
—
0
0.44
0.19
0.02
0.12
0.05
0.07
0.04
0.03
0.05
0.04
0.05
0.07
0.07
0.07

SEQID-01070
Q3SYR8
—
—
1
0.42
0.31
0.03
0.09
0.06
0.08
0.05
0.01
0.07
0.01
0.01
0.06
0.06
0.06

SEQID-01071
Q8SPP7
—
—
1
0.38
0.20
0.06
0.12
0.04
0.03
0.03
0.07
0.03
0.05
0.04
0.04
0.09
0.02

SEQID-01072
P30932
—
—
1
0.55
0.26
0.04
0.04
0.03
0.04
0.04
0.04
0.07
0.04
0.02
0.10
0.10
0.07

SEQID-01073
P0S037-2
—
—
1
0.42
0.21
0.04
0.09
0.05
0.05
0.02
0.05
0.04
0.04
0.03
0.05
0.11
0.05

SEQID-01074
P02676
—
—
1
0.41
0.15
0.02
0.08
0.06
0.07
0.02
0.06
0.07
0.04
0.02
0.04
0.06
0.09

SEQID-01075
Q2TBI0
—
—
1
0.51
0.27
0.04
0.07
0.05
0.05
0.01
0.04
0.06
0.03
0.03
0.06
0.14
0.05

SEQID-01076
Q8WML4
—
—
1
0.37
0.14
0.08
0.04
0.03
0.03
0.01
0.04
0.03
0.04
0.04
0.03
0.07
0.02

SEQID-01077
P04776
—
—
1
0.38
0.17
0.04
0.08
0.08
0.04
0.02
0.11
0.10
0.04
0.02
0.05
0.08
0.06

SEQID-01078
Q94LX2
—
—
1
0.35
0.17
0.03
0.11
0.07
0.05
0.01
0.09
0.15
0.02
0.02
0.05
0.09
0.07

SEQID-01079
Q4LER6
—
—
1
0.37
0.16
0.03
0.09
0.06
0.04
0.01
0.09
0.14
0.02
0.04
0.04
0.08
0.08

SEQID-01080
Q9SB11
—
—
1
0.35
0.17
0.03
0.09
0.06
0.06
0.01
0.10
0.11
0.03
0.03
0.04
0.08
0.05

SEQID-01081
K7LZA4
—
—
1
0.37
0.17
0.03
0.08
0.06
0.05
0.01
0.10
0.10
0.04
0.04
0.04
0.08
0.04

SEQID-01082
P11828
—
—
1
0.37
0.17
0.04
0.08
0.08
0.03
0.02
0.12
0.09
0.03
0.02
0.05
0.08
0.04

SEQID-01083
P04347
—
—
1
0.36
0.17
0.02
0.09
0.06
0.05
0.01
0.10
0.09
0.04
0.04
0.03
0.08
0.04

SEQID-01084
I1L360
—
—
1
0.46
0.17
0.03
0.09
0.04
0.05
0.01
0.05
0.12
0.03
0.04
0.05
0.08
0.08

SEQID-01085
B3TDK6
—
—
1
0.47
0.22
0.04
0.07
0.05
0.06
0.01
0.03
0.07
0.04
0.04
0.06
0.11
0.07

SEQID-01086
Q04672
—
—
1
0.46
0.18
0.03
0.09
0.04
0.04
0.01
0.05
0.12
0.03
0.04
0.05
0.08
0.08

SEQID-01087
I1JF86
—
—
1
0.48
0.19
0.03
0.08
0.04
0.04
0.01
0.04
0.12
0.03
0.04
0.05
0.10
0.08

SEQID-01088
P09439
—
—
1
0.47
0.23
0.04
0.07
0.05
0.06
0.01
0.04
0.07
0.04
0.03
0.06
0.10
0.07

SEQID-01089
I1LXD1
—
—
1
0.51
0.21
0.05
0.06
0.04
0.04
0.03
0.03
0.07
0.05
0.03
0.06
0.06
0.09

SEQID-01090
P01070
—
—
1
0.47
0.22
0.04
0.07
0.05
0.08
0.02
0.03
0.03
0.04
0.02
0.03
0.09
0.07

SEQID-01091
P08170
—
—
1
0.47
0.22
0.04
0.06
0.05
0.06
0.00
0.04
0.08
0.03
0.04
0.06
0.10
0.07

SEQID-01092
Q2I0H4
—
—
1
0.53
0.24
0.05
0.05
0.04
0.08
0.01
0.01
0.06
0.05
0.03
0.07
0.07
0.10

SEQID-01093
C6T9Z5
—
—
1
0.48
0.22
0.06
0.06
0.05
0.06
0.01
0.04
0.08
0.04
0.05
0.06
0.09
0.08

SEQID-01094
C6TN36
—
—
1
0.52
0.24
0.05
0.05
0.05
0.08
0.01
0.01
0.06
0.04
0.02
0.07
0.06
0.10

SEQID-01095
K7KL44
—
—
1
0.55
0.23
0.05
0.04
0.04
0.07
0.00
0.01
0.05
0.04
0.04
0.06
0.08
0.09

SEQID-01096
I1KC70
—
—
1
0.53
0.24
0.06
0.05
0.04
0.08
0.01
0.01
0.06
0.05
0.03
0.07
0.06
0.10

SEQID-01097
I1NGF4
—
—
0
0.41
0.22
0.03
0.10
0.07
0.05
0.00
0.08
0.09
0.02
0.02
0.06
0.11
0.05

SEQID-01098
I1NSS0
—
—
1
0.48
0.22
0.06
0.06
0.05
0.06
0.01
0.04
0.08
0.04
0.05
0.06
0.09
0.03

SEQID-01099
I1N747
—
—
1
0.46
0.22
0.12
0.09
0.01
0.03
0.00
0.05
0.08
0.04
0.03
0.03
0.10
0.05

SEQID-01100
P29531
—
—
1
0.47
0.23
0.12
0.09
0.01
0.03
0.00
0.04
0.07
0.04
0.04
0.05
0.09
0.05

SEQID-01101
I1LE33
—
—
1
0.38
0.17
0.03
0.12
0.05
0.04
0.01
0.07
0.15
0.03
0.04
0.04
0.09
0.07

SEQID-01102
I1JH86
—
—
1
0.44
0.23
0.03
0.05
0.05
0.02
0.01
0.05
0.09
0.05
0.03
0.04
0.11
0.08

SEQID-01103
P13917
—
—
1
0.47
0.22
0.04
0.05
0.06
0.03
0.03
0.10
0.02
0.04
0.04
0.04
0.11
0.03

SEQID-01104
I1MAE6
—
—
1
0.49
0.22
0.06
0.05
0.03
0.05
0.03
0.03
0.08
0.05
0.04
0.06
0.06
0.08

SEQID-01105
I1KUG6
—
—
1
0.47
0.22
0.05
0.06
0.02
0.06
0.01
0.03
0.09
0.04
0.03
0.08
0.07
0.06

SEQID-01106
I1MA91
—
—
1
0.49
0.21
0.05
0.06
0.05
0.05
0.03
0.02
0.09
0.05
0.03
0.06
0.07
0.08

SEQID-01107
Q8RVH5
—
—
1
0.48
0.21
0.04
0.04
0.06
0.03
0.03
0.10
0.02
0.04
0.06
0.04
0.11
0.04

SEQID-01108
I1KAJ4
—
—
1
0.49
0.22
0.06
0.05
0.04
0.05
0.03
0.02
0.08
0.06
0.04
0.06
0.06
0.07

SEQID-01109
Q71EW8
—
—
1
0.49
0.23
0.06
0.06
0.04
0.06
0.00
0.03
0.08
0.03
0.02
0.06
0.10
0.08

SEQID-01110
P05046
—
—
1
0.52
0.25
0.05
0.03
0.07
0.06
0.00
0.03
0.04
0.02
0.03
0.05
0.12
0.06

SEQID-01111
P19594
—
—
1
0.43
0.15
0.02
0.08
0.04
0.09
0.06
0.08
0.12
0.02
0.04
0.07
0.08
0.10

SEQID-01112
K7MJY8
—
—
1
0.49
0.23
0.04
0.08
0.04
0.05
0.01
0.04
0.10
0.03
0.04
0.06
0.11
0.06

SEQID-01113
P25698
—
—
1
0.52
0.21
0.04
0.06
0.03
0.06
0.01
0.02
0.07
0.04
0.03
0.07
0.06
0.13

SEQID-01114
I7FST9
—
—
1
0.46
0.18
0.05
0.03
0.04
0.07
0.01
0.05
0.10
0.03
0.03
0.05
0.06
0.10

SEQID-01115
C6T7Y1
—
—
1
0.47
0.21
0.05
0.07
0.02
0.06
0.01
0.03
0.09
0.04
0.03
0.08
0.07
0.06

SEQID-01116
I1JPW5
—
—
1
0.47
0.23
0.07
0.04
0.06
0.07
0.01
0.04
0.08
0.05
0.01
0.06
0.08
0.10

SEQID-01117
I1LN49
—
—
1
0.48
0.18
0.03
0.08
0.03
0.04
0.02
0.05
0.09
0.03
0.08
0.05
0.10
0.06

SEQID-01118
C6TNT2
—
—
1
0.48
0.19
0.05
0.04
0.05
0.06
0.01
0.04
0.09
0.02
0.01
0.05
0.09
0.11

SEQID-01119
O64458
—
—
1
0.45
0.18
0.04
0.05
0.04
0.06
0.02
0.05
0.09
0.04
0.04
0.06
0.08
0.08

SEQID-01120
P01064
—
—
0
0.28
0.08
0.00
0.08
0.02
0.13
0.16
0.05
0.03
0.01
0.01
0.02
0.06
0.07

SEQID-01121
C65WV3
—
—
1
0.44
0.18
0.05
0.06
0.02
0.06
0.01
0.06
0.08
0.02
0.04
0.05
0.07
0.07

SEQID-01122
C6TKH0
—
—
1
0.45
0.20
0.07
0.04
0.07
0.05
0.03
0.07
0.07
0.04
0.03
0.05
0.08
0.08

SEQID-01123
I1JGP8
—
—
1
0.50
0.24
0.08
0.04
0.04
0.05
0.01
0.02
0.07
0.05
0.02
0.06
0.11
0.08

SEQID-01124
I1K668
—
—
1
0.47
0.22
0.05
0.07
0.04
0.07
0.01
0.04
0.11
0.04
0.01
0.07
0.08
0.11

SEQID-01125
I1KAB7
—
—
1
0.47
0.20
0.05
0.03
0.05
0.07
0.01
0.05
0.11
0.03
0.03
0.05
0.07
0.10

SEQID-01126
I1NFS4
—
—
1
0.44
0.24
0.07
0.08
0.03
0.05
0.00
0.05
0.08
0.05
0.02
0.07
0.09
0.05

SEQID-01127
P25272
—
—
1
0.48
0.24
0.04
0.06
0.03
0.07
0.02
0.05
0.06
0.04
0.01
0.07
0.10
0.06

SEQID-01128
H2D553
—
—
1
0.47
0.25
0.08
0.05
0.06
0.05
0.02
0.04
0.07
0.04
0.02
0.07
0.09
0.07

SEQID-01129
I1JB84
—
—
1
0.48
0.25
0.03
0.05
0.05
0.05
0.02
0.04
0.05
0.04
0.03
0.07
0.08
0.06

SEQID-01130
I1KTX8
—
—
1
0.49
0.26
0.03
0.05
0.02
0.06
0.00
0.02
0.06
0.05
0.02
0.05
0.13
0.09

SEQID-01131
I1KU21
—
—
1
0.08
0.21
0.05
0.07
0.03
0.06
0.02
0.04
0.09
0.04
0.02
0.05
0.08
0.08

SEQID-01132
I1L3K7
—
—
1
0.45
0.22
0.07
0.04
0.05
0.06
0.01
0.05
0.08
0.05
0.02
0.06
0.08
0.10

SEQID-01133
I1K3X9
—
—
1
0.44
0.21
0.05
0.07
0.04
0.06
0.02
0.03
0.09
0.04
0.04
0.06
0.08
0.05

SEQID-01134
I1LDR2
—
—
1
0.42
0.17
0.04
0.07
0.05
0.06
0.02
0.06
0.09
0.04
0.02
0.04
0.07
0.04

SEQID-01135
O48548
—
—
1
0.46
0.24
0.06
0.08
0.04
0.06
0.01
0.04
0.04
0.04
0.03
0.06
0.11
0.05

SEQID-01136
O22518
—
—
1
0.42
0.19
0.08
0.07
0.04
0.07
0.01
0.08
0.06
0.04
0.02
0.08
0.06
0.04

SEQID-01137
Q01915
—
—
0
0.43
0.26
0.07
0.09
0.03
0.05
0.01
0.06
0.08
0.04
0.01
0.08
0.11
0.06

SEQID-01138
Q42806
—
—
1
0.50
0.25
0.06
0.06
0.04
0.06
0.02
0.02
0.07
0.04
0.02
0.07
0.10
0.09

SEQID-01139
D6C4Z9
—
—
1
0.49
0.21
0.04
0.04
0.04
0.07
0.01
0.03
0.14
0.02
0.02
0.06
0.10
0.13

SEQID-01140
I1K3K3
—
—
1
0.48
0.23
0.06
0.06
0.05
0.07
0.01
0.03
0.06
0.05
0.03
0.08
0.08
0.07

SEQID-01141
K7LEQ5
—
—
0
0.40
0.07
0.03
0.05
0.05
0.09
0.00
0.06
0.03
0.11
0.09
0.03
0.01
0.06

SEQID-01142
P26413
—
—
1
0.45
0.20
0.06
0.07
0.06
0.07
0.01
0.04
0.10
0.04
0.01
0.07
0.07
0.10

SEQID-01143
C6TG91
—
—
1
0.46
0.23
0.05
0.12
0.03
0.04
0.01
0.04
0.09
0.04
0.01
0.05
0.09
0.10

SEQID-01144
I1NJ85
—
—
1
0.48
0.24
0.07
0.05
0.04
0.06
0.02
0.03
0.05
0.05
0.03
0.07
0.09
0.07

SEQID-01145
K7M3E5
—
—
1
0.51
0.25
0.07
0.05
0.06
0.03
0.01
0.04
0.09
0.04
0.02
0.06
0.06
0.08

SEQID-01146
Q9ZNZ1
—
—
0
0.43
0.18
0.02
0.08
0.03
0.05
0.06
0.09
0.14
0.03
0.04
0.09
0.10
0.10

SEQID-01147
P27066
—
—
1
0.46
0.19
0.06
0.09
0.03
0.06
0.02
0.03
0.09
0.05
0.04
0.04
0.09
0.06

SEQID-01148
C6SVX5
—
—
1
0.45
0.16
0.06
0.14
0.04
0.04
0.03
0.03
0.04
0.04
0.04
0.04
0.06
0.11

SEQID-01149
I1JUP4
—
—
1
0.46
0.24
0.08
0.05
0.03
0.04
0.01
0.03
0.02
0.06
0.01
0.08
0.10
0.05

SEQID-01150
I1K354
—
—
1
0.50
0.23
0.06
0.06
0.04
0.06
0.02
0.04
0.08
0.04
0.02
0.06
0.10
0.08

SEQID-01151
I1K5E6
—
—
1
0.49
0.23
0.05
0.08
0.04
0.08
0.02
0.02
0.03
0.04
0.03
0.06
0.10
0.06

SEQID-01152
I1KYW3
—
—
1
0.46
0.21
0.04
0.05
0.04
0.06
0.03
0.05
0.05
0.04
0.02
0.08
0.09
0.07

SEQID-01153
I1LKD3
—
—
1
0.49
0.20
0.05
0.06
0.03
0.06
0.01
0.03
0.09
0.04
0.03
0.05
0.10
0.08

SEQID-01154
I1LQR8
—
—
1
0.46
0.19
0.06
0.06
0.05
0.03
0.07
0.03
0.02
0.05
0.07
0.03
0.09
0.02

SEQID-01155
I1LUL9
—
—
1
0.45
0.22
0.07
0.08
0.04
0.06
0.01
0.03
0.07
0.04
0.02
0.06
0.09
0.06

SEQID-01156
I1M1V8
—
—
1
0.46
0.23
0.07
0.05
0.05
0.05
0.02
0.04
0.06
0.04
0.03
0.07
0.08
0.05

SEQID-01157
K7KTR9
—
—
1
0.46
0.23
0.06
0.06
0.03
0.04
0.01
0.04
0.02
0.05
0.02
0.08
0.11
0.03

SEQID-01158
Q8LJW0
—
—
1
0.52
0.22
0.04
0.12
0.04
0.05
0.01
0.03
0.05
0.04
0.04
0.07
0.09
0.12

SEQID-01159
Q9XEY1
—
—
1
0.42
0.18
0.03
0.12
0.05
0.10
0.02
0.05
0.09
0.03
0.03
0.04
0.06
0.09

SEQID-01160
P28759
—
—
1
0.49
0.20
0.05
0.03
0.06
0.05
0.00
0.04
0.08
0.04
0.02
0.04
0.10
0.09

SEQID-01161
C6SVT0
—
—
1
0.46
0.23
0.04
0.06
0.05
0.05
0.03
0.06
0.08
0.03
0.02
0.04
0.10
0.09

SEQID-01162
C6T9B1
—
—
1
0.48
0.20
0.06
0.07
0.05
0.08
0.01
0.02
0.08
0.05
0.12
0.06
0.09
0.05

SEQID-01163
C6TGW2
—
—
1
0.39
0.19
0.08
0.08
0.03
0.07
0.01
0.03
0.14
0.02
0.01
0.05
0.10
0.07

SEQID-01164
I1JXA0
—
—
1
0.43
0.21
0.04
0.10
0.04
0.08
0.01
0.03
0.11
0.03
0.02
0.06
0.08
0.07

SEQID-01165
I1K4Q5
—
—
1
0.52
0.21
0.05
0.07
0.03
0.04
0.00
0.03
0.06
0.04
0.02
0.04
0.03
0.18

SEQID-01166
I1K5M9
—
—
1
0.46
0.21
0.05
0.06
0.04
0.07
0.01
0.02
0.08
0.05
0.03
0.06
0.08
0.07

SEQID-01167
I1MAE7
—
—
1
0.47
0.19
0.05
0.09
0.03
0.06
0.01
0.03
0.10
0.03
0.04
0.03
0.10
0.07

SEQID-01168
K7K4G2
—
—
1
0.40
0.15
0.03
0.13
0.04
0.04
0.01
0.05
0.20
0.03
0.02
0.04
0.07
0.10

SEQID-01169
K7MX62
—
—
0
0.53
0.18
0.06
0.05
0.04
0.05
0.00
0.02
0.10
0.03
0.02
0.03
0.05
0.15

SEQID-01170
P05478
—
—
1
0.48
0.17
0.03
0.08
0.06
0.07
0.00
0.02
0.12
0.02
0.01
0.04
0.04
0.11

SEQID-01171
C6SY27
—
—
0
0.52
0.24
0.05
0.14
0.03
0.08
0.00
0.03
0.04
0.01
0.00
0.07
0.07
0.17

SEQID-01172
C6T9D7
—
—
1
0.46
0.20
0.05
0.07
0.05
0.05
0.01
0.04
0.08
0.04
0.02
0.05
0.08
0.08

SEQID-01173
I1JFX0
—
—
1
0.49
0.22
0.06
0.05
0.03
0.04
0.01
0.04
0.07
0.04
0.05
0.05
0.08
0.07

SEQID-01174
I1KGP0
—
—
1
0.49
0.22
0.04
0.11
0.06
0.03
0.00
0.03
0.10
0.03
0.02
0.07
0.10
0.14

SEQID-01175
I1KJI7
—
—
1
0.49
0.22
0.05
0.07
0.03
0.05
0.00
0.04
0.03
0.05
0.02
0.10
0.05
0.07

SEQID-01176
I1L8R1
—
—
1
0.46
0.19
0.07
0.12
0.04
0.04
0.00
0.03
0.05
0.03
0.02
0.05
0.07
0.13

SEQID-01177
I1LID6
—
—
1
0.45
0.18
0.07
0.14
0.04
0.04
0.01
0.03
0.03
0.07
0.07
0.05
0.05
0.09

SEQID-01178
I1LWR4
—
—
1
0.45
0.20
0.06
0.07
0.05
0.05
0.01
0.03
0.11
0.03
0.02
0.06
0.08
0.08

SEQID-01179
I1M561
—
—
1
0.49
0.25
0.03
0.06
0.04
0.06
0.01
0.01
0.09
0.05
0.02
0.05
0.13
0.08

SEQID-01180
I1N5E4
—
—
1
0.45
0.24
0.06
0.06
0.04
0.07
0.01
0.04
0.06
0.03
0.02
0.06
0.11
0.07

SEQID-01181
K7KN32
—
—
1
0.49
0.27
0.05
0.07
0.05
0.05
0.01
0.04
0.04
0.03
0.03
0.09
0.12
0.04

SEQID-01182
Q42807
—
—
1
0.44
0.18
0.04
0.10
0.03
0.06
0.01
0.05
0.10
0.03
0.03
0.06
0.08
0.07

SEQID-01183
A0A762
—
—
1
0.43
0.14
0.04
0.03
0.04
0.12
0.01
0.02
0.13
0.03
0.02
0.04
0.06
0.12

SEQID-01184
C6SZ13
—
—
1
0.50
0.28
0.09
0.05
0.01
0.04
0.00
0.10
0.02
0.03
0.04
0.08
0.11
0.04

SEQID-01185
C6T1V2
—
—
1
0.47
0.17
0.03
0.10
0.04
0.06
0.00
0.04
0.11
0.04
0.02
0.04
0.04
0.09

SEQID-01186
I1J0H6
—
—
1
0.48
0.20
0.03
0.14
0.02
0.04
0.01
0.03
0.07
0.07
0.02
0.05
0.07
0.10

SEQID-01187
I1KUR0
—
—
1
0.46
0.23
0.03
0.10
0.03
0.08
0.01
0.08
0.07
0.04
0.01
0.06
0.10
0.05

SEQID-01188
I1KZP9
—
—
1
0.54
0.18
0.04
0.10
0.02
0.03
0.01
0.04
0.07
0.04
0.06
0.05
0.06
0.15

SEQID-01189
I1LLR5
—
—
1
0.48
0.20
0.04
0.02
0.04
0.04
0.04
0.04
0.09
0.01
0.05
0.04
0.11
0.07

SEQID-01190
I1M3C1
—
—
0
0.42
0.18
0.07
0.11
0.03
0.07
0.00
0.02
0.10
0.03
0.03
0.05
0.08
0.12

SEQID-01191
I1MUH0
—
—
1
0.51
0.28
0.08
0.07
0.01
0.05
0.01
0.02
0.01
0.04
0.03
0.04
0.16
0.03

SEQID-01192
P04670
—
—
1
0.50
0.21
0.04
0.06
0.03
0.05
0.01
0.05
0.08
0.03
0.03
0.05
0.08
0.08

SEQID-01193
P17093
—
—
1
0.52
0.17
0.04
0.11
0.04
0.01
0.02
0.03
0.04
0.05
0.04
0.08
0.04
0.15

SEQID-01194
Q9SWB6
—
—
1
0.50
0.20
0.05
0.04
0.04
0.04
0.02
0.04
0.12
0.03
0.02
0.06
0.09
0.09

SEQID-01195
C6F117
—
—
1
0.51
0.25
0.03
0.12
0.04
0.04
0.01
0.03
0.07
0.05
0.03
0.07
0.08
0.10

SEQID-01196
C6K8D0
—
—
1
0.48
0.25
0.04
0.06
0.04
0.04
0.02
0.04
0.05
0.05
0.02
0.06
0.10
0.06

SEQID-01197
C6SWG9
—
—
1
0.43
0.17
0.06
0.14
0.04
0.03
0.02
0.05
0.07
0.02
0.04
0.04
0.08
0.12

SEQID-01198
C6SXS0
—
—
1
0.46
0.22
0.03
0.14
0.03
0.04
0.01
0.05
0.07
0.04
0.01
0.06
0.08
0.10

SEQID-01199
C6SZX7
—
—
1
0.48
0.20
0.05
0.03
0.09
0.07
0.02
0.03
0.06
0.04
0.01
0.04
0.09
0.12

SEQID-01200
C6T034
—
—
1
0.47
0.20
0.08
0.03
0.01
0.10
0.01
0.03
0.11
0.03
0.01
0.05
0.08
0.12

SEQID-01201
C6T048
—
—
1
0.50
0.19
0.04
0.14
0.06
0.07
0.01
0.04
0.03
0.04
0.03
0.05
0.08
0.13

SEQID-01202
C6T871
—
—
1
0.50
0.23
0.05
0.09
0.05
0.03
0.01
0.02
0.08
0.04
0.03
0.06
0.10
0.03

SEQID-01203
C6T9G0
—
—
1
0.44
0.20
0.05
0.06
0.07
0.07
0.02
0.06
0.06
0.03
0.01
0.07
0.07
0.07

SEQID-01204
C5TFI8
—
—
1
0.47
0.19
0.03
0.13
0.03
0.06
0.00
0.02
0.05
0.02
0.02
0.03
0.04
0.14

SEQID-01205
C6THM2
—
—
1
0.43
0.20
0.06
0.07
0.03
0.05
0.01
0.04
0.07
0.03
0.06
0.06
0.10
0.09

SEQID-01206
C6TJH2
—
—
1
0.51
0.25
0.02
0.09
0.05
0.06
0.01
0.01
0.08
0.04
0.04
0.09
0.08
0.12

SEQID-01207
I1JW44
—
—
1
0.46
0.23
0.06
0.06
0.05
0.04
0.03
0.05
0.02
0.03
0.01
0.04
0.11
0.04

SEQID-01208
I1JX53
—
—
1
0.41
0.20
0.06
0.10
0.04
0.06
0.01
0.05
0.09
0.04
0.01
0.04
0.08
0.07

SEQID-01209
I1K3R6
—
—
1
0.47
0.21
0.03
0.05
0.03
0.07
0.02
0.03
0.06
0.05
0.05
0.05
0.10
0.05

SEQID-01210
I1K467
—
—
0
0.49
0.26
0.08
0.07
0.03
0.07
0.01
0.04
0.09
0.03
0.02
0.07
0.10
0.09

SEQID-01211
I1K554
—
—
0
0.45
0.18
0.03
0.19
0.00
0.05
0.10
0.05
0.03
0.05
0.03
0.01
0.12
0.06

SEQID-01212
I1KDM8
—
—
0
0.48
0.25
0.08
0.05
0.04
0.05
0.01
0.03
0.06
0.06
0.02
0.05
0.11
0.09

SEQID-01213
I1KRJ7
—
—
1
0.51
0.21
0.03
0.04
0.04
0.07
0.01
0.05
0.07
0.03
0.02
0.06
0.09
0.11

SEQID-01214
I1KZT2
—
—
1
0.48
0.21
0.04
0.07
0.03
0.06
0.01
0.03
0.10
0.04
0.02
0.05
0.08
0.09

SEQID-01215
I1LCQ1
—
—
1
0.52
0.26
0.05
0.06
0.03
0.06
0.01
0.03
0.08
0.03
0.03
0.08
0.11
0.09

SEQID-01216
I1M322
—
—
1
0.50
0.27
0.08
0.06
0.04
0.05
0.01
0.02
0.08
0.03
0.02
0.05
0.12
0.08

SEQID-01217
I1MC31
—
—
1
0.47
0.20
0.03
0.06
0.04
0.09
0.00
0.03
0.12
0.02
0.01
0.05
0.10
0.12

SEQID-01218
K7LSN8
—
—
1
0.50
0.19
0.05
0.05
0.05
0.03
0.02
0.03
0.05
0.06
0.03
0.06
0.05
0.07

SEQID-01219
K7M3Y6
—
—
1
0.52
0.26
0.04
0.07
0.02
0.08
0.02
0.04
0.06
0.03
0.05
0.06
0.11
0.06

SEQID-01220
A1VZE0
—
—
1
0.49
0.23
0.05
0.06
0.04
0.06
0.01
0.04
0.06
0.05
0.02
0.06
0.08
0.08

SEQID-01221
B2BF98
—
—
1
0.45
0.18
0.05
0.17
0.02
0.05
0.01
0.04
0.06
0.04
0.00
0.04
0.09
0.16

SEQID-01222
C6SV94
—
—
0
0.43
0.19
0.07
0.18
0.02
0.06
0.01
0.02
0.06
0.05
0.03
0.06
0.07
0.08

SEQID-01223
C63VR3
—
—
1
0.44
0.18
0.06
0.14
0.01
0.05
0.01
0.04
0.04
0.05
0.03
0.06
0.06
0.09

SEQID-01224
C6SVS3
—
—
1
0.56
0.23
0.04
0.04
0.05
0.03
0.02
0.06
0.07
0.03
0.02
0.05
0.12
0.17

SEQID-01225
C6SWA6
—
—
0
0.46
0.23
0.08
0.11
0.04
0.02
0.00
0.02
0.06
0.07
0.02
0.04
0.11
0.17

SEQID-01226
C6SWE0
—
—
1
0.54
0.27
0.07
0.03
0.04
0.06
0.01
0.01
0.10
0.05
0.02
0.08
0.10
0.11

SEQID-01227
C6SWG3
—
—
0
0.50
0.19
0.06
0.13
0.02
0.04
0.00
0.02
0.07
0.04
0.03
0.07
0.07
0.12

SEQID-01228
C6T085
—
—
0
0.47
0.22
0.05
0.03
0.05
0.07
0.02
0.05
0.06
0.05
0.04
0.06
0.08
0.08

SEQID-01229
C6T0U3
—
—
1
0.52
0.23
0.03
0.10
0.02
0.05
0.01
0.03
0.08
0.03
0.04
0.07
0.07
0.12

SEQID-01230
C6T530
—
—
0
0.47
0.22
0.04
0.13
0.03
0.06
0.00
0.02
0.09
0.02
0.02
0.05
0.08
0.12

SEQID-01231
C6T5U0
—
—
0
0.43
0.22
0.07
0.15
0.01
0.03
0.02
0.05
0.06
0.05
0.02
0.09
0.06
0.10

SEQID-01232
C6THA9
—
—
1
0.47
0.22
0.02
0.09
0.06
0.05
0.01
0.03
0.08
0.04
0.03
0.07
0.09
0.07

SEQID-01233
C6TI64
—
—
1
0.52
0.20
0.05
0.09
0.03
0.07
0.01
0.05
0.07
0.03
0.02
0.06
0.06
0.15

SEQID-01234
C6TMB5
—
—
1
0.50
0.26
0.05
0.07
0.03
0.09
0.01
0.04
0.07
0.04
0.01
0.08
0.08
0.14

SEQID-01235
I1JA95
—
—
1
0.37
0.12
0.03
0.13
0.03
0.06
0.01
0.03
0.06
0.09
0.01
0.05
0.05
0.08

SEQID-01236
I1JSJ3
—
—
1
0.44
0.23
0.08
0.06
0.05
0.04
0.01
0.05
0.08
0.04
0.01
0.04
0.12
0.07

SEQID-01237
I1JXS7
—
—
1
0.45
0.18
0.04
0.04
0.04
0.09
0.01
0.02
0.12
0.03
0.02
0.07
0.07
0.11

SEQID-01238
I1K099
—
—
1
0.46
0.21
0.06
0.08
0.02
0.05
0.01
0.03
0.09
0.04
0.02
0.05
0.10
0.08

SEQID-01239
I1K1K4
—
—
1
0.55
0.27
0.08
0.05
0.01
0.01
0.01
0.09
0.04
0.05
0.06
0.04
0.15
0.02

SEQID-01240
I1K964
—
—
1
0.45
0.23
0.05
0.05
0.05
0.06
0.00
0.06
0.05
0.06
0.03
0.06
0.08
0.05

SEQID-01241
I1K9I0
—
—
1
0.45
0.22
0.04
0.07
0.05
0.07
0.02
0.04
0.06
0.04
0.03
0.08
0.07
0.07

SEQID-01242
I1K9M9
—
—
1
0.45
0.23
0.04
0.05
0.05
0.04
0.03
0.04
0.03
0.04
0.01
0.06
0.10
0.04

SEQID-01243
I1KG34
—
—
1
0.45
0.21
0.06
0.07
0.03
0.06
0.01
0.04
0.08
0.04
0.02
0.05
0.10
0.06

SEQID-01244
I1KZY9
—
—
1
0.47
0.23
0.04
0.05
0.05
0.05
0.01
0.04
0.06
0.04
0.04
0.05
0.12
0.05

SEQID-01245
I1L0S5
—
—
1
0.49
0.23
0.09
0.04
0.07
0.03
0.01
0.03
0.08
0.06
0.03
0.05
0.14
0.07

SEQID-01246
I1L5Q0
—
—
1
0.46
0.20
0.05
0.12
0.04
0.05
0.01
0.05
0.11
0.02
0.02
0.05
0.10
0.12

SEQID-01247
I1L957
—
—
0
0.38
0.09
0.11
0.06
0.03
0.08
0.00
0.05
0.15
0.04
0.01
0.01
0.02
0.18

SEQID-01248
I1LFD6
—
—
1
0.55
0.26
0.05
0.01
0.03
0.04
0.00
0.01
0.09
0.03
0.04
0.04
0.12
0.11

SEQID-01249
I1LIT1
—
—
1
0.45
0.23
0.03
0.06
0.04
0.06
0.00
0.02
0.05
0.05
0.01
0.08
0.09
0.08

SEQID-01250
I1MIA3
—
—
0
0.44
0.22
0.06
0.10
0.03
0.14
0.00
0.03
0.08
0.03
0.01
0.05
0.10
0.05

SEQID-01251
I1N1F9
—
—
1
0.48
0.21
0.07
0.06
0.03
0.05
0.01
0.04
0.07
0.05
0.03
0.05
0.09
0.07

SEQID-01252
I1N4U1
—
—
1
0.45
0.22
0.06
0.07
0.04
0.06
0.01
0.04
0.09
0.05
0.01
0.08
0.09
0.09

SEQID-01253
I1NH02
—
—
1
0.45
0.20
0.04
0.02
0.06
0.07
0.02
0.06
0.03
0.04
0.03
0.05
0.10
0.05

SEQID-01254
O23957
—
—
0
0.40
0.13
0.06
0.09
0.05
0.05
0.00
0.05
0.07
0.08
0.06
0.03
0.06
0.08

SEQID-01255
O49857
—
—
1
0.47
0.22
0.03
0.06
0.06
0.04
0.02
0.04
0.08
0.04
0.03
0.06
0.09
0.05

SEQID-01256
P00560
—
—
1
0.51
0.25
0.07
0.05
0.04
0.07
0.00
0.02
0.08
0.05
0.02
0.06
0.10
0.12

SEQID-01257
P00359
—
—
1
0.50
0.23
0.06
0.05
0.04
0.08
0.01
0.02
0.05
0.04
0.03
0.06
0.07
0.09

SEQID-01258
P00549
—
—
1
0.43
0.24
0.06
0.07
0.05
0.07
0.01
0.02
0.07
0.04
0.02
0.08
0.07
0.09

SEQID-01259
P00358
—
—
1
0.51
0.23
0.07
0.05
0.04
0.08
0.01
0.02
0.05
0.04
0.03
0.06
0.07
0.09

SEQID-01260
P10591
—
—
1
0.45
0.20
0.06
0.06
0.05
0.08
0.00
0.04
0.09
0.04
0.01
0.06
0.08
0.10

SEQID-01261
P00360
—
—
1
0.51
0.23
0.07
0.05
0.03
0.08
0.01
0.03
0.04
0.04
0.03
0.07
0.06
0.10

SEQID-01262
P10592
—
—
1
0.45
0.20
0.06
0.06
0.05
0.08
0.00
0.04
0.10
0.04
0.01
0.06
0.08
0.10

SEQID-01263
P00942
—
—
1
0.49
0.24
0.07
0.05
0.05
0.06
0.01
0.03
0.08
0.05
0.02
0.06
0.08
0.10

SEQID-01264
P02994
—
—
1
0.52
0.21
0.05
0.06
0.04
0.06
0.01
0.03
0.08
0.05
0.03
0.07
0.05
0.13

SEQID-01265
P06169
—
—
1
0.51
0.23
0.06
0.04
0.05
0.05
0.01
0.05
0.06
0.04
0.03
0.07
0.10
0.07

SEQID-01266
P22943
—
—
0
0.35
0.10
0.08
0.04
0.03
0.11
0.00
0.07
0.12
0.06
0.02
0.01
0.03
0.16

SEQID-01267
P14540
—
—
1
0.47
0.19
0.06
0.04
0.05
0.05
0.01
0.03
0.10
0.04
0.04
0.07
0.07
0.09

SEQID-01268
P05694
—
—
1
0.40
0.22
0.05
0.06
0.05
0.06
0.00
0.04
0.08
0.03
0.02
0.06
0.09
0.09

SEQID-01269
P31539
—
—
0
0.44
0.23
0.05
0.08
0.04
0.08
0.01
0.07
0.10
0.03
0.02
0.08
0.11
0.09

SEQID-01270
P15103
—
—
1
0.48
0.21
0.04
0.05
0.04
0.07
0.00
0.03
0.15
0.02
0.01
0.07
0.10
0.12

SEQID-01271
P32324
—
—
1
0.49
0.23
0.05
0.07
0.03
0.07
0.01
0.04
0.08
0.04
0.02
0.06
0.08
0.08

SEQID-01272
Q07653
—
—
1
0.38
0.09
0.04
0.05
0.08
0.08
0.00
0.05
0.07
0.04
0.06
0.03
0.02
0.09

SEQID-01273
P34730
—
—
1
0.37
0.17
0.05
0.06
0.03
0.05
0.00
0.12
0.13
0.01
0.02
0.05
0.09
0.07

SEQID-01274
P02829
—
—
1
0.48
0.21
0.04
0.05
0.04
0.07
0.00
0.03
0.15
0.02
0.01
0.07
0.09
0.12

SEQID-01275
Q08969
—
—
1
0.25
0.05
0.01
0.10
0.09
0.13
0.00
0.17
0.06
0.07
0.03
0.01
0.04
0.03

SEQID-01276
P46367
—
—
1
0.48
0.23
0.05
0.05
0.05
0.05
0.01
0.04
0.08
0.05
0.02
0.09
0.07
0.09

SEQID-01277
P00950
—
—
1
0.45
0.22
0.06
0.07
0.05
0.07
0.00
0.04
0.08
0.03
0.02
0.05
0.11
0.11

SEQID-01278
P14126
—
—
1
0.52
0.18
0.05
0.12
0.02
0.04
0.00
0.02
0.06
0.04
0.05
0.05
0.05
0.13

SEQID-01279
P06106
—
—
1
0.47
0.20
0.06
0.04
0.05
0.05
0.00
0.05
0.07
0.05
0.05
0.06
0.08
0.07

SEQID-01280
P17709
—
—
1
0.50
0.23
0.04
0.06
0.03
0.07
0.01
0.04
0.08
0.04
0.04
0.06
0.12
0.07

SEQID-01281
P38158
—
—
1
0.48
0.15
0.03
0.06
0.05
0.08
0.01
0.03
0.08
0.03
0.03
0.06
0.06
0.09

SEQID-01282
Q12230
—
—
1
0.39
0.19
0.06
0.07
0.03
0.08
0.00
0.05
0.14
0.02
0.03
0.04
0.09
0.07

SEQID-01283
P07251
—
—
1
0.43
0.26
0.07
0.09
0.04
0.04
0.00
0.06
0.08
0.05
0.01
0.06
0.13
0.06

SEQID-01284
P11484
—
—
1
0.47
0.22
0.07
0.07
0.04
0.07
0.00
0.05
0.10
0.04
0.01
0.06
0.09
0.09

SEQID-01285
P17536
—
—
1
0.40
0.18
0.03
0.04
0.07
0.06
0.00
0.08
0.25
0.00
0.02
0.03
0.12
0.15

SEQID-01286
P60010
—
—
1
0.47
0.21
0.04
0.07
0.02
0.06
0.01
0.04
0.08
0.04
0.03
0.0B
0.07
0.06

SEQID-01287
P12709
—
—
1
0.53
0.20
0.06
0.03
0.07
0.05
0.00
0.04
0.07
0.04
0.04
0.06
0.09
0.08

SEQID-01288
P09435
—
—
1
0.44
0.19
0.06
0.08
0.05
0.08
0.00
0.04
0.09
0.04
0.01
0.06
0.07
0.08

SEQID-01289
P19414
—
—
1
0.48
0.20
0.06
0.06
0.06
0.08
0.01
0.03
0.06
0.05
0.03
0.07
0.08
0.10

SEQID-01290
P17255
—
—
1
0.46
0.21
0.05
0.07
0.04
0.06
0.01
0.03
0.09
0.04
0.02
0.06
0.08
0.08

SEQID-01291
P19382
—
—
0
0.46
0.25
0.07
0.07
0.03
0.06
0.01
0.03
0.11
0.05
0.00
0.08
0.09
0.09

SEQID-01292
P16467
—
—
1
0.51
0.24
0.06
0.05
0.05
0.05
0.01
0.04
0.07
0.04
0.03
0.07
0.10
0.07

SEQID-01293
P06115
—
—
1
0.43
0.16
0.03
0.06
0.06
0.06
0.01
0.07
0.07
0.03
0.03
0.04
0.06
0.08

SEQID-01294
Q00055
—
—
1
0.48
0.24
0.05
0.05
0.05
0.05
0.02
0.04
0.10
0.05
0.04
0.07
0.08
0.07

SEQID-01295
P04806
—
—
1
0.48
0.22
0.04
0.05
0.04
0.08
0.01
0.04
0.08
0.04
0.02
0.07
0.10
0.09

SEQID-01296
P16862
—
—
1
0.44
0.21
0.07
0.08
0.05
0.06
0.01
0.03
0.07
0.04
0.02
0.06
0.08
0.06

SEQID-01297
P0CX36
—
—
1
0.51
0.14
0.04
0.12
0.04
0.07
0.00
0.02
0.04
0.05
0.05
0.06
0.10
0.12

SEQID-01298
P53252
—
—
1
0.35
0.18
0.05
0.08
0.02
0.08
0.00
0.08
0.15
0.03
0.01
0.06
0.09
0.07

SEQID-01299
P00830
—
—
1
0.48
0.25
0.07
0.07
0.02
0.05
0.00
0.05
0.09
0.05
0.02
0.07
0.10
0.07

SEQID-01300
P16861
—
—
1
0.48
0.22
0.06
0.07
0.05
0.06
0.01
0.03
0.08
0.04
0.03
0.06
0.09
0.07

SEQID-01301
P16521
—
—
1
0.49
0.22
0.06
0.06
0.05
0.06
0.01
0.03
0.10
0.03
0.03
0.08
0.08
0.09

SEQID-01302
P11154
—
—
1
0.46
0.23
0.06
0.08
0.04
0.07
0.01
0.05
0.07
0.04
0.03
0.06
0.09
0.06

SEQID-01303
P23301
—
—
0
0.50
0.18
0.05
0.04
0.03
0.11
0.01
0.02
0.09
0.04
0.04
0.05
0.07
0.10

SEQID-01304
P41805
—
—
1
0.43
0.18
0.06
0.14
0.04
0.05
0.02
0.04
0.06
0.03
0.03
0.04
0.08
0.11

SEQID-01305
P00331
—
—
1
0.47
0.23
0.07
0.03
0.04
0.05
0.02
0.02
0.07
0.07
0.04
0.07
0.08
0.08

SEQID-01306
P10091
—
—
0
0.47
0.24
0.04
0.08
0.04
0.07
0.01
0.06
0.09
0.03
0.01
0.08
0.09
0.06

SEQID-01307
P18399
—
—
0
0.13
0.02
0.00
0.02
0.25
0.14
0.00
0.02
0.01
0.06
0.00
0.01
0.00
0.03

SEQID-01308
Q12363
—
—
1
0.47
0.19
0.03
0.05
0.05
0.08
0.00
0.03
0.07
0.03
0.03
0.07
0.06
0.07

SEQID-01309
Q12122
—
—
1
0.48
0.23
0.05
0.06
0.06
0.09
0.02
0.02
0.06
0.03
0.03
0.09
0.07
0.09

SEQID-01310
P07262
—
—
1
0.43
0.20
0.05
0.06
0.05
0.04
0.01
0.05
0.09
0.06
0.01
0.07
0.06
0.07

SEQID-01311
P37291
—
—
1
0.46
0.21
0.05
0.07
0.04
0.06
0.01
0.04
0.07
0.04
0.04
0.07
0.08
0.08

SEQID-01312
P00390
—
—
1
0.48
0.22
0.05
0.06
0.03
0.04
0.00
0.04
0.09
0.04
0.03
0.05
0.12
0.09

SEQID-01313
P38720
—
—
1
0.47
0.22
0.06
0.06
0.04
0.07
0.01
0.03
0.07
0.05
0.02
0.08
0.09
0.08

SEQID-01314
P26263
—
—
1
0.52
0.26
0.05
0.03
0.05
0.05
0.00
0.05
0.07
0.04
0.03
0.07
0.12
0.08

SEQID-01315
P33315
—
—
1
0.45
0.20
0.05
0.06
0.04
0.06
0.00
0.05
0.07
0.05
0.03
0.05
0.09
0.07

SEQID-01316
P07149
—
—
1
0.50
0.23
0.04
0.05
0.05
0.06
0.01
0.04
0.08
0.03
0.02
0.07
0.09
0.08

SEQID-01317
P0CX48
—
—
1
0.54
0.19
0.04
0.11
0.05
0.01
0.01
0.04
0.03
0.03
0.04
0.06
0.03
0.14

SEQID-01318
P15992
—
—
1
0.44
0.19
0.03
0.05
0.09
0.10
0.00
0.03
0.06
0.04
0.02
0.04
0.08
0.11

SEQID-01319
P26783
—
—
1
0.45
0.23
0.07
0.11
0.06
0.05
0.00
0.06
0.10
0.02
0.01
0.08
0.06
0.08

SEQID-01320
P35719
—
—
1
0.48
0.23
0.03
0.06
0.04
0.11
0.00
0.05
0.13
0.02
0.01
0.06
0.12
0.12

SEQID-01321
P33442
—
—
1
0.55
0.22
0.04
0.03
0.04
0.05
0.00
0.05
0.07
0.03
0.03
0.06
0.09
0.15

SEQID-01322
P23248
—
—
1
0.55
0.23
0.04
0.09
0.05
0.05
0.00
0.04
0.07
0.03
0.03
0.05
0.09
0.15

SEQID-01323
P33011
—
—
1
0.51
0.21
0.07
0.04
0.05
0.08
0.01
0.04
0.03
0.04
0.03
0.05
0.09
0.07

SEQID-01324
P15019
—
—
1
0.50
0.23
0.06
0.04
0.03
0.07
0.01
0.04
0.09
0.03
0.01
0.07
0.08
0.12

SEQID-01325
P0C590
—
—
1
0.46
0.23
0.06
0.07
0.06
0.06
0.00
0.05
0.10
0.04
0.01
0.07
0.08
0.09

SEQID-01326
P31688
—
—
1
0.48
0.21
0.03
0.07
0.06
0.07
0.01
0.06
0.07
0.02
0.02
0.05
0.10
0.09

SEQID-01327
Q02326
—
—
1
0.52
0.23
0.06
0.03
0.05
0.03
0.00
0.04
0.08
0.02
0.01
0.03
0.11
0.17

SEQID-01328
P25443
—
—
1
0.48
0.23
0.05
0.10
0.04
0.03
0.00
0.06
0.06
0.06
0.01
0.07
0.09
0.09

SEQID-01329
P05750
—
—
0
0.45
0.23
0.03
0.12
0.02
0.04
0.00
0.03
0.11
0.04
0.01
0.06
0.08
0.09

SEQID-01330
P05317
—
—
1
0.45
0.24
0.03
0.06
0.05
0.06
0.00
0.02
0.10
0.04
0.02
0.06
0.08
0.06

SEQID-01331
P38009
—
—
1
0.44
0.23
0.07
0.07
0.04
0.06
0.01
0.04
0.08
0.03
0.03
0.07
0.08
0.08

SEQID-01332
Q3E754
—
—
0
0.34
0.21
0.05
0.11
0.07
0.08
0.01
0.04
0.08
0.04
0.01
0.06
0.08
0.07

SEQID-01333
P0C2H7
—
—
1
0.57
0.18
0.06
0.08
0.02
0.01
0.00
0.03
0.07
0.03
0.05
0.03
0.04
0.19

SEQID-01334
P35691
—
—
1
0.49
0.19
0.05
0.02
0.05
0.10
0.01
0.03
0.10
0.04
0.01
0.07
0.04
0.10

SEQID-01335
Q12690
—
—
1
0.41
0.17
0.10
0.18
0.05
0.03
0.00
0.05
0.08
0.02
0.02
0.05
0.06
0.11

SEQID-01336
P10664
—
—
1
0.49
0.21
0.08
0.10
0.05
0.02
0.00
0.04
0.05
0.04
0.04
0.04
0.08
0.10

SEQID-01337
P41939
—
—
1
0.51
0.22
0.04
0.06
0.02
0.07
0.00
0.04
0.09
0.03
0.03
0.08
0.07
0.09

SEQID-01338
P16140
—
—
1
0.43
0.22
0.04
0.09
0.05
0.07
0.00
0.04
0.10
0.04
0.02
0.08
0.08
0.06

SEQID-01339
P10963
—
—
1
0.47
0.19
0.05
0.05
0.05
0.05
0.02
0.03
0.08
0.03
0.04
0.07
0.07
0.07

SEQID-01340
P37012
—
—
1
0.48
0.20
0.04
0.04
0.05
0.07
0.01
0.03
0.07
0.05
0.04
0.08
0.07
0.10

SEQID-01341
P23254
—
—
1
0.46
0.21
0.07
0.05
0.05
0.05
0.00
0.04
0.06
0.04
0.03
0.06
0.10
0.07

SEQID-01342
P0CX52
—
—
0
0.49
0.22
0.05
0.10
0.02
0.04
0.00
0.05
0.05
0.04
0.03
0.06
0.08
0.14

SEQID-01343
P05759
—
—
0
0.54
0.21
0.02
0.07
0.03
0.05
0.02
0.04
0.05
0.04
0.04
0.05
0.09
0.19

SEQID-01344
P0CX23
—
—
1
0.50
0.18
0.04
0.12
0.03
0.03
0.00
0.04
0.06
0.01
0.05
0.06
0.05
0.12

SEQID-01345
P34760
—
—
1
0.50
0.24
0.06
0.04
0.04
0.06
0.01
0.04
0.09
0.03
0.01
0.07
0.09
0.08

SEQID-01346
P0CX45
—
—
1
0.43
0.21
0.06
0.15
0.05
0.04
0.00
0.04
0.04
0.07
0.05
0.07
0.07
0.09

SEQID-01347
P46654
—
—
1
0.41
0.22
0.08
0.08
0.05
0.05
0.00
0.04
0.12
0.02
0.02
0.06
0.08
0.03

SEQID-01348
P31116
—
—
1
0.52
0.26
0.06
0.03
0.04
0.07
0.00
0.02
0.06
0.04
0.01
0.07
0.09
0.11

SEQID-01349
P53912
—
—
1
0.50
0.25
0.06
0.03
0.04
0.07
0.01
0.04
0.07
0.04
0.03
0.09
0.09
0.11

SEQID-01350
P19358
—
—
1
0.46
0.21
0.06
0.06
0.02
0.09
0.01
0.05
0.07
0.04
0.01
0.07
0.08
0.09

SEQID-01351
P06168
—
—
1
0.45
0.19
0.05
0.09
0.05
0.05
0.01
0.03
0.08
0.04
0.02
0.05
0.09
0.08

SEQID-01352
Q03558
—
—
1
0.42
0.18
0.06
0.03
0.06
0.05
0.00
0.04
0.09
0.04
0.02
0.06
0.07
0.07

SEQID-01353
P39954
—
—
1
0.50
0.24
0.07
0.05
0.04
0.05
0.02
0.04
0.08
0.04
0.04
0.07
0.09
0.08

SEQID-01354
Q00764
—
—
1
0.50
0.23
0.03
0.04
0.06
0.05
0.01
0.04
0.08
0.03
0.04
0.06
0.09
0.07

SEQID-01355
P17967
—
—
1
0.44
0.21
0.07
0.02
0.05
0.09
0.01
0.04
0.11
0.02
0.03
0.05
0.09
0.08

SEQID-01356
P04802
—
—
1
0.45
0.20
0.05
0.09
0.03
0.06
0.00
0.05
0.12
0.03
0.03
0.05
0.10
0.10

SEQID-01357
P48589
—
—
1
0.50
0.30
0.06
0.06
0.04
0.05
0.00
0.04
0.15
0.04
0.02
0.04
0.11
0.07

SEQID-01358
P14832
—
—
1
0.48
0.18
0.04
0.04
0.05
0.07
0.01
0.03
0.05
0.08
0.03
0.05
0.05
0.09

SEQID-01359
P0CX83
—
—
1
0.42
0.18
0.09
0.20
0.04
0.04
0.00
0.04
0.07
0.02
0.04
0.04
0.08
0.14

SEQID-01360
P0CX39
—
—
1
0.42
0.14
0.07
0.15
0.04
0.02
0.01
0.04
0.08
0.04
0.02
0.06
0.05
0.13

SEQID-01361
P26786
—
—
0
0.50
0.25
0.04
0.09
0.02
0.04
0.00
0.08
0.09
0.02
0.03
0.06
0.11
0.11

SEQID-01362
P05737
—
—
1
0.48
0.22
0.06
0.08
0.06
0.02
0.00
0.06
0.07
0.03
0.02
0.09
0.08
0.13

SEQID-01363
P17076
—
—
1
0.49
0.19
0.09
0.07
0.05
0.04
0.00
0.04
0.06
0.03
0.01
0.04
0.08
0.16

SEQID-01364
P07233
—
—
1
0.48
0.20
0.03
0.07
0.04
0.06
0.01
0.03
0.11
0.04
0.02
0.05
0.10
0.08

SEQID-01365
P00917
—
—
1
0.49
0.20
0.05
0.03
0.06
0.09
0.00
0.03
0.08
0.03
0.03
0.09
0.06
0.12

SEQID-01366
P18239
—
—
0
0.50
0.21
0.07
0.07
0.03
0.05
0.01
0.04
0.03
0.06
0.00
0.04
0.11
0.10

SEQID-01367
P26321
—
—
1
0.41
0.16
0.07
0.10
0.01
0.06
0.00
0.05
0.10
0.03
0.02
0.05
0.08
0.08

SEQID-01368
P17505
—
—
0
0.51
0.25
0.06
0.05
0.06
0.05
0.00
0.02
0.07
0.04
0.03
0.07
0.10
0.10

SEQID-01369
P07257
—
—
0
0.47
0.25
0.06
0.06
0.05
0.07
0.00
0.03
0.07
0.03
0.01
0.03
0.13
0.10

SEQID-01370
P31373
—
—
1
0.48
0.24
0.07
0.05
0.06
0.06
0.00
0.05
0.06
0.04
0.05
0.06
0.11
0.07

SEQID-01371
P38999
—
—
1
0.48
0.23
0.06
0.05
0.03
0.08
0.01
0.02
0.07
0.04
0.01
0.06
0.10
0.09

SEQID-01372
P07256
—
—
1
0.49
0.23
0.05
0.05
0.08
0.05
0.00
0.05
0.06
0.03
0.02
0.05
0.12
0.08

SEQID-01373
P53319
—
—
1
0.48
0.12
0.07
0.07
0.04
0.07
0.01
0.03
0.06
0.05
0.03
0.08
0.09
0.08

SEQID-01374
P54115
—
—
1
0.48
0.22
0.06
0.05
0.06
0.06
0.01
0.03
0.09
0.05
0.01
0.07
0.08
0.09

SEQID-01375
P32861
—
—
1
0.50
0.25
0.03
0.07
0.07
0.06
0.01
0.03
0.07
0.03
0.04
0.07
0.12
0.08

SEQID-01376
P32191
—
—
1
0.49
0.21
0.05
0.06
0.05
0.06
0.01
0.04
0.06
0.03
0.02
0.05
0.09
0.07

SEQID-01377
P19097
—
—
1
0.46
0.21
0.06
0.05
0.04
0.05
0.00
0.05
0.10
0.04
0.02
0.06
0.09
0.09

SEQID-01378
P38711
—
—
0
0.53
0.21
0.05
0.07
0.01
0.03
0.06
0.04
0.04
0.03
0.05
0.01
0.11
0.10

SEQID-01379
P0CX31
—
—
0
0.46
0.19
0.06
0.14
0.04
0.05
0.00
0.04
0.07
0.03
0.01
0.02
0.07
0.16

SEQID-01380
P0C0W1
—
—
1
0.51
0.25
0.04
0.10
0.05
0.04
0.01
0.04
0.05
0.04
0.04
0.10
0.0a
0.10

SEQID-01381
P39516
—
—
0
0.42
0.19
0.09
0.16
0.02
0.07
0.01
0.03
0.04
0.06
0.02
0.05
0.05
0.08

SEQID-01382
P36010
—
—
1
0.50
0.21
0.04
0.07
0.03
0.06
0.01
0.04
0.08
0.05
0.02
0.06
0.08
0.10

SEQID-01383
Q02753
—
—
0
0.46
0.19
0.04
0.12
0.04
0.02
0.01
0.06
0.06
0.04
0.05
0.05
0.05
0.12

SEQID-01384
P40159
—
—
1
0.24
0.05
0.04
0.05
0.14
0.02
0.00
0.14
0.06
0.16
0.03
0.02
0.02
0.03

SEQID-01385
P05755
—
—
0
0.41
0.20
0.06
0.17
0.02
0.05
0.00
0.03
0.10
0.03
0.02
0.05
0.10
0.10

SEQID-01386
P08067
—
—
1
0.49
0.21
0.05
0.06
0.03
0.07
0.02
0.03
0.04
0.04
0.03
0.06
0.08
0.08

SEQID-01387
Q04432
—
—
1
0.51
0.20
0.07
0.02
0.04
0.10
0.00
0.01
0.06
0.05
0.03
0.05
0.07
0.11

SEQID-01388
P39015
—
—
1
0.36
0.12
0.08
0.10
0.12
0.08
0.00
0.04
0.08
0.02
0.00
0.02
0.05
0.14

SEQID-01389
P36060
—
—
1
0.52
0.19
0.03
0.03
0.05
0.07
0.00
0.05
0.06
0.03
0.04
0.05
0.09
0.12

SEQID-01390
P53228
—
—
1
0.49
0.21
0.06
0.05
0.03
0.06
0.01
0.03
0.11
0.02
0.03
0.06
0.09
0.12

SEQID-01391
P43567
—
—
1
0.51
0.24
0.06
0.05
0.04
0.06
0.01
0.03
0.05
0.04
0.03
0.06
0.10
0.08

SEQID-01392
P41338
—
—
1
0.46
0.24
0.09
0.04
0.05
0.05
0.01
0.05
0.07
0.05
0.02
0.07
0.08
0.09

SEQID-01393
P54839
—
—
1
0.47
0.21
0.04
0.05
0.06
0.07
0.01
0.05
0.05
0.04
0.02
0.06
0.09
0.10

SEQID-01394
Q04792
—
—
1
0.49
0.20
0.04
0.05
0.05
0.05
0.01
0.04
0.09
0.03
0.05
0.05
0.10
0.08

SEQID-01395
Q01574
—
—
1
0.48
0.21
0.05
0.06
0.03
0.07
0.01
0.04
0.06
0.04
0.03
0.06
0.08
0.08

SEQID-01396
P25694
—
—
1
0.43
0.22
0.06
0.09
0.05
0.09
0.00
0.03
0.10
0.04
0.02
0.06
0.08
0.07

SEQID-01397
Q05050
—
—
1
0.44
0.17
0.06
0.05
0.06
0.06
0.00
0.05
0.13
0.02
0.02
0.05
0.07
0.14

SEQID-01398
P38427
—
—
1
0.45
0.21
0.04
0.06
0.06
0.06
0.01
0.06
0.06
0.02
0.03
0.07
0.09
0.07

SEQID-01399
P07259
—
—
1
0.47
0.24
0.05
0.07
0.05
0.06
0.01
0.03
0.08
0.03
0.02
0.07
0.09
0.07

SEQID-01400
P01097
—
—
0
0.39
0.14
0.04
0.17
0.01
0.05
0.00
0.08
0.12
0.03
0.01
0.02
0.09
0.10

SEQID-01401
Q01519
—
—
1
0.45
0.11
0.04
0.03
0.06
0.11
0.04
0.08
0.05
0.02
0.04
0.03
0.03
0.09

SEQID-01402
P38804
—
—
0
0.47
0.20
0.05
0.03
0.07
0.04
0.00
0.02
0.14
0.06
0.00
0.05
0.08
0.13

SEQID-01403
P53221
—
—
0
0.48
0.24
0.05
0.13
0.02
0.06
0.00
0.05
0.05
0.03
0.02
0.05
0.11
0.16

SEQID-01404
P14127
—
—
0
0.43
0.22
0.03
0.17
0.05
0.05
0.01
0.06
0.06
0.02
0.01
0.05
0.11
0.11

SEQID-01405
P04037
—
—
1
0.46
0.22
0.03
0.07
0.03
0.07
0.02
0.04
0.07
0.04
0.03
0.05
0.11
0.07

SEQID-01406
P00427
—
—
0
0.39
0.19
0.06
0.13
0.05
0.06
0.01
0.03
0.12
0.01
0.02
0.03
0.10
0.07

SEQID-01407
P53849
—
—
0
0.36
0.09
0.02
0.07
0.06
0.05
0.13
0.05
0.07
0.04
0.06
0.03
0.03
0.10

SEQID-01408
P04449
—
—
1
0.49
0.13
0.07
0.14
0.03
0.02
0.00
0.05
0.07
0.03
0.02
0.04
0.04
0.22

SEQID-01409
P38013
—
—
1
0.51
0.22
0.06
0.01
0.04
0.07
0.02
0.03
0.07
0.03
0.02
0.07
0.05
0.09

SEQID-01410
P05740
—
—
1
0.40
0.16
0.10
0.14
0.04
0.01
0.00
0.07
0.07
0.03
0.03
0.04
0.06
0.11

SEQID-01411
P0CX50
—
—
0
0.50
0.20
0.07
0.17
0.03
0.03
0.01
0.02
0.03
0.04
0.03
0.04
0.08
0.12

SEQID-01412
P05738
—
—
0
0.54
0.27
0.02
0.08
0.07
0.06
0.00
0.04
0.05
0.03
0.03
0.09
0.05
0.12

SEQID-01413
P00447
—
—
1
0.50
0.20
0.07
0.03
0.07
0.05
0.00
0.06
0.06
0.04
0.03
0.05
0.10
0.09

SEQID-01414
P0CX38
—
—
0
0.44
0.20
0.05
0.16
0.03
0.05
0.00
0.06
0.08
0.04
0.01
0.05
0.08
0.13

SEQID-01415
Q06146
—
—
0
0.33
0.15
0.03
0.09
0.07
0.08
0.00
0.05
0.14
0.02
0.02
0.05
0.08
0.09

SEQID-01416
P38715
—
—
1
0.52
0.24
0.03
0.04
0.04
0.06
0.02
0.04
0.08
0.03
0.04
0.07
0.11
0.10

SEQID-01417
P40531
—
—
0
0.42
0.18
0.06
0.05
0.05
0.05
0.01
0.07
0.13
0.01
0.01
0.04
0.10
0.09

SEQID-01418
P28834
—
—
1
0.51
0.24
0.05
0.07
0.06
0.05
0.00
0.03
0.07
0.05
0.03
0.09
0.08
0.08

SEQID-01419
P41940
—
—
1
0.54
0.28
0.03
0.04
0.05
0.06
0.01
0.02
0.08
0.04
0.02
0.09
0.10
0.10

SEQID-01420
P28241
—
—
1
0.48
0.25
0.05
0.07
0.06
0.04
0.01
0.02
0.06
0.04
0.02
0.08
0.10
0.06

SEQID-01421
P39714
—
—
1
0.53
0.24
0.04
0.03
0.03
0.06
0.03
0.03
0.08
0.05
0.06
0.08
0.07
0.10

SEQID-01422
Q12443
—
—
1
0.47
0.20
0.03
0.07
0.08
0.05
0.00
0.04
0.07
0.02
0.04
0.06
0.08
0.09

SEQID-01423
P07267
—
—
1
0.47
0.21
0.05
0.02
0.05
0.07
0.01
0.03
0.08
0.05
0.03
0.06
0.10
0.07

SEQID-01424
P36009
—
—
1
0.48
0.19
0.07
0.05
0.05
0.07
0.00
0.02
0.08
0.02
0.01
0.04
0.09
0.12

SEQID-01425
Q04409
—
—
1
0.47
0.24
0.03
0.08
0.04
0.05
0.02
0.03
0.09
0.04
0.03
0.06
0.12
0.06

SEQID-01426
P50095
—
—
1
0.48
0.23
0.05
0.06
0.06
0.05
0.01
0.05
0.06
0.05
0.02
0.06
0.10
0.07

SEQID-01427
P32316
—
—
1
0.48
0.21
0.05
0.07
0.06
0.07
0.01
0.03
0.07
0.03
0.05
0.06
0.08
0.07

SEQID-01428
P37302
—
—
1
0.45
0.19
0.05
0.03
0.08
0.07
0.01
0.04
0.08
0.03
0.04
0.06
0.08
0.09

SEQID-01429
Q03104
—
—
1
0.50
0.17
0.03
0.03
0.06
0.10
0.00
0.06
0.04
0.02
0.02
0.03
0.09
0.13

SEQID-01430
P15705
—
—
1
0.39
0.14
0.03
0.06
0.06
0.07
0.00
0.06
0.11
0.02
0.02
0.05
0.07
0.12

SEQID-01431
Q00711
—
—
1
0.46
0.19
0.06
0.09
0.04
0.06
0.02
0.03
0.07
0.05
0.05
0.05
0.08
0.06

SEQID-01432
P07244
—
—
1
0.48
0.25
0.06
0.05
0.04
0.07
0.01
0.05
0.06
0.05
0.03
0.07
0.09
0.06

SEQID-01433
P41053
—
—
1
0.42
0.11
0.02
0.19
0.05
0.03
0.06
0.04
0.04
0.03
0.08
0.03
0.03
0.08

SEQID-01434
P02309
—
—
0
0.47
0.23
0.04
0.19
0.01
0.03
0.00
0.02
0.05
0.08
0.02
0.07
0.09
0.12

SEQID-01435
P22803
—
—
0
0.48
0.21
0.10
0.01
0.02
0.07
0.02
0.05
0.07
0.03
0.00
0.05
0.05
0.10

SEQID-01436
P20091
—
—
1
0.48
0.25
0.02
0.05
0.05
0.07
0.01
0.03
0.05
0.08
0.01
0.08
0.07
0.07

SEQID-01437
Q04438
—
—
1
0.36
0.13
0.02
0.11
0.07
0.08
0.00
0.07
0.09
0.03
0.03
0.03
0.04
0.08

SEQID-01438
P02294
—
—
0
0.47
0.16
0.08
0.07
0.02
0.02
0.00
0.04
0.07
0.02
0.02
0.06
0.05
0.17

SEQID-01439
P38701
—
—
1
0.51
0.25
0.02
0.07
0.05
0.02
0.00
0.10
0.11
C.02
0.02
0.10
0.05
0.13

SEQID-01440
P38061
—
—
1
0.55
0.19
0.06
0.12
0.05
0.02
0.00
0.02
0.03
0.03
0.07
0.06
0.07
0.16

SEQID-01441
P32445
—
—
1
0.44
0.16
0.05
0.08
0.08
0.05
0.00
0.05
0.03
0.03
0.02
0.04
0.07
0.08

SEQID-01442
P38754
—
—
0
0.53
0.24
0.10
0.11
0.02
0.03
0.01
0.06
0.04
0.03
0.00
0.06
0.08
0.14

SEQID-01443
Q03048
—
—
1
0.44
0.19
0.05
0.07
0.04
0.09
0.01
0.01
0.08
0.03
0.01
0.04
0.08
0.09

SEQID-01444
Q01855
—
—
0
0.49
0.18
0.06
0.14
0.04
0.01
0.00
0.02
0.07
0.04
0.03
0.05
0.06
0.10

SEQID-01445
P0CX54
—
—
0
0.46
0.24
0.06
0.07
0.04
0.05
0.01
0.04
0.05
0.04
0.02
0.10
0.07
0.13

SEQID-01446
P40414
—
—
0
0.36
0.16
0.03
0.04
0.08
0.05
0.01
0.08
0.25
0.00
0.00
0.02
0.12
0.14

SEQID-01447
Q3E757
—
—
1
0.48
0.20
0.03
0.13
0.04
0.06
0.01
0.04
0.07
0.04
0.02
0.06
0.06
0.11

SEQID-01448
Q12402
—
—
1
0.54
0.27
0.05
0.04
0.03
0.03
0.00
0.04
0.04
0.03
0.01
0.08
0.13
0.07

SEQID-01449
Q96VH4
—
—
1
0.49
0.19
0.09
0.04
0.04
0.04
0.00
0.05
0.07
0.03
0.03
0.08
0.06
0.09

SEQID-01450
P52286
—
—
1
0.38
0.18
0.03
0.09
0.09
0.13
0.00
0.02
0.13
0.01
0.02
0.05
0.07
0.06

SEQID-01451
P26785
—
—
1
0.50
0.11
0.07
0.12
0.02
0.04
0.00
0.03
0.05
0.03
0.02
0.04
0.09
0.15

SEQID-01452
P32471
—
—
1
0.44
0.17
0.10
0.01
0.03
0.11
0.00
0.05
0.13
0.02
0.02
0.06
0.06
0.10

SEQID-01453
P53184
—
—
1
0.53
0.22
0.03
0.04
0.04
0.10
0.01
0.03
0.06
0.02
0.07
0.07
0.06
0.09

SEQID-01454
P32835
—
—
1
0.48
0.20
0.05
0.05
0.05
0.06
0.01
0.06
0.08
0.03
0.02
0.05
0.08
0.09

SEQID-01455
P17891
—
—
1
0.38
0.14
0.05
0.06
0.05
0.16
0.00
0.06
0.14
0.02
0.01
0.05
0.06
0.11

SEQID-01456
P05626
—
—
1
0.48
0.25
0.06
0.06
0.04
0.04
0.00
0.06
0.09
0.02
0.01
0.05
0.11
0.10

SEQID-01457
P40106
—
—
1
0.49
0.20
0.07
0.04
0.04
0.08
0.01
0.02
0.08
0.04
0.02
0.08
0.07
0.12

SEQID-01458
P27616
—
—
1
0.50
0.23
0.04
0.05
0.03
0.07
0.00
0.03
0.10
0.03
0.02
0.07
0.09
0.11

SEQID-01459
P47143
—
—
1
0.49
0.23
0.08
0.02
0.04
0.07
0.01
0.04
0.07
0.04
0.03
0.05
0.10
0.08

SEQID-01460
P32449
—
—
1
0.45
0.22
0.07
0.07
0.07
0.06
0.01
0.05
0.07
0.05
0.03
0.07
0.09
0.07

SEQID-01461
P13663
—
—
1
0.48
0.26
0.06
0.06
0.03
0.06
0.02
0.04
0.08
0.04
0.03
0.09
0.10
0.09

SEQID-01462
P32771
—
—
1
0.50
0.21
0.07
0.04
0.03
0.07
0.04
0.03
0.07
0.06
0.03
0.07
0.06
0.10

SEQID-01463
P32288
—
—
1
0.41
0.15
0.05
0.08
0.04
0.06
0.02
0.04
0.08
0.05
0.04
0.07
0.05
0.06

SEQID-01464
P09624
—
—
1
0.51
0.24
0.06
0.05
0.05
0.05
0.01
0.03
0.09
0.05
0.04
0.08
0.08
0.11

SEQID-01465
Q05911
—
—
1
0.49
0.23
0.06
0.09
0.04
0.06
0.01
0.04
0.09
0.02
0.03
0.06
0.10
0.06

SEQID-01466
P54114
—
—
1
0.50
0.21
0.06
0.03
0.05
0.07
0.01
0.04
0.07
0.04
0.01
0.07
0.08
0.11

SEQID-01467
P32582
—
—
1
0.50
0.24
0.04
0.04
0.06
0.08
0.00
0.03
0.07
0.04
0.02
0.03
0.10
0.12

SEQID-01468
P15891
—
—
1
0.36
0.14
0.06
0.04
0.05
0.08
0.00
0.04
0.15
0.02
0.01
0.05
0.05
0.12

SEQID-01469
P53051
—
—
1
0.46
0.15
0.03
0.06
0.06
0.07
0.01
0.02
0.09
0.03
0.03
0.05
0.06
0.09

SEQID-01470
P09232
—
—
1
0.47
0.18
0.05
0.04
0.06
0.09
0.01
0.04
0.08
0.05
0.05
0.06
0.07
0.11

SEQID-01471
P52910
—
—
1
0.47
0.22
0.05
0.06
0.04
0.06
0.01
0.03
0.07
0.04
0.04
0.06
0.07
0.07

SEQID-01472
P07264
—
—
1
0.47
0.20
0.05
0.06
0.04
0.07
0.01
0.04
0.03
0.04
0.03
0.07
0.08
0.09

SEQID-01473
P33416
—
—
1
0.47
0.25
0.05
0.10
0.04
0.08
0.01
0.04
0.09
0.03
0.02
0.07
0.11
0.10

SEQID-01474
P21306
—
—
0
0.40
0.15
0.12
0.07
0.05
0.02
0.00
0.08
0.04
0.02
0.00
0.05
0.07
0.08

SEQID-01475
P01095
—
—
0
0.63
0.25
0.02
0.00
0.08
0.08
0.00
0.00
0.11
0.02
0.10
0.03
0.07
0.16

SEQID-01476
P0CX26
—
—
1
0.46
0.16
0.03
0.15
0.00
0.01
0.05
0.04
0.04
0.05
0.01
0.04
0.03
0.14

SEQID-01477
P14120
—
—
0
0.52
0.28
0.05
0.04
0.04
0.02
0.00
0.04
0.06
0.04
0.00
0.07
0.13
0.13

SEQID-01478
P25373
—
—
0
0.47
0.27
0.05
0.04
0.07
0.05
0.02
0.05
0.13
0.03
0.03
0.08
0.13
0.08

SEQID-01479
Q3E792
—
—
0
0.50
0.21
0.08
0.09
0.00
0.04
0.00
0.05
0.05
0.02
0.03
0.08
0.08
0.19

SEQID-01480
P40037
—
—
0
0.47
0.25
0.10
0.03
0.08
0.05
0.01
0.03
0.07
0.01
0.03
0.07
0.07
0.06

SEQID-01481
P32463
—
—
0
0.41
0.23
0.05
0.09
0.06
0.10
0.01
0.05
0.06
0.01
0.01
0.09
0.06
0.06

SEQID-01482
P00128
—
—
1
0.44
0.24
0.06
0.03
0.04
0.06
0.01
0.04
0.11
0.01
0.03
0.09
0.12
0.08

SEQID-01483
P07281
—
—
1
0.39
0.20
0.06
0.12
0.04
0.06
0.00
0.06
0.07
0.05
0.02
0.07
0.06
0.09

SEQID-01484
P04456
—
—
0
0.51
0.22
0.09
0.07
0.05
0.04
0.00
0.02
0.04
0.02
0.01
0.05
0.08
0.18

SEQID-01485
Q12513
—
—
0
0.39
0.20
0.04
0.07
0.09
0.11
0.01
0.03
0.12
0.03
0.02
0.08
0.07
0.08

SEQID-01486
P05756
—
—
1
0.46
0.24
0.06
0.13
0.04
0.03
0.00
0.02
0.05
0.03
0.03
0.09
0.09
0.10

SEQID-01487
P39726
—
—
1
0.46
0.21
0.04
0.04
0.05
0.05
0.00
0.05
0.12
0.04
0.02
0.04
0.10
0.06

SEQID-01488
Q12408
—
—
0
0.45
0.28
0.04
0.04
0.06
0.05
0.02
0.02
0.12
0.04
0.01
0.09
0.11
0.05

SEQID-01489
P40043
—
—
1
0.56
0.16
0.02
0.02
0.02
0.08
0.01
0.03
0.13
0.02
0.10
0.04
0.05
0.13

SEQID-01490
P38886
—
—
0
0.41
0.20
0.05
0.07
0.06
0.06
0.00
0.10
0.11
0.03
0.03
0.06
0.09
0.04

SEQID-01491
Q07651
—
—
1
0.49
0.19
0.06
0.06
0.06
0.03
0.02
0.03
0.02
0.04
0.01
0.03
0.11
0.05

SEQID-01492
Q07551
—
—
1
0.48
0.22
0.04
0.04
0.04
0.05
0.00
0.06
0.09
0.02
0.02
0.07
0.10
0.10

SEQID-01493
P50107
—
—
1
0.47
0.17
0.02
0.05
0.06
0.06
0.02
0.03
0.09
0.04
0.05
0.05
0.08
0.10

SEQID-01494
P04173
—
—
1
0.50
0.26
0.07
0.04
0.04
0.07
0.01
0.03
0.08
0.04
0.02
0.07
0.12
0.09

SEQID-01495
P49723
—
—
1
0.49
0.17
0.05
0.04
0.06
0.06
0.01
0.03
0.11
0.02
0.02
0.07
0.07
0.11

SEQID-01496
P40495
—
—
0
0.45
0.25
0.06
0.08
0.04
0.06
0.01
0.05
0.07
0.05
0.01
0.08
0.09
0.08

SEQID-01497
P08524
—
—
1
0.48
0.22
0.05
0.04
0.04
0.07
0.02
0.04
0.10
0.02
0.02
0.06
0.10
0.11

SEQID-01498
Q12123
—
—
1
0.50
0.23
0.02
0.07
0.05
0.07
0.00
0.03
0.07
0.03
0.05
0.08
0.09
0.08

SEQID-01499
Q12329
—
—
0
0.34
0.14
0.03
0.07
0.06
0.06
0.00
0.06
0.13
0.03
0.04
0.04
0.06
0.07

SEQID-01500
P38219
—
—
1
0.49
0.24
0.05
0.07
0.04
0.06
0.01
0.04
0.10
0.03
0.02
0.09
0.09
0.11

SEQID-01501
P38891
—
—
1
0.49
0.21
0.05
0.06
0.05
0.04
0.01
0.04
0.07
0.04
0.02
0.05
0.10
0.08

SEQID-01502
P09938
—
—
1
0.50
0.19
0.05
0.05
0.06
0.06
0.00
0.02
0.13
0.02
0.03
0.06
0.09
0.10

SEQID-01503
P07991
—
—
1
0.51
0.24
0.07
0.04
0.03
0.05
0.02
0.04
0.07
0.04
0.06
0.07
0.11
0.03

SEQID-01504
P29952
—
—
1
0.46
0.19
0.05
0.05
0.05
0.07
0.01
0.05
0.08
0.03
0.03
0.06
0.08
0.10

SEQID-01505
P40054
—
—
1
0.47
0.26
0.05
0.04
0.07
0.04
0.01
0.06
0.07
0.03
0.03
0.09
0.10
0.06

SEQID-01506
P32481
—
—
1
0.48
0.25
0.05
0.07
0.04
0.06
0.02
0.05
0.10
0.04
0.02
0.10
0.08
0.09

SEQID-01507
P03536
—
—
1
0.45
0.24
0.04
0.09
0.04
0.07
0.00
0.05
0.07
0.03
0.03
0.08
0.10
0.05

SEQID-01508
P06208
—
—
1
0.42
0.20
0.06
0.08
0.06
0.06
0.01
0.04
0.08
0.03
0.02
0.06
0.07
0.07

SEQID-01509
P46655
—
—
1
0.50
0.21
0.05
0.07
0.05
0.09
0.01
0.03
0.07
0.03
0.02
0.07
0.08
0.11

SEQID-01510
P04801
—
—
1
0.48
0.18
0.03
0.07
0.04
0.06
0.01
0.04
0.10
0.03
0.03
0.05
0.08
0.10

SEQID-01511
P00915
—
—
1
0.47
0.24
0.05
0.04
0.04
0.06
0.01
0.05
0.10
0.03
0.02
0.06
0.11
0.09

SEQID-01512
P39730
—
—
1
0.45
0.20
0.05
0.06
0.03
0.06
0.01
0.06
0.14
0.03
0.01
0.05
0.09
0.14

SEQID-01513
P22515
—
—
1
0.48
0.22
0.04
0.05
0.06
0.08
0.01
0.04
0.08
0.03
0.02
0.06
0.10
0.09

SEQID-01514
Q00955
—
—
1
0.47
0.12
0.04
0.08
0.05
0.06
0.00
0.04
0.09
0.03
0.03
0.07
0.09
0.07

SEQID-01515
P37299
—
—
1
0.56
0.20
0.03
0.04
0.03
0.04
0.00
0.01
0.05
0.05
0.05
0.03
0.17
0.07

SEQID-01516
P50263
—
—
0
0.45
0.03
0.03
0.04
0.12
0.10
0.00
0.06
0.06
0.06
0.05
0.01
0.01
0.16

SEQID-01517
P01098
—
—
0
0.37
0.18
0.04
0.14
0.09
0.03
0.01
0.06
0.10
0.03
0.03
0.06
0.10
0.11

SEQID-01518
Q12497
—
—
0
0.42
0.12
0.03
0.13
0.05
0.10
0.00
0.06
0.07
0.03
0.03
0.02
0.08
0.13

SEQID-01519
P05745
—
—
0
0.49
0.20
0.07
0.17
0.05
0.01
0.00
0.00
0.06
0.04
0.01
0.08
0.06
0.16

SEQID-01520
Q3E841
—
—
0
0.47
0.24
0.05
0.06
0.06
0.03
0.00
0.01
0.08
0.04
0.03
0.09
0.06
0.10

SEQID-01521
P38910
—
—
0
0.51
0.29
0.06
0.04
0.05
0.07
0.00
0.07
0.06
0.04
0.00
0.07
0.11
0.12

SEQID-01522
P41056
—
—
1
0.46
0.20
0.05
0.14
0.07
0.00
0.00
0.03
0.04
0.04
0.03
0.06
0.06
0.09

SEQID-01523
P39939
—
—
0
0.37
0.16
0.08
0.19
0.07
0.03
0.03
0.01
0.04
0.01
0.03
0.05
0.03
0.14

SEQID-01524
Q08245
—
—
0
0.42
0.14
0.08
0.01
0.07
0.03
0.00
0.11
0.21
0.02
0.00
0.04
0.04
0.20

SEQID-01525
P04912
—
—
0
0.42
0.24
0.10
0.11
0.07
0.02
0.00
0.05
0.05
0.06
0.03
0.06
0.14
0.10

SEQID-01526
P0CX41
—
—
0
0.45
0.22
0.07
0.11
0.06
0.04
0.01
0.02
0.04
0.07
0.00
0.05
0.07
0.10

SEQID-01527
P07274
—
—
1
0.43
0.24
0.06
0.06
0.03
0.07
0.01
0.09
0.05
0.06
0.03
0.08
0.07
0.05

SEQID-01528
Q12305
—
—
1
0.43
0.18
0.04
0.04
0.06
0.07
0.01
0.03
0.07
0.04
0.04
0.06
0.05
0.08

SEQID-01529
P40185
—
—
0
0.48
0.23
0.07
0.05
0.09
0.03
0.01
0.04
0.06
0.01
0.03
0.04
0.08
0.08

SEQID-01530
P38879
—
—
0
0.41
0.21
0.09
0.03
0.09
0.07
0.00
0.08
0.10
0.03
0.01
0.07
0.06
0.11

SEQID-01531
P11076
—
—
1
0.49
0.22
0.04
0.09
0.07
0.04
0.01
0.03
0.09
0.04
0.01
0.06
0.10
0.06

SEQID-01532
P49435
—
—
0
0.50
0.26
0.07
0.03
0.04
0.04
0.01
0.04
0.11
0.04
0.01
0.07
0.14
0.09

SEQID-01533
P22141
—
—
0
0.45
0.23
0.03
0.08
0.02
0.09
0.00
0.07
0.06
0.03
0.02
0.07
0.10
0.08

SEQID-01534
P07260
—
—
1
0.52
0.20
0.03
0.05
0.04
0.08
0.00
0.03
0.10
0.03
0.04
0.05
0.09
0.10

SEQID-01535
Q04304
—
—
1
0.46
0.25
0.06
0.06
0.06
0.06
0.01
0.03
0.08
0.03
0.01
0.07
0.09
0.09

SEQID-01536
Q01976
—
—
1
0.48
0.23
0.03
0.07
0.04
0.07
0.02
0.05
0.09
0.03
0.02
0.08
0.08
0.10

SEQID-01537
Q12522
—
—
0
0.43
0.27
0.04
0.08
0.06
0.05
0.02
0.06
0.09
0.04
0.02
0.07
0.11
0.01

SEQID-01538
P40582
—
—
1
0.48
0.22
0.05
0.05
0.03
0.06
0.00
0.04
0.08
0.02
0.04
0.07
0.11
0.09

SEQID-01539
P39929
—
—
1
0.44
0.20
0.04
0.05
0.08
0.06
0.00
0.06
0.17
0.02
0.02
0.06
0.09
0.10

SEQID-01540
P39931
—
—
1
0.51
0.20
0.03
0.05
0.04
0.03
0.00
0.02
0.15
0.03
0.03
0.07
0.03
0.09

SEQID-01541
P00410
—
—
1
0.53
0.28
0.04
0.03
0.03
0.06
0.01
0.04
0.07
0.02
0.02
0.10
0.11
0.04

SEQID-01542
P15873
—
—
0
0.51
0.26
0.03
0.04
0.02
0.11
0.01
0.04
0.08
0.02
0.01
0.09
0.13
0.08

SEQID-01543
P32379
—
—
1
0.43
0.22
0.06
0.06
0.03
0.06
0.01
0.03
0.15
0.04
0.03
0.06
0.11
0.07

SEQID-01544
P21801
—
—
1
0.46
0.19
0.04
0.03
0.05
0.05
0.05
0.06
0.04
0.02
0.02
0.05
0.11
0.09

SEQID-01545
P30656
—
—
1
0.45
0.20
0.06
0.06
0.04
0.06
0.02
0.05
0.06
0.05
0.03
0.06
0.08
0.06

SEQID-01546
Q04491
—
—
1
0.51
0.23
0.05
0.04
0.04
0.06
0.01
0.03
0.09
0.04
0.05
0.05
0.03
0.08

SEQID-01547
P07143
—
—
1
0.43
0.16
0.08
0.07
0.04
0.05
0.01
0.03
0.07
0.04
0.03
0.03
0.08
0.07

SEQID-01548
P24280
—
—
1
0.44
0.18
0.04
0.06
0.03
0.06
0.01
0.04
0.10
0.03
0.02
0.05
0.09
0.09

SEQID-01549
P01120
—
—
0
0.37
0.17
0.05
0.00
0.11
0.06
0.01
0.08
0.07
0.05
0.01
0.05
0.06
0.08

SEQID-01550
P14065
—
—
1
0.51
0.24
0.04
0.04
0.06
0.06
0.01
0.05
0.07
0.03
0.04
0.07
0.10
0.10

SEQID-01551
P53598
—
—
0
0.51
0.22
0.06
0.04
0.02
0.04
0.01
0.07
0.07
0.06
0.02
0.10
0.07
0.10

SEQID-01552
P47120
—
—
1
0.43
0.22
0.03
0.06
0.05
0.07
0.01
0.04
0.12
0.02
0.03
0.04
0.11
0.07

SEQID-01553
Q12068
—
—
1
0.51
0.22
0.05
0.04
0.05
0.08
0.01
0.03
0.08
0.03
0.03
0.06
0.09
0.11

SEQID-01554
P38115
—
—
1
0.49
0.24
0.04
0.05
0.05
0.06
0.01
0.02
0.10
0.03
0.04
0.07
0.12
0.09

SEQID-01555
P53839
—
—
1
0.49
0.24
0.04
0.07
0.05
0.05
0.01
0.04
0.11
0.04
0.04
0.06
0.10
0.08

SEQID-01556
P32366
—
—
1
0.43
0.21
0.04
0.06
0.06
0.07
0.02
0.05
0.09
0.02
0.02
0.07
0.11
0.04

SEQID-01557
Q03102
—
—
1
0.53
0.25
0.05
0.02
0.05
0.06
0.01
0.04
0.06
0.05
0.01
0.06
0.11
0.12

SEQID-01558
Q06151
—
—
1
0.47
0.23
0.02
0.06
0.07
0.06
0.01
0.04
0.08
0.03
0.03
0.10
0.09
0.08

SEQID-01559
P32623
—
—
0
0.37
0.17
0.03
0.05
0.04
0.06
0.01
0.08
0.14
0.04
0.01
0.04
0.08
0.05

SEQID-01560
P23644
—
—
1
0.45
0.21
0.05
0.04
0.06
0.05
0.01
0.09
0.05
0.04
0.01
0.04
0.11
0.06

SEQID-01561
P32377
—
—
1
0.48
0.19
0.06
0.06
0.04
0.06
0.01
0.05
0.08
0.02
0.02
0.05
0.09
0.07

SEQID-01562
P27476
—
—
1
0.31
0.08
0.04
0.08
0.04
0.07
0.00
0.02
0.17
0.05
0.01
0.03
0.03
0.11

SEQID-01563
P36046
—
—
1
0.32
0.10
0.04
0.05
0.08
0.09
0.02
0.06
0.17
0.03
0.02
0.02
0.04
0.11

SEQID-01564
P23542
—
—
1
0.50
0.21
0.06
0.04
0.05
0.05
0.01
0.05
0.05
0.03
0.04
0.06
0.09
0.08

SEQID-01565
Q08412
—
—
1
0.35
0.14
0.03
0.09
0.06
0.10
0.00
0.06
0.15
0.02
0.03
0.03
0.06
0.08

SEQID-01566
P53549
—
—
0
0.44
0.21
0.04
0.10
0.03
0.07
0.00
0.05
0.12
0.04
0.02
0.0a
0.09
0.08

SEQID-01567
P19262
—
—
1
0.48
0.20
0.06
0.07
0.04
0.04
0.00
0.03
0.11
0.03
0.01
0.05
0.08
0.11

SEQID-01568
P02557
—
—
1
0.43
0.18
0.04
0.06
0.06
0.07
0.01
0.06
0.09
0.04
0.03
0.05
0.07
0.04

SEQID-01569
P04076
—
—
1
0.49
0.22
0.04
0.08
0.03
0.08
0.01
0.04
0.08
0.04
0.03
0.05
0.12
0.07

SEQID-01570
P07284
—
—
1
0.45
0.19
0.03
0.05
0.05
0.05
0.02
0.05
0.12
0.03
0.02
0.06
0.09
0.12

SEQID-01571
P17649
—
—
1
0.45
0.19
0.06
0.05
0.04
0.07
0.02
0.05
0.08
0.03
0.03
0.06
0.09
0.10

SEQID-01572
P08417
—
—
1
0.49
0.22
0.06
0.04
0.07
0.03
0.02
0.06
0.08
0.04
0.04
0.06
0.10
0.08

SEQID-01573
P16120
—
—
1
0.49
0.21
0.05
0.04
0.06
0.06
0.00
0.04
0.08
0.03
0.01
0.07
0.09
0.10

SEQID-01574
P14904
—
—
1
0.49
0.22
0.04
0.05
0.06
0.06
0.01
0.03
0.09
0.04
0.03
0.06
0.10
0.09

SEQID-01575
P38625
—
—
1
0.52
0.24
0.04
0.05
0.04
0.06
0.01
0.04
0.08
0.04
0.04
0.08
0.09
0.09

SEQID-01576
P30952
—
—
1
0.49
0.22
0.04
0.06
0.07
0.06
0.01
0.04
0.07
0.03
0.03
0.07
0.10
0.07

SEQID-01577
P32891
—
—
1
0.49
0.21
0.04
0.06
0.05
0.08
0.02
0.02
0.07
0.03
0.03
0.06
0.09
0.10

SEQID-01578
P38695
—
—
1
0.50
0.21
0.03
0.06
0.04
0.03
0.02
0.03
0.06
0.05
0.00
0.07
0.08
0.05

SEQID-01579
P15624
—
—
1
0.48
0.22
0.04
0.06
0.05
0.07
0.01
0.03
0.09
0.02
0.03
0.07
0.09
0.09

SEQID-01580
P32590
—
—
1
0.47
0.20
0.05
0.07
0.05
0.03
0.01
0.03
0.09
0.02
0.02
0.06
0.08
0.10

SEQID-01581
P32775
—
—
1
0.47
0.18
0.04
0.07
0.05
0.07
0.00
0.02
0.07
0.03
0.05
0.04
0.09
0.06

SEQID-01582
P53278
—
—
1
0.40
0.15
0.04
0.05
0.07
0.06
0.00
0.09
0.15
0.01
0.02
0.04
0.07
0.12

SEQID-01583
P13188
—
—
1
0.47
0.19
0.02
0.08
0.05
0.06
0.01
0.03
0.10
0.03
0.02
0.05
0.07
0.11

SEQID-01584
P07245
—
—
1
0.46
0.24
0.06
0.06
0.05
0.06
0.01
0.04
0.07
0.04
0.03
0.08
0.09
0.07

SEQID-01585
P40825
—
—
1
0.48
0.20
0.04
0.05
0.05
0.08
0.01
0.03
0.09
0.04
0.02
0.06
0.09
0.11

SEQID-01586
P20967
—
—
1
0.47
0.19
0.04
0.07
0.04
0.05
0.01
0.05
0.08
0.03
0.04
0.05
0.10
0.08

SEQID-01587
P22855
—
—
1
0.48
0.19
0.03
0.06
0.05
0.06
0.01
0.05
0.07
0.03
0.03
0.06
0.08
0.09

SEQID-01588
F0TEP7
—
—
1
0.50
0.25
0.06
0.05
0.04
0.08
0.00
0.03
0.08
0.05
0.02
0.08
0.08
0.10

SEQID-01589
F0TIG2
—
—
1
0.46
0.22
0.04
0.09
0.04
0.08
0.01
0.04
0.08
0.04
0.02
0.08
0.08
0.09

SEQID-01590
F0TIH2
—
—
1
0.47
0.20
0.05
0.11
0.05
0.05
0.00
0.04
0.05
0.06
0.05
0.09
0.07
0.13

SEQID-01591
F0TEB3
—
—
1
0.50
0.11
0.07
0.04
0.06
0.07
0.01
0.03
0.06
0.04
0.03
0.06
0.07
0.08

SEQID-01592
F0TEJ0
—
—
0
0.45
0.21
0.05
0.05
0.06
0.08
0.01
0.02
0.11
0.05
0.03
0.07
0.08
0.08

SEQID-01593
F0TDZ2
—
—
0
0.49
0.23
0.05
0.06
0.02
0.08
0.00
0.04
0.10
0.05
0.04
0.07
0.08
0.07

SEQID-01594
F0TEQ7
—
—
0
0.45
0.24
0.03
0.08
0.06
0.10
0.00
0.03
0.09
0.04
0.02
0.06
0.08
0.10

SEQID-01595
F0TFN9
—
—
1
0.48
0.22
0.05
0.06
0.04
0.10
0.00
0.06
0.08
0.03
0.01
0.07
0.07
0.08

SEQID-01596
F0TGC0
—
—
1
0.49
0.15
0.09
0.16
0.04
0.04
0.00
0.04
0.02
0.03
0.02
0.04
0.07
0.16

SEQID-01597
F0TIP0
—
—
1
0.48
0.22
0.07
0.05
0.04
0.09
0.00
0.06
0.04
0.04
0.01
0.05
0.08
0.11

SEQID-01598
F0THG3
—
—
1
0.48
0.21
0.03
0.09
0.03
0.07
0.01
0.03
0.11
0.03
0.04
0.07
0.10
0.09

SEQID-01599
F0THR9
—
—
1
0.45
0.20
0.05
0.07
0.05
0.08
0.01
0.04
0.06
0.04
0.03
0.07
0.07
0.08

SEQID-01600
F0TID9
—
—
1
0.50
0.24
0.06
0.04
0.03
0.09
0.00
0.03
0.08
0.05
0.04
0.08
0.07
0.09

SEQID-01601
F0TII4
—
—
0
0.46
0.20
0.04
0.08
0.03
0.05
0.00
0.03
0.09
0.06
0.01
0.06
0.05
0.13

SEQID-01602
F0TEP6
—
—
0
0.48
0.22
0.07
0.07
0.04
0.09
0.01
0.02
0.06
0.06
0.05
0.08
0.07
0.07

SEQID-01603
F0TFM5
—
—
1
0.46
0.20
0.05
0.08
0.07
0.07
0.00
0.06
0.08
0.03
0.03
0.06
0.06
0.14

SEQID-01604
F0TI54
—
—
1
0.50
0.19
0.09
0.02
0.08
0.06
0.00
0.02
0.03
0.04
0.01
0.02
0.06
0.12

SEQID-01605
F0TIG5
—
—
0
0.44
0.19
0.04
0.14
0.05
0.03
0.00
0.03
0.03
0.05
0.04
0.04
0.07
0.12

SEQID-01606
F0TIG7
—
—
1
0.47
0.20
0.06
0.07
0.03
0.08
0.00
0.03
0.10
0.04
0.02
0.07
0.06
0.08

SEQID-01607
F0TII6
—
—
0
0.46
0.23
0.06
0.13
0.06
0.06
0.00
0.02
0.07
0.06
0.02
0.07
0.05
0.11

SEQID-01608
F0TIG9
—
—
1
0.52
0.23
0.03
0.08
0.04
0.04
0.00
0.03
0.07
0.06
0.03
0.06
0.04
0.14

SEQID-01609
F0TIH5
—
—
1
0.44
0.20
0.07
0.14
0.05
0.05
0.00
0.05
0.08
0.05
0.02
0.08
0.06
0.10

SEQID-01610
F0TDX9
—
—
1
0.45
0.22
0.04
0.09
0.05
0.08
0.00
0.04
0.09
0.04
0.02
0.07
0.09
0.07

SEQID-01611
F0TE85
—
—
1
0.44
0.20
0.06
0.04
0.05
0.07
0.02
0.03
0.12
0.04
0.02
0.07
0.07
0.10

SEQID-01612
F0TFK9
—
—
0
0.50
0.25
0.05
0.03
0.06
0.04
0.01
0.01
0.10
0.05
0.01
0.09
0.09
0.10

SEQID-01613
F0TGI4
—
—
1
0.46
0.20
0.07
0.05
0.05
0.08
0.01
0.03
0.11
0.05
0.02
0.07
0.08
0.10

SEQID-01614
F0TI74
—
—
1
0.46
0.16
0.05
0.04
0.07
0.06
0.00
0.04
0.05
0.04
0.00
0.03
0.08
0.13

SEQID-01615
F0TI56
—
—
1
0.56
0.25
0.07
0.02
0.04
0.06
0.00
0.04
0.04
0.05
0.03
0.03
0.09
0.03

SEQID-01616
F0TJ46
—
—
1
0.43
0.17
0.05
0.03
0.11
0.04
0.00
0.05
0.03
0.04
0.01
0.06
0.04
0.09

SEQID-01617
F0TDQ0
—
—
0
0.42
0.20
0.02
0.12
0.05
0.07
0.00
0.03
0.14
0.01
0.02
0.04
0.08
0.03

SEQID-01618
F0TDS8
—
—
1
0.41
0.20
0.03
0.15
0.04
0.04
0.00
0.06
0.09
0.04
0.03
0.04
0.10
0.07

SEQID-01619
F0TE84
—
—
1
0.52
0.24
0.06
0.03
0.05
0.09
0.00
0.01
0.07
0.05
0.03
0.08
0.09
0.12

SEQID-01620
F0TED5
—
—
1
0.43
0.20
0.05
0.05
0.06
0.08
0.01
0.03
0.08
0.05
0.02
0.06
0.09
0.08

SEQID-01621
F0TEQ9
—
—
0
0.49
0.20
0.10
0.06
0.04
0.04
0.00
0.04
0.12
0.04
0.01
0.06
0.06
0.16

SEQID-01622
F0TEU3
—
—
1
0.44
0.21
0.05
0.07
0.05
0.06
0.01
0.08
0.07
0.03
0.02
0.08
0.08
0.08

SEQID-01623
F0TFQ7
—
—
0
0.45
0.23
0.05
0.19
0.01
0.04
0.00
0.03
0.09
0.04
0.04
0.07
0.04
0.09

SEQID-01624
F0TFS5
—
—
1
0.49
0.17
0.05
0.03
0.07
0.05
0.00
0.04
0.04
0.04
0.01
0.05
0.06
0.14

SEQID-01625
F0TGH0
—
—
1
0.51
0.17
0.07
0.01
0.04
0.06
0.00
0.09
0.03
0.02
0.02
0.05
0.06
0.19

SEQID-01626
F0TH33
—
—
1
0.52
0.23
0.08
0.03
0.05
0.06
0.00
0.01
0.06
0.06
0.03
0.10
0.08
0.09

SEQID-01627
F0THG4
—
—
1
0.48
0.20
0.05
0.09
0.03
0.05
0.00
0.04
0.11
0.03
0.05
0.06
0.08
0.07

SEQID-01628
F0TIG8
—
—
0
0.52
0.24
0.04
0.11
0.02
0.06
0.00
0.02
0.08
0.02
0.04
0.09
0.11
0.09

SEQID-01629
F0TIH8
—
—
0
0.47
0.19
0.01
0.13
0.06
0.05
0.00
0.02
0.06
0.01
0.03
0.04
0.02
0.16

SEQID-01630
F0TIH9
—
—
0
0.48
0.27
0.05
0.13
0.04
0.06
0.01
0.02
0.07
0.06
0.01
0.09
0.06
0.11

SEQID-01631
F0TII3
—
—
1
0.46
0.26
0.05
0.09
0.06
0.06
0.00
0.02
0.07
0.04
0.01
0.12
0.06
0.11

SEQID-01632
F0TIJ3
—
—
0
0.38
0.20
0.04
0.21
0.04
0.09
0.01
0.02
0.06
0.04
0.01
0.07
0.06
0.10

SEQID-01633
F0TIJ6
—
—
0
0.43
0.21
0.07
0.16
0.02
0.06
0.00
0.02
0.03
0.02
0.02
0.05
0.09
0.12

SEQID-01634
F0TIR8
—
—
1
0.50
0.23
0.08
0.05
0.03
0.08
0.01
0.04
0.06
0.04
0.05
0.10
0.07
0.09

SEQID-01635
F0TIS2
—
—
1
0.44
0.22
0.08
0.05
0.06
0.09
0.01
0.03
0.06
0.05
0.02
0.06
0.09
0.07

SEQID-01636
F0TIU2
—
—
1
0.45
0.24
0.08
0.06
0.05
0.09
0.00
0.05
0.09
0.05
0.01
0.08
0.08
0.09

SEQID-01637
F0TIX0
—
—
0
0.40
0.18
0.07
0.00
0.08
0.19
0.01
0.04
0.11
0.03
0.01
0.03
0.08
0.13

SEQID-01638
P13538
—
—
1
0.45
0.19
0.05
0.07
0.04
0.05
0.01
0.07
0.15
0.02
0.03
0.05
0.10
0.12

SEQID-01639
F1P3W7
—
—
1
0.45
0.19
0.05
0.07
0.04
0.05
0.01
0.07
0.15
0.02
0.02
0.05
0.10
0.12

SEQID-01640
F1P3X4
—
—
1
0.45
0.19
0.05
0.07
0.04
0.05
0.01
0.07
0.15
0.02
0.03
0.05
0.10
0.12

SEQID-01641
F1ND26
—
—
1
0.45
0.19
0.06
0.07
0.04
0.05
0.01
0.07
0.15
0.02
0.02
0.05
0.10
0.12

SEQID-01642
F1NDL1
—
—
1
0.47
0.17
0.05
0.06
0.04
0.08
0.01
0.05
0.07
0.02
0.04
0.05
0.07
0.13

SEQID-01643
F1NGF6
—
—
1
0.47
0.20
0.04
0.07
0.03
0.05
0.01
0.04
0.11
0.03
0.03
0.06
0.06
0.09

SEQID-01644
P68139
—
—
1
0.47
0.20
0.05
0.07
0.03
0.06
0.01
0.03
0.09
0.04
0.03
0.06
0.07
0.06

SEQID-01645
P00565
—
—
1
0.50
0.19
0.02
0.08
0.04
0.07
0.01
0.04
0.09
0.04
0.05
0.04
0.09
0.09

SEQID-01646
P00543
—
—
1
0.49
0.22
0.07
0.09
0.04
0.06
0.01
0.03
0.08
0.04
0.04
0.07
0.07
0.08

SEQID-01647
P16419
—
—
1
0.45
0.20
0.04
0.09
0.03
0.06
0.01
0.03
0.11
0.03
0.02
0.04
0.07
0.09

SEQID-01648
Q5ZMQ2
—
—
1
0.47
0.20
0.05
0.07
0.02
0.06
0.01
0.04
0.09
0.04
0.03
0.08
0.07
0.06

SEQID-01649
F1NU17
—
—
1
0.54
0.24
0.06
0.03
0.04
0.07
0.02
0.02
0.07
0.05
0.03
0.05
0.09
0.13

SEQID-01650
P07322
—
—
1
0.49
0.22
0.07
0.06
0.04
0.06
0.02
0.04
0.09
0.05
0.05
0.07
0.07
0.10

SEQID-01651
P20111
—
—
1
0.44
0.19
0.05
0.09
0.04
0.06
0.01
0.07
0.12
0.02
0.03
0.07
0.09
0.07

SEQID-01652
P13585
—
—
1
0.50
0.25
0.06
0.07
0.04
0.05
0.02
0.02
0.09
0.03
0.02
0.07
0.10
0.06

SEQID-01653
P00356
—
—
1
0.52
0.22
0.07
0.05
0.05
0.07
0.01
0.02
0.04
0.05
0.04
0.06
0.06
0.09

SEQID-01654
Q07734
—
—
1
0.47
0.21
0.03
0.07
0.03
0.07
0.01
0.02
0.09
0.03
0.02
0.05
0.06
0.10

SEQID-01655
F1NN63
—
—
1
0.47
0.20
0.06
0.03
0.05
0.07
0.01
0.03
0.05
0.05
0.03
0.08
0.07
0.08

SEQID-01656
F2Z4L6
—
—
1
0.43
0.18
0.04
0.06
0.03
0.07
0.05
0.06
0.09
0.02
0.03
0.06
0.07
0.09

SEQID-01657
F1NX83
—
—
1
0.46
0.20
0.04
0.08
0.05
0.05
0.03
0.04
0.07
0.03
0.05
0.06
0.09
0.06

SEQID-01658
P00940
—
—
1
0.51
0.23
0.07
0.04
0.03
0.06
0.02
0.04
0.03
0.06
0.04
0.07
0.07
0.11

SEQID-01659
F1NXK1
—
—
1
0.46
0.20
0.03
0.05
0.03
0.05
0.02
0.05
0.13
0.03
0.02
0.07
0.07
0.11

SEQID-01660
E1B5N7
—
—
1
0.45
0.21
0.04
0.09
0.05
0.06
0.01
0.04
0.09
0.03
0.03
0.06
0.09
0.06

SEQID-01661
Q02173
—
—
1
0.46
0.20
0.04
0.07
0.04
0.06
0.02
0.03
0.10
0.03
0.04
0.05
0.07
0.08

SEQID-01662
F1NW35
—
—
1
0.57
0.27
0.04
0.04
0.03
0.07
0.01
0.02
0.06
0.04
0.07
0.07
0.10
0.11

SEQID-01663
E19T53
—
—
1
0.47
0.20
0.04
0.06
0.03
0.05
0.02
0.05
0.12
0.03
0.02
0.05
0.08
0.11

SEQID-01664
P02609
—
—
1
0.48
0.17
0.05
0.05
0.05
0.09
0.01
0.03
0.11
0.04
0.01
0.07
0.05
0.11

SEQID-01665
F1NIJ6
—
—
1
0.55
0.21
0.05
0.05
0.05
0.05
0.01
0.03
0.07
0.04
0.06
0.06
0.10
0.09

SEQID-01666
P05031
—
—
0
0.50
0.22
0.03
0.07
0.01
0.06
0.01
0.04
0.11
0.05
0.03
0.05
0.10
0.13

SEQID-01667
P68246
—
—
1
0.45
0.17
0.05
0.11
0.03
0.07
0.01
0.05
0.14
0.02
0.03
0.02
0.11
0.16

SEQID-01668
P11009
—
—
1
0.45
0.21
0.04
0.11
0.04
0.07
0.02
0.03
0.07
0.04
0.03
0.04
0.10
0.07

SEQID-01669
P08106
—
—
1
0.46
0.20
0.05
0.07
0.05
0.08
0.01
0.05
0.09
0.04
0.01
0.07
0.07
0.10

SEQID-01670
P02457
—
—
1
0.24
0.09
0.08
0.08
0.03
0.05
0.01
0.04
0.07
0.16
0.01
0.02
0.04
0.05

SEQID-01671
P02604
—
—
0
0.46
0.17
0.09
0.03
0.05
0.06
0.00
0.04
0.13
0.03
0.01
0.05
0.07
0.12

SEQID-01672
Q52LN1
—
—
1
0.45
0.20
0.06
0.10
0.04
0.06
0.01
0.04
0.09
0.03
0.03
0.06
0.09
0.07

SEQID-01673
Q05623
—
—
1
0.42
0.16
0.07
0.06
0.03
0.05
0.01
0.04
0.10
0.02
0.03
0.05
0.05
0.10

SEQID-01674
E1C3E2
—
—
1
0.45
0.19
0.05
0.06
0.04
0.06
0.01
0.03
0.10
0.03
0.03
0.05
0.06
0.09

SEQID-01675
P51913
—
—
1
0.46
0.23
0.06
0.06
0.06
0.07
0.01
0.03
0.08
0.04
0.02
0.06
0.09
0.10

SEQID-01676
O73885
—
—
1
0.46
0.21
0.05
0.06
0.06
0.07
0.01
0.05
0.09
0.04
0.02
0.07
0.08
0.10

SEQID-01677
P15989
—
—
1
0.44
0.23
0.05
0.09
0.04
0.06
0.01
0.06
0.07
0.05
0.02
0.06
0.09
0.06

SEQID-01678
F1NCR0
—
—
1
0.26
0.11
0.07
0.08
0.04
0.04
0.01
0.03
0.06
0.17
0.02
0.03
0.05
0.05

SEQID-01679
F1NKY4
—
—
1
0.42
0.13
0.08
0.11
0.01
0.05
0.00
0.05
0.19
0.01
0.08
0.03
0.08
0.15

SEQID-01680
P53449
—
—
1
0.37
0.18
0.10
0.08
0.06
0.02
0.01
0.04
0.08
0.05
0.02
0.02
0.09
0.04

SEQID-01681
QSZMJ6
—
—
1
0.51
0.22
0.07
0.08
0.02
0.06
0.01
0.05
0.03
0.05
0.01
0.08
0.07
0.10

SEQID-01682
P19204
—
—
1
0.47
0.20
0.03
0.03
0.02
0.18
0.01
0.02
0.13
0.02
0.02
0.05
0.10
0.03

SEQID-01683
F1N9H4
—
—
1
0.50
0.21
0.05
0.06
0.04
0.05
0.01
0.03
0.08
0.05
0.03
0.08
0.06
0.12

SEQID-01684
E1BR47
—
—
1
0.46
0.22
0.03
0.08
0.04
0.05
0.02
0.05
0.08
0.03
0.02
0.05
0.12
0.03

SEQID-01685
F1NYI2
—
—
0
0.49
0.22
0.05
0.05
0.03
0.06
0.01
0.03
0.07
0.05
0.02
0.06
0.10
0.11

SEQID-01686
P02542
—
—
1
0.38
0.18
0.06
0.13
0.04
0.05
0.00
0.09
0.13
0.02
0.02
0.04
0.09
0.05

SEQID-01687
F1NCJ4
—
—
1
0.48
0.22
0.04
0.06
0.04
0.06
0.02
0.05
0.10
0.03
0.03
0.06
0.11
0.07

SEQID-01688
E1BVT3
—
—
0
0.49
0.25
0.07
0.06
0.05
0.04
0.02
0.03
0.07
0.05
0.02
0.07
0.10
0.09

SEQID-01689
E1BXW3
—
—
1
0.46
0.23
0.06
0.10
0.04
0.05
0.02
0.04
0.07
0.05
0.03
0.06
0.10
0.05

SEQID-01690
P79757
—
—
1
0.43
0.17
0.04
0.09
0.03
0.04
0.01
0.04
0.11
0.02
0.03
0.06
0.06
0.09

SEQID-01691
P04268
—
—
0
0.40
0.18
0.08
0.07
0.02
0.03
0.00
0.05
0.23
0.01
0.01
0.04
0.11
0.15

SEQID-01692
P00508
—
—
1
0.45
0.20
0.06
0.09
0.04
0.05
0.01
0.04
0.06
0.04
0.03
0.06
0.09
0.08

SEQID-01693
P09203
—
—
1
0.43
0.17
0.04
0.07
0.05
0.06
0.02
0.06
0.09
0.04
0.03
0.04
0.07
0.04

SEQID-01694
F1NGA2
—
—
0
0.45
0.25
0.07
0.10
0.03
0.05
0.00
0.06
0.07
0.05
0.01
0.07
0.10
0.06

SEQID-01695
P15988
—
—
1
0.38
0.17
0.04
0.09
0.03
0.07
0.02
0.05
0.08
0.08
0.01
0.06
0.07
0.07

SEQID-01696
F1NXK2
—
—
0
0.49
0.23
0.04
0.11
0.02
0.08
0.00
0.00
0.09
0.04
0.00
0.08
0.08
0.07

SEQID-01697
F1P0E4
—
—
1
0.50
0.18
0.05
0.03
0.06
0.06
0.01
0.02
0.05
0.06
0.01
0.04
0.09
0.11

SEQID-01698
E1BU93
—
—
1
0.46
0.15
0.03
0.06
0.04
0.04
0.00
0.03
0.03
0.06
0.05
0.04
0.08
0.10

SEQID-01699
P07341
—
—
1
0.44
0.20
0.08
0.06
0.04
0.04
0.02
0.07
0.07
0.04
0.02
0.05
0.10
0.08

SEQID-01700
P17785
—
—
1
0.45
0.21
0.05
0.03
0.04
0.08
0.01
0.04
0.09
0.03
0.01
0.07
0.10
0.11

SEQID-01701
E1BR89
—
—
1
0.43
0.19
0.06
0.03
0.02
0.02
0.02
0.04
0.06
0.04
0.01
0.05
0.09
0.07

SEQID-01702
F1NXR6
—
—
1
0.44
0.20
0.05
0.07
0.04
0.06
0.02
0.04
0.09
0.04
0.04
0.06
0.07
0.05

SEQID-01703
F1P0N2
—
—
1
0.46
0.18
0.04
0.08
0.04
0.05
0.01
0.05
0.08
0.02
0.04
0.05
0.09
0.07

SEQID-01704
F1NPH8
—
—
1
0.37
0.19
0.06
0.10
0.03
0.05
0.03
0.10
0.13
0.02
0.03
0.03
0.13
0.07

SEQID-01705
P04713
—
—
1
0.44
0.21
0.07
0.09
0.04
0.05
0.02
0.03
0.07
0.05
0.02
0.04
0.08
0.06

SEQID-01706
K7UZT6
—
—
1
0.45
0.22
0.06
0.03
0.04
0.05
0.01
0.05
0.09
0.05
0.02
0.04
0.10
0.06

SEQID-01707
B4F832
—
—
1
0.44
0.21
0.03
0.10
0.02
0.04
0.02
0.04
0.07
0.05
0.01
0.05
0.08
0.08

SEQID-01708
P11155
—
—
1
0.45
0.21
0.07
0.03
0.04
0.05
0.02
0.05
0.09
0.05
0.02
0.04
0.09
0.06

SEQID-01709
Q43247
—
—
1
0.52
0.23
0.06
0.05
0.04
0.07
0.01
0.02
0.07
0.05
0.02
0.06
0.06
0.10

SEQID-01710
P04712
—
—
1
0.43
0.22
0.04
0.07
0.04
0.06
0.01
0.04
0.08
0.03
0.03
0.06
0.11
0.07

SEQID-01711
B6TEC1
—
—
1
0.46
0.23
0.03
0.10
0.02
0.07
0.03
0.01
0.08
0.06
0.04
0.03
0.08
0.05

SEQID-01712
Q0QWI2
—
—
1
0.46
0.23
0.07
0.10
0.02
0.06
0.03
0.01
0.08
0.06
0.04
0.03
0.08
0.05

SEQID-01713
B4F8M9
—
—
1
0.54
0.18
0.04
0.10
0.02
0.04
0.01
0.04
0.07
0.04
0.05
0.05
0.06
0.15

SEQID-01714
Q5K3Q7
—
—
1
0.53
0.28
0.09
0.03
0.03
0.04
0.01
0.02
0.05
0.06
0.01
0.09
0.10
0.05

SEQID-01715
B4FJZ7
—
—
1
0.46
0.14
0.07
0.18
0.02
0.02
0.00
0.03
0.07
0.02
0.03
0.04
0.06
0.18

SEQID-01716
B6T1F1
—
—
1
0.47
0.14
0.06
0.18
0.02
0.03
0.00
0.03
0.06
0.02
0.04
0.04
0.07
0.18

SEQID-01717
K7URL6
—
—
1
0.53
0.28
0.09
0.03
0.03
0.04
0.01
0.02
0.05
0.06
0.01
0.09
0.10
0.05

SEQID-01718
B4FUW2
—
—
1
0.42
0.17
0.03
0.22
0.04
0.02
0.01
0.05
0.04
0.04
0.04
0.03
0.07
0.10

SEQID-01719
B6UEE8
—
—
1
0.47
0.26
0.11
0.06
0.03
0.05
0.01
0.01
0.05
0.06
0.02
0.06
0.11
0.03

SEQID-01720
B4FUK7
—
—
1
0.47
0.15
0.05
0.07
0.06
0.07
0.02
0.03
0.06
0.05
0.07
0.02
0.06
0.07

SEQID-01721
B4FY16
—
—
1
0.53
0.21
0.05
0.06
0.03
0.06
0.01
0.03
0.07
0.04
0.03
0.07
0.06
0.13

SEQID-01722
Q946V2
—
—
1
0.41
0.20
0.06
0.08
0.04
0.05
0.01
0.08
0.06
0.05
0.05
0.04
0.09
0.03

SEQID-01723
B6T1H0
—
—
0
0.44
0.17
0.04
0.17
0.04
0.06
0.01
0.05
0.05
0.04
0.00
0.04
0.08
0.15

SEQID-01724
B4F989
—
—
1
0.46
0.31
0.05
0.07
0.02
0.06
0.01
0.03
0.09
0.04
0.03
0.08
0.07
0.06

SEQID-01725
B4G1E1
—
—
1
0.46
0.20
0.05
0.07
0.03
0.06
0.02
0.03
0.09
0.04
0.03
0.08
0.07
0.06

SEQID-01726
B6TQ68
—
—
1
0.46
0.14
0.06
0.19
0.03
0.02
0.00
0.02
0.07
0.02
0.04
0.04
0.06
0.18

SEQID-01727
B6SP93
—
—
0
0.48
0.11
0.19
0.04
0.01
0.00
0.00
0.02
0.06
0.02
0.01
0.01
0.03
0.30

SEQID-01728
P08440
—
—
1
0.45
0.22
0.07
0.06
0.04
0.05
0.02
0.03
0.09
0.04
0.02
0.05
0.11
0.10

SEQID-01729
B6TQ08
—
—
1
0.47
0.21
0.05
0.07
0.02
0.06
0.01
0.03
0.08
0.04
0.03
0.08
0.07
0.06

SEQID-01730
B4FUH2
—
—
1
0.44
0.21
0.07
0.09
0.04
0.04
0.01
0.05
0.06
0.04
0.03
0.05
0.10
0.04

SEQID-01731
P21569
—
—
1
0.49
0.17
0.05
0.06
0.05
0.04
0.02
0.03
0.07
0.07
0.02
0.03
0.04
0.09

SEQID-01732
P27923
—
—
0
0.54
0.19
0.04
0.07
0.03
0.06
0.02
0.06
0.05
0.04
0.04
0.05
0.08
0.18

SEQID-01733
C0P455
—
—
1
0.46
0.20
0.07
0.13
0.05
0.04
0.00
0.03
0.05
0.04
0.02
0.04
0.08
0.11

SEQID-01734
C0PHE3
—
—
1
0.47
0.23
0.03
0.10
0.03
0.08
0.01
0.07
0.07
0.04
0.02
0.06
0.10
0.05

SEQID-01735
B6SP74
—
—
1
0.27
0.10
0.04
0.13
0.07
0.05
0.01
0.02
0.08
0.21
0.02
0.03
0.04
0.02

SEQID-01736
K7T5X3
—
—
1
0.33
0.08
0.07
0.07
0.02
0.11
0.00
0.03
0.14
0.05
0.01
0.02
0.02
0.16

SEQID-01737
K7V1U2
—
—
1
0.44
0.18
0.06
0.06
0.03
0.09
0.01
0.04
0.14
0.03
0.01
0.05
0.06
0.15

SEQID-01738
B6T879
—
—
0
0.50
0.16
0.09
0.05
0.02
0.02
0.00
0.02
0.09
0.03
0.02
0.06
0.05
0.22

SEQID-01739
Q946V3
—
—
0
0.27
0.13
0.06
0.15
0.00
0.03
0.06
0.11
0.07
0.09
0.00
0.02
0.07
0.02

SEQID-01740
P12863
—
—
1
0.49
0.24
0.08
0.04
0.04
0.04
0.02
0.05
0.09
0.05
0.02
0.05
0.07
0.08

SEQID-01741
B6TC95
—
—
0
0.47
0.08
0.19
0.04
0.02
0.01
0.00
0.01
0.05
0.01
0.01
0.01
0.04
0.31

SEQID-01742
P49106
—
—
1
0.41
0.20
0.06
0.08
0.03
0.06
0.01
0.03
0.15
0.02
0.01
0.06
0.10
0.08

SEQID-01743
B6U607
—
—
1
0.04
0.23
0.09
0.09
0.05
0.04
0.01
0.04
0.09
0.05
0.02
0.02
0.12
0.06

SEQID-01744
C0P381
—
—
0
0.30
0.11
0.02
0.02
0.03
0.01
0.05
0.37
0.05
0.02
0.11
0.03
0.05
0.02

SEQID-01745
B4G0K5
—
—
1
0.45
0.15
0.04
0.07
0.06
0.07
0.02
0.04
0.06
0.06
0.06
0.03
0.05
0.06

SEQID-01746
K7TNK3
—
—
1
0.43
0.20
0.05
0.04
0.03
0.05
0.01
0.09
0.20
0.01
0.03
0.03
0.13
0.11

SEQID-01747
B6SGI4
—
—
1
0.42
0.07
0.06
0.22
0.04
0.00
0.04
0.01
0.02
0.05
0.04
0.03
0.02
0.12

SEQID-01748
P04706
—
—
0
0.37
0.21
0.05
0.04
0.00
0.00
0.07
0.16
0.01
0.03
0.09
0.02
0.12
0.00

SEQID-01749
B6T5F2
—
—
1
0.49
0.16
0.06
0.12
0.04
0.02
0.00
0.06
0.06
0.03
0.03
0.04
0.06
0.17

SEQID-01750
B6T440
—
—
1
0.49
0.22
0.06
0.06
0.03
0.06
0.02
0.03
0.09
0.04
0.03
0.06
0.09
0.09

SEQID-01751
B6TN50
—
—
1
0.47
0.19
0.06
0.06
0.05
0.07
0.01
0.03
0.09
0.03
0.02
0.05
0.09
0.14

SEQID-01752
K7UDH4
—
—
1
0.49
0.20
0.03
0.08
0.05
0.05
0.01
0.05
0.07
0.02
0.04
0.06
0.10
0.07

SEQID-01753
P62787
—
—
0
0.47
0.22
0.04
0.21
0.02
0.03
0.00
0.02
0.05
0.09
0.02
0.07
0.08
0.11

SEQID-01754
B6SIA2
—
—
0
0.33
0.13
0.08
0.22
0.03
0.04
0.05
0.03
0.04
0.04
0.05
0.04
0.01
0.09

SEQID-01755
P01088
—
—
1
0.38
0.22
0.09
0.11
0.01
0.03
0.06
0.02
0.06
0.05
0.02
0.06
0.12
0.02

SEQID-01756
B4FK49
—
—
1
0.50
0.22
0.05
0.06
0.03
0.05
0.00
0.03
0.09
0.05
0.02
0.10
0.05
0.09

SEQID-01757
B4G1P4
—
—
1
0.48
0.19
0.05
0.06
0.05
0.07
0.02
0.05
0.07
0.03
0.04
0.05
0.08
0.09

SEQID-01758
B4F093
—
—
0
0.50
0.09
0.17
0.03
0.02
0.03
0.00
0.00
0.03
0.01
0.01
0.01
0.04
0.31

SEQID-01759
O22424
—
—
1
0.51
0.22
0.04
0.11
0.05
0.06
0.01
0.03
0.04
0.04
0.04
0.08
0.08
0.12

SEQID-01760
B8QXG4
—
—
1
0.50
0.18
0.08
0.06
0.04
0.07
0.01
0.05
0.08
0.03
0.02
0.04
0.07
0.10

SEQID-01761
B6TFX9
—
—
1
0.45
0.23
0.08
0.07
0.02
0.05
0.01
0.03
0.05
0.05
0.02
0.04
0.10
0.05

SEQID-01762
B6TDF8
—
—
1
0.46
0.21
0.08
0.06
0.04
0.06
0.01
0.01
0.05
0.04
0.02
0.06
0.06
0.08

SEQID-01763
K7VLV6
—
—
1
0.49
0.21
0.06
0.06
0.03
0.06
0.01
0.03
0.12
0.03
0.02
0.04
0.12
0.16

SEQID-01764
B65J49
—
—
0
0.41
0.18
0.05
0.21
0.03
0.00
0.09
0.03
0.06
0.04
0.05
0.00
0.11
0.01

SEQID-01765
P69246
—
—
0
0.45
0.18
0.09
0.17
0.01
0.03
0.01
0.07
0.06
0.03
0.02
0.05
0.09
0.12

SEQID-01766
P80639
—
—
0
0.49
0.20
0.04
0.04
0.04
0.09
0.02
0.04
0.09
0.04
0.05
0.06
0.06
0.11

SEQID-01767
C0HHC4
—
—
1
0.50
0.21
0.04
0.07
0.03
0.05
0.00
0.04
0.03
0.05
0.02
0.09
0.05
0.08

SEQID-01768
B4FFR7
—
—
1
0.49
0.14
0.07
0.14
0.01
0.03
0.01
0.05
0.07
0.04
0.02
0.05
0.05
0.22

SEQID-01769
B4G031
—
—
1
0.44
0.19
0.07
0.06
0.03
0.08
0.01
0.04
0.08
0.05
0.04
0.03
0.12
0.08

SEQID-01770
B4F9R4
—
—
1
0.43
0.17
0.07
0.15
0.04
0.03
0.01
0.03
0.03
0.07
0.07
0.04
0.04
0.08

SEQID-01771
Q08062
—
—
1
0.47
0.24
0.07
0.05
0.04
0.05
0.02
0.04
0.08
0.04
0.02
0.05
0.08
0.07

SEQID-01772
B6T7G7
—
—
1
0.50
0.20
0.05
0.04
0.04
0.06
0.01
0.02
0.10
0.03
0.02
0.03
0.09
0.11

SEQID-01773
P26301
—
—
1
0.46
0.22
0.06
0.04
0.06
0.06
0.01
0.04
0.09
0.05
0.01
0.07
0.08
0.10

SEQID-01774
B6TBZ8
—
—
1
0.43
0.23
0.06
0.06
0.04
0.05
0.02
0.06
0.03
0.04
0.02
0.07
0.10
0.07

SEQID-01775
B6U051
—
—
1
0.43
0.21
0.05
0.07
0.03
0.06
0.02
0.05
0.09
0.04
0.02
0.05
0.08
0.03

SEQID-01776
B6SGX0
—
—
0
0.56
0.18
0.05
0.16
0.01
0.02
0.00
0.01
0.06
0.05
0.04
0.03
0.09
0.21

SEQID-01777
Q4W1F6
—
—
1
0.56
0.21
0.13
0.01
0.01
0.04
0.02
0.03
0.10
0.02
0.05
0.04
0.05
0.12

SEQID-01778
B6SNY0
—
—
1
0.40
0.24
0.10
0.13
0.02
0.04
0.01
0.06
0.03
0.05
0.04
0.02
0.12
0.02

SEQID-01779
Q41764
—
—
1
0.44
0.18
0.05
0.03
0.04
0.10
0.01
0.05
0.06
0.02
0.01
0.06
0.06
0.10

SEQID-01780
B6T4H7
—
—
1
0.56
0.18
0.06
0.10
0.03
0.03
0.01
0.02
0.02
0.06
0.08
0.05
0.06
0.17

SEQID-01781
P25460
—
—
1
0.52
0.17
0.05
0.11
0.03
0.01
0.02
0.03
0.04
0.05
0.04
0.08
0.03
0.16

SEQID-01782
B4FUS2
—
—
1
0.51
0.20
0.02
0.16
0.05
0.07
0.01
0.04
0.04
0.04
0.03
0.04
0.09
0.12

SEQID-01783
P06673
—
—
0
0.33
0.16
0.10
0.04
0.02
0.01
0.04
0.17
0.02
0.04
0.00
0.01
0.11
0.01

SEQID-01784
B4F9R6
—
—
1
0.50
0.16
0.03
0.12
0.06
0.02
0.01
0.04
0.05
0.02
0.04
0.05
0.06
0.11

SEQID-01785
B6T782
—
—
1
0.43
0.20
0.05
0.17
0.05
0.04
0.00
0.03
0.09
0.04
0.04
0.04
0.11
0.09

SEQID-01786
B4FB55
—
—
1
0.44
0.20
0.07
0.09
0.05
0.08
0.01
0.04
0.06
0.03
0.01
0.09
0.07
0.09

SEQID-01787
P45633
—
—
1
0.42
0.17
0.07
0.16
0.04
0.05
0.03
0.03
0.05
0.04
0.03
0.04
0.06
0.11

SEQID-01788
K7UJH1
—
—
1
0.45
0.19
0.07
0.08
0.04
0.05
0.01
0.04
0.05
0.06
0.02
0.06
0.06
0.07

SEQID-01789
B6SI09
—
—
1
0.45
0.24
0.16
0.11
0.03
0.02
0.02
0.01
0.05
0.07
0.05
0.02
0.13
0.01

SEQID-01790
B4FAV3
—
—
1
0.51
0.21
0.04
0.10
0.03
0.06
0.01
0.05
0.07
0.03
0.01
0.06
0.07
0.14

SEQID-01791
P00333
—
—
1
0.50
0.21
0.06
0.05
0.05
0.04
0.03
0.02
0.09
0.05
0.04
0.06
0.06
0.08

SEQID-01792
P05494
—
—
0
0.42
0.75
0.07
0.09
0.04
0.05
0.01
0.06
0.08
0.04
0.01
0.07
0.11
0.06

SEQID-01793
P19023
—
—
0
0.44
0.24
0.07
0.09
0.03
0.06
0.00
0.05
0.07
0.05
0.02
0.07
0.09
0.05

SEQID-01794
A4GUI1
—
—
1
0.45
0.17
0.0a
0.09
0.04
0.07
0.01
0.03
0.06
0.05
0.05
0.04
0.07
0.04

SEQID-01795
B4FGQ6
—
—
0
0.47
0.19
0.03
0.17
0.02
0.01
0.01
0.06
0.04
0.03
0.02
0.04
0.07
0.18

SEQID-01796
B6T2K5
—
—
0
0.54
0.72
0.05
0.15
0.01
0.02
0.00
0.04
0.06
0.01
0.02
0.05
0.13
0.21

SEQID-01797
B4FJ41
—
—
1
0.49
0.22
0.13
0.05
0.00
0.05
0.00
0.08
0.01
0.08
0.05
0.04
0.11
0.06

SEQID-01798
Q08275
—
—
0
0.44
0.20
0.08
0.15
0.01
0.09
0.01
0.01
0.09
0.04
0.02
0.03
0.07
0.08

SEQID-01799
B6SK03
—
—
1
0.46
0.17
0.02
0.09
0.05
0.06
0.01
0.04
0.08
0.05
0.03
0.05
0.07
0.06

SEQID-01800
B6TR92
—
—
1
0.49
0.20
0.05
0.03
0.05
0.07
0.02
0.04
0.06
0.04
0.01
0.06
0.08
0.12

SEQID-01801
B6SP06
—
—
1
0.22
0.07
0.02
0.13
0.03
0.10
0.03
0.02
0.04
0.22
0.02
0.02
0.03
0.04

SEQID-01802
B6SJ08
—
—
0
0.48
0.20
0.05
0.18
0.04
0.04
0.01
0.02
0.04
0.04
0.02
0.04
0.09
0.11

SEQID-01803
B6UHQ3
—
—
1
0.39
0.19
0.17
0.03
0.01
0.06
0.02
0.07
0.04
0.04
0.05
0.01
0.13
0.02

SEQID-01804
B4F8D6
—
—
1
0.38
0.17
0.07
0.07
0.04
0.08
0.04
0.05
0.04
0.05
0.02
0.02
0.10
0.04

SEQID-01805
B4FHH2
—
—
1
0.43
0.24
0.05
0.12
0.03
0.04
0.01
0.03
0.09
0.04
0.02
0.06
0.10
0.08

SEQID-01806
C0PM74
—
—
1
0.47
0.22
0.06
0.07
0.02
0.08
0.02
0.04
0.06
0.03
0.03
0.06
0.10
0.11

SEQID-01807
B4F7Y1
—
—
1
0.54
0.22
0.06
0.10
0.04
0.03
0.01
0.04
0.07
0.03
0.02
0.05
0.10
0.18

SEQID-01808
Q84RL7
—
—
1
0.49
0.26
0.10
0.05
0.02
0.05
0.01
0.02
0.02
0.07
0.03
0.08
0.09
0.04

SEQID-01809
C0PCQ6
—
—
1
0.49
0.20
0.04
0.13
0.01
0.03
0.02
0.04
0.08
0.07
0.02
0.05
0.06
0.10

SEQID-01810
B4FBF6
—
—
1
0.47
0.20
0.09
0.06
0.03
0.03
0.02
0.08
0.03
0.05
0.01
0.05
0.08
0.08

SEQID-01811
B6THG9
—
—
0
0.42
0.16
0.06
0.11
0.04
0.08
0.00
0.03
0.08
0.04
0.03
0.05
0.08
0.11

SEQID-01812
O24573
—
—
0
0.48
0.25
0.06
0.04
0.03
0.07
0.01
0.02
0.10
0.04
0.01
0.06
0.10
0.11

SEQID-01813
B4FRC6
—
—
1
0.45
0.23
0.10
0.03
0.04
0.05
0.02
0.05
0.01
0.06
0.01
0.02
0.12
0.04

SEQID-01814
P04709
—
—
1
0.46
0.19
0.06
0.08
0.05
0.05
0.01
0.04
0.03
0.06
0.01
0.06
0.09
0.08

SEQID-01815
Q41745
—
—
1
0.57
0.26
0.06
0.09
0.01
0.04
0.01
0.03
0.05
0.03
0.02
0.06
0.12
0.07

SEQID-01816
B4FTU3
—
—
1
0.53
0.29
0.08
0.06
0.04
0.01
0.02
0.04
0.03
0.04
0.02
0.06
0.14
0.06

SEQID-01817
C0PMH6
—
—
1
0.53
0.25
0.07
0.05
0.03
0.02
0.01
0.03
0.04
0.03
0.02
0.07
0.10
0.06

SEQID-01818
B4F987
—
—
1
0.43
0.19
0.07
0.10
0.01
0.07
0.01
0.02
0.06
0.07
0.03
0.04
0.07
0.03

SEQID-01819
B4FUE0
—
—
1
0.51
0.21
0.05
0.06
0.03
0.07
0.02
0.03
0.10
0.03
0.03
0.08
0.07
0.12

SEQID-01820
B4FQ44
—
—
1
0.44
0.19
0.06
0.09
0.05
0.06
0.02
0.02
0.05
0.05
0.02
0.06
0.07
0.05

SEQID-01821
B4FAD9
—
—
1
0.51
0.27
0.03
0.04
0.07
0.06
0.01
0.03
0.09
0.03
0.01
0.08
0.11
0.10

SEQID-01822
B8A1R6
—
—
1
0.53
0.29
0.05
0.06
0.04
0.02
0.01
0.04
0.05
0.05
0.02
0.09
0.13
0.04

SEQID-01823
D3YKV1
—
—
1
0.44
0.22
0.07
0.06
0.05
0.07
0.01
0.03
0.07
0.04
0.02
0.09
0.08
0.07

SEQID-01824
C0PHH5
—
—
1
0.48
0.25
0.08
0.07
0.04
0.05
0.01
0.02
0.07
0.05
0.05
0.08
0.09
0.07

SEQID-01825
B6UDM4
—
—
1
0.54
0.23
0.06
0.09
0.01
0.04
0.01
0.03
0.03
0.05
0.03
0.03
0.15
0.09

SEQID-01826
B6SPL7
—
—
0
0.53
0.21
0.07
0.02
0.01
0.04
0.02
0.04
0.10
0.05
0.00
0.01
0.04
0.12

SEQID-01627
B4FC92
—
—
0
0.46
0.17
0.06
0.05
0.03
0.04
0.02
0.09
0.06
0.05
0.04
0.03
0.08
0.04

SEQID-01828
B4FIA6
—
—
0
0.42
0.23
0.13
0.11
0.04
0.03
0.00
0.02
0.07
0.07
0.02
0.05
0.11
0.10

SEQID-01829
B4FEE7
—
—
0
0.33
0.13
0.08
0.22
0.05
0.04
0.05
0.03
0.03
0.04
0.06
0.04
0.02
0.08

SEQID-01830
B6SHT0
—
—
1
0.46
0.22
0.09
0.09
0.04
0.07
0.01
0.02
0.07
0.04
0.01
0.04
0.08
0.08

SEQID-01831
P19950
—
—
0
0.44
0.18
0.06
0.17
0.02
0.05
0.01
0.02
0.07
0.06
0.03
0.05
0.07
0.08

SEQID-01832
B4FD90
—
—
1
0.41
0.20
0.06
0.13
0.03
0.06
0.01
0.06
0.05
0.05
0.03
0.08
0.06
0.08

SEQID-01833
B4FH43
—
—
1
0.43
0.21
0.11
0.09
0.04
0.07
0.04
0.01
0.06
0.03
0.06
0.03
0.06
0.05

SEQID-01834
B6SNQ7
—
—
0
0.43
0.20
0.06
0.18
0.01
0.04
0.01
0.05
0.05
0.04
0.00
0.06
0.07
0.11

SEQID-01835
B4G250
—
—
1
0.46
0.16
0.04
0.10
0.04
0.05
0.00
0.03
0.13
0.03
0.02
0.04
0.06
0.09

SEQID-01836
B6UD91
—
—
1
0.38
0.20
0.16
0.08
0.02
0.09
0.03
0.02
0.07
0.05
0.01
0.04
0.11
0.05

SEQID-01837
B6UI23
—
—
1
0.34
0.17
0.18
0.12
0.01
0.09
0.03
0.03
0.05
0.03
0.02
0.03
0.08
0.04

SEQID-01838
B6T1F2
—
—
1
0.50
0.22
0.03
0.13
0.03
0.04
0.01
0.03
0.04
0.05
0.05
0.06
0.07
0.11

SEQID-01839
P49076
—
—
1
0.52
0.24
0.04
0.08
0.06
0.07
0.00
0.04
0.07
0.03
0.02
0.06
0.12
0.07

SEQID-01840
P12653
—
—
1
0.48
0.23
0.08
0.05
0.04
0.04
0.02
0.03
0.09
0.02
0.02
0.03
0.13
0.08

SEQID-01841
B4F9G6
—
—
1
0.52
0.20
0.06
0.09
0.01
0.06
0.00
0.02
0.05
0.03
0.02
0.05
0.08
0.16

SEQID-01842
B4FAM6
—
—
1
0.51
0.23
0.05
0.13
0.01
0.02
0.02
0.03
0.09
0.03
0.04
0.06
0.11
0.15

SEQID-01843
B4FE06
—
—
1
0.45
0.21
0.06
0.10
0.03
0.08
0.01
0.02
0.08
0.03
0.02
0.05
0.07
0.07

SEQID-01844
B6TB84
—
—
1
0.42
0.21
0.06
0.08
0.03
0.08
0.01
0.05
0.09
0.02
0.03
0.06
0.08
0.08

SEQID-01845
A2SZW8
—
—
1
0.47
0.18
0.07
0.07
0.02
0.08
0.01
0.04
0.06
0.04
0.03
0.04
0.07
0.09

SEQID-01846
P41980
—
—
1
0.47
0.21
0.09
0.04
0.06
0.05
0.00
0.04
0.07
0.05
0.04
0.04
0.11
0.08

SEQID-01847
C4J9Y2
—
—
1
0.46
0.23
0.08
0.05
0.03
0.05
0.02
0.04
0.07
0.05
0.03
0.02
0.13
0.06

SEQID-01848
B4F848
—
—
0
0.49
0.27
0.07
0.06
0.01
0.06
0.00
0.02
0.08
0.05
0.01
0.06
0.10
0.10

SEQID-01849
B6TKC5
—
—
1
0.47
0.21
0.08
0.07
0.02
0.04
0.00
0.03
0.08
0.04
0.04
0.07
0.09
0.03

SEQID-01850
P29023
—
—
1
0.34
0.13
0.03
0.03
0.06
0.03
0.06
0.07
0.03
0.09
0.02
0.02
0.05
0.04

SEQID-01851
B4F8K1
—
—
1
0.47
0.22
0.04
0.12
0.07
0.01
0.00
0.04
0.11
0.03
0.02
0.07
0.10
0.13

SEQID-01852
B4FXR6
—
—
1
0.26
0.08
0.05
0.11
0.02
0.06
0.05
0.02
0.05
0.19
0.04
0.02
0.02
0.03

SEQID-01853
Q41814
—
—
0
0.40
0.03
0.03
0.00
0.00
0.01
0.00
0.00
0.02
0.02
0.02
0.00
0.02
0.15

SEQID-01854
B4F9T3
—
—
1
0.41
0.22
0.09
0.09
0.02
0.06
0.02
0.03
0.09
0.05
0.02
0.07
0.07
0.06

SEQID-01855
Q6XZ78
—
—
1
0.48
0.22
0.09
0.06
0.05
0.08
0.02
0.01
0.06
0.05
0.02
0.04
0.11
0.08

SEQID-01856
B4FRJ1
—
—
0
0.48
0.25
0.07
0.05
0.05
0.05
0.01
0.03
0.07
0.05
0.01
0.05
0.11
0.09

SEQID-01857
P93629
—
—
1
0.51
0.23
0.05
0.03
0.04
0.06
0.04
0.04
0.06
0.06
0.03
0.06
0.06
0.08

SEQID-01858
B4FRI1
—
—
1
0.43
0.19
0.11
0.07
0.03
0.06
0.02
0.03
0.05
0.04
0.03
0.04
0.08
0.07

SEQID-01859
B6TGG7
—
—
1
0.44
0.21
0.07
0.08
0.05
0.06
0.02
0.02
0.05
0.06
0.03
0.08
0.06
0.06

SEQID-01860
P30792
—
—
1
0.46
0.23
0.06
0.06
0.05
0.09
0.01
0.04
0.06
0.05
0.03
0.05
0.09
0.07

SEQID-01861
B6TZ53
—
—
1
0.51
0.25
0.03
0.07
0.02
0.02
0.01
0.03
0.04
0.06
0.03
0.08
0.11
0.04

SEQID-01862
B6SH97
—
—
1
0.44
0.22
0.03
0.10
0.03
0.06
0.01
0.03
0.07
0.04
0.04
0.07
0.08
0.06

SEQID-01863
B7ZZ42
—
—
1
0.45
0.21
0.06
0.07
0.05
0.08
0.01
0.04
0.10
0.04
0.01
0.07
0.07
0.09

SEQID-01864
K7UD35
—
—
1
0.47
0.21
0.06
0.11
0.03
0.06
0.01
0.03
0.05
0.04
0.03
0.04
0.10
0.05

SEQID-01865
Q9TV61
—
—
1
0.45
0.19
0.05
0.07
0.04
0.05
0.01
0.08
0.15
0.02
0.02
0.05
0.10
0.12

SEQID-01866
F1SS64
—
—
1
0.45
0.19
0.05
0.07
0.04
0.05
0.01
0.08
0.15
0.02
0.02
0.05
0.10
0.12

SEQID-01867
Q9TV62
—
—
1
0.45
0.13
0.05
0.07
0.04
0.05
0.01
0.08
0.15
0.02
0.02
0.05
0.10
0.12

SEQID-01868
P79293
—
—
1
0.44
0.19
0.05
0.08
0.05
0.05
0.01
0.07
0.15
0.02
0.02
0.04
0.11
0.12

SEQID-01869
P68137
—
—
1
0.47
0.20
0.05
0.07
0.03
0.06
0.01
0.03
0.09
0.04
0.03
0.08
0.07
0.06

SEQID-01870
I3L8Q0
—
—
1
0.45
0.19
0.06
0.09
0.02
0.03
0.01
0.05
0.12
0.03
0.03
0.06
0.05
0.09

SEQID-01871
F1RQQ8
—
—
1
0.45
0.21
0.05
0.10
0.06
0.06
0.01
0.04
0.09
0.03
0.03
0.06
0.09
0.06

SEQID-01872
F1RHL9
—
—
1
0.44
0.20
0.05
0.09
0.05
0.06
0.01
0.07
0.11
0.02
0.03
0.07
0.09
0.07

SEQID-01873
Q5XLD3
—
—
1
0.50
0.20
0.02
0.07
0.05
0.07
0.01
0.04
0.08
0.04
0.05
0.04
0.10
0.10

SEQID-01874
F1RUN2
—
—
1
0.46
0.19
0.05
0.07
0.02
0.06
0.05
0.04
0.11
0.01
0.04
0.04
0.11
0.11

SEQID-01875
Q1KYT0
—
—
1
0.48
0.23
0.06
0.06
0.05
0.06
0.01
0.03
0.08
0.05
0.02
0.06
0.09
0.10

SEQID-01876
F1RFH9
—
—
1
0.49
0.25
0.06
0.07
0.04
0.05
0.02
0.03
0.09
0.04
0.02
0.07
0.10
0.06

SEQID-01877
F15HL9
—
—
1
0.48
0.23
0.07
0.08
0.03
0.06
0.02
0.03
0.09
0.04
0.03
0.07
0.08
0.09

SEQID-01878
F1RU49
—
—
1
0.43
0.20
0.06
0.10
0.04
0.06
0.01
0.07
0.11
0.03
0.03
0.05
0.10
0.06

SEQID-01879
P00355
—
—
1
0.52
0.22
0.06
0.04
0.05
0.07
0.01
0.02
0.04
0.05
0.04
0.07
0.06
0.09

SEQID-01880
P11607
—
—
1
0.50
0.25
0.05
0.06
0.04
0.05
0.03
0.03
0.09
0.03
0.01
0.07
0.09
0.07

SEQID-01881
F1SRI8
—
—
1
0.46
0.20
0.04
0.06
0.04
0.07
0.01
0.03
0.09
0.03
0.02
0.07
0.06
0.11

SEQID-01882
F1SFA7
—
—
1
0.25
0.12
0.07
0.09
0.04
0.04
0.01
0.03
0.06
0.17
0.01
0.03
0.05
0.05

SEQID-01883
F1SHW9
—
—
1
0.47
0.15
0.05
0.03
0.06
0.06
0.01
0.05
0.06
0.01
0.04
0.05
0.07
0.16

SEQID-01884
Q9GIV4
—
—
1
0.47
0.11
0.04
0.04
0.04
0.05
0.10
0.04
0.05
0.03
0.06
0.02
0.03
0.14

SEQID-01885
A1XQT6
—
—
0
0.44
0.18
0.08
0.03
0.05
0.05
0.01
0.04
0.14
0.03
0.01
0.05
0.08
0.12

SEQID-01886
D0G7F6
—
—
1
0.49
0.23
0.08
0.05
0.05
0.05
0.02
0.04
0.09
0.05
0.03
0.06
0.07
0.10

SEQID-01887
P1S960
—
—
1
0.44
0.21
0.05
0.08
0.03
0.05
0.02
0.04
0.11
0.04
0.03
0.04
0.11
0.05

SEQID-01888
F1RZQ6
—
—
1
0.50
0.21
0.07
0.03
0.03
0.05
0.01
0.05
0.02
0.05
0.01
0.06
0.09
0.09

SEQID-01889
Q5XLD2
—
—
1
0.49
0.16
0.06
0.05
0.05
0.09
0.01
0.05
0.10
0.04
0.01
0.06
0.05
0.11

SEQID-01890
Q7SIB7
—
—
1
0.52
0.23
0.06
0.04
0.05
0.06
0.02
0.02
0.08
0.05
0.02
0.05
0.09
0.12

SEQID-01891
F1RVL5
—
—
1
0.46
0.20
0.04
0.05
0.04
0.07
0.02
0.03
0.10
0.03
0.03
0.05
0.07
0.09

SEQID-01892
P00339
—
—
1
0.54
0.28
0.04
0.05
0.05
0.05
0.01
0.03
0.07
0.04
0.04
0.07
0.11
0.09

SEQID-01893
F1RH20
—
—
1
0.46
0.20
0.04
0.07
0.03
0.06
0.01
0.04
0.11
0.04
0.02
0.05
0.07
0.10

SEQID-01894
Q55154
—
—
1
0.49
0.18
0.04
0.06
0.04
0.07
0.02
0.02
0.06
0.03
0.06
0.04
0.09
0.09

SEQID-01895
B5KJG2
—
—
1
0.47
0.18
0.06
0.10
0.03
0.05
0.01
0.03
0.10
0.04
0.04
0.06
0.09
0.09

SEQID-01896
F1SHX0
—
—
1
0.47
0.17
0.04
0.07
0.04
0.07
0.01
0.05
0.07
0.02
0.05
0.05
0.07
0.13

SEQID-01897
P02540
—
—
1
0.37
0.19
0.06
0.13
0.04
0.05
0.00
0.08
0.14
0.02
0.02
0.04
0.10
0.05

SEQID-01898
F1SE14
—
—
1
0.43
0.22
0.06
0.07
0.04
0.06
0.01
0.04
0.06
0.05
0.02
0.09
0.03
0.08

SEQID-01899
Q2HYU2
—
—
1
0.48
0.22
0.05
0.09
0.04
0.05
0.02
0.04
0.07
0.05
0.03
0.06
0.09
0.06

SEQID-01900
F1SM75
—
—
1
0.44
0.18
0.05
0.07
0.04
0.05
0.01
0.04
0.10
0.03
0.03
0.05
0.07
0.09

SEQID-01901
Q4P585
—
—
1
0.43
0.16
0.03
0.05
0.04
0.04
0.00
0.06
0.07
0.09
0.03
0.03
0.09
0.08

SEQID-01902
Q75NG9
—
—
1
0.38
0.14
0.05
0.12
0.02
0.06
0.00
0.06
0.21
0.01
0.03
0.04
0.07
0.16

SEQID-01903
F1SQT3
—
—
1
0.46
0.21
0.07
0.07
0.02
0.03
0.02
0.04
0.06
0.04
0.01
0.04
0.10
0.07

SEQID-01904
P33198
—
—
1
0.50
0.19
0.05
0.07
0.04
0.07
0.02
0.05
0.05
0.04
0.04
0.07
0.07
0.09

SEQID-01905
F1SMN5
—
—
1
0.44
0.20
0.05
0.06
0.03
0.06
0.02
0.03
0.09
0.06
0.03
0.05
0.05
0.07

SEQID-01906
Q2HYU1
—
—
1
0.44
0.21
0.04
0.12
0.04
0.07
0.02
0.04
0.07
0.04
0.03
0.05
0.10
0.06

SEQID-01907
P08059
—
—
1
0.52
0.20
0.04
0.06
0.05
0.05
0.00
0.05
0.07
0.04
0.05
0.06
0.10
0.08

SEQID-01908
F1SG00
—
—
0
0.38
0.17
0.07
0.08
0.02
0.07
0.00
0.07
0.25
0.01
0.01
0.03
0.11
0.13

SEQID-01909
F1RPS8
—
—
0
0.45
0.25
0.07
0.09
0.03
0.06
0.00
0.05
0.07
0.05
0.01
0.08
0.10
0.07

SEQID-01910
P16276
—
—
1
0.47
0.22
0.05
0.07
0.05
0.06
0.02
0.04
0.06
0.05
0.04
0.06
0.09
0.09

SEQID-01911
13L953
—
—
1
0.44
0.22
0.06
0.10
0.01
0.05
0.02
0.06
0.10
0.04
0.03
0.03
0.09
0.05

SEQID-01912
P01965
—
—
0
0.55
0.22
0.09
0.03
0.04
0.09
0.01
0.03
0.02
0.04
0.10
0.00
0.14
0.09

SEQID-01913
P02067
—
—
1
0.54
0.26
0.06
0.05
0.06
0.06
0.01
0.04
0.06
0.05
0.07
0.01
0.13
0.09

SEQID-01914
Q7M2W6
—
—
1
0.48
0.18
0.03
0.12
0.01
0.06
0.00
0.02
0.09
0.02
0.06
0.06
0.08
0.06

SEQID-01915
F1RT61
—
—
0
0.18
0.06
0.09
0.09
0.03
0.03
0.00
0.04
0.06
0.21
0.01
0.01
0.03
0.05

SEQID-01916
I3LB76
—
—
1
0.46
0.19
0.05
0.14
0.02
0.05
0.01
0.03
0.13
0.02
0.03
0.02
0.12
0.14

SEQID-01917
F1RM62
—
—
1
0.38
0.22
0.10
0.10
0.00
0.03
0.01
0.04
0.10
0.03
0.06
0.03
0.11
0.02

SEQID-01918
F6PSL2
—
—
0
0.49
0.16
0.05
0.05
0.06
0.08
0.00
0.04
0.12
0.03
0.01
0.06
0.05
0.11

SEQID-01919
P00346
—
—
0
0.49
0.25
0.07
0.05
0.04
0.04
0.02
0.03
0.06
0.05
0.02
0.07
0.10
0.09

SEQID-01920
P11708
—
—
1
0.51
0.25
0.06
0.04
0.04
0.08
0.01
0.03
0.06
0.03
0.02
0.07
0.10
0.11

SEQID-01921
F1RJ25
—
—
1
0.41
0.22
0.08
0.03
0.04
0.05
0.02
0.05
0.09
0.05
0.02
0.06
0.09
0.07

SEQID-01922
F1SLA0
—
—
0
0.45
0.25
0.08
0.07
0.02
0.06
0.00
0.06
0.08
0.05
0.02
0.07
0.10
0.05

SEQID-01923
F1RK48
—
—
1
0.35
0.16
0.06
0.07
0.03
0.06
0.01
0.05
0.15
0.06
0.03
0.04
0.09
0.05

SEQID-01924
F1SU23
—
—
1
0.39
0.16
0.05
0.11
0.03
0.09
0.01
0.06
0.05
0.03
0.03
0.01
0.11
0.06

SEQID-01925
I3LJX2
—
—
0
0.23
0.09
0.10
0.07
0.02
0.05
0.01
0.03
0.07
0.17
0.00
0.01
0.04
0.06

SEQID-01926
F1SHA2
—
—
0
0.49
0.24
0.05
0.04
0.04
0.04
0.04
0.06
0.10
0.05
0.03
0.07
0.10
0.07

SEQID-01927
F1STM4
—
—
1
0.52
0.21
0.06
0.06
0.04
0.05
0.01
0.03
0.07
0.04
0.03
0.07
0.06
0.11

SEQID-01928
F1RIS3
—
—
1
0.41
0.22
0.07
0.11
0.00
0.04
0.03
0.09
0.10
0.04
0.04
0.02
0.14
0.05

SEQID-01929
I3LP30
—
—
1
0.49
0.22
0.03
0.06
0.05
0.04
0.01
0.07
0.15
0.01
0.02
0.05
0.13
0.13

SEQID-01930
F1S557
—
—
1
0.45
0.21
0.04
0.08
0.05
0.05
0.02
0.05
0.08
0.03
0.04
0.06
0.10
0.06

SEQID-01931
B5DGM7
—
—
1
0.47
0.19
0.07
0.06
0.04
0.05
0.02
0.05
0.07
0.04
0.04
0.05
0.09
0.09

SEQID-01932
B5DGR2
—
—
1
0.53
0.22
0.07
0.05
0.05
0.07
0.01
0.01
0.05
0.05
0.05
0.07
0.05
0.09

SEQID-01933
B5DGM8
—
—
1
0.47
0.19
0.07
0.06
0.04
0.05
0.02
0.05
0.06
0.04
0.04
0.05
0.09
0.08

SEQID-01934
B5DGQ6
—
—
1
0.48
0.22
0.07
0.05
0.05
0.08
0.02
0.03
0.07
0.05
0.03
0.07
0.08
0.11

SEQID-01935
B5DGQ7
—
—
1
0.48
0.21
0.07
0.05
0.05
0.08
0.02
0.03
0.07
0.05
0.03
0.07
0.08
0.11

SEQID-01936
B5DG40
—
—
1
0.46
0.20
0.05
0.07
0.03
0.06
0.01
0.03
0.08
0.04
0.03
0.09
0.07
0.06

SEQID-01937
B5DGP0
—
—
1
0.50
0.20
0.02
0.07
0.05
0.08
0.01
0.02
0.08
0.05
0.05
0.04
0.09
0.10

SEQID-01938
B5DGL3
—
—
1
0.51
0.23
0.07
0.04
0.05
0.06
0.02
0.03
0.08
0.06
0.03
0.07
0.07
0.11

SEQID-01939
B5DGG5
—
—
1
0.50
0.19
0.03
0.07
0.04
0.08
0.01
0.03
0.08
0.05
0.05
0.04
0.09
0.10

SEQID-01940
Q91472
—
—
0
0.41
0.18
0.07
0.06
0.02
0.09
0.00
0.04
0.22
0.01
0.00
0.04
0.11
0.15

SEQID-01941
B5DGU1
—
—
1
0.49
0.21
0.06
0.09
0.03
0.06
0.02
0.03
0.08
0.04
0.04
0.08
0.07
0.09

SEQID-01942
B5DH12
—
—
0
0.43
0.18
0.08
0.04
0.05
0.09
0.00
0.04
0.11
0.04
0.01
0.04
0.07
0.10

SEQID-01943
B5DG55
—
—
1
0.48
0.21
0.05
0.08
0.05
0.06
0.01
0.04
0.09
0.03
0.04
0.06
0.09
0.09

SEQID-01944
B5DFX8
—
—
1
0.53
0.22
0.07
0.03
0.05
0.07
0.02
0.02
0.06
0.05
0.03
0.05
0.09
0.12

SEQID-01945
B5DGT1
—
—
0
0.43
0.18
0.08
0.04
0.05
0.09
0.00
0.04
0.12
0.04
0.01
0.04
0.07
0.10

SEQID-01946
Q7ZZN0
—
—
1
0.46
0.18
0.06
0.04
0.04
0.07
0.01
0.05
0.13
0.03
0.01
0.06
0.07
0.10

SEQID-01947
B5DGT9
—
—
1
0.52
0.19
0.06
0.07
0.04
0.05
0.01
0.02
0.09
0.04
0.05
0.06
0.08
0.12

SEQID-01948
O13093
—
—
1
0.54
0.18
0.05
0.06
0.03
0.06
0.00
0.04
0.14
0.02
0.03
0.04
0.09
0.20

SEQID-01949
B5DGM5
—
—
0
0.49
0.23
0.05
0.07
0.01
0.09
0.01
0.02
0.09
0.05
0.01
0.07
0.09
0.14

SEQID-01950
B5DG45
—
—
1
0.43
0.18
0.07
0.07
0.04
0.06
0.02
0.02
0.10
0.03
0.00
0.06
0.05
0.11

SEQID-01951
BS0H15
—
—
0
0.55
0.17
0.10
0.01
0.02
0.11
0.03
0.03
0.09
0.03
0.02
0.06
0.08
0.14

SEQID-01952
B5X1G7
—
—
1
0.49
0.26
0.07
0.06
0.04
0.07
0.01
0.03
0.09
0.05
0.01
0.07
0.09
0.10

SEQID-01953
B5DGZ4
—
—
1
0.39
0.14
0.05
0.11
0.02
0.05
0.00
0.04
0.25
0.01
0.03
0.04
0.06
0.17

SEQID-01954
Q98SJ9
—
—
1
0.57
0.26
0.05
0.03
0.06
0.04
0.03
0.02
0.09
0.05
0.03
0.09
0.09
0.10

SEQID-01955
B5DG10
—
—
1
0.52
0.22
0.06
0.05
0.04
0.05
0.01
0.03
0.07
0.05
0.03
0.08
0.06
0.12

SEQID-01956
B5RI24
—
—
1
0.43
0.20
0.05
0.07
0.05
0.08
0.01
0.08
0.10
0.02
0.03
0.08
0.08
0.04

SEQID-01957
B5DGZ1
—
—
1
0.51
0.20
0.07
0.07
0.03
0.05
0.01
0.05
0.03
0.05
0.01
0.09
0.06
0.10

SEQID-01958
B5DGS2
—
—
1
0.49
0.20
0.04
0.05
0.04
0.07
0.02
0.05
0.06
0.04
0.03
0.06
0.09
0.10

SEQID-01959
BSDFT9
—
—
1
0.46
0.19
0.03
0.11
0.05
0.08
0.02
0.04
0.06
0.04
0.03
0.04
0.10
0.06

SEQID-01960
B5DG78
—
—
0
0.45
0.24
0.07
0.09
0.03
0.06
0.01
0.05
0.06
0.05
0.03
0.07
0.10
0.07

SEQID-01961
B5DG72
—
—
1
0.50
0.21
0.05
0.05
0.04
0.07
0.01
0.03
0.05
0.06
0.03
0.08
0.07
0.09

SEQID-01962
406714392
—
—
1
0.41
0.20
0.05
0.09
0.05
0.04
0.00
0.06
0.09
0.04
0.01
0.06
0.09
0.06

SEQID-01963
409935420
—
—
1
0.42
0.20
0.05
0.09
0.05
0.04
0.00
0.06
0.09
0.04
0.01
0.06
0.09
0.06

SEQID-01964
291565678
—
—
1
0.45
0.23
0.09
0.03
0.05
0.06
0.00
0.03
0.12
0.05
0.01
0.07
0.09
0.08

SEQID-01965
291568131
—
—
1
0.40
0.21
0.07
0.09
0.04
0.07
0.00
0.05
0.10
0.03
0.02
0.06
0.09
0.09

SEQID-01966
406715237
—
—
1
0.42
0.22
0.07
0.09
0.03
0.09
0.00
0.04
0.10
0.04
0.02
0.06
0.09
0.08

SEQID-01967
406714893
—
—
1
0.45
0.22
0.05
0.08
0.04
0.07
0.02
0.03
0.10
0.04
0.01
0.06
0.08
0.07

SEQID-01968
291571801
—
—
1
0.45
0.22
0.05
0.08
0.04
0.07
0.02
0.03
0.10
0.04
0.01
0.06
0.08
0.07

SEQID-01969
406715272
—
—
1
0.44
0.23
0.07
0.08
0.05
0.05
0.02
0.04
0.11
0.05
0.03
0.09
0.07
0.05

SEQID-01970
406712836
—
—
0
0.43
0.21
0.09
0.07
0.04
0.06
0.01
0.05
0.08
0.04
0.05
0.07
0.07
0.05

SEQID-01971
406716509
—
—
1
0.38
0.14
0.07
0.10
0.02
0.04
0.00
0.17
0.10
0.01
0.02
0.02
0.07
0.07

SEQID-01972
406712937
—
—
1
0.39
0.20
0.07
0.06
0.05
0.06
0.01
0.09
0.09
0.03
0.02
0.05
0.10
0.06

SEQID-01973
304281792
—
—
1
0.38
0.19
0.06
0.10
0.04
0.05
0.01
0.06
0.06
0.05
0.03
0.08
0.06
0.05

SEQID-01974
406711415
—
—
1
0.48
0.25
0.06
0.06
0.03
0.07
0.01
0.02
0.05
0.04
0.03
0.07
0.09
0.06

SEQID-01975
291566625
—
—
1
0.49
0.25
0.06
0.06
0.08
0.07
0.01
0.02
0.05
0.04
0.03
0.06
0.09
0.06

SEQID-01976
406712246
—
—
1
0.40
0.17
0.04
0.11
0.06
0.04
0.00
0.09
0.07
0.03
0.01
0.05
0.07
0.04

SEQID-01977
406715559
—
—
1
0.57
0.23
0.06
0.04
0.04
0.04
0.01
0.04
0.03
0.05
0.07
0.07
0.10
0.04

SEQID-01978
406716162
—
—
1
0.44
0.25
0.05
0.12
0.03
0.06
0.00
0.04
0.13
0.04
0.02
0.09
0.10
0.07

SEQID-01979
406711547
—
—
1
0.40
0.20
0.06
0.08
0.10
0.04
0.01
0.05
0.05
0.06
0.01
0.07
0.06
0.02

SEQID-01980
406715412
—
—
1
0.42
0.22
0.04
0.11
0.04
0.07
0.00
0.05
0.09
0.04
0.02
0.06
0.09
0.06

SEQID-01981
406712949
—
—
1
0.49
0.22
0.06
0.09
0.03
0.08
0.00
0.03
0.09
0.05
0.03
0.08
0.06
0.07

SEQID-01982
291570166
—
—
1
0.44
0.17
0.04
0.07
0.04
0.05
0.01
0.07
0.09
0.05
0.03
0.07
0.07
0.07

SEQID-01983
291569320
—
—
1
0.49
0.22
0.06
0.08
0.03
0.07
0.00
0.03
0.09
0.05
0.03
0.03
0.06
0.07

SEQID-01984
406715542
—
—
1
0.47
0.21
0.07
0.06
0.04
0.06
0.01
0.03
0.07
0.05
0.04
0.05
0.09
0.06

SEQID-01985
406714412
—
—
0
0.42
0.15
0.05
0.09
0.04
0.06
0.01
0.04
0.10
0.05
0.04
0.04
0.09
0.11

SEQID-01986
406711071
—
—
0
0.47
0.27
0.09
0.07
0.04
0.06
0.00
0.05
0.11
0.06
0.00
0.09
0.09
0.0a

SEQID-01987
406712053
—
—
1
0.45
0.19
0.05
0.06
0.06
0.06
0.01
0.05
0.08
0.04
0.03
0.05
0.09
0.06

SEQID-01988
P13550
—
—
1
0.45
0.24
0.05
0.09
0.02
0.06
0.01
0.04
0.11
0.04
0.02
0.08
0.07
0.06

SEQID-01989
406715415
—
—
1
0.44
0.25
0.04
0.08
0.04
0.09
0.01
0.05
0.10
0.04
0.02
0.07
0.09
0.05

SEQID-01990
291570822
—
—
1
0.49
0.19
0.02
0.07
0.03
0.09
0.02
0.04
0.07
0.05
0.01
0.04
0.05
0.07

SEQID-01991
157042617
—
—
1
0.36
0.18
0.05
0.14
0.05
0.02
0.00
0.07
0.10
0.04
0.01
0.03
0.08
0.02

SEQID-01992
406711121
—
—
0
0.46
0.22
0.05
0.07
0.06
0.05
0.01
0.03
0.07
0.03
0.00
0.07
0.10
0.05

SEQID-01993
406715081
—
—
1
0.50
0.19
0.06
0.07
0.02
0.05
0.00
0.05
0.05
0.06
0.03
0.05
0.07
0.03

SEQID-01994
406713986
—
—
0
0.42
0.25
0.07
0.07
0.03
0.06
0.00
0.09
0.08
0.05
0.00
0.08
0.10
0.06

SEQID-01995
291570872
—
—
0
0.48
0.27
0.07
0.07
0.04
0.05
0.00
0.04
0.11
0.06
0.00
0.09
0.09
0.09

SEQID-01996
406715991
—
—
1
0.46
0.21
0.05
0.06
0.05
0.07
0.01
0.04
0.06
0.06
0.03
0.06
0.09
0.06

SEQID-01997
409938508
—
—
1
0.45
0.19
0.05
0.06
0.06
0.07
0.00
0.05
0.08
0.04
0.02
0.05
0.09
0.07

SEQID-01998
291571972
—
—
1
0.51
0.20
0.06
0.07
0.02
0.05
0.00
0.04
0.05
0.06
0.03
0.05
0.09
0.03

SEQID-01999
291565665
—
—
0
0.41
0.15
0.05
0.09
0.03
0.06
0.01
0.05
0.10
0.05
0.03
0.04
0.08
0.11

SEQID-02000
291568537
—
—
1
0.49
0.16
0.04
0.05
0.05
0.03
0.01
0.03
0.12
0.05
0.01
0.05
0.07
0.13

SEQID-02001
1524355
—
—
0
0.40
0.23
0.07
0.11
0.02
0.05
0.01
0.01
0.11
0.05
0.00
0.08
0.07
0.04

SEQID-02002
157042618
—
—
1
0.35
0.19
0.04
0.13
0.03
0.05
0.01
0.07
0.08
0.04
0.01
0.05
0.09
0.03

SEQID-02003
291568724
—
—
0
0.45
0.25
0.05
0.07
0.03
0.06
0.00
0.05
0.09
0.05
0.01
0.07
0.09
0.06

SEQID-02004
406716541
—
—
0
0.44
0.22
0.06
0.07
0.04
0.09
0.01
0.05
0.09
0.05
0.01
0.06
0.09
0.09

SEQID-02005
291568009
—
—
1
0.45
0.21
0.06
0.06
0.04
0.07
0.01
0.04
0.06
0.06
0.03
0.06
0.09
0.06

SEQID-02006
291567743
—
—
1
0.56
0.21
0.06
0.04
0.04
0.04
0.00
0.04
0.03
0.05
0.07
0.06
0.10
0.03

SEQID-02007
291569369
—
—
0
0.38
0.17
0.02
0.04
0.04
0.05
0.00
0.22
0.12
0.01
0.02
0.04
0.11
0.10

SEQID-02008
2114199
—
—
0
0.41
0.23
0.09
0.07
0.04
0.07
0.01
0.04
0.04
0.04
0.00
0.08
0.09
0.06

SEQID-02009
406716545
—
—
1
0.52
0.24
0.06
0.05
0.05
0.03
0.00
0.03
0.05
0.07
0.04
0.07
0.11
0.03

SEQID-02010
406710610
—
—
1
0.46
0.20
0.04
0.07
0.06
0.07
0.01
0.05
0.07
0.03
0.04
0.06
0.10
0.06

SEQID-02011
406712941
—
—
1
0.43
0.22
0.05
0.07
0.04
0.06
0.02
0.05
0.08
0.06
0.03
0.06
0.10
0.05

SEQID-02012
406712920
—
—
0
0.42
0.19
0.03
0.04
0.05
0.05
0.00
0.16
0.09
0.01
0.02
0.05
0.12
0.09

SEQID-02013
406716507
—
—
1
0.44
0.25
0.04
0.10
0.05
0.06
0.01
0.06
0.09
0.02
0.02
0.07
0.12
0.04

SEQID-02014
406714835
—
—
1
0.38
0.17
0.05
0.03
0.02
0.02
0.01
0.24
0.18
0.01
0.03
0.02
0.12
0.07

SEQID-02015
291566055
—
—
1
0.49
0.16
0.03
0.05
0.05
0.07
0.01
0.03
0.08
0.04
0.06
0.04
0.06
0.05

SEQID-02016
409939478
—
—
0
0.39
0.05
0.08
0.00
0.00
0.07
0.00
0.01
0.15
0.00
0.01
0.01
0.00
0.23

SEQID-02017
P72503
—
—
0
0.38
0.22
0.11
0.09
0.04
0.06
0.02
0.04
0.06
0.03
0.00
0.06
0.09
0.03

SEQID-02018
291568270
—
—
1
0.42
0.22
0.03
0.10
0.03
0.06
0.02
0.05
0.13
0.02
0.01
0.08
0.05
0.07

SEQID-02019
406714163
—
—
1
0.49
0.23
0.06
0.05
0.06
0.02
0.01
0.03
0.06
0.05
0.03
0.07
0.09
0.00

SEQID-02020
406713173
—
—
1
0.44
0.24
0.07
0.11
0.03
0.07
0.00
0.05
0.08
0.05
0.01
0.07
0.10
0.04

SEQID-02021
406711712
—
—
1
0.45
0.21
0.07
0.09
0.04
0.07
0.01
0.04
0.12
0.04
0.01
0.07
0.07
0.12

SEQID-02022
291566390
—
—
1
0.43
0.25
0.07
0.10
0.04
0.06
0.01
0.07
0.08
0.02
0.00
0.05
0.13
0.07

SEQID-02023
291565971
—
—
1
0.49
0.23
0.07
0.07
0.04
0.07
0.01
0.04
0.09
0.04
0.03
0.08
0.08
0.07

SEQID-02024
291570193
—
—
1
0.46
0.19
0.04
0.07
0.06
0.06
0.01
0.04
0.09
0.04
0.05
0.06
0.09
0.05

SEQID-02025
406711224
—
—
1
0.45
0.21
0.05
0.06
0.05
0.06
0.01
0.06
0.09
0.03
0.03
0.06
0.09
0.08

SEQID-02026
409938720
—
—
1
0.45
0.22
0.06
0.09
0.04
0.08
0.01
0.05
0.12
0.04
0.01
0.06
0.06
0.12

SEQID-02027
406715510
—
—
1
0.42
0.19
0.05
0.16
0.05
0.03
0.01
0.02
0.05
0.06
0.04
0.07
0.05
0.09

SEQID-02028
406716632
—
—
0
0.42
0.15
0.05
0.03
0.02
0.03
0.00
0.02
0.16
0.01
0.00
0.03
0.05
0.15

SEQID-02029
291567489
—
—
1
0.43
0.22
0.06
0.06
0.04
0.09
0.01
0.03
0.05
0.05
0.03
0.07
0.07
0.07

SEQID-02030
406715202
—
—
1
0.42
0.21
0.04
0.10
0.04
0.07
0.01
0.05
0.05
0.04
0.03
0.08
0.09
0.04

SEQID-02031
291572127
—
—
1
0.40
0.21
0.04
0.11
0.04
0.04
0.01
0.03
0.11
0.05
0.01
0.07
0.07
0.02

SEQID-02032
406710632
—
—
1
0.45
0.27
0.08
0.07
0.03
0.05
0.00
0.10
0.08
0.03
0.00
0.08
0.10
0.08

SEQID-02033
291569653
—
—
1
0.45
0.22
0.06
0.03
0.03
0.06
0.01
0.08
0.07
0.04
0.01
0.04
0.10
0.06

SEQID-02034
291568318
—
—
1
0.44
0.25
0.04
0.12
0.05
0.05
0.01
0.04
0.09
0.03
0.02
0.07
0.11
0.06

SEQID-02035
10303060
—
—
0
0.39
0.16
0.10
0.09
0.02
0.05
0.02
0.09
0.04
0.04
0.00
0.05
0.07
0.09

SEQID-02036
406714441
—
—
0
0.42
0.09
0.12
0.06
0.03
0.05
0.00
0.02
0.08
0.03
0.00
0.01
0.04
0.16

SEQID-02037
406713507
—
—
0
0.49
0.24
0.07
0.06
0.03
0.06
0.01
0.06
0.03
0.03
0.00
0.09
0.09
0.11

SEQID-02038
406715512
—
—
1
0.43
0.22
0.07
0.15
0.03
0.04
0.01
0.05
0.03
0.04
0.01
0.04
0.09
0.09

SEQID-02039
406716252
—
—
0
0.36
0.19
0.08
0.09
0.07
0.04
0.00
0.13
0.13
0.02
0.00
0.04
0.11
0.09

SEQID-02040
291571590
—
—
0
0.43
0.21
0.06
0.06
0.04
0.07
0.01
0.04
0.03
0.04
0.00
0.05
0.11
0.07

SEQID-02041
291571517
—
—
1
0.39
0.20
0.06
0.10
0.03
0.14
0.01
0.04
0.07
0.04
0.02
0.07
0.09
0.06

SEQID-02042
155676168
—
—
1
0.50
0.24
0.06
0.07
0.03
0.07
0.01
0.05
0.09
0.05
0.03
0.08
0.09
0.07

SEQID-02043
291565929
—
—
0
0.49
0.21
0.11
0.01
0.00
0.05
0.00
0.04
0.18
0.04
0.00
0.06
0.10
0.14

SEQID-02044
291565691
—
—
0
0.42
0.08
0.14
0.06
0.04
0.03
0.00
0.01
0.10
0.03
0.00
0.01
0.04
0.17

SEQID-02045
406713937
—
—
0
0.49
0.30
0.05
0.09
0.05
0.05
0.00
0.06
0.08
0.04
0.01
0.07
0.15
0.06

SEQID-02046
291572098
—
—
1
0.41
0.21
0.05
0.09
0.03
0.06
0.00
0.04
0.17
0.03
0.02
0.07
0.07
0.04

SEQID-02047
291571140
—
—
1
0.47
0.25
0.04
0.05
0.04
0.08
0.01
0.05
0.06
0.05
0.02
0.06
0.10
0.07

SEQID-02048
406713289
—
—
1
0.42
0.21
0.05
0.05
0.03
0.05
0.00
0.03
0.19
0.02
0.01
0.06
0.09
0.08

SEQID-02049
406714641
—
—
1
0.40
0.20
0.04
0.11
0.04
0.05
0.01
0.04
0.10
0.04
0.01
0.07
0.07
0.02

SEQID-02050
406712535
—
—
1
0.40
0.24
0.05
0.04
0.05
0.11
0.00
0.07
0.14
0.02
0.01
0.07
0.09
0.01

SEQID-02051
291567799
—
—
0
0.43
0.21
0.06
0.18
0.01
0.07
0.01
0.06
0.05
0.03
0.05
0.05
0.09
0.07

SEQID-02052
291569929
—
—
0
0.45
0.24
0.05
0.09
0.03
0.09
0.01
0.04
0.09
0.04
0.00
0.08
0.11
0.08

SEQID-02053
406716396
—
—
0
0.37
0.13
0.06
0.09
0.06
0.06
0.01
0.07
0.09
0.05
0.00
0.03
0.05
0.13

SEQID-02054
226536926
—
—
1
0.52
0.17
0.09
0.00
0.08
0.05
0.01
0.04
0.06
0.04
0.04
0.04
0.10
0.08

SEQID-02055
291566672
—
—
1
0.45
0.20
0.05
0.10
0.03
0.04
0.01
0.04
0.09
0.04
0.03
0.04
0.10
0.07

SEQID-02056
291567524
—
—
1
0.54
0.22
0.06
0.06
0.04
0.03
0.02
0.04
0.06
0.05
0.03
0.05
0.11
0.01

SEQID-02057
291571685
—
—
1
0.46
0.22
0.04
0.10
0.05
0.07
0.01
0.02
0.08
0.04
0.03
0.08
0.07
0.04

SEQID-02058
406711744
—
—
1
0.46
0.23
0.06
0.04
0.06
0.05
0.00
0.06
0.07
0.05
0.03
0.06
0.08
0.05

SEQID-02059
291567802
—
—
0
0.52
0.32
0.06
0.08
0.03
0.01
0.00
0.06
0.04
0.05
0.00
0.12
0.12
0.03

SEQID-02060
406712317
—
—
1
0.44
0.20
0.04
0.04
0.02
0.04
0.00
0.20
0.11
0.01
0.03
0.03
0.12
0.09

SEQID-02061
406715474
—
—
1
0.44
0.26
0.06
0.09
0.04
0.06
0.01
0.05
0.09
0.04
0.01
0.07
0.13
0.06

SEQID-02062
291569833
—
—
1
0.43
0.24
0.07
0.11
0.04
0.07
0.00
0.06
0.09
0.04
0.01
0.06
0.10
0.05

SEQID-02063
406715203
—
—
1
0.43
0.22
0.04
0.11
0.05
0.07
0.01
0.05
0.06
0.04
0.02
0.08
0.10
0.03

SEQID-02064
406715533
—
—
1
0.45
0.23
0.05
0.06
0.04
0.05
0.01
0.06
0.10
0.04
0.02
0.05
0.11
0.05

SEQID-02065
291570764
—
—
1
0.48
0.23
0.07
0.06
0.05
0.06
0.01
0.03
0.03
0.04
0.03
0.08
0.09
0.06

SEQID-02066
291570294
—
—
1
0.45
0.20
0.06
0.06
0.05
0.06
0.02
0.04
0.07
0.04
0.02
0.06
0.03
0.07

SEQID-02067
291565677
—
—
0
0.46
0.26
0.07
0.06
0.02
0.07
0.01
0.01
0.11
0.06
0.00
0.05
0.09
0.12

SEQID-02068
406713927
—
—
0
0.44
0.09
0.05
0.10
0.01
0.07
0.00
0.02
0.08
0.03
0.00
0.02
0.06
0.15

SEQID-02069
291565882
—
—
1
0.44
0.24
0.12
0.10
0.02
0.05
0.00
0.02
0.08
0.06
0.01
0.07
0.07
0.04

SEQID-02070
291570798
—
—
0
0.44
0.23
0.06
0.13
0.02
0.03
0.00
0.07
0.13
0.03
0.02
0.07
0.08
0.08

SEQID-02071
406711359
—
—
1
0.46
0.22
0.09
0.07
0.02
0.05
0.01
0.06
0.07
0.04
0.02
0.06
0.13
0.06

SEQID-02072
291566660
—
—
1
0.46
0.22
0.09
0.07
0.02
0.05
0.01
0.05
0.07
0.05
0.02
0.06
0.13
0.06

SEQID-02073
406715124
—
—
0
0.41
0.24
0.04
0.14
0.06
0.05
0.02
0.03
0.05
0.03
0.00
0.09
0.09
0.03

SEQID-02074
406711662
—
—
1
0.48
0.28
0.06
0.06
0.03
0.06
0.02
0.03
0.05
0.06
0.02
0.09
0.12
0.03

SEQID-02075
406715358
—
—
1
0.42
0.19
0.03
0.09
0.03
0.06
0.04
0.04
0.10
0.02
0.03
0.05
0.08
0.09

SEQID-02076
291568477
—
—
1
0.46
0.21
0.03
0.05
0.06
0.10
0.01
0.04
0.05
0.02
0.02
0.06
0.09
0.09

SEQID-02077
291567784
—
—
0
0.49
0.21
0.03
0.09
0.06
0.03
0.00
0.05
0.06
0.07
0.03
0.05
0.09
0.11

SEQID-02078
406711814
—
—
1
0.49
0.27
0.06
0.07
0.04
0.07
0.01
0.04
0.06
0.04
0.03
0.09
0.09
0.05

SEQID-02079
406714225
—
—
1
0.38
0.18
0.03
0.03
0.09
0.06
0.02
0.06
0.03
0.05
0.01
0.04
0.11
0.04

SEQID-02080
291566562
—
—
1
0.49
0.19
0.04
0.09
0.05
0.05
0.01
0.02
0.10
0.02
0.04
0.05
0.10
0.07

SEQID-02081
291566243
—
—
1
0.44
0.19
0.05
0.10
0.03
0.05
0.01
0.04
0.09
0.03
0.06
0.05
0.03
0.05

SEQID-02082
291568601
—
—
1
0.49
0.22
0.07
0.04
0.03
0.04
0.01
0.03
0.08
0.07
0.03
0.06
0.09
0.06

SEQID-02083
291568927
—
—
1
0.44
0.21
0.06
0.07
0.05
0.06
0.01
0.05
0.08
0.05
0.02
0.06
0.09
0.06

SEQID-02084
291570378
—
—
1
0.46
0.17
0.04
0.03
0.03
0.05
0.01
0.05
0.07
0.04
0.03
0.06
0.06
0.04

SEQID-02085
406712979
—
—
1
0.39
0.20
0.08
0.04
0.04
0.04
0.01
0.10
0.10
0.03
0.04
0.05
0.12
0.05

SEQID-02086
291571158
—
—
1
0.47
0.20
0.07
0.06
0.04
0.05
0.01
0.05
0.07
0.05
0.03
0.06
0.09
0.04

SEQID-02087
291570621
—
—
1
0.44
0.22
0.05
0.09
0.03
0.06
0.00
0.06
0.11
0.03
0.02
0.05
0.09
0.06

SEQID-02088
291566536
—
—
1
0.42
0.24
0.05
0.04
0.05
0.09
0.00
0.09
0.14
0.02
0.01
0.07
0.09
0.01

SEQID-02089
291568759
—
—
0
0.49
0.38
0.09
0.06
0.01
0.05
0.00
0.02
0.10
0.02
0.00
0.09
0.10
0.05

SEQID-02090
291566375
—
—
1
0.49
0.20
0.05
0.03
0.01
0.04
0.00
0.09
0.07
0.04
0.01
0.13
0.06
0.03

SEQID-02091
406715888
—
—
0
0.36
0.19
0.04
0.18
0.03
0.03
0.00
0.06
0.10
0.03
0.00
0.06
0.03
0.07

SEQID-02092
291567786
—
—
0
0.47
0.23
0.04
0.16
0.03
0.06
0.00
0.05
0.08
0.01
0.00
0.05
0.08
0.09

SEQID-02093
406715491
—
—
0
0.41
0.21
0.05
0.23
0.02
0.06
0.00
0.03
0.05
0.05
0.01
0.06
0.08
0.08

SEQID-02094
291568112
—
—
0
0.46
0.18
0.06
0.03
0.05
0.12
0.01
0.03
0.04
0.04
0.03
0.04
0.07
0.09

SEQID-02095
291565897
—
—
1
0.52
0.24
0.05
0.03
0.03
0.04
0.00
0.03
0.11
0.05
0.02
0.08
0.10
0.03

SEQID-02096
291568829
—
—
0
0.41
0.25
0.08
0.09
0.02
0.09
0.01
0.04
0.06
0.04
0.01
0.06
0.12
0.03

SEQID-02097
291567800
—
—
1
0.46
0.26
0.07
0.11
0.06
0.02
0.00
0.06
0.07
0.07
0.01
0.06
0.07
0.12

SEQID-02098
291567422
—
—
0
0.38
0.12
0.07
0.07
0.07
0.05
0.01
0.07
0.09
0.04
0.00
0.03
0.05
0.11

SEQID-02099
406715501
—
—
0
0.48
0.23
0.04
0.10
0.03
0.05
0.00
0.07
0.08
0.04
0.01
0.10
0.08
0.07

SEQID-02100
406716242
—
—
1
0.42
0.19
0.08
0.06
0.03
0.09
0.00
0.07
0.09
0.01
0.01
0.04
0.11
0.09

SEQID-02101
291567386
—
—
0
0.43
0.22
0.05
0.03
0.05
0.05
0.00
0.09
0.09
0.02
0.03
0.09
0.07
0.07

SEQID-02102
406716309
—
—
1
0.43
0.16
0.05
0.09
0.04
0.07
0.00
0.05
0.09
0.04
0.07
0.06
0.04
0.05

SEQID-02103
291565931
—
—
1
0.48
0.24
0.06
0.03
0.01
0.07
0.01
0.06
0.07
0.04
0.01
0.05
0.12
0.09

SEQID-02104
291566379
—
—
1
0.45
0.21
0.03
0.09
0.03
0.04
0.02
0.06
0.03
0.03
0.01
0.07
0.09
0.05

SEQID-02105
291571503
—
—
0
0.43
0.23
0.06
0.10
0.02
0.04
0.01
0.05
0.03
0.03
0.00
0.07
0.10
0.09

SEQID-02106
406715051
—
—
1
0.49
0.24
0.04
0.04
0.05
0.06
0.00
0.08
0.05
0.04
0.01
0.07
0.10
0.09

SEQID-02107
291566214
—
—
1
0.47
0.23
0.03
0.03
0.07
0.06
0.01
0.04
0.06
0.04
0.04
0.07
0.10
0.05

SEQID-02108
291567378
—
—
1
0.46
0.23
0.07
0.05
0.06
0.07
0.02
0.03
0.09
0.05
0.02
0.08
0.09
0.07

SEQID-02109
291572086
—
—
1
0.45
0.25
0.05
0.09
0.02
0.08
0.02
0.05
0.07
0.05
0.03
0.08
0.10
0.06

SEQID-02110
291568330
—
—
1
0.46
0.18
0.05
0.05
0.04
0.07
0.01
0.04
0.07
0.04
0.03
0.05
0.09
0.06

SEQID-02111
291565792
—
—
1
0.58
0.36
0.07
0.04
0.04
0.04
0.00
0.05
0.04
0.04
0.01
0.12
0.16
0.03

SEQID-02112
291566578
—
—
0
0.43
0.24
0.03
0.10
0.04
0.06
0.01
0.04
0.11
0.05
0.02
0.06
0.09
0.05

SEQID-02113
291569922
—
—
1
0.46
0.27
0.05
0.09
0.02
0.09
0.00
0.04
0.08
0.05
0.02
0.09
0.10
0.06

SEQID-02114
406713771
—
—
1
0.42
0.22
0.05
0.03
0.07
0.05
0.01
0.06
0.06
0.05
0.02
0.06
0.08
0.04

SEQID-02115
291566950
—
—
1
0.45
0.22
0.07
0.07
0.04
0.06
0.02
0.04
0.08
0.05
0.01
0.07
0.09
0.05

SEQID-02116
406712549
—
—
1
0.46
0.24
0.05
0.09
0.04
0.06
0.01
0.04
0.09
0.03
0.03
0.06
0.11
0.06

SEQID-02117
17974193
—
—
0
0.53
0.19
0.02
0.12
0.04
0.01
0.01
0.08
0.05
0.04
0.00
0.04
0.07
0.10

SEQID-02118
291569292
—
—
0
0.48
0.21
0.06
0.11
0.03
0.03
0.00
0.04
0.14
0.02
0.00
0.04
0.07
0.14

SEQID-02119
291569856
—
—
0
0.44
0.28
0.06
0.10
0.02
0.03
0.00
0.02
0.11
0.05
0.02
0.09
0.03
0.03

SEQID-02120
291569285
—
—
0
0.33
0.13
0.04
0.15
0.03
0.07
0.01
0.01
0.12
0.09
0.00
0.02
0.05
0.04

SEQID-02121
406714138
—
—
0
0.47
0.23
0.03
0.12
0.02
0.05
0.00
0.06
0.11
0.04
0.04
0.08
0.06
0.09

SEQID-02122
291570835
—
—
1
0.68
0.36
0.03
0.02
0.03
0.02
0.01
0.02
0.03
0.06
0.03
0.18
0.14
0.04

SEQID-02123
291568903
—
—
0
0.39
0.20
0.09
0.11
0.05
0.04
0.01
0.04
0.05
0.02
0.01
0.02
0.10
0.05

SEQID-02124
291567801
—
—
0
0.37
0.19
0.07
0.15
0.04
0.03
0.01
0.06
0.05
0.08
0.00
0.05
0.10
0.09

SEQID-02125
406713999
—
—
0
0.41
0.24
0.10
0.07
0.03
0.04
0.00
0.11
0.12
0.02
0.01
0.10
0.13
0.08

SEQID-02126
291570409
—
—
0
0.52
0.23
0.07
0.03
0.03
0.09
0.00
0.05
0.09
0.05
0.00
0.04
0.12
0.09

SEQID-02127
P13577
—
—
1
0.40
0.17
0.07
0.21
0.03
0.03
0.00
0.01
0.09
0.02
0.04
0.03
0.06
0.05

SEQID-02128
406714844
—
—
1
0.45
0.23
0.06
0.07
0.05
0.05
0.02
0.07
0.07
0.03
0.03
0.06
0.10
0.06

SEQID-02129
406713988
—
—
0
0.36
0.25
0.10
0.12
0.05
0.03
0.00
0.10
0.15
0.03
0.01
0.07
0.14
0.05

SEQID-02130
406713332
—
—
1
0.49
0.25
0.09
0.06
0.05
0.06
0.00
0.03
0.07
0.06
0.01
0.10
0.06
0.09

SEQID-02131
406713096
—
—
1
0.44
0.23
0.04
0.06
0.05
0.09
0.00
0.07
0.09
0.04
0.01
0.07
0.09
0.09

SEQID-02132
291571396
—
—
1
0.44
0.24
0.04
0.09
0.05
0.04
0.01
0.05
0.12
0.05
0.03
0.08
0.03
0.04

SEQID-02133
406714445
—
—
1
0.46
0.22
0.03
0.08
0.05
0.06
0.00
0.07
0.11
0.02
0.00
0.05
0.11
0.07

SEQID-02134
291566643
—
—
0
0.37
0.21
0.05
0.03
0.09
0.13
0.00
0.05
0.04
0.12
0.00
0.07
0.09
0.01

SEQID-02135
291568361
—
—
0
0.44
0.27
0.06
0.08
0.04
0.07
0.02
0.06
0.06
0.04
0.01
0.06
0.12
0.07

SEQID-02136
291568800
—
—
1
0.46
0.24
0.07
0.09
0.03
0.09
0.01
0.05
0.07
0.03
0.03
0.06
0.12
0.04

SEQID-02137
406712435
—
—
1
0.44
0.25
0.07
0.04
0.04
0.05
0.01
0.07
0.08
0.05
0.01
0.06
0.09
0.05

SEQID-02138
291571840
—
—
0
0.47
0.25
0.05
0.07
0.05
0.06
0.01
0.05
0.09
0.04
0.03
0.06
0.12
0.05

SEQID-02139
291571996
—
—
1
0.45
0.26
0.09
0.05
0.04
0.05
0.01
0.06
0.10
0.05
0.01
0.06
0.10
0.07

SEQID-02140
406716058
—
—
0
0.40
0.19
0.04
0.12
0.04
0.05
0.02
0.03
0.10
0.07
0.01
0.06
0.08
0.06

SEQID-02141
291568019
—
—
1
0.43
0.21
0.07
0.10
0.04
0.07
0.01
0.02
0.07
0.04
0.02
0.06
0.07
0.07

SEQID-02142
291570518
—
—
1
0.48
0.23
0.06
0.06
0.04
0.06
0.02
0.05
0.06
0.04
0.05
0.07
0.11
0.06

SEQID-02143
291566657
—
—
1
0.57
0.32
0.09
0.04
0.03
0.04
0.00
0.02
0.07
0.05
0.00
0.13
0.14
0.03

SEQID-02144
406711605
—
—
1
0.49
0.27
0.07
0.06
0.04
0.06
0.02
0.04
0.07
0.05
0.04
0.07
0.10
0.06

SEQID-02145
406713196
—
—
1
0.46
0.30
0.06
0.08
0.04
0.06
0.01
0.05
0.07
0.04
0.02
0.09
0.12
0.05

SEQID-02146
291570777
—
—
1
0.47
0.21
0.06
0.09
0.04
0.05
0.01
0.04
0.09
0.02
0.04
0.05
0.09
0.06

SEQID-02147
406712981
—
—
1
0.43
0.19
0.03
0.06
0.05
0.04
0.00
0.12
0.12
0.02
0.02
0.04
0.12
0.06

SEQID-02148
291569312
—
—
1
0.40
0.24
0.04
0.12
0.05
0.07
0.00
0.04
0.10
0.03
0.02
0.07
0.09
0.03

SEQID-02149
406713557
—
—
1
0.43
0.20
0.05
0.09
0.05
0.07
0.01
0.05
0.08
0.04
0.02
0.06
0.08
0.06

SEQID-02150
291570203
—
—
1
0.41
0.20
0.04
0.05
0.01
0.03
0.00
0.03
0.07
0.11
0.01
0.05
0.07
0.02

SEQID-02151
291565708
—
—
1
0.45
0.22
0.03
0.07
0.05
0.07
0.00
0.06
0.09
0.03
0.02
0.07
0.10
0.06

SEQID-02152
291570064
—
—
1
0.46
0.24
0.06
0.07
0.03
0.06
0.01
0.04
0.10
0.04
0.01
0.08
0.09
0.06

SEQID-02153
291572019
—
—
1
0.44
0.24
0.04
0.10
0.04
0.05
0.01
0.08
0.09
0.02
0.03
0.06
0.12
0.05

SEQID-02154
291568067
—
—
1
0.37
0.21
0.07
0.05
0.05
0.11
0.00
0.06
0.14
0.03
0.01
0.05
0.11
0.03

SEQID-02155
291568693
—
—
1
0.44
0.22
0.05
0.07
0.05
0.05
0.01
0.07
0.08
0.03
0.03
0.07
0.10
0.05

SEQID-02156
406713711
—
—
0
0.51
0.19
0.04
0.05
0.05
0.00
0.00
0.06
0.08
0.04
0.00
0.05
0.12
0.04

SEQID-02157
406715505
—
—
0
0.42
0.24
0.04
0.15
0.04
0.04
0.00
0.09
0.13
0.01
0.05
0.05
0.18
0.08

SEQID-02158
406715222
—
—
1
0.39
0.12
0.03
0.19
0.03
0.06
0.00
0.00
0.17
0.04
0.03
0.04
0.04
0.09

SEQID-02159
291571965
—
—
1
0.40
0.18
0.05
0.09
0.00
0.07
0.11
0.03
0.06
0.04
0.02
0.05
0.06
0.04

SEQID-02160
291570671
—
—
0
0.42
0.22
0.06
0.09
0.07
0.04
0.01
0.04
0.09
0.04
0.00
0.05
0.03
0.09

SEQID-02161
291567416
—
—
0
0.44
0.16
0.10
0.07
0.05
0.03
0.03
0.05
0.11
0.04
0.01
0.06
0.02
0.10

SEQID-02162
157042619
—
—
0
0.38
0.14
0.02
0.11
0.06
0.04
0.00
0.05
0.11
0.05
0.00
0.07
0.01
0.05

SEQID-02163
291566338
—
—
0
0.41
0.10
0.06
0.10
0.02
0.05
0.00
0.04
0.09
0.04
0.00
0.03
0.06
0.13

SEQID-02164
291571410
—
—
1
0.48
0.24
0.12
0.04
0.06
0.07
0.02
0.03
0.02
0.05
0.01
0.03
0.11
0.10

SEQID-02165
291568589
—
—
0
0.48
0.25
0.05
0.04
0.03
0.06
0.02
0.08
0.08
0.03
0.00
0.05
0.09
0.05

SEQID-02166
P48852
—
—
0
0.48
0.24
0.04
0.16
0.01
0.09
0.02
0.04
0.04
0.01
0.03
0.10
0.09
0.09

SEQID-02167
291567795
—
—
0
0.51
0.21
0.02
0.12
0.03
0.04
0.00
0.04
0.07
0.04
0.03
0.04
0.04
0.15

SEQID-02168
291566622
—
—
0
0.41
0.22
0.04
0.07
0.04
0.06
0.00
0.08
0.13
0.07
0.00
0.03
0.14
0.07

SEQID-02169
406713351
—
—
0
0.53
0.26
0.05
0.03
0.04
0.02
0.00
0.05
0.09
0.03
0.00
0.05
0.09
0.09

SEQID-02170
291567797
—
—
1
0.50
0.23
0.04
0.15
0.04
0.03
0.01
0.03
0.06
0.04
0.02
0.09
0.09
0.08

SEQID-02171
291565935
—
—
0
0.45
0.26
0.03
0.17
0.02
0.02
0.00
0.07
0.09
0.04
0.01
0.12
0.04
0.08

SEQID-02172
406712927
—
—
1
0.48
0.23
0.07
0.05
0.06
0.05
0.01
0.05
0.06
0.03
0.02
0.05
0.12
0.07

SEQID-02173
291569027
—
—
1
0.51
0.26
0.07
0.03
0.04
0.03
0.01
0.03
0.13
0.05
0.01
0.03
0.10
0.09

SEQID-02174
291566287
—
—
1
0.47
0.26
0.05
0.06
0.02
0.06
0.01
0.09
0.07
0.04
0.01
0.06
0.13
0.04

SEQID-02175
406715357
—
—
1
0.58
0.34
0.06
0.04
0.04
0.03
0.00
0.03
0.05
0.04
0.01
0.06
0.17
0.01

SEQID-02176
406715137
—
—
1
0.45
0.26
0.06
0.04
0.04
0.04
0.01
0.05
0.13
0.05
0.03
0.07
0.11
0.06

SEQID-02177
406710703
—
—
1
0.40
0.15
0.05
0.06
0.03
0.03
0.02
0.07
0.08
0.06
0.02
0.02
0.07
0.05

SEQID-02178
291570307
—
—
1
0.61
0.27
0.03
0.05
0.00
0.02
0.01
0.03
0.04
0.04
0.03
0.09
0.09
0.05

SEQID-02179
291569898
—
—
1
0.49
0.28
0.06
0.04
0.03
0.04
0.01
0.07
0.03
0.04
0.02
0.07
0.11
0.06

SEQID-02180
291570674
—
—
1
0.45
0.27
0.03
0.09
0.06
0.05
0.01
0.03
0.06
0.05
0.02
0.08
0.10
0.02

SEQID-02181
291565912
—
—
1
0.44
0.23
0.07
0.08
0.04
0.05
0.01
0.08
0.09
0.02
0.01
0.06
0.10
0.06

SEQID-02182
406714269
—
—
1
0.47
0.22
0.03
0.08
0.02
0.05
0.01
0.06
0.10
0.03
0.02
0.07
0.08
0.06

SEQID-02183
291571644
—
—
1
0.43
0.26
0.05
0.05
0.03
0.07
0.01
0.07
0.05
0.04
0.02
0.10
0.10
0.07

SEQID-02184
291567308
—
—
1
0.44
0.25
0.06
0.09
0.04
0.08
0.01
0.06
0.10
0.03
0.02
0.08
0.11
0.06

SEQID-02185
291571141
—
—
1
0.45
0.23
0.03
0.08
0.06
0.07
0.01
0.05
0.06
0.04
0.03
0.08
0.09
0.06

SEQID-02186
406714429
—
—
1
0.57
0.26
0.08
0.03
0.02
0.04
0.01
0.04
0.04
0.05
0.05
0.05
0.14
0.03

SEQID-02187
291566376
—
—
1
0.46
0.19
0.04
0.06
0.04
0.07
0.01
0.04
0.07
0.05
0.01
0.05
0.09
0.05

SEQID-02188
291570198
—
—
1
0.43
0.17
0.06
0.09
0.03
0.07
0.02
0.02
0.10
0.04
0.03
0.03
0.06
0.06

SEQID-02189
406715783
—
—
1
0.50
0.24
0.06
0.06
0.04
0.06
0.01
0.04
0.07
0.04
0.04
0.07
0.11
0.07

SEQID-02190
291568588
—
—
1
0.46
0.26
0.08
0.06
0.03
0.05
0.02
0.05
0.06
0.06
0.01
0.08
0.09
0.06

SEQID-02191
291569924
—
—
1
0.47
0.23
0.09
0.06
0.03
0.06
0.01
0.04
0.07
0.07
0.02
0.05
0.12
0.06

SEQID-02192
406712516
—
—
1
0.46
0.24
0.08
0.05
0.04
0.05
0.00
0.06
0.05
0.04
0.01
0.07
0.08
0.05

SEQID-02193
291568241
—
—
0
0.53
0.34
0.07
0.04
0.03
0.03
0.01
0.04
0.05
0.05
0.00
0.10
0.17
0.03

SEQID-02194
291571841
—
—
0
0.47
0.30
0.06
0.09
0.04
0.04
0.00
0.06
0.08
0.05
0.00
0.08
0.14
0.02

SEQID-02195
406712605
—
—
1
0.43
0.19
0.06
0.09
0.03
0.05
0.01
0.06
0.09
0.03
0.01
0.08
0.07
0.05

SEQID-02196
291567555
—
—
1
0.54
0.27
0.07
0.04
0.03
0.03
0.01
0.03
0.05
0.07
0.02
0.10
0.10
0.02

SEQID-02197
291569604
—
—
1
0.38
0.15
0.07
0.03
0.01
0.08
0.00
0.02
0.20
0.02
0.01
0.02
0.05
0.09

SEQID-02198
406713974
—
—
1
0.41
0.23
0.05
0.04
0.06
0.09
0.00
0.05
0.05
0.07
0.00
0.05
0.09
0.01

SEQID-02199
291571795
—
—
1
0.44
0.24
0.06
0.07
0.04
0.07
0.00
0.08
0.07
0.04
0.03
0.08
0.11
0.06

SEQID-02200
291570843
—
—
1
0.43
0.19
0.06
0.07
0.06
0.07
0.01
0.04
0.06
0.05
0.02
0.08
0.07
0.05

SEQID-02201
291569589
—
—
1
0.43
0.22
0.07
0.08
0.04
0.05
0.01
0.05
0.08
0.05
0.03
0.08
0.07
0.04

SEQID-02202
291569371
—
—
1
0.46
0.19
0.05
0.08
0.03
0.06
0.01
0.04
0.09
0.05
0.03
0.05
0.07
0.06

SEQID-02203
291566291
—
—
1
0.42
0.19
0.04
0.09
0.04
0.06
0.01
0.05
0.09
0.04
0.03
0.06
0.09
0.07

SEQID-02204
291568479
—
—
1
0.48
0.21
0.03
0.07
0.04
0.07
0.01
0.05
0.11
0.02
0.03
0.07
0.09
0.07

SEQID-02205
291566322
—
—
1
0.45
0.22
0.04
0.09
0.03
0.06
0.00
0.09
0.09
0.03
0.02
0.06
0.10
0.05

SEQID-02206
291567103
—
—
1
0.50
0.29
0.06
0.06
0.04
0.06
0.01
0.06
0.06
0.04
0.01
0.10
0.11
0.04

SEQID-02207
I3JEK7
—
—
1
0.46
0.20
0.04
0.07
0.03
0.07
0.02
0.03
0.10
0.03
0.02
0.06
0.06
0.09

SEQID-02208
I3KK23
—
—
1
0.47
0.18
0.05
0.05
0.05
0.07
0.01
0.05
0.06
0.02
0.04
0.05
0.08
0.13

SEQID-02209
I3JYT9
—
—
1
0.45
0.19
0.05
0.07
0.04
0.0G
0.01
0.07
0.15
0.02
0.02
0.04
0.10
0.12

SEQID-02210
I3IZY8
—
—
1
0.44
0.18
0.06
0.07
0.04
0.05
0.01
0.07
0.13
0.02
0.03
0.04
0.09
0.11

SEQID-02211
I3KLJ9
—
—
1
0.47
0.20
0.04
0.06
0.03
0.05
0.02
0.04
0.12
0.03
0.02
0.06
0.07
0.11

SEQID-02212
I3IZU1
—
—
1
0.46
0.19
0.06
0.07
0.04
0.05
0.01
0.07
0.14
0.02
0.02
0.05
0.09
0.11

SEQID-02213
I3K022
—
—
1
0.49
0.24
0.06
0.06
0.04
0.06
0.03
0.02
0.09
0.03
0.01
0.07
0.09
0.07

SEQID-02214
I3IZY3
—
—
1
0.40
0.18
0.06
0.10
0.04
0.06
0.00
0.10
0.18
0.02
0.02
0.03
0.10
0.12

SEQID-02215
I3K5K1
—
—
1
0.46
0.20
0.05
0.08
0.05
0.06
0.01
0.06
0.11
0.02
0.03
0.07
0.09
0.07

SEQID-02216
I3IUB3
—
—
1
0.47
0.19
0.05
0.06
0.03
0.05
0.01
0.03
0.08
0.03
0.04
0.04
0.06
0.09

SEQID-02217
I3KK81
—
—
1
0.46
0.20
0.05
0.07
0.03
0.06
0.01
0.03
0.03
0.04
0.03
0.08
0.07
0.06

SEQID-02218
I3IZX8
—
—
1
0.51
0.19
0.05
0.04
0.05
0.05
0.01
0.05
0.09
0.03
0.03
0.07
0.07
0.10

SEQID-02219
I3KU01
—
—
1
0.45
0.19
0.05
0.07
0.04
0.05
0.01
0.07
0.15
0.02
0.03
0.05
0.11
0.12

SEQID-02220
I3JT59
—
—
1
0.45
0.18
0.05
0.07
0.04
0.05
0.01
0.07
0.14
0.02
0.02
0.05
0.10
0.12

SEQID-02221
I3IZY5
—
—
1
0.49
0.20
0.05
0.05
0.05
0.05
0.01
0.04
0.03
0.03
0.02
0.07
0.08
0.03

SEQID-02222
I3KZ16
—
—
1
0.45
0.18
0.05
0.07
0.05
0.05
0.01
0.07
0.15
0.02
0.02
0.04
0.11
0.12

SEQID-02223
I3KXM4
—
—
1
0.48
0.23
0.04
0.06
0.05
0.05
0.01
0.03
0.09
0.04
0.01
0.06
0.07
0.09

SEQID-02224
I3JDJ0
—
—
1
0.47
0.19
0.05
0.06
0.03
0.05
0.02
0.03
0.03
0.04
0.03
0.06
0.06
0.09

SEQID-02225
I3JDJ1
—
—
1
0.47
0.19
0.05
0.06
0.04
0.05
0.01
0.03
0.08
0.04
0.03
0.06
0.06
0.03

SEQID-02226
I3KFP0
—
—
1
0.50
0.20
0.02
0.07
0.05
0.07
0.01
0.03
0.09
0.05
0.05
0.04
0.09
0.09

SEQID-02227
I3JE80
—
—
1
0.43
0.22
0.04
0.06
0.04
0.06
0.02
0.04
0.10
0.03
0.03
0.05
0.11
0.07

SEQID-02228
I3KW15
—
—
1
0.45
0.21
0.07
0.06
0.05
0.04
0.02
0.05
0.07
0.04
0.03
0.05
0.09
0.08

SEQID-02229
I3KVU7
—
—
1
0.43
0.20
0.04
0.06
0.04
0.07
0.02
0.02
0.10
0.03
0.02
0.06
0.06
0.11

SEQID-02230
I3JBN0
—
—
1
0.46
0.20
0.05
0.09
0.06
0.06
0.01
0.04
0.09
0.03
0.04
0.06
0.08
0.07

SEQID-02231
I3K556
—
—
1
0.52
0.22
0.06
0.05
0.05
0.06
0.01
0.01
0.06
0.05
0.04
0.07
0.05
0.10

SEQID-02232
I3J7R3
—
—
1
0.47
0.21
0.04
0.07
0.04
0.06
0.02
0.04
0.11
0.03
0.03
0.05
0.10
0.07

SEQID-02233
I3JSS0
—
—
1
0.47
0.18
0.04
0.07
0.05
0.06
0.01
0.04
0.08
0.02
0.04
0.05
0.09
0.08

SEQID-02234
I3JKR2
—
—
1
0.49
0.22
0.06
0.05
0.05
0.07
0.01
0.03
0.08
0.04
0.03
0.07
0.08
0.11

SEQID-02235
I3JL13
—
—
1
0.49
0.21
0.02
0.03
0.04
0.07
0.01
0.04
0.09
0.05
0.04
0.04
0.10
0.09

SEQID-02236
I3JRU6
—
—
1
0.48
0.20
0.04
0.06
0.04
0.05
0.01
0.03
0.10
0.04
0.03
0.04
0.06
0.09

SEQID-02237
I3JS33
—
—
1
0.47
0.18
0.04
0.12
0.03
0.05
0.02
0.05
0.07
0.04
0.04
0.06
0.07
0.08

SEQID-02238
I3JXH7
—
—
1
0.42
0.13
0.05
0.15
0.01
0.06
0.00
0.05
0.19
0.01
0.03
0.04
0.07
0.19

SEQID-02239
I3JU24
—
—
1
0.47
0.18
0.06
0.04
0.05
0.07
0.01
0.05
0.12
0.03
0.01
0.07
0.07
0.11

SEQID-02240
I3JFQ4
—
—
1
0.46
0.20
0.04
0.07
0.04
0.06
0.02
0.03
0.09
0.04
0.02
0.05
0.07
0.08

SEQID-02241
I3K6V3
—
—
0
0.46
0.21
0.05
0.04
0.06
0.09
0.01
0.05
0.09
0.04
0.03
0.04
0.11
0.07

SEQID-02242
I3IXG2
—
—
1
0.45
0.16
0.03
0.05
0.04
0.04
0.01
0.04
0.10
0.07
0.03
0.04
0.07
0.11

SEQID-02243
I3J8Q1
—
—
1
0.38
0.17
0.05
0.11
0.04
0.06
0.00
0.08
0.13
0.02
0.02
0.05
0.09
0.06

SEQID-02244
I3JXH4
—
—
1
0.26
0.10
0.08
0.09
0.04
0.04
0.01
0.03
0.06
0.16
0.02
0.02
0.05
0.05

SEQID-02245
I3J8X4
—
—
0
0.40
0.18
0.11
0.05
0.07
0.07
0.00
0.03
0.11
0.04
0.01
0.05
0.07
0.09

SEQID-02246
I3KFU1
—
—
1
0.45
0.18
0.07
0.06
0.04
0.05
0.00
0.07
0.06
0.06
0.04
0.07
0.06
0.03

SEQID-02247
I3KSF9
—
—
1
0.50
0.22
0.06
0.03
0.04
0.05
0.02
0.04
0.06
0.05
0.03
0.06
0.09
0.06

SEQID-02248
I3JGN1
—
—
1
0.26
0.09
0.08
0.08
0.02
0.06
0.02
0.04
0.07
0.15
0.01
0.02
0.04
0.05

SEQID-02249
I3JMB4
—
—
1
0.25
0.09
0.07
0.09
0.02
0.06
0.01
0.04
0.06
0.16
0.01
0.03
0.04
0.05

SEQID-02250
I3KBQ8
—
—
1
0.45
0.17
0.07
0.06
0.03
0.06
0.01
0.02
0.11
0.07
0.02
0.06
0.05
0.11

SEQID-02251
I3KB11
—
—
1
0.57
0.28
0.03
0.03
0.04
0.05
0.01
0.03
0.07
0.05
0.05
0.06
0.10
0.10

SEQID-02252
I3KBN9
—
—
1
0.44
0.18
0.07
0.06
0.04
0.06
0.02
0.03
0.10
0.03
0.01
0.06
0.05
0.12

SEQID-02253
I3JNZ0
—
—
1
0.48
0.23
0.06
0.03
0.03
0.06
0.02
0.03
0.09
0.04
0.03
0.09
0.07
0.09

SEQID-02254
I3JXF9
—
—
1
0.53
0.21
0.06
0.06
0.03
0.08
0.01
0.04
0.10
0.01
0.03
0.05
0.10
0.19

SEQID-02255
I3KMQ5
—
—
1
0.41
0.14
0.04
0.13
0.03
0.07
0.00
0.07
0.07
0.04
0.03
0.04
0.06
0.06

SEQID-02256
I3JQE5
—
—
1
0.49
0.21
0.05
0.05
0.04
0.08
0.01
0.04
0.06
0.05
0.03
0.08
0.07
0.09

SEQID-02257
I3K5C3
—
—
1
0.51
0.23
0.06
0.04
0.05
0.06
0.02
0.04
0.08
0.06
0.02
0.07
0.06
0.11

SEQID-02258
I3KL70
—
—
0
0.42
0.18
0.05
0.11
0.03
0.05
0.00
0.05
0.14
0.04
0.01
0.03
0.07
0.11

SEQID-02259
I3KER1
—
—
1
0.42
0.20
0.03
0.02
0.02
0.25
0.00
0.02
0.11
0.02
0.04
0.05
0.08
0.06

SEQID-02260
I3KCM4
—
—
0
0.48
0.25
0.04
0.07
0.01
0.09
0.01
0.04
0.09
0.05
0.01
0.07
0.10
0.14

SEQID-02261
I3J820
—
—
1
0.50
0.20
0.06
0.08
0.04
0.04
0.01
0.03
0.10
0.04
0.04
0.07
0.09
0.10

SEQID-02262
I3KM40
—
—
1
0.52
0.20
0.07
0.07
0.03
0.05
0.02
0.04
0.03
0.05
0.01
0.09
0.06
0.10

SEQID-02263
I3K3X8
—
—
1
0.46
0.19
0.06
0.03
0.04
0.05
0.04
0.06
0.09
0.03
0.06
0.04
0.09
0.09

SEQID-02264
I3IZI3
—
—
0
0.42
0.17
0.03
0.06
0.03
0.13
0.01
0.03
0.17
0.04
0.00
0.06
0.09
0.06

SEQID-02265
I3IU19
—
—
1
0.48
0.20
0.05
0.07
0.04
0.08
0.03
0.04
0.09
0.03
0.02
0.07
0.09
0.10

SEQID-02266
I3IY11
—
—
1
0.50
0.21
0.05
0.06
0.05
0.05
0.01
0.03
0.09
0.05
0.03
0.09
0.06
0.12

SEQID-02267
I3KXA2
—
—
1
0.45
0.20
0.04
0.06
0.04
0.05
0.02
0.02
0.09
0.03
0.02
0.06
0.06
0.09

SEQID-02268
I3K8C6
—
—
1
0.51
0.22
0.05
0.07
0.04
0.04
0.01
0.03
0.05
0.04
0.04
0.06
0.10
0.05

SEQID-02269
I3I2N6
—
—
1
0.46
0.20
0.04
0.09
0.04
0.06
0.02
0.04
0.07
0.04
0.04
0.04
0.10
0.05

SEQID-02270
I3JPF4
—
—
1
0.46
0.20
0.04
0.05
0.04
0.07
0.01
0.03
0.07
0.06
0.03
0.06
0.05
0.09

SEQID-02271
I3JTN2
—
—
1
0.44
0.20
0.04
0.05
0.04
0.07
0.01
0.08
0.11
0.02
0.03
0.05
0.11
0.09

SEQID-02272
P60713
—
—
1
0.47
0.20
0.05
0.07
0.02
0.06
0.01
0.04
0.08
0.04
0.03
0.09
0.07
0.06

SEQID-02273
O13751
—
—
1
0.46
0.21
0.05
0.10
0.05
0.06
0.01
0.04
0.09
0.03
0.03
0.06
0.09
0.06

SEQID-02274
P14639
—
—
1
0.46
0.18
0.05
0.06
0.02
0.07
0.05
0.04
0.10
0.01
0.04
0.02
0.11
0.11

SEQID-02275
B2MVW8
—
—
1
0.50
0.21
0.07
0.08
0.03
0.05
0.01
0.05
0.02
0.05
0.01
0.07
0.08
0.09

SEQID-02276
D7R7V6
—
—
1
0.53
0.22
0.06
0.04
0.06
0.06
0.01
0.03
0.05
0.05
0.04
0.07
0.06
0.09

SEQID-02277
C8BKC8
—
—
1
0.47
0.17
0.04
0.04
0.05
0.05
0.10
0.05
0.04
0.03
0.06
0.02
0.03
0.14

SEQID-02278
B7U168
—
—
1
0.47
0.20
0.07
0.07
0.02
0.03
0.02
0.04
0.06
0.04
0.02
0.03
0.09
0.03

SEQID-02279
B9VGZ8
—
—
1
0.47
0.16
0.06
0.06
0.05
0.09
0.01
0.05
0.10
0.04
0.01
0.06
0.05
0.10

SEQID-02280
Q9N116
—
—
1
0.43
0.23
0.05
0.08
0.05
0.06
0.03
0.06
0.09
0.05
0.02
0.07
0.08
0.09

SEQID-02281
Q9BE42
—
—
0
0.50
0.16
0.06
0.05
0.01
0.03
0.00
0.04
0.15
0.02
0.02
0.02
0.08
0.12

SEQID-02282
B2LU28
—
—
0
0.40
0.18
0.08
0.07
0.02
0.08
0.00
0.05
0.22
0.00
0.01
0.04
0.11
0.15

SEQID-02283
Q5N109
—
—
0
0.53
0.30
0.05
0.06
0.06
0.06
0.01
0.07
0.07
0.03
0.02
0.09
0.12
0.09

SEQID-02284
Q9BE43
—
—
0
0.49
0.14
0.07
0.04
0.02
0.06
0.00
0.04
0.12
0.03
0.02
0.03
0.03
0.12

SEQID-02285
Q9BE44
—
—
0
0.50
0.15
0.06
0.04
0.02
0.05
0.00
0.04
0.14
0.03
0.02
0.03
0.04
0.12

SEQID-02286
Q9N113
—
—
0
0.44
0.19
0.09
0.04
0.06
0.09
0.00
0.02
0.09
0.05
0.03
0.06
0.09
0.10

SEQID-02287
P68240
—
—
0
0.56
0.23
0.09
0.03
0.04
0.07
0.01
0.01
0.03
0.04
0.09
0.00
0.15
0.09

SEQID-02288
Q1A2D1
—
—
0
0.55
0.23
0.07
0.06
0.06
0.06
0.01
0.03
0.06
0.04
0.09
0.00
0.12
0.08

SEQID-02289
Q9N104
—
—
0
0.52
0.27
0.09
0.03
0.06
0.04
0.03
0.05
0.05
0.04
0.03
0.10
0.07
0.07

SEQID-02290
B6VCA9
—
—
0
0.50
0.16
0.05
0.04
0.06
0.08
0.00
0.05
0.12
0.03
0.01
0.05
0.06
0.12

SEQID-02291
B9VG25
—
—
1
0.57
0.32
0.05
0.05
0.03
0.05
0.00
0.04
0.05
0.03
0.02
0.09
0.15
0.10

SEQID-02292
Q7YS10
—
—
0
0.57
0.28
0.03
0.00
0.03
0.05
0.02
0.09
0.12
0.04
0.03
0.09
0.13
0.12

SEQID-02293
P79395
—
—
0
0.45
0.19
0.02
0.06
0.07
0.02
0.00
0.02
0.09
0.02
0.04
0.04
0.06
0.10

SEQID-02294
B0FZM4
—
—
0
0.47
0.21
0.03
0.05
0.06
0.06
0.01
0.04
0.14
0.05
0.03
0.02
0.10
0.07

SEQID-02295
C5IJA8
—
—
0
0.48
0.22
0.03
0.09
0.02
0.05
0.01
0.04
0.11
0.05
0.01
0.05
0.09
0.11

SEQID-02296
B2MVX2
—
—
1
0.51
0.22
0.06
0.09
0.03
0.03
0.01
0.04
0.04
0.06
0.01
0.04
0.11
0.06

SEQID-02297
H2DGR2
—
—
1
0.45
0.21
0.06
0.08
0.05
0.07
0.01
0.05
0.09
0.04
0.02
0.07
0.03
0.09

SEQID-02298
B0LRN3
—
—
0
0.41
0.19
0.09
0.18
0.01
0.03
0.01
0.07
0.06
0.03
0.02
0.06
0.09
0.10

SEQID-02299
Q35331
—
—
1
0.44
0.25
0.03
0.11
0.02
0.05
0.02
0.05
0.09
0.05
0.02
0.07
0.09
0.06

SEQID-02300
B2LSM3
—
—
1
0.38
0.16
0.06
0.12
0.04
0.05
0.01
0.07
0.07
0.04
0.04
0.05
0.07
0.04

SEQID-02301
B6E3I6
—
—
1
0.54
0.19
0.03
0.05
0.06
0.06
0.01
0.05
0.07
0.03
0.04
0.05
0.11
0.07

SEQID-02302
Q9N102
—
—
1
0.47
0.16
0.06
0.06
0.05
0.06
0.03
0.05
0.04
0.04
0.03
0.05
0.05
0.08

SEQID-02303
Q5ENY9
—
—
1
0.48
0.19
0.03
0.11
0.01
0.06
0.00
0.02
0.09
0.02
0.06
0.06
0.08
0.06

SEQID-02304
O78750
—
—
1
0.56
0.27
0.02
0.04
0.02
0.04
0.01
0.03
0.07
0.02
0.03
0.08
0.14
0.03

SEQID-02305
P29361
—
—
1
0.39
0.18
0.06
0.07
0.04
0.06
0.01
0.06
0.14
0.02
0.00
0.04
0.10
0.09

SEQID-02306
Q00555
—
—
1
0.53
0.26
0.03
0.03
0.04
0.04
0.01
0.05
0.06
0.03
0.02
0.09
0.13
0.07

SEQID-02307
B7U9A4
—
—
1
0.45
0.25
0.06
0.03
0.02
0.05
0.02
0.06
0.07
0.02
0.03
0.04
0.14
0.04

SEQID-02308
Q9M4M9
—
—
1
0.44
0.22
0.07
0.06
0.05
0.04
0.02
0.05
0.09
0.05
0.01
0.05
0.11
0.09

SEQID-02309
Q02096
—
—
1
0.47
0.21
0.03
0.05
0.06
0.07
0.03
0.03
0.05
0.05
0.03
0.08
0.07
0.07

SEQID-02310
P19464
—
—
1
0.50
0.21
0.05
0.05
0.05
0.06
0.01
0.03
0.12
0.03
0.03
0.03
0.10
0.09

SEQID-02311
P24465
—
—
1
0.52
0.26
0.04
0.08
0.04
0.05
0.01
0.02
0.09
0.03
0.04
0.06
0.14
0.07

SEQID-02312
Q7M224
—
—
1
0.47
0.20
0.06
0.06
0.04
0.04
0.00
0.05
0.14
0.03
0.02
0.02
0.07
0.11

SEQID-02313
Q9SEK6
—
—
1
0.47
0.19
0.04
0.08
0.02
0.06
0.01
0.04
0.10
0.02
0.03
0.05
0.09
0.08

SEQID-02314
Q9M4M7
—
—
1
0.48
0.22
0.04
0.05
0.05
0.06
0.02
0.04
0.06
0.05
0.04
0.05
0.08
0.06

SEQID-02315
P93680
—
—
1
0.37
0.16
0.07
0.05
0.06
0.04
0.05
0.05
0.02
0.07
0.01
0.05
0.07
0.04

SEQID-02316
Q9M7I8
—
—
1
0.54
0.21
0.06
0.02
0.02
0.07
0.02
0.03
0.09
0.03
0.06
0.04
0.11
0.10

SEQID-02317
B0FGG5
—
—
1
0.47
0.22
0.06
0.05
0.03
0.05
0.01
0.02
0.09
0.05
0.03
0.07
0.07
0.09

SEQID-02318
Q68YT2
—
—
0
0.44
0.06
0.02
0.00
0.04
0.10
0.00
0.13
0.09
0.10
0.10
0.03
0.01
0.21

SEQID-02319
P48686
—
—
1
0.46
0.19
0.06
0.03
0.03
0.06
0.02
0.03
0.03
0.05
0.04
0.04
0.09
0.06

SEQID-02320
A7XB47
—
—
1
0.52
0.22
0.06
0.05
0.03
0.06
0.02
0.04
0.08
0.04
0.03
0.07
0.09
0.09

SEQID-02321
Q6DV58
—
—
1
0.45
0.17
0.06
0.05
0.02
0.05
0.01
0.05
0.08
0.05
0.01
0.03
0.07
0.10

SEQID-02322
Q8GTA0
—
—
1
0.48
0.17
0.05
0.07
0.03
0.04
0.06
0.02
0.03
0.05
0.10
0.02
0.10
0.03

SEQID-02323
H6TDM4
—
—
1
0.45
0.18
0.06
0.07
0.02
0.07
0.02
0.04
0.09
0.04
0.05
0.04
0.11
0.07

SEQID-02324
Q9SE87
—
—
1
0.48
0.25
0.03
0.11
0.03
0.07
0.01
0.09
0.06
0.03
0.02
0.06
0.10
0.06

SEQID-02325
F8U7Z9
—
—
1
0.42
0.17
0.04
0.07
0.05
0.05
0.02
0.06
0.10
0.04
0.02
0.04
0.07
0.04

SEQID-02326
A7YX35
—
—
1
0.47
0.21
0.04
0.03
0.03
0.07
0.01
0.03
0.09
0.03
0.03
0.05
0.11
0.07

SEQID-02327
O82795
—
—
1
0.52
0.23
0.06
0.04
0.04
0.04
0.01
0.03
0.05
0.04
0.01
0.07
0.09
0.08

SEQID-02328
Q5DJU7
—
—
1
0.49
0.23
0.04
0.07
0.02
0.07
0.02
0.05
0.08
0.03
0.03
0.07
0.11
0.06

SEQID-02329
Q3HYA1
—
—
1
0.50
0.21
0.04
0.04
0.04
0.04
0.01
0.03
0.09
0.04
0.02
0.05
0.10
0.07

SEQID-02330
Q39366
—
—
1
0.46
0.21
0.03
0.03
0.04
0.06
0.01
0.03
0.10
0.05
0.01
0.05
0.08
0.02

SEQID-02331
Q6PY61
—
—
0
0.55
0.10
0.02
0.00
0.02
0.13
0.00
0.01
0.12
0.07
0.18
0.09
0.01
0.26

SEQID-02332
P09678
—
—
0
0.49
0.21
0.06
0.04
0.07
0.06
0.01
0.02
0.03
0.11
0.08
0.07
0.07
0.03

SEQID-02333
Q944W6
—
—
1
0.52
0.21
0.03
0.01
0.02
0.07
0.01
0.03
0.13
0.04
0.01
0.05
0.09
0.12

SEQID-02334
Q62292
—
—
1
0.47
0.20
0.06
0.07
0.04
0.06
0.01
0.03
0.03
0.06
0.00
0.05
0.11
0.10

SEQID-02335
D91762
—
—
1
0.44
0.22
0.06
0.09
0.04
0.05
0.02
0.03
0.09
0.04
0.03
0.07
0.07
0.06

SEQID-02336
I3Y171
—
—
1
0.47
0.21
0.06
0.09
0.05
0.07
0.01
0.02
0.10
0.02
0.03
0.03
0.12
0.09

SEQID-02337
Q4TU02
—
—
1
0.46
0.16
0.04
0.05
0.04
0.07
0.00
0.04
0.07
0.07
0.03
0.03
0.05
0.09

SEQID-02338
Q75UU6
—
—
1
0.47
0.21
0.07
0.04
0.02
0.06
0.01
0.02
0.08
0.06
0.01
0.06
0.08
0.10

SEQID-02339
O82549
—
—
1
0.46
0.20
0.04
0.08
0.03
0.03
0.01
0.05
0.07
0.04
0.05
0.09
0.07
0.06

SEQID-02340
P56294
—
—
0
0.42
0.25
0.07
0.08
0.03
0.05
0.00
0.08
0.08
0.04
0.01
0.08
0.10
0.06

SEQID-02341
P56307
—
—
1
0.51
0.21
0.06
0.08
0.03
0.05
0.01
0.03
0.05
0.06
0.03
0.05
0.09
0.03

SEQID-02342
P56308
—
—
1
0.52
0.22
0.05
0.06
0.04
0.03
0.01
0.02
0.05
0.07
0.04
0.06
0.10
0.03

SEQID-02343
P56319
—
—
1
0.55
0.21
0.06
0.06
0.04
0.03
0.01
0.04
0.05
0.05
0.03
0.05
0.11
0.02

SEQID-02344
P56341
—
—
1
0.56
0.23
0.06
0.04
0.04
0.04
0.00
0.05
0.03
0.05
0.07
0.07
0.11
0.03

SEQID-02345
P56342
—
—
1
0.55
0.22
0.06
0.04
0.03
0.04
0.01
0.05
0.03
0.05
0.07
0.06
0.12
0.02

SEQID-02346
Q8JIV4
—
—
0
0.39
0.17
0.06
0.11
0.03
0.06
0.01
0.08
0.18
0.02
0.02
0.02
0.10
0.13

SEQID-02347
Q8JJ07
—
—
1
0.43
0.13
0.03
0.13
0.03
0.08
0.00
0.05
0.17
0.02
0.03
0.04
0.07
0.19

SEQID-02348
Q98557
—
—
1
0.51
0.21
0.03
0.09
0.04
0.06
0.01
0.04
0.09
0.05
0.04
0.04
0.10
0.09

SEQID-02349
Q8AWX8
—
—
1
0.51
0.23
0.06
0.05
0.05
0.07
0.01
0.02
0.06
0.05
0.04
0.09
0.05
0.09

SEQID-02350
A7XA06
—
—
1
0.50
0.19
0.02
0.08
0.05
0.07
0.02
0.02
0.09
0.04
0.06
0.04
0.11
0.03

SEQID-02351
Q98954
—
—
1
0.53
0.21
0.04
0.02
0.06
0.06
0.01
0.07
0.08
0.03
0.04
0.09
0.08
0.08

SEQID-02352
Q98559
—
—
0
0.39
0.16
0.06
0.09
0.05
0.06
0.01
0.10
0.15
0.01
0.03
0.03
0.10
0.13

SEQID-02353
A7XA16
—
—
1
0.48
0.24
0.04
0.09
0.04
0.06
0.02
0.03
0.07
0.04
0.01
0.06
0.07
0.08

SEQID-02354
Q8QG69
—
—
1
0.49
0.17
0.10
0.07
0.02
0.09
0.01
0.03
0.10
0.02
0.04
0.04
0.10
0.16

SEQID-02355
A5I873
—
—
0
0.49
0.18
0.14
0.01
0.00
0.11
0.03
0.02
0.09
0.04
0.00
0.05
0.08
0.13

SEQID-02356
A7XA17
—
—
1
0.43
0.17
0.04
0.09
0.06
0.05
0.02
0.03
0.07
0.04
0.02
0.08
0.03
0.06

SEQID-02357
A8CZC9
—
—
1
0.51
0.22
0.05
0.05
0.04
0.06
0.01
0.03
0.07
0.05
0.03
0.03
0.06
0.12

SEQID-02358
Q5XQ56
—
—
0
0.44
0.21
0.12
0.06
0.01
0.07
0.00
0.07
0.06
0.03
0.05
0.04
0.11
0.06

SEQID-02359
Q92079
—
—
1
0.44
0.19
0.07
0.04
0.03
0.06
0.04
0.04
0.05
0.06
0.02
0.05
0.07
0.03

SEQID-02360
O98734
—
—
1
0.41
0.17
0.04
0.08
0.04
0.07
0.01
0.03
0.07
0.04
0.03
0.07
0.07
0.05

SEQID-02361
F22AL7
—
—
0
0.38
0.23
0.10
0.09
0.05
0.09
0.04
0.01
0.04
0.04
0.00
0.06
0.09
0.05

SEQID-02362
F22AL8
—
—
1
0.36
0.18
0.10
0.09
0.05
0.07
0.02
0.03
0.07
0.04
0.02
0.03
0.08
0.05

SEQID-02363
I2FJT9
—
—
0
0.40
0.23
0.10
0.09
0.07
0.07
0.02
0.05
0.05
0.03
0.00
0.03
0.11
0.04

SEQID-02364
Q9IHF8
—
—
1
0.46
0.21
0.06
0.07
0.04
0.06
0.01
0.05
0.07
0.05
0.03
0.06
0.08
0.05

SEQID-02365
I2FJU0
—
—
1
0.38
0.18
0.09
0.06
0.05
0.03
0.01
0.05
0.07
0.04
0.01
0.06
0.03
0.04

SEQID-02366
O98733
—
—
1
0.49
0.24
0.06
0.06
0.06
0.02
0.01
0.03
0.06
0.05
0.03
0.08
0.10
0.00

SEQID-02367
Q6TNX3
—
—
1
0.56
0.23
0.06
0.03
0.04
0.04
0.00
0.04
0.03
0.06
0.09
0.06
0.13
0.04

SEQID-02368
B3RG69
—
—
1
0.58
0.24
0.05
0.03
0.05
0.03
0.01
0.04
0.03
0.05
0.08
0.08
0.11
0.03

SEQID-02369
P84527
—
—
1
0.36
0.15
0.03
0.06
0.08
0.09
0.07
0.03
0.04
0.07
0.04
0.05
0.04
0.06

SEQID-02370
P81370
—
—
0
0.41
0.14
0.05
0.06
0.09
0.06
0.07
0.05
0.02
0.06
0.00
0.04
0.07
0.05

SEQID-02371
A5HII1
—
—
1
0.42
0.18
0.04
0.05
0.07
0.05
0.02
0.04
0.07
0.05
0.01
0.06
0.06
0.05

SEQID-02372
Q6TPK4
—
—
1
0.48
0.27
0.08
0.07
0.05
0.04
0.00
0.06
0.05
0.04
0.02
0.02
0.12
0.06

SEQID-02373
P85524
—
—
1
0.58
0.26
0.01
0.02
0.03
0.07
0.01
0.02
0.13
0.03
0.02
0.10
0.07
0.10

SEQID-02374
P85076
—
—
1
0.47
0.20
0.06
0.05
0.06
0.06
0.01
0.04
0.04
0.04
0.01
0.06
0.06
0.06

SEQID-02375
A5HII4
—
—
1
0.44
0.20
0.03
0.05
0.03
0.06
0.02
0.03
0.06
0.05
0.01
0.06
0.07
0.08

SEQID-02376
P43394
—
—
1
0.44
0.25
0.04
0.10
0.03
0.05
0.00
0.04
0.06
0.03
0.04
0.07
0.10
0.03

SEQID-02377
Q06AW1
—
—
1
0.39
0.19
0.04
0.11
0.05
0.04
0.01
0.08
0.09
0.04
0.04
0.06
0.08
0.03

SEQID-02378
Q06AW2
—
—
1
0.38
0.19
0.04
0.12
0.05
0.03
0.01
0.03
0.09
0.05
0.03
0.06
0.09
0.03

SEQID-02379
Q9IB39
—
—
0
0.41
0.17
0.10
0.04
0.05
0.07
0.00
0.04
0.12
0.03
0.01
0.04
0.06
0.10

SEQID-02380
Q91B37
—
—
1
0.47
0.18
0.06
0.04
0.05
0.07
0.01
0.04
0.13
0.03
0.01
0.07
0.07
0.10

SEQID-02381
Q76CT4
—
—
0
0.41
0.18
0.07
0.07
0.02
0.08
0.00
0.05
0.23
0.01
0.01
0.04
0.12
0.15

SEQID-02382
B9WPP3
—
—
1
0.50
0.21
0.05
0.05
0.05
0.05
0.00
0.03
0.08
0.05
0.03
0.06
0.07
0.09

SEQID-02383
P02074
—
—
0
0.54
0.25
0.03
0.06
0.05
0.05
0.01
0.02
0.07
0.05
0.06
0.00
0.13
0.07

SEQID-02384
G3URG5
—
—
1
0.45
0.19
0.05
0.08
0.04
0.04
0.01
0.07
0.14
0.02
0.03
0.06
0.10
0.11

SEQID-02385
G3UV20
—
—
1
0.47
0.19
0.05
0.08
0.04
0.05
0.01
0.08
0.13
0.02
0.03
0.05
0.10
0.12

SEQID-02386
G1MUC5
—
—
1
0.48
0.19
0.05
0.06
0.05
0.04
0.01
0.05
0.09
0.03
0.03
0.06
0.08
0.10

SEQID-02387
G3US01
—
—
0
0.40
0.20
0.06
0.10
0.04
0.05
0.00
0.09
0.19
0.01
0.03
0.05
0.11
0.12

SEQID-02388
G1MSQ0
—
—
1
0.44
0.19
0.05
0.07
0.05
0.06
0.01
0.08
0.14
0.02
0.03
0.04
0.11
0.12

SEQID-02389
G1NIB8
—
—
1
0.46
0.20
0.05
0.07
0.03
0.06
0.01
0.03
0.09
0.04
0.03
0.09
0.07
0.06

SEQID-02390
G1NNJ7
—
—
1
0.45
0.19
0.05
0.03
0.04
0.06
0.01
0.07
0.15
0.02
0.02
0.04
0.11
0.12

SEQID-02391
G1MS62
—
—
1
0.44
0.19
0.06
0.08
0.05
0.05
0.01
0.07
0.15
0.02
0.02
0.04
0.11
0.12

SEQID-02392
G1MUV8
—
—
1
0.45
0.19
0.05
0.03
0.04
0.06
0.01
0.07
0.14
0.02
0.02
0.05
0.11
0.12

SEQID-02393
G1MT49
—
—
1
0.52
0.21
0.04
0.06
0.06
0.03
0.01
0.05
0.07
0.03
0.03
0.06
0.10
0.10

SEQID-02394
G1NMR6
—
—
1
0.52
0.22
0.07
0.05
0.05
0.07
0.01
0.02
0.04
0.05
0.04
0.06
0.06
0.09

SEQID-02395
G3URH1
—
—
0
0.39
0.20
0.06
0.12
0.04
0.06
0.00
0.09
0.17
0.01
0.02
0.05
0.11
0.11

SEQID-02396
G1MSA4
—
—
1
0.49
0.22
0.07
0.09
0.03
0.07
0.01
0.03
0.08
0.04
0.04
0.07
0.07
0.08

SEQID-02397
G1NGT5
—
—
1
0.44
0.19
0.05
0.09
0.05
0.06
0.01
0.07
0.11
0.02
0.03
0.07
0.09
0.07

SEQID-02398
G1NAX6
—
—
1
0.48
0.21
0.04
0.06
0.03
0.06
0.01
0.03
0.13
0.03
0.02
0.07
0.07
0.12

SEQID-02399
G1N679
—
—
1
0.57
0.28
0.04
0.04
0.03
0.06
0.01
0.02
0.06
0.04
0.07
0.09
0.10
0.10

SEQID-02400
G1NAN1
—
—
1
0.47
0.21
0.04
0.06
0.03
0.05
0.02
0.04
0.11
0.03
0.03
0.06
0.07
0.10

SEQID-02401
G1NS52
—
—
1
0.47
0.20
0.05
0.07
0.02
0.06
0.01
0.04
0.09
0.04
0.03
0.09
0.07
0.06

SEQID-02402
G1NAX9
—
—
1
0.47
0.20
0.04
0.04
0.03
0.04
0.02
0.04
0.12
0.03
0.02
0.05
0.06
0.11

SEQID-02403
G1NJG2
—
—
1
0.47
0.18
0.04
0.06
0.04
0.07
0.01
0.05
0.07
0.02
0.04
0.05
0.09
0.12

SEQID-02404
G3UPH8
—
—
1
0.46
0.20
0.04
0.07
0.04
0.06
0.02
0.03
0.10
0.03
0.04
0.05
0.07
0.08

SEQID-02405
G3UV10
—
—
1
0.49
0.18
0.05
0.05
0.03
0.05
0.02
0.04
0.06
0.04
0.02
0.12
0.04
0.03

SEQID-02406
G1N3D3
—
—
1
0.54
0.23
0.06
0.03
0.05
0.06
0.02
0.02
0.08
0.05
0.03
0.06
0.09
0.12

SEQID-02407
G1NJH3
—
—
1
0.46
0.17
0.06
0.07
0.04
0.09
0.01
0.05
0.06
0.01
0.05
0.06
0.08
0.12

SEQID-02408
G1NJH4
—
—
1
0.46
0.16
0.05
0.05
0.04
0.08
0.00
0.06
0.06
0.01
0.04
0.05
0.07
0.14

SEQID-02409
H9H166
—
—
1
0.50
0.22
0.05
0.09
0.04
0.05
0.02
0.02
0.08
0.05
0.04
0.07
0.09
0.07

SEQID-02410
G1NGV6
—
—
1
0.48
0.21
0.06
0.07
0.05
0.07
0.01
0.03
0.06
0.05
0.03
0.08
0.07
0.09

SEQID-02411
G1MYI4
—
—
0
0.40
0.18
0.03
0.07
0.02
0.09
0.00
0.05
0.23
0.01
0.01
0.04
0.11
0.15

SEQID-02412
G1NCR2
—
—
1
0.43
0.18
0.04
0.06
0.03
0.07
0.05
0.05
0.09
0.01
0.02
0.06
0.07
0.10

SEQID-02413
G1NBA6
—
—
1
0.48
0.20
0.04
0.07
0.04
0.06
0.01
0.04
0.09
0.03
0.03
0.06
0.07
0.09

SEQID-02414
G1N314
—
—
1
0.54
0.31
0.05
0.04
0.05
0.05
0.01
0.04
0.06
0.04
0.06
0.07
0.09
0.03

SEQID-02415
G1NBW3
—
—
1
0.49
0.21
0.06
0.09
0.03
0.06
0.01
0.05
0.09
0.03
0.03
0.07
0.09
0.09

SEQID-02416
G1N823
—
—
1
0.42
0.14
0.06
0.14
0.02
0.07
0.00
0.06
0.14
0.02
0.02
0.05
0.08
0.20

SEQID-02417
G3URJ0
—
—
1
0.42
0.15
0.06
0.14
0.01
0.06
0.00
0.06
0.15
0.02
0.01
0.04
0.09
0.20

SEQID-02418
G1NAZ1
—
—
1
0.47
0.21
0.03
0.07
0.03
0.07
0.01
0.02
0.09
0.03
0.03
0.05
0.06
0.10

SEQID-02419
G1NMV8
—
—
1
0.49
0.14
0.09
0.04
0.03
0.06
0.02
0.05
0.09
0.06
0.04
0.08
0.06
0.10

SEQID-02420
G1NNB7
—
—
1
0.46
0.20
0.03
0.04
0.02
0.18
0.01
0.02
0.12
0.02
0.02
0.06
0.10
0.09

SEQID-02421
G1MX98
—
—
1
0.45
0.22
0.06
0.06
0.06
0.07
0.01
0.03
0.09
0.04
0.01
0.06
0.09
0.10

SEQID-02422
G1MWY3
—
—
1
0.45
0.22
0.04
0.09
0.05
0.06
0.01
0.04
0.09
0.03
0.02
0.07
0.09
0.06

SEQID-02423
G1MXU8
—
—
1
0.51
0.26
0.05
0.06
0.04
0.05
0.03
0.03
0.09
0.03
0.02
0.08
0.10
0.07

SEQID-02424
G1N5J6
—
—
1
0.46
0.20
0.04
0.08
0.05
0.05
0.03
0.04
0.07
0.04
0.04
0.06
0.09
0.06

SEQID-02425
G1NGS2
—
—
1
0.46
0.17
0.04
0.08
0.04
0.07
0.01
0.03
0.07
0.04
0.06
0.05
0.07
0.03

SEQID-02426
G1NK94
—
—
1
0.45
0.19
0.04
0.07
0.05
0.07
0.01
0.03
0.10
0.03
0.02
0.06
0.06
0.10

SEQID-02427
G1MVKB
—
—
1
0.44
0.23
0.05
0.09
0.05
0.06
0.01
0.06
0.07
0.05
0.02
0.06
0.09
0.06

SEQID-02428
G1NLT9
—
—
1
0.45
0.18
0.04
0.09
0.04
0.06
0.01
0.05
0.09
0.02
0.04
0.04
0.09
0.08

SEQID-02429
G1N2A4
—
—
1
0.43
0.21
0.09
0.07
0.04
0.06
0.02
0.05
0.03
0.04
0.02
0.05
0.09
0.07

SEQID-02430
G1MXB6
—
—
0
0.49
0.24
0.07
0.06
0.05
0.04
0.02
0.03
0.07
0.05
0.02
0.07
0.10
0.09

SEQID-02431
G1NAR9
—
—
1
0.39
0.17
0.03
0.07
0.03
0.06
0.01
0.05
0.15
0.04
0.02
0.05
0.09
0.07

SEQID-02432
G1MVB6
—
—
1
0.49
0.24
0.05
0.07
0.04
0.04
0.02
0.04
0.09
0.03
0.02
0.07
0.09
0.06

SEQID-02433
G1MT65
—
—
1
0.48
0.21
0.04
0.07
0.03
0.07
0.01
0.04
0.07
0.03
0.02
0.07
0.07
0.11

SEQID-02434
G1N3V6
—
—
1
0.49
0.21
0.05
0.06
0.04
0.05
0.01
0.03
0.09
0.05
0.02
0.09
0.06
0.11

SEQID-02435
G1NMW0
—
—
1
0.43
0.22
0.06
0.07
0.05
0.09
0.01
0.03
0.09
0.04
0.02
0.06
0.09
0.07

SEQID-02436
G1NLY5
—
—
1
0.48
0.23
0.05
0.08
0.04
0.07
0.01
0.03
0.09
0.03
0.04
0.07
0.09
0.09

SEQID-02437
G1N9H8
—
—
0
0.58
0.25
0.08
0.03
0.03
0.05
0.01
0.02
0.05
0.03
0.09
0.06
0.11
0.10

SEQID-02438
G1N8B8
—
—
1
0.45
0.17
0.06
0.11
0.03
0.06
0.01
0.05
0.13
0.02
0.03
0.02
0.12
0.16

SEQID-02439
G1MWQ3
—
—
1
0.42
0.11
0.03
0.06
0.04
0.04
0.11
0.03
0.07
0.03
0.04
0.03
0.03
0.12

SEQID-02440
G1NR17
—
—
1
0.46
0.20
0.05
0.07
0.05
0.03
0.01
0.05
0.09
0.04
0.01
0.07
0.07
0.10

SEQID-02441
G1NB19
—
—
1
0.44
0.17
0.03
0.09
0.02
0.04
0.01
0.04
0.11
0.02
0.03
0.05
0.06
0.09

SEQID-02442
P82013
—
—
1
0.50
0.19
0.05
0.03
0.06
0.06
0.01
0.02
0.05
0.06
0.01
0.05
0.09
0.11

SEQID-02443
G1N478
—
—
1
0.44
0.15
0.03
0.07
0.04
0.04
0.00
0.03
0.08
0.06
0.05
0.04
0.07
0.10

SEQID-02444
G1MSQ3
—
—
1
0.46
0.19
0.06
0.09
0.04
0.05
0.01
0.04
0.06
0.04
0.03
0.06
0.08
0.09

SEQID-02445
G1N0V4
—
—
1
0.43
0.17
0.07
0.06
0.03
0.04
0.01
0.04
0.11
0.03
0.03
0.05
0.06
0.10

SEQID-02446
G1MSW3
—
—
1
0.46
0.21
0.05
0.06
0.05
0.07
0.01
0.05
0.09
0.04
0.01
0.07
0.07
0.10

SEQID-02447
H9H1S2
—
—
0
0.51
0.22
0.05
0.03
0.05
0.03
0.04
0.06
0.08
0.05
0.02
0.06
0.09
0.10

SEQID-02448
Q6W5H1
—
—
0
0.46
0.17
0.09
0.02
0.05
0.06
0.00
0.04
0.13
0.03
0.01
0.05
0.07
0.13

SEQID-02449
G1MRV9
—
—
0
0.45
0.23
0.07
0.03
0.02
0.05
0.01
0.07
0.06
0.04
0.03
0.07
0.10
0.07

SEQID-02450
G1N0M3
—
—
1
0.42
0.21
0.03
0.12
0.05
0.05
0.02
0.04
0.09
0.05
0.03
0.05
0.10
0.06

SEQID-02451
H9H062
—
—
0
0.47
0.25
0.07
0.07
0.02
0.06
0.00
0.05
0.10
0.05
0.02
0.08
0.09
0.06

SEQID-02452
G3URQ7
—
—
1
0.45
0.19
0.07
0.03
0.01
0.03
0.00
0.06
0.12
0.02
0.03
0.06
0.04
0.09

SEQID-02453
G1NPZ8
—
—
1
0.56
0.25
0.07
0.05
0.04
0.05
0.01
0.04
0.04
0.03
0.07
0.05
0.12
0.09

SEQID-02454
G1N3B7
—
—
1
0.50
0.22
0.06
0.03
0.03
0.05
0.01
0.05
0.03
0.05
0.01
0.08
0.07
0.10

SEQID-02455
G1N8F8
—
—
1
0.44
0.17
0.05
0.06
0.05
0.05
0.02
0.05
0.10
0.04
0.03
0.03
0.08
0.04

SEQID-02456
G1MV26
—
—
1
0.47
0.23
0.05
0.09
0.04
0.05
0.02
0.04
0.07
0.05
0.03
0.06
0.10
0.06

SEQID-02457
G1NFA2
—
—
1
0.49
0.22
0.05
0.07
0.03
0.07
0.02
0.04
0.03
0.04
0.02
0.06
0.09
0.09

SEQID-02458
G1N0S1
—
—
1
0.47
0.23
0.03
0.07
0.04
0.06
0.02
0.06
0.07
0.03
0.03
0.07
0.11
0.07

SEQID-02459
G1NHY3
—
—
1
0.48
0.22
0.03
0.06
0.04
0.05
0.02
0.04
0.10
0.03
0.03
0.06
0.11
0.08

SEQID-02460
G1MUC1
—
—
1
0.47
0.20
0.04
0.06
0.03
0.05
0.02
0.04
0.11
0.03
0.02
0.05
0.09
0.11

SEQID-02461
G1NC68
—
—
0
0.43
0.26
0.05
0.10
0.03
0.07
0.01
0.04
0.07
0.05
0.01
0.08
0.09
0.06

SEQID-02462
G1NL16
—
—
1
0.49
0.21
0.03
0.08
0.05
0.09
0.01
0.04
0.07
0.05
0.04
0.04
0.11
0.09

SEQID-02463
G1NFQ5
—
—
1
0.44
0.20
0.05
0.06
0.04
0.06
0.02
0.04
0.09
0.04
0.04
0.06
0.07
0.05

SEQID-02464
G1N3X9
—
—
1
0.45
0.21
0.06
0.09
0.03
0.09
0.01
0.04
0.09
0.03
0.02
0.06
0.11
0.09

SEQID-02465
G1MUF1
—
—
1
0.43
0.21
0.06
0.10
0.04
0.07
0.01
0.04
0.09
0.04
0.02
0.07
0.09
0.06

SEQID-02466
G1MVN4
—
—
1
0.46
0.20
0.05
0.06
0.04
0.06
0.04
0.05
0.07
0.04
0.02
0.04
0.10
0.09

SEQID-02467
G1NBN7
—
—
1
0.47
0.23
0.04
0.07
0.03
0.05
0.02
0.06
0.03
0.04
0.04
0.05
0.12
0.06

SEQID-02468
G1N481
—
—
0
0.46
0.19
0.06
0.03
0.01
0.09
0.01
0.02
0.09
0.05
0.00
0.04
0.10
0.15

SEQID-02469
G1MX59
—
—
1
0.45
0.17
0.04
0.08
0.01
0.04
0.00
0.03
0.10
0.03
0.03
0.05
0.07
0.07

SEQID-02470
G1NLB3
—
—
1
0.46
0.22
0.03
0.08
0.05
0.05
0.01
0.05
0.10
0.03
0.03
0.05
0.13
0.08

SEQID-02471
G1N1G2
—
—
1
0.44
0.21
0.03
0.07
0.04
0.10
0.01
0.06
0.06
0.03
0.02
0.04
0.11
0.10

SEQID-02472
G1N071
—
—
1
0.51
0.26
0.06
0.05
0.04
0.07
0.01
0.03
0.07
0.03
0.02
0.07
0.10
0.11

SEQID-02473
G1NB81
—
—
1
0.48
0.19
0.04
0.09
0.05
0.05
0.01
0.05
0.05
0.04
0.02
0.04
0.09
0.06

SEQID-02474
G1MZD9
—
—
1
0.45
0.21
0.05
0.09
0.04
0.09
0.01
0.04
0.09
0.03
0.01
0.07
0.10
0.11

SEQID-02475
G1NL53
—
—
1
0.50
0.23
0.04
0.06
0.04
0.06
0.01
0.05
0.08
0.06
0.03
0.07
0.08
0.09

SEQID-02476
G1NAW6
—
—
1
0.50
0.25
0.03
0.09
0.04
0.06
0.01
0.05
0.09
0.03
0.01
0.09
0.10
0.06

SEQID-02477
G1NB27
—
—
1
0.40
0.16
0.05
0.07
0.06
0.05
0.01
0.09
0.07
0.03
0.03
0.04
0.09
0.03

SEQID-02478
G1NCE0
—
—
1
0.48
0.23
0.06
0.07
0.04
0.04
0.01
0.05
0.07
0.04
0.02
0.06
0.11
0.06

SEQID-02479
G1NGS1
—
—
1
0.45
0.18
0.05
0.04
0.04
0.06
0.02
0.05
0.10
0.03
0.02
0.04
0.09
0.10

SEQID-02480
G1NKX1
—
—
1
0.47
0.20
0.03
0.06
0.04
0.07
0.01
0.04
0.15
0.02
0.02
0.06
0.09
0.12

SEQID-02481
G1NRH0
—
—
0
0.51
0.16
0.06
0.03
0.02
0.02
0.00
0.03
0.06
0.03
0.04
0.06
0.05
0.18

SEQID-02482
G1NQ36
—
—
0
0.43
0.20
0.04
0.06
0.04
0.06
0.02
0.03
0.13
0.04
0.03
0.08
0.06
0.09

SEQID-02483
G1MK52
—
—
1
0.40
0.20
0.05
0.06
0.06
0.06
0.01
0.05
0.13
0.02
0.02
0.04
0.10
0.08

SEQID-02484
G1NCP5
—
—
1
0.43
0.15
0.04
0.06
0.05
0.03
0.02
0.05
0.16
0.02
0.01
0.05
0.06
0.10

SEQID-02485
G1MZ49
—
—
0
0.48
0.25
0.04
0.07
0.07
0.06
0.02
0.03
0.07
0.02
0.02
0.07
0.14
0.07

SEQID-02486
G1NGA7
—
—
1
0.50
0.21
0.06
0.06
0.02
0.02
0.02
0.04
0.06
0.04
0.01
0.05
0.09
0.08

SEQID-02487
G1NLA9
—
—
1
0.48
0.21
0.06
0.04
0.05
0.05
0.02
0.05
0.08
0.03
0.03
0.06
0.09
0.10

SEQID-02488
G1NAL4
—
—
1
0.44
0.18
0.06
0.06
0.02
0.04
0.04
0.05
0.11
0.04
0.03
0.05
0.07
0.08

SEQID-02489
G1NCM2
—
—
1
0.50
0.21
0.06
0.06
0.04
0.05
0.01
0.05
0.11
0.02
0.02
0.04
0.12
0.11

SEQID-02490
G1NP43
—
—
1
0.39
0.16
0.04
0.12
0.04
0.07
0.01
0.04
0.07
0.06
0.02
0.05
0.09
0.05

SEQID-02491
G1NMS8
—
—
1
0.48
0.23
0.07
0.06
0.03
0.05
0.01
0.06
0.06
0.05
0.02
0.06
0.09
0.10

SEQID-02492
G1MSI1
—
—
1
0.38
0.18
0.04
0.09
0.03
0.07
0.02
0.05
0.08
0.08
0.01
0.06
0.07
0.07

SEQID-02493
G1NP96
—
—
1
0.46
0.22
0.04
0.07
0.04
0.07
0.02
0.06
0.09
0.02
0.03
0.06
0.11
0.07

SEQID-02494
P07728
—
—
1
0.35
0.19
0.04
0.11
0.07
0.03
0.02
0.12
0.06
0.04
0.02
0.05
0.08
0.03

SEQID-02495
P07730
—
—
1
0.37
0.19
0.04
0.11
0.07
0.03
0.02
0.12
0.06
0.04
0.02
0.05
0.09
0.03

SEQID-02496
P14323
—
—
1
0.38
0.19
0.04
0.09
0.07
0.02
0.01
0.12
0.06
0.03
0.03
0.05
0.07
0.04

SEQID-02497
Q02897
—
—
1
0.38
0.18
0.04
0.09
0.07
0.02
0.01
0.12
0.06
0.03
0.02
0.05
0.07
0.04

SEQID-02498
P14614
—
—
1
0.38
0.19
0.05
0.10
0.08
0.02
0.01
0.12
0.07
0.04
0.03
0.05
0.09
0.03

SEQID-02499
Q09151
—
—
1
0.39
0.20
0.04
0.10
0.06
0.05
0.02
0.12
0.05
0.04
0.03
0.05
0.08
0.03

SEQID-02500
Q01401
—
—
1
0.46
0.17
0.04
0.09
0.05
0.07
0.01
0.02
0.07
0.04
0.05
0.04
0.07
0.07

SEQID-02501
Q6K508
—
—
1
0.40
0.21
0.05
0.11
0.06
0.04
0.01
0.11
0.06
0.04
0.03
0.06
0.03
0.04

SEQID-02502
Q6K7K6
—
—
1
0.42
0.20
0.05
0.10
0.05
0.04
0.01
0.11
0.06
0.03
0.04
0.05
0.09
0.03

SEQID-02503
Q0E2G5
—
—
1
0.41
0.20
0.04
0.10
0.09
0.02
0.01
0.10
0.06
0.04
0.03
0.07
0.08
0.05

SEQID-02504
Q6H6P8
—
—
1
0.43
0.17
0.05
0.09
0.04
0.07
0.01
0.02
0.07
0.05
0.04
0.04
0.07
0.05

SEQID-02505
Q7X834
—
—
1
0.44
0.21
0.05
0.08
0.05
0.09
0.01
0.04
0.05
0.04
0.04
0.05
0.08
0.04

SEQID-02506
Q0DEV5
—
—
1
0.45
0.21
0.07
0.09
0.04
0.06
0.02
0.03
0.07
0.05
0.02
0.05
0.08
0.03

SEQID-02507
Q6AVA8
—
—
1
0.45
0.21
0.07
0.09
0.03
0.05
0.02
0.04
0.09
0.05
0.03
0.04
0.09
0.06

SEQID-02508
Q43009
—
—
1
0.49
0.22
0.04
0.08
0.04
0.04
0.01
0.04
0.09
0.03
0.05
0.06
0.11
0.06

SEQID-02509
Q5VNT5
—
—
1
0.46
0.21
0.04
0.07
0.04
0.07
0.02
0.04
0.07
0.04
0.03
0.09
0.07
0.06

SEQID-02510
P15280
—
—
1
0.43
0.22
0.06
0.08
0.05
0.07
0.01
0.03
0.06
0.04
0.02
0.08
0.08
0.06

SEQID-02511
P30298
—
—
1
0.48
0.22
0.04
0.07
0.04
0.06
0.01
0.04
0.08
0.03
0.04
0.06
0.11
0.06

SEQID-02512
Q10LP5
—
—
1
0.47
0.23
0.04
0.09
0.04
0.05
0.01
0.04
0.08
0.03
0.04
0.07
0.10
0.06

SEQID-02513
Q0DI45
—
—
1
0.38
0.25
0.08
0.06
0.04
0.03
0.01
0.20
0.01
0.02
0.01
0.06
0.13
0.01

SEQID-02514
Q9AUV8
—
—
1
0.47
0.21
0.05
0.07
0.05
0.06
0.01
0.03
0.10
0.04
0.03
0.06
0.08
0.03

SEQID-02515
Q6Z7B0
—
—
1
0.46
0.22
0.05
0.07
0.05
0.07
0.01
0.04
0.12
0.05
0.01
0.07
0.08
0.11

SEQID-02516
P37833
—
—
1
0.46
0.22
0.06
0.08
0.03
0.05
0.01
0.05
0.05
0.04
0.03
0.06
0.10
0.05

SEQID-02517
Q6K5G8
—
—
1
0.52
0.22
0.06
0.05
0.04
0.07
0.01
0.02
0.07
0.04
0.03
0.06
0.06
0.10

SEQID-02518
Q6Z7B2
—
—
1
0.44
0.22
0.09
0.11
0.02
0.02
0.02
0.01
0.09
0.05
0.02
0.04
0.09
0.06

SEQID-02519
Q75GX9
—
—
1
0.33
0.16
0.06
0.18
0.03
0.05
0.01
0.06
0.13
0.04
0.03
0.04
0.07
0.04

SEQID-02520
Q2QV45
—
—
1
0.46
0.22
0.07
0.06
0.04
0.09
0.01
0.05
0.08
0.05
0.01
0.05
0.08
0.09

SEQID-02521
Q84Q83
—
—
1
0.44
0.19
0.04
0.08
0.05
0.05
0.01
0.05
0.07
0.07
0.03
0.04
0.08
0.06

SEQID-02522
O64937
—
—
1
0.52
0.21
0.04
0.06
0.04
0.06
0.01
0.02
0.08
0.04
0.03
0.07
0.06
0.13

SEQID-02523
Q6T725
—
—
1
0.40
0.20
0.03
0.09
0.07
0.03
0.01
0.11
0.07
0.03
0.03
0.06
0.03
0.03

SEQID-02524
P29835
—
—
0
0.26
0.12
0.06
0.16
0.00
0.03
0.04
0.13
0.10
0.04
0.00
0.02
0.06
0.01

SEQID-02525
Q5N725
—
—
1
0.46
0.22
0.07
0.05
0.04
0.04
0.02
0.04
0.10
0.05
0.02
0.05
0.10
0.10

SEQID-02526
Q6ZBH2
—
—
1
0.47
0.24
0.08
0.10
0.02
0.05
0.03
0.01
0.10
0.06
0.04
0.05
0.07
0.05

SEQID-02527
Q338N3
—
—
1
0.42
0.23
0.07
0.06
0.05
0.05
0.02
0.06
0.07
0.04
0.02
0.03
0.10
0.07

SEQID-02528
Q53LQ0
—
—
1
0.48
0.20
0.07
0.03
0.03
0.08
0.01
0.03
0.11
0.03
0.02
0.05
0.09
0.12

SEQID-02529
Q01B82
—
—
1
0.39
0.20
0.07
0.11
0.03
0.06
0.06
0.04
0.04
0.06
0.05
0.03
0.08
0.02

SEQID-02530
Q7FAH2
—
—
1
0.51
0.22
0.06
0.05
0.04
0.08
0.01
0.02
0.07
0.04
0.02
0.06
0.06
0.10

SEQID-02531
Q852L2
—
—
1
0.38
0.17
0.05
0.14
0.02
0.03
0.01
0.03
0.13
0.05
0.04
0.03
0.07
0.04

SEQID-02532
Q6H4L2
—
—
1
0.48
0.21
0.05
0.07
0.03
0.06
0.02
0.04
0.09
0.04
0.02
0.05
0.09
0.09

SEQID-02533
P35683
—
—
1
0.46
0.23
0.03
0.10
0.03
0.08
0.01
0.07
0.03
0.04
0.02
0.06
0.09
0.05

SEQID-02534
Q6Z2Z4
—
—
1
0.46
0.23
0.03
0.10
0.03
0.08
0.01
0.07
0.07
0.04
0.02
0.06
0.10
0.05

SEQID-02535
Q6H6C7
—
—
1
0.53
0.26
0.09
0.03
0.02
0.07
0.00
0.01
0.08
0.05
0.01
0.05
0.12
0.12

SEQID-02536
Q7XTK1
—
—
1
0.48
0.22
0.05
0.07
0.03
0.06
0.02
0.04
0.09
0.04
0.02
0.05
0.08
0.08

SEQID-02537
P20693
—
—
1
0.40
0.20
0.07
0.04
0.02
0.01
0.05
0.22
0.01
0.01
0.02
0.06
0.08
0.01

SEQID-02538
Q2QXY9
—
—
1
0.43
0.21
0.08
0.09
0.03
0.06
0.01
0.03
0.09
0.04
0.04
0.07
0.07
0.05

SEQID-02539
Q93X08
—
—
1
0.51
0.26
0.04
0.04
0.07
0.06
0.01
0.03
0.08
0.04
0.02
0.07
0.11
0.10

SEQID-02540
Q8H4L8
—
—
1
0.38
0.21
0.09
0.12
0.03
0.05
0.06
0.05
0.04
0.05
0.03
0.05
0.07
0.02

SEQID-02541
Q655T1
—
—
1
0.53
0.26
0.07
0.03
0.02
0.07
0.00
0.01
0.07
0.05
0.01
0.06
0.12
0.12

SEQID-02542
Q0J3A4
—
—
1
0.52
0.23
0.06
0.05
0.04
0.08
0.01
0.01
0.05
0.04
0.02
0.08
0.06
0.10

SEQID-02543
Q69T99
—
—
1
0.43
0.22
0.07
0.09
0.05
0.06
0.01
0.03
0.07
0.04
0.02
0.09
0.07
0.06

SEQID-02544
Q653V7
—
—
1
0.45
0.21
0.06
0.10
0.04
0.06
0.00
0.02
0.03
0.06
0.03
0.03
0.10
0.03

SEQID-02545
Q01881
—
—
1
0.36
0.20
0.09
0.13
0.02
0.05
0.06
0.04
0.04
0.05
0.03
0.02
0.09
0.01

SEQID-02546
Q8H4M4
—
—
1
0.42
0.20
0.07
0.10
0.01
0.05
0.06
0.05
0.02
0.05
0.02
0.03
0.09
0.04

SEQID-02547
Q6ZIX4
—
—
1
0.41
0.26
0.06
0.04
0.03
0.01
0.03
0.22
0.01
0.01
0.02
0.07
0.11
0.01

SEQID-02548
Q10P83
—
—
1
0.48
0.25
0.04
0.09
0.05
0.06
0.01
0.04
0.06
0.04
0.02
0.07
0.10
0.07

SEQID-02549
Q10DV7
—
—
1
0.47
0.21
0.05
0.07
0.02
0.06
0.01
0.03
0.08
0.04
0.03
0.08
0.07
0.06

SEQID-02550
Q7K8H9
—
—
1
0.37
0.20
0.10
0.10
0.02
0.06
0.06
0.04
0.04
0.07
0.02
0.03
0.08
0.02

SEQID-02551
Q0J4C6
—
—
1
0.45
0.17
0.04
0.06
0.05
0.06
0.02
0.02
0.07
0.05
0.04
0.04
0.08
0.04

SEQID-02552
A1YQF0
—
—
1
0.37
0.25
0.09
0.06
0.05
0.03
0.00
0.19
0.01
0.02
0.02
0.06
0.15
0.01

SEQID-02553
Q5Z9M9
—
—
1
0.37
0.16
0.06
0.06
0.02
0.01
0.08
0.20
0.02
0.02
0.02
0.03
0.07
0.02

SEQID-02554
P17048
—
—
1
0.41
0.24
0.06
0.04
0.03
0.01
0.03
0.22
0.01
0.01
0.02
0.07
0.10
0.01

SEQID-02555
Q5Z627
—
—
1
0.50
0.19
0.04
0.04
0.05
0.05
0.01
0.02
0.10
0.03
0.01
0.04
0.09
0.11

SEQID-02556
Q65XV6
—
—
1
0.50
0.21
0.07
0.07
0.04
0.07
0.02
0.00
0.05
0.07
0.04
0.09
0.06
0.09

SEQID-02557
Q7X7E6
—
—
1
0.35
0.19
0.11
0.11
0.02
0.06
0.06
0.03
0.05
0.06
0.02
0.03
0.08
0.02

SEQID-02558
Q8GVK7
—
—
0
0.40
0.28
0.07
0.06
0.05
0.03
0.01
0.19
0.01
0.02
0.02
0.07
0.15
0.01

SEQID-02559
Q0DJ38
—
—
1
0.39
0.25
0.06
0.05
0.04
0.03
0.01
0.18
0.01
0.02
0.01
0.06
0.16
0.01

SEQID-02560
Q7SHX0
—
—
1
0.46
0.21
0.04
0.07
0.02
0.06
0.01
0.03
0.08
0.04
0.03
0.07
0.07
0.06

SEQID-02561
Q0JKM8
—
—
1
0.46
0.32
0.07
0.06
0.04
0.05
0.02
0.06
0.05
0.06
0.03
0.06
0.09
0.06

SEQID-02562
Q7XDC8
—
—
1
0.47
0.24
0.07
0.05
0.05
0.05
0.02
0.04
0.07
0.04
0.02
0.06
0.09
0.07

SEQID-02563
Q5W6C5
—
—
1
0.42
0.19
0.06
0.03
0.04
0.06
0.01
0.04
0.04
0.04
0.03
0.03
0.10
0.04

SEQID-02564
Q10M12
—
—
1
0.45
0.15
0.04
0.07
0.06
0.07
0.02
0.04
0.07
0.06
0.07
0.04
0.05
0.06

SEQID-02565
Q6YW46
—
—
1
0.49
0.18
0.05
0.04
0.05
0.05
0.01
0.02
0.10
0.03
0.01
0.04
0.08
0.12

SEQID-02566
Q9AUQ4
—
—
1
0.48
0.21
0.06
0.05
0.04
0.08
0.01
0.03
0.06
0.05
0.02
0.05
0.07
0.09

SEQID-02567
Q01833
—
—
1
0.36
0.19
0.09
0.12
0.02
0.05
0.06
0.05
0.04
0.05
0.04
0.02
0.09
0.01

SEQID-02568
Q0J0G9
—
—
1
0.11
0.24
0.07
0.08
0.04
0.05
0.01
0.04
0.07
0.07
0.01
0.05
0.12
0.03

SEQID-02569
P49027
—
—
1
0.47
0.23
0.04
0.06
0.05
0.07
0.02
0.03
0.04
0.06
0.03
0.05
0.10
0.05

SEQID-02570
Q0ISV7
—
—
1
0.46
0.22
0.05
0.07
0.03
0.06
0.02
0.03
0.09
0.04
0.02
0.06
0.09
0.09

SEQID-02571
Q0OUA3
—
—
1
0.38
0.15
0.04
0.13
0.03
0.05
0.01
0.04
0.16
0.05
0.04
0.04
0.05
0.07

SEQID-02572
Q53NM9
—
—
1
0.45
0.21
0.06
0.07
0.05
0.09
0.01
0.05
0.09
0.04
0.01
0.08
0.07
0.09

SEQID-02573
Q07073
—
—
1
0.19
0.20
0.03
0.05
0.04
0.07
0.01
0.03
0.14
0.02
0.02
0.06
0.09
0.13

SEQID-02574
Q42465
—
—
1
0.41
0.26
0.08
0.05
0.05
0.03
0.01
0.18
0.01
0.02
0.02
0.07
0.14
0.01

SEQID-02575
P48494
—
—
1
0.49
0.25
0.07
0.05
0.04
0.05
0.02
0.05
0.09
0.05
0.01
0.06
0.07
0.08

SEQID-02576
Q2QNF3
—
—
1
0.43
0.17
0.07
0.15
0.04
0.03
0.01
0.03
0.03
0.07
0.07
0.05
0.04
0.03

SEQID-02577
Q948T6
—
—
1
0.47
0.21
0.05
0.05
0.02
0.07
0.02
0.02
0.09
0.04
0.01
0.05
0.10
0.11

SEQID-02578
Q9ZRI7
—
—
1
0.49
0.17
0.06
0.04
0.05
0.05
0.01
0.02
0.10
0.03
0.01
0.04
0.08
0.13

SEQID-02579
Q42971
—
—
1
0.45
0.22
0.07
0.04
0.06
0.06
0.01
0.05
0.09
0.05
0.01
0.06
0.08
0.10

SEQID-02580
Q0DEC8
—
—
1
0.44
0.20
0.05
0.08
0.03
0.06
0.01
0.04
0.07
0.05
0.03
0.04
0.09
0.05

SEQID-02581
Q0DDE3
—
—
1
0.39
0.19
0.07
0.10
0.03
0.09
0.01
0.03
0.07
0.05
0.03
0.03
0.07
0.05

SEQID-02582
Q07661
—
—
1
0.47
0.20
0.05
0.09
0.03
0.05
0.00
0.03
0.09
0.05
0.02
0.09
0.05
0.06

SEQID-02583
Q0D868
—
—
1
0.46
0.19
0.09
0.13
0.04
0.03
0.00
0.02
0.06
0.04
0.03
0.04
0.09
0.11

SEQID-02584
Q7XC37
—
—
1
0.51
0.23
0.05
0.07
0.03
0.03
0.00
0.03
0.10
0.05
0.02
0.03
0.06
0.03

SEQID-02585
Q6ZKC0
—
—
1
0.43
0.20
0.07
0.07
0.03
0.06
0.01
0.03
0.15
0.03
0.02
0.05
0.11
0.09

SEQID-02586
Q7XTE8
—
—
1
0.41
0.20
0.06
0.08
0.03
0.06
0.01
0.03
0.15
0.02
0.01
0.06
0.10
0.09

SEQID-02587
Q6SXA1
—
—
1
0.49
0.23
0.06
0.05
0.04
0.05
0.01
0.03
0.06
0.06
0.02
0.06
0.10
0.07

SEQID-02588
Q0OJB9
—
—
1
0.47
0.23
0.06
0.04
0.03
0.10
0.00
0.05
0.09
0.05
0.01
0.05
0.10
0.10

SEQID-02589
Q0DBN4
—
—
1
0.45
0.18
0.07
0.09
0.03
0.05
0.02
0.04
0.06
0.04
0.04
0.06
0.08
0.06

SEQID-02590
Q2QVC1
—
—
1
0.44
0.22
0.07
0.07
0.03
0.05
0.01
0.02
0.09
0.05
0.03
0.06
0.09
0.03

SEQID-02591
P0C522
—
—
0
0.42
0.25
0.07
0.09
0.04
0.05
0.01
0.06
0.03
0.04
0.01
0.07
0.10
0.06

SEQID-02592
Q01859
—
—
0
0.44
0.24
0.07
0.09
0.03
0.05
0.00
0.05
0.08
0.05
0.03
0.06
0.10
0.05

SEQID-02593
Q0J1E1
—
—
1
0.47
0.23
0.07
0.07
0.03
0.06
0.02
0.03
0.05
0.05
0.04
0.07
0.09
0.07

SEQID-02594
Q2QLY4
—
—
1
0.42
0.22
0.07
0.06
0.04
0.06
0.01
0.03
0.08
0.03
0.02
0.06
0.09
0.09

SEQID-02595
Q6YZX6
—
—
1
0.43
0.22
0.05
0.05
0.05
0.06
0.01
0.03
0.07
0.05
0.03
0.05
0.09
0.07

SEQID-02596
Q0DKN6
—
—
1
0.37
0.20
0.07
0.06
0.04
0.09
0.00
0.04
0.14
0.04
0.01
0.04
0.09
0.07

SEQID-02597
P0C030
—
—
0
0.50
0.26
0.03
0.07
0.02
0.09
0.00
0.07
0.10
0.04
0.02
0.11
0.11
0.11

SEQID-02598
P35681
—
—
1
0.49
0.21
0.03
0.02
0.02
0.12
0.01
0.05
0.09
0.05
0.01
0.04
0.10
0.11

SEQID-02599
Q8H920
—
—
1
0.44
0.21
0.17
0.09
0.02
0.02
0.02
0.03
0.03
0.07
0.04
0.01
0.16
0.01

SEQID-02600
P29421
—
—
1
0.39
0.21
0.06
0.12
0.01
0.05
0.02
0.02
0.06
0.05
0.03
0.03
0.10
0.03

SEQID-02601
Q6YTY2
—
—
1
0.47
0.23
0.05
0.11
0.03
0.04
0.01
0.03
0.08
0.04
0.02
0.06
0.09
0.09

SEQID-02602
Q10QU9
—
—
1
0.41
0.18
0.11
0.07
0.03
0.07
0.01
0.03
0.06
0.04
0.02
0.06
0.06
0.03

SEQID-02603
Q0DS36
—
—
1
0.45
0.18
0.06
0.07
0.03
0.04
0.01
0.03
0.10
0.06
0.02
0.03
0.07
0.09

SEQID-02604
Q9SXP2
—
—
1
0.47
0.22
0.07
0.07
0.04
0.06
0.01
0.03
0.07
0.05
0.04
0.06
0.09
0.09

SEQID-02605
Q5W6H1
—
—
1
0.50
0.23
0.06
0.04
0.04
0.07
0.02
0.03
0.10
0.03
0.03
0.06
0.09
0.13

SEQID-02606
P35684
—
—
1
0.54
0.18
0.03
0.10
0.01
0.04
0.02
0.04
0.06
0.04
0.05
0.05
0.06
0.15

SEQID-02607
Q6ZK46
—
—
1
0.33
0.18
0.07
0.18
0.04
0.06
0.01
0.05
0.09
0.05
0.02
0.04
0.07
0.02

SEQID-02608
Q6ZHC3
—
—
1
0.42
0.20
0.07
0.03
0.03
0.04
0.02
0.06
0.10
0.03
0.02
0.07
0.08
0.07

SEQID-02609
Q6SXK0
—
—
1
0.45
0.21
0.03
0.07
6.03
0.05
0.01
0.03
0.08
0.04
0.03
0.06
0.08
0.06

SEQID-02610
Q67IX6
—
—
1
0.47
0.21
0.07
0.04
0.04
0.10
0.01
0.03
0.09
0.02
0.03
0.05
0.10
0.09

SEQID-02611
Q6H547
—
—
1
0.41
0.20
0.06
0.10
0.03
0.06
0.01
0.05
0.09
0.04
0.01
0.05
0.08
0.07

SEQID-02612
P0C5C9
—
—
1
0.48
0.70
0.05
0.06
0.03
0.10
0.01
0.02
0.05
0.05
0.04
0.05
0.07
0.10

SEQID-02613
Q0DKF0
—
—
1
0.44
0.17
0.06
0.15
0.03
0.04
0.03
0.03
0.05
0.04
0.04
0.04
0.06
0.11

SEQID-02614
P35685
—
—
1
0.54
0.22
0.06
0.10
0.03
0.03
0.01
0.04
0.07
0.03
0.02
0.04
0.10
0.18

SEQID-02615
Q8L4L4
—
—
0
0.42
0.16
0.06
0.11
0.03
0.08
0.00
0.04
0.08
0.04
0.03
0.04
0.08
0.10

SEQID-02616
Q6Z4N6
—
—
1
0.49
0.17
0.04
0.06
0.06
0.07
0.02
0.03
0.06
0.04
0.06
0.04
0.06
0.08

SEQID-02617
Q7XHN4
—
—
1
0.43
0.20
0.06
0.07
0.05
0.06
0.02
0.05
0.03
0.05
0.02
0.05
0.07
0.05

SEQID-02618
Q6F2Y7
—
—
1
0.43
0.25
0.07
0.12
0.02
0.07
0.00
0.05
0.11
0.04
0.03
0.05
0.12
0.07

SEQID-02619
Q8GVI3
—
—
1
0.35
0.20
0.11
0.12
0.01
0.04
0.07
0.02
0.07
0.04
0.02
0.02
0.15
0.02

SEQID-02620
P27777
—
—
1
0.47
0.20
0.04
0.09
0.05
0.07
0.00
0.02
0.11
0.02
0.02
0.03
0.05
0.11

SEQID-02621
QS3NL5
—
—
1
0.41
0.18
0.09
0.09
0.03
0.08
0.01
0.03
0.04
0.06
0.04
0.04
0.10
0.04

SEQID-02622
P41095
—
—
0
0.49
0.25
0.06
0.04
0.04
0.06
0.01
0.02
0.09
0.04
0.01
0.06
0.10
0.11

SEQID-02623
Q8H916
—
—
1
0.44
0.19
0.05
0.09
0.05
0.07
0.00
0.03
0.07
0.03
0.03
0.06
0.09
0.06

SEQID-02624
Q4W8D0
—
—
1
0.42
0.18
0.05
0.08
0.05
0.07
0.01
0.03
0.06
0.06
0.04
0.07
0.05
0.06

SEQID-02625
Q9LD54
—
—
1
0.47
0.23
0.07
0.09
0.03
0.03
0.01
0.04
0.06
0.06
0.02
0.04
0.12
0.07

SEQID-02626
P46265
—
—
1
0.43
0.17
0.04
0.07
0.05
0.07
0.02
0.05
0.09
0.04
0.03
0.04
0.08
0.04

SEQID-02627
Q53M52
—
—
1
0.43
0.21
0.04
0.07
0.04
0.07
0.02
0.04
0.09
0.04
0.03
0.05
0.09
0.05

SEQID-02628
Q10R45
—
—
1
0.45
0.22
0.06
0.07
0.04
0.04
0.01
0.04
0.07
0.06
0.03
0.05
0.10
0.07

SEQID-02629
Q69P84
—
—
1
0.46
0.24
0.06
0.07
0.05
0.03
0.02
0.05
0.07
0.06
0.02
0.09
0.09
0.04

SEQID-02630
Q33AE4
—
—
1
0.45
0.21
0.06
0.03
0.04
0.09
0.00
0.03
0.05
0.05
0.02
0.06
0.09
0.07

SEQID-02631
Q0JCZ5
—
—
1
0.47
0.19
0.04
0.10
0.03
0.05
0.01
0.03
0.11
0.03
0.01
0.05
0.08
0.10

SEQID-02632
Q9FWV2
—
—
1
0.44
0.24
0.03
0.07
0.03
0.06
0.01
0.05
0.10
0.03
0.01
0.06
0.12
0.09

SEQID-02633
P31674
—
—
0
0.48
0.20
0.05
0.13
0.02
0.05
0.00
0.03
0.07
0.04
0.03
0.06
0.07
0.12

SEQID-02634
Q84Q77
—
—
1
0.44
0.16
0.04
0.09
0.03
0.07
0.00
0.04
0.11
0.04
0.02
0.05
0.05
0.10

SEQID-02635
Q0JBY8
—
—
1
0.53
0.17
0.04
0.11
0.04
0.01
0.03
0.03
0.04
0.05
0.04
0.08
0.04
0.16

SEQID-02636
Q8H590
—
—
1
0.51
0.20
0.03
0.16
0.05
0.07
0.01
0.04
0.04
0.04
0.03
0.04
0.10
0.12

SEQID-02637
Q6K1W6
—
—
1
0.41
0.16
0.07
0.14
0.05
0.03
0.01
0.05
0.07
0.03
0.04
0.05
0.06
0.11

SEQID-02638
P49199
—
—
1
0.43
0.16
0.06
0.14
0.04
0.04
0.01
0.06
0.07
0.05
0.02
0.03
0.07
0.14

SEQID-02639
Q40680
—
—
1
0.44
0.21
0.07
0.03
0.03
0.11
0.00
0.02
0.09
0.03
0.01
0.04
0.09
0.09

SEQID-02640
Q7GD79
—
—
1
0.48
0.20
0.05
0.06
0.05
0.07
0.02
0.05
0.07
0.03
0.04
0.05
0.08
0.09

SEQID-02641
Q0JDZ7
—
—
1
0.43
0.16
0.06
0.14
0.04
0.04
0.01
0.06
0.07
0.05
0.02
0.03
0.07
0.14

SEQID-02642
Q8LH97
—
—
0
0.45
0.17
0.05
0.16
0.03
0.06
0.01
0.05
0.05
0.04
0.00
0.04
0.08
0.16

SEQID-02643
Q6K8B8
—
—
1
0.51
0.20
0.04
0.10
0.03
0.06
0.01
0.05
0.07
0.03
0.01
0.06
0.07
0.14

SEQID-02644
Q84M35
—
—
1
0.49
0.20
0.04
0.13
0.02
0.03
0.01
0.03
0.07
0.07
0.02
0.04
0.06
0.10

SEQID-02645
Q75KH3
—
—
1
0.40
0.19
0.09
0.09
0.04
0.06
0.01
0.05
0.07
0.05
0.01
0.07
0.06
0.06

SEQID-02646
Q6F361
—
—
0
0.47
0.25
0.09
0.05
0.05
0.04
0.01
0.03
0.09
0.05
0.02
0.05
0.11
0.09

SEQID-02647
Q6Z9P5
—
—
1
0.53
0.14
0.05
0.05
0.03
0.07
0.01
0.02
0.07
0.04
0.04
0.09
0.09
0.06

SEQID-02648
Q75H31
—
—
1
0.51
0.13
0.09
0.03
0.02
0.05
0.00
0.05
0.07
0.04
0.04
0.03
0.13
0.08

SEQID-02649
Q6Z1J6
—
—
1
0.50
0.21
0.05
0.06
0.03
0.07
0.03
0.03
0.09
0.03
0.03
0.08
0.07
0.11

SEQID-02650
Q62744
—
—
1
0.45
0.20
0.06
0.09
0.04
0.05
0.02
0.03
0.09
0.05
0.02
0.06
0.07
0.07

SEQID-02651
Q3S0E1
—
—
1
0.53
0.23
0.05
0.05
0.05
0.07
0.02
0.02
0.05
0.04
0.04
0.08
0.11
0.09

SEQID-02652
Q10Q18
—
—
1
0.53
0.29
0.05
0.06
0.04
0.03
0.01
0.04
0.05
0.05
0.02
0.09
0.13
0.04

SEQID-02653
Q62702
—
—
1
0.43
0.18
0.07
0.09
0.03
0.06
0.02
0.03
0.07
0.04
0.02
0.05
0.06
0.07

SEQID-02654
Q2QS11
—
—
1
0.49
0.18
0.04
0.06
0.04
0.06
0.03
0.03
0.10
0.04
0.01
0.05
0.07
0.11

SEQID-02655
Q9SLX0
—
—
1
0.42
0.23
0.07
0.07
0.06
0.06
0.02
0.07
0.09
0.03
0.02
0.06
0.11
0.06

SEQID-02656
Q0IMT5
—
—
1
0.37
0.16
0.09
0.14
0.02
0.05
0.02
0.03
0.07
0.06
0.02
0.04
0.06
0.04

SEQID-02657
Q5QMK7
—
—
1
0.47
0.22
0.06
0.07
0.04
0.08
0.01
0.03
0.07
0.05
0.03
0.05
0.09
0.07

SEQID-02658
Q9LGA3
—
—
1
0.46
0.23
0.09
0.07
0.03
0.06
0.01
0.05
0.06
0.03
0.02
0.04
0.10
0.09

SEQID-02659
Q10MW3
—
—
1
0.44
0.22
0.07
0.05
0.05
0.05
0.03
0.03
0.07
0.05
0.03
0.06
0.09
0.06

SEQID-02660
Q6K4K9
—
—
1
0.46
0.28
0.06
0.07
0.03
0.06
0.02
0.06
0.09
0.02
0.02
0.07
0.13
0.05

SEQID-02661
Q75GT3
—
—
1
0.42
0.23
0.06
0.11
0.03
0.07
0.00
0.06
0.10
0.04
0.01
0.06
0.09
0.07

SEQID-02662
Q6ZHP6
—
—
0
0.35
0.14
0.12
0.10
0.03
0.06
0.00
0.01
0.17
0.09
0.00
0.00
0.08
0.05

SEQID-02663
Q0IQK9
—
—
0
0.36
0.24
0.16
0.10
0.05
0.02
0.07
0.02
0.00
0.05
0.01
0.05
0.10
0.05

SEQID-02664
Q6ZGV5
—
—
1
0.48
0.20
0.05
0.14
0.04
0.05
0.01
0.01
0.12
0.03
0.02
0.07
0.06
0.15

SEQID-02665
Q762A6
—
—
1
0.47
0.19
0.06
0.09
0.05
0.06
0.01
0.01
0.09
0.05
0.01
0.05
0.06
0.16

SEQID-02666
Q42990
—
—
1
0.50
0.24
0.12
0.06
0.00
0.05
0.00
0.03
0.03
0.07
0.04
0.05
0.11
0.06

SEQID-02667
C7IYQ9
—
—
1
0.46
0.22
0.06
0.11
0.04
0.04
0.00
0.09
0.05
0.03
0.04
0.05
0.09
0.05

SEQID-02668
Q6H7T1
—
—
0
0.44
0.18
0.06
0.16
0.02
0.05
0.01
0.02
0.07
0.06
0.03
0.05
0.07
0.09

SEQID-02669
Q67VZ0
—
—
1
0.40
0.16
0.09
0.10
0.03
0.06
0.03
0.03
0.05
0.09
0.04
0.02
0.06
0.01

SEQID-02670
Q6ZH98
—
—
1
0.49
0.17
0.04
0.07
0.04
0.05
0.03
0.02
0.06
0.09
0.03
0.04
0.04
0.08

SEQID-02671
P49210
—
—
1
0.53
0.25
0.04
0.10
0.05
0.05
0.00
0.03
0.07
0.03
0.03
0.08
0.03
0.10

SEQID-02672
Q2R4A1
—
—
1
0.44
0.23
0.08
0.12
0.06
0.05
0.01
0.04
0.07
0.02
0.03
0.09
0.07
0.08

SEQID-02673
Q6L502
—
—
1
0.46
0.20
0.06
0.03
0.05
0.09
0.01
0.04
0.05
0.04
0.01
0.09
0.07
0.09

SEQID-02674
Q10P60
—
—
1
0.39
0.19
0.06
0.16
0.03
0.09
0.00
0.04
0.09
0.04
0.01
0.02
0.07
0.05

SEQID-02675
Q9FWV6
—
—
1
0.50
0.26
0.11
0.07
0.02
0.03
0.00
0.01
0.03
0.07
0.04
0.04
0.14
0.01

SEQID-02676
Q10MT8
—
—
1
0.41
0.22
0.07
0.06
0.04
0.03
0.04
0.03
0.09
0.04
0.04
0.03
0.09
0.06

SEQID-02677
P49398
—
—
1
0.51
0.33
0.04
0.10
0.05
0.06
0.01
0.03
0.04
0.04
0.03
0.08
0.08
0.13

SEQID-02678
C7J0T2
—
—
1
0.42
0.17
0.05
0.14
0.03
0.05
0.01
0.03
0.09
0.03
0.05
0.04
0.09
0.03

SEQID-02679
Q69020
—
—
1
0.42
0.21
0.05
0.11
0.04
0.06
0.02
0.04
0.11
0.04
0.03
0.05
0.10
0.04

SEQID-02680
Q10R17
—
—
1
0.43
0.23
0.06
0.09
0.03
0.06
0.02
0.03
0.07
0.06
0.03
0.05
0.10
0.05

SEQID-02681
Q6Z4E4
—
—
1
0.46
0.31
0.07
0.07
0.05
0.06
0.01
0.04
0.06
0.04
0.01
0.06
0.09
0.06

SEQID-02682
Q10RW9
—
—
0
0.43
0.25
0.08
0.06
0.04
0.06
0.01
0.04
0.10
0.05
0.01
0.07
0.09
0.10

SEQID-02683
Q7K9A7
—
—
1
0.45
0.26
0.09
0.03
0.03
0.05
0.00
0.04
0.11
0.04
0.01
0.08
0.09
0.08

SEQID-02684
Q7XV86
—
—
1
0.45
0.18
0.05
0.04
0.03
0.10
0.01
0.02
0.13
0.03
0.02
0.07
0.07
0.13

SEQID-02685
Q7XMP6
—
—
1
0.48
0.27
0.10
0.03
0.03
0.05
0.01
0.02
0.03
0.05
0.04
0.06
0.10
0.06

SEQID-02686
Q0DCI1
—
—
1
0.47
0.23
0.07
0.05
0.03
0.05
0.02
0.05
0.06
0.04
0.04
0.06
0.10
0.07

SEQID-02687
Q0D9G9
—
—
1
0.47
0.20
0.03
0.05
0.03
0.09
0.00
0.03
0.14
0.02
0.01
0.05
0.10
0.13

SEQID-02688
Q0J716
—
—
1
0.46
0.18
0.04
0.06
0.03
0.07
0.01
0.05
0.09
0.03
0.02
0.05
0.08
0.09

SEQID-02689
Q6Z1D6
—
—
1
0.44
0.20
0.04
0.07
0.05
0.08
0.01
0.04
0.10
0.03
0.04
0.05
0.07
0.06

SEQID-02690
Q10ST8
—
—
0
0.37
0.20
0.13
0.10
0.04
0.01
0.10
0.05
0.00
0.08
0.01
0.02
0.07
0.04

SEQID-02691
Q0DT04
—
—
1
0.40
0.18
0.09
0.09
0.00
0.09
0.01
0.04
0.06
0.04
0.03
0.04
0.04
0.04

SEQID-02692
Q34ZP1
—
—
1
0.52
0.25
0.02
0.12
0.04
0.04
0.01
0.03
0.07
0.05
0.03
0.08
0.08
0.10

SEQID-02693
Q10EK7
—
—
0
0.43
0.24
0.14
0.08
0.01
0.03
0.00
0.09
0.03
0.08
0.02
0.03
0.14
0.03

SEQID-02694
Q2QXN5
—
—
1
0.45
0.20
0.06
0.18
0.03
0.05
0.01
0.02
0.05
0.03
0.03
0.05
0.05
0.13

SEQID-02695
Q0JAI2
—
—
1
0.50
0.26
0.06
0.07
0.03
0.07
0.01
0.04
0.08
0.04
0.01
0.08
0.07
0.14

SEQID-02696
Q2QQ48
—
—
0
0.49
0.30
0.04
0.04
0.05
0.09
0.02
0.04
0.08
0.04
0.05
0.07
0.06
0.11

SEQID-02697
Q7KXS5
—
—
1
0.46
0.35
0.07
0.10
0.02
0.09
0.02
0.04
0.06
0.05
0.05
0.04
0.13
0.06

SEQID-02698
Q0DK10
—
—
1
0.44
0.20
0.03
0.13
0.03
0.03
0.01
0.06
0.09
0.04
0.01
0.05
0.07
0.10

SEQID-02699
Q943F3
—
—
1
0.53
0.15
0.03
0.12
0.05
0.02
0.01
0.04
0.04
0.02
0.04
0.05
0.06
0.13

SEQID-02700
Q1DMS5
—
—
0
0.47
0.22
0.05
0.13
0.04
0.05
0.00
0.03
0.09
0.02
0.02
0.06
0.07
0.12

SEQID-02701
Q2R1JE
—
—
1
0.43
0.20
0.03
0.17
0.05
0.04
0.00
0.03
0.09
0.04
0.04
0.04
0.10
0.09

SEQID-02702
Q6YY64
—
—
1
0.51
0.18
0.07
0.09
0.02
0.07
0.00
0.02
0.05
0.04
0.02
0.05
0.08
0.16

SEQID-02703
Q6H6I1
—
—
1
0.42
0.19
0.13
0.03
0.02
0.04
0.03
0.01
0.06
0.05
0.03
0.05
0.06
0.05

SEQID-02704
Q6YTK5
—
—
1
0.42
0.25
0.16
0.06
0.02
0.04
0.00
0.02
0.06
0.03
0.04
0.03
0.12
0.05

SEQID-02705
Q6ER94
—
—
1
0.44
0.22
0.07
0.06
0.02
0.08
0.01
0.03
0.05
0.03
0.01
0.07
0.09
0.07

SEQID-02706
P52428
—
—
1
0.39
0.18
0.09
0.09
0.03
0.06
0.02
0.05
0.09
0.03
0.02
0.04
0.08
0.05

SEQID-02707
Q8HSN9
—
—
1
0.51
0.25
0.11
0.05
0.03
0.03
0.01
0.02
0.03
0.07
0.03
0.09
0.08
0.04

SEQID-02708
Q0E3B7
—
—
1
0.53
0.27
0.10
0.03
0.02
0.04
0.01
0.01
0.04
0.06
0.01
0.10
0.10
0.05

SEQID-02709
Q2R8Z5
—
—
1
0.51
0.22
0.06
0.05
0.05
0.04
0.03
0.02
0.09
0.05
0.04
0.07
0.06
0.08

SEQID-02710
Q8H8T0
—
—
1
0.48
0.19
0.04
0.06
0.04
0.08
0.02
0.03
0.05
0.03
0.02
0.06
0.08
0.08

SEQID-02711
Q85059
—
—
1
0.46
0.19
0.06
0.10
0.03
0.08
0.01
0.04
0.07
0.03
0.03
0.05
0.09
0.07

SEQID-02712
Q5JK10
—
—
1
0.45
0.24
0.08
0.06
0.03
0.07
0.01
0.04
0.06
0.03
0.01
0.06
0.10
0.09

SEQID-02713
Q67UF5
—
—
1
0.46
0.21
0.08
0.03
0.04
0.05
0.02
0.04
0.10
0.04
0.01
0.03
0.10
0.11

SEQID-02714
Q0DJ87
—
—
1
0.47
0.21
0.04
0.05
0.04
0.08
0.02
0.03
0.06
0.04
0.03
0.04
0.10
0.08

SEQID-02715
Q8RZW7
—
—
1
0.06
0.21
0.04
0.06
0.03
0.07
0.02
0.04
0.06
0.06
0.05
0.04
0.10
0.06

SEQID-02716
Q6AVT2
—
—
1
0.04
0.22
0.07
0.10
0.05
0.09
0.01
0.03
0.05
0.05
0.01
0.08
0.08
0.06

SEQID-02717
Q0JK67
—
—
1
0.42
0.21
0.07
0.10
0.04
0.07
0.02
0.03
0.05
0.04
0.03
0.05
0.10
0.03

SEQID-02718
Q0JP92
—
—
1
0.48
0.28
0.06
0.06
0.06
0.05
0.01
0.06
0.06
0.02
0.01
0.07
0.12
0.04

SEQID-02719
Q6S4U8
—
—
1
0.45
0.21
0.06
0.05
0.04
0.05
0.02
0.04
0.09
0.05
0.03
0.05
0.10
0.09

SEQID-02720
Q93VT8
—
—
1
0.47
0.23
0.05
0.06
0.03
0.05
0.01
0.05
0.06
0.05
0.02
0.09
0.09
0.09

SEQID-02721
Q6K2E8
—
—
1
0.45
0.23
0.09
0.08
0.03
0.05
0.01
0.05
0.06
0.04
0.03
0.06
0.09
0.05

SEQID-02722
Q8W1L6
—
—
1
0.51
0.26
0.06
0.07
0.03
0.05
0.01
0.04
0.06
0.05
0.02
0.07
0.11
0.09

SEQID-02723
Q9AQZ5
—
—
1
0.44
0.18
0.06
0.06
0.04
0.06
0.02
0.05
0.11
0.03
0.01
0.04
0.07
0.10

SEQID-02724
Q9ZWR4
—
—
1
0.45
0.24
0.07
0.05
0.04
0.06
0.02
0.07
0.09
0.03
0.02
0.06
0.12
0.05

SEQID-02725
P05117
—
—
1
0.46
0.23
0.04
0.03
0.10
0.05
0.03
0.06
0.05
0.04
0.02
0.10
0.05
0.08

SEQID-02726
K48249
—
—
1
0.46
0.21
0.05
0.07
0.02
0.06
0.01
0.03
0.08
0.04
0.03
0.07
0.09
0.06

SEQID-02727
P14280
—
—
1
0.48
0.22
0.06
0.05
0.05
0.07
0.01
0.06
0.04
0.03
0.02
0.06
0.09
0.06

SEQID-02728
K4BHR9
—
—
1
0.47
0.21
0.05
0.07
0.02
0.06
0.01
0.03
0.09
0.04
0.03
0.08
0.07
0.06

SEQID-02729
P17786
—
—
1
0.51
0.21
0.05
0.06
0.03
0.06
0.01
0.03
0.07
0.05
0.03
0.07
0.06
0.13

SEQID-02730
P09607
—
—
1
0.49
0.23
0.06
0.06
0.04
0.07
0.02
0.05
0.04
0.03
0.02
0.06
0.09
0.08

SEQID-02731
K4BJW4
—
—
1
0.52
0.23
0.06
0.05
0.04
0.07
0.01
0.02
0.07
0.04
0.02
0.06
0.06
0.10

SEQID-02732
K4CWR4
—
—
1
0.50
0.22
0.06
0.05
0.03
0.06
0.02
0.04
0.08
0.04
0.03
0.06
0.09
0.09

SEQID-02733
K4BN62
—
—
1
0.48
0.20
0.06
0.07
0.05
0.06
0.02
0.04
0.05
0.03
0.03
0.05
0.07
0.09

SEQID-02734
K4BWA9
—
—
1
0.52
0.22
0.06
0.05
0.05
0.09
0.01
0.02
0.05
0.05
0.02
0.07
0.06
0.11

SEQID-02735
O82575
—
—
0
0.58
0.10
0.09
0.00
0.00
0.04
0.00
0.01
0.20
0.04
0.23
0.04
0.05
0.18

SEQID-02736
O65819
—
—
0
0.53
0.17
0.09
0.05
0.02
0.03
0.00
0.03
0.09
0.02
0.02
0.07
0.05
0.23

SEQID-02737
K4CX83
—
—
1
0.48
0.23
0.06
0.06
0.04
0.07
0.01
0.03
0.04
0.05
0.03
0.06
0.07
0.08

SEQID-02738
P29000
—
—
1
0.47
0.21
0.04
0.04
0.04
0.08
0.01
0.05
0.04
0.04
0.03
0.05
0.09
0.06

SEQID-02739
K4DBN5
—
—
1
0.33
0.17
0.02
0.03
0.07
0.02
0.02
0.02
0.04
0.02
0.02
0.04
0.08
0.03

SEQID-02740
K4CQV5
—
—
1
0.44
0.22
0.07
0.05
0.05
0.03
0.02
0.05
0.10
0.05
0.01
0.04
0.11
0.09

SEQID-02741
P10967
—
—
1
0.48
0.21
0.02
0.05
0.03
0.03
0.02
0.05
0.06
0.03
0.03
0.05
0.10
0.08

SEQID-02742
Q42382
—
—
1
0.43
0.23
0.06
0.08
0.05
0.07
0.01
0.03
0.06
0.04
0.02
0.09
0.09
0.07

SEQID-02743
K4CPX6
—
—
1
0.51
0.23
0.05
0.05
0.04
0.06
0.02
0.03
0.07
0.04
0.03
0.06
0.10
0.08

SEQID-02744
K4D4C8
—
—
1
0.38
0.14
0.02
0.03
0.05
0.03
0.02
0.02
0.04
0.02
0.04
0.03
0.07
0.07

SEQID-02745
K4CL75
—
—
1
0.48
0.20
0.05
0.07
0.04
0.06
0.02
0.04
0.09
0.04
0.02
0.05
0.08
0.09

SEQID-02746
K4ASM0
—
—
1
0.42
0.22
0.03
0.06
0.06
0.05
0.01
0.03
0.08
0.03
0.04
0.06
0.10
0.07

SEQID-02747
K4CBP6
—
—
0
0.44
0.14
0.05
0.16
0.03
0.01
0.09
0.01
0.07
0.03
0.03
0.03
0.06
0.04

SEQID-02748
P14903
—
—
0
0.55
0.25
0.03
0.03
0.05
0.04
0.06
0.05
0.05
0.02
0.00
0.06
0.15
0.08

SEQID-02749
P62980
—
—
0
0.53
0.18
0.04
0.07
0.03
0.07
0.02
0.06
0.05
0.04
0.03
0.05
0.03
0.19

SEQID-02750
K4CUC1
—
—
1
0.48
0.23
0.06
0.04
0.04
0.06
0.04
0.03
0.08
0.04
0.02
0.05
0.10
0.07

SEQID-02751
K4CW40
—
—
1
0.46
0.25
0.03
0.05
0.05
0.06
0.02
0.03
0.07
0.04
0.02
0.06
0.09
0.07

SEQID-02752
K4B6D8
—
—
1
0.49
0.21
0.02
0.03
0.07
0.04
0.01
0.04
0.09
0.03
0.03
0.07
0.10
0.07

SEQID-02753
K4D422
—
—
1
0.49
0.20
0.03
0.07
0.04
0.04
0.02
0.04
0.15
0.04
0.02
0.05
0.10
0.09

SEQID-02754
K4BX34
—
—
1
0.42
0.21
0.07
0.08
0.05
0.03
0.01
0.05
0.08
0.04
0.01
0.05
0.10
0.07

SEQID-02755
P24629
—
—
1
0.46
0.21
0.05
0.06
0.05
0.07
0.01
0.04
0.10
0.04
0.01
0.07
0.07
0.10

SEQID-02756
K4AQY8
—
—
0
0.42
0.24
0.09
0.10
0.03
0.08
0.00
0.05
0.06
0.04
0.01
0.06
0.10
0.05

SEQID-02757
K4D338
—
—
1
0.49
0.22
0.06
0.06
0.04
0.06
0.01
0.04
0.08
0.03
0.02
0.06
0.09
0.09

SEQID-02758
K4DBC4
—
—
1
0.47
0.22
0.05
0.06
0.05
0.06
0.01
0.03
0.06
0.04
0.03
0.05
0.09
0.07

SEQID-02759
Q6LB28
—
—
0
0.46
0.19
0.08
0.17
0.01
0.03
0.01
0.07
0.06
0.03
0.03
0.05
0.10
0.12

SEQID-02760
K4B1G1
—
—
1
0.50
0.26
0.05
0.07
0.05
0.04
0.01
0.04
0.05
0.06
0.03
0.09
0.12
0.06

SEQID-02761
K4CI69
—
—
1
0.44
0.17
0.06
0.07
0.06
0.05
0.04
0.05
0.03
0.03
0.02
0.05
0.07
0.09

SEQID-02762
K4D1H0
—
—
1
0.34
0.13
0.05
0.09
0.07
0.05
0.05
0.05
0.02
0.07
0.02
0.05
0.06
0.03

SEQID-02763
P15003
—
—
0
0.43
0.22
0.08
0.06
0.09
0.08
0.03
0.05
0.03
0.04
0.01
0.05
0.10
0.04

SEQID-02764
K4BAW0
—
—
1
0.43
0.22
0.07
0.07
0.05
0.04
0.01
0.06
0.08
0.04
0.01
0.04
0.10
0.07

SEQID-02765
K4CHY3
—
—
1
0.52
0.27
0.07
0.03
0.03
0.07
0.00
0.02
0.08
0.06
0.01
0.05
0.12
0.12

SEQID-02766
Q6SKP4
—
—
1
0.54
0.19
0.04
0.09
0.02
0.03
0.02
0.05
0.06
0.04
0.05
0.05
0.07
0.16

SEQID-02767
K4C711
—
—
1
0.46
0.23
0.04
0.10
0.03
0.08
0.01
0.07
0.06
0.03
0.01
0.06
0.10
0.05

SEQID-02768
P26300
—
—
1
0.46
0.22
0.07
0.04
0.05
0.06
0.01
0.04
0.09
0.05
0.02
0.06
0.09
0.10

SEQID-02769
P49118
—
—
1
0.46
0.22
0.05
0.06
0.05
0.03
0.01
0.04
0.11
0.04
0.01
0.07
0.08
0.11

SEQID-02770
K4BEL1
—
—
1
0.48
0.20
0.03
0.05
0.04
0.08
0.01
0.03
0.14
0.02
0.01
0.06
0.09
0.13

SEQID-02771
K4BVW7
—
—
1
0.44
0.17
0.04
0.09
0.06
0.07
0.01
0.02
0.08
0.04
0.04
0.05
0.06
0.06

SEQID-02772
B1N678
—
—
0
0.41
0.13
0.05
0.17
0.03
0.01
0.10
0.02
0.08
0.04
0.02
0.01
0.07
0.03

SEQID-02773
K4B3H9
—
—
0
0.22
0.09
0.03
0.16
0.05
0.07
0.01
0.04
0.08
0.22
0.00
0.03
0.02
0.01

SEQID-02774
K4BNT4
—
—
1
0.59
0.27
0.02
0.01
0.03
0.05
0.02
0.02
0.11
0.03
0.07
0.12
0.10
0.12

SEQID-02775
K4CWC4
—
—
0
0.55
0.25
0.04
0.01
0.03
0.08
0.01
0.01
0.09
0.05
0.06
0.07
0.09
0.12

SEQID-02776
K4BIL3
—
—
1
0.49
0.19
0.04
0.06
0.02
0.06
0.03
0.02
0.05
0.06
0.04
0.06
0.07
0.06

SEQID-02777
K4ATQ2
—
—
1
0.43
0.20
0.04
0.18
0.03
0.05
0.00
0.04
0.08
0.03
0.03
0.03
0.10
0.09

SEQID-02778
K4BP02
—
—
1
0.41
0.17
0.03
0.22
0.03
0.02
0.01
0.05
0.04
0.04
0.03
0.03
0.07
0.10

SEQID-02779
K4C3V1
—
—
1
0.45
0.14
0.06
0.19
0.04
0.02
0.00
0.04
0.07
0.03
0.03
0.03
0.07
0.18

SEQID-02780
P12670
—
—
1
0.41
0.13
0.05
0.06
0.07
0.04
0.07
0.04
0.03
0.06
0.01
0.03
0.06
0.04

SEQID-02781
P93210
—
—
1
0.40
0.20
0.06
0.07
0.06
0.06
0.01
0.03
0.14
0.02
0.01
0.06
0.10
0.08

SEQID-02782
O65820
—
—
0
0.52
0.14
0.13
0.04
0.02
0.01
0.00
0.02
0.07
0.00
0.00
0.03
0.04
0.29

SEQID-02783
P37213
—
—
0
0.52
0.11
0.17
0.04
0.02
0.01
0.00
0.02
0.06
0.01
0.01
0.02
0.03
0.30

SEQID-02784
Q08451
—
—
1
0.52
0.24
0.08
0.06
0.03
0.03
0.01
0.03
0.04
0.06
0.03
0.08
0.09
0.04

SEQID-02785
K4DA99
—
—
1
0.54
0.26
0.09
0.05
0.02
0.03
0.01
0.02
0.04
0.06
0.04
0.10
0.08
0.05

SEQID-02786
Q3C2L6
—
—
1
0.49
0.25
0.06
0.07
0.04
0.06
0.04
0.02
0.07
0.06
0.03
0.07
0.09
0.06

SEQID-02787
P28032
—
—
1
0.51
0.23
0.06
0.05
0.04
0.05
0.03
0.02
0.08
0.05
0.04
0.06
0.09
0.08

SEQID-02788
K4CL59
—
—
1
0.47
0.24
0.05
0.06
0.04
0.05
0.01
0.03
0.07
0.04
0.02
0.06
0.10
0.06

SEQID-02789
K4ASC2
—
—
1
0.50
0.20
0.06
0.06
0.04
0.06
0.01
0.02
0.09
0.04
0.03
0.07
0.09
0.10

SEQID-02790
K4C285
—
—
1
0.50
0.26
0.04
0.04
0.07
0.07
0.01
0.03
0.06
0.03
0.02
0.07
0.12
0.10

SEQID-02791
K4B8V1
—
—
1
0.47
0.23
0.06
0.04
0.06
0.04
0.03
0.03
0.07
0.05
0.03
0.07
0.09
0.06

SEQID-02792
K4D8S6
—
—
1
0.45
0.18
0.06
0.04
0.03
0.05
0.00
0.03
0.17
0.02
0.01
0.03
0.06
0.11

SEQID-02793
K4C764
—
—
1
0.46
0.21
0.06
0.08
0.03
0.07
0.01
0.03
0.08
0.04
0.02
0.05
0.10
0.07

SEQID-02794
K4BL25
—
—
1
0.43
0.24
0.06
0.11
0.03
0.07
0.00
0.05
0.11
0.04
0.02
0.05
0.11
0.09

SEQID-02795
F6I0I5
—
—
1
0.50
0.23
0.04
0.07
0.02
0.05
0.01
0.02
0.08
0.04
0.04
0.07
0.10
0.06

SEQID-03796
A5B0L2
—
—
1
0.47
0.21
0.05
0.07
0.02
0.06
0.01
0.03
0.09
0.04
0.03
0.09
0.07
0.06

SEQID-02797
A5BXV1
—
—
1
0.47
0.21
0.05
0.07
0.02
0.06
0.01
0.03
0.09
0.04
0.03
0.07
0.07
0.06

SEQID-02793
D7T227
—
—
1
0.48
0.22
0.07
0.04
0.06
0.06
0.01
0.04
0.08
0.05
0.02
0.07
0.08
0.11

SEQID-02799
C5DBS0
—
—
1
0.47
0.22
0.05
0.06
0.04
0.08
0.01
0.03
0.08
0.06
0.04
0.06
0.08
0.08

SEQID-02800
F6H4T7
—
—
1
0.47
0.21
0.05
0.09
0.03
0.06
0.02
0.04
0.09
0.04
0.02
0.05
0.08
0.08

SEQID-02801
F6HKH3
—
—
1
0.47
0.23
0.06
0.03
0.06
0.06
0.01
0.04
0.09
0.05
0.02
0.07
0.03
0.10

SEQID-02802
F6HXK4
—
—
1
0.51
0.27
0.06
0.07
0.04
0.05
0.01
0.03
0.08
0.04
0.02
0.10
0.10
0.06

SEQID-02803
ASC5K3
—
—
1
0.50
0.22
0.05
0.05
0.03
0.06
0.02
0.04
0.08
0.05
0.03
0.07
0.09
0.09

SEQID-02804
F6HNX5
—
—
1
0.45
0.20
0.06
0.06
0.05
0.08
0.01
0.04
0.09
0.04
0.01
0.07
0.07
0.09

SEQID-02805
A5B118
—
—
1
0.46
0.22
0.07
0.06
0.04
0.03
0.02
0.03
0.10
0.05
0.02
0.04
0.11
0.10

SEQID-02806
A5CAF6
—
—
1
0.53
0.28
0.07
0.04
0.02
0.07
0.00
0.01
0.09
0.06
0.02
0.05
0.13
0.12

SEQID-02807
A5AFS1
—
—
1
0.52
0.21
0.04
0.06
0.04
0.06
0.01
0.02
0.09
0.04
0.03
0.07
0.06
0.12

SEQID-02808
A5C0I8
—
—
1
0.49
0.23
0.05
0.06
0.05
0.05
0.03
0.02
0.09
0.05
0.03
0.06
0.07
0.08

SEQID-02809
F6HLD8
—
—
1
0.45
0.20
0.06
0.06
0.05
0.08
0.01
0.04
0.09
0.04
0.01
0.07
0.07
0.10

SEQID-02810
F6HG44
—
—
1
0.52
0.23
0.06
0.05
0.04
0.08
0.01
0.01
0.06
0.04
0.03
0.07
0.06
0.10

SEQID-02811
F6HCG2
—
—
1
0.45
0.22
0.04
0.10
0.04
0.07
0.01
0.03
0.08
0.04
0.03
0.06
0.09
0.06

SEQID-02812
A5C6H7
—
—
1
0.47
0.22
0.04
0.03
0.04
0.06
0.01
0.04
0.08
0.03
0.04
0.06
0.10
0.05

SEQID-02813
F6H0C4
—
—
0
0.46
0.12
0.02
0.01
0.00
0.04
0.02
0.02
0.27
0.03
0.05
0.03
0.04
0.22

SEQID-02814
F6GSG7
—
—
1
0.53
0.23
0.06
0.05
0.04
0.07
0.01
0.01
0.07
0.05
0.03
0.07
0.06
0.10

SEQID-02815
F6HFF7
—
—
1
0.46
0.20
0.06
0.06
0.04
0.06
0.01
0.03
0.07
0.05
0.02
0.06
0.07
0.08

SEQID-02816
F6HXC8
—
—
1
0.46
0.20
0.03
0.08
0.03
0.07
0.01
0.04
0.09
0.04
0.05
0.08
0.07
0.06

SEQID-02817
D7TCM7
—
—
1
0.46
0.23
0.03
0.10
0.03
0.09
0.01
0.07
0.07
0.04
0.01
0.06
0.10
0.05

SEQID-02818
D7TBH4
—
—
1
0.47
0.24
0.05
0.06
0.04
0.05
0.01
0.05
0.09
0.04
0.02
0.06
0.12
0.09

SEQID-02819
F6I407
—
—
1
0.45
0.20
0.05
0.04
0.03
0.04
0.01
0.03
0.18
0.02
0.01
0.04
0.06
0.11

SEQID-02820
D7TQP5
—
—
1
0.42
0.21
0.06
0.10
0.03
0.08
0.02
0.03
0.11
0.04
0.02
0.07
0.08
0.07

SEQID-02821
A5BT28
—
—
1
0.48
0.22
0.06
0.09
0.05
0.06
0.01
0.03
0.10
0.02
0.04
0.06
0.11
0.09

SEQID-02822
F6I2F8
—
—
0
0.42
0.25
0.07
0.10
0.03
0.05
0.01
0.05
0.07
0.04
0.01
0.07
0.11
0.06

SEQID-02823
F6HHU9
—
—
1
0.48
0.20
0.04
0.05
0.02
0.07
0.02
0.02
0.12
0.03
0.03
0.05
0.09
0.10

SEQID-02824
D7T7Y3
—
—
1
0.46
0.21
0.05
0.07
0.05
0.06
0.01
0.03
0.06
0.04
0.03
0.06
0.08
0.06

SEQID-02825
D7SJV3
—
—
1
0.47
0.23
0.05
0.06
0.05
0.06
0.01
0.06
0.09
0.02
0.02
0.06
0.11
0.07

SEQID-02826
F6HMP1
—
—
0
0.40
0.08
0.01
0.06
0.00
0.00
0.00
0.07
0.22
0.18
0.10
0.06
0.02
0.14

SEQID-02827
A5AML5
—
—
1
0.56
0.23
0.05
0.02
0.02
0.04
0.02
0.04
0.15
0.03
0.03
0.03
0.07
0.12

SEQID-02828
D75KR5
—
—
1
0.46
0.19
0.06
0.06
0.02
0.06
0.01
0.02
0.11
0.05
0.03
0.04
0.10
0.10

SEQID-02829
F6H3T7
—
—
1
0.46
0.22
0.06
0.07
0.03
0.05
0.02
0.03
0.07
0.04
0.02
0.06
0.09
0.06

SEQID-02830
D7TJ46
—
—
1
0.49
0.23
0.07
0.05
0.03
0.05
0.01
0.02
0.10
0.05
0.01
0.07
0.08
0.11

SEQID-02831
F6I0H8
—
—
1
0.52
0.27
0.04
0.03
0.08
0.05
0.01
0.03
0.09
0.04
0.02
0.07
0.11
0.11

SEQID-02832
F6HAM6
—
—
1
0.46
0.20
0.07
0.07
0.04
0.05
0.01
0.02
0.08
0.05
0.04
0.06
0.09
0.07

SEQID-02833
F6HMN8
—
—
1
0.49
0.22
0.06
0.06
0.03
0.06
0.01
0.03
0.08
0.03
0.02
0.06
0.09
0.09

SEQID-02834
D7T1R6
—
—
1
0.47
0.22
0.05
0.06
0.05
0.06
0.01
0.03
0.07
0.05
0.03
0.06
0.08
0.07

SEQID-02835
D7TLU7
—
—
1
0.50
0.25
0.07
0.04
0.05
0.03
0.02
0.03
0.10
0.05
0.02
0.06
0.07
0.09

SEQID-02836
F6H5V8
—
—
0
0.14
0.03
0.01
0.10
0.01
0.06
0.01
0.04
0.17
0.09
0.03
0.01
0.01
0.06

SEQID-02837
D7T0U8
—
—
1
0.48
0.21
0.07
0.05
0.04
0.06
0.02
0.02
0.05
0.04
0.02
0.06
0.06
0.09

SEQID-02838
A5AEI5
—
—
0
0.52
0.26
0.02
0.07
0.03
0.09
0.00
0.09
0.08
0.04
0.02
0.09
0.12
0.11

SEQID-02839
F6HGH4
—
—
1
0.47
0.22
0.05
0.07
0.04
0.06
0.01
0.04
0.03
0.05
0.01
0.07
0.09
0.09

SEQID-02840
F6GV71
—
—
1
0.45
0.23
0.06
0.05
0.06
0.04
0.04
0.04
0.07
0.04
0.03
0.07
0.09
0.06

SEQID-02841
F6HL03
—
—
1
0.48
0.20
0.05
0.06
0.05
0.06
0.02
0.04
0.07
0.05
0.04
0.05
0.08
0.06

SEQID-02842
D75QC6
—
—
1
0.45
0.17
0.04
0.07
0.03
0.05
0.01
0.05
0.10
0.03
0.02
0.05
0.07
0.09

SEQID-02843
A5B878
—
—
1
0.51
0.23
0.03
0.07
0.04
0.04
0.00
0.02
0.09
0.06
0.03
0.10
0.06
0.08

SEQID-02844
A5AKD3
—
—
1
0.52
0.17
0.05
0.04
0.04
0.04
0.02
0.02
0.05
0.09
0.04
0.05
0.04
0.09

SEQID-02845
A5BQN6
—
—
1
0.50
0.17
0.04
0.07
0.03
0.06
0.02
0.03
0.07
0.08
0.03
0.06
0.04
0.03

SEQID-02846
Q9M4H7
—
—
0
0.31
0.12
0.12
0.00
0.01
0.04
0.00
0.03
0.36
0.00
0.00
0.00
0.01
0.10

SEQID-02847
F6HUD1
—
—
1
0.47
0.20
0.04
0.02
0.05
0.07
0.02
0.05
0.06
0.04
0.01
0.06
0.09
0.12

SEQID-02848
C5DB51
—
—
1
0.51
0.26
0.06
0.07
0.04
0.06
0.02
0.02
0.09
0.04
0.01
0.08
0.10
0.09

SEQID-02849
D7TA34
—
—
1
0.49
0.22
0.05
0.06
0.06
0.05
0.01
0.03
0.10
0.03
0.03
0.06
0.09
0.03

SEQID-02850
F6HDX3
—
—
1
0.38
0.19
0.08
0.09
0.03
0.07
0.01
0.03
0.14
0.02
0.01
0.06
0.10
0.07

SEQID-02851
D75UQ2
—
—
1
0.49
0.20
0.04
0.07
0.05
0.05
0.02
0.05
0.06
0.02
0.04
0.06
0.10
0.09

SEQID-02852
D7FBC0
—
—
1
0.47
0.25
0.03
0.05
0.05
0.05
0.02
0.04
0.07
0.04
0.03
0.06
0.09
0.07

SEQID-02853
F6HFL6
—
—
1
0.42
0.20
0.07
0.07
0.04
0.03
0.01
0.06
0.09
0.04
0.01
0.04
0.09
0.07

SEQID-02854
D7TBL7
—
—
1
0.46
0.23
0.06
0.03
0.04
0.06
0.01
0.04
0.05
0.04
0.03
0.07
0.10
0.05

SEQID-02855
F6H1L2
—
—
1
0.42
0.17
0.04
0.07
0.05
0.06
0.02
0.05
0.09
0.04
0.02
0.04
0.07
0.04

SEQID-02856
F6HLZ6
—
—
1
0.43
0.18
0.04
0.07
0.05
0.06
0.02
0.05
0.10
0.04
0.02
0.04
0.03
0.04

SEQID-02857
D7TVX5
—
—
1
0.47
0.21
0.06
0.06
0.05
0.07
0.01
0.05
0.07
0.02
0.02
0.03
0.11
0.07

SEQID-02858
F6H710
—
—
1
0.47
0.23
0.06
0.05
0.03
0.06
0.02
0.04
0.09
0.04
0.03
0.06
0.09
0.09

SEQID-02859
F6HAU0
—
—
1
0.48
0.22
0.04
0.05
0.04
0.09
0.01
0.03
0.05
0.04
0.03
0.06
0.09
0.03

SEQID-02860
D7TJI9
—
—
1
0.46
0.23
0.06
0.06
0.05
0.05
0.02
0.03
0.07
0.05
0.03
0.07
0.08
0.05

SEQID-02861
F6H7B3
—
—
1
0.47
0.22
0.05
0.06
0.04
0.09
0.01
0.04
0.11
0.04
0.01
0.09
0.09
0.11

SEQID-02862
D7TVF4
—
—
1
0.49
0.23
0.03
0.05
0.04
0.05
0.02
0.03
0.09
0.04
0.01
0.07
0.09
0.10

SEQID-02863
D7TZ79
—
—
1
0.53
0.27
0.08
0.03
0.03
0.04
0.01
0.02
0.05
0.06
0.01
0.09
0.10
0.05

SEQID-02864
F6H2N7
—
—
1
0.45
0.22
0.05
0.10
0.03
0.07
0.01
0.05
0.09
0.03
0.03
0.06
0.12
0.06

SEQID-02865
F6HQM5
—
—
0
0.22
0.09
0.03
0.16
0.05
0.06
0.01
0.04
0.08
0.19
0.00
0.04
0.03
0.01

SEQID-02866
Q9FS43
—
—
0
0.52
0.20
0.06
0.02
0.01
0.07
0.02
0.02
0.09
0.05
0.06
0.07
0.04
0.12

SEQID-02867
F6GX20
—
—
1
0.44
0.25
0.04
0.09
0.06
0.06
0.02
0.04
0.09
0.06
0.01
0.09
0.09
0.06

SEQID-02868
F6HDT7
—
—
1
0.42
0.16
0.04
0.09
0.04
0.10
0.01
0.03
0.10
0.03
0.04
0.03
0.09
0.07

SEQID-02869
F6GU22
—
—
1
0.40
0.19
0.04
0.03
0.10
0.07
0.07
0.03
0.04
0.07
0.02
0.05
0.07
0.05

SEQID-02870
A5AX75
—
—
1
0.45
0.31
0.06
0.05
0.03
0.05
0.01
0.04
0.14
0.01
0.02
0.04
0.13
0.08

SEQID-02871
Q0MX16
—
—
1
0.53
0.25
0.09
0.05
0.03
0.03
0.01
0.03
0.05
0.06
0.02
0.09
0.09
0.05

SEQID-02872
A5AP38
—
—
1
0.42
0.18
0.05
0.07
0.05
0.06
0.01
0.03
0.09
0.06
0.03
0.09
0.06
0.06

SEQID-02873
D7SZX9
—
—
1
0.49
0.24
0.06
0.03
0.04
0.03
0.01
0.04
0.03
0.05
0.01
0.05
0.11
0.08

SEQID-02874
D7TMY3
—
—
1
0.48
0.24
0.06
0.08
0.03
0.06
0.03
0.03
0.08
0.05
0.03
0.06
0.03
0.06

SEQID-02875
D7TCC4
—
—
1
0.47
0.23
0.04
0.03
0.02
0.06
0.01
0.03
0.10
0.04
0.02
0.07
0.09
0.06

SEQID-02876
F6GUN5
—
—
1
0.46
0.20
0.08
0.12
0.05
0.04
0.00
0.03
0.05
0.04
0.02
0.06
0.06
0.12

SEQID-02877
D7TVX4
—
—
1
0.47
0.21
0.03
0.09
0.04
0.06
0.02
0.03
0.07
0.03
0.03
0.04
0.10
0.07

SEQID-02878
D7UD99
—
—
1
0.44
0.17
0.03
0.10
0.06
0.06
0.01
0.03
0.06
0.03
0.05
0.05
0.07
0.05

SEQID-02879
F6I0K4
—
—
1
0.45
0.17
0.03
0.09
0.06
0.07
0.01
0.03
0.07
0.03
0.05
0.04
0.06
0.06

SEQID-02880
F6GTT4
—
—
1
0.51
0.23
0.03
0.06
0.04
0.06
0.01
0.03
0.09
0.04
0.02
0.07
0.03
0.10

SEQID-02881
F6GTT2
—
—
0
0.44
0.25
0.07
0.09
0.03
0.05
0.00
0.05
0.09
0.05
0.02
0.07
0.10
0.05

SEQID-02882
F6HEU9
—
—
1
0.34
0.16
0.05
0.05
0.04
0.06
0.01
0.13
0.03
0.03
0.04
0.04
0.07
0.03

SEQID-02883
Q4U339
—
—
1
0.51
0.28
0.05
0.05
0.01
0.04
0.01
0.04
0.07
0.05
0.01
0.08
0.13
0.03

SEQID-02884
F6HYG1
—
—
1
0.44
0.19
0.06
0.06
0.04
0.07
0.02
0.05
0.11
0.03
0.02
0.05
0.07
0.09

SEQID-02885
F6HFK7
—
—
1
0.39
0.18
0.07
0.08
0.04
0.05
0.01
0.09
0.09
0.02
0.02
0.05
0.10
0.06

SEQID-02886
A58M68
—
—
1
0.51
0.21
0.03
0.02
0.02
0.09
0.01
0.05
0.11
0.04
0.01
0.04
0.11
0.11

SEQID-02887
F6H8W9
—
—
1
0.52
0.25
0.07
0.03
0.04
0.04
0.01
0.05
0.05
0.04
0.02
0.06
0.09
0.09

SEQID-02888
A5B3K2
—
—
0
0.49
0.18
0.06
0.01
0.02
0.03
0.01
0.01
0.22
0.02
0.00
0.05
0.05
0.17

SEQID-02889
D7SYA1
—
—
1
0.46
0.15
0.05
0.19
0.03
0.02
0.00
0.03
0.07
0.02
0.03
0.03
0.07
0.18

SEQID-02890
D7U394
—
—
1
0.54
0.25
0.05
0.04
0.03
0.05
0.03
0.03
0.07
0.06
0.03
0.05
0.07
0.03

SEQID-02891
D7T745
—
—
1
0.46
0.21
0.06
0.06
0.04
0.07
0.02
0.03
0.07
0.04
0.04
0.03
0.10
0.06

SEQID-02892
A5BIQ8
—
—
1
0.48
0.20
0.04
0.14
0.01
0.04
0.01
0.03
0.07
0.07
0.02
0.05
0.06
0.10

SEQID-02893
Q5PXH0
—
—
1
0.53
0.25
0.09
0.05
0.02
0.04
0.01
0.02
0.03
0.06
0.03
0.09
0.09
0.04

SEQID-02894
F6I0K9
—
—
1
0.47
0.24
0.05
0.05
0.04
0.05
0.00
0.04
0.03
0.04
0.02
0.10
0.06
0.09

SEQID-02895
D7U9L9
—
—
1
0.46
0.23
0.05
0.08
0.03
0.06
0.01
0.02
0.10
0.04
0.03
0.08
0.09
0.08

SEQID-02896
A5BIN1
—
—
1
0.46
0.22
0.03
0.09
0.07
0.05
0.01
0.03
0.08
0.04
0.03
0.07
0.08
0.06

SEQID-02897
F6GSQ2
—
—
1
0.44
0.21
0.05
0.07
0.04
0.05
0.02
0.03
0.09
0.06
0.04
0.08
0.03
0.06

SEQID-02898
F6GY49
—
—
1
0.53
0.17
0.04
0.11
0.01
0.03
0.01
0.05
0.07
0.04
0.05
0.05
0.05
0.15

SEQID-02899
F6H2P8
—
—
1
0.49
0.26
0.07
0.06
0.03
0.05
0.02
0.03
0.07
0.04
0.02
0.06
0.12
0.08

SEQID-02900
F6H7I5
—
—
1
0.47
0.24
0.05
0.03
0.03
0.07
0.00
0.03
0.06
0.04
0.02
0.08
0.07
0.09

SEQID-02901
D7TIZ5
—
—
1
0.52
0.26
0.06
0.05
0.03
0.06
0.01
0.03
0.07
0.03
0.03
0.06
0.10
0.09

SEQID-02902
F6I1W0
—
—
1
0.49
0.22
0.04
0.07
0.05
0.05
0.01
0.02
0.10
0.03
0.02
0.06
0.08
0.07

SEQID-02903
F6HXL0
—
—
1
0.43
0.22
0.05
0.07
0.03
0.05
0.02
0.05
0.09
0.04
0.02
0.06
0.09
0.06

SEQID-02904
F6HUX3
—
—
1
0.34
0.16
0.03
0.05
0.05
0.05
0.00
0.12
0.05
0.05
0.03
0.03
0.09
0.04

SEQID-02905
F6HSN5
—
—
1
0.46
0.23
0.09
0.06
0.03
0.06
0.02
0.03
0.06
0.05
0.02
0.05
0.10
0.06

SEQID-02906
F6I6WS
—
—
1
0.47
0.23
0.05
0.05
0.04
0.05
0.02
0.06
0.06
0.04
0.03
0.05
0.12
0.09

SEQID-02907
E0CR04
—
—
1
0.47
0.23
0.04
0.06
0.05
0.05
0.01
0.04
0.07
0.04
0.02
0.06
0.10
0.08

SEQID-02908
F6HCU9
—
—
1
0.49
0.21
0.03
0.05
0.04
0.07
0.01
0.03
0.14
0.03
0.02
0.06
0.09
0.13

SEQID-02909
F6HH37
—
—
1
0.34
0.18
0.02
0.04
0.05
0.03
0.02
0.02
0.04
0.02
0.04
0.04
0.09
0.03

SEQID-02910
F6HES2
—
—
0
0.41
0.23
0.05
0.02
0.04
0.09
0.01
0.02
0.20
0.02
0.02
0.04
0.06
0.10

SEQID-02911
F6GUN0
—
—
1
0.44
0.24
0.07
0.06
0.03
0.06
0.02
0.07
0.09
0.02
0.02
0.05
0.13
0.05

SEQID-02912
A5BAX1
—
—
1
0.52
0.20
0.03
0.02
0.04
0.06
0.02
0.03
0.14
0.03
0.06
0.09
0.07
0.11

SEQID-02913
A5C3I9
—
—
0
0.50
0.20
0.04
0.04
0.03
0.11
0.02
0.04
0.07
0.05
0.06
0.07
0.06
0.11

SEQID-02914
A5C718
—
—
1
0.46
0.16
0.05
0.03
0.04
0.04
0.03
0.04
0.05
0.03
0.03
0.05
0.07
0.06

SEQID-02915
D7SJX8
—
—
1
0.57
0.22
0.03
0.04
0.03
0.05
0.00
0.02
0.07
0.07
0.03
0.05
0.10
0.11

SEQID-02916
D7UC61
—
—
1
0.46
0.15
0.09
0.04
0.04
0.04
0.01
0.02
0.17
0.02
0.01
0.02
0.06
0.19

SEQID-02917
F6HUH1
—
—
1
0.42
0.15
0.03
0.05
0.07
0.07
0.07
0.03
0.03
0.05
0.01
0.04
0.09
0.04

SEQID-02918
D7T5I6
—
—
1
0.44
0.22
0.06
0.04
0.05
0.06
0.02
0.04
0.11
0.03
0.02
0.06
0.11
0.06

SEQID-02919
D7SGX1
—
—
1
0.47
0.25
0.06
0.04
0.02
0.09
0.01
0.02
0.11
0.03
0.02
0.07
0.10
0.10

SEQID-02920
F6GSZ1
—
—
0
0.25
0.11
0.05
0.09
0.04
0.07
0.00
0.03
0.05
0.17
0.01
0.03
0.03
0.02

SEQID-02921
A5B427
—
—
1
0.50
0.24
0.04
0.06
0.04
0.07
0.01
0.00
0.08
0.04
0.05
0.06
0.11
0.05

SEQID-02922
F6H6J3
—
—
1
0.33
0.18
0.06
0.03
0.02
0.11
0.00
0.04
0.05
0.06
0.02
0.03
0.07
0.05

SEQID-02923
D7TD80
—
—
1
0.49
0.20
0.04
0.05
0.05
0.03
0.01
0.06
0.10
0.03
0.02
0.06
0.07
0.10

SEQID-02924
F6I229
—
—
1
0.46
0.18
0.06
0.04
0.02
0.06
0.01
0.05
0.09
0.05
0.00
0.04
0.09
0.11

SEQID-02925
A5BV59
—
—
1
0.50
0.22
0.05
0.08
0.03
0.09
0.02
0.02
0.04
0.04
0.03
0.06
0.09
0.07

SEQID-02926
D7SJS6
—
—
1
0.49
0.26
0.05
0.05
0.03
0.06
0.02
0.03
0.09
0.04
0.03
0.06
0.11
0.09

SEQID-02927
D7TWQ4
—
—
1
0.48
0.22
0.07
0.06
0.04
0.06
0.01
0.04
0.06
0.04
0.05
0.07
0.09
0.09

SEQID-02928
F6GU55
—
—
1
0.45
0.20
0.07
0.09
0.04
0.05
0.01
0.05
0.02
0.05
0.02
0.05
0.09
0.09

SEQID-02929
F6HUT2
—
—
1
0.42
0.19
0.06
0.06
0.05
0.06
0.02
0.06
0.03
0.05
0.03
0.07
0.09
0.04

SEQID-02930
F6HDW4
—
—
1
0.49
0.18
0.04
0.07
0.05
0.05
0.02
0.02
0.10
0.05
0.03
0.07
0.07
0.09

SEQID-02931
A5BF93
—
—
1
0.49
0.26
0.07
0.05
0.05
0.07
0.02
0.05
0.08
0.05
0.01
0.09
0.09
0.10

SEQID-02932
F6GZN9
—
—
1
0.49
0.19
0.05
0.05
0.04
0.07
0.02
0.02
0.09
0.03
0.03
0.06
0.09
0.07

SEQID-02933
D7SYS5
—
—
1
0.44
0.18
0.04
0.03
0.04
0.06
0.02
0.03
0.07
0.04
0.02
0.05
0.09
0.06

SEQID-02934
F6H955
—
—
0
0.41
0.20
0.04
0.07
0.04
0.09
0.02
0.07
0.09
0.06
0.04
0.06
0.09
0.07

SEQID-02935
F6HKX8
—
—
1
0.41
0.19
0.04
0.09
0.02
0.05
0.05
0.03
0.09
0.04
0.04
0.06
0.06
0.06

SEQID-02936
A5BZF5
—
—
1
0.43
0.21
0.05
0.07
0.04
0.07
0.02
0.04
0.09
0.04
0.03
0.05
0.09
0.05

SEQID-02937
D7T5P6
—
—
1
0.39
0.17
0.05
0.07
0.04
0.07
0.01
0.03
0.06
0.03
0.02
0.05
0.07
0.07

SEQID-02938
D7TW33
—
—
1
0.45
0.19
0.05
0.04
0.04
0.06
0.03
0.04
0.07
0.04
0.03
0.03
0.09
0.09

SEQID-02939
P56643
—
—
1
0.46
0.19
0.06
0.09
0.03
0.05
0.02
0.03
0.08
0.05
0.04
0.05
0.09
0.06

SEQID-02940
D75TI8
—
—
1
0.45
0.22
0.05
0.03
0.06
0.06
0.02
0.04
0.06
0.05
0.04
0.09
0.07
0.06

SEQID-02941
D7TK33
—
—
1
0.49
0.22
0.04
0.08
0.03
0.07
0.02
0.03
0.09
0.05
0.06
0.07
0.09
0.05

SEQID-02942
D7SYK8
—
—
1
0.47
0.23
0.06
0.07
0.03
0.05
0.01
0.04
0.07
0.05
0.03
0.09
0.03
0.07

SEQID-02943
D7SS06
—
—
1
0.46
0.22
0.06
0.07
0.03
0.06
0.01
0.04
0.08
0.04
0.02
0.05
0.10
0.06

SEQID-02944
D7SH83
—
—
1
0.46
0.21
0.06
0.07
0.03
0.06
0.01
0.04
0.10
0.03
0.03
0.05
0.09
0.09

SEQID-02945
F6HHX2
—
—
1
0.43
0.20
0.05
0.05
0.05
0.05
0.01
0.06
0.09
0.04
0.02
0.04
0.09
0.06

SEQID-02946
F6HTM3
—
—
1
0.43
0.23
0.06
0.05
0.03
0.04
0.00
0.09
0.21
0.01
0.03
0.04
0.14
0.10

SEQID-02947
D7SZW5
—
—
1
0.48
0.22
0.03
0.03
0.02
0.02
0.02
0.04
0.10
0.08
0.01
0.03
0.09
0.11

SEQID-02948
A5AQ89
—
—
1
0.48
0.23
0.06
0.02
0.02
0.06
0.02
0.07
0.07
0.07
0.02
0.10
0.09
0.05

SEQID-02949
D7TBK8
—
—
1
0.52
0.26
0.07
0.03
0.02
0.09
0.01
0.03
0.06
0.05
0.02
0.06
0.10
0.10

SEQID-02950
A5B7Q8
—
—
1
0.44
0.19
0.02
0.07
0.04
0.06
0.02
0.07
0.10
0.05
0.02
0.06
0.08
0.06

SEQID-02951
D7SIH0
—
—
0
0.52
0.22
0.06
0.06
0.05
0.05
0.01
0.03
0.04
0.03
0.01
0.05
0.09
0.09

SEQID-02952
A5BYC0
—
—
1
0.47
0.23
0.07
0.06
0.04
0.07
0.01
0.02
0.06
0.04
0.04
0.07
0.09
0.07

SEQID-02953
D7SPB2
—
—
1
0.44
0.22
0.04
0.09
0.04
0.09
0.01
0.02
0.09
0.03
0.05
0.09
0.07
0.07

SEQID-02954
D7SLS3
—
—
1
0.42
0.16
0.03
0.21
0.04
0.02
0.01
0.04
0.04
0.03
0.04
0.04
0.06
0.10

SEQID-02955
D7T475
—
—
1
0.52
0.24
0.06
0.02
0.03
0.04
0.01
0.02
0.11
0.04
0.01
0.05
0.09
0.11

SEQID-02956
D7U7S6
—
—
1
0.42
0.20
0.06
0.06
0.05
0.07
0.03
0.05
0.04
0.03
0.02
0.05
0.10
0.07

SEQID-02957
D7T6Q0
—
—
1
0.48
0.22
0.08
0.02
0.02
0.06
0.02
0.03
0.07
0.05
0.04
0.05
0.08
0.10

SEQID-02958
D7TPB9
—
—
1
0.50
0.22
0.07
0.03
0.02
0.06
0.02
0.03
0.09
0.04
0.03
0.05
0.06
0.09

SEQID-02959
F6H4V0
—
—
1
0.50
0.19
0.03
0.05
0.03
0.05
0.02
0.02
0.12
0.03
0.04
0.04
0.09
0.10

SEQID-02960
D7TRL3
—
—
0
0.45
0.18
0.04
0.16
0.02
0.04
0.02
0.05
0.07
0.04
0.00
0.04
0.09
0.15

SEQID-02961
D7TU16
—
—
1
0.48
0.23
0.07
0.06
0.03
0.09
0.01
0.02
0.09
0.03
0.02
0.05
0.13
0.09

SEQID-02962
D7UCH9
—
—
1
0.56
0.28
0.06
0.04
0.02
0.05
0.01
0.01
0.06
0.03
0.04
0.09
0.13
0.10

SEQID-02963
E0CQY0
—
—
1
0.45
0.16
0.06
0.05
0.07
0.04
0.03
0.06
0.01
0.06
0.02
0.04
0.05
0.05

SEQID-02964
E0CSN8
—
—
1
0.45
0.17
0.06
0.07
0.04
0.07
0.02
0.01
0.06
0.05
0.03
0.03
0.09
0.06

SEQID-02965
D7T4T3
—
—
1
0.46
0.22
0.04
0.05
0.03
0.06
0.03
0.07
0.09
0.04
0.05
0.04
0.09
0.06

SEQID-02966
F6GU78
—
—
1
0.43
0.18
0.03
0.10
0.05
0.09
0.02
0.03
0.11
0.04
0.01
0.03
0.09
0.11

SEQID-02967
D75R32
—
—
1
0.44
0.19
0.09
0.04
0.05
0.06
0.02
0.06
0.13
0.02
0.02
0.04
0.11
0.11

SEQID-02968
D7THS4
—
—
1
0.49
0.17
0.05
0.02
0.05
0.06
0.02
0.04
0.06
0.04
0.05
0.05
0.09
0.08

SEQID-02969
F6HQD3
—
—
1
0.47
0.21
0.04
0.07
0.03
0.07
0.02
0.01
0.09
0.04
0.05
0.05
0.08
0.05

SEQID-02970
F6GUL7
—
—
1
0.50
0.22
0.04
0.11
0.04
0.05
0.01
0.03
0.05
0.05
0.03
0.07
0.09
0.11

SEQID-02971
F6GX19
—
—
1
0.48
0.21
0.04
0.09
0.04
0.07
0.02
0.02
0.09
0.02
0.04
0.03
0.13
0.07

SEQID-02972
F6HQD6
—
—
1
0.49
0.21
0.05
0.05
0.05
0.06
0.01
0.02
0.07
0.04
0.07
0.04
0.09
0.07

SEQID-02973
D7TM77
—
—
1
0.47
0.20
0.06
0.03
0.05
0.05
0.03
0.04
0.10
0.04
0.03
0.06
0.07
0.09

SEQID-02974
F6HKS7
—
—
1
0.49
0.30
0.07
0.05
0.03
0.05
0.00
0.04
0.06
0.05
0.04
0.05
0.10
0.06

SEQID-02975
A5ARE0
—
—
1
0.51
0.24
0.04
0.04
0.04
0.06
0.01
0.02
0.08
0.06
0.02
0.05
0.10
0.08

SEQID-02976
D7TVP9
—
—
1
0.46
0.19
0.05
0.09
0.04
0.09
0.01
0.04
0.07
0.04
0.05
0.04
0.09
0.06

SEQID-02977
F6HL98
—
—
1
0.50
0.25
0.02
0.05
0.07
0.05
0.03
0.03
0.03
0.03
0.03
0.05
0.17
0.09

SEQID-02978
F6HBC6
—
—
1
0.50
0.22
0.06
0.04
0.04
0.05
0.01
0.03
0.06
0.05
0.02
0.05
0.11
0.09

SEQID-02979
D7TA50
—
—
1
0.48
0.23
0.07
0.03
0.02
0.05
0.03
0.04
0.07
0.05
0.04
0.06
0.09
0.06

SEQID-02980
D7T3J3
—
—
1
0.47
0.19
0.05
0.06
0.06
0.07
0.01
0.03
0.07
0.04
0.04
0.06
0.10
0.06

SEQID-02981
D7TKK5
—
—
1
0.49
0.22
0.05
0.06
0.04
0.07
0.02
0.04
0.10
0.03
0.03
0.08
0.08
0.11

SEQID-02982
D7U0Q3
—
—
1
0.48
0.24
0.05
0.06
0.04
0.05
0.01
0.04
0.07
0.04
0.02
0.04
0.11
0.07

SEQID-02983
F6I4H0
—
—
1
0.50
0.21
0.05
0.06
0.03
0.08
0.02
0.03
0.07
0.05
0.04
0.07
0.07
0.09

SEQID-02984
A5ALT5
—
—
0
0.41
0.16
0.03
0.07
0.03
0.07
0.03
0.08
0.11
0.05
0.02
0.04
0.07
0.11

SEQID-02985
D7T6C5
—
—
0
0.44
0.23
0.05
0.08
0.04
0.09
0.01
0.05
0.10
0.03
0.01
0.07
0.11
0.09

SEQID-02986
F6H0K6
—
—
1
0.43
0.19
0.07
0.06
0.03
0.06
0.01
0.03
0.09
0.04
0.02
0.04
0.11
0.09

SEQID-02987
F6GY09
—
—
1
0.47
0.21
0.04
0.07
0.06
0.07
0.01
0.04
0.09
0.04
0.02
0.06
0.10
0.08

SEQID-02988
F6HK38
—
—
1
0.50
0.18
0.05
0.05
0.05
0.04
0.01
0.03
0.10
0.03
0.02
0.05
0.09
0.12

SEQID-02989
F6HE13
—
—
1
0.34
0.14
0.05
0.06
0.05
0.04
0.02
0.14
0.05
0.05
0.01
0.03
0.06
0.03

SEQID-02990
D7TCZ8
—
—
1
0.47
0.19
0.04
0.07
0.04
0.07
0.01
0.03
0.09
0.04
0.04
0.05
0.09
0.07

SEQID-02991
F6GST3
—
—
1
0.44
0.22
0.05
0.08
0.04
0.05
0.01
0.04
0.09
0.04
0.02
0.06
0.10
0.07

SEQID-02992
F6HKF1
—
—
1
0.48
0.23
0.04
0.07
0.03
0.07
0.02
0.05
0.07
0.03
0.02
0.07
0.10
0.09

SEQID-02993
D7U4US
—
—
1
0.44
0.22
0.04
0.09
0.06
0.05
0.01
0.05
0.03
0.05
0.02
0.07
0.08
0.04

SEQID-02994
F6HY11
—
—
1
0.49
0.24
0.08
0.04
0.03
0.05
0.02
0.02
0.07
0.05
0.02
0.05
0.11
0.09

SEQID-02995
D7SIX7
—
—
1
0.47
0.28
0.06
0.08
0.03
0.07
0.02
0.05
0.08
0.02
0.02
0.07
0.14
0.05

SEQID-02996
F6H392
—
—
1
0.24
0.09
0.07
0.04
0.04
0.04
0.00
0.15
0.04
0.07
0.01
0.04
0.02
0.03

SEQID-02997
E0CSK6
—
—
0
0.47
0.24
0.05
0.09
0.05
0.06
0.01
0.05
0.08
0.04
0.03
0.09
0.10
0.07

SEQID-02998
Q07J21
—
—
1
0.55
0.22
0.06
0.05
0.04
0.04
0.00
0.05
0.03
0.05
0.07
0.06
0.12
0.02

SEQID-02999
E0CQR2
—
—
1
0.43
0.16
0.04
0.07
0.05
0.07
0.01
0.02
0.09
0.04
0.04
0.04
0.07
0.05

SEQID-03000
D7SRR6
—
—
0
0.34
0.18
0.05
0.08
0.07
0.05
0.01
0.10
0.06
0.06
0.03
0.04
0.08
0.02

SEQID-03001
D7STT1
—
—
1
0.47
0.22
0.06
0.06
0.04
0.06
0.02
0.04
0.09
0.03
0.02
0.05
0.10
0.06

SEQID-03002
F6HH36
—
—
1
0.45
0.21
0.04
0.07
0.05
0.06
0.02
0.03
0.09
0.03
0.03
0.06
0.09
0.05

SEQID-03003
A5AHP0
—
—
1
0.49
0.29
0.04
0.07
0.05
0.06
0.02
0.05
0.08
0.02
0.02
0.09
0.13
0.07

SEQID-03004
F6GUM1
—
—
1
0.46
0.21
0.05
0.06
0.06
0.07
0.02
0.04
0.08
0.03
0.03
0.05
0.10
0.06

SEQID-03005
D7T3A6
—
—
1
0.46
0.20
0.03
0.07
0.04
0.07
0.01
0.06
0.10
0.02
0.04
0.05
0.09
0.08

SEQID-03006
6273402
—
—
1
0.41
0.17
0.04
0.09
0.06
0.05
0.01
0.08
0.09
0.03
0.03
0.04
0.09
0.06

SEQID-03007
83173888
—
—
0
0.44
0.26
0.02
0.09
0.06
0.04
0.00
0.07
0.12
0.02
0.02
0.09
0.11
0.07

SEQID-03008
21952337
—
—
1
0.48
0.22
0.06
0.06
0.04
0.06
0.01
0.03
0.08
0.03
0.02
0.06
0.09
0.09

SEQID-03009
367460278
—
—
1
0.46
0.16
0.05
0.06
0.06
0.08
0.01
0.00
0.05
0.04
0.01
0.09
0.06
0.09

SEQID-03010
2103286
—
—
1
0.39
0.16
0.04
0.08
0.06
0.02
0.03
0.09
0.11
0.04
0.02
0.03
0.11
0.04

SEQID-03011
3319882
—
—
1
0.52
0.22
0.04
0.05
0.04
0.06
0.01
0.03
0.09
0.04
0.02
0.06
0.07
0.13

SEQID-03012
301131212
—
—
1
0.47
0.21
0.05
0.07
0.02
0.06
0.01
0.03
0.09
0.04
0.03
0.08
0.07
0.06

SEQID-03013
21068668
—
—
1
0.47
0.22
0.03
0.10
0.06
0.08
0.00
0.01
0.12
0.01
0.03
0.06
0.09
0.05

SEQID-03014
3021333
—
—
1
0.46
0.24
0.08
0.05
0.05
0.04
0.01
0.04
0.09
0.05
0.02
0.05
0.11
0.08

SEQID-03015
13437787
—
—
1
0.43
0.22
0.06
0.08
0.05
0.06
0.01
0.03
0.06
0.04
0.02
0.09
0.09
0.07

SEQID-03016
3413165
—
—
1
0.52
0.25
0.06
0.05
0.04
0.08
0.01
0.01
0.06
0.04
0.01
0.09
0.09
0.09

SEQID-03017
3175990
—
—
1
0.48
0.22
0.04
0.05
0.04
0.09
0.01
0.02
0.07
0.04
0.03
0.05
0.10
0.09

SEQID-03018
197089784
—
—
1
0.46
0.20
0.06
0.09
0.03
0.06
0.02
0.03
0.08
0.05
0.04
0.05
0.09
0.06

SEQID-03019
38566732
—
—
1
0.52
0.17
0.03
0.02
0.04
0.04
0.02
0.04
0.06
0.09
0.04
0.05
0.04
0.12

SEQID-03020
10334493
—
—
1
0.47
0.25
0.07
0.05
0.05
0.05
0.02
0.04
0.07
0.04
0.03
0.06
0.09
0.07

SEQID-03021
4586588
—
—
1
0.53
0.18
0.06
0.07
0.02
0.06
0.03
0.02
0.07
0.04
0.03
0.09
0.06
0.12

SEQID-03022
143612111
—
—
1
0.39
0.19
0.07
0.08
0.04
0.07
0.01
0.03
0.14
0.02
0.01
0.06
0.10
0.07

SEQID-03023
10334503
—
—
1
0.46
0.19
0.05
0.06
0.05
0.07
0.02
0.07
0.07
0.03
0.04
0.05
0.07
0.09

SEQID-03024
4586594
—
—
0
0.55
0.26
0.02
0.05
0.03
0.09
0.00
0.08
0.07
0.03
0.01
0.10
0.10
0.12

SEQID-03025
20975622
—
—
1
0.53
0.20
0.02
0.02
0.05
0.03
0.02
0.04
0.09
0.03
0.07
0.05
0.08
0.12

SEQID-03026
228552592
—
—
1
0.40
0.19
0.06
0.07
0.05
0.07
0.01
0.03
0.14
0.02
0.02
0.05
0.09
0.09

SEQID-03027
7208773
—
—
1
0.48
0.24
0.04
0.06
0.04
0.06
0.01
0.05
0.09
0.03
0.03
0.09
0.11
0.07

SEQID-03028
3043428
—
—
1
0.44
0.24
0.06
0.13
0.06
0.06
0.01
0.04
0.05
0.02
0.03
0.09
0.07
0.09

SEQID-03029
60219077
—
—
1
0.49
0.23
0.05
0.06
0.04
0.06
0.02
0.04
0.09
0.04
0.02
0.07
0.09
0.07

SEQID-03030
84569909
—
—
1
0.44
0.16
0.05
0.09
0.04
0.08
0.11
0.02
0.06
0.03
0.03
0.01
0.09
0.09

SEQID-03031
7208784
—
—
1
0.53
0.19
0.04
0.07
0.03
0.06
0.00
0.03
0.05
0.04
0.03
0.03
0.09
0.18

SEQID-03032
207003822
—
—
0
0.54
0.17
0.08
0.05
0.02
0.02
0.00
0.02
0.10
0.02
0.02
0.07
0.04
0.23

SEQID-03033
499171
—
—
0
0.47
0.21
0.06
0.01
0.05
0.04
0.01
0.03
0.11
0.06
0.02
0.06
0.06
0.13

SEQID-03034
219725672
—
—
1
0.43
0.19
0.09
0.07
0.05
0.07
0.01
0.07
0.06
0.03
0.02
0.09
0.06
0.04

SEQID-03035
315440443
—
—
0
0.49
0.09
0.09
0.04
0.04
0.03
0.00
0.04
0.10
0.08
0.03
0.01
0.01
0.12

SEQID-03036
45720184
—
—
1
0.49
0.25
0.06
0.09
0.02
0.06
0.02
0.03
0.10
0.03
0.06
0.06
0.07
0.06

SEQID-03037
4586580
—
—
1
0.43
0.19
0.06
0.06
0.07
0.07
0.02
0.06
0.06
0.03
0.01
0.07
0.07
0.07

SEQID-03038
6469141
—
—
1
0.47
0.22
0.03
0.09
0.07
0.06
0.01
0.03
0.07
0.04
0.03
0.06
0.09
0.07

SEQID-03039
6850936
—
—
0
0.52
0.28
0.09
0.07
0.04
0.09
0.01
0.05
0.05
0.03
0.02
0.08
0.12
0.11

SEQID-03040
4586578
—
—
1
0.53
0.26
0.06
0.07
0.05
0.04
0.03
0.01
0.07
0.06
0.01
0.12
0.08
0.08

SEQID-03041
O65759
—
—
0
0.44
0.23
0.03
0.10
0.05
0.02
0.00
0.04
0.07
0.06
0.02
0.05
0.11
0.11

SEQID-03042
O49817
—
—
0
0.40
0.03
0.10
0.04
0.03
0.03
0.00
0.17
0.08
0.04
0.02
0.01
0.01
0.16

SEQID-03043
3928152
—
—
1
0.50
0.21
0.04
0.06
0.04
0.02
0.02
0.04
0.08
0.03
0.02
0.04
0.08
0.03

SEQID-03044
21684781
—
—
1
0.43
0.18
0.03
0.09
0.07
0.06
0.01
0.04
0.05
0.04
0.04
0.05
0.09
0.06

SEQID-03045
K9I869
—
—
1
0.50
0.20
0.05
0.06
0.05
0.09
0.00
0.03
0.05
0.04
0.04
0.06
0.03
0.07

SEQID-03046
K9I432
—
—
1
0.54
0.18
0.04
0.11
0.02
0.04
0.00
0.02
0.06
0.04
0.06
0.05
0.06
0.13

SEQID-03047
K9HSF5
—
—
1
0.53
0.26
0.06
0.02
0.05
0.05
0.01
0.07
0.06
0.05
0.04
0.07
0.10
0.09

SEQID-03048
K9HCC6
—
—
1
0.49
0.23
0.07
0.04
0.06
0.05
0.01
0.06
0.04
0.04
0.02
0.08
0.06
0.07

SEQID-03049
K9HXR0
—
—
1
0.46
0.21
0.06
0.09
0.04
0.07
0.00
0.05
0.09
0.03
0.01
0.05
0.09
0.09

SEQID-03050
K9HXM3
—
—
1
0.49
0.23
0.04
0.07
0.04
0.07
0.01
0.04
0.08
0.04
0.02
0.06
0.03
0.09

SEQID-03051
K9HHN3
—
—
1
0.43
0.20
0.03
0.0s
0.05
0.07
0.00
0.04
0.04
0.04
0.04
0.03
0.09
0.09

SEQID-03052
K9I0P5
—
—
1
0.46
0.19
0.05
0.07
0.06
0.06
0.01
0.01
0.07
0.03
0.04
0.07
0.06
0.07

SEQID-03053
K9I1X4
—
—
1
0.44
0.24
0.07
0.10
0.03
0.05
0.01
0.05
0.07
0.05
0.01
0.07
0.10
0.06

SEQID-03054
K9HML4
—
—
1
0.45
0.23
0.07
0.07
0.04
0.06
0.01
0.04
0.09
0.03
0.02
0.06
0.09
0.06

SEQID-03055
KSHHZ0
—
—
1
0.46
0.22
0.06
0.03
0.03
0.06
0.01
0.05
0.07
0.05
0.03
0.07
0.07
0.06

SEQID-03056
K9HIT2
—
—
1
0.48
0.24
0.06
0.07
0.05
0.06
0.01
0.04
0.07
0.04
0.03
0.06
0.10
0.08

SEQID-03057
K9HU82
—
—
1
0.46
0.21
0.07
0.07
0.02
0.05
0.00
0.05
0.08
0.04
0.03
0.07
0.07
0.07

SEQID-03058
K9I9C0
—
—
1
0.42
0.20
0.06
0.07
0.05
0.07
0.00
0.04
0.10
0.05
0.01
0.07
0.07
0.03

SEQID-03059
K9HD94
—
—
1
0.47
0.24
0.05
0.09
0.03
0.05
0.02
0.05
0.09
0.03
0.03
0.09
0.09
0.06

SEQID-03060
K9ICT4
—
—
0
0.42
0.21
0.06
0.11
0.01
0.03
0.01
0.07
0.11
0.04
0.02
0.04
0.09
0.09

SEQID-03061
K9HUL5
—
—
1
0.47
0.23
0.07
0.03
0.05
0.06
0.00
0.04
0.08
0.05
0.02
0.09
0.09
0.10

SEQID-03062
K9HE05
—
—
1
0.53
0.21
0.05
0.03
0.05
0.04
0.01
0.05
0.07
0.05
0.03
0.07
0.07
0.08

SEQID-03063
K9HNG2
—
—
1
0.45
0.20
0.07
0.15
0.04
0.03
0.01
0.03
0.04
0.06
0.06
0.07
0.06
0.09

SEQID-03064
K9HUX9
—
—
1
0.47
0.22
0.07
0.07
0.04
0.06
0.01
0.04
0.06
0.04
0.03
0.06
0.10
0.06

SEQID-03065
K9IBU7
—
—
1
0.53
0.21
0.05
0.05
0.04
0.06
0.01
0.02
0.08
0.05
0.03
0.09
0.05
0.13

SEQID-03066
K9HFT9
—
—
1
0.51
0.20
0.06
0.05
0.05
0.06
0.00
0.05
0.06
0.04
0.04
0.06
0.09
0.08

SEQID-03067
K9I536
—
—
1
0.47
0.31
0.07
0.07
0.02
0.07
0.01
0.04
0.06
0.06
0.04
0.04
0.09
0.09

SEQID-03068
K9HV44
—
—
1
0.48
0.21
0.05
0.06
0.04
0.07
0.00
0.03
0.07
0.03
0.01
0.05
0.10
0.08

SEQID-03069
K9I985
—
—
1
0.45
0.22
0.06
0.03
0.05
0.05
0.00
0.04
0.09
0.03
0.03
0.05
0.11
0.06

SEQID-03070
K9HT30
—
—
0
0.47
0.24
0.08
0.06
0.05
0.05
0.00
0.02
0.09
0.04
0.01
0.06
0.09
0.07

SEQID-03071
K9I6L1
—
—
1
0.41
0.16
0.07
0.11
0.02
0.07
0.00
0.03
0.12
0.03
0.02
0.04
0.07
0.12

SEQID-03072
K9H8Q7
—
—
1
0.48
0.23
0.06
0.06
0.05
0.07
0.01
0.02
0.05
0.05
0.02
0.07
0.06
0.09

SEQID-03073
K9HHA9
—
—
1
0.46
0.21
0.05
0.07
0.03
0.06
0.02
0.04
0.09
0.04
0.03
0.07
0.09
0.06

SEQID-03074
K9HDW7
—
—
1
0.45
0.20
0.06
0.06
0.03
0.03
0.01
0.05
0.10
0.06
0.02
0.05
0.09
0.07

SEQID-03075
K9H7U6
—
—
1
0.47
0.17
0.05
0.07
0.05
0.09
0.01
0.05
0.06
0.04
0.05
0.06
0.07
0.07

SEQID-03076
K9HES3
—
—
1
0.46
0.21
0.04
0.03
0.05
0.05
0.01
0.04
0.09
0.03
0.03
0.06
0.10
0.07

SEQID-03077
K9HVW3
—
—
1
0.51
0.22
0.05
0.13
0.02
0.03
0.01
0.04
0.05
0.03
0.05
0.05
0.10
0.13

SEQID-03078
K9HRT5
—
—
1
0.45
0.21
0.06
0.12
0.05
0.02
0.00
0.05
0.09
0.03
0.01
0.09
0.08
0.12

SEQID-03079
K9HST7
—
—
1
0.46
0.21
0.07
0.14
0.05
0.03
0.00
0.05
0.04
0.03
0.03
0.04
0.09
0.10

SEQID-03080
K9H972
—
—
1
0.43
0.22
0.07
0.09
0.03
0.06
0.01
0.04
0.07
0.03
0.04
0.05
0.11
0.06

SEQID-03081
K9I188
—
—
1
0.45
0.19
0.06
0.05
0.05
0.05
0.00
0.04
0.10
0.03
0.01
0.04
0.09
0.10

SEQID-03082
K9I379
—
—
1
0.50
0.24
0.04
0.07
0.05
0.08
0.01
0.04
0.06
0.03
0.03
0.08
0.10
0.09

SEQID-03083
K9H9R8
—
—
1
0.44
0.20
0.07
0.06
0.05
0.03
0.01
0.05
0.07
0.05
0.02
0.06
0.07
0.06

SEQID-03084
K9I8C2
—
—
1
0.47
0.25
0.05
0.08
0.05
0.07
0.01
0.04
0.06
0.04
0.03
0.09
0.09
0.06

SEQID-03085
K9I5N9
—
—
1
0.45
0.18
0.04
0.07
0.05
0.06
0.01
0.04
0.08
0.03
0.04
0.06
0.07
0.06

SEQID-03086
K9HMI3
—
—
1
0.48
0.23
0.06
0.07
0.03
0.06
0.00
0.04
0.09
0.03
0.02
0.06
0.10
0.08

SEQID-03087
K9I6J8
—
—
1
0.50
0.22
0.06
0.07
0.03
0.05
0.01
0.01
0.08
0.05
0.03
0.08
0.07
0.08

SEQID-03088
K9HM52
—
—
1
0.50
0.23
0.02
0.15
0.06
0.07
0.01
0.06
0.03
0.04
0.04
0.06
0.09
0.11

SEQID-03089
K9I6I9
—
—
1
0.51
0.26
0.02
0.12
0.06
0.07
0.01
0.04
0.06
0.04
0.03
0.10
0.08
0.09

SEQID-03090
K9HF90
—
—
1
0.41
0.13
0.04
0.16
0.05
0.04
0.03
0.04
0.06
0.03
0.02
0.06
0.06
0.10

SEQID-03091
K9H895
—
—
1
0.41
0.13
0.07
0.07
0.03
0.08
0.01
0.04
0.13
0.01
0.02
0.05
0.09
0.07

SEQID-03092
K9HYF2
—
—
1
0.50
0.19
0.09
0.03
0.03
0.03
0.00
0.06
0.06
0.03
0.02
0.04
0.08
0.16

SEQID-03093
K9H8Q4
—
—
1
0.50
0.28
0.07
0.05
0.05
0.05
0.00
0.02
0.07
0.05
0.02
0.06
0.12
0.08

SEQID-03094
K9HEE4
—
—
1
0.45
0.22
0.06
0.06
0.05
0.06
0.02
0.03
0.07
0.04
0.04
0.06
0.09
0.07

SEQID-03095
K9HUG1
—
—
1
0.48
0.19
0.04
0.05
0.04
0.07
0.01
0.05
0.08
0.03
0.05
0.06
0.08
0.05

SEQID-03096
K9HV61
—
—
1
0.45
0.21
0.07
0.06
0.04
0.05
0.00
0.05
0.06
0.05
0.04
0.06
0.09
0.05

SEQID-03097
K9I1Z8
—
—
0
0.51
0.18
0.03
0.09
0.01
0.06
0.02
0.06
0.04
0.04
0.02
0.07
0.09
0.18

SEQID-03098
K9I4C3
—
—
1
0.42
0.20
0.04
0.15
0.03
0.05
0.01
0.03
0.07
0.05
0.03
0.09
0.06
0.10

SEQID-03099
K9HY15
—
—
1
0.42
0.22
0.06
0.19
0.02
0.05
0.00
0.03
0.08
0.03
0.03
0.06
0.11
0.09

SEQID-03100
K9I3C6
—
—
1
0.52
0.25
0.05
0.04
0.04
0.05
0.00
0.05
0.08
0.03
0.02
0.07
0.14
0.10

SEQID-03101
K9HE77
—
—
1
0.48
0.21
0.04
0.15
0.02
0.06
0.01
0.05
0.06
0.03
0.02
0.07
0.03
0.15

SEQID-03102
K9HMK1
—
—
1
0.48
0.19
0.06
0.09
0.02
0.04
0.00
0.04
0.07
0.04
0.02
0.03
0.08
0.15

SEQID-03103
K9HVM2
—
—
0
0.48
0.21
0.07
0.07
0.03
0.04
0.00
0.03
0.03
0.07
0.00
0.04
0.09
0.09

SEQID-03104
K9I7D4
—
—
1
0.49
0.22
0.07
0.05
0.03
0.05
0.01
0.04
0.10
0.04
0.02
0.06
0.06
0.13

SEQID-03105
K9HVE8
—
—
1
0.48
0.22
0.05
0.06
0.04
0.06
0.01
0.04
0.03
0.06
0.03
0.07
0.07
0.09

SEQID-03106
K9HYK9
—
—
1
0.45
0.21
0.06
0.07
0.04
0.08
0.00
0.05
0.09
0.03
0.02
0.07
0.03
0.03

SEQID-03107
K9HHM1
—
—
1
0.51
0.25
0.06
0.07
0.05
0.04
0.01
0.02
0.07
0.03
0.03
0.08
0.11
0.06

SEQID-03108
K9HE89
—
—
1
0.47
0.21
0.06
0.07
0.08
0.02
0.01
0.09
0.03
0.05
0.02
0.07
0.06
0.02

SEQID-03109
K9HJ57
—
—
1
0.37
0.17
0.06
0.11
0.02
0.09
0.01
0.04
0.13
0.04
0.03
0.06
0.06
0.09

SEQID-03110
K9I7S9
—
—
1
0.40
0.17
0.02
0.21
0.06
0.02
0.01
0.04
0.03
0.04
0.06
0.04
0.05
0.10

SEQID-03111
K9I5Q6
—
—
1
0.49
0.22
0.04
0.06
0.06
0.05
0.01
0.05
0.08
0.03
0.05
0.06
0.09
0.07

SEQID-03112
K9HMM0
—
—
1
0.47
0.23
0.06
0.09
0.04
0.09
0.01
0.04
0.06
0.03
0.05
0.06
0.10
0.07

SEQID-03113
K9I794
—
—
1
0.46
0.17
0.05
0.06
0.05
0.05
0.02
0.04
0.07
0.04
0.05
0.04
0.09
0.06

SEQID-03114
K9I1B2
—
—
1
0.47
0.19
0.04
0.07
0.03
0.09
0.01
0.03
0.09
0.03
0.02
0.04
0.09
0.09

SEQID-03115
K9I6M4
—
—
1
0.47
0.22
0.04
0.05
0.04
0.07
0.01
0.03
0.13
0.02
0.01
0.07
0.10
0.11

SEQID-03116
K9HWR2
—
—
1
0.46
0.24
0.05
0.08
0.04
0.07
0.01
0.04
0.06
0.03
0.03
0.06
0.11
0.06

SEQID-03117
K5HA66
—
—
1
0.45
0.20
0.07
0.06
0.05
0.07
0.01
0.04
0.06
0.05
0.03
0.07
0.08
0.07

SEQID-03118
K9HQF1
—
—
1
0.48
0.20
0.04
0.03
0.04
0.07
0.01
0.04
0.07
0.04
0.03
0.05
0.08
0.06

SEQID-03119
K9HZD5
—
—
1
0.55
0.18
0.04
0.04
0.05
0.07
0.01
0.04
0.04
0.07
0.03
0.04
0.05
0.10

SEQID-03120
K9HRR8
—
—
1
0.52
0.21
0.04
0.05
0.06
0.05
0.02
0.04
0.09
0.04
0.03
0.06
0.08
0.10

SEQID-03121
K9HM68
—
—
1
0.49
0.21
0.07
0.12
0.00
0.05
0.01
0.04
0.05
0.06
0.01
0.05
0.09
0.10

SEQID-03122
K9I509
—
—
1
0.45
0.20
0.10
0.07
0.05
0.06
0.01
0.04
0.07
0.03
0.03
0.08
0.06
0.05

SEQID-03123
K9HMX1
—
—
0
0.46
0.27
0.09
0.03
0.03
0.06
0.01
0.04
0.05
0.05
0.02
0.06
0.11
0.07

SEQID-03124
K9HI03
—
—
1
0.43
0.21
0.06
0.08
0.04
0.05
0.01
0.04
0.10
0.04
0.01
0.07
0.08
0.07

SEQID-03125
K9HPE6
—
—
1
0.43
0.21
0.05
0.03
0.06
0.05
0.01
0.04
0.07
0.03
0.04
0.07
0.07
0.06

SEQID-03126
K9HEC5
—
—
1
0.44
0.21
0.07
0.07
0.05
0.06
0.01
0.05
0.06
0.04
0.02
0.05
0.11
0.07

SEQID-03127
K9H4L4
—
—
1
0.52
0.22
0.06
0.03
0.05
0.06
0.01
0.04
0.06
0.05
0.03
0.08
0.07
0.09

SEQID-03128
K9H4N1
—
—
1
0.51
0.22
0.06
0.04
0.04
0.04
0.01
0.03
0.07
0.06
0.03
0.07
0.07
0.09

SEQID-03129
K9HK61
—
—
1
0.50
0.20
0.06
0.05
0.04
0.05
0.01
0.03
0.07
0.05
0.05
0.06
0.09
0.06

SEQID-03130
K9HQA9
—
—
1
0.53
0.26
0.05
0.07
0.02
0.02
0.02
0.04
0.06
0.06
0.03
0.08
0.11
0.05

SEQID-03131
K9HAR9
—
—
1
0.45
0.22
0.05
0.09
0.03
0.07
0.01
0.03
0.08
0.05
0.02
0.06
0.10
0.07

SEQID-03132
K9I219
—
—
1
0.46
0.20
0.05
0.03
0.04
0.07
0.01
0.03
0.06
0.04
0.03
0.06
0.09
0.06

SEQID-03133
K9HC31
—
—
1
0.47
0.20
0.04
0.06
0.05
0.05
0.01
0.04
0.08
0.04
0.04
0.04
0.10
0.06

SEQID-03134
K9HCT6
—
—
1
0.42
0.17
0.04
0.10
0.03
0.04
0.01
0.04
0.08
0.05
0.01
0.05
0.05
0.04

SEQID-03135
K9HHW4
—
—
1
0.50
0.21
0.06
0.03
0.06
0.02
0.01
0.08
0.03
0.04
0.03
0.05
0.07
0.02

SEQID-03136
K9HP63
—
—
1
0.48
0.21
0.03
0.13
0.04
0.05
0.01
0.04
0.03
0.02
0.01
0.06
0.08
0.13

SEQID-03137
K9HN29
—
—
1
0.50
0.22
0.04
0.06
0.04
0.08
0.01
0.02
0.05
0.04
0.04
0.05
0.08
0.06

SEQID-03138
K9HQ79
—
—
1
0.43
0.20
0.05
0.07
0.03
0.08
0.01
0.03
0.07
0.03
0.05
0.06
0.08
0.08

SEQID-03139
K9HPY6
—
—
1
0.47
0.22
0.05
0.03
0.03
0.06
0.01
0.07
0.07
0.06
0.02
0.06
0.10
0.06

SEQID-03140
K9HJ92
—
—
1
0.42
0.19
0.06
0.03
0.04
0.06
0.01
0.04
0.06
0.04
0.03
0.06
0.08
0.05

SEQID-03141
K9I7R9
—
—
1
0.50
0.24
0.05
0.06
0.03
0.07
0.01
0.03
0.07
0.05
0.03
0.08
0.08
0.10

SEQID-03142
K9HJT2
—
—
1
0.47
0.22
0.05
0.05
0.06
0.06
0.00
0.03
0.07
0.05
0.02
0.08
0.08
0.08

SEQID-03143
K9I574
—
—
1
0.44
0.20
0.08
0.05
0.07
0.05
0.01
0.04
0.03
0.04
0.02
0.06
0.08
0.03

SEQID-03144
K9HQA4
—
—
1
0.43
0.20
0.07
0.08
0.04
0.07
0.02
0.03
0.06
0.05
0.04
0.06
0.07
0.06

SEQID-03145
K9H297
—
—
1
0.47
0.21
0.05
0.07
0.05
0.07
0.01
0.04
0.07
0.04
0.04
0.04
0.11
0.07

SEQID-03146
K9I361
—
—
1
0.47
0.24
0.07
0.03
0.04
0.06
0.01
0.04
0.07
0.04
0.02
0.09
0.09
0.05

SEQID-03147
K9HBR0
—
—
0
0.41
0.24
0.09
0.05
0.02
0.06
0.02
0.10
0.08
0.03
0.02
0.11
0.05
0.08

SEQID-03148
K9I7W3
—
—
0
0.54
0.18
0.06
0.07
0.04
0.09
0.00
0.03
0.02
0.03
0.03
0.06
0.06
0.17

SEQID-03149
K9I1Y2
—
—
1
0.48
0.29
0.01
0.14
0.06
0.03
0.01
0.04
0.04
0.05
0.04
0.12
0.09
0.07

SEQID-03150
K9H0T0
—
—
1
0.42
0.16
0.03
0.11
0.06
0.06
0.02
0.04
0.06
0.04
0.01
0.05
0.05
0.04

SEQID-03151
K9HT24
—
—
1
0.48
0.23
0.07
0.06
0.01
0.08
0.01
0.04
0.06
0.03
0.02
0.07
0.09
0.09

SEQID-03152
K9I2D5
—
—
1
0.47
0.21
0.04
0.17
0.03
0.03
0.00
0.03
0.06
0.02
0.03
0.07
0.07
0.09

SEQID-03153
K9HI94
—
—
1
0.45
0.17
0.08
0.14
0.04
0.03
0.00
0.04
0.07
0.03
0.04
0.05
0.06
0.11

SEQID-03154
K9I5L3
—
—
1
0.48
0.25
0.06
0.10
0.05
0.07
0.00
0.06
0.05
0.03
0.02
0.09
0.09
0.10

SEQID-03155
K9HP79
—
—
1
0.46
0.19
0.04
0.03
0.04
0.06
0.00
0.04
0.07
0.03
0.04
0.07
0.08
0.06

SEQID-03156
K9H787
—
—
0
0.46
0.15
0.05
0.05
0.05
0.05
0.00
0.03
0.07
0.03
0.00
0.03
0.09
0.09

SEQID-03157
K9HEU3
—
—
1
0.51
0.16
0.07
0.03
0.02
0.03
0.00
0.04
0.07
0.05
0.03
0.06
0.05
0.09

SEQID-03158
K9HGS4
—
—
1
0.51
0.14
0.05
0.03
0.04
0.06
0.00
0.02
0.07
0.02
0.00
0.03
0.06
0.10

SEQID-03159
K9HNK9
—
—
1
0.44
0.19
0.08
0.10
0.01
0.06
0.01
0.05
0.09
0.04
0.03
0.07
0.06
0.06

SEQID-03160
K9HGC5
—
—
1
0.43
0.23
0.07
0.07
0.04
0.07
0.02
0.05
0.06
0.04
0.01
0.07
0.10
0.05

SEQID-03161
K9HVR1
—
—
1
0.51
0.20
0.04
0.07
0.03
0.06
0.01
0.04
0.07
0.04
0.07
0.05
0.07
0.07

SEQID-03162
K9HJD1
—
—
1
0.40
0.14
0.06
0.05
0.03
0.05
0.02
0.09
0.09
0.05
0.06
0.04
0.07
0.09

SEQID-03163
K9HWF5
—
—
1
0.49
0.22
0.07
0.05
0.03
0.07
0.01
0.04
0.08
0.04
0.01
0.05
0.10
0.12

SEQID-03164
K9HFM8
—
—
1
0.47
0.24
0.06
0.05
0.05
0.07
0.03
0.03
0.07
0.05
0.01
0.08
0.09
0.09

SEQID-03165
K9HCU6
—
—
1
0.47
0.18
0.05
0.06
0.03
0.05
0.00
0.04
0.09
0.05
0.03
0.05
0.08
0.09

SEQID-03166
K9I5M1
—
—
1
0.46
0.23
0.05
0.07
0.06
0.07
0.00
0.03
0.07
0.04
0.04
0.07
0.11
0.06

SEQID-03167
K9HP80
—
—
1
0.47
0.21
0.03
0.04
0.05
0.06
0.01
0.02
0.05
0.04
0.05
0.05
0.09
0.05

SEQID-03168
K9I3Y1
—
—
1
0.48
0.23
0.07
0.05
0.05
0.05
0.01
0.04
0.07
0.05
0.02
0.08
0.07
0.09

SEQID-03169
K9HRV8
—
—
0
0.46
0.24
0.07
0.09
0.03
0.06
0.00
0.05
0.09
0.05
0.02
0.07
0.09
0.06

SEQID-03170
K9HB49
—
—
1
0.43
0.16
0.05
0.09
0.05
0.06
0.01
0.07
0.06
0.03
0.05
0.04
0.06
0.04

SEQID-03171
K9IB94
—
—
1
0.47
0.22
0.04
0.07
0.02
0.05
0.02
0.04
0.08
0.04
0.05
0.06
0.09
0.05

SEQID-03172
K9I3N1
—
—
1
0.49
0.24
0.05
0.06
0.03
0.05
0.01
0.04
0.03
0.04
0.03
0.06
0.10
0.07

SEQID-03173
K9HP17
—
—
1
0.45
0.22
0.06
0.07
0.04
0.06
0.01
0.04
0.07
0.04
0.02
0.06
0.09
0.06

SEQID-03174
K9HRI9
—
—
1
0.54
0.24
0.04
0.07
0.02
0.04
0.01
0.02
0.08
0.03
0.04
0.08
0.09
0.15

SEQID-03175
K9HXT8
—
—
1
0.52
0.24
0.06
0.13
0.02
0.05
0.00
0.03
0.06
0.03
0.02
0.07
0.09
0.14

SEQID-03176
K9HZL6
—
—
0
0.42
0.22
0.09
0.13
0.01
0.04
0.01
0.06
0.05
0.05
0.01
0.06
0.09
0.11

SEQID-03177
K9HHS6
—
—
1
0.51
0.23
0.04
0.12
0.01
0.03
0.00
0.05
0.05
0.03
0.04
0.09
0.09
0.11

SEQID-03178
K9HJC3
—
—
1
0.47
0.25
0.08
0.07
0.03
0.06
0.01
0.04
0.09
0.04
0.02
0.09
0.09
0.12

SEQID-03179
K9HXR3
—
—
1
0.50
0.18
0.04
0.14
0.03
0.05
0.01
0.04
0.02
0.04
0.02
0.06
0.06
0.13

SEQID-03180
K9I3A2
—
—
0
0.50
0.17
0.09
0.11
0.05
0.07
0.00
0.02
0.04
0.01
0.04
0.05
0.06
0.18

SEQID-03181
K9I737
—
—
0
0.45
0.17
0.05
0.14
0.05
0.03
0.01
0.04
0.06
0.03
0.06
0.06
0.02
0.09

SEQID-03182
K9I4D4
—
—
0
0.52
0.23
0.05
0.15
0.02
0.04
0.00
0.02
0.04
0.04
0.05
0.07
0.11
0.13

SEQID-03183
K9HA62
—
—
1
0.55
0.26
0.03
0.06
0.05
0.06
0.01
0.04
0.05
0.03
0.02
0.06
0.13
0.16

SEQID-03184
K9H9H7
—
—
1
0.57
0.26
0.08
0.06
0.03
0.04
0.02
0.05
0.02
0.03
0.05
0.09
0.12
0.06

SEQID-03185
K9HVR7
—
—
1
0.46
0.21
0.03
0.08
0.04
0.06
0.01
0.04
0.09
0.04
0.03
0.04
0.07
0.06

SEQID-03186
K9HU08
—
—
1
0.49
0.26
0.05
0.06
0.04
0.09
0.01
0.03
0.07
0.05
0.05
0.06
0.12
0.05

SEQID-03187
K9I3W7
—
—
1
0.50
0.22
0.04
0.09
0.04
0.05
0.00
0.06
0.08
0.03
0.05
0.05
0.09
0.06

SEQID-03188
K9I5W6
—
—
1
0.42
0.16
0.07
0.07
0.03
0.09
0.02
0.03
0.05
0.06
0.03
0.05
0.06
0.05

SEQID-03189
K9I0R0
—
—
1
0.51
0.24
0.05
0.04
0.05
0.06
0.00
0.03
0.07
0.03
0.04
0.05
0.12
0.09

SEQID-03190
K9HPF6
—
—
1
0.40
0.22
0.07
0.04
0.04
0.05
0.01
0.07
0.12
0.03
0.01
0.09
0.09
0.09

SEQID-03191
K9HZH4
—
—
1
0.43
0.25
0.06
0.08
0.03
0.05
0.01
0.08
0.07
0.04
0.02
0.09
0.07
0.04

SEQID-03192
K9H560
—
—
1
0.45
0.23
0.04
0.06
0.04
0.04
0.01
0.04
0.09
0.04
0.03
0.08
0.03
0.07

SEQID-03193
K9HMV4
—
—
1
0.45
0.22
0.06
0.05
0.06
0.06
0.01
0.04
0.09
0.04
0.04
0.06
0.07
0.05

SEQID-03194
K9HNW8
—
—
1
0.47
0.17
0.05
0.06
0.05
0.07
0.02
0.03
0.03
0.04
0.03
0.04
0.07
0.06

SEQID-03195
K9HPX5
—
—
1
0.48
0.23
0.06
0.07
0.04
0.05
0.01
0.03
0.06
0.05
0.02
0.06
0.09
0.07

SEQID-03196
K9HUE6
—
—
1
0.44
0.24
0.07
0.09
0.04
0.05
0.02
0.05
0.06
0.03
0.04
0.09
0.07
0.04

SEQID-03197
K9HUI8
—
—
1
0.48
0.20
0.05
0.03
0.02
0.05
0.01
0.03
0.10
0.04
0.03
0.07
0.09
0.08

SEQID-03198
K9HCR7
—
—
1
0.47
0.21
0.07
0.06
0.03
0.06
0.02
0.03
0.09
0.04
0.07
0.06
0.10
0.06

SEQID-03199
K9HE21
—
—
1
0.48
0.23
0.04
0.07
0.04
0.06
0.00
0.04
0.03
0.04
0.02
0.06
0.13
0.05

SEQID-03200
K9HEI4
—
—
1
0.47
0.24
0.06
0.09
0.04
0.06
0.00
0.04
0.07
0.03
0.04
0.05
0.11
0.05

SEQID-03201
K9HY34
—
—
1
0.49
0.21
0.07
0.06
0.04
0.06
0.01
0.05
0.06
0.06
0.02
0.09
0.09
0.09

SEQID-03202
K9HS49
—
—
1
0.49
0.20
0.05
0.03
0.03
0.06
0.01
0.06
0.07
0.05
0.03
0.07
0.07
0.07

SEQID-03203
K9H5L7
—
—
1
0.45
0.22
0.06
0.07
0.06
0.04
0.01
0.05
0.09
0.03
0.04
0.06
0.10
0.05

SEQID-03204
K9I6Y5
—
—
1
0.50
0.20
0.06
0.06
0.04
0.09
0.01
0.03
0.09
0.05
0.04
0.05
0.07
0.10

SEQID-03205
K9HUY3
—
—
1
0.46
0.22
0.05
0.07
0.03
0.06
0.01
0.05
0.09
0.04
0.02
0.06
0.09
0.07

SEQID-03206
K9ICM5
—
—
1
0.49
0.21
0.05
0.05
0.03
0.06
0.00
0.05
0.07
0.03
0.04
0.06
0.09
0.07

SEQID-03207
K9HFN2
—
—
1
0.50
0.17
0.04
0.05
0.04
0.07
0.01
0.03
0.07
0.04
0.04
0.04
0.07
0.07

SEQID-03208
K9I3M2
—
—
1
0.46
0.17
0.04
0.07
0.04
0.09
0.01
0.04
0.05
0.03
0.04
0.05
0.07
0.07

SEQID-03209
K9HV87
—
—
1
0.42
0.17
0.05
0.07
0.06
0.08
0.01
0.04
0.06
0.05
0.04
0.04
0.07
0.04

SEQID-03210
K9I6W6
—
—
1
0.45
0.21
0.05
0.09
0.05
0.05
0.02
0.06
0.05
0.04
0.03
0.06
0.06
0.06

SEQID-03211
K9HXM7
—
—
1
0.47
0.22
0.05
0.08
0.04
0.07
0.01
0.03
0.08
0.05
0.02
0.05
0.10
0.07

SEQID-03212
K9HBK9
—
—
1
0.46
0.24
0.06
0.09
0.03
0.05
0.00
0.03
0.08
0.04
0.03
0.05
0.10
0.08

SEQID-03213
K9HH69
—
—
1
0.43
0.21
0.07
0.08
0.04
0.06
0.01
0.04
0.08
0.03
0.03
0.05
0.10
0.05

SEQID-03214
K9HKG7
—
—
0
0.46
0.23
0.04
0.19
0.02
0.03
0.00
0.01
0.05
0.09
0.02
0.09
0.09
0.12

SEQID-03215
K9I3L2
—
—
1
0.59
0.23
0.09
0.07
0.02
0.04
0.00
0.02
0.03
0.02
0.05
0.09
0.09
0.21

SEQID-03216
K9HK97
—
—
1
0.44
0.20
0.04
0.17
0.04
0.01
0.00
0.03
0.03
0.05
0.02
0.07
0.06
0.11

SEQID-03217
K9HLM3
—
—
0
0.43
0.18
0.11
0.18
0.01
0.03
0.00
0.07
0.06
0.02
0.02
0.04
0.10
0.11

SEQID-03218
K9HB34
—
—
0
0.43
0.21
0.04
0.17
0.04
0.06
0.00
0.04
0.08
0.02
0.02
0.06
0.09
0.09

SEQID-03219
K9HHM4
—
—
1
0.53
0.19
0.03
0.11
0.04
0.02
0.00
0.02
0.06
0.07
0.09
0.05
0.07
0.12

SEQID-03220
K9I2C7
—
—
1
0.41
0.14
0.04
0.10
0.03
0.03
0.01
0.03
0.06
0.09
0.01
0.02
0.07
0.07

SEQID-03221
K9I0P4
—
—
0
0.46
0.23
0.07
0.14
0.01
0.05
0.01
0.04
0.06
0.05
0.03
0.05
0.08
0.07

SEQID-03222
K9HQL8
—
—
0
0.48
0.25
0.04
0.13
0.05
0.05
0.00
0.05
0.09
0.02
0.02
0.05
0.10
0.10

SEQID-03223
K9HQV1
—
—
1
0.43
0.20
0.05
0.06
0.05
0.07
0.00
0.03
0.09
0.05
0.01
0.07
0.06
0.08

SEQID-03224
K9I5G0
—
—
1
0.45
0.24
0.04
0.09
0.02
0.06
0.00
0.01
0.09
0.03
0.02
0.07
0.11
0.07

SEQID-03225
K9ICR1
—
—
1
0.47
0.18
0.07
0.19
0.04
0.03
0.00
0.05
0.06
0.03
0.04
0.05
0.07
0.15

SEQID-03226
K9HNM9
—
—
1
0.40
0.15
0.07
0.16
0.04
0.03
0.00
0.06
0.06
0.04
0.04
0.05
0.07
0.11

SEQID-03227
K9HSQ2
—
—
1
0.48
0.24
0.04
0.10
0.02
0.06
0.01
0.05
0.07
0.04
0.03
0.06
0.09
0.08

SEQID-03228
K9HPQ3
—
—
1
0.43
0.21
0.07
0.03
0.03
0.05
0.00
0.03
0.11
0.04
0.03
0.06
0.10
0.09

SEQID-03229
K9H7S5
—
—
1
0.50
0.26
0.06
0.06
0.04
0.06
0.01
0.03
0.07
0.05
0.02
0.06
0.09
0.07

SEQID-03230
K9HUD2
—
—
1
0.43
0.27
0.07
0.03
0.04
0.06
0.00
0.04
0.06
0.05
0.01
0.07
0.09
0.07

SEQID-03231
K9HP00
—
—
0
0.40
0.18
0.07
0.03
0.04
0.05
0.00
0.06
0.09
0.04
0.04
0.04
0.09
0.06

SEQID-03232
K9I605
—
—
1
0.51
0.26
0.04
0.05
0.04
0.04
0.00
0.04
0.10
0.04
0.03
0.10
0.11
0.09

SEQID-03233
K9HHI3
—
—
1
0.48
0.21
0.05
0.11
0.03
0.06
0.01
0.05
0.09
0.02
0.04
0.06
0.09
0.06

SEQID-03234
K9I835
—
—
1
0.47
0.21
0.03
0.03
0.03
0.06
0.01
0.04
0.09
0.04
0.05
0.06
0.09
0.04

SEQID-03235
K9HTL8
—
—
1
0.46
0.24
0.03
0.10
0.05
0.06
0.01
0.07
0.09
0.03
0.04
0.08
0.09
0.06

SEQID-03236
K9HZX9
—
—
1
0.41
0.18
0.06
0.03
0.04
0.06
0.03
0.04
0.04
0.06
0.01
0.04
0.09
0.03

SEQID-03237
K9HV97
—
—
1
0.42
0.18
0.07
0.11
0.05
0.08
0.03
0.02
0.04
0.04
0.03
0.06
0.07
0.03

SEQID-03238
K9HKZ1
—
—
1
0.43
0.25
0.07
0.04
0.04
0.05
0.01
0.07
0.09
0.02
0.00
0.09
0.09
0.06

SEQID-03239
K9HNA4
—
—
1
0.46
0.20
0.08
0.04
0.04
0.07
0.01
0.07
0.10
0.03
0.01
0.08
0.09
0.02

SEQID-03240
K9HR04
—
—
1
0.46
0.22
0.07
0.09
0.03
0.05
0.01
0.02
0.09
0.04
0.02
0.05
0.09
0.06

SEQID-03241
K9I209
—
—
1
0.45
0.16
0.04
0.09
0.03
0.05
0.01
0.03
0.09
0.04
0.05
0.05
0.07
0.05

SEQID-03242
K9I4P0
—
—
1
0.46
0.23
0.07
0.07
0.04
0.05
0.01
0.02
0.09
0.04
0.03
0.05
0.10
0.09

SEQID-03243
K9I7A5
—
—
1
0.47
0.22
0.06
0.08
0.03
0.05
0.01
0.05
0.08
0.04
0.03
0.07
0.10
0.06

SEQID-03244
K9HKA6
—
—
1
0.46
0.17
0.05
0.06
0.05
0.05
0.01
0.07
0.05
0.05
0.03
0.05
0.07
0.04

SEQID-03245
K9I1J7
—
—
1
0.48
0.20
0.07
0.05
0.04
0.05
0.02
0.03
0.09
0.05
0.07
0.09
0.09
0.05

SEQID-03246
K9I4A6
—
—
1
0.47
0.27
0.05
0.07
0.04
0.06
0.01
0.05
0.06
0.04
0.03
0.07
0.09
0.06

SEQID-03247
C9HJ05
—
—
1
0.43
0.20
0.05
0.10
0.04
0.06
0.02
0.04
0.07
0.03
0.04
0.07
0.09
0.05

SEQID-03248
K9HP50
—
—
1
0.50
0.22
0.05
0.07
0.04
0.07
0.00
0.03
0.06
0.04
0.03
0.08
0.07
0.07

SEQID-03249
K9HY17
—
—
1
0.53
0.30
0.05
0.07
0.03
0.03
0.01
0.04
0.05
0.04
0.01
0.09
0.14
0.04

SEQID-03250
K9HXU7
—
—
1
0.47
0.18
0.09
0.05
0.05
0.06
0.00
0.03
0.07
0.04
0.03
0.04
0.08
0.08

SEQID-03251
K9I7E3
—
—
1
0.43
0.21
0.06
0.09
0.03
0.06
0.01
0.04
0.09
0.04
0.02
0.05
0.09
0.07

SEQID-03252
K9I7B3
—
—
1
0.49
0.22
0.06
0.07
0.03
0.05
0.00
0.05
0.10
0.02
0.03
0.05
0.12
0.10

SEQID-03253
K9HBS2
—
—
1
0.48
0.21
0.05
0.07
0.05
0.06
0.01
0.04
0.03
0.03
0.06
0.06
0.09
0.07

SEQID-03254
K9HB75
—
—
1
0.45
0.21
0.06
0.09
0.05
0.06
0.01
0.03
0.07
0.06
0.04
0.09
0.09
0.06

SEQID-03255
K9HWN9
—
—
1
0.52
0.25
0.07
0.07
0.04
0.04
0.01
0.02
0.05
0.04
0.02
0.09
0.10
0.04

SEQID-03256
K9HS66
—
—
1
0.44
0.19
0.07
0.09
0.03
0.06
0.01
0.04
0.09
0.05
0.05
0.06
0.09
0.05

SEQID-03257
K9H5W9
—
—
1
0.45
0.20
0.03
0.09
0.03
0.05
0.01
0.05
0.10
0.03
0.05
0.05
0.10
0.07

SEQID-03258
K9HDE7
—
—
1
0.50
0.21
0.06
0.07
0.02
0.06
0.01
0.02
0.07
0.05
0.05
0.07
0.07
0.07

SEQID-03259
K9HXH0
—
—
1
0.47
0.21
0.05
0.06
0.05
0.07
0.00
0.04
0.10
0.05
0.02
0.06
0.03
0.09

SEQID-03260
K9HJZ1
—
—
1
0.53
0.23
0.04
0.06
0.04
0.05
0.00
0.04
0.04
0.03
0.04
0.07
0.10
0.05

SEQID-03261
K9I493
—
—
1
0.42
0.21
0.06
0.10
0.04
0.09
0.01
0.04
0.09
0.04
0.01
0.07
0.09
0.06

SEQID-03262
K9HTI2
—
—
1
0.45
0.22
0.06
0.10
0.04
0.06
0.01
0.04
0.07
0.05
0.04
0.07
0.09
0.05

SEQID-03263
K9IS87
—
—
1
0.46
0.27
0.05
0.09
0.03
0.06
0.00
0.04
0.06
0.03
0.02
0.07
0.12
0.05

SEQID-03264
K9HZD7
—
—
1
0.48
0.23
0.06
0.07
0.03
0.06
0.01
0.03
0.07
0.05
0.03
0.03
0.09
0.07

SEQID-03265
K9HS81
—
—
1
0.49
0.20
0.03
0.06
0.04
0.07
0.01
0.04
0.09
0.03
0.04
0.06
0.09
0.09

SEQID-03266
K9I1P6
—
—
1
0.49
0.22
0.04
0.09
0.04
0.04
0.01
0.04
0.05
0.04
0.03
0.07
0.10
0.05

SEQID-03267
K9IB16
—
—
1
0.45
0.17
0.06
0.12
0.03
0.09
0.00
0.05
0.09
0.01
0.05
0.04
0.07
0.07

SEQID-03268
K9HBH5
—
—
1
0.38
0.16
0.09
0.17
0.06
0.03
0.00
0.00
0.05
0.04
0.03
0.06
0.01
0.12

SEQID-03269
K9HG97
—
—
0
0.41
0.23
0.09
0.09
0.04
0.03
0.00
0.05
0.08
0.08
0.03
0.04
0.12
0.13

SEQID-03270
K9HJ84
—
—
1
0.48
0.18
0.05
0.09
0.04
0.03
0.02
0.02
0.10
0.04
0.02
0.03
0.09
0.11

SEQID-03271
K9HNE7
—
—
1
0.42
0.21
0.09
0.04
0.06
0.07
0.06
0.05
0.00
0.04
0.03
0.03
0.05
0.04

SEQID-03272
K9HE11
—
—
0
0.48
0.15
0.10
0.06
0.02
0.02
0.00
0.02
0.07
0.03
0.02
0.07
0.04
0.19

SEQID-03273
K9HHP1
—
—
1
0.44
0.18
0.04
0.09
0.04
0.08
0.02
0.02
0.03
0.03
0.02
0.07
0.08
0.05

SEQID-03274
K9HIA6
—
—
1
0.55
0.27
0.04
0.02
0.04
0.04
0.01
0.02
0.10
0.03
0.06
0.10
0.12
0.11

SEQID-03275
K9HNG3
—
—
1
0.48
0.21
0.04
0.12
0.06
0.04
0.01
0.02
0.06
0.06
0.01
0.04
0.08
0.17

SEQID-03276
K9H7R8
—
—
1
0.46
0.13
0.07
0.17
0.01
0.02
0.00
0.08
0.05
0.04
0.02
0.05
0.04
0.17

SEQID-03277
K9HK30
—
—
0
0.41
0.20
0.03
0.03
0.03
0.04
0.02
0.02
0.09
0.05
0.00
0.07
0.09
0.06

SEQID-03278
K9HT12
—
—
1
0.40
0.17
0.05
0.12
0.03
0.04
0.00
0.05
0.09
0.05
0.02
0.04
0.09
0.09

SEQID-03279
K9HZV3
—
—
1
0.50
0.16
0.03
0.04
0.04
0.05
0.00
0.03
0.07
0.05
0.02
0.04
0.07
0.05

SEQID-03280
K9IGL3
—
—
0
0.48
0.19
0.05
0.02
0.04
0.09
0.01
0.03
0.10
0.03
0.00
0.04
0.09
0.12

SEQID-03281
K9H6B7
—
—
1
0.41
0.19
0.07
0.12
0.05
0.06
0.01
0.04
0.04
0.03
0.01
0.06
0.12
0.04

SEQID-03282
K9HB81
—
—
0
0.48
0.23
0.05
0.09
0.03
0.04
0.01
0.06
0.07
0.02
0.01
0.05
0.12
0.09

SEQID-03283
K9I5V8
—
—
1
0.44
0.23
0.05
0.11
0.04
0.09
0.01
0.05
0.04
0.03
0.04
0.07
0.07
0.05

SEQID-03284
K9I6Q8
—
—
1
0.46
0.22
0.06
0.07
0.05
0.06
0.01
0.04
0.07
0.03
0.02
0.07
0.08
0.08

SEQID-03285
K9HEZ0
—
—
1
0.47
0.23
0.03
0.05
0.03
0.05
0.01
0.04
0.07
0.04
0.03
0.09
0.08
0.06

SEQID-03286
K9HAI6
—
—
1
0.50
0.21
0.09
0.04
0.07
0.04
0.00
0.04
0.07
0.03
0.06
0.09
0.10
0.09

SEQID-03287
K9HQU8
—
—
1
0.44
0.20
0.06
0.07
0.04
0.06
0.02
0.04
0.06
0.06
0.03
0.06
0.06
0.04

SEQID-03288
K9HRI1
—
—
1
0.53
0.20
0.03
0.02
0.04
0.07
0.00
0.04
0.09
0.02
0.06
0.05
0.09
0.10

SEQID-03289
K9HWB2
—
—
1
0.46
0.25
0.08
0.06
0.05
0.04
0.01
0.05
0.08
0.04
0.01
0.08
0.07
0.07

SEQID-03290
K9I4L8
—
—
1
0.41
0.15
0.04
0.06
0.03
0.09
0.00
0.07
0.03
0.09
0.02
0.04
0.06
0.04

SEQID-03291
K9IAZ9
—
—
1
0.48
0.22
0.06
0.07
0.02
0.06
0.01
0.07
0.12
0.03
0.04
0.06
0.09
0.06

SEQID-03292
K9HC09
—
—
1
0.49
0.20
0.05
0.08
0.05
0.06
0.02
0.03
0.06
0.05
0.02
0.05
0.07
0.06

SEQID-03293
K9KG89
—
—
0
0.50
0.23
0.06
0.06
0.02
0.04
0.00
0.04
0.07
0.04
0.00
0.07
0.09
0.10

SEQID-03294
K9HYS1
—
—
1
0.54
0.22
0.07
0.07
0.03
0.02
0.00
0.05
0.01
0.02
0.02
0.06
0.11
0.05

SEQID-03295
K9H7W0
—
—
1
0.45
0.19
0.05
0.07
0.03
0.06
0.01
0.06
0.07
0.04
0.03
0.05
0.09
0.06

SEQID-03296
K9HZB7
—
—
1
0.44
0.25
0.08
0.09
0.03
0.05
0.00
0.07
0.08
0.03
0.01
0.08
0.09
0.06

SEQID-03297
K9I599
—
—
1
0.62
0.29
0.07
0.03
0.02
0.02
0.00
0.02
0.04
0.03
0.05
0.11
0.12
0.05

SEQID-03298
K9HF28
—
—
1
0.44
0.25
0.06
0.11
0.04
0.05
0.00
0.06
0.07
0.04
0.03
0.06
0.12
0.06

SEQID-03299
K9HS24
—
—
0
0.47
0.25
0.05
0.06
0.06
0.06
0.01
0.02
0.06
0.05
0.01
0.09
0.10
0.07

SEQID-03300
K9HVI9
—
—
1
0.54
0.25
0.07
0.04
0.03
0.04
0.00
0.03
0.07
0.05
0.01
0.07
0.09
0.10

SEQID-03301
K9I026
—
—
1
0.45
0.22
0.07
0.08
0.04
0.04
0.01
0.04
0.09
0.05
0.01
0.08
0.08
0.06

SEQID-03302
K9HG59
—
—
1
0.47
0.23
0.07
0.05
0.02
0.05
0.03
0.04
0.07
0.05
0.05
0.08
0.07
0.07

SEQID-03303
K9HA97
—
—
1
0.52
0.30
0.07
0.06
0.04
0.05
0.01
0.02
0.07
0.04
0.03
0.08
0.16
0.07

SEQID-03304
K9HJX8
—
—
1
0.47
0.25
0.06
0.07
0.02
0.05
0.02
0.04
0.07
0.05
0.05
0.06
0.10
0.06

SEQID-03305
K9HL00
—
—
1
0.50
0.23
0.05
0.08
0.03
0.07
0.01
0.02
0.07
0.04
0.05
0.07
0.08
0.07

SEQID-03306
K9I4Y2
—
—
0
0.46
0.24
0.08
0.05
0.04
0.06
0.01
0.05
0.06
0.05
0.02
0.08
0.06
0.08

SEQID-03307
K9I6P1
—
—
1
0.47
0.19
0.07
0.05
0.03
0.06
0.01
0.04
0.04
0.03
0.02
0.04
0.11
0.04

SEQID-03308
K9HYS9
—
—
1
0.46
0.21
0.05
0.07
0.04
0.05
0.01
0.03
0.07
0.05
0.03
0.05
0.09
0.07

SEQID-03309
K9H2C3
—
—
1
0.47
0.20
0.03
0.10
0.05
0.07
0.00
0.06
0.11
0.02
0.04
0.06
0.09
0.09

SEQID-03310
K91376
—
—
1
0.46
0.21
0.05
0.07
0.05
0.04
0.01
0.05
0.05
0.05
0.04
0.06
0.07
0.04

SEQID-03311
K9IA06
—
—
1
0.43
0.20
0.03
0.10
0.03
0.05
0.01
0.04
0.05
0.03
0.04
0.04
0.10
0.02

SEQID-03312
K9HZ98
—
—
0
0.46
0.25
0.05
0.10
0.03
0.04
0.01
0.05
0.10
0.04
0.02
0.07
0.10
0.09

SEQID-03313
K914C4
—
—
1
0.48
0.25
0.04
0.10
0.03
0.08
0.01
0.06
0.07
0.03
0.01
0.08
0.09
0.05

SEQID-03314
K9I7S4
—
—
1
0.44
0.20
0.06
0.08
0.04
0.05
0.00
0.05
0.08
0.05
0.01
0.05
0.08
0.08

SEQID-03315
K9I9Q1
—
—
1
0.52
0.25
0.06
0.04
0.05
0.06
0.00
0.02
0.08
0.05
0.02
0.06
0.11
0.12

SEQID-03316
K9I3E2
—
—
1
0.50
0.18
0.04
0.05
0.03
0.04
0.00
0.03
0.08
0.05
0.05
0.04
0.09
0.08

SEQID-03317
K91BU9
—
—
1
0.45
0.21
0.07
0.08
0.05
0.05
0.01
0.04
0.06
0.04
0.03
0.06
0.10
0.07

SEQID-03318
K9I7V8
—
—
1
0.45
0.20
0.09
0.06
0.03
0.06
0.00
0.03
0.08
0.03
0.01
0.07
0.07
0.09

SEQID-03319
K9HS31
—
—
1
0.42
0.19
0.04
0.09
0.03
0.06
0.01
0.04
0.07
0.04
0.03
0.07
0.07
0.05

SEQID-03320
WHBKS
—
—
1
0.49
0.24
0.05
0.06
0.04
0.05
0.01
0.03
0.07
0.04
0.06
0.07
0.11
0.06

SEQID-03321
K9HSCD
—
—
1
0.47
0.22
0.04
0.10
0.02
0.07
0.00
0.05
0.08
0.04
0.03
0.05
0.11
0.06

SEQID-03322
K9HY69
—
—
1
0.48
0.24
0.06
0.08
0.04
0.06
0.02
0.03
0.07
0.03
0.01
0.08
0.09
0.07

SEQID-03323
K9I3V1
—
—
1
0.47
0.25
0.06
0.05
0.06
0.05
0.01
0.02
0.08
0.05
0.03
0.08
0.09
0.06

SEQID-03324
K9I3X6
—
—
1
0.48
0.22
0.05
0.06
0.06
0.05
0.01
0.04
0.07
0.03
0.05
0.06
0.10
0.06

SEQID-03325
K9H2Q3
—
—
1
0.44
0.21
0.07
0.07
0.03
0.05
0.00
0.04
0.08
0.03
0.04
0.07
0.09
0.06

SEQID-03326
K9HTU2
—
—
1
0.47
0.23
0.08
0.07
0.04
0.04
0.01
0.03
0.08
0.05
0.02
0.05
0.09
0.07

SEQID-03327
K9HX91
—
—
1
0.46
0.18
0.05
0.08
0.03
0.07
0.01
0.03
0.09
0.03
0.03
0.04
0.10
0.07

SEQID-03328
K9HZK9
—
—
1
0.46
0.21
0.07
0.07
0.05
0.05
0.01
0.06
0.05
0.05
0.02
0.07
0.08
0.06

SEQID-03329
K91853
—
—
1
0.34
0.17
0.07
0.04
0.07
0.07
0.03
0.04
0.04
0.05
0.00
0.04
0.08
0.02

SEQID-03330
K9I6R8
—
—
1
0.48
0.17
0.04
0.04
0.04
0.06
0.01
0.04
0.08
0.04
0.04
0.04
0.09
0.06

SEQID-03331
K3HIF4
—
—
1
0.46
0.19
0.05
0.07
0.04
0.08
0.01
0.04
0.06
0.03
0.04
0.05
0.09
0.05

SEQID-03332
K9H9TS
—
—
1
0.49
0.20
0.06
0.07
0.03
0.05
0.01
0.05
0.06
0.03
0.05
0.05
0.09
0.05

SEQID-03333
K9HBV6
—
—
1
0.50
0.22
0.06
0.09
0.03
0.03
0.01
0.04
0.07
0.04
0.01
0.05
0.12
0.04

SEQID-03334
K9HKCS
—
—
1
0.46
0.21
0.07
0.07
0.05
0.07
0.00
0.04
0.09
0.04
0.02
0.07
0.07
0.09

SEQID-03335
K9HT37
—
—
1
0.50
0.27
0.06
0.08
0.04
0.04
0.01
0.02
0.05
0.04
0.03
0.10
0.09
0.05

SEQID-03336
K9HPY2
—
—
1
0.48
0.21
0.09
0.05
0.04
0.05
0.01
0.04
0.06
0.05
0.02
0.06
0.07
0.08

SEQID-03337
K9HWU9
—
—
1
0.43
0.20
0.07
0.07
0.05
0.07
0.01
0.03
0.06
0.05
0.02
0.06
0.07
0.04

SEQID-03338
K9HX18
—
—
1
0.52
0.24
0.04
0.07
0.04
0.05
0.01
0.04
0.08
0.03
0.04
0.07
0.11
0.04

SEQID-03339
K9HZ01
—
—
1
0.46
0.22
0.06
0.08
0.05
0.07
0.01
0.04
0.06
0.03
0.04
0.05
0.10
0.05

SEQID-03340
K9HPA6
—
—
1
0.49
0.21
0.05
0.06
0.05
0.05
0.01
0.04
0.06
0.03
0.02
0.06
0.09
0.07

SEQID-03341
K9HCQ7
—
—
1
0.46
0.20
0.05
0.09
0.04
0.05
0.01
0.03
0.06
0.05
0.03
0.06
0.08
0.03

SEQID-03342
K9IDW4
—
—
1
0.45
0.19
0.05
0.09
0.04
0.06
0.01
0.05
0.07
0.04
0.05
0.05
0.08
0.06

SEQID-03343
K9HZG6
—
—
1
0.49
0.20
0.05
0.07
0.05
0.07
0.01
0.03
0.08
0.03
0.03
0.05
0.09
0.09

SEQID-03344
K9IB19
—
—
1
0.47
0.20
0.05
0.06
0.03
0.09
0.01
0.03
0.10
0.03
0.03
0.06
0.08
0.08

SEQID-03345
K9HB63
—
—
1
0.48
0.25
0.07
0.06
0.04
0.05
0.01
0.04
0.07
0.04
0.02
0.07
0.10
0.07

SEQID-03346
77737588
—
—
1
0.49
0.22
0.08
0.05
0.00
0.04
0.01
0.10
0.02
0.08
0.04
0.05
0.10
0.05

SEQID-03347
77737572
—
—
1
0.48
0.21
0.08
0.05
0.00
0.03
0.01
0.10
0.03
0.08
0.04
0.05
0.10
0.06

SEQID-03348
218319228
—
—
1
0.51
0.24
0.05
0.07
0.03
0.05
0.02
0.02
0.06
0.04
0.01
0.07
0.09
0.05

SEQID-03349
P48417
—
—
1
0.47
0.21
0.05
0.06
0.04
0.05
0.01
0.03
0.07
0.03
0.01
0.05
0.10
0.08

SEQID-03350
57118119
—
—
1
0.47
0.21
0.05
0.07
0.02
0.06
0.01
0.03
0.09
0.04
0.03
0.07
0.07
0.06

SEQID-03351
76056895
—
—
1
0.39
0.15
0.07
0.11
0.06
0.04
0.03
0.04
0.06
0.04
0.02
0.05
0.05
0.03

SEQID-03352
41411212
—
—
1
0.50
0.23
0.08
0.04
0.05
0.07
0.02
0.01
0.07
0.05
0.01
0.06
0.06
0.13

SEQID-03353
296S11511
—
—
1
0.47
0.18
0.04
0.10
0.05
0.06
0.00
0.01
0.14
0.03
0.02
0.05
0.06
0.10

SEQID-03354
20502190
—
—
1
0.33
0.14
0.04
0.09
0.01
0.04
0.04
0.26
0.05
0.06
0.01
0.05
0.05
0.03

SEQID-03355
20502192
—
—
1
0.32
0.15
0.04
0.10
0.01
0.05
0.04
0.24
0.05
0.05
0.01
0.04
0.07
0.04

SEQID-03356
237637012
—
—
1
0.45
0.19
0.06
0.09
0.03
0.05
0.02
0.03
0.09
0.05
0.04
0.04
0.09
0.06

SEQID-03357
P82381
—
—
1
0.48
0.20
0.06
0.12
0.07
0.05
0.03
0.00
0.07
0.04
0.05
0.04
0.03
0.07

SEQID-03358
295416082
—
—
1
0.47
0.23
0.04
0.22
0.02
0.03
0.00
0.02
0.04
0.07
0.02
0.07
0.08
0.11

SEQID-03359
257712682
—
—
1
0.23
0.04
0.09
0.03
0.08
0.01
0.07
0.07
0.04
0.02
0.06
0.10
0.05
0.04

SEQID-03360
206981241
—
—
1
0.51
0.16
0.09
0.06
0.04
0.02
0.00
0.02
0.11
0.02
0.02
0.06
0.05
0.23

SEQID-03361
77737574
—
—
1
0.47
0.25
0.03
0.05
0.01
0.03
0.00
0.10
0.02
0.07
0.03
0.06
0.11
0.03

SEQID-03362
257712524
—
—
1
0.44
0.16
0.06
0.14
0.04
0.04
0.03
0.05
0.04
0.04
0.03
0.05
0.06
0.11

SEQID-03363
395146536
—
—
1
0.47
0.21
0.05
0.06
0.03
0.08
0.01
0.03
0.09
0.04
0.02
0.06
0.10
0.09

SEQID-03364
227304504
—
—
1
0.54
0.22
0.04
0.11
0.05
0.05
0.01
0.02
0.04
0.04
0.04
0.07
0.10
0.13

SEQID-03365
77737580
—
—
1
0.51
0.26
0.08
0.06
0.01
0.03
0.00
0.10
0.01
0.06
0.03
0.07
0.11
0.03

SEQID-03366
219922540
—
—
1
0.45
0.18
0.06
0.09
0.07
0.03
0.03
0.04
0.02
0.06
0.01
0.05
0.07
0.03

SEQID-03367
395146556
—
—
1
0.45
0.24
0.09
0.06
0.06
0.04
0.00
0.01
0.06
0.05
0.01
0.08
0.10
0.06

SEQID-03368
395146543
—
—
1
0.48
0.26
0.07
0.04
0.07
0.05
0.01
0.03
0.07
0.06
0.01
0.06
0.10
0.09

SEQID-03369
219725692
—
—
1
0.42
0.17
0.09
0.07
0.04
0.07
0.01
0.07
0.06
0.04
0.02
0.07
0.06
0.04

SEQID-03370
290760343
—
—
1
0.56
0.24
0.02
0.07
0.03
0.08
0.03
0.03
0.09
0.04
0.02
0.05
0.14
0.15

SEQID-03371
257672199
—
—
1
0.43
0.23
0.09
0.10
0.03
0.03
0.01
0.04
0.06
0.06
0.02
0.05
0.11
0.13

SEQID-03372
77737576
—
—
1
0.48
0.26
0.08
0.06
0.01
0.02
0.00
0.10
0.02
0.07
0.03
0.06
0.11
0.02

SEQID-03373
21B339750
—
—
1
0.46
0.28
0.06
0.08
0.05
0.07
0.02
0.04
0.07
0.07
0.02
0.08
0.12
0.04

SEQID-03374
218401648
—
—
1
0.55
0.21
0.04
0.04
0.03
0.05
0.00
0.02
0.06
0.07
0.04
0.05
0.10
0.13

SEQID-03375
168304
—
—
1
0.52
0.26
0.02
0.07
0.03
0.08
0.00
0.09
0.08
0.04
0.02
0.10
0.12
0.11

SEQID-03376
296520445
—
—
1
0.47
0.23
0.09
0.07
0.04
0.04
0.01
0.04
0.07
0.06
0.01
0.07
0.06
0.08

SEQID-03377
219789721
—
—
1
0.48
0.25
0.08
0.05
0.05
0.05
0.02
0.04
0.06
0.04
0.02
0.06
0.09
0.07

SEQID-03378
295416104
—
—
0
0.46
0.24
0.06
0.06
0.02
0.07
0.00
0.06
0.09
0.05
0.03
0.07
0.09
0.06

SEQID-03379
213573202
—
—
0
0.48
0.23
0.03
0.07
0.03
0.07
0.02
0.04
0.10
0.03
0.04
0.07
0.10
0.08

SEQID-03380
291048676
—
—
1
0.49
0.25
0.05
0.05
0.05
0.03
0.02
0.05
0.09
0.06
0.01
0.08
0.09
0.07

SEQID-03381
395146546
—
—
1
0.47
0.21
0.05
0.08
0.04
0.07
0.01
0.04
0.08
0.04
0.04
0.06
0.08
0.07

SEQID-03382
M0ZKT2
—
—
0
0.45
0.18
0.09
0.17
0.01
0.03
0.01
0.07
0.06
0.03
0.02
0.05
0.08
0.12

SEQID-03383
M1AM20
—
—
1
0.54
0.27
0.02
0.04
0.08
0.07
0.02
0.03
0.04
0.03
0.02
0.07
0.11
0.09

SEQID-03384
MWMY4
—
—
1
0.52
0.27
0.02
0.04
0.06
0.08
0.02
0.04
0.03
0.03
0.02
0.07
0.10
0.08

SEQID-03385
M0ZXL4
—
—
0
0.51
0.26
0.02
0.07
0.03
0.08
0.00
0.09
0.08
0.04
0.02
0.09
0.12
0.10

SEQID-03386
M1AMV9
—
—
0
0.57
0.22
0.01
0.05
0.05
0.07
0.02
0.04
0.04
0.05
0.03
0.07
0.07
0.12

SEQID-03387
M1AKE5
—
—
0
0.47
0.27
0.02
0.05
0.08
0.05
0.04
0.04
0.04
0.04
0.00
0.08
0.12
0.06

SEQID-03388
M1AGXS
—
—
1
0.47
0.20
0.06
0.04
0.06
0.06
0.00
0.05
0.07
0.04
0.02
0.05
0.10
0.07

SEQID-03389
M1C5FS
—
—
1
0.48
0.21
0.05
0.07
0.02
0.06
0.01
0.03
0.09
0.04
0.03
0.07
0.08
0.06

SEQID-03390
M18VW6
—
—
1
0.48
0.22
0.04
0.06
0.05
0.06
0.00
0.04
0.08
0.03
0.03
0.06
0.11
0.07

SEQID-03391
M02HXS
—
—
0
0.54
0.17
0.06
0.05
0.02
0.02
0.00
0.02
0.10
0.03
0.02
0.07
0.05
0.23

SEQID-03392
M02HUS
—
—
0
0.47
0.22
0.04
0.21
0.02
0.03
0.00
0.02
0.05
0.09
0.02
0.07
0.08
0.11

SEQID-03393
J7EQ13
—
—
0
0.39
0.16
0.05
0.03
0.06
0.03
0.10
0.01
0.08
0.05
0.02
0.04
0.07
0.09

SEQID-03394
M1S3W0
—
—
1
0.48
0.20
0.06
0.02
0.05
0.06
0.00
0.05
0.07
0.02
0.02
0.04
0.11
0.07

SEQID-03395
09M3H3
—
—
1
0.44
0.23
0.06
0.10
0.03
0.07
0.01
0.03
0.13
0.02
0.03
0.05
0.12
0.08

SEQID-03396
QSLK04
—
—
1
0.51
0.22
0.06
0.05
0.04
0.08
0.01
0.01
0.07
0.05
0.02
0.06
0.06
0.10

SEQID-03397
M1ACZ6
—
—
1
0.53
0.24
0.04
0.06
0.05
0.06
0.01
0.02
0.11
0.02
0.03
0.07
0.08
0.11

SEQID-03398
MQZI18
—
—
1
0.45
0.20
0.05
0.06
0.05
0.08
0.01
0.04
0.10
0.04
0.01
0.07
0.07
0.10

SEQID-03399
M1BF10
—
—
0
0.45
0.19
0.07
0.07
0.04
0.09
0.00
0.02
0.10
0.01
0.00
0.00
0.14
0.16

SEQID-03400
M1B1VV6
—
—
1
0.52
0.24
0.04
0.08
0.06
0.07
0.00
0.04
0.07
0.03
0.03
0.06
0.12
0.07

SEQID-03401
M16QM9
—
—
1
0.52
0.21
0.04
0.06
0.03
0.06
0.01
0.03
0.07
0.05
0.03
0.07
0.06
0.12

SEQID-03402
K7WJX9
—
—
0
0.44
0.10
0.06
0.16
0.04
0.01
0.09
0.00
0.07
0.03
0.03
0.01
0.06
0.03

SEQID-03403
M1CQ57
—
—
0
0.45
0.17
0.06
0.15
0.02
0.05
0.01
0.02
0.07
0.06
0.03
0.06
0.07
0.09

SEQID-03404
M02VD2
—
—
1
0.42
0.20
0.07
0.06
0.05
0.05
0.01
0.04
0.08
0.05
0.01
0.05
0.11
0.07

SEQID-03405
M161K7
—
—
0
0.39
0.22
0.08
0.11
0.06
0.02
0.00
0.04
0.06
0.08
0.02
0.05
0.11
0.10

SEQID-03406
M1B8F8
—
—
0
0.38
0.15
0.04
0.02
0.04
0.03
0.11
0.02
0.07
0.06
0.03
0.05
0.07
0.08

SEQID-03407
M1AW0
—
—
1
0.50
0.24
0.05
0.04
0.03
0.06
0.02
0.03
0.08
0.04
0.02
0.06
0.09
0.09

SEQID-03408
M1CVH4
—
—
1
0.44
0.17
0.04
0.09
0.05
0.07
0.02
0.03
0.07
0.03
0.05
0.05
0.06
0.06

SEQID-03409
M1CQ02
—
—
1
0.49
0.22
0.06
0.06
0.04
0.06
0.01
0.03
0.08
0.03
0.02
0.06
0.09
0.08

SEQID-03410
MWR3
—
—
0
0.48
0.21
0.07
0.11
0.06
0.04
0.02
0.01
0.03
0.06
0.00
0.07
0.05
0.13

SEQID-03411
M1AMY3
—
—
1
0.51
0.26
0.03
0.02
0.10
0.08
0.02
0.01
0.06
0.03
0.03
0.06
0.11
0.07

SEQID-03412
M0ZI9B
—
—
1
0.47
0.22
0.07
0.07
0.05
0.06
0.01
0.03
0.08
0.04
0.04
0.06
0.09
0.08

SEQID-03413
MQZSD6
—
—
1
0.47
0.22
0.07
0.04
0.05
0.06
0.01
0.04
0.09
0.05
0.02
0.06
0.08
0.10

SEQID-03414
M1D7J7
—
—
1
0.46
0.23
0.06
0.06
0.04
0.04
0.02
0.04
0.09
0.04
0.02
0.06
0.11
0.07

SEQID-03415
M0ZS12
—
—
1
0.52
0.26
0.08
0.03
0.03
0.05
0.01
0.01
0.06
0.06
0.01
0.09
0.11
0.06

SEQID-03416
A0Z275
—
—
1
0.58
0.21
0.05
0.10
0.08
0.02
0.00
0.00
0.06
0.03
0.08
0.13
0.06
0.12

SEQID-03417
A1A073
—
—
1
0.61
0.15
0.03
0.09
0.02
0.07
0.00
0.02
0.05
0.04
0.09
0.04
0.02
0.16

SEQID-03418
A1A091
—
—
0
0.45
0.26
0.03
0.13
0.05
0.04
0.00
0.03
0.09
0.03
0.02
0.08
0.08
0.08

SEQID-03419
A2WLS0
—
—
0
0.37
0.09
0.04
0.00
0.04
0.07
0.16
0.02
0.12
0.07
0.02
0.02
0.00
0.16

SEQID-03420
A2YN17
—
—
1
0.36
0.17
0.05
0.14
0.01
0.06
0.02
0.05
0.11
0.08
0.04
0.01
0.10
0.06

SEQID-03421
A1GGCS
—
—
1
0.51
0.24
0.04
0.20
0.06
0.02
0.01
0.04
0.01
0.02
0.03
0.12
0.09
0.10

SEQID-03422
A4GYV1
—
—
1
0.58
0.21
0.04
0.10
0.10
0.02
0.00
0.00
0.04
0.03
0.08
0.10
0.09
0.12

SEQID-03423
ASA779
—
—
1
0.44
0.24
0.04
0.10
0.04
0.05
0.03
0.06
0.10
0.01
0.04
0.01
0.18
0.04

SEQID-03424
ASLHGJ
—
—
1
0.36
0.20
0.05
0.26
0.00
0.04
0.02
0.05
0.03
0.04
0.03
0.04
0.15
0.04

SEQID-03425
ASVI25
—
—
1
0.34
0.15
0.04
0.04
0.03
0.26
0.00
0.03
0.14
0.02
0.03
0.04
0.07
0.05

SEQID-03426
A5VIV3
—
—
1
0.51
0.22
0.04
0.06
0.03
0.07
0.02
0.01
0.10
0.04
0.05
0.06
0.10
0.09

SEQID-03427
A5Y79S
—
—
1
0.37
0.15
0.04
0.07
0.05
0.05
0.10
0.04
0.10
0.04
0.01
0.03
0.08
0.09

SEQID-03428
A6QLV3
—
—
1
0.49
0.27
0.03
0.06
0.08
0.04
0.01
0.03
0.09
0.02
0.03
0.05
0.18
0.10

SEQID-03429
A6QPV8
—
—
1
0.50
0.15
0.06
0.04
0.02
0.03
0.01
0.04
0.08
0.08
0.03
0.04
0.05
0.18

SEQID-03430
A6ZNN4
—
—
0
0.36
0.04
0.00
0.00
0.02
0.05
0.27
0.02
0.12
0.05
0.04
0.02
0.02
0.18

SEQID-03431
A62UT6
—
—
1
0.53
0.13
0.03
0.08
0.05
0.10
0.00
0.02
0.08
0.03
0.04
0.04
0.06
0.23

SEQID-03432
A7V3J1
—
—
1
0.58
0.19
0.03
0.12
0.06
0.03
0.00
0.00
0.05
0.03
0.09
0.11
0.06
0.13

SEQID-03433
A7YWC8
—
—
0
0.31
0.22
0.12
0.15
0.01
0.05
0.01
0.09
0.12
0.03
0.02
0.02
0.17
0.01

SEQID-03434
B1A953
—
—
1
0.43
0.21
0.04
0.27
0.05
0.02
0.01
0.04
0.01
0.02
0.03
0.11
0.08
0.07

SEQID-03435
B1A969
—
—
0
0.40
0.22
0.02
0.32
0.03
0.00
0.07
0.06
0.03
0.03
0.03
0.15
0.03
0.11

SEQID-03436
B2G634
—
—
1
0.57
0.24
0.04
0.01
0.05
0.06
0.00
0.03
0.09
0.03
0.03
0.08
0.09
0.12

SEQID-03437
B2G729
—
—
1
0.41
0.09
0.05
0.05
0.08
0.09
0.00
0.07
0.09
0.00
0.03
0.04
0.04
0.01

SEQID-03438
83WC71
—
—
1
0.37
0.17
0.04
0.00
0.06
0.16
0.00
0.05
0.15
0.02
0.01
0.04
0.09
0.03

SEQID-03439
BSK212
—
—
1
0.45
0.17
0.05
0.05
0.04
0.08
0.06
0.04
0.08
0.04
0.04
0.02
0.07
0.06

SEQID-03440
B5K9P2
—
—
1
0.44
0.17
0.05
0.05
0.04
0.09
0.06
0.04
0.08
0.03
0.04
0.02
0.06
0.06

SEQID-03441
B7GNC2
—
—
0
0.57
0.29
0.05
0.12
0.09
0.03
0.00
0.02
0.06
0.03
0.06
0.05
0.10
0.10

SEQID-03442
B7GND6
—
—
1
0.61
0.15
0.03
0.09
0.02
0.07
0.00
0.02
0.05
0.04
0.08
0.04
0.02
0.17

SEQID-03443
B3DW17
—
—
1
0.60
0.15
0.03
0.10
0.02
0.07
0.00
0.02
0.04
0.04
0.09
0.04
0.02
0.15

SEQID-03444
E1BLN6
—
—
1
0.23
0.12
0.02
0.11
0.01
0.02
0.10
0.10
0.06
0.03
0.01
0.02
0.04
0.03

SEQID-03445
E7Q5T7
—
—
1
0.42
0.19
0.03
0.05
0.07
0.06
0.00
0.06
0.16
0.01
0.02
0.05
0.11
0.11

SEQID-03446
F1MUE4
—
—
1
0.49
0.24
0.04
0.07
0.03
0.05
0.01
0.05
0.12
0.03
0.02
0.02
0.16
0.08

SEQID-03447
F1MWJ0
—
—
1
0.30
0.18
0.02
0.03
0.02
0.02
0.03
0.05
0.01
0.12
0.02
0.05
0.07
0.04

SEQID-03448
F1SGG1
—
—
1
0.40
0.23
0.05
0.11
0.04
0.06
0.00
0.07
0.12
0.03
0.02
0.05
0.13
0.06

SEQID-03449
G1NEV4
—
—
1
0.38
0.19
0.05
0.10
0.04
0.04
0.00
0.05
0.09
0.10
0.01
0.04
0.10
0.06

SEQID-03450
G3MXL3
—
—
1
0.37
0.18
0.05
0.08
0.04
0.04
0.01
0.06
0.08
0.12
0.01
0.04
0.09
0.06

SEQID-03451
I3LR13
—
—
1
0.40
0.19
0.04
0.11
0.02
0.04
0.01
0.07
0.09
0.03
0.04
0.02
0.12
0.02

SEQID-03452
O04433
—
—
1
0.51
0.14
0.03
0.07
0.01
0.02
0.02
0.03
0.09
0.02
0.02
0.02
0.07
0.32

SEQID-03453
O42395
—
—
1
0.32
0.09
0.04
0.12
0.03
0.05
0.12
0.03
0.09
0.06
0.06
0.04
0.03
0.08

SEQID-03454
O62650
—
—
1
0.37
0.15
0.03
0.07
0.05
0.06
0.10
0.04
0.10
0.04
0.01
0.03
0.08
0.09

SEQID-03455
P00127
—
—
1
0.35
0.14
0.04
0.03
0.02
0.15
0.01
0.06
0.27
0.02
0.06
0.01
0.07
0.07

SEQID-03456
P02313
—
—
0
0.34
0.03
0.12
0.07
0.04
0.10
0.00
0.04
0.10
0.06
0.00
0.00
0.01
0.29

SEQID-03457
P02314
—
—
0
0.37
0.03
0.11
0.07
0.04
0.09
0.00
0.04
0.10
0.05
0.00
0.00
0.01
0.30

SEQID-03458
P02687
—
—
1
0.39
0.10
0.05
0.15
0.01
0.06
0.00
0.06
0.01
0.08
0.07
0.02
0.06
0.09

SEQID-03459
P04101
—
—
0
0.10
0.05
0.02
0.60
0.00
0.00
0.16
0.00
0.00
0.00
0.02
0.02
0.00
0.00

SEQID-03460
P05016
—
—
1
0.54
0.27
0.03
0.04
0.07
0.04
0.02
0.03
0.10
0.01
0.02
0.04
0.17
0.10

SEQID-03461
P05739
—
—
1
0.53
0.23
0.05
0.08
0.04
0.03
0.00
0.04
0.09
0.02
0.01
0.01
0.11
0.17

SEQID-03462
P07107
—
—
1
0.52
0.13
0.06
0.02
0.02
0.09
0.00
0.03
0.13
0.03
0.03
0.05
0.06
0.19

SEQID-03463
P07924
—
—
0
0.41
0.20
0.04
0.17
0.03
0.05
0.00
0.09
0.06
0.04
0.04
0.12
0.06
0.09

SEQID-03464
P03771
—
—
1
0.52
0.17
0.02
0.15
0.09
0.02
0.00
0.06
0.03
0.02
0.11
0.07
0.07
0.06

SEQID-03465
P0C074
—
—
0
0.40
0.19
0.02
0.14
0.03
0.05
0.00
0.09
0.03
0.03
0.03
0.05
0.12
0.09

SEQID-03466
P0C0T4
—
—
0
0.49
0.21
0.09
0.09
0.00
0.04
0.00
0.05
0.05
0.02
0.03
0.08
0.08
0.19

SEQID-03467
P0C453
—
—
1
0.52
0.11
0.02
0.11
0.03
0.00
0.00
0.06
0.02
0.02
0.02
0.03
0.03
0.22

SEQID-03468
P0C5N1
—
—
1
0.62
0.25
0.02
0.21
0.03
0.00
0.02
0.00
0.04
0.03
0.15
0.10
0.12
0.04

SEQID-03469
P0C5N3
—
—
1
0.60
0.23
0.02
0.03
0.05
0.04
0.00
0.04
0.13
0.02
0.01
0.06
0.14
0.16

SEQID-03470
P10669
—
—
1
0.37
0.15
0.03
0.06
0.05
0.05
0.10
0.04
0.11
0.04
0.01
0.03
0.03
0.09

SEQID-03471
P12902
—
—
0
0.36
0.01
0.12
0.06
0.04
0.07
0.00
0.01
0.18
0.03
0.01
0.00
0.01
0.29

SEQID-03472
P13204
—
—
1
0.35
0.23
0.04
0.17
0.01
0.05
0.03
0.07
0.08
0.07
0.04
0.02
0.16
0.01

SEQID-03473
P14402
—
—
0
0.06
0.01
0.01
0.72
0.00
0.00
0.00
0.00
0.00
0.02
0.00
0.00
0.00
0.00

SEQID-03474
P15720
—
—
1
0.41
0.10
0.04
0.16
0.01
0.04
0.00
0.03
0.02
0.09
0.10
0.02
0.04
0.03

SEQID-03475
P13114
—
—
1
0.56
0.26
0.03
0.04
0.06
0.04
0.02
0.03
0.09
0.01
0.02
0.04
0.17
0.11

SEQID-03476
P19948
—
—
1
0.50
0.25
0.04
0.18
0.05
0.03
0.01
0.04
0.00
0.02
0.02
0.12
0.10
0.11

SEQID-03477
P20158
—
—
0
0.28
0.06
0.03
0.18
0.07
0.02
0.16
0.10
0.02
0.09
0.00
0.04
0.00
0.10

SEQID-03478
P20159
—
—
0
0.29
0.10
0.03
0.15
0.04
0.04
0.16
0.10
0.03
0.09
0.00
0.02
0.02
0.10

SEQID-03479
P23935
—
—
0
0.52
0.25
0.04
0.05
0.03
0.02
0.01
0.06
0.14
0.03
0.02
0.07
0.13
0.13

SEQID-03480
P24052
—
—
1
0.49
0.14
0.07
0.04
0.02
0.04
0.07
0.02
0.09
0.05
0.01
0.02
0.09
0.23

SEQID-03481
P25362
—
—
1
0.52
0.19
0.04
0.05
0.03
0.07
0.02
0.03
0.10
0.01
0.03
0.04
0.11
0.09

SEQID-03482
P27007
—
—
1
0.45
0.30
0.07
0.10
0.02
0.05
0.00
0.05
0.11
0.00
0.01
0.03
0.10
0.10

SEQID-03483
P30562
—
—
1
0.60
0.21
0.06
0.04
0.02
0.05
0.00
0.02
0.10
0.04
0.10
0.06
0.12
0.14

SEQID-03484
P31162
—
—
1
0.62
0.20
0.03
0.09
0.08
0.02
0.00
0.00
0.04
0.04
0.07
0.11
0.06
0.17

SEQID-03485
P31853
—
—
0
0.54
0.26
0.06
0.03
0.03
0.05
0.00
0.05
0.10
0.01
0.01
0.06
0.16
0.12

SEQID-03486
P32046
—
—
1
0.57
0.16
0.06
0.09
0.01
0.01
0.04
0.03
0.03
0.05
0.03
0.06
0.03
0.20

SEQID-03487
P32344
—
—
1
0.53
0.15
0.03
0.17
0.04
0.01
0.01
0.04
0.04
0.04
0.01
0.04
0.07
0.13

SEQID-03488
P32570
—
—
1
0.52
0.24
0.04
0.05
0.07
0.06
0.01
0.07
0.12
0.00
0.01
0.07
0.11
0.07

SEQID-03489
P32760
—
—
1
0.50
0.09
0.03
0.04
0.04
0.03
0.07
0.09
0.09
0.04
0.01
0.01
0.05
0.24

SEQID-03490
P33309
—
—
1
0.54
0.23
0.03
0.01
0.04
0.09
0.01
0.03
0.09
0.02
0.02
0.07
0.11
0.16

SEQID-03491
P36047
—
—
1
0.52
0.28
0.01
0.03
0.10
0.07
0.00
0.03
0.10
0.01
0.03
0.08
0.17
0.11

SEQID-03492
P36071
—
—
1
0.63
0.23
0.01
0.09
0.05
0.02
0.00
0.02
0.07
0.00
0.03
0.10
0.10
0.10

SEQID-03493
P36493
—
—
0
0.60
0.15
0.04
0.12
0.05
0.00
0.00
0.02
0.00
0.02
0.00
0.05
0.05
0.24

SEQID-03494
P36835
—
—
1
0.54
0.25
0.03
0.04
0.06
0.05
0.02
0.04
0.09
0.01
0.02
0.03
0.18
0.10

SEQID-03495
P37360
—
—
0
0.24
0.01
0.05
0.00
0.00
0.03
0.30
0.02
0.17
0.06
0.00
0.00
0.00
0.15

SEQID-03496
P38202
—
—
1
0.51
0.13
0.04
0.11
0.02
0.07
0.00
0.05
0.09
0.02
0.03
0.03
0.07
0.23

SEQID-03497
P38828
—
—
1
0.54
0.25
0.01
0.05
0.05
0.05
0.00
0.09
0.03
0.03
0.01
0.09
0.07
0.14

SEQID-03498
P40060
—
—
0
0.45
0.24
0.02
0.05
0.03
0.10
0.00
0.03
0.14
0.01
0.01
0.08
0.11
0.09

SEQID-03499
P40062
—
—
0
0.58
0.24
0.02
0.10
0.04
0.03
0.02
0.00
0.04
0.01
0.04
0.05
0.15
0.13

SEQID-03500
P40509
—
—
1
0.43
0.24
0.04
0.01
0.03
0.07
0.01
0.07
0.10
0.02
0.02
0.05
0.15
0.08

SEQID-03501
P40619
—
—
1
0.41
0.07
0.03
0.04
0.05
0.11
0.00
0.05
0.11
0.03
0.01
0.01
0.03
0.23

SEQID-03502
P40620
—
—
1
0.40
0.08
0.06
0.03
0.04
0.10
0.01
0.02
0.18
0.04
0.01
0.01
0.03
0.23

SEQID-03503
P41648
—
—
1
0.47
0.28
0.00
0.15
0.03
0.06
0.00
0.09
0.01
0.03
0.03
0.07
0.18
0.09

SEQID-03504
P43389
—
—
0
0.35
0.14
0.03
0.00
0.05
0.12
0.16
0.02
0.06
0.05
0.00
0.05
0.00
0.12

SEQID-03505
P46963
—
—
1
0.50
0.19
0.02
0.06
0.05
0.09
0.01
0.05
0.06
0.00
0.04
0.05
0.11
0.09

SEQID-03506
P46988
—
—
1
0.51
0.22
0.03
0.06
0.05
0.06
0.01
0.03
0.09
0.00
0.01
0.04
0.13
0.14

SEQID-03507
P47005
—
—
1
0.50
0.24
0.02
0.05
0.09
0.07
0.01
0.04
0.06
0.00
0.03
0.09
0.12
0.09

SEQID-03508
P47815
—
—
1
0.41
0.19
0.03
0.10
0.04
0.13
0.02
0.03
0.10
0.06
0.02
0.06
0.07
0.13

SEQID-03509
P50291
—
—
1
0.37
0.15
0.04
0.07
0.05
0.05
0.10
0.04
0.10
0.04
0.01
0.03
0.03
0.09

SEQID-03510
P53079
—
—
1
0.51
0.25
0.01
0.04
0.09
0.09
0.01
0.07
0.05
0.00
0.03
0.06
0.15
0.07

SEQID-03511
P53335
—
—
1
0.53
0.13
0.03
0.08
0.05
0.10
0.00
0.02
0.08
0.03
0.04
0.04
0.07
0.23

SEQID-03512
P53910
—
—
0
0.61
0.26
0.03
0.10
0.03
0.02
0.00
0.04
0.05
0.02
0.06
0.10
0.09
0.14

SEQID-03513
P53970
—
—
1
0.54
0.26
0.03
0.05
0.03
0.06
0.02
0.03
0.10
0.04
0.03
0.05
0.15
0.11

SEQID-03514
P55944
—
—
0
0.24
0.01
0.05
0.00
0.00
0.03
0.30
0.02
0.17
0.06
0.00
0.00
0.00
0.15

SEQID-03515
P60577
—
—
1
0.58
0.18
0.03
0.10
0.05
0.01
0.00
0.00
0.09
0.02
0.08
0.03
0.04
0.12

SEQID-03516
P60750
—
—
1
0.53
0.17
0.06
0.01
0.03
0.07
0.00
0.09
0.05
0.03
0.02
0.05
0.07
0.18

SEQID-03517
P61848
—
—
0
0.60
0.14
0.02
0.10
0.04
0.00
0.00
0.04
0.00
0.03
0.00
0.06
0.06
0.25

SEQID-03518
P63080
—
—
1
0.58
0.21
0.06
0.04
0.02
0.05
0.00
0.02
0.10
0.04
0.10
0.05
0.12
0.14

SEQID-03519
P71479
—
—
0
0.49
0.29
0.06
0.11
0.03
0.10
0.00
0.04
0.07
0.04
0.05
0.09
0.11
0.05

SEQID-03520
P80272
—
—
0
0.36
0.03
0.12
0.07
0.04
0.10
0.00
0.04
0.09
0.06
0.00
0.00
0.01
0.30

SEQID-03521
P80680
—
—
1
0.46
0.21
0.09
0.10
0.01
0.06
0.01
0.04
0.12
0.03
0.03
0.02
0.05
0.09

SEQID-03522
P81558
—
—
1
0.38
0.09
0.06
0.15
0.01
0.06
0.00
0.06
0.01
0.09
0.07
0.02
0.06
0.09

SEQID-03523
P82010
—
—
0
0.33
0.04
0.04
0.09
0.07
0.04
0.16
0.05
0.05
0.03
0.00
0.00
0.02
0.10

SEQID-03524
P82920
—
—
1
0.39
0.14
0.03
0.22
0.05
0.03
0.03
0.01
0.09
0.02
0.01
0.06
0.05
0.07

SEQID-03525
P83487
—
—
1
0.39
0.11
0.04
0.17
0.01
0.06
0.00
0.05
0.01
0.09
0.07
0.02
0.06
0.08

SEQID-03526
P84997
—
—
1
0.59
0.20
0.07
0.02
0.03
0.05
0.00
0.03
0.11
0.04
0.10
0.04
0.11
0.13

SEQID-03527
Q02368
—
—
1
0.37
0.13
0.05
0.16
0.01
0.07
0.03
0.05
0.11
0.02
0.04
0.01
0.09
0.07

SEQID-03528
Q034H8
—
—
1
0.53
0.28
0.05
0.06
0.03
0.07
0.00
0.05
0.09
0.05
0.05
0.08
0.13
0.09

SEQID-03529
Q034Z7
—
—
1
0.49
0.28
0.04
0.11
0.05
0.07
0.00
0.01
0.07
0.04
0.01
0.11
0.09
0.11

SEQID-03530
Q03525
—
—
1
0.50
0.11
0.03
0.03
0.04
0.07
0.00
0.01
0.09
0.04
0.03
0.02
0.05
0.27

SEQID-03531
Q038I0
—
—
1
0.56
0.20
0.05
0.18
0.05
0.03
0.00
0.02
0.00
0.03
0.06
0.05
0.08
0.15

SEQID-03532
Q03919
—
—
0
0.58
0.31
0.01
0.04
0.01
0.05
0.00
0.07
0.12
0.04
0.05
0.08
0.16
0.12

SEQID-03533
Q03AJ7
—
—
1
0.46
0.20
0.05
0.14
0.07
0.05
0.00
0.04
0.07
0.03
0.04
0.04
0.11
0.13

SEQID-03534
Q03AZ8
—
—
1
0.37
0.17
0.04
0.00
0.06
0.17
0.00
0.05
0.14
0.02
0.01
0.04
0.09
0.03

SEQID-03535
Q042Y3
—
—
1
0.54
0.28
0.03
0.06
0.04
0.08
0.01
0.04
0.03
0.03
0.02
0.09
0.14
0.12

SEQID-03536
Q043Y8
—
—
0
0.52
0.29
0.04
0.04
0.07
0.06
0.00
0.07
0.07
0.03
0.02
0.07
0.14
0.11

SEQID-03537
Q045P3
—
—
1
0.37
0.19
0.03
0.03
0.06
0.19
0.00
0.05
0.11
0.02
0.01
0.04
0.09
0.02

SEQID-03538
Q046A4
—
—
0
0.54
0.27
0.03
0.09
0.03
0.06
0.00
0.00
0.09
0.03
0.03
0.10
0.09
0.09

SEQID-03539
Q04869
—
—
1
0.51
0.23
0.06
0.03
0.05
0.07
0.01
0.04
0.07
0.04
0.03
0.06
0.09
0.11

SEQID-03540
Q048Z6
—
—
1
0.37
0.19
0.05
0.03
0.03
0.20
0.00
0.04
0.15
0.02
0.02
0.04
0.09
0.01

SEQID-03541
Q04935
—
—
1
0.47
0.14
0.04
0.05
0.04
0.05
0.01
0.11
0.06
0.02
0.02
0.04
0.08
0.11

SEQID-03542
Q049N0
—
—
1
0.49
0.29
0.06
0.06
0.03
0.09
0.01
0.03
0.08
0.04
0.03
0.09
0.11
0.10

SEQID-03543
Q04C52
—
—
1
0.34
0.14
0.03
0.06
0.05
0.25
0.00
0.03
0.14
0.02
0.03
0.04
0.06
0.04

SEQID-03544
Q05462
—
—
1
0.62
0.21
0.04
0.07
0.02
0.06
0.01
0.02
0.03
0.02
0.02
0.03
0.09
0.23

SEQID-03545
Q05566
—
—
1
0.50
0.09
0.03
0.11
0.05
0.00
0.00
0.06
0.02
0.02
0.02
0.03
0.03
0.22

SEQID-03546
Q06071
—
—
1
0.49
0.23
0.01
0.03
0.09
0.05
0.01
0.04
0.10
0.00
0.03
0.07
0.12
0.10

SEQID-03547
Q06162
—
—
1
0.43
0.26
0.03
0.07
0.04
0.05
0.00
0.12
0.11
0.01
0.02
0.07
0.18
0.03

SEQID-03548
Q06835
—
—
1
0.44
0.19
0.01
0.10
0.07
0.07
0.11
0.04
0.04
0.04
0.02
0.05
0.08
0.14

SEQID-03549
Q06831
—
—
1
0.44
0.26
0.02
0.12
0.03
0.08
0.03
0.06
0.06
0.00
0.01
0.07
0.15
0.04

SEQID-03550
Q03273
—
—
1
0.44
0.14
0.06
0.07
0.07
0.08
0.07
0.06
0.07
0.01
0.04
0.06
0.02
0.07

SEQID-03551
Q03423
—
—
0
0.48
0.16
0.01
0.36
0.01
0.01
0.00
0.02
0.00
0.00
0.24
0.01
0.13
0.03

SEQID-03552
Q09MB5
—
—
0
0.56
0.25
0.00
0.06
0.06
0.02
0.00
0.05
0.12
0.01
0.05
0.04
0.21
0.07

SEQID-03553
Q09ME2
—
—
1
0.47
0.27
0.03
0.20
0.07
0.04
0.01
0.00
0.06
0.04
0.01
0.14
0.09
0.07

SEQID-03554
Q09MF5
—
—
1
0.43
0.24
0.04
0.25
0.06
0.02
0.01
0.04
0.01
0.01
0.02
0.11
0.09
0.06

SEQID-03555
Q0II65
—
—
1
0.50
0.13
0.04
0.12
0.02
0.03
0.00
0.02
0.20
0.02
0.02
0.02
0.07
0.11

SEQID-03556
Q0P5B3
—
—
1
0.44
0.18
0.04
0.08
0.05
0.09
0.09
0.06
0.04
0.04
0.02
0.03
0.11
0.09

SEQID-03557
Q0VCD4
—
—
1
0.50
0.23
0.04
0.10
0.04
0.06
0.01
0.03
0.08
0.03
0.05
0.04
0.12
0.04

SEQID-03558
Q0VD26
—
—
1
0.44
0.14
0.03
0.11
0.06
0.04
0.01
0.03
0.10
0.09
0.03
0.01
0.03
0.06

SEQID-03559
Q12028
—
—
1
0.51
0.28
0.03
0.04
0.07
0.09
0.01
0.04
0.07
0.02
0.02
0.09
0.15
0.09

SEQID-03560
Q14FD4
—
—
1
0.43
0.23
0.05
0.24
0.07
0.02
0.01
0.04
0.01
0.01
0.02
0.10
0.11
0.05

SEQID-03561
Q17Q91
—
—
1
0.37
0.12
0.03
0.13
0.07
0.06
0.04
0.03
0.07
0.02
0.01
0.02
0.06
0.09

SEQID-03562
Q1G940
—
—
0
0.46
0.24
0.06
0.04
0.04
0.05
0.00
0.04
0.10
0.05
0.00
0.06
0.10
0.11

SEQID-03563
Q1G9J5
—
—
1
0.61
0.18
0.02
0.11
0.07
0.02
0.00
0.02
0.00
0.03
0.02
0.02
0.07
0.19

SEQID-03564
Q1GBQ3
—
—
1
0.33
0.14
0.04
0.06
0.05
0.25
0.00
0.03
0.14
0.02
0.03
0.04
0.06
0.04

SEQID-03565
Q2KI95
—
—
1
0.40
0.12
0.03
0.03
0.01
0.06
0.11
0.05
0.03
0.03
0.04
0.04
0.06
0.09

SEQID-03566
Q2KIA3
—
—
1
0.44
0.19
0.04
0.08
0.05
0.07
0.09
0.04
0.05
0.03
0.02
0.03
0.12
0.10

SEQID-03567
Q2K1T5
—
—
1
0.34
0.13
0.04
0.06
0.03
0.07
0.10
0.05
0.13
0.05
0.01
0.01
0.03
0.05

SEQID-03568
Q2L927
—
—
1
0.44
0.23
0.04
0.26
0.05
0.02
0.01
0.04
0.01
0.02
0.03
0.11
0.09
0.09

SEQID-03569
Q2M2S7
—
—
1
0.33
0.11
0.05
0.10
0.06
0.05
0.08
0.04
0.08
0.03
0.04
0.01
0.05
0.06

SEQID-03570
Q2MI60
—
—
1
0.59
0.21
0.04
0.09
0.07
0.03
0.00
0.00
0.05
0.03
0.09
0.11
0.08
0.12

SEQID-03571
Q2MJS5
—
—
0
0.24
0.01
0.05
0.00
0.00
0.05
0.28
0.02
0.15
0.05
0.00
0.00
0.00
0.15

SEQID-03572
Q2T9Q2
—
—
1
0.44
0.25
0.03
0.11
0.01
0.04
0.01
0.08
0.13
0.02
0.04
0.02
0.17
0.07

SEQID-03573
Q2TBR9
—
—
0
0.55
0.15
0.04
0.11
0.02
0.06
0.01
0.06
0.07
0.02
0.02
0.04
0.07
0.24

SEQID-03574
Q2YDK0
—
—
1
0.44
0.12
0.02
0.05
0.03
0.04
0.11
0.02
0.09
0.03
0.05
0.04
0.05
0.11

SEQID-03575
Q32L75
—
—
1
0.50
0.17
0.04
0.10
0.04
0.01
0.01
0.12
0.10
0.01
0.07
0.02
0.12
0.08

SEQID-03576
Q32PJ6
—
—
1
0.42
0.18
0.05
0.07
0.03
0.03
0.05
0.04
0.09
0.03
0.04
0.02
0.08
0.04

SEQID-03577
Q332T6
—
—
1
0.57
0.22
0.04
0.10
0.09
0.02
0.00
0.00
0.05
0.03
0.07
0.12
0.08
0.12

SEQID-03578
Q332U3
—
—
0
0.37
0.19
0.02
0.35
0.03
0.00
0.07
0.06
0.03
0.03
0.03
0.13
0.03
0.11

SEQID-03579
Q3E731
—
—
1
0.37
0.13
0.03
0.07
0.07
0.09
0.04
0.05
0.07
0.04
0.04
0.01
0.11
0.07

SEQID-03580
Q3E732
—
—
0
0.55
0.24
0.03
0.10
0.05
0.05
0.00
0.00
0.00
0.00
0.00
0.09
0.10
0.14

SEQID-03581
Q3E747
—
—
0
0.60
0.19
0.03
0.10
0.02
0.01
0.00
0.05
0.07
0.02
0.03
0.00
0.15
0.30

SEQID-03582
Q3E794
—
—
0
0.54
0.23
0.02
0.18
0.04
0.06
0.00
0.02
0.00
0.00
0.09
0.11
0.09
0.06

SEQID-03583
Q3E813
—
—
0
0.42
0.15
0.02
0.23
0.04
0.02
0.05
0.02
0.06
0.04
0.02
0.02
0.13
0.00

SEQID-03584
Q3E843
—
—
0
0.53
0.19
0.01
0.03
0.02
0.09
0.02
0.02
0.07
0.01
0.03
0.04
0.13
0.07

SEQID-03585
Q3SZ70
—
—
0
0.25
0.08
0.07
0.20
0.02
0.03
0.04
0.03
0.14
0.06
0.05
0.01
0.05
0.00

SEQID-03586
Q3T0Q6
—
—
1
0.30
0.08
0.04
0.13
0.03
0.06
0.12
0.03
0.10
0.07
0.06
0.03
0.03
0.08

SEQID-03587
Q3T0V7
—
—
0
0.46
0.19
0.07
0.10
0.03
0.06
0.00
0.09
0.09
0.04
0.03
0.07
0.07
0.16

SEQID-03588
Q3T0Z3
—
—
1
0.56
0.24
0.02
0.05
0.05
0.09
0.02
0.03
0.05
0.03
0.03
0.09
0.09
0.13

SEQID-03589
Q3T0ZB
—
—
1
0.45
0.23
0.01
0.05
0.07
0.04
0.01
0.01
0.15
0.06
0.01
0.03
0.13
0.07

SEQID-03590
Q3V4Z3
—
—
1
0.58
0.21
0.03
0.10
0.06
0.02
0.00
0.00
0.09
0.03
0.09
0.11
0.07
0.11

SEQID-03591
Q3ZBK6
—
—
1
0.42
0.18
0.02
0.13
0.04
0.04
0.02
0.08
0.07
0.09
0.02
0.06
0.07
0.09

SEQID-03592
Q48585
—
—
1
0.52
0.19
0.04
0.07
0.05
0.02
0.00
0.04
0.08
0.02
0.03
0.04
0.09
0.19

SEQID-03593
Q4VZK1
—
—
0
0.39
0.19
0.02
0.34
0.02
0.00
0.07
0.06
0.03
0.01
0.03
0.15
0.02
0.11

SEQID-03594
Q5BCS7
—
—
1
0.46
0.20
0.07
0.03
0.01
0.05
0.00
0.05
0.17
0.02
0.01
0.05
0.09
0.12

SEQID-03595
Q58DW3
—
—
1
0.47
0.11
0.11
0.13
0.05
0.01
0.01
0.04
0.03
0.03
0.04
0.03
0.06
0.22

SEQID-03596
Q5BIS3
—
—
1
0.46
0.13
0.02
0.14
0.04
0.04
0.02
0.04
0.07
0.06
0.05
0.04
0.05
0.09

SEQID-03597
Q5E9Z8
—
—
0
0.48
0.29
0.02
0.09
0.02
0.07
0.00
0.07
0.13
0.03
0.03
0.09
0.13
0.08

SEQID-03598
Q5EA80
—
—
1
0.44
0.24
0.04
0.09
0.04
0.05
0.03
0.07
0.10
0.02
0.03
0.02
0.18
0.04

SEQID-03599
Q5F4C4
—
—
1
0.51
0.27
0.02
0.06
0.09
0.04
0.01
0.03
0.09
0.03
0.02
0.05
0.18
0.10

SEQID-03600
Q5FHT1
—
—
1
0.52
0.20
0.04
0.01
0.06
0.09
0.01
0.04
0.08
0.03
0.03
0.10
0.06
0.13

SEQID-03601
Q5FJI3
—
—
1
0.58
0.18
0.03
0.13
0.05
0.03
0.00
0.02
0.00
0.03
0.02
0.02
0.06
0.30

SEQID-03602
Q5FK48
—
—
1
0.51
0.23
0.03
0.03
0.03
0.09
0.03
0.01
0.10
0.04
0.05
0.08
0.10
0.07

SEQID-03603
Q5FKL2
—
—
0
0.53
0.29
0.03
0.03
0.06
0.06
0.00
0.07
0.09
0.03
0.02
0.08
0.14
0.12

SEQID-03604
Q5FLW3
—
—
1
0.37
0.19
0.04
0.03
0.05
0.21
0.00
0.06
0.09
0.03
0.02
0.04
0.09
0.02

SEQID-03605
Q5FM69
—
—
0
0.54
0.27
0.03
0.09
0.03
0.07
0.00
0.00
0.08
0.03
0.03
0.10
0.09
0.09

SEQID-03606
Q5FM79
—
—
0
0.60
0.34
0.03
0.03
0.08
0.04
0.00
0.03
0.06
0.06
0.03
0.05
0.01
0.26

SEQID-03607
Q5FME7
—
—
1
0.32
0.14
0.04
0.05
0.06
0.24
0.00
0.02
0.12
0.02
0.02
0.04
0.06
0.05

SEQID-03608
Q5QHW1
—
—
1
0.51
0.22
0.04
0.06
0.03
0.07
0.02
0.01
0.10
0.04
0.05
0.06
0.10
0.09

SEQID-03609
Q5ZHK9
—
—
0
0.53
0.16
0.05
0.12
0.03
0.05
0.01
0.05
0.08
0.03
0.01
0.02
0.10
0.24

SEQID-03610
Q5ZI72
—
—
1
0.35
0.11
0.01
0.06
0.05
0.06
0.01
0.08
0.09
0.09
0.01
0.03
0.04
0.10

SEQID-03611
Q5ZIR5
—
—
0
0.37
0.03
0.08
0.07
0.04
0.03
0.00
0.04
0.17
0.04
0.00
0.00
0.01
0.26

SEQID-03612
Q5ZJI6
—
—
1
0.45
0.23
0.05
0.10
0.02
0.05
0.02
0.07
0.08
0.03
0.08
0.04
0.12
0.07

SEQID-03613
Q5ZK81
—
—
1
0.45
0.15
0.02
0.16
0.01
0.04
0.02
0.04
0.07
0.06
0.05
0.04
0.05
0.07

SEQID-03614
Q6PV25
—
—
1
0.38
0.19
0.05
0.10
0.04
0.04
0.00
0.05
0.09
0.10
0.01
0.04
0.10
0.06

SEQID-03615
Q6Q311
—
—
1
0.51
0.19
0.07
0.07
0.04
0.08
0.01
0.02
0.04
0.04
0.01
0.03
0.10
0.25

SEQID-03616
Q6Q546
—
—
0
0.53
0.31
0.01
0.04
0.04
0.08
0.01
0.06
0.03
0.03
0.03
0.05
0.14
0.13

SEQID-03617
Q6XXM1
—
—
1
0.31
0.19
0.07
0.27
0.00
0.02
0.01
0.06
0.05
0.02
0.02
0.01
0.14
0.02

SEQID-03618
Q74IM0
—
—
1
0.52
0.28
0.05
0.05
0.05
0.07
0.00
0.03
0.08
0.04
0.02
0.10
0.10
0.11

SEQID-03619
Q74IV9
—
—
0
0.52
0.29
0.05
0.04
0.07
0.06
0.00
0.07
0.07
0.03
0.03
0.07
0.14
0.11

SEQID-03620
Q74I20
—
—
1
0.54
0.28
0.04
0.06
0.04
0.08
0.01
0.04
0.03
0.03
0.02
0.09
0.14
0.12

SEQID-03621
Q74LG3
—
—
1
0.35
0.16
0.03
0.05
0.05
0.23
0.00
0.04
0.13
0.02
0.03
0.05
0.07
0.04

SEQID-03622
Q7Y1H8
—
—
1
0.35
0.14
0.10
0.11
0.01
0.09
0.02
0.02
0.05
0.09
0.01
0.02
0.07
0.09

SEQID-03623
Q85WU8
—
—
1
0.49
0.29
0.00
0.16
0.02
0.06
0.00
0.09
0.01
0.03
0.03
0.07
0.18
0.09

SEQID-03624
Q88V14
—
—
1
0.39
0.20
0.04
0.01
0.07
0.19
0.00
0.07
0.10
0.03
0.01
0.06
0.09
0.01

SEQID-03625
Q88V75
—
—
1
0.47
0.13
0.03
0.10
0.01
0.07
0.02
0.06
0.10
0.03
0.02
0.06
0.09
0.05

SEQID-03626
Q88WJ7
—
—
0
0.41
0.21
0.04
0.05
0.06
0.07
0.00
0.07
0.12
0.01
0.04
0.08
0.09
0.07

SEQID-03627
Q88WK6
—
—
1
0.57
0.18
0.04
0.16
0.05
0.03
0.00
0.02
0.00
0.03
0.06
0.02
0.06
0.16

SEQID-03628
QSEX0S
—
—
1
0.54
0.19
0.04
0.01
0.06
0.06
0.00
0.05
0.03
0.03
0.01
0.04
0.10
0.18

SEQID-03629
Q88XW8
—
—
0
0.56
0.31
0.06
0.13
0.02
0.05
0.00
0.06
0.04
0.03
0.06
0.12
0.10
0.12

SEQID-03630
Q88Z77
—
—
1
0.33
0.16
0.04
0.03
0.03
0.28
0.00
0.04
0.10
0.03
0.02
0.05
0.09
0.05

SEQID-03631
Q3H7U1
—
—
1
0.43
0.17
0.04
0.07
0.05
0.07
0.02
0.05
0.09
0.04
0.03
0.03
0.03
0.04

SEQID-03632
Q3HZ03
—
—
1
0.45
0.26
0.05
0.10
0.03
0.05
0.05
0.06
0.08
0.04
0.02
0.06
0.18
0.07

SEQID-03633
Q8LJS2
—
—
1
0.42
0.14
0.05
0.01
0.03
0.12
0.01
0.04
0.11
0.04
0.03
0.03
0.06
0.15

SEQID-03634
Q8SPJ1
—
—
1
0.45
0.24
0.06
0.07
0.05
0.05
0.02
0.06
0.07
0.03
0.03
0.05
0.13
0.05

SEQID-03635
Q3TGQ5
—
—
0
0.40
0.08
0.06
0.17
0.06
0.06
0.09
0.00
0.02
0.02
0.02
0.00
0.04
0.09

SEQID-03636
Q3TGU5
—
—
1
0.65
0.24
0.02
0.07
0.05
0.05
0.00
0.00
0.00
0.03
0.09
0.05
0.10
0.14

SEQID-03637
Q90370
—
—
1
0.43
0.13
0.03
0.09
0.03
0.04
0.01
0.09
0.08
0.02
0.12
0.02
0.08
0.05

SEQID-03638
Q90888
—
—
1
0.43
0.13
0.03
0.09
0.03
0.04
0.01
0.09
0.09
0.02
0.12
0.02
0.09
0.05

SEQID-03639
Q9SKV7
—
—
1
0.47
0.19
0.04
0.12
0.02
0.03
0.00
0.03
0.09
0.04
0.01
0.03
0.10
0.05

SEQID-03640
Q9M4U5
—
—
1
0.42
0.13
0.05
0.00
0.03
0.13
0.01
0.03
0.13
0.04
0.03
0.02
0.06
0.16

SEQID-03641
W5P481
—
—
1
0.24
0.10
0.07
0.09
0.02
0.05
0.01
0.05
0.06
0.15
0.01
0.02
0.04
0.05

SEQID-03642
W5PVF9
—
—
1
0.37
0.15
0.04
0.09
0.05
0.06
0.02
0.05
0.08
0.03
0.04
0.03
0.07
0.06

SEQID-03643
A1A080
—
—
0
0.51
0.26
0.05
0.13
0.01
0.06
0.00
0.07
0.03
0.04
0.02
0.07
0.04
0.17

SEQID-03644
A1A092
—
—
0
0.42
0.21
0.00
0.25
0.05
0.00
0.07
0.06
0.03
0.03
0.06
0.08
0.00
0.09

SEQID-03645
A1A093
—
—
0
0.43
0.20
0.05
0.19
0.04
0.06
0.01
0.04
0.06
0.04
0.01
0.10
0.07
0.12

SEQID-03646
A1A1E3
—
—
0
0.46
0.19
0.18
0.09
0.08
0.03
0.00
0.04
0.04
0.03
0.03
0.05
0.06
0.19

SEQID-03647
A1A2C3
—
—
0
0.51
0.14
0.07
0.15
0.05
0.02
0.00
0.02
0.04
0.04
0.06
0.00
0.10
0.18

SEQID-03648
A1A4Q4
—
—
0
0.52
0.08
0.06
0.02
0.00
0.03
0.00
0.09
0.15
0.06
0.00
0.02
0.06
0.36

SEQID-03649
A2QCV8
—
—
1
0.49
0.19
0.04
0.02
0.06
0.09
0.03
0.03
0.04
0.07
0.02
0.09
0.05
0.10

SEQID-03650
A2QEJ9
—
—
1
0.44
0.18
0.05
0.05
0.07
0.09
0.02
0.02
0.05
0.04
0.02
0.05
0.08
0.06

SEQID-03651
A2WNH1
—
—
0
0.46
0.17
0.03
0.05
0.02
0.01
0.14
0.05
0.05
0.07
0.08
0.07
0.05
0.09

SEQID-03652
A2Y1D7
—
—
0
0.38
0.09
0.04
0.00
0.03
0.08
0.15
0.02
0.11
0.07
0.04
0.02
0.00
0.15

SEQID-03653
A2Y720
—
—
0
0.39
0.05
0.16
0.04
0.01
0.08
0.00
0.09
0.11
0.05
0.03
0.01
0.02
0.16

SEQID-03654
A3B0Y1
—
—
0
0.36
0.09
0.04
0.00
0.05
0.06
0.15
0.02
0.11
0.07
0.02
0.02
0.00
0.15

SEQID-03655
A4GG84
—
—
1
0.54
0.25
0.03
0.08
0.05
0.02
0.01
0.07
0.07
0.04
0.02
0.15
0.05
0.13

SEQID-03656
A4GGE4
—
—
0
0.61
0.14
0.05
0.09
0.06
0.00
0.02
0.02
0.00
0.02
0.00
0.06
0.07
0.23

SEQID-03657
A4GGF3
—
—
0
0.50
0.22
0.00
0.12
0.04
0.03
0.00
0.11
0.08
0.03
0.03
0.09
0.11
0.13

SEQID-03658
A5D962
—
—
1
0.35
0.12
0.05
0.10
0.01
0.07
0.02
0.03
0.11
0.04
0.01
0.03
0.07
0.09

SEQID-03659
A5VJC3
—
—
0
0.46
0.14
0.03
0.11
0.04
0.04
0.02
0.04
0.07
0.01
0.07
0.02
0.09
0.13

SEQID-03660
A5VKX3
—
—
0
0.55
0.07
0.04
0.16
0.06
0.02
0.00
0.03
0.00
0.04
0.04
0.00
0.06
0.32

SEQID-03661
A5VLI2
—
—
0
0.53
0.16
0.02
0.14
0.05
0.00
0.07
0.06
0.03
0.03
0.06
0.05
0.00
0.23

SEQID-03662
A5VLK1
—
—
1
0.56
0.15
0.03
0.03
0.00
0.06
0.00
0.02
0.06
0.05
0.05
0.03
0.04
0.16

SEQID-03663
A6QQ14
—
—
0
0.35
0.18
0.15
0.10
0.01
0.08
0.02
0.05
0.10
0.04
0.00
0.04
0.10
0.05

SEQID-03664
A6QQ66
—
—
0
0.34
0.12
0.03
0.01
0.06
0.13
0.02
0.02
0.25
0.01
0.03
0.03
0.08
0.07

SEQID-03665
A7Y3K4
—
—
0
0.56
0.24
0.01
0.10
0.05
0.02
0.00
0.06
0.08
0.02
0.04
0.07
0.13
0.18

SEQID-03666
B0JEU3
—
—
1
0.35
0.16
0.03
0.12
0.06
0.04
0.02
0.13
0.11
0.04
0.02
0.04
0.07
0.06

SEQID-03667
B1A991
—
—
0
0.50
0.22
0.00
0.14
0.06
0.03
0.00
0.06
0.07
0.02
0.02
0.07
0.12
0.15

SEQID-03668
B2G5T7
—
—
0
0.49
0.24
0.14
0.00
0.02
0.13
0.00
0.00
0.11
0.04
0.00
0.07
0.08
0.16

SEQID-03669
B2G6N9
—
—
0
0.44
0.16
0.05
0.04
0.07
0.06
0.00
0.06
0.14
0.00
0.02
0.03
0.08
0.09

SEQID-03670
B2G7V3
—
—
0
0.48
0.15
0.06
0.15
0.02
0.03
0.00
0.02
0.05
0.03
0.07
0.04
0.09
0.18

SEQID-03671
B2G8D6
—
—
0
0.43
0.16
0.04
0.03
0.05
0.09
0.00
0.17
0.08
0.02
0.01
0.04
0.07
0.10

SEQID-03672
B3Y1Y0
—
—
0
0.62
0.14
0.02
0.08
0.03
0.00
0.05
0.03
0.05
0.03
0.07
0.03
0.06
0.21

SEQID-03673
B2Y203
—
—
0
0.51
0.20
0.00
0.13
0.07
0.04
0.01
0.09
0.00
0.02
0.03
0.05
0.12
0.15

SEQID-03674
B3DQC5
—
—
0
0.51
0.25
0.05
0.12
0.02
0.05
0.00
0.07
0.07
0.05
0.02
0.07
0.04
0.16

SEQID-03675
B3DQT3
—
—
0
0.53
0.15
0.07
0.13
0.03
0.03
0.00
0.05
0.04
0.04
0.08
0.02
0.10
0.30

SEQID-03676
B3DRN7
—
—
0
0.29
0.13
0.11
0.00
0.03
0.13
0.00
0.19
0.14
0.02
0.00
0.03
0.06
0.02

SEQID-03677
B30S06
—
—
1
0.53
0.19
0.05
0.03
0.00
0.05
0.00
0.04
0.17
0.03
0.06
0.05
0.10
0.09

SEQID-03678
B3DSB0
—
—
0
0.46
0.21
0.18
0.09
0.08
0.03
0.00
0.04
0.04
0.03
0.03
0.06
0.09
0.17

SEQID-03679
B3LMP9
—
—
1
0.48
0.20
0.02
0.09
0.06
0.09
0.00
0.04
0.04
0.04
0.02
0.05
0.06
0.07

SEQID-03680
B3W9Z1
—
—
0
0.49
0.14
0.04
0.03
0.02
0.09
0.00
0.11
0.09
0.04
0.00
0.07
0.04
0.13

SEQID-03681
B3WF72
—
—
0
0.46
0.18
0.04
0.01
0.03
0.10
0.00
0.18
0.06
0.02
0.00
0.06
0.09
0.11

SEQID-03682
B7GRY8
—
—
0
0.44
0.21
0.18
0.10
0.09
0.03
0.00
0.04
0.04
0.03
0.03
0.06
0.09
0.16

SEQID-03683
B7GUP0
—
—
0
0.33
0.15
0.03
0.00
0.03
0.13
0.00
0.19
0.14
0.02
0.00
0.03
0.06
0.02

SEQID-03684
B8DSI4
—
—
0
0.40
0.25
0.09
0.07
0.02
0.08
0.00
0.04
0.15
0.02
0.01
0.06
0.10
0.00

SEQID-03685
B8DSQ1
—
—
0
0.57
0.14
0.09
0.16
0.02
0.03
0.00
0.04
0.02
0.04
0.06
0.00
0.10
0.20

SEQID-03686
B8DUL7
—
—
0
0.41
0.17
0.15
0.14
0.07
0.02
0.00
0.07
0.04
0.02
0.01
0.07
0.05
0.15

SEQID-03687
B8DV05
—
—
0
0.37
0.09
0.05
0.33
0.06
0.00
0.00
0.02
0.00
0.03
0.03
0.02
0.04
0.10

SEQID-03688
B8DW24
—
—
0
0.53
0.27
0.04
0.13
0.01
0.06
0.00
0.06
0.07
0.05
0.02
0.07
0.04
0.17

SEQID-03689
D5DEH5
—
—
1
0.41
0.17
0.06
0.03
0.07
0.07
0.00
0.04
0.04
0.05
0.02
0.04
0.06
0.09

SEQID-03690
E1UMM6
—
—
1
0.43
0.17
0.04
0.04
0.08
0.06
0.01
0.02
0.04
0.06
0.01
0.06
0.03
0.07

SEQID-03691
E1UQB7
—
—
1
0.52
0.16
0.05
0.01
0.03
0.10
0.00
0.05
0.09
0.03
0.01
0.03
0.09
0.23

SEQID-03692
E1UV85
—
—
0
0.44
0.20
0.07
0.01
0.06
0.05
0.00
0.14
0.07
0.04
0.00
0.05
0.06
0.13

SEQID-03693
E7Q903
—
—
1
0.34
0.09
0.03
0.07
0.10
0.08
0.00
0.10
0.06
0.05
0.01
0.03
0.04
0.09

SEQID-03694
I1LP26
—
—
1
0.49
0.17
0.03
0.05
0.05
0.09
0.01
0.04
0.07
0.02
0.03
0.05
0.07
0.17

SEQID-03695
K1WSX8
—
—
1
0.38
0.14
0.07
0.10
0.02
0.04
0.00
0.17
0.10
0.01
0.02
0.02
0.07
0.07

SEQID-03696
K7K247
—
—
1
0.48
0.12
0.04
0.04
0.05
0.04
0.01
0.07
0.15
0.01
0.03
0.03
0.07
0.19

SEQID-03697
O13555
—
—
0
0.42
0.23
0.03
0.05
0.04
0.16
0.02
0.00
0.25
0.00
0.01
0.03
0.13
0.07

SEQID-03693
O49224
—
—
0
0.47
0.07
0.00
0.40
0.00
0.00
0.00
0.04
0.00
0.05
0.00
0.00
0.04
0.25

SEQID-03699
P00126
—
—
0
0.37
0.17
0.02
0.10
0.01
0.09
0.05
0.05
0.24
0.02
0.04
0.00
0.13
0.06

SEQID-03700
P00227
—
—
0
0.37
0.19
0.06
0.02
0.00
0.12
0.05
0.04
0.15
0.03
0.01
0.04
0.05
0.05

SEQID-03701
P01249
—
—
0
0.49
0.27
0.04
0.06
0.04
0.04
0.00
0.07
0.12
0.02
0.02
0.00
0.18
0.11

SEQID-03702
P01250
—
—
0
0.47
0.27
0.04
0.06
0.04
0.04
0.00
0.05
0.14
0.01
0.00
0.00
0.18
0.11

SEQID-03703
P01251
—
—
0
0.49
0.27
0.04
0.06
0.04
0.02
0.00
0.05
0.16
0.01
0.02
0.00
0.18
0.11

SEQID-03704
P02318
—
—
0
0.17
0.06
0.01
0.60
0.00
0.00
0.11
0.02
0.00
0.02
0.02
0.02
0.02
0.00

SEQID-03705
P02405
—
—
0
0.56
0.12
0.03
0.10
0.01
0.01
0.04
0.09
0.03
0.04
0.04
0.00
0.06
0.24

SEQID-03706
P02633
—
—
0
0.49
0.21
0.02
0.00
0.03
0.05
0.00
0.06
0.19
0.03
0.00
0.03
0.15
0.16

SEQID-03707
P02777
—
—
0
0.45
0.22
0.03
0.05
0.01
0.07
0.04
0.05
0.09
0.04
0.03
0.06
0.13
0.11

SEQID-03708
P04464
—
—
0
0.45
0.17
0.03
0.04
0.02
0.01
0.13
0.05
0.05
0.07
0.08
0.07
0.05
0.08

SEQID-03709
P04568
—
—
0
0.27
0.09
0.04
0.16
0.02
0.06
0.00
0.09
0.16
0.10
0.00
0.02
0.05
0.08

SEQID-03710
P04650
—
—
0
0.46
0.11
0.06
0.22
0.11
0.00
0.00
0.08
0.00
0.00
0.00
0.07
0.04
0.16

SEQID-03711
P05747
—
—
0
0.56
0.08
0.10
0.09
0.07
0.02
0.00
0.02
0.00
0.03
0.12
0.02
0.05
0.25

SEQID-03712
P05936
—
—
0
0.46
0.18
0.04
0.04
0.02
0.00
0.13
0.03
0.06
0.09
0.09
0.08
0.03
0.07

SEQID-03713
P07249
—
—
0
0.42
0.16
0.03
0.09
0.04
0.09
0.01
0.03
0.09
0.02
0.01
0.06
0.06
0.09

SEQID-03714
P07269
—
—
1
0.40
0.16
0.03
0.06
0.14
0.10
0.00
0.07
0.05
0.01
0.04
0.06
0.09
0.05

SEQID-03715
P09441
—
—
0
0.29
0.04
0.07
0.11
0.06
0.09
0.00
0.06
0.03
0.10
0.03
0.01
0.01
0.07

SEQID-03716
P0C225
—
—
0
0.26
0.16
0.06
0.03
0.02
0.10
0.04
0.02
0.12
0.04
0.02
0.04
0.10
0.02

SEQID-03717
P0C5A4
—
—
0
0.38
0.05
0.16
0.04
0.01
0.09
0.00
0.09
0.11
0.04
0.03
0.01
0.02
0.16

SEQID-03718
P0C5Q9
—
—
0
0.42
0.09
0.07
0.12
0.06
0.00
0.00
0.07
0.07
0.03
0.00
0.03
0.06
0.10

SEQID-03719
P0CSR4
—
—
1
0.56
0.25
0.01
0.11
0.04
0.06
0.02
0.05
0.02
0.01
0.05
0.10
0.09
0.07

SEQID-03720
P0CG92
—
—
0
0.29
0.13
0.11
0.00
0.03
0.13
0.00
0.19
0.14
0.02
0.00
0.03
0.06
0.02

SEQID-03721
P10961
—
—
1
0.39
0.15
0.03
0.07
0.15
0.09
0.00
0.04
0.06
0.02
0.03
0.05
0.07
0.06

SEQID-03722
P12230
—
—
0
0.40
0.23
0.02
0.28
0.03
0.00
0.07
0.06
0.03
0.03
0.03
0.15
0.03
0.12

SEQID-03723
P14164
—
—
1
0.39
0.16
0.03
0.04
0.15
0.12
0.00
0.04
0.07
0.02
0.07
0.05
0.06
0.08

SEQID-03724
P14724
—
—
0
0.38
0.15
0.03
0.04
0.14
0.14
0.00
0.06
0.06
0.01
0.06
0.05
0.09
0.05

SEQID-03725
P14936
—
—
0
0.39
0.19
0.05
0.01
0.01
0.11
0.04
0.06
0.12
0.04
0.05
0.04
0.07
0.07

SEQID-03726
P14937
—
—
0
0.41
0.19
0.05
0.01
0.01
0.09
0.05
0.07
0.14
0.04
0.04
0.04
0.06
0.06

SEQID-03727
P15341
—
—
0
0.10
0.06
0.01
0.63
0.00
0.00
0.11
0.06
0.00
0.00
0.00
0.00
0.02
0.00

SEQID-03728
P17639
—
—
0
0.34
0.10
0.04
0.11
0.02
0.05
0.00
0.10
0.16
0.10
0.03
0.02
0.06
0.12

SEQID-03729
P17803
—
—
0
0.50
0.19
0.02
0.06
0.05
0.05
0.02
0.09
0.05
0.02
0.00
0.09
0.09
0.11

SEQID-03730
P19515
—
—
1
0.45
0.22
0.04
0.05
0.04
0.06
0.02
0.03
0.06
0.04
0.03
0.07
0.09
0.03

SEQID-03731
P19757
—
—
0
0.16
0.06
0.01
0.48
0.01
0.03
0.04
0.09
0.05
0.02
0.07
0.01
0.02
0.00

SEQID-03732
P19782
—
—
0
0.19
0.05
0.03
0.38
0.00
0.02
0.04
0.03
0.05
0.05
0.07
0.02
0.02
0.01

SEQID-03733
P20422
—
—
0
0.46
0.18
0.06
0.00
0.03
0.08
0.01
0.01
0.11
0.07
0.03
0.03
0.04
0.09

SEQID-03734
P22613
—
—
0
0.39
0.07
0.01
0.27
0.05
0.04
0.03
0.02
0.00
0.04
0.04
0.00
0.05
0.20

SEQID-03735
P22701
—
—
0
0.30
0.09
0.04
0.13
0.01
0.05
0.00
0.06
0.18
0.10
0.00
0.02
0.05
0.10

SEQID-03736
P26351
—
—
0
0.49
0.11
0.03
0.00
0.05
0.05
0.00
0.08
0.19
0.00
0.00
0.02
0.07
0.21

SEQID-03737
P26377
—
—
0
0.32
0.06
0.01
0.22
0.04
0.01
0.05
0.09
0.01
0.02
0.12
0.01
0.02
0.09

SEQID-03738
P27013
—
—
0
0.37
0.10
0.03
0.14
0.05
0.06
0.03
0.06
0.06
0.02
0.03
0.02
0.06
0.02

SEQID-03739
P28318
—
—
0
0.52
0.22
0.02
0.04
0.04
0.07
0.01
0.14
0.07
0.02
0.12
0.06
0.10
0.09

SEQID-03740
P28804
—
—
0
0.59
0.17
0.05
0.09
0.05
0.00
0.00
0.02
0.02
0.02
0.00
0.07
0.07
0.23

SEQID-03741
P31395
—
—
0
0.42
0.14
0.07
0.08
0.05
0.03
0.00
0.05
0.23
0.01
0.03
0.03
0.09
0.17

SEQID-03742
P32389
—
—
1
0.41
0.16
0.03
0.05
0.14
0.08
0.00
0.04
0.07
0.02
0.05
0.05
0.07
0.09

SEQID-03743
P32450
—
—
0
0.38
0.14
0.01
0.21
0.02
0.04
0.04
0.11
0.01
0.01
0.13
0.06
0.06
0.03

SEQID-03744
P37219
—
—
0
0.60
0.12
0.09
0.00
0.01
0.04
0.00
0.02
0.17
0.04
0.25
0.03
0.04
0.18

SEQID-03745
P372J0
—
—
0
0.56
0.11
0.10
0.04
0.02
0.02
0.00
0.04
0.14
0.04
0.19
0.03
0.04
0.22

SEQID-03746
P38236
—
—
1
0.41
0.15
0.05
0.04
0.13
0.03
0.00
0.06
0.11
0.01
0.04
0.03
0.09
0.09

SEQID-03747
P38243
—
—
0
0.45
0.14
0.03
0.07
0.05
0.08
0.00
0.04
0.07
0.01
0.04
0.04
0.10
0.10

SEQID-03748
P38284
—
—
0
0.41
0.13
0.02
0.09
0.06
0.04
0.01
0.04
0.08
0.03
0.04
0.05
0.06
0.10

SEQID-03749
P39549
—
—
1
0.41
0.11
0.02
0.07
0.06
0.04
0.03
0.04
0.14
0.02
0.03
0.04
0.06
0.04

SEQID-03750
P39973
—
—
0
0.56
0.16
0.02
0.05
0.05
0.04
0.02
0.01
0.04
0.00
0.06
0.04
0.09
0.14

SEQID-03751
P41651
—
—
0
0.47
0.16
0.06
0.10
0.03
0.07
0.01
0.00
0.02
0.02
0.02
0.07
0.04
0.20

SEQID-03752
P42755
—
—
0
0.31
0.10
0.04
0.16
0.00
0.03
0.00
0.05
0.22
0.10
0.01
0.02
0.06
0.08

SEQID-03753
P46298
—
—
1
0.54
0.24
0.04
0.11
0.00
0.04
0.01
0.02
0.05
0.03
0.05
0.09
0.11
0.15

SEQID-03754
P46517
—
—
0
0.32
0.10
0.04
0.15
0.00
0.04
0.00
0.08
0.17
0.10
0.01
0.01
0.05
0.09

SEQID-03755
P46520
—
—
0
0.26
0.09
0.04
0.15
0.01
0.05
0.00
0.10
0.17
0.11
0.00
0.02
0.04
0.08

SEQID-03756
P50415
—
—
0
0.32
0.21
0.03
0.19
0.03
0.04
0.02
0.07
0.07
0.02
0.00
0.02
0.14
0.04

SEQID-03757
P51426
—
—
0
0.53
0.10
0.02
0.24
0.05
0.02
0.00
0.02
0.00
0.01
0.04
0.07
0.03
0.16

SEQID-03758
P52193
—
—
1
0.42
0.14
0.03
0.03
0.04
0.13
0.01
0.04
0.15
0.03
0.02
0.05
0.06
0.11

SEQID-03759
P53222
—
—
0
0.40
0.14
0.04
0.13
0.09
0.04
0.01
0.03
0.06
0.00
0.02
0.06
0.05
0.09

SEQID-03760
P53334
—
—
1
0.39
0.18
0.10
0.02
0.06
0.06
0.01
0.05
0.05
0.03
0.01
0.05
0.05
0.06

SEQID-03761
P53869
—
—
1
0.48
0.12
0.01
0.16
0.01
0.05
0.00
0.04
0.05
0.02
0.01
0.02
0.07
0.11

SEQID-03762
P60741
—
—
0
0.59
0.22
0.04
0.02
0.11
0.04
0.00
0.02
0.08
0.05
0.03
0.07
0.01
0.26

SEQID-03761
P62144
—
—
0
0.44
0.16
0.04
0.04
0.02
0.01
0.12
0.06
0.05
0.06
0.06
0.08
0.05
0.07

SEQID-03764
P62326
—
—
0
0.46
0.09
0.03
0.00
0.02
0.07
0.00
0.08
0.20
0.01
0.00
0.04
0.04
0.23

SEQID-03765
P63212
—
—
0
0.45
0.18
0.12
0.06
0.06
0.04
0.03
0.03
0.10
0.00
0.02
0.06
0.09
0.11

SEQID-03766
P63314
—
—
0
0.50
0.11
0.04
0.03
0.02
0.07
0.00
0.05
0.18
0.01
0.00
0.07
0.05
0.20

SEQID-03767
P67833
—
—
0
0.17
0.06
0.01
0.62
0.00
0.00
0.11
0.02
0.11
0.01
0.02
0.00
0.02
0.00

SEQID-03768
P69328
—
—
1
0.42
0.17
0.07
0.04
0.04
0.08
0.01
0.03
0.05
0.04
0.01
0.04
0.07
0.02

SEQID-03769
P79105
—
—
0
0.59
0.26
0.02
0.04
0.03
0.10
0.00
0.06
0.08
0.02
0.06
0.08
0.11
0.12

SEQID-03770
P81451
—
—
0
0.56
0.20
0.06
0.00
0.05
0.06
0.00
0.03
0.07
0.04
0.05
0.06
0.11
0.17

SEQID-03771
P83005
—
—
0
0.28
0.15
0.05
0.11
0.02
0.10
0.04
0.02
0.11
0.03
0.05
0.02
0.10
0.00

SEQID-03772
P83489
—
—
0
0.28
0.16
0.05
0.08
0.02
0.10
0.04
0.02
0.12
0.04
0.05
0.02
0.10
0.02

SEQID-03773
P83704
—
—
0
0.46
0.21
0.07
0.02
0.04
0.04
0.01
0.12
0.10
0.01
0.02
0.03
0.14
0.10

SEQID-03774
P84083
—
—
0
0.38
0.11
0.06
0.08
0.00
0.06
0.01
0.07
0.23
0.04
0.01
0.02
0.07
0.17

SEQID-03775
P86315
—
—
0
0.30
0.14
0.05
0.08
0.02
0.10
0.04
0.05
0.12
0.04
0.02
0.00
0.10
0.02

SEQID-03776
P94522
—
—
1
0.43
0.17
0.04
0.03
0.08
0.06
0.01
0.03
0.03
0.06
0.01
0.06
0.09
0.07

SEQID-03777
Q00747
—
—
0
0.46
0.03
0.14
0.07
0.02
0.05
0.00
0.06
0.11
0.06
0.03
0.00
0.01
0.17

SEQID-03778
Q03323
—
—
0
0.39
0.18
0.03
0.03
0.13
0.06
0.01
0.06
0.12
0.02
0.03
0.05
0.07
0.08

SEQID-03779
Q033K5
—
—
0
0.53
0.09
0.04
0.28
0.02
0.00
0.00
0.02
0.02
0.03
0.05
0.00
0.04
0.19

SEQID-03780
Q035G1
—
—
0
0.47
0.17
0.07
0.15
0.01
0.05
0.00
0.05
0.03
0.03
0.05
0.03
0.09
0.16

SEQID-03781
Q035T6
—
—
0
0.52
0.15
0.04
0.11
0.04
0.00
0.07
0.05
0.07
0.02
0.05
0.00
0.06
0.16

SEQID-03782
Q037X5
—
—
0
0.46
0.18
0.04
0.01
0.03
0.10
0.00
0.18
0.06
0.03
0.00
0.06
0.09
0.11

SEQID-03783
Q038A1
—
—
0
0.55
0.09
0.05
0.18
0.00
0.01
0.00
0.07
0.00
0.02
0.09
0.01
0.06
0.20

SEQID-03784
Q038J5
—
—
0
0.38
0.17
0.06
0.07
0.05
0.07
0.00
0.05
0.11
0.01
0.03
0.03
0.11
0.06

SEQID-03785
Q038L1
—
—
0
0.50
0.13
0.07
0.09
0.01
0.07
0.01
0.05
0.05
0.03
0.09
0.00
0.08
0.09

SEQID-03786
Q033F0
—
—
0
0.35
0.11
0.05
0.07
0.06
0.07
0.00
0.04
0.11
0.02
0.04
0.01
0.08
0.04

SEQID-03787
Q045U8
—
—
0
0.46
0.16
0.07
0.04
0.04
0.13
0.00
0.11
0.04
0.05
0.00
0.05
0.07
0.12

SEQID-03788
Q046B4
—
—
0
0.58
0.22
0.05
0.02
0.11
0.04
0.00
0.02
0.08
0.05
0.03
0.07
0.01
0.26

SEQID-03789
Q046C1
—
—
1
0.57
0.18
0.04
0.09
0.00
0.04
0.00
0.02
0.06
0.04
0.04
0.06
0.03
0.14

SEQID-03790
Q04C04
—
—
0
0.57
0.24
0.07
0.02
0.10
0.03
0.00
0.00
0.03
0.06
0.02
0.06
0.01
0.22

SEQID-03791
Q04C49
—
—
0
0.49
0.11
0.05
0.05
0.05
0.05
0.01
0.03
0.08
0.04
0.03
0.05
0.02
0.14

SEQID-03792
Q06648
—
—
1
0.41
0.15
0.03
0.07
0.09
0.05
0.00
0.05
0.06
0.01
0.04
0.04
0.08
0.03

SEQID-03793
Q08655
—
—
0
0.59
0.13
0.08
0.01
0.00
0.04
0.00
0.01
0.18
0.03
0.19
0.04
0.06
0.20

SEQID-03794
Q08745
—
—
1
0.43
0.18
0.02
0.07
0.04
0.03
0.00
0.09
0.10
0.02
0.03
0.04
0.08
0.09

SEQID-03795
Q09MC8
—
—
0
0.62
0.15
0.07
0.08
0.06
0.00
0.02
0.00
0.00
0.03
0.00
0.04
0.10
0.24

SEQID-03796
Q0G9R4
—
—
0
0.59
0.16
0.05
0.10
0.06
0.00
0.00
0.02
0.00
0.04
0.00
0.06
0.07
0.27

SEQID-03797
Q0IIJ2
—
—
0
0.56
0.11
0.09
0.05
0.02
0.02
0.00
0.03
0.03
0.02
0.01
0.03
0.02
0.34

SEQID-03798
Q0JNL7
—
—
0
0.46
0.17
0.03
0.05
0.02
0.01
0.13
0.05
0.05
0.04
0.08
0.04
0.05
0.08

SEQID-03799
Q0MUU2
—
—
0
0.37
0.17
0.06
0.07
0.06
0.01
0.01
0.07
0.12
0.03
0.00
0.07
0.05
0.12

SEQID-03800
Q0VBZ8
—
—
1
0.33
0.15
0.05
0.16
0.02
0.04
0.01
0.05
0.07
0.02
0.02
0.02
0.09
0.04

SEQID-03801
Q12034
—
—
1
0.38
0.13
0.03
0.05
0.15
0.05
0.00
0.06
0.07
0.02
0.01
0.06
0.06
0.10

SEQID-03802
Q12087
—
—
0
0.49
0.16
0.04
0.15
0.05
0.00
0.00
0.04
0.04
0.04
0.02
0.00
0.06
0.20

SEQID-03803
Q12515
—
—
0
0.42
0.15
0.04
0.06
0.15
0.07
0.00
0.03
0.06
0.05
0.03
0.04
0.04
0.12

SEQID-03804
Q148C4
—
—
0
0.36
0.06
0.06
0.07
0.03
0.08
0.00
0.13
0.11
0.05
0.00
0.03
0.00
0.15

SEQID-03805
Q14FC3
—
—
0
0.38
0.20
0.03
0.32
0.03
0.00
0.07
0.06
0.03
0.03
0.03
0.15
0.05
0.12

SEQID-03806
Q1G9G5
—
—
0
0.55
0.23
0.04
0.01
0.01
0.05
0.00
0.06
0.09
0.05
0.04
0.04
0.03
0.19

SEQID-03807
Q1GAQ4
—
—
0
0.46
0.17
0.15
0.10
0.05
0.04
0.00
0.06
0.04
0.01
0.02
0.05
0.08
0.19

SEQID-03808
Q1GBK7
—
—
0
0.56
0.24
0.07
0.02
0.10
0.03
0.00
0.00
0.09
0.06
0.02
0.06
0.01
0.20

SEQID-03809
Q1GBL4
—
—
1
0.57
0.17
0.05
0.09
0.00
0.07
0.00
0.04
0.05
0.03
0.05
0.04
0.04
0.15

SEQID-03810
Q1JQB5
—
—
1
0.33
0.16
0.06
0.10
0.02
0.06
0.06
0.04
0.09
0.03
0.03
0.03
0.08
0.05

SEQID-03811
Q29S17
—
—
0
0.36
0.20
0.04
0.10
0.03
0.04
0.00
0.07
0.25
0.01
0.05
0.02
0.15
0.03

SEQID-03812
Q2KU9
—
—
0
0.33
0.12
0.02
0.13
0.02
0.02
0.01
0.04
0.23
0.02
0.02
0.02
0.07
0.08

SEQID-03813
Q2KJD8
—
—
0
0.36
0.22
0.11
0.19
0.03
0.10
0.01
0.03
0.06
0.06
0.04
0.01
0.14
0.00

SEQID-03814
Q2L961
—
—
0
0.58
0.16
0.06
0.10
0.06
0.00
0.00
0.02
0.02
0.02
0.00
0.04
0.07
0.23

SEQID-03815
Q2MID0
—
—
0
0.55
0.24
0.01
0.12
0.05
0.02
0.00
0.06
0.07
0.02
0.04
0.07
0.12
0.16

SEQID-03816
Q2PMN0
—
—
0
0.60
0.12
0.03
0.10
0.05
0.00
0.02
0.02
0.00
0.02
0.00
0.05
0.05
0.23

SEQID-03817
Q2PMN9
—
—
0
0.48
0.22
0.00
0.17
0.03
0.04
0.00
0.07
0.06
0.02
0.02
0.10
0.09
0.14

SEQID-03818
Q2PMP7
—
—
1
0.51
0.25
0.03
0.08
0.06
0.03
0.02
0.08
0.06
0.04
0.01
0.15
0.05
0.12

SEQID-03819
Q2TBJ3
—
—
1
0.48
0.20
0.03
0.02
0.06
0.10
0.00
0.00
0.14
0.01
0.02
0.07
0.08
0.07

SEQID-03820
Q2V2P1
—
—
0
0.41
0.13
0.05
0.07
0.08
0.07
0.01
0.11
0.13
0.00
0.02
0.05
0.06
0.07

SEQID-03821
Q32KM6
—
—
1
0.44
0.11
0.02
0.06
0.05
0.07
0.01
0.06
0.08
0.07
0.02
0.03
0.04
0.12

SEQID-03822
Q32KN2
—
—
1
0.45
0.17
0.02
0.07
0.04
0.05
0.00
0.04
0.09
0.03
0.04
0.04
0.10
0.08

SEQID-03823
Q32LI5
—
—
1
0.39
0.13
0.03
0.10
0.04
0.06
0.01
0.07
0.10
0.01
0.01
0.04
0.02
0.14

SEQID-03824
Q32IJ0
—
—
0
0.36
0.11
0.05
0.10
0.01
0.03
0.01
0.16
0.15
0.01
0.00
0.03
0.04
0.15

SEQID-03825
Q32PA2
—
—
0
0.28
0.12
0.04
0.05
0.01
0.03
0.02
0.09
0.30
0.06
0.03
0.00
0.08
0.06

SEQID-03826
Q32PA4
—
—
1
0.38
0.17
0.06
0.06
0.00
0.10
0.01
0.05
0.06
0.05
0.04
0.07
0.02
0.09

SEQID-03827
Q32PD7
—
—
0
0.42
0.16
0.08
0.00
0.04
0.20
0.00
0.02
0.10
0.05
0.02
0.02
0.09
0.04

SEQID-03828
Q332T8
—
—
1
0.49
0.24
0.03
0.10
0.05
0.03
0.01
0.08
0.08
0.04
0.02
0.15
0.06
0.10

SEQID-03829
Q3E742
—
—
0
0.54
0.12
0.04
0.06
0.07
0.00
0.03
0.05
0.08
0.03
0.05
0.01
0.06
0.30

SEQID-03830
Q3E764
—
—
0
0.52
0.11
0.07
0.02
0.02
0.07
0.00
0.11
0.04
0.06
0.00
0.03
0.07
0.31

SEQID-03831
Q3E807
—
—
1
0.56
0.17
0.01
0.05
0.04
0.03
0.02
0.03
0.04
0.01
0.05
0.05
0.08
0.12

SEQID-03832
Q3I5G7
—
—
0
0.44
0.17
0.09
0.00
0.02
0.05
0.00
0.05
0.17
0.07
0.01
0.02
0.03
0.13

SEQID-03833
Q3MIC0
—
—
1
0.56
0.16
0.06
0.11
0.01
0.01
0.04
0.02
0.03
0.05
0.03
0.06
0.03
0.19

SEQID-03834
Q35WY1
—
—
1
0.39
0.16
0.06
0.09
0.01
0.03
0.02
0.04
0.09
0.05
0.04
0.01
0.11
0.09

SEQID-03835
Q3T051
—
—
0
0.54
0.12
0.01
0.22
0.05
0.00
0.00
0.06
0.00
0.02
0.04
0.07
0.05
0.18

SEQID-03836
Q3T0F2
—
—
1
0.55
0.18
0.04
0.05
0.06
0.08
0.00
0.02
0.06
0.02
0.07
0.04
0.08
0.07

SEQID-03837
Q3V4Y6
—
—
0
0.57
0.13
0.05
0.10
0.04
0.00
0.00
0.04
0.02
0.02
0.00
0.03
0.03
0.24

SEQID-03838
Q3V500
—
—
0
0.42
0.22
0.02
0.28
0.03
0.00
0.07
0.06
0.03
0.03
0.03
0.15
0.03
0.14

SEQID-03839
Q3ZBD4
—
—
0
0.35
0.16
0.06
0.07
0.06
0.01
0.01
0.07
0.12
0.04
0.00
0.09
0.04
0.12

SEQID-03840
Q41784
—
—
1
0.43
0.17
0.04
0.07
0.05
0.06
0.02
0.05
0.10
0.04
0.03
0.04
0.08
0.04

SEQID-03841
Q4VZK0
—
—
1
0.49
0.26
0.02
0.17
0.07
0.03
0.01
0.02
0.05
0.04
0.02
0.15
0.08
0.07

SEQID-03842
Q4VZL1
—
—
0
0.49
0.22
0.00
0.12
0.05
0.02
0.00
0.07
0.08
0.02
0.03
0.02
0.12
0.16

SEQID-03843
Q4VZN0
—
—
1
0.48
0.25
0.03
0.10
0.05
0.04
0.04
0.08
0.07
0.05
0.02
0.14
0.06
0.09

SEQID-03844
Q5E9A0
—
—
1
0.37
0.15
0.05
0.09
0.02
0.06
0.03
0.05
0.08
0.03
0.03
0.02
0.07
0.08

SEQID-03845
Q5EAE6
—
—
1
0.41
0.10
0.06
0.08
0.00
0.07
0.00
0.08
0.07
0.04
0.09
0.05
0.01
0.11

SEQID-03846
Q5F3Z5
—
—
1
0.40
0.10
0.04
0.10
0.04
0.05
0.00
0.04
0.11
0.06
0.03
0.02
0.05
0.09

SEQID-03847
Q5FIW8
—
—
0
0.58
0.07
0.05
0.20
0.01
0.01
0.00
0.05
0.00
0.03
0.12
0.01
0.03
0.18

SEQID-03848
Q5FKE7
—
—
0
0.32
0.10
0.05
0.07
0.04
0.09
0.00
0.07
0.11
0.00
0.01
0.00
0.07
0.04

SEQID-03849
Q5FM68
—
—
0
0.52
0.16
0.02
0.14
0.03
0.00
0.07
0.06
0.03
0.03
0.09
0.05
0.00
0.17

SEQID-03850
Q5FM86
—
—
1
0.55
0.17
0.05
0.07
0.00
0.09
0.00
0.04
0.02
0.03
0.05
0.05
0.04
0.13

SEQID-03851
Q5SMI4
—
—
0
0.53
0.10
0.02
0.22
0.05
0.02
0.00
0.04
0.00
0.01
0.04
0.07
0.03
0.16

SEQID-03852
Q5ZMM5
—
—
0
0.46
0.09
0.08
0.04
0.01
0.04
0.02
0.18
0.05
0.01
0.05
0.03
0.04
0.19

SEQID-03853
Q5ZMN0
—
—
0
0.34
0.20
0.01
0.05
0.06
0.14
0.01
0.01
0.23
0.03
0.01
0.03
0.14
0.06

SEQID-03854
Q6SMX0
—
—
1
0.46
0.16
0.05
0.06
0.05
0.08
0.00
0.05
0.06
0.05
0.06
0.04
0.06
0.07

SEQID-03855
Q66QC7
—
—
0
0.09
0.06
0.01
0.65
0.00
0.00
0.12
0.04
0.00
0.00
0.00
0.00
0.02
0.00

SEQID-03856
Q6RFL5
—
—
1
0.44
0.18
0.05
0.09
0.02
0.04
0.00
0.04
0.10
0.02
0.09
0.03
0.12
0.06

SEQID-03857
Q74IL4
—
—
0
0.59
0.21
0.03
0.01
0.01
0.04
0.00
0.03
0.10
0.04
0.04
0.05
0.02
0.22

SEQID-03858
Q74L00
—
—
0
0.49
0.16
0.07
0.03
0.05
0.12
0.00
0.10
0.04
0.05
0.00
0.05
0.07
0.14

SEQID-03859
Q74LZ9
—
—
0
0.53
0.16
0.06
0.03
0.00
0.08
0.00
0.04
0.18
0.06
0.02
0.04
0.04
0.29

SEQID-03860
Q7DMN9
—
—
0
0.45
0.17
0.03
0.05
0.03
0.01
0.13
0.05
0.05
0.07
0.08
0.07
0.04
0.08

SEQID-03861
Q7M2P1
—
—
0
0.49
0.10
0.02
0.21
0.01
0.00
0.01
0.06
0.03
0.01
0.02
0.04
0.01
0.22

SEQID-03862
Q7XC27
—
—
1
0.50
0.21
0.03
0.08
0.05
0.09
0.00
0.02
0.10
0.02
0.01
0.07
0.09
0.07

SEQID-03863
Q7YQJ3
—
—
0
0.27
0.13
0.06
0.08
0.01
0.10
0.01
0.05
0.15
0.06
0.00
0.03
0.04
0.03

SEQID-03864
Q88VD4
—
—
0
0.44
0.14
0.15
0.12
0.08
0.06
0.00
0.01
0.03
0.01
0.00
0.05
0.04
0.17

SEQID-03865
Q88WD3
—
—
0
0.50
0.12
0.06
0.04
0.01
0.14
0.00
0.05
0.10
0.04
0.00
0.00
0.04
0.27

SEQID-03866
Q88WM6
—
—
0
0.40
0.18
0.06
0.00
0.07
0.05
0.00
0.17
0.17
0.03
0.00
0.01
0.12
0.06

SEQID-03867
Q88WN5
—
—
0
0.55
0.19
0.06
0.04
0.01
0.07
0.00
0.07
0.05
0.06
0.02
0.05
0.01
0.16

SEQID-03868
Q88WU7
—
—
0
0.59
0.12
0.07
0.13
0.03
0.00
0.00
0.07
0.02
0.02
0.06
0.05
0.05
0.24

SEQID-03869
Q88XY2
—
—
1
0.57
0.17
0.03
0.08
0.00
0.10
0.00
0.02
0.01
0.04
0.07
0.07
0.04
0.15

SEQID-03870
Q88YP9
—
—
0
0.52
0.14
0.06
0.01
0.04
0.12
0.00
0.11
0.03
0.03
0.00
0.02
0.05
0.11

SEQID-03871
Q8G435
—
—
0
0.44
0.12
0.03
0.19
0.05
0.03
0.06
0.02
0.08
0.02
0.02
0.02
0.05
0.12

SEQID-03872
Q8GC82
—
—
1
0.47
0.20
0.03
0.05
0.12
0.06
0.00
0.01
0.04
0.05
0.03
0.09
0.05
0.08

SEQID-03873
Q8HYY9
—
—
0
0.26
0.16
0.06
0.11
0.02
0.10
0.04
0.02
0.12
0.04
0.05
0.04
0.10
0.00

SEQID-03874
Q8TGT3
—
—
0
0.62
0.22
0.00
0.12
0.00
0.03
0.03
0.03
0.06
0.00
0.00
0.06
0.11
0.16

SEQID-03875
Q8TGU1
—
—
0
0.43
0.17
0.00
0.06
0.09
0.04
0.04
0.02
0.15
0.03
0.05
0.04
0.11
0.14

SEQID-03876
Q8TGV0
—
—
0
0.26
0.14
0.00
0.28
0.03
0.00
0.03
0.08
0.00
0.00
0.00
0.03
0.10
0.04

SEQID-03877
Q90953
—
—
1
0.45
0.18
0.04
0.04
0.03
0.06
0.01
0.04
0.12
0.03
0.03
0.05
0.06
0.06

SEQID-03878
Q96386
—
—
0
0.39
0.09
0.05
0.00
0.05
0.10
0.15
0.02
0.06
0.04
0.02
0.05
0.00
0.11

SEQID-03879
Q98TFS
—
—
0
0.56
0.12
0.01
0.20
0.05
0.00
0.00
0.06
0.00
0.02
0.04
0.07
0.05
0.20

SEQID-03880
Q9DET5
—
—
0
0.52
0.12
0.00
0.00
0.04
0.07
0.04
0.02
0.20
0.00
0.00
0.02
0.06
0.27

SEQID-03881
Q9N250
—
—
0
0.49
0.20
0.09
0.00
0.03
0.03
0.00
0.06
0.19
0.04
0.01
0.02
0.01
0.15

SEQID-03882
Q9P305
—
—
0
0.39
0.18
0.04
0.10
0.06
0.08
0.00
0.04
0.04
0.04
0.02
0.05
0.09
0.11

SEQID-03883
Q9SP22
—
—
1
0.44
0.14
0.05
0.02
0.03
0.14
0.00
0.03
0.12
0.03
0.03
0.06
0.05
0.14

SEQID-03884
Q9URQ5
—
—
0
0.42
0.19
0.02
0.10
0.14
0.01
0.01
0.06
0.13
0.00
0.01
0.05
0.12
0.08

SEQID-03885
Q9XSK7
—
—
1
0.34
0.09
0.05
0.06
0.03
0.05
0.01
0.02
0.23
0.05
0.02
0.01
0.06
0.13

SEQID-03886
Q92T46
—
—
0
0.50
0.20
0.03
0.04
0.04
0.08
0.00
0.05
0.07
0.06
0.04
0.07
0.07
0.10

SEQID-03887
Q9ZT47
—
—
0
0.51
0.18
0.03
0.03
0.04
0.08
0.01
0.02
0.08
0.07
0.06
0.06
0.07
0.12

SEQID-03888
Q9ZZV8
—
—
0
0.39
0.07
0.02
0.16
0.08
0.04
0.00
0.00
0.02
0.04
0.00
0.02
0.02
0.13

SEQID-03889
W5PEW5
—
—
1
0.42
0.20
0.03
0.06
0.04
0.04
0.01
0.10
0.18
0.01
0.02
0.03
0.13
0.11

SEQID-03890
Q2YDE5
—
6:66
0
0.45
0.23
0.00
0.09
0.08
0.00
0.06
0.04
0.02
0.22
0.16
0.02
0.00
0.02

SEQID-03891
Q06698
—
151:201
0
0.57
0.16
0.00
0.07
0.00
0.04
0.13
0.10
0.02
0.13
0.14
0.06
0.01
0.07

SEQID-03892
P53061
—
251:301
0
0.57
0.14
0.00
0.07
0.00
0.02
0.05
0.05
0.05
0.07
0.24
0.02
0.01
0.11

SEQID-03893
P53061
—
251:306
0
0.56
0.14
0.00
0.06
0.00
0.02
0.05
0.04
0.05
0.08
0.24
0.02
0.01
0.10

SEQID-03894
P53061
—
251:311
0
0.56
0.16
0.00
0.06
0.00
0.02
0.08
0.04
0.04
0.10
0.23
0.02
0.01
0.10

SEQID-03895
P53061
—
251:316
0
0.57
0.17
0.00
0.06
0.00
0.02
0.08
0.04
0.04
0.11
0.22
0.02
0.01
0.09

SEQID-03896
Q90980
—
381:431
0
0.58
0.26
0.00
0.04
0.00
0.02
0.07
0.10
0.07
0.11
0.16
0.02
0.03
0.02

SEQID-03897
Q00194
—
426:476
0
0.60
0.24
0.00
0.04
0.00
0.02
0.09
0.10
0.05
0.11
0.18
0.02
0.02
0.02

SEQID-03898
Q00194
—
426:481
0
0.59
0.24
0.00
0.03
0.00
0.02
0.10
0.09
0.07
0.10
0.17
0.02
0.03
0.04

SEQID-03899
Q90805
—
466:521
0
0.67
0.24
0.00
0.05
0.00
0.04
0.09
0.05
0.05
0.12
0.21
0.02
0.03
0.04

SEQID-03900
Q35Z12
—
86:136
0
0.57
0.21
0.00
0.07
0.00
0.02
0.04
0.10
0.09
0.05
0.23
0.04
0.03
0.02

SEQID-03901
P04467
—
121:171
0
0.56
0.25
0.01
0.08
0.01
0.00
0.12
0.03
0.00
0.23
0.15
0.04
0.04
0.05

SEQID-03902
Q0P584
—
166:216
0
0.51
0.23
0.00
0.02
0.03
0.02
0.06
0.20
0.00
0.22
0.14
0.04
0.02
0.02

SEQID-03903
Q2NL14
—
211:261
0
0.52
0.24
0.03
0.04
0.03
0.07
0.00
0.15
0.00
0.22
0.17
0.00
0.02
0.02

SEQID-03904
Q10MN8
—
211:276
0
0.32
0.25
0.01
0.01
0.05
0.04
0.06
0.20
0.01
0.22
0.00
0.02
0.09
0.02

SEQID-03905
P58797
—
266:316
0
0.47
0.31
0.02
0.06
0.08
0.00
0.08
0.08
0.02
0.26
0.16
0.00
0.05
0.00

SEQID-03906
A7A1V1
—
41:91
0
0.49
0.33
0.02
0.06
0.03
0.02
0.09
0.13
0.07
0.24
0.08
0.00
0.00
0.00

SEQID-03907
P50275
—
491:546
0
0.47
0.27
0.00
0.03
0.04
0.00
0.05
0.05
0.03
0.22
0.08
0.00
0.01
0.07

SEQID-03908
Q60CZ8
—
591:646
0
0.42
0.29
0.01
0.03
0.04
0.00
0.16
0.14
0.03
0.22
0.04
0.02
0.03
0.00

SEQID-03909
Q9AWA5
—
821:876
0
0.45
0.30
0.01
0.05
0.01
0.02
0.09
0.14
0.02
0.22
0.06
0.00
0.03
0.02


































Aller-













SolveScore

NetChg

genHo-
Aller-
Tox-
Anti-

SEQID
M
F
P
S
T
W
Y
V
(pH 7)
AggScore
(pH 7)
pI
mology
genicity
icity
nutricity



SEQID-00001
0.05
0.07
0.03
0.03
0.04
0.01
0.04
0.07
−18.29
0.50
−0.03
4.96
1.00
1.00
0.20
0.42

SEQID-00002
0.02
0.06
0.05
0.05
0.03
0.01
0.03
0.05
−18.75
0.40
−0.01
5.25
1.00
1.00
0.19
0.21

SEQID-00003
0.03
0.03
0.04
0.03
0.05
0.03
0.03
0.04
−20.98
0.56
−0.04
4.66
1.00
1.00
0.00
0.24

SEQID-00004
0.03
0.05
0.07
0.06
0.02
0.02
0.07
0.05
−21.19
0.32
−0.05
4.70
1.00
1.00
0.23
0.23

SEQID-00005
0.04
0.05
0.14
0.06
0.04
0.01
0.03
0.08
−15.50
0.50
−0.03
5.06
1.00
1.00
0.24
0.12

SEQID-00006
0.02
0.05
0.01
0.05
0.05
0.05
0.04
0.05
−20.52
0.44
−0.04
4.73
1.00
1.00
0.26
0.25

SEQID-00007
0.00
0.02
0.01
0.03
0.00
0.00
0.15
0.03
−28.17
0.11
0.00
6.98
0.29
0.19
0.37
0.33

SEQID-00008
0.05
0.08
0.01
0.04
0.05
0.00
0.02
0.05
−30.62
0.31
−0.21
3.67
0.95
0.93
0.23
0.00

SEQID-00009
0.02
0.02
0.03
0.03
0.02
0.00
0.02
0.03
−38.14
0.22
−0.23
3.59
0.23
0.41
0.23
0.25

SEQID-00010
0.03
0.05
0.07
0.06
0.03
0.00
0.04
0.06
−5.26
0.69
0.01
9.42
0.28
0.39
0.25
0.00

SEQID-00011
0.03
0.07
0.04
0.03
0.05
0.01
0.07
0.06
−21.57
0.36
−0.02
5.81
0.25
0.32
0.24
0.00

SEQID-00012
0.00
0.02
0.01
0.03
0.00
0.00
0.15
0.03
−28.17
0.11
0.00
6.98
0.29
0.19
0.37
0.33

SEQID-00013
0.00
0.02
0.02
0.03
0.00
0.00
0.16
0.03
−27.17
0.12
0.00
7.00
0.30
0.19
0.38
0.34

SEQID-00014
0.00
0.02
0.02
0.03
0.00
0.00
0.13
0.03
−28.08
0.11
0.02
7.69
0.31
0.20
0.38
0.31

SEQID-00015
0.00
0.03
0.02
0.03
0.00
0.00
0.14
0.04
−27.01
0.12
0.02
7.75
0.31
0.13
0.38
0.28

SEQID-00016
0.05
0.03
0.04
0.04
0.04
0.02
0.03
0.02
−20.72
0.65
−0.13
3.73
0.40
0.44
0.26
0.25

SEQID-00017
0.05
0.10
0.04
0.05
0.02
0.02
0.06
0.04
−19.76
0.63
−0.12
3.86
0.48
0.51
0.00
0.30

SEQID-00018
0.04
0.06
0.00
0.05
0.02
0.05
0.08
0.02
−20.08
0.50
0.25
12.35
0.22
0.24
0.00
0.24

SEQID-00019
0.00
0.10
0.00
0.00
0.00
0.00
0.00
0.06
−27.12
0.34
0.37
13.67
0.26
0.23
0.00
0.25

SEQID-00020
0.03
0.10
0.03
0.05
0.03
0.00
0.04
0.05
−19.74
0.39
0.13
10.65
0.42
0.47
0.25
0.26

SEQID-00021
0.02
0.00
0.05
0.06
0.03
0.00
0.12
0.07
−17.96
0.43
0.12
10.56
0.26
0.30
0.25
0.00

SEQID-00022
0.03
0.05
0.08
0.05
0.04
0.00
0.05
0.06
−4.43
0.72
0.01
8.97
0.29
0.39
0.25
0.00

SEQID-00023
0.01
0.01
0.06
0.06
0.00
0.00
0.03
0.05
−6.27
0.79
0.02
9.33
0.36
0.39
0.00
0.00

SEQID-00024
0.00
0.07
0.04
0.02
0.06
0.00
0.00
0.10
−15.79
0.80
−0.03
4.45
0.28
0.31
0.00
1.00

SEQID-00025
0.00
0.05
0.03
0.06
0.04
0.00
0.00
0.03
−16.50
0.84
0.08
3.94
0.25
0.29
0.00
1.00

SEQID-00026
0.00
0.05
0.00
0.00
0.03
0.07
0.00
0.03
−9.16
2.04
−0.04
4.15
0.28
0.32
0.24
0.26

SEQID-00027
0.02
0.02
0.03
0.04
0.03
0.00
0.12
0.09
−16.31
0.80
−0.05
4.39
0.23
0.32
0.00
0.00

SEQID-00028
0.00
0.03
0.01
0.08
0.05
0.00
0.03
0.15
−21.97
1.00
−0.25
3.10
0.28
0.30
0.00
0.25

SEQID-00029
0.03
0.01
0.02
0.04
0.02
0.00
0.13
0.06
−24.09
0.41
−0.12
3.93
0.00
0.31
0.00
0.00

SEQID-00030
0.00
0.00
0.00
0.05
0.03
0.00
0.00
0.05
−28.44
0.16
−0.04
4.97
0.33
0.36
0.00
0.00

SEQID-00031
0.00
0.00
0.00
0.02
0.04
0.00
0.01
0.04
−36.33
0.16
−0.04
4.90
0.32
0.33
0.00
0.00

SEQID-00032
0.02
0.00
0.00
0.03
0.06
0.00
0.00
0.03
−36.17
0.22
−0.12
4.27
0.32
0.35
0.25
0.27

SEQID-00033
0.02
0.00
0.01
0.04
0.06
0.02
0.01
0.07
−27.36
0.49
0.01
8.97
0.30
0.34
0.00
0.30

SEQID-00034
0.04
0.00
0.03
0.03
0.05
0.03
0.03
0.04
−20.74
0.58
0.00
6.54
0.84
0.94
0.29
0.28

SEQID-00035
0.02
0.01
0.04
0.05
0.06
0.00
0.00
0.09
−18.18
0.64
0.05
10.26
0.26
0.30
0.00
0.00

SEQID-00036
0.02
0.08
0.01
0.03
0.04
0.06
0.06
0.06
−17.32
0.73
0.03
8.48
0.51
0.60
0.26
0.24

SEQID-00037
0.06
0.07
0.00
0.00
0.10
0.05
0.00
0.09
−14.15
1.56
0.19
11.98
0.14
0.26
0.23
0.24

SEQID-00038
0.01
0.06
0.03
0.06
0.02
0.08
0.01
0.07
−19.01
0.72
0.00
7.29
0.26
0.33
0.25
0.27

SEQID-00039
0.02
0.03
0.02
0.03
0.03
0.02
0.05
0.06
−24.37
0.51
0.05
9.49
0.27
0.30
0.24
0.26

SEQID-00040
0.00
0.08
0.04
0.02
0.05
0.00
0.03
0.11
−17.17
0.77
−0.03
4.50
0.27
0.31
0.00
1.00

SEQID-00041
0.03
0.06
0.01
0.05
0.03
0.05
0.08
0.02
−21.00
0.47
0.22
12.17
0.19
0.25
0.00
0.00

SEQID-00042
0.01
0.04
0.12
0.11
0.06
0.00
0.06
0.04
−24.24
0.16
−0.21
3.55
0.29
0.32
0.26
0.30

SEQID-00043
0.00
0.05
0.04
0.00
0.05
0.00
0.00
0.11
−17.59
0.99
−0.02
4.77
0.32
0.20
0.00
1.00

SEQID-00044
0.00
0.05
0.03
0.00
0.05
0.00
0.00
0.11
−17.59
1.04
−0.02
4.77
0.32
0.20
0.00
1.00

SEQID-00045
0.00
0.03
0.03
0.02
0.05
0.00
0.00
0.10
−18.20
0.93
−0.04
4.46
0.32
0.21
0.00
1.00

SEQID-00046
0.00
0.03
0.03
0.02
0.05
0.00
0.00
0.10
−18.55
0.92
−0.04
4.46
0.33
0.21
0.33
1.00

SEQID-00047
0.00
0.03
0.04
0.02
0.06
0.00
0.00
0.11
−16.30
1.04
−0.04
4.39
0.35
0.22
0.00
1.00

SEQID-00048
0.00
0.00
0.05
0.06
0.05
0.00
0.00
0.00
−45.65
0.00
0.64
13.78
0.38
0.15
0.44
0.39

SEQID-00049
0.02
0.06
0.03
0.03
0.07
0.01
0.05
0.06
−21.74
0.30
−0.01
6.61
0.23
0.31
0.23
0.00

SEQID-00050
0.02
0.10
0.09
0.00
0.02
0.00
0.00
0.09
−16.62
0.92
0.05
9.51
1.00
0.63
0.00
0.34

SEQID-00051
0.00
0.10
0.09
0.00
0.02
0.00
0.00
0.09
−17.98
0.90
0.07
10.22
1.00
0.63
0.00
0.00

SEQID-00052
0.00
0.10
0.09
0.00
0.02
0.00
0.00
0.11
−16.59
0.95
0.05
9.51
1.00
0.63
0.00
0.32

SEQID-00053
0.00
0.10
0.09
0.00
0.02
0.00
0.00
0.11
−16.79
0.87
0.05
9.51
1.00
0.63
0.00
0.33

SEQID-00054
0.00
0.10
0.09
0.00
0.02
0.00
0.00
0.11
−18.37
0.77
0.03
8.55
1.00
0.63
0.00
0.30

SEQID-00055
0.00
0.10
0.09
0.00
0.02
0.00
0.00
0.11
−18.37
0.71
0.03
8.55
1.00
0.63
0.00
0.32

SEQID-00056
0.00
0.00
0.05
0.09
0.00
0.00
0.08
0.08
−26.42
0.21
−0.04
4.99
1.00
0.63
0.26
0.00

SEQID-00057
0.00
0.00
0.07
0.09
0.00
0.00
0.08
0.08
−24.84
0.25
−0.03
5.78
1.00
0.63
0.26
0.00

SEQID-00058
0.00
0.00
0.07
0.07
0.00
0.00
0.08
0.08
−24.93
0.20
−0.02
5.78
1.00
0.63
0.26
0.00

SEQID-00059
0.00
0.00
0.07
0.04
0.00
0.00
0.08
0.08
−26.10
0.22
0.00
7.53
1.00
0.63
0.26
0.00

SEQID-00060
0.02
0.06
0.03
0.03
0.06
0.01
0.05
0.06
−24.08
0.29
−0.11
4.40
0.22
0.31
0.23
0.30

SEQID-00061
0.02
0.06
0.03
0.03
0.05
0.01
0.05
0.06
−25.02
0.25
0.16
11.10
0.32
0.30
0.23
0.00

SEQID-00062
0.01
0.07
0.02
0.04
0.04
0.00
0.01
0.11
−10.77
1.44
0.03
8.52
0.25
0.29
0.27
0.28

SEQID-00063
0.04
0.05
0.04
0.07
0.05
0.00
0.08
0.09
−5.74
1.81
−0.03
4.13
0.37
0.30
0.24
0.23

SEQID-00064
0.02
0.06
0.03
0.07
0.04
0.01
0.10
0.06
−6.82
1.66
−0.04
3.88
0.23
0.28
0.22
0.25

SEQID-00065
0.03
0.03
0.04
0.06
0.05
0.02
0.01
0.08
−5.87
1.50
0.02
10.29
0.22
0.31
0.24
0.24

SEQID-00066
0.01
0.16
0.03
0.03
0.03
0.00
0.07
0.10
−10.37
1.56
0.03
9.86
0.25
0.31
0.22
0.22

SEQID-00067
0.02
0.05
0.03
0.05
0.05
0.01
0.07
0.09
−7.86
1.69
0.03
9.42
0.23
0.29
0.22
0.24

SEQID-00068
0.01
0.00
0.00
0.06
0.02
0.01
0.06
0.10
−21.10
0.87
−0.05
4.70
0.76
0.43
0.00
0.20

SEQID-00069
0.01
0.01
0.03
0.06
0.04
0.00
0.00
0.12
−14.66
1.17
−0.03
3.87
0.26
0.29
0.00
0.83

SEQID-00070
0.01
0.03
0.03
0.06
0.04
0.00
0.00
0.09
−16.34
0.91
−0.08
3.94
0.23
0.28
0.00
0.95

SEQID-00071
0.00
0.05
0.02
0.00
0.05
0.00
0.00
0.14
−17.59
1.19
−0.02
4.77
0.32
0.20
0.00
0.94

SEQID-00072
0.08
0.07
0.01
0.02
0.04
0.00
0.03
0.04
−31.39
0.32
−0.18
3.79
0.37
0.43
0.21
0.22

SEQID-00073
0.03
0.05
0.00
0.02
0.04
0.03
0.01
0.05
−32.67
0.32
−0.10
4.22
0.39
0.54
0.26
0.25

SEQID-00074
0.08
0.08
0.01
0.03
0.03
0.00
0.02
0.04
−30.64
0.26
−0.18
3.81
0.38
0.45
0.25
0.22

SEQID-00075
0.08
0.07
0.01
0.02
0.04
0.00
0.03
0.04
−31.40
0.32
−0.18
3.79
0.37
0.43
0.21
0.22

SEQID-00076
0.08
0.07
0.01
0.02
0.04
0.00
0.03
0.04
−31.40
0.32
−0.18
3.79
0.37
0.43
0.21
0.22

SEQID-00077
0.05
0.09
0.01
0.04
0.06
0.00
0.01
0.04
−29.63
0.32
−0.21
3.61
1.00
1.00
0.25
0.00

SEQID-00078
0.03
0.07
0.01
0.01
0.04
0.00
0.03
0.04
−31.05
0.32
−0.19
3.74
0.37
0.41
0.21
0.20

SEQID-00079
0.04
0.07
0.08
0.03
0.02
0.03
0.03
0.06
−13.19
1.21
0.09
10.26
0.32
0.21
0.27
0.28

SEQID-00080
0.02
0.14
0.04
0.07
0.05
0.03
0.06
0.04
−9.71
1.15
−0.02
5.52
0.21
0.31
0.23
0.24

SEQID-00081
0.05
0.09
0.01
0.09
0.01
0.05
0.06
0.04
−12.67
1.02
0.04
8.87
0.26
0.27
0.29
0.00

SEQID-00082
0.02
0.03
0.04
0.05
0.04
0.03
0.02
0.08
−14.94
0.85
0.03
8.78
0.00
0.33
0.23
0.23

SEQID-00083
0.05
0.04
0.09
0.06
0.05
0.02
0.02
0.04
−15.80
0.76
0.08
10.61
0.28
0.24
0.30
0.30

SEQID-00084
0.04
0.02
0.01
0.01
0.02
0.03
0.05
0.02
−24.13
0.24
−0.21
3.63
0.68
0.52
0.32
0.31

SEQID-00085
0.05
0.07
0.02
0.02
0.05
0.00
0.04
0.08
−23.50
0.38
−0.09
4.29
0.37
0.46
0.00
0.18

SEQID-00086
0.07
0.07
0.02
0.03
0.05
0.00
0.03
0.07
−23.76
0.32
−0.08
4.24
0.36
0.45
0.22
0.23

SEQID-00087
0.05
0.09
0.02
0.03
0.05
0.00
0.01
0.05
−23.80
0.35
−0.08
4.24
0.37
0.49
0.23
0.27

SEQID-00088
0.05
0.06
0.07
0.08
0.02
0.02
0.08
0.02
−15.45
0.39
−0.08
3.93
0.29
0.32
1.00
0.34

SEQID-00089
0.03
0.05
0.02
0.05
0.05
0.02
0.04
0.06
−23.87
0.28
−0.07
4.43
0.43
0.63
0.00
0.21

SEQID-00090
0.05
0.07
0.03
0.05
0.05
0.02
0.05
0.06
−19.97
0.34
−0.06
4.45
0.40
0.54
0.00
0.21

SEQID-00091
0.03
0.06
0.04
0.05
0.06
0.02
0.06
0.07
−19.21
0.44
−0.05
4.51
0.92
0.99
0.00
0.00

SEQID-00092
0.08
0.08
0.01
0.03
0.03
0.00
0.02
0.04
−30.84
0.27
−0.18
3.91
0.37
0.45
0.25
0.23

SEQID-00093
0.08
0.09
0.01
0.03
0.04
0.00
0.00
0.03
−30.31
0.28
−0.18
3.81
0.38
0.47
0.25
0.24

SEQID-00094
0.09
0.09
0.01
0.03
0.04
0.00
0.00
0.03
−30.14
0.30
−0.18
3.81
0.37
0.47
0.25
0.23

SEQID-00095
0.03
0.02
0.04
0.04
0.06
0.01
0.02
0.07
−21.15
0.62
−0.06
4.42
0.65
0.74
0.00
0.23

SEQID-00096
0.02
0.05
0.01
0.05
0.05
0.05
0.04
0.05
−21.02
0.44
−0.05
4.61
0.99
1.00
0.26
0.26

SEQID-00097
0.03
0.00
0.00
0.03
0.02
0.00
0.03
0.02
−36.52
0.12
−0.10
4.38
0.58
0.70
0.25
0.21

SEQID-00098
0.03
0.07
0.00
0.02
0.05
0.00
0.02
0.11
−33.16
0.40
−0.25
3.57
0.27
0.24
0.34
0.00

SEQID-00099
0.03
0.05
0.03
0.05
0.01
0.00
0.00
0.11
−27.07
0.41
−0.19
3.67
0.31
0.30
0.41
0.24

SEQID-00100
0.03
0.08
0.01
0.05
0.03
0.00
0.02
0.04
−29.97
0.29
−0.21
3.67
0.35
0.35
0.42
0.30

SEQID-00101
0.03
0.05
0.00
0.09
0.02
0.00
0.02
0.10
−29.38
0.37
−0.15
3.90
0.23
0.29
0.38
0.23

SEQID-00102
0.04
0.08
0.01
0.04
0.04
0.00
0.02
0.04
−30.86
0.24
−0.20
3.75
0.30
0.30
0.38
0.00

SEQID-00103
0.08
0.07
0.01
0.03
0.06
0.00
0.01
0.05
−27.55
0.34
−0.16
3.79
0.39
0.46
0.22
0.24

SEQID-00104
0.07
0.07
0.01
0.02
0.05
0.00
0.01
0.05
−28.96
0.24
−0.15
3.88
0.43
0.49
0.22
0.21

SEQID-00105
0.04
0.07
0.01
0.10
0.03
0.00
0.00
0.04
−23.64
0.35
−0.13
3.92
0.39
0.46
0.25
0.26

SEQID-00106
0.07
0.08
0.01
0.03
0.05
0.00
0.01
0.05
−29.02
0.23
−0.15
3.87
0.44
0.51
0.23
0.21

SEQID-00107
0.01
0.06
0.05
0.03
0.03
0.04
0.05
0.04
−30.63
0.26
−0.13
4.06
0.32
0.49
0.00
0.22

SEQID-00108
0.01
0.04
0.0S
0.04
0.04
0.05
0.06
0.03
−31.29
0.25
−0.10
4.28
0.34
0.55
0.00
0.22

SEQID-00109
0.00
0.03
0.03
0.03
0.03
0.03
0.06
0.14
−21.85
0.87
−0.26
2.83
0.31
0.21
0.27
0.35

SEQID-00110
0.00
0.03
0.02
0.05
0.04
0.06
0.03
0.02
−25.30
0.46
−0.18
3.78
0.36
0.22
0.33
0.34

SEQID-00111
0.02
0.00
0.05
0.01
0.02
0.03
0.05
0.03
−27.81
0.25
−0.10
4.35
0.33
0.21
0.34
0.29

SEQID-00112
0.06
0.07
0.03
0.00
0.02
0.03
0.05
0.03
−22.49
0.43
−0.13
3.90
0.33
0.21
0.31
0.35

SEQID-00113
0.04
0.11
0.01
0.02
0.01
0.03
0.02
0.03
−22.06
0.51
−0.13
4.12
0.29
0.21
0.28
0.27

SEQID-00114
0.05
0.05
0.05
0.02
0.05
0.03
0.00
0.12
−28.91
0.42
−0.16
4.04
0.37
0.20
0.28
0.37

SEQID-00115
0.02
0.01
0.03
0.04
0.11
0.00
0.03
0.03
−38.34
0.23
−0.32
3.45
0.31
0.35
0.26
0.33

SEQID-00116
0.02
0.01
0.03
0.04
0.11
0.00
0.03
0.04
−37.93
0.23
−0.31
3.46
0.31
0.35
0.26
0.33

SEQID-00117
0.03
0.10
0.02
0.02
0.03
0.03
0.05
0.05
−21.01
0.41
−0.10
4.21
0.24
0.31
0.00
0.28

SEQID-00118
0.03
0.12
0.02
0.04
0.03
0.02
0.01
0.03
−23.16
0.43
−0.10
4.17
0.23
0.28
0.00
0.00

SEQID-00119
0.04
0.05
0.03
0.04
0.03
0.02
0.03
0.10
−23.37
0.44
−0.12
4.07
0.23
0.29
0.25
0.24

SEQID-00120
0.02
0.06
0.03
0.04
0.05
0.02
0.03
0.09
−25.42
0.36
−0.12
4.08
0.28
0.30
0.00
0.26

SEQID-00121
0.02
0.03
0.08
0.04
0.07
0.00
0.12
0.05
−25.73
0.12
−0.21
3.49
0.25
0.39
0.00
0.27

SEQID-00122
0.01
0.03
0.06
0.05
0.07
0.00
0.13
0.05
−27.56
0.08
−02.2
3.50
0.00
0.31
0.24
0.24

SEQID-00123
0.01
0.05
0.01
0.06
0.08
0.02
0.03
0.06
−26.58
0.34
−0.13
4.03
0.48
0.59
0.00
0.22

SEQID-00124
0.02
0.05
0.02
0.05
0.08
0.02
0.03
0.06
−27.93
0.29
−0.12
4.12
0.50
0.61
0.00
0.25

SEQID-00125
0.02
0.03
0.02
0.10
0.04
0.01
0.06
0.09
−17.21
0.63
−0.10
3.73
0.24
0.32
0.00
0.22

SEQID-00126
0.01
0.05
0.07
0.11
0.05
0.01
0.05
0.03
−25.09
0.15
−0.18
3.64
0.23
0.33
0.00
0.26

SEQID-00127
0.03
0.02
0.04
0.04
0.06
0.01
0.02
0.07
−21.15
0.62
−0.06
4.42
0.65
0.74
0.00
0.23

SEQID-00128
0.03
0.07
0.04
0.06
0.06
0.01
0.02
0.07
−16.81
0.57
0.04
9.31
0.25
0.30
0.23
0.25

SEQID-00129
0.03
0.06
0.04
0.03
0.04
0.02
0.04
0.11
−16.17
0.61
−0.01
6.63
0.24
0.30
0.00
0.28

SEQID-00130
0.02
0.07
0.03
0.03
0.05
0.05
0.02
0.07
−17.34
0.56
0.03
8.89
0.23
0.34
0.00
0.23

SEQID-00131
0.03
0.03
0.04
0.03
0.04
0.02
0.03
0.05
−21.19
0.47
−0.03
5.04
0.96
0.99
0.22
0.24

SEQID-00132
0.00
0.05
0.02
0.03
0.02
0.03
0.03
0.05
−15.02
1.17
0.02
9.22
0.35
0.22
0.34
0.35

SEQID-00133
0.04
0.02
0.00
0.01
0.02
0.06
0.03
0.03
−23.93
1.02
0.04
9.95
0.33
0.21
0.00
0.35

SEQID-00134
0.02
0.03
0.03
0.14
0.05
0.00
0.00
0.07
−10.60
1.38
−0.03
4.49
0.33
0.22
0.00
0.34

SEQID-00135
0.00
0.03
0.04
0.06
0.04
0.00
0.00
0.09
−15.04
0.70
−0.02
6.67
0.32
0.21
0.00
0.31

SEQID-00136
0.00
0.03
0.04
0.08
0.04
0.00
0.00
0.09
−16.20
0.65
0.00
7.09
0.31
0.20
0.00
0.29

SEQID-00137
0.02
0.03
0.00
0.03
0.09
0.00
0.03
0.09
−18.91
0.89
−0.03
4.79
0.31
0.20
0.00
0.32

SEQID-00138
0.02
0.00
0.04
0.06
0.09
0.00
0.00
0.04
−14.32
0.74
−0.02
6.22
0.33
0.22
0.00
0.28

SEQID-00139
0.00
0.00
0.00
0.03
0.03
0.00
0.03
0.07
−31.57
0.29
−0.03
5.00
0.33
0.21
0.00
0.31

SEQID-00140
0.02
0.10
0.03
0.08
0.07
0.03
0.00
0.09
−17.13
0.77
−0.01
7.52
0.31
0.20
0.31
0.28

SEQID-00141
0.02
0.05
0.05
0.01
0.03
0.03
0.05
0.05
−16.98
0.76
0.01
7.61
0.30
0.19
0.25
0.17

SEQID-00142
0.02
0.02
0.00
0.01
0.08
0.06
0.03
0.03
−20.09
0.24
0.08
10.05
0.32
0.21
0.29
0.30

SEQID-00143
0.02
0.07
0.05
0.03
0.05
0.03
0.05
0.11
−19.93
0.52
0.02
8.49
0.33
0.22
0.32
0.32

SEQID-00144
0.04
0.15
0.02
0.01
0.07
0.03
0.03
0.07
−17.29
0.58
0.00
7.25
0.31
0.20
0.39
0.32

SEQID-00145
0.02
0.03
0.02
0.05
0.02
0.03
0.03
0.13
−16.57
0.79
−0.04
4.79
0.90
0.58
0.33
0.24

SEQID-00146
0.02
0.10
0.03
0.08
0.09
0.03
0.00
0.07
−16.05
0.65
−0.01
6.50
0.32
0.20
0.28
0.31

SEQID-00147
0.03
0.03
0.03
0.07
0.06
0.02
0.03
0.12
−16.21
0.73
−0.03
4.70
0.24
0.23
0.00
0.23

SEQID-00148
0.00
0.01
0.05
0.02
0.01
0.05
0.00
0.11
−17.15
0.83
0.04
10.46
0.31
0.30
0.30
0.00

SEQID-00149
0.02
0.01
0.04
0.05
0.06
0.00
0.00
0.09
−17.64
0.65
0.04
9.98
0.27
0.30
0.00
0.00

SEQID-00150
0.04
0.13
0.00
0.03
0.06
0.02
0.04
0.06
−21.64
0.55
−0.01
6.24
0.25
0.26
0.26
0.26

SEQID-00151
0.02
0.04
0.01
0.02
0.03
0.02
0.05
0.07
−24.45
0.54
0.09
10.51
0.29
0.32
0.24
0.25

SEQID-00152
0.02
0.06
0.02
0.04
0.02
0.02
0.05
0.06
−23.71
0.37
0.03
9.12
0.26
0.30
0.27
0.29

SEQID-00153
0.02
0.03
0.03
0.05
0.05
0.02
0.03
0.06
−22.23
0.52
−0.06
4.38
0.72
0.74
0.00
0.13

SEQID-00154
0.03
0.08
0.03
0.05
0.02
0.03
0.03
0.09
−18.41
0.58
0.01
7.51
0.26
0.29
0.29
0.25

SEQID-00155
0.03
0.02
0.05
0.01
0.04
0.05
0.11
0.07
−17.59
0.58
0.00
7.40
0.58
0.60
0.00
0.23

SEQID-00156
0.02
0.05
0.02
0.04
0.03
0.02
0.06
0.06
−22.73
0.51
0.04
9.19
0.23
0.29
0.26
0.26

SEQID-00157
0.04
0.04
0.03
0.05
0.05
0.01
0.06
0.07
−19.38
0.39
−0.02
5.62
0.31
0.44
0.00
0.21

SEQID-00158
0.03
0.07
0.02
0.05
0.05
0.02
0.04
0.08
−19.98
0.57
−0.02
5.35
0.00
0.31
0.00
0.24

SEQID-00159
0.04
0.07
0.05
0.06
0.05
0.01
0.03
0.07
−17.02
0.48
−0.04
4.70
0.47
0.53
0.00
0.22

SEQID-00160
0.03
0.09
0.01
0.05
0.06
0.02
0.04
0.08
−19.43
0.57
−0.02
5.68
0.18
0.31
0.22
0.26

SEQID-00161
0.03
0.03
0.04
0.06
0.09
0.01
0.06
0.10
−15.61
0.48
0.04
9.92
0.29
0.38
0.00
0.22

SEQID-00162
0.05
0.00
0.10
0.06
0.02
0.00
0.03
0.05
−6.47
1.39
−0.02
5.45
0.34
0.22
0.28
0.36

SEQID-00163
0.01
0.13
0.03
0.04
0.02
0.02
0.07
0.04
−11.56
1.34
0.03
9.43
0.22
0.27
0.00
0.23

SEQID-00164
0.04
0.07
0.01
0.03
0.03
0.03
0.05
0.22
−5.03
1.99
0.02
9.17
0.29
0.22
0.00
0.34

SEQID-00165
0.02
0.00
0.03
0.07
0.08
0.06
0.03
0.17
−4.16
1.81
0.00
6.41
0.30
0.23
0.27
0.00

SEQID-00166
0.03
0.05
0.07
0.02
0.08
0.00
0.03
0.08
−5.92
1.63
0.00
7.70
0.25
0.30
0.00
0.27

SEQID-00167
0.04
0.05
0.07
0.05
0.10
0.03
0.02
0.02
−6.50
1.19
0.02
10.10
0.21
0.33
0.00
0.24

SEQID-00168
0.05
0.04
0.06
0.05
0.10
0.03
0.02
0.03
−6.42
1.26
0.01
9.66
0.21
0.33
0.00
0.00

SEQID-00169
0.04
0.09
0.14
0.04
0.02
0.00
0.03
0.05
−5.08
1.18
−0.03
4.18
0.29
0.20
0.32
0.33

SEQID-00170
0.05
0.04
0.07
0.06
0.09
0.03
0.02
0.02
−6.50
1.19
0.02
9.72
0.21
0.33
0.00
0.00

SEQID-00171
0.04
0.06
0.07
0.03
0.09
0.04
0.03
0.05
−5.71
1.32
0.02
10.04
0.23
0.31
0.00
0.22

SEQID-00172
0.09
0.06
0.01
0.05
0.07
0.00
0.05
0.07
−5.77
1.52
−0.01
6.20
0.26
0.28
0.00
0.24

SEQID-00173
0.05
0.07
0.07
0.03
0.09
0.04
0.03
0.05
−6.03
1.24
0.01
9.63
0.21
0.33
0.00
0.20

SEQID-00174
0.04
0.08
0.08
0.03
0.10
0.06
0.01
0.04
−7.89
1.02
0.02
10.42
0.23
0.32
0.00
0.26

SEQID-00175
0.04
0.11
0.02
0.00
0.05
0.03
0.08
0.05
−6.10
1.53
−0.05
3.93
0.29
0.21
0.00
0.26

SEQID-00176
0.06
0.08
0.05
0.06
0.10
0.02
0.01
0.05
−6.48
1.21
0.02
10.57
0.00
0.32
0.00
0.00

SEQID-00177
0.02
0.11
0.01
0.07
0.06
0.03
0.06
0.09
−4.33
1.65
−0.01
5.45
0.00
0.30
0.22
0.27

SEQID-00178
0.05
0.14
0.04
0.04
0.03
0.02
0.06
0.05
−6.01
1.52
0.00
7.34
0.22
0.28
0.27
0.20

SEQID-00179
0.01
0.11
0.04
0.07
0.03
0.03
0.06
0.04
−9.40
1.40
−0.02
4.73
0.23
0.33
0.00
0.27

SEQID-00180
0.06
0.05
0.07
0.05
0.07
0.08
0.04
0.02
−7.83
1.16
0.00
6.95
0.20
0.30
0.00
0.27

SEQID-00181
0.07
0.10
0.03
0.03
0.09
0.02
0.04
0.01
−8.86
1.29
−0.01
5.65
0.29
0.32
0.00
0.23

SEQID-00182
0.05
0.08
0.05
0.06
0.04
0.05
0.06
0.04
−7.84
1.36
0.02
9.13
0.25
0.28
0.00
0.25

SEQID-00183
0.02
0.10
0.02
0.03
0.03
0.02
0.04
0.03
−9.90
1.21
−0.04
4.17
0.18
0.28
0.23
0.27

SEQID-00184
0.04
0.16
0.02
0.05
0.03
0.05
0.07
0.06
−10.84
1.38
−0.04
4.29
0.27
0.28
0.27
0.23

SEQID-00185
0.02
0.11
0.03
0.08
0.03
0.05
0.06
0.04
−10.00
1.28
0.01
8.21
0.26
0.31
0.24
0.26

SEQID-00186
0.05
0.14
0.02
0.03
0.05
0.04
0.04
0.07
−9.98
1.54
0.02
9.17
0.25
0.28
0.00
0.22

SEQID-00187
0.02
0.18
0.03
0.05
0.05
0.02
0.03
0.07
−7.42
1.30
0.01
8.23
0.23
0.28
0.20
0.27

SEQID-00188
0.04
0.03
0.07
0.04
0.10
0.03
0.00
0.04
−6.18
1.52
0.00
7.72
0.25
0.33
0.00
0.26

SEQID-00189
0.07
0.04
0.08
0.05
0.11
0.07
0.01
0.01
−6.44
1.10
0.06
12.27
0.23
0.29
0.00
0.30

SEQID-00190
0.05
0.01
0.08
0.05
0.12
0.03
0.01
0.01
−5.82
1.11
0.01
9.35
0.27
0.30
0.24
0.27

SEQID-00191
0.05
0.01
0.09
0.05
0.12
0.02
0.01
0.02
−6.73
1.12
0.03
10.24
0.27
0.30
0.00
0.29

SEQID-00192
0.04
0.00
0.07
0.05
0.12
0.00
0.00
0.03
−6.30
1.37
0.00
7.72
0.23
0.27
0.00
0.29

SEQID-00193
0.02
0.03
0.03
0.08
0.04
0.00
0.00
0.04
−18.69
0.54
0.02
9.44
0.29
0.18
0.24
0.35

SEQID-00194
0.02
0.03
0.03
0.08
0.04
0.00
0.00
0.04
−17.31
0.54
0.04
10.49
0.31
0.20
0.24
0.33

SEQID-00195
0.02
0.00
0.03
0.09
0.04
0.00
0.00
0.04
−17.40
0.47
0.04
10.49
0.31
0.20
0.22
0.34

SEQID-00196
0.03
0.04
0.03
0.06
0.04
0.00
0.02
0.04
−22.65
0.39
0.00
7.42
0.24
0.32
0.25
0.25

SEQID-00197
0.03
0.04
0.03
0.06
0.04
0.00
0.02
0.04
−22.50
0.39
0.00
7.42
0.20
0.32
0.25
0.25

SEQID-00198
0.03
0.04
0.03
0.06
0.04
0.00
0.02
0.04
−22.35
0.39
0.00
7.42
0.00
0.32
0.25
0.26

SEQID-00199
0.03
0.04
0.03
0.06
0.04
0.00
0.02
0.04
−22.74
0.39
0.00
6.53
0.23
0.32
0.00
0.25

SEQID-00200
0.03
0.04
0.03
0.06
0.04
0.00
0.02
0.04
−22.59
0.39
0.00
6.53
0.23
0.32
0.00
0.25

SEQID-00201
0.03
0.04
0.03
0.06
0.04
0.00
0.02
0.04
−22.97
0.38
−0.01
5.82
0.22
0.32
0.24
0.25

SEQID-00202
0.03
0.04
0.03
0.06
0.04
0.00
0.02
0.04
−23.34
0.38
−0.02
5.32
0.22
0.32
0.24
0.25

SEQID-00203
0.03
0.04
0.03
0.05
0.04
0.00
0.02
0.04
−23.25
0.38
−0.02
5.32
0.22
0.32
0.24
0.25

SEQID-00204
0.03
0.04
0.03
0.05
0.04
0.00
0.02
0.04
−23.61
0.37
−0.02
5.06
0.25
0.32
0.00
0.2S

SEQID-00205
0.03
0.04
0.04
0.06
0.04
0.00
0.02
0.04
−24.11
0.36
−0.04
4.67
0.25
0.32
0.23
0.26

SEQID-00206
0.00
0.02
0.02
0.00
0.03
0.09
0.03
0.08
−27.16
0.30
0.10
10.48
0.32
0.10
0.29
0.25

SEQID-00207
0.02
0.02
0.01
0.00
0.04
0.07
0.02
0.06
−33.49
0.15
0.01
7.70
0.31
0.26
0.26
0.00

SEQID-00208
0.02
0.02
0.00
0.00
0.03
0.00
0.00
0.03
−37.87
0.12
0.18
4.11
0.34
0.23
0.29
0.27

SEQID-00209
0.01
0.04
0.01
0.01
0.03
0.04
0.01
0.05
−29.13
0.21
0.02
9.15
0.30
0.31
0.00
0.00

SEQID-00210
0.02
0.02
0.01
0.00
0.03
0.05
0.01
0.04
−32.93
0.17
−0.04
5.09
0.30
0.34
0.25
0.23

SEQID-00211
0.02
0.02
0.01
0.01
0.03
0.04
0.01
0.04
−33.59
0.15
−0.05
4.95
0.30
0.34
0.25
0.00

SEQID-00212
0.00
0.00
0.00
0.01
0.03
0.00
0.03
0.05
−36.26
0.21
−0.06
4.77
0.34
0.21
0.29
0.33

SEQID-00213
0.00
0.00
0.00
0.01
0.05
0.00
0.03
0.05
−34.27
0.27
−0.04
4.76
0.35
0.22
0.25
0.00

SEQID-00214
0.00
0.00
0.00
0.01
0.06
0.00
0.02
0.05
−32.73
0.22
−0.04
4.66
0.29
0.25
0.31
0.00

SEQID-00215
0.00
0.00
0.00
0.03
0.03
0.00
0.02
0.06
−34.50
0.23
0.00
7.54
0.31
0.21
0.00
0.00

SEQID-00216
0.00
0.02
0.00
0.02
0.03
0.00
0.02
0.05
−34.08
0.25
0.00
7.54
0.32
0.26
0.00
0.00

SEQID-00217
0.00
0.00
0.00
0.01
0.05
0.00
0.03
0.06
−35.54
0.25
−0.09
4.33
0.34
0.23
0.00
0.00

SEQID-00218
0.00
0.00
0.00
0.01
0.05
0.00
0.03
0.05
−34.67
0.22
−0.07
4.60
0.34
0.23
0.25
0.00

SEQID-00219
0.00
0.00
0.00
0.03
0.03
0.00
0.03
0.07
−33.39
0.29
−0.02
5.81
0.32
0.20
0.00
0.31

SEQID-00220
0.00
0.00
0.00
0.01
0.05
0.00
0.02
0.05
−37.57
0.19
−0.07
4.55
0.31
0.25
0.31
0.00

SEQID-00221
0.00
0.00
0.00
0.02
0.03
0.00
0.02
0.06
−35.42
0.21
−0.01
5.88
0.32
0.24
0.21
0.00

SEQID-00222
0.00
0.03
0.00
0.03
0.05
0.00
0.00
0.02
−30.85
0.13
−0.10
4.23
0.36
0.23
0.00
0.33

SEQID-00223
0.00
0.02
0.00
0.01
0.03
0.00
0.03
0.03
−33.68
0.26
−0.02
5.81
0.36
0.23
0.00
0.00

SEQID-00224
0.00
0.00
0.00
0.01
0.06
0.00
0.02
0.06
−37.47
0.23
−0.05
4.66
0.33
0.25
0.00
0.00

SEQID-00225
0.00
0.01
0.00
0.02
0.04
0.00
0.01
0.04
−33.38
0.20
−0.02
5.31
0.30
0.31
0.00
0.00

SEQID-00226
0.00
0.01
0.00
0.02
0.04
0.00
0.01
0.04
−32.78
0.18
−0.03
5.01
0.30
0.33
0.27
0.29

SEQID-00227
0.00
0.01
0.00
0.02
0.03
0.00
0.03
0.04
−36.89
0.16
−0.03
5.07
0.33
0.35
0.00
0.00

SEQID-00228
0.00
0.01
0.00
0.02
0.04
0.00
0.02
0.04
−37.66
0.15
−0.03
4.97
0.33
0.39
0.00
0.00

SEQID-00229
0.02
0.02
0.00
0.03
0.07
0.00
0.00
0.02
−32.91
0.12
−0.10
4.28
0.38
0.25
0.00
0.00

SEQID-00230
0.00
0.03
0.00
0.03
0.02
0.00
0.00
0.02
−29.21
0.16
0.02
9.18
0.39
0.25
0.00
0.27

SEQID-00231
0.01
0.03
0.00
0.04
0.05
0.00
0.00
0.02
−28.20
0.17
−0.03
4.75
0.30
0.31
0.00
0.00

SEQID-00232
0.00
0.03
0.00
0.03
0.05
0.00
0.00
0.03
−30.24
0.12
0.04
10.27
0.31
0.33
0.00
0.00

SEQID-00233
0.00
0.06
0.02
0.07
0.05
0.00
0.00
0.08
−16.02
0.94
−0.06
4.03
0.26
0.32
0.00
1.00

SEQID-00234
0.00
0.07
0.02
0.07
0.04
0.00
0.00
0.08
−16.69
0.94
−0.07
4.03
0.23
0.30
0.00
1.00

SEQID-00235
0.00
0.07
0.01
0.08
0.04
0.00
0.03
0.06
−17.69
0.65
−0.06
4.15
0.26
0.31
0.00
1.00

SEQID-00236
0.02
0.00
0.00
0.01
0.05
0.00
0.00
0.03
−34.37
0.07
−0.06
4.67
0.36
0.29
0.00
0.00

SEQID-00237
0.02
0.00
0.00
0.01
0.05
0.00
0.00
0.03
−38.56
0.08
−0.02
5.12
0.38
0.24
0.00
0.00

SEQID-00238
0.02
0.00
0.00
0.01
0.03
0.00
0.00
0.03
−38.44
0.16
−0.09
4.53
0.35
0.24
0.27
0.32

SEQID-00239
0.06
0.02
0.00
0.01
0.02
0.00
0.00
0.00
−41.59
0.04
−0.02
5.16
0.42
0.26
0.00
0.00

SEQID-00240
0.04
0.00
0.00
0.03
0.02
0.00
0.00
0.00
−40.29
0.04
−0.04
4.82
0.37
0.23
0.28
0.00

SEQID-00241
0.02
0.00
0.00
0.01
0.07
0.00
0.00
0.03
−35.70
0.11
−0.05
4.83
0.31
0.36
0.26
0.22

SEQID-00242
0.00
0.10
0.05
0.03
0.05
0.07
0.00
0.03
−5.77
1.91
−0.02
4.18
0.33
0.20
0.29
0.00

SEQID-00243
0.00
0.11
0.05
0.03
0.05
0.03
0.06
0.02
−4.36
1.69
0.00
6.23
0.31
0.19
0.00
0.33

SEQID-00244
0.05
0.00
0.04
0.11
0.15
0.03
0.00
0.00
−3.56
1.26
0.02
9.70
0.37
0.24
0.27
0.29

SEQID-00245
0.02
0.08
0.07
0.08
0.12
0.03
0.00
0.03
−5.24
1.22
0.00
7.55
0.30
0.19
0.00
0.36

SEQID-00246
0.00
0.08
0.02
0.03
0.04
0.03
0.00
0.05
−6.47
1.61
−0.05
3.87
0.29
0.19
0.00
0.29

SEQID-00247
0.04
0.04
0.04
0.06
0.04
0.02
0.03
0.06
−7.06
1.30
−0.01
6.50
0.26
0.31
0.00
0.26

SEQID-00248
0.07
0.03
0.12
0.03
0.09
0.03
0.00
0.00
−6.58
1.34
0.00
6.49
0.33
0.22
0.00
0.29

SEQID-00249
0.07
0.04
0.09
0.02
0.06
0.02
0.00
0.02
−8.69
1.28
0.02
10.33
0.24
0.29
0.00
0.26

SEQID-00250
0.00
0.00
0.05
0.02
0.09
0.07
0.03
0.04
−9.82
1.03
−0.05
4.57
0.33
0.21
0.00
0.37

SEQID-00251
0.03
0.04
0.03
0.06
0.09
0.02
0.04
0.04
−11.82
1.17
0.05
10.32
0.28
0.23
0.29
0.27

SEQID-00252
0.00
0.00
0.02
0.00
0.07
0.03
0.06
0.05
−14.21
1.08
0.05
10.00
0.31
0.20
0.36
0.30

SEQID-00253
0.01
0.06
0.04
0.03
0.04
0.04
0.06
0.09
−10.95
1.37
0.02
3.24
0.25
0.27
0.27
0.28

SEQID-00254
0.01
0.05
0.04
0.03
0.04
0.02
0.07
0.09
−11.95
1.26
0.02
8.49
0.28
0.29
0.00
0.31

SEQID-00255
0.00
0.08
0.09
0.05
0.04
0.03
0.00
0.05
−7.56
1.49
0.05
10.79
0.36
0.23
0.35
0.31

SEQID-00256
0.02
0.08
0.07
0.03
0.04
0.03
0.00
0.07
−8.27
1.48
0.02
9.54
0.33
0.22
0.36
0.33

SEQID-00257
0.07
0.05
0.06
0.03
0.10
0.06
0.03
0.03
−3.63
1.30
0.02
9.30
0.35
0.24
0.00
0.00

SEQID-00258
0.09
0.02
0.03
0.04
0.03
0.03
0.00
0.03
−17.37
0.94
0.23
13.28
0.30
0.19
0.00
0.27

SEQID-00259
0.00
0.05
0.02
0.05
0.06
0.00
0.00
0.02
−19.14
0.66
0.00
7.36
0.33
0.21
0.00
0.39

SEQID-00260
0.02
0.08
0.04
0.03
0.08
0.00
0.00
0.07
−10.46
1.44
0.00
7.25
0.30
0.19
0.23
0.34

SEQID-00261
0.00
0.10
0.03
0.04
0.07
0.00
0.03
0.03
−11.32
1.17
−0.03
4.54
0.31
0.20
0.00
0.29

SEQID-00262
0.00
0.07
0.02
0.07
0.06
0.00
0.03
0.03
−17.75
0.73
−0.01
6.51
0.31
0.21
0.27
0.22

SEQID-00263
0.04
0.07
0.03
0.04
0.07
0.00
0.14
0.05
−5.22
1.51
0.00
7.24
0.37
0.24
0.00
0.29

SEQID-00264
0.02
0.01
0.00
0.02
0.05
0.00
0.00
0.02
−37.24
0.08
−0.07
4.58
0.29
0.37
0.22
0.00

SEQID-00265
0.01
0.01
0.00
0.04
0.03
0.00
0.01
0.03
−34.97
0.13
−0.06
4.60
0.29
0.40
0.23
0.22

SEQID-00266
0.00
0.00
0.00
0.01
0.05
0.00
0.02
0.03
−37.57
0.13
−0.07
4.55
0.31
0.25
0.32
0.00

SEQID-00267
0.00
0.00
0.00
0.01
0.05
0.00
0.02
0.01
−37.57
0.17
−0.07
4.55
0.33
0.27
0.32
0.00

SEQID-00268
0.00
0.00
0.00
0.01
0.05
0.00
0.02
0.00
−36.50
0.23
−0.09
4.42
0.35
0.28
0.33
0.00

SEQID-00269
0.00
0.00
0.00
0.01
0.04
0.00
0.02
0.00
−36.42
0.23
−0.09
4.42
0.34
0.27
0.00
0.00

SEQID-00270
0.00
0.00
0.00
0.01
0.04
0.00
0.02
0.00
−36.42
0.28
−0.09
4.42
0.38
0.31
0.00
0.26

SEQID-00271
0.00
0.00
0.00
0.01
0.03
0.00
0.02
0.00
−36.19
0.40
−0.09
4.42
0.35
0.29
0.00
0.00

SEQID-00272
0.00
0.00
0.00
0.01
0.05
0.00
0.02
0.00
−37.57
0.19
−0.07
4.55
0.33
0.27
0.33
0.00

SEQID-00273
0.00
0.00
0.00
0.01
0.05
0.00
0.02
0.00
−37.42
0.26
−0.07
4.55
0.35
0.28
0.00
0.00

SEQID-00274
0.00
0.00
0.00
0.01
0.04
0.00
0.02
0.00
−37.34
0.37
−0.07
4.55
0.35
0.28
0.00
0.00

SEQID-00275
0.00
0.00
0.00
0.01
0.03
0.00
0.02
0.00
−37.26
0.37
−0.07
4.55
0.34
0.18
0.36
0.00

SEQID-00276
0.00
0.00
0.00
0.00
0.04
0.00
0.00
0.00
−37.16
0.47
−0.07
4.55
0.35
0.29
0.00
0.00

SEQID-00277
0.03
0.06
0.02
0.06
0.09
0.02
0.05
0.11
−13.06
1.31
0.07
9.64
0.23
0.29
0.22
0.25

SEQID-00278
0.02
0.08
0.06
0.05
0.06
0.05
0.11
0.07
−18.57
0.24
−0.01
5.38
0.25
0.38
0.20
0.21

SEQID-00279
0.00
0.00
0.00
0.01
0.04
0.00
0.02
0.00
−36.27
0.40
−0.09
4.42
0.35
0.29
0.00
0.00

SEQID-00280
0.00
0.00
0.00
0.01
0.03
0.00
0.02
0.00
−37.26
0.37
−0.07
4.55
0.35
0.28
0.00
0.00

SEQID-00281
0.02
0.05
0.03
0.03
0.05
0.05
0.06
0.08
−19.78
0.35
−0.03
5.12
0.21
0.33
0.00
0.20

SEQID-00282
0.04
0.10
0.00
0.03
0.07
0.06
0.00
0.10
−19.86
1.03
0.09
9.58
0.44
0.14
0.42
0.38

SEQID-00283
0.02
0.05
0.03
0.01
0.05
0.03
0.05
0.08
−26.91
0.45
0.12
10.39
0.28
0.18
0.30
0.22

SEQID-00284
0.04
0.04
0.04
0.04
0.05
0.01
0.04
0.08
−25.52
0.46
0.01
7.51
0.23
0.29
0.00
0.25

SEQID-00285
0.04
0.06
0.01
0.01
0.07
0.03
0.02
0.08
−25.31
0.52
0.09
10.56
0.31
0.23
0.00
0.00

SEQID-00286
0.04
0.05
0.00
0.03
0.06
0.03
0.05
0.09
−20.36
0.77
0.06
9.29
0.34
0.23
0.31
0.22

SEQID-00287
0.02
0.05
0.00
0.04
0.06
0.02
0.04
0.08
−23.00
0.80
−0.02
5.64
0.29
0.27
0.00
0.24

SEQID-00288
0.03
0.03
0.03
0.06
0.05
0.04
0.04
0.07
−21.14
0.53
0.01
7.38
0.20
0.33
0.19
0.17

SEQID-00289
0.04
0.07
0.02
0.06
0.06
0.06
0.03
0.08
−20.21
0.69
0.01
7.63
0.23
0.33
0.00
0.21

SEQID-00290
0.04
0.04
0.05
0.05
0.04
0.01
0.04
0.08
−19.04
0.52
0.00
6.72
0.21
0.32
0.00
0.19

SEQID-00291
0.01
0.07
0.02
0.05
0.05
0.04
0.03
0.08
−20.82
0.80
−0.02
5.66
0.23
0.27
0.00
0.25

SEQID-00292
0.02
0.05
0.00
0.04
0.06
0.02
0.04
0.07
−23.98
0.70
−0.02
5.64
0.29
0.25
0.27
0.25

SEQID-00293
0.02
0.05
0.01
0.04
0.07
0.02
0.04
0.08
−22.45
0.79
−0.02
5.64
0.28
0.27
0.27
0.25

SEQID-00294
0.02
0.07
0.01
0.04
0.06
0.02
0.04
0.08
−22.10
0.80
−0.02
5.64
0.28
0.27
0.28
0.24

SEQID-00295
0.02
0.05
0.00
0.04
0.07
0.02
0.04
0.07
−22.75
0.77
−0.02
5.64
0.30
0.28
0.31
0.25

SEQID-00296
0.02
0.05
0.00
0.05
0.07
0.02
0.04
0.07
−23.28
0.71
−0.03
5.00
0.29
0.28
0.28
0.25

SEQID-00297
0.03
0.06
0.02
0.03
0.03
0.02
0.02
0.05
−22.84
0.36
0.01
7.50
0.24
0.30
0.23
0.24

SEQID-00298
0.03
0.06
0.02
0.03
0.03
0.02
0.02
0.05
−22.93
0.57
0.01
7.54
0.29
0.30
0.23
0.22

SEQID-00299
0.03
0.06
0.02
0.04
0.03
0.02
0.02
0.05
−23.45
0.34
0.01
7.38
0.24
0.31
0.21
0.13

SEQID-00300
0.02
0.07
0.04
0.03
0.03
0.02
0.05
0.06
−29.09
0.40
−0.18
3.78
0.22
0.31
0.00
0.23

SEQID-00301
0.03
0.07
0.04
0.03
0.03
0.02
0.05
0.07
−28.15
0.40
−0.17
3.78
0.22
0.31
0.00
0.21

SEQID-00302
0.02
0.05
0.03
0.06
0.05
0.01
0.02
0.08
−19.36
0.48
−0.03
4.71
0.23
0.33
0.21
0.22

SEQID-00303
0.03
0.06
0.04
0.05
0.05
0.02
0.06
0.05
−19.91
0.43
−0.03
5.01
0.20
0.31
0.00
0.23

SEQID-00304
0.03
0.04
0.04
0.03
0.04
0.01
0.08
0.07
−23.25
0.38
−0.03
5.16
0.21
0.32
0.00
0.18

SEQID-00305
0.01
0.03
0.05
0.04
0.05
0.01
0.05
0.05
−18.71
0.40
0.02
8.31
0.20
0.33
0.00
0.21

SEQID-00306
0.04
0.05
0.04
0.05
0.04
0.02
0.02
0.09
−20.25
0.45
0.01
8.46
0.23
0.33
0.21
0.23

SEQID-00307
0.02
0.05
0.03
0.05
0.08
0.02
0.04
0.04
−20.51
0.44
0.02
9.38
0.00
0.31
0.00
0.21

SEQID-00308
0.02
0.04
0.04
0.07
0.06
0.02
0.04
0.05
−20.65
0.37
0.00
7.10
0.22
0.33
0.22
0.22

SEQID-00309
0.02
0.02
0.05
0.06
0.05
0.05
0.07
0.04
−21.70
0.29
−0.04
4.65
0.23
0.33
0.20
0.20

SEQID-00310
0.05
0.09
0.04
0.03
0.04
0.03
0.05
0.06
−20.85
0.36
0.00
7.29
0.23
0.32
0.24
0.25

SEQID-00311
0.03
0.08
0.04
0.03
0.04
0.03
0.07
0.05
−19.63
0.26
0.05
9.70
0.21
0.30
0.25
0.23

SEQID-00312
0.04
0.03
0.03
0.07
0.06
0.01
0.05
0.07
−20.18
0.48
−0.06
4.54
0.00
0.30
0.00
0.00

SEQID-00313
0.03
0.03
0.04
0.08
0.06
0.02
0.04
0.07
−20.16
0.44
−0.02
5.53
0.21
0.34
0.22
0.22

SEQID-00314
0.06
0.05
0.02
0.05
0.07
0.01
0.04
0.04
−23.28
0.41
0.05
10.12
0.21
0.33
0.16
0.19

SEQID-00315
0.03
0.06
0.03
0.04
0.05
0.02
0.06
0.04
−21.95
0.32
−0.04
4.83
0.18
0.31
0.00
0.13

SEQID-00316
0.03
0.07
0.04
0.05
0.06
0.02
0.04
0.03
−20.35
0.36
0.02
8.34
0.21
0.33
0.19
0.20

SEQID-00317
0.03
0.05
0.02
0.08
0.08
0.01
0.04
0.05
−20.14
0.25
−0.02
4.83
0.21
0.34
0.00
0.21

SEQID-00318
0.02
0.06
0.04
0.06
0.05
0.05
0.08
0.04
−17.30
0.36
−0.01
6.18
0.00
0.33
0.00
0.20

SEQID-00319
0.03
0.05
0.03
0.04
0.05
0.04
0.07
0.06
−19.59
0.36
−0.02
6.07
0.20
0.34
0.00
0.20

SEQID-00320
0.03
0.06
0.02
0.03
0.03
0.02
0.07
0.04
−28.07
0.20
−0.01
6.59
0.23
0.34
0.22
0.21

SEQID-00321
0.04
0.04
0.02
0.05
0.03
0.01
0.07
0.06
−22.70
0.40
0.03
9.29
0.23
0.33
0.00
0.00

SEQID-00322
0.03
0.03
0.03
0.05
0.06
0.04
0.07
0.06
−19.27
0.31
−0.01
6.37
0.22
0.34
0.22
0.21

SEQID-00323
0.01
0.06
0.04
0.06
0.04
0.03
0.07
0.04
−21.48
0.31
0.04
9.36
0.00
0.33
0.00
0.00

SEQID-00324
0.03
0.09
0.04
0.06
0.04
0.03
0.09
0.03
−20.93
0.27
−0.01
6.45
0.16
0.33
0.00
0.19

SEQID-00325
0.02
0.03
0.04
0.03
0.05
0.01
0.14
0.05
−22.26
0.22
0.04
9.39
0.23
0.30
0.21
0.00

SEQID-00326
0.03
0.07
0.05
0.05
0.05
0.03
0.07
0.05
−19.44
0.37
−0.01
6.51
0.26
0.30
0.24
0.23

SEQID-00327
0.03
0.06
0.02
0.08
0.03
0.01
0.04
0.06
−22.60
0.39
0.00
6.53
0.26
0.29
0.30
0.00

SEQID-00328
0.05
0.04
0.01
0.03
0.02
0.01
0.02
0.05
−26.69
0.22
0.21
12.35
0.25
0.29
0.24
0.23

SEQID-00329
0.02
0.01
0.03
0.06
0.05
0.01
0.03
0.12
−26.66
0.27
0.18
11.94
0.24
0.23
0.20
0.25

SEQID-00330
0.02
0.03
0.01
0.02
0.06
0.02
0.04
0.06
−24.07
0.28
0.09
10.90
0.23
0.29
0.00
0.21

SEQID-00331
0.03
0.04
0.02
0.07
0.03
0.04
0.07
0.04
−19.13
0.41
0.04
9.73
0.23
0.30
0.24
0.27

SEQID-00332
0.03
0.03
0.02
0.05
0.03
0.02
0.06
0.04
−21.07
0.23
−0.04
4.72
0.22
0.34
0.00
0.20

SEQID-00333
0.02
0.07
0.01
0.03
0.03
0.04
0.08
0.05
−19.36
0.44
0.05
9.83
0.18
0.31
0.28
0.22

SEQID-00334
0.02
0.05
0.03
0.03
0.03
0.01
0.05
0.06
−26.57
0.23
0.10
10.93
0.00
0.33
0.00
0.20

SEQID-00335
0.03
0.01
0.04
0.04
0.03
0.01
0.07
0.07
−21.68
0.28
0.10
11.31
0.22
0.30
0.00
0.26

SEQID-00336
0.05
0.02
0.04
0.05
0.02
0.02
0.03
0.05
−29.65
0.18
0.22
12.00
0.24
0.32
0.18
0.23

SEQID-00337
0.01
0.08
0.05
0.02
0.05
0.01
0.06
0.06
−20.90
0.36
0.00
6.86
0.19
0.34
0.00
0.00

SEQID-00338
0.04
0.03
0.05
0.04
0.05
0.02
0.02
0.04
−21.97
0.28
−0.01
6.37
0.00
0.35
0.25
0.00

SEQID-00339
0.02
0.02
0.03
0.03
0.04
0.04
0.06
0.05
−25.07
0.25
−0.03
5.57
0.19
0.30
0.21
0.00

SEQID-00340
0.00
0.02
0.03
0.04
0.05
0.02
0.04
0.07
−22.52
0.30
0.05
10.51
0.21
0.31
0.00
0.00

SEQID-00341
0.03
0.02
0.03
0.09
0.05
0.01
0.07
0.04
−23.40
0.23
−0.06
4.54
0.21
0.33
0.00
0.20

SEQID-00342
0.04
0.07
0.03
0.05
0.06
0.03
0.04
0.03
−20.62
0.33
0.02
9.39
0.21
0.32
0.00
0.21

SEQID-00343
0.01
0.03
0.01
0.04
0.04
0.01
0.06
0.06
−26.83
0.33
0.02
8.41
0.24
0.31
0.00
0.00

SEQID-00344
0.01
0.02
0.06
0.07
0.05
0.02
0.04
0.07
−16.90
0.50
0.03
0.12
0.22
0.31
0.00
0.00

SEQID-00345
0.02
0.05
0.05
0.02
0.04
0.02
0.06
0.06
−18.75
0.39
−0.02
5.68
0.20
0.34
0.19
0.00

SEQID-00346
0.03
0.05
0.03
0.03
0.05
0.01
0.06
0.07
−19.87
0.46
−0.02
5.27
0.21
0.31
0.00
0.00

SEQID-00347
0.03
0.04
0.03
0.08
0.05
0.01
0.05
0.05
−21.72
0.35
−0.01
6.27
0.23
0.33
0.00
0.23

SEQID-00348
0.04
0.02
0.03
0.06
0.05
0.03
0.02
0.12
−18.43
0.59
0.01
7.75
0.24
0.33
0.21
0.22

SEQID-00349
0.02
0.05
0.03
0.04
0.05
0.02
0.08
0.06
−21.95
0.32
−0.02
6.35
0.20
0.31
0.00
0.21

SEQID-00350
0.02
0.05
0.05
0.06
0.03
0.00
0.03
0.05
−18.20
0.43
0.02
8.65
0.00
0.32
0.00
0.23

SEQID-00351
0.02
0.05
0.04
0.06
0.06
0.01
0.03
0.09
−19.26
0.50
−0.01
6.19
0.23
0.34
0.00
0.22

SEQID-00352
0.02
0.05
0.04
0.04
0.06
0.01
0.03
0.09
−30.47
0.53
−0.01
5.58
0.23
0.33
0.00
0.21

SEQID-00353
0.03
0.05
0.06
0.06
0.03
0.02
0.08
0.07
−17.60
0.45
−0.03
4.69
0.21
0.32
0.00
0.20

SEQID-00354
0.04
0.05
0.04
0.05
0.04
0.02
0.02
0.09
−20.25
0.45
0.01
8.46
0.23
0.33
0.21
0.23

SEQID-00355
0.02
0.07
0.05
0.08
0.07
0.01
0.02
0.06
−17.37
0.50
0.00
6.65
0.21
0.35
0.00
1.00

SEQID-00356
0.01
0.05
0.05
0.05
0.04
0.01
0.03
0.09
−19.88
0.46
−0.02
4.98
0.21
0.33
0.00
0.22

SEQID-00357
0.03
0.02
0.05
0.05
0.04
0.01
0.03
0.06
−18.65
0.48
−0.02
5.37
0.21
0.34
0.21
0.21

SEQID-00358
0.04
0.07
0.04
0.03
0.06
0.03
0.04
0.05
−20.25
0.37
−0.01
6.46
0.20
0.35
0.20
0.21

SEQID-00359
0.03
0.02
0.04
0.05
0.04
0.01
0.03
0.06
−22.70
0.38
0.01
9.34
0.21
0.34
0.21
0.21

SEQID-00360
0.03
0.06
0.05
0.04
0.03
0.04
0.07
0.06
−19.19
0.37
−0.02
5.22
0.21
0.33
0.21
0.22

SEQID-00361
0.03
0.06
0.04
0.04
0.04
0.00
0.04
0.07
−22.15
0.34
0.00
6.94
0.21
0.31
0.00
0.21

SEQID-00362
0.03
0.07
0.05
0.05
0.04
0.02
0.06
0.06
−23.27
0.34
−0.01
6.22
0.21
0.33
0.19
0.22

SEQID-00363
0.00
0.05
0.03
0.11
0.11
0.05
0.07
0.06
−15.13
0.40
−0.06
3.96
0.21
0.33
0.00
0.21

SEQID-00364
0.03
0.02
0.07
0.01
0.02
0.04
0.14
0.03
−45.75
0.03
−0.24
4.02
0.30
0.23
0.28
0.29

SEQID-00365
0.01
0.03
0.04
0.03
0.03
0.15
0.05
0.03
−24.44
0.13
0.04
8.21
0.26
0.27
0.28
0.27

SEQID-00366
0.00
0.14
0.07
0.06
0.05
0.13
0.04
0.01
−22.70
0.11
0.04
10.10
0.27
0.24
0.00
0.27

SEQID-00367
0.02
0.02
0.04
0.05
0.05
0.00
0.22
0.01
−27.90
0.00
−0.17
3.77
0.30
0.27
0.28
0.26

SEQID-00368
0.03
0.05
0.01
0.04
0.04
0.02
0.02
0.02
−26.53
0.31
−0.04
4.88
0.23
0.26
0.00
0.21

SEQID-00369
0.02
0.00
0.00
0.03
0.06
0.00
0.00
0.03
−22.97
0.22
0.01
7.80
0.35
0.30
0.00
0.00

SEQID-00370
0.02
0.02
0.00
0.01
0.04
0.00
0.00
0.02
−25.72
0.17
−0.03
4.31
0.34
0.31
0.00
0.32

SEQID-00371
0.01
0.01
0.00
0.02
0.03
0.02
0.03
0.03
−32.01
0.12
−0.15
4.19
0.34
0.34
0.00
0.25

SEQID-00372
0.03
0.05
0.01
0.02
0.02
0.02
0.06
0.04
−24.83
0.16
−0.01
5.63
0.27
0.23
0.00
0.00

SEQID-00373
0.01
0.05
0.04
0.09
0.02
0.02
0.04
0.03
−23.94
0.21
−0.02
5.07
0.27
0.26
0.00
0.29

SEQID-00374
0.03
0.06
0.01
0.03
0.03
0.04
0.03
0.08
−25.39
0.30
0.05
10.23
0.25
0.27
0.00
0.24

SEQID-00375
0.03
0.04
0.04
0.03
0.02
0.02
0.06
0.07
−28.50
0.25
0.14
11.20
0.31
0.26
0.00
0.21

SEQID-00376
0.01
0.02
0.04
0.02
0.05
0.01
0.01
0.09
−24.79
0.46
0.11
11.40
0.26
0.31
0.27
0.23

SEQID-00377
0.00
0.02
0.00
0.05
0.09
0.01
0.00
0.04
−24.99
0.04
−0.13
3.98
0.27
0.35
0.22
0.00

SEQID-00378
0.02
0.01
0.02
0.06
0.05
0.01
0.02
0.03
−25.00
0.15
−0.07
4.35
0.24
0.33
0.00
0.25

SEQID-00379
0.01
0.01
0.00
0.02
0.03
0.02
0.00
0.05
−25.41
0.18
−0.02
6.12
0.29
0.35
0.24
0.27

SEQID-00380
0.02
0.02
0.00
0.06
0.04
0.02
0.00
0.02
−28.46
0.17
−0.05
4.69
0.35
0.33
0.00
0.23

SEQID-00381
0.02
0.01
0.02
0.03
0.02
0.01
0.02
0.04
−30.97
0.39
0.05
9.63
0.29
0.34
0.24
0.25

SEQID-00382
0.03
0.02
0.04
0.04
0.01
0.02
0.00
0.08
−33.88
0.23
0.14
11.31
0.33
0.29
0.30
0.21

SEQID-00383
0.02
0.03
0.02
0.01
0.01
0.02
0.08
0.02
−29.58
0.21
0.10
10.66
0.25
0.22
0.24
0.00

SEQID-00384
0.02
0.05
0.01
0.02
0.03
0.02
0.04
0.05
−25.11
0.31
0.12
11.78
0.23
0.30
0.00
0.00

SEQID-00385
0.03
0.02
0.03
0.05
0.08
0.00
0.00
0.13
−26.46
0.42
0.07
11.42
0.29
0.24
0.00
0.00

SEQID-00386
0.02
0.00
0.04
0.14
0.04
0.03
0.01
0.06
−19.07
0.39
−0.03
4.51
0.24
0.30
0.00
0.24

SEQID-00387
0.03
0.01
0.05
0.06
0.04
0.02
0.01
0.11
−23.24
0.49
0.02
9.25
0.00
0.30
0.00
0.23

SEQID-00388
0.03
0.01
0.05
0.06
0.04
0.02
0.00
0.11
−23.34
0.50
0.0;
9.30
0.25
0.30
0.00
0.24

SEQID-00389
0.03
0.01
0.05
0.04
0.03
0.00
0.03
0.11
−21.13
0.37
0.09
10.92
0.21
0.33
0.00
0.25

SEQID-00390
0.02
0.03
0.03
0.05
0.07
0.02
0.05
0.04
−21.63
0.38
0.01
9.14
0.00
0.30
0.00
0.00

SEQID-00391
0.03
0.02
0.04
0.08
0.06
0.02
0.04
0.06
−20.87
0.38
−0.02
5.05
0.22
0.34
0.22
0.22

SEQID-00392
0.02
0.06
0.03
0.04
0.05
0.02
0.06
0.04
−22.88
0.23
−0.04
4.76
0.18
0.31
0.00
0.00

SEQID-00393
0.03
0.07
0.04
0.06
0.06
0.02
0.04
0.03
−19.96
0.35
0.01
8.65
0.21
0.33
0.00
0.21

SEQID-00394
0.02
0.05
0.04
0.06
0.06
0.05
0.09
0.04
−17.65
0.27
−0.02
5.57
0.19
0.33
0.00
0.00

SEQID-00395
0.02
0.05
0.06
0.06
0.03
0.02
0.08
0.06
−18.60
0.38
−0.04
4.52
0.21
0.32
0.00
0.21

SEQID-00396
0.01
0.04
0.00
0.05
0.06
0.02
0.07
0.04
−25.26
0.21
0.01
8.44
0.17
0.30
0.00
0.00

SEQID-00397
0.01
0.04
0.06
0.06
0.05
0.04
0.04
0.04
−20.27
0.20
0.06
10.19
0.21
0.31
0.00
0.21

SEQID-00398
0.04
0.03
0.04
0.04
0.05
0.02
0.07
0.06
−21.47
0.27
0.01
3.63
0.22
0.32
0.00
0.00

SEQID-00399
0.02
0.03
0.04
0.05
0.04
0.02
0.07
0.06
−25.17
0.29
−0.05
4.89
0.20
0.34
0.00
0.20

SEQID-00400
0.03
0.06
0.01
0.05
0.07
0.04
0.05
0.06
−23.79
0.29
−0.01
6.64
0.23
0.30
0.00
0.00

SEQID-00401
0.01
0.05
0.04
0.05
0.10
0.01
0.04
0.08
−18.97
0.39
−0.01
5.14
0.27
0.31
0.00
0.28

SEQID-00402
0.01
0.03
0.02
0.07
0.06
0.02
0.04
0.06
−25.96
0.30
0.00
7.19
0.21
0.32
0.00
0.00

SEQID-00403
0.02
0.04
0.04
0.07
0.05
0.02
0.05
0.05
−21.38
0.33
0.00
6.70
0.22
0.33
0.00
0.22

SEQID-00404
0.02
0.06
0.04
0.07
0.14
0.01
0.03
0.02
−16.05
0.35
0.03
9.57
0.21
0.30
0.18
0.25

SEQID-00405
0.02
0.03
0.04
0.10
0.06
0.03
0.10
0.03
−15.43
0.25
0.00
6.53
0.19
0.33
0.00
0.21

SEQID-00406
0.02
0.07
0.03
0.05
0.06
0.01
0.04
0.04
−24.16
0.24
−0.02
4.90
0.20
0.31
0.00
0.00

SEQID-00407
0.02
0.05
0.03
0.07
0.07
0.04
0.07
0.05
−17.75
0.22
−0.02
5.71
0.21
0.33
0.00
0.21

SEQID-00408
0.02
0.05
0.06
0.05
0.07
0.02
0.07
0.03
−18.90
0.25
−0.05
4.66
0.22
0.31
0.00
0.00

SEQID-00409
0.02
0.03
0.05
0.05
0.07
0.06
0.07
0.06
−18.43
0.31
−0.03
4.61
0.22
0.33
0.21
0.21

SEQID-00410
0.02
0.05
0.04
0.06
0.10
0.02
0.06
0.05
−15.30
0.48
−0.04
4.32
0.00
0.31
0.23
0.00

SEQID-00411
0.03
0.04
0.04
0.06
0.06
0.03
0.06
0.08
−20.87
0.35
−0.02
5.28
0.19
0.33
0.00
0.22

SEQID-00412
0.02
0.06
0.06
0.06
0.06
0.03
0.09
0.06
−18.00
0.33
−0.03
4.78
0.20
0.33
0.18
0.20

SEQID-00413
0.01
0.05
0.04
0.10
0.10
0.04
0.06
0.06
−15.67
0.31
−0.04
4.36
0.21
0.34
0.00
0.22

SEQID-00414
0.01
0.05
0.05
0.07
0.07
0.03
0.09
0.06
−16.00
0.35
−0.03
4.79
0.19
0.34
0.20
0.21

SEQID-00415
0.02
0.05
0.05
0.07
0.06
0.05
0.08
0.06
−16.54
0.34
−0.03
4.83
0.19
0.33
0.00
0.21

SEQID-00416
0.01
0.04
0.05
0.04
0.09
0.03
0.07
0.07
−16.52
0.36
−0.05
4.28
0.21
0.34
0.00
0.20

SEQID-00417
0.02
0.04
0.04
0.07
0.06
0.04
0.06
0.06
−17.25
0.33
−0.01
6.40
0.21
0.33
0.22
0.00

SEQID-00418
0.03
0.04
0.04
0.06
0.07
0.06
0.06
0.06
−16.75
0.27
−0.04
4.69
0.23
0.33
0.00
0.20

SEQID-00419
0.02
0.04
0.05
0.06
0.06
0.04
0.08
0.06
−16.77
0.32
−0.04
4.34
0.26
0.36
0.00
0.21

SEQID-00420
0.00
0.04
0.02
0.09
0.11
0.03
0.04
0.06
−17.45
0.28
0.00
6.65
0.27
0.41
0.23
0.21

SEQID-00421
0.01
0.06
0.05
0.07
0.06
0.05
0.08
0.06
−15.20
0.37
−0.03
4.87
0.20
0.37
0.20
0.20

SEQID-00422
0.02
0.06
0.04
0.10
0.06
0.01
0.09
0.06
−18.05
0.33
−0.03
4.46
0.23
0.39
0.23
0.21

SEQID-00423
0.01
0.05
0.03
0.05
0.05
0.06
0.09
0.05
−21.13
0.21
−0.03
5.23
0.23
0.36
0.00
0.21

SEQID-00424
0.02
0.04
0.04
0.06
0.08
0.04
0.11
0.05
−16.16
0.36
−0.05
4.29
1.00
1.00
0.19
0.21

SEQID-00425
0.01
0.07
0.04
0.05
0.04
0.03
0.07
0.06
−22.68
0.27
−0.03
5.42
0.19
0.32
0.20
0.20

SEQID-00426
0.00
0.08
0.04
0.05
0.07
0.03
0.06
0.06
−17.18
0.33
−0.03
4.81
0.00
0.31
0.00
0.24

SEQID-00427
0.01
0.07
0.07
0.06
0.07
0.02
0.06
0.06
−13.64
0.49
−0.01
5.68
0.22
0.34
0.21
0.23

SEQID-00428
0.34
0.00
0.00
0.01
0.04
0.00
0.02
0.00
−36.89
0.05
−0.09
4.42
0.22
0.22
0.00
0.18

SEQID-00429
0.00
0.00
0.00
0.01
0.04
0.00
0.02
0.00
−43.92
0.00
−0.01
6.93
0.23
0.23
0.25
0.34

SEQID-00430
0.34
0.00
0.00
0.01
0.04
0.00
0.02
0.00
−36.89
0.05
−0.09
4.42
0.27
0.22
0.00
0.18

SEQID-00431
0.00
0.00
0.00
0.01
0.04
0.00
0.02
0.00
−43.92
0.00
−0.01
6.93
0.28
0.23
0.25
0.54

SEQID-00432
0.00
0.00
0.00
0.01
0.04
0.00
0.02
0.00
−58.85
0.00
0.23
10.67
0.31
0.25
0.29
0.29

SEQID-00433
0.00
0.00
0.00
0.01
0.04
0.00
0.02
0.00
−58.85
0.00
0.23
11.81
0.36
0.30
0.23
0.31

SEQID-00434
0.00
0.00
0.00
0.01
0.04
0.00
0.02
0.00
−39.46
0.00
−0.09
4.42
0.35
0.29
0.22
0.26

SEQID-00435
0.00
0.00
0.00
0.01
0.02
0.00
0.02
0.00
−40.87
0.16
0.02
9.33
0.38
0.31
0.29
0.00

SEQID-00436
0.03
0.07
0.00
0.00
0.08
0.05
0.00
0.05
−38.16
0.28
−0.06
5.16
0.28
0.22
0.00
0.00

SEQID-00437
0.03
0.07
0.00
0.00
0.11
0.05
0.00
0.05
−26.97
0.35
0.36
12.12
0.28
0.23
0.00
0.00

SEQID-00438
0.00
0.00
0.00
0.01
0.04
0.00
0.02
0.00
−36.42
0.27
−0.09
4.42
0.32
0.26
0.27
0.00

SEQID-00439
0.00
0.00
0.00
0.01
0.04
0.00
0.02
0.10
−36.42
0.25
−0.09
4.42
0.33
0.27
0.00
0.00

SEQID-00440
0.00
0.15
0.00
0.01
0.04
0.00
0.02
0.00
−36.51
0.19
−0.09
4.42
0.33
0.27
0.00
0.29

SEQID-00441
0.00
0.00
0.00
0.01
0.04
0.18
0.02
0.00
−37.14
0.07
−0.09
4.42
0.30
0.25
0.30
0.00

SEQID-00442
0.00
0.00
0.00
0.01
0.15
0.00
0.02
0.00
−37.04
0.07
−0.09
4.42
0.35
0.23
0.00
0.25

SEQID-00443
0.13
0.00
0.00
0.01
0.04
0.00
0.02
0.00
−36.60
0.15
−0.09
4.42
0.30
0.25
0.00
0.00

SEQID-00444
0.00
0.00
0.00
0.01
0.04
0.00
0.02
0.01
−33.92
0.05
−0.06
6.07
0.33
0.27
0.00
0.32

SEQID-00445
0.00
0.00
0.00
0.01
0.04
0.00
0.02
0.00
−37.58
0.04
−0.09
4.42
0.33
0.27
0.00
0.00

SEQID-00446
0.00
0.00
0.00
0.01
0.04
0.00
0.02
0.00
−38.20
0.17
−0.06
4.55
0.37
0.30
0.00
0.00

SEQID-00447
0.00
0.00
0.00
0.01
0.04
0.00
0.02
0.00
−45.68
0.04
0.05
9.76
0.35
0.28
0.26
0.31

SEQID-00448
0.00
0.00
0.00
0.01
0.04
0.00
0.02
0.00
−45.68
0.04
0.05
11.23
0.38
0.31
0.00
0.00

SEQID-00449
0.00
0.00
0.00
0.01
0.04
0.00
0.02
0.00
−36.42
0.32
−0.09
4.42
0.27
0.22
0.00
0.00

SEQID-00450
0.00
0.00
0.00
0.01
0.04
0.00
0.02
0.28
−36.42
0.28
−0.09
4.42
0.29
0.23
0.00
0.00

SEQID-00451
0.00
0.37
0.00
0.01
0.04
0.00
0.02
0.00
−36.67
0.12
−0.09
4.42
0.24
0.20
0.23
0.29

SEQID-00452
0.00
0.00
0.00
0.01
0.03
0.42
0.02
0.00
−38.31
0.00
−0.09
4.42
0.74
0.20
0.26
0.22

SEQID-00453
0.00
0.00
0.00
0.01
0.33
0.00
0.02
0.00
−38.04
0.00
−0.09
4.42
0.30
0.24
0.20
0.31

SEQID-00454
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
−46.29
0.00
0.67
13.81
0.37
0.28
0.00
0.27

SEQID-00455
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
−38.19
0.38
0.55
13.66
0.32
0.24
0.30
0.00

SEQID-00456
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
−30.09
0.62
0.43
13.62
0.33
0.25
0.00
0.00

SEQID-00457
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
−53.15
0.00
−0.67
2.38
0.36
0.27
0.31
0.39

SEQID-00458
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
−43.89
0.46
−0.55
2.44
0.32
0.24
0.37
0.34

SEQID-00459
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
−34.54
0.80
−0.43
2.56
0.37
0.27
0.00
0.39

SEQID-00460
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
−49.89
0.00
−0.03
5.00
0.39
0.29
0.00
0.33

SEQID-00461
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
−40.78
0.40
0.05
10.57
0.36
0.27
0.00
0.00

SEQID-00462
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
−32.52
0.72
−0.03
4.79
0.34
0.26
0.00
0.00

SEQID-00463
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
−46.29
0.10
0.67
13.81
0.33
0.25
0.30
0.00

SEQID-00464
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
−40.50
0.37
0.58
13.76
0.28
0.21
0.00
0.00

SEQID-00465
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
−33.56
0.58
0.48
13.62
0.33
0.25
0.00
0.30

SEQID-00466
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
−53.15
0.15
−0.67
2.38
0.35
0.27
0.34
0.43

SEQID-00467
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
−46.49
0.45
−0.58
2.44
0.34
0.25
0.38
0.34

SEQID-00468
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
−38.56
0.69
−0.48
2.50
0.32
0.24
0.00
0.35

SEQID-00469
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
−49.95
0.13
−0.03
4.97
0.33
0.25
0.00
0.33

SEQID-00470
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
−43.82
0.43
−0.05
4.72
0.31
0.23
0.00
0.00

SEQID-00471
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
−36.05
0.60
0.02
9.27
0.33
0.25
0.00
0.30

SEQID-00472
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
−48.60
0.78
0.70
13.83
0.29
0.22
0.00
0.31

SEQID-00473
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
−40.50
0.43
0.58
13.56
0.32
0.24
0.00
0.00

SEQID-00474
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
−33.56
0.90
0.48
13.68
0.31
0.23
0.00
0.00

SEQID-00475
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
−55.80
0.32
−0.70
2.36
0.32
0.24
0.37
0.39

SEQID-00476
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
−46.64
0.53
−0.58
2.40
0.28
0.21
0.30
0.32

SEQID-00477
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
−38.51
1.01
−0.48
2.52
0.35
0.26
0.29
0.00

SEQID-00478
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
−52.37
0.31
−0.03
5.03
0.32
0.24
0.00
0.30

SEQID-00479
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
−42.55
0.44
0.18
11.72
0.35
0.26
0.00
0.30

SEQID-00480
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
−36.35
0.97
−0.05
4.63
0.32
0.24
0.00
0.00

SEQID-00481
0.02
0.10
0.06
0.04
0.08
0.05
0.09
0.05
−11.08
0.66
0.07
10.46
0.22
0.30
0.00
0.00

SEQID-00482
0.05
0.02
0.02
0.07
0.04
0.01
0.00
0.04
−27.29
0.18
−0.03
4.37
0.24
0.35
0.00
0.00

SEQID-00483
0.01
0.03
0.05
0.16
0.10
0.04
0.06
0.07
−12.63
0.44
0.00
7.74
0.18
0.31
0.22
0.23

SEQID-00484
0.00
0.07
0.02
0.05
0.03
0.01
0.01
0.02
−33.66
0.11
−0.13
4.08
0.23
0.32
0.00
0.21

SEQID-00485
0.02
0.11
0.03
0.05
0.05
0.01
0.11
0.03
−20.39
0.29
0.01
8.37
0.21
0.30
0.00
0.00

SEQID-00486
0.09
0.04
0.05
0.07
0.07
0.04
0.06
0.05
−14.98
0.69
−0.05
4.44
0.21
0.31
0.00
0.19

SEQID-00487
0.06
0.09
0.04
0.06
0.07
0.05
0.06
0.09
−12.20
0.88
0.02
9.25
0.21
0.29
0.00
0.19

SEQID-00488
0.02
0.08
0.04
0.01
0.06
0.02
0.05
0.07
−20.86
0.42
0.00
7.03
0.22
0.31
0.19
0.00

SEQID-00489
0.01
0.06
0.05
0.06
0.06
0.06
0.01
0.06
−24.06
0.27
−0.03
5.17
0.24
0.31
0.00
0.22

SEQID-00490
0.06
0.09
0.03
0.07
0.06
0.01
0.02
0.12
−9.86
1.25
−0.03
4.30
0.20
0.31
0.00
0.22

SEQID-00491
0.05
0.02
0.03
0.05
0.02
0.02
0.03
0.05
−30.76
0.15
0.22
11.99
0.21
0.31
0.21
0.23

SEQID-00492
0.02
0.02
0.04
0.04
0.03
0.05
0.09
0.06
−25.46
0.19
0.21
11.95
0.21
0.31
0.00
0.20

SEQID-00493
0.06
0.02
0.03
0.04
0.03
0.01
0.01
0.03
−32.41
0.15
0.04
9.50
0.25
0.34
0.23
0.21

SEQID-00494
0.01
0.07
0.01
0.05
0.03
0.02
0.06
0.09
−17.65
0.90
0.03
9.78
0.18
0.31
0.19
0.22

SEQID-00495
0.02
0.04
0.05
0.05
0.03
0.02
0.01
0.06
−29.07
0.23
0.01
8.19
0.24
0.35
0.00
0.24

SEQID-00496
0.03
0.03
0.03
0.07
0.02
0.03
0.02
0.07
−30.33
0.30
−0.12
4.11
0.00
0.31
0.00
0.22

SEQID-00497
0.01
0.11
0.05
0.03
0.02
0.00
0.05
0.05
−18.49
0.58
−0.03
4.75
0.00
0.31
0.00
0.26

SEQID-00498
0.05
0.04
0.02
0.05
0.04
0.00
0.02
0.08
−19.54
0.57
0.00
6.55
0.23
0.52
0.00
0.24

SEQID-00499
0.01
0.02
0.05
0.03
0.05
0.02
0.04
0.06
−19.08
0.62
−0.01
6.25
0.27
0.32
0.26
0.25

SEQID-00500
0.02
0.06
0.04
0.02
0.06
0.05
0.06
0.07
−15.40
0.43
−0.01
6.65
0.26
0.30
0.26
0.26

SEQID-00501
0.04
0.12
0.05
0.06
0.05
0.06
0.07
0.05
−16.94
0.34
−0.03
4.74
0.21
0.29
0.22
0.24

SEQID-00502
0.01
0.09
0.03
0.05
0.04
0.01
0.05
0.06
−20.99
0.33
0.00
7.18
0.23
0.32
0.25
0.25

SEQID-00503
0.01
0.04
0.03
0.04
0.04
0.01
0.04
0.04
−29.34
0.19
0.72
11.43
0.23
0.31
0.23
0.24

SEQID-00504
0.03
0.03
0.03
0.06
0.11
0.04
0.02
0.09
−11.10
0.46
0.02
9.37
0.22
0.30
0.28
0.24

SEQID-00505
0.03
0.02
0.04
0.06
0.07
0.01
0.05
0.08
−22.47
0.46
−0.03
4.82
0.22
0.29
0.00
0.26

SEQID-00506
0.03
0.11
0.03
0.04
0.04
0.07
0.08
0.07
−11.44
1.03
0.02
9.04
0.20
0.30
0.00
0.22

SEQID-00507
0.05
0.12
0.06
0.07
0.05
0.04
0.06
0.05
−19.34
0.32
−0.01
5.15
0.25
0.33
0.00
0.24

SEQID-00508
0.03
0.06
0.03
0.05
0.06
0.03
0.03
0.13
−17.01
0.60
−0.01
6.50
0.27
0.32
0.22
0.00

SEQID-00509
0.02
0.03
0.01
0.04
0.02
0.01
0.01
0.02
−39.60
0.07
0.05
10.23
0.25
0.35
0.22
0.00

SEQID-00510
0.03
0.07
0.04
0.04
0.04
0.03
0.05
0.04
−25.37
0.32
−0.03
4.91
0.21
0.32
0.24
0.23

SEQID-00511
0.03
0.06
0.06
0.04
0.06
0.02
0.10
0.06
−16.64
0.38
−0.01
6.12
0.22
0.30
0.22
0.00

SEQID-00512
0.02
0.05
0.02
0.05
0.03
0.07
0.04
0.05
−10.38
0.87
0.03
9.59
0.24
0.35
0.28
0.24

SEQID-00513
0.13
0.00
0.07
0.05
0.03
0.01
0.12
0.04
−6.89
0.52
0.01
8.00
0.26
0.34
0.00
0.23

SEQID-00514
0.01
0.01
0.04
0.04
0.04
0.01
0.01
0.13
−19.37
0.48
0.10
11.46
0.00
0.34
0.00
0.23

SEQID-00515
0.01
0.05
0.02
0.05
0.07
0.01
0.06
0.01
−25.21
0.03
−0.07
4.34
0.27
0.33
0.23
0.22

SEQID-00516
0.02
0.03
0.06
0.05
0.07
0.02
0.05
0.06
−20.21
0.76
0.00
6.92
0.22
0.32
0.00
0.00

SEQID-00517
0.01
0.07
0.02
0.07
0.04
0.01
0.01
0.04
−29.09
0.17
0.22
11.90
0.17
0.33
0.21
0.26

SEQID-00518
0.03
0.02
0.04
0.04
0.06
0.01
0.04
0.13
−22.45
0.33
0.08
10.62
0.24
0.33
0.00
0.25

SEQID-00519
0.05
0.03
0.04
0.02
0.04
0.03
0.04
0.05
−18.59
0.62
−0.04
4.41
0.27
0.35
0.21
0.25

SEQID-00520
0.05
0.02
0.02
0.04
0.02
0.01
0.02
0.04
−32.61
0.15
0.04
9.81
0.25
0.33
0.26
0.24

SEQID-00521
0.04
0.02
0.02
0.06
0.06
0.00
0.11
0.06
−16.77
0.44
0.00
6.60
0.23
0.30
0.21
0.25

SEQID-00522
0.04
0.03
0.01
0.04
0.13
0.00
0.01
0.01
−25.65
0.04
0.02
9.76
0.23
0.32
0.22
0.25

SEQID-00523
0.04
0.09
0.06
0.04
0.11
0.03
0.05
0.02
−12.76
0.65
0.00
6.65
0.27
0.19
0.32
0.26

SEQID-00524
0.03
0.06
0.06
0.11
0.04
0.02
0.04
0.09
−18.82
0.26
0.05
10.11
0.27
0.23
0.25
0.23

SEQID-00525
0.02
0.05
0.02
0.02
0.06
0.00
0.02
0.11
−27.49
0.79
−0.01
6.80
0.32
0.30
0.00
1.00

SEQID-00526
0.09
0.09
0.03
0.06
0.06
0.00
0.00
0.05
−18.31
0.55
0.07
8.61
0.31
0.29
0.34
0.30

SEQID-00527
0.04
0.02
0.04
0.06
0.08
0.02
0.06
0.07
−17.85
0.43
−0.01
5.74
0.29
0.29
0.27
0.28

SEQID-00528
0.01
0.05
0.04
0.07
0.11
0.00
0.02
0.08
−16.90
0.49
0.03
9.51
0.29
0.29
0.23
0.29

SEQID-00529
0.09
0.05
0.03
0.08
0.05
0.00
0.07
0.06
−21.10
0.31
0.00
6.83
0.00
0.28
0.00
0.00

SEQID-00530
0.04
0.03
0.04
0.05
0.04
0.00
0.03
0.10
−9.31
0.92
0.08
9.06
0.32
0.32
0.29
0.30

SEQID-00531
0.07
0.06
0.05
0.05
0.09
0.00
0.03
0.04
−15.35
0.71
0.01
7.73
0.26
0.28
0.25
0.26

SEQID-00532
0.04
0.03
0.03
0.08
0.05
0.00
0.06
0.15
−17.89
0.60
−0.01
5.70
0.21
0.30
0.00
0.00

SEQID-00533
0.02
0.07
0.07
0.01
0.07
0.00
0.03
0.11
−24.25
0.43
0.06
10.72
0.29
0.32
0.00
0.25

SEQID-00534
0.04
0.05
0.02
0.06
0.05
0.02
0.06
0.06
−24.70
0.24
−0.02
4.91
0.26
0.30
0.29
0.27

SEQID-00535
0.01
0.04
0.03
0.16
0.07
0.02
0.06
0.06
−11.86
0.30
0.01
8.20
0.22
0.28
0.27
0.28

SEQID-00536
0.01
0.05
0.02
0.00
0.01
0.00
0.03
0.02
−32.67
0.27
0.00
7.00
0.21
0.31
0.24
0.27

SEQID-00537
0.01
0.02
0.01
0.04
0.05
0.00
0.00
0.05
−31.23
0.13
−0.02
5.11
0.29
0.33
0.27
0.22

SEQID-00538
0.02
0.07
0.02
0.06
0.06
0.00
0.00
0.05
−22.79
0.30
−0.06
5.19
0.27
0.30
0.00
0.24

SEQID-00539
0.06
0.03
0.02
0.03
0.04
0.00
0.01
0.09
−19.20
0.71
0.00
7.52
0.27
0.32
0.00
0.23

SEQID-00540
0.04
0.00
0.02
0.03
0.07
0.00
0.05
0.07
−26.07
0.29
0.14
11.85
0.22
0.29
0.28
0.00

SEQID-00541
0.02
0.03
0.02
0.06
0.02
0.01
0.04
0.09
−19.28
0.56
0.10
11.02
0.23
0.30
0.24
0.22

SEQID-00542
0.01
0.01
0.03
0.07
0.00
0.00
0.03
0.07
−20.95
0.42
0.08
10.68
0.25
0.31
0.26
0.00

SEQID-00543
0.02
0.05
0.01
0.04
0.10
0.05
0.10
0.07
−19.52
0.31
0.00
7.18
0.00
0.30
0.24
0.25

SEQID-00544
0.05
0.01
0.03
0.06
0.07
0.00
0.04
0.05
−17.82
0.44
−0.01
6.35
0.25
0.33
0.29
0.25

SEQID-00545
0.01
0.08
0.04
0.04
0.04
0.00
0.08
0.06
−26.17
0.22
−0.01
5.86
0.25
0.31
0.19
0.25

SEQID-00546
0.03
0.02
0.02
0.06
0.04
0.00
0.04
0.05
−27.22
0.22
−0.08
4.33
0.21
0.31
0.22
0.27

SEQID-00547
0.07
0.00
0.04
0.04
0.13
0.00
0.02
0.06
−20.21
0.09
0.03
9.81
0.25
0.34
0.27
0.24

SEQID-00548
0.03
0.03
0.00
0.04
0.07
0.04
0.00
0.07
−21.35
0.47
−0.05
4.76
0.30
0.15
0.33
0.33

SEQID-00549
0.02
0.02
0.03
0.09
0.10
0.03
0.10
0.03
−14.48
0.26
0.06
10.19
0.30
0.23
0.00
0.34

SEQID-00550
0.02
0.00
0.01
0.09
0.03
0.02
0.04
0.18
−17.01
0.91
−0.04
4.37
0.33
0.29
0.00
0.27

SEQID-00551
0.03
0.08
0.03
0.05
0.06
0.00
0.00
0.07
−17.92
0.64
0.12
10.11
0.32
0.32
0.30
0.31

SEQID-00552
0.16
0.02
0.00
0.06
0.02
0.02
0.02
0.00
−26.95
0.02
0.02
9.05
0.25
0.24
0.25
0.26

SEQID-00553
0.01
0.00
0.24
0.06
0.07
0.00
0.00
0.04
−29.60
0.05
0.00
7.54
0.33
0.35
0.33
0.34

SEQID-00554
0.03
0.02
0.04
0.04
0.01
0.01
0.05
0.09
−23.36
0.31
0.16
11.12
0.27
0.34
0.24
0.29

SEQID-00555
0.03
0.03
0.03
0.02
0.05
0.00
0.04
0.10
−23.32
0.33
0.10
11.21
0.20
0.29
0.24
0.00

SEQID-00556
0.01
0.03
0.07
0.02
0.01
0.00
0.03
0.07
−23.75
0.29
0.17
11.60
0.23
0.30
0.23
0.26

SEQID-00557
0.02
0.03
0.06
0.13
0.07
0.05
0.02
0.10
−12.39
0.59
0.02
8.90
0.29
0.33
0.24
0.26

SEQID-00558
0.04
0.03
0.03
0.05
0.05
0.00
0.06
0.03
−21.91
0.09
0.03
7.88
0.25
0.31
0.28
0.26

SEQID-00559
0.02
0.02
0.03
0.02
0.08
0.00
0.04
0.05
−25.27
0.34
−0.01
5.85
0.00
0.33
0.00
0.00

SEQID-00560
0.01
0.00
0.00
0.07
0.00
0.00
0.00
0.01
−38.09
0.15
0.02
7.57
0.29
0.30
0.27
0.28

SEQID-00561
0.04
0.13
0.04
0.04
0.04
0.04
0.01
0.04
−8.41
1.32
0.01
8.53
0.19
0.28
0.21
0.00

SEQID-00562
0.01
0.05
0.01
0.04
0.01
0.00
0.01
0.07
−31.55
0.39
−0.16
3.88
0.24
0.30
0.24
0.25

SEQID-00563
0.05
0.05
0.02
0.04
0.04
0.02
0.04
0.07
−18.88
0.52
0.03
8.84
0.24
0.31
0.00
0.23

SEQID-00564
0.02
0.04
0.07
0.06
0.04
0.00
0.03
0.05
−24.85
0.23
0.11
10.77
0.28
0.33
0.26
0.23

SEQID-00565
0.01
0.07
0.04
0.06
0.04
0.03
0.03
0.06
−18.34
0.73
0.02
8.87
0.23
0.31
0.23
0.00

SEQID-00566
0.02
0.03
0.05
0.06
0.06
0.00
0.10
0.04
−15.35
0.46
0.00
6.76
0.24
0.32
0.25
0.81

SEQID-00567
0.01
0.03
0.04
0.03
0.04
0.04
0.07
0.07
−25.61
0.22
0.21
12.15
0.23
0.31
0.00
0.22

SEQID-00568
0.04
0.05
0.02
0.03
0.05
0.02
0.02
0.06
−26.59
0.30
0.13
11.42
0.25
0.33
0.20
0.20

SEQID-00569
0.02
0.06
0.02
0.06
0.13
0.04
0.01
0.05
−16.16
0.52
0.04
10.35
0.23
0.32
0.00
0.24

SEQID-00570
0.03
0.06
0.05
0.07
0.04
0.00
0.04
0.11
−15.90
0.43
0.03
9.76
0.23
0.30
0.24
0.00

SEQID-00571
0.02
0.09
0.02
0.01
0.03
0.02
0.02
0.12
−18.31
0.58
0.00
7.24
0.28
0.31
0.21
0.25

SEQID-00572
0.03
0.04
0.05
0.08
0.06
0.00
0.02
0.04
−26.28
0.23
0.13
10.87
0.28
0.32
0.25
0.26

SEQID-00573
0.03
0.04
0.05
0.06
0.05
0.00
0.03
0.05
−26.70
0.25
0.13
10.82
0.25
0.32
0.19
0.21

SEQID-00574
0.04
0.01
0.05
0.06
0.05
0.00
0.07
0.09
−21.11
0.22
0.15
11.42
0.23
0.31
0.00
0.00

SEQID-00575
0.01
0.03
0.08
0.02
0.01
0.00
0.04
0.07
−24.56
0.26
0.17
11.38
0.24
0.28
0.25
0.25

SEQID-00576
0.01
0.07
0.05
0.06
0.06
0.01
0.05
0.13
−11.59
0.55
0.00
7.24
0.27
0.31
0.23
0.27

SEQID-00577
0.02
0.02
0.03
0.12
0.08
0.00
0.06
0.05
−22.27
0.21
0.11
10.74
0.24
0.29
0.00
0.25

SEQID-00578
0.02
0.02
0.03
0.05
0.04
0.00
0.03
0.05
−28.89
0.26
0.24
11.90
0.24
0.31
0.27
0.25

SEQID-00579
0.01
0.01
0.04
0.05
0.07
0.00
0.07
0.08
−25.22
0.20
0.25
11.95
0.25
0.30
0.26
0.25

SEQID-00580
0.06
0.05
0.01
0.04
0.03
0.01
0.06
0.04
−24.98
0.25
0.21
11.84
0.00
0.27
0.00
0.22

SEQID-00581
0.04
0.02
0.04
0.05
0.05
0.00
0.04
0.13
−25.40
0.28
0.12
11.02
0.23
0.29
0.22
0.00

SEQID-00582
0.01
0.08
0.03
0.04
0.05
0.01
0.06
0.06
−24.01
0.19
0.11
10.65
0.00
0.32
0.25
0.00

SEQID-00583
0.05
0.02
0.05
0.03
0.05
0.00
0.01
0.06
−28.61
0.28
0.24
12.14
0.26
0.31
0.21
0.20

SEQID-00584
0.09
0.02
0.04
0.06
0.07
0.03
0.07
0.02
−18.12
0.37
0.01
8.20
0.24
0.28
0.00
0.21

SEQID-00585
0.04
0.01
0.02
0.04
0.01
0.00
0.03
0.03
−29.34
0.13
0.03
8.91
0.28
0.30
0.27
0.30

SEQID-00586
0.08
0.07
0.07
0.09
0.05
0.00
0.03
0.02
−26.12
0.09
0.07
10.60
0.24
0.31
0.17
0.00

SEQID-00587
0.02
0.04
0.04
0.04
0.04
0.00
0.01
0.11
−19.76
0.50
0.02
9.69
0.27
0.31
0.00
0.26

SEQID-00588
0.02
0.04
0.04
0.08
0.03
0.02
0.07
0.07
−20.29
0.26
0.18
12.08
0.26
0.29
0.25
0.19

SEQID-00589
0.04
0.05
0.05
0.03
0.05
0.00
0.03
0.02
−30.06
0.12
0.06
10.32
0.22
0.31
0.25
0.25

SEQID-00590
0.01
0.06
0.04
0.04
0.04
0.00
0.00
0.08
−24.08
0.36
0.05
10.32
0.30
0.31
0.00
0.00

SEQID-00591
0.01
0.03
0.04
0.03
0.01
0.00
0.05
0.02
−27.30
0.13
0.09
10.47
0.30
0.32
0.00
0.27

SEQID-00592
0.06
0.02
0.02
0.06
0.10
0.02
0.02
0.16
−18.59
0.39
−0.01
5.02
0.30
0.30
0.26
0.24

SEQID-00593
0.01
0.09
0.05
0.04
0.10
0.04
0.05
0.03
−16.04
0.63
−0.01
5.76
0.26
0.27
0.00
0.23

SEQID-00594
0.06
0.12
0.03
0.06
0.06
0.00
0.00
0.05
−19.01
0.53
0.08
8.31
0.30
0.29
0.30
0.28

SEQID-00595
0.09
0.13
0.03
0.06
0.06
0.00
0.00
0.02
−18.17
0.56
0.07
8.61
0.29
0.28
0.30
0.28

SEQID-00596
0.02
0.09
0.01
0.04
0.05
0.02
0.02
0.05
−22.57
0.60
0.00
7.12
0.34
0.32
0.33
0.29

SEQID-00597
0.02
0.12
0.02
0.03
0.04
0.00
0.00
0.05
−21.54
0.57
0.11
9.35
0.28
0.26
0.32
0.29

SEQID-00598
0.05
0.02
0.04
0.04
0.05
0.05
0.00
0.13
−20.52
0.43
0.05
9.60
0.30
0.26
0.00
0.99

SEQID-00599
0.01
0.04
0.02
0.09
0.06
0.06
0.04
0.09
−19.09
0.44
−0.02
5.99
0.22
0.31
0.00
0.20

SEQID-00600
0.04
0.03
0.05
0.04
0.04
0.03
0.08
0.07
−15.69
0.57
0.04
9.53
0.21
0.30
0.00
0.00

SEQID-00601
0.01
0.03
0.04
0.03
0.03
0.05
0.08
0.04
−21.74
0.27
−0.01
6.72
0.20
0.33
0.00
0.20

SEQID-00602
0.03
0.03
0.01
0.10
0.06
0.01
0.07
0.06
−20.45
0.28
0.09
10.47
0.22
0.31
0.00
0.22

SEQID-00603
0.00
0.02
0.03
0.07
0.06
0.08
0.03
0.08
−20.14
0.42
−0.03
5.54
0.21
0.32
0.00
0.20

SEQID-00604
0.00
0.05
0.03
0.07
0.08
0.02
0.06
0.08
−17.58
0.35
0.02
9.31
0.21
0.32
0.00
0.21

SEQID-00605
0.01
0.04
0.04
0.05
0.07
0.01
0.03
0.05
−20.32
0.40
0.00
6.81
0.21
0.31
0.00
0.00

SEQID-00606
0.02
0.04
0.04
0.03
0.04
0.01
0.03
0.04
−21.52
0.39
−0.03
6.47
0.21
0.34
0.00
0.21

SEQID-00607
0.02
0.04
0.05
0.04
0.06
0.03
0.01
0.05
−22.65
0.19
0.02
9.92
0.21
0.33
0.17
0.00

SEQID-00608
0.01
0.08
0.05
0.07
0.05
0.02
0.06
0.03
−18.71
0.25
−0.02
5.97
0.22
0.31
0.23
0.24

SEQID-00609
0.00
0.03
0.04
0.06
0.06
0.01
0.02
0.05
−27.26
0.10
0.04
10.39
0.21
0.33
0.00
0.21

SEQID-00610
0.03
0.06
0.04
0.06
0.05
0.00
0.01
0.05
−20.53
0.46
−0.06
4.45
0.21
0.32
0.21
0.21

SEQID-00611
0.03
0.06
0.06
0.03
0.05
0.04
0.05
0.08
−10.14
0.90
0.01
8.79
0.22
0.33
0.00
0.25

SEQID-00612
0.02
0.03
0.07
0.07
0.02
0.01
0.02
0.10
−14.35
0.60
0.01
7.63
0.24
0.34
0.21
0.23

SEQID-00613
0.03
0.02
0.02
0.06
0.04
0.01
0.01
0.04
−23.29
0.20
−0.03
4.72
0.25
0.33
0.00
0.00

SEQID-00614
0.01
0.08
0.03
0.04
0.07
0.04
0.02
0.05
−13.56
0.91
0.04
9.96
0.21
0.32
0.22
0.19

SEQID-00615
0.05
0.00
0.00
0.00
0.02
0.00
0.06
0.00
−27.63
0.18
0.00
6.97
0.43
0.23
0.33
0.36

SEQID-00616
0.04
0.03
0.03
0.06
0.05
0.00
0.03
0.05
−24.45
0.32
0.20
12.14
0.25
0.27
0.00
0.25

SEQID-00617
0.04
0.06
0.04
0.05
0.07
0.00
0.00
0.08
−20.50
0.46
0.01
8.23
0.27
0.30
0.00
0.23

SEQID-00618
0.01
0.01
0.07
0.03
0.03
0.00
0.04
0.08
−21.61
0.44
0.15
11.36
0.26
0.30
0.00
0.27

SEQID-00619
0.02
0.04
0.05
0.05
0.04
0.00
0.03
0.04
−27.42
0.25
0.13
10.79
0.26
0.33
0.25
0.25

SEQID-00620
0.03
0.01
0.01
0.04
0.05
0.02
0.00
0.15
−22.84
0.58
−0.07
4.39
0.23
0.31
0.00
0.24

SEQID-00621
0.01
0.03
0.04
0.08
0.01
0.00
0.03
0.07
−18.26
0.35
0.09
11.09
0.25
0.31
0.27
0.22

SEQID-00622
0.02
0.05
0.05
0.06
0.05
0.02
0.08
0.11
−18.79
0.43
−0.02
5.65
0.26
0.33
0.20
0.00

SEQID-00623
0.03
0.04
0.06
0.05
0.05
0.00
0.03
0.05
−25.75
0.25
0.13
10.85
0.28
0.31
0.22
0.00

SEQID-00624
0.06
0.03
0.03
0.06
0.04
0.00
0.00
0.06
−25.21
0.43
−0.07
4.34
0.25
0.34
0.23
0.00

SEQID-00625
0.03
0.04
0.02
0.03
0.01
0.02
0.03
0.10
−28.78
0.34
0.14
11.14
0.26
0.34
0.23
0.23

SEQID-00626
0.03
0.02
0.03
0.05
0.03
0.01
0.06
0.08
−21.94
0.44
0.03
9.85
0.24
0.30
0.20
0.15

SEQID-00627
0.02
0.02
0.02
0.02
0.06
0.01
0.02
0.07
−30.26
0.19
0.08
10.61
0.23
0.30
0.00
0.23

SEQID-00628
0.02
0.01
0.03
0.04
0.07
0.01
0.02
0.10
−23.95
0.29
0.05
10.21
0.25
0.29
0.22
0.00

SEQID-00629
0.02
0.01
0.06
0.05
0.01
0.00
0.05
0.07
−25.54
0.24
0.20
11.52
0.18
0.30
0.21
0.22

SEQID-00630
0.02
0.02
0.05
0.14
0.09
0.02
0.09
0.05
−12.56
0.23
0.01
8.03
0.25
0.34
0.29
0.25

SEQID-00631
0.02
0.00
0.02
0.03
0.05
0.00
0.05
0.03
−29.33
0.29
0.11
10.97
0.24
0.33
0.29
0.24

SEQID-00632
0.01
0.06
0.02
0.06
0.07
0.00
0.05
0.07
−22.73
0.35
−0.03
4.74
0.26
0.33
0.25
0.27

SEQID-00633
0.02
0.03
0.02
0.06
0.02
0.00
0.06
0.06
−29.53
0.07
−0.03
5.00
0.29
0.33
0.00
0.26

SEQID-00634
0.02
0.00
0.03
0.07
0.03
0.02
0.05
0.05
−24.75
0.38
0.15
11.02
0.22
0.26
0.00
0.24

SEQID-00635
0.02
0.05
0.03
0.06
0.04
0.02
0.03
0.09
−18.64
0.27
0.16
11.63
0.24
0.30
0.00
0.21

SEQID-00636
0.02
0.01
0.02
0.02
0.06
0.02
0.04
0.08
−24.50
0.28
0.19
12.27
0.20
0.29
0.00
0.26

SEQID-00637
0.04
0.01
0.03
0.07
0.08
0.02
0.05
0.02
−22.79
0.13
0.25
12.25
0.25
0.28
0.25
0.25

SEQID-00638
0.01
0.04
0.06
0.04
0.08
0.00
0.00
0.10
−26.77
0.32
0.04
10.37
0.25
0.29
0.00
0.28

SEQID-00639
0.03
0.01
0.00
0.05
0.09
0.02
0.06
0.08
−21.28
0.30
0.19
11.06
0.26
0.29
0.28
0.23

SEQID-00640
0.04
0.01
0.02
0.04
0.05
0.00
0.11
0.12
−28.97
0.26
0.14
10.65
0.19
0.27
0.00
0.00

SEQID-00641
0.03
0.06
0.02
0.03
0.04
0.00
0.02
0.03
−29.69
0.09
0.07
10.79
0.27
0.28
0.00
0.31

SEQID-00642
0.03
0.08
0.04
0.03
0.03
0.08
0.05
0.04
−23.31
0.20
−0.04
5.02
0.26
0.26
0.00
0.25

SEQID-00643
0.07
0.05
0.04
0.00
0.04
0.00
0.02
0.05
−26.01
0.39
0.04
8.90
0.25
0.25
0.27
0.00

SEQID-00644
0.02
0.05
0.02
0.04
0.02
0.02
0.08
0.14
−21.12
0.33
0.03
9.08
0.27
0.26
0.00
0.27

SEQID-00645
0.05
0.07
0.08
0.06
0.08
0.04
0.06
0.01
−15.18
0.44
0.02
9.00
0.26
0.25
0.00
0.26

SEQID-00646
0.03
0.07
0.01
0.03
0.04
0.05
0.08
0.05
−18.27
0.71
0.09
10.32
0.31
0.23
0.00
0.00

SEQID-00647
0.02
0.00
0.04
0.04
0.04
0.00
0.00
0.01
−27.75
0.24
0.04
10.19
0.34
0.30
0.27
0.30

SEQID-00648
0.05
0.05
0.05
0.01
0.04
0.02
0.02
0.04
−33.89
0.16
0.01
7.70
0.27
0.23
0.00
0.00

SEQID-00649
0.01
0.06
0.07
0.05
0.06
0.01
0.04
0.08
−14.83
0.68
0.01
7.78
0.25
0.33
0.22
0.22

SEQID-00650
0.02
0.05
0.03
0.06
0.10
0.03
0.03
0.07
−23.09
0.36
−0.02
4.88
0.27
0.17
0.30
0.35

SEQID-00651
0.04
0.04
0.03
0.03
0.03
0.03
0.04
0.05
−14.04
0.78
−0.01
6.41
0.25
0.34
0.25
0.24

SEQID-00652
0.06
0.03
0.05
0.12
0.03
0.00
0.05
0.00
−23.90
0.31
−0.04
4.69
0.26
0.27
0.31
1.00

SEQID-00653
0.05
0.04
0.07
0.03
0.05
0.00
0.01
0.10
−20.09
0.49
0.03
9.96
0.25
0.31
0.22
0.24

SEQID-00654
0.02
0.04
0.03
0.04
0.06
0.01
0.01
0.06
−19.75
0.51
−0.03
5.30
0.19
0.32
0.22
0.28

SEQID-00655
0.04
0.04
0.01
0.03
0.05
0.00
0.03
0.07
−25.19
0.32
−0.03
4.99
0.20
0.35
0.20
0.00

SEQID-00656
0.00
0.01
0.04
0.05
0.07
0.03
0.03
0.08
−19.20
0.26
0.00
8.72
0.00
0.36
0.00
0.20

SEQID-00657
0.02
0.05
0.04
0.04
0.06
0.04
0.06
0.05
−22.10
0.20
0.00
7.80
0.20
0.32
0.00
0.21

SEQID-00658
0.01
0.03
0.01
0.09
0.04
0.01
0.02
0.05
−26.41
0.23
0.00
6.84
0.22
0.37
0.20
0.22

SEQID-00659
0.03
0.06
0.04
0.05
0.05
0.05
0.07
0.07
−17.32
0.26
0.01
8.00
0.22
0.30
0.00
0.21

SEQID-00660
0.02
0.07
0.02
0.06
0.06
0.01
0.03
0.05
−23.14
0.27
−0.01
5.82
0.24
0.33
0.00
0.22

SEQID-00661
0.02
0.02
0.03
0.09
0.06
0.01
0.07
0.11
−14.17
0.48
0.01
8.58
1.00
1.00
0.23
0.22

SEQID-00662
0.02
0.03
0.04
0.09
0.05
0.08
0.10
0.03
−15.75
0.26
0.00
6.53
0.00
0.33
0.00
0.22

SEQID-00663
0.02
0.05
0.03
0.08
0.06
0.04
0.07
0.06
−17.59
0.23
0.02
9.22
0.37
0.49
0.24
0.21

SEQID-00664
0.01
0.06
0.01
0.05
0.09
0.02
0.02
0.09
−20.23
0.27
0.02
9.02
0.00
0.33
0.00
0.23

SEQID-00665
0.01
0.03
0.03
0.07
0.08
0.01
0.11
0.07
−17.78
0.25
0.00
6.87
0.22
0.32
0.21
0.21

SEQID-00666
0.03
0.05
0.02
0.04
0.05
0.00
0.05
0.08
−20.08
0.44
−0.05
4.40
0.55
0.71
0.19
0.23

SEQID-00667
0.02
0.04
0.02
0.04
0.05
0.02
0.07
0.05
−26.85
0.17
−0.01
5.26
0.21
0.33
0.00
0.00

SEQID-00668
0.02
0.03
0.00
0.05
0.06
0.01
0.07
0.06
−30.38
0.14
0.03
9.69
0.23
0.35
0.00
0.20

SEQID-00669
0.04
0.04
0.05
0.04
0.05
0.02
0.02
0.04
−21.61
0.30
0.00
6.69
0.00
0.35
0.25
0.00

SEQID-00670
0.04
0.03
0.05
0.04
0.05
0.02
0.02
0.04
−21.61
0.31
0.00
6.69
0.00
0.35
0.25
0.00

SEQID-00671
0.05
0.03
0.05
0.04
0.05
0.02
0.02
0.04
−21.67
0.30
−0.01
6.03
0.00
0.35
0.25
0.00

SEQID-00672
0.04
0.03
0.05
0.04
0.05
0.02
0.02
0.04
−21.97
0.28
−0.01
6.37
0.00
0.35
0.25
0.00

SEQID-00673
0.04
0.03
0.05
0.04
0.05
0.02
0.03
0.04
−21.69
0.29
−0.01
6.03
0.00
0.35
0.25
0.00

SEQID-00674
0.04
0.03
0.05
0.04
0.05
0.02
0.02
0.04
−21.66
0.30
−0.01
6.03
0.00
0.32
0.25
0.00

SEQID-00675
0.04
0.03
0.05
0.04
0.05
0.02
0.02
0.04
−21.68
0.30
−0.01
6.03
0.00
0.32
0.25
0.00

SEQID-00676
0.04
0.03
0.05
0.04
0.05
0.02
0.02
0.04
−21.66
0.29
−0.01
6.03
0.00
0.33
0.25
0.00

SEQID-00677
0.04
0.03
0.05
0.04
0.05
0.02
0.02
0.04
−21.66
0.31
−0.01
6.03
0.00
0.32
0.25
0.23

SEQID-00678
0.04
0.03
0.05
0.04
0.05
0.02
0.02
0.04
−21.97
0.28
−0.01
6.37
0.00
0.34
0.25
0.00

SEQID-00679
0.04
0.03
0.05
0.04
0.05
0.02
0.02
0.04
−21.66
0.31
−0.01
6.03
0.00
0.32
0.25
0.23

SEQID-00680
0.04
0.03
0.05
0.04
0.05
0.02
0.02
0.04
−21.70
0.28
−0.01
6.03
0.00
0.32
0.25
0.00

SEQID-00681
0.04
0.03
0.05
0.04
0.05
0.02
0.02
0.04
−21.68
0.29
−0.01
6.03
0.00
0.32
0.25
0.00

SEQID-00682
0.04
0.03
0.05
0.04
0.05
0.02
0.02
0.05
−21.66
0.31
−0.01
6.03
0.00
0.32
0.25
0.23

SEQID-00683
0.02
0.05
0.03
0.07
0.07
0.04
0.07
0.05
−17.73
0.22
−0.02
5.71
0.21
0.38
0.00
0.21

SEQID-00684
0.02
0.05
0.03
0.06
0.07
0.04
0.06
0.05
−17.50
0.25
−0.01
6.00
0.21
0.39
0.00
0.22

SEQID-00685
0.02
0.05
0.03
0.07
0.07
0.04
0.06
0.05
−17.72
0.22
−0.02
5.71
0.21
0.39
0.00
0.21

SEQID-00686
0.02
0.05
0.03
0.07
0.07
0.04
0.06
0.05
−17.59
0.22
−0.02
5.84
0.22
0.40
0.00
0.22

SEQID-00687
0.02
0.05
0.03
0.07
0.07
0.04
0.07
0.05
−17.70
0.22
−0.02
5.59
0.21
0.38
0.00
0.21

SEQID-00688
0.02
0.05
0.03
0.07
0.07
0.04
0.06
0.05
−17.70
0.23
−0.02
5.73
0.21
0.40
0.00
0.21

SEQID-00689
0.02
0.05
0.03
0.07
0.07
0.04
0.06
0.05
−17.72
0.22
−0.02
5.71
0.21
0.40
0.00
0.22

SEQID-00690
0.02
0.05
0.03
0.06
0.07
0.04
0.06
0.05
−17.68
0.26
−0.01
6.46
0.22
0.40
0.00
0.20

SEQID-00691
0.02
0.05
0.03
0.06
0.07
0.04
0.06
0.05
−17.79
0.24
−0.01
6.57
0.21
0.39
0.00
0.21

SEQID-00692
0.02
0.05
0.03
0.06
0.07
0.04
0.06
0.05
−17.59
0.25
−0.01
6.35
0.21
0.40
0.00
0.21

SEQID-00693
0.02
0.05
0.03
0.06
0.07
0.04
0.06
0.05
−17.85
0.23
−0.01
6.35
0.21
0.39
0.21
0.21

SEQID-00694
0.02
0.05
0.03
0.06
0.07
0.04
0.06
0.05
−17.74
0.24
−0.01
6.24
0.21
0.00
0.00
0.21

SEQID-00695
0.02
0.05
0.03
0.07
0.07
0.04
0.06
0.05
−17.72
0.22
−0.02
5.71
0.21
0.40
0.00
0.22

SEQID-00696
0.02
0.05
0.03
0.06
0.07
0.04
0.06
0.05
−17.57
0.26
−0.01
6.35
0.21
0.39
0.00
0.22

SEQID-00697
0.02
0.05
0.03
0.07
0.07
0.04
0.06
0.05
−17.50
0.25
−0.01
6.00
0.22
0.39
0.00
0.21

SEQID-00698
0.03
0.05
0.03
0.07
0.07
0.04
0.06
0.05
−17.44
0.25
−0.01
6.20
0.21
0.39
0.00
0.21

SEQID-00699
0.02
0.05
0.03
0.07
0.07
0.04
0.06
0.05
−17.62
0.23
−0.02
5.35
0.21
0.40
0.00
0.21

SEQID-00700
0.02
0.05
0.03
0.06
0.07
0.04
0.06
0.05
−17.48
0.27
−0.01
6.46
0.22
0.39
0.00
0.21

SEQID-00701
0.02
0.05
0.03
0.06
0.07
0.04
0.06
0.05
−17.57
0.26
−0.01
6.35
0.21
0.39
0.00
0.22

SEQID-00702
0.02
0.05
0.03
0.06
0.07
0.04
0.06
0.05
−17.59
0.25
−0.01
6.35
0.21
0.39
0.00
0.22

SEQID-00703
0.02
0.05
0.03
0.07
0.07
0.04
0.06
0.05
−17.80
0.23
−0.02
5.85
0.21
0.40
0.00
0.21

SEQID-00704
0.02
0.05
0.03
0.06
0.07
0.04
0.06
0.05
−17.90
0.24
0.00
6.69
0.21
0.39
0.00
0.21

SEQID-00705
0.02
0.05
0.03
0.06
0.07
0.04
0.06
0.06
−17.58
0.25
−0.01
6.35
0.22
0.40
0.21
0.21

SEQID-00706
0.02
0.05
0.03
0.07
0.07
0.03
0.07
0.05
−17.53
0.23
−0.02
5.44
0.22
0.40
0.00
0.21

SEQID-00707
0.02
0.05
0.03
0.07
0.07
0.03
0.07
0.05
−17.53
0.23
−0.02
5.44
0.22
0.40
0.00
0.21

SEQID-00708
0.02
0.05
0.03
0.07
0.07
0.03
0.07
0.05
−17.53
0.23
−0.02
5.44
0.22
0.40
0.00
0.21

SEQID-00709
0.02
0.05
0.03
0.07
0.07
0.03
0.07
0.05
−17.53
0.23
−0.02
5.44
0.22
0.40
0.00
0.21

SEQID-00710
0.02
0.05
0.03
0.07
0.07
0.04
0.07
0.05
−17.62
0.22
−0.02
5.845
0.21
0.375
0
0.2083

SEQID-00711
0.02
0.05
0.03
0.07
0.07
0.04
0.07
0.05
−17.66
0.22
−0.02
5.946
0.21
0.375
0
0.2083

SEQID-00712
0.02
0.05
0.03
0.07
0.07
0.04
0.07
0.05
−17.64
0.22
−0.02
5.844
0.21
0.375
0
0.2083

SEQID-00713
0.02
0.05
0.04
0.07
0.07
0.04
0.07
0.05
−17.62
0.22
−0.02
5.844
0.21
0.375
0
0.2083

SEQID-00714
0.02
0.05
0.03
0.07
0.07
0.04
0.07
0.05
−17.63
0.22
−0.02
5.844
0.21
0.375
0
0.2083

SEQID-00715
0.02
0.05
0.03
0.07
0.07
0.04
0.07
0.05
−17.74
0.22
−0.01
5.973
0.21
0.375
0
0.2098

SEQID-00716
0.05
0.03
0.05
0.04
0.04
0.01
0.03
0.04
−22.86
0.27
0.00
6.68
0.00
0.35
0.25
0.22

SEQID-00717
0.02
0.02
0.02
0.06
0.05
0.01
0.04
0.03
−26.21
0.21
0.00
6.81
0.00
0.37
0.17
0.18

SEQID-00718
0.02
0.02
0.02
0.05
0.04
0.01
0.04
0.03
−26.84
0.21
0.00
6.67
0.00
0.38
0.17
0.19

SEQID-00719
0.02
0.03
0.02
0.06
0.04
0.01
0.04
0.04
−26.53
0.21
0.00
6.85
0.00
0.38
0.18
0.18

SEQID-00720
0.04
0.01
0.05
0.05
0.06
0.01
0.04
0.06
−17.51
0.47
−0.01
6.05
0.20
0.33
0.00
0.20

SEQID-00721
0.04
0.04
0.01
0.09
0.03
0.01
0.05
0.05
−18.44
0.28
0.01
8.63
0.68
0.89
0.21
0.21

SEQID-00722
0.02
0.04
0.02
0.05
0.09
0.00
0.02
0.05
−23.26
0.35
0.00
7.76
0.22
0.32
0.00
0.00

SEQID-00723
0.02
0.04
0.03
0.04
0.04
0.00
0.04
0.05
−24.71
0.36
−0.02
5.10
0.20
0.35
0.35
0.20

SEQID-00724
0.02
0.08
0.03
0.05
0.07
0.03
0.04
0.06
−17.74
0.39
−0.01
6.43
0.20
0.34
0.00
0.20

SEQID-00725
0.03
0.03
0.03
0.10
0.06
0.01
0.05
0.04
−18.15
0.28
0.04
9.15
0.20
0.32
0.00
0.21

SEQID-00726
0.05
0.05
0.04
0.05
0.06
0.02
0.06
0.05
−19.47
0.43
−0.03
5.16
0.21
0.31
0.00
0.22

SEQID-00727
0.03
0.03
0.02
0.06
0.05
0.00
0.08
0.05
−25.41
0.34
0.00
7.39
0.21
0.32
0.00
0.00

SEQID-00728
0.02
0.09
0.05
0.05
0.05
0.02
0.04
0.06
−20.49
0.42
0.02
8.79
0.27
0.35
0.00
0.23

SEQID-00729
0.01
0.02
0.05
0.07
0.06
0.01
0.01
0.07
−25.53
0.22
−0.10
4.24
0.17
0.34
0.20
0.22

SEQID-00730
0.02
0.05
0.03
0.05
0.06
0.02
0.06
0.07
−19.93
0.43
0.00
7.52
0.20
0.33
0.00
0.20

SEQID-00731
0.02
0.01
0.02
0.07
0.05
0.01
0.03
0.05
−23.80
0.35
−0.02
5.11
0.25
0.36
0.20
0.22

SEQID-00732
0.03
0.05
0.05
0.07
0.07
0.01
0.05
0.07
−16.46
0.43
−0.03
4.71
0.18
0.41
0.19
0.21

SEQID-00733
0.04
0.05
0.04
0.05
0.06
0.02
0.03
0.09
−20.09
0.45
0.04
9.88
0.21
0.33
0.00
0.21

SEQID-00734
0.02
0.02
0.02
0.09
0.04
0.01
0.04
0.03
−28.10
0.11
−0.05
4.66
0.23
0.38
0.00
0.21

SEQID-00735
0.03
0.04
0.03
0.06
0.06
0.01
0.03
0.05
−20.57
0.37
−0.03
5.11
0.19
0.39
0.17
0.19

SEQID-00736
0.03
0.06
0.05
0.05
0.04
0.00
0.04
0.08
−18.67
0.55
−0.02
5.26
0.20
0.34
0.19
0.23

SEQID-00737
0.01
0.01
0.13
0.07
0.10
0.01
0.08
0.06
−10.66
0.25
0.03
7.94
0.25
0.34
0.23
0.25

SEQID-00738
0.01
0.04
0.02
0.08
0.04
0.00
0.04
0.06
−22.90
0.30
0.00
7.02
0.49
0.70
0.00
0.22

SEQID-00739
0.04
0.04
0.04
0.04
0.05
0.01
0.03
0.08
−20.80
0.45
0.01
7.95
0.21
0.31
0.00
0.21

SEQID-00740
0.04
0.03
0.05
0.05
0.05
0.00
0.03
0.05
−24.77
0.34
−0.01
5.84
0.22
0.34
0.00
0.22

SEQID-00741
0.02
0.05
0.03
0.07
0.03
0.01
0.06
0.04
−22.26
0.32
−0.01
6.31
0.21
0.33
0.00
0.21

SEQID-00742
0.03
0.04
0.03
0.05
0.04
0.01
0.03
0.06
−23.79
0.32
0.00
6.55
0.19
0.37
0.37
0.20

SEQID-00743
0.01
0.00
0.28
0.02
0.03
0.00
0.00
0.07
−17.20
0.07
0.05
8.50
0.40
0.43
0.31
0.27

SEQID-00744
0.02
0.05
0.05
0.05
0.06
0.01
0.04
0.06
−21.41
0.40
−0.03
4.98
0.18
0.33
0.00
0.20

SEQID-00745
0.02
0.08
0.06
0.04
0.04
0.02
0.05
0.06
−20.48
0.24
0.00
7.10
0.37
0.56
0.00
0.22

SEQID-00746
0.02
0.03
0.11
0.03
0.05
0.05
0.03
0.05
−19.27
0.23
−0.01
6.42
0.22
0.32
0.23
0.25

SEQID-00747
0.03
0.04
0.04
0.05
0.05
0.00
0.05
0.07
−18.93
0.47
−0.01
5.90
0.21
0.33
0.00
0.22

SEQID-00748
0.03
0.06
0.06
0.05
0.04
0.02
0.04
0.06
−18.69
0.48
0.04
10.26
0.19
0.40
0.19
0.21

SEQID-00749
0.02
0.04
0.06
0.05
0.06
0.01
0.05
0.08
−20.08
0.43
−0.01
6.51
0.00
0.33
0.00
0.20

SEQID-00750
0.03
0.06
0.04
0.05
0.05
0.01
0.02
0.06
−22.29
0.42
−0.03
5.11
0.22
0.33
0.00
0.23

SEQID-00751
0.01
0.02
0.16
0.09
0.04
0.01
0.06
0.05
−15.46
0.16
0.03
8.07
0.22
0.36
0.20
0.24

SEQID-00752
0.03
0.04
0.05
0.07
0.08
0.00
0.03
0.07
−21.91
0.33
0.01
9.44
0.21
0.34
0.22
0.21

SEQID-00753
0.01
0.05
0.02
0.07
0.05
0.01
0.04
0.04
−20.98
0.47
−0.02
5.20
0.19
0.35
0.00
0.21

SEQID-00754
0.03
0.02
0.07
0.09
0.03
0.01
0.02
0.05
−30.38
0.15
−0.04
4.71
0.22
0.35
0.20
0.23

SEQID-00755
0.04
0.05
0.02
0.06
0.05
0.06
0.04
0.05
−21.04
0.43
−0.03
5.03
0.00
0.32
0.00
0.21

SEQID-00756
0.01
0.02
0.20
0.04
0.03
0.01
0.02
0.03
−14.62
0.15
0.00
7.76
0.59
0.30
0.20
0.39

SEQID-00757
0.02
0.03
0.08
0.12
0.06
0.01
0.02
0.04
−20.53
0.21
0.00
7.12
0.18
0.38
0.19
0.19

SEQID-00758
0.02
0.04
0.05
0.06
0.06
0.03
0.05
0.08
−19.05
0.40
−0.01
6.39
0.19
0.33
0.00
0.21

SEQID-00759
0.02
0.03
0.04
0.07
0.04
0.03
0.06
0.06
−23.41
0.23
−0.03
5.04
0.00
0.31
0.21
0.25

SEQID-00760
0.04
0.05
0.05
0.04
0.05
0.01
0.04
0.07
−21.34
0.43
0.00
6.82
0.20
0.33
0.19
0.21

SEQID-00761
0.00
0.02
0.10
0.27
0.03
0.00
0.04
0.06
−8.13
0.28
0.02
8.77
0.25
0.52
0.22
0.27

SEQID-00762
0.02
0.08
0.02
0.02
0.03
0.02
0.02
0.11
−19.85
0.47
0.01
7.35
0.26
0.30
0.15
0.25

SEQID-00763
0.05
0.05
0.04
0.05
0.06
0.02
0.06
0.05
−19.53
0.43
−0.03
5.15
0.21
0.31
0.00
0.22

SEQID-00764
0.02
0.07
0.04
0.07
0.05
0.01
0.03
0.08
−17.08
0.44
0.02
8.94
0.25
0.34
0.26
0.27

SEQID-00765
0.02
0.04
0.02
0.04
0.04
0.03
0.03
0.04
−25.78
0.23
−0.04
4.94
0.16
0.36
0.18
0.19

SEQID-00766
0.05
0.07
0.03
0.05
0.05
0.02
0.05
0.06
−19.72
0.34
−0.06
4.46
0.40
0.54
0.00
0.22

SEQID-00767
0.03
0.04
0.05
0.04
0.06
0.01
0.04
0.08
−22.21
0.39
0.03
9.56
0.22
0.35
0.21
0.22

SEQID-00768
0.03
0.04
0.04
0.04
0.06
0.01
0.04
0.06
−23.12
0.37
−0.03
4.87
0.68
0.90
0.00
0.21

SEQID-00769
0.04
0.03
0.02
0.06
0.04
0.01
0.06
0.04
−26.06
0.29
−0.07
4.36
0.22
0.33
0.23
0.00

SEQID-00770
0.03
0.06
0.04
0.05
0.05
0.01
0.06
0.08
−19.57
0.40
−0.05
4.68
0.80
0.90
0.22
0.22

SEQID-00771
0.03
0.04
0.04
0.05
0.03
0.01
0.04
0.05
−23.12
0.39
−0.01
5.89
0.21
0.36
0.00
0.22

SEQID-00772
0.02
0.05
0.03
0.04
0.03
0.02
0.08
0.05
−24.11
0.37
−0.05
4.75
0.20
0.33
0.00
0.20

SEQID-00773
0.02
0.04
0.01
0.04
0.03
0.03
0.03
0.03
−27.93
0.22
−0.06
4.57
0.17
0.36
0.18
0.18

SEQID-00774
0.01
0.04
0.09
0.07
0.05
0.04
0.01
0.06
−19.68
0.37
0.08
10.85
0.23
0.32
0.00
0.25

SEQID-00775
0.01
0.02
0.04
0.07
0.05
0.01
0.02
0.06
−21.63
0.29
0.04
9.61
0.19
0.37
0.22
0.21

SEQID-00776
0.02
0.08
0.01
0.10
0.04
0.00
0.03
0.05
−16.79
0.24
−0.01
5.66
0.62
0.91
0.21
0.22

SEQID-00777
0.03
0.03
0.02
0.03
0.03
0.01
0.03
0.04
−28.02
0.23
−0.02
5.49
0.18
0.42
0.17
0.18

SEQID-00778
0.03
0.04
0.01
0.03
0.03
0.01
0.02
0.03
−29.55
0.22
−0.02
5.34
0.19
0.42
0.18
0.18

SEQID-00779
0.03
0.05
0.04
0.05
0.05
0.02
0.04
0.07
−18.79
0.42
−0.01
6.24
0.19
0.34
0.19
0.19

SEQID-00780
0.03
0.05
0.04
0.06
0.06
0.01
0.08
0.06
−22.58
0.29
0.02
8.69
1.00
1.00
0.18
0.00

SEQID-00781
0.04
0.04
0.01
0.09
0.03
0.01
0.05
0.05
−18.68
0.26
0.01
8.78
0.69
0.89
0.21
0.21

SEQID-00782
0.02
0.03
0.02
0.07
0.05
0.00
0.04
0.05
−26.50
0.17
−0.04
4.77
0.30
0.44
0.00
0.21

SEQID-00783
0.03
0.04
0.02
0.06
0.07
0.03
0.04
0.06
−22.76
0.29
−0.01
6.25
0.00
0.31
0.00
0.22

SEQID-00784
0.02
0.03
0.03
0.04
0.05
0.00
0.03
0.06
−25.48
0.36
0.01
8.05
0.20
0.34
0.43
0.22

SEQID-00785
0.03
0.04
0.05
0.04
0.06
0.02
0.04
0.09
−20.73
0.43
0.03
9.50
0.23
0.32
0.00
0.22

SEQID-00786
0.03
0.05
0.03
0.05
0.05
0.01
0.05
0.05
−28.05
0.31
−0.05
4.66
0.65
0.88
0.00
0.21

SEQID-00787
0.04
0.10
0.02
0.07
0.03
0.02
0.07
0.05
−16.15
0.45
0.05
10.26
0.22
0.33
0.00
0.19

SEQID-00788
0.03
0.04
0.05
0.04
0.06
0.00
0.04
0.08
−17.76
0.53
−0.03
4.92
0.22
0.36
0.23
0.22

SEQID-00789
0.02
0.03
0.03
0.04
0.03
0.05
0.02
0.05
−23.69
0.42
0.03
9.29
0.24
0.35
0.00
0.00

SEQID-00790
0.02
0.02
0.04
0.02
0.05
0.00
0.03
0.04
−25.14
0.25
0.11
10.51
0.22
0.30
0.27
0.00

SEQID-00791
0.02
0.06
0.06
0.04
0.04
0.02
0.04
0.05
−18.94
0.44
0.01
7.91
0.18
0.34
0.21
0.22

SEQID-00792
0.03
0.05
0.02
0.05
0.05
0.01
0.05
0.05
−23.78
0.31
0.00
7.09
0.18
0.34
0.18
0.18

SEQID-00793
0.03
0.07
0.05
0.05
0.06
0.02
0.07
0.08
−21.12
0.40
−0.03
5.00
0.25
0.39
0.00
0.00

SEQID-00794
0.02
0.04
0.04
0.09
0.04
0.01
0.04
0.04
−22.19
0.35
−0.01
6.31
0.20
0.34
0.20
0.20

SEQID-00795
0.04
0.03
0.04
0.06
0.05
0.02
0.03
0.07
−18.67
0.51
0.00
6.89
0.17
0.34
0.18
0.19

SEQID-00796
0.02
0.06
0.04
0.05
0.05
0.01
0.06
0.07
−19.06
0.46
−0.01
6.44
0.19
0.37
0.19
0.20

SEQID-00797
0.01
0.03
0.02
0.07
0.04
0.01
0.02
0.04
−24.56
0.24
0.00
6.34
0.22
0.34
0.00
0.22

SEQID-00798
0.03
0.07
0.04
0.06
0.05
0.02
0.06
0.07
−19.87
0.41
−0.05
4.37
0.20
0.33
0.00
0.21

SEQID-00799
0.03
0.06
0.04
0.05
0.04
0.01
0.06
0.06
−20.28
0.40
0.00
6.88
0.21
0.33
0.20
0.21

SEQID-00800
0.02
0.05
0.04
0.05
0.06
0.02
0.07
0.05
−23.63
0.24
0.01
8.40
0.90
0.95
0.00
0.00

SEQID-00801
0.03
0.03
0.05
0.08
0.05
0.02
0.04
0.05
−26.41
0.21
0.05
10.06
0.20
0.33
0.00
0.21

SEQID-00802
0.03
0.04
0.02
0.09
0.03
0.00
0.04
0.05
−22.03
0.28
0.00
6.55
0.56
0.76
0.00
0.22

SEQID-00803
0.03
0.04
0.07
0.07
0.02
0.02
0.07
0.04
−19.42
0.33
−0.02
5.12
0.88
0.89
0.00
0.21

SEQID-00804
0.03
0.05
0.03
0.06
0.05
0.01
0.05
0.06
−22.56
0.39
0.00
6.80
0.22
0.33
0.00
0.21

SEQID-00805
0.04
0.05
0.13
0.05
0.04
0.01
0.02
0.09
−15.61
0.52
−0.03
5.06
0.92
0.94
0.23
0.22

SEQID-00806
0.05
0.05
0.05
0.06
0.05
0.02
0.06
0.06
−19.07
0.45
−0.02
6.01
0.20
0.30
0.00
0.21

SEQID-00807
0.02
0.04
0.04
0.07
0.06
0.02
0.04
0.06
−22.08
0.41
0.01
7.91
0.20
0.34
0.00
0.20

SEQID-00808
0.03
0.04
0.04
0.06
0.05
0.01
0.04
0.05
−24.86
0.25
−0.07
4.43
0.19
0.35
0.00
0.20

SEQID-00809
0.02
0.05
0.09
0.05
0.07
0.01
0.07
0.06
−15.74
0.43
−0.01
6.10
0.84
0.95
0.00
0.24

SEQID-00810
0.03
0.06
0.03
0.06
0.04
0.01
0.03
0.07
−21.00
0.44
−0.04
4.78
0.19
0.32
0.00
0.22

SEQID-00811
0.03
0.06
0.02
0.05
0.06
0.02
0.05
0.04
−21.49
0.37
−0.02
5.48
0.22
0.32
0.00
0.22

SEQID-00812
0.02
0.05
0.01
0.09
0.08
0.01
0.05
0.04
−23.69
0.30
−0.07
4.28
0.22
0.31
0.22
0.00

SEQID-00813
0.04
0.07
0.04
0.04
0.04
0.03
0.05
0.05
−20.90
0.36
0.00
6.68
0.20
0.33
0.00
0.21

SEQID-00814
0.02
0.04
0.02
0.06
0.04
0.07
0.03
0.04
−15.97
0.54
0.06
9.25
1.00
1.00
0.00
0.25

SEQID-00815
0.02
0.07
0.03
0.06
0.04
0.03
0.06
0.04
−21.94
0.26
−0.02
5.45
0.20
0.33
0.00
0.20

SEQID-00816
0.02
0.04
0.03
0.05
0.05
0.01
0.03
0.07
−21.25
0.54
−0.02
5.30
0.19
0.34
0.00
0.20

SEQID-00817
0.03
0.06
0.03
0.08
0.05
0.02
0.03
0.05
−17.92
0.47
−0.03
4.98
0.22
0.31
0.00
0.22

SEQID-00818
0.03
0.05
0.03
0.08
0.04
0.01
0.02
0.04
−22.52
0.26
0.01
8.12
0.19
0.33
0.00
0.20

SEQID-00819
0.02
0.03
0.01
0.02
0.06
0.00
0.06
0.08
−23.82
0.30
0.01
11.91
0.19
0.23
0.00
0.28

SEQID-00820
0.05
0.05
0.05
0.07
0.05
0.01
0.05
0.02
−22.32
0.13
0.00
6.55
0.19
0.33
0.19
0.70

SEQID-00821
0.02
0.06
0.03
0.05
0.05
0.01
0.04
0.05
−27.82
0.30
−0.05
4.54
0.75
0.89
0.00
0.21

SEQID-00822
0.03
0.03
0.04
0.04
0.05
0.01
0.01
0.09
−21.46
0.48
0.00
6.76
0.21
0.33
0.18
0.21

SEQID-00823
0.03
0.05
0.05
0.06
0.04
0.02
0.04
0.07
−19.60
0.45
0.03
9.21
0.21
0.38
0.00
0.23

SEQID-00824
0.02
0.07
0.05
0.06
0.05
0.03
0.07
0.06
−18.82
0.38
0.01
7.62
0.43
0.70
0.21
0.21

SEQID-00825
0.02
0.04
0.01
0.06
0.05
0.01
0.03
0.03
−27.73
0.20
−0.01
5.87
0.20
0.34
0.21
0.12

SEQID-00826
0.02
0.05
0.04
0.07
0.05
0.03
0.04
0.06
−23.22
0.17
−0.06
4.46
0.22
0.32
0.00
0.22

SEQID-00827
0.02
0.05
0.05
0.09
0.05
0.02
0.04
0.05
−18.66
0.36
−0.01
6.55
0.18
0.33
0.19
0.19

SEQID-00828
0.02
0.05
0.04
0.06
0.05
0.00
0.05
0.06
−21.15
0.40
−0.01
5.88
0.19
0.33
0.00
0.22

SEQID-00829
0.04
0.02
0.03
0.06
0.03
0.01
0.02
0.04
−27.07
0.18
0.00
6.97
0.19
0.36
0.19
0.17

SEQID-00830
0.05
0.05
0.04
0.04
0.03
0.02
0.05
0.02
−31.03
0.20
0.03
9.50
0.21
0.31
0.18
0.23

SEQID-00831
0.02
0.06
0.03
0.07
0.05
0.03
0.04
0.06
−20.27
0.49
−0.01
6.52
0.19
0.32
0.00
0.20

SEQID-00832
0.03
0.07
0.07
0.04
0.03
0.03
0.03
0.05
−19.84
0.49
−0.01
6.35
0.23
0.33
0.24
0.23

SEQID-00833
0.03
0.03
0.04
0.08
0.05
0.03
0.03
0.06
−18.70
0.04
−0.02
5.99
0.00
0.36
0.00
0.18

SEQID-00834
0.03
0.04
0.07
0.06
0.05
0.03
0.04
0.05
−19.80
0.30
0.03
9.51
0.21
0.33
0.00
0.20

SEQID-00835
0.02
0.06
0.03
0.04
0.05
0.00
0.04
0.06
−21.75
0.42
0.04
9.78
0.20
0.33
0.00
0.20

SEQID-00836
0.02
0.02
0.01
0.07
0.05
0.01
0.01
0.04
−28.27
0.15
−0.06
4.67
0.00
0.36
0.16
0.19

SEQID-00837
0.01
0.07
0.01
0.04
0.02
0.01
0.04
0.04
−23.16
0.37
0.01
8.05
0.44
0.59
0.00
0.21

SEQID-00838
0.02
0.09
0.04
0.07
0.07
0.05
0.08
0.05
−17.20
0.33
−0.04
4.36
0.23
0.43
0.00
0.21

SEQID-00839
0.02
0.09
0.04
0.07
0.07
0.05
0.08
0.05
−17.20
0.33
−0.04
4.36
0.23
0.43
0.00
0.21

SEQID-00840
0.02
0.05
0.06
0.08
0.06
0.03
0.04
0.07
−16.79
0.41
−0.03
4.92
0.23
0.41
0.00
0.22

SEQID-00841
0.02
0.07
0.06
0.05
0.06
0.03
0.06
0.08
−15.70
0.45
0.01
8.78
0.21
0.33
0.00
0.21

SEQID-00842
0.02
0.08
0.05
0.06
0.06
0.07
0.05
0.05
−15.37
0.40
−0.01
6.24
0.21
0.33
0.00
0.20

SEQID-00843
0.02
0.05
0.03
0.05
0.04
0.05
0.09
0.04
−19.75
0.35
−0.06
4.34
0.21
0.33
0.00
0.21

SEQID-00844
0.02
0.08
0.05
0.07
0.04
0.04
0.03
0.06
−17.13
0.43
0.03
9.49
0.20
0.33
0.00
0.21

SEQID-00845
0.02
0.06
0.05
0.05
0.06
0.04
0.03
0.05
−19.30
0.37
0.02
8.68
0.20
0.33
0.00
0.21

SEQID-00846
0.01
0.07
0.06
0.06
0.03
0.03
0.03
0.08
−19.54
0.47
−0.01
5.25
0.21
0.37
0.21
0.22

SEQID-00847
0.02
0.07
0.04
0.05
0.06
0.04
0.05
0.04
−15.64
0.32
0.00
7.17
0.21
0.31
0.35
0.21

SEQID-00848
0.02
0.05
0.02
0.06
0.06
0.04
0.03
0.04
−20.06
0.27
−0.02
5.45
0.21
0.31
0.29
0.21

SEQID-00849
0.02
0.08
0.02
0.09
0.08
0.05
0.06
0.07
−17.01
0.41
−0.06
4.10
0.25
0.35
0.00
0.22

SEQID-00850
0.01
0.03
0.03
0.12
0.08
0.03
0.06
0.09
−14.72
0.43
−0.03
4.43
0.22
0.41
0.00
0.23

SEQID-00851
0.01
0.07
0.06
0.05
0.03
0.04
0.07
0.05
−16.72
0.46
−0.01
5.64
0.25
0.31
0.00
0.00

SEQID-00852
0.03
0.08
0.03
0.08
0.06
0.05
0.06
0.06
−11.63
0.39
0.03
8.62
0.29
0.37
0.00
0.19

SEQID-00853
0.01
0.05
0.06
0.07
0.01
0.03
0.07
0.05
−21.01
0.41
0.02
8.22
0.28
0.30
0.25
0.26

SEQID-00854
0.02
0.04
0.05
0.05
0.04
0.03
0.09
0.03
−22.92
0.44
0.01
7.66
0.20
0.28
0.21
0.22

SEQID-00855
0.02
0.06
0.03
0.05
0.05
0.02
0.06
0.04
−22.85
0.50
−0.02
5.69
0.28
0.32
0.23
0.22

SEQID-00856
0.03
0.04
0.05
0.07
0.07
0.02
0.02
0.05
−21.90
0.33
0.04
9.19
0.21
0.29
0.00
0.00

SEQID-00857
0.02
0.05
0.06
0.06
0.04
0.04
0.03
0.05
−20.43
0.34
−0.04
4.89
0.21
0.33
0.20
0.21

SEQID-00858
0.02
0.05
0.04
0.05
0.07
0.00
0.05
0.04
−19.78
0.44
0.00
6.90
0.20
0.30
0.00
0.00

SEQID-00859
0.02
0.03
0.04
0.09
0.07
0.00
0.01
0.03
−22.27
0.41
−0.01
6.63
0.20
0.33
0.23
0.22

SEQID-00860
0.03
0.03
0.02
0.06
0.05
0.00
0.08
0.05
−25.41
0.34
0.00
7.39
0.21
0.32
0.00
0.00

SEQID-00861
0.05
0.05
0.04
0.05
0.06
0.02
0.06
0.05
−19.53
0.43
−0.03
5.15
0.21
0.31
0.00
0.22

SEQID-00862
0.05
0.05
0.04
0.05
0.06
0.02
0.06
0.05
−19.52
0.43
−0.03
5.16
0.21
0.31
0.00
0.22

SEQID-00863
0.02
0.04
0.02
0.03
0.08
0.00
0.02
0.05
−23.67
0.33
0.00
7.90
0.22
0.31
0.23
0.21

SEQID-00864
0.07
0.08
0.01
0.03
0.05
0.00
0.01
0.04
−28.98
0.24
−0.15
3.89
0.44
0.48
0.24
0.19

SEQID-00865
0.08
0.07
0.01
0.03
0.06
0.00
0.01
0.05
−27.55
0.34
−0.16
3.79
0.39
0.46
0.22
0.24

SEQID-00866
0.06
0.08
0.01
0.03
0.04
0.00
0.00
0.07
−29.02
0.33
−0.16
3.88
0.39
0.44
0.23
0.24

SEQID-00867
0.05
0.07
0.01
0.04
0.05
0.00
0.02
0.04
−28.60
0.33
−0.18
3.76
0.44
0.49
0.24
0.23

SEQID-00868
0.09
0.10
0.01
0.05
0.04
0.00
0.03
0.03
−24.77
0.34
−0.12
3.96
0.34
0.45
0.00
0.00

SEQID-00869
0.06
0.07
0.02
0.01
0.06
0.00
0.01
0.06
−28.16
0.29
−0.14
3.97
0.44
0.47
0.23
0.25

SEQID-00870
0.07
0.07
0.01
0.04
0.04
0.02
0.02
0.04
−28.99
0.30
−0.13
4.03
0.35
0.45
0.00
0.00

SEQID-00871
0.02
0.04
0.04
0.03
0.06
0.00
0.03
0.06
−25.67
0.29
−0.03
4.94
0.23
0.34
0.00
0.00

SEQID-00872
0.04
0.03
0.03
0.04
0.07
0.00
0.05
0.08
−25.39
0.32
0.01
8.62
0.00
0.33
0.00
0.23

SEQID-00873
0.03
0.03
0.03
0.04
0.06
0.00
0.06
0.07
−25.16
0.32
0.02
8.95
0.22
0.33
0.00
0.22

SEQID-00874
0.01
0.04
0.03
0.03
0.03
0.03
0.07
0.05
−25.15
0.33
−0.08
4.45
0.25
0.31
0.21
0.25

SEQID-00875
0.02
0.04
0.03
0.03
0.04
0.03
0.07
0.05
−25.71
0.29
0.08
4.36
0.21
0.34
0.21
0.25

SEQID-00876
0.02
0.03
0.02
0.04
0.05
0.05
0.02
0.05
−26.34
0.38
−0.10
4.27
0.23
0.31
0.22
0.22

SEQID-00877
0.03
0.03
0.02
0.05
0.02
0.02
0.06
0.07
−27.67
0.29
0.10
4.27
0.23
0.31
0.00
0.22

SEQID-00878
0.03
0.05
0.03
0.04
0.03
0.01
0.04
0.06
−26.25
0.35
−0.01
5.48
0.21
0.33
0.00
0.23

SEQID-00879
0.03
0.05
0.03
0.05
0.03
0.01
0.04
0.07
−25.44
0.39
0.00
7.29
0.20
0.31
0.00
0.22

SEQID-00880
0.03
0.02
0.09
0.06
0.01
0.00
0.00
0.00
−21.21
0.14
0.01
8.06
0.35
0.34
0.34
0.36

SEQID-00881
0.02
0.00
0.06
0.09
0.13
0.00
0.00
0.01
−15.62
0.24
0.01
7.37
0.27
0.31
0.30
0.31

SEQID-00882
0.04
0.01
0.01
0.08
0.05
0.00
0.02
0.02
−29.20
0.07
−0.02
5.28
0.29
0.30
0.00
0.30

SEQID-00883
0.01
0.05
0.04
0.03
0.04
0.01
0.01
0.03
−23.50
0.25
0.05
8.55
0.23
0.35
0.25
0.25

SEQID-00884
0.02
0.03
0.04
0.12
0.02
0.00
0.01
0.04
−19.99
0.33
0.07
10.84
0.23
0.35
0.24
0.23

SEQID-00885
0.03
0.04
0.03
0.05
0.04
0.01
0.02
0.03
−20.99
0.15
0.08
11.70
0.24
0.37
0.25
0.25

SEQID-00886
0.04
0.05
0.01
0.00
0.04
0.01
0.02
0.05
−30.02
0.32
0.07
10.21
0.21
0.28
0.21
1.00

SEQID-00887
0.01
0.06
0.03
0.00
0.03
0.02
0.02
0.07
−32.84
0.06
0.07
10.25
0.29
0.28
0.28
0.27

SEQID-00888
0.01
0.03
0.01
0.00
0.03
0.02
0.05
0.04
−44.55
0.23
−0.34
3.56
0.30
0.29
0.19
0.10

SEQID-00889
0.07
0.04
0.02
0.00
0.01
0.02
0.04
0.02
−33.51
0.19
−0.10
4.35
0.28
0.32
0.00
0.26

SEQID-00890
0.04
0.02
0.01
0.00
0.02
0.01
0.04
0.04
−35.96
0.10
−0.02
5.48
0.27
0.35
0.20
0.25

SEQID-00891
0.07
0.02
0.00
0.00
0.01
0.01
0.01
0.03
−33.58
0.07
−0.04
5.39
0.28
0.33
0.25
0.25

SEQID-00892
0.04
0.05
0.03
0.00
0.05
0.02
0.03
0.03
−29.13
0.16
0.07
10.36
0.29
0.28
0.00
0.26

SEQID-00893
0.01
0.08
0.03
0.00
0.01
0.04
0.04
0.02
−34.20
0.12
0.07
9.83
0.30
0.26
0.28
0.28

SEQID-00894
0.03
0.04
0.01
0.04
0.04
0.01
0.03
0.04
−28.24
0.23
−0.02
5.45
0.18
0.56
0.18
0.18

SEQID-00895
0.03
0.04
0.01
0.03
0.05
0.01
0.03
0.04
−28.12
0.24
−0.02
5.53
0.18
0.56
0.18
0.17

SEQID-00896
0.02
0.05
0.04
0.06
0.07
0.02
0.04
0.08
−21.96
0.34
−0.02
5.52
0.00
0.34
0.00
0.00

SEQID-00897
0.03
0.04
0.01
0.04
0.04
0.01
0.03
0.04
−28.40
0.22
−0.02
5.45
0.19
0.53
0.18
0.18

SEQID-00898
0.05
0.04
0.04
0.05
0.06
0.02
0.06
0.05
−19.69
0.41
−0.03
5.05
0.19
0.30
0.00
0.20

SEQID-00899
0.05
0.05
0.04
0.05
0.06
0.02
0.06
0.05
−19.52
0.43
−0.03
5.16
0.21
0.31
0.00
0.22

SEQID-00900
0.03
0.04
0.01
0.04
0.04
0.01
0.03
0.04
−27.76
0.23
−0.02
5.43
0.19
0.54
0.18
0.18

SEQID-00901
0.03
0.06
0.04
0.04
0.04
0.02
0.03
0.06
−23.59
0.31
0.00
7.14
0.42
0.64
0.00
0.19

SEQID-00902
0.03
0.06
0.03
0.03
0.04
0.02
0.06
0.06
−22.21
0.34
0.00
7.11
0.19
0.33
0.00
0.20

SEQID-00903
0.03
0.04
0.03
0.03
0.04
0.03
0.04
0.03
−24.33
0.29
−0.03
5.13
0.20
0.30
0.00
0.20

SEQID-00904
0.03
0.04
0.03
0.03
0.04
0.03
0.03
0.04
−23.52
0.31
−0.03
5.12
0.21
0.35
0.00
0.20

SEQID-00905
0.02
0.00
0.00
0.04
0.02
0.00
0.03
0.03
−36.76
0.12
−0.09
4.39
0.58
0.69
0.22
0.22

SEQID-00906
0.03
0.05
0.04
0.04
0.03
0.01
0.04
0.07
−20.67
0.42
0.01
7.85
0.85
0.99
0.20
0.22

SEQID-00907
0.02
0.04
0.06
0.04
0.06
0.03
0.05
0.07
−23.89
0.29
−0.01
5.48
0.19
0.35
0.19
0.20

SEQID-00908
0.03
0.00
0.00
0.03
0.02
0.00
0.03
0.03
−37.05
0.12
−0.10
4.35
0.56
0.68
0.21
0.19

SEQID-00909
0.04
0.06
0.03
0.04
0.06
0.02
0.04
0.09
−17.81
0.47
0.02
8.58
0.69
0.85
0.00
0.22

SEQID-00910
0.03
0.03
0.03
0.05
0.03
0.03
0.03
0.09
−18.50
0.56
0.01
8.14
0.23
0.32
0.00
0.21

SEQID-00911
0.02
0.05
0.04
0.06
0.05
0.03
0.05
0.08
−22.55
0.33
−0.01
6.39
0.18
0.34
0.19
0.20

SEQID-00912
0.04
0.06
0.06
0.03
0.03
0.00
0.02
0.05
−22.92
0.34
−0.04
4.67
0.32
0.46
0.00
0.24

SEQID-00913
0.01
0.06
0.04
0.04
0.05
0.01
0.05
0.05
−25.08
0.34
−0.02
6.09
1.00
1.00
0.20
0.21

SEQID-00914
0.04
0.05
0.04
0.04
0.06
0.02
0.03
0.03
−19.09
0.62
−0.02
4.93
0.18
0.35
0.19
0.20

SEQID-00915
0.04
0.04
0.04
0.04
0.05
0.01
0.03
0.08
−20.80
0.45
0.01
7.95
0.21
0.31
0.00
0.21

SEQID-00916
0.02
0.07
0.04
0.05
0.05
0.01
0.05
0.06
−18.96
0.48
0.00
6.80
0.21
0.31
0.00
0.22

SEQID-00917
0.01
0.07
0.03
0.04
0.05
0.02
0.07
0.06
−21.16
0.25
0.07
8.51
0.21
0.31
0.23
0.23

SEQID-00918
0.01
0.05
0.07
0.06
0.04
0.05
0.06
0.04
−20.38
0.30
0.01
7.96
0.22
0.31
0.00
0.22

SEQID-00919
0.04
0.05
0.03
0.05
0.06
0.02
0.03
0.07
−19.53
0.46
0.01
8.37
0.20
0.34
0.00
0.20

SEQID-00920
0.03
0.02
0.03
0.05
0.05
0.02
0.09
0.05
−25.14
0.21
0.04
9.57
0.00
0.34
0.00
0.00

SEQID-00921
0.03
0.07
0.04
0.05
0.06
0.04
0.03
0.05
−18.81
0.42
0.01
7.80
0.20
0.35
0.00
0.21

SEQID-00922
0.04
0.01
0.03
0.04
0.03
0.02
0.02
0.05
−31.38
0.24
−0.08
10.51
0.25
0.34
0.00
0.20

SEQID-00923
0.02
0.05
0.06
0.04
0.06
0.02
0.04
0.09
−23.98
0.32
0.00
6.83
0.19
0.36
0.19
0.20

SEQID-00924
0.02
0.05
0.07
0.05
0.07
0.01
0.04
0.09
−18.81
0.32
−0.02
5.87
0.00
0.39
0.16
0.22

SEQID-00925
0.04
0.01
0.00
0.02
0.03
0.01
0.02
0.04
−33.82
0.22
−0.05
4.71
0.49
0.68
0.23
0.00

SEQID-00926
0.04
0.05
0.04
0.05
0.04
0.02
0.02
0.09
−20.25
0.45
0.01
3.46
0.23
0.33
0.21
0.23

SEQID-00927
0.05
0.09
0.03
0.03
0.05
0.01
0.02
0.05
−25.17
0.31
−0.04
4.62
0.39
0.58
0.23
0.00

SEQID-00928
0.06
0.02
0.03
0.04
0.03
0.01
0.01
0.03
−32.56
0.15
0.04
9.50
0.25
0.34
0.23
0.21

SEQID-00929
0.01
0.04
0.04
0.04
0.05
0.03
0.02
0.09
−19.07
0.45
0.00
6.93
0.64
0.83
0.20
0.23

SEQID-00930
0.01
0.10
0.08
0.07
0.04
0.02
0.02
0.05
−23.31
0.29
0.01
7.38
0.25
0.35
0.23
0.23

SEQID-00931
0.02
0.01
0.04
0.02
0.02
0.01
0.03
0.03
−33.39
0.06
−0.01
6.23
0.23
0.36
0.23
0.25

SEQID-00932
0.02
0.05
0.05
0.04
0.05
0.02
0.04
0.06
−22.04
0.35
0.01
8.31
0.38
0.56
0.21
0.21

SEQID-00933
0.02
0.04
0.02
0.06
0.05
0.00
0.04
0.05
−25.40
0.19
−0.03
4.94
0.30
0.45
0.20
0.22

SEQID-00934
0.04
0.06
0.04
0.05
0.06
0.03
0.03
0.08
−18.24
0.65
−0.02
4.99
0.19
0.35
0.19
0.19

SEQID-00935
0.03
0.04
0.05
0.04
0.06
0.00
0.04
0.08
−17.76
0.53
−0.03
4.92
0.22
0.36
0.23
0.22

SEQID-00936
0.04
0.03
0.04
0.03
0.05
0.05
0.03
0.04
−23.52
0.27
0.03
9.32
0.22
0.28
0.21
0.00

SEQID-00937
0.02
0.05
0.05
0.05
0.04
0.03
0.06
0.06
−19.26
0.33
0.00
6.76
0.18
0.35
0.18
0.19

SEQID-00938
0.03
0.06
0.04
0.04
0.06
0.03
0.05
0.06
−20.58
0.35
0.02
8.95
0.21
0.31
0.00
0.21

SEQID-00939
0.02
0.04
0.03
0.06
0.04
0.00
0.04
0.07
−19.40
0.45
0.02
9.64
0.21
0.33
0.00
0.22

SEQID-00940
0.01
0.06
0.06
0.06
0.05
0.00
0.03
0.08
−18.74
0.44
0.00
6.43
0.00
0.55
0.17
0.56

SEQID-00941
0.05
0.07
0.03
0.02
0.05
0.00
0.02
0.04
−24.70
0.26
−0.04
4.72
0.30
0.48
0.19
0.23

SEQID-00942
0.03
0.05
0.09
0.04
0.02
0.00
0.03
0.08
−23.23
0.35
−0.02
5.20
0.28
0.42
0.00
0.24

SEQID-00943
0.02
0.05
0.04
0.07
0.05
0.03
0.06
0.07
−21.97
0.31
−0.01
6.50
0.18
0.34
0.19
0.19

SEQID-00944
0.05
0.11
0.04
0.01
0.05
0.00
0.03
0.04
−25.95
0.30
−0.05
4.56
0.40
0.58
0.00
0.00

SEQID-00945
0.04
0.03
0.03
0.04
0.07
0.00
0.05
0.08
−24.69
0.33
0.01
8.63
0.00
0.33
0.00
0.23

SEQID-00946
0.01
0.05
0.08
0.07
0.05
0.05
0.04
0.05
−19.88
0.23
−0.01
6.36
0.21
0.32
0.22
0.25

SEQID-00947
0.03
0.06
0.03
0.03
0.05
0.01
0.02
0.09
−17.51
0.57
0.00
6.89
0.20
0.31
0.00
0.20

SEQID-00948
0.03
0.05
0.06
0.05
0.07
0.00
0.02
0.08
−16.36
0.55
0.02
8.73
0.51
0.69
0.22
0.21

SEQID-00949
0.02
0.05
0.03
0.04
0.06
0.01
0.03
0.06
−22.43
0.35
−0.01
5.66
0.71
0.90
0.00
0.21

SEQID-00950
0.02
0.09
0.02
0.03
0.04
0.02
0.02
0.11
−19.79
0.53
0.01
7.77
0.28
0.30
0.24
0.25

SEQID-00951
0.03
0.06
0.04
0.05
0.04
0.03
0.05
0.06
−18.10
0.43
0.03
9.45
0.22
0.31
0.00
0.21

SEQID-00952
0.02
0.05
0.04
0.05
0.03
0.03
0.05
0.07
−22.51
0.46
−0.03
4.87
0.20
0.33
0.19
0.20

SEQID-00953
0.01
0.04
0.07
0.07
0.03
0.01
0.03
0.04
−23.78
0.26
−0.09
4.20
0.22
0.42
0.20
0.23

SEQID-00954
0.02
0.03
0.03
0.04
0.04
0.01
0.03
0.05
−25.81
0.25
−0.01
5.77
0.00
0.41
0.00
0.18

SEQID-00955
0.02
0.07
0.04
0.07
0.05
0.01
0.03
0.08
−17.08
0.44
0.02
8.94
0.25
0.34
0.26
0.27

SEQID-00956
0.04
0.05
0.06
0.09
0.04
0.01
0.05
0.03
−17.66
0.20
0.02
9.66
0.24
0.41
0.26
0.25

SEQID-00957
0.04
0.02
0.03
0.06
0.04
0.03
0.03
0.10
−18.85
0.58
−0.01
6.40
0.24
0.32
0.00
0.00

SEQID-00958
0.02
0.07
0.05
0.05
0.05
0.04
0.04
0.06
−18.60
0.41
0.00
7.56
0.23
0.34
0.19
0.20

SEQID-00959
0.03
0.05
0.04
0.04
0.07
0.31
0.03
0.06
−22.45
0.34
−0.02
5.16
0.73
0.93
0.00
0.22

SEQID-00960
0.01
0.04
0.12
0.06
0.02
0.01
0.04
0.08
−16.72
0.46
−0.01
6.39
0.25
0.32
0.25
0.26

SEQID-00961
0.03
0.03
0.03
0.02
0.01
0.01
0.02
0.03
−37.46
0.14
0.01
6.56
0.25
0.35
0.22
0.21

SEQID-00962
0.02
0.05
0.06
0.09
0.04
0.01
0.04
0.06
−19.01
0.20
0.02
9.32
0.21
0.35
0.19
0.24

SEQID-00963
0.05
0.08
0.05
0.04
0.04
0.02
0.08
0.05
−20.90
0.32
0.01
7.78
0.20
0.30
0.20
0.21

SEQID-00964
0.02
0.05
0.11
0.09
0.06
0.01
0.06
0.04
−15.14
0.27
0.01
7.95
0.20
0.45
0.20
0.21

SEQID-00965
0.04
0.08
0.05
0.03
0.02
0.03
0.07
0.03
−23.11
0.36
0.00
7.49
0.52
0.68
0.21
0.23

SEQID-00966
0.03
0.09
0.02
0.04
0.04
0.03
0.06
0.07
−16.84
0.56
0.07
10.36
0.21
0.34
0.00
0.00

SEQID-00967
0.03
0.04
0.03
0.05
0.04
0.02
0.03
0.08
−20.61
0.55
0.00
6.53
0.25
0.34
0.17
0.00

SEQID-00968
0.03
0.02
0.01
0.06
0.04
0.01
0.08
0.05
−25.41
0.27
−0.06
4.52
0.25
0.34
0.00
0.00

SEQID-00969
0.01
0.07
0.02
0.05
0.10
0.02
0.06
0.04
−18.46
0.31
0.01
8.89
0.21
0.31
0.00
0.00

SEQID-00970
0.03
0.06
0.04
0.04
0.05
0.01
0.06
0.06
−20.02
0.37
−0.05
4.69
0.94
1.00
0.20
0.22

SEQID-00971
0.02
0.05
0.08
0.04
0.04
0.01
0.04
0.06
−20.64
0.33
−0.02
5.02
0.27
0.56
0.21
0.33

SEQID-00972
0.03
0.04
0.04
0.03
0.07
0.00
0.03
0.04
−24.05
0.30
0.15
11.71
0.24
0.30
0.22
0.00

SEQID-00973
0.03
0.02
0.04
0.05
0.04
0.00
0.02
0.10
−21.20
0.60
0.00
7.44
0.20
0.33
0.00
0.23

SEQID-00974
0.03
0.06
0.07
0.03
0.06
0.02
0.03
0.05
−22.31
0.45
−0.01
6.30
0.50
0.56
0.00
0.00

SEQID-00975
0.04
0.03
0.02
0.04
0.03
0.01
0.07
0.04
−26.62
0.33
−0.07
4.36
0.24
0.32
0.00
0.00

SEQID-00976
0.01
0.04
0.05
0.05
0.05
0.03
0.04
0.06
−20.20
0.42
0.05
9.78
0.20
0.34
0.00
0.21

SEQID-00977
0.02
0.04
0.03
0.06
0.05
0.02
0.05
0.06
−18.41
0.38
−0.01
5.34
0.21
0.31
0.18
0.22

SEQID-00978
0.01
0.05
0.07
0.04
0.03
0.03
0.02
0.06
−20.46
0.43
0.00
7.02
0.21
0.33
0.21
0.24

SEQID-00979
0.02
0.03
0.01
0.02
0.06
0.00
0.06
0.08
−23.82
0.30
0.18
11.91
0.19
0.28
0.00
0.28

SEQID-00980
0.09
0.09
0.01
0.03
0.06
0.00
0.01
0.04
−29.38
0.32
−0.16
3.85
0.39
0.45
0.00
0.25

SEQID-00981
0.02
0.01
0.03
0.04
0.03
0.00
0.03
0.06
−21.47
0.40
0.14
11.55
0.24
0.33
0.00
0.24

SEQID-00982
0.03
0.02
0.04
0.09
0.06
0.00
0.06
0.06
−23.96
0.22
0.15
11.00
0.25
0.30
0.22
0.22

SEQID-00983
0.02
0.10
0.05
0.05
0.04
0.02
0.04
0.05
−20.43
0.40
0.02
8.61
0.28
0.36
0.23
0.24

SEQID-00984
0.05
0.03
0.04
0.08
0.06
0.00
0.03
0.09
−18.31
0.47
0.07
10.55
0.00
0.31
0.00
0.24

SEQID-00985
0.03
0.04
0.05
0.04
0.02
0.02
0.08
0.05
−17.45
0.42
0.00
7.44
0.30
0.39
0.00
0.23

SEQID-00986
0.03
0.07
0.04
0.03
0.03
0.03
0.06
0.04
−23.98
0.30
−0.06
4.53
0.22
0.32
0.00
0.22

SEQID-00987
0.03
0.03
0.06
0.07
0.07
0.02
0.02
0.05
−21.44
0.23
0.06
10.42
0.23
0.32
0.00
0.24

SEQID-00988
0.03
0.04
0.06
0.09
0.04
0.01
0.04
0.10
−18.81
0.50
0.03
9.15
0.21
0.31
0.00
0.00

SEQID-00989
0.01
0.08
0.05
0.07
0.05
0.02
0.06
0.03
−18.71
0.25
−0.02
5.97
0.22
0.31
0.23
0.24

SEQID-00990
0.02
0.05
0.08
0.05
0.04
0.01
0.04
0.06
−18.94
0.32
0.01
8.02
0.21
0.35
0.00
0.21

SEQID-00991
0.03
0.03
0.02
0.06
0.05
0.00
0.08
0.05
−25.41
0.34
0.00
7.39
0.21
0.32
0.00
0.00

SEQID-00992
0.02
0.05
0.04
0.07
0.04
0.00
0.05
0.07
−15.67
0.41
0.02
9.07
0.21
0.34
0.00
0.23

SEQID-00993
0.03
0.05
0.08
0.05
0.06
0.00
0.02
0.09
−18.97
0.44
0.02
9.36
0.20
0.36
0.20
0.21

SEQID-00994
0.03
0.04
0.05
0.05
0.05
0.02
0.04
0.08
−20.80
0.41
0.03
9.50
0.22
0.34
0.00
0.22

SEQID-00995
0.04
0.04
0.04
0.06
0.05
0.03
0.06
0.06
−17.23
0.44
0.01
8.29
0.21
0.33
0.22
0.22

SEQID-00996
0.03
0.04
0.10
0.05
0.06
0.02
0.02
0.07
−17.11
0.45
0.01
8.25
0.21
0.36
0.22
0.22

SEQID-00997
0.04
0.05
0.02
0.05
0.05
0.00
0.05
0.03
−25.20
0.37
−0.02
5.65
0.19
0.34
0.00
0.20

SEQID-00998
0.02
0.04
0.05
0.04
0.05
0.02
0.04
0.05
−19.46
0.39
0.01
7.90
0.20
0.32
0.00
0.21

SEQID-00999
0.03
0.04
0.02
0.04
0.05
0.01
0.05
0.04
−28.98
0.30
−0.05
4.64
0.65
0.86
0.00
0.20

SEQID-01000
0.02
0.05
0.05
0.05
0.05
0.03
0.04
0.06
−23.33
0.29
−0.01
5.62
0.19
0.33
0.20
0.20

SEQID-01001
0.02
0.05
0.03
0.05
0.05
0.02
0.04
0.07
−21.41
0.40
0.00
7.13
1.00
1.00
0.00
0.21

SEQID-01002
0.02
0.05
0.03
0.06
0.05
0.03
0.04
0.07
−21.00
0.42
0.00
7.04
0.93
1.00
0.00
0.21

SEQID-01003
0.02
0.05
0.05
0.06
0.06
0.02
0.05
0.06
−18.58
0.39
−0.02
5.31
0.16
0.35
0.18
0.19

SEQID-01004
0.06
0.08
0.03
0.07
0.07
0.02
0.05
0.05
−19.09
0.45
−0.03
4.97
0.57
0.74
0.00
0.45

SEQID-01005
0.02
0.04
0.02
0.06
0.04
0.07
0.03
0.04
−15.97
0.54
0.06
9.25
1.00
1.00
0.00
0.25

SEQID-01006
0.02
0.07
0.03
0.05
0.06
0.00
0.04
0.03
−20.07
0.51
−0.05
4.51
1.00
1.00
0.24
1.00

SEQID-01007
0.01
0.03
0.04
0.05
0.07
0.00
0.06
0.06
−20.24
0.39
−0.0
6.57
0.22
0.59
0.21
1.00

SEQID-01008
0.03
0.06
0.04
0.06
0.06
0.02
0.06
0.07
−17.92
0.49
−0.0
5.89
0.18
0.34
0.18
0.99

SEQID-01009
0.03
0.07
0.05
0.07
0.03
0.02
0.06
0.08
−15.59
0.51
0.01
7.60
0.19
0.32
0.00
0.48

SEQID-01010
0.06
0.07
0.04
0.06
0.07
0.02
0.03
0.05
−19.62
0.48
−0.0
4.66
0.64
0.78
0.21
0.46

SEQID-01011
0.05
0.05
0.03
0.07
0.06
0.02
0.04
0.05
−19.80
0.44
0.01
8.46
0.59
0.71
0.00
0.44

SEQID-01012
0.03
0.07
0.04
0.05
0.05
0.02
0.01
0.05
−23.91
0.24
−0.03
5.29
0.22
0.33
0.00
0.21

SEQID-01013
0.02
0.03
0.08
0.06
0.05
0.03
0.02
0.10
−14.17
0.62
−0.01
6.50
0.22
0.33
0.00
0.23

SEQID-01014
0.01
0.07
0.02
0.06
0.06
0.00
0.00
0.06
−22.97
0.30
−0.06
5.19
0.27
0.30
0.25
0.25

SEQID-01015
0.04
0.04
0.07
0.07
0.06
0.01
0.02
0.09
−14.50
0.66
−0.02
5.76
0.22
0.33
0.00
0.24

SEQID-01016
0.03
0.08
0.04
0.06
0.06
0.02
0.06
0.07
−16.56
0.51
0.01
8.22
0.20
0.34
0.00
0.41

SEQID-01017
0.03
0.04
0.04
0.07
0.07
0.02
0.08
0.05
−17.85
0.37
−0.01
6.00
0.19
0.33
0.19
0.20

SEQID-01018
0.02
0.06
0.02
0.06
0.13
0.04
0.01
0.05
−16.16
0.52
0.04
10.35
0.23
0.32
0.00
0.24

SEQID-01019
0.04
0.04
0.03
0.10
0.04
0.04
0.05
0.02
−21.68
0.27
−0.04
4.91
0.21
0.31
0.22
0.21

SEQID-01020
0.05
0.04
0.02
0.06
0.07
0.02
0.06
0.07
−23.98
0.52
−0.01
5.41
0.28
0.31
0.00
0.28

SEQID-01021
0.03
0.05
0.03
0.06
0.05
0.03
0.06
0.06
−16.96
0.39
−0.01
6.29
0.38
0.59
0.00
0.20

SEQID-01022
0.04
0.06
0.04
0.07
0.06
0.08
0.11
0.04
−10.42
0.83
0.11
9.33
0.31
0.25
0.36
0.29

SEQID-01023
0.02
0.07
0.06
0.02
0.02
0.02
0.07
0.08
−17.26
0.50
0.02
8.56
0.21
0.31
0.00
0.24

SEQID-01024
0.03
0.03
0.03
0.07
0.03
0.01
0.05
0.08
−18.61
0.64
0.01
7.82
0.24
0.30
0.24
1.00

SEQID-01025
0.01
0.09
0.03
0.06
0.06
0.06
0.03
0.06
−17.18
0.51
0.03
8.58
0.26
0.30
0.00
0.23

SEQID-01026
0.02
0.05
0.10
0.06
0.08
0.01
0.07
0.06
−14.96
0.42
0.00
6.78
0.98
1.00
0.00
0.24

SEQID-01027
0.03
0.05
0.04
0.06
0.06
0.01
0.08
0.06
−22.58
0.29
0.02
8.69
1.00
1.00
0.18
0.00

SEQID-01028
0.03
0.03
0.04
0.03
0.05
0.02
0.03
0.05
−20.98
0.57
−0.04
4.66
0.99
1.00
0.00
0.24

SEQID-01029
0.01
0.05
0.04
0.05
0.05
0.03
0.04
0.06
−19.81
0.44
0.02
8.38
1.00
1.00
0.00
0.21

SEQID-01030
0.03
0.07
0.05
0.05
0.06
0.01
0.04
0.06
−18.85
0.43
0.01
7.72
0.19
0.33
0.19
0.20

SEQID-01031
0.02
0.04
0.04
0.05
0.06
0.02
0.05
0.08
−21.17
0.42
0.00
6.82
0.18
0.32
0.19
0.24

SEQID-01032
0.02
0.07
0.04
0.05
0.06
0.04
0.05
0.04
−15.64
0.38
0.00
7.17
0.21
0.31
0.35
0.21

SEQID-01033
0.03
0.06
0.06
0.06
0.03
0.04
0.03
0.07
−21.14
0.51
−0.03
4.35
0.20
0.35
0.20
0.22

SEQID-01034
0.01
0.05
0.05
0.07
0.06
0.03
0.05
0.09
−19.28
0.39
0.00
7.29
0.20
0.37
0.00
0.21

SEQID-01035
0.02
0.06
0.05
0.05
0.06
0.04
0.03
0.05
−19.30
0.37
0.02
8.68
0.20
0.33
0.00
0.21

SEQID-01036
0.02
0.03
0.04
0.09
0.07
0.00
0.01
0.03
−22.27
0.41
−0.01
6.68
0.20
0.33
0.23
0.22

SEQID-01037
0.03
0.02
0.03
0.07
0.06
0.01
0.04
0.07
−19.70
0.36
−0.01
6.13
0.20
0.38
0.00
0.22

SEQID-01038
0.02
0.06
0.04
0.07
0.05
0.03
0.06
0.07
−19.11
0.39
0.02
8.68
0.21
0.45
0.00
0.22

SEQID-01039
0.02
0.05
0.04
0.06
0.06
0.03
0.05
0.06
−17.74
0.44
−0.05
4.44
0.21
0.32
0.20
0.22

SEQID-01040
0.02
0.05
0.04
0.05
0.05
0.02
0.05
0.05
−21.57
0.37
0.00
7.08
0.59
0.71
0.21
0.21

SEQID-01041
0.01
0.03
0.05
0.16
0.10
0.04
0.06
0.07
−12.63
0.44
0.00
7.74
0.18
0.31
0.22
0.23

SEQID-01042
0.01
0.07
0.06
0.11
0.07
0.04
0.03
0.10
−16.09
0.53
−0.03
4.64
0.22
0.34
0.00
0.21

SEQID-01043
0.01
0.06
0.07
0.11
0.07
0.03
0.04
0.09
−16.92
0.42
−0.02
5.16
0.22
0.35
0.19
0.23

SEQID-01044
0.02
0.05
0.06
0.06
0.04
0.04
0.08
0.05
−20.43
0.34
−0.04
4.39
0.21
0.33
0.20
0.21

SEQID-01045
0.02
0.08
0.05
0.05
0.06
0.02
0.06
0.07
−17.05
0.58
0.01
8.22
0.22
0.33
0.00
0.21

SEQID-01046
0.03
0.04
0.05
0.03
0.03
0.01
0.02
0.04
−28.00
0.22
−0.05
4.87
0.23
0.35
0.00
0.23

SEQID-01047
0.02
0.06
0.06
0.06
0.02
0.02
0.06
0.04
−20.51
0.34
0.05
9.68
0.21
0.36
0.21
0.22

SEQID-01048
0.01
0.02
0.06
0.11
0.10
0.03
0.05
0.06
−15.19
0.47
−0.01
5.69
0.21
0.32
0.00
0.22

SEQID-01049
0.02
0.04
0.06
0.09
0.09
0.03
0.05
0.10
−17.98
0.41
0.01
7.92
0.20
0.31
0.00
0.23

SEQID-01050
0.02
0.05
0.02
0.06
0.06
0.04
0.08
0.04
−20.06
0.27
−0.02
5.45
0.21
0.31
0.29
0.21

SEQID-01051
0.00
0.04
0.04
0.16
0.07
0.02
0.06
0.06
−11.96
0.30
0.01
8.20
0.22
0.31
0.27
0.28

SEQID-01052
0.02
0.07
0.05
0.06
0.05
0.05
0.07
0.06
−15.49
0.41
0.02
8.00
0.25
0.39
0.52
0.32

SEQID-01053
0.03
0.08
0.03
0.07
0.06
0.01
0.05
0.06
−15.78
0.68
0.02
8.87
0.19
0.31
0.20
0.20

SEQID-01054
0.03
0.05
0.05
0.06
0.05
0.02
0.03
0.06
−16.22
0.48
−0.01
6.42
0.17
0.35
0.17
0.19

SEQID-01055
0.01
0.05
0.09
0.13
0.07
0.03
0.01
0.08
−10.74
0.51
−0.01
6.21
0.22
0.31
0.20
0.24

SEQID-01056
0.02
0.07
0.04
0.07
0.07
0.03
0.02
0.08
−14.33
0.87
0.00
7.51
0.20
0.33
0.00
0.20

SEQID-01057
0.01
0.02
0.05
0.14
0.09
0.02
0.09
0.05
−12.66
0.22
0.01
8.03
0.24
0.34
0.29
0.23

SEQID-01058
0.04
0.06
0.01
0.04
0.12
0.03
0.02
0.10
−21.36
0.43
0.00
7.51
0.43
0.53
0.20
0.20

SEQID-01059
0.02
0.06
0.03
0.05
0.05
0.02
0.06
0.04
−22.85
0.50
−0.02
5.69
0.28
0.32
0.23
0.22

SEQID-01060
0.03
0.04
0.05
0.07
0.07
0.02
0.02
0.05
−21.90
0.38
0.04
9.19
0.21
0.29
0.00
0.00

SEQID-01061
0.02
0.04
0.06
0.05
0.04
0.09
0.05
0.03
−19.03
0.26
0.02
7.89
0.21
0.31
0.20
0.24

SEQID-01062
0.01
0.07
0.03
0.05
0.06
0.01
0.04
0.06
−19.76
0.52
−0.02
5.84
0.27
0.39
0.00
1.00

SEQID-01063
0.04
0.05
0.03
0.04
0.05
0.03
0.06
0.05
−21.17
0.34
−0.01
6.52
0.21
0.32
0.00
0.20

SEQID-01064
0.02
0.03
0.06
0.05
0.05
0.04
0.07
0.08
−19.14
0.35
0.03
8.38
0.22
0.43
0.21
0.26

SEQID-01065
0.02
0.08
0.05
0.07
0.04
0.04
0.03
0.06
−17.13
0.43
0.03
9.49
0.20
0.33
0.00
0.21

SEQID-01066
0.02
0.07
0.04
0.04
0.07
0.00
0.07
0.08
−14.90
0.75
0.02
8.31
0.35
0.39
0.26
0.26

SEQID-01067
0.01
0.05
0.06
0.07
0.01
0.03
0.07
0.05
−21.01
0.41
0.02
8.22
0.28
0.30
0.25
0.26

SEQID-01068
0.02
0.03
0.06
0.13
0.07
0.05
0.02
0.10
−12.39
0.59
0.02
8.90
0.29
0.33
0.24
0.26

SEQID-01069
0.03
0.06
0.06
0.04
0.04
0.00
0.06
0.05
−21.65
0.52
0.05
9.04
0.24
0.31
0.23
0.25

SEQID-01070
0.03
0.02
0.04
0.06
0.07
0.01
0.05
0.08
−22.47
0.46
−0.03
4.82
0.22
0.29
0.00
0.26

SEQID-01071
0.02
0.01
0.05
0.05
0.03
0.05
0.09
0.07
−14.44
0.45
0.06
9.70
0.00
0.29
0.00
0.24

SEQID-01072
0.04
0.10
0.03
0.04
0.04
0.02
0.04
0.06
−16.09
1.02
0.00
6.72
0.22
0.30
0.00
0.20

SEQID-01073
0.03
0.05
0.08
0.06
0.03
0.01
0.07
0.06
−16.32
0.42
0.04
9.51
0.21
0.32
0.00
0.21

SEQID-01074
0.03
0.02
0.05
0.05
0.06
0.05
0.07
0.05
−22.62
0.18
0.01
8.31
0.21
0.33
0.19
0.22

SEQID-01075
0.02
0.08
0.05
0.06
0.05
0.01
0.04
0.07
−16.97
0.49
0.00
7.11
0.21
0.33
0.00
0.22

SEQID-01076
0.01
0.03
0.13
0.17
0.11
0.01
0.04
0.04
−9.51
0.35
0.00
7.31
0.22
0.33
0.23
0.22

SEQID-01077
0.02
0.06
0.05
0.05
0.04
0.01
0.03
0.04
−19.53
0.40
−0.01
6.14
1.00
1.00
0.20
0.22

SEQID-01078
0.01
0.06
0.06
0.06
0.02
0.01
0.03
0.04
−26.15
0.38
−0.03
4.84
1.00
1.00
0.19
0.20

SEQID-01079
0.01
0.06
0.05
0.06
0.02
0.01
0.03
0.04
−26.21
0.36
−0.03
5.48
0.96
1.00
0.00
0.20

SEQID-01080
0.01
0.04
0.06
0.06
0.03
0.02
0.04
0.05
−23.03
0.33
−0.04
4.95
1.00
1.00
0.00
0.20

SEQID-01081
0.01
0.05
0.06
0.06
0.04
0.01
0.04
0.06
−20.74
0.36
−0.03
5.47
1.00
1.00
0.00
0.21

SEQID-01082
0.01
0.08
0.05
0.05
0.03
0.01
0.03
0.05
−18.72
0.42
−0.01
5.78
1.00
1.00
0.19
0.22

SEQID-01083
0.01
0.05
0.06
0.06
0.04
0.01
0.04
0.06
−20.28
0.34
−0.02
5.75
1.00
1.00
0.00
0.22

SEQID-01084
0.02
0.09
0.04
0.06
0.04
0.01
0.02
0.05
−24.13
0.42
−0.01
6.47
0.45
0.63
0.00
0.21

SEQID-01085
0.02
0.06
0.05
0.05
0.05
0.03
0.05
0.05
−20.29
0.39
−0.01
6.55
0.20
0.33
0.00
0.21

SEQID-01086
0.02
0.09
0.04
0.06
0.04
0.01
0.02
0.05
−24.06
0.41
0.00
6.87
0.44
0.63
0.00
0.21

SEQID-01087
0.02
0.08
0.04
0.06
0.05
0.01
0.02
0.05
−23.27
0.45
−0.01
6.57
0.46
0.66
0.18
021

SEQID-01088
0.02
0.05
0.05
0.05
0.05
0.02
0.06
0.06
−19.35
0.40
0.00
6.73
0.20
0.34
0.00
0.21

SEQID-01089
0.02
0.07
0.05
0.04
0.07
0.02
0.03
0.08
−18.23
0.50
0.01
8.02
0.25
0.34
0.00
0.21

SEQID-01090
0.02
0.09
0.04
0.06
0.04
0.02
0.03
0.06
−20.83
0.56
−0.03
4.72
1.00
1.00
0.25
1.00

SEQID-01091
0.02
0.05
0.05
0.06
0.05
0.03
0.06
0.05
−19.29
0.37
−0.01
6.35
0.20
0.35
0.00
0.21

SEQID-01092
0.02
0.06
0.03
0.05
0.06
0.03
0.04
0.09
−20.78
0.50
0.00
7.27
0.84
0.94
0.00
0.21

SEQID-01093
0.02
0.04
0.05
0.03
0.05
0.02
0.05
0.07
−20.34
0.33
−0.01
6.76
0.22
0.31
0.00
0.21

SEQID-01094
0.02
0.06
0.03
0.05
0.06
0.03
0.04
0.11
−20.35
0.49
0.00
7.61
0.86
0.96
0.20
0.20

SEQID-01095
0.02
0.08
0.03
0.07
0.06
0.02
0.05
0.09
−16.22
0.57
0.01
7.36
0.67
0.94
0.19
0.21

SEQID-01096
0.02
0.06
0.03
0.05
0.06
0.03
0.04
0.10
−20.79
0.50
0.00
7.27
0.84
0.94
0.00
0.21

SEQID-01097
0.01
0.08
0.04
0.06
0.02
0.00
0.04
0.05
−21.37
0.48
−0.01
6.14
1.00
1.00
0.21
0.22

SEQID-01098
0.02
0.04
0.04
0.03
0.05
0.02
0.05
0.07
−19.99
0.38
−0.01
6.76
0.21
0.31
0.00
0.20

SEQID-01099
0.01
0.04
0.05
0.04
0.10
0.01
0.03
0.09
−15.86
0.67
0.02
9.38
0.23
0.76
0.00
0.24

SEQID-01100
0.01
0.04
0.05
0.04
0.10
0.01
0.03
0.09
−16.06
0.72
0.02
9.38
0.47
0.71
0.00
0.21

SEQID-01101
0.01
0.07
0.05
0.05
0.02
0.00
0.03
0.04
−27.12
0.37
−0.01
6.26
0.60
0.86
0.19
0.20

SEQID-01102
0.01
0.03
0.04
0.06
0.05
0.01
0.05
0.08
−17.38
0.42
0.01
7.63
0.21
0.32
0.00
0.22

SEQID-01103
0.03
0.07
0.06
0.07
0.07
0.01
0.02
0.07
−11.30
0.50
0.02
8.38
0.22
0.34
0.20
0.22

SEQID-01104
0.03
0.07
0.05
0.05
0.05
0.01
0.02
0.09
−18.02
0.50
−0.01
6.50
0.27
0.36
0.22
0.21

SEQID-01105
0.05
0.04
0.05
0.06
0.05
0.02
0.06
0.07
−19.68
0.46
−0.03
5.17
0.21
0.33
0.00
0.21

SEQID-01106
0.02
0.07
0.05
0.04
0.06
0.02
0.03
0.08
−19.23
0.47
0.00
6.76
0.24
0.33
0.00
0.21

SEQID-01107
0.03
0.07
0.06
0.07
0.06
0.01
0.02
0.06
−11.25
0.48
0.02
8.32
0.22
0.33
0.00
0.21

SEQID-01108
0.02
0.06
0.05
0.05
0.05
0.01
0.03
0.10
−17.31
0.52
−0.01
6.43
0.27
0.36
0.00
0.20

SEQID-01109
0.02
0.05
0.04
0.06
0.06
0.03
0.05
0.07
−19.81
0.42
−0.01
6.26
0.88
0.98
0.00
0.21

SEQID-01110
0.01
0.07
0.05
0.10
0.08
0.04
0.03
0.07
−15.10
0.55
−0.01
5.94
1.00
1.00
0.53
0.23

SEQID-01111
0.06
0.02
0.02
0.04
0.04
0.01
0.01
0.01
−29.45
0.31
−0.04
4.98
0.36
0.39
0.23
0.36

SEQID-01112
0.02
0.06
0.04
0.03
0.05
0.02
0.05
0.06
−21.45
0.41
−0.01
6.32
0.20
0.32
0.00
0.21

SEQID-01113
0.03
0.05
0.05
0.04
0.07
0.01
0.04
0.08
−22.27
0.40
0.03
9.56
0.22
0.35
0.20
0.22

SEQID-01114
0.01
0.11
0.05
0.06
0.03
0.01
0.04
0.07
−22.15
0.41
−0.04
4.82
0.21
0.58
0.20
0.22

SEQID-01115
0.05
0.04
0.05
0.05
0.06
0.02
0.06
0.06
−19.69
0.44
−0.03
5.16
0.20
0.33
0.00
0.21

SEQID-01116
0.02
0.04
0.03
0.04
0.05
0.02
0.05
0.09
−19.41
0.46
−0.01
5.37
0.91
0.98
0.20
0.22

SEQID-01117
0.04
0.05
0.05
0.04
0.04
0.01
0.07
0.03
−20.78
0.29
0.00
7.07
0.22
0.29
0.00
0.00

SEQID-01118
0.03
0.08
0.07
0.05
0.04
0.03
0.05
0.05
−21.32
0.34
−0.01
6.11
0.22
0.37
0.00
0.21

SEQID-01119
0.02
0.04
0.02
0.07
0.04
0.04
0.07
0.04
−20.86
0.36
−0.02
5.88
1.00
1.00
0.00
0.35

SEQID-01120
0.06
0.03
0.05
0.12
0.03
0.00
0.05
0.00
−23.90
0.31
−0.04
4.69
0.26
0.27
0.31
1.00

SEQID-01121
0.06
0.04
0.08
0.07
0.03
0.03
0.05
0.06
−20.07
0.32
−0.02
6.03
0.21
0.32
0.21
0.00

SEQID-01122
0.03
0.05
0.05
0.04
0.05
0.01
0.03
0.08
−16.87
0.43
0.00
6.85
0.25
0.34
0.24
0.00

SEQID-01123
0.02
0.05
0.04
0.08
0.06
0.02
0.02
0.07
−16.39
0.59
0.00
7.14
0.21
0.35
0.20
0.21

SEQID-01124
0.02
0.04
0.03
0.04
0.05
0.01
0.03
0.07
−25.16
0.41
−0.02
5.27
0.87
1.00
0.00
0.21

SEQID-01125
0.00
0.10
0.05
0.06
0.03
0.01
0.04
0.07
−21.91
0.46
−0.05
4.62
0.22
0.55
0.20
0.22

SEQID-01126
0.02
0.04
0.05
0.06
0.06
0.00
0.04
0.08
−18.33
0.49
−0.01
6.05
0.21
0.33
0.20
0.22

SEQID-01127
0.02
0.08
0.04
0.05
0.05
0.02
0.04
0.07
−18.52
0.64
−0.02
4.72
1.00
1.00
0.00
1.00

SEQID-01128
0.03
0.03
0.05
0.05
0.05
0.03
0.03
0.09
−16.77
0.56
−0.01
6.25
0.27
0.34
0.20
0.20

SEQID-01129
0.04
0.03
0.05
0.05
0.05
0.03
0.03
0.11
−15.32
0.61
0.00
7.46
0.27
0.34
0.00
0.23

SEQID-01130
0.02
0.04
0.05
0.08
0.04
0.01
0.02
0.09
−17.73
0.53
0.01
8.68
0.23
0.33
0.21
0.22

SEQID-01131
0.05
0.05
0.04
0.05
0.05
0.02
0.04
0.08
−21.19
0.38
−0.01
5.97
0.19
0.33
0.00
0.21

SEQID-01132
0.02
0.04
0.03
0.05
0.04
0.02
0.05
0.08
−19.78
0.43
−0.01
6.20
0.90
0.98
0.20
0.23

SEQID-01133
0.03
0.06
0.04
0.05
0.05
0.01
0.06
0.08
−19.26
0.41
−0.04
4.77
0.81
0.90
0.19
0.22

SEQID-01134
0.05
0.07
0.04
0.05
0.05
0.02
0.05
0.06
−19.53
0.34
−0.05
4.46
0.39
0.55
0.00
0.21

SEQID-01135
0.02
0.05
0.05
0.08
0.05
0.01
0.04
0.07
−16.45
0.48
0.01
8.66
0.21
0.34
0.22
0.22

SEQID-01136
0.03
0.04
0.08
0.03
0.05
0.04
0.03
0.05
−17.04
0.43
−0.03
4.88
0.21
0.31
0.20
0.22

SEQID-01137
0.02
0.04
0.04
0.05
0.05
0.00
0.05
0.07
−18.87
0.48
0.00
6.55
0.21
0.33
0.00
0.22

SEQID-01138
0.05
0.02
0.05
0.05
0.07
0.01
0.03
0.08
−19.52
0.52
0.01
7.63
0.22
0.34
0.00
0.22

SEQID-01139
0.03
0.06
0.02
0.05
0.04
0.01
0.04
0.05
−28.20
0.33
−0.05
4.66
0.67
0.83
0.00
0.20

SEQID-01140
0.03
0.05
0.05
0.04
0.06
0.01
0.03
0.06
−18.65
0.44
−0.02
5.97
0.19
0.32
0.00
0.21

SEQID-01141
0.01
0.01
0.02
0.04
0.16
0.00
0.11
0.03
−18.99
0.11
−0.01
6.80
0.26
0.37
0.23
0.24

SEQID-01142
0.03
0.05
0.03
0.04
0.05
0.01
0.03
0.07
−23.21
0.36
−0.02
5.12
0.71
0.91
0.00
0.20

SEQID-01143
0.03
0.04
0.04
0.04
0.04
0.01
0.04
0.10
−22.76
0.46
0.05
10.21
0.23
0.30
0.00
0.19

SEQID-01144
0.03
0.05
0.05
0.05
0.06
0.00
0.04
0.08
−16.78
0.51
0.00
6.97
0.20
0.33
0.20
0.21

SEQID-01145
0.01
0.05
0.03
0.04
0.05
0.05
0.03
0.13
−17.92
0.55
0.00
6.52
0.69
0.85
0.00
0.23

SEQID-01146
0.07
0.01
0.02
0.04
0.02
0.01
0.01
0.00
−26.27
0.38
−0.01
6.35
0.37
0.39
0.26
0.37

SEQID-01147
0.02
0.06
0.04
0.03
0.06
0.03
0.05
0.06
−20.17
0.37
−0.01
6.40
0.22
0.33
0.00
0.22

SEQID-01148
0.03
0.08
0.05
0.05
0.02
0.01
0.03
0.06
−22.38
0.28
0.13
11.03
0.24
0.29
0.19
0.21

SEQID-01149
0.01
0.06
0.04
0.07
0.09
0.01
0.11
0.06
−11.77
0.89
0.02
9.20
0.45
0.66
0.00
0.26

SEQID-01150
0.04
0.03
0.04
0.03
0.06
0.03
0.04
0.07
−19.34
0.53
−0.01
6.04
0.20
0.33
0.21
0.21

SEQID-01151
0.01
0.03
0.02
0.08
0.07
0.06
0.04
0.08
−18.83
0.44
0.01
7.81
0.21
0.30
0.00
0.00

SEQID-01152
0.01
0.07
0.05
0.07
0.04
0.03
0.07
0.05
−17.08
0.48
0.00
7.30
0.51
0.65
0.20
0.51

SEQID-01153
0.04
0.08
0.04
0.07
0.04
0.01
0.04
0.05
−20.47
0.46
−0.02
5.96
0.99
1.00
0.00
0.22

SEQID-01154
0.01
0.07
0.06
0.07
0.07
0.02
0.03
0.07
−11.40
0.52
0.02
7.89
0.40
0.52
0.00
0.32

SEQID-01155
0.03
0.06
0.04
0.08
0.04
0.01
0.04
0.06
−18.29
0.46
0.00
7.32
0.21
0.33
0.00
0.22

SEQID-01156
0.01
0.06
0.05
0.05
0.05
0.02
0.05
0.08
−16.00
0.53
−0.01
6.03
0.20
0.32
0.18
0.21

SEQID-01157
0.02
0.04
0.04
0.10
0.12
0.01
0.10
0.04
−11.42
0.75
0.02
3.90
0.28
0.66
0.21
0.24

SEQID-01158
0.03
0.05
0.04
0.03
0.05
0.01
0.04
0.06
−23.09
0.36
0.11
10.94
0.20
0.32
0.00
0.00

SEQID-01159
0.01
0.03
0.04
0.04
0.03
0.05
0.01
0.08
−28.74
0.19
−0.01
6.52
0.51
0.68
0.00
0.22

SEQID-01160
0.02
0.07
0.06
0.05
0.03
0.05
0.05
0.06
−18.96
0.36
−0.02
5.68
0.34
0.48
0.00
0.20

SEQID-01161
0.04
0.03
0.03
0.05
0.05
0.01
0.05
0.09
−19.80
0.48
0.00
7.21
0.21
0.29
0.00
0.23

SEQID-01162
0.02
0.04
0.04
0.03
0.04
0.01
0.03
0.04
−21.52
0.39
−0.03
6.47
0.21
0.34
0.00
0.21

SEQID-01163
0.03
0.04
0.03
0.07
0.04
0.01
0.06
0.04
−25.01
0.32
−0.07
4.39
0.23
0.32
0.00
0.00

SEQID-01164
0.02
0.06
0.05
0.05
0.04
0.00
0.03
0.06
−24.61
0.35
−0.03
4.86
0.19
0.33
0.00
0.20

SEQID-01165
0.01
0.06
0.08
0.04
0.03
0.01
0.04
0.08
−23.84
0.38
0.12
10.90
0.00
0.31
0.00
0.23

SEQID-01166
0.02
0.07
0.04
0.06
0.05
0.01
0.05
0.07
−19.45
0.42
−0.02
5.20
0.20
0.34
0.00
0.22

SEQID-01167
0.04
0.05
0.05
0.03
0.04
0.04
0.05
0.06
−23.34
0.35
−0.02
5.84
0.21
0.31
0.19
0.22

SEQID-01168
0.02
0.05
0.03
0.04
0.03
0.02
0.02
0.04
−32.07
0.35
−0.03
5.18
0.22
0.50
0.00
0.21

SEQID-01169
0.04
0.08
0.05
0.04
0.07
0.00
0.02
0.11
−24.06
0.34
0.04
10.06
0.23
0.31
0.00
0.20

SEQID-01170
0.02
0.10
0.06
0.06
0.03
0.03
0.00
0.09
−26.89
0.25
−0.01
5.88
0.71
0.83
0.00
0.22

SEQID-01171
0.03
0.04
0.02
0.03
0.01
0.02
0.03
0.10
−28.78
0.34
0.14
11.14
0.26
0.34
0.23
0.23

SEQID-01172
0.03
0.06
0.04
0.04
0.05
0.02
0.06
0.07
−19.93
0.37
0.01
7.90
0.21
0.33
0.00
0.22

SEQID-01173
0.06
0.04
0.04
0.07
0.04
0.01
0.04
0.09
−17.74
0.54
0.00
7.20
0.19
0.32
0.00
0.23

SEQID-01174
0.02
0.04
0.03
0.02
0.02
0.01
0.07
0.05
−26.31
0.28
0.10
10.61
0.24
0.32
0.00
0.00

SEQID-01175
0.02
0.07
0.05
0.06
0.04
0.05
0.04
0.07
−18.65
0.43
0.00
6.91
0.27
0.35
0.25
0.25

SEQID-01176
0.03
0.03
0.05
0.07
0.03
0.03
0.03
0.08
−22.07
0.32
0.11
11.15
0.22
0.33
0.00
0.19

SEQID-01177
0.02
0.05
0.05
0.03
0.04
0.01
0.03
0.08
−19.41
0.37
0.12
11.44
0.00
0.33
0.20
0.25

SEQID-01178
0.02
0.06
0.04
0.05
0.04
0.03
0.05
0.06
−22.03
0.34
−0.02
5.45
0.19
0.34
0.00
0.20

SEQID-01179
0.02
0.06
0.04
0.06
0.04
0.02
0.02
0.06
−19.17
0.54
−0.02
5.11
0.20
0.35
0.00
0.23

SEQID-01180
0.01
0.04
0.04
0.09
0.05
0.02
0.05
0.07
−19.10
0.38
0.00
5.53
0.22
0.34
0.21
0.21

SEQID-01181
0.01
0.05
0.04
0.10
0.05
0.02
0.04
0.07
−15.33
0.56
0.01
7.73
0.21
0.33
0.00
0.23

SEQID-01182
0.04
0.05
0.05
0.05
0.06
0.03
0.05
0.04
−23.47
0.27
−0.01
6.04
0.21
0.31
0.00
0.20

SEQID-01183
0.01
0.05
0.06
0.04
0.04
0.05
0.06
0.04
−29.60
0.23
−0.11
4.19
0.37
0.55
0.00
0.22

SEQID-01184
0.02
0.04
0.06
0.06
0.06
0.01
0.06
0.09
−11.24
1.01
0.03
9.70
0.72
0.48
0.00
0.26

SEQID-01185
0.03
0.07
0.05
0.06
0.04
0.03
0.00
0.09
−25.30
0.28
0.00
6.32
0.73
0.34
0.00
0.21

SEQID-01186
0.02
0.06
0.04
0.03
0.07
0.02
0.02
0.08
−22.51
0.39
0.09
11.06
0.20
0.33
0.00
0.25

SEQID-01187
0.04
0.06
0.03
0.04
0.06
0.01
0.04
0.08
−20.50
0.45
−0.02
5.09
0.21
0.33
0.00
0.00

SEQID-01188
0.02
0.05
0.03
0.03
0.06
0.02
0.05
0.08
−24.54
0.31
0.12
10.75
0.68
0.79
0.00
0.00

SEQID-01189
0.01
0.07
0.06
0.07
0.03
0.04
0.08
0.06
−18.06
0.47
−0.03
5.52
0.43
0.61
0.21
0.21

SEQID-01190
0.02
0.04
0.03
0.03
0.04
0.00
0.09
0.06
−27.23
0.36
0.04
9.73
0.19
0.31
0.00
0.00

SEQID-01191
0.02
0.07
0.06
0.06
0.06
0.02
0.07
0.08
−11.49
1.06
0.03
9.41
0.37
0.50
0.23
0.27

SEQID-01192
0.01
0.07
0.04
0.06
0.06
0.03
0.06
0.08
−20.15
0.37
0.01
8.19
0.17
0.32
0.00
0.00

SEQID-01193
0.02
0.07
0.04
0.05
0.06
0.01
0.04
0.04
−21.17
0.30
0.17
11.45
0.23
0.31
0.20
0.22

SEQID-01194
0.04
0.05
0.02
0.06
0.05
0.06
0.04
0.05
−21.04
0.43
−0.03
5.03
0.00
0.32
0.00
0.21

SEQID-01195
0.04
0.06
0.02
0.04
0.02
0.01
0.06
0.10
−21.65
0.54
0.07
10.46
0.00
0.31
0.24
0.24

SEQID-01196
0.01
0.07
0.06
0.07
0.04
0.03
0.04
0.09
−15.53
0.59
0.01
8.47
0.47
0.64
0.18
0.47

SEQID-01197
0.01
0.04
0.04
0.06
0.04
0.01
0.04
0.05
−24.61
0.22
0.12
10.98
0.21
0.30
0.00
0.21

SEQID-01198
0.03
0.06
0.02
0.05
0.03
0.01
0.06
0.08
−23.27
0.36
0.08
10.54
0.21
0.32
0.00
0.25

SEQID-01199
0.01
0.09
0.03
0.05
0.04
0.01
0.05
0.06
−20.99
0.33
0.00
7.18
0.23
0.32
0.25
0.25

SEQID-01200
0.03
0.04
0.04
0.05
0.05
0.02
0.03
0.07
−25.01
0.35
−0.07
4.28
0.37
0.58
0.00
0.00

SEQID-01201
0.04
0.04
0.01
0.03
0.04
0.02
0.03
0.07
−25.72
0.31
0.13
11.26
0.25
0.31
0.22
0.21

SEQID-01202
0.05
0.07
0.03
0.04
0.05
0.04
0.05
0.08
−17.45
0.56
0.00
6.68
0.00
0.33
0.00
0.20

SEQID-01203
0.03
0.05
0.03
0.05
0.06
0.02
0.07
0.07
−19.45
0.37
−0.01
5.34
0.22
0.33
0.00
0.21

SEQID-01204
0.03
0.03
0.03
0.07
0.05
0.01
0.03
0.12
−27.72
0.21
0.16
11.65
0.24
0.29
0.00
0.23

SEQID-01205
0.03
0.03
0.03
0.06
0.07
0.01
0.07
0.04
−20.53
0.39
0.03
9.09
0.22
0.32
0.00
0.00

SEQID-01206
0.02
0.05
0.01
0.06
0.04
0.01
0.03
0.08
−24.54
0.33
0.05
10.05
0.00
0.31
0.00
0.24

SEQID-01207
0.02
0.07
0.07
0.08
0.09
0.01
0.04
0.07
−12.03
0.56
0.02
8.63
0.39
0.57
0.19
0.22

SEQID-01208
0.02
0.05
0.05
0.06
0.04
0.02
0.04
0.08
−21.37
0.38
0.00
6.41
0.19
0.33
0.00
0.21

SEQID-01209
0.02
0.06
0.06
0.07
0.04
0.04
0.05
0.06
−18.32
0.37
−0.03
5.77
0.21
0.34
0.00
0.22

SEQID-01210
0.04
0.02
0.02
0.04
0.05
0.00
0.02
0.09
−21.67
0.55
−0.01
6.45
0.21
0.34
0.00
0.21

SEQID-01211
0.02
0.12
0.02
0.03
0.04
0.00
0.00
0.05
−21.54
0.57
0.11
9.35
0.28
0.26
0.32
0.29

SEQID-01212
0.03
0.04
0.05
0.06
0.05
0.00
0.04
0.10
−16.48
0.54
0.01
8.30
0.53
0.74
0.00
0.23

SEQID-01213
0.03
0.05
0.07
0.04
0.06
0.02
0.04
0.06
−21.02
0.30
0.00
6.94
0.71
0.81
0.00
0.22

SEQID-01214
0.02
0.06
0.04
0.02
0.07
0.01
0.09
0.08
−22.28
0.35
−0.01
5.81
0.78
0.33
0.00
0.21

SEQID-01215
0.02
0.05
0.04
0.06
0.06
0.01
0.03
0.08
−20.11
0.52
0.00
7.40
0.21
0.31
0.00
0.21

SEQID-01216
0.03
0.04
0.04
0.06
0.05
0.01
0.02
0.09
−18.22
0.67
0.00
6.95
0.21
0.36
0.20
0.22

SEQID-01217
0.02
0.06
0.02
0.07
0.04
0.02
0.04
0.05
−28.13
0.27
−0.05
4.64
0.43
0.69
0.00
0.20

SEQID-01218
0.04
0.08
0.05
0.11
0.09
0.01
0.02
0.07
−13.96
0.43
0.03
9.02
0.20
0.96
0.00
0.21

SEQID-01219
0.05
0.02
0.03
0.07
0.06
0.02
0.02
0.09
−19.87
0.53
−0.01
6.56
0.20
0.37
0.17
0.00

SEQID-01220
0.03
0.06
0.05
0.04
0.05
0.03
0.04
0.08
−18.51
0.48
0.00
7.07
0.21
0.34
0.00
0.20

SEQID-01221
0.01
0.04
0.03
0.05
0.04
0.01
0.03
0.05
−27.59
0.24
0.16
11.39
0.21
0.34
0.22
0.00

SEQID-01222
0.03
0.04
0.04
0.05
0.07
0.00
0.01
0.06
−23.57
0.34
0.09
11.50
0.22
0.29
0.18
0.22

SEQID-01223
0.03
0.04
0.04
0.07
0.04
0.02
0.06
0.06
−21.05
0.23
0.10
10.83
0.22
0.23
0.00
0.20

SEQID-01224
0.05
0.05
0.03
0.05
0.02
0.02
0.03
0.07
−22.77
0.40
0.09
10.51
0.22
0.30
0.00
0.21

SEQID-01225
0.01
0.01
0.07
0.03
0.03
0.00
0.04
0.08
−21.61
0.44
0.15
11.36
0.26
0.30
0.00
0.27

SEQID-01226
0.02
0.07
0.04
0.05
0.04
0.01
0.02
0.09
−20.11
0.58
−0.02
5.23
0.40
0.43
0.24
0.00

SEQID-01227
0.05
0.07
0.06
0.04
0.03
0.00
0.03
0.06
−22.82
0.40
0.10
11.11
0.00
0.29
0.00
0.23

SEQID-01228
0.07
0.04
0.01
0.05
0.02
0.00
0.06
0.08
−18.17
0.45
−0.02
6.08
0.26
0.30
0.24
0.24

SEQID-01229
0.03
0.01
0.05
0.04
0.07
0.01
0.02
0.09
−24.32
0.28
0.06
10.25
0.21
0.33
0.00
0.24

SEQID-01230
0.02
0.05
0.04
0.04
0.04
0.00
0.05
0.09
−27.23
0.33
0.07
10.42
0.20
0.32
0.00
0.22

SEQID-01231
0.01
0.06
0.04
0.03
0.02
0.00
0.06
0.06
−21.84
0.51
0.12
10.79
0.23
0.32
0.00
0.00

SEQID-01232
0.03
0.05
0.06
0.04
0.06
0.01
0.04
0.06
−20.35
0.32
0.01
8.31
0.20
0.32
0.00
0.22

SEQID-01233
0.03
0.05
0.02
0.04
0.05
0.02
0.03
0.07
−25.82
0.25
0.08
10.50
0.20
0.30
0.00
0.00

SEQID-01234
0.02
0.02
0.06
0.05
0.05
0.01
0.00
0.11
−23.74
0.48
0.03
9.63
0.20
0.32
0.00
0.25

SEQID-01235
0.02
0.10
0.10
0.03
0.03
0.02
0.07
0.02
−20.74
0.19
0.05
10.10
0.29
0.45
0.00
0.29

SEQID-01236
0.02
0.03
0.05
0.07
0.05
0.03
0.05
0.07
−16.99
0.43
0.00
6.77
0.22
0.34
0.00
0.21

SEQID-01237
0.01
0.06
0.06
0.05
0.02
0.04
0.05
0.04
−26.99
0.40
−0.06
4.51
0.41
0.71
0.00
0.22

SEQID-01238
0.03
0.04
0.04
0.06
0.05
0.02
0.05
0.07
−20.81
0.36
0.00
7.00
0.22
0.21
0.22
0.22

SEQID-01239
0.06
0.04
0.05
0.04
0.08
0.01
0.02
0.08
−9.86
0.97
0.02
8.55
0.42
0.55
0.00
0.23

SEQID-01240
0.03
0.04
0.03
0.06
0.06
0.02
0.07
0.09
−15.50
0.47
−0.02
5.23
0.22
0.35
0.00
0.23

SEQID-01241
0.03
0.05
0.04
0.05
0.05
0.01
0.06
0.07
−19.27
0.43
0.00
6.91
0.20
0.31
0.19
0.20

SEQID-01242
0.02
0.07
0.07
0.09
0.07
0.01
0.06
0.08
−12.30
0.51
0.01
8.06
0.37
0.55
0.00
0.22

SEQID-01243
0.04
0.05
0.05
0.05
0.06
0.02
0.06
0.07
−19.43
0.38
−0.02
5.16
0.21
0.33
0.00
0.21

SEQID-01244
0.01
0.06
0.08
0.06
0.05
0.03
0.04
0.06
−16.02
0.43
−0.01
6.23
0.22
0.34
0.22
0.23

SEQID-01245
0.01
0.04
0.02
0.06
0.09
0.02
0.03
0.04
−16.05
0.52
0.00
6.94
0.23
0.32
0.00
0.24

SEQID-01246
0.00
0.08
0.02
0.05
0.02
0.02
0.03
0.05
−27.51
0.35
0.05
10.27
0.21
0.34
0.00
0.19

SEQID-01247
0.02
0.01
0.01
0.04
0.07
0.00
0.06
0.05
−31.20
0.10
0.00
6.28
0.22
0.36
0.23
0.22

SEQID-01248
0.01
0.06
0.07
0.06
0.04
0.03
0.04
0.10
−19.05
0.58
−0.01
6.40
0.29
0.39
0.00
0.22

SEQID-01249
0.03
0.05
0.04
0.11
0.04
0.02
0.04
0.06
−16.73
0.49
0.01
9.15
0.23
0.32
0.00
0.21

SEQID-01250
0.04
0.09
0.03
0.06
0.03
0.00
0.01
0.07
−25.26
0.42
−0.08
4.21
0.27
0.36
0.24
0.26

SEQID-01251
0.02
0.07
0.04
0.05
0.05
0.02
0.04
0.07
−18.30
0.43
0.00
7.16
0.51
0.78
0.20
0.23

SEQID-01252
0.03
0.04
0.03
0.04
0.04
0.02
0.06
0.06
−20.96
0.44
−0.01
5.63
0.21
0.33
0.21
0.22

SEQID-01253
0.02
0.07
0.06
0.06
0.05
0.04
0.09
0.05
−14.18
0.42
−0.03
4.68
0.36
0.59
0.00
0.18

SEQID-01254
0.02
0.01
0.05
0.07
0.11
0.00
0.03
0.04
−20.46
0.18
0.03
9.81
0.35
0.57
0.22
0.25

SEQID-01255
0.03
0.06
0.05
0.03
0.04
0.04
0.08
0.07
−18.03
0.39
−0.02
5.40
0.20
0.32
0.00
0.19

SEQID-01256
0.01
0.06
0.04
0.05
0.04
0.01
0.03
0.08
−21.42
0.48
0.00
7.81
0.22
0.34
0.20
0.20

SEQID-01257
0.03
0.04
0.03
0.06
0.07
0.01
0.05
0.10
−19.33
0.45
0.00
6.96
0.67
0.90
0.00
0.72

SEQID-01258
0.03
0.04
0.04
0.04
0.07
0.00
0.04
0.09
−20.05
0.47
0.00
7.78
0.21
0.31
0.19
0.21

SEQID-01259
0.03
0.05
0.03
0.06
0.06
0.02
0.05
0.10
−19.34
0.46
0.00
6.96
0.67
0.90
0.23
0.00

SEQID-01260
0.02
0.06
0.04
0.05
0.07
0.00
0.02
0.06
−22.84
0.34
−0.03
4.73
0.76
0.93
0.19
0.21

SEQID-01261
0.03
0.04
0.04
0.06
0.07
0.02
0.05
0.10
−19.20
0.47
0.01
8.57
0.67
0.90
0.00
0.00

SEQID-01262
0.02
0.06
0.04
0.05
0.07
0.00
0.02
0.06
−22.96
0.34
−0.03
4.68
0.77
0.93
0.19
0.21

SEQID-01263
0.00
0.06
0.03
0.05
0.05
0.02
0.04
0.10
−20.31
0.47
−0.01
5.81
0.50
0.60
0.00
0.23

SEQID-01264
0.02
0.05
0.04
0.04
0.06
0.02
0.03
0.09
−21.72
0.43
0.03
9.58
0.22
0.34
0.00
0.21

SEQID-01265
0.03
0.06
0.04
0.04
0.07
0.02
0.05
0.06
−16.92
0.48
−0.01
6.11
0.21
0.33
0.00
0.22

SEQID-01266
0.02
0.03
0.02
0.06
0.02
0.00
0.06
0.06
−29.53
0.07
−0.03
5.00
0.29
0.33
0.00
0.26

SEQID-01267
0.03
0.06
0.04
0.04
0.05
0.01
0.06
0.06
−20.53
0.36
−0.03
5.59
0.21
0.31
0.00
0.21

SEQID-01268
0.01
0.07
0.04
0.05
0.05
0.02
0.05
0.07
−21.13
0.39
−0.01
6.41
0.47
0.79
0.00
0.20

SEQID-01269
0.02
0.04
0.03
0.04
0.04
0.00
0.04
0.05
−24.71
0.37
−0.02
5.10
0.19
0.35
0.35
0.20

SEQID-01270
0.02
0.06
0.03
0.05
0.05
0.01
0.04
0.05
−27.58
0.30
−0.06
4.43
0.76
0.59
0.00
0.20

SEQID-01271
0.03
0.06
0.04
0.04
0.05
0.02
0.03
0.09
−21.10
0.46
−0.01
6.23
0.19
0.32
0.00
0.20

SEQID-01272
0.02
0.02
0.05
0.11
0.09
0.00
0.05
0.04
−22.42
0.06
−0.02
6.36
0.18
0.34
0.19
0.20

SEQID-01273
0.02
0.02
0.02
0.09
0.05
0.01
0.05
0.04
−23.40
0.25
−0.05
4.54
0.21
0.37
0.00
0.00

SEQID-01274
0.02
0.06
0.03
0.05
0.05
0.01
0.04
0.05
−27.83
0.30
−0.05
4.54
0.75
0.89
0.00
0.21

SEQID-01275
0.01
0.05
0.02
0.05
0.07
0.01
0.06
0.01
−25.21
0.03
−0.07
4.34
0.27
0.33
0.23
0.22

SEQID-01276
0.02
0.06
0.04
0.06
0.05
0.02
0.05
0.07
−18.75
0.39
0.00
6.72
0.54
0.69
0.18
0.12

SEQID-01277
0.01
0.03
0.06
0.05
0.03
0.03
0.05
0.06
−22.75
0.33
0.02
9.34
0.20
0.38
0.00
0.00

SEQID-01278
0.02
0.05
0.03
0.04
0.06
0.03
0.04
0.08
−23.46
0.33
0.11
10.96
0.76
0.36
0.00
0.16

SEQID-01279
0.01
0.08
0.04
0.05
0.05
0.02
0.07
0.07
−17.43
0.40
−0.01
6.41
0.22
0.33
0.22
0.22

SEQID-01280
0.03
0.05
0.04
0.05
0.07
0.01
0.04
0.06
−20.24
0.42
−0.02
6.13
0.22
0.33
0.00
0.21

SEQID-01281
0.02
0.09
0.04
0.06
0.05
0.05
0.06
0.03
−23.17
0.27
−0.02
5.44
0.21
0.33
0.00
0.20

SEQID-01282
0.02
0.03
0.04
0.06
0.04
0.01
0.05
0.06
−25.53
0.22
−0.08
4.34
0.21
0.35
0.00
0.21

SEQID-01283
0.01
0.04
0.03
0.06
0.05
0.01
0.04
0.07
−18.54
0.48
0.01
9.50
0.22
0.36
0.21
0.22

SEQID-01284
0.02
0.06
0.03
0.06
0.07
0.00
0.02
0.08
−21.88
0.41
−0.02
5.08
0.59
0.81
0.00
0.21

SEQID-01285
0.01
0.01
0.00
0.05
0.03
0.02
0.01
0.03
−37.09
0.07
−0.12
4.28
0.28
0.40
0.27
0.25

SEQID-01286
0.05
0.05
0.04
0.06
0.05
0.02
0.05
0.06
−19.01
0.47
−0.02
5.43
0.20
0.30
0.00
0.20

SEQID-01287
0.02
0.08
0.03
0.05
0.07
0.03
0.04
0.06
−17.74
0.39
−0.01
6.43
0.20
0.34
0.00
0.20

SEQID-01288
0.02
0.06
0.03
0.05
0.08
0.00
0.03
0.05
−22.82
0.33
−0.03
4.79
0.74
0.93
0.21
0.21

SEQID-01289
0.02
0.05
0.05
0.04
0.06
0.02
0.04
0.05
−20.52
0.37
0.01
8.25
0.19
0.33
0.00
0.11

SEQID-01290
0.03
0.05
0.04
0.06
0.05
0.02
0.06
0.07
−20.89
0.37
−0.01
6.05
0.20
0.33
0.20
0.19

SEQID-01291
0.02
0.03
0.04
0.05
0.06
0.00
0.02
0.08
−21.70
0.46
−0.02
4.95
0.21
0.32
0.20
0.22

SEQID-01292
0.03
0.05
0.04
0.04
0.07
0.02
0.05
0.07
−17.32
0.48
−0.01
6.40
0.20
0.32
0.00
0.21

SEQID-01293
0.01
0.08
0.05
0.05
0.05
0.02
0.08
0.06
−20.30
0.23
−0.01
6.51
0.30
0.50
0.00
0.21

SEQID-01294
0.02
0.05
0.03
0.05
0.04
0.03
0.04
0.08
−18.83
0.47
−0.03
5.16
0.21
0.31
0.00
0.21

SEQID-01295
0.03
0.05
0.05
0.04
0.05
0.01
0.05
0.05
−21.84
0.41
−0.02
5.10
0.21
0.33
0.00
0.22

SEQID-01296
0.03
0.04
0.04
0.06
0.06
0.02
0.05
0.06
−18.84
0.41
0.00
6.65
0.20
0.32
0.00
0.20

SEQID-01297
0.01
0.05
0.04
0.02
0.05
0.01
0.05
0.08
−23.48
0.33
0.09
10.73
0.19
0.33
0.00
0.00

SEQID-01298
0.01
0.03
0.04
0.07
0.04
0.01
0.05
0.03
−26.76
0.21
−0.09
4.26
0.22
0.33
0.00
0.24

SEQID-01299
0.02
0.05
0.04
0.04
0.07
0.00
0.03
0.08
−18.91
0.51
−0.01
5.41
0.22
0.35
0.20
0.22

SEQID-01300
0.02
0.05
0.03
0.06
0.06
0.02
0.03
0.07
−20.35
0.44
−0.01
6.35
0.19
0.34
0.19
0.20

SEQID-01301
0.03
0.05
0.04
0.05
0.05
0.02
0.03
0.06
−22.18
0.42
−0.01
5.91
0.20
0.34
0.19
0.19

SEQID-01302
0.03
0.05
0.04
0.04
0.05
0.01
0.04
0.08
−20.21
0.40
−0.01
6.15
0.19
0.33
0.20
0.20

SEQID-01303
0.06
0.05
0.03
0.07
0.06
0.00
0.02
0.06
−23.96
0.40
−0.06
4.56
0.26
0.29
0.00
0.00

SEQID-01304
0.02
0.06
0.04
0.04
0.02
0.01
0.06
0.06
−24.23
0.28
0.10
10.63
0.23
0.32
0.00
0.00

SEQID-01305
0.02
0.03
0.04
0.06
0.04
0.03
0.06
0.09
−16.90
0.51
0.00
6.73
0.73
0.90
0.00
0.21

SEQID-01306
0.04
0.06
0.03
0.04
0.06
0.00
0.04
0.07
−21.66
0.45
−0.03
4.75
0.22
0.31
0.00
0.19

SEQID-01307
0.01
0.02
0.00
0.21
0.00
0.00
0.15
0.01
−21.89
0.01
−0.06
4.06
0.23
0.43
0.23
0.26

SEQID-01308
0.01
0.06
0.04
0.09
0.03
0.03
0.05
0.06
−20.01
0.29
−0.03
5.00
0.21
0.33
0.00
0.22

SEQID-01309
0.02
0.05
0.03
0.05
0.05
0.00
0.04
0.07
−21.77
0.36
−0.01
6.25
0.22
0.34
0.20
0.21

SEQID-01310
0.02
0.05
0.03
0.07
0.04
0.02
0.06
0.07
−18.68
0.38
−0.01
5.39
0.22
0.33
0.22
0.22

SEQID-01311
0.03
0.04
0.04
0.05
0.05
0.01
0.07
0.06
−15.91
0.35
0.01
7.47
0.21
0.33
0.00
0.21

SEQID-01312
0.01
0.05
0.04
0.06
0.05
0.02
0.06
0.05
−20.58
0.42
0.01
8.65
0.22
0.34
0.00
0.22

SEQID-01313
0.03
0.06
0.04
0.05
0.04
0.03
0.05
0.05
−19.18
0.46
0.00
6.60
0.21
0.33
0.00
0.22

SEQID-01314
0.01
0.06
0.04
0.05
0.07
0.02
0.05
0.07
−17.18
0.47
−0.01
6.11
0.21
0.33
0.00
0.22

SEQID-01315
0.02
0.06
0.04
0.07
0.05
0.02
0.06
0.06
−19.03
0.36
−0.01
6.05
0.19
0.34
0.00
0.20

SEQID-01316
0.02
0.07
0.05
0.06
0.06
0.02
0.04
0.07
−19.19
0.43
−0.01
5.73
0.18
0.35
0.18
0.19

SEQID-01317
0.01
0.07
0.04
0.04
0.07
0.01
0.06
0.09
−19.96
0.34
0.17
11.44
0.23
0.30
0.00
0.22

SEQID-01318
0.01
0.07
0.06
0.06
0.03
0.02
0.05
0.07
−23.65
0.27
−0.02
5.15
0.00
0.45
0.00
0.00

SEQID-01319
0.02
0.04
0.03
0.03
0.06
0.01
0.02
0.09
−22.45
0.39
0.01
9.04
0.22
0.31
0.00
0.00

SEQID-01320
0.01
0.08
0.03
0.06
0.04
0.01
0.01
0.05
−29.34
0.21
−0.07
4.40
0.22
0.32
0.00
0.00

SEQID-01321
0.02
0.06
0.02
0.05
0.06
0.01
0.01
0.08
−24.62
0.30
0.03
10.75
0.24
0.32
0.00
0.00

SEQID-01322
0.02
0.06
0.02
0.05
0.06
0.01
0.01
0.09
−24.64
0.30
0.03
10.78
0.00
0.30
0.00
0.00

SEQID-01323
0.03
0.04
0.02
0.07
0.07
0.06
0.03
0.07
−17.42
0.43
−0.01
6.16
0.22
0.36
0.21
0.00

SEQID-01324
0.01
0.06
0.03
0.06
0.06
0.01
0.05
0.07
−22.79
0.46
0.00
6.33
0.20
0.30
0.21
0.20

SEQID-01325
0.02
0.05
0.03
0.06
0.07
0.00
0.02
0.08
−21.39
0.39
−0.01
5.24
0.49
0.78
0.00
0.22

SEQID-01326
0.02
0.05
0.03
0.06
0.05
0.04
0.05
0.06
−21.70
0.31
0.01
8.29
0.19
0.33
0.00
0.20

SEQID-01327
0.01
0.05
0.04
0.04
0.04
0.01
0.04
0.08
−24.49
0.35
0.11
10.81
0.22
0.33
0.00
0.27

SEQID-01328
0.01
0.04
0.06
0.04
0.07
0.02
0.02
0.08
−18.01
0.47
0.08
11.13
0.22
0.33
0.19
0.20

SEQID-01329
0.03
0.04
0.04
0.03
0.05
0.00
0.04
0.09
−22.67
0.45
0.03
9.94
0.23
0.34
0.00
0.00

SEQID-01330
0.02
0.07
0.04
0.06
0.04
0.01
0.04
0.10
−19.25
0.55
−0.05
4.46
0.00
0.45
0.00
0.21

SEQID-01331
0.01
0.05
0.05
0.06
0.04
0.02
0.06
0.07
−19.89
0.43
−0.01
6.52
0.20
0.34
0.00
0.21

SEQID-01332
0.01
0.00
0.02
0.07
0.02
0.02
0.08
0.07
−23.86
0.20
−0.01
5.85
0.27
0.29
0.00
0.26

SEQID-01333
0.01
0.09
0.04
0.04
0.04
0.01
0.04
0.11
−24.55
0.35
0.16
11.08
0.22
0.31
0.25
0.00

SEQID-01334
0.05
0.07
0.03
0.03
0.04
0.02
0.06
0.08
−24.22
0.34
−0.09
4.17
0.56
0.61
0.00
0.00

SEQID-01335
0.01
0.05
0.04
0.02
0.04
0.01
0.02
0.06
−25.90
0.30
0.14
11.76
0.23
0.31
0.00
0.26

SEQID-01336
0.01
0.03
0.04
0.06
0.07
0.03
0.03
0.09
−18.37
0.41
0.10
11.33
0.20
0.33
0.00
0.21

SEQID-01337
0.03
0.05
0.03
0.04
0.07
0.02
0.06
0.06
−22.66
0.39
−0.01
6.08
0.22
0.32
0.00
0.21

SEQID-01338
0.03
0.05
0.05
0.05
0.05
0.00
0.05
0.05
−22.25
0.33
−0.04
4.69
0.21
0.32
0.18
0.21

SEQID-01339
0.03
0.05
0.05
0.06
0.06
0.02
0.06
0.05
−18.50
0.38
−0.01
6.31
0.20
0.31
0.20
0.21

SEQID-01340
0.02
0.07
0.04
0.05
0.05
0.02
0.07
0.01
−20.27
0.35
0.00
6.59
0.23
0.35
0.19
0.22

SEQID-01341
0.02
0.06
0.05
0.07
0.05
0.02
0.06
0.06
−17.18
0.38
0.00
7.01
0.20
0.33
0.19
0.21

SEQID-01342
0.01
0.06
0.04
0.06
0.04
0.00
0.06
0.09
−21.26
0.41
0.12
10.91
0.21
0.29
0.19
0.00

SEQID-01343
0.01
0.03
0.02
0.04
0.06
0.00
0.06
0.07
−25.42
0.31
0.13
10.52
0.23
0.35
0.23
0.27

SEQID-01344
0.03
0.07
0.03
0.05
0.04
0.02
0.07
0.07
−23.79
0.20
0.13
10.92
0.00
0.31
0.00
0.22

SEQID-01345
0.01
0.07
0.05
0.03
0.06
0.03
0.04
0.08
−19.47
0.58
−0.03
4.77
0.29
0.37
0.00
0.24

SEQID-01346
0.01
0.03
0.04
0.05
0.04
0.01
0.04
0.07
−20.01
0.36
0.12
11.68
0.23
0.34
0.22
0.00

SEQID-01347
0.01
0.04
0.06
0.03
0.05
0.02
0.04
0.08
−20.44
0.47
−0.06
4.40
0.00
0.33
0.00
0.00

SEQID-01348
0.01
0.06
0.04
0.08
0.07
0.01
0.04
0.09
−18.50
0.53
0.00
7.71
0.22
0.32
0.00
0.00

SEQID-01349
0.02
0.05
0.05
0.04
0.04
0.01
0.05
0.07
−20.33
0.50
−0.01
6.12
0.23
0.36
0.00
0.22

SEQID-01350
0.02
0.05
0.04
0.05
0.06
0.02
0.06
0.06
−21.78
0.39
−0.03
4.93
0.23
0.31
0.00
0.21

SEQID-01351
0.02
0.05
0.04
0.04
0.06
0.03
0.07
0.05
−20.92
0.30
0.02
9.42
0.22
0.31
0.00
0.22

SEQID-01352
0.01
0.06
0.05
0.03
0.04
0.03
0.07
0.05
−20.99
0.27
0.01
6.53
0.22
0.31
0.00
0.21

SEQID-01353
0.03
0.05
0.03
0.04
0.04
0.02
0.04
0.07
−18.95
0.51
−0.02
6.20
0.22
0.36
0.00
0.21

SEQID-01354
0.02
0.06
0.03
0.06
0.05
0.03
0.06
0.08
−18.88
0.42
−0.02
6.00
0.20
0.32
0.00
0.21

SEQID-01355
0.02
0.08
0.04
0.05
0.03
0.01
0.06
0.07
−22.02
0.40
−0.09
4.13
0.26
0.51
0.00
0.22

SEQID-01356
0.02
0.06
0.04
0.04
0.04
0.00
0.05
0.05
−25.30
0.31
−0.01
6.53
0.22
0.35
0.20
0.23

SEQID-01357
0.03
0.01
0.01
0.04
0.05
0.02
0.00
0.15
−22.84
0.58
−0.07
4.39
0.23
0.31
0.00
0.24

SEQID-01358
0.02
0.10
0.06
0.05
0.05
0.01
0.05
0.09
−17.80
0.34
0.01
7.57
0.73
0.90
0.00
0.26

SEQID-01359
0.01
0.01
0.01
0.04
0.03
0.02
0.03
0.06
−28.98
0.20
0.18
11.91
0.25
0.31
0.00
0.22

SEQID-01360
0.01
0.05
0.02
0.07
0.05
0.02
0.04
0.04
−24.31
0.18
0.14
11.33
0.18
0.29
0.00
0.21

SEQID-01361
0.01
0.06
0.05
0.05
0.04
0.00
0.02
0.08
−22.96
0.37
0.06
10.53
0.19
0.30
0.00
0.24

SEQID-01362
0.01
0.05
0.04
0.04
0.03
0.01
0.06
0.05
−21.23
0.30
0.10
10.79
0.21
0.33
0.20
0.20

SEQID-01363
0.01
0.04
0.05
0.03
0.05
0.01
0.05
0.07
−22.07
0.39
0.10
10.72
0.23
0.33
0.18
0.00

SEQID-01364
0.01
0.10
0.03
0.04
0.05
0.01
0.05
0.05
−23.63
0.37
−0.03
4.88
0.00
0.32
0.00
0.00

SEQID-01365
0.01
0.05
0.06
0.04
0.06
0.03
0.06
0.04
−22.68
0.28
−0.02
5.25
0.18
0.32
0.00
0.00

SEQID-01366
0.04
0.09
0.03
0.06
0.04
0.02
0.06
0.06
−16.35
0.58
0.06
10.33
0.21
0.32
0.00
0.00

SEQID-01367
0.01
0.06
0.03
0.04
0.06
0.01
0.08
0.04
−24.70
0.29
0.00
6.81
0.22
0.33
0.00
0.23

SEQID-01368
0.02
0.05
0.05
0.06
0.05
0.00
0.01
0.08
−19.00
0.47
0.01
8.96
0.58
0.76
0.00
0.18

SEQID-01369
0.00
0.07
0.03
0.07
0.05
0.00
0.06
0.08
−20.78
0.37
0.00
8.30
0.00
0.35
0.00
0.25

SEQID-01370
0.01
0.05
0.04
0.06
0.07
0.01
0.04
0.07
−17.38
0.42
−0.01
6.51
0.23
0.32
0.00
0.00

SEQID-01371
0.02
0.04
0.04
0.06
0.06
0.02
0.07
0.06
−20.40
0.42
−0.02
4.87
0.21
0.34
0.20
0.21

SEQID-01372
0.02
0.06
0.03
0.08
0.05
0.03
0.03
0.07
−17.92
0.37
0.00
7.35
0.21
0.34
0.00
0.23

SEQID-01373
0.03
0.06
0.04
0.05
0.04
0.03
0.05
0.05
−19.21
0.48
0.00
7.32
0.20
0.33
0.21
0.22

SEQID-01374
0.03
0.06
0.04
0.04
0.07
0.01
0.05
0.07
−19.45
0.41
−0.02
5.08
0.49
0.60
0.00
0.22

SEQID-01375
0.02
0.06
0.04
0.06
0.05
0.01
0.03
0.06
−20.98
0.35
0.01
7.50
0.21
0.31
0.20
0.23

SEQID-01376
0.03
0.06
0.04
0.05
0.06
0.02
0.05
0.07
−18.69
0.42
0.01
3.01
0.20
0.32
0.00
0.21

SEQID-01377
0.03
0.05
0.04
0.06
0.05
0.02
0.04
0.06
−20.70
0.39
−0.02
5.11
0.18
0.37
0.18
0.19

SEQID-01378
0.01
0.05
0.04
0.07
0.11
0.00
0.02
0.08
−16.90
0.49
0.08
9.51
0.29
0.29
0.28
0.29

SEQID-01379
0.01
0.07
0.02
0.04
0.03
0.00
0.04
0.10
−26.89
0.28
0.14
11.20
0.24
0.32
0.00
0.21

SEQID-01380
0.03
0.05
0.02
0.05
0.03
0.01
0.04
0.07
−19.88
0.52
0.08
10.55
0.23
0.33
0.20
0.23

SEQID-01381
0.03
0.03
0.03
0.05
0.03
0.00
0.02
0.09
−21.31
0.33
0.08
11.20
0.27
0.33
0.18
0.26

SEQID-01382
0.02
0.06
0.03
0.06
0.04
0.04
0.03
0.03
−22.43
0.32
0.02
9.05
0.23
0.30
0.00
0.00

SEQID-01383
0.03
0.04
0.03
0.04
0.04
0.00
0.07
0.09
−21.66
0.27
0.13
11.00
0.20
0.30
0.00
0.24

SEQID-01384
0.01
0.09
0.07
0.05
0.01
0.01
0.04
0.01
−12.40
0.17
0.01
7.89
0.32
0.46
0.25
0.33

SEQID-01385
0.01
0.05
0.04
0.05
0.03
0.00
0.04
0.05
−27.28
0.27
0.08
10.72
0.23
0.33
0.00
0.00

SEQID-01386
0.04
0.05
0.05
0.07
0.05
0.02
0.03
0.07
−18.11
0.53
0.01
8.21
0.23
0.31
0.20
0.22

SEQID-01387
0.01
0.09
0.03
0.04
0.07
0.01
0.05
0.07
−21.39
0.38
−0.02
5.14
0.62
0.74
0.22
0.00

SEQID-01388
0.00
0.03
0.04
0.06
0.06
0.01
0.02
0.05
−27.26
0.10
0.04
10.39
0.21
0.33
0.00
0.21

SEQID-01389
0.02
0.10
0.05
0.06
0.04
0.02
0.04
0.05
−20.63
0.41
0.02
9.11
0.22
0.31
0.00
0.00

SEQID-01390
0.03
0.05
0.03
0.06
0.05
0.00
0.06
0.06
−23.89
0.37
−0.01
6.33
0.23
0.32
0.00
0.00

SEQID-01391
0.02
0.07
0.04
0.03
0.05
0.02
0.04
0.08
−16.70
0.53
0.01
8.14
0.22
0.33
0.00
0.21

SEQID-01392
0.02
0.04
0.03
0.06
0.04
0.01
0.03
0.09
−17.38
0.54
0.00
7.46
0.22
0.34
0.20
0.21

SEQID-01393
0.02
0.05
0.03
0.06
0.06
0.01
0.08
0.06
−20.13
0.33
0.01
8.32
0.20
0.33
0.22
0.22

SEQID-01394
0.03
0.06
0.04
0.06
0.04
0.03
0.04
0.05
−20.20
0.39
−0.01
6.61
0.20
0.33
0.00
0.20

SEQID-01395
0.01
0.05
0.05
0.06
0.06
0.03
0.06
0.07
−19.55
0.44
−0.01
6.60
0.19
0.34
0.20
0.21

SEQID-01396
0.03
0.04
0.04
0.04
0.04
0.01
0.03
0.07
−23.63
0.38
−0.05
4.56
0.20
0.33
0.00
0.21

SEQID-01397
0.03
0.02
0.02
0.08
0.06
0.01
0.03
0.04
−26.82
0.19
−0.01
6.26
0.19
0.35
0.00
0.20

SEQID-01398
0.02
0.05
0.05
0.09
0.05
0.02
0.04
0.05
−18.87
0.35
−0.01
6.61
0.18
0.35
0.19
0.20

SEQID-01399
0.03
0.05
0.04
0.06
0.05
0.01
0.05
0.08
−19.41
0.45
−0.02
5.60
0.19
0.36
0.18
0.19

SEQID-01400
0.03
0.06
0.02
0.08
0.04
0.00
0.02
0.03
−29.69
0.09
0.07
10.79
0.27
0.28
0.00
0.31

SEQID-01401
0.03
0.08
0.04
0.03
0.03
0.08
0.05
0.04
−23.31
0.20
−0.04
5.02
0.26
0.26
0.00
0.25

SEQID-01402
0.01
0.06
0.02
0.06
0.07
0.00
0.05
0.07
−22.73
0.35
−0.03
4.74
0.26
0.33
0.25
0.27

SEQID-01403
0.01
0.02
0.03
0.07
0.02
0.00
0.03
0.08
−26.26
0.33
0.14
11.18
0.25
0.31
0.24
0.00

SEQID-01404
0.02
0.02
0.02
0.06
0.05
0.00
0.05
0.06
−26.18
0.28
0.13
11.15
0.24
0.31
0.26
0.00

SEQID-01405
0.02
0.03
0.06
0.05
0.07
0.02
0.05
0.06
−20.21
0.26
0.00
6.92
0.22
0.32
0.00
0.00

SEQID-01406
0.01
0.08
0.04
0.04
0.04
0.00
0.08
0.06
−26.17
0.22
−0.01
5.86
0.25
0.31
0.19
0.25

SEQID-01407
0.04
0.03
0.03
0.05
0.05
0.00
0.06
0.03
−21.91
0.09
0.03
7.88
0.25
0.31
0.28
0.26

SEQID-01408
0.01
0.07
0.02
0.07
0.04
0.01
0.01
0.04
−29.09
0.17
0.22
11.90
0.17
0.33
0.21
0.26

SEQID-01409
0.01
0.05
0.04
0.07
0.06
0.04
0.05
0.10
−17.79
0.45
−0.03
4.78
0.37
0.44
0.00
0.20

SEQID-01410
0.01
0.04
0.02
0.06
0.05
0.02
0.05
0.06
−21.71
0.18
0.13
11.53
0.20
0.32
0.00
0.23

SEQID-01411
0.01
0.06
0.04
0.04
0.06
0.00
0.02
0.08
−21.92
0.43
0.17
12.23
0.21
0.31
0.00
0.25

SEQID-01412
0.02
0.05
0.02
0.03
0.06
0.00
0.05
0.12
−22.05
0.33
0.06
10.34
0.23
0.30
0.00
0.22

SEQID-01413
0.01
0.06
0.03
0.03
0.06
0.04
0.05
0.05
−17.44
0.33
0.01
8.87
0.48
0.55
0.00
0.20

SEQID-01414
0.01
0.05
0.03
0.03
0.04
0.00
0.03
0.07
−27.84
0.28
0.12
11.14
0.20
0.31
0.21
0.00

SEQID-01415
0.02
0.02
0.03
0.11
0.04
0.00
0.04
0.03
−28.18
0.14
−0.06
4.54
0.23
0.33
0.00
0.22

SEQID-01416
0.01
0.06
0.04
0.04
0.04
0.03
0.05
0.05
−20.77
0.35
0.00
7.09
0.21
0.31
0.00
0.18

SEQID-01417
0.03
0.05
0.03
0.07
0.06
0.00
0.04
0.05
−23.05
0.23
−0.04
4.62
0.23
0.33
0.00
0.00

SEQID-01418
0.03
0.04
0.03
0.04
0.08
0.01
0.03
0.06
−19.66
0.40
0.02
9.54
0.00
0.33
0.00
0.22

SEQID-01419
0.02
0.04
0.05
0.04
0.06
0.01
0.04
0.10
−19.31
0.49
−0.01
6.27
0.22
0.32
0.00
0.20

SEQID-01420
0.01
0.05
0.05
0.07
0.08
0.00
0.04
0.07
−16.80
0.45
0.02
9.01
0.00
0.31
0.00
0.21

SEQID-01421
0.03
0.05
0.04
0.05
0.04
0.02
0.02
0.09
−19.36
0.50
−0.01
6.55
0.21
0.33
0.00
0.21

SEQID-01422
0.02
0.05
0.04
0.07
0.07
0.00
0.05
0.05
−20.93
0.40
0.03
9.71
0.22
0.33
0.00
0.19

SEQID-01423
0.01
0.08
0.04
0.05
0.06
0.02
0.08
0.04
−17.98
0.41
−0.05
4.45
0.37
0.54
0.00
0.23

SEQID-01424
0.02
0.07
0.05
0.04
0.03
0.04
0.06
0.06
−22.06
0.41
0.01
8.13
0.21
0.35
0.00
0.21

SEQID-01425
0.02
0.05
0.03
0.06
0.06
0.01
0.05
0.05
−20.51
0.40
−0.01
6.21
0.21
0.33
0.00
0.21

SEQID-01426
0.05
0.05
0.03
0.06
0.06
0.00
0.04
0.06
−17.68
0.46
0.00
7.46
0.21
0.34
0.21
0.21

SEQID-01427
0.03
0.06
0.06
0.04
0.05
0.02
0.04
0.06
−20.62
0.32
0.00
6.77
0.20
0.32
0.20
0.22

SEQID-01428
0.02
0.07
0.04
0.04
0.04
0.01
0.08
0.05
−20.04
0.36
−0.04
4.95
0.21
0.34
0.00
0.21

SEQID-01429
0.02
0.05
0.02
0.09
0.05
0.07
0.06
0.05
−24.14
0.19
0.00
7.83
0.20
0.34
0.00
0.21

SEQID-01430
0.03
0.03
0.04
0.05
0.05
0.01
0.06
0.03
−25.39
0.21
−0.02
5.26
0.20
0.34
0.00
0.21

SEQID-01431
0.03
0.04
0.03
0.05
0.07
0.02
0.05
0.06
−19.82
0.35
0.01
7.53
0.21
0.35
0.00
0.21

SEQID-01432
0.03
0.05
0.05
0.05
0.06
0.01
0.03
0.09
−17.16
0.51
−0.03
4.89
0.19
0.31
0.00
0.20

SEQID-01433
0.02
0.09
0.01
0.05
0.02
0.03
0.05
0.04
−24.24
0.10
0.16
10.56
0.28
0.20
0.34
0.32

SEQID-01434
0.01
0.03
0.01
0.05
0.05
0.00
0.06
0.07
−23.87
0.28
0.18
11.91
0.28
0.32
0.00
0.27

SEQID-01435
0.05
0.07
0.03
0.07
0.04
0.02
0.06
0.11
−18.32
0.50
−0.03
4.54
0.42
0.50
0.00
0.21

SEQID-01436
0.01
0.06
0.08
0.05
0.06
0.02
0.04
0.09
−16.92
0.35
−0.01
5.83
0.26
0.32
0.22
0.33

SEQID-01437
0.04
0.04
0.04
0.09
0.02
0.01
0.05
0.06
−25.69
0.12
0.00
6.81
0.25
0.29
0.00
0.20

SEQID-01438
0.02
0.02
0.03
0.12
0.08
0.00
0.06
0.05
−22.27
0.21
0.11
10.74
0.24
0.29
0.00
0.25

SEQID-01439
0.02
0.01
0.03
0.04
0.07
0.01
0.02
0.10
−23.95
0.29
0.05
10.21
0.25
0.29
0.22
0.00

SEQID-01440
0.02
0.04
0.03
0.05
0.05
0.01
0.03
0.06
−23.29
0.31
0.19
11.79
0.21
0.31
0.00
0.00

SEQID-01441
0.03
0.08
0.01
0.06
0.07
0.01
0.06
0.05
−22.02
0.27
0.01
8.81
0.24
0.29
0.00
0.23

SEQID-01442
0.02
0.03
0.03
0.04
0.05
0.05
0.01
0.10
−20.71
0.50
0.14
11.62
0.23
0.32
0.24
0.23

SEQID-01443
0.02
0.07
0.02
0.09
0.05
0.01
0.07
0.07
−22.98
0.32
−0.03
4.81
0.23
0.30
0.24
0.00

SEQID-01444
0.07
0.06
0.05
0.04
0.05
0.00
0.04
0.07
−20.84
0.29
0.11
11.34
0.00
0.28
0.00
0.20

SEQID-01445
0.01
0.03
0.06
0.05
0.03
0.00
0.02
0.07
−22.28
0.39
0.04
10.10
0.22
0.34
0.24
0.25

SEQID-01446
0.02
0.01
0.00
0.07
0.02
0.02
0.03
0.01
−36.22
0.05
−0.12
4.18
0.32
0.38
0.22
0.27

SEQID-01447
0.03
0.05
0.02
0.04
0.06
0.01
0.04
0.08
−24.67
0.26
0.07
10.55
0.22
0.31
0.00
0.24

SEQID-01448
0.02
0.08
0.03
0.07
0.06
0.03
0.09
0.06
−14.24
0.78
0.02
9.33
0.22
0.30
0.00
0.00

SEQID-01449
0.01
0.06
0.06
0.05
0.03
0.03
0.05
0.06
−17.40
0.41
0.00
6.97
0.20
0.35
0.00
0.20

SEQID-01450
0.03
0.03
0.03
0.07
0.02
0.03
0.02
0.07
−30.33
0.30
−0.12
4.11
0.00
0.31
0.00
0.22

SEQID-01451
0.01
0.06
0.03
0.05
0.04
0.01
0.06
0.03
−22.94
0.32
0.15
11.21
0.00
0.32
0.00
0.00

SEQID-01452
0.02
0.07
0.03
0.06
0.04
0.02
0.02
0.05
−25.66
0.28
−0.11
4.05
0.54
0.78
0.22
0.23

SEQID-01453
0.03
0.03
0.04
0.04
0.06
0.04
0.07
0.08
−23.36
0.37
−0.02
6.23
0.23
0.31
0.20
0.00

SEQID-01454
0.02
0.07
0.05
0.02
0.05
0.02
0.06
0.07
−20.72
0.37
−0.01
6.52
0.21
0.30
0.00
0.00

SEQID-01455
0.00
0.07
0.02
0.05
0.03
0.01
0.01
0.02
−33.66
0.11
−0.13
4.03
0.23
0.32
0.00
0.21

SEQID-01456
0.03
0.04
0.02
0.03
0.04
0.01
0.04
0.03
−20.05
0.44
0.02
9.63
0.21
0.33
0.00
0.00

SEQID-01457
0.01
0.07
0.05
0.03
0.04
0.03
0.05
0.06
−22.23
0.41
−0.01
6.05
0.22
0.33
0.20
0.00

SEQID-01458
0.01
0.05
0.04
0.05
0.06
0.03
0.06
0.06
−23.62
0.34
−0.01
5.74
0.21
0.34
0.00
0.21

SEQID-01459
0.02
0.07
0.04
0.05
0.05
0.01
0.04
0.03
−17.88
0.50
−0.03
4.77
0.21
0.32
0.00
0.21

SEQID-01460
0.03
0.03
0.04
0.05
0.06
0.01
0.03
0.06
−18.90
0.42
0.00
6.94
0.00
0.33
0.00
0.21

SEQID-01461
0.01
0.04
0.05
0.05
0.04
0.01
0.03
0.07
−15.76
0.57
0.00
6.71
0.22
0.34
0.00
0.21

SEQID-01462
0.02
0.06
0.03
0.04
0.07
0.01
0.03
0.08
−19.62
0.49
0.00
6.76
0.29
0.40
0.22
0.23

SEQID-01463
0.04
0.05
0.04
0.04
0.04
0.03
0.08
0.04
−21.36
0.25
−0.01
6.29
0.20
0.30
0.00
0.20

SEQID-01464
0.02
0.05
0.03
0.04
0.05
0.00
0.03
0.08
−20.94
0.43
0.01
8.22
0.22
0.36
0.00
0.21

SEQID-01465
0.03
0.06
0.03
0.05
0.05
0.02
0.03
0.06
−21.35
0.43
−0.01
6.39
0.21
0.31
0.00
0.21

SEQID-01466
0.02
0.08
0.04
0.05
0.06
0.02
0.05
0.07
−19.43
0.41
0.01
5.42
0.50
0.70
0.18
0.21

SEQID-01467
0.01
0.04
0.03
0.06
0.05
0.01
0.05
0.06
−22.02
0.39
0.00
6.65
0.21
0.35
0.00
0.22

SEQID-01468
0.01
0.04
0.10
0.07
0.03
0.02
0.03
0.06
−27.18
0.16
−0.08
4.31
0.21
0.36
0.19
0.23

SEQID-01469
0.02
0.08
0.04
0.06
0.04
0.05
0.07
0.03
−23.56
0.24
−0.03
5.13
0.21
0.36
0.00
0.20

SEQID-01470
0.01
0.06
0.03
0.07
0.05
0.01
0.03
0.05
−23.15
0.32
−0.02
6.36
0.42
0.89
0.20
0.21

SEQID-01471
0.02
0.04
0.05
0.05
0.06
0.03
0.07
0.08
−19.05
0.43
−0.01
6.67
0.20
0.32
0.00
0.21

SEQID-01472
0.02
0.06
0.05
0.05
0.06
0.02
0.03
0.06
−21.68
0.36
−0.02
5.69
0.20
0.34
0.00
0.21

SEQID-01473
0.02
0.03
0.03
0.04
0.05
0.00
0.03
0.06
−25.57
0.35
0.01
8.24
0.20
0.34
0.43
0.22

SEQID-01474
0.02
0.02
0.03
0.09
0.10
0.03
0.10
0.03
−14.48
0.26
0.06
10.19
0.30
0.23
0.00
0.34

SEQID-01475
0.02
0.05
0.02
0.02
0.06
0.00
0.02
0.10
−27.25
0.23
−0.01
6.80
0.32
0.30
0.00
1.00

SEQID-01476
0.03
0.01
0.00
0.05
0.09
0.02
0.06
0.08
−21.28
0.30
0.19
11.06
0.26
0.29
0.23
0.23

SEQID-01477
0.02
0.03
0.02
0.08
0.06
0.00
0.09
0.08
−17.20
0.58
0.08
10.35
0.25
0.30
0.00
0.23

SEQID-01478
0.02
0.02
0.03
0.02
0.04
0.00
0.05
0.06
−21.71
0.38
−0.05
4.72
0.22
0.30
0.00
0.25

SEQID-01479
0.02
0.00
0.03
0.07
0.03
0.02
0.05
0.05
−24.75
0.38
0.15
11.02
0.22
0.26
0.00
0.24

SEQID-01480
0.04
0.05
0.04
0.06
0.04
0.00
0.04
0.10
−16.44
0.61
−0.03
5.10
0.24
0.36
0.20
0.00

SEQID-01481
0.03
0.05
0.03
0.09
0.04
0.00
0.04
0.08
−22.13
0.30
−0.04
4.57
0.24
0.29
0.24
0.25

SEQID-01482
0.02
0.03
0.05
0.04
0.03
0.01
0.07
0.03
−22.78
0.33
−0.02
5.70
0.24
0.32
0.00
0.00

SEQID-01483
0.02
0.03
0.03
0.05
0.01
0.01
0.06
0.07
−22.48
0.28
0.04
10.12
0.23
0.31
0.27
0.24

SEQID-01484
0.02
0.02
0.04
0.03
0.06
0.00
0.08
0.09
−22.18
0.26
0.13
10.75
0.00
0.31
0.22
0.00

SEQID-01485
0.03
0.02
0.02
0.06
0.04
0.00
0.04
0.05
−27.22
0.22
−0.08
4.33
0.21
0.31
0.22
0.27

SEQID-01486
0.02
0.02
0.04
0.07
0.03
0.02
0.07
0.06
−20.48
0.39
0.11
11.04
0.24
0.29
0.26
0.00

SEQID-01487
0.03
0.02
0.04
0.06
0.08
0.03
0.05
0.08
−19.96
0.23
−0.06
4.38
0.00
0.30
0.00
0.24

SEQID-01488
0.01
0.05
0.08
0.02
0.05
0.00
0.06
0.07
−19.31
0.54
−0.08
4.08
0.00
0.33
0.22
0.24

SEQID-01489
0.01
0.08
0.03
0.02
0.06
0.01
0.04
0.07
−29.68
0.20
−0.04
6.14
0.00
0.31
0.00
0.18

SEQID-01490
0.03
0.06
0.04
0.06
0.05
0.00
0.01
0.05
−20.53
0.46
−0.06
4.45
0.21
0.32
0.21
0.21

SEQID-01491
0.02
0.11
0.05
0.06
0.07
0.04
0.07
0.05
−12.60
0.73
0.04
9.74
0.00
0.31
0.00
0.22

SEQID-01492
0.01
0.06
0.04
0.05
0.05
0.02
0.07
0.05
−20.65
0.33
−0.01
6.07
0.19
0.30
0.00
0.00

SEQID-01493
0.02
0.08
0.04
0.05
0.05
0.02
0.06
0.04
−22.18
0.31
0.00
6.84
0.32
0.43
0.00
0.00

SEQID-01494
0.02
0.04
0.06
0.06
0.04
0.02
0.02
0.07
−19.30
0.51
−0.02
5.48
0.00
0.33
0.00
0.20

SEQID-01495
0.05
0.10
0.03
0.05
0.04
0.02
0.07
0.03
−23.42
0.33
−0.03
4.86
0.19
0.32
0.00
0.21

SEQID-01496
0.02
0.04
0.04
0.05
0.06
0.00
0.04
0.07
−19.57
0.43
0.01
8.18
0.19
0.33
0.00
0.20

SEQID-01497
0.02
0.06
0.02
0.04
0.04
0.02
0.08
0.05
−23.62
0.41
−0.02
5.11
0.22
0.33
0.00
0.19

SEQID-01498
0.02
0.05
0.04
0.04
0.04
0.03
0.07
0.06
−22.22
0.37
−0.01
6.62
0.21
0.31
0.00
0.22

SEQID-01499
0.01
0.03
0.08
0.05
0.04
0.00
0.09
0.04
−24.80
0.18
−0.05
4.73
0.21
0.36
0.00
0.22

SEQID-01500
0.02
0.05
0.04
0.04
0.04
0.01
0.04
0.06
−23.45
0.41
0.00
7.50
0.21
0.36
0.00
0.23

SEQID-01501
0.02
0.05
0.06
0.03
0.07
0.03
0.06
0.05
−17.52
0.36
0.02
9.27
0.22
0.34
0.00
0.20

SEQID-01502
0.03
0.10
0.03
0.05
0.03
0.02
0.04
0.04
−24.51
0.40
−0.04
4.90
0.21
0.33
0.00
0.00

SEQID-01503
0.02
0.05
0.05
0.05
0.04
0.02
0.04
0.06
−17.28
0.56
0.00
6.95
0.21
0.31
0.00
0.21

SEQID-01504
0.03
0.08
0.06
0.05
0.03
0.01
0.04
0.04
−22.29
0.34
−0.02
5.83
0.21
0.31
0.00
0.22

SEQID-01505
0.03
0.04
0.03
0.07
0.06
0.01
0.04
0.07
−16.42
0.49
−0.02
5.28
0.21
0.33
0.20
0.22

SEQID-01506
0.02
0.04
0.05
0.04
0.05
0.01
0.02
0.07
−21.58
0.44
0.00
6.78
0.21
0.33
0.20
0.21

SEQID-01507
0.01
0.06
0.05
0.05
0.04
0.02
0.05
0.06
−20.35
0.44
−0.02
5.62
0.20
0.34
0.00
0.21

SEQID-01508
0.02
0.05
0.04
0.07
0.04
0.02
0.05
0.07
−20.70
0.35
−0.01
5.85
0.21
0.31
0.00
0.21

SEQID-01509
0.03
0.05
0.04
0.03
0.05
0.03
0.05
0.06
−24.81
0.31
0.00
7.62
0.21
0.33
0.00
0.20

SEQID-01510
0.03
0.07
0.03
0.05
0.04
0.03
0.05
0.05
−23.53
0.29
0.00
7.03
0.20
0.35
0.00
0.20

SEQID-01511
0.02
0.05
0.04
0.06
0.04
0.01
0.04
0.08
−20.83
0.44
−0.03
4.94
0.20
0.32
0.00
0.21

SEQID-01512
0.02
0.03
0.03
0.05
0.04
0.01
0.03
0.06
−27.97
0.35
−0.02
5.45
0.20
0.37
0.19
0.19

SEQID-01513
0.02
0.08
0.04
0.06
0.05
0.01
0.04
0.07
−21.63
0.39
−0.04
4.72
0.20
0.34
0.20
0.20

SEQID-01514
0.03
0.05
0.04
0.05
0.05
0.02
0.04
0.06
−20.51
0.39
−0.01
6.21
0.17
0.33
0.18
0.19

SEQID-01515
0.05
0.07
0.08
0.06
0.08
0.04
0.06
0.01
−15.18
0.44
0.02
9.00
0.26
0.25
0.00
0.26

SEQID-01516
0.16
0.02
0.00
0.06
0.02
0.02
0.02
0.00
−26.95
0.02
0.02
9.05
0.25
0.24
0.25
0.26

SEQID-01517
0.01
0.03
0.04
0.03
0.01
0.00
0.05
0.02
−27.30
0.13
0.09
10.47
0.30
0.32
0.00
0.27

SEQID-01518
0.04
0.05
0.05
0.03
0.05
0.00
0.03
0.02
−30.06
0.12
0.06
10.32
0.22
0.31
0.25
0.25

SEQID-01519
0.04
0.03
0.03
0.06
0.05
0.00
0.03
0.05
−24.45
0.32
0.20
12.14
0.25
0.27
0.00
0.25

SEQID-01520
0.01
0.05
0.05
0.06
0.05
0.00
0.08
0.08
−18.79
0.42
0.03
9.40
0.23
0.28
0.00
0.29

SEQID-01521
0.02
0.04
0.04
0.04
0.04
0.00
0.01
0.11
−19.76
0.50
0.02
9.69
0.27
0.31
0.00
0.26

SEQID-01522
0.02
0.05
0.03
0.06
0.04
0.02
0.08
0.09
−18.64
0.27
0.16
11.63
0.24
0.30
0.00
0.71

SEQID-01523
0.02
0.01
0.06
0.05
0.01
0.00
0.05
0.07
−25.54
0.24
0.20
11.55
0.18
0.30
0.21
0.22

SEQID-01524
0.01
0.02
0.01
0.04
0.05
0.00
0.00
0.05
−31.23
0.13
−0.02
5.11
0.29
0.33
0.27
0.22

SEQID-01525
0.01
0.01
0.03
0.05
0.04
0.00
0.03
0.04
−18.10
0.37
0.10
11.34
0.26
0.30
0.28
0.25

SEQID-01526
0.05
0.03
0.05
0.06
0.02
0.03
0.02
0.10
−17.41
0.58
0.09
11.03
0.25
0.29
0.27
0.00

SEQID-01527
0.02
0.02
0.03
0.04
0.05
0.03
0.07
0.08
−16.35
0.41
−0.02
5.59
0.37
0.37
0.23
0.19

SEQID-01528
0.03
0.04
0.06
0.10
0.01
0.04
0.06
0.07
−19.64
0.29
−0.01
6.35
0.21
0.30
0.22
0.00

SEQID-01529
0.03
0.06
0.05
0.07
0.04
0.00
0.04
0.11
−15.90
0.43
0.03
9.76
0.23
0.30
0.24
0.00

SEQID-01530
0.03
0.03
0.03
0.04
0.03
0.00
0.02
0.07
−22.46
0.32
−0.04
4.57
0.38
0.44
0.21
0.21

SEQID-01531
0.04
0.06
0.01
0.05
0.06
0.05
0.04
0.06
−19.58
0.45
0.00
7.51
0.00
0.32
0.00
0.22

SEQID-01532
0.01
0.11
0.05
0.03
0.02
0.00
0.05
0.05
−18.49
0.53
−0.03
4.75
0.00
0.31
0.00
0.26

SEQID-01533
0.03
0.05
0.03
0.06
0.04
0.00
0.08
0.07
−22.34
0.40
−0.01
6.13
0.24
0.31
0.00
0.22

SEQID-01534
0.01
0.06
0.05
6.06
0.06
0.06
0.01
0.06
−24.06
0.27
−0.03
5.17
0.24
0.31
0.00
0.22

SEQID-01535
0.02
0.05
0.02
0.06
0.04
0.01
0.05
0.09
−20.98
0.45
−0.01
5.45
0.22
0.34
0.24
0.00

SEQID-01536
0.03
0.05
0.04
0.04
0.05
0.01
0.03
0.06
−23.96
0.38
−0.01
6.30
0.22
0.33
0.00
0.21

SEQID-01537
0.01
0.03
0.03
0.07
0.08
0.00
0.04
0.09
−16.54
0.54
−0.06
4.27
0.23
0.31
0.21
0.00

SEQID-01538
0.03
0.08
0.05
0.07
0.01
0.02
0.07
0.04
−21.18
0.36
−0.01
6.64
0.23
0.34
0.00
0.00

SEQID-01539
0.05
0.02
0.02
0.07
0.04
0.01
0.00
0.04
−27.29
0.18
−0.08
4.37
0.24
0.35
0.00
0.00

SEQID-01540
0.02
0.07
0.03
0.03
0.03
0.02
0.03
0.05
−28.85
0.29
−0.09
4.76
0.23
0.30
0.00
0.22

SEQID-01541
0.04
0.06
0.04
0.04
0.06
0.03
0.08
0.07
−15.44
0.75
−0.06
4.20
0.21
0.32
0.00
0.20

SEQID-01542
0.03
0.09
0.03
0.07
0.04
0.00
0.02
0.04
−22.95
0.51
−0.08
4.18
0.23
0.32
0.00
0.22

SEQID-01543
0.03
0.04
0.02
0.07
0.05
0.01
0.05
0.05
−23.39
0.40
−0.08
4.38
0.00
0.33
0.22
0.00

SEQID-01544
0.04
0.03
0.04
0.05
0.06
0.02
0.06
0.03
−18.90
0.44
0.05
8.97
0.22
0.31
0.00
0.20

SEQID-01545
0.02
0.06
0.02
0.06
0.05
0.04
0.06
0.06
−18.02
0.41
−0.01
6.16
0.20
0.32
0.00
0.00

SEQID-01546
0.00
0.02
0.03
0.07
0.06
0.08
0.03
0.08
−20.14
0.42
−0.03
5.54
0.21
0.32
0.00
0.20

SEQID-01547
0.02
0.05
0.06
0.06
0.06
0.03
0.07
0.05
−18.75
0.39
0.01
8.29
0.21
0.35
0.20
0.22

SEQID-01548
0.03
0.07
0.05
0.05
0.03
0.02
0.08
0.04
−22.52
0.29
−0.02
5.16
0.21
0.32
0.00
0.25

SEQID-01549
0.03
0.02
0.02
0.08
0.07
0.00
0.06
0.07
−19.16
0.29
0.00
7.40
0.22
0.31
0.22
0.18

SEQID-01550
0.01
0.03
0.05
0.04
0.05
0.04
0.04
0.07
−20.54
0.32
0.01
8.22
0.23
0.31
0.00
0.20

SEQID-01551
0.03
0.06
0.05
0.05
0.07
0.00
0.03
0.06
−17.15
0.48
0.01
8.76
0.21
0.31
0.00
0.20

SEQID-01552
0.02
0.04
0.04
0.04
0.04
0.01
0.04
0.06
−23.14
0.35
−0.06
4.51
0.22
0.31
0.00
0.00

SEQID-01553
0.02
0.08
0.03
0.06
0.04
0.01
0.03
0.07
−22.22
0.40
−0.01
6.06
0.22
0.32
0.00
0.00

SEQID-01554
0.02
0.05
0.05
0.04
0.05
0.02
0.06
0.05
−21.32
0.33
−0.02
5.83
0.23
0.32
0.00
0.22

SEQID-01555
0.02
0.05
0.05
0.04
0.05
0.01
0.02
0.08
−21.34
0.43
−0.01
6.30
0.21
0.32
0.23
0.22

SEQID-01556
0.03
0.06
0.02
0.05
0.06
0.02
0.09
0.03
−20.12
0.32
−0.07
4.22
0.19
0.35
0.00
0.18

SEQID-01557
0.01
0.07
0.03
0.05
0.04
0.03
0.05
0.08
−18.69
0.55
0.01
8.39
0.20
0.35
0.00
0.20

SEQID-01558
0.03
0.04
0.04
0.04
0.04
0.03
0.08
0.04
−21.38
0.36
−0.01
6.19
0.20
0.32
0.00
0.20

SEQID-01559
0.03
0.04
0.06
0.06
0.07
0.00
0.02
0.06
−20.66
0.33
−0.10
3.97
0.21
0.35
0.00
0.22

SEQID-01560
0.02
0.07
0.05
0.08
0.06
0.01
0.04
0.05
−15.08
0.37
−0.01
5.18
0.22
0.33
0.21
0.21

SEQID-01561
0.03
0.07
0.03
0.03
0.07
0.03
0.04
0.05
−19.53
0.40
−0.02
5.49
0.20
0.33
0.00
0.20

SEQID-01562
0.01
0.05
0.03
0.17
0.03
0.01
0.02
0.03
−38.73
0.13
−0.05
4.58
0.26
0.57
0.21
0.22

SEQID-01563
0.02
0.03
0.04
0.09
0.04
0.00
0.02
0.04
−29.57
0.13
−0.11
4.19
0.22
0.32
0.23
0.22

SEQID-01564
0.02
0.06
0.04
0.05
0.06
0.02
0.05
0.06
−17.13
0.41
0.01
8.55
0.22
0.35
0.00
0.20

SEQID-01565
0.01
0.03
0.06
0.07
0.05
0.02
0.01
0.04
−30.23
0.14
−0.08
4.43
0.21
0.34
0.00
0.22

SEQID-01566
0.03
0.05
0.04
0.03
0.05
0.00
0.03
0.04
−25.47
0.32
−0.02
5.45
0.22
0.32
0.20
0.22

SEQID-01567
0.03
0.04
0.05
0.07
0.03
0.00
0.03
0.07
−21.91
0.33
0.01
9.44
0.21
0.34
0.22
0.21

SEQID-01568
0.04
0.07
0.03
0.06
0.05
0.02
0.04
0.06
−19.23
0.32
−0.06
4.37
0.40
0.54
0.00
0.21

SEQID-01569
0.03
0.06
0.02
0.05
0.06
0.02
0.05
0.04
−21.49
0.37
−0.02
5.48
0.22
0.32
0.00
0.22

SEQID-01570
0.01
0.06
0.03
0.05
0.02
0.02
0.06
0.05
−25.30
0.30
−0.01
5.94
0.21
0.34
0.19
0.21

SEQID-01571
0.01
0.06
0.05
0.05
0.03
0.02
0.07
0.04
−21.09
0.35
0.00
6.79
0.21
0.37
0.00
0.21

SEQID-01572
0.03
0.06
0.04
0.06
0.05
0.01
0.02
0.06
−17.35
0.38
0.02
8.40
0.21
0.31
0.00
0.21

SEQID-01573
0.02
0.08
0.03
0.06
0.05
0.01
0.05
0.05
−20.75
0.36
−0.01
5.30
0.22
0.14
0.00
0.21

SEQID-01574
0.01
0.07
0.04
0.05
0.05
0.02
0.04
0.06
−20.80
0.41
−0.02
5.63
0.20
0.33
0.00
0.21

SEQID-01575
0.03
0.05
0.04
0.04
0.06
0.02
0.04
0.07
−20.18
0.41
−0.01
6.47
0.21
0.33
0.00
0.21

SEQID-01576
0.03
0.05
0.05
0.03
0.06
0.02
0.05
0.06
−19.53
0.33
0.00
7.20
0.20
0.32
0.00
0.21

SEQID-01577
0.03
0.04
0.04
0.05
0.06
0.02
0.04
0.06
−21.89
0.35
0.00
6.82
0.21
0.32
0.20
0.21

SEQID-01578
0.04
0.09
0.03
0.06
0.06
0.03
0.07
0.07
−14.76
0.73
0.00
7.66
0.20
0.33
0.00
0.22

SEQID-01579
0.03
0.06
0.04
0.05
0.05
0.01
0.04
0.06
−22.28
0.11
−0.02
5.55
0.21
0.34
0.00
0.21

SEQID-01580
0.02
0.05
0.04
0.05
0.06
0.01
0.04
0.07
−24.31
0.31
−0.02
5.29
0.46
0.61
0.00
0.21

SEQID-01581
0.03
0.08
0.04
0.05
0.04
0.03
0.08
0.05
−20.71
0.35
−0.02
6.10
0.21
0.31
0.00
0.21

SEQID-01582
0.01
0.02
0.03
0.07
0.08
0.01
0.03
0.04
−28.38
0.10
−0.05
4.68
0.21
0.40
0.00
0.20

SEQID-01583
0.02
0.06
0.04
0.05
0.05
0.02
0.06
0.07
−24.33
0.25
0.01
8.67
0.20
0.33
0.00
0.20

SEQID-01584
0.02
0.05
0.05
0.04
0.06
0.00
0.03
0.07
−18.52
0.45
0.00
6.83
0.19
0.34
0.00
0.20

SEQID-01585
0.01
0.07
0.03
0.04
0.05
0.01
0.05
0.05
−23.50
0.29
−0.02
5.39
0.20
0.35
0.19
0.20

SEQID-01586
0.01
0.06
0.04
0.06
0.05
0.03
0.05
0.05
−20.61
0.30
0.00
7.23
0.19
0.33
0.20
0.20

SEQID-01587
0.02
0.07
0.04
0.06
0.05
0.04
0.06
0.05
−21.13
0.26
0.00
7.26
0.19
0.32
0.19
0.20

SEQID-01588
0.04
0.04
0.03
0.04
0.07
0.00
0.02
0.08
−21.16
0.46
−0.02
5.25
0.21
0.32
0.21
0.21

SEQID-01589
0.03
0.04
0.04
0.04
0.05
0.01
0.04
0.07
−22.57
0.34
0.00
7.14
0.19
0.35
0.19
0.19

SEQID-01590
0.02
0.01
0.04
0.05
0.05
0.01
0.04
0.05
−22.07
0.27
0.11
11.06
0.21
0.34
0.17
0.23

SEQID-01591
0.04
0.04
0.03
0.05
0.09
0.01
0.05
0.07
−18.50
0.40
−0.01
6.10
0.42
0.59
0.00
0.20

SEQID-01592
0.04
0.04
0.03
0.04
0.05
0.00
0.05
0.06
−22.72
0.32
−0.06
4.52
0.49
0.68
0.00
0.20

SEQID-01593
0.03
0.04
0.04
0.01
0.08
0.00
0.04
0.09
−22.55
0.42
−0.06
4.66
0.22
0.35
0.00
0.21

SEQID-01594
0.01
0.05
0.02
0.07
0.03
0.00
0.02
0.10
−25.27
0.36
−0.02
5.08
0.21
0.31
0.21
0.23

SEQID-01595
0.05
0.05
0.04
0.02
0.05
0.02
0.03
0.08
−23.32
0.48
−0.05
4.51
0.21
0.33
0.23
0.00

SEQID-01596
0.06
0.05
0.01
0.04
0.03
0.01
0.06
0.04
−24.98
0.25
0.21
11.84
0.00
0.27
0.00
0.22

SEQID-01597
0.04
0.04
0.05
0.04
0.05
0.01
0.04
0.10
−19.93
0.37
0.02
9.66
0.21
0.32
0.00
0.00

SEQID-01598
0.04
0.04
0.03
0.03
0.04
0.03
0.04
0.04
−25.91
0.31
−0.01
6.52
0.21
0.32
0.00
0.20

SEQID-01599
0.02
0.05
0.04
0.05
0.05
0.03
0.05
0.06
−21.91
0.32
−0.01
6.39
0.20
0.33
0.00
0.20

SEQID-01600
0.04
0.03
0.04
0.04
0.04
0.02
0.04
0.03
−20.96
0.45
−0.03
5.00
0.24
0.33
0.20
0.00

SEQID-01601
0.01
0.03
0.04
0.05
0.07
0.00
0.06
0.10
−23.64
0.26
0.04
9.92
0.24
0.30
0.00
0.24

SEQID-01602
0.04
0.05
0.02
0.03
0.05
0.00
0.05
0.07
−20.74
0.48
−0.03
5.74
0.21
0.32
0.22
0.22

SEQID-01603
0.03
0.03
0.04
0.04
0.04
0.00
0.02
0.08
−25.70
0.29
0.04
10.27
0.19
0.33
0.00
0.20

SEQID-01604
0.01
0.04
0.03
0.07
0.13
0.00
0.08
0.10
−16.36
0.36
0.03
9.90
0.23
0.36
0.23
0.23

SEQID-01605
0.04
0.01
0.05
0.06
0.05
0.00
0.07
0.09
−21.11
0.22
0.15
11.42
0.23
0.31
0.00
0.00

SEQID-01606
0.04
0.05
0.04
0.04
0.06
0.01
0.04
0.07
−22.99
0.36
−0.04
4.73
0.19
0.35
0.00
0.21

SEQID-01607
0.04
0.02
0.03
0.04
0.04
0.00
0.01
0.11
−23.44
0.40
0.07
10.98
0.00
0.30
0.00
0.24

SEQID-01608
0.03
0.02
0.04
0.04
0.06
0.01
0.04
0.13
−22.45
0.33
0.08
10.62
0.24
0.33
0.00
0.25

SEQID-01609
0.03
0.02
0.03
0.03
0.04
0.04
0.03
0.06
−23.54
0.22
0.07
10.93
0.00
0.33
0.00
0.00

SEQID-01610
0.03
0.04
0.04
0.04
0.06
0.01
0.04
0.07
−22.98
0.34
−0.02
5.30
0.21
0.37
0.00
0.22

SEQID-01611
0.03
0.02
0.04
0.05
0.05
0.02
0.05
0.06
−23.03
0.35
−0.05
4.54
0.42
0.59
0.00
0.00

SEQID-01612
0.05
0.03
0.05
0.05
0.06
0.00
0.05
0.06
−18.79
0.54
−0.02
5.06
0.21
0.32
0.00
0.23

SEQID-01613
0.03
0.04
0.02
0.03
0.04
0.02
0.04
0.05
−23.26
0.34
−0.05
4.63
0.21
0.34
0.24
0.00

SEQID-01614
0.02
0.05
0.03
0.07
0.03
0.04
0.07
0.06
−19.94
0.27
0.05
10.11
0.21
0.33
0.00
0.21

SEQID-01615
0.03
0.08
0.04
0.04
0.06
0.01
0.04
0.09
−15.06
0.74
0.00
6.63
0.21
0.35
0.00
0.20

SEQID-01616
0.02
0.03
0.03
0.08
0.11
0.01
0.09
0.07
−15.18
0.29
0.04
9.91
0.21
0.33
0.22
0.21

SEQID-01617
0.03
0.05
0.03
0.03
0.04
0.00
0.07
0.08
−29.91
0.24
−0.02
5.24
0.23
0.32
0.00
0.17

SEQID-01618
0.03
0.03
0.03
0.05
0.03
0.02
0.06
0.06
−23.87
0.26
0.05
10.31
0.00
0.30
0.00
0.23

SEQID-01619
0.03
0.05
0.04
0.04
0.04
0.01
0.02
0.08
−21.83
0.44
−0.02
5.34
0.23
0.35
0.24
0.21

SEQID-01620
0.03
0.06
0.03
0.05
0.04
0.01
0.08
0.05
−21.00
0.36
−0.04
4.69
0.21
0.33
0.00
0.22

SEQID-01621
0.01
0.06
0.04
0.04
0.04
0.00
0.00
0.08
−24.08
0.36
0.05
10.32
0.30
0.31
0.00
0.00

SEQID-01622
0.04
0.05
0.03
0.04
0.04
0.01
0.07
0.06
−20.44
0.39
0.01
7.92
0.20
0.31
0.00
0.21

SEQID-01623
0.01
0.03
0.03
0.01
0.06
0.00
0.04
0.11
−26.56
0.28
0.10
11.20
0.23
0.33
0.00
0.00

SEQID-01624
0.03
0.05
0.04
0.06
0.06
0.03
0.09
0.06
−19.40
0.27
0.06
10.13
0.20
0.34
0.20
0.20

SEQID-01625
0.03
0.03
0.01
0.10
0.06
0.01
0.07
0.06
−20.45
0.28
0.09
10.47
0.22
0.31
0.00
0.22

SEQID-01626
0.05
0.07
0.05
0.05
0.04
0.02
0.03
0.06
−16.88
0.71
−0.01
6.08
0.19
0.35
0.20
0.20

SEQID-01627
0.03
0.04
0.03
0.04
0.06
0.03
0.05
0.06
−23.61
0.26
−0.02
6.28
0.21
0.34
0.00
0.22

SEQID-01628
0.05
0.03
0.06
0.06
0.08
0.00
0.01
0.04
−23.11
0.37
0.04
10.15
0.25
0.27
0.00
0.00

SEQID-01629
0.04
0.01
0.02
0.04
0.05
0.00
0.11
0.12
−28.97
0.26
0.14
10.65
0.19
0.27
0.00
0.00

SEQID-01630
0.02
0.03
0.03
0.05
0.04
0.00
0.01
0.12
−23.06
0.57
0.07
10.72
0.27
0.33
0.25
0.23

SEQID-01631
0.03
0.02
0.03
0.05
0.03
0.01
0.06
0.08
−21.94
0.44
0.03
9.85
0.24
0.30
0.20
0.18

SEQID-01632
0.02
0.00
0.02
0.03
0.05
0.00
0.05
0.08
−29.33
0.29
0.11
10.97
0.24
0.33
0.29
0.24

SEQID-01633
0.05
0.02
0.02
0.02
0.06
0.00
0.03
0.08
−27.40
0.39
0.09
10.88
0.27
0.32
0.23
0.24

SEQID-01634
0.03
0.05
0.03
0.04
0.04
0.02
0.04
0.05
−19.86
0.54
−0.01
6.70
0.20
0.34
0.00
0.21

SEQID-01635
0.03
0.04
0.05
0.05
0.04
0.01
0.05
0.07
−18.51
0.45
−0.03
4.81
0.21
0.33
0.20
0.12

SEQID-01636
0.02
0.01
0.02
0.03
0.07
0.00
0.02
0.08
−22.43
0.41
−0.03
4.70
0.21
0.35
0.23
0.12

SEQID-01637
0.01
0.05
0.01
0.04
0.01
0.00
0.01
0.07
−31.55
0.39
−0.16
3.88
0.24
0.30
0.24
0.25

SEQID-01638
0.03
0.04
0.01
0.04
0.04
0.01
0.03
0.04
−28.30
0.24
−0.02
5.58
0.19
0.55
0.18
0.00

SEQID-01639
0.03
0.04
0.01
0.04
0.04
0.01
0.03
0.04
−28.28
0.23
−0.02
5.65
0.19
0.55
0.18
0.17

SEQID-01640
0.03
0.04
0.01
0.04
0.04
0.01
0.03
0.04
−28.28
0.23
−0.02
5.64
0.18
0.54
0.18
0.00

SEQID-01641
0.03
0.04
0.01
0.04
0.04
0.01
0.03
0.04
−28.15
0.23
−0.02
5.68
0.18
0.55
0.18
0.00

SEQID-01642
0.03
0.02
0.03
0.05
0.04
0.02
0.08
0.05
−25.06
0.21
0.03
9.44
0.00
0.34
0.00
0.00

SEQID-01643
0.02
0.04
0.05
0.06
0.07
0.02
0.05
0.08
−22.60
0.30
−0.01
6.25
0.00
0.34
0.00
0.18

SEQID-01644
0.05
0.04
0.04
0.05
0.06
0.02
0.06
0.05
−19.69
0.41
−0.03
5.05
0.19
0.30
0.00
0.20

SEQID-01645
0.04
0.06
0.05
0.04
0.04
0.02
0.03
0.05
−24.11
0.30
0.00
7.00
0.43
0.66
0.00
0.20

SEQID-01646
0.05
0.04
0.03
0.04
0.04
0.01
0.02
0.08
−21.25
0.45
0.01
7.66
0.21
0.35
0.00
0.21

SEQID-01647
0.02
0.04
0.06
0.04
0.05
0.03
0.03
0.09
−24.19
0.30
0.00
6.53
0.18
0.34
0.20
0.21

SEQID-01648
0.05
0.05
0.04
0.05
0.06
0.02
0.06
0.05
−19.52
0.43
−0.03
5.16
0.21
0.31
0.00
0.22

SEQID-01649
0.04
0.06
0.03
0.05
0.04
0.02
0.01
0.10
−20.59
0.46
0.01
8.29
0.23
0.36
0.00
0.22

SEQID-01650
0.03
0.05
0.03
0.04
0.04
0.01
0.03
0.07
−21.15
0.42
0.01
7.67
0.81
0.98
0.21
0.21

SEQID-01651
0.04
0.04
0.03
0.04
0.04
0.03
0.04
0.03
−24.31
0.28
−0.08
5.06
0.20
0.36
0.00
0.19

SEQID-01652
0.03
0.05
0.04
0.04
0.06
0.02
0.03
0.08
−18.95
0.64
−0.02
5.08
0.19
0.35
0.15
0.20

SEQID-01653
0.04
0.05
0.03
0.05
0.06
0.02
0.04
0.10
−17.92
0.49
0.02
8.82
0.70
0.86
0.00
0.20

SEQID-01654
0.02
0.03
0.07
0.05
0.07
0.03
0.05
0.09
−23.26
0.28
−0.01
6.41
0.21
0.34
0.00
0.23

SEQID-01655
0.03
0.07
0.04
0.04
0.05
0.01
0.05
0.06
−19.82
0.43
0.02
9.18
0.20
0.36
0.19
0.21

SEQID-01656
0.04
0.07
0.04
0.05
0.03
0.00
0.05
0.05
−22.74
0.38
−0.02
5.47
1.00
1.00
0.00
0.20

SEQID-01657
0.03
0.05
0.05
0.04
0.04
0.03
0.06
0.05
−19.55
0.37
0.00
6.98
0.18
0.34
0.19
0.00

SEQID-01658
0.01
0.04
0.03
0.04
0.04
0.03
0.02
0.08
−19.93
0.45
0.00
7.24
0.67
0.30
0.23
0.22

SEQID-01659
0.01
0.04
0.05
0.05
0.07
0.02
0.04
0.07
−23.94
0.29
−0.02
5.25
0.19
0.37
0.19
0.19

SEQID-01660
0.03
0.06
0.04
0.03
0.04
0.02
0.06
0.06
−22.25
0.32
−0.01
6.28
0.19
0.32
0.00
0.21

SEQID-01661
0.01
0.05
0.04
0.06
0.05
0.03
0.06
0.08
−22.31
0.32
−0.01
6.28
0.19
0.34
0.19
0.20

SEQID-01662
0.03
0.03
0.03
0.06
0.04
0.03
0.02
0.10
−19.92
0.55
0.02
8.02
0.23
0.32
0.20
0.19

SEQID-01663
0.01
0.04
0.03
0.06
0.07
0.02
0.04
0.07
−24.15
0.31
−0.02
5.47
0.00
0.33
0.00
0.00

SEQID-01664
0.05
0.09
0.04
0.03
0.05
0.01
0.02
0.05
−25.42
0.34
−0.05
4.48
0.41
0.59
0.23
0.23

SEQID-01665
0.03
0.07
0.04
0.04
0.06
0.04
0.04
0.05
−19.34
0.41
0.01
8.10
0.21
0.32
0.00
0.20

SEQID-01666
0.03
0.03
0.03
0.04
0.06
0.00
0.06
0.07
−25.16
0.32
0.02
8.95
0.22
0.33
0.00
0.22

SEQID-01667
0.05
0.02
0.02
0.04
0.02
0.01
0.02
0.04
−32.61
0.15
0.04
9.81
0.25
0.33
0.26
0.24

SEQID-01668
0.03
0.05
0.05
0.04
0.05
0.02
0.04
0.07
−22.22
0.37
0.02
8.84
0.38
0.60
0.00
0.22

SEQID-01669
0.03
0.05
0.03
0.04
0.07
0.00
0.04
0.06
−23.34
0.33
−0.01
5.34
0.71
0.89
0.00
0.21

SEQID-01670
0.02
0.03
0.19
0.03
0.03
0.01
0.02
0.03
−14.79
0.16
−0.01
5.27
0.61
0.78
0.21
0.39

SEQID-01671
0.04
0.07
0.07
0.02
0.04
0.00
0.01
0.05
−23.56
0.32
−0.04
4.68
0.31
0.49
0.00
0.22

SEQID-01672
0.03
0.04
0.05
0.03
0.04
0.05
0.03
0.05
−22.65
0.31
0.01
7.60
0.23
0.30
0.20
0.20

SEQID-01673
0.02
0.03
0.11
0.04
0.06
0.02
0.03
0.06
−21.53
0.26
0.01
7.60
0.21
0.41
0.21
0.22

SEQID-01674
0.02
0.05
0.04
0.06
0.05
0.03
0.05
0.08
−22.52
0.31
−0.02
5.83
0.19
0.33
0.19
0.19

SEQID-01675
0.02
0.05
0.03
0.04
0.04
0.01
0.04
0.08
−21.06
0.43
0.00
6.53
0.85
0.96
0.21
0.22

SEQID-01676
0.02
0.05
0.04
0.04
0.07
0.01
0.03
0.06
−22.28
0.54
−0.02
5.31
0.73
0.91
0.20
0.22

SEQID-01677
0.02
0.06
0.05
0.05
0.05
0.00
0.03
0.08
−18.73
0.43
0.00
6.68
0.00
0.52
0.18
1.00

SEQID-01678
0.01
0.03
0.19
0.03
0.03
0.01
0.02
0.03
−13.57
0.17
0.01
9.57
0.84
0.96
0.22
0.39

SEQID-01679
0.00
0.02
0.02
0.02
0.02
0.02
0.03
0.02
−36.28
0.11
0.01
7.24
0.24
0.37
0.23
0.23

SEQID-01680
0.02
0.03
0.06
0.07
0.06
0.03
0.06
0.06
−14.89
0.38
0.00
6.51
0.23
0.33
0.24
0.24

SEQID-01681
0.03
0.08
0.02
0.04
0.03
0.03
0.06
0.07
−17.57
0.56
0.06
10.24
0.20
0.31
0.22
0.00

SEQID-01682
0.03
0.08
0.03
0.02
0.03
0.02
0.03
0.05
−31.94
0.40
−0.19
3.81
0.21
0.33
0.00
0.23

SEQID-01683
0.03
0.04
0.05
0.05
0.06
0.02
0.04
0.08
−20.68
0.41
0.08
9.50
0.21
0.34
0.00
0.22

SEQID-01684
0.02
0.07
0.06
0.05
0.05
0.01
0.05
0.04
−20.28
0.38
0.01
8.43
0.22
0.32
0.19
0.23

SEQID-01685
0.04
0.04
0.04
0.05
0.06
0.00
0.07
0.07
−19.87
0.58
0.01
8.17
0.22
0.34
0.00
0.21

SEQID-01686
0.03
0.04
0.01
0.05
0.05
0.00
0.04
0.05
−25.43
0.13
−0.02
5.27
0.29
0.46
0.00
0.21

SEQID-01687
0.03
0.06
0.03
0.05
0.04
0.02
0.04
0.05
−21.38
0.46
−0.02
5.37
0.00
0.34
0.00
0.16

SEQID-01688
0.03
0.05
0.06
0.05
0.06
0.00
0.02
0.08
−16.80
0.55
0.02
8.74
0.51
0.70
0.00
0.00

SEQID-01689
0.04
0.04
0.03
0.05
0.05
0.02
0.04
0.07
−18.64
0.49
0.01
7.89
0.19
0.34
0.00
0.21

SEQID-01690
0.02
0.04
0.05
0.10
0.07
0.01
0.04
0.06
−22.89
0.22
0.01
3.52
0.19
0.40
0.20
0.20

SEQID-01691
0.02
0.00
0.00
0.04
0.03
0.00
0.03
0.03
−36.78
0.12
−0.09
4.39
0.59
0.70
0.26
0.22

SEQID-01692
0.04
0.05
0.03
0.06
0.04
0.03
0.05
0.05
−19.60
0.40
0.04
9.78
0.21
0.32
0.00
0.20

SEQID-01693
0.05
0.07
0.04
0.05
0.06
0.01
0.05
0.06
−19.49
0.81
−0.05
4.52
0.40
0.54
0.00
0.22

SEQID-01694
0.03
0.04
0.03
0.05
0.05
0.00
0.04
0.08
−18.98
0.46
0.02
9.56
0.21
0.34
0.00
0.22

SEQID-01695
0.02
0.04
0.08
0.04
0.05
0.01
0.04
0.05
−20.77
0.84
−0.01
5.62
0.26
0.54
0.20
0.30

SEQID-01696
0.00
0.05
0.03
0.06
0.11
0.03
0.03
0.07
−23.51
0.85
−0.02
4.88
0.30
0.19
0.00
0.36

SEQID-01697
0.01
0.07
0.02
0.08
0.09
0.02
0.06
0.05
−17.82
0.80
0.01
8.88
0.20
0.32
0.00
0.00

SEQID-01698
0.04
0.05
0.08
0.06
0.05
0.01
0.06
0.04
−20.82
0.18
0.08
9.60
0.18
0.33
0.00
0.23

SEQID-01699
0.02
0.04
0.04
0.06
0.07
0.01
0.05
0.05
−17.51
0.40
0.02
8.79
0.10
0.33
0.00
0.21

SEQID-01700
0.03
0.03
0.02
0.05
0.04
0.00
0.07
0.04
−25.38
0.85
0.00
7.40
0.21
0.33
0.00
0.00

SEQID-01701
0.04
0.09
0.05
0.05
0.04
0.03
0.07
0.05
−16.01
0.54
0.04
9.63
0.19
0.30
0.00
0.21

SEQID-01702
0.02
0.06
0.04
0.04
0.06
0.01
0.06
0.06
−20.11
0.87
−0.05
4.74
0.95
1.00
0.20
0.22

SEQID-01703
0.04
0.06
0.04
0.05
0.04
0.01
0.07
0.05
−21.59
0.82
0.00
7.30
0.20
0.31
0.00
0.21

SEQID-01704
0.02
0.02
0.03
0.06
0.03
0.02
0.02
0.03
−24.91
0.22
−0.08
5.14
0.20
0.37
0.00
0.21

SEQID-01705
0.04
0.05
0.05
0.04
0.04
0.02
0.05
0.08
−18.71
0.48
0.00
7.01
0.20
0.32
0.19
0.21

SEQID-01706
0.04
0.05
0.04
0.04
0.04
0.02
0.03
0.08
−19.28
0.44
−0.01
5.54
0.20
0.36
0.00
0.23

SEQID-01707
0.03
0.04
0.06
0.04
0.05
0.02
0.04
0.08
−19.01
0.52
0.04
9.77
0.21
0.34
0.22
0.23

SEQID-01708
0.04
0.05
0.04
0.04
0.05
0.02
0.02
0.07
−19.00
0.45
−0.01
5.91
0.20
0.33
0.00
0.21

SEQID-01709
0.03
0.05
0.03
0.06
0.06
0.03
0.04
0.11
−19.75
0.48
0.00
7.59
0.88
0.98
0.20
0.00

SEQID-01710
0.03
0.06
0.04
0.05
0.04
0.02
0.07
0.05
−20.59
0.40
−0.01
6.34
0.20
0.34
0.00
0.21

SEQID-01711
0.04
0.05
0.05
0.04
0.03
0.01
0.02
0.12
−19.29
0.53
0.00
6.72
0.27
0.34
0.00
0.21

SEQID-01712
0.05
0.05
0.05
0.04
0.03
0.01
0.02
0.12
−19.24
0.54
0.00
6.72
0.27
0.33
0.00
0.20

SEQID-01713
0.03
0.05
0.03
0.03
0.06
0.02
0.05
0.06
−24.64
0.80
0.18
10.78
0.67
0.76
0.00
0.18

SEQID-01714
0.03
0.08
0.03
0.06
0.06
0.02
0.04
0.08
−12.35
0.97
−0.01
5.13
0.20
0.34
0.19
0.20

SEQID-01715
0.05
0.02
0.04
0.04
0.02
0.01
0.03
0.04
−29.46
0.20
0.22
11.90
0.25
0.32
0.00
0.22

SEQID-01716
0.04
0.02
0.03
0.05
0.03
0.02
0.03
0.04
−29.79
0.14
0.22
11.90
0.26
0.31
0.18
0.10

SEQID-01717
0.03
0.08
0.03
0.06
0.06
0.02
0.05
0.08
−12.15
0.97
−0.01
5.37
0.20
0.34
0.20
0.21

SEQID-01718
0.01
0.03
0.04
0.03
0.04
0.04
0.07
0.07
−25.61
0.22
0.21
12.15
0.23
0.31
0.00
0.22

SEQID-01719
0.03
0.07
0.03
0.06
0.05
0.01
0.05
0.09
−12.62
0.98
−0.02
5.14
0.20
0.34
0.21
0.21

SEQID-01720
0.02
0.05
0.05
0.04
0.03
0.06
0.03
0.08
−20.31
0.88
0.00
7.19
0.22
0.33
0.22
0.22

SEQID-01721
0.03
0.05
0.04
0.04
0.07
0.01
0.04
0.08
−22.00
0.41
0.04
9.79
0.22
0.35
0.21
0.22

SEQID-01722
0.03
0.06
0.04
0.07
0.02
0.01
0.05
0.08
−16.23
0.49
0.00
6.79
0.37
0.58
0.00
0.22

SEQID-01723
0.02
0.04
0.03
0.05
0.05
0.00
0.03
0.05
−27.65
0.24
0.16
11.39
0.20
0.34
0.19
0.00

SEQID-01724
0.05
0.04
0.05
0.06
0.05
0.02
0.06
0.06
−19.93
0.44
−0.08
5.06
0.21
0.34
0.00
0.19

SEQID-01725
0.05
0.04
0.04
0.05
0.06
0.02
0.06
0.05
−19.69
0.41
−0.08
5.05
0.20
0.31
0.00
0.21

SEQID-01726
0.04
0.02
0.04
0.05
0.03
0.02
0.03
0.05
−29.76
0.17
0.22
12.00
0.26
0.32
0.20
0.23

SEQID-01727
0.01
0.01
0.13
0.04
0.04
0.00
0.01
0.07
−23.43
0.24
0.21
11.50
0.29
0.39
0.24
0.26

SEQID-01728
0.01
0.03
0.04
0.04
0.06
0.01
0.06
0.06
−20.62
0.42
0.01
7.71
0.22
0.33
0.22
0.21

SEQID-01729
0.05
0.04
0.05
0.05
0.06
0.02
0.06
0.06
−19.71
0.44
−0.03
5.16
0.20
0.33
0.00
0.21

SEQID-01730
0.04
0.05
0.05
0.07
0.05
0.01
0.05
0.06
−16.27
0.44
0.01
8.56
0.21
0.34
0.00
0.22

SEQID-01731
0.04
0.09
0.05
0.04
0.06
0.01
0.03
0.10
−17.51
0.37
0.03
8.95
0.80
0.34
0.00
0.24

SEQID-01732
0.01
0.04
0.02
0.01
0.07
0.00
0.06
0.06
−25.48
0.31
0.12
10.46
0.25
0.31
0.22
0.00

SEQID-01733
0.03
0.03
0.05
0.05
0.04
0.03
0.03
0.08
−23.98
0.34
0.11
11.32
0.22
0.37
0.00
0.19

SEQID-01734
0.04
0.07
0.03
0.04
0.05
0.01
0.04
0.07
−21.67
0.43
−1.02
5.11
0.21
0.33
0.00
0.21

SEQID-01735
0.03
0.05
0.00
0.04
0.04
0.02
0.09
0.03
−16.81
0.18
0.00
6.53
0.33
0.50
0.26
0.35

SEQID-01736
0.01
0.04
0.05
0.12
0.03
0.00
0.01
0.04
−31.20
0.13
−0.04
4.73
0.18
0.43
0.20
0.23

SEQID-01737
0.02
0.03
0.06
0.03
0.04
0.01
0.02
0.06
−29.88
0.33
−0.04
4.86
0.19
0.35
0.19
0.18

SEQID-01738
0.02
0.04
0.07
0.06
0.04
0.00
0.03
0.05
−24.32
0.23
0.12
10.82
0.28
0.32
0.26
0.27

SEQID-01739
0.04
0.02
0.07
0.03
0.02
0.04
0.07
0.04
−16.56
0.35
0.03
8.54
0.36
0.53
0.24
0.25

SEQID-01740
0.01
0.04
0.04
0.05
0.05
0.04
0.02
0.13
−17.37
0.51
−0.01
5.39
0.88
0.94
0.00
0.00

SEQID-01741
0.01
0.01
0.14
0.04
0.05
0.00
0.02
0.03
−23.90
0.14
0.23
11.53
0.26
0.40
0.27
0.23

SEQID-01742
0.03
0.03
0.02
0.06
0.05
0.01
0.07
0.04
−26.09
0.32
−0.06
4.46
0.23
0.31
0.00
0.00

SEQID-01743
0.02
0.05
0.03
0.05
0.05
0.02
0.03
0.09
−18.35
0.48
0.00
6.53
0.22
0.35
0.23
0.23

SEQID-01744
0.02
0.02
0.04
0.06
0.02
0.00
0.05
0.04
−12.99
0.30
0.00
7.03
0.37
0.54
0.21
0.22

SEQID-01745
0.02
0.06
0.05
0.03
0.03
0.06
0.04
0.07
−20.06
0.31
−0.01
6.79
0.21
0.32
0.23
0.22

SEQID-01746
0.02
0.02
0.01
0.07
0.05
0.00
0.02
0.04
−29.01
0.19
−0.09
4.37
0.22
0.39
0.18
0.18

SEQID-01747
0.04
0.06
0.03
0.07
0.03
0.02
0.05
0.02
−22.79
0.13
0.25
12.25
0.25
0.23
0.25
0.25

SEQID-01748
0.01
0.01
0.21
0.04
0.04
0.00
0.03
0.07
−6.36
0.48
0.03
3.03
0.33
0.41
0.29
0.24

SEQID-01749
0.03
0.04
0.04
0.02
0.05
0.02
0.03
0.06
−25.48
0.20
0.17
11.40
0.21
0.32
0.23
0.20

SEQID-01750
0.04
0.04
0.03
0.04
0.06
0.02
0.04
0.07
−20.83
0.49
−0.02
5.70
0.22
0.35
0.23
0.21

SEQID-01751
0.03
0.05
0.03
0.06
0.04
0.01
0.04
0.05
−25.28
0.31
0.02
9.52
0.21
0.33
0.20
0.21

SEQID-01752
0.03
0.05
0.05
0.03
0.05
0.04
0.06
0.04
−20.99
0.33
0.02
9.01
0.16
0.35
0.17
0.18

SEQID-01753
0.02
0.03
0.01
0.02
0.06
0.00
0.06
0.07
−23.82
0.31
0.18
12.01
0.00
0.23
0.00
0.29

SEQID-01754
0.01
0.03
0.08
0.02
0.01
0.00
0.04
0.07
−24.56
0.26
0.17
11.38
0.24
0.23
0.25
0.25

SEQID-01755
0.02
0.01
0.09
0.08
0.05
0.05
0.02
0.04
−14.26
0.60
0.01
7.87
0.49
0.59
0.25
1.00

SEQID-01756
0.02
0.07
0.05
0.06
0.03
0.05
0.04
0.07
−19.52
0.43
0.00
6.81
0.23
0.33
0.24
0.21

SEQID-01757
0.02
0.06
0.05
0.01
0.06
0.01
0.07
0.07
−21.11
0.37
0.00
7.15
0.20
0.34
0.00
0.00

SEQID-01758
0.01
0.01
0.14
0.04
0.06
0.00
0.02
0.04
−23.91
0.15
0.22
11.47
0.27
0.38
0.28
0.27

SEQID-01759
0.03
0.05
0.04
0.03
0.05
0.01
0.04
0.06
−22.82
0.35
0.10
10.82
0.21
0.31
0.00
0.00

SEQID-01760
0.04
0.05
0.04
0.03
0.07
0.03
0.02
0.07
−21.26
0.39
0.00
6.69
0.22
0.34
1.00
0.00

SEQID-01761
0.02
0.06
0.07
0.03
0.05
0.03
0.03
0.09
−15.03
0.55
0.00
6.67
0.27
0.46
0.21
0.22

SEQID-01762
0.03
0.05
0.04
0.08
0.06
0.02
0.04
0.09
−17.42
0.45
0.02
8.86
0.61
0.88
0.00
0.21

SEQID-01763
0.02
0.03
0.03
0.05
0.05
0.01
0.03
0.04
−26.38
0.34
0.02
9.46
0.21
0.36
0.22
0.22

SEQID-01764
0.03
0.08
0.03
0.05
0.06
0.00
0.00
0.07
−17.92
0.64
0.12
10.11
0.32
0.32
0.30
0.31

SEQID-01765
0.02
0.05
0.04
0.03
0.07
0.00
0.02
0.04
−23.97
0.30
0.15
11.86
0.23
0.31
0.26
0.00

SEQID-01766
0.01
0.05
0.03
0.06
0.06
0.00
0.02
0.08
−23.42
0.37
−0.03
5.87
0.25
0.30
0.00
0.21

SEQID-01767
0.04
0.07
0.05
0.04
0.02
0.06
0.05
0.08
−19.94
0.40
0.00
7.76
0.27
0.32
0.00
0.24

SEQID-01768
0.01
0.04
0.03
0.04
0.04
0.01
0.04
0.04
−29.34
0.19
0.22
11.43
0.23
0.31
0.23
0.24

SEQID-01769
0.02
0.07
0.06
0.04
0.04
0.01
0.04
0.04
−20.43
0.34
−0.03
5.16
0.26
0.33
0.22
0.21

SEQID-01770
0.02
0.04
0.05
0.04
0.04
0.01
0.04
0.08
−19.28
0.34
0.13
11.66
0.00
0.35
0.22
0.24

SEQID-01771
0.04
0.03
0.05
0.06
0.05
0.02
0.03
0.10
−17.25
0.53
−0.01
5.98
0.25
0.34
0.19
0.22

SEQID-01772
0.03
0.07
0.06
0.04
0.04
0.03
0.06
0.08
−22.03
0.34
−0.01
6.42
0.22
0.36
0.00
0.20

SEQID-01773
0.03
0.04
0.03
0.05
0.04
0.02
0.05
0.07
−19.84
0.40
−0.02
4.95
0.89
0.98
0.22
0.22

SEQID-01774
0.02
0.05
0.05
0.05
0.03
0.01
0.06
0.05
−18.41
0.45
0.00
6.62
0.21
0.33
0.00
0.22

SEQID-01775
0.05
0.05
0.04
0.04
0.05
0.02
0.04
0.07
−20.94
0.40
−0.01
6.28
0.19
0.33
0.00
0.21

SEQID-01776
0.05
0.02
0.05
0.03
0.05
0.00
0.01
0.06
−28.61
0.28
0.24
12.14
0.26
0.31
0.21
0.20

SEQID-01777
0.03
0.06
0.04
0.03
0.05
0.01
0.01
0.11
−19.18
0.65
−0.01
6.67
0.60
0.69
0.25
0.20

SEQID-01778
0.02
0.02
0.07
0.02
0.03
0.04
0.05
0.10
−14.55
0.53
0.05
10.62
0.37
0.41
0.28
1.00

SEQID-01779
0.03
0.08
0.01
0.08
0.03
0.01
0.05
0.06
−24.77
0.26
−0.01
5.29
0.22
0.29
0.21
0.23

SEQID-01780
0.03
0.06
0.05
0.02
0.03
0.01
0.05
0.07
−21.15
0.33
0.18
11.37
0.23
0.30
0.00
0.19

SEQID-01781
0.01
0.07
0.04
0.05
0.05
0.01
0.04
0.06
−21.09
0.35
0.17
11.28
0.25
0.30
0.21
0.22

SEQID-01782
0.04
0.05
0.02
0.03
0.05
0.02
0.02
0.06
−26.59
0.30
0.13
11.42
0.25
0.33
0.20
0.20

SEQID-01783
0.13
0.00
0.07
0.05
0.03
0.01
0.12
0.04
−6.89
0.52
0.01
8.00
0.26
0.34
0.00
0.23

SEQID-01784
0.04
0.07
0.04
0.03
0.06
0.03
0.08
0.05
−21.92
0.25
0.15
11.07
0.23
0.28
0.00
0.00

SEQID-01785
0.02
0.05
0.03
0.03
0.02
0.01
0.05
0.06
−25.46
0.28
0.10
10.94
0.21
0.33
0.00
0.00

SEQID-01786
0.02
0.06
0.02
0.05
0.06
0.02
0.04
0.03
−22.05
0.39
0.01
8.44
0.00
0.30
0.20
0.24

SEQID-01787
0.03
0.05
0.04
0.04
0.02
0.01
0.05
0.06
−23.74
0.25
0.13
10.91
0.21
0.31
0.00
0.25

SEQID-01788
0.02
0.08
0.04
0.08
0.05
0.01
0.02
0.08
−17.07
0.47
0.03
9.88
0.24
0.81
0.00
0.24

SEQID-01789
0.04
0.04
0.04
0.02
0.03
0.03
0.04
0.10
−11.71
0.93
0.04
10.01
0.23
0.35
0.26
0.24

SEQID-01790
0.03
0.05
0.02
0.04
0.05
0.02
0.03
0.08
−25.32
0.30
0.08
10.48
0.21
0.31
0.00
0.00

SEQID-01791
0.04
0.07
0.05
0.04
0.05
0.01
0.02
0.09
−18.66
0.49
0.00
6.72
0.24
0.32
0.00
0.22

SEQID-01792
0.03
0.03
0.04
0.05
0.04
0.00
0.05
0.07
−18.93
0.46
−0.01
5.90
0.21
0.37
0.00
0.23

SEQID-01793
0.02
0.04
0.05
0.05
0.06
0.00
0.04
0.08
−18.17
0.47
−0.01
6.37
0.22
0.33
0.00
0.22

SEQID-01794
0.04
0.08
0.04
0.05
0.04
0.03
0.07
0.06
−19.95
0.32
−0.02
6.31
0.19
0.32
0.00
0.21

SEQID-01795
0.01
0.01
0.04
0.05
0.07
0.00
0.07
0.08
−25.22
0.20
0.25
11.95
0.25
0.30
0.26
0.25

SEQID-01796
0.02
0.02
0.03
0.05
0.04
0.00
0.03
0.05
−26.89
0.26
0.24
11.90
0.24
0.31
0.27
0.25

SEQID-01797
0.06
0.04
0.03
0.04
0.06
0.01
0.03
0.06
−11.76
0.85
0.03
10.18
0.58
0.79
0.30
0.23

SEQID-01798
0.05
0.03
0.06
0.01
0.05
0.00
0.03
0.10
−26.63
0.40
0.01
8.46
0.39
0.52
0.23
0.25

SEQID-01799
0.05
0.05
0.05
0.05
0.06
0.02
0.05
0.05
−21.19
0.26
0.00
6.94
0.22
0.32
0.22
0.22

SEQID-01800
0.01
0.09
0.05
0.03
0.05
0.01
0.06
0.06
−19.85
0.36
0.01
8.43
0.22
0.33
0.22
0.25

SEQID-01801
0.01
0.04
0.02
0.04
0.02
0.01
0.10
0.03
−18.98
0.10
−0.01
6.26
0.29
0.49
0.28
0.32

SEQID-01802
0.03
0.06
0.05
0.03
0.05
0.00
0.02
0.08
−22.83
0.42
0.16
12.03
0.00
0.30
0.00
0.24

SEQID-01803
0.04
0.04
0.03
0.03
0.03
0.03
0.04
0.05
−14.04
0.78
−0.01
6.41
0.25
0.34
0.25
0.24

SEQID-01804
0.01
0.07
0.06
0.05
0.03
0.04
0.07
0.05
−16.72
0.46
−0.01
5.64
0.25
0.31
0.00
0.00

SEQID-01805
0.04
0.05
0.03
0.04
0.04
0.01
0.04
0.09
−21.68
0.44
0.05
10.22
0.23
0.30
0.00
0.00

SEQID-01806
0.03
0.03
0.06
0.05
0.04
0.01
0.02
0.06
−23.13
0.34
0.01
7.97
0.00
0.31
0.23
0.00

SEQID-01807
0.02
0.04
0.05
0.02
0.04
0.02
0.02
0.07
−24.75
0.37
0.14
11.12
0.00
0.31
0.24
0.21

SEQID-01808
0.01
0.08
0.04
0.05
0.05
0.03
0.07
0.08
−11.36
0.94
0.01
7.97
0.23
0.33
0.00
0.21

SEQID-01809
0.02
0.06
0.05
0.03
0.07
0.02
0.02
0.09
−20.81
0.41
0.08
10.85
0.23
0.33
0.20
0.26

SEQID-01810
0.04
0.08
0.04
0.04
0.05
0.02
0.05
0.07
−14.40
0.53
0.05
10.22
0.22
0.31
0.00
0.15

SEQID-01811
0.02
0.05
0.03
0.04
0.04
0.00
0.08
0.04
−26.68
0.27
0.04
9.78
0.19
0.37
0.00
0.23

SEQID-01812
0.02
0.05
0.05
0.06
0.04
0.00
0.05
0.09
−21.32
0.56
−0.02
4.93
0.23
0.49
0.00
0.00

SEQID-01813
0.02
0.07
0.07
0.09
0.07
0.01
0.03
0.09
−9.80
0.68
0.00
7.68
0.22
0.32
0.22
0.21

SEQID-01814
0.03
0.09
0.03
0.06
0.03
0.02
0.07
0.05
−16.57
0.45
0.06
10.35
0.21
0.33
0.00
0.21

SEQID-01815
0.04
0.08
0.04
0.06
0.04
0.07
0.02
0.07
−17.44
0.77
0.05
10.58
0.21
0.32
0.18
0.19

SEQID-01816
0.03
0.07
0.05
0.07
0.05
0.02
0.04
0.09
−11.10
0.84
0.06
10.53
0.21
0.31
0.00
0.22

SEQID-01817
0.05
0.08
0.05
0.09
0.04
0.04
0.05
0.08
−11.63
0.77
0.04
10.12
0.21
0.30
0.00
0.20

SEQID-01818
0.04
0.04
0.06
0.06
0.06
0.03
0.04
0.03
−17.52
0.45
−0.01
6.14
0.25
0.32
0.00
0.24

SEQID-01819
0.02
0.08
0.04
0.03
0.03
0.02
0.03
0.06
−23.99
0.39
0.00
6.74
0.23
0.32
0.00
0.22

SEQID-01820
0.03
0.06
0.05
0.06
0.06
0.04
0.07
0.06
−17.01
0.43
0.01
8.42
0.22
0.31
0.00
0.22

SEQID-01821
0.01
0.05
0.05
0.05
0.04
0.01
0.03
0.08
−20.56
0.44
−0.02
4.99
0.21
0.34
0.00
0.22

SEQID-01822
0.03
0.09
0.03
0.06
0.05
0.01
0.06
0.07
−12.55
0.92
0.02
9.11
0.20
0.33
0.00
0.22

SEQID-01823
0.03
0.05
0.05
0.04
0.04
0.01
0.06
0.05
−19.29
0.44
−0.02
5.12
0.21
0.30
0.00
0.21

SEQID-01824
0.02
0.04
0.04
0.05
0.05
0.00
0.02
0.09
−17.75
0.51
0.00
7.07
0.21
0.35
0.20
0.22

SEQID-01825
0.03
0.07
0.01
0.03
0.04
0.05
0.08
0.05
−18.27
0.71
0.09
10.32
0.31
0.28
0.00
0.00

SEQID-01826
0.06
0.02
0.02
0.06
0.10
0.02
0.02
0.16
−18.59
0.39
−0.01
5.02
0.30
0.30
0.26
0.24

SEQID-01627
0.05
0.12
0.06
0.05
0.04
0.00
0.05
0.06
−14.20
0.51
−0.02
6.07
0.53
0.60
0.00
0.22

SEQID-01828
0.02
0.02
0.03
0.04
0.03
0.00
0.04
0.06
−18.73
0.48
0.08
10.91
0.24
0.30
0.31
0.22

SEQID-01829
0.01
0.03
0.07
0.02
0.01
0.00
0.03
0.07
−23.75
0.29
0.17
11.60
0.23
0.30
0.23
0.26

SEQID-01830
0.03
0.04
0.06
0.04
0.07
0.01
0.01
0.10
−19.88
0.43
0.02
9.21
0.26
0.34
0.16
0.26

SEQID-01831
0.03
0.05
0.04
0.04
0.03
0.00
0.01
0.06
−23.32
0.35
0.09
11.36
0.24
0.32
0.00
0.23

SEQID-01832
0.02
0.04
0.05
0.04
0.02
0.02
0.06
0.07
−21.28
0.28
0.07
10.53
0.22
0.30
0.20
0.21

SEQID-01833
0.05
0.02
0.04
0.06
0.03
0.01
0.03
0.12
−18.22
0.58
0.00
7.15
0.19
0.31
0.24
0.25

SEQID-01834
0.02
0.05
0.05
0.02
0.05
0.00
0.07
0.07
−23.53
0.36
0.15
11.29
0.24
0.31
0.00
0.21

SEQID-01835
0.01
0.09
0.05
0.07
0.05
0.03
0.00
0.07
−25.23
0.26
−0.01
5.78
0.74
0.88
0.00
0.28

SEQID-01836
0.03
0.03
0.04
0.02
0.04
0.03
0.04
0.05
−18.59
0.62
−0.04
4.41
0.27
0.35
0.21
0.25

SEQID-01837
0.01
0.02
0.05
0.03
0.05
0.02
0.04
0.06
−19.08
0.62
−0.01
6.25
0.27
0.32
0.26
0.25

SEQID-01838
0.02
0.03
0.06
0.03
0.06
0.01
0.05
0.10
−21.38
0.32
0.12
11.06
0.22
0.28
0.00
0.25

SEQID-01839
0.03
0.06
0.01
0.03
0.07
0.04
0.04
0.06
−20.86
0.45
0.00
6.80
0.22
0.31
0.00
0.25

SEQID-01840
0.04
0.04
0.05
0.04
0.04
0.03
0.06
0.07
−18.59
0.47
−0.02
5.34
0.25
0.33
0.21
0.23

SEQID-01841
0.02
0.07
0.06
0.05
0.05
0.01
0.03
0.07
−24.15
0.39
0.10
10.85
0.23
0.31
0.00
0.00

SEQID-01842
0.04
0.01
0.04
0.03
0.03
0.02
0.05
0.06
−25.12
0.36
0.13
10.87
0.20
0.31
0.20
0.00

SEQID-01843
0.03
0.06
0.01
0.06
0.05
0.02
0.05
0.10
−23.04
0.39
−0.01
5.80
0.20
0.29
0.00
0.00

SEQID-01844
0.03
0.04
0.06
0.05
0.02
0.01
0.07
0.07
−23.20
0.42
−0.02
5.39
0.22
0.33
0.20
0.22

SEQID-01845
0.04
0.05
0.06
0.03
0.07
0.01
0.04
0.07
−21.00
0.36
0.00
6.79
0.81
0.91
0.23
0.20

SEQID-01846
0.02
0.03
0.04
0.04
0.03
0.05
0.06
0.07
−16.96
0.39
0.00
7.32
0.75
0.94
0.21
0.00

SEQID-01847
0.02
0.08
0.05
0.07
0.04
0.01
0.04
0.08
−16.06
0.59
−0.01
6.23
0.23
0.33
0.24
0.00

SEQID-01848
0.02
0.02
0.04
0.07
0.07
0.00
0.04
0.12
−19.65
0.63
0.01
8.90
0.17
0.34
0.23
0.00

SEQID-01849
0.03
0.05
0.04
0.06
0.04
0.03
0.05
0.05
−18.97
0.54
0.02
9.46
0.24
0.31
0.20
0.23

SEQID-01850
0.01
0.07
0.05
0.05
0.04
0.03
0.08
0.06
−12.44
0.40
0.04
8.62
0.51
0.65
0.19
0.24

SEQID-01851
0.02
0.04
0.03
0.02
0.01
0.01
0.06
0.06
−25.38
0.30
0.10
10.72
0.23
0.33
0.22
0.00

SEQID-01852
0.02
0.06
0.06
0.08
0.02
0.01
0.05
0.04
−15.19
0.11
0.01
7.81
0.29
0.49
0.23
0.29

SEQID-01853
0.00
0.00
0.38
0.04
0.20
0.00
0.09
0.01
−12.64
0.12
0.10
10.61
0.26
0.54
0.29
0.25

SEQID-01854
0.04
0.05
0.05
0.05
0.02
0.01
0.04
0.08
−19.12
0.53
−0.01
5.47
0.21
0.33
0.00
0.00

SEQID-01855
0.03
0.08
0.04
0.05
0.04
0.02
0.02
0.07
−18.77
0.58
−0.02
5.23
0.00
0.33
0.00
0.19

SEQID-01856
0.03
0.05
0.05
0.07
0.05
0.00
0.03
0.09
−17.27
0.52
0.00
8.03
0.53
0.71
0.00
0.22

SEQID-01857
0.03
0.05
0.04
0.04
0.05
0.02
0.03
0.11
−17.00
0.54
0.00
6.82
0.28
0.35
0.20
0.21

SEQID-01858
0.03
0.07
0.06
0.06
0.03
0.01
0.04
0.08
−16.63
0.53
0.01
8.46
0.22
0.35
0.00
0.22

SEQID-01859
0.03
0.06
0.05
0.05
0.05
0.01
0.04
0.07
−17.33
0.54
0.01
7.73
0.22
0.33
0.20
0.22

SEQID-01860
0.03
0.05
0.04
0.04
0.04
0.02
0.04
0.09
−20.27
0.38
−0.02
5.18
0.22
0.34
0.22
0.23

SEQID-01861
0.04
0.09
0.04
0.06
0.04
0.03
0.05
0.06
−12.27
0.91
0.03
9.53
0.20
0.33
0.00
0.21

SEQID-01862
0.02
0.03
0.05
0.06
0.07
0.01
0.03
0.07
−19.54
0.41
0.00
7.45
0.21
0.34
0.18
0.21

SEQID-01863
0.03
0.04
0.03
0.04
0.06
0.01
0.03
0.06
−23.07
0.38
−0.03
4.84
0.71
0.91
0.00
0.20

SEQID-01864
0.03
0.07
0.04
0.05
0.05
0.03
0.04
0.07
−18.51
0.52
0.02
9.23
0.19
0.33
0.20
0.20

SEQID-01865
0.03
0.04
0.01
0.04
0.05
0.01
0.03
0.04
−28.16
0.23
−0.02
5.50
0.18
0.58
0.18
0.18

SEQID-01866
0.03
0.04
0.01
0.04
0.05
0.01
0.03
0.04
−28.15
0.23
−0.02
5.56
0.18
0.55
0.18
0.17

SEQID-01867
0.03
0.04
0.01
0.04
0.04
0.01
0.03
0.04
−28.30
0.23
−0.02
5.50
0.19
0.55
0.18
0.17

SEQID-01868
0.03
0.04
0.01
0.04
0.04
0.01
0.03
0.04
−28.42
0.22
−0.02
5.48
0.18
0.53
0.18
0.19

SEQID-01869
0.05
0.04
0.04
0.05
0.06
0.02
0.06
0.05
−19.69
0.41
−0.03
5.05
0.19
0.30
0.00
0.20

SEQID-01870
0.02
0.04
0.06
0.05
0.08
0.01
0.04
0.08
−22.75
0.31
0.01
8.67
0.18
0.35
0.18
0.19

SEQID-01871
0.03
0.06
0.03
0.03
0.04
0.02
0.06
0.06
−22.38
0.34
0.00
7.11
0.19
0.31
0.00
0.20

SEQID-01872
0.03
0.04
0.03
0.03
0.04
0.03
0.04
0.03
−24.32
0.29
−0.03
5.13
0.20
0.36
0.00
0.20

SEQID-01873
0.03
0.05
0.04
0.04
0.04
0.02
0.04
0.07
−23.56
0.32
0.00
7.11
0.42
0.54
0.00
0.00

SEQID-01874
0.00
0.07
0.04
0.03
0.04
0.01
0.05
0.05
−24.99
0.33
−0.01
6.33
0.80
0.90
0.00
0.22

SEQID-01875
0.03
0.05
0.03
0.04
0.04
0.01
0.04
0.07
−20.83
0.43
0.01
8.12
0.85
0.99
0.21
0.22

SEQID-01876
0.04
0.05
0.04
0.04
0.06
0.02
0.03
0.08
−19.08
0.62
−0.02
4.92
0.19
0.35
0.18
0.20

SEQID-01877
0.04
0.04
0.04
0.04
0.05
0.01
0.03
0.08
−20.69
0.45
0.01
7.94
0.22
0.31
0.00
0.22

SEQID-01878
0.04
0.04
0.03
0.03
0.04
0.03
0.03
0.04
−23.47
0.31
−0.03
5.12
0.21
0.34
0.00
0.20

SEQID-01879
0.04
0.06
0.03
0.05
0.06
0.02
0.04
0.09
−17.84
0.47
0.02
8.58
0.69
0.85
0.00
0.21

SEQID-01880
0.04
0.06
0.04
0.05
0.06
0.03
0.03
0.08
−18.26
0.64
−0.02
4.99
0.18
0.35
0.19
0.20

SEQID-01881
0.02
0.04
0.06
0.05
0.05
0.03
0.05
0.07
−23.52
0.30
−0.01
6.23
0.19
0.33
0.19
0.20

SEQID-01882
0.01
0.02
0.18
0.03
0.03
0.01
0.02
0.04
−13.80
0.20
0.01
9.54
0.95
1.00
0.21
0.39

SEQID-01883
0.04
0.03
0.03
0.05
0.04
0.01
0.09
0.04
−24.90
0.20
0.04
9.62
0.18
0.33
0.19
0.18

SEQID-01884
0.01
0.08
0.03
0.04
0.05
0.02
0.07
0.06
−21.41
0.25
0.07
8.46
0.22
0.30
0.21
0.23

SEQID-01885
0.04
0.06
0.06
0.03
0.03
0.00
0.02
0.05
−23.23
0.36
−0.04
4.61
0.33
0.46
0.00
0.25

SEQID-01886
0.01
0.04
0.04
0.03
0.05
0.03
0.02
0.09
−19.17
0.44
0.00
7.03
0.65
0.34
0.00
0.22

SEQID-01887
0.03
0.05
0.05
0.04
0.04
0.02
0.04
0.06
−21.09
0.44
−0.04
4.95
0.00
0.41
0.00
0.18

SEQID-01888
0.03
0.09
0.02
0.04
0.03
0.03
0.06
0.07
−16.87
0.54
0.07
10.33
0.21
0.34
0.00
0.00

SEQID-01889
0.05
0.09
0.03
0.02
0.05
0.01
0.02
0.05
−25.05
0.32
−0.04
4.61
0.41
0.59
0.25
0.23

SEQID-01890
0.04
0.05
0.04
0.05
0.03
0.02
0.01
0.09
−20.27
0.44
0.01
8.04
0.22
0.35
0.21
0.22

SEQID-01891
0.02
0.05
0.05
0.06
0.05
0.03
0.05
0.09
−22.19
0.34
−0.03
5.09
0.19
0.34
0.19
0.18

SEQID-01892
0.03
0.03
0.03
0.05
0.03
0.03
0.03
0.10
−18.61
0.56
0.01
8.23
0.23
0.31
0.00
0.21

SEQID-01893
0.02
0.05
0.06
0.04
0.05
0.02
0.04
0.09
−23.86
0.30
0.00
6.49
0.19
0.35
0.19
0.30

SEQID-01894
0.01
0.05
0.07
0.05
0.05
0.05
0.06
0.05
−20.39
0.32
0.02
7.97
0.23
0.31
0.00
0.22

SEQID-01895
0.04
0.03
0.05
0.03
0.05
0.05
0.03
0.04
−23.30
0.27
0.02
9.03
0.21
0.30
0.21
0.20

SEQID-01896
0.02
0.02
0.03
0.05
0.05
0.02
0.09
0.06
−25.22
0.18
0.04
9.62
0.00
0.34
0.18
0.18

SEQID-01897
0.02
0.04
0.02
0.06
0.05
0.00
0.04
0.05
−25.35
0.18
−0.03
4.94
0.30
0.45
0.20
0.23

SEQID-01898
0.03
0.07
0.04
0.05
0.05
0.01
0.05
0.06
−19.06
0.43
0.00
7.01
0.21
0.52
0.00
0.22

SEQID-01899
0.04
0.04
0.02
0.04
0.07
0.02
0.03
0.07
−19.21
0.46
0.01
8.28
0.20
0.34
0.00
0.20

SEQID-01900
0.02
0.04
0.04
0.06
0.05
0.03
0.06
0.07
−22.22
0.31
−0.01
6.46
0.18
0.35
0.19
0.19

SEQID-01901
0.04
0.05
0.06
0.09
0.05
0.01
0.05
0.04
−17.28
0.20
0.01
8.67
0.24
0.40
0.25
0.25

SEQID-01902
0.02
0.01
0.03
0.02
0.01
0.01
0.03
0.03
−38.43
0.07
−0.01
6.36
0.23
0.36
0.23
0.23

SEQID-01903
0.03
0.06
0.06
0.05
0.04
0.02
0.07
0.07
−15.95
0.55
0.04
9.68
0.20
0.34
0.00
0.21

SEQID-01904
0.02
0.06
0.03
0.04
0.06
0.03
0.05
0.06
−21.24
0.34
0.02
8.76
0.21
0.31
0.00
0.21

SEQID-01905
0.02
0.05
0.07
0.05
0.07
0.01
0.04
0.09
−18.84
0.32
−0.02
5.81
0.00
0.39
0.17
0.22

SEQID-01906
0.03
0.05
0.04
0.04
0.05
0.02
0.04
0.06
−22.41
0.34
0.01
3.31
0.37
0.56
0.00
0.20

SEQID-01907
0.03
0.07
0.04
0.05
0.06
0.04
0.03
0.05
−19.24
0.41
0.01
8.17
0.20
0.33
0.00
0.21

SEQID-01908
0.04
0.00
0.00
0.03
0.03
0.00
0.02
0.03
−36.92
0.12
−0.11
4.32
0.55
0.68
0.23
0.35

SEQID-01909
0.02
0.04
0.03
0.05
0.05
0.00
0.05
0.07
−19.57
0.43
0.01
9.19
0.21
0.32
0.00
0.21

SEQID-01910
0.02
0.04
0.05
0.04
0.05
0.02
0.04
0.05
−19.81
0.39
0.01
8.14
0.20
0.33
0.00
0.21

SEQID-01911
0.02
0.03
0.04
0.06
0.07
0.02
0.02
0.10
−20.99
0.34
−0.01
6.28
0.21
0.32
0.19
0.21

SEQID-01912
0.01
0.07
0.04
0.06
0.0S
0.01
0.02
0.09
−16.91
0.42
0.03
9.14
0.24
0.31
0.00
0.26

SEQID-01913
0.02
0.07
0.02
0.03
0.01
0.02
0.02
0.12
−18.96
0.49
0.01
7.84
0.25
0.31
0.24
0.26

SEQID-01914
0.01
0.10
0.09
0.07
0.04
0.02
0.02
0.05
−23.35
0.27
0.01
7.38
0.24
0.35
0.23
0.24

SEQID-01915
0.03
0.02
0.24
0.03
0.01
0.00
0.00
0.02
−12.61
0.11
0.02
10.55
0.70
0.80
0.31
0.48

SEQID-01916
0.04
0.01
0.03
0.04
0.03
0.02
0.02
0.05
−30.81
0.23
0.07
10.33
0.26
0.33
0.00
0.21

SEQID-01917
0.01
0.04
0.13
0.05
0.02
0.01
0.04
0.08
−16.73
0.44
−0.01
6.39
0.27
0.33
0.29
0.27

SEQID-01918
0.04
0.11
0.04
0.02
0.05
0.00
0.02
0.05
−26.07
0.31
−0.05
4.56
0.41
0.60
0.00
0.00

SEQID-01919
0.03
0.05
0.06
0.05
0.06
0.00
0.02
0.08
−16.12
0.56
0.02
8.90
0.51
0.69
0.22
0.21

SEQID-01920
0.03
0.04
0.03
0.06
0.04
0.02
0.03
0.08
−20.62
0.54
0.00
6.53
0.25
0.33
0.17
0.00

SEQID-01921
0.01
0.03
0.05
0.04
0.04
0.01
0.05
0.07
−19.18
0.43
0.00
6.63
0.20
0.33
0.00
0.21

SEQID-01922
0.03
0.04
0.05
0.04
0.06
0.00
0.04
0.08
−17.78
0.51
−0.03
4.92
0.22
0.33
0.23
0.22

SEQID-01923
0.02
0.05
0.08
0.06
0.03
0.01
0.03
0.03
−23.01
0.25
−0.09
4.22
0.23
0.40
0.20
0.23

SEQID-01924
0.02
0.04
0.05
0.05
0.04
0.03
0.09
0.03
−22.92
0.44
0.01
7.66
0.20
0.28
0.21
0.22

SEQID-01925
0.01
0.03
0.21
0.04
0.03
0.01
0.01
0.03
−13.36
0.14
0.00
5.29
0.50
0.73
0.29
0.46

SEQID-01926
0.04
0.06
0.03
0.03
0.04
0.00
0.02
0.07
−17.97
0.56
−0.03
5.11
0.22
0.30
0.00
0.23

SEQID-01927
0.04
0.05
0.04
0.05
0.06
0.02
0.03
0.09
−20.09
0.45
0.04
9.88
0.21
0.33
0.00
0.21

SEQID-01928
0.02
0.04
0.06
0.04
0.02
0.03
0.03
0.07
−20.39
0.43
−0.01
6.51
0.22
0.34
0.22
0.23

SEQID-01929
0.02
0.04
0.01
0.04
0.05
0.01
0.04
0.04
−28.64
0.25
−0.01
6.48
0.22
0.40
0.00
0.20

SEQID-01930
0.03
0.05
0.05
0.05
0.04
0.03
0.06
0.05
−19.50
0.38
0.00
6.80
0.19
0.35
0.18
0.19

SEQID-01931
0.02
0.04
0.04
0.04
0.06
0.02
0.05
0.06
−18.28
0.41
0.02
8.47
0.24
0.31
0.00
0.20

SEQID-01932
0.03
0.05
0.03
0.05
0.06
0.03
0.05
0.10
−18.27
0.46
0.02
8.91
0.69
0.84
0.00
0.22

SEQID-01933
0.02
0.04
0.04
0.05
0.06
0.02
0.05
0.05
−18.20
0.40
0.02
8.61
0.24
0.31
0.00
0.20

SEQID-01934
0.02
0.05
0.03
0.04
0.03
0.01
0.04
0.06
−21.81
0.39
0.00
7.27
0.98
1.00
0.21
0.21

SEQID-01935
0.02
0.05
0.03
0.04
0.04
0.01
0.04
0.06
−21.72
0.38
0.00
7.09
1.00
1.00
0.20
0.22

SEQID-01936
0.05
0.04
0.04
0.05
0.06
0.02
0.06
0.05
−19.65
0.42
−0.03
5.05
0.19
0.30
0.00
0.19

SEQID-01937
0.04
0.06
0.04
0.04
0.05
0.02
0.03
0.06
−23.67
0.30
0.00
6.93
0.43
0.61
0.00
0.21

SEQID-01938
0.02
0.04
0.03
0.04
0.04
0.04
0.02
0.09
−19.79
0.43
0.01
7.89
0.68
0.76
0.22
0.00

SEQID-01939
0.05
0.06
0.04
0.04
0.04
0.02
0.03
0.06
−23.33
0.31
0.00
6.92
0.43
0.64
0.00
0.20

SEQID-01940
0.02
0.00
0.00
0.04
0.04
0.00
0.03
0.03
−36.46
0.13
−0.10
4.34
0.53
0.68
0.25
0.22

SEQID-01941
0.04
0.04
0.03
0.04
0.05
0.01
0.03
0.06
−21.67
0.42
0.01
8.12
0.20
0.35
0.00
0.22

SEQID-01942
0.0S
0.06
0.07
0.02
0.03
0.00
0.02
0.07
−23.48
0.34
−0.06
4.40
0.28
0.37
0.00
0.24

SEQID-01943
0.04
0.06
0.03
0.03
0.03
0.02
0.06
0.06
−22.73
0.34
0.00
7.18
0.20
0.33
0.00
0.20

SEQID-01944
0.04
0.06
0.03
0.04
0.04
0.01
0.01
0.09
−20.06
0.45
0.01
8.29
0.22
0.35
0.00
0.21

SEQID-01945
0.05
0.06
0.07
0.02
0.03
0.00
0.02
0.07
−23.48
0.34
−0.06
4.40
0.28
0.37
0.00
0.24

SEQID-01946
0.04
0.09
0.03
0.04
0.04
0.01
0.03
0.06
−23.98
0.39
−0.06
4.41
0.41
0.54
0.00
0.33

SEQID-01947
0.04
0.03
0.04
0.03
0.05
0.05
0.03
0.04
−23.93
0.30
0.03
9.29
0.21
0.30
0.20
0.00

SEQID-01948
0.09
0.01
0.01
0.04
0.02
0.01
0.01
0.05
−31.08
0.29
0.04
10.04
0.28
0.36
0.22
0.75

SEQID-01949
0.04
0.03
0.03
0.04
0.04
0.00
0.05
0.07
−25.50
0.40
0.01
8.17
0.00
0.33
0.00
0.21

SEQID-01950
0.02
0.03
0.09
0.03
0.07
0.02
0.04
0.07
−22.65
0.29
−0.01
5.76
0.21
0.44
0.00
0.23

SEQID-01951
0.02
0.14
0.01
0.02
0.35
0.00
0.00
0.04
−24.37
0.45
−0.04
4.73
1.00
1.00
0.24
0.22

SEQID-01952
0.04
0.02
0.03
0.03
0.06
0.00
0.02
0.10
−20.88
0.50
−0.01
5.38
0.20
0.35
0.19
0.22

SEQID-01953
0.01
0.02
0.04
0.03
0.02
0.01
0.01
0.04
−39.35
0.11
−0.03
5.20
0.24
0.40
0.23
0.25

SEQID-01954
0.04
0.06
0.03
0.02
0.06
0.01
0.01
0.09
−19.05
0.60
0.00
6.97
0.22
0.32
0.00
0.22

SEQID-01955
0.03
0.04
0.04
0.04
0.06
0.02
0.04
0.08
−20.42
0.45
0.03
9.75
0.21
0.31
0.00
0.21

SEQID-01956
0.04
0.05
0.02
0.04
0.05
0.02
0.04
0.04
−22.36
0.29
−0.07
4.39
0.20
0.34
0.00
0.21

SEQID-01957
0.04
0.09
0.02
0.05
0.04
0.03
0.06
0.05
−16.87
0.53
0.06
10.30
0.20
0.31
0.00
0.20

SEQID-01958
0.03
0.06
0.04
0.04
0.06
0.03
0.06
0.06
−20.42
0.37
0.01
7.71
0.21
0.34
0.00
0.20

SEQID-01959
0.04
0.05
0.04
0.04
0.06
0.02
0.03
0.05
−21.88
0.34
0.01
7.73
0.37
0.59
0.00
0.21

SEQID-01960
0.03
0.03
0.04
0.05
0.05
0.00
0.04
0.09
−18.98
0.44
0.02
9.29
0.21
0.33
0.19
0.22

SEQID-01961
0.03
0.07
0.04
0.05
0.05
0.01
0.05
0.07
−18.96
0.44
0.00
7.19
0.21
0.33
0.00
0.21

SEQID-01962
0.02
0.07
0.04
0.06
0.05
0.01
0.07
0.06
−19.47
0.32
0.01
9.19
0.20
0.33
0.00
0.20

SEQID-01963
0.02
0.07
0.04
0.06
0.05
0.01
0.07
0.06
−19.50
0.32
0.01
9.03
0.20
0.33
0.00
0.20

SEQID-01964
0.04
0.02
0.03
0.03
0.06
0.00
0.02
0.07
−22.39
0.45
−0.03
4.71
0.21
0.34
0.22
0.22

SEQID-01965
0.02
0.02
0.06
0.07
0.05
0.00
0.02
0.09
−22.73
0.33
−0.02
5.25
0.19
0.34
0.20
0.20

SEQID-01966
0.02
0.02
0.05
0.05
0.05
0.00
0.01
0.09
−21.32
0.37
−0.02
5.11
0.20
0.36
0.00
0.21

SEQID-01967
0.03
0.06
0.04
0.04
0.04
0.01
0.05
0.09
−21.62
0.44
−0.03
4.79
0.19
0.32
0.00
0.22

SEQID-01968
0.03
0.06
0.04
0.04
0.04
0.01
0.05
0.08
−21.87
0.43
−0.03
4.68
0.20
0.33
0.00
0.22

SEQID-01969
0.05
0.04
0.03
0.04
0.04
0.01
0.02
0.07
−19.58
0.53
−0.03
5.04
0.18
0.32
0.20
0.22

SEQID-01970
0.04
0.03
0.04
0.05
0.05
0.00
0.05
0.07
−18.79
0.41
−0.02
6.01
0.20
0.31
0.00
0.10

SEQID-01971
0.02
0.04
0.05
0.04
0.06
0.03
0.01
0.05
−22.65
0.19
0.02
9.92
0.21
0.33
0.17
0.00

SEQID-01972
0.01
0.04
0.04
0.04
0.03
0.03
0.07
0.05
−20.52
0.33
−0.03
4.96
0.18
0.36
0.19
0.19

SEQID-01973
0.01
0.03
0.05
0.09
0.05
0.02
0.04
0.06
−17.93
0.33
0.01
8.33
0.20
0.35
0.20
0.21

SEQID-01974
0.03
0.02
0.03
0.05
0.07
0.03
0.04
0.10
−17.52
0.53
−0.01
6.51
0.46
0.62
0.00
0.20

SEQID-01975
0.03
0.02
0.03
0.05
0.07
0.03
0.04
0.10
−17.78
0.52
0.00
6.72
0.46
0.62
0.00
0.19

SEQID-01976
0.03
0.07
0.06
0.04
0.06
0.03
0.07
0.05
−18.64
0.28
0.02
9.52
0.22
0.31
0.00
0.20

SEQID-01977
0.03
0.09
0.04
0.05
0.05
0.06
0.04
0.05
−12.42
0.65
0.01
7.91
0.20
0.34
0.00
0.21

SEQID-01978
0.02
0.04
0.03
0.03
0.04
0.00
0.03
0.06
−24.74
0.39
−0.02
5.17
0.20
0.33
0.52
0.21

SEQID-01979
0.01
0.05
0.06
0.09
0.09
0.01
0.03
0.07
−13.51
0.41
0.00
6.95
0.20
0.37
0.20
0.20

SEQID-01980
0.02
0.04
0.05
0.04
0.04
0.01
0.05
0.07
−22.92
0.34
−0.02
5.09
0.20
0.34
0.20
0.20

SEQID-01981
0.04
0.04
0.04
0.02
0.03
0.00
0.03
0.08
−22.02
0.46
−0.03
5.12
0.22
0.31
0.20
0.22

SEQID-01982
0.04
0.04
0.05
0.03
0.06
0.02
0.07
0.04
−19.89
0.33
0.00
6.79
0.21
0.34
0.00
0.00

SEQID-01983
0.04
0.04
0.04
0.02
0.03
0.00
0.03
0.08
−21.44
0.46
−0.03
5.22
0.21
0.31
0.20
0.22

SEQID-01984
0.02
0.05
0.04
0.05
0.05
0.03
0.05
0.07
−18.58
0.45
−0.02
5.96
0.21
0.33
0.00
0.22

SEQID-01985
0.04
0.02
0.04
0.03
0.07
0.00
0.06
0.03
−24.96
0.23
0.02
9.66
0.00
0.30
0.21
0.25

SEQID-01986
0.04
0.02
0.02
0.04
0.06
0.00
0.01
0.09
−20.21
0.51
−0.03
4.60
0.21
0.35
0.22
0.21

SEQID-01987
0.02
0.05
0.03
0.05
0.07
0.03
0.05
0.05
−20.16
0.29
−0.03
5.06
0.16
0.35
0.18
0.19

SEQID-01988
0.03
0.04
0.04
0.05
0.05
0.01
0.04
0.09
−21.92
0.44
−0.04
4.75
0.20
0.32
0.00
0.20

SEQID-01989
0.02
0.03
0.04
0.04
0.06
0.01
0.03
0.09
−22.26
0.39
−0.06
4.33
0.19
0.34
0.20
0.20

SEQID-01990
0.05
0.10
0.05
0.04
0.05
0.03
0.03
0.10
−21.67
0.43
−0.03
4.62
0.35
0.46
0.00
0.23

SEQID-01991
0.03
0.05
0.03
0.05
0.04
0.02
0.08
0.07
−19.43
0.27
0.01
9.01
0.23
0.32
0.00
0.23

SEQID-01992
0.04
0.07
0.06
0.03
0.06
0.03
0.03
0.06
−16.92
0.43
−0.02
4.62
0.21
0.33
0.00
0.00

SEQID-01993
0.03
0.13
0.05
0.04
0.05
0.06
0.03
0.07
−14.71
0.55
−0.01
6.13
0.22
0.36
0.22
0.23

SEQID-01994
0.03
0.03
0.04
0.05
0.05
0.00
0.05
0.07
−18.50
0.48
−0.03
4.53
0.21
0.32
0.21
0.21

SEQID-01995
0.04
0.01
0.02
0.04
0.06
0.00
0.01
0.09
−20.53
0.52
−0.03
4.70
0.22
0.34
0.22
0.21

SEQID-01996
0.03
0.07
0.04
0.05
0.04
0.01
0.05
0.06
−18.00
0.45
−0.02
5.27
0.19
0.33
0.00
0.22

SEQID-01997
0.02
0.05
0.03
0.05
0.06
0.0)
0.05
0.05
−20.64
0.28
−0.03
4.99
0.16
0.35
0.13
0.19

SEQID-01998
0.03
0.11
0.05
0.04
0.05
0.06
0.04
0.07
−14.37
0.56
−0.01
6.40
0.22
0.36
0.00
0.23

SEQID-01999
0.04
0.02
0.04
0.04
0.07
0.00
0.06
0.03
−24.83
0.23
0.02
8.66
0.24
0.31
0.00
0.00

SEQID-02000
0.03
0.07
0.05
0.03
0.07
0.01
0.05
0.04
−22.75
0.22
0.02
8.96
0.22
0.28
0.19
0.21

SEQID-02001
0.05
0.03
0.03
0.06
0.06
0.00
0.09
0.09
−20.51
0.45
−0.03
4.60
0.00
0.31
0.26
0.24

SEQID-02002
0.02
0.05
0.03
0.09
0.05
0.01
0.09
0.06
−19.91
0.29
0.01
8.38
0.21
0.34
0.00
0.00

SEQID-02003
0.04
0.05
0.05
0.05
0.05
0.00
0.04
0.09
−18.47
0.49
−0.03
4.64
0.21
0.33
0.21
0.22

SEQID-02004
0.02
0.03
0.04
0.04
0.07
0.00
0.02
0.08
−22.66
0.36
−0.04
4.52
0.49
0.78
0.00
0.21

SEQID-02005
0.03
0.07
0.04
0.05
0.04
0.01
0.05
0.06
−17.91
0.46
−0.03
5.03
0.21
0.33
0.00
0.22

SEQID-02006
0.03
0.09
0.04
0.04
0.05
0.07
0.06
0.05
−12.46
0.63
0.00
7.04
0.20
0.31
0.00
0.20

SEQID-02007
0.01
0.03
0.02
0.07
0.05
0.00
0.03
0.02
−24.40
0.16
−0.03
4.85
0.22
0.39
0.00
0.19

SEQID-02008
0.04
0.02
0.02
0.06
0.06
0.00
0.11
0.06
−16.77
0.44
0.00
6.60
0.23
0.30
0.21
0.25

SEQID-02009
0.03
0.09
0.04
0.04
0.03
0.06
0.05
0.06
−12.75
0.69
−0.01
6.58
0.21
0.34
0.00
0.22

SEQID-02010
0.03
0.05
0.04
0.03
0.04
0.03
0.07
0.05
−20.82
0.31
−0.02
6.11
0.20
0.34
0.00
0.20

SEQID-02011
0.03
0.04
0.05
0.05
0.04
0.02
0.04
0.06
−18.19
0.42
−0.02
5.59
0.20
0.34
0.20
0.21

SEQID-02012
0.01
0.04
0.03
0.07
0.06
0.00
0.04
0.03
−22.36
0.24
−0.01
5.90
0.22
0.35
0.19
0.21

SEQID-02013
0.02
0.04
0.04
0.05
0.06
0.00
0.04
0.06
−20.36
0.41
−0.02
5.32
0.22
0.31
0.00
0.00

SEQID-02014
0.01
0.02
0.01
0.05
0.07
0.01
0.00
0.04
−24.24
0.09
−0.09
4.24
0.23
0.36
0.20
0.21

SEQID-02015
0.03
0.09
0.05
0.03
0.04
0.06
0.07
0.05
−20.47
0.34
−0.04
5.55
0.19
0.36
0.00
0.20

SEQID-02016
0.01
0.00
0.24
0.06
0.07
0.00
0.00
0.04
−39.60
0.05
0.00
7.54
0.33
0.35
0.33
0.34

SEQID-02017
0.04
0.04
0.03
0.09
0.06
0.00
0.05
0.07
−16.22
0.56
−0.02
4.71
0.00
0.32
0.23
0.23

SEQID-02018
0.03
0.02
0.03
0.03
0.06
0.01
0.05
0.03
−23.78
0.41
−0.03
4.90
0.24
0.31
0.00
0.24

SEQID-02019
0.04
0.10
0.04
0.06
0.04
0.05
0.06
0.07
−10.97
0.74
−0.02
5.24
0.21
0.31
0.00
0.20

SEQID-02020
0.02
0.06
0.04
0.03
0.05
0.01
0.02
0.07
−20.48
0.50
−0.02
5.04
0.21
0.33
0.21
0.23

SEQID-02021
0.04
0.03
0.02
0.03
0.04
0.01
0.02
0.07
−26.59
0.33
−0.01
5.56
0.22
0.34
0.19
0.00

SEQID-02022
0.02
0.04
0.03
0.05
0.05
0.01
0.03
0.07
−21.00
0.39
0.00
8.02
0.21
0.33
0.00
0.00

SEQID-02023
0.04
0.04
0.03
0.03
0.07
0.01
0.03
0.09
−19.81
0.47
−0.02
5.81
0.22
0.32
0.00
0.21

SEQID-02024
0.03
0.05
0.05
0.04
0.04
0.04
0.06
0.05
−19.74
0.33
−0.02
6.18
0.19
0.33
0.00
0.20

SEQID-02025
0.02
0.05
0.03
0.04
0.05
0.02
0.06
0.06
−21.52
0.37
−0.02
5.59
0.19
0.33
0.19
0.20

SEQID-02026
0.03
0.03
0.02
0.03
0.04
0.01
0.02
0.07
−27.34
0.28
−0.01
5.56
0.23
0.33
0.00
0.00

SEQID-02027
0.02
0.01
0.06
0.05
0.05
0.01
0.04
0.07
−21.18
0.31
0.13
11.71
0.25
0.35
0.21
0.24

SEQID-02028
0.01
0.04
0.21
0.03
0.06
0.01
0.02
0.06
−24.60
0.34
−0.01
5.18
0.23
0.44
0.26
0.24

SEQID-02029
0.03
0.05
0.04
0.06
0.07
0.02
0.04
0.09
−18.14
0.47
−0.02
5.39
0.58
0.79
0.00
0.22

SEQID-02030
0.02
0.07
0.04
0.06
0.05
0.02
0.08
0.05
−18.45
0.35
0.00
7.05
0.23
0.32
0.00
0.22

SEQID-02031
0.03
0.06
0.06
0.05
0.04
0.03
0.04
0.06
−19.68
0.41
−0.04
4.61
0.22
0.35
0.00
0.23

SEQID-02032
0.01
0.05
0.03
0.05
0.03
0.01
0.02
0.08
−19.30
0.61
0.00
7.53
0.23
0.33
0.00
0.00

SEQID-02033
0.02
0.08
0.05
0.05
0.05
0.02
0.03
0.08
−18.53
0.45
0.00
6.31
0.22
0.33
0.00
0.22

SEQID-02034
0.03
0.03
0.04
0.03
0.03
0.02
0.04
0.07
−22.24
0.40
0.01
8.52
0.20
0.34
0.00
0.21

SEQID-02035
0.04
0.05
0.03
0.06
0.06
0.00
0.09
0.04
−17.35
0.41
0.05
9.69
0.26
0.30
0.00
0.23

SEQID-02036
0.06
0.05
0.11
0.05
0.07
0.00
0.02
0.04
−22.02
0.20
0.06
10.52
0.28
0.37
0.27
0.26

SEQID-02037
0.03
0.04
0.03
0.06
0.06
0.01
0.02
0.08
−20.55
0.45
0.02
9.48
0.21
0.33
0.00
0.24

SEQID-02038
0.01
0.02
0.03
0.04
0.05
0.03
0.03
0.09
−23.12
0.36
0.06
10.69
0.00
0.30
0.23
0.21

SEQID-02039
0.03
0.02
0.02
0.06
0.04
0.01
0.01
0.04
−23.29
0.20
−0.03
4.72
0.25
0.33
0.00
0.00

SEQID-02040
0.00
0.09
0.06
0.06
0.07
0.00
0.05
0.06
−18.92
0.43
−0.03
4.56
0.21
0.31
0.21
0.21

SEQID-02041
0.04
0.02
0.03
0.03
0.03
0.02
0.07
0.05
−25.62
0.42
−0.06
4.47
0.21
0.32
0.22
0.18

SEQID-02042
0.02
0.06
0.02
0.04
0.07
0.01
0.02
0.07
−20.68
0.45
−0.03
4.97
0.00
0.33
0.00
0.19

SEQID-02043
0.06
0.03
0.03
0.06
0.04
0.00
0.00
0.06
−25.21
0.43
−0.07
4.34
0.25
0.34
0.23
0.00

SEQID-02044
0.06
0.05
0.10
0.07
0.06
0.00
0.02
0.03
−22.27
0.22
0.07
10.62
0.25
0.37
0.26
0.27

SEQID-02045
0.05
0.04
0.02
0.05
0.04
0.00
0.02
0.08
−19.54
0.57
0.00
6.55
0.23
0.32
0.00
0.24

SEQID-02046
0.03
0.04
0.04
0.06
0.06
0.00
0.02
0.07
−24.59
0.32
−0.11
4.15
0.22
0.35
0.00
0.00

SEQID-02047
0.03
0.04
0.04
0.05
0.04
0.01
0.04
0.09
−18.87
0.49
−0.02
4.99
0.21
0.34
0.20
0.22

SEQID-02048
0.03
0.04
0.05
0.03
0.05
0.00
0.03
0.06
−25.99
0.25
−0.11
4.09
0.22
0.36
0.00
0.22

SEQID-02049
0.03
0.06
0.07
0.06
0.05
0.03
0.04
0.06
−19.40
0.39
−0.04
4.55
0.21
0.33
0.00
0.23

SEQID-02050
0.00
0.10
0.02
0.06
0.05
0.01
0.04
0.07
−22.40
0.42
−0.19
3.30
0.16
0.41
0.18
0.19

SEQID-02051
0.01
0.03
0.01
0.05
0.05
0.00
0.04
0.08
−24.36
0.33
0.09
11.10
0.23
0.29
0.26
0.00

SEQID-02052
0.04
0.03
0.04
0.04
0.04
0.02
0.05
0.05
−22.91
0.49
−0.03
4.73
0.21
0.32
0.00
0.23

SEQID-02053
0.02
0.04
0.05
0.09
0.05
0.01
0.02
0.05
−22.60
0.23
0.02
9.77
0.25
0.32
0.00
0.25

SEQID-02054
0.03
0.09
0.05
0.06
0.05
0.05
0.03
0.04
−16.03
0.28
−0.03
5.51
0.40
0.48
0.00
0.24

SEQID-02055
0.04
0.05
0.04
0.04
0.04
0.02
0.05
0.06
−21.40
0.40
0.01
8.44
0.20
0.33
0.00
0.00

SEQID-02056
0.03
0.14
0.04
0.04
0.05
0.07
0.03
0.06
−11.96
0.78
−0.01
5.83
0.20
0.32
0.00
0.23

SEQID-02057
0.05
0.05
0.04
0.02
0.02
0.04
0.07
0.07
−21.18
0.39
−0.03
5.20
0.21
0.31
0.00
0.20

SEQID-02058
0.03
0.04
0.07
0.05
0.06
0.02
0.03
0.09
−15.02
0.54
−0.02
5.10
0.29
0.45
0.00
0.23

SEQID-02059
0.04
0.07
0.05
0.05
0.04
0.02
0.04
0.09
−10.95
1.04
0.03
10.49
0.21
0.34
0.00
0.21

SEQID-02060
0.02
0.01
0.01
0.06
0.07
0.01
0.02
0.05
−22.39
0.18
−0.02
5.77
0.23
0.36
0.18
0.21

SEQID-02061
0.01
0.04
0.05
0.04
0.05
0.01
0.02
0.06
−20.56
0.42
−0.02
4.99
0.20
0.33
0.21
0.21

SEQID-02062
0.04
0.05
0.05
0.04
0.04
0.01
0.02
0.08
−20.85
0.52
−0.02
4.76
0.21
0.36
0.20
0.22

SEQID-02063
0.02
0.07
0.05
0.04
0.05
0.01
0.06
0.04
−19.08
0.36
0.00
6.75
0.20
0.35
0.00
0.21

SEQID-02064
0.03
0.05
0.05
0.04
0.06
0.02
0.04
0.07
−18.79
0.44
−0.04
4.64
0.19
0.34
0.00
0.21

SEQID-02065
0.04
0.06
0.05
0.04
0.05
0.01
0.05
0.06
−18.55
0.43
−0.02
5.32
0.19
0.35
0.00
0.20

SEQID-02066
0.03
0.05
0.04
0.05
0.05
0.03
0.05
0.06
−18.95
0.40
−0.01
6.14
0.18
0.35
0.20
0.13

SEQID-02067
0.02
0.01
0.04
0.06
0.04
0.00
0.05
0.12
−22.91
0.61
−0.02
4.88
0.25
0.32
0.25
0.00

SEQID-02068
0.08
0.07
0.07
0.09
0.05
0.00
0.03
0.02
−26.12
0.09
0.07
10.60
0.24
0.31
0.17
0.00

SEQID-02069
0.04
0.04
0.04
0.03
0.05
0.02
0.04
0.11
−17.36
0.62
−0.01
5.87
0.25
0.30
0.00
0.26

SEQID-02070
0.01
0.03
0.03
0.03
0.08
0.00
0.04
0.08
−23.78
0.34
0.02
9.75
0.25
0.34
0.27
0.23

SEQID-02071
0.03
0.06
0.04
0.05
0.04
0.04
0.05
0.03
−17.18
0.59
0.00
6.52
0.21
0.34
0.24
0.00

SEQID-02072
0.03
0.06
0.04
0.05
0.03
0.04
0.05
0.04
−17.10
0.62
0.00
6.52
0.21
0.34
0.24
0.00

SEQID-02073
0.01
0.05
0.10
0.03
0.06
0.01
0.05
0.07
−18.26
0.47
0.03
9.73
0.25
0.31
0.00
0.24

SEQID-02074
0.04
0.04
0.03
0.08
0.06
0.01
0.05
0.09
−14.10
0.64
−0.02
4.89
0.28
0.34
0.00
0.00

SEQID-02075
0.03
0.05
0.06
0.03
0.03
0.01
0.07
0.06
−24.22
0.34
0.00
6.97
0.22
0.31
0.00
0.23

SEQID-02076
0.02
0.04
0.06
0.06
0.07
0.03
0.05
0.07
−20.99
0.36
−0.03
4.68
0.42
0.53
0.00
0.24

SEQID-02077
0.03
0.03
0.05
0.04
0.09
0.00
0.04
0.07
−19.18
0.30
0.03
10.75
0.22
0.32
0.18
0.26

SEQID-02078
0.03
0.04
0.06
0.05
0.03
0.03
0.02
0.09
−17.54
0.60
−0.02
5.90
0.17
0.34
0.00
0.19

SEQID-02079
0.01
0.05
0.05
0.06
0.06
0.02
0.10
0.03
−13.17
0.30
−0.02
4.59
0.22
0.32
0.00
0.23

SEQID-02080
0.02
0.11
0.03
0.04
0.04
0.03
0.06
0.04
−23.47
0.37
0.00
6.91
0.20
0.32
0.00
0.20

SEQID-02081
0.04
0.05
0.06
0.04
0.05
0.01
0.06
0.05
−20.97
0.33
0.00
6.80
0.21
0.33
0.00
0.00

SEQID-02082
0.04
0.07
0.05
0.04
0.06
0.01
0.04
0.07
−16.07
0.50
−0.02
5.43
0.22
0.33
0.00
0.22

SEQID-02083
0.03
0.05
0.04
0.04
0.05
0.02
0.06
0.06
−18.69
0.44
−0.02
4.94
0.21
0.34
0.21
0.21

SEQID-02084
0.06
0.07
0.05
0.04
0.06
0.05
0.08
0.05
−17.64
0.40
−0.02
5.65
0.20
0.31
0.00
0.21

SEQID-02085
0.00
0.03
0.03
0.05
0.04
0.02
0.08
0.03
−18.57
0.29
−0.04
4.95
0.21
0.33
0.22
0.22

SEQID-02086
0.04
0.06
0.05
0.04
0.07
0.02
0.05
0.05
−16.31
0.46
−0.02
5.48
0.20
0.33
0.00
0.21

SEQID-02087
0.03
0.04
0.03
0.03
0.04
0.01
0.05
0.07
−23.59
0.37
−0.03
4.89
0.19
0.33
0.00
0.20

SEQID-02088
0.00
0.10
0.03
0.06
0.05
0.01
0.04
0.08
−20.74
0.42
−0.17
3.39
0.15
0.41
0.19
0.19

SEQID-02089
0.02
0.00
0.01
0.09
0.03
0.02
0.04
0.18
−17.01
0.91
−0.04
4.37
0.33
0.29
0.00
0.27

SEQID-02090
0.01
0.09
0.05
0.04
0.10
0.04
0.05
0.03
−16.04
0.63
−0.01
5.76
0.26
0.27
0.00
0.23

SEQID-02091
0.02
0.03
0.06
0.06
0.05
0.00
0.05
0.05
−24.85
0.21
0.03
10.85
0.25
0.30
0.00
0.00

SEQID-02092
0.02
0.07
0.07
0.01
0.07
0.00
0.03
0.11
−24.25
0.43
0.06
10.72
0.29
0.32
0.00
0.25

SEQID-02093
0.04
0.00
0.02
0.03
0.07
0.00
0.05
0.07
−26.07
0.29
0.14
11.85
0.22
0.29
0.28
0.00

SEQID-02094
0.02
0.06
0.02
0.04
0.09
0.00
0.09
0.09
−20.86
0.38
−0.04
4.59
0.25
0.34
0.25
0.22

SEQID-02095
0.03
0.07
0.04
0.05
0.03
0.04
0.01
0.06
−20.82
0.50
−0.01
6.27
0.25
0.30
0.23
0.22

SEQID-02096
0.01
0.02
0.03
0.03
0.08
0.00
0.10
0.07
−19.24
0.42
−0.04
4.45
0.00
0.31
0.00
0.24

SEQID-02097
0.01
0.01
0.04
0.04
0.04
0.01
0.01
0.13
−19.37
0.48
0.10
11.46
0.00
0.34
0.00
0.23

SEQID-02098
0.02
0.04
0.05
0.09
0.07
0.01
0.02
0.04
−21.54
0.21
0.03
9.97
0.25
0.33
0.00
0.23

SEQID-02099
0.06
0.05
0.04
0.04
0.05
0.00
0.04
0.06
−20.26
0.40
0.03
9.94
0.00
0.30
0.00
0.22

SEQID-02100
0.04
0.04
0.03
0.07
0.05
0.01
0.05
0.05
−23.47
0.38
−0.04
4.61
0.23
0.33
0.00
0.00

SEQID-02101
0.03
0.02
0.04
0.04
0.05
0.00
0.05
0.07
−21.34
0.25
0.01
8.71
0.31
0.31
0.00
0.25

SEQID-02102
0.02
0.04
0.02
0.04
0.07
0.02
0.09
0.06
−23.24
0.21
−0.03
6.18
0.22
0.29
0.21
0.12

SEQID-02103
0.04
0.03
0.04
0.04
0.06
0.01
0.03
0.07
−21.63
0.38
0.01
8.67
0.20
0.31
0.19
0.00

SEQID-02104
0.05
0.04
0.09
0.05
0.08
0.01
0.05
0.05
−17.60
0.49
0.00
7.29
0.21
0.30
0.23
0.19

SEQID-02105
0.02
0.06
0.04
0.04
0.06
0.03
0.04
0.06
−21.56
0.46
0.04
9.87
0.25
0.36
0.00
0.00

SEQID-02106
0.03
0.09
0.05
0.04
0.03
0.01
0.04
0.06
−17.76
0.58
0.01
8.77
0.22
0.35
0.00
0.20

SEQID-02107
0.03
0.06
0.04
0.04
0.05
0.02
0.06
0.06
−19.10
0.39
−0.01
6.27
0.21
0.33
0.00
0.13

SEQID-02108
0.03
0.04
0.03
0.05
0.06
0.02
0.03
0.05
−19.58
0.47
−0.04
4.60
0.51
0.68
0.21
0.21

SEQID-02109
0.02
0.02
0.04
0.03
0.06
0.03
0.05
0.08
−20.33
0.44
−0.02
5.35
0.21
0.35
0.00
0.23

SEQID-02110
0.04
0.07
0.06
0.04
0.06
0.02
0.06
0.05
−19.17
0.36
−0.04
4.63
0.21
0.33
0.20
0.21

SEQID-02111
0.03
0.07
0.02
0.06
0.05
0.02
0.02
0.09
−11.09
1.13
−0.01
4.93
0.20
0.32
0.00
0.21

SEQID-02112
0.04
0.05
0.05
0.04
0.04
0.00
0.04
0.09
−22.16
0.40
−0.04
4.71
0.11
0.32
0.00
0.21

SEQID-02113
0.03
0.03
0.06
0.04
0.05
0.30
0.03
0.08
−20.86
0.51
−0.03
4.69
0.19
0.34
0.00
0.21

SEQID-02114
0.02
0.03
0.06
0.05
0.06
0.03
0.04
0.03
−16.41
0.40
−0.01
5.65
0.10
0.39
0.00
0.21

SEQID-02115
0.04
0.05
0.06
0.04
0.06
0.01
0.03
0.06
−18.27
0.45
−0.03
4.75
0.18
0.33
0.00
0.22

SEQID-02116
0.01
0.04
0.04
0.04
0.03
0.04
0.04
0.09
−20.93
0.45
−0.02
5.70
0.18
0.37
0.19
0.20

SEQID-02117
0.05
0.06
0.04
0.01
0.10
0.02
0.04
0.08
−19.43
0.36
0.13
11.09
0.26
0.22
0.19
0.25

SEQID-02118
0.01
0.04
0.06
0.04
0.08
0.00
0.00
0.10
−26.77
0.32
0.04
10.37
0.35
0.29
0.00
0.28

SEQID-02119
0.04
0.03
0.08
0.08
0.05
0.00
0.06
0.15
−17.89
0.60
−0.01
5.70
0.21
0.30
0.00
0.00

SEQID-02120
0.05
0.02
0.06
0.05
0.02
0.06
0.06
0.06
−24.70
0.24
−0.02
4.91
0.36
0.30
0.29
0.27

SEQID-02121
0.03
0.02
0.04
0.03
0.06
0.00
0.03
0.09
−24.80
0.40
0.03
9.83
0.23
0.29
0.23
0.00

SEQID-02122
0.04
0.13
0.04
0.04
0.04
0.04
0.01
0.04
−8.41
1.32
0.01
8.53
0.19
0.28
0.21
0.00

SEQID-02123
0.03
0.04
0.05
0.08
0.06
0.00
0.06
0.03
−17.19
0.53
0.04
10.00
0.26
0.31
0.24
0.75

SEQID-02124
0.02
0.03
0.04
0.08
0.05
0.00
0.02
0.04
−18.96
0.32
0.11
11.71
0.25
0.31
0.16
0.26

SEQID-02125
0.03
0.03
0.01
0.05
0.02
0.00
0.04
0.02
−21.54
0.50
−0.02
4.88
0.24
0.36
0.25
0.25

SEQID-02126
0.01
0.09
0.02
0.03
0.06
0.03
0.03
0.06
−20.43
0.65
−0.04
4.40
0.00
0.32
0.12
0.23

SEQID-02127
0.06
0.02
0.03
0.06
0.05
0.01
0.05
0.08
−24.19
0.25
0.10
11.65
0.23
0.31
0.00
0.22

SEQID-02128
0.03
0.07
0.03
0.05
0.03
0.01
0.05
0.07
−18.79
0.54
0.00
6.77
0.24
0.30
0.00
0.23

SEQID-02129
0.01
0.03
0.00
0.04
0.02
0.00
0.02
0.04
−22.65
0.43
−0.03
4.83
0.27
0.35
0.00
0.21

SEQID-02130
0.03
0.05
0.03
0.04
0.06
0.01
0.03
0.09
−17.91
0.60
−0.01
5.86
0.30
0.35
0.22
0.20

SEQID-02131
0.03
0.03
0.02
0.07
0.04
0.01
0.03
0.07
−32.77
0.31
−0.03
4.71
0.22
0.34
0.00
0.21

SEQID-02132
0.03
0.04
0.03
0.05
0.05
0.02
0.04
0.08
−20.20
0.43
−0.05
4.58
0.38
0.50
0.17
0.25

SEQID-02133
0.03
0.07
0.02
0.06
0.05
0.02
0.03
0.05
−23.22
0.29
−0.03
4.63
0.22
0.33
0.23
0.00

SEQID-02134
0.02
0.06
0.02
0.04
0.06
0.00
0.04
0.05
−16.13
0.39
−0.12
3.40
0.26
0.39
0.33
0.26

SEQID-02135
0.04
0.01
0.04
0.05
0.04
0.00
0.04
0.09
−18.90
0.49
−0.01
6.38
0.23
0.31
0.21
0.23

SEQID-02136
0.05
0.04
0.03
0.05
0.05
0.01
0.03
0.06
−19.17
0.55
−0.03
5.05
0.22
0.33
0.00
0.00

SEQID-02137
0.02
0.05
0.06
0.03
0.06
0.01
0.05
0.11
−15.26
0.59
−0.04
4.43
0.21
0.32
0.20
0.13

SEQID-02138
0.05
0.04
0.05
0.04
0.04
0.00
0.05
0.07
−18.34
0.47
−0.02
5.32
0.19
0.31
0.20
0.19

SEQID-02139
0.04
0.03
0.04
0.04
0.04
0.00
0.03
0.10
−17.78
0.55
−0.03
4.78
0.22
0.39
0.22
0.21

SEQID-02140
0.01
0.06
0.04
0.04
0.07
0.00
0.04
0.05
−21.80
0.30
0.00
6.75
0.22
0.34
0.00
0.13

SEQID-02141
0.04
0.03
0.04
0.04
0.04
0.01
0.07
0.08
−30.82
0.37
0.01
8.41
0.22
0.33
0.00
0.18

SEQID-02142
0.03
0.05
0.05
0.04
0.07
0.00
0.04
0.05
−17.71
0.43
−0.01
6.55
0.11
0.34
0.00
0.20

SEQID-02143
0.03
0.09
0.04
0.06
0.05
0.00
0.01
0.12
−11.30
1.31
−0.05
4.02
0.21
0.34
0.00
0.22

SEQID-02144
0.03
0.04
0.03
0.04
0.06
0.01
0.03
0.09
−17.41
0.56
−0.02
5.83
0.21
0.34
0.00
0.22

SEQID-02145
0.03
0.02
0.04
0.04
0.04
0.00
0.03
0.09
−18.17
0.53
−0.03
5.38
0.12
0.33
0.00
0.22

SEQID-02146
0.03
0.06
0.04
0.03
0.04
0.03
0.05
0.08
−21.40
0.41
−0.01
6.68
0.20
0.31
0.00
0.21

SEQID-02147
0.03
0.04
0.02
0.06
0.05
0.04
0.05
0.03
−22.57
0.18
−0.04
4.69
0.20
0.34
0.00
0.20

SEQID-02148
0.03
0.03
0.05
0.06
0.06
0.01
0.03
0.07
−22.27
0.37
−0.04
4.57
0.19
0.35
0.00
0.21

SEQID-02149
0.03
0.04
0.03
0.04
0.05
0.02
0.07
0.05
−31.30
0.34
−0.02
5.61
0.20
0.32
0.00
0.20

SEQID-02150
0.10
0.03
0.02
0.14
0.04
0.02
0.09
0.09
−11.67
0.51
−0.03
4.42
0.21
0.43
0.19
0.22

SEQID-02151
0.02
0.07
0.04
0.04
0.03
0.03
0.07
0.05
−21.86
0.34
−0.04
4.62
0.19
0.33
0.00
0.20

SEQID-02152
0.03
0.04
0.05
0.04
0.06
0.01
0.05
0.07
−19.74
0.46
−0.03
4.67
0.19
0.37
0.13
0.20

SEQID-02153
0.02
0.04
0.04
0.05
0.04
0.02
0.05
0.05
−20.57
0.34
−0.01
6.46
0.19
0.33
0.19
0.10

SEQID-02154
0.03
0.05
0.03
0.06
0.05
0.00
0.03
0.06
−24.92
0.30
−0.17
3.61
0.20
0.35
0.20
0.21

SEQID-02155
0.01
0.06
0.05
0.04
0.05
0.03
0.06
0.05
−18.77
0.38
−0.03
5.27
0.18
0.37
0.19
0.19

SEQID-02156
0.04
0.09
0.06
0.04
0.11
0.03
0.05
0.02
−13.76
0.65
0.00
6.65
0.27
0.19
0.31
0.26

SEQID-02157
0.02
0.00
0.04
0.04
0.04
0.00
0.00
0.01
−27.75
0.24
0.04
10.19
0.34
0.30
0.37
0.30

SEQID-02158
0.05
0.05
0.05
0.01
0.04
0.02
0.03
0.04
−33.89
0.16
0.01
7.70
0.27
0.23
0.00
0.00

SEQID-02159
0.04
0.02
0.04
0.06
0.09
0.02
0.06
0.07
−17.85
0.43
−0.01
5.74
0.29
0.29
0.37
0.38

SEQID-02160
0.02
0.05
0.02
0.04
0.02
0.02
0.09
0.14
−21.12
0.33
0.03
9.08
0.27
0.26
0.00
0.27

SEQID-02161
0.04
0.06
0.04
0.05
0.07
0.00
0.00
0.09
−20.90
0.46
0.01
8.23
0.27
0.30
0.00
0.23

SEQID-02162
0.09
0.05
0.03
0.09
0.05
0.00
0.07
0.06
−21.10
0.31
0.00
6.83
0.00
0.28
0.00
0.00

SEQID-02163
0.07
0.09
0.09
0.10
0.04
0.00
0.01
0.02
−23.49
0.11
0.07
10.67
0.27
0.39
0.33
0.27

SEQID-02164
0.03
0.05
0.03
0.04
0.03
0.02
0.04
0.10
−15.36
0.73
0.03
9.19
0.36
0.31
0.29
0.00

SEQID-02165
0.04
0.04
0.06
0.04
0.06
0.03
0.04
0.13
−16.83
0.54
−0.05
4.34
0.40
0.46
0.00
0.24

SEQID-02166
0.02
0.03
0.05
0.04
0.09
0.00
0.03
0.04
−25.16
0.37
0.07
10.46
0.27
0.28
0.00
0.00

SEQID-02167
0.04
0.03
0.04
0.05
0.05
0.00
0.04
0.13
−25.40
0.23
0.12
11.02
0.23
0.39
0.23
0.00

SEQID-02168
0.05
0.03
0.03
0.03
0.03
0.00
0.03
0.06
−22.21
0.32
−0.05
4.38
0.24
0.32
0.28
0.24

SEQID-02169
0.03
0.08
0.06
0.03
0.07
0.01
0.05
0.12
−16.54
0.74
−0.01
5.19
0.22
0.32
0.00
0.21

SEQID-02170
0.04
0.02
0.03
0.04
0.10
0.01
0.03
0.07
−20.64
0.43
0.09
11.06
0.24
0.30
0.00
0.23

SEQID-02171
0.03
0.03
0.03
0.02
0.05
0.00
0.04
0.10
−23.32
0.33
0.10
11.21
0.20
0.29
0.34
0.00

SEQID-02172
0.02
0.05
0.05
0.02
0.06
0.03
0.06
0.06
−17.37
0.50
0.00
6.52
0.31
0.31
0.21
0.12

SEQID-02173
0.03
0.04
0.03
0.04
0.08
0.01
0.02
0.08
−16.83
0.69
−0.04
4.48
0.00
0.33
0.00
0.21

SEQID-02174
0.01
0.07
0.05
0.04
0.06
0.01
0.06
0.07
−16.84
0.65
−0.03
4.65
0.33
0.31
0.00
0.14

SEQID-02175
0.06
0.09
0.03
0.07
0.06
0.01
0.02
0.12
−9.86
1.25
−0.03
4.30
0.20
0.31
0.00
0.22

SEQID-02176
0.02
0.03
0.05
0.05
0.04
0.02
0.02
0.08
−19.08
0.45
−0.06
4.48
0.00
0.33
0.00
0.23

SEQID-02177
0.03
0.06
0.06
0.04
0.06
0.02
0.10
0.06
−16.64
0.38
−0.01
6.12
0.22
0.30
0.22
0.00

SEQID-02178
0.06
0.09
0.04
0.06
0.07
0.05
0.06
0.09
−12.20
0.88
0.02
9.25
0.21
0.29
0.00
0.19

SEQID-02179
0.02
0.04
0.05
0.05
0.06
0.02
0.03
0.09
−15.62
0.57
−0.02
5.15
0.20
0.32
0.00
0.24

SEQID-02180
0.04
0.03
0.05
0.05
0.06
0.01
0.03
0.10
−15.23
0.64
−0.02
4.99
0.27
0.38
0.00
0.00

SEQID-02181
0.05
0.03
0.03
0.05
0.05
0.01
0.03
0.07
−20.34
0.42
−0.01
5.12
0.24
0.34
0.00
0.19

SEQID-02182
0.02
0.07
0.04
0.03
0.05
0.02
0.06
0.07
−21.19
0.43
−0.02
5.47
0.22
0.31
0.00
0.00

SEQID-02183
0.03
0.03
0.06
0.04
0.05
0.03
0.05
0.06
−16.88
0.56
−0.01
6.36
0.20
0.31
0.00
0.00

SEQID-02184
0.02
0.03
0.03
0.05
0.06
0.01
0.03
0.06
−22.05
0.41
−0.04
4.61
0.24
0.31
0.00
0.00

SEQID-02185
0.03
0.05
0.05
0.03
0.05
0.01
0.07
0.06
−20.27
0.37
−0.01
6.51
0.21
0.34
0.00
0.00

SEQID-02186
0.02
0.11
0.04
0.02
0.05
0.04
0.06
0.07
−11.45
0.82
−0.01
6.51
0.22
0.31
0.00
0.21

SEQID-02187
0.02
0.06
0.05
0.08
0.06
0.07
0.04
0.05
−18.36
0.40
−0.04
4.52
0.19
0.34
0.00
0.21

SEQID-02188
0.05
0.08
0.03
0.04
0.04
0.01
0.06
0.07
−22.44
0.39
−0.04
4.83
0.20
0.32
0.17
0.20

SEQID-02189
0.04
0.05
0.05
0.03
0.05
0.02
0.03
0.06
−18.28
0.54
−0.01
6.44
0.17
0.31
0.23
0.21

SEQID-02190
0.04
0.03
0.05
0.04
0.06
0.01
0.03
0.08
−15.62
0.60
0.00
5.94
0.22
0.33
0.00
0.24

SEQID-02191
0.03
0.06
0.03
0.06
0.06
0.01
0.03
0.05
−16.55
0.51
−0.02
5.25
0.23
0.32
0.23
0.21

SEQID-02192
0.04
0.03
0.07
0.05
0.09
0.01
0.04
0.09
−14.81
0.52
−0.01
5.23
0.21
0.33
0.18
0.21

SEQID-02193
0.03
0.06
0.06
0.05
0.03
0.04
0.05
0.07
−10.43
1.03
−0.01
4.79
0.22
0.34
0.00
0.23

SEQID-02194
0.01
0.07
0.03
0.04
0.06
0.01
0.02
0.08
−15.31
0.79
−0.03
4.51
0.23
0.33
0.23
0.22

SEQID-02195
0.02
0.05
0.09
0.03
0.06
0.05
0.04
0.05
−19.05
0.33
−0.02
4.95
0.22
0.39
0.21
0.22

SEQID-02196
0.03
0.09
0.05
0.05
0.05
0.05
0.03
0.03
−10.73
0.96
−0.02
5.16
0.21
0.32
0.00
0.22

SEQID-02197
0.00
0.02
0.10
0.07
0.10
0.02
0.00
0.08
−26.49
0.28
−0.14
3.92
0.21
0.43
0.21
0.23

SEQID-02198
0.01
0.09
0.10
0.06
0.06
0.01
0.02
0.10
−13.64
0.45
−0.03
3.66
0.26
0.35
0.21
0.24

SEQID-02199
0.02
0.04
0.04
0.04
0.04
0.02
0.05
0.05
−18.35
0.42
−0.02
5.50
0.20
0.31
0.00
0.21

SEQID-02200
0.03
0.04
0.05
0.06
0.07
0.02
0.05
0.05
−18.13
0.35
−0.03
4.90
0.22
0.33
0.00
0.21

SEQID-02201
0.04
0.04
0.05
0.04
0.04
0.02
0.05
0.07
−17.57
0.46
−0.02
5.62
0.21
0.32
0.20
0.21

SEQID-02202
0.03
0.04
0.05
0.04
0.06
0.05
0.05
0.06
−20.49
0.35
−0.02
5.54
0.00
0.32
0.00
0.22

SEQID-02203
0.02
0.05
0.05
0.04
0.05
0.01
0.06
0.05
−21.67
0.31
−0.01
6.52
0.18
0.32
0.00
0.21

SEQID-02204
0.02
0.06
0.03
0.05
0.07
0.01
0.05
0.05
−23.34
0.33
−0.04
4.74
0.25
0.40
0.00
0.20

SEQID-02205
0.03
0.05
0.05
0.04
0.05
0.03
0.04
0.06
−20.67
0.33
−0.03
4.77
0.42
0.71
0.00
0.21

SEQID-02206
0.02
0.05
0.04
0.05
0.05
0.03
0.03
0.07
−15.97
0.76
−0.02
4.80
0.19
0.34
0.18
0.20

SEQID-02207
0.02
0.03
0.06
0.04
0.07
0.03
0.04
0.03
−23.26
0.31
−0.01
5.64
0.00
0.35
0.00
0.00

SEQID-02208
0.03
0.03
0.03
0.05
0.05
0.02
0.09
0.05
−23.56
0.26
0.04
9.73
0.00
0.35
0.00
0.17

SEQID-02209
0.03
0.03
0.01
0.04
0.04
0.01
0.03
0.04
−28.21
0.23
−0.02
5.45
0.19
0.56
0.19
0.00

SEQID-02210
0.03
0.04
0.02
0.04
0.04
0.01
0.03
0.04
−26.63
0.25
−0.01
5.91
0.20
0.53
0.19
0.18

SEQID-02211
0.02
0.04
0.04
0.06
0.06
0.02
0.03
0.08
−24.06
0.30
−0.01
6.23
0.00
0.38
0.00
0.00

SEQID-02212
0.04
0.04
0.02
0.03
0.05
0.01
0.03
0.05
−26.31
0.29
−0.02
5.33
0.26
0.54
0.18
0.18

SEQID-02213
0.03
0.05
0.04
0.05
0.06
0.02
0.04
0.09
−19.00
0.62
−0.03
4.86
0.19
0.35
0.00
0.20

SEQID-02214
0.04
0.00
0.00
0.03
0.03
0.00
0.01
0.05
−32.13
0.13
−0.03
5.10
0.33
0.55
0.21
0.21

SEQID-02215
0.04
0.04
0.02
0.03
0.05
0.03
0.04
0.04
−23.77
0.30
−0.03
4.98
0.21
0.34
0.00
0.19

SEQID-02216
0.02
0.04
0.06
0.07
0.07
0.02
0.05
0.09
−19.87
0.35
0.01
8.15
0.18
0.38
0.19
0.21

SEQID-02217
0.05
0.04
0.04
0.05
0.06
0.02
0.06
0.05
−19.66
0.42
−0.03
5.05
0.00
0.30
0.00
0.20

SEQID-02218
0.04
0.07
0.04
0.03
0.06
0.01
0.06
0.05
−20.75
0.42
−0.01
6.25
0.21
0.33
0.00
0.21

SEQID-02219
0.03
0.04
0.01
0.04
0.04
0.01
0.03
0.04
−27.49
0.25
−0.02
5.63
0.18
0.53
0.18
0.18

SEQID-02220
0.04
0.04
0.01
0.04
0.04
0.01
0.03
0.04
−27.72
0.23
−0.02
5.64
0.19
0.51
0.18
0.18

SEQID-02221
0.05
0.06
0.04
0.04
0.07
0.01
0.06
0.06
−19.58
0.45
−0.01
6.33
0.21
0.34
0.21
0.19

SEQID-02222
0.03
0.04
0.01
0.04
0.04
0.01
0.03
0.03
−28.29
0.22
−0.02
5.42
0.19
0.49
0.18
0.18

SEQID-02223
0.01
0.03
0.06
0.05
0.08
0.03
0.05
0.10
−20.80
0.34
0.00
7.29
0.19
0.32
0.18
0.21

SEQID-02224
0.02
0.05
0.06
0.06
0.06
0.03
0.06
0.07
−19.95
0.34
0.00
6.73
0.19
0.37
0.20
0.19

SEQID-02225
0.03
0.05
0.05
0.06
0.06
0.03
0.07
0.07
−20.00
0.32
−0.01
6.59
0.18
0.33
0.19
0.19

SEQID-02226
0.03
0.05
0.04
0.04
0.04
0.02
0.03
0.06
−23.59
0.30
0.00
6.84
0.42
0.64
0.00
0.20

SEQID-02227
0.04
0.06
0.03
0.06
0.04
0.02
0.04
0.06
−21.10
0.46
−0.02
5.40
0.00
0.35
0.00
0.19

SEQID-02228
0.02
0.03
0.05
0.04
0.06
0.01
0.06
0.06
−18.44
0.42
0.02
8.30
0.20
0.30
0.00
0.21

SEQID-02229
0.03
0.04
0.05
0.04
0.05
0.03
0.05
0.08
−24.61
0.31
−0.01
5.58
0.20
0.33
0.19
0.19

SEQID-02230
0.04
0.05
0.03
0.02
0.04
0.02
0.06
0.06
−22.56
0.34
0.00
7.09
0.20
0.33
0.00
0.20

SEQID-02231
0.04
0.05
0.03
0.05
0.05
0.02
0.05
0.09
−19.29
0.45
0.01
8.31
0.72
0.89
0.00
0.00

SEQID-02232
0.04
0.06
0.04
0.05
0.04
0.02
0.04
0.06
−22.05
0.44
−0.04
4.80
0.00
0.41
0.00
0.18

SEQID-02233
0.04
0.07
0.04
0.04
0.04
0.01
0.07
0.05
−22.35
0.33
0.00
6.87
0.20
0.33
0.00
0.21

SEQID-02234
0.02
0.05
0.03
0.04
0.04
0.02
0.03
0.06
−22.15
0.37
0.00
6.79
0.94
0.99
0.21
0.22

SEQID-02235
0.03
0.05
0.04
0.04
0.04
0.02
0.03
0.07
−22.81
0.33
0.00
6.74
0.44
0.65
0.00
0.00

SEQID-02236
0.02
0.05
0.04
0.05
0.06
0.03
0.05
0.10
−21.98
0.35
0.00
6.84
0.19
0.33
0.19
0.19

SEQID-02237
0.05
0.05
0.03
0.04
0.04
0.03
0.04
0.04
−22.90
0.32
0.05
9.86
0.00
0.29
0.00
0.24

SEQID-02238
0.02
0.03
0.02
0.03
0.02
0.01
0.01
0.02
−40.08
0.09
0.07
10.40
0.26
0.39
0.24
0.00

SEQID-02239
0.04
0.03
0.03
0.05
0.04
0.01
0.03
0.05
−24.45
0.38
−0.06
4.47
0.39
0.54
0.00
0.19

SEQID-02240
0.01
0.05
0.04
0.05
0.06
0.03
0.06
0.09
−21.66
0.35
−0.01
5.77
0.20
0.33
0.19
0.21

SEQID-02241
0.05
0.06
0.03
0.04
0.04
0.00
0.04
0.06
−21.24
0.38
−0.07
4.39
0.27
0.38
0.00
0.24

SEQID-02242
0.04
0.06
0.08
0.06
0.05
0.01
0.03
0.05
−20.78
0.20
0.01
7.73
0.24
0.39
0.22
0.26

SEQID-02243
0.04
0.03
0.01
0.08
0.05
0.00
0.04
0.03
−25.45
0.16
−0.03
5.11
0.31
0.49
0.00
0.21

SEQID-02244
0.02
0.02
0.16
0.04
0.04
0.01
0.02
0.03
−14.16
0.16
0.02
9.58
0.57
0.83
0.21
0.39

SEQID-02245
0.05
0.06
0.09
0.03
0.02
0.00
0.03
0.06
−21.06
0.37
−0.05
4.40
0.26
0.35
0.00
0.24

SEQID-02246
0.04
0.03
0.07
0.07
0.07
0.02
0.03
0.05
−17.43
0.28
0.02
9.52
0.22
0.32
0.22
0.21

SEQID-02247
0.05
0.05
0.03
0.04
0.07
0.02
0.03
0.07
−18.04
0.51
0.01
8.27
0.20
0.34
0.00
0.21

SEQID-02248
0.03
0.03
0.18
0.03
0.04
0.01
0.01
0.03
−15.17
0.17
−0.01
5.18
0.54
0.80
0.21
0.38

SEQID-02249
0.02
0.03
0.18
0.05
0.04
0.01
0.02
0.03
−14.55
0.17
−0.01
6.05
0.59
0.80
0.21
0.33

SEQID-02250
0.02
0.04
0.04
0.05
0.05
0.02
0.04
0.06
−22.44
0.34
−0.01
5.99
0.21
0.50
0.19
0.21

SEQID-02251
0.05
0.02
0.03
0.06
0.04
0.03
0.02
0.12
−18.26
0.58
0.01
7.70
0.24
0.34
0.00
0.20

SEQID-02252
0.01
0.04
0.09
0.04
0.06
0.02
0.03
0.07
−23.00
0.39
0.00
5.90
0.21
0.41
0.21
0.22

SEQID-02253
0.04
0.04
0.03
0.04
0.06
0.01
0.03
0.09
−21.44
0.45
0.01
7.94
0.21
0.33
0.00
0.21

SEQID-02254
0.05
0.01
0.03
0.04
0.03
0.02
0.02
0.06
−29.51
0.27
0.05
10.02
0.23
0.36
0.23
0.18

SEQID-02255
0.03
0.05
0.04
0.06
0.07
0.03
0.04
0.04
−23.64
0.19
0.02
9.54
0.22
0.31
0.00
0.22

SEQID-02256
0.03
0.07
0.04
0.05
0.05
0.01
0.05
0.06
−19.33
0.42
−0.01
6.21
0.22
0.34
0.00
0.22

SEQID-02257
0.02
0.05
0.03
0.04
0.04
0.03
0.02
0.10
−20.09
0.43
0.00
7.41
0.67
0.34
0.00
0.00

SEQID-02258
0.03
0.02
0.04
0.06
0.06
0.00
0.01
0.09
−27.31
0.16
0.01
8.77
0.23
0.32
0.00
0.19

SEQID-02259
0.02
0.07
0.04
0.03
0.01
0.03
0.04
0.06
−34.51
0.37
−0.27
3.56
0.21
0.32
0.21
0.22

SEQID-02260
0.02
0.03
0.03
0.05
0.03
0.00
0.06
0.09
−25.52
0.42
0.01
8.15
0.24
0.30
0.00
0.22

SEQID-02261
0.04
0.03
0.05
0.03
0.04
0.05
0.03
0.05
−22.63
0.32
0.03
9.34
0.20
0.30
0.19
0.00

SEQID-02262
0.04
0.10
0.03
0.03
0.05
0.03
0.06
0.05
−17.15
0.58
0.06
10.27
0.23
0.34
0.22
0.00

SEQID-02263
0.03
0.05
0.01
0.05
0.04
0.02
0.04
0.05
−21.13
0.35
0.02
8.10
0.21
0.33
0.00
0.21

SEQID-02264
0.09
0.08
0.01
0.04
0.04
0.00
0.02
0.03
−30.26
0.28
−0.19
3.71
0.36
0.43
0.22
0.23

SEQID-02265
0.03
0.07
0.01
0.04
0.06
0.01
0.05
0.05
−23.75
0.45
−0.01
5.76
0.20
0.31
0.21
0.20

SEQID-02266
0.03
0.04
0.05
0.04
0.06
0.02
0.04
0.09
−20.89
0.41
0.03
9.59
0.21
0.31
0.00
0.22

SEQID-02267
0.01
0.04
0.06
0.07
0.08
0.03
0.05
0.09
−19.83
0.34
−0.01
5.53
0.20
0.34
0.19
0.21

SEQID-02268
0.03
0.00
0.03
0.06
0.05
0.04
0.07
0.07
−16.17
0.70
0.02
9.14
0.20
0.33
0.00
0.20

SEQID-02269
0.03
0.05
0.05
0.05
0.05
0.03
0.06
0.07
−19.20
0.36
0.00
6.73
0.19
0.32
0.19
0.19

SEQID-02270
0.02
0.05
0.07
0.05
0.07
0.01
0.05
0.09
−19.23
0.30
−0.01
6.31
0.00
0.37
0.17
0.21

SEQID-02271
0.03
0.03
0.03
0.07
0.05
0.02
0.02
0.05
−23.98
0.25
−0.05
4.70
0.00
0.36
0.00
0.00

SEQID-02272
0.05
0.05
0.04
0.05
0.06
0.02
0.06
0.05
−19.53
0.43
−0.03
5.15
0.21
0.31
0.00
0.22

SEQID-02273
0.03
0.06
0.03
0.03
0.04
0.02
0.06
0.06
−22.21
0.34
0.00
7.11
0.19
0.33
0.00
0.20

SEQID-02274
0.01
0.07
0.04
0.04
0.05
0.01
0.05
0.05
−25.20
0.34
−0.02
6.06
0.92
0.93
0.21
0.21

SEQID-02275
0.03
0.09
0.02
0.04
0.04
0.03
0.06
0.07
−16.86
0.55
0.07
10.36
0.20
0.34
0.00
0.00

SEQID-02276
0.04
0.06
0.03
0.04
0.06
0.02
0.04
0.09
−17.85
0.47
0.02
8.58
0.69
0.85
0.00
0.22

SEQID-02277
0.01
0.07
0.03
0.04
0.05
0.02
0.07
0.06
−21.18
0.25
0.07
8.51
0.21
0.32
0.21
0.23

SEQID-02278
0.04
0.09
0.06
0.05
0.03
0.02
0.09
0.07
−16.15
0.52
0.05
9.72
0.20
0.34
0.00
0.21

SEQID-02279
0.05
0.09
0.03
0.02
0.05
0.01
0.03
0.05
−24.33
0.31
−0.04
4.60
0.40
0.60
0.00
0.19

SEQID-02280
0.01
0.04
0.04
0.02
0.05
0.01
0.04
0.09
−20.24
0.49
0.00
7.29
0.19
0.33
0.24
0.23

SEQID-02281
0.05
0.08
0.05
0.02
0.06
0.00
0.01
0.03
−28.13
0.33
−0.05
4.67
0.22
0.26
0.00
0.21

SEQID-02282
0.02
0.00
0.00
0.04
0.02
0.00
0.03
0.03
−36.76
0.12
−0.09
4.39
0.58
0.69
0.22
0.22

SEQID-02283
0.05
0.03
0.02
0.03
0.04
0.00
0.01
0.09
−19.35
0.71
0.00
7.52
0.24
0.32
0.00
0.25

SEQID-02284
0.07
0.08
0.06
0.05
0.06
0.00
0.01
0.03
−24.42
0.31
−0.02
5.21
0.19
0.28
0.00
0.00

SEQID-02285
0.07
0.08
0.06
0.05
0.06
0.00
0.01
0.08
−24.41
0.32
−0.02
5.22
0.25
0.30
0.00
0.00

SEQID-02286
0.04
0.06
0.04
0.03
0.02
0.00
0.07
0.06
−21.17
0.39
−0.03
5.14
0.90
0.91
0.00
0.23

SEQID-02287
0.02
0.07
0.04
0.07
0.06
0.01
0.03
0.09
−16.53
0.44
0.03
9.09
0.25
0.33
0.22
0.26

SEQID-02288
0.02
0.08
0.02
0.02
0.03
0.02
0.02
0.11
−19.85
0.47
0.01
7.35
0.27
0.30
0.25
0.25

SEQID-02289
0.01
0.04
0.06
0.02
0.10
0.00
0.01
0.09
−14.29
0.62
0.00
7.39
0.59
0.65
0.24
0.25

SEQID-02290
0.05
0.11
0.04
0.02
0.05
0.00
0.02
0.05
−25.98
0.30
−0.05
4.56
0.41
0.59
0.23
0.00

SEQID-02291
0.01
0.07
0.01
0.05
0.03
0.02
0.06
0.09
−17.65
0.90
0.03
9.78
0.18
0.31
0.19
0.22

SEQID-02292
0.00
0.03
0.00
0.04
0.07
0.04
0.00
0.07
−21.86
0.40
−0.05
4.76
0.33
0.16
0.33
0.33

SEQID-02293
0.00
0.06
0.06
0.11
0.04
0.02
0.04
0.09
−19.05
0.25
0.05
10.11
0.27
0.23
0.25
0.24

SEQID-02294
0.06
0.06
0.02
0.02
0.05
0.00
0.04
0.09
−23.42
0.39
−0.08
4.32
0.38
0.46
0.25
0.00

SEQID-02295
0.04
0.03
0.03
0.04
0.07
0.00
0.05
0.08
−24.69
0.33
0.01
8.63
0.00
0.33
0.00
0.23

SEQID-02296
0.05
0.09
0.04
0.05
0.09
0.01
0.06
0.07
−14.96
0.61
0.05
10.35
0.21
0.33
0.00
0.24

SEQID-02297
0.02
0.05
0.03
0.04
0.06
0.01
0.03
0.06
−22.33
0.36
−0.01
5.96
0.71
0.89
0.00
0.21

SEQID-02298
0.01
0.04
0.04
0.04
0.05
0.00
0.03
0.03
−23.86
0.30
0.14
11.71
0.24
0.30
0.00
0.21

SEQID-02299
0.03
0.04
0.04
0.04
0.04
0.01
0.01
0.10
−20.10
0.57
0.00
6.92
0.21
0.34
0.21
0.22

SEQID-02300
0.03
0.06
0.04
0.05
0.03
0.02
0.07
0.04
−20.39
0.35
0.02
8.61
0.19
0.32
0.22
0.21

SEQID-02301
0.05
0.09
0.03
0.03
0.04
0.06
0.04
0.03
−20.36
0.39
−0.02
6.09
0.51
0.63
0.25
0.25

SEQID-02302
0.03
0.10
0.05
0.03
0.04
0.03
0.06
0.06
−17.77
0.42
0.02
8.21
0.00
0.31
0.00
0.24

SEQID-02303
0.01
0.10
0.08
0.07
0.04
0.02
0.02
0.05
−23.34
0.27
0.01
7.38
0.25
0.35
0.23
0.23

SEQID-02304
0.09
0.04
0.05
0.07
0.07
0.04
0.06
0.05
−14.98
0.69
−0.05
4.44
0.21
0.31
0.00
0.19

SEQID-02305
0.03
0.03
0.02
0.06
0.04
0.31
0.06
0.04
−25.77
0.30
−0.05
4.48
0.24
0.33
0.00
0.23

SEQID-02306
0.03
0.07
0.02
0.07
0.05
0.02
0.04
0.05
−18.34
0.62
0.02
9.36
0.18
0.35
0.19
0.20

SEQID-02307
0.02
0.04
0.06
0.09
0.05
0.02
0.03
0.07
−17.22
0.57
−0.01
6.46
0.00
0.39
0.16
0.19

SEQID-02308
0.01
0.03
0.04
0.05
0.06
0.01
0.05
0.06
−18.98
0.41
0.00
6.89
0.22
0.33
0.00
0.20

SEQID-02309
0.03
0.05
0.04
0.09
0.06
0.03
0.03
0.05
−18.07
0.40
−0.01
6.18
0.38
0.61
0.18
0.21

SEQID-02310
0.05
0.07
0.05
0.03
0.04
0.02
0.04
0.07
−22.73
0.36
−0.04
4.83
0.21
0.35
0.00
0.22

SEQID-02311
0.02
0.06
0.04
0.05
0.04
0.02
0.03
0.06
−20.55
0.57
0.00
6.88
0.21
0.33
0.00
0.22

SEQID-02312
0.01
0.05
0.03
0.05
0.04
0.03
0.04
0.11
−24.64
0.30
−0.02
5.77
0.38
0.44
0.00
1.00

SEQID-02313
0.03
0.06
0.05
0.05
0.05
0.03
0.05
0.05
−23.03
0.33
−0.01
6.04
0.23
0.30
0.00
0.20

SEQID-02314
0.03
0.06
0.05
0.05
0.05
0.03
0.04
0.08
−17.36
0.45
−0.02
5.73
0.18
0.33
0.00
0.21

SEQID-02315
0.01
0.06
0.06
0.06
0.06
0.04
0.09
0.04
−12.07
0.45
0.01
7.96
1.00
1.00
0.22
0.22

SEQID-02316
0.03
0.06
0.04
0.04
0.04
0.04
0.06
0.06
−20.46
0.37
−0.02
6.41
0.27
0.35
0.00
0.23

SEQID-02317
0.02
0.07
0.04
0.05
0.03
0.02
0.09
0.09
−19.61
0.47
−0.01
6.03
0.22
0.32
0.21
0.22

SEQID-02318
0.04
0.01
0.02
0.04
0.01
0.00
0.03
0.03
−29.34
0.13
0.03
8.91
0.28
0.30
0.27
0.30

SEQID-02319
0.02
0.06
0.04
0.03
0.06
0.03
0.05
0.06
−19.82
0.38
−0.01
6.24
0.20
0.32
0.00
0.22

SEQID-02320
0.05
0.04
0.03
0.03
0.07
0.03
0.03
0.07
−19.93
0.49
−0.02
5.51
0.20
0.34
0.21
0.21

SEQID-02321
0.01
0.08
0.05
0.09
0.07
0.01
0.04
0.06
−19.55
0.31
0.00
7.25
0.19
0.34
0.00
0.23

SEQID-02322
0.02
0.09
0.06
0.09
0.06
0.02
0.02
0.06
−13.94
0.45
0.03
7.94
0.41
0.56
0.21
0.32

SEQID-02323
0.02
0.08
0.06
0.03
0.04
0.01
0.03
0.04
−21.81
0.30
−0.03
5.79
0.23
0.33
0.00
0.00

SEQID-02324
0.04
0.06
0.03
0.04
0.06
0.01
0.03
0.09
−21.10
0.45
0.00
7.46
0.00
0.35
0.21
0.22

SEQID-02325
0.05
0.07
0.03
0.06
0.05
0.02
0.06
0.06
−19.60
0.34
−0.05
4.53
0.39
0.56
0.19
0.21

SEQID-02326
0.02
0.05
0.06
0.04
0.05
0.03
0.05
0.05
−22.14
0.36
−0.02
5.59
0.20
0.33
0.19
0.20

SEQID-02327
0.01
0.07
0.07
0.05
0.09
0.02
0.05
0.07
−14.97
0.56
0.01
8.44
0.24
0.33
0.00
0.29

SEQID-02328
0.02
0.04
0.03
0.03
0.08
0.02
0.06
0.05
−21.37
0.41
−0.03
5.10
0.21
0.32
0.00
0.21

SEQID-02329
0.03
0.06
0.07
0.07
0.08
0.03
0.05
0.06
−16.53
0.52
−0.01
6.12
0.27
0.35
0.21
0.26

SEQID-02330
0.03
0.06
0.04
0.03
0.05
0.01
0.08
0.09
−22.17
0.37
−0.02
4.90
0.74
0.33
0.00
0.00

SEQID-02331
0.01
0.00
0.00
0.07
0.00
0.00
0.00
0.01
−38.09
0.15
0.02
7.57
0.29
0.30
0.27
0.28

SEQID-02332
0.02
0.05
0.04
0.05
0.09
0.00
0.00
0.07
−13.98
0.45
−0.03
6.21
0.80
0.83
0.26
0.28

SEQID-02333
0.01
0.09
0.04
0.02
0.06
0.02
0.07
0.06
−24.33
0.38
−0.07
4.36
0.39
0.46
0.00
0.25

SEQID-02334
0.02
0.09
0.02
0.07
0.03
0.02
0.07
0.04
−17.50
0.49
0.05
10.21
0.20
0.34
0.00
0.00

SEQID-02335
0.04
0.05
0.05
0.05
0.04
0.00
0.04
0.07
−19.22
0.43
0.00
6.65
0.21
0.33
0.20
0.22

SEQID-02336
0.03
0.03
0.02
0.05
0.05
0.02
0.05
0.06
−24.82
0.37
−0.01
6.33
0.21
0.33
0.20
0.00

SEQID-02337
0.01
0.07
0.05
0.05
0.07
0.04
0.07
0.07
−19.39
0.29
−0.01
5.93
0.19
0.34
0.00
0.22

SEQID-02338
0.02
0.07
0.04
0.05
0.04
0.01
0.06
0.08
−19.98
0.45
−0.01
5.60
0.22
0.35
0.22
0.22

SEQID-02339
0.03
0.06
0.04
0.05
0.04
0.03
0.05
0.06
−21.72
0.36
−0.03
5.69
0.21
0.33
0.00
0.21

SEQID-02340
0.02
0.03
0.03
0.05
0.05
0.00
0.06
0.07
−18.32
0.47
0.00
5.95
0.22
0.34
0.21
0.22

SEQID-02341
0.02
0.11
0.04
0.05
0.05
0.06
0.04
0.07
−14.51
0.60
−0.01
6.51
0.21
0.33
0.20
0.23

SEQID-02342
0.03
0.09
0.05
0.05
0.04
0.07
0.06
0.06
−13.27
0.60
0.00
7.04
0.22
0.33
0.00
0.22

SEQID-02343
0.03
0.14
0.03
0.04
0.06
0.06
0.03
0.06
−12.54
0.77
−0.01
6.51
0.19
0.32
0.00
0.22

SEQID-02344
0.03
0.09
0.04
0.05
0.05
0.06
0.04
0.05
−12.00
0.61
0.01
7.52
0.19
0.33
0.00
0.20

SEQID-02345
0.02
0.10
0.04
0.05
0.06
0.07
0.05
0.05
−11.60
0.64
0.00
7.08
0.19
0.35
0.00
0.21

SEQID-02346
0.03
0.00
0.00
0.04
0.04
0.00
0.02
0.06
−33.43
0.12
−0.02
5.63
0.41
0.55
0.23
0.22

SEQID-02347
0.02
0.03
0.01
0.04
0.02
0.01
0.01
0.02
−39.60
0.07
0.05
10.23
0.25
0.35
0.22
0.00

SEQID-02348
0.04
0.06
0.03
0.05
0.05
0.03
0.02
0.07
−22.00
0.36
0.03
9.13
0.45
0.64
0.00
0.00

SEQID-02349
0.04
0.06
0.03
0.05
0.05
0.02
0.04
0.09
−19.04
0.46
0.01
8.10
0.72
0.86
0.00
0.21

SEQID-02350
0.02
0.06
0.04
0.04
0.05
0.03
0.04
0.04
−23.29
0.32
0.00
7.11
0.48
0.64
0.00
0.00

SEQID-02351
0.06
0.09
0.02
0.03
0.05
0.01
0.06
0.04
−18.81
0.53
−0.03
5.29
0.20
0.29
0.21
0.00

SEQID-02352
0.03
0.02
0.00
0.06
0.02
0.00
0.01
0.03
−30.87
0.09
−0.01
6.28
0.30
0.33
0.24
0.21

SEQID-02353
0.02
0.03
0.05
0.05
0.07
0.03
0.04
0.11
−20.20
0.39
0.00
7.27
0.21
0.31
0.22
0.23

SEQID-02354
0.06
0.01
0.03
0.05
0.03
0.02
0.01
0.04
−28.42
0.26
0.02
9.14
0.29
0.35
0.18
0.26

SEQID-02355
0.01
0.13
0.00
0.05
0.02
0.02
0.01
0.05
−23.06
0.63
−0.06
4.34
1.00
1.00
0.27
0.26

SEQID-02356
0.02
0.02
0.06
0.07
0.09
0.04
0.05
0.06
−19.29
0.23
0.00
6.90
0.24
0.31
0.21
0.24

SEQID-02357
0.03
0.04
0.04
0.05
0.05
0.02
0.04
0.08
−20.45
0.42
0.03
9.69
0.22
0.33
0.20
0.22

SEQID-02358
0.04
0.01
0.03
0.06
0.07
0.00
0.04
0.05
−17.94
0.44
−0.01
6.35
0.25
0.34
0.29
0.23

SEQID-02359
0.02
0.06
0.04
0.09
0.06
0.02
0.05
0.06
−16.62
0.42
−0.01
6.49
0.48
0.62
0.21
0.21

SEQID-02360
0.03
0.06
0.06
0.07
0.05
0.04
0.08
0.04
−19.45
0.29
−0.02
5.66
0.24
0.30
0.35
0.24

SEQID-02361
0.04
0.03
0.03
0.10
0.03
0.00
0.05
0.08
−15.55
0.61
−0.01
5.20
0.24
0.32
0.24
0.24

SEQID-02362
0.03
0.03
0.03
0.06
0.04
0.01
0.09
0.03
−18.99
0.37
−0.02
5.25
0.24
0.32
0.24
0.00

SEQID-02363
0.04
0.03
0.02
0.06
0.04
0.00
0.04
0.09
−16.78
0.53
−0.01
4.90
0.22
0.32
0.26
0.26

SEQID-02364
0.04
0.05
0.03
0.04
0.06
0.02
0.06
0.06
−18.19
0.40
−0.02
5.63
0.20
0.33
0.00
0.22

SEQID-02365
0.03
0.03
0.03
0.09
0.03
0.01
0.10
0.03
−14.55
0.33
−0.01
5.16
0.22
0.30
0.23
0.24

SEQID-02366
0.04
0.09
0.04
0.07
0.04
0.05
0.05
0.07
−11.27
0.75
−0.02
5.25
0.00
0.31
0.00
0.22

SEQID-02367
0.03
0.09
0.04
0.06
0.06
0.05
0.04
0.04
−11.91
0.63
0.00
7.04
0.22
0.35
0.00
0.20

SEQID-02368
0.05
0.09
0.04
0.05
0.05
0.05
0.05
0.05
−10.93
0.65
0.01
7.57
0.20
0.31
0.00
0.21

SEQID-02369
0.01
0.01
0.05
0.09
0.06
0.03
0.03
0.05
−19.00
0.25
−0.02
6.21
1.00
1.00
0.23
0.26

SEQID-02370
0.01
0.12
0.06
0.04
0.08
0.02
0.03
0.03
−13.69
0.41
0.02
7.95
1.00
1.00
0.21
0.58

SEQID-02371
0.02
0.06
0.03
0.06
0.07
0.04
0.09
0.06
−17.33
0.41
−0.03
4.66
1.00
1.00
0.22
0.32

SEQID-02372
0.02
0.05
0.03
0.05
0.02
0.04
0.05
0.13
−15.63
0.68
0.03
9.85
1.00
1.00
0.00
1.00

SEQID-02373
0.04
0.07
0.01
0.04
0.07
0.02
0.07
0.08
−23.85
0.48
−0.07
4.41
1.00
1.00
0.25
0.23

SEQID-02374
0.01
0.09
0.03
0.06
0.09
0.04
0.09
0.09
−15.49
0.50
0.00
7.28
1.00
1.00
0.54
0.20

SEQID-02375
0.03
0.04
0.03
0.07
0.05
0.03
0.08
0.06
−17.98
0.34
0.01
8.01
0.71
0.30
0.20
0.34

SEQID-02376
0.01
0.04
0.08
0.07
0.05
0.02
0.06
0.08
−17.15
0.45
0.01
8.40
0.21
0.31
0.00
0.21

SEQID-02377
0.03
0.05
0.04
0.06
0.04
0.01
0.03
0.05
−19.83
0.38
0.00
7.06
0.52
0.73
0.30
0.22

SEQID-02378
0.03
0.05
0.04
0.06
0.04
0.01
0.03
0.04
−19.64
0.38
0.00
7.34
0.52
0.73
0.21
0.22

SEQID-02379
0.06
0.05
0.07
0.03
0.03
0.00
0.04
0.07
−22.04
0.36
−0.05
4.44
0.26
0.38
0.00
0.24

SEQID-02380
0.04
0.09
0.04
0.04
0.05
0.01
0.03
0.05
−24.42
0.37
−0.06
4.36
0.38
0.54
0.22
0.19

SEQID-02381
0.03
0.00
0.00
0.03
0.03
0.00
0.03
0.03
−36.74
0.12
−0.09
4.39
0.59
0.70
0.25
0.21

SEQID-02382
0.03
0.05
0.06
0.05
0.06
0.03
0.04
0.09
−18.72
0.43
0.01
7.75
0.00
0.32
0.00
0.18

SEQID-02383
0.02
0.09
0.02
0.02
0.03
0.02
0.02
0.12
−18.31
0.58
0.00
7.24
0.28
0.31
0.21
0.25

SEQID-02384
0.03
0.05
0.01
0.05
0.04
0.01
0.04
0.04
−26.24
0.28
−0.01
6.55
0.19
0.55
0.19
0.17

SEQID-02385
0.03
0.05
0.02
0.04
0.05
0.01
0.03
0.04
−26.69
0.24
0.01
8.53
0.20
0.55
0.18
0.17

SEQID-02386
0.04
0.09
0.03
0.04
0.05
0.01
0.06
0.05
−21.50
0.39
0.01
8.45
0.19
0.34
0.00
0.20

SEQID-02387
0.02
0.01
0.00
0.04
0.03
0.00
0.01
0.04
−32.95
0.10
−0.04
5.11
0.39
0.55
0.21
0.21

SEQID-02388
0.03
0.03
0.01
0.04
0.04
0.01
0.03
0.03
−27.94
0.21
−0.02
5.55
0.19
0.53
0.18
0.18

SEQID-02389
0.05
0.04
0.04
0.05
0.06
0.02
0.06
0.05
−19.68
0.41
−0.03
5.05
0.19
0.31
0.00
0.20

SEQID-02390
0.03
0.04
0.01
0.04
0.04
0.01
0.03
0.03
−28.44
0.23
−0.02
5.55
0.19
0.51
0.18
0.19

SEQID-02391
0.03
0.04
0.01
0.04
0.03
0.01
0.03
0.04
−28.04
0.22
−0.02
5.44
0.18
0.54
0.18
0.19

SEQID-02392
0.03
0.04
0.01
0.04
0.04
0.01
0.03
0.03
−28.31
0.24
−0.02
5.66
0.18
0.50
0.17
0.17

SEQID-02393
0.03
0.10
0.02
0.06
0.04
0.01
0.05
0.05
−19.60
0.46
0.04
9.84
0.21
0.32
0.00
0.20

SEQID-02394
0.04
0.05
0.03
0.05
0.06
0.02
0.04
0.10
−17.92
0.49
0.02
8.82
0.70
0.86
0.00
0.20

SEQID-02395
0.02
0.01
0.00
0.05
0.02
0.00
0.01
0.04
−32.33
0.12
−0.02
5.54
0.38
0.54
0.21
0.19

SEQID-02396
0.05
0.04
0.03
0.04
0.04
0.01
0.02
0.09
−21.27
0.45
0.01
7.68
0.21
0.33
0.00
0.22

SEQID-02397
0.04
0.04
0.03
0.04
0.04
0.03
0.04
0.03
−24.38
0.28
−0.03
5.17
0.20
0.36
0.00
0.19

SEQID-02398
0.01
0.04
0.06
0.04
0.06
0.02
0.04
0.07
−26.13
0.30
−0.02
5.29
0.00
0.41
0.17
0.18

SEQID-02399
0.03
0.03
0.03
0.06
0.03
0.03
0.02
0.10
−19.78
0.56
0.02
8.27
0.23
0.32
0.21
0.19

SEQID-02400
0.02
0.04
0.04
0.06
0.06
0.02
0.05
0.09
−22.74
0.31
−0.01
6.33
0.00
0.34
0.17
0.19

SEQID-02401
0.05
0.05
0.04
0.05
0.06
0.02
0.06
0.05
−19.47
0.43
−0.03
5.16
0.21
0.31
0.00
0.22

SEQID-02402
0.01
0.04
0.07
0.06
0.07
0.02
0.04
0.09
−22.43
0.31
−0.01
5.31
0.00
0.40
0.00
0.18

SEQID-02403
0.02
0.02
0.03
0.05
0.05
0.02
0.09
0.06
−24.64
0.20
0.03
9.41
0.00
0.34
0.17
0.18

SEQID-02404
0.01
0.05
0.04
0.06
0.05
0.03
0.06
0.07
−22.26
0.33
−0.01
6.27
0.18
0.34
0.19
0.19

SEQID-02405
0.09
0.02
0.04
0.06
0.07
0.03
0.07
0.03
−18.28
0.36
0.01
8.20
0.25
0.28
0.00
0.00

SEQID-02406
0.04
0.06
0.04
0.04
0.04
0.02
0.01
0.09
−20.16
0.47
0.01
7.53
0.23
0.35
0.00
0.31

SEQID-02407
0.03
0.01
0.03
0.05
0.03
0.03
0.08
0.04
−24.99
0.22
0.02
8.88
0.20
0.32
0.00
0.19

SEQID-02408
0.04
0.03
0.04
0.05
0.04
0.02
0.09
0.04
−24.99
0.20
0.03
9.54
0.19
0.33
0.18
0.18

SEQID-02409
0.03
0.04
0.03
0.04
0.07
0.02
0.03
0.06
−19.75
0.46
0.02
8.25
0.21
0.32
0.00
0.21

SEQID-02410
0.02
0.07
0.04
0.04
0.05
0.01
0.05
0.05
−19.79
0.43
0.02
8.78
0.20
0.36
0.00
0.21

SEQID-02411
0.02
0.00
0.00
0.04
0.03
0.00
0.03
0.03
−36.78
0.12
−0.09
4.39
0.59
0.70
0.26
0.22

SEQID-02412
0.04
0.05
0.03
0.06
0.03
0.00
0.05
0.05
−23.93
0.35
−0.01
6.37
0.88
1.00
0.18
0.21

SEQID-02413
0.02
0.04
0.04
0.05
0.06
0.03
0.04
0.09
−22.25
0.35
−0.01
6.34
0.18
0.32
0.19
0.20

SEQID-02414
0.03
0.06
0.04
0.04
0.06
0.04
0.04
0.06
−17.89
0.44
0.01
8.09
0.20
0.32
0.20
0.21

SEQID-02415
0.03
0.05
0.05
0.03
0.05
0.04
0.02
0.05
−22.74
0.33
0.02
9.12
0.21
0.30
0.21
0.20

SEQID-02416
0.01
0.02
0.01
0.02
0.02
0.02
0.03
0.02
−37.68
0.11
0.09
10.58
0.26
0.36
0.24
0.00

SEQID-02417
0.01
0.03
0.01
0.03
0.02
0.02
0.04
0.02
−37.55
0.11
0.09
10.51
0.26
0.36
0.20
0.00

SEQID-02418
0.02
0.03
0.07
0.04
0.07
0.03
0.05
0.09
−23.17
0.28
0.00
6.53
0.20
0.34
0.19
0.23

SEQID-02419
0.01
0.04
0.02
0.05
0.04
0.03
0.03
0.09
−19.87
0.48
−0.01
6.39
0.70
0.80
0.26
0.22

SEQID-02420
0.03
0.08
0.03
0.03
0.03
0.02
0.03
0.05
−31.95
0.40
−0.19
3.81
0.21
0.33
0.00
0.23

SEQID-02421
0.02
0.05
0.03
0.04
0.04
0.01
0.04
0.07
−21.29
0.41
0.00
6.39
0.85
0.96
0.00
0.22

SEQID-02422
0.04
0.06
0.04
0.04
0.04
0.02
0.06
0.06
−21.28
0.35
−0.02
5.14
0.19
0.34
0.00
0.20

SEQID-02423
0.04
0.05
0.03
0.06
0.06
0.02
0.03
0.03
−18.90
0.66
−0.02
5.14
0.19
0.33
0.00
0.20

SEQID-02424
0.03
0.05
0.05
0.04
0.04
0.03
0.06
0.05
−19.61
0.37
0.00
7.02
0.17
0.34
0.19
0.00

SEQID-02425
0.02
0.04
0.07
0.06
0.03
0.05
0.04
0.06
−21.89
0.25
0.02
8.05
0.22
0.31
0.24
0.21

SEQID-02426
0.02
0.04
0.05
0.05
0.06
0.03
0.05
0.07
−23.80
0.29
−0.02
5.46
0.19
0.32
0.19
0.19

SEQID-02427
0.02
0.06
0.05
0.05
0.05
0.00
0.03
0.09
−18.62
0.43
0.00
6.55
0.00
0.52
0.17
0.97

SEQID-02428
0.03
0.07
0.05
0.05
0.04
0.02
0.07
0.05
−21.75
0.30
0.01
7.98
0.19
0.31
0.00
0.20

SEQID-02429
0.02
0.03
0.04
0.05
0.06
0.01
0.05
0.07
−18.78
0.43
0.00
6.62
0.19
0.33
0.00
0.23

SEQID-02430
0.03
0.06
0.06
0.05
0.06
0.00
0.02
0.07
−16.81
0.55
0.02
8.74
0.51
0.69
0.00
0.00

SEQID-02431
0.02
0.05
0.06
0.07
0.05
0.01
0.04
0.04
−24.73
0.28
−0.07
4.42
0.20
0.40
0.00
0.22

SEQID-02432
0.04
0.05
0.04
0.05
0.07
0.03
0.03
0.03
−18.45
0.60
−0.01
5.73
0.19
0.32
0.00
0.20

SEQID-02433
0.01
0.04
0.05
0.06
0.06
0.02
0.04
0.07
−22.41
0.32
0.01
8.58
0.19
0.35
0.19
0.20

SEQID-02434
0.03
0.04
0.05
0.05
0.05
0.02
0.04
0.03
−21.07
0.40
0.03
9.43
0.22
0.34
0.00
0.22

SEQID-02435
0.03
0.05
0.03
0.05
0.03
0.01
0.04
0.07
−21.68
0.43
−0.05
4.55
0.82
0.96
0.21
0.22

SEQID-02436
0.04
0.05
0.04
0.04
0.03
0.02
0.05
0.07
−22.82
0.38
0.00
6.73
0.21
0.32
0.00
0.21

SEQID-02437
0.02
0.07
0.04
0.03
0.06
0.00
0.04
0.08
−17.52
0.62
0.03
8.71
0.23
0.31
0.00
0.22

SEQID-02438
0.04
0.02
0.02
0.04
0.02
0.01
0.02
0.03
−32.14
0.15
0.06
10.17
0.26
0.31
0.26
0.00

SEQID-02439
0.01
0.07
0.04
0.05
0.04
0.03
0.07
0.05
−21.60
0.24
0.06
8.37
0.21
0.32
0.23
0.23

SEQID-02440
0.03
0.05
0.03
0.04
0.07
0.01
0.04
0.06
−23.37
0.33
−0.01
5.71
0.72
0.89
0.19
0.21

SEQID-02441
0.03
0.04
0.05
0.10
0.07
0.01
0.04
0.06
−23.33
0.22
0.01
8.53
0.19
0.40
0.19
0.19

SEQID-02442
0.00
0.07
0.02
0.08
0.09
0.02
0.06
0.05
−17.94
0.30
0.01
8.88
0.20
0.32
0.00
0.00

SEQID-02443
0.04
0.05
0.09
0.07
0.05
0.01
0.06
0.03
−20.79
0.13
0.04
9.80
0.18
0.34
0.00
0.23

SEQID-02444
0.04
0.05
0.04
0.06
0.04
0.03
0.05
0.05
−19.86
0.39
0.03
9.43
0.22
0.31
0.00
0.21

SEQID-02445
0.01
0.03
0.10
0.05
0.07
0.02
0.03
0.06
−21.39
0.27
0.00
6.99
0.20
0.43
0.20
0.22

SEQID-02446
0.02
0.05
0.03
0.05
0.07
0.01
0.03
0.06
−22.59
0.34
−0.02
5.16
0.74
0.93
0.21
0.22

SEQID-02447
0.04
0.07
0.03
0.03
0.06
0.00
0.03
0.07
−17.51
0.50
0.01
7.98
0.23
0.31
0.00
0.00

SEQID-02448
0.05
0.06
0.07
0.02
0.04
0.00
0.02
0.05
−23.59
0.32
−0.04
4.68
0.31
0.48
0.00
0.22

SEQID-02449
0.02
0.05
0.03
0.05
0.06
0.00
0.06
0.06
−18.88
0.43
0.02
9.26
0.19
0.31
0.00
0.22

SEQID-02450
0.02
0.04
0.04
0.04
0.05
0.02
0.04
0.05
−22.04
0.23
0.01
8.21
0.37
0.54
0.00
0.20

SEQID-02451
0.03
0.04
0.05
0.03
0.96
0.00
0.04
0.03
−19.05
0.43
−0.04
4.75
0.22
0.33
0.20
0.20

SEQID-02452
0.02
0.02
0.07
0.06
0.09
0.01
0.03
0.10
−21.92
0.31
0.01
9.07
0.19
0.34
0.19
0.19

SEQID-02453
0.02
0.06
0.03
0.05
0.03
0.05
0.02
0.09
−16.92
0.54
0.04
9.64
0.23
0.33
0.20
0.21

SEQID-02454
0.03
0.09
0.02
0.04
0.03
0.03
0.07
0.07
−17.65
0.55
0.07
10.22
0.23
0.31
0.00
0.00

SEQID-02455
0.05
0.07
0.05
0.05
0.07
0.01
0.05
0.06
−18.76
0.33
−0.04
4.68
0.39
0.53
0.00
0.21

SEQID-02456
0.03
0.04
0.02
0.05
0.06
0.02
0.04
0.07
−18.79
0.48
0.01
7.64
0.19
0.33
0.00
0.22

SEQID-02457
0.04
0.05
0.05
0.04
0.05
0.01
0.04
0.07
−21.29
0.44
0.00
6.93
0.20
0.33
0.19
0.20

SEQID-02458
0.02
0.06
0.04
0.05
0.03
0.03
0.05
0.06
−20.31
0.48
0.00
7.09
0.18
0.32
0.20
0.19

SEQID-02459
0.03
0.06
0.03
0.06
0.04
0.02
0.05
0.05
−21.32
0.46
−0.02
5.69
0.00
0.33
0.00
0.19

SEQID-02460
0.01
0.04
0.03
0.06
0.07
0.02
0.04
0.07
−23.81
0.32
−0.01
6.06
0.00
0.36
0.00
0.00

SEQID-02461
0.03
0.03
0.04
0.06
0.05
0.00
0.05
0.09
−19.82
0.44
0.00
7.49
0.21
0.33
0.00
0.23

SEQID-02462
0.04
0.06
0.04
0.04
0.04
0.02
0.03
0.06
−22.56
0.35
−0.01
6.40
0.42
0.65
0.00
0.19

SEQID-02463
0.02
0.06
0.04
0.04
0.06
0.01
0.06
0.07
−19.71
0.37
−0.05
4.70
0.93
1.00
0.19
0.33

SEQID-02464
0.03
0.04
0.01
0.05
0.04
0.00
0.05
0.05
−24.76
0.39
−0.01
5.89
0.22
0.33
0.00
0.20

SEQID-02465
0.03
0.06
0.05
0.04
0.04
0.01
0.03
0.05
−21.99
0.39
−0.03
4.94
0.20
0.33
0.00
0.72

SEQID-02466
0.03
0.06
0.04
0.06
0.06
0.02
0.04
0.07
−20.05
0.45
0.00
7.09
0.18
0.99
0.18
0.20

SEQID-02467
0.03
0.04
0.04
0.05
0.05
0.02
0.05
0.06
−19.09
0.43
−0.01
6.58
0.19
0.33
0.19
0.20

SEQID-02468
0.03
0.06
0.05
0.03
0.04
0.00
0.10
0.05
−24.58
0.43
−0.01
5.16
0.26
0.29
0.00
0.00

SEQID-02469
0.02
0.06
0.09
0.09
0.05
0.05
0.04
0.05
−20.66
0.25
0.00
6.69
0.22
0.31
0.00
0.22

SEQID-02470
0.02
0.03
0.04
0.05
0.03
0.04
0.04
0.05
−22.96
0.32
−0.01
6.64
0.21
0.31
0.00
0.20

SEQID-02471
0.03
0.02
0.03
0.07
0.04
0.02
0.05
0.06
−23.64
0.29
−0.01
5.78
0.19
0.33
0.00
0.00

SEQID-02472
0.03
0.04
0.04
0.05
0.04
0.02
0.03
0.09
−20.58
0.56
0.00
7.45
0.25
0.33
0.00
0.00

SEQID-02473
0.04
0.07
0.03
0.05
0.06
0.05
0.04
0.05
−18.23
0.38
0.02
8.89
0.19
0.32
0.00
0.00

SEQID-02474
0.03
0.03
0.02
0.05
0.04
0.00
0.07
0.04
−25.38
0.35
0.00
7.40
0.21
0.33
0.00
0.00

SEQID-02475
0.02
0.06
0.04
0.03
0.05
0.03
0.05
0.07
−20.38
0.41
0.01
8.20
0.21
0.32
0.00
0.22

SEQID-02476
0.04
0.05
0.02
0.03
0.06
0.02
0.03
0.07
−21.76
0.49
−0.01
5.82
0.21
0.33
0.21
0.20

SEQID-02477
0.02
0.04
0.08
0.05
0.05
0.02
0.04
0.04
−20.44
0.24
0.01
8.55
0.20
0.36
0.20
0.21

SEQID-02478
0.02
0.09
0.04
0.05
0.06
0.01
0.05
0.06
−17.07
0.48
0.01
8.48
0.20
0.35
0.00
0.21

SEQID-02479
0.02
0.05
0.07
0.07
0.05
0.02
0.02
0.05
−21.00
0.33
−0.02
5.10
0.18
0.33
0.20
0.21

SEQID-02480
0.03
0.04
0.02
0.04
0.05
0.01
0.05
0.05
−28.79
0.30
−0.05
4.73
0.65
0.36
0.00
0.21

SEQID-02481
0.03
0.02
0.03
0.09
0.07
0.00
0.06
0.06
−23.72
0.21
0.14
10.93
0.26
0.30
0.00
0.21

SEQID-02482
0.05
0.07
0.03
0.02
0.05
0.00
0.05
0.06
−24.45
0.38
−0.05
4.74
0.42
0.52
0.00
0.22

SEQID-02483
0.02
0.02
0.02
0.06
0.04
0.01
0.08
0.05
−24.51
0.30
−0.06
4.50
0.25
0.32
0.22
0.00

SEQID-02484
0.03
0.07
0.04
0.04
0.04
0.03
0.05
0.04
−25.47
0.32
−0.03
4.91
0.22
0.32
0.00
0.23

SEQID-02485
0.02
0.05
0.04
0.05
0.07
0.03
0.05
0.04
−19.78
0.44
0.00
6.90
0.20
0.30
0.00
0.00

SEQID-02486
0.04
0.09
0.05
0.05
0.04
0.03
0.08
0.07
−15.73
0.57
0.04
9.53
0.21
0.30
0.00
0.00

SEQID-02487
0.03
0.05
0.05
0.04
0.04
0.03
0.05
0.06
−19.73
0.11
0.00
7.19
0.21
0.33
0.00
0.00

SEQID-02488
0.02
0.05
0.05
0.04
0.04
0.03
0.05
0.06
−20.63
0.35
−0.01
6.50
0.21
0.33
0.00
0.19

SEQID-02489
0.03
0.07
0.02
0.03
0.04
0.02
0.04
0.05
−24.46
0.45
0.00
6.80
0.21
0.32
0.00
0.20

SEQID-02490
0.03
0.07
0.03
0.09
0.04
0.02
0.05
0.04
−21.89
0.31
0.00
7.33
0.22
0.36
0.20
0.21

SEQID-02491
0.03
0.05
0.04
0.04
0.05
0.00
0.04
0.09
−18.41
0.48
0.03
9.56
0.19
0.35
0.00
0.21

SEQID-02492
0.02
0.04
0.07
0.05
0.04
0.01
0.04
0.05
−20.66
0.34
−0.01
5.44
0.26
0.55
0.21
0.30

SEQID-02493
0.03
0.05
0.03
0.06
0.04
0.02
0.05
0.05
−21.97
0.38
−0.02
5.70
0.19
0.34
0.00
0.20

SEQID-02494
0.01
0.06
0.04
0.06
0.04
0.01
0.06
0.07
−17.07
0.38
0.02
9.01
0.47
0.64
0.21
0.21

SEQID-02495
0.01
0.06
0.04
0.06
0.04
0.01
0.06
0.07
−16.80
0.38
0.02
8.77
0.46
0.63
0.20
0.21

SEQID-02496
0.01
0.07
0.04
0.06
0.03
0.01
0.05
0.06
−16.41
0.40
0.03
9.41
0.45
0.61
0.21
0.21

SEQID-02497
0.01
0.09
0.04
0.07
0.04
0.01
0.06
0.06
−16.25
0.37
0.02
9.18
0.45
0.62
0.00
0.21

SEQID-02498
0.02
0.07
0.04
0.04
0.03
0.01
0.05
0.06
−16.80
0.40
0.02
8.96
0.45
0.61
0.00
0.21

SEQID-02499
0.01
0.06
0.03
0.06
0.04
0.01
0.06
0.07
−17.37
0.42
0.02
8.61
0.45
0.60
0.00
0.22

SEQID-02500
0.04
0.07
0.04
0.05
0.05
0.03
0.07
0.06
−21.43
0.31
0.00
6.82
0.19
0.33
0.00
0.20

SEQID-02501
0.01
0.07
0.04
0.04
0.03
0.01
0.05
0.06
−17.67
0.44
0.03
9.55
0.42
0.56
0.00
0.22

SEQID-02502
0.02
0.07
0.04
0.06
0.04
0.02
0.03
0.07
−16.73
0.44
0.02
8.95
0.41
0.60
0.21
0.22

SEQID-02503
0.01
0.07
0.04
0.04
0.04
0.01
0.04
0.05
−17.57
0.40
0.04
9.98
0.41
0.59
0.00
0.21

SEQID-02504
0.04
0.07
0.05
0.06
0.03
0.03
0.07
0.06
−20.04
0.31
−0.02
5.99
0.19
0.36
0.00
0.21

SEQID-02505
0.02
0.06
0.04
0.07
0.04
0.03
0.06
0.07
−18.61
0.37
−0.01
6.20
0.19
0.34
0.00
0.20

SEQID-02506
0.03
0.05
0.05
0.04
0.04
0.02
0.05
0.07
−19.04
0.45
0.01
3.22
0.21
0.33
0.20
0.21

SEQID-02507
0.04
0.05
0.04
0.04
0.05
0.01
0.03
0.08
−19.62
0.43
−0.01
6.31
0.20
0.35
0.00
0.21

SEQID-02508
0.03
0.06
0.04
0.04
0.05
0.02
0.06
0.05
−20.08
0.42
−0.01
6.59
0.19
0.31
0.00
0.21

SEQID-02509
0.04
0.06
0.04
0.05
0.06
0.01
0.05
0.05
−19.78
0.42
−0.02
5.49
0.20
0.30
0.00
0.21

SEQID-02510
0.03
0.04
0.04
0.06
0.04
0.01
0.06
0.06
−19.00
0.46
0.00
7.04
0.21
0.32
0.00
0.21

SEQID-02511
0.03
0.06
0.04
0.04
0.04
0.02
0.06
0.05
−20.23
0.42
−0.01
6.35
0.20
0.31
0.00
0.20

SEQID-02512
0.02
0.06
0.04
0.04
0.04
0.02
0.07
0.06
−20.16
0.41
−0.01
6.52
0.20
0.34
0.00
0.22

SEQID-02513
0.01
0.09
0.03
0.05
0.02
0.01
0.10
0.06
−9.08
0.66
0.01
8.91
0.31
0.41
0.21
0.20

SEQID-02514
0.02
0.05
0.04
0.05
0.04
0.03
0.05
0.07
−21.93
0.35
−0.02
5.75
0.19
0.36
0.00
0.20

SEQID-02515
0.02
0.05
0.03
0.03
0.05
0.01
0.04
0.07
−25.25
0.39
−0.03
4.82
0.89
0.99
0.00
0.21

SEQID-02516
0.04
0.05
0.05
0.06
0.05
0.02
0.05
0.06
−16.46
0.49
0.01
8.09
0.23
0.33
0.00
0.20

SEQID-02517
0.03
0.05
0.03
0.05
0.06
0.03
0.04
0.10
−19.93
0.49
0.01
8.07
0.83
0.95
0.00
0.21

SEQID-02518
0.04
0.04
0.05
0.04
0.05
0.02
0.05
0.09
−17.47
0.55
0.04
9.88
0.22
0.34
0.22
0.22

SEQID-02519
0.01
0.05
0.04
0.05
0.03
0.01
0.03
0.06
−25.87
0.41
0.01
8.23
0.37
0.51
0.18
0.21

SEQID-02520
0.02
0.04
0.04
0.05
0.07
0.00
0.01
0.09
−21.36
0.39
−0.02
4.86
0.46
0.77
0.00
0.22

SEQID-02521
0.02
0.07
0.04
0.07
0.05
0.01
0.03
0.07
−17.87
0.36
0.01
8.44
0.22
0.44
0.20
0.22

SEQID-02522
0.03
0.04
0.05
0.04
0.06
0.01
0.04
0.09
−22.21
0.39
0.03
9.56
0.22
0.35
0.21
0.22

SEQID-02523
0.01
0.07
0.04
0.05
0.05
0.01
0.05
0.06
−17.00
0.39
0.01
8.01
0.43
0.60
0.20
0.21

SEQID-02524
0.07
0.04
0.04
0.09
0.01
0.01
0.07
0.04
−19.56
0.33
0.00
7.60
0.36
0.49
0.25
0.24

SEQID-02525
0.01
0.03
0.04
0.05
0.06
0.01
0.05
0.07
−19.79
0.39
0.01
8.33
0.21
0.33
0.00
0.00

SEQID-02526
0.04
0.05
0.04
0.03
0.03
0.01
0.02
0.11
−19.49
0.55
−0.01
6.43
0.26
0.35
0.20
0.20

SEQID-02527
0.02
0.05
0.05
0.05
0.03
0.01
0.06
0.05
−17.50
0.46
0.00
6.62
0.21
0.32
0.00
0.22

SEQID-02528
0.01
0.09
0.05
0.04
0.03
0.01
0.05
0.07
−23.43
0.40
−0.04
4.76
0.24
0.63
0.19
0.21

SEQID-02529
0.04
0.02
0.05
0.04
0.03
0.02
0.05
0.09
−15.87
0.52
0.02
7.90
1.00
1.00
0.27
0.32

SEQID-02530
0.02
0.06
0.03
0.05
0.06
0.03
0.04
0.10
−20.63
0.47
0.00
6.80
0.89
0.96
0.23
0.00

SEQID-02531
0.02
0.06
0.04
0.07
0.03
0.01
0.03
0.07
−23.43
0.45
0.00
7.26
0.39
0.54
0.22
0.23

SEQID-02532
0.05
0.05
0.04
0.04
0.05
0.02
0.04
0.09
−21.12
0.40
−0.01
6.03
0.20
0.33
0.00
0.21

SEQID-02533
0.04
0.06
0.03
0.04
0.05
0.01
0.05
0.08
−21.73
0.43
−0.02
5.23
0.22
0.33
0.00
0.21

SEQID-02534
0.04
0.07
0.03
0.04
0.05
0.01
0.04
0.07
−21.79
0.40
−0.02
5.35
0.22
0.33
0.00
0.20

SEQID-02535
0.03
0.05
0.04
0.04
0.06
0.01
0.02
0.09
−20.07
0.56
−0.01
5.57
0.24
0.36
0.00
0.22

SEQID-02536
0.05
0.05
0.04
0.05
0.04
0.02
0.04
0.09
−21.12
0.40
−0.01
6.03
0.19
0.33
0.00
0.21

SEQID-02537
0.05
0.08
0.04
0.06
0.03
0.01
0.06
0.06
−7.72
0.63
0.02
8.14
0.33
0.48
0.27
0.26

SEQID-02538
0.02
0.04
0.04
0.07
0.06
0.01
0.04
0.07
−19.34
0.40
0.00
6.93
0.20
0.33
0.00
0.20

SEQID-02539
0.01
0.05
0.05
0.05
0.05
0.01
0.03
0.08
−20.15
0.43
−0.02
5.26
0.24
0.32
0.00
0.22

SEQID-02540
0.03
0.03
0.06
0.04
0.04
0.02
0.06
0.10
−15.06
0.53
0.02
8.09
1.00
1.00
0.28
0.33

SEQID-02541
0.02
0.05
0.04
0.05
0.06
0.01
0.03
0.08
−19.70
0.53
0.00
6.55
0.23
0.33
0.22
0.21

SEQID-02542
0.03
0.05
0.03
0.06
0.06
0.03
0.04
0.09
−19.94
0.46
0.00
7.13
0.93
0.99
0.00
0.21

SEQID-02543
0.03
0.05
0.04
0.05
0.05
0.01
0.06
0.05
−18.88
0.46
0.00
6.64
0.21
0.31
0.00
0.21

SEQID-02544
0.02
0.07
0.06
0.05
0.06
0.03
0.06
0.09
−15.70
0.45
0.01
8.78
0.21
0.33
0.00
0.21

SEQID-02545
0.05
0.03
0.06
0.04
0.02
0.02
0.07
0.09
−15.58
0.53
0.02
8.09
1.00
1.00
0.29
0.33

SEQID-02546
0.07
0.04
0.07
0.03
0.03
0.01
0.06
0.09
−14.38
0.66
0.03
8.41
1.00
1.00
0.27
0.30

SEQID-02547
0.01
0.06
0.04
0.06
0.02
0.02
0.07
0.03
−7.89
0.67
0.02
8.47
0.32
0.46
0.25
0.23

SEQID-02548
0.03
0.04
0.04
0.05
0.05
0.03
0.03
0.07
−20.17
0.43
0.02
9.64
0.00
0.30
0.00
0.00

SEQID-02549
0.05
0.04
0.05
0.05
0.06
0.02
0.06
0.06
−19.73
0.44
−0.03
5.16
0.20
0.34
0.00
0.21

SEQID-02550
0.05
0.04
0.05
0.04
0.03
0.01
0.05
0.09
−14.39
0.68
0.01
7.57
0.34
0.40
0.27
0.37

SEQID-02551
0.04
0.09
0.05
0.05
0.04
0.04
0.07
0.06
−18.24
0.37
−0.03
5.44
0.20
0.34
0.00
0.22

SEQID-02552
0.01
0.06
0.03
0.06
0.01
0.01
0.10
0.05
−9.62
0.60
0.02
9.47
0.29
0.40
0.26
0.23

SEQID-02553
0.09
0.05
0.05
0.07
0.02
0.02
0.04
0.05
−9.85
0.49
0.02
7.95
0.35
0.49
0.30
0.29

SEQID-02554
0.01
0.07
0.04
0.06
0.03
0.02
0.09
0.07
−7.89
0.65
0.02
8.46
0.31
0.48
0.26
0.24

SEQID-02555
0.04
0.07
0.06
0.04
0.04
0.03
0.06
0.06
−21.89
0.35
0.00
6.39
0.21
0.35
0.00
0.20

SEQID-02556
0.05
0.05
0.02
0.04
0.04
0.02
0.04
0.07
−18.88
0.52
0.03
8.84
0.24
0.31
0.00
0.23

SEQID-02557
0.06
0.03
0.04
0.06
0.02
0.01
0.04
0.09
−15.43
0.71
0.01
7.57
0.33
0.39
0.26
0.38

SEQID-02558
0.01
0.07
0.03
0.05
0.02
0.00
0.10
0.06
−9.17
0.67
0.02
8.91
0.31
0.41
0.26
0.23

SEQID-02559
0.01
0.07
0.04
0.06
0.02
0.02
0.10
0.04
−10.06
0.62
0.00
7.33
0.28
0.36
0.22
0.23

SEQID-02560
0.05
0.04
0.05
0.06
0.05
0.02
0.06
0.07
−19.68
0.43
−0.03
5.15
0.21
0.32
0.00
0.19

SEQID-02561
0.03
0.06
0.04
0.06
0.05
0.02
0.05
0.08
−15.24
0.55
0.00
7.05
0.24
0.55
0.19
0.22

SEQID-02562
0.04
0.03
0.05
0.06
0.06
0.02
0.03
0.09
−16.37
0.54
−0.01
5.97
0.25
0.35
0.21
0.21

SEQID-02563
0.02
0.04
0.06
0.06
0.05
0.05
0.10
0.06
−16.23
0.41
0.00
7.12
0.70
0.91
0.00
0.21

SEQID-02564
0.02
0.06
0.05
0.03
0.03
0.06
0.04
0.06
−20.60
0.31
−0.01
6.79
0.22
0.32
0.22
0.23

SEQID-02565
0.04
0.07
0.07
0.04
0.03
0.03
0.06
0.06
−21.89
0.34
0.00
6.69
0.21
0.33
0.21
0.21

SEQID-02566
0.03
0.07
0.04
0.07
0.06
0.01
0.05
0.08
−13.93
0.44
−0.02
5.28
0.21
0.33
0.00
0.21

SEQID-02567
0.04
0.03
0.06
0.04
0.03
0.03
0.06
0.09
−15.22
0.52
0.01
7.31
1.00
1.00
0.26
0.32

SEQID-02568
0.01
0.07
0.06
0.03
0.04
0.01
0.06
0.07
−15.31
0.51
−0.03
4.64
0.26
0.35
0.00
0.24

SEQID-02569
0.01
0.04
0.03
0.09
0.06
0.06
0.05
0.09
−16.43
0.41
−0.01
6.41
0.21
0.32
0.00
0.22

SEQID-02570
0.03
0.04
0.05
0.05
0.06
0.03
0.04
0.07
−19.99
0.46
0.00
7.01
0.21
0.34
0.22
0.21

SEQID-02571
0.02
0.04
0.03
0.05
0.04
0.02
0.02
0.06
−28.49
0.36
−0.03
5.45
0.22
0.43
0.00
0.20

SEQID-02572
0.03
0.04
0.03
0.04
0.06
0.01
0.03
0.06
−22.92
0.37
−0.03
4.84
0.71
0.91
0.00
0.21

SEQID-02573
0.03
0.05
0.02
0.05
0.04
0.02
0.04
0.05
−28.14
0.31
−0.05
4.69
0.66
0.83
0.00
0.20

SEQID-02574
0.01
0.07
0.03
0.06
0.03
0.01
0.09
0.06
−8.93
0.63
0.01
3.42
0.31
0.42
0.23
0.25

SEQID-02575
0.01
0.04
0.03
0.06
0.05
0.04
0.02
0.12
−17.90
0.51
−0.01
5.15
0.87
0.93
0.00
0.00

SEQID-02576
0.02
0.04
0.05
0.04
0.04
0.01
0.04
0.09
−19.24
0.34
0.13
11.57
0.00
0.35
0.00
0.24

SEQID-02577
0.02
0.05
0.04
0.02
0.06
0.01
0.09
0.06
−23.20
0.38
−0.01
5.31
1.00
1.00
0.20
0.22

SEQID-02578
0.04
0.07
0.06
0.04
0.04
0.03
0.06
0.06
−22.11
0.34
0.00
6.40
0.21
0.33
0.00
0.21

SEQID-02579
0.03
0.04
0.03
0.05
0.04
0.02
0.05
0.09
−19.55
0.44
−0.02
5.23
0.88
0.93
0.20
0.21

SEQID-02580
0.03
0.06
0.06
0.05
0.04
0.04
0.06
0.07
−17.64
0.45
−0.01
6.24
0.20
0.34
0.00
0.22

SEQID-02581
0.03
0.04
0.07
0.04
0.03
0.03
0.05
0.08
−21.18
0.39
−0.02
5.14
0.20
0.34
0.00
0.22

SEQID-02582
0.04
0.07
0.05
0.05
0.02
0.06
0.05
0.07
−20.45
0.39
0.00
6.81
0.23
0.33
0.19
0.23

SEQID-02583
0.02
0.04
0.05
0.05
0.04
0.02
0.03
0.07
−21.54
0.36
0.11
11.32
0.21
0.39
0.00
0.19

SEQID-02584
0.03
0.07
0.04
0.04
0.02
0.04
0.04
0.09
−19.60
0.45
0.00
7.77
0.00
0.32
0.26
0.22

SEQID-02585
0.03
0.03
0.03
0.05
0.04
0.01
0.07
0.05
−25.84
0.30
−0.06
4.49
0.22
0.32
0.00
0.00

SEQID-02586
0.03
0.03
0.02
0.06
0.05
0.01
0.07
0.04
−26.08
0.30
−0.06
4.46
0.24
0.32
0.00
0.00

SEQID-02587
0.02
0.07
0.05
0.07
0.05
0.03
0.03
0.09
−16.51
0.51
−0.01
6.05
0.26
0.48
0.00
0.23

SEQID-02588
0.02
0.04
0.04
0.05
0.07
0.00
0.01
0.08
−22.86
0.38
−0.06
4.32
0.47
0.66
0.22
0.23

SEQID-02589
0.05
0.05
0.05
0.05
0.04
0.02
0.04
0.04
−18.82
0.37
0.02
8.39
0.22
0.35
0.20
0.23

SEQID-02590
0.04
0.03
0.04
0.06
0.04
0.02
0.06
0.07
−20.00
0.41
0.00
7.05
0.22
0.34
0.20
0.22

SEQID-02591
0.03
0.04
0.04
0.05
0.05
0.00
0.05
0.07
−18.93
0.47
−0.01
5.90
0.21
0.33
0.00
0.22

SEQID-02592
0.02
0.04
0.05
0.04
0.06
0.00
0.04
0.03
−18.09
0.47
−0.01
6.31
0.21
0.35
0.21
0.22

SEQID-02593
0.04
0.04
0.06
0.05
0.05
0.00
0.04
0.08
−17.29
0.50
0.01
8.18
0.20
0.33
0.19
0.21

SEQID-02594
0.03
0.05
0.04
0.06
0.06
0.03
0.05
0.07
−19.28
0.43
−0.01
6.23
0.87
0.96
0.00
0.20

SEQID-02595
0.03
0.06
0.05
0.05
0.05
0.02
0.05
0.08
−18.26
0.43
−0.02
5.89
0.20
0.34
0.00
0.21

SEQID-02596
0.02
0.03
0.05
0.07
0.04
0.01
0.03
0.07
−24.35
0.36
−0.10
4.09
0.19
0.40
0.20
0.19

SEQID-02597
0.02
0.02
0.03
0.02
0.03
0.00
0.04
0.05
−25.27
0.34
−0.01
5.85
0.00
0.33
0.00
0.00

SEQID-02598
0.02
0.09
0.03
0.03
0.03
0.02
0.06
0.07
−24.82
0.35
−0.07
4.28
0.38
0.44
0.24
0.24

SEQID-02599
0.02
0.05
0.02
0.05
0.03
0.07
0.04
0.05
−10.38
0.87
0.03
9.59
0.24
0.35
0.23
0.24

SEQID-02600
0.01
0.04
0.10
0.07
0.05
0.03
0.04
0.08
−17.05
0.50
0.02
8.49
0.30
0.39
0.00
1.00

SEQID-02601
0.04
0.05
0.04
0.04
0.04
0.01
0.04
0.08
−21.61
0.44
0.05
10.15
0.21
0.31
0.00
0.21

SEQID-02602
0.03
0.04
0.07
0.03
0.05
0.05
0.04
0.06
−17.05
0.50
−0.04
4.61
0.20
0.35
0.20
0.00

SEQID-02603
0.02
0.06
0.05
0.05
0.03
0.04
0.04
0.08
−20.46
0.47
0.01
8.42
0.42
0.69
0.22
0.20

SEQID-02604
0.03
0.03
0.04
0.03
0.04
0.02
0.06
0.06
−19.79
0.39
0.00
7.19
0.21
0.31
0.00
0.19

SEQID-02605
0.02
0.03
0.03
0.05
0.05
0.00
0.03
0.09
−24.17
0.42
0.00
7.09
0.21
0.33
0.00
0.21

SEQID-02606
0.03
0.05
0.03
0.04
0.05
0.02
0.05
0.07
−24.29
0.30
0.13
10.75
0.67
0.75
0.00
0.20

SEQID-02607
0.03
0.03
0.04
0.07
0.03
0.01
0.02
0.07
−22.97
0.41
0.01
8.58
0.41
0.60
0.21
0.23

SEQID-02608
0.02
0.06
0.05
0.05
0.04
0.00
0.05
0.06
−20.67
0.39
−0.01
6.22
0.20
0.34
0.00
0.21

SEQID-02609
0.03
0.06
0.05
0.07
0.04
0.01
0.04
0.07
−17.99
0.49
−0.01
6.39
0.21
0.33
0.00
0.21

SEQID-02610
0.01
0.09
0.05
0.05
0.05
0.01
0.04
0.05
−22.39
0.44
−0.06
4.53
0.21
0.51
0.00
0.21

SEQID-02611
0.02
0.05
0.04
0.07
0.05
0.02
0.04
0.07
−21.82
0.36
0.00
6.87
0.19
0.32
0.00
0.21

SEQID-02612
0.03
0.05
0.07
0.04
0.05
0.02
0.04
0.09
−21.82
0.35
−0.01
6.40
0.86
0.93
0.00
0.00

SEQID-02613
0.03
0.05
0.04
0.05
0.02
0.02
0.04
0.06
−22.91
0.24
0.14
11.03
0.22
0.31
0.24
0.26

SEQID-02614
0.02
0.04
0.05
0.02
0.04
0.02
0.02
0.07
−25.19
0.35
0.14
11.09
0.22
0.31
0.20
0.22

SEQID-02615
0.02
0.05
0.02
0.03
0.06
0.00
0.09
0.04
−26.16
0.26
0.03
9.40
0.22
0.31
0.00
0.00

SEQID-02616
0.02
0.06
0.05
0.04
0.04
0.06
0.03
0.07
−20.47
0.36
0.01
7.28
0.19
0.33
0.22
0.21

SEQID-02617
0.02
0.09
0.05
0.06
0.05
0.02
0.07
0.03
−14.92
0.47
0.00
7.33
0.52
0.70
0.00
0.21

SEQID-02618
0.02
0.03
0.03
0.03
0.03
0.00
0.02
0.03
−24.23
0.41
−0.01
6.17
0.22
0.38
0.39
0.21

SEQID-02619
0.04
0.01
0.06
0.04
0.05
0.01
0.06
0.03
−16.32
0.61
0.01
7.57
0.51
0.55
0.26
0.56

SEQID-02620
0.02
0.07
0.05
0.06
0.03
0.03
0.00
0.12
−27.11
0.32
0.00
6.56
0.75
0.85
0.19
0.24

SEQID-02621
0.02
0.06
0.04
0.04
0.04
0.03
0.10
0.05
−17.30
0.52
−0.01
6.60
0.36
0.50
0.00
0.20

SEQID-02622
0.03
0.04
0.05
0.06
0.04
0.00
0.05
0.10
−20.36
0.59
−0.02
5.14
0.20
0.53
0.21
0.23

SEQID-02623
0.01
0.09
0.05
0.07
0.06
0.02
0.06
0.04
−20.14
0.28
−0.02
5.66
0.23
0.31
0.00
0.00

SEQID-02624
0.03
0.03
0.05
0.05
0.04
0.05
0.06
0.06
−19.35
0.33
−0.01
6.65
0.21
0.32
0.00
0.23

SEQID-02625
0.04
0.05
0.06
0.05
0.05
0.01
0.04
0.07
−16.45
0.59
0.04
10.09
0.21
0.34
0.00
0.22

SEQID-02626
0.05
0.07
0.03
0.05
0.05
0.02
0.05
0.06
−19.72
0.35
−0.06
4.46
0.40
0.54
0.00
0.21

SEQID-02627
0.03
0.06
0.04
0.06
0.04
0.01
0.06
0.03
−19.97
0.39
−0.05
4.57
0.81
0.90
0.23
0.22

SEQID-02628
0.03
0.04
0.05
0.04
0.05
0.01
0.06
0.09
−17.24
0.44
0.01
8.43
0.22
0.34
0.21
0.22

SEQID-02629
0.03
0.05
0.05
0.05
0.05
0.02
0.03
0.07
−15.14
0.55
0.00
7.08
0.28
0.33
0.21
0.22

SEQID-02630
0.02
0.03
0.05
0.06
0.04
0.02
0.04
0.06
−18.89
0.43
0.00
6.66
0.21
0.32
0.00
0.21

SEQID-02631
0.03
0.07
0.03
0.06
0.05
0.02
0.05
0.06
−24.34
0.34
0.02
9.28
0.38
0.61
0.00
0.21

SEQID-02632
0.02
0.04
0.04
0.05
0.04
0.01
0.04
0.06
−21.94
0.46
−0.02
5.13
0.20
0.35
0.18
0.20

SEQID-02633
0.05
0.05
0.06
0.03
0.03
0.00
0.05
0.06
−23.57
0.36
0.10
10.85
0.23
0.29
0.20
0.25

SEQID-02634
0.01
0.09
0.06
0.09
0.03
0.03
0.00
0.06
−25.01
0.26
−0.01
5.86
0.72
0.35
0.18
0.22

SEQID-02635
0.01
0.07
0.05
0.03
0.06
0.01
0.04
0.06
−21.44
0.34
0.18
11.23
0.21
0.31
0.26
0.22

SEQID-02636
0.04
0.05
0.03
0.03
0.05
0.02
0.02
0.06
−36.57
0.30
0.13
11.42
0.24
0.32
0.20
0.23

SEQID-02637
0.02
0.03
0.04
0.05
0.03
0.01
0.05
0.05
−24.26
0.31
0.12
10.98
0.31
0.30
0.20
0.23

SEQID-02638
0.02
0.03
0.02
0.05
0.05
0.03
0.05
0.06
−25.95
0.18
0.13
11.09
0.23
0.34
0.00
0.19

SEQID-02639
0.03
0.04
0.03
0.09
0.05
0.02
0.06
0.03
−23.36
0.38
−0.08
4.12
0.39
0.54
0.00
0.00

SEQID-02640
0.02
0.06
0.05
0.01
0.05
0.01
0.07
0.07
−21.08
0.37
0.00
7.15
0.20
0.30
0.00
0.20

SEQID-02641
0.02
0.02
0.02
0.05
0.05
0.03
0.05
0.05
−25.83
0.18
0.13
11.09
0.23
0.33
0.00
0.20

SEQID-02642
0.02
0.05
0.03
0.04
0.05
0.00
0.03
0.05
−27.95
0.23
0.16
11.35
0.20
0.33
0.17
0.18

SEQID-02643
0.03
0.05
0.02
0.04
0.05
0.02
0.03
0.09
−25.27
0.31
0.08
10.53
0.30
0.30
0.00
0.00

SEQID-02644
0.02
0.06
0.05
0.03
0.06
0.02
0.02
0.10
−21.54
0.40
0.09
10.94
0.32
0.33
0.20
0.25

SEQID-02645
0.03
0.05
0.05
0.04
0.05
0.01
0.05
0.06
−19.10
0.45
−0.01
5.83
0.26
0.36
0.00
0.00

SEQID-02646
0.02
0.05
0.05
0.06
0.05
0.00
0.03
0.10
−16.61
0.56
0.01
8.30
0.53
0.71
0.00
0.23

SEQID-02647
0.05
0.06
0.04
0.06
0.05
0.02
0.03
0.06
−17.98
0.57
−0.03
5.23
0.00
0.31
0.00
0.22

SEQID-02648
0.02
0.09
0.04
0.07
0.04
0.01
0.02
0.03
−16.79
0.55
−0.02
6.09
0.71
0.81
0.00
1.00

SEQID-02649
0.01
0.09
0.04
0.04
0.03
0.02
0.03
0.06
−23.65
0.39
0.00
6.74
0.24
0.31
0.00
0.21

SEQID-02650
0.05
0.04
0.05
0.05
0.05
0.02
0.03
0.07
−19.93
0.36
0.00
6.72
0.21
0.35
0.19
0.21

SEQID-02651
0.04
0.07
0.05
0.04
0.05
0.01
0.03
0.03
−18.84
0.50
0.01
8.22
0.45
0.69
0.00
0.21

SEQID-02652
0.03
0.09
0.03
0.05
0.05
0.01
0.06
0.07
−12.69
0.92
0.01
9.25
0.21
0.33
0.00
0.22

SEQID-02653
0.04
0.06
0.05
0.05
0.06
0.01
0.04
0.09
−18.81
0.43
0.00
7.37
0.21
0.33
0.21
0.21

SEQID-02654
0.03
0.06
0.04
0.04
0.05
0.05
0.05
0.07
−23.42
0.31
0.00
7.06
0.20
0.33
0.20
0.21

SEQID-02655
0.02
0.03
0.04
0.06
0.04
0.02
0.02
0.06
−19.52
0.47
−0.03
4.96
0.21
0.33
0.00
0.22

SEQID-02656
0.03
0.04
0.06
0.06
0.05
0.03
0.03
0.06
−19.16
0.33
0.03
9.42
0.22
0.37
0.21
0.22

SEQID-02657
0.03
0.05
0.04
0.04
0.04
0.02
0.04
0.09
−20.62
0.40
−0.02
5.39
0.21
0.33
0.21
0.22

SEQID-02658
0.03
0.04
0.05
0.06
0.04
0.03
0.02
0.07
−18.73
0.55
0.02
9.11
0.20
0.33
0.00
0.22

SEQID-02659
0.02
0.05
0.05
0.05
0.04
0.02
0.05
0.09
−16.18
0.54
−0.02
5.61
0.21
0.31
0.19
0.22

SEQID-02660
0.03
0.04
0.04
0.05
0.02
0.02
0.03
0.03
−19.63
0.60
−0.04
4.66
0.20
0.34
0.00
0.22

SEQID-02661
0.03
0.04
0.03
0.05
0.04
0.01
0.03
0.06
−23.81
0.34
0.00
6.56
0.20
0.36
0.38
0.21

SEQID-02662
0.04
0.04
0.06
0.02
0.06
0.02
0.00
0.07
−23.42
0.38
−0.08
4.21
0.28
0.36
0.28
0.31

SEQID-02663
0.01
0.00
0.04
0.09
0.05
0.00
0.03
0.09
−9.95
0.75
0.08
9.58
0.71
0.80
0.28
0.28

SEQID-02664
0.02
0.02
0.02
0.02
0.06
0.01
0.02
0.07
−30.26
0.19
0.08
10.61
0.23
0.30
0.00
0.23

SEQID-02665
0.02
0.04
0.01
0.04
0.04
0.01
0.06
0.03
−26.30
0.32
0.06
10.16
0.30
0.34
0.24
0.00

SEQID-02666
0.05
0.04
0.03
0.05
0.06
0.01
0.03
0.08
−13.01
0.91
0.03
10.18
0.59
0.80
0.29
0.23

SEQID-02667
0.02
0.06
0.03
0.06
0.03
0.04
0.03
0.08
−18.21
0.45
0.05
10.66
0.52
0.63
0.26
0.00

SEQID-02668
0.03
0.04
0.04
0.05
0.09
0.00
0.02
0.06
−23.27
0.33
0.03
11.13
0.23
0.30
0.18
0.23

SEQID-02669
0.02
0.06
0.04
0.02
0.06
0.05
0.06
0.07
−15.40
0.43
−0.01
6.65
0.26
0.30
0.26
0.26

SEQID-02670
0.04
0.10
0.04
0.05
0.06
0.01
0.03
0.09
−17.99
0.40
0.02
8.49
0.82
0.85
0.00
0.24

SEQID-02671
0.03
0.05
0.01
0.03
0.07
0.01
0.03
0.09
−22.31
0.39
0.05
10.24
0.22
0.31
0.00
0.21

SEQID-02672
0.03
0.03
0.03
0.05
0.04
0.01
0.04
0.06
−21.21
0.39
0.05
10.27
0.00
0.30
0.00
0.13

SEQID-02673
0.02
0.06
0.02
0.05
0.07
0.02
0.04
0.03
−22.00
0.39
0.01
8.44
0.23
0.30
0.16
0.23

SEQID-02674
0.06
0.03
0.05
0.05
0.03
0.03
0.01
0.10
−24.56
0.35
0.00
7.53
0.00
0.45
0.22
0.24

SEQID-02675
0.03
0.06
0.06
0.03
0.05
0.04
0.05
0.08
−10.14
0.90
0.01
8.79
0.32
0.33
0.00
0.25

SEQID-02676
0.00
0.04
0.06
0.02
0.02
0.02
0.09
0.10
−19.85
0.53
−0.03
5.34
0.50
0.79
0.20
0.24

SEQID-02677
0.02
0.05
0.04
0.03
0.05
0.01
0.04
0.06
−22.73
0.36
0.10
10.80
0.20
0.31
0.00
0.00

SEQID-02678
0.03
0.06
0.06
0.05
0.05
0.03
0.06
0.05
−20.62
0.36
0.02
8.92
0.20
0.31
0.00
0.20

SEQID-02679
0.02
0.06
0.03
0.06
0.04
0.01
0.02
0.07
−22.98
0.35
−0.05
4.65
0.20
0.33
0.00
0.23

SEQID-02680
0.01
0.06
0.04
0.06
0.04
0.01
0.04
0.09
−18.07
0.45
0.00
6.84
0.21
0.35
0.18
0.22

SEQID-02681
0.04
0.06
0.05
0.06
0.05
0.02
0.02
0.07
−17.09
0.51
−0.01
6.28
0.30
0.43
0.00
0.21

SEQID-02682
0.04
0.02
0.02
0.05
0.06
0.00
0.02
0.09
−20.90
0.43
−0.01
5.39
0.21
0.33
0.22
0.22

SEQID-02683
0.02
0.03
0.03
0.07
0.05
0.00
0.01
0.09
−20.47
0.54
−0.02
5.11
0.21
0.33
0.20
0.22

SEQID-02684
0.01
0.04
0.07
0.03
0.03
0.04
0.04
0.05
−28.42
0.38
−0.07
4.45
0.43
0.73
0.19
0.21

SEQID-02685
0.02
0.03
0.05
0.05
0.05
0.00
0.02
0.10
−17.41
0.58
0.00
7.33
0.21
0.35
0.22
0.21

SEQID-02686
0.03
0.04
0.04
0.06
0.05
0.01
0.05
0.07
−17.37
0.46
0.00
7.27
0.20
0.35
0.00
0.22

SEQID-02687
0.02
0.04
0.03
0.07
0.04
0.02
0.05
0.05
−28.42
0.24
−0.05
4.61
0.44
0.69
0.00
0.20

SEQID-02688
0.02
0.07
0.04
0.07
0.05
0.02
0.04
0.05
−22.43
0.31
−0.01
5.79
0.19
0.55
0.00
0.20

SEQID-02689
0.03
0.05
0.03
0.07
0.04
0.02
0.04
0.07
−22.87
0.32
−0.05
4.72
0.18
0.33
0.19
0.19

SEQID-02690
0.04
0.03
0.04
0.05
0.04
0.00
0.03
0.10
−9.31
0.92
0.09
9.06
0.32
0.33
0.29
0.30

SEQID-02691
0.02
0.05
0.05
0.06
0.05
0.02
0.06
0.11
−16.79
0.43
−0.02
5.65
0.26
0.33
0.20
0.00

SEQID-02692
0.04
0.07
0.02
0.05
0.03
0.01
0.04
0.10
−21.68
0.56
0.07
10.55
0.00
0.30
0.23
0.26

SEQID-02693
0.02
0.05
0.04
0.05
0.07
0.00
0.03
0.07
−10.89
0.88
0.03
10.62
0.47
0.64
0.26
0.22

SEQID-02694
0.02
0.02
0.02
0.06
0.04
0.01
0.03
0.11
−27.06
0.27
0.15
11.62
0.22
0.30
0.17
0.22

SEQID-02695
0.03
0.01
0.05
0.05
0.05
0.01
0.00
0.11
−23.24
0.48
0.03
9.90
0.21
0.31
0.00
0.21

SEQID-02696
0.03
0.04
0.03
0.06
0.06
0.00
0.03
0.07
−23.44
0.37
−0.03
5.87
0.00
0.30
0.00
0.25

SEQID-02697
0.04
0.01
0.02
0.05
0.03
0.03
0.04
0.09
−20.38
0.49
0.00
6.79
0.00
0.31
0.23
0.25

SEQID-02698
0.03
0.05
0.01
0.06
0.03
0.01
0.06
0.09
−23.35
0.29
0.09
10.48
0.00
0.33
0.00
0.23

SEQID-02699
0.04
0.09
0.04
0.02
0.07
0.03
0.09
0.04
−22.58
0.23
0.16
11.08
0.22
0.28
0.00
0.00

SEQID-02700
0.02
0.05
0.04
0.02
0.04
0.00
0.06
0.09
−26.58
0.31
0.07
10.37
0.22
0.30
0.00
0.26

SEQID-02701
0.02
0.05
0.03
0.03
0.02
0.01
0.05
0.06
−25.76
0.30
0.09
10.90
0.00
0.33
0.00
0.00

SEQID-02702
0.02
0.06
0.06
0.04
0.06
0.01
0.04
0.05
−24.24
0.34
0.10
10.81
0.23
0.32
0.00
0.00

SEQID-02703
0.01
0.06
0.07
0.05
0.06
0.01
0.04
0.09
−14.83
0.68
0.01
7.78
0.25
0.33
0.22
0.22

SEQID-02704
0.02
0.03
0.07
0.07
0.02
0.01
0.02
0.10
−14.35
0.60
0.01
7.83
0.24
0.34
0.21
0.23

SEQID-02705
0.01
0.07
0.06
0.09
0.04
0.01
0.04
0.06
−13.24
0.49
−0.01
5.77
0.24
0.41
0.00
0.23

SEQID-02706
0.03
0.05
0.03
0.06
0.04
0.01
0.06
0.06
−20.80
0.37
−0.02
5.22
0.00
0.34
0.00
0.17

SEQID-02707
0.02
0.09
0.04
0.04
0.05
0.03
0.06
0.08
−10.43
0.97
0.02
8.57
0.19
0.33
0.22
0.22

SEQID-02708
0.04
0.07
0.04
0.07
0.07
0.02
0.04
0.07
−11.61
0.98
0.00
6.52
0.00
0.34
0.20
0.22

SEQID-02709
0.04
0.07
0.05
0.03
0.05
0.01
0.02
0.09
−18.52
0.51
−0.01
6.63
0.24
0.32
0.00
0.20

SEQID-02710
0.04
0.07
0.06
0.04
0.04
0.04
0.06
0.06
−19.76
0.38
−0.01
6.06
0.21
0.33
0.00
0.22

SEQID-02711
0.03
0.05
0.04
0.04
0.06
0.03
0.05
0.05
−22.74
0.35
0.00
6.86
0.22
0.31
0.00
0.20

SEQID-02712
0.01
0.04
0.05
0.07
0.05
0.02
0.05
0.07
−18.77
0.43
0.00
6.33
0.21
0.32
0.20
0.23

SEQID-02713
0.01
0.07
0.06
0.06
0.03
0.03
0.03
0.08
−19.54
0.47
−0.01
5.25
0.21
0.37
0.21
0.22

SEQID-02714
0.04
0.05
0.04
0.05
0.06
0.00
0.09
0.07
−20.73
0.39
−0.02
5.64
0.21
0.32
0.00
0.22

SEQID-02715
0.02
0.04
0.05
0.05
0.04
0.04
0.06
0.06
−18.43
0.36
−0.02
6.00
0.22
0.33
0.00
0.23

SEQID-02716
0.03
0.06
0.04
0.06
0.04
0.02
0.04
0.06
−19.43
0.47
0.00
7.43
0.21
0.33
0.00
0.22

SEQID-02717
0.02
0.05
0.06
0.06
0.05
0.03
0.04
0.06
−17.83
0.44
0.00
6.87
0.21
0.34
0.00
0.22

SEQID-02718
0.03
0.07
0.06
0.06
0.04
0.02
0.04
0.08
−15.17
0.68
−0.01
5.53
0.20
0.33
0.00
0.22

SEQID-02719
0.03
0.05
0.05
0.05
0.05
0.01
0.06
0.06
−18.34
0.42
−0.01
6.38
0.21
0.33
0.00
0.22

SEQID-02720
0.03
0.06
0.04
0.06
0.05
0.01
0.05
0.07
−17.71
0.48
0.01
7.76
0.21
0.35
0.21
0.21

SEQID-02721
0.03
0.04
0.07
0.04
0.05
0.02
0.04
0.08
−16.52
0.52
0.00
6.96
0.20
0.34
0.19
0.22

SEQID-02722
0.04
0.05
0.05
0.05
0.04
0.01
0.03
0.09
−17.69
0.56
0.02
9.42
0.20
0.33
0.00
0.21

SEQID-02723
0.03
0.05
0.05
0.04
0.05
0.01
0.04
0.07
−23.11
0.36
−0.03
4.91
0.41
0.59
0.00
0.20

SEQID-02724
0.04
0.05
0.03
0.06
0.04
0.01
0.05
0.06
−18.16
0.55
−0.05
4.33
0.19
0.33
0.00
0.20

SEQID-02725
0.01
0.05
0.03
0.09
0.04
0.02
0.04
0.07
−16.41
0.39
0.00
6.82
0.38
0.65
0.00
0.21

SEQID-02726
0.05
0.04
0.05
0.05
0.06
0.02
0.06
0.07
−19.70
0.45
−0.03
5.16
0.19
0.35
0.00
0.21

SEQID-02727
0.04
0.05
0.03
0.06
0.06
0.02
0.06
0.07
−16.67
0.51
0.00
6.78
0.20
0.69
0.51
0.21

SEQID-02728
0.06
0.04
0.05
0.05
0.05
0.07
0.06
0.06
−19.71
0.44
−0.03
5.16
0.19
0.33
0.00
0.20

SEQID-02729
0.03
0.04
0.05
0.03
0.06
0.01
0.04
0.08
−21.97
0.41
0.03
9.64
0.21
0.35
0.20
0.22

SEQID-02730
0.03
0.05
0.03
0.06
0.06
0.02
0.06
0.03
−17.45
0.53
0.02
8.69
0.21
0.68
0.51
0.20

SEQID-02731
0.03
0.06
0.03
0.05
0.06
0.03
0.04
0.10
−20.31
0.50
0.01
8.19
0.24
0.94
0.22
0.00

SEQID-02732
0.04
0.04
0.04
0.04
0.07
0.02
0.04
0.07
−19.63
0.47
−0.02
5.66
0.20
0.31
0.00
0.22

SEQID-02733
0.02
0.05
0.03
0.07
0.06
0.02
0.04
0.03
−19.85
0.43
0.02
3.30
0.21
0.58
0.46
0.20

SEQID-02734
0.04
0.05
0.03
0.05
0.06
0.03
0.04
0.10
−19.88
0.45
0.01
3.72
0.54
0.91
0.00
0.21

SEQID-02735
0.01
0.05
0.02
0.00
0.01
0.00
0.03
0.02
−32.67
0.27
0.00
7.00
0.21
0.31
0.24
0.27

SEQID-02736
0.02
0.04
0.06
0.05
0.05
0.00
0.03
0.05
−25.93
0.25
0.13
10.85
0.28
0.31
0.00
0.00

SEQID-02737
0.03
0.04
0.04
0.09
0.06
0.02
0.04
0.09
−17.54
0.44
0.01
8.66
0.59
0.88
0.12
0.21

SEQID-02738
0.01
0.05
0.05
0.07
0.05
0.05
0.06
0.07
−16.83
0.38
−0.02
5.73
0.99
1.00
0.00
0.21

SEQID-02739
0.01
0.07
0.28
0.07
0.02
0.00
0.07
0.05
−10.31
0.32
0.00
6.61
0.20
0.41
0.21
0.22

SEQID-02740
0.02
0.03
0.04
0.05
0.06
0.01
0.05
0.07
−18.93
0.33
0.00
7.69
0.22
0.34
0.00
0.27

SEQID-02741
0.02
0.06
0.06
0.06
0.06
0.01
0.06
0.06
−20.59
0.35
−0.02
5.81
0.21
0.33
0.00
0.20

SEQID-02742
0.03
0.04
0.04
0.07
0.03
0.01
0.06
0.05
−19.66
0.44
0.00
6.93
0.20
0.32
0.00
0.22

SEQID-02743
0.03
0.06
0.04
0.05
0.05
0.02
0.05
0.08
−18.64
0.49
0.00
6.93
0.21
0.33
0.00
0.21

SEQID-02744
0.01
0.05
0.22
0.09
0.06
0.01
0.07
0.04
−13.87
0.30
0.02
8.68
0.21
0.45
0.24
0.22

SEQID-02745
0.05
0.05
0.04
0.04
0.05
0.02
0.04
0.08
−21.23
0.37
−0.01
6.06
0.19
0.35
0.00
0.21

SEQID-02746
0.01
0.05
0.05
0.05
0.04
0.04
0.06
0.06
−20.01
0.36
−0.01
6.46
0.19
0.35
0.00
0.20

SEQID-02747
0.06
0.12
0.03
0.06
0.06
0.00
0.00
0.05
−19.01
0.53
0.08
8.81
0.30
0.29
0.30
0.23

SEQID-02748
0.07
0.06
0.05
0.05
0.09
0.00
0.03
0.04
−15.35
0.71
0.01
7.73
0.26
0.28
0.25
0.26

SEQID-02749
0.01
0.04
0.02
0.01
0.07
0.00
0.06
0.05
−26.09
0.28
0.11
10.44
0.24
0.31
0.24
0.28

SEQID-02750
0.01
0.03
0.05
0.05
0.04
0.02
0.04
0.08
−18.50
0.55
−0.03
4.81
0.20
0.31
0.00
0.22

SEQID-02751
0.03
0.03
0.05
0.06
0.04
0.02
0.03
0.10
−16.97
0.56
−0.01
6.25
0.26
0.34
0.20
0.22

SEQID-02752
0.03
0.09
0.05
0.06
0.04
0.02
0.05
0.04
−18.54
0.32
−0.03
4.97
0.00
0.34
0.00
0.00

SEQID-02753
0.05
0.05
0.02
0.05
0.03
0.05
0.01
0.06
−24.99
0.39
−0.03
4.92
0.22
0.33
0.00
0.21

SEQID-02754
0.02
0.03
0.05
0.07
0.05
0.03
0.05
0.06
−18.14
0.38
0.01
9.15
0.23
0.35
0.00
0.22

SEQID-02755
0.03
0.05
0.04
0.04
0.06
0.01
0.03
0.07
−23.11
0.38
−0.03
4.88
0.70
0.93
0.20
0.21

SEQID-02756
0.03
0.04
0.03
0.06
0.05
0.00
0.03
0.09
−18.71
0.49
−0.01
5.32
0.19
0.35
0.00
0.22

SEQID-02757
0.02
0.05
0.04
0.06
0.05
0.03
0.05
0.07
−19.94
0.41
−0.01
5.35
0.88
1.00
0.00
0.20

SEQID-02758
0.03
0.06
0.05
0.07
0.05
0.02
0.05
0.08
−17.81
0.43
0.00
6.97
0.19
0.33
0.20
0.21

SEQID-02759
0.02
0.04
0.04
0.02
0.07
0.00
0.03
0.04
−24.18
0.30
0.15
11.74
0.24
0.30
0.00
0.26

SEQID-02760
0.03
0.04
0.05
0.04
0.05
0.03
0.04
0.06
−16.13
0.48
0.02
9.09
0.20
0.33
0.20
0.19

SEQID-02761
0.02
0.08
0.04
0.07
0.05
0.03
0.05
0.04
−16.70
0.36
0.05
9.16
0.22
0.32
0.00
0.21

SEQID-02762
0.02
0.07
0.07
0.07
0.04
0.04
0.06
0.03
−14.12
0.35
0.02
8.29
0.70
0.35
0.21
0.23

SEQID-02763
0.03
0.06
0.01
0.07
0.06
0.00
0.03
0.07
−15.16
0.53
−0.02
4.73
0.00
0.32
0.00
0.21

SEQID-02764
0.03
0.04
0.05
0.07
0.05
0.03
0.05
0.09
−16.89
0.42
0.01
8.17
0.21
0.34
0.00
0.20

SEQID-02765
0.03
0.05
0.04
0.05
0.04
0.01
0.03
0.09
−19.66
0.54
−0.01
5.85
0.23
0.33
0.23
0.21

SEQID-02766
0.02
0.06
0.03
0.03
0.06
0.02
0.05
0.07
−24.03
0.34
0.13
10.76
0.67
0.75
0.21
0.22

SEQID-02767
0.04
0.07
0.03
0.04
0.05
0.01
0.04
0.07
−21.28
0.43
−0.01
5.55
0.22
0.33
0.00
0.20

SEQID-02768
0.02
0.04
0.03
0.05
0.04
0.02
0.05
0.09
−20.12
0.41
−0.01
5.75
0.39
0.95
0.22
0.23

SEQID-02769
0.02
0.04
0.03
0.03
0.06
0.01
0.03
0.07
−24.92
0.41
−0.03
4.83
0.91
0.99
0.00
0.21

SEQID-02770
0.03
0.05
0.02
0.05
0.04
0.01
0.05
0.05
−28.29
0.30
−0.04
4.75
0.68
0.33
0.00
0.20

SEQID-02771
0.03
0.07
0.04
0.06
0.03
0.03
0.07
0.06
−21.30
0.29
−0.02
6.00
0.19
0.32
0.00
0.20

SEQID-02772
0.09
0.09
0.03
0.06
0.06
0.00
0.00
0.05
−18.31
0.55
0.07
8.61
0.31
0.29
0.34
0.30

SEQID-02773
0.02
0.04
0.00
0.04
0.03
0.02
0.09
0.03
−19.07
0.13
−0.01
5.32
0.31
0.54
0.28
0.32

SEQID-02774
0.01
0.04
0.03
0.05
0.05
0.03
0.03
0.05
−21.86
0.45
−0.02
6.41
0.36
0.44
0.23
0.20

SEQID-02775
0.02
0.05
0.02
0.05
0.06
0.00
0.06
0.09
−21.70
0.35
−0.03
5.54
0.74
0.89
0.24
0.22

SEQID-02776
0.02
0.07
0.01
0.03
0.07
0.04
0.07
0.06
−16.91
0.43
0.00
5.77
0.26
0.32
0.00
0.22

SEQID-02777
0.03
0.05
0.02
0.03
0.03
0.01
0.05
0.06
−26.92
0.30
0.09
10.85
0.22
0.32
0.00
0.21

SEQID-02778
0.03
0.02
0.03
0.04
0.04
0.04
0.08
0.07
−24.90
0.20
0.20
12.00
0.22
0.31
0.20
0.22

SEQID-02779
0.04
0.02
0.04
0.04
0.02
0.02
0.03
0.04
−29.43
0.17
0.22
12.05
0.00
0.30
0.22
0.24

SEQID-02780
0.02
0.03
0.08
0.04
0.09
0.03
0.06
0.04
−13.34
0.33
0.02
7.96
1.00
1.00
0.22
0.50

SEQID-02781
0.03
0.03
0.02
0.06
0.04
0.01
0.07
0.04
−24.89
0.32
−0.06
4.37
0.21
0.34
0.21
0.00

SEQID-02782
0.02
0.02
0.11
0.05
0.05
0.00
0.02
0.08
−25.13
0.22
0.20
11.32
0.24
0.38
0.24
0.25

SEQID-02783
0.01
0.02
0.12
0.04
0.06
0.00
0.01
0.06
−24.43
0.15
0.22
11.47
0.29
0.43
0.25
0.29

SEQID-02784
0.04
0.09
0.05
0.04
0.05
0.03
0.05
0.06
−12.46
0.86
0.01
8.31
0.21
0.34
0.24
0.20

SEQID-02785
0.02
0.09
0.04
0.03
0.05
0.03
0.07
0.09
−11.82
0.99
0.01
8.30
0.22
0.34
0.00
0.00

SEQID-02786
0.04
0.05
0.05
0.03
0.04
0.01
0.02
0.09
−18.30
0.52
−0.01
6.24
0.25
0.33
0.00
0.23

SEQID-02787
0.03
0.06
0.04
0.04
0.05
0.01
0.03
0.10
−18.28
0.54
−0.01
6.43
0.26
0.35
0.00
0.22

SEQID-02788
0.03
0.05
0.05
0.07
0.04
0.02
0.06
0.09
−17.31
0.52
0.00
6.63
0.21
0.33
0.00
0.21

SEQID-02789
0.03
0.06
0.02
0.04
0.06
0.03
0.05
0.05
−22.14
0.37
0.00
6.79
0.22
0.34
0.17
0.21

SEQID-02790
0.02
0.05
0.05
0.06
0.05
0.01
0.03
0.09
−19.53
0.41
−0.01
6.03
0.21
0.33
0.00
0.21

SEQID-02791
0.01
0.06
0.04
0.06
0.05
0.02
0.04
0.08
−16.02
0.52
−0.01
6.30
0.20
0.32
0.19
0.21

SEQID-02792
0.01
0.05
0.07
0.04
0.07
0.02
0.04
0.09
−25.79
0.30
−0.07
4.36
0.20
0.41
0.18
0.22

SEQID-02793
0.04
0.06
0.05
0.05
0.05
0.02
0.06
0.07
−19.92
0.39
−0.02
5.10
0.20
0.36
0.00
0.22

SEQID-02794
0.02
0.02
0.03
0.04
0.04
0.01
0.03
0.07
−24.57
0.38
−0.01
6.02
0.23
0.38
0.38
0.21

SEQID-02795
0.05
0.06
0.05
0.06
0.05
0.02
0.05
0.06
−18.56
0.53
−0.01
6.68
0.21
0.33
0.00
0.23

SEQID-03796
0.05
0.04
0.05
0.05
0.06
0.02
0.06
0.06
−19.72
0.44
−0.03
5.17
0.20
0.34
0.00
0.20

SEQID-02797
0.05
0.04
0.05
0.05
0.06
0.02
0.06
0.06
−19.74
0.43
−0.03
5.16
0.21
0.31
0.00
0.21

SEQID-02793
0.03
0.04
0.03
0.05
0.04
0.02
0.04
0.03
−20.29
0.44
0.00
6.53
0.91
1.00
0.22
0.22

SEQID-02799
0.03
0.05
0.04
0.04
0.04
0.02
0.05
0.09
−21.22
0.38
−0.02
5.73
0.21
0.33
0.20
0.22

SEQID-02800
0.05
0.05
0.04
0.04
0.05
0.02
0.04
0.03
−21.15
0.39
−0.01
5.97
0.19
0.33
0.00
0.21

SEQID-02801
0.02
0.04
0.03
0.04
0.04
0.02
0.05
0.08
−19.95
0.44
−0.01
5.53
0.39
0.99
0.20
0.22

SEQID-02802
0.03
0.05
0.04
0.05
0.05
0.03
0.03
0.07
−18.37
0.70
−0.02
5.50
0.19
0.33
0.00
0.20

SEQID-02803
0.04
0.04
0.04
0.04
0.06
0.02
0.04
0.07
−19.89
0.43
−0.01
6.30
0.21
0.33
0.21
0.21

SEQID-02804
0.03
0.04
0.03
0.04
0.06
0.01
0.03
0.06
−22.76
0.37
−0.03
4.91
0.71
0.91
0.21
0.20

SEQID-02805
0.02
0.03
0.04
0.03
0.06
0.01
0.06
0.07
−19.40
0.41
0.01
8.03
0.23
0.34
0.00
0.22

SEQID-02806
0.02
0.05
0.04
0.06
0.04
0.01
0.03
0.09
−20.35
0.54
0.00
6.70
0.24
0.33
0.20
0.21

SEQID-02807
0.03
0.05
0.05
0.04
0.06
0.01
0.04
0.03
−22.17
0.41
0.03
9.53
0.22
0.33
0.21
0.21

SEQID-02808
0.03
0.07
0.04
0.05
0.05
0.01
0.02
0.09
−19.02
0.51
−0.01
6.35
0.25
0.34
0.00
0.20

SEQID-02809
0.03
0.05
0.04
0.04
0.06
0.01
0.03
0.07
−22.81
0.37
−0.02
4.91
0.71
0.91
0.00
0.21

SEQID-02810
0.03
0.05
0.03
0.07
0.06
0.03
0.04
0.10
−20.69
0.47
0.00
7.21
0.86
0.93
0.00
0.19

SEQID-02811
0.03
0.04
0.04
0.06
0.04
0.03
0.04
0.06
−21.89
0.38
−0.01
6.31
0.19
0.33
0.20
0.19

SEQID-02812
0.03
0.06
0.04
0.05
0.04
0.02
0.06
0.06
−20.34
0.41
−0.02
6.02
0.19
0.35
0.00
0.21

SEQID-02813
0.01
0.03
0.07
0.05
0.04
0.00
0.01
0.05
−38.34
0.12
−0.07
4.92
0.28
0.45
0.13
0.26

SEQID-02814
0.03
0.06
0.03
0.05
0.06
0.03
0.04
0.10
−20.33
0.49
0.01
8.08
0.84
0.94
0.19
0.22

SEQID-02815
0.03
0.07
0.04
0.07
0.04
0.02
0.05
0.06
−19.57
0.42
0.00
6.53
0.20
0.34
0.00
0.21

SEQID-02816
0.03
0.06
0.05
0.04
0.04
0.03
0.05
0.05
−22.17
0.35
−0.03
5.57
0.12
0.32
0.00
0.20

SEQID-02817
0.04
0.07
0.03
0.04
0.05
0.01
0.05
0.08
−21.34
0.43
−0.02
5.22
0.21
0.33
0.00
0.20

SEQID-02818
0.02
0.05
0.04
0.05
0.04
0.01
0.06
0.06
−19.05
0.50
0.00
6.68
0.20
0.32
0.20
0.21

SEQID-02819
0.01
0.05
0.09
0.03
0.05
0.02
0.03
0.09
−25.75
0.35
−0.07
4.40
0.20
0.48
0.19
0.21

SEQID-02820
0.02
0.05
0.04
0.05
0.04
0.00
0.03
0.06
−24.83
0.35
−0.03
4.89
0.20
0.34
0.00
0.21

SEQID-02821
0.01
0.03
0.01
0.03
0.07
0.02
0.05
0.04
−24.60
0.40
0.01
7.68
0.23
0.31
0.00
0.00

SEQID-02822
0.03
0.04
0.04
0.06
0.03
0.00
0.05
0.07
−18.84
0.46
0.00
7.93
0.22
0.32
0.00
0.22

SEQID-02823
0.02
0.08
0.04
0.06
0.03
0.03
0.05
0.06
−24.66
0.39
−0.05
4.72
0.20
0.32
0.00
0.23

SEQID-02824
0.03
0.06
0.05
0.07
0.05
0.02
0.05
0.07
−17.72
0.41
0.00
7.12
0.18
0.38
0.20
0.21

SEQID-02825
0.03
0.06
0.04
0.04
0.04
0.01
0.05
0.07
−19.88
0.46
−0.02
5.18
0.19
0.36
0.18
0.19

SEQID-02826
0.05
0.00
0.00
0.00
0.02
0.00
0.06
0.00
−27.63
0.13
0.00
6.97
0.43
0.28
0.33
0.36

SEQID-02827
0.03
0.07
0.03
0.03
0.04
0.04
0.00
0.13
−23.66
0.49
−0.04
4.98
0.56
0.68
0.00
0.00

SEQID-02828
0.02
0.07
0.07
0.04
0.04
0.01
0.04
0.04
−22.83
0.33
−0.02
5.93
0.24
0.35
0.20
0.23

SEQID-02829
0.03
0.06
0.06
0.06
0.04
0.03
0.05
0.07
−17.67
0.51
−0.01
5.99
0.22
0.33
0.00
0.23

SEQID-02830
0.01
0.06
0.03
0.03
0.04
0.02
0.07
0.08
−20.80
0.48
0.00
6.69
0.22
0.33
0.00
0.22

SEQID-02831
0.01
0.05
0.05
0.05
0.04
0.01
0.03
0.09
−19.87
0.44
0.00
8.05
0.21
0.33
0.00
0.22

SEQID-02832
0.02
0.04
0.04
0.06
0.05
0.03
0.05
0.06
−18.85
0.43
0.00
7.06
0.20
0.35
0.00
0.21

SEQID-02833
0.03
0.05
0.04
0.06
0.05
0.02
0.05
0.07
−20.31
0.41
−0.01
6.47
0.87
0.98
0.00
0.20

SEQID-02834
0.04
0.05
0.05
0.06
0.05
0.02
0.05
0.03
−18.23
0.43
0.00
6.85
0.20
0.34
0.00
0.21

SEQID-02835
0.01
0.05
0.04
0.05
0.04
0.04
0.02
0.12
−17.44
0.54
0.00
6.77
0.79
0.86
0.23
0.23

SEQID-02836
0.00
0.02
0.10
0.09
0.01
0.00
0.19
0.01
−27.00
0.03
−0.08
4.40
0.25
0.38
0.21
0.26

SEQID-02837
0.03
0.05
0.04
0.09
0.07
0.02
0.04
0.09
−17.36
0.45
0.02
8.78
0.57
0.89
0.21
0.22

SEQID-02838
0.02
0.04
0.02
0.03
0.09
0.00
0.02
0.05
−23.65
0.34
0.00
7.88
0.22
0.31
0.23
0.21

SEQID-02839
0.03
0.05
0.02
0.06
0.03
0.03
0.05
0.06
−20.86
0.43
0.00
7.03
0.22
0.35
0.22
0.21

SEQID-02840
0.02
0.05
0.05
0.06
0.05
0.02
0.05
0.09
−15.77
0.52
−0.01
6.24
0.22
0.33
0.00
0.21

SEQID-02841
0.03
0.06
0.04
0.04
0.05
0.03
0.04
0.07
−18.06
0.42
−0.02
5.81
0.19
0.32
0.00
0.20

SEQID-02842
0.02
0.07
0.05
0.07
0.05
0.02
0.04
0.06
−22.46
0.30
−0.01
6.38
0.20
0.58
0.00
0.21

SEQID-02843
0.02
0.07
0.04
0.07
0.03
0.05
0.03
0.07
−19.11
0.43
0.00
7.78
0.25
0.33
0.00
0.21

SEQID-02844
0.04
0.10
0.04
0.07
0.07
0.01
0.02
0.09
−16.02
0.43
0.03
8.97
0.91
0.96
0.00
0.27

SEQID-02845
0.04
0.10
0.04
0.05
0.07
0.01
0.02
0.03
−18.91
0.35
0.01
7.97
0.88
0.94
0.00
0.27

SEQID-02846
0.01
0.00
0.12
0.02
0.08
0.00
0.00
0.11
−32.61
0.13
−0.25
3.61
0.42
0.48
0.26
0.28

SEQID-02847
0.05
0.08
0.04
0.07
0.03
0.01
0.06
0.05
−20.86
0.34
0.00
7.29
0.22
0.31
0.00
0.23

SEQID-02848
0.05
0.02
0.04
0.05
0.06
0.01
0.02
0.09
−19.41
0.56
0.00
7.59
0.21
0.33
0.00
0.21

SEQID-02849
0.03
0.05
0.04
0.04
0.05
0.03
0.05
0.07
−21.14
0.40
−0.01
6.25
0.20
0.31
0.00
0.22

SEQID-02850
0.04
0.03
0.02
0.07
0.03
0.01
0.06
0.03
−25.82
0.32
−0.07
4.40
0.22
0.33
0.19
0.00

SEQID-02851
0.01
0.07
0.05
0.02
0.05
0.02
0.07
0.05
−20.48
0.38
0.04
9.21
0.21
0.34
0.00
0.00

SEQID-02852
0.03
0.02
0.04
0.05
0.04
0.03
0.03
0.10
−16.82
0.56
0.00
6.62
0.25
0.33
0.00
0.21

SEQID-02853
0.03
0.04
0.05
0.07
0.05
0.03
0.05
0.06
−17.53
0.38
0.01
8.99
0.22
0.35
0.00
0.23

SEQID-02854
0.03
0.05
0.05
0.05
0.05
0.02
0.06
0.06
−17.07
0.49
0.00
7.38
0.22
0.35
0.00
0.22

SEQID-02855
0.06
0.06
0.04
0.06
0.05
0.02
0.06
0.06
−19.18
0.33
−0.05
4.51
0.40
0.53
0.22
0.23

SEQID-02856
0.06
0.07
0.03
0.05
0.05
0.02
0.05
0.06
−19.74
0.35
−0.05
4.49
0.40
0.54
0.00
0.21

SEQID-02857
0.03
0.07
0.04
0.06
0.04
0.02
0.05
0.06
−19.73
0.45
−0.02
5.50
0.21
0.32
0.00
0.22

SEQID-02858
0.02
0.07
0.04
0.07
0.03
0.01
0.05
0.07
−19.33
0.50
−0.02
5.62
0.21
0.34
0.19
0.22

SEQID-02859
0.03
0.05
0.05
0.05
0.06
0.05
0.07
0.07
−17.75
0.42
−0.07
4.19
0.68
0.38
0.00
0.21

SEQID-02860
0.01
0.05
0.05
0.05
0.05
0.02
0.05
0.08
−16.60
0.51
−0.02
5.87
0.21
0.32
0.17
0.21

SEQID-02861
0.02
0.04
0.03
0.04
0.06
0.01
0.03
0.07
−24.91
0.41
−0.03
4.78
0.90
1.00
0.00
0.21

SEQID-02862
0.02
0.06
0.04
0.05
0.04
0.03
0.07
0.07
−20.75
0.43
0.00
7.12
0.20
0.34
0.00
0.21

SEQID-02863
0.04
0.09
0.03
0.07
0.06
0.02
0.04
0.09
−12.26
0.95
−0.01
5.12
0.20
0.34
0.18
0.30

SEQID-02864
0.03
0.04
0.04
0.04
0.04
0.02
0.05
0.05
−22.85
0.36
0.01
6.07
0.20
0.32
0.00
0.21

SEQID-02865
0.02
0.05
0.00
0.09
0.02
0.02
0.09
0.02
−18.40
0.16
0.00
6.75
0.31
0.49
0.29
0.32

SEQID-02866
0.02
0.06
0.05
0.04
0.06
0.00
0.06
0.09
−21.29
0.39
−0.02
6.39
0.62
0.68
0.00
0.25

SEQID-02867
0.02
0.03
0.04
0.05
0.04
0.03
0.02
0.09
−19.69
0.49
0.00
6.52
0.26
0.33
0.00
0.25

SEQID-02868
0.03
0.06
0.04
0.03
0.02
0.04
0.07
0.05
−26.81
0.28
−0.06
4.66
0.21
0.31
0.00
0.24

SEQID-02869
0.02
0.03
0.06
0.09
0.06
0.03
0.02
0.07
−14.19
0.47
−0.03
4.73
0.66
0.89
0.24
0.24

SEQID-02870
0.04
0.03
0.02
0.07
0.05
0.02
0.07
0.05
−23.48
0.40
−0.06
4.51
0.23
0.34
0.21
0.00

SEQID-02871
0.03
0.09
0.04
0.04
0.06
0.03
0.05
0.06
−12.89
0.89
0.01
8.58
0.20
0.33
0.23
0.23

SEQID-02872
0.02
0.04
0.06
0.04
0.05
0.05
0.07
0.05
−19.05
0.32
−0.02
5.27
0.22
0.34
0.00
0.34

SEQID-02873
0.02
0.07
0.05
0.06
0.05
0.02
0.06
0.03
−16.01
0.52
−0.01
5.46
0.28
0.41
0.00
0.23

SEQID-02874
0.05
0.05
0.05
0.04
0.03
0.01
0.02
0.11
−18.46
0.52
−0.01
6.41
0.25
0.33
0.00
0.25

SEQID-02875
0.05
0.05
0.04
0.05
0.05
0.02
0.05
0.09
−21.45
0.46
−0.03
5.01
0.00
0.30
0.00
0.19

SEQID-02876
0.04
0.03
0.05
0.05
0.03
0.03
0.04
0.07
−21.33
0.34
0.10
11.11
0.22
0.36
0.00
0.22

SEQID-02877
0.03
0.07
0.05
0.07
0.05
0.02
0.06
0.06
−20.45
0.39
0.01
7.72
0.22
0.33
0.23
0.22

SEQID-02878
0.02
0.09
0.07
0.05
0.04
0.03
0.06
0.05
−20.84
0.28
0.01
7.39
0.39
0.59
0.00
0.21

SEQID-02879
0.01
0.09
0.06
0.04
0.04
0.02
0.06
0.06
−21.17
0.28
0.00
7.21
0.39
0.61
0.00
0.21

SEQID-02880
0.03
0.07
0.04
0.06
0.04
0.02
0.03
0.09
−21.19
0.53
0.00
7.50
0.20
0.34
0.00
0.22

SEQID-02881
0.02
0.04
0.05
0.06
0.06
0.00
0.03
0.09
−18.04
0.48
−0.01
6.31
0.21
0.33
0.00
0.22

SEQID-02882
0.03
0.04
0.10
0.10
0.04
0.00
0.05
0.05
−14.55
0.27
−0.02
5.91
0.22
0.49
0.19
0.21

SEQID-02883
0.05
0.05
0.05
0.07
0.05
0.03
0.04
0.08
−13.95
0.84
−0.03
4.60
0.19
0.36
0.00
0.21

SEQID-02884
0.03
0.05
0.05
0.05
0.05
0.01
0.03
0.08
−22.71
0.37
−0.03
4.87
0.39
0.60
0.00
0.20

SEQID-02885
0.04
0.04
0.06
0.06
0.04
0.01
0.06
0.03
−19.93
0.30
−0.01
6.37
0.19
0.40
0.00
0.21

SEQID-02886
0.02
0.09
0.03
0.03
0.04
0.02
0.06
0.07
−24.09
0.38
−0.08
4.23
0.38
0.43
0.21
0.25

SEQID-02887
0.03
0.07
0.06
0.06
0.06
0.01
0.03
0.10
−14.57
0.56
0.01
3.69
0.31
0.40
0.00
0.26

SEQID-02888
0.01
0.06
0.05
0.05
0.06
0.01
0.02
0.07
−28.50
0.34
−0.06
4.50
0.00
0.38
0.00
0.27

SEQID-02889
0.05
0.02
0.03
0.05
0.02
0.02
0.03
0.05
−30.76
0.15
0.22
11.99
0.21
0.31
0.21
0.23

SEQID-02890
0.03
0.06
0.03
0.05
0.06
0.03
0.03
0.13
−17.01
0.60
−0.01
6.50
0.27
0.32
0.22
0.00

SEQID-02891
0.01
0.10
0.05
0.07
0.04
0.01
0.04
0.08
−18.28
0.49
−0.02
5.59
0.23
0.34
0.00
0.24

SEQID-02892
0.02
0.05
0.04
0.03
0.06
0.02
0.03
0.09
−22.47
0.39
0.09
10.89
0.22
0.33
0.21
0.23

SEQID-02893
0.02
0.09
0.04
0.05
0.06
0.03
0.07
0.08
−11.49
0.93
0.01
8.30
0.20
0.33
0.00
0.21

SEQID-02894
0.01
0.06
0.05
0.06
0.05
0.01
0.05
0.03
−19.70
0.42
−0.01
6.07
0.75
0.85
0.00
0.00

SEQID-02895
0.01
0.03
0.05
0.05
0.05
0.03
0.05
0.05
−21.54
0.35
−0.01
6.12
0.22
0.33
0.00
0.00

SEQID-02896
0.04
0.05
0.06
0.04
0.05
0.01
0.04
0.07
−20.51
0.34
0.00
6.96
0.19
0.33
0.00
0.23

SEQID-02897
0.02
0.03
0.06
0.05
0.04
0.04
0.06
0.06
−18.54
0.42
0.00
6.73
0.00
0.36
0.00
0.23

SEQID-02898
0.03
0.05
0.03
0.03
0.06
0.02
0.05
0.07
−24.52
0.30
0.13
10.89
0.66
0.75
0.22
0.21

SEQID-02899
0.04
0.05
0.05
0.07
0.04
0.01
0.02
0.09
−17.42
0.63
0.00
7.36
0.22
0.34
0.00
0.22

SEQID-02900
0.03
0.04
0.09
0.07
0.05
0.00
0.03
0.09
−20.10
0.43
0.02
9.93
0.21
0.36
0.00
0.23

SEQID-02901
0.03
0.05
0.03
0.07
0.05
0.01
0.03
0.09
−19.38
0.56
0.00
7.33
0.23
0.33
0.00
0.22

SEQID-02902
0.04
0.05
0.03
0.05
0.06
0.03
0.05
0.09
−21.33
0.44
−0.02
5.43
0.21
0.33
0.00
0.21

SEQID-02903
0.02
0.06
0.05
0.07
0.04
0.01
0.05
0.06
−18.75
0.41
−0.02
5.54
0.21
0.35
0.00
0.21

SEQID-02904
0.03
0.03
0.14
0.09
0.04
0.01
0.04
0.05
−14.76
0.16
−0.01
6.40
0.22
0.46
0.20
0.23

SEQID-02905
0.03
0.06
0.06
0.06
0.04
0.02
0.03
0.09
−16.86
0.58
−0.01
6.30
0.21
0.33
0.00
0.22

SEQID-02906
0.03
0.05
0.04
0.05
0.06
0.01
0.05
0.06
−17.48
0.43
0.01
7.80
0.21
0.33
0.00
0.22

SEQID-02907
0.02
0.05
0.05
0.06
0.05
0.02
0.05
0.07
−19.25
0.37
0.00
7.77
0.20
0.33
0.00
0.21

SEQID-02908
0.03
0.06
0.03
0.05
0.04
0.01
0.04
0.05
−27.98
0.32
−0.04
4.71
0.66
0.31
0.00
0.21

SEQID-02909
0.01
0.06
0.28
0.09
0.02
0.00
0.06
0.05
−10.68
0.33
−0.01
6.22
0.22
0.40
0.22
0.23

SEQID-02910
0.01
0.01
0.06
0.07
0.05
0.00
0.00
0.13
−28.57
0.28
−0.15
3.96
0.20
0.36
0.00
0.22

SEQID-02911
0.04
0.04
0.04
0.06
0.04
0.02
0.03
0.05
−19.16
0.55
−0.05
4.51
0.19
0.33
0.20
0.20

SEQID-02912
0.01
0.05
0.03
0.06
0.07
0.03
0.03
0.05
−24.87
0.26
−0.06
4.92
0.34
0.41
0.22
0.23

SEQID-02913
0.02
0.04
0.03
0.05
0.06
0.00
0.03
0.07
−23.29
0.37
−0.03
5.87
0.22
0.28
0.00
0.20

SEQID-02914
0.05
0.05
0.06
0.05
0.07
0.04
0.07
0.05
−17.27
0.37
0.04
9.15
0.25
0.29
0.00
0.23

SEQID-02915
0.04
0.09
0.04
0.06
0.07
0.02
0.02
0.07
−18.33
0.49
0.03
9.69
0.58
0.31
0.00
0.25

SEQID-02916
0.02
0.04
0.05
0.05
0.03
0.02
0.01
0.06
−29.07
0.23
0.01
8.19
0.24
0.35
0.00
0.24

SEQID-02917
0.01
0.09
0.07
0.06
0.11
0.02
0.05
0.02
−14.45
0.36
−0.01
4.89
0.76
0.39
0.21
0.54

SEQID-02918
0.03
0.03
0.04
0.07
0.05
0.01
0.04
0.06
−19.39
0.45
−0.07
4.26
0.00
0.31
0.00
0.20

SEQID-02919
0.02
0.02
0.03
0.07
0.05
0.02
0.05
0.09
−23.16
0.51
−0.07
4.38
0.37
0.57
0.00
0.00

SEQID-02920
0.01
0.07
0.03
0.12
0.03
0.00
0.11
0.05
−14.97
0.20
−0.03
4.47
0.26
0.49
0.26
0.27

SEQID-02921
0.04
0.06
0.05
0.05
0.06
0.01
0.05
0.09
−18.77
0.48
−0.04
5.01
0.19
0.31
0.00
0.22

SEQID-02922
0.01
0.02
0.10
0.04
0.03
0.02
0.10
0.08
−20.10
0.34
−0.05
4.42
0.24
0.38
0.23
0.26

SEQID-02923
0.03
0.07
0.03
0.05
0.05
0.03
0.04
0.07
−20.52
0.39
0.00
7.13
0.22
0.31
0.00
0.31

SEQID-02924
0.01
0.07
0.05
0.07
0.09
0.01
0.04
0.06
−19.54
0.35
0.00
6.12
0.23
0.33
0.20
0.23

SEQID-02925
0.01
0.03
0.02
0.08
0.08
0.06
0.04
0.07
−19.59
0.44
0.01
7.81
0.21
0.33
0.00
0.00

SEQID-02926
0.03
0.03
0.04
0.06
0.04
0.03
0.05
0.09
−19.09
0.55
−0.01
6.17
0.21
0.31
0.00
0.19

SEQID-02927
0.04
0.03
0.04
0.03
0.04
0.02
0.05
0.07
−18.99
0.43
0.01
7.43
0.21
0.32
0.00
0.19

SEQID-02928
0.03
0.09
0.02
0.07
0.03
0.02
0.07
0.06
−16.20
0.47
0.06
10.25
0.22
0.31
0.00
0.21

SEQID-02929
0.02
0.07
0.05
0.06
0.03
0.03
0.09
0.04
−15.04
0.41
0.00
7.03
0.46
0.69
0.21
0.20

SEQID-02930
0.04
0.07
0.03
0.05
0.05
0.03
0.05
0.05
−20.89
0.33
−0.01
6.44
0.21
0.32
0.00
0.20

SEQID-02931
0.03
0.04
0.02
0.04
0.04
0.00
0.02
0.09
−20.45
0.50
−0.01
5.86
0.24
0.33
0.00
0.71

SEQID-02932
0.03
0.06
0.05
0.04
0.03
0.07
0.04
0.05
−21.27
0.39
−0.04
4.86
0.21
0.32
0.00
0.19

SEQID-02933
0.03
0.06
0.04
0.06
0.06
0.03
0.07
0.05
−19.56
0.32
−0.01
5.95
0.22
0.33
0.00
0.20

SEQID-02934
0.02
0.05
0.03
0.06
0.05
0.00
0.04
0.05
−22.41
0.31
−0.04
4.85
0.21
0.30
0.00
0.20

SEQID-02935
0.01
0.05
0.05
0.07
0.04
0.02
0.04
0.06
−20.31
0.35
−0.01
6.72
0.20
0.31
0.19
0.22

SEQID-02936
0.03
0.06
0.04
0.06
0.05
0.01
0.06
0.09
−19.63
0.38
−0.05
4.64
0.82
0.90
0.20
0.21

SEQID-02937
0.02
0.05
0.06
0.06
0.05
0.01
0.05
0.05
−19.29
0.30
−0.01
5.88
0.19
0.31
0.18
0.20

SEQID-02938
0.04
0.06
0.04
0.08
0.04
0.01
0.07
0.07
−18.49
0.41
−0.01
6.29
0.21
0.33
0.21
0.22

SEQID-02939
0.02
0.06
0.04
0.03
0.06
0.03
0.05
0.06
−19.69
0.38
0.00
6.79
0.20
0.33
0.18
0.22

SEQID-02940
0.03
0.04
0.04
0.05
0.05
0.01
0.05
0.07
−18.93
0.42
0.00
7.40
0.21
0.34
0.19
0.21

SEQID-02941
0.03
0.05
0.03
0.04
0.05
0.03
0.04
0.06
−20.20
0.55
−0.02
6.29
0.20
0.34
0.19
0.21

SEQID-02942
0.02
0.06
0.04
0.06
0.05
0.01
0.05
0.07
−17.95
0.49
0.00
7.37
0.21
0.35
0.00
0.21

SEQID-02943
0.04
0.05
0.05
0.05
0.06
0.02
0.06
0.07
−19.44
0.39
−0.02
5.02
0.20
0.35
0.00
0.22

SEQID-02944
0.02
0.06
0.04
0.05
0.05
0.01
0.05
0.07
−21.66
0.38
−0.01
6.19
0.21
0.33
0.00
0.20

SEQID-02945
0.02
0.05
0.06
0.09
0.06
0.03
0.04
0.07
−17.43
0.38
−0.03
4.85
0.18
0.40
0.19
0.19

SEQID-02946
0.01
0.01
0.00
0.07
0.04
0.00
0.01
0.05
−28.23
0.22
−0.09
4.43
0.21
0.40
0.19
0.18

SEQID-02947
0.02
0.07
0.06
0.07
0.03
0.02
0.06
0.10
−17.49
0.42
0.01
8.20
0.29
0.36
0.21
0.25

SEQID-02948
0.05
0.03
0.05
0.02
0.07
0.03
0.06
0.04
−15.48
0.46
−0.05
4.33
0.90
0.94
0.25
0.26

SEQID-02949
0.01
0.07
0.04
0.05
0.05
0.01
0.03
0.09
−19.80
0.54
−0.03
4.97
0.40
0.50
0.20
0.24

SEQID-02950
0.06
0.03
0.06
0.03
0.06
0.02
0.04
0.06
−20.78
0.34
−0.04
4.59
0.19
0.30
0.21
0.21

SEQID-02951
0.06
0.08
0.02
0.03
0.05
0.00
0.04
0.08
−17.44
0.49
0.04
9.84
0.20
0.28
0.00
0.21

SEQID-02952
0.04
0.05
0.03
0.05
0.04
0.01
0.08
0.07
−19.06
0.55
−0.01
6.24
0.25
0.32
0.00
0.24

SEQID-02953
0.04
0.05
0.06
0.06
0.01
0.01
0.06
0.07
−22.91
0.40
−0.02
5.85
0.23
0.32
0.21
0.21

SEQID-02954
0.02
0.02
0.04
0.04
0.03
0.05
0.09
0.06
−25.46
0.19
0.21
11.95
0.21
0.31
0.00
0.20

SEQID-02955
0.01
0.08
0.06
0.07
0.06
0.01
0.02
0.10
−19.22
0.48
−0.02
5.00
0.23
0.34
0.00
0.00

SEQID-02956
0.04
0.04
0.04
0.07
0.05
0.01
0.09
0.05
−17.31
0.47
0.00
7.36
0.19
0.30
0.21
0.00

SEQID-02957
0.02
0.06
0.06
0.05
0.02
0.03
0.06
0.09
−17.40
0.53
−0.01
6.15
0.00
0.35
0.00
0.25

SEQID-02958
0.03
0.07
0.06
0.05
0.03
0.04
0.04
0.11
−19.49
0.49
−0.03
4.99
0.20
0.33
0.00
0.24

SEQID-02959
0.04
0.07
0.04
0.04
0.01
0.05
0.06
0.05
−23.42
0.35
−0.02
5.65
0.54
0.65
0.20
0.22

SEQID-02960
0.02
0.05
0.03
0.05
0.04
0.00
0.03
0.05
−27.13
0.26
0.15
11.29
0.22
0.33
0.21
0.19

SEQID-02961
0.02
0.07
0.05
0.05
0.03
0.02
0.04
0.06
−21.97
0.48
−0.03
4.82
0.21
0.31
0.00
0.23

SEQID-02962
0.01
0.07
0.04
0.06
0.04
0.03
0.03
0.06
−18.34
0.73
0.02
8.87
0.23
0.31
0.23
0.00

SEQID-02963
0.03
0.08
0.03
0.09
0.06
0.05
0.06
0.06
−11.63
0.39
0.03
6.84
0.29
0.37
0.00
0.19

SEQID-02964
0.05
0.09
0.05
0.07
0.03
0.02
0.05
0.06
−17.63
0.47
−0.01
6.39
0.22
0.33
0.00
0.24

SEQID-02965
0.02
0.03
0.05
0.04
0.06
0.02
0.06
0.09
−19.23
0.41
−0.03
5.74
0.22
0.34
0.00
0.18

SEQID-02966
0.03
0.05
0.04
0.03
0.04
0.01
0.03
0.07
−27.55
0.31
0.00
6.78
0.21
0.31
0.00
0.20

SEQID-02967
0.01
0.05
0.01
0.04
0.04
0.02
0.06
0.04
−24.79
0.29
−0.04
4.81
0.23
0.32
0.00
0.00

SEQID-02968
0.03
0.08
0.05
0.06
0.04
0.03
0.06
0.04
−17.45
0.36
0.00
6.84
0.21
0.34
0.00
0.00

SEQID-02969
0.02
0.07
0.06
0.06
0.03
0.03
0.05
0.09
−20.02
0.45
−0.04
5.20
0.22
0.33
0.00
0.00

SEQID-02970
0.02
0.06
0.04
0.04
0.05
0.01
0.04
0.06
−21.16
0.42
0.10
10.87
0.19
0.31
0.00
0.19

SEQID-02971
0.03
0.07
0.05
0.05
0.04
0.03
0.03
0.05
−22.23
0.31
−0.01
6.60
0.23
0.31
0.00
0.21

SEQID-02972
0.03
0.07
0.06
0.05
0.02
0.03
0.05
0.07
−18.72
0.44
−0.01
6.56
0.22
0.30
0.20
0.00

SEQID-02973
0.03
0.06
0.04
0.04
0.04
0.02
0.06
0.07
−19.70
0.48
−0.02
5.27
0.19
0.31
0.00
0.21

SEQID-02974
0.02
0.07
0.06
0.05
0.07
0.03
0.05
0.05
−16.20
0.43
0.00
6.87
0.32
0.56
0.00
0.21

SEQID-02975
0.02
0.08
0.05
0.07
0.04
0.03
0.03
0.09
−17.95
0.53
−0.02
5.26
0.27
0.43
0.00
0.23

SEQID-02976
0.04
0.07
0.04
0.05
0.02
0.02
0.04
0.06
−22.45
0.37
−0.01
6.32
0.22
0.31
0.00
0.00

SEQID-02977
0.02
0.09
0.06
0.08
0.04
0.01
0.03
0.03
−16.20
0.41
0.03
8.98
0.19
0.39
0.00
0.21

SEQID-02978
0.02
0.10
0.07
0.06
0.05
0.01
0.03
0.06
−16.32
0.50
0.01
7.98
0.22
0.31
0.00
0.18

SEQID-02979
0.03
0.06
0.05
0.04
0.05
0.01
0.06
0.08
−15.90
0.61
−0.02
5.54
0.21
0.33
0.00
0.22

SEQID-02980
0.02
0.08
0.06
0.06
0.03
0.04
0.04
0.03
−19.54
0.34
−0.02
6.05
0.22
0.36
0.00
0.20

SEQID-02981
0.01
0.08
0.04
0.04
0.03
0.02
0.03
0.06
−23.94
0.40
−0.01
6.61
0.21
0.32
0.00
0.21

SEQID-02982
0.04
0.04
0.05
0.05
0.03
0.03
0.06
0.09
−17.80
0.47
0.00
6.52
0.22
0.32
0.00
0.22

SEQID-02983
0.02
0.06
0.04
0.03
0.06
0.02
0.03
0.07
−21.58
0.39
−0.02
5.91
0.22
0.33
0.00
0.20

SEQID-02984
0.03
0.05
0.04
0.04
0.04
0.00
0.04
0.05
−24.33
0.21
−0.01
5.95
0.22
0.33
0.00
0.22

SEQID-02985
0.03
0.04
0.04
0.04
0.04
0.00
0.02
0.06
−25.10
0.40
−0.04
4.72
0.22
0.33
0.00
0.22

SEQID-02986
0.02
0.06
0.06
0.09
0.03
0.02
0.05
0.04
−19.85
0.35
0.00
7.65
0.22
0.35
0.21
0.23

SEQID-02987
0.03
0.07
0.02
0.05
0.05
0.01
0.04
0.05
−22.33
0.36
−0.02
5.27
0.21
0.33
0.00
0.21

SEQID-02988
0.03
0.07
0.06
0.04
0.03
0.33
0.05
0.06
−22.46
0.33
0.02
8.89
0.22
0.35
0.19
0.22

SEQID-02989
0.04
0.04
0.09
0.04
0.05
0.03
0.07
0.05
−14.73
0.27
−0.01
5.49
0.24
0.45
0.21
0.21

SEQID-02990
0.03
0.07
0.06
0.06
0.04
0.03
0.02
0.06
−21.06
0.34
−0.02
6.17
0.21
0.32
0.20
0.21

SEQID-02991
0.03
0.04
0.04
0.06
0.04
0.02
0.06
0.07
−20.54
0.38
0.00
7.00
0.22
0.33
0.20
0.71

SEQID-02992
0.04
0.05
0.05
0.06
0.04
0.01
0.04
0.06
−20.34
0.41
0.01
7.74
0.21
0.32
0.00
0.71

SEQID-02993
0.02
0.06
0.05
0.06
0.06
0.03
0.03
0.06
−14.67
0.41
0.03
9.69
0.21
0.31
0.00
0.22

SEQID-02994
0.03
0.04
0.04
0.09
0.05
0.02
0.02
0.09
−16.75
0.58
0.00
7.11
0.22
0.33
0.20
0.22

SEQID-02995
0.03
0.05
0.05
0.05
0.03
0.01
0.03
0.07
−19.38
0.60
−0.03
4.83
0.20
0.33
0.19
0.22

SEQID-02996
0.02
0.01
0.12
0.09
0.06
0.01
0.10
0.03
−11.88
0.11
−0.01
6.00
0.28
0.41
0.20
0.24

SEQID-02997
0.03
0.06
0.03
0.07
0.04
0.00
0.03
0.06
−20.23
0.45
−0.01
6.09
0.19
0.32
0.00
0.21

SEQID-02998
0.02
0.09
0.04
0.05
0.05
0.07
0.05
0.04
−12.06
0.63
0.00
7.14
0.20
0.35
0.00
0.20

SEQID-02999
0.03
0.07
0.04
0.06
0.04
0.03
0.07
0.06
−21.11
0.31
−0.04
5.06
0.19
0.32
0.00
0.21

SEQID-03000
0.04
0.03
0.07
0.10
0.04
0.00
0.01
0.06
−15.56
0.26
−0.02
5.67
0.22
0.37
0.19
0.22

SEQID-03001
0.02
0.07
0.03
0.06
0.04
0.03
0.05
0.07
−19.76
0.47
−0.03
5.03
0.19
0.32
0.00
0.20

SEQID-03002
0.03
0.05
0.03
0.06
0.05
0.03
0.06
0.06
−20.82
0.39
−0.04
4.80
0.19
0.33
0.00
0.20

SEQID-03003
0.03
0.03
0.03
0.06
0.05
0.01
0.04
0.07
−19.78
0.57
−0.01
5.64
0.19
0.32
0.19
0.20

SEQID-03004
0.02
0.09
0.04
0.06
0.04
0.02
0.03
0.06
−20.40
0.42
−0.03
4.91
0.19
0.34
0.19
0.20

SEQID-03005
0.03
0.07
0.04
0.04
0.04
0.02
0.07
0.06
−24.11
0.26
−0.02
5.83
0.19
0.34
0.13
0.19

SEQID-03006
0.01
0.08
0.04
0.06
0.03
0.01
0.03
0.04
−31.51
0.41
−0.01
6.63
0.56
0.74
0.19
0.22

SEQID-03007
0.01
0.07
0.03
0.09
0.02
0.00
0.01
0.07
−33.03
0.55
−0.01
6.35
0.50
0.91
0.00
0.22

SEQID-03008
0.02
0.06
0.04
0.06
0.05
0.03
0.05
0.07
−30.05
0.43
−0.01
6.37
0.86
0.98
0.00
0.20

SEQID-03009
0.02
0.11
0.03
0.05
0.06
0.01
0.11
0.03
−20.47
0.29
0.01
8.37
0.21
0.30
0.00
0.00

SEQID-03010
0.02
0.11
0.05
0.06
0.03
0.01
0.03
0.03
−19.04
0.49
−0.02
5.21
0.68
0.78
0.24
0.28

SEQID-03011
0.03
0.05
0.06
0.04
0.06
0.01
0.04
0.09
−21.63
0.39
0.03
9.63
0.22
0.35
0.00
0.22

SEQID-03012
0.05
0.04
0.05
0.06
0.05
0.02
0.06
0.06
−19.72
0.44
−0.03
5.16
0.20
0.33
0.00
0.19

SEQID-03013
0.02
0.06
0.03
0.05
0.05
0.04
0.04
0.07
−25.34
0.45
−0.06
4.56
0.22
0.30
0.23
0.22

SEQID-03014
0.01
0.03
0.04
0.05
0.06
0.01
0.05
0.07
−18.24
0.43
0.00
6.64
0.31
0.32
0.00
0.21

SEQID-03015
0.03
0.04
0.04
0.07
0.04
0.01
0.06
0.06
−18.93
0.43
0.00
6.94
0.21
0.32
0.00
0.21

SEQID-03016
0.01
0.06
0.03
0.06
0.03
0.02
0.03
0.10
−19.58
0.53
−0.02
5.04
0.83
0.93
0.00
0.20

SEQID-03017
0.04
0.06
0.04
0.05
0.04
0.00
0.07
0.07
−21.13
0.44
−0.02
5.82
0.21
0.32
0.19
0.21

SEQID-03018
0.02
0.06
0.04
0.03
0.06
0.03
0.05
0.06
−20.23
0.36
−0.01
6.46
0.20
0.31
0.00
0.22

SEQID-03019
0.02
0.10
0.04
0.09
0.05
0.01
0.01
0.08
−17.15
0.29
0.03
8.90
0.92
0.96
0.25
0.29

SEQID-03020
0.03
0.03
0.05
0.06
0.04
0.02
0.03
0.09
−16.97
0.56
−0.01
6.25
0.25
0.33
0.00
0.22

SEQID-03021
0.03
0.05
0.01
0.03
0.09
0.02
0.05
0.03
−22.71
0.45
0.04
8.97
0.23
0.35
0.20
0.24

SEQID-03022
0.03
0.04
0.03
0.06
0.04
0.01
0.06
0.04
−24.82
0.32
−0.06
4.42
0.23
0.32
0.00
0.00

SEQID-03023
0.01
0.08
0.05
0.01
0.05
0.01
0.06
0.07
−20.92
0.34
0.00
6.86
0.20
0.34
0.00
0.00

SEQID-03024
0.02
0.04
0.02
0.04
0.10
0.00
0.01
0.06
−23.57
0.35
−0.01
5.90
0.23
0.30
0.24
0.00

SEQID-03025
0.03
0.04
0.02
0.04
0.04
0.04
0.06
0.07
−24.54
0.25
−0.02
6.43
0.34
0.45
0.26
0.22

SEQID-03026
0.03
0.03
0.02
0.06
0.04
0.01
0.07
0.05
−25.35
0.27
−0.06
4.51
0.20
0.31
0.00
0.00

SEQID-03027
0.01
0.04
0.05
0.06
0.05
0.04
0.06
0.05
−19.12
0.36
−0.02
5.88
0.21
0.33
0.19
0.21

SEQID-03028
0.02
0.03
0.03
0.06
0.04
0.01
0.04
0.08
−21.36
0.43
0.06
10.49
0.00
0.31
0.00
0.00

SEQID-03029
0.03
0.04
0.03
0.04
0.06
0.02
0.04
0.07
−19.49
0.49
−0.02
5.52
0.21
0.33
0.21
0.23

SEQID-03030
0.02
0.09
0.01
0.04
0.05
0.02
0.02
0.05
−22.57
0.60
0.00
7.12
0.34
0.32
0.33
0.29

SEQID-03031
0.01
0.06
0.07
0.05
0.05
0.01
0.03
0.07
−24.45
0.29
0.12
10.85
0.00
0.34
0.18
0.23

SEQID-03032
0.03
0.04
0.05
0.06
0.05
0.00
0.03
0.05
−35.70
0.25
0.13
10.82
0.25
0.32
0.19
0.21

SEQID-03033
0.02
0.04
0.04
0.03
0.06
0.00
0.08
0.09
−20.37
0.36
−0.03
5.31
0.69
0.73
0.00
0.00

SEQID-03034
0.03
0.04
0.08
0.03
0.05
0.04
0.03
0.05
−17.12
0.45
−0.03
4.86
0.21
0.13
0.19
0.00

SEQID-03035
0.07
0.00
0.04
0.04
0.13
0.00
0.02
0.06
−20.21
0.09
0.03
9.81
0.25
0.34
0.27
0.24

SEQID-03036
0.04
0.03
0.03
0.03
0.04
0.01
0.03
0.12
−21.66
0.60
−0.02
6.08
0.21
0.29
0.00
0.22

SEQID-03037
0.04
0.05
0.03
0.06
0.05
0.02
0.06
0.06
−19.45
0.37
−0.01
5.34
0.22
0.33
0.00
0.20

SEQID-03038
0.03
0.05
0.05
0.04
0.06
0.01
0.04
0.06
−20.55
0.32
0.01
7.69
0.21
0.32
0.00
0.20

SEQID-03039
0.02
0.07
0.01
0.04
0.04
0.00
0.02
0.03
−20.98
0.57
0.03
9.26
0.37
0.26
0.00
0.00

SEQID-03040
0.01
0.08
0.02
0.05
0.06
0.03
0.03
0.07
−16.75
0.76
0.02
3.49
0.91
0.95
0.21
0.24

SEQID-03041
0.01
0.03
0.04
0.07
0.03
0.00
0.03
0.07
−18.61
0.39
0.09
11.01
0.26
0.30
0.25
0.00

SEQID-03042
0.04
0.03
0.01
0.04
0.13
0.00
0.01
0.01
−25.65
0.04
0.02
9.76
0.23
0.32
0.22
0.25

SEQID-03043
0.03
0.07
0.06
0.06
0.04
0.04
0.06
0.09
−17.32
0.45
0.03
9.14
0.21
0.32
0.00
0.23

SEQID-03044
0.01
0.06
0.04
0.05
0.05
0.04
0.10
0.03
−19.15
0.23
0.00
7.43
0.21
0.33
0.00
0.21

SEQID-03045
0.01
0.08
0.05
0.04
0.07
0.03
0.05
0.06
−20.02
0.37
−0.01
6.24
0.21
0.32
0.00
0.21

SEQID-03046
0.03
0.06
0.04
0.04
0.06
0.02
0.04
0.07
−23.48
0.33
0.12
10.99
0.79
0.90
0.00
0.23

SEQID-03047
0.02
0.06
0.06
0.03
0.05
0.01
0.03
0.09
−16.16
0.52
0.00
6.97
0.26
0.35
0.00
0.00

SEQID-03048
0.02
0.06
0.02
0.06
0.07
0.02
0.04
0.09
−15.02
0.50
0.01
8.45
0.35
0.45
0.00
0.20

SEQID-03049
0.02
0.05
0.03
0.05
0.07
0.01
0.03
0.09
−22.62
0.39
−0.01
5.23
0.57
0.81
0.00
0.21

SEQID-03050
0.03
0.06
0.04
0.04
0.06
0.01
0.04
0.08
−21.59
0.42
0.00
6.52
0.19
0.34
0.00
0.21

SEQID-03051
0.00
0.05
0.03
0.07
0.09
0.02
0.06
0.09
−17.58
0.35
0.02
9.31
0.21
0.32
0.00
0.21

SEQID-03052
0.03
0.05
0.05
0.05
0.04
0.04
0.08
0.06
−20.46
0.29
0.00
7.34
0.20
0.31
0.00
0.00

SEQID-03053
0.03
0.04
0.04
0.06
0.05
0.01
0.04
0.07
−18.67
0.44
0.02
9.52
0.22
0.33
0.00
0.22

SEQID-03054
0.02
0.04
0.04
0.06
0.05
0.02
0.05
0.09
−19.24
0.43
−0.01
5.92
0.19
0.34
0.19
0.20

SEQID-03055
0.03
0.05
0.04
0.05
0.06
0.01
0.04
0.09
−19.08
0.41
0.00
6.72
0.19
0.34
0.20
0.20

SEQID-03056
0.01
0.04
0.03
0.04
0.05
0.03
0.05
0.09
−19.53
0.43
0.01
7.61
0.00
0.34
0.00
0.21

SEQID-03057
0.01
0.05
0.06
0.05
0.05
0.04
0.04
0.06
−19.12
0.43
0.00
6.92
0.22
0.34
0.00
0.21

SEQID-03058
0.02
0.05
0.04
0.06
0.06
0.01
0.04
0.06
−22.49
0.34
−0.03
4.80
0.77
0.94
0.00
0.22

SEQID-03059
0.02
0.05
0.03
0.05
0.06
0.00
0.04
0.07
−20.31
0.50
0.00
6.69
0.19
0.32
0.00
0.21

SEQID-03060
0.02
0.06
0.05
0.04
0.03
0.00
0.05
0.09
−22.21
0.35
0.02
9.07
0.00
0.31
0.00
0.20

SEQID-03061
0.01
0.04
0.04
0.06
0.05
0.02
0.04
0.06
−19.15
0.39
−0.01
5.92
0.69
0.81
0.21
0.22

SEQID-03062
0.04
0.07
0.04
0.04
0.03
0.02
0.04
0.07
−16.48
0.42
0.01
7.99
0.52
0.66
0.21
0.21

SEQID-03063
0.01
0.03
0.04
0.03
0.06
0.01
0.05
0.08
−20.11
0.35
0.13
11.50
0.00
0.33
0.23
0.00

SEQID-03064
0.02
0.06
0.04
0.05
0.05
0.03
0.05
0.06
−18.36
0.44
0.00
6.68
0.22
0.33
0.20
0.20

SEQID-03065
0.03
0.05
0.04
0.04
0.06
0.02
0.03
0.08
−21.98
0.43
0.03
9.72
0.21
0.35
0.20
0.21

SEQID-03066
0.02
0.09
0.03
0.06
0.05
0.03
0.04
0.05
−18.92
0.43
0.00
6.98
0.30
0.33
0.20
0.21

SEQID-03067
0.02
0.05
0.04
0.05
0.05
0.02
0.04
0.08
−19.81
0.42
0.01
7.32
0.21
0.34
0.23
0.23

SEQID-03068
0.02
0.06
0.04
0.06
0.07
0.03
0.06
0.06
−19.97
0.37
−0.02
5.11
0.20
0.33
0.00
0.20

SEQID-03069
0.01
0.05
0.04
0.06
0.04
0.03
0.05
0.06
−19.66
0.39
0.00
6.90
0.19
0.35
0.19
0.20

SEQID-03070
0.03
0.07
0.05
0.04
0.05
0.00
0.04
0.09
−18.54
0.56
−0.02
5.09
0.00
0.47
0.00
0.00

SEQID-03071
0.01
0.07
0.03
0.04
0.04
0.01
0.07
0.04
−28.05
0.24
0.01
8.70
0.23
0.33
0.00
0.00

SEQID-03072
0.03
0.04
0.03
0.05
0.05
0.02
0.05
0.11
−18.60
0.46
0.01
7.87
0.67
0.85
0.00
0.21

SEQID-03073
0.03
0.06
0.05
0.05
0.06
0.02
0.05
0.06
−19.47
0.46
−0.03
5.16
0.21
0.31
0.00
0.22

SEQID-03074
0.02
0.05
0.04
0.05
0.05
0.03
0.05
0.05
−18.35
0.42
−0.01
5.93
0.21
0.34
0.22
0.22

SEQID-03075
0.02
0.08
0.02
0.04
0.04
0.05
0.06
0.04
−21.86
0.28
−0.01
6.47
0.20
0.32
0.00
0.21

SEQID-03076
0.02
0.07
0.04
0.06
0.06
0.01
0.06
0.05
−19.88
0.35
0.00
5.88
0.18
0.32
0.20
0.20

SEQID-03077
0.02
0.05
0.05
0.05
0.02
0.01
0.04
0.07
−22.48
0.31
0.15
11.36
0.21
0.33
0.24
0.00

SEQID-03078
0.01
0.05
0.04
0.03
0.04
0.01
0.05
0.05
−23.11
0.29
0.10
10.88
0.19
0.34
0.23
0.18

SEQID-03079
0.01
0.04
0.05
0.05
0.04
0.02
0.02
0.09
−20.31
0.40
0.12
11.80
0.00
0.34
0.00
0.22

SEQID-03080
0.02
0.04
0.06
0.05
0.06
0.03
0.03
0.06
−19.58
0.48
0.01
3.06
0.22
0.31
0.00
0.22

SEQID-03081
0.01
0.07
0.05
0.05
0.04
0.03
0.06
0.06
−21.85
0.36
−0.02
5.16
0.21
0.37
0.00
0.21

SEQID-03082
0.03
0.05
0.03
0.05
0.05
0.01
0.04
0.05
−21.22
0.37
0.01
8.03
0.20
0.34
0.00
0.21

SEQID-03083
0.02
0.07
0.05
0.05
0.05
0.03
0.06
0.06
−16.47
0.45
0.00
7.52
0.27
0.41
0.00
0.21

SEQID-03084
0.03
0.02
0.05
0.04
0.07
0.01
0.04
0.07
−18.74
0.50
−0.01
6.52
0.20
0.32
0.00
0.21

SEQID-03085
0.02
0.06
0.05
0.04
0.06
0.04
0.07
0.05
−20.33
0.31
−0.03
5.48
0.20
0.31
0.00
0.21

SEQID-03086
0.02
0.06
0.05
0.06
0.05
0.03
0.04
0.07
−20.38
0.42
0.00
7.06
0.47
0.79
0.00
0.21

SEQID-03087
0.04
0.06
0.05
0.05
0.04
0.03
0.05
0.06
−19.20
0.47
0.01
8.45
0.21
0.29
0.26
0.00

SEQID-03088
0.01
0.03
0.02
0.03
0.05
0.02
0.02
0.07
−24.99
0.26
0.12
11.41
0.22
0.31
0.22
0.23

SEQID-03089
0.03
0.03
0.01
0.04
0.06
0.01
0.02
0.09
−23.22
0.37
0.05
10.11
0.22
0.30
0.00
0.21

SEQID-03090
0.02
0.05
0.04
0.04
0.03
0.01
0.07
0.06
−23.97
0.27
0.13
10.81
0.23
0.33
0.21
0.24

SEQID-03091
0.04
0.02
0.02
0.06
0.06
0.01
0.06
0.05
−26.20
0.23
−0.08
4.33
0.24
0.33
0.18
0.20

SEQID-03092
0.02
0.05
0.06
0.00
0.05
0.01
0.03
0.07
−21.77
0.43
0.12
11.07
0.24
0.32
0.00
0.21

SEQID-03093
0.01
0.04
0.05
0.07
0.05
0.01
0.04
0.11
−16.57
0.61
0.01
8.40
0.50
0.78
0.22
0.22

SEQID-03094
0.03
0.03
0.03
0.04
0.06
0.02
0.06
0.07
−18.75
0.45
−0.01
6.56
0.22
0.33
0.00
0.22

SEQID-03095
0.02
0.06
0.05
0.03
0.05
0.05
0.07
0.05
−19.90
0.35
−0.04
4.93
0.21
0.31
0.00
0.21

SEQID-03096
0.01
0.05
0.04
0.06
0.06
0.02
0.06
0.06
−16.33
0.42
0.00
6.83
0.20
0.33
0.00
0.21

SEQID-03097
0.02
0.04
0.04
0.04
0.07
0.00
0.05
0.04
−24.94
0.30
0.13
10.64
0.19
0.31
0.00
0.26

SEQID-03098
0.03
0.06
0.04
0.03
0.06
0.01
0.03
0.05
−23.63
0.37
0.09
10.91
0.19
0.33
0.00
0.23

SEQID-03099
0.01
0.03
0.04
0.03
0.02
0.01
0.04
0.05
−25.92
0.31
0.10
11.08
0.23
0.31
0.00
0.22

SEQID-03100
0.03
0.05
0.05
0.04
0.06
0.02
0.05
0.05
−19.28
0.44
−0.01
6.29
0.27
0.39
0.24
0.21

SEQID-03101
0.01
0.04
0.04
0.03
0.04
0.01
0.04
0.06
−27.30
0.32
0.14
11.16
0.00
0.30
0.21
0.00

SEQID-03102
0.01
0.05
0.06
0.05
0.06
0.01
0.05
0.07
−22.87
0.31
0.09
10.73
0.20
0.31
0.24
0.00

SEQID-03103
0.04
0.09
0.02
0.07
0.04
0.02
0.08
0.07
−15.74
0.53
0.06
10.38
0.00
0.35
0.00
0.21

SEQID-03104
0.02
0.04
0.04
0.05
0.07
0.02
0.03
0.09
−21.48
0.38
0.01
8.42
0.22
0.31
0.00
0.00

SEQID-03105
0.02
0.04
0.05
0.04
0.06
0.02
0.05
0.09
−19.87
0.41
0.00
7.00
0.21
0.32
0.22
0.21

SEQID-03106
0.01
0.05
0.05
0.05
0.07
0.01
0.04
0.07
−22.28
0.37
−0.02
5.36
0.54
0.74
0.00
0.20

SEQID-03107
0.02
0.07
0.05
0.05
0.05
0.03
0.05
0.07
−16.48
0.71
0.01
8.20
0.19
0.32
0.00
0.20

SEQID-03108
0.03
0.03
0.03
0.06
0.11
0.04
0.02
0.09
−11.10
0.46
0.02
9.37
0.22
0.30
0.28
0.24

SEQID-03109
0.01
0.02
0.03
0.05
0.03
0.02
0.07
0.06
−28.09
0.25
−0.03
5.14
0.21
0.30
0.25
0.23

SEQID-03110
0.01
0.01
0.04
0.03
0.02
0.03
0.10
0.08
−25.01
0.16
0.21
11.85
0.23
0.33
0.00
0.23

SEQID-03111
0.02
0.05
0.06
0.04
0.04
0.04
0.04
0.07
−20.07
0.33
−0.01
6.71
0.22
0.30
0.00
0.20

SEQID-03112
0.01
0.05
0.04
0.04
0.05
0.02
0.05
0.07
−20.65
0.42
0.00
6.93
0.21
0.35
0.20
0.22

SEQID-03113
0.04
0.07
0.06
0.05
0.04
0.03
0.05
0.05
−17.86
0.33
−0.01
6.64
0.21
0.32
0.21
0.22

SEQID-03114
0.02
0.07
0.04
0.05
0.05
0.02
0.07
0.06
−23.81
0.31
−0.02
5.72
0.19
0.34
0.00
0.21

SEQID-03115
0.02
0.06
0.03
0.06
0.05
0.01
0.05
0.05
−26.40
0.31
−0.05
4.56
0.70
0.90
0.00
0.21

SEQID-03116
0.02
0.04
0.06
0.05
0.05
0.03
0.05
0.07
−19.40
0.39
−0.01
6.30
0.19
0.33
0.00
0.20

SEQID-03117
0.02
0.05
0.05
0.05
0.06
0.02
0.04
0.06
−18.78
0.43
−0.01
6.39
0.19
0.34
0.00
0.21

SEQID-03118
0.01
0.07
0.04
0.05
0.05
0.06
0.05
0.07
−20.64
0.35
−0.02
5.83
0.20
0.33
0.00
0.20

SEQID-03119
0.03
0.11
0.02
0.05
0.08
0.01
0.03
0.09
−18.42
0.35
0.02
9.48
0.74
0.39
0.00
0.23

SEQID-03120
0.02
0.08
0.04
0.01
0.06
0.02
0.05
0.07
−20.86
0.42
0.00
7.03
0.22
0.31
0.19
0.00

SEQID-03121
0.03
0.07
0.05
0.03
0.05
0.02
0.03
0.07
−20.22
0.50
0.09
10.96
0.22
0.35
0.21
0.23

SEQID-03122
0.02
0.04
0.06
0.03
0.06
0.06
0.03
0.06
−18.08
0.50
−0.02
5.17
0.21
0.35
0.00
0.20

SEQID-03123
0.01
0.05
0.06
0.07
0.05
0.00
0.03
0.09
−16.57
0.58
0.01
9.02
0.64
0.76
0.25
0.21

SEQID-03124
0.02
0.05
0.04
0.05
0.05
0.02
0.07
0.06
−20.22
0.36
−0.02
5.13
0.21
0.31
0.00
0.20

SEQID-03125
0.02
0.08
0.04
0.05
0.06
0.01
0.06
0.07
−18.92
0.41
0.00
7.29
0.20
0.31
0.22
0.21

SEQID-03126
0.02
0.04
0.05
0.04
0.06
0.02
0.06
0.05
−18.56
0.40
0.00
7.20
0.21
0.31
0.19
0.22

SEQID-03127
0.02
0.06
0.03
0.04
0.06
0.03
0.04
0.07
−17.56
0.40
−0.01
6.33
0.56
0.71
0.00
0.20

SEQID-03128
0.02
0.06
0.04
0.04
0.09
0.02
0.05
0.08
−16.71
0.43
0.00
7.69
0.54
0.70
0.20
0.23

SEQID-03129
0.03
0.07
0.04
0.05
0.07
0.02
0.05
0.05
−17.23
0.44
−0.02
6.08
0.21
0.33
0.23
0.21

SEQID-03130
0.03
0.09
0.04
0.06
0.05
0.03
0.05
0.03
−13.47
0.77
0.03
9.36
0.20
0.33
0.20
0.21

SEQID-03131
0.02
0.05
0.04
0.06
0.05
0.00
0.05
0.06
−21.15
0.40
−0.01
5.88
0.19
0.33
0.00
0.22

SEQID-03132
0.02
0.07
0.05
0.06
0.06
0.02
0.06
0.05
−20.38
0.37
−0.01
6.55
0.20
0.33
0.20
0.20

SEQID-03133
0.02
0.07
0.04
0.07
0.05
0.03
0.05
0.06
−18.93
0.32
−0.01
6.24
0.18
0.35
0.19
0.20

SEQID-03134
0.02
0.05
0.02
0.04
0.10
0.03
0.09
0.07
−13.89
0.33
−0.01
5.92
0.24
0.31
0.00
0.26

SEQID-03135
0.04
0.07
0.03
0.08
0.09
0.04
0.02
0.08
−11.66
0.50
0.03
9.90
0.00
0.30
0.28
0.25

SEQID-03136
0.02
0.05
0.03
0.07
0.05
0.01
0.03
0.07
−25.76
0.21
0.09
10.74
0.22
0.31
0.20
0.00

SEQID-03137
0.01
0.04
0.02
0.09
0.06
0.06
0.04
0.09
−19.09
0.44
−0.02
5.99
0.22
0.31
0.00
0.20

SEQID-03138
0.01
0.06
0.04
0.05
0.05
0.04
0.06
0.05
−21.71
0.32
−0.02
6.32
0.21
0.33
0.00
0.00

SEQID-03139
0.02
0.07
0.04
0.06
0.05
0.03
0.05
0.06
−16.14
0.42
−0.03
4.74
0.36
0.50
0.00
0.22

SEQID-03140
0.02
0.05
0.07
0.09
0.05
0.03
0.02
0.05
−17.71
0.32
0.00
6.92
0.21
0.34
0.21
0.23

SEQID-03141
0.02
0.05
0.04
0.05
0.06
0.01
0.03
0.03
−20.24
0.46
0.00
7.17
0.21
0.33
0.21
0.22

SEQID-03142
0.01
0.07
0.04
0.07
0.05
0.01
0.06
0.06
−17.74
0.41
−0.01
6.16
0.20
0.33
0.00
0.22

SEQID-03143
0.01
0.06
0.04
0.10
0.08
0.05
0.06
0.06
−12.84
0.45
−0.01
5.65
0.21
0.34
0.00
0.21

SEQID-03144
0.02
0.03
0.05
0.04
0.05
0.03
0.07
0.07
−19.25
0.38
0.00
6.95
0.26
0.40
0.18
0.20

SEQID-03145
0.02
0.05
0.03
0.04
0.05
0.03
0.05
0.07
−21.13
0.34
−0.01
6.35
0.21
0.33
0.00
0.21

SEQID-03146
0.03
0.06
0.04
0.04
0.05
0.02
0.03
0.06
−18.57
0.66
−0.02
5.13
0.19
0.34
0.00
0.30

SEQID-03147
0.01
0.01
0.03
0.04
0.04
0.00
0.07
0.08
−18.97
0.52
−0.01
5.70
0.31
0.36
0.24
0.25

SEQID-03148
0.00
0.08
0.03
0.04
0.05
0.01
0.06
0.06
−24.21
0.19
0.11
10.65
0.26
0.32
0.00
0.00

SEQID-03149
0.02
0.03
0.02
0.06
0.02
0.01
0.04
0.09
−19.28
0.56
0.10
11.02
0.23
0.30
0.24
0.22

SEQID-03150
0.02
0.05
0.01
0.04
0.10
0.05
0.10
0.07
−19.52
0.31
0.00
7.18
0.00
0.30
0.24
0.25

SEQID-03151
0.02
0.04
0.07
0.04
0.03
0.04
0.05
0.07
−20.14
0.43
0.00
7.41
0.24
0.31
0.25
0.00

SEQID-03152
0.03
0.07
0.05
0.05
0.03
0.02
0.05
0.06
−23.90
0.27
0.13
11.56
0.21
0.29
0.00
0.23

SEQID-03153
0.01
0.05
0.03
0.02
0.06
0.01
0.05
0.06
−23.46
0.29
0.11
11.09
0.20
0.31
0.00
0.25

SEQID-03154
0.02
0.03
0.03
0.05
0.05
0.01
0.03
0.09
−22.13
0.44
0.06
10.50
0.20
0.33
0.00
0.23

SEQID-03155
0.02
0.07
0.06
0.04
0.05
0.04
0.09
0.04
−20.56
0.29
0.00
7.23
0.24
0.33
0.22
0.00

SEQID-03156
0.02
0.10
0.07
0.05
0.06
0.04
0.08
0.03
−18.82
0.29
0.00
8.30
0.24
0.31
0.00
0.21

SEQID-03157
0.03
0.07
0.07
0.06
0.10
0.03
0.05
0.06
−15.40
0.39
0.01
7.78
0.43
0.64
0.19
0.00

SEQID-03158
0.05
0.12
0.06
0.07
0.05
0.04
0.06
0.05
−19.34
0.32
−0.01
5.15
0.25
0.33
0.00
0.24

SEQID-03159
0.04
0.05
0.03
0.04
0.06
0.01
0.06
0.05
−20.81
0.42
0.00
6.80
0.21
0.34
0.00
0.00

SEQID-03160
0.03
0.02
0.04
0.05
0.04
0.04
0.05
0.06
−17.94
0.47
−0.02
5.16
0.34
0.50
0.00
0.00

SEQID-03161
0.04
0.06
0.04
0.05
0.04
0.03
0.04
0.09
−20.27
0.40
0.01
7.31
0.21
0.31
0.22
0.20

SEQID-03162
0.01
0.03
0.04
0.03
0.03
0.05
0.09
0.04
−21.74
0.27
−0.01
6.72
0.20
0.33
0.00
0.20

SEQID-03163
0.02
0.05
0.03
0.05
0.05
0.02
0.04
0.07
−21.91
0.44
0.00
6.81
0.21
0.33
0.00
0.00

SEQID-03164
0.03
0.05
0.04
0.03
0.03
0.01
0.06
0.07
−19.32
0.48
−0.01
6.16
0.25
0.39
0.00
0.20

SEQID-03165
0.01
0.06
0.05
0.06
0.06
0.04
0.05
0.05
−20.50
0.34
0.00
6.93
0.21
0.31
0.00
0.21

SEQID-03166
0.02
0.05
0.06
0.05
0.05
0.01
0.04
0.05
−19.02
0.38
−0.02
5.74
0.22
0.35
0.00
0.22

SEQID-03167
0.02
0.06
0.05
0.07
0.07
0.01
0.04
0.09
−15.61
0.47
−0.01
6.34
0.49
0.84
0.21
0.21

SEQID-03168
0.02
0.05
0.05
0.05
0.06
0.03
0.04
0.07
−18.10
0.42
−0.01
6.13
0.51
0.71
0.20
0.21

SEQID-03169
0.03
0.05
0.05
0.05
0.06
0.00
0.03
0.03
−18.31
0.47
−0.01
5.40
0.22
0.34
0.22
0.23

SEQID-03170
0.02
0.09
0.06
0.05
0.04
0.03
0.05
0.06
−18.69
0.25
0.00
6.94
0.35
0.55
0.00
0.21

SEQID-03171
0.01
0.04
0.05
0.06
0.05
0.04
0.04
0.09
−19.15
0.39
−0.02
6.05
0.20
0.33
0.00
0.21

SEQID-03172
0.02
0.04
0.04
0.05
0.06
0.02
0.05
0.09
−18.65
0.46
−0.01
6.13
0.21
0.35
0.00
0.21

SEQID-03173
0.02
0.05
0.04
0.06
0.05
0.02
0.05
0.07
−19.08
0.43
−0.01
5.87
0.00
0.36
0.00
0.19

SEQID-03174
0.01
0.01
0.04
0.06
0.07
0.01
0.04
0.08
−23.53
0.27
0.07
10.34
0.26
0.30
0.00
0.25

SEQID-03175
0.03
0.05
0.04
0.04
0.03
0.02
0.01
0.09
−24.39
0.38
0.13
11.46
0.22
0.30
0.21
0.24

SEQID-03176
0.02
0.04
0.03
0.04
0.03
0.00
0.09
0.07
−20.30
0.46
0.11
10.74
0.22
0.29
0.24
0.00

SEQID-03177
0.02
0.03
0.06
0.07
0.07
0.02
0.04
0.05
−21.07
0.32
0.12
11.31
0.00
0.30
0.18
0.21

SEQID-03178
0.02
0.02
0.06
0.06
0.05
0.01
0.01
0.09
−21.32
0.43
0.03
9.87
0.26
0.33
0.23
0.24

SEQID-03179
0.01
0.07
0.02
0.04
0.07
0.01
0.06
0.07
−22.64
0.21
0.16
11.37
0.21
0.29
0.19
0.23

SEQID-03180
0.02
0.03
0.03
0.05
0.07
0.00
0.04
0.06
−25.68
0.26
0.14
11.09
0.24
0.30
0.00
0.00

SEQID-03181
0.04
0.05
0.04
0.03
0.06
0.00
0.06
0.03
−21.97
0.25
0.11
10.99
0.22
0.28
0.00
0.19

SEQID-03182
0.01
0.05
0.04
0.05
0.06
0.00
0.02
0.04
−23.82
0.39
0.15
11.77
0.00
0.32
0.00
0.24

SEQID-03183
0.03
0.04
0.04
0.06
0.03
0.01
0.03
0.07
−22.66
0.40
0.09
10.61
0.23
0.32
0.20
0.20

SEQID-03184
0.01
0.08
0.03
0.04
0.07
0.04
0.02
0.05
−13.56
0.91
0.04
9.96
0.21
0.32
0.22
0.19

SEQID-03185
0.01
0.05
0.05
0.06
0.05
0.03
0.05
0.10
−20.75
0.33
−0.01
6.52
0.20
0.31
0.00
0.00

SEQID-03186
0.04
0.04
0.05
0.04
0.04
0.02
0.02
0.09
−17.89
0.52
−0.04
5.16
0.24
0.32
0.00
0.20

SEQID-03187
0.06
0.03
0.03
0.06
0.05
0.02
0.03
0.09
−19.76
0.43
0.00
7.02
0.19
0.29
0.00
0.00

SEQID-03188
0.04
0.05
0.04
0.06
0.05
0.03
0.09
0.05
−17.81
0.34
−0.01
6.51
0.18
0.31
0.00
0.21

SEQID-03189
0.02
0.03
0.06
0.05
0.04
0.05
0.04
0.07
−19.54
0.34
0.00
6.92
0.22
0.33
0.00
0.00

SEQID-03190
0.03
0.06
0.03
0.03
0.05
0.02
0.03
0.05
−21.71
0.44
−0.05
4.46
0.21
0.33
0.18
0.17

SEQID-03191
0.03
0.03
0.04
0.07
0.04
0.00
0.03
0.10
−17.00
0.45
0.00
6.52
0.21
0.34
0.00
0.20

SEQID-03192
0.03
0.03
0.04
0.06
0.04
0.02
0.08
0.07
−19.23
0.37
−0.01
6.52
0.20
0.30
0.00
0.00

SEQID-03193
0.03
0.04
0.04
0.05
0.03
0.01
0.06
0.08
−19.80
0.43
−0.01
6.29
0.21
0.33
0.00
0.21

SEQID-03194
0.02
0.10
0.05
0.08
0.03
0.05
0.05
0.06
−17.54
0.41
0.01
7.55
0.00
0.32
0.00
0.20

SEQID-03195
0.03
0.04
0.04
0.06
0.07
0.01
0.05
0.07
−17.53
0.44
0.01
8.79
0.19
0.33
0.00
0.00

SEQID-03196
0.01
0.05
0.07
0.06
0.05
0.01
0.03
0.08
−16.08
0.54
0.00
6.79
0.23
0.32
0.00
0.20

SEQID-03197
0.03
0.04
0.05
0.04
0.06
0.04
0.05
0.05
−21.77
0.37
−0.01
6.53
0.10
0.31
0.00
0.21

SEQID-03198
0.02
0.05
0.05
0.04
0.04
0.03
0.04
0.05
−19.67
0.43
−0.02
6.25
0.21
0.31
0.00
0.21

SEQID-03199
0.02
0.04
0.06
0.05
0.07
0.04
0.03
0.05
−18.77
0.41
−0.03
4.85
0.21
0.33
0.00
0.22

SEQID-03200
0.03
0.03
0.02
0.09
0.06
0.02
0.04
0.08
−19.56
0.40
−0.01
6.64
0.21
0.36
0.13
0.22

SEQID-03201
0.03
0.06
0.03
0.04
0.04
0.03
0.04
0.05
−19.13
0.47
0.00
7.63
0.20
0.34
0.21
0.24

SEQID-03202
0.03
0.06
0.03
0.04
0.06
0.03
0.04
0.06
−19.73
0.37
0.01
7.59
0.21
0.34
0.00
0.21

SEQID-03203
0.02
0.05
0.06
0.04
0.05
0.02
0.04
0.06
−18.35
0.41
−0.01
6.24
0.21
0.33
0.00
0.23

SEQID-03204
0.04
0.06
0.03
0.03
0.05
0.01
0.04
0.07
−23.29
0.40
−0.02
5.84
0.21
0.32
0.19
0.21

SEQID-03205
0.04
0.05
0.04
0.05
0.06
0.01
0.05
0.07
−20.04
0.39
−0.02
5.26
0.22
0.32
0.00
0.21

SEQID-03206
0.01
0.07
0.05
0.05
0.05
0.03
0.07
0.05
−19.44
0.36
−0.01
6.21
0.21
0.31
0.00
0.20

SEQID-03207
0.01
0.09
0.05
0.05
0.06
0.05
0.05
0.06
−19.96
0.34
−0.02
5.78
0.34
0.59
0.00
0.21

SEQID-03208
0.01
0.09
0.05
0.06
0.05
0.03
0.06
0.06
−20.97
0.33
−0.02
6.23
0.21
0.32
0.00
0.21

SEQID-03209
0.03
0.06
0.06
0.05
0.05
0.04
0.05
0.06
−18.60
0.29
−0.04
5.00
0.38
0.78
0.00
0.21

SEQID-03210
0.04
0.06
0.06
0.05
0.04
0.01
0.05
0.07
−17.85
0.39
0.04
9.85
0.20
0.33
0.00
0.21

SEQID-03211
0.02
0.05
0.04
0.05
0.05
0.03
0.04
0.07
−20.85
0.38
−0.01
5.93
0.23
0.36
0.00
0.21

SEQID-03212
0.02
0.04
0.04
0.05
0.05
0.01
0.05
0.09
−20.43
0.43
0.01
9.10
0.20
0.33
0.19
0.20

SEQID-03213
0.01
0.05
0.04
0.06
0.05
0.02
0.05
0.06
−19.53
0.38
−0.03
5.97
0.19
0.34
0.20
0.20

SEQID-03214
0.01
0.03
0.01
0.03
0.06
0.00
0.06
0.06
−23.82
0.32
0.18
11.91
0.25
0.32
0.00
0.27

SEQID-03215
0.01
0.03
0.03
0.06
0.05
0.02
0.03
0.06
−23.53
0.31
0.17
11.20
0.00
0.27
0.00
0.22

SEQID-03216
0.02
0.04
0.04
0.09
0.03
0.02
0.07
0.07
−20.29
0.26
0.18
12.08
0.26
0.29
0.25
0.19

SEQID-03217
0.02
0.05
0.03
0.04
0.06
0.00
0.02
0.04
−23.81
0.32
0.15
12.05
0.27
0.33
0.00
0.23

SEQID-03218
0.02
0.04
0.05
0.04
0.07
0.00
0.03
0.07
−25.82
0.26
0.08
11.01
0.21
0.30
0.00
0.24

SEQID-03219
0.02
0.05
0.05
0.03
0.04
0.02
0.05
0.07
−22.01
0.33
0.13
11.13
0.00
0.33
0.00
0.23

SEQID-03220
0.09
0.06
0.20
0.01
0.03
0.01
0.00
0.05
−15.94
0.30
0.05
10.92
0.29
0.39
0.26
0.32

SEQID-03221
0.03
0.04
0.04
0.05
0.07
0.00
0.02
0.10
−20.37
0.49
0.06
10.80
0.22
0.30
0.00
0.26

SEQID-03222
0.01
0.05
0.04
0.05
0.05
0.00
0.01
0.10
−24.53
0.39
0.07
10.84
0.21
0.32
0.00
0.22

SEQID-03223
0.03
0.03
0.07
0.06
0.05
0.03
0.04
0.07
−20.93
0.28
−0.03
4.70
0.23
0.30
0.00
0.22

SEQID-03224
0.02
0.03
0.04
0.07
0.05
0.02
0.10
0.06
−21.73
0.39
0.00
6.96
0.21
0.32
0.00
0.19

SEQID-03225
0.03
0.01
0.02
0.03
0.04
0.02
0.02
0.06
−28.52
0.22
0.20
12.12
0.22
0.32
0.21
0.22

SEQID-03226
0.01
0.03
0.03
0.05
0.05
0.02
0.05
0.04
−23.70
0.14
0.13
11.45
0.23
0.30
0.22
0.19

SEQID-03227
0.02
0.04
0.03
0.05
0.06
0.01
0.05
0.10
−21.72
0.46
0.02
9.07
0.22
0.31
0.22
0.21

SEQID-03228
0.00
0.03
0.03
0.05
0.06
0.01
0.09
0.06
−21.24
0.35
−0.02
5.72
0.22
0.32
0.00
0.00

SEQID-03229
0.03
0.04
0.04
0.04
0.06
0.01
0.04
0.11
−18.46
0.55
−0.01
6.36
0.20
0.34
0.22
0.00

SEQID-03230
0.02
0.06
0.03
0.05
0.06
0.01
0.03
0.10
−17.47
0.56
0.01
3.42
0.25
0.33
0.00
0.20

SEQID-03231
0.03
0.05
0.04
0.03
0.03
0.00
0.06
0.05
−19.05
0.35
0.00
6.73
0.00
0.32
0.00
0.00

SEQID-03232
0.01
0.04
0.04
0.05
0.07
0.01
0.03
0.05
−20.32
0.40
0.00
6.81
0.21
0.31
0.00
0.00

SEQID-03233
0.04
0.07
0.03
0.04
0.06
0.01
0.05
0.06
−22.57
0.41
0.00
7.08
0.21
0.32
0.00
0.00

SEQID-03234
0.03
0.05
0.04
0.04
0.06
0.03
0.06
0.06
−20.07
0.38
−0.03
5.55
0.20
0.31
0.00
0.19

SEQID-03235
0.01
0.04
0.03
0.04
0.05
0.01
0.04
0.09
−22.51
0.37
−0.01
6.59
0.19
0.31
0.00
0.00

SEQID-03236
0.02
0.06
0.07
0.09
0.10
0.01
0.07
0.06
−12.65
0.42
−0.04
4.25
0.20
0.35
0.00
0.22

SEQID-03237
0.03
0.04
0.02
0.09
0.06
0.04
0.03
0.05
−18.70
0.42
0.00
6.76
0.21
0.35
0.00
0.21

SEQID-03238
0.02
0.06
0.03
0.06
0.06
0.02
0.05
0.06
−17.19
0.55
−0.03
4.58
0.20
0.31
0.25
0.00

SEQID-03239
0.03
0.07
0.02
0.03
0.05
0.02
0.03
0.04
−21.62
0.41
−0.06
4.29
0.21
0.35
0.00
0.00

SEQID-03240
0.06
0.05
0.06
0.05
0.04
0.01
0.04
0.09
−18.85
0.46
−0.01
6.33
0.00
0.33
0.00
0.21

SEQID-03241
0.03
0.06
0.06
0.06
0.07
0.03
0.05
0.04
−20.80
0.30
0.00
6.30
0.20
0.31
0.00
0.18

SEQID-03242
0.02
0.04
0.05
0.07
0.05
0.02
0.05
0.09
−19.28
0.45
0.00
7.65
0.22
0.32
0.00
0.22

SEQID-03243
0.01
0.04
0.06
0.04
0.06
0.05
0.03
0.05
−18.94
0.41
0.00
7.11
0.22
0.32
0.00
0.22

SEQID-03244
0.02
0.08
0.05
0.06
0.06
0.07
0.05
0.05
−15.37
0.40
−0.01
6.24
0.21
0.33
0.00
0.20

SEQID-03245
0.02
0.04
0.05
0.04
0.06
0.04
0.04
0.04
−18.05
0.44
−0.02
6.25
0.23
0.35
0.20
0.22

SEQID-03246
0.00
0.04
0.04
0.07
0.04
0.02
0.06
0.11
−17.67
0.48
0.00
7.36
0.23
0.34
0.00
0.21

SEQID-03247
0.03
0.05
0.05
0.05
0.05
0.01
0.06
0.04
−19.69
0.31
0.00
7.20
0.20
0.38
0.00
0.22

SEQID-03248
0.02
0.05
0.05
0.04
0.03
0.03
0.04
0.07
−20.12
0.41
−0.01
6.60
0.20
0.56
0.00
0.23

SEQID-03249
0.05
0.06
0.04
0.06
0.04
0.03
0.04
0.07
−13.17
0.92
0.01
8.54
0.22
0.34
0.00
0.22

SEQID-03250
0.03
0.04
0.06
0.05
0.07
0.03
0.04
0.06
−18.89
0.33
−0.01
6.37
0.21
0.31
0.00
0.21

SEQID-03251
0.02
0.06
0.05
0.06
0.04
0.01
0.04
0.07
−21.06
0.40
−0.01
6.27
0.21
0.34
0.18
0.22

SEQID-03252
0.03
0.03
0.02
0.05
0.04
0.03
0.05
0.06
−24.02
0.32
0.01
8.68
0.23
0.33
0.19
0.22

SEQID-03253
0.03
0.06
0.05
0.06
0.03
0.02
0.04
0.06
−20.06
0.38
−0.01
6.73
0.21
0.33
0.00
0.21

SEQID-03254
0.04
0.05
0.04
0.06
0.05
0.02
0.03
0.06
−18.37
0.41
−0.01
6.41
0.21
0.32
0.00
0.22

SEQID-03255
0.03
0.09
0.04
0.04
0.06
0.04
0.06
0.07
−14.89
0.76
0.01
7.81
0.21
0.32
0.00
0.21

SEQID-03256
0.03
0.05
0.04
0.04
0.06
0.02
0.05
0.05
−20.06
0.33
−0.01
6.69
0.20
0.34
0.00
0.21

SEQID-03257
0.03
0.05
0.06
0.05
0.04
0.01
0.05
0.05
−22.75
0.32
0.00
7.14
0.21
0.31
0.19
0.21

SEQID-03258
0.01
0.04
0.05
0.04
0.07
0.04
0.05
0.08
−18.56
0.43
0.00
7.05
0.20
0.33
0.00
0.21

SEQID-03259
0.02
0.05
0.03
0.05
0.06
0.01
0.03
0.07
−22.67
0.39
−0.04
4.80
0.64
0.83
0.00
0.21

SEQID-03260
0.03
0.03
0.04
0.06
0.07
0.04
0.06
0.06
−15.35
0.63
0.00
7.32
0.20
0.32
0.00
0.21

SEQID-03261
0.04
0.05
0.05
0.04
0.04
0.00
0.03
0.06
−22.98
0.36
−0.04
4.68
0.18
0.34
0.00
0.21

SEQID-03262
0.03
0.04
0.03
0.05
0.05
0.02
0.03
0.06
−18.67
0.40
0.00
7.04
0.19
0.33
0.00
0.21

SEQID-03263
0.01
0.05
0.05
0.09
0.05
0.02
0.04
0.07
−18.10
0.66
0.00
6.69
0.18
0.32
0.18
0.20

SEQID-03264
0.02
0.05
0.05
0.05
0.05
0.02
0.05
0.07
−18.67
0.47
0.00
7.29
0.20
0.33
0.19
0.20

SEQID-03265
0.02
0.03
0.05
0.04
0.05
0.02
0.04
0.06
−23.47
0.32
−0.02
6.17
0.19
0.34
0.19
0.19

SEQID-03266
0.03
0.09
0.04
0.05
0.04
0.03
0.07
0.05
−17.08
0.61
0.02
9.11
0.18
0.33
0.19
0.13

SEQID-03267
0.01
0.03
0.02
0.04
0.06
0.05
0.05
0.07
−26.35
0.30
0.01
7.85
0.26
0.28
0.27
0.23

SEQID-03268
0.02
0.02
0.04
0.05
0.01
0.01
0.05
0.10
−23.54
0.31
0.16
11.12
0.27
0.33
0.24
0.29

SEQID-03269
0.01
0.01
0.03
0.07
0.00
0.00
0.03
0.07
−20.95
0.42
0.03
10.68
0.25
0.31
0.26
0.00

SEQID-03270
0.03
0.06
0.04
0.03
0.04
0.04
0.04
0.05
−23.36
0.23
0.04
9.56
0.23
0.33
0.25
0.27

SEQID-03271
0.01
0.07
0.05
0.06
0.06
0.01
0.05
0.13
−11.59
0.55
0.00
7.24
0.27
0.31
0.23
0.27

SEQID-03272
0.02
0.03
0.04
0.12
0.07
0.00
0.04
0.04
−21.64
0.22
0.13
10.94
0.27
0.32
0.00
0.26

SEQID-03273
0.04
0.05
0.09
0.06
0.07
0.03
0.06
0.02
−17.54
0.44
0.00
7.34
0.22
0.28
0.23
0.29

SEQID-03274
0.01
0.06
0.06
0.04
0.04
0.01
0.04
0.05
−19.71
0.44
0.00
6.88
0.00
0.30
0.25
0.21

SEQID-03275
0.01
0.05
0.04
0.06
0.02
0.02
0.01
0.09
−24.57
0.37
0.14
11.24
0.00
0.31
0.00
0.23

SEQID-03276
0.02
0.04
0.03
0.05
0.05
0.01
0.03
0.05
−25.87
0.20
0.22
12.19
0.00
0.29
0.23
0.22

SEQID-03277
0.04
0.05
0.06
0.08
0.05
0.01
0.05
0.05
−17.99
0.52
−0.01
5.28
0.23
0.31
0.25
0.24

SEQID-03278
0.02
0.04
0.06
0.03
0.03
0.03
0.09
0.05
−23.44
0.24
0.05
10.04
0.23
0.33
0.23
0.24

SEQID-03279
0.04
0.12
0.05
0.06
0.05
0.06
0.07
0.05
−16.94
0.34
−0.03
4.74
0.21
0.29
0.22
0.24

SEQID-03280
0.04
0.09
0.03
0.06
0.04
0.01
0.09
0.08
−23.77
0.34
−0.05
4.37
0.56
0.61
0.00
0.19

SEQID-03281
0.02
0.07
0.06
0.06
0.05
0.02
0.06
0.02
−18.20
0.32
0.03
9.82
0.24
0.31
0.23
0.00

SEQID-03282
0.02
0.07
0.01
0.06
0.06
0.00
0.07
0.05
−20.98
0.65
0.05
9.94
0.21
0.32
0.00
0.24

SEQID-03283
0.02
0.04
0.04
0.09
0.05
0.02
0.01
0.09
−20.15
0.42
0.01
8.11
0.18
0.33
0.20
0.24

SEQID-03284
0.01
0.04
0.01
0.08
0.09
0.02
0.06
0.07
−19.83
0.40
0.00
6.79
0.00
0.31
0.22
0.00

SEQID-03285
0.02
0.04
0.09
0.06
0.05
0.04
0.03
0.06
−16.16
0.48
−0.01
6.51
0.19
0.31
0.00
0.23

SEQID-03286
0.01
0.04
0.04
0.04
0.05
0.05
0.05
0.02
−17.98
0.31
0.01
7.90
0.51
0.66
0.00
0.00

SEQID-03287
0.04
0.04
0.03
0.04
0.06
0.03
0.06
0.09
−16.83
0.43
−0.02
5.59
0.20
0.32
0.23
0.00

SEQID-03288
0.03
0.07
0.06
0.04
0.02
0.04
0.06
0.06
−22.43
0.32
−0.02
6.37
0.00
0.33
0.00
0.00

SEQID-03289
0.01
0.04
0.05
0.05
0.06
0.02
0.02
0.10
−17.38
0.54
−0.01
5.87
0.57
0.68
0.00
0.18

SEQID-03290
0.02
0.09
0.08
0.05
0.05
0.04
0.05
0.04
−15.00
0.25
−0.02
4.98
0.27
0.41
0.22
0.25

SEQID-03291
0.04
0.05
0.02
0.05
0.06
0.01
0.02
0.07
−22.01
0.41
−0.05
4.84
0.23
0.30
0.00
0.21

SEQID-03292
0.05
0.06
0.03
0.05
0.09
0.01
0.02
0.07
−18.19
0.51
−0.01
6.36
0.20
0.31
0.21
0.00

SEQID-03293
0.03
0.08
0.05
0.06
0.03
0.04
0.05
0.09
−17.68
0.69
0.04
10.16
0.22
0.31
0.20
0.22

SEQID-03294
0.02
0.10
0.06
0.04
0.09
0.05
0.09
0.05
−11.08
0.66
0.07
10.46
0.22
0.30
0.00
0.00

SEQID-03295
0.03
0.05
0.03
0.06
0.07
0.02
0.09
0.05
−18.78
0.34
−0.01
6.16
0.19
0.32
0.00
0.00

SEQID-03296
0.02
0.04
0.03
0.06
0.05
0.01
0.03
0.08
−19.15
0.47
0.01
8.42
0.21
0.33
0.00
0.00

SEQID-03297
0.00
0.11
0.03
0.04
0.04
0.07
0.08
0.07
−11.44
1.03
0.02
9.04
0.20
0.30
0.00
0.22

SEQID-03298
0.02
0.05
0.03
0.05
0.04
0.01
0.03
0.07
−19.38
0.42
0.03
10.12
0.21
0.32
0.21
0.00

SEQID-03299
0.03
0.05
0.04
0.06
0.07
0.00
0.08
0.06
−16.95
0.52
−0.01
5.76
0.00
0.32
0.00
0.00

SEQID-03300
0.01
0.07
0.04
0.03
0.09
0.01
0.04
0.09
−17.72
0.54
0.02
9.70
0.23
0.35
0.00
0.21

SEQID-03301
0.03
0.04
0.04
0.04
0.07
0.02
0.04
0.06
−19.05
0.048
−0.01
5.81
0.00
0.36
0.00
0.20

SEQID-03302
0.02
0.02
0.04
0.05
0.06
0.02
0.06
0.08
−17.63
0.45
0.00
6.86
0.45
0.56
0.00
0.20

SEQID-03303
0.03
0.04
0.05
0.05
0.04
0.01
0.03
0.07
−16.74
0.83
0.00
7.03
0.23
0.33
0.21
0.23

SEQID-03304
0.01
0.05
0.06
0.04
0.04
0.02
0.03
0.08
−17.49
0.49
0.00
7.20
0.24
0.37
0.00
0.22

SEQID-03305
0.02
0.06
0.04
0.05
0.05
0.02
0.04
0.08
−20.38
0.46
−0.01
6.58
0.21
0.33
0.00
0.22

SEQID-03306
0.03
0.04
0.04
0.07
0.05
0.00
0.03
0.10
−17.13
0.50
0.01
7.88
0.21
0.33
0.00
0.17

SEQID-03307
0.02
0.01
0.05
0.05
0.09
0.04
0.05
0.04
−14.77
0.44
−0.01
5.62
0.23
0.35
0.00
0.22

SEQID-03308
0.02
0.05
0.04
0.08
0.05
0.02
0.04
0.06
−18.98
0.43
0.01
7.64
0.21
0.35
0.00
0.22

SEQID-03309
0.02
0.04
0.04
0.03
0.06
0.01
0.03
0.05
−26.26
0.31
0.00
6.97
0.22
0.32
0.00
0.23

SEQID-03310
0.02
0.06
0.05
0.07
0.07
0.02
0.05
0.07
−15.17
0.43
0.01
7.62
0.24
0.31
0.20
0.22

SEQID-03311
0.02
0.07
0.08
0.08
0.05
0.03
0.06
0.05
−16.81
0.49
0.01
7.97
0.21
0.32
0.00
0.20

SEQID-03312
0.04
0.03
0.04
0.05
0.03
0.00
0.03
0.08
−21.81
0.41
0.02
9.64
0.24
0.34
0.00
0.22

SEQID-03313
0.03
0.05
0.02
0.04
0.07
0.01
0.04
0.08
−20.78
0.47
−0.02
5.19
0.21
0.32
0.00
0.20

SEQID-03314
0.02
0.04
0.04
0.05
0.06
0.03
0.07
0.06
−19.61
0.37
0.02
9.42
0.21
0.36
0.20
0.22

SEQID-03315
0.02
0.06
0.04
0.04
0.04
0.01
0.02
0.09
−20.60
0.46
0.01
8.22
0.22
0.32
0.00
0.22

SEQID-03316
0.03
0.07
0.06
0.06
0.04
0.04
0.07
0.05
−18.95
0.34
0.00
7.31
0.21
0.34
0.00
0.23

SEQID-03317
0.02
0.05
0.05
0.06
0.05
0.02
0.05
0.05
−17.55
0.38
0.02
9.43
0.21
0.33
0.00
0.21

SEQID-03318
0.02
0.04
0.06
0.03
0.07
0.01
0.03
0.05
−19.66
0.40
0.00
8.17
0.21
0.35
0.19
0.24

SEQID-03319
0.02
0.07
0.05
0.06
0.05
0.02
0.07
0.06
−19.89
0.37
−0.01
6.07
0.21
0.35
0.00
0.22

SEQID-03320
0.03
0.03
0.05
0.04
0.05
0.03
0.05
0.06
−18.30
0.45
0.00
6.89
0.21
0.33
0.00
0.22

SEQID-03321
0.04
0.06
0.03
0.05
0.04
0.02
0.03
0.06
−22.56
0.37
−0.01
6.34
0.21
0.33
0.20
0.23

SEQID-03322
0.02
0.06
0.04
0.05
0.06
0.03
0.03
0.08
−19.07
0.49
0.00
6.74
0.20
0.34
0.21
0.21

SEQID-03323
0.01
0.05
0.04
0.05
0.05
0.02
0.06
0.03
−17.29
0.57
−0.02
5.65
0.22
0.40
0.00
0.21

SEQID-03324
0.03
0.06
0.05
0.07
0.05
0.01
0.03
0.06
−18.12
0.43
0.00
6.80
0.21
0.32
0.20
0.23

SEQID-03325
0.01
0.03
0.05
0.03
0.03
0.02
0.05
0.06
−18.57
0.39
−0.01
6.46
0.20
0.34
0.00
0.23

SEQID-03326
0.02
0.07
0.04
0.07
0.05
0.02
0.04
0.08
−17.44
0.49
0.01
8.19
0.31
0.48
0.19
0.21

SEQID-03327
0.03
0.06
0.04
0.05
0.04
0.05
0.05
0.04
−22.15
0.32
−0.02
5.53
0.21
0.36
0.00
0.21

SEQID-03328
0.03
0.05
0.05
0.06
0.06
0.02
0.02
0.06
−16.03
0.48
0.01
8.92
0.28
0.43
0.00
0.22

SEQID-03329
0.02
0.06
0.05
0.12
0.06
0.01
0.07
0.05
−13.60
0.41
−0.05
3.95
0.20
0.36
0.20
0.21

SEQID-03330
0.02
0.06
0.06
0.05
0.08
0.05
0.06
0.05
−17.92
0.32
−0.03
5.13
0.22
0.34
0.00
0.21

SEQID-03331
0.02
0.07
0.06
0.05
0.05
0.05
0.04
0.05
−19.69
0.36
−0.04
4.95
0.20
0.35
0.00
0.21

SEQID-03332
0.02
0.08
0.06
0.07
0.06
0.03
0.03
0.05
−16.53
0.47
0.01
7.73
0.20
0.35
0.21
0.21

SEQID-03333
0.03
0.11
0.05
0.04
0.05
0.05
0.05
0.05
−15.34
0.71
0.01
8.35
0.20
0.32
0.00
0.21

SEQID-03334
0.03
0.04
0.03
0.05
0.06
0.00
0.02
0.07
−21.94
0.41
−0.01
5.83
0.45
0.73
0.00
0.22

SEQID-03335
0.02
0.06
0.05
0.07
0.04
0.04
0.05
0.03
−15.52
0.75
0.02
9.45
0.19
0.35
0.00
0.20

SEQID-03336
0.02
0.06
0.05
0.05
0.07
0.02
0.04
0.08
−16.52
0.52
0.00
7.91
0.19
0.42
0.19
0.21

SEQID-03337
0.02
0.05
0.06
0.08
0.06
0.03
0.04
0.07
−16.79
0.41
−0.03
4.92
0.23
0.41
0.00
0.22

SEQID-03338
0.03
0.08
0.04
0.04
0.06
0.03
0.04
0.05
−18.38
0.57
−0.03
5.16
0.18
0.34
0.00
0.20

SEQID-03339
0.02
0.05
0.04
0.05
0.06
0.01
0.05
0.07
−18.47
0.44
0.00
6.70
0.20
0.33
0.00
0.20

SEQID-03340
0.03
0.08
0.04
0.06
0.06
0.03
0.06
0.06
−17.65
0.54
0.01
8.36
0.18
0.35
0.00
0.21

SEQID-03341
0.03
0.05
0.06
0.05
0.05
0.01
0.06
0.06
−19.20
0.38
0.04
9.98
0.19
0.36
0.00
0.21

SEQID-03342
0.02
0.05
0.06
0.04
0.06
0.03
0.05
0.05
−20.08
0.29
0.00
7.25
0.20
0.32
0.20
0.20

SEQID-03343
0.03
0.06
0.05
0.04
0.05
0.04
0.03
0.05
−21.66
0.35
0.00
6.85
0.19
0.35
0.19
0.18

SEQID-03344
0.03
0.05
0.06
0.04
0.05
0.02
0.04
0.06
−23.33
0.36
−0.05
4.64
0.19
0.73
0.19
0.20

SEQID-03345
0.02
0.04
0.04
0.06
0.07
0.02
0.04
0.08
−17.42
0.52
−0.01
6.42
0.18
0.33
0.19
0.20

SEQID-03346
0.04
0.05
0.05
0.05
0.08
0.01
0.04
0.07
−11.85
0.77
0.03
9.95
0.51
0.70
0.00
0.00

SEQID-03347
0.04
0.05
0.05
0.06
0.07
0.01
0.04
0.07
−11.94
0.76
0.04
10.04
0.52
0.70
0.00
0.21

SEQID-03348
0.03
0.09
0.05
0.05
0.06
0.02
0.05
0.08
−15.96
0.61
−0.01
6.14
0.21
0.33
0.00
0.23

SEQID-03349
0.03
0.09
0.07
0.07
0.05
0.01
0.05
0.06
−18.41
0.41
0.00
7.53
0.21
0.34
0.20
0.21

SEQID-03350
0.05
0.05
0.05
0.06
0.05
0.02
0.06
0.06
−19.76
0.45
−0.02
5.86
0.20
0.33
0.00
0.20

SEQID-03351
0.02
0.04
0.04
0.02
0.05
0.07
0.10
0.05
−17.47
0.27
0.02
8.46
0.57
0.59
0.00
0.24

SEQID-03352
0.02
0.05
0.04
0.06
0.06
0.01
0.02
0.10
−20.36
0.52
0.02
8.82
0.85
0.94
0.00
0.25

SEQID-03353
0.04
0.08
0.05
0.07
0.03
0.03
0.00
0.07
−26.77
0.30
−0.02
5.42
0.69
0.81
0.19
0.21

SEQID-03354
0.03
0.05
0.01
0.05
0.04
0.03
0.03
0.04
−17.00
0.34
0.01
7.63
0.35
0.39
0.25
0.29

SEQID-03355
0.02
0.04
0.01
0.04
0.03
0.03
0.03
0.05
−18.73
0.33
0.01
7.63
0.38
0.43
0.25
0.34

SEQID-03356
0.02
0.06
0.04
0.03
0.06
0.03
0.06
0.06
−19.94
0.35
−0.01
6.51
0.20
0.33
0.00
0.22

SEQID-03357
0.03
0.02
0.04
0.05
0.05
0.05
0.00
0.13
−20.80
0.43
0.05
9.60
0.30
0.26
0.00
1.00

SEQID-03358
0.02
0.01
0.02
0.02
0.06
0.02
0.04
0.08
−24.50
0.28
0.19
12.27
0.20
0.29
0.00
0.26

SEQID-03359
0.02
0.06
0.03
0.04
0.05
0.01
0.04
0.07
−20.90
0.43
−0.02
5.34
0.21
0.33
0.00
0.22

SEQID-03360
0.02
0.04
0.05
0.05
0.04
0.00
0.03
0.04
−27.42
0.25
0.13
10.79
0.26
0.33
0.25
0.25

SEQID-03361
0.02
0.04
0.04
0.07
0.10
0.01
0.06
0.08
−9.68
0.87
0.02
9.72
0.66
0.34
0.26
0.25

SEQID-03362
0.03
0.06
0.05
0.03
0.02
0.01
0.03
0.06
−21.73
0.28
0.14
11.17
0.21
0.29
0.19
0.23

SEQID-03363
0.02
0.05
0.04
0.06
0.06
0.02
0.05
0.06
−22.51
0.37
−0.03
5.01
0.19
0.32
0.00
0.20

SEQID-03364
0.03
0.05
0.04
0.04
0.05
0.01
0.03
0.06
−22.74
0.37
0.11
10.93
0.19
0.32
0.00
0.20

SEQID-03365
0.04
0.04
0.03
0.05
0.10
0.01
0.05
0.08
−10.26
0.95
0.04
10.29
0.74
0.36
0.00
0.25

SEQID-03366
0.03
0.09
0.05
0.06
0.06
0.05
0.04
0.06
−12.29
0.53
0.04
9.54
0.31
0.42
0.00
0.22

SEQID-03367
0.03
0.04
0.05
0.09
0.05
0.02
0.05
0.06
−14.63
0.57
0.00
7.65
0.24
0.32
0.00
0.24

SEQID-03368
0.02
0.05
0.05
0.05
0.05
0.00
0.03
0.10
−16.64
0.55
0.00
6.28
0.54
0.73
0.00
0.00

SEQID-03369
0.04
0.05
0.08
0.03
0.05
0.04
0.04
0.04
−17.25
0.45
−0.03
4.77
0.21
0.36
0.00
0.00

SEQID-03370
0.06
0.05
0.04
0.00
0.04
0.00
0.02
0.05
−26.32
0.37
0.04
8.90
0.25
0.25
0.25
0.00

SEQID-03371
0.02
0.03
0.03
0.08
0.01
0.00
0.03
0.07
−20.23
0.45
0.10
10.98
0.26
0.32
0.25
0.24

SEQID-03372
0.02
0.04
0.04
0.07
0.09
0.01
0.05
0.09
−9.77
0.87
0.03
9.83
0.67
0.85
0.20
0.25

SEQID-03373
0.04
0.03
0.02
0.06
0.03
0.02
0.02
0.08
−17.25
0.59
−0.02
4.93
0.26
0.31
0.24
0.00

SEQID-03374
0.03
0.07
0.03
0.06
0.06
0.02
0.04
0.07
−19.34
0.47
0.04
9.86
0.57
0.84
0.24
0.24

SEQID-03375
0.02
0.03
0.02
0.03
0.08
0.00
0.02
0.04
−23.63
0.33
0.00
7.82
0.22
0.31
0.00
0.00

SEQID-03376
0.04
0.04
0.02
0.08
0.04
0.01
0.02
0.10
−16.89
0.58
0.03
9.87
0.27
0.37
0.19
0.00

SEQID-03377
0.03
0.02
0.04
0.06
0.05
0.03
0.03
0.10
−17.05
0.55
0.00
6.78
0.26
0.33
0.20
0.22

SEQID-03378
0.02
0.05
0.04
0.05
0.06
0.00
0.04
0.07
−19.37
0.46
−0.03
4.82
0.23
0.33
0.00
0.21

SEQID-03379
0.04
0.05
0.03
0.04
0.04
0.00
0.04
0.07
−23.44
0.42
−0.03
5.37
0.21
0.31
0.19
0.00

SEQID-03380
0.03
0.05
0.04
0.05
0.05
0.02
0.02
0.07
−16.45
0.54
−0.01
6.09
0.29
0.38
0.20
0.23

SEQID-03381
0.04
0.06
0.04
0.05
0.04
0.01
0.05
0.07
−21.01
0.38
−0.01
6.34
0.19
0.31
0.00
0.20

SEQID-03382
0.02
0.05
0.04
0.03
0.07
0.00
0.02
0.05
−23.57
0.30
0.15
11.86
0.23
0.31
0.26
0.00

SEQID-03383
0.03
0.07
0.04
0.04
0.05
0.01
0.04
0.09
−17.64
0.57
0.02
8.47
0.91
0.98
0.22
0.94

SEQID-03384
0.02
0.07
0.05
0.05
0.05
0.01
0.05
0.09
−17.85
0.54
0.00
7.45
0.94
0.96
0.00
0.94

SEQID-03385
0.02
0.04
0.02
0.03
0.08
0.00
0.02
0.05
−23.64
0.33
0.00
7.90
0.22
0.31
0.23
0.21

SEQID-03386
0.04
0.10
0.04
0.03
0.06
0.00
0.05
0.09
−19.69
0.44
0.05
9.49
0.85
0.33
0.00
0.85

SEQID-03387
0.01
0.07
0.06
0.07
0.05
0.01
0.05
0.07
−14.46
0.61
0.01
7.89
0.78
0.98
0.23
0.92

SEQID-03388
0.03
0.06
0.04
0.05
0.08
0.01
0.06
0.05
−17.52
0.43
−0.03
4.85
0.87
0.98
0.00
0.20

SEQID-03389
0.05
0.04
0.05
0.05
0.06
0.02
0.05
0.06
−19.76
0.44
−0.03
5.29
0.21
0.31
0.00
0.21

SEQID-03390
0.01
0.06
0.06
0.05
0.06
0.03
0.05
0.05
−20.16
0.37
−0.02
5.65
0.19
0.35
0.00
0.20

SEQID-03391
0.03
0.04
0.05
0.08
0.06
0.00
0.02
0.04
−26.28
0.23
0.13
10.87
0.28
0.32
0.25
0.26

SEQID-03392
0.02
0.03
0.01
0.02
0.06
0.00
0.06
0.07
−23.82
0.31
0.18
12.01
0.00
0.28
0.00
0.29

SEQID-03393
0.03
0.04
0.06
0.05
0.04
0.00
0.10
0.05
−16.95
0.53
0.00
7.08
0.25
0.32
0.26
0.98

SEQID-03394
0.04
0.05
0.04
0.06
0.09
0.01
0.07
0.05
−17.36
0.37
−0.03
4.65
0.95
1.00
0.00
0.00

SEQID-03395
0.01
0.02
0.02
0.04
0.05
0.02
0.06
0.06
−26.96
0.40
−0.03
5.23
0.24
0.34
0.00
0.00

SEQID-03396
0.03
0.06
0.03
0.05
0.05
0.03
0.04
0.09
−20.88
0.47
0.00
6.80
0.86
0.93
0.23
0.21

SEQID-03397
0.02
0.05
0.04
0.03
0.06
0.03
0.03
0.08
−24.40
0.39
−0.02
5.55
0.21
0.34
0.00
0.20

SEQID-03398
0.03
0.04
0.04
0.04
0.06
0.01
0.03
0.06
−22.95
0.36
−0.02
4.83
0.72
0.91
0.19
0.20

SEQID-03399
0.04
0.02
0.03
0.07
0.03
0.00
0.05
0.05
−29.35
0.21
0.02
9.01
0.98
0.69
0.00
0.34

SEQID-03400
0.03
0.06
0.01
0.03
0.06
0.04
0.04
0.06
−20.96
0.45
0.00
6.96
0.22
0.31
0.00
0.25

SEQID-03401
0.03
0.05
0.05
0.04
0.06
0.01
0.04
0.08
−22.02
0.41
0.03
9.66
0.21
0.35
0.21
0.22

SEQID-03402
0.09
0.13
0.03
0.06
0.06
0.00
0.00
0.02
−18.17
0.56
0.07
8.61
0.29
0.29
0.30
0.28

SEQID-03403
0.04
0.04
0.04
0.05
0.09
0.00
0.01
0.05
−23.24
0.34
0.08
11.26
0.23
0.30
0.22
0.23

SEQID-03404
0.01
0.05
0.03
0.05
0.04
0.04
0.09
0.04
−18.45
0.29
−0.02
5.06
0.24
0.33
0.00
0.24

SEQID-03405
0.01
0.03
0.04
0.08
0.01
0.00
0.03
0.07
−18.26
0.35
0.09
11.09
0.25
0.31
0.27
0.22

SEQID-03406
0.02
0.03
0.05
0.06
0.06
0.00
0.10
0.04
−15.35
0.46
0.00
6.76
0.24
0.32
0.25
0.81

SEQID-03407
0.03
0.06
0.04
0.04
0.04
0.02
0.06
0.08
−19.27
0.53
−0.02
5.37
0.21
0.33
0.20
0.22

SEQID-03408
0.02
0.08
0.06
0.04
0.05
0.02
0.06
0.06
−21.28
0.28
0.00
7.03
0.39
0.56
0.00
0.21

SEQID-03409
0.02
0.05
0.04
0.06
0.06
0.03
0.05
0.07
−19.93
0.41
0.00
6.59
0.88
1.00
0.00
0.20

SEQID-03410
0.06
0.03
0.05
0.04
0.03
0.02
0.02
0.09
−19.41
0.55
0.12
11.19
0.25
0.30
0.25
0.24

SEQID-03411
0.02
0.07
0.05
0.05
0.05
0.01
0.05
0.09
−18.21
0.52
−0.04
4.58
0.82
0.91
0.21
0.82

SEQID-03412
0.03
0.03
0.05
0.03
0.05
0.02
0.05
0.06
−19.98
0.38
0.00
7.14
0.72
0.32
0.23
0.22

SEQID-03413
0.02
0.04
0.03
0.05
0.04
0.02
0.05
0.08
−20.30
0.40
−0.01
5.55
0.89
0.96
0.21
0.22

SEQID-03414
0.03
0.05
0.04
0.04
0.05
0.01
0.07
0.06
−18.95
0.51
−0.01
5.86
0.20
0.33
0.00
0.20

SEQID-03415
0.04
0.09
0.03
0.08
0.05
0.01
0.05
0.07
−13.29
0.89
−0.02
4.72
0.20
0.34
0.21
0.20

SEQID-03416
0.04
0.04
0.04
0.03
0.07
0.02
0.02
0.02
−21.96
0.35
0.12
11.31
0.24
0.31
0.00
0.28

SEQID-03417
0.04
0.08
0.04
0.03
0.08
0.02
0.00
0.08
−26.04
0.20
0.12
10.98
0.28
0.29
0.00
0.18

SEQID-03418
0.06
0.02
0.03
0.02
0.02
0.00
0.08
0.09
−23.37
0.42
0.04
9.88
0.30
0.27
0.26
0.19

SEQID-03419
0.02
0.02
0.00
0.08
0.05
0.00
0.03
0.08
−24.14
0.27
−0.03
4.99
0.31
0.24
0.33
0.31

SEQID-03420
0.02
0.04
0.03
0.07
0.02
0.01
0.04
0.06
−23.80
0.29
0.00
7.24
0.23
0.33
0.22
0.21

SEQID-03421
0.03
0.04
0.01
0.05
0.05
0.01
0.05
0.04
−22.10
0.45
0.22
12.43
0.23
0.29
0.00
0.25

SEQID-03422
0.04
0.04
0.04
0.03
0.08
0.02
0.02
0.03
−20.50
0.33
0.15
11.74
0.26
0.29
0.00
0.25

SEQID-03423
0.01
0.04
0.05
0.05
0.04
0.04
0.03
0.05
−20.61
0.42
−0.02
5.73
0.21
0.33
0.20
0.22

SEQID-03424
0.01
0.01
0.04
0.08
0.04
0.03
0.04
0.01
−23.48
0.39
0.17
12.30
0.27
0.30
0.30
0.25

SEQID-03425
0.02
0.05
0.01
0.04
0.03
0.02
0.04
0.04
−37.76
0.22
−0.30
3.51
0.21
0.30
0.13
0.23

SEQID-03426
0.01
0.04
0.03
0.05
0.07
0.03
0.04
0.06
−23.41
0.28
−0.02
6.39
0.00
0.33
0.00
0.23

SEQID-03427
0.02
0.02
0.04
0.06
0.05
0.03
0.04
0.04
−21.76
0.33
−0.01
5.87
0.21
0.33
0.22
0.25

SEQID-03428
0.02
0.02
0.05
0.08
0.05
0.00
0.03
0.03
−20.38
0.35
0.01
8.68
0.22
0.33
0.00
0.23

SEQID-03429
0.06
0.05
0.06
0.06
0.02
0.01
0.02
0.06
−21.84
0.28
0.08
10.52
0.25
0.33
0.00
0.27

SEQID-03430
0.02
0.00
0.03
0.10
0.08
0.00
0.00
0.01
−24.63
0.17
0.00
6.95
0.29
0.25
0.32
0.32

SEQID-03431
0.02
0.04
0.02
0.05
0.04
0.03
0.01
0.02
−34.55
0.18
0.11
10.64
0.22
0.32
0.00
0.22

SEQID-03432
0.04
0.05
0.03
0.05
0.07
0.02
0.02
0.02
−23.50
0.27
0.15
11.53
0.25
0.28
0.00
0.00

SEQID-03433
0.01
0.01
0.07
0.04
0.03
0.00
0.00
0.03
−21.17
0.34
−0.03
5.07
0.27
0.35
0.27
0.26

SEQID-03434
0.01
0.04
0.00
0.06
0.05
0.01
0.06
0.02
−24.25
0.30
0.24
12.58
0.25
0.28
0.00
0.23

SEQID-03435
0.03
0.00
0.02
0.04
0.00
0.00
0.00
0.04
−28.57
0.45
0.33
12.42
0.34
0.16
0.32
0.30

SEQID-03436
0.07
0.05
0.05
0.05
0.05
0.01
0.02
0.07
−20.41
0.43
−0.01
6.26
0.22
0.30
0.26
0.23

SEQID-03437
0.07
0.13
0.03
0.05
0.05
0.02
0.07
0.01
−21.35
0.15
−0.12
3.96
0.22
0.20
0.21
0.27

SEQID-03438
0.02
0.07
0.03
0.06
0.04
0.02
0.05
0.05
−27.53
0.31
−0.26
3.23
0.24
0.28
0.00
0.24

SEQID-03439
0.00
0.03
0.03
0.05
0.06
0.09
0.03
0.07
−20.71
0.39
−0.06
4.55
0.18
0.32
0.00
0.23

SEQID-03440
0.00
0.03
0.03
0.06
0.05
0.09
0.03
0.08
−21.25
0.33
−0.05
4.65
0.21
0.32
0.22
0.22

SEQID-03441
0.02
0.00
0.03
0.00
0.11
0.00
0.00
0.13
−20.61
0.26
0.09
11.27
0.30
0.23
0.00
0.29

SEQID-03442
0.04
0.08
0.04
0.02
0.08
0.02
0.00
0.08
−26.48
0.23
0.12
11.03
0.26
0.27
0.00
0.00

SEQID-03443
0.04
0.08
0.04
0.04
0.08
0.02
0.00
0.08
−25.24
0.20
0.13
11.21
0.26
0.27
0.00
0.00

SEQID-03444
0.01
0.02
0.16
0.09
0.04
0.01
0.06
0.05
−15.46
0.16
0.03
8.07
0.22
0.36
0.20
0.24

SEQID-03445
0.02
0.02
0.02
0.09
0.04
0.01
0.04
0.03
−28.10
0.11
−0.05
4.66
0.23
0.38
0.00
0.21

SEQID-03446
0.03
0.06
0.04
0.05
0.05
0.01
0.02
0.06
−22.29
0.42
−0.03
5.11
0.22
0.33
0.00
0.23

SEQID-03447
0.00
0.02
0.10
0.27
0.03
0.00
0.04
0.06
−8.13
0.28
0.02
8.77
0.25
0.52
0.22
0.27

SEQID-03448
0.02
0.01
0.02
0.07
0.05
0.01
0.03
0.05
−23.80
0.25
−0.02
5.21
0.25
0.36
0.20
0.22

SEQID-03449
0.04
0.04
0.01
0.09
0.03
0.01
0.05
0.05
−18.68
0.26
0.01
8.78
0.69
0.89
0.21
0.21

SEQID-03450
0.02
0.08
0.01
0.10
0.04
0.00
0.03
0.05
−16.79
0.24
−0.01
5.68
0.62
0.91
0.21
0.22

SEQID-03451
0.02
0.03
0.11
0.03
0.05
0.05
0.03
0.05
−19.27
0.23
−0.01
6.42
0.22
0.32
0.23
0.25

SEQID-03452
0.05
0.02
0.03
0.09
0.04
0.01
0.04
0.05
−27.05
0.26
0.15
10.77
0.23
0.30
0.23
0.25

SEQID-03453
0.03
0.03
0.02
0.05
0.04
0.01
0.05
0.02
−24.50
0.11
0.03
7.86
0.24
0.31
0.26
0.26

SEQID-03454
0.03
0.02
0.04
0.06
0.05
0.03
0.04
0.04
−22.24
0.31
−0.02
5.35
0.23
0.34
0.22
0.25

SEQID-03455
0.02
0.03
0.02
0.00
0.03
0.01
0.04
0.05
−39.36
0.23
−0.30
3.73
0.27
0.35
0.22
0.29

SEQID-03456
0.01
0.00
0.11
0.02
0.01
0.00
0.00
0.02
−33.42
0.00
0.11
10.67
0.32
0.31
0.30
0.31

SEQID-03457
0.01
0.00
0.11
0.03
0.02
0.00
0.00
0.02
−33.41
0.00
0.13
10.79
0.30
0.31
0.30
0.30

SEQID-03458
0.01
0.06
0.06
0.09
0.04
0.01
0.04
0.02
−20.51
0.13
0.13
11.83
0.26
0.31
0.00
0.27

SEQID-03459
0.03
0.00
0.03
0.04
0.02
0.00
0.05
0.03
−36.62
0.10
0.50
12.47
0.29
0.18
0.34
0.31

SEQID-03460
0.04
0.04
0.03
0.05
0.07
0.01
0.04
0.05
−20.18
0.49
0.00
6.51
0.22
0.32
0.33
0.24

SEQID-03461
0.01
0.05
0.05
0.03
0.06
0.01
0.04
0.09
−24.13
0.37
0.10
10.78
0.23
0.33
0.00
0.26

SEQID-03462
0.05
0.04
0.03
0.03
0.04
0.04
0.06
0.03
−30.24
0.13
−0.01
6.54
0.27
0.31
0.00
0.00

SEQID-03463
0.04
0.00
0.03
0.05
0.04
0.01
0.05
0.02
−24.71
0.14
0.10
11.18
0.00
0.31
0.25
0.00

SEQID-03464
0.07
0.05
0.02
0.04
0.02
0.03
0.03
0.02
−20.78
0.43
0.15
13.24
0.25
0.28
0.21
0.22

SEQID-03465
0.03
0.00
0.01
0.07
0.05
0.02
0.09
0.02
−25.38
0.12
0.08
10.34
0.24
0.27
0.00
0.00

SEQID-03466
0.02
0.00
0.03
0.07
0.02
0.02
0.05
0.05
−24.70
0.38
0.15
11.02
0.22
0.26
0.00
0.00

SEQID-03467
0.04
0.06
0.04
0.13
0.04
0.03
0.05
0.04
−24.12
0.22
0.27
12.15
0.28
0.21
0.28
0.26

SEQID-03468
0.04
0.04
0.00
0.03
0.02
0.09
0.00
0.03
−21.62
0.41
0.20
12.60
0.30
0.20
0.28
0.30

SEQID-03469
0.10
0.03
0.03
0.03
0.03
0.04
0.00
0.03
−26.22
0.36
0.01
9.11
0.26
0.26
0.00
0.00

SEQID-03470
0.02
0.02
0.04
0.06
0.05
0.03
0.04
0.04
−23.20
0.32
−0.02
5.35
0.23
0.33
0.22
0.25

SEQID-03471
0.01
0.00
0.09
0.04
0.04
0.00
0.00
0.00
−38.40
0.01
0.07
10.23
0.32
0.32
0.27
0.29

SEQID-03472
0.02
0.03
0.03
0.05
0.01
0.02
0.01
0.04
−20.01
0.23
0.02
8.25
0.31
0.30
0.34
0.30

SEQID-03473
0.02
0.00
0.00
0.09
0.03
0.00
0.10
0.01
−45.36
0.00
0.63
13.20
0.30
0.21
0.34
0.27

SEQID-03474
0.02
0.07
0.06
0.11
0.03
0.01
0.03
0.03
−20.32
0.14
0.14
12.12
0.25
0.31
0.00
0.25

SEQID-03475
0.04
0.04
0.02
0.05
0.07
0.01
0.04
0.04
−20.61
0.43
0.00
7.29
0.23
0.31
0.24
0.24

SEQID-03476
0.02
0.04
0.01
0.05
0.05
0.01
0.07
0.04
−21.37
0.41
0.21
12.16
0.21
0.29
0.18
0.00

SEQID-03477
0.03
0.06
0.04
0.03
0.00
0.04
0.00
0.02
−20.63
0.09
0.16
9.35
0.35
0.20
0.34
0.32

SEQID-03478
0.00
0.06
0.04
0.03
0.00
0.04
0.00
0.06
−20.63
0.16
0.12
8.80
0.36
0.21
0.33
0.32

SEQID-03479
0.03
0.00
0.06
0.02
0.05
0.06
0.04
0.05
−23.08
0.39
0.01
8.46
0.30
0.35
0.23
0.00

SEQID-03480
0.03
0.02
0.03
0.04
0.02
0.05
0.04
0.03
−25.60
0.37
0.12
10.07
0.25
0.30
0.25
0.28

SEQID-03481
0.01
0.09
0.03
0.05
0.06
0.05
0.05
0.04
−23.17
0.35
−0.04
5.01
0.20
0.32
0.21
0.00

SEQID-03482
0.04
0.03
0.06
0.05
0.05
0.02
0.03
0.06
−24.86
0.31
0.01
8.90
0.25
0.33
0.00
0.00

SEQID-03483
0.02
0.07
0.02
0.03
0.03
0.03
0.01
0.03
−24.64
0.35
0.04
9.60
0.25
0.32
0.00
0.19

SEQID-03484
0.04
0.06
0.04
0.04
0.07
0.02
0.02
0.03
−22.32
0.36
0.18
11.65
0.24
0.26
0.00
0.27

SEQID-03485
0.04
0.05
0.06
0.07
0.07
0.00
0.02
0.04
−20.22
0.43
0.00
6.06
0.19
0.35
0.00
0.00

SEQID-03486
0.05
0.01
0.00
0.05
0.09
0.04
0.06
0.07
−21.49
0.30
0.21
11.05
0.19
0.28
0.28
0.24

SEQID-03487
0.11
0.03
0.04
0.05
0.09
0.01
0.01
0.04
−22.55
0.26
0.10
12.41
0.23
0.37
0.22
0.00

SEQID-03488
0.05
0.03
0.01
0.04
0.09
0.01
0.01
0.06
−22.64
0.42
−0.06
4.32
0.22
0.29
0.22
0.22

SEQID-03489
0.01
0.02
0.04
0.02
0.09
0.05
0.01
0.02
−27.29
0.11
0.14
10.34
0.22
0.30
0.26
0.25

SEQID-03490
0.03
0.06
0.03
0.05
0.05
0.00
0.07
0.05
−25.31
0.43
−0.02
5.41
0.22
0.34
0.00
0.00

SEQID-03491
0.01
0.03
0.02
0.07
0.05
0.01
0.03
0.03
−24.17
0.20
−0.03
5.20
0.23
0.32
0.00
0.25

SEQID-03492
0.07
0.09
0.03
0.02
0.11
0.01
0.05
0.03
−20.36
0.49
0.09
10.76
0.23
0.30
0.18
0.26

SEQID-03493
0.02
0.07
0.02
0.10
0.06
0.06
0.03
0.05
−23.62
0.33
0.31
12.73
0.35
0.34
0.29
0.24

SEQID-03494
0.04
0.04
0.02
0.05
0.03
0.01
0.05
0.04
−30.69
0.48
0.00
7.29
0.21
0.31
0.22
0.24

SEQID-03495
0.02
0.00
0.06
0.08
0.06
0.00
0.00
0.01
−23.02
0.18
−0.05
4.51
0.28
0.24
0.33
0.30

SEQID-03496
0.03
0.04
0.01
0.07
0.03
0.02
0.01
0.03
−34.51
0.02
0.15
10.95
0.27
0.31
0.00
0.28

SEQID-03497
0.01
0.06
0.02
0.06
0.05
0.03
0.02
0.03
−23.27
0.32
0.04
10.07
0.21
0.33
0.00
0.00

SEQID-03498
0.02
0.00
0.05
0.05
0.09
0.01
0.06
0.05
−28.10
0.22
−0.10
4.15
0.27
0.32
0.27
0.00

SEQID-03499
0.03
0.10
0.05
0.08
0.03
0.00
0.04
0.03
−20.87
0.44
0.14
11.02
0.25
0.31
0.25
0.23

SEQID-03500
0.01
0.05
0.01
0.04
0.07
0.01
0.08
0.04
−20.42
0.41
−0.08
4.18
0.00
0.33
0.00
0.00

SEQID-03501
0.02
0.05
0.04
0.05
0.03
0.01
0.03
0.04
−34.30
0.20
0.02
9.53
0.25
0.32
0.21
0.26

SEQID-03502
0.02
0.04
0.05
0.05
0.02
0.01
0.04
0.04
−37.06
0.18
−0.03
4.96
0.24
0.31
0.21
0.26

SEQID-03503
0.01
0.01
0.01
0.08
0.03
0.03
0.06
0.04
−21.65
0.32
0.13
11.37
0.28
0.30
0.00
0.26

SEQID-03504
0.04
0.00
0.03
0.09
0.05
0.00
0.03
0.09
−21.49
0.33
−0.07
4.18
0.28
0.22
0.33
0.28

SEQID-03505
0.02
0.05
0.03
0.06
0.09
0.02
0.06
0.03
−23.32
0.27
−0.02
6.29
0.22
0.32
0.00
0.00

SEQID-03506
0.04
0.01
0.01
0.05
0.07
0.01
0.05
0.05
−25.65
0.19
0.04
9.69
0.27
0.30
0.00
0.26

SEQID-03507
0.03
0.06
0.04
0.06
0.04
0.01
0.05
0.03
−20.67
0.37
0.00
6.69
0.18
0.33
0.00
0.20

SEQID-03508
0.03
0.02
0.02
0.01
0.02
0.01
0.05
0.06
−31.80
0.29
−0.04
4.84
0.21
0.30
0.20
0.00

SEQID-03509
0.02
0.02
0.04
0.06
0.05
0.03
0.04
0.04
−21.76
0.32
−0.01
5.87
0.31
0.33
0.22
0.25

SEQID-03510
0.01
0.06
0.03
0.06
0.03
0.01
0.04
0.04
−20.40
0.31
−0.03
4.96
0.30
0.31
0.00
0.20

SEQID-03511
0.02
0.04
0.02
0.06
0.04
0.03
0.01
0.02
−34.54
0.18
0.11
10.66
0.23
0.32
0.00
0.22

SEQID-03512
0.06
0.03
0.03
0.03
0.07
0.00
0.03
0.08
−21.60
0.44
0.14
11.38
0.22
0.30
0.00
0.21

SEQID-03513
0.01
0.07
0.03
0.03
0.04
0.02
0.04
0.06
−22.41
0.48
−0.01
6.17
0.24
0.34
0.24
0.00

SEQID-03514
0.02
0.00
0.06
0.08
0.06
0.00
0.00
0.01
−23.02
0.22
−0.05
4.51
0.39
0.25
0.33
0.31

SEQID-03515
0.05
0.04
0.05
0.04
0.09
0.02
0.03
0.06
−22.65
0.33
0.11
10.98
0.33
0.28
0.00
0.00

SEQID-03516
0.03
0.04
0.01
0.07
0.03
0.01
0.06
0.06
−22.44
0.28
0.06
10.10
0.00
0.33
0.00
0.00

SEQID-03517
0.02
0.07
0.02
0.11
0.05
0.06
0.03
0.03
−23.64
0.23
0.31
12.59
0.31
0.20
0.26
0.29

SEQID-03518
0.02
0.06
0.03
0.03
0.03
0.02
0.02
0.03
−25.15
0.34
0.03
9.43
0.25
0.31
0.23
0.21

SEQID-03519
0.03
0.03
0.03
0.02
0.04
0.00
0.02
0.09
−22.86
0.50
−0.02
5.88
0.19
0.31
0.00
0.22

SEQID-03520
0.01
0.00
0.11
0.03
0.01
0.00
0.00
0.03
−33.31
0.00
0.13
10.79
0.31
0.32
0.29
0.31

SEQID-03521
0.01
0.09
0.05
0.01
0.02
0.02
0.03
0.14
−24.48
0.31
−0.02
5.75
0.27
0.30
0.00
0.26

SEQID-03522
0.01
0.06
0.07
0.03
0.04
0.01
0.04
0.02
−20.66
0.12
0.13
11.83
0.25
0.33
0.00
0.28

SEQID-03523
0.03
0.09
0.06
0.05
0.04
0.04
0.03
0.02
−20.10
0.31
0.06
8.20
0.33
0.19
0.33
0.31

SEQID-03524
0.07
0.03
0.02
0.01
0.04
0.02
0.08
0.03
−28.01
0.20
0.13
10.72
0.25
0.27
0.00
0.25

SEQID-03525
0.01
0.06
0.06
0.09
0.04
0.01
0.03
0.03
−21.42
0.14
0.13
11.89
0.38
0.33
0.00
0.27

SEQID-03526
0.03
0.06
0.02
0.03
0.04
0.02
0.02
0.05
−23.48
0.35
0.01
7.23
0.25
0.31
0.22
0.22

SEQID-03527
0.05
0.05
0.05
0.01
0.01
0.01
0.06
0.04
−29.27
0.21
0.02
8.32
0.22
0.30
0.24
0.24

SEQID-03528
0.02
0.03
0.03
0.03
0.05
0.01
0.02
0.07
−21.60
0.44
−0.02
6.04
0.20
0.32
0.24
0.00

SEQID-03529
0.03
0.02
0.03
0.05
0.03
0.01
0.06
0.09
−23.91
0.47
0.05
10.14
0.24
0.31
0.00
0.00

SEQID-03530
0.01
0.03
0.01
0.10
0.03
0.03
0.02
0.03
−34.65
0.13
0.16
10.91
0.23
0.33
0.24
0.25

SEQID-03531
0.02
0.02
0.01
0.06
0.06
0.05
0.00
0.07
−23.63
0.20
0.24
12.74
0.30
0.23
0.00
0.30

SEQID-03532
0.03
0.02
0.02
0.03
0.06
0.00
0.02
0.09
−23.72
0.40
−0.02
6.25
0.30
0.29
0.00
0.29

SEQID-03533
0.03
0.02
0.02
0.01
0.03
0.01
0.06
0.04
−26.72
0.24
0.11
10.79
0.23
0.29
0.24
0.25

SEQID-03534
0.02
0.07
0.03
0.06
0.04
0.02
0.05
0.05
−27.54
0.31
−0.26
3.23
0.25
0.30
0.00
0.24

SEQID-03535
0.03
0.05
0.01
0.04
0.04
0.01
0.07
0.06
−21.01
0.48
0.04
9.70
0.00
0.30
0.20
0.00

SEQID-03536
0.01
0.04
0.02
0.04
0.05
0.00
0.03
0.09
−20.34
0.46
0.00
6.82
0.22
0.32
0.00
0.00

SEQID-03537
0.02
0.06
0.01
0.07
0.04
0.02
0.06
0.07
−27.33
0.33
−0.24
3.35
0.27
0.31
0.24
0.26

SEQID-03538
0.05
0.04
0.04
0.02
0.06
0.00
0.06
0.10
−23.10
0.36
0.02
8.98
0.27
0.24
0.00
0.27

SEQID-03539
0.00
0.09
0.04
0.04
0.04
0.01
0.04
0.09
−20.60
0.47
−0.01
6.61
0.21
0.31
0.00
0.22

SEQID-03540
0.02
0.07
0.01
0.06
0.04
0.02
0.04
0.06
−30.13
0.36
−0.29
3.26
0.29
0.32
0.23
0.24

SEQID-03541
0.03
0.06
0.04
0.09
0.03
0.03
0.02
0.02
−20.94
0.29
0.04
10.11
0.22
0.33
0.00
0.22

SEQID-03542
0.03
0.01
0.05
0.04
0.02
0.01
0.02
0.10
−22.09
0.50
−0.02
5.44
0.22
0.31
0.20
0.22

SEQID-03543
0.04
0.05
0.01
0.04
0.03
0.02
0.03
0.04
−37.89
0.20
−0.30
3.53
0.23
0.31
0.00
0.22

SEQID-03544
0.02
0.09
0.03
0.03
0.06
0.01
0.04
0.09
−26.74
0.38
0.17
11.00
0.24
0.30
0.23
0.29

SEQID-03545
0.04
0.06
0.04
0.11
0.03
0.03
0.05
0.03
−24.11
0.18
0.27
12.15
0.31
0.23
0.00
0.27

SEQID-03546
0.05
0.03
0.03
0.05
0.04
0.01
0.06
0.03
−24.14
0.36
0.01
8.21
0.18
0.29
0.25
0.25

SEQID-03547
0.01
0.05
0.01
0.09
0.04
0.01
0.05
0.02
−20.44
0.34
−0.07
4.32
0.24
0.33
0.25
0.21

SEQID-03548
0.02
0.05
0.03
0.03
0.01
0.02
0.03
0.06
−24.19
0.35
0.09
3.87
0.20
0.30
0.28
0.29

SEQID-03549
0.01
0.06
0.05
0.04
0.05
0.01
0.05
0.04
−21.47
0.39
−0.01
5.98
0.23
0.34
0.00
0.25

SEQID-03550
0.04
0.03
0.03
0.04
0.04
0.08
0.00
0.05
−22.98
0.25
−0.03
5.60
0.24
0.26
0.23
0.22

SEQID-03551
0.01
0.04
0.03
0.02
0.00
0.00
0.07
0.02
−30.43
0.46
0.38
12.96
0.25
0.28
0.24
0.21

SEQID-03552
0.05
0.05
0.04
0.03
0.06
0.03
0.06
0.00
−21.47
0.39
−0.01
6.51
0.22
0.12
0.26
0.31

SEQID-03553
0.03
0.03
0.02
0.03
0.05
0.01
0.04
0.04
−23.53
0.48
0.13
11.75
0.22
0.30
0.00
0.24

SEQID-03554
0.03
0.03
0.00
0.06
0.04
0.01
0.07
0.04
−22.98
0.39
0.23
12.48
0.21
0.29
0.00
0.23

SEQID-03555
0.01
0.09
0.01
0.03
0.01
0.11
0.01
0.04
−33.41
0.19
−0.02
5.58
0.21
0.34
0.19
0.00

SEQID-03556
0.05
0.06
0.02
0.02
0.03
0.01
0.05
0.04
−21.03
0.45
0.02
7.83
0.19
0.29
0.25
0.26

SEQID-03557
0.09
0.06
0.05
0.04
0.03
0.01
0.03
0.07
−20.34
0.44
−0.01
6.51
0.21
0.33
0.00
0.23

SEQID-03558
0.02
0.13
0.01
0.06
0.05
0.01
0.04
0.04
−20.27
0.31
0.01
3.43
0.21
0.31
0.26
0.25

SEQID-03559
0.01
0.05
0.02
0.07
0.05
0.01
0.04
0.04
−21.00
0.47
−0.02
5.09
0.19
0.35
0.00
0.20

SEQID-03560
0.02
0.04
0.00
0.05
0.05
0.01
0.07
0.01
−21.98
0.35
0.21
12.36
0.25
0.27
0.25
0.23

SEQID-03561
0.09
0.03
0.07
0.06
0.03
0.02
0.05
0.04
−23.21
0.17
0.05
8.98
0.24
0.25
0.26
0.27

SEQID-03562
0.03
0.05
0.04
0.04
0.04
0.00
0.09
0.07
−20.11
0.48
−0.01
5.42
0.24
0.32
0.00
0.24

SEQID-03563
0.02
0.04
0.03
0.09
0.10
0.05
0.00
0.10
−21.01
0.16
0.23
12.72
0.28
0.21
0.00
0.31

SEQID-03564
0.04
0.05
0.01
0.04
0.03
0.02
0.03
0.04
−37.86
0.21
−0.30
3.53
0.22
0.31
0.00
0.22

SEQID-03565
0.01
0.07
0.03
0.05
0.04
0.02
0.06
0.02
−23.04
0.33
0.01
7.44
0.24
0.30
0.23
0.21

SEQID-03566
0.04
0.05
0.02
0.02
0.03
0.01
0.07
0.04
−21.55
0.44
0.04
8.27
0.25
0.30
0.24
0.25

SEQID-03567
0.01
0.04
0.06
0.04
0.06
0.02
0.03
0.04
−22.19
0.29
−0.09
4.12
0.21
0.31
0.26
0.24

SEQID-03568
0.02
0.03
0.00
0.06
0.04
0.01
0.06
0.03
−24.22
0.33
0.24
12.55
0.23
0.29
0.00
0.22

SEQID-03569
0.03
0.05
0.05
0.01
0.06
0.03
0.07
0.05
−21.51
0.27
0.02
7.62
0.26
0.28
0.26
0.27

SEQID-03570
0.04
0.04
0.04
0.05
0.08
0.02
0.02
0.03
−21.28
0.35
0.11
11.14
0.24
0.28
0.00
0.27

SEQID-03571
0.02
0.00
0.07
0.09
0.06
0.00
0.00
0.01
−23.06
0.21
−0.05
4.50
0.30
0.25
0.33
0.33

SEQID-03572
0.02
0.02
0.06
0.04
0.03
0.01
0.02
0.06
−24.00
0.34
0.00
6.80
0.22
0.30
0.00
0.21

SEQID-03573
0.06
0.00
0.02
0.03
0.04
0.04
0.01
0.05
−33.26
0.16
0.18
11.10
0.30
0.32
0.25
0.23

SEQID-03574
0.02
0.09
0.03
0.06
0.04
0.02
0.07
0.03
−22.16
0.27
0.02
7.57
0.21
0.33
0.23
0.24

SEQID-03575
0.09
0.04
0.01
0.02
0.02
0.03
0.04
0.03
−23.30
0.22
0.06
10.14
0.22
0.29
0.28
0.24

SEQID-03576
0.00
0.03
0.03
0.09
0.05
0.08
0.03
0.07
−20.50
0.40
−0.06
4.47
0.21
0.32
0.00
0.22

SEQID-03577
0.04
0.04
0.04
0.04
0.07
0.03
0.02
0.03
−21.01
0.39
0.13
11.51
0.28
0.31
0.00
0.28

SEQID-03578
0.03
0.00
0.02
0.04
0.00
0.00
0.00
0.04
−30.44
0.26
0.35
12.51
0.34
0.16
0.29
0.30

SEQID-03579
0.07
0.01
0.06
0.05
0.04
0.02
0.06
0.01
−22.91
0.12
−0.03
5.10
0.25
0.29
0.23
0.25

SEQID-03580
0.06
0.07
0.04
0.06
0.04
0.00
0.11
0.07
−20.66
0.47
0.16
10.79
0.31
0.15
0.29
0.32

SEQID-03581
0.01
0.00
0.04
0.06
0.06
0.00
0.00
0.04
−31.33
0.10
0.28
11.81
0.24
0.29
0.00
0.25

SEQID-03582
0.02
0.05
0.02
0.13
0.09
0.00
0.00
0.03
−21.40
0.48
0.15
12.39
0.26
0.17
0.00
0.28

SEQID-03583
0.04
0.05
0.05
0.04
0.00
0.15
0.00
0.00
−21.55
0.34
0.10
11.60
0.28
0.17
0.31
0.31

SEQID-03584
0.12
0.00
0.00
0.10
0.09
0.04
0.09
0.02
−21.49
0.40
−0.06
4.43
0.30
0.17
0.29
0.00

SEQID-03585
0.01
0.01
0.08
0.03
0.03
0.06
0.04
0.03
−24.54
0.11
0.00
6.92
0.28
0.30
0.25
0.30

SEQID-03586
0.01
0.03
0.02
0.06
0.03
0.01
0.05
0.02
−24.37
0.12
0.02
7.74
0.24
0.30
0.27
0.26

SEQID-03587
0.01
0.00
0.03
0.03
0.06
0.02
0.01
0.05
−26.49
0.18
0.08
10.72
0.23
0.32
0.27
0.00

SEQID-03588
0.03
0.02
0.00
0.01
0.06
0.04
0.09
0.07
−24.87
0.30
0.03
8.70
0.24
0.22
0.00
0.00

SEQID-03589
0.08
0.02
0.04
0.03
0.02
0.02
0.09
0.07
−21.33
0.38
−0.07
4.34
0.25
0.28
0.00
0.00

SEQID-03590
0.05
0.04
0.04
0.03
0.09
0.02
0.02
0.03
−22.89
0.36
0.09
10.89
0.24
0.28
0.00
0.26

SEQID-03591
0.05
0.02
0.04
0.02
0.03
0.02
0.03
0.05
−21.51
0.26
0.03
10.64
0.26
0.33
0.20
0.28

SEQID-03592
0.01
0.02
0.02
0.05
0.05
0.03
0.09
0.06
−25.97
0.21
0.14
10.63
0.22
0.32
0.00
0.19

SEQID-03593
0.06
0.00
0.02
0.04
0.00
0.00
0.00
0.02
−30.48
0.37
0.35
12.51
0.29
0.14
0.29
0.29

SEQID-03594
0.09
0.02
0.03
0.05
0.03
0.01
0.01
0.06
−28.02
0.34
−0.03
4.85
0.23
0.32
0.00
0.00

SEQID-03595
0.04
0.02
0.07
0.05
0.03
0.01
0.02
0.02
−24.47
0.12
0.26
12.35
0.23
0.34
0.23
0.26

SEQID-03596
0.09
0.03
0.04
0.05
0.03
0.04
0.00
0.04
−22.88
0.26
0.09
10.76
0.27
0.27
0.27
0.24

SEQID-03597
0.02
0.03
0.03
0.03
0.04
0.00
0.03
0.07
−25.66
0.39
−0.04
4.87
0.26
0.30
0.24
0.25

SEQID-03598
0.01
0.04
0.05
0.05
0.04
0.04
0.03
0.05
−20.75
0.41
−0.03
5.31
0.21
0.33
0.20
0.21

SEQID-03599
0.02
0.04
0.04
0.07
0.06
0.00
0.02
0.04
−20.97
0.39
0.02
9.10
0.21
0.33
0.00
0.21

SEQID-03600
0.03
0.06
0.04
0.03
0.06
0.01
0.05
0.05
−22.46
0.32
−0.03
5.03
0.20
0.30
0.24
0.00

SEQID-03601
0.02
0.02
0.04
0.05
0.09
0.05
0.02
0.10
−24.18
0.14
0.25
12.31
0.27
0.31
0.30
0.30

SEQID-03602
0.01
0.04
0.04
0.04
0.08
0.03
0.03
0.06
−23.47
0.28
−0.03
5.59
0.22
0.31
0.22
0.20

SEQID-03603
0.02
0.04
0.02
0.05
0.04
0.00
0.03
0.08
−22.08
0.46
0.00
5.71
0.20
0.31
0.00
0.00

SEQID-03604
0.02
0.05
0.01
0.05
0.04
0.02
0.07
0.07
−27.64
0.33
−0.24
3.42
0.00
0.29
0.29
0.00

SEQID-03605
0.05
0.04
0.04
0.02
0.06
0.00
0.06
0.10
−23.12
0.36
0.02
8.98
0.25
0.23
0.00
0.30

SEQID-03606
0.02
0.02
0.01
0.06
0.04
0.00
0.00
0.17
−25.73
0.39
0.15
10.95
0.29
0.28
0.22
0.28

SEQID-03607
0.03
0.04
0.02
0.05
0.02
0.02
0.05
0.04
−36.23
0.21
−0.26
3.59
0.22
0.31
0.23
0.22

SEQID-03608
0.01
0.04
0.03
0.05
0.07
0.03
0.04
0.06
−23.92
0.27
−0.02
6.15
0.00
0.32
0.00
0.24

SEQID-03609
0.05
0.00
0.03
0.03
0.02
0.04
0.01
0.04
−32.73
0.13
0.19
11.18
0.25
0.32
0.23
0.00

SEQID-03610
0.02
0.05
0.03
0.06
0.04
0.01
0.11
0.03
−22.40
0.17
0.00
7.41
0.21
0.34
0.21
0.23

SEQID-03611
0.01
0.00
0.10
0.04
0.03
0.00
0.00
0.03
−33.57
0.01
0.09
10.58
0.29
0.33
0.26
0.32

SEQID-03612
0.01
0.02
0.05
0.01
0.02
0.01
0.09
0.07
−22.57
0.29
0.03
8.10
0.28
0.30
0.00
0.00

SEQID-03613
0.09
0.03
0.04
0.07
0.02
0.04
0.00
0.06
−23.00
0.27
0.09
10.90
0.28
0.28
0.23
0.24

SEQID-03614
0.04
0.04
0.01
0.09
0.03
0.01
0.05
0.05
−18.44
0.28
0.01
8.63
0.68
0.39
0.21
0.21

SEQID-03615
0.01
0.01
0.04
0.04
0.03
0.01
0.04
0.06
−28.73
0.25
0.15
10.85
0.23
0.34
0.34
0.00

SEQID-03616
0.02
0.03
0.01
0.04
0.03
0.00
0.06
0.12
−23.86
0.38
−0.01
6.51
0.00
0.00
0.26
0.27

SEQID-03617
0.02
0.04
0.10
0.02
0.02
0.01
0.05
0.03
−21.83
0.41
0.15
12.23
0.28
0.31
0.28
0.28

SEQID-03618
0.03
0.02
0.05
0.03
0.06
0.01
0.02
0.08
−20.99
0.50
0.00
6.97
0.21
0.34
0.00
0.24

SEQID-03619
0.01
0.04
0.02
0.04
0.04
0.00
0.03
0.08
−20.09
0.47
0.00
7.10
0.22
0.35
0.23
0.00

SEQID-03620
0.02
0.05
0.01
0.04
0.01
0.01
0.07
0.06
−21.54
0.48
0.04
9.69
0.00
0.31
0.00
0.00

SEQID-03621
0.03
0.05
0.02
0.04
0.01
0.02
0.03
0.04
−35.16
0.19
−0.27
3.58
0.25
0.31
0.00
0.22

SEQID-03622
0.04
0.04
0.03
0.10
0.03
0.02
0.05
0.06
−20.52
0.33
0.02
8.89
0.00
0.33
0.24
0.24

SEQID-03623
0.01
0.03
0.01
0.09
0.03
0.02
0.05
0.04
−22.33
0.41
0.14
11.77
0.32
0.32
0.00
0.24

SEQID-03624
0.04
0.08
0.02
0.03
0.04
0.02
0.04
0.04
−25.73
0.39
−0.25
3.16
0.24
0.29
0.00
0.25

SEQID-03625
0.02
0.12
0.02
0.01
0.04
0.03
0.03
0.04
−22.01
0.50
−0.04
1.68
0.25
0.32
0.24
0.25

SEQID-03626
0.02
0.04
0.01
0.04
0.02
0.00
0.13
0.04
−24.81
0.22
−0.07
4.54
0.22
0.30
0.00
0.24

SEQID-03627
0.03
0.02
0.01
0.06
0.07
0.05
0.02
0.10
−23.81
0.15
0.24
12.43
0.31
0.24
0.00
0.26

SEQID-03628
0.02
0.03
0.01
0.11
0.09
0.02
0.06
0.06
−20.14
0.29
0.09
10.41
0.24
0.33
0.00
0.00

SEQID-03629
0.02
0.02
0.03
0.04
0.03
0.00
0.00
0.09
−21.66
0.47
0.11
11.35
0.31
0.23
0.26
0.00

SEQID-03630
0.02
0.04
0.02
0.05
0.03
0.02
0.05
0.04
−35.69
0.23
−0.29
3.45
0.20
0.30
0.24
0.21

SEQID-03631
0.05
0.07
0.03
0.05
0.05
0.02
0.05
0.06
−19.72
0.34
−0.06
4.46
0.40
0.54
0.00
0.22

SEQID-03632
0.02
0.02
0.02
0.04
0.05
0.01
0.01
0.02
−20.44
0.47
0.02
7.98
0.22
0.33
0.23
0.28

SEQID-03633
0.01
0.02
0.06
0.09
0.05
0.01
0.02
0.06
−27.34
0.22
−0.06
4.54
0.22
0.33
0.24
0.25

SEQID-03634
0.04
0.01
0.05
0.05
0.06
0.01
0.04
0.06
−17.51
0.47
−0.01
6.05
0.20
0.33
0.00
0.20

SEQID-03635
0.02
0.00
0.03
0.08
0.05
0.13
0.00
0.04
−23.52
0.09
0.13
9.75
0.37
0.16
0.33
0.33

SEQID-03636
0.03
0.07
0.00
0.10
0.04
0.04
0.04
0.09
−20.21
0.35
0.15
11.00
0.33
0.16
0.30
0.31

SEQID-03637
0.03
0.04
0.05
0.09
0.05
0.01
0.03
0.04
−21.12
0.13
0.02
7.73
0.20
0.33
0.00
0.00

SEQID-03638
0.03
0.04
0.05
0.09
0.05
0.01
0.03
0.04
−21.08
0.13
0.02
7.72
0.21
0.33
0.00
0.20

SEQID-03639
0.09
0.04
0.04
0.04
0.04
0.06
0.07
0.06
−20.76
0.41
0.02
9.59
0.23
0.31
0.21
0.00

SEQID-03640
0.02
0.04
0.05
0.09
0.05
0.01
0.02
0.04
−29.86
0.19
−0.08
4.39
0.22
0.34
0.00
0.23

SEQID-03641
0.01
0.02
0.20
0.04
0.03
0.01
0.02
0.03
−14.62
0.15
0.00
7.76
0.59
0.30
0.20
0.39

SEQID-03642
0.02
0.03
0.08
0.12
0.06
0.01
0.02
0.04
−20.93
0.21
0.00
7.12
0.18
0.38
0.19
0.19

SEQID-03643
0.02
0.00
0.02
0.02
0.04
0.00
0.00
0.15
−27.81
0.37
0.11
11.10
0.00
0.32
0.00
0.20

SEQID-03644
0.06
0.00
0.04
0.04
0.00
0.00
0.00
0.14
−23.87
0.48
0.25
12.14
0.29
0.13
0.32
0.33

SEQID-03645
0.01
0.01
0.03
0.00
0.09
0.00
0.05
0.03
−27.88
0.26
0.12
11.11
0.23
0.30
0.26
0.23

SEQID-03646
0.01
0.00
0.00
0.04
0.03
0.00
0.02
0.09
−21.23
0.40
0.16
11.45
0.29
0.30
0.00
0.30

SEQID-03647
0.09
0.00
0.01
0.09
0.04
0.00
0.00
0.04
−24.81
0.15
0.23
12.43
0.30
0.24
0.00
0.26

SEQID-03648
0.04
0.02
0.04
0.02
0.01
0.00
0.00
0.00
−36.23
0.05
0.17
10.80
0.31
0.25
0.29
0.31

SEQID-03649
0.00
0.04
0.02
0.09
0.11
0.03
0.04
0.06
−17.45
0.28
0.00
6.65
0.27
0.41
0.23
0.21

SEQID-03650
0.02
0.03
0.05
0.05
0.07
0.06
0.07
0.06
−18.43
0.31
−0.03
4.61
0.22
0.33
0.21
0.21

SEQID-03651
0.01
0.01
0.05
0.00
0.01
0.05
0.14
0.05
−28.98
0.34
−0.15
3.87
0.44
0.51
0.23
0.21

SEQID-03652
0.04
0.02
0.00
0.06
0.04
0.00
0.05
0.07
−24.65
0.29
−0.04
5.01
0.27
0.22
0.32
0.31

SEQID-03653
0.03
0.01
0.00
0.06
0.11
0.00
0.02
0.03
−25.79
0.15
0.00
6.98
0.23
0.34
0.27
0.25

SEQID-03654
0.04
0.02
0.00
0.06
0.04
0.00
0.05
0.07
−24.44
0.39
−0.05
4.69
0.29
0.23
0.32
0.29

SEQID-03655
0.02
0.04
0.03
0.02
0.04
0.03
0.05
0.04
−21.52
0.40
0.09
10.57
0.21
0.32
0.00
0.23

SEQID-03656
0.02
0.12
0.02
0.08
0.07
0.03
0.05
0.02
−20.58
0.35
0.26
11.66
0.27
0.18
0.30
0.22

SEQID-03657
0.01
0.09
0.03
0.07
0.03
0.00
0.05
0.03
−22.79
0.22
0.15
11.36
0.27
0.30
0.27
0.00

SEQID-03658
0.03
0.03
0.13
0.08
0.05
0.02
0.02
0.03
−24.84
0.20
−0.01
5.98
0.23
0.33
0.22
0.25

SEQID-03659
0.01
0.09
0.01
0.04
0.04
0.00
0.14
0.03
−25.61
0.25
0.11
10.02
0.22
0.28
0.30
0.24

SEQID-03660
0.07
0.10
0.03
0.06
0.05
0.00
0.02
0.01
−26.25
0.07
0.31
12.76
0.26
0.21
0.00
0.28

SEQID-03661
0.09
0.00
0.04
0.04
0.00
0.00
0.00
0.11
−36.34
0.39
0.29
11.49
0.32
0.15
0.33
0.32

SEQID-03662
0.03
0.09
0.04
0.06
0.07
0.02
0.05
0.08
−24.61
0.25
0.10
10.56
0.26
0.32
0.30
0.00

SEQID-03663
0.01
0.05
0.06
0.02
0.06
0.00
0.01
0.04
−20.55
0.45
−0.04
4.54
0.30
0.32
0.26
0.26

SEQID-03664
0.05
0.03
0.04
0.07
0.03
0.00
0.02
0.01
−35.30
0.23
−0.28
3.63
0.28
0.31
0.25
0.24

SEQID-03665
0.01
0.05
0.00
0.05
0.05
0.00
0.05
0.04
−27.65
0.27
0.15
10.99
0.27
0.30
0.00
0.24

SEQID-03666
0.01
0.07
0.03
0.04
0.02
0.01
0.04
0.04
−23.16
0.37
0.01
8.05
0.44
0.59
0.00
0.21

SEQID-03667
0.01
0.08
0.00
0.09
0.02
0.00
0.04
0.03
−26.95
0.21
0.17
11.40
0.28
0.23
0.00
0.26

SEQID-03668
0.01
0.04
0.02
0.05
0.04
0.00
0.00
0.09
−25.82
0.49
−0.08
4.18
0.28
0.33
0.26
0.27

SEQID-03669
0.03
0.07
0.02
0.02
0.07
0.00
0.10
0.05
−35.38
0.28
−0.07
4.41
0.27
0.23
0.00
0.13

SEQID-03670
0.04
0.03
0.03
0.05
0.00
0.02
0.06
0.03
−28.28
0.10
0.22
11.46
0.27
0.23
0.00
0.23

SEQID-03671
0.06
0.04
0.03
0.03
0.06
0.00
0.03
0.05
−23.14
0.15
−0.04
4.59
0.26
0.30
0.19
0.00

SEQID-03672
0.02
0.11
0.06
0.01
0.06
0.00
0.02
0.05
−24.34
0.38
0.22
11.00
0.30
0.25
0.29
0.00

SEQID-03673
0.03
0.03
0.00
0.07
0.07
0.00
0.06
0.03
−22.85
0.16
0.20
11.53
0.25
0.23
0.28
0.28

SEQID-03674
0.02
0.00
0.03
0.04
0.06
0.00
0.00
0.14
−25.40
0.34
0.11
11.18
0.00
0.31
0.00
0.20

SEQID-03675
0.06
0.00
0.01
0.06
0.04
0.00
0.00
0.04
−26.36
0.07
0.23
12.05
0.25
0.20
0.00
0.30

SEQID-03676
0.02
0.04
0.03
0.04
0.08
0.00
0.02
0.04
−22.75
0.14
−0.22
3.08
0.33
0.28
0.00
0.00

SEQID-03677
0.07
0.04
0.01
0.04
0.07
0.02
0.05
0.04
−25.14
0.25
−0.08
4.58
0.28
0.30
0.00
0.00

SEQID-03678
0.01
0.00
0.00
0.03
0.03
0.00
0.02
0.07
−20.36
0.41
0.14
11.42
0.28
0.30
0.00
0.26

SEQID-03679
0.02
0.02
0.02
0.06
0.05
0.09
0.08
0.09
−21.80
0.30
0.01
8.83
0.25
0.28
0.20
0.24

SEQID-03680
0.15
0.03
0.03
0.02
0.05
0.00
0.03
0.03
−24.71
0.20
−0.04
4.53
0.22
0.29
0.22
0.23

SEQID-03681
0.08
0.06
0.01
0.03
0.04
0.00
0.05
0.03
−22.61
0.19
−0.05
4.29
0.23
0.31
0.00
0.00

SEQID-03682
0.01
0.00
0.00
0.03
0.03
0.00
0.02
0.07
−20.36
0.41
0.14
11.57
0.28
0.30
0.00
0.24

SEQID-03683
0.02
0.04
0.03
0.04
0.11
0.00
0.02
0.05
−22.90
0.13
−0.22
3.08
0.32
0.27
0.00
0.00

SEQID-03684
0.04
0.03
0.08
0.02
0.08
0.03
0.02
0.09
−20.40
0.40
−0.14
3.73
0.28
0.31
0.00
0.22

SEQID-03685
0.09
0.00
0.01
0.02
0.07
0.03
0.00
0.04
−25.89
0.17
0.25
12.44
0.30
0.24
0.29
0.00

SEQID-03686
0.03
0.02
0.00
0.05
0.03
0.00
0.02
0.04
−22.07
0.36
0.17
11.95
0.26
0.29
0.00
0.23

SEQID-03687
0.07
0.06
0.02
0.05
0.04
0.00
0.00
0.02
−28.97
0.12
0.39
13.58
0.27
0.15
0.30
0.29

SEQID-03688
0.02
0.00
0.02
0.03
0.04
0.00
0.00
0.16
−27.06
0.42
0.12
11.21
0.24
0.31
0.00
0.00

SEQID-03689
0.01
0.03
0.03
0.07
0.09
0.01
0.11
0.07
−17.78
0.25
0.00
6.87
0.22
0.32
0.21
0.21

SEQID-03690
0.02
0.03
0.04
0.09
0.05
0.08
0.10
0.03
−15.75
0.26
0.00
6.53
0.00
0.33
0.00
0.22

SEQID-03691
0.02
0.03
0.00
0.05
0.06
0.01
0.07
0.06
−30.38
0.14
0.03
9.69
0.23
0.35
0.00
0.20

SEQID-03692
0.00
0.01
0.04
0.05
0.07
0.03
0.03
0.03
−19.20
0.26
0.00
8.72
0.00
0.36
0.00
0.20

SEQID-03693
0.05
0.05
0.05
0.07
0.05
0.01
0.05
0.02
−22.32
0.13
0.00
6.55
0.19
0.33
0.19
0.20

SEQID-03694
0.03
0.03
0.05
0.09
0.05
0.02
0.04
0.05
−26.41
0.21
0.05
10.06
0.20
0.33
0.00
0.21

SEQID-03695
0.02
0.04
0.05
0.04
0.06
0.03
0.01
0.05
−22.65
0.19
0.02
9.92
0.21
0.33
0.17
0.00

SEQID-03696
0.05
0.05
0.04
0.04
0.03
0.02
0.05
0.02
−31.03
0.20
0.03
9.50
0.21
0.31
0.18
0.23

SEQID-03697
0.05
0.02
0.00
0.03
0.04
0.00
0.00
0.07
−39.00
0.31
−0.28
3.65
0.26
0.34
0.23
0.23

SEQID-03693
0.13
0.00
0.00
0.03
0.03
0.00
0.00
0.03
−39.85
0.11
0.56
13.35
0.32
0.10
0.32
0.32

SEQID-03699
0.02
0.03
0.02
0.04
0.05
0.00
0.00
0.05
−34.84
0.17
−0.16
4.16
0.30
0.33
0.24
0.26

SEQID-03700
0.00
0.06
0.03
0.07
0.06
0.00
0.06
0.10
−24.50
0.40
−0.19
3.59
0.25
0.28
0.00
0.00

SEQID-03701
0.00
0.03
0.03
0.03
0.05
0.00
0.06
0.09
−23.52
0.27
0.00
7.53
0.35
0.22
0.00
0.00

SEQID-03702
0.00
0.03
0.05
0.05
0.05
0.00
0.06
0.09
−24.58
0.31
−0.02
4.92
0.33
0.20
0.00
0.31

SEQID-03703
0.00
0.03
0.05
0.03
0.05
0.00
0.06
0.09
−24.92
0.27
−0.02
5.78
0.36
0.22
0.00
0.27

SEQID-03704
0.02
0.02
0.00
0.03
0.04
0.00
0.05
0.03
−37.34
0.12
0.51
12.70
0.33
0.21
0.33
0.30

SEQID-03705
0.01
0.06
0.02
0.01
0.09
0.00
0.04
0.06
−26.05
0.18
0.26
11.32
0.22
0.31
0.25
0.21

SEQID-03706
0.01
0.03
0.04
0.07
0.02
0.00
0.02
0.03
−28.24
0.23
−0.08
4.34
0.34
0.34
0.27
0.28

SEQID-03707
0.00
0.03
0.07
0.07
0.06
0.00
0.02
0.03
−21.71
0.33
−0.01
6.49
0.27
0.30
0.26
0.28

SEQID-03708
0.01
0.01
0.05
0.00
0.01
0.05
0.15
0.05
−29.44
0.24
−0.16
3.86
0.43
0.49
0.22
0.22

SEQID-03709
0.04
0.01
0.01
0.03
0.05
0.00
0.02
0.02
−28.31
0.07
−0.01
5.26
0.28
0.31
0.00
0.30

SEQID-03710
0.06
0.02
0.03
0.01
0.05
0.06
0.03
0.00
−25.89
0.07
0.13
13.06
0.31
0.20
0.00
0.00

SEQID-03711
0.02
0.02
0.04
0.03
0.06
0.00
0.05
0.01
−25.32
0.12
0.30
11.95
0.30
0.22
0.25
0.28

SEQID-03712
0.01
0.01
0.04
0.00
0.03
0.05
0.15
0.04
−30.09
0.32
−0.16
3.33
0.35
0.42
0.20
0.22

SEQID-03713
0.01
0.03
0.07
0.09
0.12
0.00
0.03
0.05
−24.01
0.27
−0.03
4.92
0.20
0.31
0.00
0.25

SEQID-03714
0.02
0.06
0.04
0.09
0.06
0.01
0.02
0.02
−21.00
0.23
−0.04
4.70
0.20
0.33
0.20
0.20

SEQID-03715
0.05
0.02
0.02
0.04
0.09
0.00
0.08
0.01
−23.13
0.06
−0.01
6.12
0.25
0.34
0.24
0.27

SEQID-03716
0.00
0.05
0.12
0.00
0.00
0.00
0.12
0.02
−23.49
0.20
−0.12
4.05
0.33
0.20
0.29
0.30

SEQID-03717
0.03
0.01
0.00
0.07
0.11
0.00
0.02
0.03
−25.89
0.15
−0.01
6.15
0.24
0.34
0.27
0.26

SEQID-03718
0.03
0.04
0.00
0.02
0.16
0.00
0.13
0.00
−20.29
0.17
0.12
10.45
0.30
0.12
0.29
0.00

SEQID-03719
0.02
0.08
0.00
0.03
0.05
0.03
0.09
0.07
−20.63
0.48
0.07
9.72
0.30
0.17
0.00
0.27

SEQID-03720
0.02
0.04
0.03
0.04
0.09
0.00
0.02
0.04
−22.75
0.15
−0.22
3.08
0.28
0.23
0.00
0.28

SEQID-03721
0.02
0.05
0.05
0.09
0.07
0.01
0.03
0.03
−20.94
0.13
−0.03
5.06
0.19
0.34
0.17
0.19

SEQID-03722
0.03
0.00
0.04
0.04
0.00
0.00
0.00
0.05
−26.69
0.47
0.30
12.31
0.32
0.15
0.32
0.32

SEQID-03723
0.02
0.03
0.03
0.08
0.04
0.00
0.04
0.05
−24.41
0.19
−0.07
4.67
0.18
0.33
0.18
0.21

SEQID-03724
0.02
0.03
0.01
0.07
0.07
0.00
0.03
0.02
−25.20
0.11
−0.10
4.27
0.20
0.28
0.24
0.20

SEQID-03725
0.00
0.05
0.04
0.05
0.03
0.00
0.09
0.07
−23.75
0.36
−0.12
4.11
0.28
0.30
0.23
0.26

SEQID-03726
0.00
0.09
0.03
0.05
0.04
0.00
0.05
0.08
−22.85
0.43
−0.14
3.96
0.23
0.34
0.26
0.27

SEQID-03727
0.02
0.00
0.00
0.05
0.02
0.00
0.05
0.04
−39.39
0.04
0.54
12.73
0.38
0.24
0.32
0.28

SEQID-03728
0.04
0.01
0.01
0.05
0.04
0.00
0.02
0.02
−26.12
0.06
0.01
7.70
0.27
0.31
0.00
0.29

SEQID-03729
0.03
0.12
0.03
0.07
0.03
0.01
0.04
0.03
−20.53
0.38
0.05
10.07
0.22
0.28
0.00
0.22

SEQID-03730
0.00
0.05
0.04
0.07
0.09
0.03
0.09
0.07
−15.74
0.44
−0.04
4.58
0.22
0.33
0.00
0.00

SEQID-03731
0.01
0.00
0.03
0.04
0.02
0.00
0.04
0.03
−37.31
0.04
0.32
12.55
0.31
0.32
0.30
0.26

SEQID-03732
0.02
0.00
0.09
0.04
0.04
0.00
0.05
0.02
−28.34
0.06
0.25
12.48
0.27
0.31
0.31
0.27

SEQID-03733
0.01
0.10
0.04
0.07
0.06
0.00
0.05
0.10
−20.09
0.34
−0.09
4.15
0.27
0.32
0.25
0.26

SEQID-03734
0.00
0.02
0.02
0.11
0.05
0.00
0.03
0.02
−32.91
0.00
0.36
12.46
0.26
0.18
0.31
0.27

SEQID-03735
0.04
0.01
0.01
0.09
0.05
0.00
0.03
0.02
−28.66
0.09
−0.02
4.97
0.28
0.32
0.26
0.29

SEQID-03736
0.03
0.03
0.06
0.05
0.10
0.00
0.00
0.02
−32.42
0.06
−0.02
4.98
0.35
0.18
0.35
0.27

SEQID-03737
0.02
0.00
0.07
0.15
0.04
0.00
0.02
0.03
−23.09
0.01
0.25
12.40
0.26
0.34
0.28
0.25

SEQID-03738
0.13
0.06
0.03
0.07
0.03
0.00
0.09
0.02
−20.71
0.22
0.02
8.20
0.24
0.28
0.00
0.00

SEQID-03739
0.02
0.04
0.01
0.03
0.04
0.00
0.02
0.05
−24.16
0.40
0.00
6.97
0.27
0.32
0.25
0.24

SEQID-03740
0.02
0.07
0.01
0.09
0.05
0.06
0.05
0.03
−22.98
0.30
0.26
11.93
0.32
0.23
0.33
0.00

SEQID-03741
0.03
0.03
0.03
0.04
0.02
0.00
0.00
0.02
−35.11
0.12
−0.01
6.55
0.27
0.34
0.24
0.25

SEQID-03742
0.01
0.05
0.04
0.10
0.06
0.00
0.02
0.03
−21.70
0.23
−0.03
5.63
0.20
0.33
0.00
0.19

SEQID-03743
0.03
0.03
0.02
0.06
0.02
0.00
0.09
0.03
−23.45
0.22
0.18
11.09
0.23
0.26
0.21
0.22

SEQID-03744
0.02
0.03
0.01
0.01
0.00
0.00
0.03
0.05
−30.92
0.34
0.02
7.34
0.23
0.30
0.22
0.25

SEQID-03745
0.01
0.04
0.02
0.01
0.00
0.00
0.01
0.04
−30.77
0.31
0.12
10.52
0.20
0.27
0.00
0.26

SEQID-03746
0.06
0.03
0.03
0.09
0.05
0.00
0.05
0.02
−20.04
0.16
−0.02
5.80
0.21
0.34
0.00
0.00

SEQID-03747
0.04
0.05
0.02
0.16
0.09
0.00
0.02
0.00
−23.42
0.21
0.01
8.43
0.24
0.31
0.00
0.25

SEQID-03748
0.01
0.09
0.04
0.14
0.05
0.00
0.05
0.02
−22.65
0.13
0.04
9.95
0.23
0.33
0.00
0.22

SEQID-03749
0.01
0.11
0.04
0.04
0.06
0.02
0.07
0.01
−23.48
0.16
−0.09
4.43
0.26
0.24
0.31
0.28

SEQID-03750
0.02
0.09
0.07
0.07
0.10
0.00
0.07
0.03
−20.25
0.24
0.10
10.30
0.28
0.29
0.22
0.28

SEQID-03751
0.02
0.04
0.03
0.14
0.04
0.00
0.04
0.04
−25.76
0.34
0.16
10.96
0.32
0.28
0.00
0.25

SEQID-03752
0.05
0.01
0.01
0.07
0.05
0.00
0.02
0.02
−30.53
0.08
−0.04
4.83
0.29
0.31
0.00
0.30

SEQID-03753
0.01
0.03
0.04
0.08
0.05
0.02
0.05
0.05
−23.34
0.34
0.14
11.07
0.00
0.30
0.25
0.20

SEQID-03754
0.03
0.02
0.01
0.07
0.07
0.00
0.02
0.04
−28.01
0.09
0.00
7.55
0.29
0.30
0.27
0.32

SEQID-03755
0.05
0.00
0.01
0.07
0.05
0.00
0.03
0.02
−27.72
0.07
−0.01
5.27
0.29
0.31
0.24
0.30

SEQID-03756
0.02
0.02
0.14
0.06
0.02
0.03
0.01
0.05
−21.30
0.29
0.08
11.45
0.25
0.34
0.24
0.24

SEQID-03757
0.06
0.05
0.04
0.01
0.06
0.06
0.05
0.00
−28.84
0.08
0.34
12.70
0.27
0.17
0.24
0.29

SEQID-03758
0.01
0.06
0.05
0.03
0.03
0.04
0.05
0.04
−30.63
0.26
−0.13
4.06
0.32
0.49
0.00
0.22

SEQID-03759
0.03
0.02
0.02
0.15
0.09
0.00
0.01
0.03
−22.70
0.32
0.08
11.04
0.25
0.30
0.00
0.22

SEQID-03760
0.01
0.03
0.03
0.12
0.08
0.03
0.06
0.09
−14.72
0.43
−0.03
4.43
0.22
0.41
0.00
0.23

SEQID-03761
0.02
0.14
0.05
0.04
0.04
0.03
0.08
0.03
−26.38
0.13
0.13
10.96
0.25
0.27
0.28
0.25

SEQID-03762
0.02
0.02
0.01
0.04
0.05
0.00
0.00
0.14
−26.13
0.39
0.13
10.85
0.27
0.26
0.32
0.29

SEQID-03761
0.01
0.00
0.07
0.00
0.02
0.05
0.16
0.04
−28.55
0.19
−0.16
3.84
0.47
0.53
0.21
0.24

SEQID-03764
0.05
0.03
0.06
0.07
0.06
0.00
0.00
0.00
−35.85
0.01
−0.05
4.72
0.33
0.18
0.30
0.28

SEQID-03765
0.05
0.06
0.05
0.04
0.03
0.00
0.02
0.04
−21.74
0.44
0.02
8.22
0.33
0.29
0.24
0.00

SEQID-03766
0.05
0.03
0.04
0.05
0.10
0.00
0.00
0.00
−33.95
0.07
−0.02
5.02
0.27
0.15
0.33
0.33

SEQID-03767
0.02
0.02
0.00
0.03
0.04
0.00
0.05
0.04
−38.70
0.11
0.53
12.73
0.33
0.21
0.33
0.29

SEQID-03768
0.00
0.05
0.03
0.11
0.11
0.05
0.07
0.06
−15.13
0.40
−0.06
3.96
0.21
0.38
0.00
0.21

SEQID-03769
0.01
0.07
0.02
0.02
0.07
0.00
0.02
0.06
−26.47
0.34
−0.02
6.35
0.31
0.32
0.25
0.32

SEQID-03770
0.03
0.06
0.06
0.02
0.04
0.00
0.04
0.04
−21.97
0.50
0.04
9.61
0.27
0.23
0.32
0.00

SEQID-03771
0.00
0.05
0.12
0.00
0.00
0.03
0.11
0.03
−24.09
0.12
−0.11
4.21
0.33
0.20
0.29
0.33

SEQID-03772
0.00
0.05
0.12
0.00
0.00
0.00
0.12
0.04
−23.97
0.13
−0.11
4.21
0.33
0.20
0.35
0.35

SEQID-03773
0.00
0.07
0.03
0.03
0.07
0.00
0.06
0.03
−20.39
0.22
−0.02
5.00
0.28
0.26
0.00
0.24

SEQID-03774
0.05
0.02
0.04
0.01
0.02
0.00
0.02
0.02
−36.47
0.14
−0.05
4.75
0.26
0.33
0.25
0.00

SEQID-03775
0.02
0.05
0.09
0.00
0.04
0.00
0.12
0.04
−23.92
0.09
−0.12
4.05
0.33
0.20
0.29
0.33

SEQID-03776
0.02
0.03
0.04
0.10
0.06
0.08
0.10
0.03
−15.43
0.25
0.00
6.53
0.19
0.33
0.00
0.21

SEQID-03777
0.07
0.02
0.01
0.01
0.14
0.00
0.02
0.02
−25.61
0.08
0.05
10.21
0.31
0.34
0.00
0.29

SEQID-03778
0.03
0.02
0.04
0.09
0.05
0.00
0.03
0.06
−22.47
0.20
−0.06
4.44
0.00
0.31
0.00
0.22

SEQID-03779
0.07
0.05
0.02
0.03
0.07
0.00
0.00
0.05
−31.12
0.15
0.38
13.11
0.30
0.17
0.30
0.33

SEQID-03780
0.04
0.03
0.04
0.05
0.00
0.02
0.05
0.05
−25.62
0.07
0.20
11.73
0.25
0.28
0.00
0.24

SEQID-03781
0.02
0.05
0.03
0.02
0.09
0.00
0.03
0.09
−23.27
0.32
0.17
10.49
0.30
0.18
0.29
0.30

SEQID-03782
0.08
0.06
0.01
0.03
0.04
0.00
0.05
0.03
−21.91
0.20
−0.04
4.37
0.23
0.31
0.00
0.00

SEQID-03783
0.07
0.06
0.01
0.08
0.05
0.00
0.02
0.01
−26.74
0.11
0.32
12.83
0.24
0.20
0.00
0.27

SEQID-03784
0.02
0.04
0.01
0.041
0.05
0.00
0.14
0.04
−23.57
0.27
−0.06
4.60
0.28
0.33
0.00
0.25

SEQID-03785
0.01
0.08
0.01
0.02
0.06
0.04
0.09
0.06
−22.59
0.26
0.05
9.40
0.17
0.25
0.00
0.22

SEQID-03786
0.04
0.08
0.03
0.06
0.04
0.00
0.14
0.01
−23.30
0.15
−0.08
4.43
0.28
0.28
0.00
0.26

SEQID-03787
0.11
0.04
0.02
0.03
0.03
0.00
0.01
0.05
−23.23
0.25
−0.03
4.64
0.22
0.29
0.00
0.24

SEQID-03788
0.02
0.02
0.01
0.04
0.04
0.00
0.00
0.14
−26.07
0.39
0.13
10.85
0.27
0.26
0.31
0.29

SEQID-03789
0.02
0.08
0.04
0.06
0.09
0.02
0.03
0.08
−22.78
0.32
0.10
10.83
0.28
0.32
0.00
0.27

SEQID-03790
0.03
0.02
0.00
0.07
0.05
0.00
0.00
0.17
−22.17
0.45
0.10
10.80
0.25
0.24
0.00
0.19

SEQID-03791
0.03
0.13
0.03
0.06
0.05
0.00
0.07
0.04
−22.87
0.25
0.04
9.47
0.27
0.30
0.24
0.26

SEQID-03792
0.02
0.06
0.05
0.14
0.05
0.00
0.03
0.02
−20.96
0.15
0.04
10.05
0.23
0.33
0.00
0.20

SEQID-03793
0.01
0.04
0.01
0.01
0.02
0.00
0.02
0.02
−32.65
0.32
0.02
7.39
0.18
0.31
0.23
0.27

SEQID-03794
0.02
0.03
0.04
0.02
0.06
0.02
0.14
0.05
−22.93
0.22
0.03
9.12
0.23
0.30
0.21
0.00

SEQID-03795
0.02
0.08
0.02
0.07
0.07
0.06
0.03
0.02
−20.65
0.38
0.27
11.98
0.33
0.21
0.27
0.28

SEQID-03796
0.02
0.05
0.02
0.13
0.03
0.06
0.00
0.03
−23.50
0.29
0.31
13.02
0.26
0.18
0.28
0.32

SEQID-03797
0.01
0.01
0.07
0.08
0.07
0.00
0.02
0.06
−27.59
0.13
0.28
11.65
0.23
0.32
0.00
0.26

SEQID-03798
0.01
0.01
0.05
0.00
0.01
0.05
0.15
0.05
−28.97
0.24
−0.15
3.88
0.43
0.49
0.22
0.21

SEQID-03799
0.03
0.02
0.12
0.05
0.03
0.00
0.02
0.05
−21.47
0.18
0.03
9.78
0.26
0.30
0.27
0.29

SEQID-03800
0.02
0.03
0.16
0.09
0.05
0.01
0.01
0.04
−20.32
0.21
0.05
11.22
0.23
0.34
0.21
0.24

SEQID-03801
0.02
0.05
0.04
0.09
0.04
0.01
0.07
0.01
−20.88
0.15
0.03
9.74
0.21
0.33
0.00
0.21

SEQID-03802
0.04
0.02
0.07
0.04
0.06
0.00
0.05
0.10
−24.31
0.18
0.26
12.22
0.31
0.24
0.22
0.00

SEQID-03803
0.02
0.05
0.04
0.08
0.05
0.00
0.02
0.04
−21.78
0.20
0.04
10.22
0.21
0.31
0.00
0.20

SEQID-03804
0.04
0.06
0.03
0.06
0.04
0.00
0.00
0.03
−28.60
0.12
0.00
6.83
0.27
0.21
0.22
0.31

SEQID-03805
0.03
0.00
0.02
0.04
0.00
0.00
0.00
0.00
−28.57
0.42
0.33
12.42
0.34
0.16
0.34
0.30

SEQID-03806
0.01
0.04
0.03
0.04
0.04
0.00
0.07
0.16
−24.25
0.46
0.06
9.93
0.00
0.26
0.21
0.00

SEQID-03807
0.03
0.02
0.01
0.05
0.05
0.00
0.02
0.04
−23.55
0.21
0.16
11.44
0.27
0.28
0.00
0.31

SEQID-03808
0.03
0.02
0.00
0.07
0.05
0.00
0.00
0.17
−22.29
0.45
0.08
10.60
0.26
0.26
0.00
0.00

SEQID-03809
0.03
0.09
0.04
0.05
0.06
0.02
0.02
0.09
−24.75
0.35
0.10
10.81
0.23
0.28
0.00
0.28

SEQID-03810
0.02
0.05
0.13
0.05
0.02
0.01
0.03
0.05
−20.20
0.30
−0.02
5.86
0.20
0.34
0.22
0.23

SEQID-03811
0.05
0.00
0.03
0.08
0.03
0.00
0.00
0.03
−30.72
0.19
−0.15
4.15
0.31
0.33
0.25
0.28

SEQID-03812
0.06
0.04
0.10
0.07
0.00
0.01
0.01
0.03
−31.97
0.09
−0.06
4.71
0.26
0.32
0.23
0.23

SEQID-03813
0.04
0.02
0.04
0.01
0.03
0.01
0.01
0.07
−21.63
0.35
0.00
6.96
0.26
0.31
0.32
0.30

SEQID-03814
0.02
0.0
0.02
0.10
0.05
0.06
0.03
0.05
−22.85
0.32
0.26
12.23
0.35
0.24
0.26
0.00

SEQID-03815
0.01
0.06
0.00
0.04
0.04
0.00
0.05
0.06
−26.78
0.29
0.16
11.14
0.26
0.28
0.25
0.27

SEQID-03816
0.02
0.12
0.02
0.08
0.08
0.03
0.05
0.02
−21.98
0.31
0.28
11.91
0.25
0.17
0.30
0.22

SEQID-03817
0.01
0.07
0.02
0.06
0.02
0.00
0.07
0.03
−28.81
0.21
0.17
11.50
0.27
0.23
0.25
0.23

SEQID-03818
0.02
0.04
0.02
0.03
0.04
0.02
0.05
0.05
−20.79
0.41
0.09
10.56
0.20
0.31
0.00
0.22

SEQID-03819
0.03
0.05
0.05
0.07
0.12
0.00
0.02
0.05
−25.03
0.29
−0.14
3.85
0.21
0.33
0.00
0.22

SEQID-03820
0.04
0.04
0.00
0.07
0.11
0.00
0.00
0.01
−25.34
0.08
−0.06
4.48
0.32
0.25
0.26
0.27

SEQID-03821
0.02
0.06
0.04
0.02
0.02
0.08
0.07
0.04
−25.02
0.16
0.01
7.95
0.21
0.33
0.00
0.23

SEQID-03822
0.03
0.05
0.05
0.14
0.05
0.03
0.02
0.03
−21.29
0.32
0.00
6.89
0.23
0.31
0.18
0.22

SEQID-03823
0.02
0.03
0.02
0.04
0.02
0.03
0.14
0.06
−30.29
0.05
0.06
9.65
0.24
0.26
0.00
0.21

SEQID-03824
0.05
0.04
0.07
0.02
0.01
0.00
0.02
0.04
−30.01
0.08
0.04
9.78
0.28
0.23
0.22
0.29

SEQID-03825
0.04
0.01
0.03
0.09
0.02
0.00
0.00
0.04
−31.12
0.21
−0.20
3.87
0.25
0.31
0.28
0.33

SEQID-03826
0.02
0.01
0.03
0.05
0.02
0.03
0.14
0.07
−22.84
0.23
−0.02
5.60
0.27
0.32
0.00
0.26

SEQID-03827
0.06
0.12
0.05
0.01
0.02
0.00
0.03
0.05
−26.24
0.22
−0.24
3.42
0.32
0.23
0.30
0.28

SEQID-03828
0.03
0.04
0.03
0.02
0.04
0.02
0.05
0.04
−21.39
0.39
0.06
10.34
0.22
0.30
0.00
0.00

SEQID-03829
0.02
0.04
0.02
0.02
0.01
0.00
0.06
0.05
−31.10
0.27
0.26
10.97
0.31
0.26
0.28
0.26

SEQID-03830
0.08
0.02
0.04
0.05
0.00
0.00
0.00
0.01
−28.50
0.16
0.19
11.06
0.27
0.22
0.28
0.31

SEQID-03831
0.02
0.14
0.01
0.04
0.04
0.04
0.15
0.03
−20.48
0.33
0.10
9.76
0.24
0.20
0.26
0.26

SEQID-03832
0.04
0.02
0.03
0.02
0.08
0.00
0.04
0.12
−23.18
0.40
−0.07
4.32
0.26
0.34
0.25
0.26

SEQID-03833
0.05
0.01
0.00
0.05
0.09
0.04
0.06
0.07
−21.49
0.30
0.21
11.11
0.18
0.25
0.28
0.24

SEQID-03834
0.02
0.04
0.13
0.06
0.04
0.02
0.03
0.04
−20.06
0.25
0.14
9.69
0.23
0.35
0.21
0.25

SEQID-03835
0.04
0.05
0.03
0.04
0.05
0.06
0.03
0.00
−27.60
0.10
0.36
13.06
0.24
0.15
0.00
0.00

SEQID-03836
0.06
0.13
0.03
0.05
0.02
0.02
0.05
0.06
−20.29
0.42
−0.01
6.51
0.24
0.29
0.23
0.00

SEQID-03837
0.02
0.11
0.01
0.12
0.05
0.03
0.03
0.06
−22.98
0.34
0.26
12.24
0.31
0.22
0.00
0.00

SEQID-03838
0.03
0.00
0.02
0.02
0.00
0.00
0.04
0.04
−28.59
0.44
0.33
12.09
0.34
0.16
0.32
0.27

SEQID-03839
0.03
0.02
0.14
0.05
0.02
0.00
0.02
0.04
−21.42
0.13
0.03
9.78
0.26
0.30
0.32
0.31

SEQID-03840
0.05
0.07
0.03
0.05
0.05
0.02
0.05
0.06
−19.97
0.34
−0.06
4.45
0.40
0.54
0.00
0.21

SEQID-03841
0.04
0.02
0.03
0.03
0.05
0.02
0.04
0.03
−21.54
0.49
0.12
11.67
0.21
0.31
0.00
0.21

SEQID-03842
0.02
0.04
0.00
0.09
0.03
0.00
0.05
0.05
−26.92
0.20
0.14
11.01
0.26
0.27
0.26
0.29

SEQID-03843
0.02
0.05
0.03
0.02
0.02
0.02
0.04
0.04
−21.07
0.42
0.06
10.30
0.20
0.31
0.00
0.00

SEQID-03844
0.03
0.02
0.05
0.14
0.04
0.01
0.04
0.05
−21.65
0.19
0.01
8.01
0.23
0.33
0.00
0.00

SEQID-03845
0.02
0.03
0.13
0.06
0.04
0.02
0.00
0.04
−24.03
0.22
0.05
10.20
0.26
0.30
0.27
0.27

SEQID-03846
0.01
0.12
0.04
0.07
0.04
0.01
0.05
0.04
−24.67
0.15
0.02
9.29
0.21
0.34
0.00
0.21

SEQID-03847
0.10
0.06
0.02
0.03
0.05
0.00
0.00
0.03
−27.07
0.07
0.33
13.12
0.25
0.20
0.00
0.00

SEQID-03848
0.09
0.06
0.02
0.07
0.02
0.00
0.16
0.02
−24.96
0.12
−0.10
4.09
0.30
0.28
0.00
0.28

SEQID-03849
0.09
0.00
0.09
0.02
0.00
0.00
0.00
0.11
−23.49
0.40
0.25
11.37
0.33
0.16
0.33
0.33

SEQID-03850
0.03
0.07
0.04
0.07
0.08
0.02
0.03
0.08
−22.85
0.33
0.07
10.48
0.25
0.29
0.00
0.26

SEQID-03851
0.06
0.05
0.04
0.01
0.06
0.06
0.05
0.00
−27.66
0.08
0.32
12.62
0.29
0.18
0.00
0.29

SEQID-03852
0.03
0.03
0.07
0.02
0.06
0.00
0.02
0.02
−23.24
0.21
0.13
10.63
0.28
0.26
0.26
0.27

SEQID-03853
0.02
0.02
0.03
0.03
0.02
0.00
0.02
0.03
−38.14
0.22
−0.28
3.59
0.23
0.41
0.23
0.25

SEQID-03854
0.02
0.05
0.03
0.04
0.05
0.06
0.09
0.06
−20.82
0.21
−0.01
6.58
0.23
0.35
0.00
0.22

SEQID-03855
0.02
0.00
0.00
0.04
0.01
0.00
0.05
0.04
−40.55
0.04
0.55
12.69
0.38
0.24
0.32
0.30

SEQID-03856
0.01
0.06
0.12
0.05
0.03
0.01
0.02
0.04
−21.58
0.29
0.01
7.37
0.21
0.31
0.21
0.00

SEQID-03857
0.01
0.04
0.03
0.03
0.07
0.00
0.07
0.14
−26.17
0.37
0.08
10.22
0.31
0.31
0.00
0.00

SEQID-03858
0.11
0.04
0.02
0.01
0.03
0.00
0.01
0.05
−23.03
0.26
−0.01
5.15
0.26
0.30
0.00
0.25

SEQID-03859
0.02
0.00
0.00
0.02
0.03
0.00
0.00
0.09
−37.46
0.02
0.04
9.75
0.31
0.21
0.28
0.32

SEQID-03860
0.01
0.01
0.05
0.00
0.01
0.05
0.15
0.05
−29.01
0.23
−0.15
3.88
0.43
0.51
0.23
0.21

SEQID-03861
0.00
0.02
0.06
0.07
0.09
0.04
0.04
0.05
−30.00
0.10
0.34
12.54
0.24
0.23
0.00
0.23

SEQID-03862
0.03
0.12
0.03
0.05
0.05
0.01
0.02
0.05
−24.40
0.41
−0.06
4.40
0.24
0.35
0.21
0.24

SEQID-03863
0.05
0.02
0.02
0.15
0.04
0.00
0.02
0.06
−24.15
0.17
−0.13
3.83
0.28
0.27
0.00
0.28

SEQID-03864
0.06
0.02
0.01
0.05
0.06
0.00
0.04
0.05
−24.03
0.22
0.14
11.24
0.30
0.31
0.00
0.24

SEQID-03865
0.05
0.02
0.00
0.05
0.04
0.00
0.00
0.07
−36.76
0.07
0.04
9.93
0.30
0.27
0.23
0.26

SEQID-03866
0.05
0.05
0.03
0.02
0.06
0.00
0.00
0.05
−21.90
0.14
−0.14
3.67
0.28
0.27
0.31
0.00

SEQID-03867
0.01
0.04
0.02
0.00
0.12
0.00
0.07
0.13
−22.28
0.38
0.06
10.13
0.25
0.33
0.25
0.00

SEQID-03868
0.04
0.06
0.03
0.02
0.08
0.00
0.02
0.03
−25.74
0.09
0.31
12.57
0.30
0.24
0.00
0.25

SEQID-03869
0.03
0.07
0.04
0.06
0.07
0.02
0.05
0.06
−24.42
0.26
0.09
10.48
0.24
0.33
0.00
0.26

SEQID-03870
0.15
0.03
0.03
0.02
0.09
0.00
0.01
0.07
−21.44
0.24
−0.04
4.40
0.24
0.27
0.00
0.22

SEQID-03871
0.04
0.02
0.04
0.01
0.12
0.00
0.02
0.01
−27.74
0.20
0.14
10.57
0.32
0.23
0.30
0.33

SEQID-03872
0.02
0.05
0.03
0.08
0.06
0.04
0.07
0.06
−17.59
0.23
0.02
9.22
0.37
0.49
0.24
0.21

SEQID-03873
0.00
0.05
0.10
0.00
0.00
0.00
0.12
0.02
−23.97
0.19
−0.11
4.21
0.34
0.21
0.29
0.32

SEQID-03874
0.03
0.11
0.05
0.02
0.05
0.05
0.04
0.05
−26.20
0.42
0.15
10.69
0.31
0.13
0.29
0.31

SEQID-03875
0.02
0.06
0.02
0.07
0.04
0.00
0.00
0.02
−28.87
0.20
0.01
7.42
0.33
0.19
0.28
0.35

SEQID-03876
0.04
0.04
0.06
0.10
0.00
0.00
0.15
0.00
−21.57
0.23
0.27
11.87
0.35
0.11
0.27
0.35

SEQID-03877
0.03
0.04
0.05
0.10
0.11
0.01
0.04
0.07
−20.80
0.29
−0.08
4.25
0.00
0.33
0.16
0.18

SEQID-03878
0.06
0.00
0.03
0.08
0.10
0.00
0.02
0.04
−20.20
0.24
−0.05
4.54
0.28
0.23
0.29
0.30

SEQID-03879
0.04
0.05
0.03
0.04
0.05
0.06
0.03
0.00
−27.60
0.10
0.36
13.00
0.26
0.17
0.27
0.00

SEQID-03880
0.03
0.03
0.04
0.07
0.08
0.00
0.00
0.04
−38.18
0.01
0.00
6.58
0.33
0.18
0.30
0.24

SEQID-03881
0.02
0.02
0.01
0.06
0.08
0.00
0.01
0.17
−24.25
0.36
−0.05
4.62
0.26
0.31
0.26
0.25

SEQID-03882
0.04
0.02
0.07
0.15
0.02
0.00
0.05
0.04
−22.20
0.08
0.06
10.38
0.24
0.29
0.26
0.26

SEQID-03883
0.01
0.04
0.05
0.04
0.04
0.05
0.06
0.03
−31.29
0.25
−0.10
4.28
0.34
0.55
0.00
0.22

SEQID-03884
0.07
0.02
0.02
0.07
0.04
0.00
0.02
0.02
−23.97
0.24
0.03
9.28
0.27
0.26
0.00
0.27

SEQID-03885
0.01
0.04
0.07
0.05
0.03
0.01
0.03
0.03
−31.94
0.12
−0.09
4.39
0.23
0.34
0.21
0.24

SEQID-03886
0.06
0.08
0.05
0.02
0.00
0.02
0.05
0.06
−21.81
0.31
−0.02
6.00
0.23
0.32
0.22
0.00

SEQID-03887
0.06
0.06
0.05
0.03
0.00
0.02
0.05
0.05
−21.79
0.27
−0.01
6.63
0.25
0.31
0.00
0.00

SEQID-03888
0.13
0.02
0.13
0.03
0.03
0.00
0.08
0.03
−22.77
0.03
0.18
11.37
0.29
0.18
0.25
0.30

SEQID-03889
0.02
0.02
0.01
0.07
0.05
0.01
0.01
0.04
−28.27
0.15
−0.06
4.67
0.00
0.36
0.16
0.19

SEQID-03890
0.03
0.00
0.01
0.00
0.04
0.05
0.14
0.00
−30.54
0.16
−0.02
5.10
0.28
0.21
0.00
0.00

SEQID-03891
0.05
0.00
0.06
0.03
0.03
0.00
0.04
0.02
−31.55
0.14
0.05
9.84
0.28
0.18
0.29
0.28

SEQID-03892
0.03
0.00
0.02
0.03
0.05
0.06
0.10
0.02
−33.88
0.05
0.12
10.44
0.31
0.20
0.29
0.31

SEQID-03893
0.03
0.01
0.01
0.03
0.05
0.05
0.13
0.01
−34.98
0.09
0.09
10.08
0.31
0.21
0.27
0.32

SEQID-03894
0.03
0.01
0.01
0.02
0.04
0.05
0.12
0.01
−35.89
0.09
0.09
9.84
0.30
0.23
0.28
0.30

SEQID-03895
0.04
0.01
0.01
0.05
0.04
0.05
0.11
0.02
−34.48
0.10
0.05
9.55
0.30
0.25
0.28
0.29

SEQID-03896
0.02
0.00
0.03
0.06
0.05
0.00
0.10
0.08
−31.95
0.24
0.06
10.01
0.33
0.21
0.00
0.32

SEQID-03897
0.02
0.00
0.05
0.06
0.05
0.00
0.08
0.08
−33.43
0.21
0.08
10.22
0.27
0.17
0.00
0.34

SEQID-03898
0.01
0.02
0.04
0.05
0.05
0.00
0.08
0.07
−31.96
0.29
0.06
9.66
0.29
0.20
0.15
0.32

SEQID-03899
0.01
0.00
0.06
0.06
0.02
0.00
0.08
0.07
−31.03
0.21
0.08
10.25
0.27
0.19
0.27
0.27

SEQID-03900
0.00
0.00
0.02
0.03
0.00
0.10
0.08
0.06
−32.21
0.17
0.18
11.19
0.30
0.19
0.00
0.00

SEQID-03901
0.00
0.00
0.07
0.00
0.03
0.00
0.13
0.02
−31.13
0.24
−0.08
4.33
0.41
0.26
0.00
0.32

SEQID-03902
0.03
0.02
0.05
0.00
0.03
0.04
0.04
0.02
−30.04
0.23
0.20
11.63
0.29
0.19
0.33
0.23

SEQID-03903
0.02
0.02
0.02
0.00
0.03
0.02
0.13
0.02
−30.82
0.25
0.17
11.01
0.33
0.21
0.35
0.33

SEQID-03904
0.01
0.01
0.00
0.00
0.02
0.00
0.20
0.01
−31.14
0.38
−0.08
4.54
0.32
0.26
0.00
0.25

SEQID-03905
0.00
0.00
0.00
0.00
0.03
0.00
0.13
0.03
−30.46
0.34
0.00
5.81
0.34
0.22
0.00
0.00

SEQID-03906
0.00
0.03
0.02
0.03
0.00
0.04
0.11
0.02
−29.86
0.39
−0.02
5.79
0.29
0.19
0.20
0.31

SEQID-03907
0.01
0.02
0.06
0.00
0.02
0.06
0.23
0.01
−30.42
0.29
−0.16
3.92
0.32
0.22
0.23
0.32

SEQID-03908
0.03
0.02
0.02
0.06
0.02
0.00
0.10
0.03
−31.04
0.39
−0.11
4.13
0.28
0.20
0.31
0.23

SEQID-03909
0.03
0.00
0.05
0.00
0.02
0.00
0.16
0.06
−31.07
0.42
−0.07
4.57
0.29
0.20
0.00
0.30